
<html lang="en"     class="pb-page"  data-request-id="801f14c8-3435-4e00-9dc9-4fe767bfe021"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-8;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c01833;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains" /></meta><meta name="dc.Creator" content="Akanksha  Sharma" /></meta><meta name="dc.Creator" content="Maria  De Rosa" /></meta><meta name="dc.Creator" content="Neha  Singla" /></meta><meta name="dc.Creator" content="Gurpal  Singh" /></meta><meta name="dc.Creator" content="Ravi P.  Barnwal" /></meta><meta name="dc.Creator" content="Ankur  Pandey" /></meta><meta name="dc.Description" content="Tuberculosis (TB) is a slow growing, potentially debilitating disease that has plagued humanity for centuries and has claimed numerous lives across the globe. Concerted efforts by researchers have ..." /></meta><meta name="Description" content="Tuberculosis (TB) is a slow growing, potentially debilitating disease that has plagued humanity for centuries and has claimed numerous lives across the globe. Concerted efforts by researchers have ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 7, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01833" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01833" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01833" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01833" /></link>
        
    
    

<title>Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01833" /></meta><meta property="og:title" content="Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0032.jpeg" /></meta><meta property="og:description" content="Tuberculosis (TB) is a slow growing, potentially debilitating disease that has plagued humanity for centuries and has claimed numerous lives across the globe. Concerted efforts by researchers have culminated in the development of various strategies to combat this malady. This review aims to raise awareness of the rapidly increasing incidences of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis, highlighting the significant modifications that were introduced in the TB treatment regimen over the past decade. A description of the role of pathogen–host immune mechanisms together with strategies for prevention of the disease is discussed. The struggle to develop novel drug therapies has continued in an effort to reduce the treatment duration, improve patient compliance and outcomes, and circumvent TB resistance mechanisms. Herein, we give an overview of the extensive medicinal chemistry efforts made during the past decade toward the discovery of new chemotypes, which are potentially active against TB-resistant strains." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01833"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01833">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01833&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01833&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01833&amp;href=/doi/10.1021/acs.jmedchem.0c01833" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 4359-4395</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01686" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.1c00051" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Akanksha Sharma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Akanksha Sharma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biophysics, Panjab University, Chandigarh 160014, India</div><div class="loa-info-affiliations-info">UIPS, Panjab University, Chandigarh 160014, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Akanksha++Sharma">Akanksha Sharma</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maria De Rosa</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maria De Rosa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Ri.MED Foundation, Palermo 90133, Italy</div></div><span class="conrtib-corresp"><strong>*</strong>(M.D.R.) Email: <a href="/cdn-cgi/l/email-protection#45282120372a362405232a2b21243f2c2a2b20372c2820216b262a28"><span class="__cf_email__" data-cfemail="92fff6f7e0fde1f3d2f4fdfcf6f3e8fbfdfcf7e0fbfff7f6bcf1fdff">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maria++De+Rosa">Maria De Rosa</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4087-2554" title="Orcid link">http://orcid.org/0000-0002-4087-2554</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Neha Singla</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Neha Singla</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biophysics, Panjab University, Chandigarh 160014, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Neha++Singla">Neha Singla</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gurpal Singh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gurpal Singh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UIPS, Panjab University, Chandigarh 160014, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gurpal++Singh">Gurpal Singh</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ravi P. Barnwal</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ravi P. Barnwal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biophysics, Panjab University, Chandigarh 160014, India</div></div><span class="conrtib-corresp"><strong>*</strong>(R.P.B.) Email: <a href="/cdn-cgi/l/email-protection#0d6f6c7f637a6c614d7d78236c6e236463"><span class="__cf_email__" data-cfemail="076566756970666b477772296664296e69">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ravi+P.++Barnwal">Ravi P. Barnwal</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3156-5357" title="Orcid link">http://orcid.org/0000-0003-3156-5357</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Ankur Pandey</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ankur Pandey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, Panjab University, Chandigarh 160014, India</div></div><span class="conrtib-corresp"><strong>*</strong>(A.P.) Email: <a href="/cdn-cgi/l/email-protection#93f2e3f2fdf7f6ead3e3e6bdf2f0bdfafd"><span class="__cf_email__" data-cfemail="c8a9b8a9a6acadb188b8bde6a9abe6a1a6">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ankur++Pandey">Ankur Pandey</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01833&amp;href=/doi/10.1021%2Facs.jmedchem.0c01833" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 4359–4395</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 7, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 October 2020</li><li><span class="item_label"><b>Published</b> online</span>7 April 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 April 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01833" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01833</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4359%26pageCount%3D37%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAkanksha%2BSharma%252C%2BMaria%2BDe%2BRosa%252C%2BNeha%2BSingla%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D8%26contentID%3Dacs.jmedchem.0c01833%26title%3DTuberculosis%253A%2BAn%2BOverview%2Bof%2Bthe%2BImmunogenic%2BResponse%252C%2BDisease%2BProgression%252C%2Band%2BMedicinal%2BChemistry%2BEfforts%2Bin%2Bthe%2BLast%2BDecade%2Btoward%2Bthe%2BDevelopment%2Bof%2BPotential%2BDrugs%2Bfor%2BExtensively%2BDrug-Resistant%2BTuberculosis%2BStrains%26numPages%3D37%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4395%26publicationDate%3DApril%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01833"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1068</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01833" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Akanksha&quot;,&quot;last_name&quot;:&quot;Sharma&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;De Rosa&quot;},{&quot;first_name&quot;:&quot;Neha&quot;,&quot;last_name&quot;:&quot;Singla&quot;},{&quot;first_name&quot;:&quot;Gurpal&quot;,&quot;last_name&quot;:&quot;Singh&quot;},{&quot;first_name&quot;:&quot;Ravi&quot;,&quot;last_name&quot;:&quot;P. Barnwal&quot;},{&quot;first_name&quot;:&quot;Ankur&quot;,&quot;last_name&quot;:&quot;Pandey&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;4359-4395&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01833&quot;},&quot;abstract&quot;:&quot;Tuberculosis (TB) is a slow growing, potentially debilitating disease that has plagued humanity for centuries and has claimed numerous lives across the globe. Concerted efforts by researchers have culminated in the development of various strategies to combat this malady. This review aims to raise awareness of the rapidly increasing incidences of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis, highlighting the significant modifications that were introduced in the TB treatment regimen over the past decade. A description of the role of pathogen–host immune mechanisms together with strategies for prevention of the disease is discussed. The struggle to develop novel drug therapies has continued in an effort to reduce the treatment duration, improve patient compliance and outcomes, and circumvent TB resistance mechanisms. Herein, we give an overview of the extensive medicinal chemistry efforts made during the past decade toward the discovery of new chemotypes, which are potentially acti&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01833&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01833" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01833&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01833" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01833&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01833" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01833&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01833&amp;href=/doi/10.1021/acs.jmedchem.0c01833" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01833" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01833" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01833%26sid%3Dliteratum%253Aachs%26pmid%3D33826327%26genre%3Darticle%26aulast%3DSharma%26date%3D2021%26atitle%3DTuberculosis%253A%2BAn%2BOverview%2Bof%2Bthe%2BImmunogenic%2BResponse%252C%2BDisease%2BProgression%252C%2Band%2BMedicinal%2BChemistry%2BEfforts%2Bin%2Bthe%2BLast%2BDecade%2Btoward%2Bthe%2BDevelopment%2Bof%2BPotential%2BDrugs%2Bfor%2BExtensively%2BDrug-Resistant%2BTuberculosis%2BStrains%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D8%26spage%3D4359%26epage%3D4395%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=291430" title="Infectious diseases">Infectious diseases</a>,</li><li><a href="/action/doSearch?ConceptID=292227" title="Drug resistance">Drug resistance</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/jmcmar.2021.64.issue-8/20210422/jmcmar.2021.64.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0032.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Tuberculosis (TB) is a slow growing, potentially debilitating disease that has plagued humanity for centuries and has claimed numerous lives across the globe. Concerted efforts by researchers have culminated in the development of various strategies to combat this malady. This review aims to raise awareness of the rapidly increasing incidences of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis, highlighting the significant modifications that were introduced in the TB treatment regimen over the past decade. A description of the role of pathogen–host immune mechanisms together with strategies for prevention of the disease is discussed. The struggle to develop novel drug therapies has continued in an effort to reduce the treatment duration, improve patient compliance and outcomes, and circumvent TB resistance mechanisms. Herein, we give an overview of the extensive medicinal chemistry efforts made during the past decade toward the discovery of new chemotypes, which are potentially active against TB-resistant strains.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32550" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32550" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Tuberculosis (TB), a fatal disease caused by <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>), is considered as one of the primary worldwide causes of death mediated by infectious disease along with human immunodeficiency virus (HIV) infection. According to the World Health Organization (WHO), in 2019, 10 million people were infected, and around 1.4 million people died from TB (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a><i>Mtb</i> is an intracellular parasite that spreads in the body via blood and the lymphatic system to the organs. This aerobic bacterium can spread through air and upon entry into a susceptible host can have different possible outcomes. The first possibility is its annihilation by the host immune response; alternatively, the bacteria may enter into a dormant stage leading to a latent TB infection. The third possibility is that the latent TB infection turns into an active TB infection.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> TB can be classified into various forms of the disease depending upon the symptoms and modes of action it exhibits: active, miliary, and latent.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Both active and miliary are considered as the agile/active forms of TB that rapidly invade organs. In particular, miliary TB is an extremely severe form of the disease in which a lesion of bacterial growth enters inside a vascular vessel leading to rapid infection. If it goes untreated, mortality rates could reach 100%.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The disease primarily affects the lungs but may spread to other organs, as seen in several cases.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5−7)</a> This chronic debilitating disease lasts for years in a latent stage, impeding its follow up and eradication.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. World map with incidences of TB in 2019 as provided by the WHO, grouped by region. Each region is represented by a different color, with the areas of highest incident being South East Asian countries and those of lowest incident being American countries. The map was generated using <a href="http://Mapchart.net" class="extLink">Mapchart.net</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The distribution of TB cases worldwide is not homogeneous, with the areas of highest incidence being in developing countries. TB is also classified as an opportunistic disease in immunosuppressed patients.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The drugs commonly used for the treatment of TB include isoniazid, rifampicin, pyrazinamide, and ethambutol, also known as first-line agents.</div><div class="NLM_p">Unfortunately, <i>Mtb</i> can quickly develop resistance to antimicrobial drugs and requires renewed efforts to overcome it. Multidrug-resistant (MDR) TB refers to infections caused by <i>Mtb</i> strains that have developed resistance to at least two of the first-line drugs, such as isoniazid and rifampicin.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> With MDR-TB accounting for 3.3% of new TB cases throughout the world,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> it remains a public health crisis and health security threat. The WHO estimates about 500 000 new cases of TB with resistance to rifampicin, the most effective first-line drug, in 2019, of which ∼78% exhibit MDR.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">Extensively drug-resistant (XDR) TB is a more severe form of MDR-TB whereby <i>Mtb</i> has developed resistance to strong first-line anti-TB drugs (isoniazid and rifampicin), beside fluoroquinolones, and to at least one of the three injectable second-line drugs, such as amikacin, capreomycin, or kanamycin.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Fluoroquinolones, commonly used for the treatment of drug-resistant TB, seem to have become a major contributory factor toward the development of XDR-TB.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">In addition to MDR- and XDR-TB, <i>Mtb</i> strains resistant to all the first- and second-line antibiotics have emerged; such strains are called totally drug-resistant TB (TDR-TB) strains.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> TDR-TB strains pose a serious threat to global efforts in (a) curbing the growing drug resistance and (b) controlling the spread of the disease. Several cases of TDR have been reported from India, which is a worrisome turn of events.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> A report by the WHO in 2020 revealed that 27% of the MDR or rifampicin-resistant (RR) TB cases were reported solely from India, which together with China and Russia account for half of the world’s cases. The treatment success rate is just 57% throughout the world.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">In recent years, the global TB incidence rate has been falling at a rate of 2% per year, although a 4–5% decline in the incidence rate was needed in order to reach the milestone set for 2020 under the End TB campaign. Nevertheless, it is the health target of the Sustainable Development Goals to eradicate this epidemic by 2030. WHO aims at curbing the spread of TB and associated forms of the disease, including MDR-TB and XDR-TB, with the End TB campaign beginning from 2016 to 2035,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> concordant to which an Indian National Strategic Plan 2017–2025 for TB elimination is currently in place. WHO provides extensive guidelines for drug-resistant TB prevention and treatment, at the national level, by means of National TB Programs (NTPs), and at the individual level.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p last">In this review, we give an overview of TB disease, its immunogenic response, disease progression, and medicinal chemistry efforts made over the past decade toward the identification of novel antituberculosis active ingredients against XDR-TB strains.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Involvement and Activation of the Immune System</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15438" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15438" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">TB being an infectious lung disease that is transmitted through air can easily cause an outbreak, especially in crowded areas. The primary infection begins with the inhalation of particles of <i>Mtb</i>. The mycobacterium is capable of staying inactive for long periods inside the body and causes disease when the host immune system is compromised.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> When TB bacilli are inhaled, they rapidly pass through the mouth, then the nose, and finally enter the smallest and lowermost parts of the airways, i.e., the terminal bronchioli and alveoli of the lung.</div><div class="NLM_p">Several cytokines, such as interleukins (IL), interferons (IFN), natural killer (NK) cells, tumor necrosis factor (TNF), and CD4+ T-cells, work in synergism to control the <i>Mtb</i> organism in the body as the disease is well-known to spread to organs such as the bones, eyes, lymph nodes, abdomen, meninges, skeletal system, central nervous system (CNS),<a onclick="showRef(event, 'ref6 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref6 ref17 ref18">(6,17,18)</a> and kidneys.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The spread of TB to organs other than the lungs is generally referred to as extrapulmonary tuberculosis (EPTB). EPTB is especially common in people suffering from HIV and among children.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The development of the disease may be active<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> or latent.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The symptoms of the active form are a cough lasting for more than 3 weeks, blood or sputum expulsion while coughing, pain in the chest, fever, weight loss, excessive sweating at night, and hemoptysis.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> While the latent form of the disease is asymptomatic, some abnormalities associated with the disease include thoracic lymphadenopathy and lung cavities.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Other symptoms include abnormalities in chest radiography.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p">Since <i>Mtb</i> initially infects the lungs, the alveolar macrophages and dendritic cells (DCs) are the first ones to come into effect. These cells phagocytose the pathogen to limit the spread of infection.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The dendritic cells serve as a link between innate and adaptive immune responses and, along with the phagocytosed pathogen, migrate toward the lymph node from the site of infection: this is essentially the first step toward mounting of an immune response against the pathogen.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> These cells promote differentiation of naïve T-cells into cytotoxic T-cells (T<sub>C</sub>) and helper T-cells (T<sub>H</sub>).</div><div class="NLM_p">Activation of T-cells is an indication of successful invasion of the host by the bacterium, as these cells are the mediators of the adaptive immune response that comes into play when the innate immunity barriers are breached. T-cells form an important part of immunity against TB.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The activation of T<sub>H</sub> cells, also called CD4<sup>+</sup> cells, is followed by cytotoxic T-cells (CD8<sup>+</sup> cells), as shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. These cells are initially triggered in the pulmonary lymph nodes. T-cells then migrate to the infection site.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> DCs and macrophages present the antigen to T-cells in association with the major histocompatibility complex (MHC) type I and II.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> CD4<sup>+</sup> T-cells further produce IFN γ and TNFs that activate phagocytes to kill the pathogen residing in the cell, thus defending the host.<a onclick="showRef(event, 'ref28 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref30">(28,30)</a> Stimulation of naive CD4<sup>+</sup> cells by IL-2 leads to their differentiation into effector cells, thus secreting granzyme B and perforin proteins.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Inflammation onset in the host body is the result of production of IL-17 and IL-23. In TB-affected individuals, IL-22 is also commonly detected. Humoral immunity involving the production of antibodies by B-cells is also triggered, and this process has been studied to upregulate the innate and cell-mediated immune response.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> People suffering from MDR-TB are predicted to have higher counts of NK cells and T-cells of the γδ type, pointing toward suppression of the immune response and contributing to high drug resistance.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Moreover, the bacterium harbors drug efflux systems for effectively driving the drug out of the cell, ensuring its survival. The pathogen possesses enzymes such as β-lactamases capable of chemically modifying the drugs and nullifying their effects.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Immune system activation in response to <i>Mtb</i> infection. As soon as <i>Mtb</i> infects the lungs, innate and adaptive immune systems are activated. The disease progresses to either latent or active TB. Macrophages, neutrophils, γδ T-cells, and NK cell-mediators of innate immunity along with T-cells of adaptive immunity attempt to kill the pathogen by different mechanisms. CD4<sup>+</sup> T-cells regulate cytokine levels; CD8<sup>+</sup> T-cells, NK cells, and γδ T-cells secrete IFN-γ, a crucial step in activating macrophages to engulf the bacteria and resulting in phagolysosome formation and ultimately in killing the bacteria.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The figure was made using <a href="http://Biorender.com" class="extLink">Biorender.com</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3.  Disease Progression</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30706" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30706" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">TB infection manifests in four different stages: (I) the initial macrophage response; (II) the growth stage; (III) the immune control stage; and (IV) the lung cavitation stage. These four stages occur over a span of approximately 30 days. Stage I begins with the introduction of the TB bacillus into the body via inhalation. Once the bacillus reaches the pulmonary alveoli, macrophages recognize and engulf these target cells. Macrophages are usually present within the alveolar tissue and play an important role in swallowing and inactivating any foreign object entering the alveolar space. These events depend in large part on the density of TB bacilli introduced in the body and on the intensity of the immune response by the macrophages. Large quantities of TB bacilli or weak macrophages could allow the bacilli to replicate in the macrophages. The parent and the surrounding macrophages, which attempt to engulf the continuously replicating TB bacilli, are ultimately destroyed. If the alveolar macrophages fail to contain the TB bacillus replication in stage I, the TB infection enters stage II, after about 1 week. During this phase, the TB bacilli start reproducing exponentially, leading to two new microorganisms for every initial bacillus, thus causing a rapid amplification of the initial infecting TB bacillus and making macrophages incapable of containing those. Stage II lasts until the third week from the initial infection. At the end of stage II, the bacilli cease this exponential growth, thereby marking the beginning of stage III, where bacilli growth and destruction by macrophages are equitable. During phase III, the body produces more immune cells to stabilize the infection sites, in an attempt to control the spread of infection. In most of the cases, the disease progression ends at stage III (for at least 9 out of 10 patients infected), and affected patients no longer show any symptoms or physical signs of active disease. The TB bacilli and macrophages develop a circular complex in the lungs, namely, a Ghon focus, with the TB bacilli and infected macrophages localized at the core, and enveloped by healthy macrophages.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Often, TB bacilli may invade the vicinal lymph nodes. The TB bacilli can survive within the macrophages for years even though the lung tissue itself can shield them. These are deemed noncontagious infections: the TB bacilli cannot be coughed out or exhaled and are thereby restricted from entering the airways to spread the infection. If the immune mechanisms of the patient are strong, the primary complex heals and leaves only a small cavity, or in the worst cases, generates a scar in the tissue visible on X-rays. However, about 5% of such cases do not recover from stage III as the primary complex does not heal, therefore leading to stage IV. During this phase, the TB bacilli reactivate after a period of 12–24 months from the initial infection and begin rapid reproduction; a cavity develops in the tissue where the body’s immune system cannot respond effectively against the infection. The TB bacilli quickly spread through this cavity into the surrounding tissues, and finally the patient develops signs and symptoms of active TB, majorly manifesting as cough. At this stage, the infection is highly contagious as active TB bacteria can spread to other people via sputum. Apart from the failed recovery of stage III, reactivation can also occur if the immune system is weakened by other comorbid conditions, such as HIV infection or malnutrition.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">4.  Factors Responsible for Disease Transmission</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36810" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36810" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">TB presents a strong association with multiple socioeconomic factors, such as malnutrition, alcohol abuse, drug abuse, tobacco consumption, and social inequality. Alcohol consumption strongly correlates with the development of the infection since it affects the immune system. In fact, it disrupts T-cell and B-cell functionality and affects cell signaling pathways.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Extensive literature, for example, links poverty and tobacco use to incidents of TB.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> In the past few years, the impact of tobacco smoking and burning of biomass has been found to contribute prominently to the rising global incidents of TB.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The majority of TB cases are in low or intermediate income countries, where tobacco use, HIV infection, and AIDS are the most common factors linked to incidents of TB. Similarly, faulty treatment is the prime cause for the spread of MDR-TB globally. Further, XDR-TB is the result of improper treatment of MDR-TB.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Transmission of drug-resistant (DR) TB is generally due to poor disease treatment, low compliance, or direct contact of the infected individual with uninfected ones.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a> However, several other factors responsible for aggravating the problem include a lack of resources, negligence, and inadequate treatment.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> In addition, nosocomial transmission of the disease, chiefly responsible for MDR-TB, is very commonly seen.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Health care workers are highly vulnerable to the disease, especially the drug-resistant form of bacterium, due to their constant exposure to TB patients.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Moreover, high drug resistance is common in patients having the comorbidity of HIV/AIDS. HIV infections contribute to spread of MDR-TB by making the individual more susceptible to this disease.<a onclick="showRef(event, 'ref42 ref47'); return false;" href="javascript:void(0);" class="ref ref42 ref47">(42,47)</a></div><div class="NLM_p">Droplets generated due to coughing, sneezing, speaking, and shouting carry the pathogens, which on being inhaled by a susceptible individual may cause the disease (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Persons with severe lung TB may emit more droplets due to persistent coughing. Children less than 5 years of age and individuals with HIV infections are susceptible to develop the disease.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The frequency of communication between infected and susceptible individuals greatly influences the TB transmission. Determining the transmission is difficult since the infection is mostly latent and the period for its development into active disease varies among individuals. Proximity is known to increase the chances of infection.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> In a study, it has been reported that close contacts are at a greater risk of getting infected, and the infection may develop into disease within a year or so.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Transmission of tuberculosis from infected to healthy individuals. Coughing, sneezing, and speaking/shouting generate aerosols, which remain suspended in the air and infect healthy individuals. The figure was made using <a href="http://Biorender.com" class="extLink">Biorender.com</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Even though <i>Mtb</i> is the causative agent of tuberculosis in humans, it can also be caused due to <i>M</i>. <i>bovis</i> infection leading to bovine TB, which in turn gives rise to zoonotic TB in humans. Bovine TB spreads principally due to close contact with infected cattle, consumption of unpasteurized and contaminated milk, and other dairy products.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, there are several other risk factors aggravating the spread.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Routes of transmission of zoonotic TB in humans. Zoonotic TB arises from transmission of bovine TB from infected cattle and wildlife to people who come into close contact with such animals. The mode of transmission includes the consumption of unpasteurized dairy products and uncooked meat. It is known to spread via the fecal–oral route, through blood transfusion, and via transmission from mother to child during pregnancy. The figure was made using <a href="http://Biorender.com" class="extLink">Biorender.com</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">5.  Detection and Diagnosis</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38124" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38124" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Tuberculosis continues to be a major health problem worldwide, affecting millions of people each year. Hence, antibiotic susceptibility testing (AST) is essential for detecting prevalence of drug resistance among <i>Mtb</i> isolates.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> However, this testing approach is time-consuming and requires about 12 weeks for detecting drug-resistant isolates on Lowenstein–Jensen (LJ) media.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> On the other hand, current modern methods for diagnosis exhibit swift results but are either inaccurate or take too long to be definitive. Thus, there is no particular paradigm for TB detection, and no single test can detect all the mutations responsible for TB resistance to drugs.</div><div class="NLM_p">The current routine diagnostic tests for TB such as chest X-rays, tissue culture, tuberculin skin test (TST), and acid-fast staininghave some limitations. A chest X-ray alone is inconclusive; a tissue culture takes too long to produce a result; the TST lacks specificity and reliability; and acid-fast staining depends on a large number of bacteria in the sputum to give an accurate reading. Serological tests using different TB antigens to detect <i>Mtb</i> infection are fast but lack the desired sensitivity. Studies have demonstrated that patients previously immunized with the Bacillus Calmette–Guérin (BCG) vaccine might also test positive for this disease, which is endorsed by the tuberculin test, discovered in 1890 by Robert Koch.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div><div class="NLM_p">Of late, new methods have been developed, such as nucleic acid amplification technology, which, although specific, can yield false-positive results.<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55,56)</a> Immunological tests (QuantiFERON and T-SPOT.TB), measuring the production of IFN-γ by TB-specific T lymphocytes after encountering <i>Mtb</i> antigens, have certain advantages over conventional tests. GeneXpert is a cartridge-based nucleic acid amplification test (NAAT) recommended by the WHO for early diagnosis of TB and for AST to determine resistance to rifampicin in a very short duration of time.<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57,58)</a> Moreover, whole-genome sequencing has further opened ways to distinguish virulent from nonvirulent strains<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> as it aids in identification of the organism’s genotype.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> However, the need remains for a cost-effective, accurate, and rapid method of diagnosing both active and latent TB infections.</div><div class="NLM_p">In order to identify individuals with XDR-TB and tackle it, development of sensitive diagnostic kits or markers is the need of the hour. The development of new drugs would be aided if comprehensive data regarding drug resistance patterns with respect to complete gene analysis are collected from various regions of the world. Furthermore, comparisons of this trend with regard to therapeutic drug monitoring and adverse event assessment are other important factors to consider, before designing or developing drugs against XDR-TB. Recently, whole-genome sequencing has gained immense attention in the scientific community, and the TB-Profiler Web server has gained recognition as a reliable tool for the management of this consumptive disease.<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60,61)</a> Globally, people have considered this profiling as a portable, cost-effective and rapid detection tool to analyze drug resistance. To gain success in the field of XDR-TB, data related to epidemiological studies with respect to patient compliance, drug-susceptibility testing, treatment duration, and treatment outcome need to be carefully recorded, monitored, and analyzed at a global level.</div><div class="NLM_p">The lack of proper methodologies for the diagnosis of TB makes its management difficult in areas where it is endemic. Many of these methodologies are either time-consuming or expensive, and often the sensitivity is very low. To overcome this problem, antibody-based biomarkers can serve as effective tools. Because of their high sensitivity and specificity, these can be used for detection and diagnosis of TB. One such biomarker is mannose-capped lipoarabinomannan (Man-LAM) found among body fluids such as urine, blood, and sputum of TB patients.<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62,63)</a> Man-LAM is a glycolipid, which is found in the mycobacterial cell wall, crucial for entry and survival of <i>Mtb</i> inside phagocytes and for regulation of immune responses of the host; hence, it can be targeted for clearance by the host immune system.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Indeed, an antibody, My2F12, specific to this glycolipid biomarker has been characterized and utilized for the development of a diagnostic test for TB.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><div class="NLM_p">Detection of EPTB is also very difficult. Different sites of the body including the central nervous system (CNS), lymph nodes, and urogenital system are affected by this disease (shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), TB lymphadenitis being the most common among all the EPTB cases.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> The diagnosis involves biopsy and examination of body fluids. NAAT-based tests such as Xpert MTB/RIF with very high sensitivity and specificity seem to be extremely helpful in EPTB diagnosis.<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67,68)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Extrapulmonary tuberculosis in humans. <i>Mtb</i> affects the central nervous system, causing TB meningitis; infection of lymph nodes leading to lymphadenitis and peritonitis, abdominal TB; urogenital system, causing renal TB; skeletal TB manifests in bone and joint TB and Pott’s disease. The figure was made using <a href="http://Biorender.com" class="extLink">Biorender.com</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">6.  Prevention Programs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38472" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38472" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The spread of TB cannot be completely prevented; however, the BCG vaccine imparts protection to the infection in infants.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> BCG is a live vaccine prepared from a strain of weakened <i>M. bovis</i>. BCG is currently the only licensed vaccine against TB and has been in use since 1921. It is one of the most widely used vaccines worldwide and is the most effective in preventing the spread of <i>Mtb</i> infection.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> A person with infectious tuberculosis can infect up to 10–15 other people per year.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Once diagnosed with TB and started on treatment with antibiotics, the majority of patients are no longer infectious after 2 weeks of starting the medication,<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> thereby limiting the spread of TB.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Malnutrition worsens the immune response against TB, while a healthy immune system is the best form of defense against TB. Therefore, encouraging people to take immunity boosters and food ingredients that elevate the levels of immune bodies in the blood and the lymphatic system are other steps for active defense against the disease.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> To overcome and completely eradicate TB from its regions, several countries have launched specific programs for prevention, which propose to eliminate TB by 2035.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Many countries have drafted timelines for TB elimination, and many others provide access to TB treatment without any cost.<a onclick="showRef(event, 'ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref76 ref77">(76,77)</a></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">7.  Chronology of Tuberculous Chemotherapy and Treatment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00703" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00703" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the late 19th century, a technique called thoracoplasty was brought into use for the treatment of pulmonary TB as it helped reduce the thoracic cavity volume and collapsed the tuberculous cavities. Thoracoplasty was forsaken after the introduction of antituberculous drugs.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a><a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> depicts the first- and second-line drugs for TB treatment.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) First- and (b) second-line drugs used for TB treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It was not until the mid-1900s that the first anti-TB drug, streptomycin (<b>1</b>), was introduced.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Its discovery was soon followed by resistance in bacterial strains found to be mainly due to a mutation in the <i>rpsL</i> gene.<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80,81)</a> Although <i>p</i>-amino salicylic acid (<b>2</b>) was developed before streptomycin, it was introduced a couple of years later, and just three years after its discovery, rapid development of resistance was noted.<a onclick="showRef(event, 'ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref82 ref83">(82,83)</a> Trials by the British Medical Research Council (BMRC) led to an axiom of tuberculous chemotherapy to never treat an active TB with a single agent. Indeed, when streptomycin and <i>p</i>-amino salicylic acid were used in combination, a reduction in occurrence of drug resistance was observed as compared to their use alone.<a onclick="showRef(event, 'ref80 ref84'); return false;" href="javascript:void(0);" class="ref ref80 ref84">(80,84)</a> A few years later, in 1952, a new drug, isoniazid (<b>3</b>), was introduced which was known to be far better than other drugs owing to its effectiveness, safety, and inexpensiveness. Despite the great success, there were cases of resistance developing due to mutations in several <i>Mtb</i> genes such as <i>katG</i> and <i>inhA</i>.<a onclick="showRef(event, 'ref80 ref85'); return false;" href="javascript:void(0);" class="ref ref80 ref85">(80,85)</a> Thereafter, several other drugs were discovered, but the introduction of rifampicin (<b>4</b>) marked a keystone in TB therapeutics. The use of rifampicin in combination with isoniazid and ethambutol (<b>5</b>) shortened the therapy to nine months and improved cure rates. However, mutations in the <i>rpoB</i> gene were soon observed to cause resistance to rifampicin. Pyrazinamide (<b>6</b>) was found to be noxious when used in first-line therapeutics, but administration of a low dose was found to further shorten the course of therapy.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></div><div class="NLM_p">The combination of four first-line drugs (isoniazid, pyrazinamide, rifampicin, and ethambutol) has been in use for 40 years now and has enabled favorable results in tuberculous therapy.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> However, recent studies have shown that this four-drug treatment makes <i>Mtb</i> more susceptible to become drug-resistant in immunocompromised individuals.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Second-line drugs, such as fluoroquinolones (ciprofloxacin (<b>7</b>), gemifloxacin (<b>8</b>), and moxifloxacin (<b>9</b>)),<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> kanamycin (<b>10</b>), capreomycin (<b>11</b>), and viomycin (<b>12</b>) are a part of successful therapeutic regimens for treating MDR-TB. However, inadequate, incomplete, or poor treatment has led to XDR-TB, wherein the bacterial strain is not only resistant to isoniazid and rifampicin, as in the case of MDR-TB, but also to fluoroquinolones and at least to one of the three injectable second-line drugs (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> This detrimental condition was first discovered in 2006 during the Tugela Ferry outbreak and brought worldwide attention to TB drug resistance.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></div><div class="NLM_p">Resistance patterns and specificity are important factors considered in selecting a drug for the treatment.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Drug-susceptible TB is treated by the Directly Observed Treatment, Short-course (DOTS) strategy, recommended by the WHO. The DOTS strategy involves oral administration of different anti-TB drugs, such as rifampicin, isoniazid, pyrazinamide, ethambutol, and streptomycin (also known as B first-line drugs) for a period of six months. Patient compliance is very important in this regard, and patients must take the medicines on a regular basis even if they begin feeling better. This helps curb increasing drug resistance (DR).<a onclick="showRef(event, 'ref90 ref91'); return false;" href="javascript:void(0);" class="ref ref90 ref91">(90,91)</a></div><div class="NLM_p">Treatment of DR-TB is very difficult, with a success rate at around 56%,<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> which is compounded by increasingly ineffective antibiotics. MDR-TB is treated using one of the second-line anti-TB drugs in combination with a fluoroquinolone,<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> with the treatment lasting for a minimum of 18 months. A combination therapy consisting of at least 5–6 drugs seems to be the only way out in the longer run.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Further, for controlling XDR-TB, the biggest challenge is the limited availability of drugs, which leaves very few options for effective treatment. Contemporary <i>in vitro</i> studies show disulfiram and diethyldithiocarbamate (DDC) to be potential agents against XDR-TB.<a onclick="showRef(event, 'ref95 ref96'); return false;" href="javascript:void(0);" class="ref ref95 ref96">(95,96)</a> Another promising candidate is the antipsychotic drug thioridazine<a onclick="showRef(event, 'ref97 ref98'); return false;" href="javascript:void(0);" class="ref ref97 ref98">(97,98)</a> which has indicated high efficiency in combination with first-line anti-TB drugs. However, these drugs are not yet available for TB patients. Moreover, studies have demonstrated that people with both HIV and TB have poor prognosis due to suppression of the immune system by the HIV virus, which is further exacerbated by MDR- and XDR-TB.<a onclick="showRef(event, 'ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref99 ref100">(99,100)</a> Recently, diabetes mellitus (DM) was identified as another threat, which worsens TB treatment outcomes due to impairment of the immune system caused by homeostatic insulin–glucose imbalance.<a onclick="showRef(event, 'ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref101 ref102">(101,102)</a> Unfortunately, drugs used for TB treatment show considerable hepatotoxicity.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><div class="NLM_p last">Because of the various complexities of therapeutics, WHO and the International Union against TB and Lung Diseases (The Union) proposed a strategy having the combination of at least two B first-line drugs in single dosage forms. These new dosage forms were termed fixed dose combinations (FDC). An overview of case studies from 2016 showed that an estimated 490 000 people globally contracted MDR-TB in that year. The root cause of continued multidrug resistance is negligent TB treatment and subsequent infection spreading from person to person. In particular, drug resistance develops because of the inappropriate use of anti-TB drugs (single-drug regimen and poor-quality medicines) and premature interruption of the treatment regimen.<a onclick="showRef(event, 'ref104 ref105'); return false;" href="javascript:void(0);" class="ref ref104 ref105">(104,105)</a></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">8.  Drug Resistance</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36552" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36552" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Drug resistance can be primary or acquired due to several factors that contribute to drug resistance among <i>Mtb</i> isolates including the impenetrability of the cell wall to antibiotics,<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> mutations in <i>Mtb</i> genes,<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> and <i>Mtb</i> efflux pumps,<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> to name a few. Acquired drug resistance constitutes the selection of genetic mutants, deriving from substandard treatment or inefficiency in adherence to prescriptions by the patient.<a onclick="showRef(event, 'ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref109 ref110">(109,110)</a> Moreover, recent studies showed that induction of the mycobacterial drug efflux pump that affects pharmacokinetic–pharmacodynamic variability scenarios is responsible for the development of genetic mutations in <i>Mtb</i>.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Resistance to each drug seems to be independent of other drugs and occurs one at a time through unlinked processes, thereby leading to a stepwise accumulation of resistance to various drugs.<a onclick="showRef(event, 'ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref112 ref113">(112,113)</a> Several strains responsible for drug resistance do not seem to harbor any mutations in their genome, which further complicates the situation.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div><div class="NLM_p">To examine how the efflux of drugs mediated by efflux pumps confers drug resistance and to examine the redundancy of their functions, Balganesh et al. compared the sensitivities of wild-type (WT) <i>Mtb</i> isolates with four efflux pump knockout mutants (KO).<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> The resistance of MDR/XDR <i>Mtb</i> isolates to spectinomycin is due to the upregulation of the efflux pump Rv1258c.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Deletion of this transporter is associated with reduced resistance to spectinomycin.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></div><div class="NLM_p">Spectinomycin is a well-known inhibitor of bacterial protein synthesis,<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> but its efficacy against TB infections is relatively poor. However, it is ideal for use due to exhibiting very low toxicity and minor side effects.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Semisynthetic analogues of this drug, called spectinamides were designed against <i>Mtb</i>. The spectinamides are strong ribosomal inhibitors and evade efflux by <i>Mtb</i> for attaining good efficiency <i>in vivo.</i> In the studies carried out, it was observed that these spectinamides maintain their activities against a variety of <i>Mtb</i> isolates, including drug-susceptible and drug-resistant (MDR and XDR) forms. Further, antibacterial activity was observed specifically against the <i>Mtb</i> strains used for the study along with a few other pathogenic species from the genus <i>Mycobacterium</i> such as <i>M</i>. <i>marinum</i> and <i>M</i>. <i>ulcerans</i>, but not against other Gram-positive or Gram-negative bacteria. Since the spectinomycin binding site is conserved in bacteria, the results highlighted poor retention or active efflux of the drug as the major reason for its inactivity in various bacterial species.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Similarly, Rv1218c, an ABC transporter, is also involved in arbitrating efflux in <i>Mtb</i>. An Rv1218c knockout mutant of <i>Mtb</i> exhibited a 4–8-fold increase in bactericidal and inhibitory activities of several different classes of compounds, thus suggesting its role in antibiotic resistance.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></div><div class="NLM_p">Drug resistance seems to develop more readily in people who live in a country with already high incidences of TB. A person infected with TB may develop resistance due to inadequate treatment and then transmit drug-resistant TB.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Four types of drug resistance are known in the literature for <i>Mtb</i> based on the kind of drug the pathogen has developed resistance to, as shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> In particular, there are high rates of resistance to the first- and second-line anti-TB drugs mentioned in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Classifications of drug-resistant TB: Four main types of drug-resistant TB are known so far which occur by mutually exclusive mechanisms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Spontaneous genetic mutations in the bacterial genome leading to drug resistance are a serious cause of concern.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Long-term exposure to a drug gives an opportunity for the bacteria to develop resistance to that particular drug; thus, a combinatorial treatment of at least two drugs acting via different molecular mechanisms and preferably on different targets is always recommended in order to severely reduce the chances for drug resistance.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Ongoing research in the field is focused on developing new drugs to treat resistant forms of the bacterium. Together with that, a better understanding of mechanisms of drug resistance and its impacts would be of help in treating the disease and in vaccine or drug development.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> lists the genes causing resistance to the drugs used in the current treatment. MDR-TB involves resistance to at least two first-line drugs, such as isoniazid and rifampicin, and effective treatment thereof requires second-line anti-TB drugs such as fluoroquinolones, which are found to be the most effective drugs in MDR-TB regimens despite their toxic effects.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Genes responsible for drug resistance to first and second-line anti-TB regimens<a onclick="showRef(event, 'ref85 ref109'); return false;" href="javascript:void(0);" class="ref ref85 ref109">(85,109)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Isoniazid (<b>3</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) enters the <i>Mtb</i> cell as a prodrug by passive diffusion,<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> which is activated by the catalase-peroxidase (KatG) enzyme in <i>Mtb</i>. The <i>katG</i> gene thus serves as an important site for mutations giving rise to isoniazid resistance.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> The KatG enzyme activates isoniazid by means of peroxidation to produce reactive isoniazid species. Oxidants such as superoxide and hydrogen peroxide promote this oxidation process.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> KatG activates isoniazid by production of a variety of oxygen-, carbon-, and nitrogen-based free-radical species.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> It seems that nitric oxide scavengers can protect against NO<b><sup>•</sup></b> free-radicals formed from isoniazid, as a result of oxidation by KatG.<a onclick="showRef(event, 'ref130 ref131'); return false;" href="javascript:void(0);" class="ref ref130 ref131">(130,131)</a></div><div class="NLM_p">On the other hand, rifampicin (<b>4</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) acts against growing as well as nongrowing <i>Mtb</i>.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Rifampicin binds the RNA polymerase β subunit, thus preventing elongation of mRNA.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> The β subunit of RNA polymerase is encoded by the gene <i>rpoB</i>. Studies have confirmed that about 95% of the <i>Mtb</i> strains resistant to rifampicin have mutations in a region of the gene <i>rpoB</i>, which is termed “rifampicin resistance determining region”. Most of these mutations that cause resistance to rifampicin are single nucleotide substitutions, among which the Ser<sup>531</sup>Leu mutation was the most commonly reported. Point mutations were also observed in the His<sup>526</sup> codon.<a onclick="showRef(event, 'ref133 ref134 ref135'); return false;" href="javascript:void(0);" class="ref ref133 ref134 ref135">(133−135)</a> Substitution of the conserved residues of <i>rpoB</i> gene responsible for rifampicin resistance leads to conformational changes in the drug, ultimately resulting in its defective binding.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a><i>Mtb</i> strains resistant to rifampicin are also usually resistant to other drugs such as isoniazid.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a></div><div class="NLM_p">The drug pyrazinamide (<b>6</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) shortens TB treatment by three months and is known to effectively target replicating and nonreplicating forms of the pathogen.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> It effectively targets latent <i>Mtb</i> in low pH environments arising during inflammation, which is not achievable by the use of other drugs.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Pyrazinamide is an essential first-line drug which is also used as second-line therapy for treatment of MDR-TB, with encouraging results in most patients.<a onclick="showRef(event, 'ref139 ref140'); return false;" href="javascript:void(0);" class="ref ref139 ref140">(139,140)</a> Pyrazinamide is available as a prodrug and is converted into pyrazinoic acid (POA) by the <i>Mtb</i> enzyme pyrazinamidase (PZase). The <i>in vitr</i>o activity of the drug is observable at low pH.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> It is known to enter the bacterial cell through passive diffusion and gets converted into POA, which is pumped out of the cell by passive diffusion and poor efflux mechanisms of <i>Mtb</i>. Outside the cell, in acidic conditions, some POA is converted to its protonated form (HPOA), which freely passes through the cell membrane. The influx of POA facilitated by low pH overcomes the POA efflux, thus leading to accumulation of POA inside the cell. Proton accumulation resulting from buildup of HPOA inside the cell can cause acidification of the cytoplasm, thus leading to inhibition of vital enzymes.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> The clinical isolates of <i>Mtb</i> resistant to pyrazinamide lose enzyme activity due to mutations in the gene <i>pncA</i> that encodes PZase.<a onclick="showRef(event, 'ref143 ref144'); return false;" href="javascript:void(0);" class="ref ref143 ref144">(143,144)</a></div><div class="NLM_p">Ethambutol (<b>5</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) is among the five first-line drugs used against TB and is used in combination therapy. This drug targets Emb proteins, encoded by <i>embCAB</i> genes, which are arranged as an operon code for arabinosyltransferase, involved in synthesis of arabinogalactan (AG), an important cell wall component.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> The arabinosyltransferase complexes are formed from heterodimeric EmbB-EmbC and homodimeric EmbC. Both are linked with two copies of acyl carrier protein AcpM.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Ethambutol is found to bind in the conserved active site of EmbB and EmbC. Mutations of these proteins were observed in resistant strains.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></div><div class="NLM_p">Ethionamide is a second-line anti-TB thioamide drug, similar in structure to isoniazid. It targets mycolic acid synthesis, which is an important component of the cell envelope.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> The mutation of serine 94 to alanine in <i>inhA</i> (the gene encoding the InhA enoyl-acyl ACP reductase) makes <i>Mtb</i> resistant to ethionamide as well as to isoniazid.<a onclick="showRef(event, 'ref149 ref150'); return false;" href="javascript:void(0);" class="ref ref149 ref150">(149,150)</a> Previous research has shown that enhanced expression of <i>ethA</i>, a gene that codes for the EthA monooxygenase, increased sensitivity of the bacterium to ethionamide in <i>M</i>. <i>smegmatis</i>.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Ethionamide is oxidized to ethionamide sulfoxide by monooxygenase. It is a crucial step for activation of ethionamide, followed by the formation of nitrile, benzamide, and ultimately 2-ethyl-4-amidopyridine. This step is further followed by the release of the nicotinamide adenine dinucleotide (NAD) adduct. The newly formed adduct inhibits InhA, which ultimately causes cell death.<a onclick="showRef(event, 'ref152 ref153 ref154'); return false;" href="javascript:void(0);" class="ref ref152 ref153 ref154">(152−154)</a> This process is regulated negatively by the repressor EthR since it controls the production of EthA.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a></div><div class="NLM_p">Several efforts to inhibit EthR have been made, such as by the synthesis of ketone-based ligands to boost EthA transcription for the activation of ethionamide. One of these ligands, benzylacetone, exhibited bacteriostatic activity when administered along with a low dose of ethionamide. No such effect was observed in the absence of ethionamide, which suggests strong synergy with the drug. Another inhibitor of EthR, BDM31343, when coadministered with a low dose of ethionamide also showed antimycobacterial activity.<a onclick="showRef(event, 'ref155 ref156'); return false;" href="javascript:void(0);" class="ref ref155 ref156">(155,156)</a> Recently, a compound SMARt-420 from the spiroisoxazoline family was able to de-repress an alternative pathway for ethionamide bioactivation by targeting a transcriptional regulator, EthR<sub>2</sub>. SMARt-420 successfully restored resistance to ethionamide in isolates with mutated EthA by evading the EthA-dependent ethionamide activation.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Further studies were carried out by comparing the bioactivation by EthA and EthA<sub>2</sub> for 18 ethionamide analogues in order to determine substrate specificity of both enzymes.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a></div><div class="NLM_p last">Pretomanid (<b>15</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), also referred to as PA-824, is an anti-TB drug able to inhibit replicating and nonreplicating <i>Mtb</i>.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Together with delamanid, these represent the only two novel classes of compounds, which have been clinically approved for use against TB in the past 50 years.<a onclick="showRef(event, 'ref160 ref161'); return false;" href="javascript:void(0);" class="ref ref160 ref161">(160,161)</a> Treatment of the bacterium with PA-824 interferes with mycolic acid synthesis by reducing the levels of ketomycolates while promoting accumulation of hydroxymycolic acid.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> A combination treatment of pretomanid and moxifloxacin has been evaluated in clinical trials against TB infections, keeping in mind the promising results obtained against drug-resistant and -susceptible <i>Mtb</i> isolates using other drug combinations.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> The outcome of the studies using an <i>in vitro</i> strategy also highlighted that interaction between both drugs has an additive effect on different phases of the pathogen’s growth and synergic pharmacodynamics.</div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">9.  Molecular <i>Mtb</i> Drug Targets</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47152" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47152" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Developing novel drugs against <i>Mtb</i> is challenging for several reasons. For example, slow metabolism of the pathogen can lead to moderate replication, which is responsible for latent infections. In addition to this, the mycobacterial cell wall is relatively thick and impermeable. Further, pathogenic bacteria have evolved several effective mechanisms to negate host defenses, such as the function of efflux pumps to flush out the antibiotics administered to the host. The efflux of drugs using these pumps is also a major contributing factor to increased DR.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> All together, these factors lead to the lack of an effective treatment.<a onclick="showRef(event, 'ref165 ref166'); return false;" href="javascript:void(0);" class="ref ref165 ref166">(165,166)</a></div><div class="NLM_p">The impermeable mycobacterial cell wall is a primary line of defense against host immune responses. The outer layer is composed of peptidoglycan (PG), which is synthesized via a complex multistep process by ATP-dependent enzymes called Mur ligases, present in most bacterial pathogens. Keeping in mind their importance and the presence of conserved regions, these enzymes can be targeted for drug development. The X-ray crystallographic structure of a Mur protein of <i>Mtb</i> has already been reported.<a onclick="showRef(event, 'ref167 ref168'); return false;" href="javascript:void(0);" class="ref ref167 ref168">(167,168)</a></div><div class="NLM_p">Synthesis of mycolic acids is also vital for maintaining the cell wall integrity and for the survival of the microorganism.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> Mycolic acids are long cyclopropanated fatty acids and serve as a major energy source while the pathogen is invading a host system. The enzyme system involved in fatty acid synthesis is called fatty acid synthase (FAS). Two FAS types (I and II) are known, with the latter being prevalent among bacteria. Hence, this system is validated as an antibacterial drug target.<a onclick="showRef(event, 'ref170 ref171'); return false;" href="javascript:void(0);" class="ref ref170 ref171">(170,171)</a> InhA is a recently discovered target and has been found to be a component of the FAS type II class of enzymes.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a></div><div class="NLM_p">The polyketide synthase enzyme (Pks13) is essential for lipid and mycolic acid biosynthesis in <i>Mtb</i> and is also an important constituent of the bacterial cell wall. A compound TAM16 that disrupts Pks13 has been identified (<b>14</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>C).<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Molecular interactions between protein–drug seen in the <i>Mtb</i> targets. (A) A complex consisting of <i>Mtb</i> ATP synthase F<sub>0</sub> rotor ring in association with the drug bedaquiline <b>13</b> (shown in yellow); a detailed view of the residues (shown in orange) involved in the interaction between the drug and the enzyme is shown in the box (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4V1F">4V1F</a>). (B) Structure of the <i>Mtb</i> polyketide synthase 13 and its inhibitor TAM 16 (5V8) (<b>14</b>) (shown in red) along with a sulfate molecule (shown in magenta) (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V3Y">5V3Y</a>). (C) Crystal structure of <i>Mtb</i> DNA gyrase and fluoroquinolone <b>9</b>: interaction with magnesium ions, water molecules, and gyrase subunits are shown in the box (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5BS8">5BS8</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Alanine racemase enzyme, present in the <i>Mtb</i> bacterium, is another important target for drug development along with metabolic pathways of peptidoglycan formation, arabinogalactan and lipoarabino-mannan syntheses.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> The inhibition of the biosynthesis of essential amino acids can impair the synthesis of structural and functional proteins important for <i>Mtb</i> survival. Hence, inhibition of enzymes that catalyze amino acid biosynthesis is a valid approach to block the <i>Mtb</i> life cycle. This may prove to be an effective approach as amino acid biosynthesis is crucial for the survival of a pathogen inside the host.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> The biochemical pathway of oxidative phosphorylation is another target for antimycobacterial drugs that inhibit ATP synthase, ultimately preventing ATP production.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a></div><div class="NLM_p">Various drugs are already in preclinical and clinical trials for some of these targets. For instance, diarylquinolines target the ATP synthase, while imidazopyridines work to disrupt cytochrome bc<sub>1</sub> complex, respectively.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> The diarylquinoline drug bedaquiline (<b>13</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) is known to disrupt ATP synthesis in the bacterium through inhibition of ATP synthase. This drug has been found to interact with rotor rings of the enzyme with several residues being involved in the interaction<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A). ATP synthases are protein complexes of the mitochondrial membrane, which possess F<sub>1</sub> and F<sub>0</sub> subunits. The F<sub>1</sub> subunit is soluble, while the F<sub>0</sub> is embedded in the membrane and is responsible for translocation of protons.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> Further, the F<sub>0</sub> subunit is comprised of a structurally conserved subunit “a” along with a “c” subunit that has nine rings.<a onclick="showRef(event, 'ref180 ref181'); return false;" href="javascript:void(0);" class="ref ref180 ref181">(180,181)</a> The structure of <i>M. smegmatis</i> ATP synthase has been recently determined, both in association with bedaquiline (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JGC">7JGC</a>) and in apo form (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JG5">7JG5</a>).<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> These cryo-EM structures suggest that the extensions from α-subunits prevent enzyme reversal, inhibiting ATP hydrolysis and conserving energy.</div><div class="NLM_p">Compounds that interfere with translocation of protons and rotor movement in the F<sub>0</sub> region lead to inhibition of ATP synthesis and ATP synthase-mediated hydrolysis.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> Mycobacterial ATP synthase becomes inhibited in the presence of bedaquiline due to its interaction with the F<sub>0</sub> region.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> It has been studied that even though a concentration of bedaquiline in the nanomolar range is sufficient for inhibition of bacterial growth, a concentration in the micromolar range is needed for bactericidal activity.<a onclick="showRef(event, 'ref185 ref186'); return false;" href="javascript:void(0);" class="ref ref185 ref186">(185,186)</a></div><div class="NLM_p">Moreover, intrinsically disordered proteins (IDPs) are abundantly present in the <i>Mtb</i> genome and can act as key targets for drug development since they are biologically significant and are involved in physiological processes, such as the cell cycle and cell signaling.<a onclick="showRef(event, 'ref187 ref188'); return false;" href="javascript:void(0);" class="ref ref187 ref188">(187,188)</a> IDPs are also present in many eukaryotes wherein they play an active role in causing cancer, diabetes, and Alzheimer’s disease.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> Rv3221c is one of the IDPs identified in the <i>Mtb</i> genome.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> Additionally, two protein families known as proline-glutamate and proline-proline-glutamate (PE and PPE) are present in the mycobacterial genome and may assist the pathogen in escaping the host immune responses.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> Both these protein families have been found to alter the innate immune pathways within the host.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a></div><div class="NLM_p">As previously mentioned, fluoroquinolones have been in use for quite some time to treat TB, and resistance against this class of drugs is emerging rapidly. In particular, fluoroquinolones are involved in inhibition of DNA supercoiling and act by targeting the <i>Mtb</i> gyrase enzyme (<i>GyrA</i> or <i>Topoisomerase IV</i>). This prevents repair of the double-strand breaks in <i>Mtb</i> DNA.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> Furthermore, the pathogen’s replication and repair mechanisms may be targeted for the development of new drugs.</div><div class="NLM_p">Imidazoline compounds are shown to be another potent class of bactericides.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> The serine/threonine (Ser/Thr) protein kinases (Pkn) play an important role in signaling pathways among eukaryotes as well as prokaryotes, apart from their role in cellular functions. The <i>Mtb</i> genome comprises about 11 Pkn (from PknA to PknL). Hence, targeting them can prove to be advantageous in curbing the spread of the disease.<a onclick="showRef(event, 'ref195 ref196'); return false;" href="javascript:void(0);" class="ref ref195 ref196">(195,196)</a></div><div class="NLM_p"><i>Mtb</i> uses various metabolic pathways for carbon utilization in order to persist inside the host. The strains lacking crucial enzymes for these metabolic cycles show reduced virulence <i>in vivo</i>. In one study, it was shown that triose phosphate isomerase (TPI) is required for <i>Mtb</i> growth in mouse lungs due to the lack of an alternative enzyme for glycolysis and gluconeogenesis.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> Thus, targeting this enzyme would effectively inhibit <i>Mtb</i> persistence <i>in vivo</i>.</div><div class="NLM_p">The operation of the tricarboxylic acid cycle (TCA) cycle in <i>Mtb</i> requires functioning of bacterial citrate lyase for anaerobic citrate fermentation. This enzyme comprises α (CitF), β (CitE), and γ (CitD) subunits. The <i>Mtb</i> genome codes for homologues of the β subunit, called CitE1 and CitE2, while α and γ subunit homologues do not exist.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> Studies on CitE1 and CitE2 confirm the importance of these enzymes in pathogenesis of <i>Mtb</i>, hence marking them as potential drug targets. Deletion of genes for both the enzymes renders <i>Mtb</i> susceptible to oxidative stress along with reducing persistence inside macrophages and reducing growth in guinea pigs.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a></div><div class="NLM_p">Protein tyrosine phosphatase B (mPTPB) is a virulence factor of <i>Mtb</i>. It is secreted inside the macrophages, where it mediates the survival of the bacterium. On this account, it is of interest to understand the mechanism that mPTPB employs to escape the host immune response.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> It was already reported that deletion of mPTPB inhibits the survival of <i>Mtb</i> inside macrophages activated by IFN-γ and reduces bacterial load in a guinea pig model of TB infection.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> In this direction, a salicylic acid-based inhibitor, I-A09 of mPTPB, was identified that prevents the growth of <i>Mtb</i> inside macrophages, thereby providing a therapeutic approach for treatment of TB. Potential inhibitors against protein tyrosine phosphatases were synthesized, and their antitubercular activity alone and in combination with a standard regimen for TB was tested in guinea pigs.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> These inhibitors, found to be nontoxic to the animal, were rapidly absorbed and had good bioavailability. Targeting mPTPB not only reduces MDR-TB persistence inside host macrophages but also enhances the efficacy of antimycobacterial drugs such as isoniazid and rifampicin. A 4-phenylethynyl-containing analogue, with additional modifications, was identified to be the most potent in inhibiting mPTPB. Corroboration of the mode of binding for mPTPB involved mutagenesis studies on key residues of mPTPB.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a></div><div class="NLM_p last">To provide genetic evidence for the attenuation of BCG for its use as a vaccine, avirulent <i>M. bovis</i> BCG from virulent <i>Mtb</i> and <i>M. bovis</i> was distinguished by detecting genetic differences, termed regions of difference (RD) using genomic subtractive hybridization. This led to the identification of three regions of difference (RD1, RD2, and RD3), which were also sequenced and their junctions thus recognized. <i>M. bovis</i> BCG had these regions of difference deleted from the genome. These regions are considered important for the virulence of <i>Mtb</i>. RD1, a region 9.8 kb in size, underwent deletion during derivation of BCG in 1908–1921,<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> contributing to attenuation of the BCG vaccine. Further mutations for another region, RD2 (a DNA segment of 10.7 kb) which was lost during 1927–1931 appeared, and researchers reported additional attenuation of the BCG vaccine. The deletion of RD2 reduced bacterial load in lungs and spleen.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> RD3, 9.3 kb segment, was not detected in BCG and in the majority of clinical isolates but was isolated from virulent <i>M. bovis</i> and <i>Mtb</i> laboratory strains.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">10.  Medicinal Chemistry Efforts toward the Development of Novel Anti-TB Drugs Active against MDR-TB and XDR-TB</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88753" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88753" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As of 2019, TB has been identified as one of the top 10 causes of mortality worldwide despite the availability of several classes of drugs for its treatment.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The current therapeutic treatments are more than 40 years old. The complexity and long duration of TB infections often leads to poor compliance and misuse of drug regimens, causing an increased disease burden and the potential for development of drug resistance. The emergence of resistant strains, such as MDR- and XDR-TB, represents a serious health threat.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> Worldwide, it is now estimated that MDR-TB and XDR-TB represent 21% and 2%, respectively, of all reported TB cases.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Recent reports suggest a new emerging threatening strain, namely, totally drug-resistant tuberculosis (TDR-TB), which is resistant to every known treatment.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a></div><div class="NLM_p">In August 2019, the United States Food and Drug Administration finally approved a new drug, namely, pretomanid (<b>15</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>),<a onclick="showRef(event, 'ref206 ref207'); return false;" href="javascript:void(0);" class="ref ref206 ref207">(206,207)</a> which is only the third tuberculosis drug, after bedaquiline (<b>13</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) and delamanid (<b>16</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>)<a onclick="showRef(event, 'ref208 ref209'); return false;" href="javascript:void(0);" class="ref ref208 ref209">(208,209)</a> to receive approval in more than 40 years.<a onclick="showRef(event, 'ref210 ref211'); return false;" href="javascript:void(0);" class="ref ref210 ref211">(210,211)</a> Pretomanid structurally belongs to the nitroimidazole class, and it is given in combination with bedaquiline (<b>13</b>) and linezolid (<b>17</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>)<a onclick="showRef(event, 'ref212 ref213'); return false;" href="javascript:void(0);" class="ref ref212 ref213">(212,213)</a> for the treatment of a specific type of highly treatment-resistant TB of the lungs. However, in many poor countries, TB remains untreated due to several factors discussed earlier as well as by Laurence et al.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> Discovering new antitubercular drugs remains a challenging task, and there is an ever-growing urgent need of developing novel chemical entities, acting through new targets and with reduced toxicity and reduced costs.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structure of antitubercular drugs approved in the last 40 years and currently used for TB treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In this scenario, many research groups have been focusing on the development of new small molecules with potential anti-TB activity, and mainly chemo types of heterocyclic nature seem to be of very high interest. This review gives a chronological overview of the major efforts in the early phases of drug discovery programs spanning the past decade, for the identification of new chemical entities showing potential toward the treatment of MDR- and XDR-TB strains.</div><div id="sec10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">10.1.  New Generation of Rigidified Oxazolidinone-Based Structure Derivatives</h3><div class="NLM_p">Oxazolidinones are a new class of antibacterial agents that inhibit bacterial protein synthesis, via competitive binding to the 23S rRNA in the catalytic site of bacterial 50S ribosomes.<a onclick="showRef(event, 'ref215 ref216'); return false;" href="javascript:void(0);" class="ref ref215 ref216">(215,216)</a> A few compounds containing the 2-oxazolidinone structural moieties are currently under clinical development for the treatment of MDR- and XDR-TB, such as sutezolid (<b>18</b>, phase II study),<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a> delpazolid (<b>19</b>),<a onclick="showRef(event, 'ref218 ref219'); return false;" href="javascript:void(0);" class="ref ref218 ref219">(218,219)</a> and TBI223 (<b>20</b>) (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(220)</a> Sutezolid has displayed improved anti-TB activity and safety profile compared to linezolid (<b>17</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) and structurally differs from the latter by having a thiomorpholine substituent.<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a> However, toxicity limits the use of this class of drugs and seems to be mediated by the inhibition of mitochondrial protein synthesis (MPS) and monoamine oxidase (MAO).<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a> Therefore, the discovery of new oxazolidinones with an improved pharmacokinetic profile is extremely necessary.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structure of antitubercular agents based on oxazolidinone pharmacophore under clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Zhao and co-workers focused on the lead optimization of previously discovered conformationally constrained oxazolidinones,<a onclick="showRef(event, 'ref223'); return false;" href="javascript:void(0);" class="ref ref223">(223)</a> toward the development of new rigidified analogues, with improved safety and efficacy profiles for the treatment of MDR-TB.<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> Starting from the lead compound <b>21</b> (MIC = 0.391 μg/mL), they first investigated the stereochemistry of the core structure, showing that the 3<i>S</i>, 3<i>aS</i> configuration was optimal for anti-TB activity (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). Further optimization was centered on the variation of the R<sub>1</sub> group of the benzene ring and on the R<sub>2</sub> group of the oxazolidinone core. A deep structure–activity relationship exploration (SAR) was undertaken, including the introduction in R<sub>1</sub> of several cyclic secondary amines (morpholine, 4,4-difluoropiperid-1-yl, etc.). To improve the metabolic stability, a bridge thiomorpholine was also introduced in R<sub>1</sub>, with the aim of achieving increased steric hindrance. In R<sub>2</sub> many different groups were investigated, such as cyclopropanecarboxamido, cyclobutanecarboxamido, methyl carbamate, pyiridine-4-carboxyamide, acetamide, etc. All final compounds were evaluated for their inhibitory activity against <i>Mtb</i> H37Rv, with oxazolidinone <b>22</b> being the most promising candidate in this class of compounds.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. General structure of the rigidified oxazolidinones, SAR exploration, and structure of the optimized lead compound <b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In <i>in vivo</i> efficacy studies of TB infection in a mouse model, compound <b>22</b> showed improved anti-TB activity and safety profile when compared to linezolid (<b>17</b>) and sutezolid (<b>18</b>). The druglike profile of compound <b>22</b> was demonstrated in a panel of assays including microsomal stability, cytotoxicity, cytochrome P450 enzyme inhibition, and pharmacokinetics in animals. Compound <b>22</b> exhibited an excellent safety profile in several assays (hERG K<sup>+</sup>, MAO, and genotoxicity). It also appeared to have less toxicity (less bone marrow suppression than linezolid), when tested in a four-week repeated dose toxicology study in rats. <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> summarizes some of the pharmacokinetic properties of the compound <b>22</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. MIC Values against Wild-Type and MDR-TB Strains, Cytotoxicity, Mouse Liver Microsome Stability, and Mitochondrial Protein Synthesis Inhibition of Compound <b>22</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">MIC (μg/mL)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center" char=".">MIC (μg/mL)</th><th class="colsep0 rowsep0" align="center" char=".">cytotoxicity (IC<sub>50</sub>, μg/mL)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">MPSi IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">MLM<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a>, %</th><th class="colsep0 rowsep0" align="center" char=".">H37Rv</th><th class="colsep0 rowsep0" align="center" char=".">12525<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">L-R<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="char" char=".">>64</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">48.7</td><td class="colsep0 rowsep0" align="char" char=".">0.06</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="char" char=".">0.24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">linezolid</td><td class="colsep0 rowsep0" align="char" char=".">0.45</td><td class="colsep0 rowsep0" align="char" char=".">>64</td><td class="colsep0 rowsep0" align="left">7.98</td><td class="colsep0 rowsep0" align="left">110.9</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="char" char=".">0.23</td><td class="colsep0 rowsep0" align="char" char=".">3.92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sutezolid</td><td class="colsep0 rowsep0" align="char" char=".">0.10</td><td class="colsep0 rowsep0" align="char" char=".">>64</td><td class="colsep0 rowsep0" align="left">8.17</td><td class="colsep0 rowsep0" align="left">54.8</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">0.06</td><td class="colsep0 rowsep0" align="char" char=".">0.96</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Vero cell line.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Mitochondrial protein synthesis inhibition.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Mouse liver microsome: Stability was determined as a percentage of substrate concentrations remaining after a 30 min incubation with NADPH.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Resistance to isoniazid and rifampicin.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Resistance to linezolid.</p></div></div></div></div><div id="sec10_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">10.2.  4<i>H</i>-Chromen-4-one Derivatives</h3><div class="NLM_p">Recently, Zhao et al. reported a series of 4<i>H</i>-chromen-4-one derivatives obtained by scaffold morphing of the Pks13 inhibitor TAM16 (<b>14</b>, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), a benzofuran structure-based compound.<a onclick="showRef(event, 'ref225'); return false;" href="javascript:void(0);" class="ref ref225">(225)</a> Pks13 enzyme belongs to the type I polyketide synthase gene family and has a critical role in mycolic acid biosynthesis in <i>Mtb</i>. Pks13 promotes the joining of the α-alkyl C26 fatty acid branch (by the fatty acid synthase, FAS-I enzyme) to the meromycolic acid (C48–C64) branch (by FAS-II enzyme) through a Claisen-type condensation reaction, to finally form α-alkyl β-ketoacids.<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a> Therefore, Pks13 is a promising druggable target for the development of new TB drugs. On the basis of the crystal structure of TAM16 (<b>14</b>) within the binding site of the target Pks13 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V3Y">5V3Y</a>), a new compound <b>23a</b> was rationally designed and tested <i>in vitro</i>. <b>23a</b> displayed a moderate MIC (3.84 μg/mL) against <i>Mtb</i> H37Rv (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). This outcome encouraged the group to explore the systematic SAR of this new class of compounds, to further demonstrate the potential of the scaffold for hit-to-lead optimization. A set of 27 compounds (<b>23a</b>–<b>z</b>, <b>24</b>) were synthesized focusing on the substitution pattern of R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup>, identified as the sites of diversification (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). When tested <i>in vitro</i>, these compounds showed MICs in the range 32–0.45 μg/mL. The SAR studies demonstrated that the aryl group at the C-2 position was essential for activity (compound <b>24</b> lost complete activity), and the 4-hydroxyphenyl substituent was the most favorable group for activity (see for example compounds <b>23a</b>–<b>d</b>). The free C-3 position of the 4<i>H</i>-chromen-4-one core produced the best compounds (<b>23c</b>–<b>d</b>).</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Rational design of new 4<i>H</i>-chromen-4-one derivatives (<b>23a</b>–<b>z</b>, <b>24</b>) and SAR outcomes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Substitution Pattern and MIC Values of the New 4<i>H</i>-Chromen-4-one Derivatives <b>23a</b>–<b>z</b> and <b>24</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0030.gif" alt="" id="fx1" /></img><div></div></div><div class="NLM_p last">Compounds with a small secondary-amine ring at the C-5 position (<b>23a</b>, <b>23c</b>–<b>d</b>) showed potent activities against <i>Mtb</i> H37Rv. Compound <b>23d</b> emerged as the best inhibitor, with the highest MIC value of 0.45 μg/mL against H37Rv, and it was active against drug-sensitive (DS) and MDR-TB. A preliminary druggability assessment for <b>23d</b> showed a favorable mouse and human microsomal stability (96% after 30 min incubation with NADPH), low cytotoxicity (IC<sub>50</sub> of 8.8 μg/mL), and acceptable oral bioavailability (20%, not shown here). Furthermore, this compound showed modest efficacy in an acute mouse model of TB, after three weeks of treatment at a dose of 100 mg/kg. Hence, compound <b>23d</b> resulted as a promising anti-TB lead compound to be further optimized in the development phase.</div></div><div id="sec10_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">10.3.  Novel Coumestan Derivatives</h3><div class="NLM_p">In 2019, Zhang’s group reported the identification of a second generation of novel coumestan derivatives<a onclick="showRef(event, 'ref227'); return false;" href="javascript:void(0);" class="ref ref227">(227)</a> in continuation of their previous work.<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> Through a whole-genome sequencing, they could confirm that this natural scaffold coumestan targets the <i>Mtb</i> Pks13 thioesterase domain, as shown by the N1640K, N1640S, D1644G, and A1667V mutations observed in the resistant mutants. A deep SAR exploration resulted in the synthesis and biological evaluation of 19 analogues (<b>25a</b>–<b>s</b>) and showed the importance of R<sub>1</sub> substitution. <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a> summarizes the structure and the substitution pattern of this second generation of coumestans. Compound <b>25a</b> was the most promising of this first new series, with an MIC value 0.125 μg/mL (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Deletion of R<sub>1</sub> substitution resulted in complete loss of activity (see <b>25b</b>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structure and substitution pattern of coumestan of new generation <b>25a</b>–<b>s</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. MIC Values against H37Rv of Coumestan of New Generation <b>25a</b>–<b>s</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">MIC (μg/mL)</th><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">MIC (μg/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25a</b></td><td class="colsep0 rowsep0" align="left">0.125–0.25</td><td class="colsep0 rowsep0" align="left"><b>25k</b></td><td class="colsep0 rowsep0" align="left">>64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25b</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left"><b>25l</b></td><td class="colsep0 rowsep0" align="left">>64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25c</b></td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left"><b>25m</b></td><td class="colsep0 rowsep0" align="left">>64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25d</b></td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left"><b>25n</b></td><td class="colsep0 rowsep0" align="left">>64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25e</b></td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left"><b>25o</b></td><td class="colsep0 rowsep0" align="left">>64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25f</b></td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left"><b>25p</b></td><td class="colsep0 rowsep0" align="left">>64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25g</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left"><b>25q</b></td><td class="colsep0 rowsep0" align="left">>64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25h</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left"><b>25r</b></td><td class="colsep0 rowsep0" align="left">>64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25i</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left"><b>25s</b></td><td class="colsep0 rowsep0" align="left">>64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25j</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">isoniazid</td><td class="colsep0 rowsep0" align="left">0.04</td></tr></tbody></table></div></div><div class="NLM_p">A smaller pyrrolidin-1-yl-methyl (<b>25c</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) and various methyl-substituted piperidin-1-yl-methyl substituents at R<sub>1</sub> (see <b>25d</b>–<b>f</b>) were also introduced, but the corresponding compounds were less active (MIC in the range 2.0–0–5 μg/mL, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Shifting the R1 substituent from the C-4 to the C-6 position (<b>25r</b>) resulted in a loss of activity (MIC value > 64 μg/mL), further supporting the importance of R1 substitution at the C-4 site of the coumestan core. Next, the substitutions at the C-6 and C-7 positions of the coumestan derivative were explored (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Substituents at the C-6 position were generally found to be detrimental to the activity (<b>26a</b>–<b>b</b> were completely inactive, with an MIC value > 64 μg/mL). Electron-donating groups at the C-6 position (<b>26c</b>–<b>d</b>) had at least a 16–32-fold increase in activity (MIC value of 2–4 μg/mL), whereas in contrast, electron-donating substituents at the C-7 position (<b>26e</b>–<b>f</b>) favored antitubercular activity, with MIC values of 0.125 and 0.0625–0.125 μg/mL, respectively. The introduction of a hydroxyl group at the C-4′ position resulted in two extremely potent analogues <b>26i</b> and <b>26k</b>. These molecules possessed excellent antitubercular activity against both the drug-susceptible (MICs of 0.0039 and 0.0078 μg/mL, respectively) and drug-resistant <i>Mtb</i> strains (0.0010 > MIC > 0.0078 μg/mL). Moreover, the excellent <i>in vitro</i> activity was strengthened by an <i>in vivo</i> mouse study (mouse serum inhibitory titration assay); coumestan <b>26i</b> was administered at 100 mg/kg and showed an 8-fold higher activity compared to isoniazid given at 10 or 100 mg/kg, respectively. Preliminary absorption, distribution, metabolism, excretion, toxicity (ADMET) data for the coumestans were promising, warranting further <i>in vivo</i> efficacy assessments of this new generation of derivatives.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Substitution Pattern and MIC Values against H37Rv of Coumestan of New Generation <b>26a</b>–<b>n</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0031.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">H37Rv MIC (μg/mL)</th><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">H37Rv MIC (μg/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26a</b></td><td class="colsep0 rowsep0" align="left">(6)-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left"><b>26h</b></td><td class="colsep0 rowsep0" align="left">(7)-Br</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26b</b></td><td class="colsep0 rowsep0" align="left">(6)-Br</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left"><b>26i</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4′-OH</td><td class="colsep0 rowsep0" align="left">0.0039</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26c</b></td><td class="colsep0 rowsep0" align="left">(6)-OMe</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left"><b>26j</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">5′-OH</td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26d</b></td><td class="colsep0 rowsep0" align="left">(6)-OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4.0</td><td class="colsep0 rowsep0" align="left"><b>26k</b></td><td class="colsep0 rowsep0" align="left">(7)-<i>t</i>Bu</td><td class="colsep0 rowsep0" align="left">4′-OH</td><td class="colsep0 rowsep0" align="left">0.0039</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26e</b></td><td class="colsep0 rowsep0" align="left">(7)-<i>t</i>Bu</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.0625–0.125</td><td class="colsep0 rowsep0" align="left"><b>26l</b></td><td class="colsep0 rowsep0" align="left">(7)-<i>t</i>Bu</td><td class="colsep0 rowsep0" align="left">5′-OH</td><td class="colsep0 rowsep0" align="left">0.125</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26f</b></td><td class="colsep0 rowsep0" align="left">(7)-Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.125</td><td class="colsep0 rowsep0" align="left"><b>26m</b></td><td class="colsep0 rowsep0" align="left">(6)–OH</td><td class="colsep0 rowsep0" align="left">4′-OH</td><td class="colsep0 rowsep0" align="left">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26g</b></td><td class="colsep0 rowsep0" align="left">(7)-Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left"><b>26n</b></td><td class="colsep0 rowsep0" align="left">(6)–OH</td><td class="colsep0 rowsep0" align="left">4′,5′-di-OH</td><td class="colsep0 rowsep0" align="left">32</td></tr></tbody></table></div></div></div><div id="sec10_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">10.4.  Azaaurones Structure-Based Compounds</h3><div class="NLM_p">Campanico et al. had reported a new class of azaaurone based molecules (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) capable of inhibiting <i>Mtb</i> growth.<a onclick="showRef(event, 'ref229'); return false;" href="javascript:void(0);" class="ref ref229">(229)</a> A series of 25 molecules were designed (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>), synthesized, and biologically evaluated. In general, <i>N</i>-acetylazaaurones (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) showed a higher potency than the corresponding azaaurones (values not shown here),<a onclick="showRef(event, 'ref229'); return false;" href="javascript:void(0);" class="ref ref229">(229)</a> suggesting that a more lipophilic structure is favorable and may facilitate crossing the mycobacterial cell wall compared to deacetylated analogues. Nine derivatives displayed MIC<sub>99</sub> (μg/mL) values ranging from 0.4 to 2.0 μM (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structure of <i>N</i>-acetylazaaurone derivatives <b>27a</b>–<b>y</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Antimycobacterial Activity of Compounds <b>27a</b>–<b>y</b> against <i>Mtb</i> H37Rv and Antimycobacterial Values of Selected Compounds (<b>27a</b>–<b>c</b> and <b>27e</b>) against DT-TB, MDR-TB, and XDR-TB Clinical Isolates</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">H37Rv</th><th class="rowsep1 colsep0" colspan="4" align="center">MIC (μM)</th><th class="rowsep1 colsep0" align="center">HEK293T CC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">MIC<sub>90</sub> (μM)</th><th class="colsep0 rowsep0" align="center">MIC<sub>99</sub> (μM)</th><th class="colsep0 rowsep0" align="center">DR-TB<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">MDR-TB<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">XDR-TB<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">H37Rv</th><th class="colsep0 rowsep0" align="center">ND</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27a</b></td><td class="colsep0 rowsep0" align="left">0.31</td><td class="colsep0 rowsep0" align="left">0.37</td><td class="colsep0 rowsep0" align="left">15.2</td><td class="colsep0 rowsep0" align="left">9.15</td><td class="colsep0 rowsep0" align="left">15.2</td><td class="colsep0 rowsep0" align="left">15.2</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27b</b></td><td class="colsep0 rowsep0" align="left">1.32</td><td class="colsep0 rowsep0" align="left">2.29</td><td class="colsep0 rowsep0" align="left">12.3</td><td class="colsep0 rowsep0" align="left">12.3</td><td class="colsep0 rowsep0" align="left">12.3</td><td class="colsep0 rowsep0" align="left">12.3</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27c</b></td><td class="colsep0 rowsep0" align="left">2.32</td><td class="colsep0 rowsep0" align="left">4.05</td><td class="colsep0 rowsep0" align="left">8.37</td><td class="colsep0 rowsep0" align="left">10.4</td><td class="colsep0 rowsep0" align="left">8.37</td><td class="colsep0 rowsep0" align="left">8.37</td><td class="colsep0 rowsep0" align="left">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27d</b></td><td class="colsep0 rowsep0" align="left">1.26</td><td class="colsep0 rowsep0" align="left">1.98</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27e</b></td><td class="colsep0 rowsep0" align="left">2.71</td><td class="colsep0 rowsep0" align="left">4.37</td><td class="colsep0 rowsep0" align="left">17.7</td><td class="colsep0 rowsep0" align="left">17.7</td><td class="colsep0 rowsep0" align="left">17.7</td><td class="colsep0 rowsep0" align="left">14.8</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27f</b></td><td class="colsep0 rowsep0" align="left">2.65</td><td class="colsep0 rowsep0" align="left">4.3</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27g</b></td><td class="colsep0 rowsep0" align="left">1.44</td><td class="colsep0 rowsep0" align="left">3.19</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27h</b></td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27i</b></td><td class="colsep0 rowsep0" align="left">0.649</td><td class="colsep0 rowsep0" align="left">0.736</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27j</b></td><td class="colsep0 rowsep0" align="left">0.336</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27k</b></td><td class="colsep0 rowsep0" align="left">3.16</td><td class="colsep0 rowsep0" align="left">3.66</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27l</b></td><td class="colsep0 rowsep0" align="left">1.89</td><td class="colsep0 rowsep0" align="left">2.58</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27m</b></td><td class="colsep0 rowsep0" align="left">6.2</td><td class="colsep0 rowsep0" align="left">8.4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27n</b></td><td class="colsep0 rowsep0" align="left">4.49</td><td class="colsep0 rowsep0" align="left">4.94</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27o</b></td><td class="colsep0 rowsep0" align="left">5.1</td><td class="colsep0 rowsep0" align="left">5.66</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27p</b></td><td class="colsep0 rowsep0" align="left">6.44</td><td class="colsep0 rowsep0" align="left">7.85</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27q</b></td><td class="colsep0 rowsep0" align="left">11.6</td><td class="colsep0 rowsep0" align="left">17.5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27r</b></td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27s</b></td><td class="colsep0 rowsep0" align="left">2.65</td><td class="colsep0 rowsep0" align="left">3.13</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27t</b></td><td class="colsep0 rowsep0" align="left">3.19</td><td class="colsep0 rowsep0" align="left">3.34</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27u</b></td><td class="colsep0 rowsep0" align="left">4.93</td><td class="colsep0 rowsep0" align="left">5.61</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27v</b></td><td class="colsep0 rowsep0" align="left">1.24</td><td class="colsep0 rowsep0" align="left">1.39</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27w</b></td><td class="colsep0 rowsep0" align="left">6.02</td><td class="colsep0 rowsep0" align="left">6.87</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27x</b></td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27y</b></td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rifampicin</td><td class="colsep0 rowsep0" align="left">0.00291</td><td class="colsep0 rowsep0" align="left">0.00482</td><td class="colsep0 rowsep0" align="left">0.377</td><td class="colsep0 rowsep0" align="left">>12.2</td><td class="colsep0 rowsep0" align="left">>12.2</td><td class="colsep0 rowsep0" align="left">0.377</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Resistant to isoniazid.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Resistant to isoniazid, rifampicin, ethambutol, pyrazinamide, capreomycin, and ethionamide.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Resistant to isoniazid, rifampicin, ethambutol, pyrazinamide, streptomycin, capreomycin, amikacin, kanamycin, ofloxacin, and ethionamide.</p></div></div></div><div class="NLM_p last">Overall, substitution at the para (C-4) position of the phenyl ring seemed optimal for the antimycobacterial activity, while substitution at the meta (C-3) was detrimental (compare <b>27b</b>, <b>27c</b>, <b>27f</b>, <b>27g</b>, <b>27i</b>, <b>27j</b> to <b>27n</b>, <b>27p</b>, <b>27q</b>, <b>27r</b>, <b>27s</b>, and <b>27t</b>, respectively). Substitution at the C-5 position of the azaaurone ring was possible (compare <b>27m</b> to <b>27w</b>). In particular, the most potent compounds <b>27a</b>, <b>27i</b>, and <b>27j</b> with MIC<sub>99</sub> values in the sub-micromolar range and active against MDR and XDR strains contained electron-withdrawing and/or lipophilic substituents at the C-4 position of the phenyl moiety. Analogue <b>27j</b> was the best compound of this new class, with excellent activity against MDR and XDR-TB from clinical isolates (MIC of 7.55 μM). However, while azaaurones were non-cytotoxic against HEK293T cells, with CC<sub>50</sub> values > 100 μM (not shown here), the <i>N</i>-acetylazaaurones derivatives showed CC<sub>50</sub> values in the range of 4–20 μM, thus indicating poor selectivity of the latter against <i>Mtb</i>. The mechanism of action of azaaurones still remains unclear, but they may serve as lead compounds for the generation of new antimycobacterial agents.</div></div><div id="sec10_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">10.5.  1,3,4-Oxadiazole Structure-Based Compounds</h3><div class="NLM_p">Early 2019, Makane et al., inspired by previous studies,<a onclick="showRef(event, 'ref230 ref231 ref232'); return false;" href="javascript:void(0);" class="ref ref230 ref231 ref232">(230−232)</a> disclosed oxadiazole based compounds as potent antitubercular agents.<a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a> Starting from the reference compounds <b>28</b> and <b>29</b> (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>), the new series of molecules were designed by introducing two main variations. First, the 2-alkyl chain of the 1,3,4-oxadiazole ring was replaced with a thiol group in order to (a) get compounds with the ability to form intermolecular hydrogen bond interactions (possibly with a biological target); (b) developing compounds less lipophilic (with lower clogP values) and making them more druglike.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structure of novel 1,3,4-oxadiazole derivatives <b>30a</b>–<b>x</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Second, the pyridine moiety was replaced by potentially less toxic groups, with the aim of avoiding issues associated with liver toxicity due to hepatic metabolism and formation of reactive species.<a onclick="showRef(event, 'ref234 ref235 ref236'); return false;" href="javascript:void(0);" class="ref ref234 ref235 ref236">(234−236)</a> The novel compounds <b>30a</b>–<b>x</b> were synthesized and screened against <i>Mtb</i> H37Rv, and the MIC values were compared to antibacterial activity of rifampicin (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Compounds with an MIC < 5 μg/mL against <i>Mtb</i> H37Rv were also evaluated for their toxicity on CHO-K1 cells (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Three categories of compounds could be identified: (I) potent inhibitors (<b>30a</b>, <b>30i</b>, <b>30j</b>, <b>30l</b>, <b>30s</b>, <b>30v</b>, <b>30w</b>, and <b>30x)</b> with MIC ranging from 0.6–3.1 μg/mL); (II) moderately active inhibitors (<b>30g</b>, <b>30k</b>, <b>30p</b>, and <b>30q</b>) with MIC values of 5–10 μg/mL; and (III) compounds with weak anti-TB activity (<b>30m</b>, <b>30o</b>, and <b>30t</b>, MIC 10–25 μg/mL). A few compounds (<b>30b</b>, <b>30e</b>–<b>f</b>, <b>30n</b>, <b>30r</b>, and <b>30u</b>) were inactive (MIC > 25 μg/mL). Analogues <b>30i</b> with a 4-iodo-phenyl substituent and <b>30j</b> with a 4-hydroxyphenyl moiety showed the highest activity in this new class of compounds, with MICs of 0.9 and 0.6 μg/mL, respectively. The position of the iodo substituent on the phenyl ring turned out to be very important, as shown by comparing structures <b>30c</b> and <b>30i</b> (MICs of 15.2 and 0.9 mg/mL, respectively). Compound <b>30a</b> with an unsubstituted phenyl ring showed potent antitubercular activity but also showed high toxicity in CHO-K1 cells. The use of cyclohexyl moiety as the R<sup>1</sup> substituent afforded a weak antitubercular compound (<b>30r</b>), while several compounds with heterocyclic substituents (<b>30s</b>, <b>30v</b>, <b>30w</b>, and <b>30x</b>) showed potent antitubercular activity.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. MIC Values of 1,3,4-Oxadiazole <b>30a</b>–<b>x</b> against <i>Mtb</i> H37Rv and Their Toxicity (IC<sub>50</sub>) toward CHO-K1 Cells</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">MIC (μg/mL)</th><th class="colsep0 rowsep0" align="center" char=".">SI<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (μg/mL)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">MIC (μg/mL)</th><th class="colsep0 rowsep0" align="center" char=".">SI<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μg/mL)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30a</b></td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="char" char=".">15.1</td><td class="colsep0 rowsep0" align="char" char="±">33.3 ± 0.36</td><td class="colsep0 rowsep0" align="left"><b>30n</b></td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30b</b></td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="left"><b>30o</b></td><td class="colsep0 rowsep0" align="left">21.0</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30c</b></td><td class="colsep0 rowsep0" align="left">15.2</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="left"><b>30p</b></td><td class="colsep0 rowsep0" align="left">10.5</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30d</b></td><td class="colsep0 rowsep0" align="left">21.2</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="left"><b>30q</b></td><td class="colsep0 rowsep0" align="left">6.7</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30e</b></td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="left"><b>30r</b></td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30f</b></td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="left"><b>30s</b></td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="char" char=".">25.6</td><td class="colsep0 rowsep0" align="left">35.5 ± 0.81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30g</b></td><td class="colsep0 rowsep0" align="left">5.3</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="left"><b>30t</b></td><td class="colsep0 rowsep0" align="left">21.3</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30h</b></td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="left"><b>30u</b></td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30i</b></td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="char" char=".">51.8</td><td class="colsep0 rowsep0" align="char" char="±">46.7 ± 0.30</td><td class="colsep0 rowsep0" align="left"><b>30v</b></td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="char" char=".">36.1</td><td class="colsep0 rowsep0" align="left">21.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30j</b></td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="char" char=".">39.6</td><td class="colsep0 rowsep0" align="char" char="±">23.8 ± 1.00</td><td class="colsep0 rowsep0" align="left"><b>30w</b></td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="char" char=".">16.6</td><td class="colsep0 rowsep0" align="left">21.6 ± 0.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30k</b></td><td class="colsep0 rowsep0" align="left">9.6</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="left"><b>30x</b></td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="char" char=".">26.4</td><td class="colsep0 rowsep0" align="left">34.4 ± 0.80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30l</b></td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="left">rifampicin</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30m</b></td><td class="colsep0 rowsep0" align="left">20.8</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Selectivity index (SI).</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">On CHO-K1 cells.</p></div></div></div><div class="NLM_p">Overall, these results indicated that the substitution pattern on 1,3,4-oxadiazoles with a 2-mercapto moiety at the C-2 position plays a crucial role in the observed anti-TB activity. In addition, all the compounds were tested against a few bacteria (<i>Escherichia coli</i> ATCC 25922, <i>Staphylococcus aureus</i> ATCC 29213, <i>Klebsiella pneumoniae</i> BAA 1705, <i>Acinetobacter baumannii</i> BAA 1605, <i>Pseudomonas aeruginosa</i> ATCC 27853), and none of them showed inhibition, thus indicating their selectivity in attenuating <i>Mtb</i>. In particular, compounds <b>30i</b>, <b>30j</b>, and <b>30v</b> exhibited high selectivity index (SI > 36; SI = IC<sub>50</sub>/MIC <i>Mtb</i>) and were safe for CHO-K1 cells, while other nontoxic potent antitubercular compounds (<b>30a</b>, <b>30s</b>, <b>30w</b>, and <b>30x</b>) were less selective (15 < SI < 26). Analogue <b>30j</b> was identified as the lead compound for this new series. In order to better understand the binding mode of the 1,3,4-oxadiazole derivatives, a molecular docking study on <i>Mtb InhA</i> was also performed.<a onclick="showRef(event, 'ref237'); return false;" href="javascript:void(0);" class="ref ref237">(237)</a> Analogues <b>30v</b>, <b>30j</b>, and <b>30i</b> showed a significant binding affinity. Finally, the lead compound <b>30j</b> was tested against TB-resistant clinical isolates (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>), and streptomycin and ethionamide were used as the positive controls for comparative effectiveness. Derivative <b>30j</b> was able to kill a few drug-resistant strains, although with limited activity. Of note, compound <b>30j</b> inhibited the pre-XDR isolate<a onclick="showRef(event, 'ref238'); return false;" href="javascript:void(0);" class="ref ref238">(238)</a> (entry <b>A</b>) with an MIC of 2 μg/mL. Taken together, these results hint that compounds analogous to <b>30j</b> hold promise in developing more potent inhibitors against drug-resistant TB.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Antitubercular Activity of Lead Compound <b>30j</b> against Resistant Strains</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">MIC (μg/mL)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">isolate</th><th class="colsep0 rowsep0" align="center">description</th><th class="colsep0 rowsep0" align="center"><b>30j</b></th><th class="colsep0 rowsep0" align="center">S<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">E<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>A</b></td><td class="colsep0 rowsep0" align="left">resistant to isoniazid, streptomycin, ethambutol and ethionamide</td><td class="colsep0 rowsep0" align="left">>32</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">114</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>B</b></td><td class="colsep0 rowsep0" align="left">resistant to isoniazid and ethionamide</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">>114</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>C</b></td><td class="colsep0 rowsep0" align="left">resistant to isoniazid, streptomycin, and rifampicin (MDR)</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>D</b></td><td class="colsep0 rowsep0" align="left">resistant to isoniazid and rifampicin (MDR)</td><td class="colsep0 rowsep0" align="left">>32</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>E</b></td><td class="colsep0 rowsep0" align="left">resistant to isoniazid and ethionamide</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">>80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>F</b></td><td class="colsep0 rowsep0" align="left">resistant to isoniazid, streptomycin, and ethionamide</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">>16</td><td class="colsep0 rowsep0" align="left">>80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>G</b></td><td class="colsep0 rowsep0" align="left">resistant to isoniazid, streptomycin, rifampicin, ethambutol, and ethionamide (MDR)</td><td class="colsep0 rowsep0" align="left">>32</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>114</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>H</b></td><td class="colsep0 rowsep0" align="left">resistant to isoniazid, streptomycin, rifampicin, ethambutol, ethionamide, and ofloxacin (pre-XDR)</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">114</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Streptomycin.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Ethionamide.</p></div></div></div></div><div id="sec10_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">10.6.  Pyrazolo[1,5-<i>a</i>]pyrimidine Structure-Based Compounds</h3><div class="NLM_p">Modi et al. reported a new class of pyrazolo[1,5-<i>a</i>]pyrimidine compounds as potential anti-TB entities (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>).<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(239)</a> These condensed heterocyclic derivatives target the FAS type I enzyme.<a onclick="showRef(event, 'ref240'); return false;" href="javascript:void(0);" class="ref ref240">(240)</a> Mycolic acids are the main component of the <i>Mtb</i> cell wall. These are structurally β-hydroxylated C60–C90 branched-chain fatty acids and are covalently bound to arabinogalactan-peptidoglycan, thus forming the mycolyl-arabinogalactan-peptidoglycan complex.<a onclick="showRef(event, 'ref241'); return false;" href="javascript:void(0);" class="ref ref241">(241)</a> They are critical for the pathogenesis of <i>Mtb</i> and have been shown to be important for virulence and persistence <i>in vivo</i>.<a onclick="showRef(event, 'ref242 ref243 ref244'); return false;" href="javascript:void(0);" class="ref ref242 ref243 ref244">(242−244)</a> Enzymes involved in the biosynthesis of <i>Mtb</i> cell wall are emerging as novel targets for the development of new antitubercular agents. Modi and co-workers designed and synthesized 26 analogues of pyrazolo[1,5-<i>a</i>]pyrimidine compounds (<b>31a</b>–<b>z</b>) using molecular docking studies. These compounds were further evaluated for <i>in vitro</i> antitubercular activity against the <i>MTb</i> H37Rv strain. Most of the newly synthesized compounds displayed potent activities as shown in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>. Compound <b>31p</b> was the most potent of this series with an excellent MIC of 0.8 μg/mL against the <i>Mtb</i> H37Rv strain. Compounds <b>31g</b> and <b>31n</b> yielded an MIC of 3.12 μg/mL and were as potent as the standard drugs ciprofloxacin and pyrazinamide, while compound <b>31h</b>, with an MIC of 6.25 mg/mL, was comparable to streptomycin. Exploration of SAR studies helped in understanding the importance of electron-withdrawing groups at R or R′, or at both the aryl rings attached to the pyrazolo[1,5-<i>a</i>]pyrimidine scaffold, in order to achieve good anti-TB activity. Similarly, the introduction of electron-donating substituents at one or both of the phenyl rings reduced the antitubercular activity.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures of 7-hydroxy-5-methyl-<i>N</i>-substituted phenyl-pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide <b>31a</b>–<b>z</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Antimycobacterial Activity of Pyrazolo[1,5-<i>a</i>]pyrimidine (<b>31a</b>–<b>z</b>)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">MIC (μg/mL)</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">H37Rv</th><th class="colsep0 rowsep0" align="center">MDR-TB</th><th class="colsep0 rowsep0" align="center">XDR-TB</th><th class="colsep0 rowsep0" align="center">cytotoxicity IC<sub>50</sub> (μg/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31a</b></td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31b</b></td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31c</b></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31d</b></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31e</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31f</b></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31g</b></td><td class="colsep0 rowsep0" align="left">3.12</td><td class="colsep0 rowsep0" align="left">6.25</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">20.99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31h</b></td><td class="colsep0 rowsep0" align="left">6.25</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">29.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31i</b></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31j</b></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31k</b></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31l</b></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31m</b></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31n</b></td><td class="colsep0 rowsep0" align="left">3.12</td><td class="colsep0 rowsep0" align="left">6.25</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">21.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31o</b></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31p</b></td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">3.12</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">13.57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31q</b></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31r</b></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31s</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31t</b></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31u</b></td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31v</b></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31w</b></td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31x</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31y</b></td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31z</b></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pyrazinamide</td><td class="colsep0 rowsep0" align="left">3.12</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ciprofloxacin</td><td class="colsep0 rowsep0" align="left">3.12</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">streptomycin</td><td class="colsep0 rowsep0" align="left">6.25</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">isoniazid</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">6.25</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div></div><div class="NLM_p last">Furthermore, heteroaromatic rings at the R′ position decreased the potency. Among all the tested compounds, <b>31g</b>, <b>31h</b>, <b>31n</b>, and <b>31p</b> exhibited promising antitubercular activities on the <i>Mtb</i> H37Rv and were next evaluated for activity against MDR-TB, XDR-TB, and cytotoxicity (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). None of these potent compounds exhibited high cytotoxicity, and hence they could be potential leads for further development of new potent antitubercular agents.</div></div><div id="sec10_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">10.7.  Indolizine Structure-Based Compounds</h3><div class="NLM_p">Chandrashekharappa et al. reported for the first time indolizine structure-based compounds, as novel heterocyclic entities with anti-TB activity.<a onclick="showRef(event, 'ref245'); return false;" href="javascript:void(0);" class="ref ref245">(245)</a> In their work, 18 analogues (<b>32a</b>–<b>r</b>, <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>) were described, and the <i>in vitro</i> qualitative antitubercular activity against the <i>Mtb</i> H37Rv strain was reported at three different concentrations (25, 50, and 100 μg/mL, <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). Compounds <b>32a</b>–<b>c</b>, <b>32f</b>–<b>g</b>, <b>32i</b>–<b>j</b>, <b>32l</b>, <b>32o</b>–<b>p</b>, and <b>32r</b> were active against <i>Mtb</i> at all three concentrations, while compounds <b>32d</b>–<b>e</b>, <b>32h</b>, <b>32k</b>, <b>32m</b>–<b>n</b>, and <b>32p</b> were found to be inactive in the same assay conditions. Importantly, the active compounds shared the presence of an ethyl ester moiety at the C-1 position and either hydrogen or ethyl ester at the C-2 position of the indolizine nucleus. The presence of an ethyl ester group at the C-1 position and a methyl or ethyl function at the C-2 position of the indolizine core were common features of the inactive analogues.</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Structure of ethyl 7-acetyl-2-substituted-3-(4-substituted benzoyl)indolizine-1-carboxylates (<b>32a</b>–<b>r</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Antitubercular Activity of Indolizines <b>32a</b>–<b>r</b> against <i>Mtb</i> H37Rv at Three Different Concentrations</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">[concentration] (μg/mL)</th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">[concentration] (μg/mL)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center"><b>25</b></th><th class="colsep0 rowsep0" align="center"><b>50</b></th><th class="colsep0 rowsep0" align="center"><b>100</b></th><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center"><b>25</b></th><th class="colsep0 rowsep0" align="center"><b>50</b></th><th class="colsep0 rowsep0" align="center"><b>100</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32a</b></td><td class="colsep0 rowsep0" align="left">S<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left"><b>32k</b></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">R</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32b</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left"><b>32l</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32c</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left"><b>32m</b></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">R</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32d</b></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left"><b>32n</b></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">R</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32e</b></td><td class="colsep0 rowsep0" align="left">R<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left"><b>32o</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32f</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left"><b>32p</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32g</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left"><b>32q</b></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">R</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32h</b></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left"><b>32r</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32i</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">streptomycin</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32j</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">pyrazinamide</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">S</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">R = resistant; S = sensitive.</p></div></div></div><div class="NLM_p last">The results showed that there is wide room for structural improvement in order to develop more potent antitubercular indolizine structure-based compounds.</div></div><div id="sec10_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">10.8.  Dipeptidic Compounds</h3><div class="NLM_p">With the aim of developing new chemo types, in 2019, Baravkar et. al investigated a series of dipeptides (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>), in which different amino acids were tethered to the 2-aminothiophene ring.<a onclick="showRef(event, 'ref246'); return false;" href="javascript:void(0);" class="ref ref246">(246)</a> Derivatives containing the proline (Pro) residue were the most promising and were reported as a new class of tuberculosis inhibitors with potent <i>in vitro</i> and <i>ex-vivo</i> anti-TB activity against both active and dormant <i>Mtb</i> H37Ra (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>). A clear SAR study showed that the change in the chirality of Pro ring does not affect the activity.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Structures of 2-amino-thiophene-proline conjugates <b>33a</b>–<b>k</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. <i>In Vitro</i> Bioactivity Activity of Compounds <b>33a</b>–<b>k</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">anti-TB activity<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="3" align="center">cytotoxicity<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="2" align="center">SI<a class="ref internalNav" href="#t10fn3" aria-label="c">c</a> HeLa</th><th class="rowsep1 colsep0" colspan="2" align="center">SI<a class="ref internalNav" href="#t10fn4" aria-label="d">d</a> MCF-7</th><th class="rowsep1 colsep0" colspan="2" align="center">SI<a class="ref internalNav" href="#t10fn5" aria-label="e">e</a> HUVEC</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center"><i>a</i></th><th class="colsep0 rowsep0" align="center"><i>d</i></th><th class="colsep0 rowsep0" align="center">HeLa</th><th class="colsep0 rowsep0" align="center">MCF-7</th><th class="colsep0 rowsep0" align="center">HUVEC</th><th class="colsep0 rowsep0" align="center"><i>a</i></th><th class="colsep0 rowsep0" align="center"><i>d</i></th><th class="colsep0 rowsep0" align="center"><i>a</i></th><th class="colsep0 rowsep0" align="center"><i>d</i></th><th class="colsep0 rowsep0" align="center"><i>a</i></th><th class="colsep0 rowsep0" align="center"><i>d</i></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33a</b></td><td class="colsep0 rowsep0" align="left">11.97</td><td class="colsep0 rowsep0" align="left">3.35</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">20.88</td><td class="colsep0 rowsep0" align="left">74.62</td><td class="colsep0 rowsep0" align="left">20.88</td><td class="colsep0 rowsep0" align="left">74.62</td><td class="colsep0 rowsep0" align="left">20.88</td><td class="colsep0 rowsep0" align="left">74.62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33b</b></td><td class="colsep0 rowsep0" align="left">10.83</td><td class="colsep0 rowsep0" align="left">8.78</td><td class="colsep0 rowsep0" align="left">91.39</td><td class="colsep0 rowsep0" align="left">179.09</td><td class="colsep0 rowsep0" align="left">95.77</td><td class="colsep0 rowsep0" align="left">8.43</td><td class="colsep0 rowsep0" align="left">10.40</td><td class="colsep0 rowsep0" align="left">16.53</td><td class="colsep0 rowsep0" align="left">20.39</td><td class="colsep0 rowsep0" align="left">8.84</td><td class="colsep0 rowsep0" align="left">10.90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33c</b></td><td class="colsep0 rowsep0" align="left">15.88</td><td class="colsep0 rowsep0" align="left">6.74</td><td class="colsep0 rowsep0" align="left">90.58</td><td class="colsep0 rowsep0" align="left">162.98</td><td class="colsep0 rowsep0" align="left">91.35</td><td class="colsep0 rowsep0" align="left">5.70</td><td class="colsep0 rowsep0" align="left">13.43</td><td class="colsep0 rowsep0" align="left">10.26</td><td class="colsep0 rowsep0" align="left">24.18</td><td class="colsep0 rowsep0" align="left">5.75</td><td class="colsep0 rowsep0" align="left">13.55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33d</b></td><td class="colsep0 rowsep0" align="left">9.08</td><td class="colsep0 rowsep0" align="left">7.62</td><td class="colsep0 rowsep0" align="left">35.31</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">3.88</td><td class="colsep0 rowsep0" align="left">4.63</td><td class="colsep0 rowsep0" align="left">27.53</td><td class="colsep0 rowsep0" align="left">32.80</td><td class="colsep0 rowsep0" align="left">27.53</td><td class="colsep0 rowsep0" align="left">32.80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33e</b></td><td class="colsep0 rowsep0" align="left">24.74</td><td class="colsep0 rowsep0" align="left">23.67</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">10.10</td><td class="colsep0 rowsep0" align="left">10.56</td><td class="colsep0 rowsep0" align="left">10.10</td><td class="colsep0 rowsep0" align="left">10.56</td><td class="colsep0 rowsep0" align="left">10.10</td><td class="colsep0 rowsep0" align="left">10.56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33f</b></td><td class="colsep0 rowsep0" align="left">21.11</td><td class="colsep0 rowsep0" align="left">3.76</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">11.84</td><td class="colsep0 rowsep0" align="left">66.48</td><td class="colsep0 rowsep0" align="left">11.84</td><td class="colsep0 rowsep0" align="left">66.48</td><td class="colsep0 rowsep0" align="left">11.84</td><td class="colsep0 rowsep0" align="left">66.48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33g</b></td><td class="colsep0 rowsep0" align="left">23.21</td><td class="colsep0 rowsep0" align="left">2.03</td><td class="colsep0 rowsep0" align="left">94.87</td><td class="colsep0 rowsep0" align="left">96.61</td><td class="colsep0 rowsep0" align="left">148.86</td><td class="colsep0 rowsep0" align="left">4.08</td><td class="colsep0 rowsep0" align="left">46.73</td><td class="colsep0 rowsep0" align="left">4.16</td><td class="colsep0 rowsep0" align="left">47.59</td><td class="colsep0 rowsep0" align="left">6.41</td><td class="colsep0 rowsep0" align="left">73.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33h</b></td><td class="colsep0 rowsep0" align="left">24.63</td><td class="colsep0 rowsep0" align="left">4.92</td><td class="colsep0 rowsep0" align="left">92.82</td><td class="colsep0 rowsep0" align="left">162.41</td><td class="colsep0 rowsep0" align="left">137.39</td><td class="colsep0 rowsep0" align="left">3.76</td><td class="colsep0 rowsep0" align="left">18.86</td><td class="colsep0 rowsep0" align="left">6.59</td><td class="colsep0 rowsep0" align="left">33.01</td><td class="colsep0 rowsep0" align="left">5.57</td><td class="colsep0 rowsep0" align="left">27.92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33i</b></td><td class="colsep0 rowsep0" align="left">8.23</td><td class="colsep0 rowsep0" align="left">1.08</td><td class="colsep0 rowsep0" align="left">109.41</td><td class="colsep0 rowsep0" align="left">89.69</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">13.29</td><td class="colsep0 rowsep0" align="left">101.3</td><td class="colsep0 rowsep0" align="left">10.89</td><td class="colsep0 rowsep0" align="left">83.04</td><td class="colsep0 rowsep0" align="left">30.37</td><td class="colsep0 rowsep0" align="left">231.48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33j</b></td><td class="colsep0 rowsep0" align="left">20.39</td><td class="colsep0 rowsep0" align="left">16.11</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">12.26</td><td class="colsep0 rowsep0" align="left">15.51</td><td class="colsep0 rowsep0" align="left">12.26</td><td class="colsep0 rowsep0" align="left">15.51</td><td class="colsep0 rowsep0" align="left">12.26</td><td class="colsep0 rowsep0" align="left">15.51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33k</b></td><td class="colsep0 rowsep0" align="left">9.46</td><td class="colsep0 rowsep0" align="left">6.67</td><td class="colsep0 rowsep0" align="left">190.96</td><td class="colsep0 rowsep0" align="left">147.58</td><td class="colsep0 rowsep0" align="left">88.57</td><td class="colsep0 rowsep0" align="left">20.18</td><td class="colsep0 rowsep0" align="left">28.62</td><td class="colsep0 rowsep0" align="left">15.60</td><td class="colsep0 rowsep0" align="left">22.12</td><td class="colsep0 rowsep0" align="left">9.36</td><td class="colsep0 rowsep0" align="left">13.27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">std</td><td class="colsep0 rowsep0" align="left">0.75<a class="ref internalNav" href="#t10fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">0.91<a class="ref internalNav" href="#t10fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">0.0048<a class="ref internalNav" href="#t10fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">0.0021</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">Anti-TB activity against active (a) and dormant (d) strains of <i>Mtb</i> H37Ra as MIC (μg/mL).</p></div><div class="footnote" id="t10fn2"><sup><sup>b</sup></sup><p class="last">Cytotoxicity studies are indicated as growth inhibition (GI<sub>50</sub>) (μg/mL).</p></div><div class="footnote" id="t10fn3"><sup><sup>c</sup></sup><p class="last">Selectivity index = IC<sub>50</sub> (cytotoxicity)/MIC (anti-TB) for HeLa for both active (<i>a</i>) and dormant (<i>d</i>) strains.</p></div><div class="footnote" id="t10fn4"><sup><sup>d</sup></sup><p class="last">Selectivity index for MCF-7.</p></div><div class="footnote" id="t10fn5"><sup><sup>e</sup></sup><p class="last">Selectivity index for HUVEC.</p></div><div class="footnote" id="t10fn6"><sup><sup>f</sup></sup><p class="last">Rifampicin used as a positive control.</p></div><div class="footnote" id="t10fn7"><sup><sup>g</sup></sup><p class="last">Paclitaxel used as a positive control for anticancer studies.</p></div></div></div><div class="NLM_p last">Compounds containing a methylene group at the C-terminus ester (see benzyl ester <b>33f</b> in <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) were more active than those lacking the methylene group (phenyl ester, <b>33e</b>). Smaller hydrophobic groups at the C-terminal ester moiety were preferred (compare for example <b>33a</b>–<b>c</b> to <b>33e</b>–<b>f</b>). These 2-aminothiophene-based analogues were more potent against multiresistant strains than the standard anti-TB drug rifampicin. Some of the reported compounds were highly specific (as shown by the selectivity index of cytotoxicity studies in human cells, HeLa, MCF-7, and HUVEC, <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>) and seem to possess the potential to become drug candidates. The mechanism of action was explored by docking studies and revealed a possible inhibition of the enzyme <i>InhA</i>.</div></div><div id="sec10_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">10.9.  Spiroindoline, Pyrrolidine, Azetidine, and Tetrazole Structure-Based Compounds</h3><div class="NLM_p">Porras de Francisco et al., from GlaxoSmithKline, filed a number of patents describing four different scaffolds (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>): (I) spiroindoline,<a onclick="showRef(event, 'ref247'); return false;" href="javascript:void(0);" class="ref ref247">(247)</a> (II) pyrrolidine/piperidine (wherein the aliphatic ring is substituted at the C-4 position by various benzyl, phenyl, or heterocyclic groups),<a onclick="showRef(event, 'ref248'); return false;" href="javascript:void(0);" class="ref ref248">(248)</a> (III) azetidines,<a onclick="showRef(event, 'ref249'); return false;" href="javascript:void(0);" class="ref ref249">(249)</a> and (IV) tetrazole<a onclick="showRef(event, 'ref250'); return false;" href="javascript:void(0);" class="ref ref250">(250)</a> structure-based compounds suitable for the development of novel anti-TB compounds.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Chemical structures of the scaffolds disclosed by GlaxoSmithKline for the development of novel potential antitubercular compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds with scaffold I, II, and III were designed with the aim of potentiating the activity of drugs already used in the treatment of TB, and in particular, drugs that are activated via the EthA pathway,<a onclick="showRef(event, 'ref251'); return false;" href="javascript:void(0);" class="ref ref251">(251)</a> such as ethionamide. EthA enzyme is a FAD-containing monooxygenase responsible for the activation of several thiocarbamide-containing prodrugs into cytotoxic species. EthA catalyzes the oxidation of the antitubercular prodrug ethionamide to the corresponding sulfoxide, which is further oxidized by EthA itself to 2-ethyl-4-amidopyridine, probably via the unstable doubly oxidized sulfinic acid intermediate;<a onclick="showRef(event, 'ref251'); return false;" href="javascript:void(0);" class="ref ref251">(251)</a> the final metabolite 2-ethyl-4-amidopyridine has no antitubercular activity. The compounds were screened for their antibacterial activity on <i>Mtb</i> H37Rv and on a mutant strain, and the EC<sub>50</sub>_H37Rv and EC<sub>50</sub>_Mutant, respectively, were reported. EC<sub>50</sub>_H37Rv measures the ability of the compounds to potentiate the antibacterial activity of ethionamide against H37Rv strains, whereas EC<sub>50</sub>_Mutant measures the ability of the compounds to potentiate ethionamide activity against <i>Mtb</i>-resistant strains.</div><div class="NLM_p">The EC<sub>50</sub>_H37Rv values of spiroindolines (scaffold I) were in the range <0.75–0.038 μM, and EC<sub>50</sub>_Mutant values were between <3–0.14 μM, respectively. Furthermore, the compounds were tested <i>in vitro</i> on H37Rv in human macrophages THP-1 (whole-cell assay) and were found to have an IC<sub>50</sub> in the range of 0.5–0.05 μM.<a onclick="showRef(event, 'ref247'); return false;" href="javascript:void(0);" class="ref ref247">(247)</a> Compounds of formula II (pyrrolidine/piperidine structure-based) showed EC<sub>50</sub>_H37Rv < 150 nM and an average EC<sub>50</sub>_Mutant < 1.3 μM, respectively. In the whole-cell assay, the compounds showed 10 μM < IC<sub>50</sub> < 50 nM.<a onclick="showRef(event, 'ref248'); return false;" href="javascript:void(0);" class="ref ref248">(248)</a> Azetidines (scaffold III) were found to have an average EC<sub>50</sub>_H37Rv of <10 nM and an EC<sub>50</sub>_Mutant of <75 nM, respectively. Again, in the whole-cell assay, they exhibited 10 μM < IC<sub>50</sub> < 50 nM.<a onclick="showRef(event, 'ref249'); return false;" href="javascript:void(0);" class="ref ref249">(249)</a></div><div class="NLM_p last">Compounds of tetrazole structure (scaffold IV) were designed as potential inhibitors of <i>Mtb</i> tryptophan synthase (TS), which is a pyridoxal-phosphate-dependent complex catalyzing the last two steps of tryptophan biosynthesis.<a onclick="showRef(event, 'ref252'); return false;" href="javascript:void(0);" class="ref ref252">(252)</a><i>Mtb</i> can synthesize its own tryptophan and unlike other intracellular pathogens is able to survive the intracellular tryptophan starvation.<a onclick="showRef(event, 'ref253'); return false;" href="javascript:void(0);" class="ref ref253">(253)</a> Additionally, tryptophan biosynthesis is lacking in mammals, suggesting the potential for selective inhibition of this target. The tetrazoles were tested in the intracellular assay, and the MIC_H37Rv values ranged between 0.1 μM and 25 μM.<a onclick="showRef(event, 'ref250'); return false;" href="javascript:void(0);" class="ref ref250">(250)</a></div></div><div id="sec10_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">10.10.  DNF-3: A Dinaphthofurandione Structure-Based Lead Compound</h3><div class="NLM_p">Islam et al., in an attempt to discover new drug candidates active against drug-resistant TB strains, screened a chemical library containing approximately a thousand small molecules with high chemical and structural diversity.<a onclick="showRef(event, 'ref254'); return false;" href="javascript:void(0);" class="ref ref254">(254)</a> In the preliminary screening, a compound from the dinaphthofurandione class, namely, dinaphthofuroquinone methyl 5-(2-diethylaminoethoxy)-7,12-dioxo-7,12-dihydrodinaphtho[1,2-<i>b</i>;2,3-<i>d</i>]furan-6-carboxylate (<b>34</b>, DNF-3, <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>), showed strong activity against <i>Mtb</i> strains, with an MIC<sub>50</sub> of 0.19 μg/mL, both against H37Rv and XDR-TB, respectively. DNF-3 was then selected for further study to determine if it would be suitable as a potential anti-TB drug.</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Chemical structure of dinaphthofuroquinone methyl 5-(2-diethylaminoethoxy)-7,12-dioxo-7,12-dihydrodinaphtho[1,2-<i>b</i>;2,3-<i>d</i>]furan-6-carboxylate (DNF-3, <b>34</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>DNF-3</b> was then tested against 22 additional clinically isolated MDR-TB and XDR-TB strains (<a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a>) and showed MICs ranging from 0.02–0.39 μg/mL. When combined with rifampicin and streptomycin, an intense synergistic effect of <b>DNF-3</b> against XDR-TB was noticed. Furthermore, <b>DNF-3</b> showed a more prolonged post-antibiotic effect (PAE) compared to isoniazid, streptomycin, and ethambutol. An extended PAE can allow a reduced number of dosing, without loss of therapeutic efficacy<a onclick="showRef(event, 'ref255'); return false;" href="javascript:void(0);" class="ref ref255">(255)</a> and in the case of TB treatment, would reduce costs and toxicities. Moreover, <b>DNF-3</b> was not toxic for any of the several mammalian cell lines tested, with an SI > 32, suggesting that this molecule might be pharmacologically safe. The activity of <b>DNF-3</b> was also evaluated against many clinically significant Gram-positive and Gram-negative bacteria. This lead compound showed a high antibacterial profile against nontuberculosis mycobacteria (NTM) and other Gram-positive pathogens, but it was inactive against Gram-negatives. All the evidence taken together suggest <b>DNF-3</b> as a powerful candidate not only for its potential antimycobacterial activity but also for the broad-spectrum profile against NTM and other Gram-positive bacteria. Overall, <b>DNF-3</b> seemed to be a suitable candidate for further evaluation, including preclinical experiments and animal efficacy assays.</div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Anti-Tb Activity of Lead Compound DFN-3 and Positive Controls against a Panel of <i>Mtb</i>-Resistant Strains</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">MIC (μg/mL)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">strain</th><th class="colsep0 rowsep0" align="center" char=".">DNF-3</th><th class="colsep0 rowsep0" align="center">isoniazid</th><th class="colsep0 rowsep0" align="center">rifampicin</th><th class="colsep0 rowsep0" align="center">streptomycin</th><th class="colsep0 rowsep0" align="center" char=".">ethambutol</th><th class="colsep0 rowsep0" align="center">pyrazinamide</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H37Rv</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="left">0.19</td><td class="colsep0 rowsep0" align="left">0.049</td><td class="colsep0 rowsep0" align="left">0.19</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDR1</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDR2</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">1.56</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDR3</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="left">3.13</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="char" char=".">3.13</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDR4</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDR5</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">3.13</td><td class="colsep0 rowsep0" align="left">3.13</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDR6</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDR7</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDR8</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">3.13</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDR9</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="char" char=".">3.13</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDR10</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="left">3.13</td><td class="colsep0 rowsep0" align="left">3.13</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDR11</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">3.13</td><td class="colsep0 rowsep0" align="left">3.13</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">XDR-TB</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">XDR1</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">XDR2</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="left">3.13</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">XDR3</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="left">3.13</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">XDR4</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">6.25</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">XDR5</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">XDR6</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">XDR7</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="left">6.25</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="char" char=".">12.5</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">XDR8</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">XDR9</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">XDR10</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">6.25</td><td class="colsep0 rowsep0" align="left"><0.09</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">XDR11</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="left">6.25</td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="left">>200</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup><sup>a</sup></sup><p class="last">XDR-TB strain KMRC 0 0203-0 0197.<a onclick="showRef(event, 'ref254'); return false;" href="javascript:void(0);" class="ref ref254">(254)</a></p></div></div></div></div><div id="sec10_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">10.11.  Benzylsulfanyl Benzo-heterocycle Amides and Hydrazones</h3><div class="NLM_p">In 2017, Lu et al. designed two novel class of compounds by molecular hybridization between pyridyl amide or hydrazone pharmacophore and benzylsulfanyl benzo-heterocycle pharmacophore.<a onclick="showRef(event, 'ref256'); return false;" href="javascript:void(0);" class="ref ref256">(256)</a> A set of 12 new molecules having the structure of benzylsulfanyl benzo-heterocycle amides <b>35a</b>–<b>f</b> and hydrazones <b>36a</b>–<b>f</b> was developed (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>).</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Chemical structure of benzylsulfanyl benzo-heterocycle amide (<b>35a</b>–<b>f</b>) and hydrazone (<b>36a</b>–<b>f</b>) derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">When tested against <i>Mtb</i> H37Rv, hydrazones, in general, were more active than the corresponding amides. In particular, <b>36d</b>, <b>36e</b>, and <b>36f</b> showed significant activities (<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a>), with MIC values of 0.23 μM, 0.24 μM, and 0.24 μM, respectively, and were better than the positive controls (isoniazid, moxifloxacin, streptomycin) but less potent than rifampicin. While most of benzylsulfanyl benzazole amides showed poor antimycobacterial activity (MIC in the range of 0.9–128 μM), compound <b>35e</b> was the only example of this group with antimycobacterial activity equivalent to isoniazid (MIC of 0.9 μM). From the results, it seemed that the isonicotinic moiety could serve as a key function for good antitubercular activity. The four most active compounds (<b>35e</b>, <b>36d</b>–<b>f</b>) were then screened against <i>Mtb</i> drug-susceptible (DS), MDR, and XDR clinical strains (<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a>). The amide compound <b>35e</b> was potent only against MDR-TB (MIC of 2.0 μM).</div><div class="NLM_table-wrap" id="tbl12"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 12. Antibacterial Activity of Analogues <b>35a</b>–<b>f</b> and <b>36a</b>–<b>f</b> against <i>Mtb</i> H37Rv and Clinical Resistant Strains</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center">MIC (μg/mL)</th><th class="rowsep1 colsep0" colspan="3" align="center">MIC (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">H37Rv</th><th class="colsep0 rowsep0" align="center">960 (DS-TB)</th><th class="colsep0 rowsep0" align="center">330 (MDR-TB)</th><th class="colsep0 rowsep0" align="center">431 (XDR-TB)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35a</b></td><td class="colsep0 rowsep0" align="left">60.3</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35b</b></td><td class="colsep0 rowsep0" align="left">58.2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35c</b></td><td class="colsep0 rowsep0" align="left">>128</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35d</b></td><td class="colsep0 rowsep0" align="left">120.5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35e</b></td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">16.0</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">16.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35f</b></td><td class="colsep0 rowsep0" align="left">>128</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36a</b></td><td class="colsep0 rowsep0" align="left">114.4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36b</b></td><td class="colsep0 rowsep0" align="left">24.8</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36c</b></td><td class="colsep0 rowsep0" align="left">>128</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36d</b></td><td class="colsep0 rowsep0" align="left">0.23</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">6.4</td><td class="colsep0 rowsep0" align="left">>128</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36e</b></td><td class="colsep0 rowsep0" align="left">0.24</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">6.4</td><td class="colsep0 rowsep0" align="left">3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36f</b></td><td class="colsep0 rowsep0" align="left">0.28</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">6.4</td><td class="colsep0 rowsep0" align="left">>128</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">isoniazid</td><td class="colsep0 rowsep0" align="left">0.81</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rifampicin</td><td class="colsep0 rowsep0" align="left">0.08</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">moxifloxacin</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">0.07</td><td class="colsep0 rowsep0" align="left">>19</td><td class="colsep0 rowsep0" align="left">>19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">streptomycin</td><td class="colsep0 rowsep0" align="left">0.48</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pretomanid</td><td class="colsep0 rowsep0" align="left">0.44</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ftivazide</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">32</td></tr></tbody></table></div></div><div class="NLM_p">The hydrazones <b>36d</b>–<b>f</b> exhibited good activities against DS-TB as well as MDR-TB (MIC of 6.4 μM) and were more potent than the positive controls. Significantly, hydrazone <b>36e</b> containing a benzoxazole moiety was 10- and 20-fold more potent against XDR-TB than were ftivazide and isoniazid, respectively. Given the evidence that hydrazones <b>36d</b>–<b>f</b> had sub-micromolar MIC values against the H37Rv <i>Mtb</i> strain and potent antitubercular activities against MDR-TB strains, the authors decided to further screen those molecules against a panel of single drug-resistant (SDR-TB) strains, using ftivazide as the control drug (<a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">Table <a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">13</a></a>). The three hydrazones showed excellent activities against a panel of ATCC SDR-TB with MIC values comparable to ftivazide. Moreover, these three derivatives exhibited low toxicity, as they did not kill more than 10% of the cells at the maximum concentration tested. More importantly, compounds <b>36d</b> and <b>36e</b> were less cytotoxic than ftivazide. <i>In vitro</i> metabolic stability of the best compounds <b>36d</b>–<b>f</b> was evaluated using human liver microsomes. All compounds showed some metabolism after 60 min of incubation, with <b>36e</b> being the least metabolized and then the most stable. These results provided the basis for the next <i>in vivo</i> evaluation of the lead compound <b>36e</b>, which exhibited a constant antitubercular activity against <i>Mtb</i> H37Ra <i>in vivo</i> during six consecutive days, and its activity (3.1 mg/kg/day) was as good as the positive drug control rifampicin (10 mg/kg/day dose). This evidence strongly indicated the potential of compound <b>36e</b> to be a promising lead compound for further development.</div><div class="NLM_table-wrap" id="tbl13"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 13. Antimycobacterial Activity of <b>36d</b>–<b>f</b> against the Single Drug-Resistant <i>Mtb</i> Strains</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">MIC (μg/mL)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">SDR-TB</th><th class="colsep0 rowsep0" align="center" char="."><b>36d</b></th><th class="colsep0 rowsep0" align="center" char="."><b>36e</b></th><th class="colsep0 rowsep0" align="center" char="."><b>36f</b></th><th class="colsep0 rowsep0" align="center" char=".">ftivizide</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ATCC 35837 ethambutol</td><td class="colsep0 rowsep0" align="char" char=".">0.156</td><td class="colsep0 rowsep0" align="char" char=".">0.156</td><td class="colsep0 rowsep0" align="char" char=".">0.312</td><td class="colsep0 rowsep0" align="char" char=".">0.312</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ATCC 35830 ethionamide</td><td class="colsep0 rowsep0" align="char" char=".">1.25</td><td class="colsep0 rowsep0" align="char" char=".">1.25</td><td class="colsep0 rowsep0" align="char" char=".">1.25</td><td class="colsep0 rowsep0" align="char" char=".">1.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ATCC 35827 kanamycin</td><td class="colsep0 rowsep0" align="char" char=".">0.156</td><td class="colsep0 rowsep0" align="char" char=".">0.156</td><td class="colsep0 rowsep0" align="char" char=".">0.312</td><td class="colsep0 rowsep0" align="char" char=".">0.156</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ATCC 35821 <i>p</i>-NH<sub>2</sub>-salicylic acid</td><td class="colsep0 rowsep0" align="char" char=".">0.312</td><td class="colsep0 rowsep0" align="char" char=".">0.312</td><td class="colsep0 rowsep0" align="char" char=".">0.625</td><td class="colsep0 rowsep0" align="char" char=".">0.312</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ATCC 35820 streptomycin</td><td class="colsep0 rowsep0" align="char" char=".">0.156</td><td class="colsep0 rowsep0" align="char" char=".">0.156</td><td class="colsep0 rowsep0" align="char" char=".">0.312</td><td class="colsep0 rowsep0" align="char" char=".">0.312</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H37Rv rifampicin</td><td class="colsep0 rowsep0" align="char" char=".">0.312</td><td class="colsep0 rowsep0" align="char" char=".">0.312</td><td class="colsep0 rowsep0" align="char" char=".">0.625</td><td class="colsep0 rowsep0" align="char" char=".">0.312</td></tr></tbody></table></div></div></div><div id="sec10_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36">10.12.  Isonicotinohydrazide Derivatives</h3><div class="NLM_p">In 2016, Chhabria et al.<a onclick="showRef(event, 'ref257'); return false;" href="javascript:void(0);" class="ref ref257">(257)</a> designed a series of <i>N</i>′-substituted isonicotinohydrazide derivatives based on pharmacophore modeling (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Chemical structures of <i>N</i>′-substituted isonicotinohydrazides <b>37a</b>–<b>y</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In this study, all synthesized derivatives were evaluated for their antimycobacterial activity against <i>Mtb</i> H37Rv strain, and the MIC values are shown in <a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">Table <a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">14</a></a> and compared to those of standard drugs (pyrazinamide, streptomycin, and ciprofloxacin). In general, compounds with unsaturation at the R side chain (<b>37b</b>) had good antitubercular activity, and the potency increased when electron-donating groups were present on the aromatic ring attached to the unsaturated bond (<b>37d</b>–<b>e</b>). The sulfonyl moiety at the side chain was beneficial (<b>37a</b> and <b>37t</b>, MICs of 12.5 and 50 μg/mL, respectively). The furan moiety and other heteroaromatic rings were also favorable (<b>37d</b> and <b>37g</b>, MICs of 12.5 μg/mL in both cases). Electron-withdrawing groups afforded better activity as compared to the electron-donating ones, especially when substituting the C-3 (<i>meta</i>) and C-4 (<i>ortho</i>) carbons on the side chain aromatic ring (<b>37h</b> and <b>37q</b>). Compounds having a 2-substituted phenyl acetic acid group at the <i>N</i>′-position of the isonicotinohydrazide resulted in good inhibition, suggesting that a one to two carbon distance between the (hetero) aromatic ring and the side chain carbonyl group is optimal for better antitubercular activity. In particular, analogue <b>37m</b> was the most potent of this series (MIC of 6.25 μg/mL) and was further screened against MDR-TB and XDR-TB strains, exhibiting MICs of 62.5 and 250 μg/mL, respectively. These results provided valuable information regarding further structural modification required for the isonicotinohydrazide scaffold substituted at the <i>N</i>′ position. Thus, compound <b>37m</b> can be considered as a promising novel lead for further studies, in order to afford more potent antitubercular chemical entities.</div><div class="NLM_table-wrap" id="tbl14"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 14. Anti-TB Activities of Isonicotinhydrazides <b>37a</b>–<b>y</b> against <i>Mtb</i> H37Rv</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">MIC (μg/mL) H37Rv</th><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">MIC (μg/mL) H37Rv</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37a</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left"><b>37o</b></td><td class="colsep0 rowsep0" align="left">12.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37b</b></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"><b>37p</b></td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37c</b></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"><b>37q</b></td><td class="colsep0 rowsep0" align="left">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37d</b></td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left"><b>37r</b></td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37e</b></td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left"><b>37s</b></td><td class="colsep0 rowsep0" align="left">12.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37f</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left"><b>37t</b></td><td class="colsep0 rowsep0" align="left">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37g</b></td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left"><b>37u</b></td><td class="colsep0 rowsep0" align="left">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37h</b></td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left"><b>37v</b></td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37i</b></td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left"><b>37w</b></td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37j</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left"><b>37x</b></td><td class="colsep0 rowsep0" align="left">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37k</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left"><b>37y</b></td><td class="colsep0 rowsep0" align="left">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37l</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">pyrazinamide</td><td class="colsep0 rowsep0" align="left">3.125</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37m</b></td><td class="colsep0 rowsep0" align="left">6.25<a class="ref internalNav" href="#t14fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">streptomycin</td><td class="colsep0 rowsep0" align="left">6.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37n</b></td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">ciprofloxacin</td><td class="colsep0 rowsep0" align="left">3.125</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t14fn1"><div class="footnote" id="t14fn1"><sup><sup>a</sup></sup><p class="last">Compound <b>37m</b> was further screened against MDR-TB and XDR-TB strains, and the observed MICs values were 62.5 and 250 μg/mL, respectively.</p></div></div></div></div><div id="sec10_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38">10.13.  Benzoxazole-5-pyrazolin(3-yl) Structure-Based Compounds</h3><div class="NLM_p">In 2016, Soni et al. reported a new class of novel benzoxazole-based pyrazoline derivatives (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>)<a onclick="showRef(event, 'ref258'); return false;" href="javascript:void(0);" class="ref ref258">(258)</a> obtained by combining two pharmacophores, such as pyrazoline and benzoxazole nucleus. All the newly synthesized target compounds (<b>38a</b>–<b>i</b>, <b>39</b>–<b>40</b>, <b>41a</b>–<b>k</b>, <b>42</b>–<b>43</b>) were primarily screened against the <i>Mtb</i> H37Rv strain (<a class="ref showTableEvent internalNav" data-ID="tbl15" href="#tbl15">Table <a class="ref showTableEvent internalNav" data-ID="tbl15" href="#tbl15">15</a></a>) and were found to possess satisfactory potency. Derivatives <b>38d</b>–<b>e</b>, <b>39</b>–<b>40</b>, and <b>42</b> were as potent as a streptomycin reference compound (MIC of 6.25 μg/mL), while compounds <b>38f</b> and <b>38i</b>, with MICs of 0.8 and 1.6 μg/mL, respectively, exhibited higher potency than all the positive controls (streptomycin, pyrazinamide, and ciprofloxacin). The most potent compounds <b>38d</b>–<b>e</b>, <b>38i, 39–40</b>, <b>41f</b>, and <b>42</b> were further tested against MDR-TB and XDR-TB strains, and some of them (<b>38d</b>, <b>38i</b>, <b>41f</b>) showed better activity than isoniazid (<a class="ref showTableEvent internalNav" data-ID="tbl15" href="#tbl15">Table <a class="ref showTableEvent internalNav" data-ID="tbl15" href="#tbl15">15</a></a>).</div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Chemical structures of novel benzoxazole-based pyrazoline derivatives <b>38a</b>–<b>i</b>, <b>39</b>–<b>40</b>, <b>41a</b>–<b>k</b>, and <b>42</b>–<b>43</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl15"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 15. <i>In Vitro</i> Antitubercular Activity of Target Compounds (<b>38a</b>–<b>i</b>, <b>39</b>–<b>40</b>, <b>41a</b>–<b>k</b>, <b>42</b>–<b>43</b>) against <i>Mtb</i> H37Rv and MICs against MDR-TB and XDR-TB, and IC<sub>50</sub>’s of Selected Analogues (<b>38d</b>–<b>e</b>, <b>38i</b>, <b>40</b>, <b>41f</b>, and <b>42</b>)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">MIC (μg/mL)</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">H37Rv</th><th class="colsep0 rowsep0" align="center">MDR-TB</th><th class="colsep0 rowsep0" align="center">XDR-TB</th><th class="colsep0 rowsep0" align="center">cytotoxicity IC<sub>50</sub> (μg/mL)</th><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">MIC H37Rv (μg/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38a</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>41b</b></td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38b</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>41c</b></td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38c</b></td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>41d</b></td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38d</b></td><td class="colsep0 rowsep0" align="left">6.25</td><td class="colsep0 rowsep0" align="left">3.12</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">>62.5</td><td class="colsep0 rowsep0" align="left"><b>41e</b></td><td class="colsep0 rowsep0" align="left">12.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38e</b></td><td class="colsep0 rowsep0" align="left">6.25</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>41f</b></td><td class="colsep0 rowsep0" align="left">0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38f</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>41g</b></td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38g</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>41h</b></td><td class="colsep0 rowsep0" align="left">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38h</b></td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>41i</b></td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38i</b></td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">3.12</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">>62.5</td><td class="colsep0 rowsep0" align="left"><b>41j</b></td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">6.25</td><td class="colsep0 rowsep0" align="left">6.25</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>41k</b></td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">6.25</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">12.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41a</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">pyrazinamide</td><td class="colsep0 rowsep0" align="left">3.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41f</b></td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">3.12</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">32.5</td><td class="colsep0 rowsep0" align="left">ciprofloxacin</td><td class="colsep0 rowsep0" align="left">3.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left">6.25</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">streptomycin</td><td class="colsep0 rowsep0" align="left">6.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">isoniazid</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">6.25</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div></div><div class="NLM_p last">The compounds were safe when tested for cytotoxicity and displayed an SI > 10, suggesting that they could be explored as potential leads for further development. Overall, the pharmacophore combination approach seemed to be a useful strategy for the discovery of novel chemo types of antitubercular agents.</div></div><div id="sec10_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40">10.14.  Triazole Structure-Based Compounds</h3><div class="NLM_p">In the beginning of 2016, Yempalla et al. disclosed a new generation of triazole-scaffold-based 6-nitro-2,3-dihydroimidazo-2-oxazole functionality<a onclick="showRef(event, 'ref259'); return false;" href="javascript:void(0);" class="ref ref259">(259)</a> as novel potential antitubercular agents (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>).</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Chemical structures of novel triazoles <b>44a</b>–<b>v</b> as potential antitubercular agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">All the newly synthesized compounds (<b>44a</b>–<b>v</b>) were tested against both replicating and nonreplicating stages of <i>Mtb</i> and exhibited MIC values ranging from 0.12 to 8 μg/mL (<a class="ref showTableEvent internalNav" data-ID="tbl16" href="#tbl16">Table <a class="ref showTableEvent internalNav" data-ID="tbl16" href="#tbl16">16</a></a>). Seven analogues (<b>44j</b>–<b>k</b>, <b>44m</b>–<b>n</b>, <b>44q</b>–<b>r</b>, and <b>44u</b>) showed MIC values <1.0 μg/mL, and three of them (<b>44k</b>, <b>44q</b>, and <b>44u</b>) were very potent against replicating (MICs of 0.12, 0.25, and 0.25 μg/mL, respectively) and nonreplicating stages of <i>Mtb</i> H37Rv (MIC of 0.25, 0.5, and 0.25 μg/mL, respectively). Moreover, all the tested compounds were screened against both MDR-TB and XDR-TB; five derivatives (<b>44k</b>, <b>44q</b>, <b>44s</b>, <b>44t</b>, and <b>44u</b>) showed MIC values < 1.0 μg/mL. Compound <b>44k</b> was the most potent compound of this class. Structurally, the presence of a phenyl-oxy moiety (substituted at the C-3 or C-4 position with a halogen or an alkyl chain) as the R<sup>1</sup> group demonstrated superlative anti-TB activity. When the methoxy bridge between the triazole scaffold and the phenyl R<sup>1</sup> was replaced by a thiol group (see <b>44t</b>), the antimycobacterial activity was retained. Overall, these results suggested that there is room for improvement in triazole structure-based derivatives for developing potent antitubercular drugs.</div><div class="NLM_table-wrap" id="tbl16"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 16. <i>In Vitro</i> Antitubercular Activity of Compounds <b>44a</b>–<b>v</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">MIC (μg/mL)</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">H37Rv</th><th class="colsep0 rowsep0" align="center">nonreplicating strain</th><th class="colsep0 rowsep0" align="center">MIC (Rif)</th><th class="colsep0 rowsep0" align="center">MDR-TB</th><th class="colsep0 rowsep0" align="center">XDR-TB</th><th class="colsep0 rowsep0" align="center">cytotoxicity (μg/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44a</b></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44b</b></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44c</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44d</b></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44e</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44f</b></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44g</b></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44h</b></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44i</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44j</b></td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44k</b></td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44l</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44m</b></td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44n</b></td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44o</b></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44p</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44q</b></td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44r</b></td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44s</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44t</b></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44u</b></td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44v</b></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">>40</td></tr></tbody></table></div></div></div><div id="sec10_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42">10.15.  IMB-T130: A Potent Thiazole Structure-Based Compound</h3><div class="NLM_p">Going back to 2015, Zhu et al. reported a new molecule, namely, IMB-T130 (<b>45</b>, <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>), able to inhibit the growth of MDR-TB and XDR-TB, by targeting tyrosyl-tRNA synthetase (TyrRS), one of the aminoacyl tRNA synthetases that catalyzes the attachment of amino acids to their cognate tRNAs.<a onclick="showRef(event, 'ref260'); return false;" href="javascript:void(0);" class="ref ref260">(260)</a></div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Chemical structure of IMB-T130 (<b>45</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In this study, 78 hits were identified through a phenotype screening of 20 000 compounds with <i>M. smegmatis</i>. <b>IMB-T130</b>, with a thiazole core structure, was the only compound showing potent inhibitory activity against TyrRS <i>in vitro</i> at 10 mg/L. Compound <b>45</b> was then screened against a few <i>Mtb</i> strains in order to evaluate its anti-TB activity and was found to be a potent inhibitor of H37Rv (MIC of 0.08 μg/mL, <a class="ref showTableEvent internalNav" data-ID="tbl17" href="#tbl17">Table <a class="ref showTableEvent internalNav" data-ID="tbl17" href="#tbl17">17</a></a>). For WT clinical strains FJ05349 and FJ05060, the MIC value was of 0.08 μg/mL, while against MDR-TB clinical strains (MDR-FJ05120 and MDR-FJ05189), the MICs were 0.25 and 4 mg/mL, respectively. Finally, for the XDR-TB clinical strain (XDR-FJ05195), compound <b>45</b> exhibited an MIC of 0.25 μg/mL. Overall, these results indicated that <b>IMB-T130</b> had anti-TB activity against susceptible strains comparable to the first-line drugs, such as rifampicin (MICs ranging from 0.0625 to 0.125 μg/mL) and isoniazid (MICs ranging from 0.0625 to 0.125 μg/mL). Moreover, <b>IMB-T130</b> was found to be a selective inhibitor of <i>Mtb</i> (<a class="ref showTableEvent internalNav" data-ID="tbl17" href="#tbl17">Table <a class="ref showTableEvent internalNav" data-ID="tbl17" href="#tbl17">17</a></a>), showing a weak inhibitory activity only against <i>Staphylococcus epidermidis</i> and <i>Staphylococcus aureus</i> and suggesting a promising selectivity. Thus, this target compound seems to be a good starting point for further optimization and development of a new class of drugs with novel mechanism of action.</div><div class="NLM_table-wrap" id="tbl17"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 17. <i>In Vitro</i> MIC Values of <b>IMB-T130</b> (<b>45</b>) against H37Rv and Other Strains</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">MIC (μg/mL)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">strains</th><th class="colsep0 rowsep0" align="center">IMB-T130 (<b>45</b>)</th><th class="colsep0 rowsep0" align="center">rifampicin</th><th class="colsep0 rowsep0" align="center">isoniazid</th><th class="colsep0 rowsep0" align="center">levofloxacin</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H37Rv</td><td class="colsep0 rowsep0" align="left">0.08</td><td class="colsep0 rowsep0" align="left">0.125</td><td class="colsep0 rowsep0" align="left">0.125</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STB-FJ05349</td><td class="colsep0 rowsep0" align="left">0.08</td><td class="colsep0 rowsep0" align="left"><0.5</td><td class="colsep0 rowsep0" align="left"><0.5</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STB-FJ05060</td><td class="colsep0 rowsep0" align="left">0.08</td><td class="colsep0 rowsep0" align="left"><0.5</td><td class="colsep0 rowsep0" align="left"><0.5</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDR-FJ05120</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">>256</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDR-FJ05189</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">>256</td><td class="colsep0 rowsep0" align="left"><0.5</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">XDR-FJ05195</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">>256</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>S. aureus</i> 29213</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>E. coli</i> 25922</td><td class="colsep0 rowsep0" align="left">256</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>S. epidermidis</i></td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.25</td></tr></tbody></table></div></div></div><div id="sec10_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44">10.16.  Thiophene-Based Compounds</h3><div class="NLM_p">In 2013, Wilson et al. described a new class of thiophenes targeting the <i>Mtb</i> cell wall by inhibiting Pks13.<a onclick="showRef(event, 'ref261'); return false;" href="javascript:void(0);" class="ref ref261">(261)</a> A library of 1113 compounds was screened with known activity against <i>Mtb</i>, on a whole-cell basis. Compounds able to cause a 4-fold or greater induction of <i>iniBAC</i> operon expression<a onclick="showRef(event, 'ref262'); return false;" href="javascript:void(0);" class="ref ref262">(262)</a> were selected, and this resulted in the identification of a number of thiophene derivatives which were chosen for further studies (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>). The MIC values of these new molecules against <i>Mtb</i> H37Rv strains ranged from 0.5 to 20.2 μM (<a class="ref showTableEvent internalNav" data-ID="tbl18" href="#tbl18">Table <a class="ref showTableEvent internalNav" data-ID="tbl18" href="#tbl18">18</a></a>), with compounds <b>46a</b> and <b>47a</b> being the most promising and having an MIC of 0.5 and 1.0 μM, respectively. These two molecules were equally active on MDR-TB strains. SAR investigation suggested that replacement of the pentafluorophenyl amide moiety in the most potent compound with a 2-fluorophenylamide or 4-methylphenylamide (compare <b>46a</b> to <b>47a</b> or <b>47b</b>) resulted in substantial loss of activity. Substitution of the 3-alkyl ester with a primary amide (compare <b>46a</b> to <b>47c</b>) or with a carboxylic acid (compare <b>47a</b> to <b>47d</b>) was also detrimental. Ultimately, the transposition of the 3-ester and 5-amide functionalities (compare <b>47a</b> to <b>47e</b>) also caused a drastic reduction of whole-cell activity.</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Thiophene-based structure compounds <b>46a</b>–<b>e</b>, <b>47a</b>–<b>f</b>, and <b>48a</b>–<b>b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl18"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 18. Thiophene MIC Values against <i>Mtb</i></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">MIC (μg/mL)</th><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center" char=".">MIC (μg/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46a</b></td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left"><b>47c</b></td><td class="colsep0 rowsep0" align="char" char=".">78.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46b</b></td><td class="colsep0 rowsep0" align="left">20.2</td><td class="colsep0 rowsep0" align="left"><b>47d</b></td><td class="colsep0 rowsep0" align="char" char=".">4.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46c</b></td><td class="colsep0 rowsep0" align="left">>20.2</td><td class="colsep0 rowsep0" align="left"><b>47e</b></td><td class="colsep0 rowsep0" align="char" char=".">7.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46d</b></td><td class="colsep0 rowsep0" align="left">15.3</td><td class="colsep0 rowsep0" align="left"><b>47f</b></td><td class="colsep0 rowsep0" align="char" char=".">3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46e</b></td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left"><b>48a</b></td><td class="colsep0 rowsep0" align="char" char=".">2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47a</b></td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left"><b>48b</b></td><td class="colsep0 rowsep0" align="char" char=".">10.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47b</b></td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div></div><div class="NLM_p last">The same study also demonstrated that a F79S mutation near residue Ser55 within the catalytic site in Pks13 caused resistance to this class of compounds.<a onclick="showRef(event, 'ref261'); return false;" href="javascript:void(0);" class="ref ref261">(261)</a> Overall, thiophenes were able to inhibit the mycolic acid biosynthesis in wild-type <i>Mtb</i>, but they were less effective against resistant strains. Treatment with these compounds was bactericidal and equivalent to the treatment with the first-line drug isoniazid. The combined treatment with isoniazid and thiophenes resulted in sterilizing activity. Computational docking studies helped the authors identify a possible binding site of thiophenes within the Pks13 acyl carrier protein domain, thus confirming that <i>Mtb</i> Pks13 is required for the mycolic acid biosynthesis process and validating Pks13 as a novel druggable target to cure tuberculosis.</div></div><div id="sec10_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46">10.17.  Benzothiazole Structure-Based Compounds</h3><div class="NLM_p">In the same year, benzothiazole-derivative <b>49</b> (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>) was reported by Wang’s group to be a potent anti-TB agent against drug-resistant and persistent tuberculosis.<a onclick="showRef(event, 'ref263'); return false;" href="javascript:void(0);" class="ref ref263">(263)</a></div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Chemical structure of <b>49</b>, a potent and selective <i>Mtb</i> inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compound <b>49</b> was identified through a cell-based screening involving the growth of mycobacteria as an <i>in vitro</i> pellicle. It was shown to have potent bactericidal activity against both replicating (WT and drug-resistant) and nonreplicating <i>Mtb</i> and proved efficacious in acute and chronic <i>Mtb</i> infection mouse models, both alone and in combination with isoniazid and rifampicin. In-depth biochemical and genetic studies showed that the compound functions by a very unique mechanism of action, inhibiting two distinct biosynthetic pathways (cell wall and molybdenum cofactor biosynthesis) with concomitant down-regulation of genes known to be involved in mycobacterial persistence.</div></div><div id="sec10_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47">10.18.  Fluoroquinolones</h3><div class="NLM_p">Fluoroquinolones are second-line drugs for TB treatment, and some of them represent an important tool to fight MDR-TB strains in combination therapy.<a onclick="showRef(event, 'ref264'); return false;" href="javascript:void(0);" class="ref ref264">(264)</a> Fluoroquinolones act by targeting the <i>DNA gyrase</i> (DNA supercoiling), thus inhibiting the <i>Mtb</i> replication cycle, and causing cell death.<a onclick="showRef(event, 'ref265'); return false;" href="javascript:void(0);" class="ref ref265">(265)</a> The increased use of fluoroquinolones has led to drug resistance via different mechanistic pathways: (a) point mutations in <i>gyrA</i> and <i>gyrB</i> genes, in the so-called quinolone resistance determining regions (QRDRs quinolone binding region);<a onclick="showRef(event, 'ref266'); return false;" href="javascript:void(0);" class="ref ref266">(266)</a> (b) mutations in regions of <i>gyrA</i> or <i>gyrB</i> outside of the QRDRs; (c) decreased cell wall permeability to the drug; (d) an active drug efflux pump mechanism, with sequestration or drug inactivation. XDR is in fact an extended MDR, and applies to strains resistant to any fluoroquinolones and to at least one of the three second-line injectable anti-TB drugs (amikacin, capreomycin, and kanamycin). Within the fluoroquinolone class of drugs, the newer levofloxacin (<b>50</b>, <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>) and moxifloxacin (<b>9</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) are preferred over ofloxacin (<b>51</b>, <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>).<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> In light of MDR and XDR <i>Mtb</i> drug resistance, the discovery of new drugs is essential in order to successfully combat resistance in TB, and, in this regard, gyrase inhibitors are of key importance in antitubercular treatment.</div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Structure of clinically used fluoroquinolones [ciprofloxacin (<b>7</b>) and levofloxacin (<b>50</b>)] and ofloxacin (<b>51</b>); structure of lead compound pirfloxacin (<b>52</b>) and novel fluoroquinolone analogues <b>53a</b>–<b>u</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2013, Guerrini et al. reported a study on novel fluoroquinolones, designed as structural modifications of pirfloxacin (<b>52</b>, <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>).<a onclick="showRef(event, 'ref267'); return false;" href="javascript:void(0);" class="ref ref267">(267)</a> Compound <b>52</b> was described in 1985 as an antibacterial agent with good antimicrobial spectrum against both Gram-positive and Gram-negative strains.<a onclick="showRef(event, 'ref268'); return false;" href="javascript:void(0);" class="ref ref268">(268)</a> However, when tested against <i>Mtb</i>, <b>52</b> showed antimycobacterial activity lower than other clinically known fluoroquinolone anti-TB drugs (with MIC<sub>50</sub> and MIC<sub>90</sub> values of 8 and 16 μg/mL, respectively). Moreover, it was structurally interesting and was a starting point good enough for the design of new potential more potent anti-TB drugs. In fact, this lead compound, having a nonbasic heteroaromatic moiety at the C-7 position, differs from clinically useful fluoroquinolones ciprofloxacin (<b>7</b>) and levofloxacin (<b>50</b>) (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>). This is characterized by the presence of pyrrolidine-/piperazine-based substituents that have been widely explored to improve pharmacodynamic and pharmacokinetic profiles of fluoroquinolones. On the basis of structural modifications to compound <b>52</b>, Guerrini et al. designed and synthesized new molecules (compounds <b>53a</b>–<b>u</b>). First, the N-1 ethyl group was substituted with a branched and bulkier alkyl group <i>tert</i>-butyl, and for comparison a few examples with cyclopropyl, 3,3-dimethylbutyl, and 1,1-dimethylpropyl groups were also designed and synthesized. Second, an (hetero)-aromatic moiety at the C-7 position of the quinolone nucleus was introduced as an isosteric replacement of the pyrrole ring. The fluoro substituent at the C-6 position was retained, as desfluoro derivatives of pirfloxacin were inactive against mycobacteria.<a onclick="showRef(event, 'ref267'); return false;" href="javascript:void(0);" class="ref ref267">(267)</a></div><div class="NLM_p">Out of 21 newly synthesized molecules, quinolones <b>53o</b> and <b>53n</b> were as potent as ciprofloxacin (<b>7</b>) and levofloxacin (<b>40</b>) for the <i>Mtb</i> H37Rv strain and maintained the same activity during the five weeks of the assay (same MIC value of 0.25 μg/mL, <a class="ref showTableEvent internalNav" data-ID="tbl19" href="#tbl19">Table <a class="ref showTableEvent internalNav" data-ID="tbl19" href="#tbl19">19</a></a>), while most of the other compounds proved to be less favorable for antitubercular activity. The two most active fluoroquinolones <b>53o</b> and <b>53n</b> retained their anti-TB activity when tested against one fluoroquinolone-sensitive and nine fluoroquinolone-resistant clinical isolates of <i>Mtb</i> (<a class="ref showTableEvent internalNav" data-ID="tbl20" href="#tbl20">Table <a class="ref showTableEvent internalNav" data-ID="tbl20" href="#tbl20">20</a></a>) bearing different point mutations in QRDRs of <i>gyrA</i> and <i>gyrB</i> genes. In particular, compound <b>53o</b> was more active than ciprofloxacin against all tested fluoroquinolones-resistant strains (with a 4-fold difference of MIC value for the strain 199-00, <a class="ref showTableEvent internalNav" data-ID="tbl20" href="#tbl20">Table <a class="ref showTableEvent internalNav" data-ID="tbl20" href="#tbl20">20</a></a>), while compound <b>53n</b> was more active than ciprofloxacin against fluoroquinolones-resistant strains tested, except for the 742-0 strain. The difference in MIC values suggests the potential of these two novel structures, <b>53n</b> and <b>53o</b>, and the need to further carry these molecules into the development stage.</div><div class="NLM_table-wrap" id="tbl19"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 19. MIC (μg/mL) of Compounds <b>53a</b>–<b>u</b> and Positive Controls Ciprofloxacin (<b>7</b>) and Levofloxacin (<b>50</b>) against <i>Mtb</i> H37Rv</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">MIC (μg/mL) <i>Mtb</i> H37Rv</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">MIC (μg/mL) <i>Mtb</i> H37Rv</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">clogP<a class="ref internalNav" href="#t19fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">2 w</th><th class="colsep0 rowsep0" align="center">3 w</th><th class="colsep0 rowsep0" align="center">4 w</th><th class="colsep0 rowsep0" align="center">5 w</th><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">clogP<a class="ref internalNav" href="#t19fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">2 w</th><th class="colsep0 rowsep0" align="center">3 w</th><th class="colsep0 rowsep0" align="center">4 w</th><th class="colsep0 rowsep0" align="center">5 w</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53a</b></td><td class="colsep0 rowsep0" align="left">4.34</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left"><b>53m</b></td><td class="colsep0 rowsep0" align="left">3.17</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53b</b></td><td class="colsep0 rowsep0" align="left">3.78</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left"><b>53n</b></td><td class="colsep0 rowsep0" align="left">2.58</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53c</b></td><td class="colsep0 rowsep0" align="left">3.91</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left"><b>53o</b></td><td class="colsep0 rowsep0" align="left">3.52</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53d</b></td><td class="colsep0 rowsep0" align="left">4.23</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left"><b>53p</b></td><td class="colsep0 rowsep0" align="left">4.28</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53e</b></td><td class="colsep0 rowsep0" align="left">4.47</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left"><b>53q</b></td><td class="colsep0 rowsep0" align="left">5.59</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53f</b></td><td class="colsep0 rowsep0" align="left">4.47</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left"><b>53r</b></td><td class="colsep0 rowsep0" align="left">4.18</td><td class="colsep0 rowsep0" align="left">>16</td><td class="colsep0 rowsep0" align="left">>16</td><td class="colsep0 rowsep0" align="left">>16</td><td class="colsep0 rowsep0" align="left">>16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53g</b></td><td class="colsep0 rowsep0" align="left">4.47</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left"><b>53s</b></td><td class="colsep0 rowsep0" align="left">3.17</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53h</b></td><td class="colsep0 rowsep0" align="left">4.44</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left"><b>53t</b></td><td class="colsep0 rowsep0" align="left">5.08</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53i</b></td><td class="colsep0 rowsep0" align="left">4.40</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left"><b>53u</b></td><td class="colsep0 rowsep0" align="left">4.44</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53j</b></td><td class="colsep0 rowsep0" align="left">4.44</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">ciprofloxacin</td><td class="colsep0 rowsep0" align="left">1.32</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53k</b></td><td class="colsep0 rowsep0" align="left">3.79</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">levofloxacin</td><td class="colsep0 rowsep0" align="left">1.35</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53l</b></td><td class="colsep0 rowsep0" align="left">3.79</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t19fn1"><div class="footnote" id="t19fn1"><sup><sup>a</sup></sup><p class="last">Calculated.</p></div></div></div><div class="NLM_table-wrap" id="tbl20"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 20. MICs of Compounds <b>53n</b> and <b>53o</b> Determined against Nine Fluoroquinolone-Resistant Strains</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="11" align="center">MIC (μg/mL) <i>Mtb</i>-resistant strains<a class="ref internalNav" href="#t20fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">199-00</th><th class="colsep0 rowsep0" align="center">581-17</th><th class="colsep0 rowsep0" align="center">410-11</th><th class="colsep0 rowsep0" align="center">742-0</th><th class="colsep0 rowsep0" align="center">666-0</th><th class="colsep0 rowsep0" align="center">383-0</th><th class="colsep0 rowsep0" align="center">152-0</th><th class="colsep0 rowsep0" align="center">427-18</th><th class="colsep0 rowsep0" align="center">775-0</th><th class="colsep0 rowsep0" align="center">124-0</th><th class="colsep0 rowsep0" align="center">H37Rv</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53n</b></td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53o</b></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ciprofloxacin</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">0.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t20fn1"><div class="footnote" id="t20fn1"><sup><sup>a</sup></sup><p class="last">199-00: <i>gyr A</i> = c270t (A90 V); <i>gyrB</i> = WT; 581-17: <i>gyr A</i> = c270t (A90 V); <i>gyrB</i> = WT; 410-11: <i>gyr A</i> = WT; <i>gyrB</i> = WT; 742-0: <i>gyr A</i> = a282g (D94G); <i>gyrB</i> = WT; 666-0: <i>gyr A</i> = WT; <i>gyrB</i> = WT; 383-0: <i>gyr A</i> = WT; <i>gyrB</i> = WT; 152-0: <i>gyr A</i> = WT; <i>gyrB</i> = WT; 427-18: <i>gyr A</i> = c270t (A90 V); <i>gyrB</i> = WT; 775-0: <i>gyr A</i> = c270t (A90 V); <i>gyrB</i> = WT; 124-0: <i>gyr A</i> = WT; <i>gyrB</i> = WT; H37Rv: <i>gyr A</i> = WT; <i>gyrB</i> = WT.</p></div></div></div><div class="NLM_p last">Overall, the obtained results indicated that the N-1 <i>tert</i>-butyl chain does not always ensure good anti-TB activity, and its replacement with other bulkier alkyl groups was detrimental. Moreover, the replacement of the classical pyrrolidinyl or piperazinyl groups with (hetero) aryl moieties at the C-7 position was tolerated and produced the two most potent compounds <b>53n</b> and <b>53o</b>. Finally, changes in lipophilicity alone did not affect antimycobacterial activity in a predictable way since all the active compounds had clogP values higher than the positive controls ciprofloxacin and levofloxacin (<a class="ref showTableEvent internalNav" data-ID="tbl19" href="#tbl19">Table <a class="ref showTableEvent internalNav" data-ID="tbl19" href="#tbl19">19</a></a>). Therefore, the introduction of substituents that enhance lipophilicity could probably improve bacterial cell penetration by passive diffusion but may decrease the activity of the fluoroquinolones by reducing their affinity for the DNA gyrase binding site.</div></div></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50">11.  Nanotechnology-Based Approaches for Drug Delivery</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44254" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44254" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Conventional drug delivery suffers from various shortcomings such as poor bioavailability, low solubility, a lack of site-specific delivery. and generalized adverse effects. Therefore, nanotechnology for drug delivery has the potential for enhancing the current treatment options with site-specific delivery and fewer side effects.<a onclick="showRef(event, 'ref269'); return false;" href="javascript:void(0);" class="ref ref269">(269)</a></div><div class="NLM_p">There is a need to develop innovative drug delivery systems, which would enable high treatment adherence, have low adverse effects, and exhibit equal safety and efficacy for adults as well as children. Development of novel drug-loaded nanotechnological platforms has ensured potential avenues for improvement of TB pharmacotherapy.<a onclick="showRef(event, 'ref270'); return false;" href="javascript:void(0);" class="ref ref270">(270)</a> In fact, tremendous efforts have been directed toward assessing the first-line anti-TB drug delivery systems<a onclick="showRef(event, 'ref271'); return false;" href="javascript:void(0);" class="ref ref271">(271)</a> since these are the most effective and low-priced options. The advancement of nanotechnology has led to the development of suitable nanosized carriers, which have been extremely useful to overcome the major physicochemical limitations of anti-TB drugs such as low aqueous solubility, chemical stability, and oral bioavailability.<a onclick="showRef(event, 'ref272'); return false;" href="javascript:void(0);" class="ref ref272">(272)</a></div><div class="NLM_p">In general, nanotechnology can thoroughly investigate and exploit novel factors and characteristics of materials in order to develop new strategies and delivery systems for diagnosis and treatment of diseases, as well as to enhance the properties of previously manufactured systems. Interestingly, by combining and connecting the most recent knowledge of nanomaterials with the understanding of different biological processes, nanotechnology can potentially ameliorate and trigger the usage of brand new drug/antigen delivery systems. Explicitly, nanotechnology represents a versatile alternative, in which different approaches have been studied to assess diverse types of nanocarriers, based on biomaterials with different administration routes.<a onclick="showRef(event, 'ref273'); return false;" href="javascript:void(0);" class="ref ref273">(273)</a></div><div class="NLM_p">Main advantages of nanoparticle-based drug delivery system for treatment of TB include the ability to carry multiple drugs in encapsulated form and better availability of drugs because of their slow release. <a class="ref showTableEvent internalNav" data-ID="tbl21" href="#tbl21">Table <a class="ref showTableEvent internalNav" data-ID="tbl21" href="#tbl21">21</a></a> summarizes different types of nanoparticles (NPs), their application, and the advantages associated with their use. Moreover, various modes of administration of drugs via NPs further prove advantageous. Importantly, side effects associated with their use as carriers are negligible.<a onclick="showRef(event, 'ref274'); return false;" href="javascript:void(0);" class="ref ref274">(274)</a> Commonly, the treatment of TB involves the uptake of NPs through various methods that involve transport through M-cells; uptake within the cells and movement via the epithelial cells of the intestine; and finally, uptake by means of Peyer’s patch. The success of oral administration has been possible due to the stability and sustained release of drugs from NPs. The three main drugs rifampin, isoniazid, and pyrazinamide were encapsulated in PLG NPs, and their concentrations were maintained in tissues until about 10 days after administration.<a onclick="showRef(event, 'ref275'); return false;" href="javascript:void(0);" class="ref ref275">(275)</a> Apart from the polymer-based nanocarriers, liposomes were also developed by encapsulating the two front-line drugs leading to the reduction in doses to once weekly administration for six weeks. Furthermore, isoniazid and rifampicin were encapsulated within the lung-specific stealth liposome and used against <i>Mtb</i> infection. It was then observed that the encapsulated drugs at therapeutic and at a lower concentration in liposomes were more effective than free drugs against TB. Besides, isoniazid-loaded solid lipid NPs improved <i>in vitro</i> uptake of the fluorescent delivery system in dTHP-1 cells. Thus, nanomedicines stand out to be an attractive tool with multiple advantages to tackle this mycobacterial infection. Future preclinical and clinical data are still required to gain better understanding of their potential to become commercially viable nanotechnological formulations.<a onclick="showRef(event, 'ref274'); return false;" href="javascript:void(0);" class="ref ref274">(274)</a></div><div class="NLM_table-wrap" id="tbl21"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 21. NPs for TB Treatment</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">s. no.</th><th class="colsep0 rowsep0" align="center">NP types</th><th class="colsep0 rowsep0" align="center">bioavailability/toxicity</th><th class="colsep0 rowsep0" align="center">application</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.</td><td class="colsep0 rowsep0" align="left">silica (Si)</td><td class="colsep0 rowsep0" align="left">biocompatible and increased efficacy of pH-based Si NPs for drug delivery</td><td class="colsep0 rowsep0" align="left">(a) reducing toxicity of TB drugs to nontarget organs</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref276'); return false;" href="javascript:void(0);" class="ref ref276">(276)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">(b) enhancing drug uptake</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2.</td><td class="colsep0 rowsep0" align="left">chitosan-Ag</td><td class="colsep0 rowsep0" align="left">biocompatible and greater efficacy for antimicrobial peptides delivery</td><td class="colsep0 rowsep0" align="left">increases the potential of AMPs against the bacterium</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref277'); return false;" href="javascript:void(0);" class="ref ref277">(277)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3.</td><td class="colsep0 rowsep0" align="left">graphene oxide</td><td class="colsep0 rowsep0" align="left">biocompatible, sustained release of TB drug ethambutol</td><td class="colsep0 rowsep0" align="left">(a) excellent drug delivery system against cancer</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref278'); return false;" href="javascript:void(0);" class="ref ref278">(278)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">(b) inhibiting biofilm formation by <i>Mycobacterium</i> species</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4.</td><td class="colsep0 rowsep0" align="left">gold (Au)</td><td class="colsep0 rowsep0" align="left">biocompatible, sustained multidrug release for 264 h</td><td class="colsep0 rowsep0" align="left">treatment of diseases such as TB, HIV, cancer, diabetes, Alzheimer’s</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref279'); return false;" href="javascript:void(0);" class="ref ref279">(279)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5.</td><td class="colsep0 rowsep0" align="left">nanostructure lipid carrier (NLC)-Cu</td><td class="colsep0 rowsep0" align="left">activity increased by 27 times</td><td class="colsep0 rowsep0" align="left">(a) better drug stability</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref280'); return false;" href="javascript:void(0);" class="ref ref280">(280)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">(b) can be administered orally, reducing duration of TB treatment, be injected, or used as creams, capsules, and tablets</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">(c) Activity against <i>E</i>. <i>coli</i>, <i>S</i>. <i>aureus</i>, and <i>Mtb</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6.</td><td class="colsep0 rowsep0" align="left">silver-zinc oxide (Ag-ZnO)</td><td class="colsep0 rowsep0" align="left">ability to kill <i>Mtb</i> XDR strains</td><td class="colsep0 rowsep0" align="left">antibacterial properties against <i>Mtb</i> without contributing to drug resistance</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref281'); return false;" href="javascript:void(0);" class="ref ref281">(281)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7.</td><td class="colsep0 rowsep0" align="left">lectin (lectide-co-glycolide)</td><td class="colsep0 rowsep0" align="left">increased relative bioavailability to uncoated rifampicin, isoniazid, and pyrazinamide</td><td class="colsep0 rowsep0" align="left">reduction of drug dose frequency</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref282'); return false;" href="javascript:void(0);" class="ref ref282">(282)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8.</td><td class="colsep0 rowsep0" align="left">polylactide-co-glycolide (PLG)</td><td class="colsep0 rowsep0" align="left">slow release of drug, thereby reducing adverse effects</td><td class="colsep0 rowsep0" align="left">(a) antimycobacterial agents, besides reducing side effects</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref283'); return false;" href="javascript:void(0);" class="ref ref283">(283)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">(b) safe carriers for TB drugs because of almost no inflammation on administration</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">9.</td><td class="colsep0 rowsep0" align="left">titanium oxide (TiO<sub>2</sub>)</td><td class="colsep0 rowsep0" align="left">negligible toxicity (>10%) at 20 mg/mL and less toxicity (>25%) at 100 mg/mL after 24 h treatment, revealing that TiO<sub>2</sub> NPs have less toxicity</td><td class="colsep0 rowsep0" align="left">(a) preventing formation of biofilms by <i>Streptococcus mutans</i></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref284'); return false;" href="javascript:void(0);" class="ref ref284">(284)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">(b) negative controls in toxicology studies</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">(c) inhibition of biofilm formation by <i>Mycobacterium</i> species</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div></div></div><div id="sec12" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">12.  Current Trends and Future Prospects</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74221" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74221" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Treatment of TB is a long-drawn process which is exacerbated with MDR- and XDR-TB strains. The latter require substantially longer treatment times along with the use of more expensive second-line drugs with higher adverse effects. Owing to the rising incidence of these forms, current research is being directed toward testing several alternative regimens. Gut microbiota play important roles in determining host responses to any infection. Any disturbance in the gut population of microbes was found to be associated with chronic illnesses including immune dysfunctions. Hence, attempts to maintain and restore a healthy population of microbes in the gut can prove to be a crucial factor in the battle against hardy pathogens such as <i>Mtb</i>.<a onclick="showRef(event, 'ref285'); return false;" href="javascript:void(0);" class="ref ref285">(285)</a> Several components of the innate immunity can be channelized in a manner that can help develop effective vaccines or drugs against a number of pathogenic microbes, as it is the first line of defense, and hence, very important for the host. Pattern recognition receptors (PRRs) that include toll-like receptors (TLRs), C-type lectin receptors (CLRs), and other components of immune response, pivotal to get rid of the pathogen, can possibly be aimed at, in order to develop novel compounds for curbing increased drug resistance among clinical isolates of <i>Mtb</i> across the world.<a onclick="showRef(event, 'ref286'); return false;" href="javascript:void(0);" class="ref ref286">(286)</a></div><div class="NLM_p">The current treatment strategies against TB are contributing to drug resistance, and there is a dire need for alternative strategies for its treatment as it concerns the lives and livelihood of millions of people worldwide. As described in this review, over the past decade, there has been a continuous and growing interest in the scientific community toward the development of new molecules potentially active against <i>Mtb</i>. Several research groups are engaged in medicinal chemistry programs and are mainly focusing on the discovery of new chemotypes. A lot of effort is still required to optimize the chemistry of these compounds, which would culminate with the identification of more lead compounds with druglike properties, to be carried out in the development phase and clinical trials, hopefully overcoming limitations such as resistance and toxicity.</div><div class="NLM_p last">Development of antimicrobial peptides (AMPs) can be a flicker of hope in this direction. These antimicrobial products isolated from a variety of organisms including bacteria, fungi, plants, and even humans have proven toxicities for pathogens. Moreover, these have been classified into different types based on differences in structures, some of which target the lipid content of bacterial cells. These can thus act against the mycobacterial cell wall, inducing killing of the pathogen, while others target metabolic pathways of the host. Prominent AMPs such as bacteriocins lead to formation of pores in the <i>Mtb</i> membrane, while lactoferrins promote nutrient deprivation, such as inhibiting the availability of iron for <i>Mtb</i>. Likewise, several AMPs specifically targeting <i>Mtb</i> have been discovered; these can be tapped for their potential in developing an effective cure against the disease in combination with antibiotics.<a onclick="showRef(event, 'ref287 ref288'); return false;" href="javascript:void(0);" class="ref ref287 ref288">(287,288)</a> We believe that the remarkable efficacy of antimicrobial peptides can prove to be a ray of hope in developing more effective therapies to eradicate antimycobacterial drug resistance.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01833" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25041" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25041" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria De Rosa</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Ri.MED Foundation, Palermo 90133, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4087-2554" title="Orcid link">http://orcid.org/0000-0002-4087-2554</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#18757c7d6a776b79587e77767c79627177767d6a71757d7c367b7775"><span class="__cf_email__" data-cfemail="54393031263b273514323b3a30352e3d3b3a31263d3931307a373b39">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ravi P. Barnwal</span> - <span class="hlFld-Affiliation affiliation">Department
of Biophysics, Panjab University, Chandigarh 160014, India</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3156-5357" title="Orcid link">http://orcid.org/0000-0003-3156-5357</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3b595a49554c5a577b4b4e155a58155255"><span class="__cf_email__" data-cfemail="d3b1b2a1bda4b2bf93a3a6fdb2b0fdbabd">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ankur Pandey</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Panjab University, Chandigarh 160014, India</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c5a4b5a4aba1a0bc85b5b0eba4a6ebacab"><span class="__cf_email__" data-cfemail="fb9a8b9a959f9e82bb8b8ed59a98d59295">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Akanksha Sharma</span> - <span class="hlFld-Affiliation affiliation">Department
of Biophysics, Panjab University, Chandigarh 160014, India</span>; 
    <span class="hlFld-Affiliation affiliation">UIPS, Panjab
University, Chandigarh 160014, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neha Singla</span> - <span class="hlFld-Affiliation affiliation">Department
of Biophysics, Panjab University, Chandigarh 160014, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gurpal Singh</span> - <span class="hlFld-Affiliation affiliation">UIPS, Panjab
University, Chandigarh 160014, India</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>A.S. and M.D.R. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70385" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70385" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Akanksha Sharma</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=BIO-d7e11138-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Akanksha Sharma</b> is currently pursuing her Ph.D. at Department of Biophysics, Panjab University, Chandigarh. She completed her Masters in Microbiology from Central Research Institute, Kasauli, an institution pioneer in vaccine development. Her current area of work involves the study of RNA dynamics.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Maria De Rosa</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=BIO-d7e11143-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Maria De Rosa</b> holds a Principal Investigator of Medicinal Chemistry position in the Drug Discovery Unit of Ri.MED Foundation. She completed her studies from Siena University, Italy; Uppsala University, Sweden; and RWTH-Aachen University, Germany. Her areas of interest are cancer, neurodegeneration, and infectious diseases.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Neha Singla</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=BIO-d7e11148-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Neha Singla</b> is a DST-Inspire faculty member at the Department of Biophysics, Panjab University, Chandigarh. She received her masters as well as Ph.D. from the same institution. Her research areas are metals induced toxicity and neurodegenerative disorders using different animal models.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Gurpal Singh</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=BIO-d7e11153-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Gurpal Singh</b> is UGC-Assistant Professor, which is funded by UGC, Government of India. He earned his M.Pharm. (Pharmaceutical Biotechnology) from Poona College of Pharmacy and Ph.D. from Centre for Biomedical Engineering, IIT Delhi, India. His field of specialization includes different arenas of biomedical sciences and pharmaceutical biotechnology.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Ravi P. Barnwal</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=BIO-d7e11158-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ravi P. Barnwal</b> is working as Assistant Professor at Department of Biophysics, Panjab University, Chandigarh. He completed his college from DDU Gorakhpur University, Gorakhpur, followed by a Ph.D. at Tata Institute of Fundamental Research, Mumbai, in the field of NMR spectroscopy. Subsequently, he did his postdoctoral work at University of Washington, Seattle. He currently works in the field of chemical and structural biology, i.e., biomolecular NMR spectroscopy, peptide/protein/RNA studies, and molecular biology techniques.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Ankur Pandey</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=BIO-d7e11163-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ankur Pandey</b> holds a UGC-Assistant Professor position at Department of Chemistry, Panjab University, Chandigarh. He obtained his Ph.D. from RWTH-Aachen University, Germany. Thereafter, he did a stint as a postdoctoral researcher at Uppsala University, Sweden. His area of interest is peptidomimetics targeting neuropathic pain and use of thiourea organocatalysis for the development of indole-substituted alkylidene/arylidene malonates.</p></figure></div><div class="ack" id="ACK-d7e11220-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i60">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15255" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15255" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank Dr. Gwion Harfoot for critically reading the manuscript. G.S., R.P.B., and A.P. are supported by the UGC-Faculty Recharge Program. R.P.B. is also funded by DBT (BT/PR27444/BRB/10/1645/2018) and DST (ECR/2017/000124) grants. A.P. is also funded by a DST-SERB (ECR/2017/000938) grant.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AMP</td><td class="NLM_def"><p class="first last">antimicrobial peptide</p></td></tr><tr><td class="NLM_term">FAS</td><td class="NLM_def"><p class="first last">fatty acid synthase</p></td></tr><tr><td class="NLM_term">MDR-TB</td><td class="NLM_def"><p class="first last">multidrug-resistant tuberculosis</p></td></tr><tr><td class="NLM_term"><i>Mtb</i></td><td class="NLM_def"><p class="first last"><i>Mycobacterium tuberculosis</i></p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">XDR-TB</td><td class="NLM_def"><p class="first last">extremely drug-resistant tuberculosis</p></td></tr><tr><td class="NLM_term">WHO</td><td class="NLM_def"><p class="first last">World Health Organization</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71475" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71475" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 288 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span> <i>Global
Tuberculosis Report 2020</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2020</span>; <a href="https://www.who.int/publications/i/item/9789240013131" class="extLink">https://www.who.int/publications/i/item/9789240013131</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global%0ATuberculosis+Report+2020%3B+World+Health+Organization%3A+Geneva%2C+2020%3B+https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2F9789240013131+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlobal%250ATuberculosis%2520Report%25202020%26pub%3DWorld%2520Health%2520Organization%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, E. A.</span>; <span class="NLM_string-name">Raffa, B. J.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium Tuberculosis</span>. In  <i>Molecular Medical Microbiology</i>, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.-W.</span>, <span class="NLM_string-name">Sussman, M.</span>, <span class="NLM_string-name">Liu, D.</span>, <span class="NLM_string-name">Poxton, I.</span>, <span class="NLM_string-name">Schwartzman, J.</span></span>, Eds.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Boston</span>, <span class="NLM_year">2015</span>; Vol.  <span class="NLM_volume">3</span>, pp  <span class="NLM_fpage">1637</span>– <span class="NLM_lpage">1653</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=1637-1653&author=E.+A.+Talbot&author=B.+J.+Raffaauthor=Y.-W.+Tang&author=M.+Sussman&author=D.+Liu&author=I.+Poxton&author=J.+Schwartzman&title=Molecular+Medical+Microbiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DTalbot%26aufirst%3DE.%2BA.%26atitle%3DMycobacterium%2520Tuberculosis%26btitle%3DMolecular%2520Medical%2520Microbiology%26aulast%3DTang%26aufirst%3DY.-W.%26pub%3DAcademic%2520Press%26date%3D2015%26volume%3D3%26spage%3D1637%26epage%3D1653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span> <span> </span><span class="NLM_article-title">Miliary tuberculosis: A new look at an old foe</span>. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1016/j.jctube.2016.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.jctube.2016.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31723681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BB3MjovVentw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=13-27&author=S.+K.+Sharmaauthor=A.+Mohanauthor=A.+Sharma&title=Miliary+tuberculosis%3A+A+new+look+at+an+old+foe&doi=10.1016%2Fj.jctube.2016.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Miliary tuberculosis: A new look at an old foe</span></div><div class="casAuthors">Sharma Surendra K; Mohan Alladi; Sharma Animesh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical tuberculosis and other mycobacterial diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Miliary tuberculosis (TB), is a fatal form of disseminated TB characterized by tiny tubercles evident on gross pathology similar to innumerable millet seeds in size and appearance.  Global HIV/AIDS pandemic and increasing use of immunosuppressive drugs have altered the epidemiology of miliary TB.  Keeping in mind its protean manifestations, clinicians should have a low threshold for suspecting miliary TB.  Careful physical examination should focus on identifying organ system involvement early, particularly TB meningitis, as this has therapeutic significance.  Fundus examination for detecting choroid tubercles can help in early diagnosis as their presence is pathognomonic of miliary TB.  Imaging modalities help in recognizing the miliary pattern, define the extent of organ system involvement and facilitate image guided fine-needle aspiration cytology or biopsy from various organ sites.  Sputum or BAL fluid examination, pleural, pericardial, peritoneal fluid and cerebrospinal fluid studies, fine needle aspiration cytology or biopsy of the lymph nodes, needle biopsy of the liver, bone marrow aspiration and biopsy, testing of body fluids must be carried out.  GeneXpert MTB/RIF, line probe assay, mycobacterial culture and drug-susceptibility testing must be carried out as appropriate and feasible.  Treatment of miliary TB should be started at the earliest as this can be life saving.  Response to first-line anti-TB drugs is good.  Screening and monitoring for complications like acute respiratory distress syndrome (ARDS), adverse drug reactions like drug-induced liver injury, drug-drug interactions, especially in patients co-infected with HIV/AIDS, are warranted.  Sparse data are available from randomized controlled trials regarding optimum regimen and duration of anti-TB treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTP1DB8jXwFg4vKgEt20y1XfW6udTcc2eaqqsHwap7PMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjovVentw%253D%253D&md5=f6394a0cabdd00070d8318a5484b47f0</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.jctube.2016.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jctube.2016.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BK.%26aulast%3DMohan%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DA.%26atitle%3DMiliary%2520tuberculosis%253A%2520A%2520new%2520look%2520at%2520an%2520old%2520foe%26jtitle%3DJournal%2520of%2520Clinical%2520Tuberculosis%2520and%2520Other%2520Mycobacterial%2520Diseases%26date%3D2016%26volume%3D3%26spage%3D13%26epage%3D27%26doi%3D10.1016%2Fj.jctube.2016.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rafiei, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulley, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trauer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkin, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, B. A.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis: Active disease and latent infection in a renal transplant cohort</span>. <i>Nephrology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1111/nep.13386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1111%2Fnep.13386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29660203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1MjjtFymsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=569-574&author=N.+Rafieiauthor=J.+Williamsauthor=W.+R.+Mulleyauthor=J.+M.+Trauerauthor=G.+A.+Jenkinauthor=B.+A.+Rogers&title=Mycobacterium+tuberculosis%3A+Active+disease+and+latent+infection+in+a+renal+transplant+cohort&doi=10.1111%2Fnep.13386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Mycobacterium tuberculosis: Active disease and latent infection in a renal transplant cohort</span></div><div class="casAuthors">Rafiei Nastaran; Williams Jackie; Jenkin Grant A; Rogers Benjamin A; Mulley William R; Mulley William R; Rogers Benjamin A; Trauer James M</div><div class="citationInfo"><span class="NLM_cas:title">Nephrology (Carlton, Vic.)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">569-574</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIM:  Our aim was threefold: first, to determine the incidence of active TB in our cohort, second to investigate the risk factors for active TB and third, to understand current screening practices.  The ultimate goal was to use our findings to inform development of local and national guidelines.  METHODS:  The records of all adult patients who underwent renal transplantation at our centre from 2005 to 2014 were retrospectively reviewed to assess current screening practices, the risks for and burden of active TB.  RESULTS:  A total of 660 individuals underwent renal transplantation during this period, totalling 3647 person years of follow up.  Two patients were diagnosed with active TB after renal transplant, resulting in an incidence of 55 per 100 000 person-years.  Of 656 transplant recipients, 102 (15.5%) were born in high TB incidence countries and 89 (13.5%) had an interferon gamma release assay (IGRA) at any point.  Individuals born in high TB risk countries had a much higher incidence of active TB (353 per 100 000 person-years).  Ten individuals had positive IGRA tests, of whom two were treated for active TB, two received chemoprophylaxis and six were not treated.  CONCLUSIONS:  In the absence of formal guidelines, IGRA-based screening for LTBI was infrequently performed.  Our data suggest that screening and treatment of renal transplant recipients born in high incidence countries is an important preventive measure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQK4RU5kHzSqS-bLEOO4dYpfW6udTcc2eaqqsHwap7PMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjjtFymsg%253D%253D&md5=e164f9ab1bc3e237cf465e5ca4a7e02b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fnep.13386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnep.13386%26sid%3Dliteratum%253Aachs%26aulast%3DRafiei%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DMulley%26aufirst%3DW.%2BR.%26aulast%3DTrauer%26aufirst%3DJ.%2BM.%26aulast%3DJenkin%26aufirst%3DG.%2BA.%26aulast%3DRogers%26aufirst%3DB.%2BA.%26atitle%3DMycobacterium%2520tuberculosis%253A%2520Active%2520disease%2520and%2520latent%2520infection%2520in%2520a%2520renal%2520transplant%2520cohort%26jtitle%3DNephrology%26date%3D2019%26volume%3D24%26spage%3D569%26epage%3D574%26doi%3D10.1111%2Fnep.13386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torrelles, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlesinger, L. S.</span></span> <span> </span><span class="NLM_article-title">Integrating lung physiology, immunology, and tuberculosis</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">688</span>– <span class="NLM_lpage">697</span>, <span class="refDoi"> DOI: 10.1016/j.tim.2017.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.tim.2017.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28366292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVSqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=688-697&author=J.+B.+Torrellesauthor=L.+S.+Schlesinger&title=Integrating+lung+physiology%2C+immunology%2C+and+tuberculosis&doi=10.1016%2Fj.tim.2017.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Integrating Lung Physiology, Immunology, and Tuberculosis</span></div><div class="casAuthors">Torrelles, Jordi B.; Schlesinger, Larry S.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">688-697</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lungs are directly exposed to the air, have enormous surface area, and enable gas exchange in air-breathing animals.  They are constantly 'attacked' by microbes from both outside and inside and thus possess a unique, highly regulated local immune defense system which efficiently allows for microbial clearance while minimizing damaging inflammatory responses.  As a prototypic host-adapted airborne pathogen, Mycobacterium tuberculosis traverses the lung and has several 'interaction points' (IPs) which it must overcome to cause infection.  These interactions are crit., not only from a pathogenesis perspective but also in considering the effectiveness of therapies and vaccines in the lungs.  Here we discuss emerging views on immunol. interactions occurring in the lungs for M. tuberculosis and their impact on infection and persistence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpluIeURoTrE7Vg90H21EOLACvtfcHk0lh2zMfUBECqBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVSqtLg%253D&md5=ef5351aa0dffcbad56c8886991b0b1b4</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2017.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2017.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DTorrelles%26aufirst%3DJ.%2BB.%26aulast%3DSchlesinger%26aufirst%3DL.%2BS.%26atitle%3DIntegrating%2520lung%2520physiology%252C%2520immunology%252C%2520and%2520tuberculosis%26jtitle%3DTrends%2520Microbiol.%26date%3D2017%26volume%3D25%26spage%3D688%26epage%3D697%26doi%3D10.1016%2Fj.tim.2017.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raven, M. L.</span></span> <span> </span><span class="NLM_article-title">Ocular tuberculosis</span>. <i>Microbiol. Spectrum</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">TNMI7-0001-2016</span>, <span class="refDoi"> DOI: 10.1128/microbiolspec.TNMI7-0001-2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2Fmicrobiolspec.TNMI7-0001-2016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=TNMI7-0001-2016&author=D.+M.+Albertauthor=M.+L.+Raven&title=Ocular+tuberculosis&doi=10.1128%2Fmicrobiolspec.TNMI7-0001-2016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1128%2Fmicrobiolspec.TNMI7-0001-2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmicrobiolspec.TNMI7-0001-2016%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DD.%2BM.%26aulast%3DRaven%26aufirst%3DM.%2BL.%26atitle%3DOcular%2520tuberculosis%26jtitle%3DMicrobiol.%2520Spectrum%26date%3D2016%26volume%3D4%26spage%3DTNMI7-0001-2016%26doi%3D10.1128%2Fmicrobiolspec.TNMI7-0001-2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharmendra, S.</span></span> <span> </span><span class="NLM_article-title">Female genital tuberculosis: Revisited</span>. <i>Indian J. Med. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">S71</span>– <span class="NLM_lpage">S83</span>, <span class="refDoi"> DOI: 10.4103/ijmr.IJMR_648_18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4103%2Fijmr.IJMR_648_18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30964083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslGms7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=S71-S83&author=J.+B.+Sharmaauthor=E.+Sharmaauthor=S.+Sharmaauthor=S.+Dharmendra&title=Female+genital+tuberculosis%3A+Revisited&doi=10.4103%2Fijmr.IJMR_648_18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Female genital tuberculosis: revisited</span></div><div class="casAuthors">Sharma, Jai Bhagwan; Sharma, Eshani; Sharma, Sangeeta; Dharmendra, Sona</div><div class="citationInfo"><span class="NLM_cas:title">Indian Journal of Medical Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">7Suppl.1</span>),
    <span class="NLM_cas:pages">71-83</span>CODEN:
                <span class="NLM_cas:coden">IMIREV</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications</span>)
        </div><div class="casAbstract">A review.  Female genital tuberculosis (FGTB) is caused by Mycobacterium tuberculosis (rarely Mycobacterium bovis and/or atypical mycobacteria) being usually secondary to TB of the lungs or other organs with infection reaching through haematogenous, lymphatic route or direct spread from abdominal TB.  In FGTB, fallopian tubes are affected in 90 per cent women, whereas uterine endometrium is affected in 70 per cent and ovaries in about 25 per cent women.  It causes menstrual dysfunction and infertility through the damage of genital organs.  Some cases may be asymptomatic.  Diagnosis is often made from proper history taking, meticulous clin. examn. and judicious use of investigations, esp. endometrial aspirate (or biopsy) and endoscopy.  Treatment is through multi-drug antitubercular treatment for adequate time period (rifampicin, isoniazid, pyrazinamide, ethambutol daily for 60 days followed by rifampicin, isoniazid, ethambutol daily for 120 days).  Treatment is given for 18-24 mo using the second-line drugs for drug-resistant (DR) cases.  With the advent of increased access to rapid diagnostics and newer drugs, the management protocol is moving towards achieving universal drug sensitivity testing and treatment with injection-free regimens contg. newer drugs, esp. for new and previously treated DR cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5weO-lT0TmrVg90H21EOLACvtfcHk0lhysFaNZoUvBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslGms7bK&md5=11e86fdd55640e7f71e85deda1e0225d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.4103%2Fijmr.IJMR_648_18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252Fijmr.IJMR_648_18%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DJ.%2BB.%26aulast%3DSharma%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DDharmendra%26aufirst%3DS.%26atitle%3DFemale%2520genital%2520tuberculosis%253A%2520Revisited%26jtitle%3DIndian%2520J.%2520Med.%2520Res.%26date%3D2018%26volume%3D148%26spage%3DS71%26epage%3DS83%26doi%3D10.4103%2Fijmr.IJMR_648_18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span> <i>Tuberculosis (TB) Disease: Symptoms and Risk Factors</i>; <span class="NLM_publisher-name">CDC</span>: <span class="NLM_publisher-loc">Atlanta, GA</span>;<a href="https://www.cdc.gov/tb/topic/basics/default.htm" class="extLink">https://www.cdc.gov/tb/topic/basics/default.htm</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Tuberculosis+%28TB%29+Disease%3A+Symptoms+and+Risk+Factors%3B+CDC%3A+Atlanta%2C+GA%3Bhttps%3A%2F%2Fwww.cdc.gov%2Ftb%2Ftopic%2Fbasics%2Fdefault.htm+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DTuberculosis%2520%2528TB%2529%2520Disease%253A%2520Symptoms%2520and%2520Risk%2520Factors%26pub%3DCDC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, D.</span></span> <span> </span><span class="NLM_article-title">Treatment of drug-resistant tuberculosis</span>. <i>Infect. Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.2147/IDR.S10332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.2147%2FIDR.S10332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21904458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3MfitlGjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=129-135&author=L.+Pintoauthor=D.+Menzies&title=Treatment+of+drug-resistant+tuberculosis&doi=10.2147%2FIDR.S10332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of drug-resistant tuberculosis</span></div><div class="casAuthors">Pinto Lancelot; Menzies Dick</div><div class="citationInfo"><span class="NLM_cas:title">Infection and drug resistance</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CLINICAL QUESTION:  What is the best approach to the treatment of drug-resistant tuberculosis (TB)?  RESULTS:  Evidence-based treatment of drug-susceptible TB is the best means of preventing the development of drug-resistant disease.  Suspecting the possibility of drug-resistant TB, and prompt detection of all forms of drug-resistant TB, not only multidrug-resistant and extensively drug-resistant TB, should be part of the algorithm for diagnosis and management of all patients with active TB.  IMPLEMENTATION:  Treatment of all forms of drug-resistant TB must be tailored to the specific form of resistance with appropriate and effective drug regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_00VQQycDMA8IxFYvehhofW6udTcc2eYJsIS4KBkfa7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfitlGjug%253D%253D&md5=73c50b904da8eff6211a2161eae860a7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2147%2FIDR.S10332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIDR.S10332%26sid%3Dliteratum%253Aachs%26aulast%3DPinto%26aufirst%3DL.%26aulast%3DMenzies%26aufirst%3DD.%26atitle%3DTreatment%2520of%2520drug-resistant%2520tuberculosis%26jtitle%3DInfect.%2520Drug%2520Resist.%26date%3D2011%26volume%3D4%26spage%3D129%26epage%3D135%26doi%3D10.2147%2FIDR.S10332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliori, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotgiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muetterlein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirsten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruesch-Gerdes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group">German TBNET Group</span> <span> </span><span class="NLM_article-title">Multidrug- and extensively drug-resistant tuberculosis, Germany</span>. <i>Emerging Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1700</span>– <span class="NLM_lpage">1706</span>, <span class="refDoi"> DOI: 10.3201/eid1411.080729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3201%2Feid1411.080729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=18976552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD1cjhtlGitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1700-1706&author=B.+Ekerauthor=J.+Ortmannauthor=G.+B.+Miglioriauthor=G.+Sotgiuauthor=R.+Muetterleinauthor=R.+Centisauthor=H.+Hoffmannauthor=D.+Kirstenauthor=T.+Schabergauthor=S.+Ruesch-Gerdesauthor=C.+Langeauthor=German+TBNET+Group&title=Multidrug-+and+extensively+drug-resistant+tuberculosis%2C+Germany&doi=10.3201%2Feid1411.080729"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug- and extensively drug-resistant tuberculosis, Germany</span></div><div class="casAuthors">Eker Barbara; Ortmann Johannes; Migliori Giovanni B; Sotgiu Giovanni; Muetterlein Ralf; Centis Rosella; Hoffmann Harald; Kirsten Detlef; Schaberg Tom; Ruesch-Gerdes Sabine; Lange Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Emerging infectious diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1700-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We evaluated risk factors and treatment outcomes associated with multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) in Germany in 2004-2006.  In 177 (4%) of 4,557 culture-positive TB cases, Mycobacterium tuberculosis isolates were identified as MDR TB; an additional 7 (0.15%) met criteria for XDR TB.  Of these 184 patients, 148 (80%) were born in countries of the former Soviet Union.  In patients with XDR TB, hospitalization was longer (mean +/- SD 202 +/- 130 vs. 123 +/- 81 days; p = 0.015) and resistance to all first-line drugs was more frequent (36% vs. 86%; p = 0.013) than in patients with MDR TB.  Seventy-four (40%) of these 184 patients received treatment with linezolid.  Treatment success rates ranged from 59% for the entire cohort (59% for MDR TB and 57% for XDR TB) to 87% for those with a definitive outcome (n = 125; 89% for MDR TB and 80% for XDR TB).  Extensive drug susceptibility testing and availability of second- and third-line drugs under inpatient management conditions permit relatively high treatment success rates in MDR- and XDR TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLoYYbyenxnWBAiYWy6n3SfW6udTcc2eYJsIS4KBkfa7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjhtlGitA%253D%253D&md5=4b7a295b71561ea764630adeba04ef0a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3201%2Feid1411.080729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3201%252Feid1411.080729%26sid%3Dliteratum%253Aachs%26aulast%3DEker%26aufirst%3DB.%26aulast%3DOrtmann%26aufirst%3DJ.%26aulast%3DMigliori%26aufirst%3DG.%2BB.%26aulast%3DSotgiu%26aufirst%3DG.%26aulast%3DMuetterlein%26aufirst%3DR.%26aulast%3DCentis%26aufirst%3DR.%26aulast%3DHoffmann%26aufirst%3DH.%26aulast%3DKirsten%26aufirst%3DD.%26aulast%3DSchaberg%26aufirst%3DT.%26aulast%3DRuesch-Gerdes%26aufirst%3DS.%26aulast%3DLange%26aufirst%3DC.%26aulast%3D%26atitle%3DMultidrug-%2520and%2520extensively%2520drug-resistant%2520tuberculosis%252C%2520Germany%26jtitle%3DEmerging%2520Infect.%2520Dis.%26date%3D2008%26volume%3D14%26spage%3D1700%26epage%3D1706%26doi%3D10.3201%2Feid1411.080729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, R.</span></span> <span> </span><span class="NLM_article-title">Pre-XDR & XDR in MDR and ofloxacin and kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2012.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.tube.2012.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22789499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GmsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=404-406&author=A.+Jainauthor=P.+Dixitauthor=R.+Prasad&title=Pre-XDR+%26+XDR+in+MDR+and+ofloxacin+and+kanamycin+resistance+in+non-MDR+Mycobacterium+tuberculosis+isolates&doi=10.1016%2Fj.tube.2012.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Pre-XDR & XDR in MDR and Ofloxacin and Kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates</span></div><div class="casAuthors">Jain, Amita; Dixit, Pratima; Prasad, Rajendra</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">404-406</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Resistance to second line anti tubercular drugs is a cause of serious concern.  The present study reports the prevalence of Ofloxacin (OFX) and Kanamycin (KM) resistance in Mycobacterium tuberculosis isolates from cases of pulmonary tuberculosis, who received anti tubercular treatment for >4 wk in past.  Of total 438 enrolled patients, 361 were culture pos. for M. tuberculosis, of which, 95 (26.3%) were OFX resistant & 49 (13.5%) were KM resistant.  Total 130 isolates were Multidrug resistant, of which, 55 (42.3%) were resistant to either OFX or KM (Pre-XDR) & 11 (8.5%) were resistant to both KM & OFX (XDR).  Resistance to quinolones & aminoglycosides should be routinely assessed in areas endemic for tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriluXA41LmmrVg90H21EOLACvtfcHk0lgViVq5y5-NPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GmsL3I&md5=c4911d6676949c87fe627b078df84bed</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2012.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2012.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DA.%26aulast%3DDixit%26aufirst%3DP.%26aulast%3DPrasad%26aufirst%3DR.%26atitle%3DPre-XDR%2520%2526%2520XDR%2520in%2520MDR%2520and%2520ofloxacin%2520and%2520kanamycin%2520resistance%2520in%2520non-MDR%2520Mycobacterium%2520tuberculosis%2520isolates%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2012%26volume%3D92%26spage%3D404%26epage%3D406%26doi%3D10.1016%2Fj.tube.2012.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velayati, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masjedi, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farnia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabarsi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghanavi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ZiaZarifi, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffner, S. E.</span></span> <span> </span><span class="NLM_article-title">Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1378/chest.08-2427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1378%2Fchest.08-2427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19349380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD1Mrkt1entQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=420-425&author=A.+A.+Velayatiauthor=M.+R.+Masjediauthor=P.+Farniaauthor=P.+Tabarsiauthor=J.+Ghanaviauthor=A.+H.+ZiaZarifiauthor=S.+E.+Hoffner&title=Emergence+of+new+forms+of+totally+drug-resistant+tuberculosis+bacilli%3A+super+extensively+drug-resistant+tuberculosis+or+totally+drug-resistant+strains+in+Iran&doi=10.1378%2Fchest.08-2427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran</span></div><div class="casAuthors">Velayati Ali Akbar; Masjedi Mohammad Reza; Tabarsi Payam; ZiaZarifi Abol Hassan; Farnia Parissa; Ghanavi Jalladein; Hoffner Sven Eric</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-425</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The study documented the emergence of new forms of resistant bacilli (totally drug-resistant [TDR] or super extensively drug-resistant [XDR] tuberculosis [TB] strains) among patients with multidrug-resistant TB (MDR-TB).  METHODS:  Susceptibility testing against first- and second-line drugs was performed on isolated Mycobacterium tuberculosis strains.  Subsequently, the strains identified as XDR or TDR M tuberculosis were subjected to spoligotyping and variable numbers of tandem repeats (VNTR).  RESULTS:  Of 146 MDR-TB strains, 8 XDR isolates (5.4%) and 15 TDR isolates (10.3%) were identified.  The remaining strains were either susceptible (67%) or had other resistant patterns (20%).  Overall, the median of treatments and drugs previously received by MDR-TB patients was two courses of therapy of 15 months' duration with five drugs (isoniazid [INH], rifampicin [RF], streptomycin, ethambutol, and pyrazinamide).  The median of in vitro drug resistance for all studied cases was INH and RF.  The XDR or TDR strains were collected from both immigrants (Afghan, 30.4%; Azerbaijani, 8.6%; Iraqi, 4.3%) and Iranian (56.5%) MDR-TB cases.  In such cases, the smear and cultures remained positive after 18 months of medium treatment with second-line drugs (ethionamide, para-aminosalicylic acid, cycloserine, ofloxacin, amikacin, and ciprofloxacin).  Spoligotyping revealed Haarlem (39.1%), Beijing (21.7%), EAI (21.7%), and CAS (17.3%) superfamilies of M tuberculosis.  These superfamilies had different VNTR profiles, which eliminated the recent transmission among MDR-TB cases.  CONCLUSIONS:  The isolation of TDR strains from MDR-TB patients from different regional countries is alarming and underlines the possible dissemination of such strains in Asian countries.  Now the next question is how one should control and treat such cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTN1nU8IQjBBGLFM_lbR1VmfW6udTcc2eZS9hEsZXsgJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mrkt1entQ%253D%253D&md5=b7f110877e3a4ffb4a9f5831803ca52c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1378%2Fchest.08-2427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.08-2427%26sid%3Dliteratum%253Aachs%26aulast%3DVelayati%26aufirst%3DA.%2BA.%26aulast%3DMasjedi%26aufirst%3DM.%2BR.%26aulast%3DFarnia%26aufirst%3DP.%26aulast%3DTabarsi%26aufirst%3DP.%26aulast%3DGhanavi%26aufirst%3DJ.%26aulast%3DZiaZarifi%26aufirst%3DA.%2BH.%26aulast%3DHoffner%26aufirst%3DS.%2BE.%26atitle%3DEmergence%2520of%2520new%2520forms%2520of%2520totally%2520drug-resistant%2520tuberculosis%2520bacilli%253A%2520super%2520extensively%2520drug-resistant%2520tuberculosis%2520or%2520totally%2520drug-resistant%2520strains%2520in%2520Iran%26jtitle%3DChest%26date%3D2009%26volume%3D136%26spage%3D420%26epage%3D425%26doi%3D10.1378%2Fchest.08-2427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Udwadia, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amale, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajbani, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, C.</span></span> <span> </span><span class="NLM_article-title">Totally drug-resistant tuberculosis in India</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">579</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1093/cid/cir889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fcid%2Fcir889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22190562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC387ptF2hsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2012&pages=579-581&author=Z.+F.+Udwadiaauthor=R.+A.+Amaleauthor=K.+K.+Ajbaniauthor=C.+Rodrigues&title=Totally+drug-resistant+tuberculosis+in+India&doi=10.1093%2Fcid%2Fcir889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Totally drug-resistant tuberculosis in India</span></div><div class="casAuthors">Udwadia Zarir F; Amale Rohit A; Ajbani Kanchan K; Rodrigues Camilla</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">579-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2_G3WsdaydUbxh97K6Vt6fW6udTcc2eZS9hEsZXsgJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387ptF2hsQ%253D%253D&md5=237f5c180e0daee51adf5df45a93d428</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcir889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcir889%26sid%3Dliteratum%253Aachs%26aulast%3DUdwadia%26aufirst%3DZ.%2BF.%26aulast%3DAmale%26aufirst%3DR.%2BA.%26aulast%3DAjbani%26aufirst%3DK.%2BK.%26aulast%3DRodrigues%26aufirst%3DC.%26atitle%3DTotally%2520drug-resistant%2520tuberculosis%2520in%2520India%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2012%26volume%3D54%26spage%3D579%26epage%3D581%26doi%3D10.1093%2Fcid%2Fcir889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uplekar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonnroth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falzon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargioni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getahun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilpin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaziou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzemska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzayev, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raviglione, M.</span></span> <span> </span><span class="NLM_article-title">WHO’s new End TB Strategy</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">1799</span>– <span class="NLM_lpage">1801</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)60570-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS0140-6736%2815%2960570-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25814376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2MnosFertw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=1799-1801&author=M.+Uplekarauthor=D.+Weilauthor=K.+Lonnrothauthor=E.+Jaramilloauthor=C.+Lienhardtauthor=H.+M.+Diasauthor=D.+Falzonauthor=K.+Floydauthor=G.+Gargioniauthor=H.+Getahunauthor=C.+Gilpinauthor=P.+Glaziouauthor=M.+Grzemskaauthor=F.+Mirzayevauthor=H.+Nakataniauthor=M.+Raviglione&title=WHO%E2%80%99s+new+End+TB+Strategy&doi=10.1016%2FS0140-6736%2815%2960570-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">WHO's new end TB strategy</span></div><div class="casAuthors">Uplekar Mukund; Weil Diana; Lonnroth Knut; Jaramillo Ernesto; Lienhardt Christian; Dias Hannah Monica; Falzon Dennis; Floyd Katherine; Gargioni Giuliano; Getahun Haileyesus; Gilpin Christopher; Glaziou Philippe; Grzemska Malgorzata; Mirzayev Fuad; Nakatani Hiroki; Raviglione Mario</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">9979</span>),
    <span class="NLM_cas:pages">1799-1801</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTakrzeTv28qPcsfMJQC1ZdfW6udTcc2eZS9hEsZXsgJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnosFertw%253D%253D&md5=604506d9629c94f0aadebdc380dc10ce</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2960570-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252960570-0%26sid%3Dliteratum%253Aachs%26aulast%3DUplekar%26aufirst%3DM.%26aulast%3DWeil%26aufirst%3DD.%26aulast%3DLonnroth%26aufirst%3DK.%26aulast%3DJaramillo%26aufirst%3DE.%26aulast%3DLienhardt%26aufirst%3DC.%26aulast%3DDias%26aufirst%3DH.%2BM.%26aulast%3DFalzon%26aufirst%3DD.%26aulast%3DFloyd%26aufirst%3DK.%26aulast%3DGargioni%26aufirst%3DG.%26aulast%3DGetahun%26aufirst%3DH.%26aulast%3DGilpin%26aufirst%3DC.%26aulast%3DGlaziou%26aufirst%3DP.%26aulast%3DGrzemska%26aufirst%3DM.%26aulast%3DMirzayev%26aufirst%3DF.%26aulast%3DNakatani%26aufirst%3DH.%26aulast%3DRaviglione%26aufirst%3DM.%26atitle%3DWHO%25E2%2580%2599s%2520new%2520End%2520TB%2520Strategy%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D1799%26epage%3D1801%26doi%3D10.1016%2FS0140-6736%2815%2960570-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span>W <i>HO Consolidated Guidelines on Tuberculosis, Module
4: Treatment-
Drug-Resistant Tuberculosis Treatment</i>; <span class="NLM_publisher-name">World
Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2020</span>; <a href="https://www.who.int/publications/i/item/9789240007048" class="extLink">https://www.who.int/publications/i/item/9789240007048</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=W+HO+Consolidated+Guidelines+on+Tuberculosis%2C+Module%0A4%3A+Treatment-%0ADrug-Resistant+Tuberculosis+Treatment%3B+World%0AHealth+Organization%3A+Geneva%2C+2020%3B+https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2F9789240007048+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DHO%2520Consolidated%2520Guidelines%2520on%2520Tuberculosis%252C%2520Module%250A4%253A%2520Treatment-%250ADrug-Resistant%2520Tuberculosis%2520Treatment%26pub%3DWorld%250AHealth%2520Organization%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gengenbacher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, S. H.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis: success through dormancy</span>. <i>FEMS Microbiology Reviews</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1111/j.1574-6976.2012.00331.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1111%2Fj.1574-6976.2012.00331.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22320122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmtlygs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=514-532&author=M.+Gengenbacherauthor=S.+H.+Kaufmann&title=Mycobacterium+tuberculosis%3A+success+through+dormancy&doi=10.1111%2Fj.1574-6976.2012.00331.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mycobacterium tuberculosis: success through dormancy</span></div><div class="casAuthors">Gengenbacher, Martin; Kaufmann, Stefan H. E.</div><div class="citationInfo"><span class="NLM_cas:title">FEMS Microbiology Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">514-532</span>CODEN:
                <span class="NLM_cas:coden">FMREE4</span>;
        ISSN:<span class="NLM_cas:issn">0168-6445</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB) remains a major health threat, killing nearly 2 million individuals around this globe, annually.  The only vaccine, developed almost a century ago, provides limited protection only during childhood.  After decades without the introduction of new antibiotics, several candidates are currently undergoing clin. investigation.  Curing TB requires prolonged combination of chemotherapy with several drugs.  Moreover, monitoring the success of therapy is questionable owing to the lack of reliable biomarkers.  To substantially improve the situation, a detailed understanding of the cross-talk between human host and the pathogen Mycobacterium tuberculosis (Mtb) is vital.  Principally, the enormous success of Mtb is based on three capacities: first, reprogramming of macrophages after primary infection/phagocytosis to prevent its own destruction; second, initiating the formation of well-organized granulomas, comprising different immune cells to create a confined environment for the host-pathogen standoff; third, the capability to shut down its own central metab., terminate replication, and thereby transit into a stage of dormancy rendering itself extremely resistant to host defense and drug treatment.  Here, we review the mol. mechanisms underlying these processes, draw conclusions in a working model of mycobacterial dormancy, and highlight gaps in our understanding to be addressed in future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2gfZpCQZ6L7Vg90H21EOLACvtfcHk0liXj2IPJac23Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmtlygs7c%253D&md5=b2bd225607ef8873b4120344c90654ff</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1574-6976.2012.00331.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1574-6976.2012.00331.x%26sid%3Dliteratum%253Aachs%26aulast%3DGengenbacher%26aufirst%3DM.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DMycobacterium%2520tuberculosis%253A%2520success%2520through%2520dormancy%26jtitle%3DFEMS%2520Microbiology%2520Reviews%26date%3D2012%26volume%3D36%26spage%3D514%26epage%3D532%26doi%3D10.1111%2Fj.1574-6976.2012.00331.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harisinghani, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLoud, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shroff, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, P. R.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis from head to toe</span>. <i>Radiographics</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1148/radiographics.20.2.g00mc12449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1148%2Fradiographics.20.2.g00mc12449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10715343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD3c7otF2qsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=449-470&author=M.+G.+Harisinghaniauthor=T.+C.+McLoudauthor=J.+A.+Shepardauthor=J.+P.+Koauthor=M.+M.+Shroffauthor=P.+R.+Mueller&title=Tuberculosis+from+head+to+toe&doi=10.1148%2Fradiographics.20.2.g00mc12449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberculosis from head to toe</span></div><div class="casAuthors">Harisinghani M G; McLoud T C; Shepard J A; Ko J P; Shroff M M; Mueller P R</div><div class="citationInfo"><span class="NLM_cas:title">Radiographics : a review publication of the Radiological Society of North America, Inc</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">449-70; quiz 528-9, 532</span>
        ISSN:<span class="NLM_cas:issn">0271-5333</span>.
    </div><div class="casAbstract">Tuberculosis can affect virtually any organ system in the body and can be devastating if left untreated.  The increasing prevalence of tuberculosis in both immunocompetent and immunocompromised individuals in recent years makes this disease a topic of universal concern.  Because tuberculosis demonstrates a variety of clinical and radiologic findings and has a known propensity for dissemination from its primary site, it can mimic numerous other disease entities.  Primary pulmonary tuberculosis typically manifests radiologically as parenchymal disease, lymphadenopathy, pleural effusion, miliary disease, or lobar or segmental atelectasis.  In postprimary tuberculosis, the earliest radiologic finding is the development of patchy, ill-defined segmental consolidation.  Both computed tomography (CT) and magnetic resonance (MR) imaging are helpful in diagnosing tuberculous spondylitis and tuberculous arthritis.  CT is especially useful in depicting gastrointestinal and genitourinary tuberculosis.  In tuberculosis involving the central nervous system, CT and MR imaging findings vary depending on the stage of disease and the character of the lesion.  A high degree of clinical suspicion and familiarity with the various radiologic manifestations of tuberculosis allow early diagnosis and timely initiation of appropriate therapy, thereby reducing patient morbidity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0Enk79OtqnVMGsG_HTXYFfW6udTcc2eaMwtVMu5qA7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7otF2qsg%253D%253D&md5=3cb545c401ba549124fca37ae7461920</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1148%2Fradiographics.20.2.g00mc12449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1148%252Fradiographics.20.2.g00mc12449%26sid%3Dliteratum%253Aachs%26aulast%3DHarisinghani%26aufirst%3DM.%2BG.%26aulast%3DMcLoud%26aufirst%3DT.%2BC.%26aulast%3DShepard%26aufirst%3DJ.%2BA.%26aulast%3DKo%26aufirst%3DJ.%2BP.%26aulast%3DShroff%26aufirst%3DM.%2BM.%26aulast%3DMueller%26aufirst%3DP.%2BR.%26atitle%3DTuberculosis%2520from%2520head%2520to%2520toe%26jtitle%3DRadiographics%26date%3D2000%26volume%3D20%26spage%3D449%26epage%3D470%26doi%3D10.1148%2Fradiographics.20.2.g00mc12449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rathi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambhire, P.</span></span> <span> </span><span class="NLM_article-title">Abdominal tuberculosis</span>. <i>J. Assoc. Physicians India</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">47</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27730779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2svpt12rtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=38-47&author=P.+Rathiauthor=P.+Gambhire&title=Abdominal+tuberculosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Abdominal Tuberculosis</span></div><div class="casAuthors">Rathi Pravin; Gambhire Pravir</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of the Association of Physicians of India</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">38-47</span>
        ISSN:<span class="NLM_cas:issn">0004-5772</span>.
    </div><div class="casAbstract">Abdomen is involved in 11% of patients with extra-pulmonary tuberculosis; The most common site of involvement is the ileocaecal region, other locations of involvement, in order of descending frequency, are the ascending colon, jejunum, appendix, duodenum, stomach, oesophagus, sigmoid colon, and rectum.  Apart from the basic work up, Investigations like CT scan, EUS, Capsule endoscopy, Balloon enteroscopy, Ascitic fluid ADA, TB-PCR, GeneXpert, Laproscopy are being increasingly used to diagnose tuberculosis.Therapy with standard antituberculous drugs is usually highly effective for intestinal TB.  Six-months therapy is as effective as nine-months therapy.  Multi-Drug Resistance (MDR) has been observed in 13% of MTB isolates.  The development of Drug Induced Hepatotoxicity (DIH) during therapy for TB is the most common reason leading to interruption of therapy.  There are various guidelines for the management of TB post DIH.  Surgery is usually reserved for patients who have developed complications or obstruction not responding to medical management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAr-tYS4tz7PSAs_PE1QvifW6udTcc2eaMwtVMu5qA7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svpt12rtQ%253D%253D&md5=8ad4422cafc6ff9ccdd9cbc392a23cd3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRathi%26aufirst%3DP.%26aulast%3DGambhire%26aufirst%3DP.%26atitle%3DAbdominal%2520tuberculosis%26jtitle%3DJ.%2520Assoc.%2520Physicians%2520India%26date%3D2016%26volume%3D64%26spage%3D38%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakroun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharbi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chebil, M.</span></span> <span> </span><span class="NLM_article-title">Renal tuberculosis mimicking renal cell carcinoma: a case report</span>. <i>J. Med. Case Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">139</span>, <span class="refDoi"> DOI: 10.1186/s13256-019-2073-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1186%2Fs13256-019-2073-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31077255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ks1ejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=139&author=K.+Chakerauthor=M.+Chakrounauthor=M.+Gharbiauthor=M.+Chebil&title=Renal+tuberculosis+mimicking+renal+cell+carcinoma%3A+a+case+report&doi=10.1186%2Fs13256-019-2073-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Renal tuberculosis mimicking renal cell carcinoma: a case report</span></div><div class="casAuthors">Chaker Kays; Chakroun Marouene; Gharbi Maroua; Chebil Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medical case reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">139</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Urogenital tuberculosis is still a frequent presentation, and it constitutes a current public health problem in endemic areas.  The clinical presentation of this form of the disease may be misleading.  The pseudotumoral type of renal tuberculosis is extremely uncommon.  CASE PRESENTATION:  We present a case of a 52-year-old African woman who presented with urogenital tuberculosis in its pseudotumoral form.  This case was initially diagnosed and managed as renal cancer.  Histopathology confirmed the diagnosis of pseudotumoral renal tuberculosis.  CONCLUSIONS:  The pseudotumoral form of urinary tuberculosis can be difficult to diagnose.  Only bacteriological or histological confirmation allows diagnosis for adequate treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLLeVlNQNhpBBrI9DTGjC0fW6udTcc2eZVcqhEE5Vsm7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ks1ejtg%253D%253D&md5=a850291570fc34582ade24df5ac7cdff</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1186%2Fs13256-019-2073-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13256-019-2073-0%26sid%3Dliteratum%253Aachs%26aulast%3DChaker%26aufirst%3DK.%26aulast%3DChakroun%26aufirst%3DM.%26aulast%3DGharbi%26aufirst%3DM.%26aulast%3DChebil%26aufirst%3DM.%26atitle%3DRenal%2520tuberculosis%2520mimicking%2520renal%2520cell%2520carcinoma%253A%2520a%2520case%2520report%26jtitle%3DJ.%2520Med.%2520Case%2520Rep.%26date%3D2019%26volume%3D13%26spage%3D139%26doi%3D10.1186%2Fs13256-019-2073-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeds, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurbatova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Rio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraft, C. S.</span></span> <span> </span><span class="NLM_article-title">Site of extrapulmonary tuberculosis is associated with HIV infection</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1093/cid/cis303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fcid%2Fcis303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22423123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC38vntVKqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=75-81&author=I.+L.+Leedsauthor=M.+J.+Mageeauthor=E.+V.+Kurbatovaauthor=C.+del+Rioauthor=H.+M.+Blumbergauthor=M.+K.+Leonardauthor=C.+S.+Kraft&title=Site+of+extrapulmonary+tuberculosis+is+associated+with+HIV+infection&doi=10.1093%2Fcid%2Fcis303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Site of extrapulmonary tuberculosis is associated with HIV infection</span></div><div class="casAuthors">Leeds Ira L; Magee Matthew J; Kurbatova Ekaterina V; del Rio Carlos; Blumberg Henry M; Leonard Michael K; Kraft Colleen S</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  In the United States, the proportion of patients with extrapulmonary tuberculosis (EPTB) has increased relative to cases of pulmonary tuberculosis.  Patients with central nervous system (CNS)/meningeal and disseminated EPTB and those with human immunodeficiency virus (HIV)/AIDS have increased mortality.  The purpose of our study was to determine risk factors associated with particular types of EPTB.  METHODS:  We retrospectively reviewed 320 cases of EPTB from 1995-2007 at a single urban US public hospital.  Medical records were reviewed to determine site of EPTB and patient demographic and clinical characteristics.  Multivariable logistic regression analyses were performed to determine independent associations between patient characteristics and site of disease.  RESULTS:  Patients were predominantly male (67%), African American (82%), and US-born (76%).  Mean age was 40 years (range 18-89).  The most common sites of EPTB were lymphatic (28%), disseminated (23%), and CNS/meningeal (22%) disease.  One hundred fifty-four (48.1%) were HIV-infected, 40% had concomitant pulmonary tuberculosis, and 14.7% died within 12 months of EPTB diagnosis.  Multivariable analysis demonstrated that HIV-infected patients were less likely to have pleural (adjusted odds ratio [AOR] 0.3; 95% confidence interval [CI] .2, .6) as site of EPTB disease than HIV-uninfected patients.  Among patients with EPTB and HIV-infection, patients with CD4 lymphocyte cell count <100 were more likely to have severe forms of EPTB (CNS/meningeal and/or disseminated) (AOR 1.6; 95% CI, 1.0, 2.4).  CONCLUSIONS:  Among patients hospitalized with EPTB, patients coinfected with HIV and low CD4 counts were more likely to have CNS/meningeal and disseminated disease.  Care for similar patients should include consideration of these forms of EPTB since they carry a high risk of death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYC_8i9nfhJ7qxQ2mb9Pu8fW6udTcc2eZVcqhEE5Vsm7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vntVKqtw%253D%253D&md5=ffd4b6f5aec3862de0a15cd4b357c699</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcis303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcis303%26sid%3Dliteratum%253Aachs%26aulast%3DLeeds%26aufirst%3DI.%2BL.%26aulast%3DMagee%26aufirst%3DM.%2BJ.%26aulast%3DKurbatova%26aufirst%3DE.%2BV.%26aulast%3Ddel%2BRio%26aufirst%3DC.%26aulast%3DBlumberg%26aufirst%3DH.%2BM.%26aulast%3DLeonard%26aufirst%3DM.%2BK.%26aulast%3DKraft%26aufirst%3DC.%2BS.%26atitle%3DSite%2520of%2520extrapulmonary%2520tuberculosis%2520is%2520associated%2520with%2520HIV%2520infection%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2012%26volume%3D55%26spage%3D75%26epage%3D81%26doi%3D10.1093%2Fcid%2Fcis303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnappinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, D.</span></span> <span> </span><span class="NLM_article-title">The spectrum of latent tuberculosis: rethinking the biology and intervention strategies</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">845</span>– <span class="NLM_lpage">855</span>, <span class="refDoi"> DOI: 10.1038/nrmicro2236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnrmicro2236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19855401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSqsLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=845-855&author=C.+E.+Barryauthor=H.+I.+Boshoffauthor=V.+Dartoisauthor=T.+Dickauthor=S.+Ehrtauthor=J.+Flynnauthor=D.+Schnappingerauthor=R.+J.+Wilkinsonauthor=D.+Young&title=The+spectrum+of+latent+tuberculosis%3A+rethinking+the+biology+and+intervention+strategies&doi=10.1038%2Fnrmicro2236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The spectrum of latent tuberculosis: rethinking the biology and intervention strategies</span></div><div class="casAuthors">Barry, Clifton E., III; Boshoff, Helena I.; Dartois, Veronique; Dick, Thomas; Ehrt, Sabine; Flynn, JoAnne; Schnappinger, Dirk; Wilkinson, Robert J.; Young, Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">845-855</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Immunol. tests provide evidence of latent tuberculosis in one third of the global population, which corresponds to more than two billion individuals.  Latent tuberculosis is defined by the absence of clin. symptoms but carries a risk of subsequent progression to clin. disease, particularly in the context of co-infection with HIV.  In this Review we discuss the biol. of latent tuberculosis as part of a broad range of responses that occur following infection with Mycobacterium tuberculosis, which result in the formation of physiol. distinct granulomatous lesions that provide microenvironments with differential ability to support or suppress the persistence of viable bacteria.  We then show how this model can be used to develop a rational program to discover effective drugs for the eradication of M. tuberculosis infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2NPD_m2QYSLVg90H21EOLACvtfcHk0lidtIlNhIfVug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSqsLbN&md5=df1f98b80f2701c6b3757017420a7755</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro2236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro2236%26sid%3Dliteratum%253Aachs%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DDick%26aufirst%3DT.%26aulast%3DEhrt%26aufirst%3DS.%26aulast%3DFlynn%26aufirst%3DJ.%26aulast%3DSchnappinger%26aufirst%3DD.%26aulast%3DWilkinson%26aufirst%3DR.%2BJ.%26aulast%3DYoung%26aufirst%3DD.%26atitle%3DThe%2520spectrum%2520of%2520latent%2520tuberculosis%253A%2520rethinking%2520the%2520biology%2520and%2520intervention%2520strategies%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2009%26volume%3D7%26spage%3D845%26epage%3D855%26doi%3D10.1038%2Fnrmicro2236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, A. N.</span></span> <span> </span><span class="NLM_article-title">Pulmonary tuberculosis: the essentials</span>. <i>Radiology</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1148/radiology.210.2.r99ja34307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1148%2Fradiology.210.2.r99ja34307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10207408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaK1M3itlyitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=1999&pages=307-322&author=A.+N.+Leung&title=Pulmonary+tuberculosis%3A+the+essentials&doi=10.1148%2Fradiology.210.2.r99ja34307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary tuberculosis: the essentials</span></div><div class="casAuthors">Leung A N</div><div class="citationInfo"><span class="NLM_cas:title">Radiology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">307-22</span>
        ISSN:<span class="NLM_cas:issn">0033-8419</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSx8GQCyEiVP_IW7hznt0zpfW6udTcc2eYYoa4_RXN2srntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3itlyitw%253D%253D&md5=be24063a412cd89cfb86811ba666aad4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1148%2Fradiology.210.2.r99ja34307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1148%252Fradiology.210.2.r99ja34307%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DA.%2BN.%26atitle%3DPulmonary%2520tuberculosis%253A%2520the%2520essentials%26jtitle%3DRadiology%26date%3D1999%26volume%3D210%26spage%3D307%26epage%3D322%26doi%3D10.1148%2Fradiology.210.2.r99ja34307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadkowski, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, J. E.</span></span> <span> </span><span class="NLM_article-title">Cavitary pulmonary disease</span>. <i>Clin. Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1128/CMR.00060-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FCMR.00060-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=18400799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtFKlsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=305-333&author=L.+B.+Gadkowskiauthor=J.+E.+Stout&title=Cavitary+pulmonary+disease&doi=10.1128%2FCMR.00060-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cavitary pulmonary disease</span></div><div class="casAuthors">Gadkowski, L. Beth; Stout, Jason E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">305-333</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">0893-8512</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  A pulmonary cavity is a gas-filled area of the lung in the center of a nodule or area of consolidation and may be clin. obsd. by use of plain chest radiog. or computed tomog.  Cavities are present in a wide variety of infectious and noninfectious processes.  This review discusses the differential diagnosis of pathol. processes assocd. with lung cavities, focusing on infections assocd. with lung cavities.  The goal is to provide the clinician and clin. microbiologist with an overview of the diseases most commonly assocd. with lung cavities, with attention to the epidemiol. and clin. characteristics of the host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAm2coDPVGy7Vg90H21EOLACvtfcHk0lidtIlNhIfVug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtFKlsrg%253D&md5=37803c47a218749586267d649f1a861e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1128%2FCMR.00060-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00060-07%26sid%3Dliteratum%253Aachs%26aulast%3DGadkowski%26aufirst%3DL.%2BB.%26aulast%3DStout%26aufirst%3DJ.%2BE.%26atitle%3DCavitary%2520pulmonary%2520disease%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2008%26volume%3D21%26spage%3D305%26epage%3D333%26doi%3D10.1128%2FCMR.00060-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nachiappan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahbar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortani
Barbosa, E. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shroff, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocazionez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlesinger, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammer, M. M.</span></span> <span> </span><span class="NLM_article-title">Pulmonary tuberculosis: role of radiology in diagnosis and management</span>. <i>Radiographics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1148/rg.2017160032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1148%2Frg.2017160032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28076011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ks1Shsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=52-72&author=A.+C.+Nachiappanauthor=K.+Rahbarauthor=X.+Shiauthor=E.+S.+Guyauthor=E.+J.+Mortani%0ABarbosaauthor=G.+S.+Shroffauthor=D.+Ocazionezauthor=A.+E.+Schlesingerauthor=S.+I.+Katzauthor=M.+M.+Hammer&title=Pulmonary+tuberculosis%3A+role+of+radiology+in+diagnosis+and+management&doi=10.1148%2Frg.2017160032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary Tuberculosis: Role of Radiology in Diagnosis and Management</span></div><div class="casAuthors">Nachiappan Arun C; Rahbar Kasra; Shi Xiao; Guy Elizabeth S; Mortani Barbosa Eduardo J Jr; Shroff Girish S; Ocazionez Daniel; Schlesinger Alan E; Katz Sharyn I; Hammer Mark M</div><div class="citationInfo"><span class="NLM_cas:title">Radiographics : a review publication of the Radiological Society of North America, Inc</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-72</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis is a public health problem worldwide, including in the United States-particularly among immunocompromised patients and other high-risk groups.  Tuberculosis manifests in active and latent forms.  Active disease can occur as primary tuberculosis, developing shortly after infection, or postprimary tuberculosis, developing after a long period of latent infection.  Primary tuberculosis occurs most commonly in children and immunocompromised patients, who present with lymphadenopathy, pulmonary consolidation, and pleural effusion.  Postprimary tuberculosis may manifest with cavities, consolidations, and centrilobular nodules.  Miliary tuberculosis refers to hematogenously disseminated disease that is more commonly seen in immunocompromised patients, who present with miliary lung nodules and multiorgan involvement.  The principal means of testing for active tuberculosis is sputum analysis, including smear, culture, and nucleic acid amplification testing.  Imaging findings, particularly the presence of cavitation, can affect treatment decisions, such as the duration of therapy.  Latent tuberculosis is an asymptomatic infection that can lead to postprimary tuberculosis in the future.  Patients who are suspected of having latent tuberculosis may undergo targeted testing with a tuberculin skin test or interferon-γ release assay.  Chest radiographs are used to stratify for risk and to assess for asymptomatic active disease.  Sequelae of previous tuberculosis that is now inactive manifest characteristically as fibronodular opacities in the apical and upper lung zones.  Stability of radiographic findings for 6 months distinguishes inactive from active disease.  Nontuberculous mycobacterial disease can sometimes mimic the findings of active tuberculosis, and laboratory confirmation is required to make the distinction.  Familiarity with the imaging, clinical, and laboratory features of tuberculosis is important for diagnosis and management. (©)RSNA, 2017.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSt7Z38okWFjLGbPKh4T9eAfW6udTcc2ebm3IZyc85BXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ks1Shsg%253D%253D&md5=edfd416f4a9360dc47c80cf73862b5b0</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1148%2Frg.2017160032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1148%252Frg.2017160032%26sid%3Dliteratum%253Aachs%26aulast%3DNachiappan%26aufirst%3DA.%2BC.%26aulast%3DRahbar%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DGuy%26aufirst%3DE.%2BS.%26aulast%3DMortani%2BBarbosa%26aufirst%3DE.%2BJ.%26aulast%3DShroff%26aufirst%3DG.%2BS.%26aulast%3DOcazionez%26aufirst%3DD.%26aulast%3DSchlesinger%26aufirst%3DA.%2BE.%26aulast%3DKatz%26aufirst%3DS.%2BI.%26aulast%3DHammer%26aufirst%3DM.%2BM.%26atitle%3DPulmonary%2520tuberculosis%253A%2520role%2520of%2520radiology%2520in%2520diagnosis%2520and%2520management%26jtitle%3DRadiographics%26date%3D2017%26volume%3D37%26spage%3D52%26epage%3D72%26doi%3D10.1148%2Frg.2017160032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guirado, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlesinger, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, G.</span></span> <span> </span><span class="NLM_article-title">Macrophages in tuberculosis: friend or foe</span>. <i>Semin. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.1007/s00281-013-0388-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1007%2Fs00281-013-0388-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23864058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSit7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2013&pages=563-583&author=E.+Guiradoauthor=L.+S.+Schlesingerauthor=G.+Kaplan&title=Macrophages+in+tuberculosis%3A+friend+or+foe&doi=10.1007%2Fs00281-013-0388-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophages in tuberculosis: friend or foe</span></div><div class="casAuthors">Guirado, Evelyn; Schlesinger, Larry S.; Kaplan, Gilla</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunopathology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">563-583</span>CODEN:
                <span class="NLM_cas:coden">SIEMB7</span>;
        ISSN:<span class="NLM_cas:issn">1863-2297</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB) remains one of the greatest threats to human health.  The causative bacterium, Mycobacterium tuberculosis (Mtb), is acquired by the respiratory route.  It is exquisitely human adapted and a prototypic intracellular pathogen of macrophages, with alveolar macrophages (AMs) being the primary conduit of infection and disease.  The outcome of primary infection is most often a latently infected healthy human host, in whom the bacteria are held in check by the host immune response.  Such individuals can develop active TB later in life with impairment in the immune system.  In contrast, in a minority of infected individuals, the host immune response fails to control the growth of bacilli, and progressive granulomatous disease develops, facilitating spread of the bacilli via infectious aerosols coughed out into the environment and inhaled by new hosts.  The mol. details of the Mtb-macrophage interaction continue to be elucidated.  However, it is clear that a no. of complex processes are involved at the different stages of infection that may benefit either the bacterium or the host.  Macrophages demonstrate tremendous phenotypic heterogeneity and functional plasticity which, depending on the site and stage of infection, facilitate the diverse outcomes.  Moreover, host responses vary depending on the specific characteristics of the infecting Mtb strain.  In this chapter, we describe a contemporary view of the behavior of AMs and their interaction with various Mtb strains in generating unique immunol. lung-specific responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_a9_M6jGdo7Vg90H21EOLACvtfcHk0ljLSfHiCKpUmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSit7vJ&md5=937f28d7e8402bc88a6e7ef1187da03a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00281-013-0388-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00281-013-0388-2%26sid%3Dliteratum%253Aachs%26aulast%3DGuirado%26aufirst%3DE.%26aulast%3DSchlesinger%26aufirst%3DL.%2BS.%26aulast%3DKaplan%26aufirst%3DG.%26atitle%3DMacrophages%2520in%2520tuberculosis%253A%2520friend%2520or%2520foe%26jtitle%3DSemin.%2520Immunopathol.%26date%3D2013%26volume%3D35%26spage%3D563%26epage%3D583%26doi%3D10.1007%2Fs00281-013-0388-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demangel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertolino, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britton, W. J.</span></span> <span> </span><span class="NLM_article-title">Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">994</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1002/1521-4141(200204)32:4<994::AID-IMMU994>3.0.CO;2-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1002%2F1521-4141%28200204%2932%3A4%3C994%3A%3AAID-IMMU994%3E3.0.CO%3B2-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=11920565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtFWntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2002&pages=994-1002&author=C.+Demangelauthor=P.+Bertolinoauthor=W.+J.+Britton&title=Autocrine+IL-10+impairs+dendritic+cell+%28DC%29-derived+immune+responses+to+mycobacterial+infection+by+suppressing+DC+trafficking+to+draining+lymph+nodes+and+local+IL-12+production&doi=10.1002%2F1521-4141%28200204%2932%3A4%3C994%3A%3AAID-IMMU994%3E3.0.CO%3B2-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production</span></div><div class="casAuthors">Demangel, Caroline; Bertolino, Patrick; Britton, Warwick J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">994-1002</span>CODEN:
                <span class="NLM_cas:coden">EJIMAF</span>;
        ISSN:<span class="NLM_cas:issn">0014-2980</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">The prodn. of IL-12 by dendritic cells (DC) early in an immune response is considered crit. for the polarization of CD4+ T lymphocyte response towards a Th1 pattern, a key process in the clearance of intracellular pathogens.  Infection of bone marrow-derived DC with Mycobacterium bovis Bacillus Calmette Guerin (BCG) induced a concurrent and dose-dependent release of IL-10 and IL-12.  Here we examd. whether the prodn. of IL-10 by DC affected their IL-12 response to mycobacterial infection and the generation of protective immune responses in vivo.  Compared to wild-type (WT) DC, DC deficient for IL-10 synthesis (IL-10-/-) showed increased IL-12 prodn. in response to BCG infection and CD40 stimuli in vitro.  Moreover, when transferred into mice, infected IL-10-/- DC were more efficient than WT DC at inducing IFN-γ prodn. to mycobacterial antigens in the draining lymph nodes (DLN).  This effect was assocd. with increased trafficking of IL-10-/- DC to the DLN and enhanced IL-12 prodn. by DC within the DLN.  These data show that autocrine IL-10 exerts a dual inhibitory effect on the induction of primary immune responses by DC: first, by down-regulating the migration of infected DC to the DLN and second, by modulating the IL-12 prodn. by DC in the DLN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroiPyZSKrvhrVg90H21EOLACvtfcHk0ljQieBMbtsyuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtFWntb4%253D&md5=15d5be82e17a97d034254f7bbf74d842</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2F1521-4141%28200204%2932%3A4%3C994%3A%3AAID-IMMU994%3E3.0.CO%3B2-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-4141%2528200204%252932%253A4%253C994%253A%253AAID-IMMU994%253E3.0.CO%253B2-6%26sid%3Dliteratum%253Aachs%26aulast%3DDemangel%26aufirst%3DC.%26aulast%3DBertolino%26aufirst%3DP.%26aulast%3DBritton%26aufirst%3DW.%2BJ.%26atitle%3DAutocrine%2520IL-10%2520impairs%2520dendritic%2520cell%2520%2528DC%2529-derived%2520immune%2520responses%2520to%2520mycobacterial%2520infection%2520by%2520suppressing%2520DC%2520trafficking%2520to%2520draining%2520lymph%2520nodes%2520and%2520local%2520IL-12%2520production%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2002%26volume%3D32%26spage%3D994%26epage%3D1002%26doi%3D10.1002%2F1521-4141%28200204%2932%3A4%3C994%3A%3AAID-IMMU994%3E3.0.CO%3B2-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, P. A.</span></span> <span> </span><span class="NLM_article-title">Immunocompetent cells in resistance to bacterial infections</span>. <i>Bacteriol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1128/BR.40.2.284-313.1976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FBR.40.2.284-313.1976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=786253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaE283nslCrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1976&pages=284-313&author=P.+A.+Campbell&title=Immunocompetent+cells+in+resistance+to+bacterial+infections&doi=10.1128%2FBR.40.2.284-313.1976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Immunocompetent cells in resistance to bacterial infections</span></div><div class="casAuthors">Campbell P A</div><div class="citationInfo"><span class="NLM_cas:title">Bacteriological reviews</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">284-313</span>
        ISSN:<span class="NLM_cas:issn">0005-3678</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRaUgmrYG_fa7xanA7vODO6fW6udTcc2eY1tQgzx1Yty7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE283nslCrug%253D%253D&md5=4f22b5ef1f9d50a65aa795ea7f0e951b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1128%2FBR.40.2.284-313.1976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FBR.40.2.284-313.1976%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DP.%2BA.%26atitle%3DImmunocompetent%2520cells%2520in%2520resistance%2520to%2520bacterial%2520infections%26jtitle%3DBacteriol.%2520Rev.%26date%3D1976%26volume%3D40%26spage%3D284%26epage%3D313%26doi%3D10.1128%2FBR.40.2.284-313.1976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. M.</span></span> <span> </span><span class="NLM_article-title">Cell-mediated immune responses in tuberculosis</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.021908.132703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1146%2Fannurev.immunol.021908.132703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19302046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFSltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=393-422&author=A.+M.+Cooper&title=Cell-mediated+immune+responses+in+tuberculosis&doi=10.1146%2Fannurev.immunol.021908.132703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-mediated immune responses in tuberculosis</span></div><div class="casAuthors">Cooper, Andrea M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">393-422</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Tuberculosis is primarily a disease of the lung, and dissemination of the disease depends on productive infection of this crit. organ.  Upon aerosol infection with Mycobacterium tuberculosis (Mtb), the acquired cellular immune response is slow to be induced and to be expressed within the lung.  This slowness allows infection to become well established; thus, the acquired response is expressed in an inflammatory site that has been initiated and modulated by the bacterium.  Mtb has a variety of surface mols. that interact with the innate response, and this interaction along with the autoregulation of the immune response by several mechanisms results in less-than-optimal control of bacterial growth.  To improve current vaccine strategies, the factors must understand that mediate induction, expression, and regulation of the immune response in the lung.  Also, it has to be detd. how to induce both known and novel immunoprotective responses without inducing immunopathol. consequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw8sN_3Z8az7Vg90H21EOLACvtfcHk0lg3Ehu8JLWK5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFSltrs%253D&md5=6671250240f7077287d41319359a8664</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.021908.132703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.021908.132703%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DA.%2BM.%26atitle%3DCell-mediated%2520immune%2520responses%2520in%2520tuberculosis%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D27%26spage%3D393%26epage%3D422%26doi%3D10.1146%2Fannurev.immunol.021908.132703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mihret, A.</span></span> <span> </span><span class="NLM_article-title">The role of dendritic cells in Mycobacterium tuberculosis infection</span>. <i>Virulence</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">654</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.4161/viru.22586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4161%2Fviru.22586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23154283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3s7js1aitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=654-659&author=A.+Mihret&title=The+role+of+dendritic+cells+in+Mycobacterium+tuberculosis+infection&doi=10.4161%2Fviru.22586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The role of dendritic cells in Mycobacterium tuberculosis infection</span></div><div class="casAuthors">Mihret Adane</div><div class="citationInfo"><span class="NLM_cas:title">Virulence</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">654-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The immune response against Mycobacterium tuberculosis is multifactorial, involving a network of innate and adaptive immune responses.  Characterization of the immune response, a clear understanding of the dynamics and interplay of different arms of the immune response are critical to allow the development of better tools for combating tuberculosis.  Dendritic cells (DCs) are one of the key cells in bridging innate and adaptive immune response through their significant role in capturing, processing and presenting antigens.  The outcome of interaction of M. tuberculosis with DCs is not fully understood and the available reports are contradictory were some findings reported that DCs strengthen the cellular immune response against mycobacterium infection whereas others reported M. tuberculosis impairs the function of DCs were infected DCs are poor stimulators of M. tuberculosis Ag-specific CD4 T cells.  Other studies showed that the outcome depends on M. tuberculosis strain type and type of receptor on DCs during recognition.  In this review I shall highlight the recent findings in the outcome of interaction of Mycobacterium tuberculosis with DCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0UHQu1DLNKa_dlEzl_fBafW6udTcc2ebORqs-pO9mKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7js1aitg%253D%253D&md5=4d727a916354c22068f9f351aa20b90a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.4161%2Fviru.22586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fviru.22586%26sid%3Dliteratum%253Aachs%26aulast%3DMihret%26aufirst%3DA.%26atitle%3DThe%2520role%2520of%2520dendritic%2520cells%2520in%2520Mycobacterium%2520tuberculosis%2520infection%26jtitle%3DVirulence%26date%3D2012%26volume%3D3%26spage%3D654%26epage%3D659%26doi%3D10.4161%2Fviru.22586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S.</span></span> <span> </span><span class="NLM_article-title">Alternative activation of macrophages</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1038/nri978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnri978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=12511873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=23-35&author=S.+Gordon&title=Alternative+activation+of+macrophages&doi=10.1038%2Fnri978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Alternative activation of macrophages</span></div><div class="casAuthors">Gordon, Siamon</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-35</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The classical pathway of interferon-γ-dependent activation of macrophages by T helper 1 (TH1)-type responses is a well-established feature of cellular immunity to infection with intracellular pathogens, such as Mycobacterium tuberculosis and HIV.  The concept of an alternative pathway of macrophage activation by the TH2-type cytokines interleukin-4 (IL-4) and IL-13 has gained credence in the past decade, to account for a distinctive macrophage phenotype that is consistent with a different role in humoral immunity and repair.  In this review, I assess the evidence in favor of alternative macrophage activation in the light of macrophage heterogeneity, and define its limits and relevance to a range of immune and inflammatory conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVdXdqFvv23bVg90H21EOLACvtfcHk0lg3Ehu8JLWK5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVw%253D&md5=7719c1deabe5175706b9828ec4f0b51f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnri978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri978%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DS.%26atitle%3DAlternative%2520activation%2520of%2520macrophages%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D23%26epage%3D35%26doi%3D10.1038%2Fnri978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qui, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagymasi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Rose, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanarasimhaiah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menoret, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittler, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiner, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vella, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adler, A. J.</span></span> <span> </span><span class="NLM_article-title">CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">3555</span>– <span class="NLM_lpage">3564</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1101244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4049%2Fjimmunol.1101244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21880986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2gsrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2011&pages=3555-3564&author=H.+Z.+Quiauthor=A.+T.+Hagymasiauthor=S.+Bandyopadhyayauthor=M.-C.+St.+Roseauthor=R.+Ramanarasimhaiahauthor=A.+Menoretauthor=R.+S.+Mittlerauthor=S.+M.+Gordonauthor=S.+L.+Reinerauthor=A.+T.+Vellaauthor=A.+J.+Adler&title=CD134+plus+CD137+dual+costimulation+induces+Eomesodermin+in+CD4+T+cells+to+program+cytotoxic+Th1+differentiation&doi=10.4049%2Fjimmunol.1101244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">CD134 Plus CD137 Dual Costimulation Induces Eomesodermin in CD4 T Cells To Program Cytotoxic Th1 Differentiation</span></div><div class="casAuthors">Qui, Harry Z.; Hagymasi, Adam T.; Bandyopadhyay, Suman; St. Rose, Marie-Clare; Ramanarasimhaiah, Raghunath; Menoret, Antoine; Mittler, Robert S.; Gordon, Scott M.; Reiner, Steven L.; Vella, Anthony T.; Adler, Adam J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3555-3564</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Cytotoxic CD4 Th1 cells are emerging as a therapeutically useful T cell lineage that can effectively target tumors, but until now the pathways that govern their differentiation have been poorly understood.  We demonstrate that CD134 (OX40) costimulation programs naive self- and virus-reactive CD4 T cells to undergo in vivo differentiation into cytotoxic Th1 effectors.  CD137 (4-1BB) costimulation maximized clonal expansion, and IL-2 was necessary for cytotoxic Th1 differentiation.  Importantly, the T-box transcription factor Eomesodermin was crit. for inducing the cytotoxic marker granzyme B. CD134 plus CD137 dual costimulation also imprinted a cytotoxic phenotype on bystanding CD4 T cells.  Thus, to our knowledge, the current study identifies for the first time a specific costimulatory pathway and an intracellular mechanism relying on Eomesodermin that induces both Ag-specific and bystander cytotoxic CD4 Th1 cells.  This mechanism might be therapeutically useful because CD134 plus CD137 dual costimulation induced CD4 T cell-dependent tumoricidal function in a mouse melanoma model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqekdAnJgyI8LVg90H21EOLACvtfcHk0lhkwCOKGJYT6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2gsrfM&md5=4b8ee6f56140e844da29ac766a133f8d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1101244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1101244%26sid%3Dliteratum%253Aachs%26aulast%3DQui%26aufirst%3DH.%2BZ.%26aulast%3DHagymasi%26aufirst%3DA.%2BT.%26aulast%3DBandyopadhyay%26aufirst%3DS.%26aulast%3DSt.%2BRose%26aufirst%3DM.-C.%26aulast%3DRamanarasimhaiah%26aufirst%3DR.%26aulast%3DMenoret%26aufirst%3DA.%26aulast%3DMittler%26aufirst%3DR.%2BS.%26aulast%3DGordon%26aufirst%3DS.%2BM.%26aulast%3DReiner%26aufirst%3DS.%2BL.%26aulast%3DVella%26aufirst%3DA.%2BT.%26aulast%3DAdler%26aufirst%3DA.%2BJ.%26atitle%3DCD134%2520plus%2520CD137%2520dual%2520costimulation%2520induces%2520Eomesodermin%2520in%2520CD4%2520T%2520cells%2520to%2520program%2520cytotoxic%2520Th1%2520differentiation%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D187%26spage%3D3555%26epage%3D3564%26doi%3D10.4049%2Fjimmunol.1101244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Valliere, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuertz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoft, D. F.</span></span> <span> </span><span class="NLM_article-title">Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies</span>. <i>Infect. Immun.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">6711</span>– <span class="NLM_lpage">6720</span>, <span class="refDoi"> DOI: 10.1128/IAI.73.10.6711-6720.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FIAI.73.10.6711-6720.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=16177348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVyhurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2005&pages=6711-6720&author=S.+de%0AValliereauthor=G.+Abateauthor=A.+Blazevicauthor=R.+M.+Heuertzauthor=D.+F.+Hoft&title=Enhancement+of+innate+and+cell-mediated+immunity+by+antimycobacterial+antibodies&doi=10.1128%2FIAI.73.10.6711-6720.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies</span></div><div class="casAuthors">de Valliere, S.; Abate, G.; Blazevic, A.; Heuertz, R. M.; Hoft, D. F.</div><div class="citationInfo"><span class="NLM_cas:title">Infection and Immunity</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6711-6720</span>CODEN:
                <span class="NLM_cas:coden">INFIBR</span>;
        ISSN:<span class="NLM_cas:issn">0019-9567</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The authors investigated the ability of human antibodies induced by Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccination to protect against mycobacterial infections.  Serum samples contg. mycobacterium-specific antibodies were obtained from volunteers who had received two intradermal BCG vaccinations 6 mo apart.  Significant increases in lipoarabinomannan (LAM)-specific IgG were detected after both the primary and booster vaccinations.  Effects of mycobacterium-specific antibodies on surface binding and internalization of BCG by neutrophils and monocytes/macrophages were studied, using green fluorescent protein (gfp)-expressing BCG.  Surface-bound gfp-expressing BCG were distinguished from intracellular BCG by surface labeling with LAM-specific monoclonal antibody.  Internalization of BCG by phagocytic cells was shown to be significantly enhanced in postvaccination serum samples.  Furthermore, the inhibitory effects of neutrophils and monocytes/macrophages on mycobacterial growth were significantly enhanced by BCG-induced antibodies.  The growth-inhibiting effects of postvaccination sera were reversed by preabsorption of IgG with Protein G.  Finally, the helper effects of antimycobacterial antibodies for the induction of cell-mediated immune responses were investigated.  BCG-induced antibodies significantly enhanced proliferation and gamma interferon prodn. in mycobacterium-specific CD4+ and CD8+ T cells, as well as the proportion of proliferating and degranulating CD8+ T cells.  The authors conclude that mycobacterium-specific antibodies are capable of enhancing both innate and cell-mediated immune responses to mycobacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofSyEXpFmcmLVg90H21EOLACvtfcHk0lhkwCOKGJYT6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVyhurbL&md5=5e2f2d3c66ea8e31382e30dff24b1704</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1128%2FIAI.73.10.6711-6720.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FIAI.73.10.6711-6720.2005%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BValliere%26aufirst%3DS.%26aulast%3DAbate%26aufirst%3DG.%26aulast%3DBlazevic%26aufirst%3DA.%26aulast%3DHeuertz%26aufirst%3DR.%2BM.%26aulast%3DHoft%26aufirst%3DD.%2BF.%26atitle%3DEnhancement%2520of%2520innate%2520and%2520cell-mediated%2520immunity%2520by%2520antimycobacterial%2520antibodies%26jtitle%3DInfect.%2520Immun.%26date%3D2005%26volume%3D73%26spage%3D6711%26epage%3D6720%26doi%3D10.1128%2FIAI.73.10.6711-6720.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagatay, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagatay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yurt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzergoz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurol, A. O.</span></span> <span> </span><span class="NLM_article-title">Can immune parameters be used as predictors to distinguish between pulmonary multidrug-resistant and drug-sensitive tuberculosis?</span>. <i>Arch. Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.5114/aoms.2010.13511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.5114%2Faoms.2010.13511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22371724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovV2qtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=77-82&author=B.+Kiranauthor=T.+Cagatayauthor=P.+Clarkauthor=F.+Kosarauthor=P.+Cagatayauthor=S.+Yurtauthor=F.+Suzergozauthor=A.+O.+Gurol&title=Can+immune+parameters+be+used+as+predictors+to+distinguish+between+pulmonary+multidrug-resistant+and+drug-sensitive+tuberculosis%3F&doi=10.5114%2Faoms.2010.13511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Can immune parameters be used as predictors to distinguish between pulmonary multidrug-resistant and drug-sensitive tuberculosis?</span></div><div class="casAuthors">Kiran, Bayram; Cagatay, Tulin; Clark, Philip; Kosar, Filiz; Cagatay, Penbe; Yurt, Sibel; Suzergoz, Faruk; Gurol, Ali Osman</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Medical Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-82</span>CODEN:
                <span class="NLM_cas:coden">AMSRDQ</span>;
        ISSN:<span class="NLM_cas:issn">1734-1922</span>.
    
            (<span class="NLM_cas:orgname">Termedia Publishing House</span>)
        </div><div class="casAbstract">Introduction: Despite the development and wide implementation of Directly Obsd. Therapy Strategies (DOTS), multidrug-resistant tuberculosis (MDR-TB) remains a serious global health threat.  In this study, the role of host immune response in patients with MDR-TB is investigated and compared with that of patients with smear-pos. drug-sensitive tuberculosis (SP-TB).  Material and methods: 27 patients with SP-TB, 20 patients with MDR-TB, and 20 healthy controls were included in the study.  Immune parameters were detd. by flow cytometry using monoclonal antibodies in order to compare the percentage values of these markers in the two study groups and the control group.  Results: The levels of lymphocyte subgroups in the gate of CD45(+)/CD14(-) lymphocyte: CD45(+), CD3(+), CD4(+), NK, CD3/HLA-DR, CD 95(+) cells were significantly lower; by contrast CD23(+), CD25(+), CD19(+), CD4(+)/CD8(+), HLA-DR cells were found to be lower, but not significantly so in patients with MDR-TB, compared to levels in patients in the SP-TB and control groups.  Besides these findings, the levels of NKT cells and γδ TCR(+) cells were significantly higher in the MDR-TB than in the healthy control and SP-TB group.  Conclusions: The lower levels of CD3/HLA-DR, CD4 (+), Fas (+), and NK, and the higher level of NKT together with γδ T cells in patients with MDR-TB compared to those in SP-TB may indicate a profound immune suppression in MDR-TB patients and thereby may denote an accumulation in the bacterial load.  Our findings may shed light on the pathogenesis and prognosis of MDR tuberculosis, and may point towards the use of flow cytometry findings as an aid to early diagnosis in MDR-TB patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNW7FhvUZ2iLVg90H21EOLACvtfcHk0lhkwCOKGJYT6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovV2qtL0%253D&md5=e90a3551b950562f6e84aa73d4bc103c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.5114%2Faoms.2010.13511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5114%252Faoms.2010.13511%26sid%3Dliteratum%253Aachs%26aulast%3DKiran%26aufirst%3DB.%26aulast%3DCagatay%26aufirst%3DT.%26aulast%3DClark%26aufirst%3DP.%26aulast%3DKosar%26aufirst%3DF.%26aulast%3DCagatay%26aufirst%3DP.%26aulast%3DYurt%26aufirst%3DS.%26aulast%3DSuzergoz%26aufirst%3DF.%26aulast%3DGurol%26aufirst%3DA.%2BO.%26atitle%3DCan%2520immune%2520parameters%2520be%2520used%2520as%2520predictors%2520to%2520distinguish%2520between%2520pulmonary%2520multidrug-resistant%2520and%2520drug-sensitive%2520tuberculosis%253F%26jtitle%3DArch.%2520Med.%2520Sci.%26date%3D2010%26volume%3D6%26spage%3D77%26epage%3D82%26doi%3D10.5114%2Faoms.2010.13511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkhill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiglmeier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tekaia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badcock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chillingworth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devlin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltwell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamlin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holroyd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornsby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagels, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajandream, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squares, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squares, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulston, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitehead, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrell, B. G.</span></span> <span> </span><span class="NLM_article-title">Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>393</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1038/31159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2F31159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=9634230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK1cXjvV2ksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=393&publication_year=1998&pages=537-544&author=S.+T.+Coleauthor=R.+Broschauthor=J.+Parkhillauthor=T.+Garnierauthor=C.+Churcherauthor=D.+Harrisauthor=S.+V.+Gordonauthor=K.+Eiglmeierauthor=S.+Gasauthor=C.+E.+Barryauthor=F.+Tekaiaauthor=K.+Badcockauthor=D.+Bashamauthor=D.+Brownauthor=T.+Chillingworthauthor=R.+Connorauthor=R.+Daviesauthor=K.+Devlinauthor=T.+Feltwellauthor=S.+Gentlesauthor=N.+Hamlinauthor=S.+Holroydauthor=T.+Hornsbyauthor=K.+Jagelsauthor=A.+Kroghauthor=J.+McLeanauthor=S.+Mouleauthor=L.+Murphyauthor=K.+Oliverauthor=J.+Osborneauthor=M.+A.+Quailauthor=M.+A.+Rajandreamauthor=J.+Rogersauthor=S.+Rutterauthor=K.+Seegerauthor=J.+Skeltonauthor=R.+Squaresauthor=S.+Squaresauthor=J.+E.+Sulstonauthor=K.+Taylorauthor=S.+Whiteheadauthor=B.+G.+Barrell&title=Deciphering+the+biology+of+Mycobacterium+tuberculosis+from+the+complete+genome+sequence&doi=10.1038%2F31159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence</span></div><div class="casAuthors">Cole, S. T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S. V.; Eiglmeier, K.; Gas, S.; Barry, C. E., III; Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.; Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M. A.; Rajandream, M.-A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J. E.; Taylor, K.; Whitehead, S.; Barrell, B. G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">393</span>
        (<span class="NLM_cas:issue">6685</span>),
    <span class="NLM_cas:pages">537-544</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Countless millions of people have died from tuberculosis, a chronic infectious disease caused by the tubercle bacillus.  The complete genome sequence of the best-characterized strain of Mycobacterium tuberculosis, H37Rv, was detd. and analyzed in order to improve our understanding of the biol. of this slow-growing pathogen and to help the conception of new prophylactic and therapeutic interventions.  The genome comprises 4,411,529 base pairs, contains around 4000 genes, and has a very high G+C content that is reflected in the biased amino acid content of the proteins.  M. tuberculosis differs radically from other bacteria in that a very large portion of its coding capacity is devoted to the prodn. of enzymes involved in lipogenesis and lipolysis, and to 2 new families of glycine-rich proteins with a repetitive structure that may represent a source of antigenic variation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9Q-iByIunurVg90H21EOLACvtfcHk0lg5GYH-r5POMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjvV2ksrY%253D&md5=44d23e7674bfeb1a3e30b55abf5268d2</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2F31159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F31159%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DS.%2BT.%26aulast%3DBrosch%26aufirst%3DR.%26aulast%3DParkhill%26aufirst%3DJ.%26aulast%3DGarnier%26aufirst%3DT.%26aulast%3DChurcher%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DD.%26aulast%3DGordon%26aufirst%3DS.%2BV.%26aulast%3DEiglmeier%26aufirst%3DK.%26aulast%3DGas%26aufirst%3DS.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DTekaia%26aufirst%3DF.%26aulast%3DBadcock%26aufirst%3DK.%26aulast%3DBasham%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DChillingworth%26aufirst%3DT.%26aulast%3DConnor%26aufirst%3DR.%26aulast%3DDavies%26aufirst%3DR.%26aulast%3DDevlin%26aufirst%3DK.%26aulast%3DFeltwell%26aufirst%3DT.%26aulast%3DGentles%26aufirst%3DS.%26aulast%3DHamlin%26aufirst%3DN.%26aulast%3DHolroyd%26aufirst%3DS.%26aulast%3DHornsby%26aufirst%3DT.%26aulast%3DJagels%26aufirst%3DK.%26aulast%3DKrogh%26aufirst%3DA.%26aulast%3DMcLean%26aufirst%3DJ.%26aulast%3DMoule%26aufirst%3DS.%26aulast%3DMurphy%26aufirst%3DL.%26aulast%3DOliver%26aufirst%3DK.%26aulast%3DOsborne%26aufirst%3DJ.%26aulast%3DQuail%26aufirst%3DM.%2BA.%26aulast%3DRajandream%26aufirst%3DM.%2BA.%26aulast%3DRogers%26aufirst%3DJ.%26aulast%3DRutter%26aufirst%3DS.%26aulast%3DSeeger%26aufirst%3DK.%26aulast%3DSkelton%26aufirst%3DJ.%26aulast%3DSquares%26aufirst%3DR.%26aulast%3DSquares%26aufirst%3DS.%26aulast%3DSulston%26aufirst%3DJ.%2BE.%26aulast%3DTaylor%26aufirst%3DK.%26aulast%3DWhitehead%26aufirst%3DS.%26aulast%3DBarrell%26aufirst%3DB.%2BG.%26atitle%3DDeciphering%2520the%2520biology%2520of%2520Mycobacterium%2520tuberculosis%2520from%2520the%2520complete%2520genome%2520sequence%26jtitle%3DNature%26date%3D1998%26volume%3D393%26spage%3D537%26epage%3D544%26doi%3D10.1038%2F31159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span> <span> </span><span class="NLM_article-title">Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">696</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1164/rccm.201006-0963PP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1164%2Frccm.201006-0963PP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21075901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVWnuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2011&pages=696-707&author=S.+Schwanderauthor=K.+Dheda&title=Human+lung+immunity+against+Mycobacterium+tuberculosis%3A+insights+into+pathogenesis+and+protection&doi=10.1164%2Frccm.201006-0963PP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Human lung Immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection</span></div><div class="casAuthors">Schwander, Stephan; Dheda, Keertan</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">696-707</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  The study of human pulmonary immunity against Mycobacterium tuberculosis (M.tb) provides a unique window into the biol. interactions between the human host and M.tb within the bronchoalveolar microenvironment, the site of natural infection.  Studies of bronchoalveolar cells (BACs) and lung tissue evaluate innate, adaptive, and regulatory immune mechanisms that collectively contribute to immunol. protection or its failure.  In aerogenically M.tb-exposed healthy persons lung immune responses reflect early host pathogen interactions that may contribute to sterilization, the development of latent M.tb infection, or progression to active disease.  Studies in these persons may allow the identification of biomarkers of protective immunity before the initiation of inflammatory and disease-assocd. immunopathol. changes.  In healthy close contacts of patients with tuberculosis (TB) and during active pulmonary TB, immune responses are compartmentalized to the lungs and characterized by an exuberant helper T-cell type 1 response, which as suggested by recent evidence is counteracted by local suppressive immune mechanisms.  Here we discuss how exploring human lung immunity may provide insights into disease progression and mechanisms of failure of immunol. protection at the site of the initial host-pathogen interaction.  These findings may also aid in the identification of new biomarkers of protective immunity that are urgently needed for the development of new and the improvement of current TB vaccines, adjuvant immunotherapies, and diagnostic technologies.  To facilitate further work in this area, methodol. and procedural approaches for bronchoalveolar lavage studies and their limitations are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQkEypfHM-_bVg90H21EOLACvtfcHk0lg5GYH-r5POMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVWnuro%253D&md5=171b0ed617c3a7fb1a62d3d11348dc11</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1164%2Frccm.201006-0963PP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201006-0963PP%26sid%3Dliteratum%253Aachs%26aulast%3DSchwander%26aufirst%3DS.%26aulast%3DDheda%26aufirst%3DK.%26atitle%3DHuman%2520lung%2520immunity%2520against%2520Mycobacterium%2520tuberculosis%253A%2520insights%2520into%2520pathogenesis%2520and%2520protection%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2011%26volume%3D183%26spage%3D696%26epage%3D707%26doi%3D10.1164%2Frccm.201006-0963PP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence</span>. <i>Clin. Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1128/CMR.16.3.463-496.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FCMR.16.3.463-496.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=12857778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsV2qt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2003&pages=463-496&author=I.+Smith&title=Mycobacterium+tuberculosis+pathogenesis+and+molecular+determinants+of+virulence&doi=10.1128%2FCMR.16.3.463-496.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence</span></div><div class="casAuthors">Smith, Issar</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">463-496</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">0893-8512</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB), one of the oldest known human diseases is still is one of the major causes of mortality, since two million people die each year from this malady.  TB has many manifestations, affecting bone, the central nervous system, and many other organ systems, but it is primarily a pulmonary disease that is initiated by the deposition of Mycobacterium tuberculosis, contained in aerosol droplets, onto lung alveolar surfaces.  From this point, the progression of the disease can have several outcomes, detd. largely by the response of the host immune system.  The efficacy of this response is affected by intrinsic factors such as the genetics of the immune system as well as extrinsic factors, e.g., insults to the immune system and the nutritional and physiol. state of the host.  In addn., the pathogen may play a role in disease progression since some M. tuberculosis strains are reportedly more virulent than others, as defined by increased transmissibility as well as being assocd. with higher morbidity and mortality in infected individuals.  Despite the widespread use of an attenuated live vaccine and several antibiotics, there is more TB than ever before, requiring new vaccines and drugs and more specific and rapid diagnostics.  Researchers are utilizing information obtained from the complete sequence of the M. tuberculosis genome and from new genetic and physiol. methods to identify targets in M. tuberculosis that will aid in the development of these sorely needed antitubercular agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-PFlCxatfLLVg90H21EOLACvtfcHk0lhD6IOob2Or4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsV2qt7c%253D&md5=34257497807bda4aafc60632318486cf</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1128%2FCMR.16.3.463-496.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.16.3.463-496.2003%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DI.%26atitle%3DMycobacterium%2520tuberculosis%2520pathogenesis%2520and%2520molecular%2520determinants%2520of%2520virulence%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2003%26volume%3D16%26spage%3D463%26epage%3D496%26doi%3D10.1128%2FCMR.16.3.463-496.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lonnroth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, C.</span></span> <span> </span><span class="NLM_article-title">Alcohol use as a risk factor for tuberculosis - a systematic review</span>. <i>BMC Public Health</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">289</span>, <span class="refDoi"> DOI: 10.1186/1471-2458-8-289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1186%2F1471-2458-8-289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=18702821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD1crpsFGntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=289&author=K.+Lonnrothauthor=B.+G.+Williamsauthor=S.+Stadlinauthor=E.+Jaramilloauthor=C.+Dye&title=Alcohol+use+as+a+risk+factor+for+tuberculosis+-+a+systematic+review&doi=10.1186%2F1471-2458-8-289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Alcohol use as a risk factor for tuberculosis - a systematic review</span></div><div class="casAuthors">Lonnroth Knut; Williams Brian G; Stadlin Stephanie; Jaramillo Ernesto; Dye Christopher</div><div class="citationInfo"><span class="NLM_cas:title">BMC public health</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">289</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  It has long been evident that there is an association between alcohol use and risk of tuberculosis.  It has not been established to what extent this association is confounded by social and other factors related to alcohol use.  Nor has the strength of the association been established.  The objective of this study was to systematically review the available evidence on the association between alcohol use and the risk of tuberculosis.  METHODS:  Based on a systematic literature review, we identified 3 cohort and 18 case control studies.  These were further categorized according to definition of exposure, type of tuberculosis used as study outcome, and confounders controlled for.  Pooled effect sizes were obtained for each sub-category of studies.  RESULTS:  The pooled relative risk across all studies that used an exposure cut-off level set at 40 g alcohol per day or above, or defined exposure as a clinical diagnosis of an alcohol use disorder, was 3.50 (95% CI: 2.01-5.93).  After exclusion of small studies, because of suspected publication bias, the pooled relative risk was 2.94 (95% CI: 1.89-4.59).  Subgroup analyses of studies that had controlled for various sets of confounders did not give significantly different results and did not explain the significant heterogeneity that was found across the studies.  CONCLUSION:  The risk of active tuberculosis is substantially elevated in people who drink more than 40 g alcohol per day, and/or have an alcohol use disorder.  This may be due to both increased risk of infection related to specific social mixing patterns associated with alcohol use, as well as influence on the immune system of alcohol itself and of alcohol related conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6wjgXo3uPKiSm0e6ZOaemfW6udTcc2eb-uTVyfwUmQbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1crpsFGntw%253D%253D&md5=845b5506105d5e79f9b0a4e1dc7765ac</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1186%2F1471-2458-8-289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2458-8-289%26sid%3Dliteratum%253Aachs%26aulast%3DLonnroth%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DB.%2BG.%26aulast%3DStadlin%26aufirst%3DS.%26aulast%3DJaramillo%26aufirst%3DE.%26aulast%3DDye%26aufirst%3DC.%26atitle%3DAlcohol%2520use%2520as%2520a%2520risk%2520factor%2520for%2520tuberculosis%2520-%2520a%2520systematic%2520review%26jtitle%3DBMC%2520Public%2520Health%26date%3D2008%26volume%3D8%26spage%3D289%26doi%3D10.1186%2F1471-2458-8-289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span> <i>Systematic Review
of the Link Between Tobacco and Poverty</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2011</span>; <a href="https://www.who.int/tobacco/publications/economics/syst_rev_tobacco_poverty/en/" class="extLink">https://www.who.int/tobacco/publications/economics/syst_rev_tobacco_poverty/en/</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Systematic+Review%0Aof+the+Link+Between+Tobacco+and+Poverty%3B+World+Health+Organization%3A+Geneva%2C+2011%3B+https%3A%2F%2Fwww.who.int%2Ftobacco%2Fpublications%2Feconomics%2Fsyst_rev_tobacco_poverty%2Fen%2F+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DSystematic%2520Review%250Aof%2520the%2520Link%2520Between%2520Tobacco%2520and%2520Poverty%26pub%3DWorld%2520Health%2520Organization%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezzati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, M.</span></span> <span> </span><span class="NLM_article-title">Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e20</span>, <span class="refDoi"> DOI: 10.1371/journal.pmed.0040020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pmed.0040020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=17227135" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=e20&author=H.+H.+Linauthor=M.+Ezzatiauthor=M.+Murray&title=Tobacco+smoke%2C+indoor+air+pollution+and+tuberculosis%3A+a+systematic+review+and+meta-analysis&doi=10.1371%2Fjournal.pmed.0040020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0040020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0040020%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%2BH.%26aulast%3DEzzati%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DM.%26atitle%3DTobacco%2520smoke%252C%2520indoor%2520air%2520pollution%2520and%2520tuberculosis%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DPLoS%2520Med.%26date%3D2007%26volume%3D4%26spage%3De20%26doi%3D10.1371%2Fjournal.pmed.0040020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LoBue, P.</span></span> <span> </span><span class="NLM_article-title">Extensively drug-resistant tuberculosis</span>. <i>Curr. Opin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1097/QCO.0b013e3283229fab</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1097%2FQCO.0b013e3283229fab" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19283912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD1M3gsFOhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=167-173&author=P.+LoBue&title=Extensively+drug-resistant+tuberculosis&doi=10.1097%2FQCO.0b013e3283229fab"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Extensively drug-resistant tuberculosis</span></div><div class="casAuthors">LoBue Philip</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in infectious diseases</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  To describe the origin, epidemiology, diagnosis, treatment, prevention, and control of extensively drug-resistant tuberculosis (XDR TB).  RECENT FINDINGS:  XDR TB is defined as the occurrence of TB in persons whose Mycobacterium tuberculosis isolates are resistant to isoniazid and rifampin and to any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin).  As of June 2008, XDR TB has been found in 49 countries including the United States.  It generally takes several weeks to detect XDR TB using conventional culture-based methods, although some progress is being made in developing rapid molecular tests.  Treatment for XDR TB is difficult, usually requiring at least 18-24 months of four to six second-line anti-TB drugs.  Treatment success rates are generally 30-50%, with very poor outcomes in HIV-infected patients.  Management of contacts to infectious XDR TB patients is complicated by the lack of a proven effective treatment for XDR latent tuberculosis infection.  SUMMARY:  XDR TB is an emerging global health threat.  The disease is difficult and expensive to diagnose and treat, and outcomes are frequently poor.  New rapid diagnostic tests and new classes of anti-TB drugs are needed to successfully combat this global problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKbrLBFx7v2AWRJ3OJdH_qfW6udTcc2eY8IvJ98XAUhbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3gsFOhuw%253D%253D&md5=eacd3674848373ef008f3623df463665</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1097%2FQCO.0b013e3283229fab&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQCO.0b013e3283229fab%26sid%3Dliteratum%253Aachs%26aulast%3DLoBue%26aufirst%3DP.%26atitle%3DExtensively%2520drug-resistant%2520tuberculosis%26jtitle%3DCurr.%2520Opin.%2520Infect.%2520Dis.%26date%3D2009%26volume%3D22%26spage%3D167%26epage%3D173%26doi%3D10.1097%2FQCO.0b013e3283229fab" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caminero, J. A.</span></span> <span> </span><span class="NLM_article-title">Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">877</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=18647445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD1cvmvFeqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=869-877&author=J.+A.+Caminero&title=Likelihood+of+generating+MDR-TB+and+XDR-TB+under+adequate+National+Tuberculosis+Control+Programme+implementation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation</span></div><div class="casAuthors">Caminero J A</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">869-77</span>
        ISSN:<span class="NLM_cas:issn">1027-3719</span>.
    </div><div class="casAbstract">The most frequent factors associated with selection of resistance at the community level and the generation of multidrug-resistant tuberculosis (MDR-TB) under epidemic conditions have been described in the last decades.  These factors are multiple, and it is often a combination of these that has been implicated in the origin of MDR-TB epidemics in specific zones or countries.  The analysis of and correct approach to the causes should be the first and most important step in the fight against this critical problem.  However, it has never been investigated whether specific circumstances, even under adequate implementation of a National TB Control Programme (NTP), could lead to selection or amplification of resistance.  The NTP should consider explanations for when there is no decline in MDR-TB rates even after appropriate control measures have been implemented.  Under the special circumstances analysed in this article, the World Health Organization (WHO) Category I regimen can amplify resistance to rifampicin (in initial isoniazid-resistant cases) or ethambutol (EMB) + pyrazinamide (in initial MDR-TB cases).  The WHO Category II regimen can also amplify resistance to EMB or streptomycin.  The subsequent addition of the only second-line drugs available in many countries (fluoroquinolones and/or injectables) can worsen the situation and generate extensively drug-resistant TB.  Strategies for minimising these risks of amplifying resistance are discussed in this article.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSt74dEoWIBbu98rul4nhSdfW6udTcc2eaKu0Gma4MTVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvmvFeqsg%253D%253D&md5=d256bde49c2f3814fb3cecdf1a9e4292</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaminero%26aufirst%3DJ.%2BA.%26atitle%3DLikelihood%2520of%2520generating%2520MDR-TB%2520and%2520XDR-TB%2520under%2520adequate%2520National%2520Tuberculosis%2520Control%2520Programme%2520implementation%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D2008%26volume%3D12%26spage%3D869%26epage%3D877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azevedo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coetzee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coetzee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Cutsem, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goemaere, E.</span></span> <span> </span><span class="NLM_article-title">Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e13901</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0013901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pone.0013901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21085569" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=e13901&author=H.+S.+Coxauthor=C.+McDermidauthor=V.+Azevedoauthor=O.+Mullerauthor=D.+Coetzeeauthor=J.+Simpsonauthor=M.+Barnardauthor=G.+Coetzeeauthor=G.+van+Cutsemauthor=E.+Goemaere&title=Epidemic+levels+of+drug+resistant+tuberculosis+%28MDR+and+XDR-TB%29+in+a+high+HIV+prevalence+setting+in+Khayelitsha%2C+South+Africa&doi=10.1371%2Fjournal.pone.0013901"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0013901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0013901%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DH.%2BS.%26aulast%3DMcDermid%26aufirst%3DC.%26aulast%3DAzevedo%26aufirst%3DV.%26aulast%3DMuller%26aufirst%3DO.%26aulast%3DCoetzee%26aufirst%3DD.%26aulast%3DSimpson%26aufirst%3DJ.%26aulast%3DBarnard%26aufirst%3DM.%26aulast%3DCoetzee%26aufirst%3DG.%26aulast%3Dvan%2BCutsem%26aufirst%3DG.%26aulast%3DGoemaere%26aufirst%3DE.%26atitle%3DEpidemic%2520levels%2520of%2520drug%2520resistant%2520tuberculosis%2520%2528MDR%2520and%2520XDR-TB%2529%2520in%2520a%2520high%2520HIV%2520prevalence%2520setting%2520in%2520Khayelitsha%252C%2520South%2520Africa%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26spage%3De13901%26doi%3D10.1371%2Fjournal.pone.0013901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benatar, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upshur, R.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis and poverty: what could (and should) be done?</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1215</span>– <span class="NLM_lpage">1221</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=20843410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3cfislCgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=1215-1221&author=S.+R.+Benatarauthor=R.+Upshur&title=Tuberculosis+and+poverty%3A+what+could+%28and+should%29+be+done%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberculosis and poverty: what could (and should) be done?</span></div><div class="casAuthors">Benatar S R; Upshur R</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1215-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJGSKKqrSo6Rcr74wzj5o5fW6udTcc2eaKu0Gma4MTVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cfislCgtg%253D%253D&md5=1a73de5091c69c726f03b935c4d36999</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBenatar%26aufirst%3DS.%2BR.%26aulast%3DUpshur%26aufirst%3DR.%26atitle%3DTuberculosis%2520and%2520poverty%253A%2520what%2520could%2520%2528and%2520should%2529%2520be%2520done%253F%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D2010%26volume%3D14%26spage%3D1215%26epage%3D1221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lonnroth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raviglione, M.</span></span> <span> </span><span class="NLM_article-title">Drivers of tuberculosis epidemics: the role of risk factors and social determinants</span>. <i>Social Science and Medicine</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2240</span>– <span class="NLM_lpage">2246</span>, <span class="refDoi"> DOI: 10.1016/j.socscimed.2009.03.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.socscimed.2009.03.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19394122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD1Mvhs1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2009&pages=2240-2246&author=K.+Lonnrothauthor=E.+Jaramilloauthor=B.+G.+Williamsauthor=C.+Dyeauthor=M.+Raviglione&title=Drivers+of+tuberculosis+epidemics%3A+the+role+of+risk+factors+and+social+determinants&doi=10.1016%2Fj.socscimed.2009.03.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Drivers of tuberculosis epidemics: the role of risk factors and social determinants</span></div><div class="casAuthors">Lonnroth Knut; Jaramillo Ernesto; Williams Brian G; Dye Christopher; Raviglione Mario</div><div class="citationInfo"><span class="NLM_cas:title">Social science & medicine (1982)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2240-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The main thrust of the World Health Organization's global tuberculosis (TB) control strategy is to ensure effective and equitable delivery of quality assured diagnosis and treatment of TB.  Options for including preventive efforts have not yet been fully considered.  This paper presents a narrative review of the historical and recent progress in TB control and the role of TB risk factors and social determinants.  The review was conducted with a view to assess the prospects of effectively controlling TB under the current strategy, and the potential to increase epidemiological impact through additional preventive interventions.  The review suggests that, while the current strategy is effective in curing patients and saving lives, the epidemiological impact has so far been less than predicted.  In order to reach long-term epidemiological targets for global TB control, additional interventions to reduce peoples' vulnerability for TB may therefore be required.  Risk factors that seem to be of importance at the population level include poor living and working conditions associated with high risk of TB transmission, and factors that impair the host's defence against TB infection and disease, such as HIV infection, malnutrition, smoking, diabetes, alcohol abuse, and indoor air pollution.  Preventive interventions may target these factors directly or via their underlying social determinants.  The identification of risk groups also helps to target strategies for early detection of people in need of TB treatment.  More research is needed on the suitability, feasibility and cost-effectiveness of these intervention options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAX7fiC2q5IsULxIEhxUjPfW6udTcc2eZ-NnVDylmtpLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mvhs1CktA%253D%253D&md5=511292622073a7edafb5c4ef15429824</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.socscimed.2009.03.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.socscimed.2009.03.041%26sid%3Dliteratum%253Aachs%26aulast%3DLonnroth%26aufirst%3DK.%26aulast%3DJaramillo%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DB.%2BG.%26aulast%3DDye%26aufirst%3DC.%26aulast%3DRaviglione%26aufirst%3DM.%26atitle%3DDrivers%2520of%2520tuberculosis%2520epidemics%253A%2520the%2520role%2520of%2520risk%2520factors%2520and%2520social%2520determinants%26jtitle%3DSocial%2520Science%2520and%2520Medicine%26date%3D2009%26volume%3D68%26spage%3D2240%26epage%3D2246%26doi%3D10.1016%2Fj.socscimed.2009.03.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crudu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noroc, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romancenco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemann, S.</span></span> <span> </span><span class="NLM_article-title">Nosocomial transmission of multidrug-resistant tuberculosis</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1520</span>– <span class="NLM_lpage">1523</span>, <span class="refDoi"> DOI: 10.5588/ijtld.15.0327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.5588%2Fijtld.15.0327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26614195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC28vlvFOjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=1520-1523&author=V.+Cruduauthor=M.+Merkerauthor=C.+Langeauthor=E.+Norocauthor=E.+Romancencoauthor=D.+Chesovauthor=G.+Guntherauthor=S.+Niemann&title=Nosocomial+transmission+of+multidrug-resistant+tuberculosis&doi=10.5588%2Fijtld.15.0327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Nosocomial transmission of multidrug-resistant tuberculosis</span></div><div class="casAuthors">Crudu V; Noroc E; Romancenco E; Merker M; Niemann S; Lange C; Chesov D; Gunther G</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1520-3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Nosocomial transmission of multidrug-resistant tuberculosis (MDR-TB) was ascertained by 24-locus mycobacterial interspersed repetitive units-variable number of tandem repeats (MIRU-VNTR) and spoligotyping at four hospitals in the Republic of Moldova, a high MDR-TB burden country.  Overall, 5.1% of patients with pan-susceptible TB at baseline were identified with MDR-TB during in-patient treatment.  In 75% of cases, the MDR-TB strain was genetically distinct from the non-MDR-TB strain at baseline, suggesting a high rate of nosocomial transmission of MDR-TB.  The highest proportion (40.3%) of follow-up MDR-TB isolates was associated with the M. tuberculosis URAL 163-15 strain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5nTpLjFNsobBItaL1WaVAfW6udTcc2eZ-NnVDylmtpLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vlvFOjug%253D%253D&md5=bae354656c7282547300f23ffefbe708</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.5588%2Fijtld.15.0327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5588%252Fijtld.15.0327%26sid%3Dliteratum%253Aachs%26aulast%3DCrudu%26aufirst%3DV.%26aulast%3DMerker%26aufirst%3DM.%26aulast%3DLange%26aufirst%3DC.%26aulast%3DNoroc%26aufirst%3DE.%26aulast%3DRomancenco%26aufirst%3DE.%26aulast%3DChesov%26aufirst%3DD.%26aulast%3DGunther%26aufirst%3DG.%26aulast%3DNiemann%26aufirst%3DS.%26atitle%3DNosocomial%2520transmission%2520of%2520multidrug-resistant%2520tuberculosis%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D2015%26volume%3D19%26spage%3D1520%26epage%3D1523%26doi%3D10.5588%2Fijtld.15.0327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">von
Delft, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dramowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khosa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotze, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lederer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosidi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Westhuizen, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Delft, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeurer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mwaba, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyirenda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zumla, A.</span></span> <span> </span><span class="NLM_article-title">Why healthcare workers are sick of TB</span>. <i>Int. J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1016/j.ijid.2014.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.ijid.2014.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25809771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2MnotFarsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=147-151&author=A.+von%0ADelftauthor=A.+Dramowskiauthor=C.+Khosaauthor=K.+Kotzeauthor=P.+Ledererauthor=T.+Mosidiauthor=J.+A.+Petersauthor=J.+Smithauthor=H.+M.+van+der+Westhuizenauthor=D.+von+Delftauthor=B.+Willemsauthor=M.+Batesauthor=G.+Craigauthor=M.+Maeurerauthor=B.+J.+Maraisauthor=P.+Mwabaauthor=E.+A.+Nunesauthor=T.+Nyirendaauthor=M.+Oliverauthor=A.+Zumla&title=Why+healthcare+workers+are+sick+of+TB&doi=10.1016%2Fj.ijid.2014.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Why healthcare workers are sick of TB</span></div><div class="casAuthors">von Delft Arne; Dramowski Angela; Khosa Celso; Kotze Koot; van der Westhuizen Helene-Mari; Willems Bart; Lederer Philip; Mosidi Thato; Peters Jurgens A; von Delft Dalene; Smith Jonathan; Bates Matthew; Mwaba Peter; Craig Gill; Maeurer Markus; Marais Ben J; Nunes Elizabete A; Nyirenda Thomas; Oliver Matt; Zumla Alimuddin</div><div class="citationInfo"><span class="NLM_cas:title">International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">147-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dr Thato Mosidi never expected to be diagnosed with tuberculosis (TB), despite widely prevalent exposure and very limited infection control measures.  The life-threatening diagnosis of primary extensively drug-resistant TB (XDR-TB) came as an even greater shock.  The inconvenient truth is that, rather than being protected, Dr Mosidi and thousands of her healthcare colleagues are at an increased risk of TB and especially drug-resistant TB.  In this viewpoint paper we debunk the widely held false belief that healthcare workers are somehow immune to TB disease (TB-proof) and explore some of the key factors contributing to the pervasive stigmatization and subsequent non-disclosure of occupational TB.  Our front-line workers are some of the first to suffer the consequences of a progressively more resistant and fatal TB epidemic, and urgent interventions are needed to ensure the safety and continued availability of these precious healthcare resources.  These include the rapid development and scale-up of improved diagnostic and treatment options, strengthened infection control measures, and focused interventions to tackle stigma and discrimination in all its forms.  We call our colleagues to action to protect themselves and those they care for.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR3ahRjARP6kYIRAdBLKY41fW6udTcc2eZ-NnVDylmtpLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnotFarsw%253D%253D&md5=985f2f3878f94f6513879b0c796114b9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ijid.2014.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijid.2014.12.003%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BDelft%26aufirst%3DA.%26aulast%3DDramowski%26aufirst%3DA.%26aulast%3DKhosa%26aufirst%3DC.%26aulast%3DKotze%26aufirst%3DK.%26aulast%3DLederer%26aufirst%3DP.%26aulast%3DMosidi%26aufirst%3DT.%26aulast%3DPeters%26aufirst%3DJ.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BWesthuizen%26aufirst%3DH.%2BM.%26aulast%3Dvon%2BDelft%26aufirst%3DD.%26aulast%3DWillems%26aufirst%3DB.%26aulast%3DBates%26aufirst%3DM.%26aulast%3DCraig%26aufirst%3DG.%26aulast%3DMaeurer%26aufirst%3DM.%26aulast%3DMarais%26aufirst%3DB.%2BJ.%26aulast%3DMwaba%26aufirst%3DP.%26aulast%3DNunes%26aufirst%3DE.%2BA.%26aulast%3DNyirenda%26aufirst%3DT.%26aulast%3DOliver%26aufirst%3DM.%26aulast%3DZumla%26aufirst%3DA.%26atitle%3DWhy%2520healthcare%2520workers%2520are%2520sick%2520of%2520TB%26jtitle%3DInt.%2520J.%2520Infect.%2520Dis.%26date%3D2015%26volume%3D32%26spage%3D147%26epage%3D151%26doi%3D10.1016%2Fj.ijid.2014.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cegielski, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laserson, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtz, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weyer, K.</span></span> <span> </span><span class="NLM_article-title">HIV infection and multidrug-resistant tuberculosis: the perfect storm</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>196</i></span>,  <span class="NLM_fpage">S86</span>– <span class="NLM_lpage">S107</span>, <span class="refDoi"> DOI: 10.1086/518665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1086%2F518665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=17624830" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=196&publication_year=2007&pages=S86-S107&author=C.+D.+Wellsauthor=J.+P.+Cegielskiauthor=L.+J.+Nelsonauthor=K.+F.+Lasersonauthor=T.+H.+Holtzauthor=A.+Finlayauthor=K.+G.+Castroauthor=K.+Weyer&title=HIV+infection+and+multidrug-resistant+tuberculosis%3A+the+perfect+storm&doi=10.1086%2F518665"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1086%2F518665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F518665%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DC.%2BD.%26aulast%3DCegielski%26aufirst%3DJ.%2BP.%26aulast%3DNelson%26aufirst%3DL.%2BJ.%26aulast%3DLaserson%26aufirst%3DK.%2BF.%26aulast%3DHoltz%26aufirst%3DT.%2BH.%26aulast%3DFinlay%26aufirst%3DA.%26aulast%3DCastro%26aufirst%3DK.%2BG.%26aulast%3DWeyer%26aufirst%3DK.%26atitle%3DHIV%2520infection%2520and%2520multidrug-resistant%2520tuberculosis%253A%2520the%2520perfect%2520storm%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2007%26volume%3D196%26spage%3DS86%26epage%3DS107%26doi%3D10.1086%2F518665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Churchyard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustomjee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathema, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasmar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardenas, V.</span></span> <span> </span><span class="NLM_article-title">What We Know About Tuberculosis Transmission: An Overview</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>216</i></span>,  <span class="NLM_fpage">S629</span>– <span class="NLM_lpage">S635</span>, <span class="refDoi"> DOI: 10.1093/infdis/jix362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Finfdis%2Fjix362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29112747" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=2017&pages=S629-S635&author=G.+Churchyardauthor=P.+Kimauthor=N.+S.+Shahauthor=R.+Rustomjeeauthor=N.+Gandhiauthor=B.+Mathemaauthor=D.+Dowdyauthor=A.+Kasmarauthor=V.+Cardenas&title=What+We+Know+About+Tuberculosis+Transmission%3A+An+Overview&doi=10.1093%2Finfdis%2Fjix362"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjix362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjix362%26sid%3Dliteratum%253Aachs%26aulast%3DChurchyard%26aufirst%3DG.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DN.%2BS.%26aulast%3DRustomjee%26aufirst%3DR.%26aulast%3DGandhi%26aufirst%3DN.%26aulast%3DMathema%26aufirst%3DB.%26aulast%3DDowdy%26aufirst%3DD.%26aulast%3DKasmar%26aufirst%3DA.%26aulast%3DCardenas%26aufirst%3DV.%26atitle%3DWhat%2520We%2520Know%2520About%2520Tuberculosis%2520Transmission%253A%2520An%2520Overview%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2017%26volume%3D216%26spage%3DS629%26epage%3DS635%26doi%3D10.1093%2Finfdis%2Fjix362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fox, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britton, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, G. B.</span></span> <span> </span><span class="NLM_article-title">Contact investigation for tuberculosis: a systematic review and meta-analysis</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1183/09031936.00070812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1183%2F09031936.00070812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22936710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC38bivFCrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=140-156&author=G.+J.+Foxauthor=S.+E.+Barryauthor=W.+J.+Brittonauthor=G.+B.+Marks&title=Contact+investigation+for+tuberculosis%3A+a+systematic+review+and+meta-analysis&doi=10.1183%2F09031936.00070812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Contact investigation for tuberculosis: a systematic review and meta-analysis</span></div><div class="casAuthors">Fox Gregory J; Barry Simone E; Britton Warwick J; Marks Guy B</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">140-56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Investigation of contacts of patients with tuberculosis (TB) is a priority for TB control in high-income countries, and is increasingly being considered in resource-limited settings.  This review was commissioned for a World Health Organization Expert Panel to develop global contact investigation guidelines.  We performed a systematic review and meta-analysis of all studies reporting the prevalence of TB and latent TB infection, and the annual incidence of TB among contacts of patients with TB.  After screening 9,555 titles, we included 203 published studies.  In 95 studies from low- and middle-income settings, the prevalence of active TB in all contacts was 3.1% (95% CI 2.2-4.4%, I(2)=99.4%), microbiologically proven TB was 1.2% (95% CI 0.9-1.8%, I(2)=95.9%), and latent TB infection was 51.5% (95% CI 47.1-55.8%, I(2)=98.9%).  The prevalence of TB among household contacts was 3.1% (95% CI 2.1-4.5%, I(2)=98.8%) and among contacts of patients with multidrug-resistant or extensively drug-resistant TB was 3.4% (95% CI 0.8-12.6%, I(2)=95.7%).  Incidence was greatest in the first year after exposure.  In 108 studies from high-income settings, the prevalence of TB among contacts was 1.4% (95% CI 1.1-1.8%, I(2)=98.7%), and the prevalence of latent infection was 28.1% (95% CI 24.2-32.4%, I(2)=99.5%).  There was substantial heterogeneity among published studies.  Contacts of TB patients are a high-risk group for developing TB, particularly within the first year.  Children <5 yrs of age and people living with HIV are particularly at risk.  Policy recommendations must consider evidence of the cost-effectiveness of various contact tracing strategies, and also incorporate complementary strategies to enhance case finding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZeTXPSNnEVn6oPH0mYWL1fW6udTcc2ebSPnyg9pxZvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bivFCrtQ%253D%253D&md5=18f9513f091a72f06f4eaa5fb934181a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1183%2F09031936.00070812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00070812%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DG.%2BJ.%26aulast%3DBarry%26aufirst%3DS.%2BE.%26aulast%3DBritton%26aufirst%3DW.%2BJ.%26aulast%3DMarks%26aufirst%3DG.%2BB.%26atitle%3DContact%2520investigation%2520for%2520tuberculosis%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D41%26spage%3D140%26epage%3D156%26doi%3D10.1183%2F09031936.00070812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathema, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgdorff, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynn, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustomjee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silk, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, R.</span></span> <span> </span><span class="NLM_article-title">Drivers of tuberculosis transmission</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>216</i></span>,  <span class="NLM_fpage">S644</span>– <span class="NLM_lpage">S653</span>, <span class="refDoi"> DOI: 10.1093/infdis/jix354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Finfdis%2Fjix354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29112745" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=2017&pages=S644-S653&author=B.+Mathemaauthor=J.+R.+Andrewsauthor=T.+Cohenauthor=M.+W.+Borgdorffauthor=M.+Behrauthor=J.+R.+Glynnauthor=R.+Rustomjeeauthor=B.+J.+Silkauthor=R.+Wood&title=Drivers+of+tuberculosis+transmission&doi=10.1093%2Finfdis%2Fjix354"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjix354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjix354%26sid%3Dliteratum%253Aachs%26aulast%3DMathema%26aufirst%3DB.%26aulast%3DAndrews%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DT.%26aulast%3DBorgdorff%26aufirst%3DM.%2BW.%26aulast%3DBehr%26aufirst%3DM.%26aulast%3DGlynn%26aufirst%3DJ.%2BR.%26aulast%3DRustomjee%26aufirst%3DR.%26aulast%3DSilk%26aufirst%3DB.%2BJ.%26aulast%3DWood%26aufirst%3DR.%26atitle%3DDrivers%2520of%2520tuberculosis%2520transmission%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2017%26volume%3D216%26spage%3DS644%26epage%3DS653%26doi%3D10.1093%2Finfdis%2Fjix354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Gonzalez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soberanis-Ramos, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Gamboa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez-Mazari, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios-Herrera, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Rojas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz-Hervert, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Garcia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Aguirre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponce de Leon-Garduño, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sifuentes-Osornio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobadilla-Del-Valle, M.</span></span> <span> </span><span class="NLM_article-title">Prevalence of latent and active tuberculosis among dairy farm workers exposed to cattle infected by Mycobacterium bovis</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e2177</span>, <span class="refDoi"> DOI: 10.1371/journal.pntd.0002177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pntd.0002177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23638198" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=e2177&author=P.+Torres-Gonzalezauthor=O.+Soberanis-Ramosauthor=A.+Martinez-Gamboaauthor=B.+Chavez-Mazariauthor=M.+T.+Barrios-Herreraauthor=M.+Torres-Rojasauthor=L.+P.+Cruz-Hervertauthor=L.+Garcia-Garciaauthor=M.+Singhauthor=A.+Gonzalez-Aguirreauthor=A.+Ponce+de+Leon-Gardu%C3%B1oauthor=J.+Sifuentes-Osornioauthor=M.+Bobadilla-Del-Valle&title=Prevalence+of+latent+and+active+tuberculosis+among+dairy+farm+workers+exposed+to+cattle+infected+by+Mycobacterium+bovis&doi=10.1371%2Fjournal.pntd.0002177"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0002177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0002177%26sid%3Dliteratum%253Aachs%26aulast%3DTorres-Gonzalez%26aufirst%3DP.%26aulast%3DSoberanis-Ramos%26aufirst%3DO.%26aulast%3DMartinez-Gamboa%26aufirst%3DA.%26aulast%3DChavez-Mazari%26aufirst%3DB.%26aulast%3DBarrios-Herrera%26aufirst%3DM.%2BT.%26aulast%3DTorres-Rojas%26aufirst%3DM.%26aulast%3DCruz-Hervert%26aufirst%3DL.%2BP.%26aulast%3DGarcia-Garcia%26aufirst%3DL.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DGonzalez-Aguirre%26aufirst%3DA.%26aulast%3DPonce%2Bde%2BLeon-Gardu%25C3%25B1o%26aufirst%3DA.%26aulast%3DSifuentes-Osornio%26aufirst%3DJ.%26aulast%3DBobadilla-Del-Valle%26aufirst%3DM.%26atitle%3DPrevalence%2520of%2520latent%2520and%2520active%2520tuberculosis%2520among%2520dairy%2520farm%2520workers%2520exposed%2520to%2520cattle%2520infected%2520by%2520Mycobacterium%2520bovis%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2013%26volume%3D7%26spage%3De2177%26doi%3D10.1371%2Fjournal.pntd.0002177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simons, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Soolingen, D.</span></span> <span> </span><span class="NLM_article-title">Drug susceptibility testing for optimizing tuberculosis treatment</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2863</span>– <span class="NLM_lpage">2874</span>, <span class="refDoi"> DOI: 10.2174/138161211797470255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.2174%2F138161211797470255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21834762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSis7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2863-2874&author=S.+O.+Simonsauthor=D.+van+Soolingen&title=Drug+susceptibility+testing+for+optimizing+tuberculosis+treatment&doi=10.2174%2F138161211797470255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Drug susceptibility testing for optimizing tuberculosis treatment</span></div><div class="casAuthors">Simons, Sami O.; van Soolingen, Dick</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">2863-2874</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The principles of our current drug susceptibility testing (DST) for tuberculosis (TB) have already been laid out in 1963.  Since then, DST has not gained much popularity owing to the long turn-around time and the introduction of potent antituberculosis drug regimens.  These and other barriers have led to a crit. gap in lab. capacity in DST of Mycobacterium tuberculosis.  However, owing to the emergence of multidrug resistant tuberculosis there is a pressing need for adequate and rapid DST.  In recent years, methods for fastening the diagnosis of drug resistant tuberculosis were developed.  Semi-automated (non)- radiometric liq. culture systems reduced the turn-around-time significantly.  With the introduction of mol. diagnostic methods, such as reverse line probes and the recently introduced semi-automated real-time PCR, the turn-around time of at least an indicative resistance testing has dropped from days to hours.  However, much more can be gained in the development of fast phenotypic and mol. DST methodologies.  Recently also pharmacodynamic studies have also added significantly to our understanding of resistance development in tuberculosis treatment.  This article provides an overview of the most important DST techniques now available, with their characteristics, biosafety aspects, reproducibility, and required quality control.  Also the findings in pharmacodynamic studies and required future research are discussed.  We will argue that drug susceptibility testing in TB treatment is an essential tool for adequate TB control and prevention of resistance and should be applied to all patients to guide TB treatment.  Perhaps in the near future even individualized treatment doses could be an important help to prevent further emergence or further development of resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL_XdGBt8ZBrVg90H21EOLACvtfcHk0lg8atAJUQN2MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSis7jE&md5=81546ef81057f80908efd58d294be474</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2174%2F138161211797470255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161211797470255%26sid%3Dliteratum%253Aachs%26aulast%3DSimons%26aufirst%3DS.%2BO.%26aulast%3Dvan%2BSoolingen%26aufirst%3DD.%26atitle%3DDrug%2520susceptibility%2520testing%2520for%2520optimizing%2520tuberculosis%2520treatment%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2011%26volume%3D17%26spage%3D2863%26epage%3D2874%26doi%3D10.2174%2F138161211797470255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Migliori, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Ambrosio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spanevello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borroni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotgiu, G.</span></span> <span> </span><span class="NLM_article-title">Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease?</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1379</span>– <span class="NLM_lpage">1380</span>, <span class="refDoi"> DOI: 10.1093/cid/cis128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fcid%2Fcis128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22492321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC38rjvFOhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2012&pages=1379-1380&author=G.+B.+Miglioriauthor=R.+Centisauthor=L.+D%E2%80%99Ambrosioauthor=A.+Spanevelloauthor=E.+Borroniauthor=D.+M.+Cirilloauthor=G.+Sotgiu&title=Totally+drug-resistant+and+extremely+drug-resistant+tuberculosis%3A+the+same+disease%3F&doi=10.1093%2Fcid%2Fcis128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease?</span></div><div class="casAuthors">Migliori G B; Centis R; D'Ambrosio L; Spanevello A; Borroni E; Cirillo D M; Sotgiu G</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1379-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSoLioDKQt2VkmhnSqMnvzDfW6udTcc2ebRr35MIk9sZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rjvFOhsA%253D%253D&md5=a8a0866120a71ef761e45c8c17d04583</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcis128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcis128%26sid%3Dliteratum%253Aachs%26aulast%3DMigliori%26aufirst%3DG.%2BB.%26aulast%3DCentis%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Ambrosio%26aufirst%3DL.%26aulast%3DSpanevello%26aufirst%3DA.%26aulast%3DBorroni%26aufirst%3DE.%26aulast%3DCirillo%26aufirst%3DD.%2BM.%26aulast%3DSotgiu%26aufirst%3DG.%26atitle%3DTotally%2520drug-resistant%2520and%2520extremely%2520drug-resistant%2520tuberculosis%253A%2520the%2520same%2520disease%253F%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2012%26volume%3D54%26spage%3D1379%26epage%3D1380%26doi%3D10.1093%2Fcid%2Fcis128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharjya, B.</span></span> <span> </span><span class="NLM_article-title">Mantoux test and its interpretation</span>. <i>Indian Dermatology Online Journal</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.4103/2229-5178.93479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4103%2F2229-5178.93479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23130251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3s7ht1KrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=2-6&author=S.+Nayakauthor=B.+Acharjya&title=Mantoux+test+and+its+interpretation&doi=10.4103%2F2229-5178.93479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Mantoux test and its interpretation</span></div><div class="casAuthors">Nayak Surajit; Acharjya Basanti</div><div class="citationInfo"><span class="NLM_cas:title">Indian dermatology online journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The tuberculin skin test is one of the few investigations dating from the 19(th) century that are still widely used as an important test for diagnosing tuberculosis.  Though very commonly used by physicians worldwide its interpretation always remains difficult and controversial.  Various factors like age, immunological status coexisting illness etc influence its outcome, so also its interpretation.  Utmost care is required while interpreting the result and giving an opinion.  This article has been written with the purpose of elucidating the performance and interpretation of the standard tuberculin test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8kcGdtk6yZlUIs6wFK5xJfW6udTcc2ebRr35MIk9sZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7ht1KrsA%253D%253D&md5=707982e5e889f6a5cf8345556c20c057</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.4103%2F2229-5178.93479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F2229-5178.93479%26sid%3Dliteratum%253Aachs%26aulast%3DNayak%26aufirst%3DS.%26aulast%3DAcharjya%26aufirst%3DB.%26atitle%3DMantoux%2520test%2520and%2520its%2520interpretation%26jtitle%3DIndian%2520Dermatology%2520Online%2520Journal%26date%3D2012%26volume%3D3%26spage%3D2%26epage%3D6%26doi%3D10.4103%2F2229-5178.93479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idrees, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afzal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, A.</span></span> <span> </span><span class="NLM_article-title">PCR could be a method of choice for identification of both pulmonary and extra-pulmonary tuberculosis</span>. <i>BMC Res. Notes</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">332</span>, <span class="refDoi"> DOI: 10.1186/1756-0500-4-332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1186%2F1756-0500-4-332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21899772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3MfltV2mtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=332&author=I.+Aminauthor=M.+Idreesauthor=Z.+Awanauthor=M.+Shahidauthor=S.+Afzalauthor=A.+Hussain&title=PCR+could+be+a+method+of+choice+for+identification+of+both+pulmonary+and+extra-pulmonary+tuberculosis&doi=10.1186%2F1756-0500-4-332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">PCR could be a method of choice for identification of both pulmonary and extra-pulmonary tuberculosis</span></div><div class="casAuthors">Amin Iram; Idrees Muhammad; Awan Zunaira; Shahid Muhammad; Afzal Samia; Hussain Abrar</div><div class="citationInfo"><span class="NLM_cas:title">BMC research notes</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">332</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Nucleic acid amplification assays including PCR have revolutionized the detection of Mycobacterium tuberculosis (MTB).  Tuberculosis spread to almost every organ of the body and is characterized on the basis of localization of infection.  Therefore, different types of body fluids and tissues can be used for the detection of MTB.From 2004 to 2010 total 766 different types of smear negative samples from patients, clinically suspected for tuberculosis were received and investigated at Division of Molecular Diagnostics, University of the Punjab Lahore for the diagnosis of tuberculosis.  Mycobacterial DNA was extracted followed by PCR amplification.  FINDINGS:  A total of 356 (46.5%) samples were found positive by PCR for MTB.  These included; serum (4.8%), blood (36.3%), urine (46.6%), cerebro spinal fluid (CSF) (42.1%), ascetic fluid (67.6%), pleural fluid (52%), pericardial fluid (30%), pus (38.6%), bone marrow (60%), sputum (38.8%) and bronchoalveolar lavage (BAL) (70%).  Over all there was no significant difference in males and females neither in different age groups for the identification of MTB.  CONCLUSION:  We conclude that PCR is a useful and sensitive tool for the early diagnosis of MTB in variety of clinical samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQH6R-VpJ9QV2LFM_lbR1VmfW6udTcc2eaJrovQR92MiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfltV2mtw%253D%253D&md5=63945e244379068bf7af38f73d6761ed</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1186%2F1756-0500-4-332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-0500-4-332%26sid%3Dliteratum%253Aachs%26aulast%3DAmin%26aufirst%3DI.%26aulast%3DIdrees%26aufirst%3DM.%26aulast%3DAwan%26aufirst%3DZ.%26aulast%3DShahid%26aufirst%3DM.%26aulast%3DAfzal%26aufirst%3DS.%26aulast%3DHussain%26aufirst%3DA.%26atitle%3DPCR%2520could%2520be%2520a%2520method%2520of%2520choice%2520for%2520identification%2520of%2520both%2520pulmonary%2520and%2520extra-pulmonary%2520tuberculosis%26jtitle%3DBMC%2520Res.%2520Notes%26date%3D2011%26volume%3D4%26spage%3D332%26doi%3D10.1186%2F1756-0500-4-332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe
Pinhata, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cergole-Novella, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira dos Santos Carmo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruivo Ferro e Silva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrazoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares Sacchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siqueira de Oliveira, R.</span></span> <span> </span><span class="NLM_article-title">Rapid detection of Mycobacterium tuberculosis complex by real-time PCR in sputum samples and its use in the routine diagnosis in a reference laboratory</span>. <i>J. Med. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1040</span>– <span class="NLM_lpage">1045</span>, <span class="refDoi"> DOI: 10.1099/jmm.0.000121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1099%2Fjmm.0.000121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26297002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC287lt1WisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=1040-1045&author=J.+M.+Watanabe%0APinhataauthor=M.+C.+Cergole-Novellaauthor=A.+Moreira+dos+Santos+Carmoauthor=R.+Ruivo+Ferro+e+Silvaauthor=L.+Ferrazoliauthor=C.+Tavares+Sacchiauthor=R.+Siqueira+de+Oliveira&title=Rapid+detection+of+Mycobacterium+tuberculosis+complex+by+real-time+PCR+in+sputum+samples+and+its+use+in+the+routine+diagnosis+in+a+reference+laboratory&doi=10.1099%2Fjmm.0.000121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid detection of Mycobacterium tuberculosis complex by real-time PCR in sputum samples and its use in the routine diagnosis in a reference laboratory</span></div><div class="casAuthors">Watanabe Pinhata Juliana Maira; Ferrazoli Lucilaine; Siqueira de Oliveira Rosangela; Cergole-Novella Maria Cecilia; Moreira Dos Santos Carmo Andreia; Ruivo Ferro E Silva Regina; Tavares Sacchi Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medical microbiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1040-1045</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis (TB) is an infectious disease of global distribution, constituting a serious public health problem in Brazil.  Sao Paulo State, located in the south-east of Brazil, notified 16,580 new TB cases in 2013.  The Instituto Adolfo Lutz is a public health reference laboratory for TB diagnosis for all the State.  Considering that rapid and accurate diagnosis is essential for TB control, the aim of this study was to evaluate the use of an in-house real-time (RT)-PCR assay targeting the mpt64 gene in the routine diagnosis of TB, and to compare this technique with smear microscopy and culture.  From August 2012 to October 2013, 715 sputum samples from 657 patients were included in the study.  Smear microscopy, culture, phenotypic and PRA-hsp65 identification of mycobacteria, and mpt64 RT-PCR were performed.  With respect to confirmed TB cases (n = 62/657; 9.4%), smear microscopy had a sensitivity of 82.3%.  Culture and RT-PCR showed the same sensitivity, i.e. 90.3%.  Specificity was 99.7, 99.4 and 98.6% for smear microscopy, culture and RT-PCR, respectively. mpt64 RT-PCR showed high sensitivity and specificity for the detection of Mycobacterium tuberculosis complex in sputum samples.  This technique can be deployed in laboratories that do not have a rapid test for TB available, enabling the performance of TB diagnosis in up to 5 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdsAqFyKtJQGx8TEN9K18QfW6udTcc2eaJrovQR92MiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287lt1WisA%253D%253D&md5=390ada9132debac5ac3d91cb1fdf2bbe</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1099%2Fjmm.0.000121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fjmm.0.000121%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%2BPinhata%26aufirst%3DJ.%2BM.%26aulast%3DCergole-Novella%26aufirst%3DM.%2BC.%26aulast%3DMoreira%2Bdos%2BSantos%2BCarmo%26aufirst%3DA.%26aulast%3DRuivo%2BFerro%2Be%2BSilva%26aufirst%3DR.%26aulast%3DFerrazoli%26aufirst%3DL.%26aulast%3DTavares%2BSacchi%26aufirst%3DC.%26aulast%3DSiqueira%2Bde%2BOliveira%26aufirst%3DR.%26atitle%3DRapid%2520detection%2520of%2520Mycobacterium%2520tuberculosis%2520complex%2520by%2520real-time%2520PCR%2520in%2520sputum%2520samples%2520and%2520its%2520use%2520in%2520the%2520routine%2520diagnosis%2520in%2520a%2520reference%2520laboratory%26jtitle%3DJ.%2520Med.%2520Microbiol.%26date%3D2015%26volume%3D64%26spage%3D1040%26epage%3D1045%26doi%3D10.1099%2Fjmm.0.000121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abeel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desjardins, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, J.</span></span>; <span class="NLM_contrib-group">TBResist Global Genome Consortium</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrielian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jodals, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joloba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jureen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malinga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordenberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noroc, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romancenco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ssengooba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velayati, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winglee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalutskaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Via, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassell, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farnia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galagan, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crudu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homorodean, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pym, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skrahina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Walt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishai, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birren, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earl, A. M.</span></span> <span> </span><span class="NLM_article-title">Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1038/ng.3767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fng.3767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28092681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCls7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=395-402&author=A.+L.+Mansonauthor=K.+A.+Cohenauthor=T.+Abeelauthor=C.+A.+Desjardinsauthor=D.+T.+Armstrongauthor=C.+E.+Barryauthor=J.+Brandauthor=TBResist+Global+Genome+Consortiumauthor=S.+B.+Chapmanauthor=S.+N.+Choauthor=A.+Gabrielianauthor=J.+Gomezauthor=A.+M.+Jodalsauthor=M.+Jolobaauthor=P.+Jureenauthor=J.+S.+Leeauthor=L.+Malingaauthor=M.+Maigaauthor=D.+Nordenbergauthor=E.+Norocauthor=E.+Romancencoauthor=A.+Salazarauthor=W.+Ssengoobaauthor=A.+A.+Velayatiauthor=K.+Wingleeauthor=A.+Zalutskayaauthor=L.+E.+Viaauthor=G.+H.+Cassellauthor=S.+E.+Dormanauthor=J.+Ellnerauthor=P.+Farniaauthor=J.+E.+Galaganauthor=A.+Rosenthalauthor=V.+Cruduauthor=D.+Homorodeanauthor=P.+R.+Hsuehauthor=S.+Narayananauthor=A.+S.+Pymauthor=A.+Skrahinaauthor=S.+Swaminathanauthor=M.+Van+der+Waltauthor=D.+Allandauthor=W.+R.+Bishaiauthor=T.+Cohenauthor=S.+Hoffnerauthor=B.+W.+Birrenauthor=A.+M.+Earl&title=Genomic+analysis+of+globally+diverse+Mycobacterium+tuberculosis+strains+provides+insights+into+the+emergence+and+spread+of+multidrug+resistance&doi=10.1038%2Fng.3767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance</span></div><div class="casAuthors">Manson, Abigail L.; Cohen, Keira A.; Abeel, Thomas; Desjardins, Christopher A.; Armstrong, Derek T.; Barry, Clifton E., III; Brand, Jeannette; Jureen, Pontus; Malinga, Lesibana; Nordenberg, Dale; Velayati, A. A.; Cassell, Gail H.; Farnia, Parissa; Homorodean, Daniela; Van der Walt, Martie; Hoffner, Sven; Chapman, Sinead B.; Cho, Sang-Nae; Gabrielian, Andrei; Gomez, James; Jodals, Andreea M.; Joloba, Moses; Lee, Jong Seok; Maiga, Mamoudou; Noroc, Ecaterina; Romancenco, Elena; Salazar, Alex; Ssengooba, Willy; Winglee, Kathryn; Zalutskaya, Aksana; Via, Laura E.; Dorman, Susan E.; Ellner, Jerrold; Galagan, James E.; Rosenthal, Alex; Crudu, Valeriu; Hsueh, Po-Ren; Narayanan, Sujatha; Pym, Alexander S.; Skrahina, Alena; Swaminathan, Soumya; Alland, David; Bishai, William R.; Cohen, Ted; Birren, Bruce W.; Earl, Ashlee M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">395-402</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Multidrug-resistant tuberculosis (MDR-TB), caused by drug-resistant strains of Mycobacterium tuberculosis, is an increasingly serious problem worldwide.  We examd. a data set of whole-genome sequences from 5310 M. tuberculosis isolates from 5 continents.  Despite the great diversity of these isolates with respect to geog. point of isolation, genetic background, and drug resistance, the patterns for the emergence of drug resistance were conserved globally.  We have identified harbinger mutations that often precede multidrug resistance.  In particular, the katG mutation encoding p.Ser315Thr, which confers resistance to isoniazid, overwhelmingly arose before mutations that conferred rifampicin resistance across all of the lineages, geog. regions, and time periods.  Therefore, mol. diagnostics that include markers for rifampicin resistance alone will be insufficient to identify pre-MDR strains.  Incorporating knowledge of polymorphisms that occur before the emergence of multidrug resistance, particularly katG p.Ser315Thr, into mol. diagnostics should enable targeted treatment of patients with pre-MDR-TB to prevent further development of MDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY1jG-Jbg1MLVg90H21EOLACvtfcHk0lgT0ESeBmkYng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCls7k%253D&md5=9f7153c7db5c35d6a31164f82af54109</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fng.3767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.3767%26sid%3Dliteratum%253Aachs%26aulast%3DManson%26aufirst%3DA.%2BL.%26aulast%3DCohen%26aufirst%3DK.%2BA.%26aulast%3DAbeel%26aufirst%3DT.%26aulast%3DDesjardins%26aufirst%3DC.%2BA.%26aulast%3DArmstrong%26aufirst%3DD.%2BT.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBrand%26aufirst%3DJ.%26aulast%3D%26aulast%3DChapman%26aufirst%3DS.%2BB.%26aulast%3DCho%26aufirst%3DS.%2BN.%26aulast%3DGabrielian%26aufirst%3DA.%26aulast%3DGomez%26aufirst%3DJ.%26aulast%3DJodals%26aufirst%3DA.%2BM.%26aulast%3DJoloba%26aufirst%3DM.%26aulast%3DJureen%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DMalinga%26aufirst%3DL.%26aulast%3DMaiga%26aufirst%3DM.%26aulast%3DNordenberg%26aufirst%3DD.%26aulast%3DNoroc%26aufirst%3DE.%26aulast%3DRomancenco%26aufirst%3DE.%26aulast%3DSalazar%26aufirst%3DA.%26aulast%3DSsengooba%26aufirst%3DW.%26aulast%3DVelayati%26aufirst%3DA.%2BA.%26aulast%3DWinglee%26aufirst%3DK.%26aulast%3DZalutskaya%26aufirst%3DA.%26aulast%3DVia%26aufirst%3DL.%2BE.%26aulast%3DCassell%26aufirst%3DG.%2BH.%26aulast%3DDorman%26aufirst%3DS.%2BE.%26aulast%3DEllner%26aufirst%3DJ.%26aulast%3DFarnia%26aufirst%3DP.%26aulast%3DGalagan%26aufirst%3DJ.%2BE.%26aulast%3DRosenthal%26aufirst%3DA.%26aulast%3DCrudu%26aufirst%3DV.%26aulast%3DHomorodean%26aufirst%3DD.%26aulast%3DHsueh%26aufirst%3DP.%2BR.%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DPym%26aufirst%3DA.%2BS.%26aulast%3DSkrahina%26aufirst%3DA.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DVan%2Bder%2BWalt%26aufirst%3DM.%26aulast%3DAlland%26aufirst%3DD.%26aulast%3DBishai%26aufirst%3DW.%2BR.%26aulast%3DCohen%26aufirst%3DT.%26aulast%3DHoffner%26aufirst%3DS.%26aulast%3DBirren%26aufirst%3DB.%2BW.%26aulast%3DEarl%26aufirst%3DA.%2BM.%26atitle%3DGenomic%2520analysis%2520of%2520globally%2520diverse%2520Mycobacterium%2520tuberculosis%2520strains%2520provides%2520insights%2520into%2520the%2520emergence%2520and%2520spread%2520of%2520multidrug%2520resistance%26jtitle%3DNat.%2520Genet.%26date%3D2017%26volume%3D49%26spage%3D395%26epage%3D402%26doi%3D10.1038%2Fng.3767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riaz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhtar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslam, M.</span></span> <span> </span><span class="NLM_article-title">GeneXpert technology. A breakthrough for the diagnosis of tuberculous pericarditis and pleuritis in less than 2 h</span>. <i>Saudi Medical Journal</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.15537/smj.2017.7.17694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.15537%2Fsmj.2017.7.17694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28674714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1cjkt1OksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=699-705&author=M.+Saeedauthor=M.+Ahmadauthor=S.+Iramauthor=S.+Riazauthor=M.+Akhtarauthor=M.+Aslam&title=GeneXpert+technology.+A+breakthrough+for+the+diagnosis+of+tuberculous+pericarditis+and+pleuritis+in+less+than+2+h&doi=10.15537%2Fsmj.2017.7.17694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">GeneXpert technology. A breakthrough for the diagnosis of tuberculous pericarditis and pleuritis in less than 2 hours</span></div><div class="casAuthors">Saeed Muhammad; Ahmad Mobeen; Iram Shagufta; Riaz Saba; Akhtar Mehwish; Aslam Maleeha</div><div class="citationInfo"><span class="NLM_cas:title">Saudi medical journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">699-705</span>
        ISSN:<span class="NLM_cas:issn">0379-5284</span>.
    </div><div class="casAbstract">OBJECTIVES:  To evaluate the diagnostic validity of GeneXpert for the detection of Mycobacterium tuberculosis (MTB) in pericardial and pleural effusions samples.  METHODS:  A cross sectional study was conducted at the Mycobacteriology Laboratory, Allama Iqbal Medical College, Lahore, Pakistan.  A total of 286 (158 pleural and 128 pericardial fluids) samples were received from tuberculosis (TB) suspects between January 2014 and August 2016.  Every sample was processed for Ziehl-Neelsen (Zn) smear, Lowenstein Jensen (LJ) culture, GeneXpert MTB/RIF assay according to standard protocols.  Validity of GeneXpert assay for the detection of MTB was evaluated using LJ culture as gold standard.  RESULTS:  Out of 286 effusions samples, MTB was isolated by LJ culture in 51 (17.8%) samples followed by GeneXpert in 43 (15%), and acid- fast bacilli (AFB)  was detected by Zn smear microscopy in 11 (3.8%) samples.  GeneXpert showed high sensitivity (84.3%), specificity (100%), with positive predictive value (100%), and  negative predictive value (96.7%), while Zn smear showed sensitivity 18.3%, specificity 99.1%, positive predictive value 81.8%, and negative predictive value  85.4%.  A strikingly high sensitivity of 72.2% was observed for pericardial fluid by GeneXpert.  CONCLUSION:  GeneXpert assay is an innovative tool, for prompt detection of MTB and drug resistance.  It is definitely an attractive point of care test, with high sensitivity and specificity along with turn around time of 2 hours, which facilitates timely diagnosis and appropriate management of TB pleuritis and pericarditis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmFP6kSY9-NB0LsK7uFuY7fW6udTcc2ea6Cc7-XqcUebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjkt1OksQ%253D%253D&md5=9ab5d770106566578a6e5dcdb0c49f15</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.15537%2Fsmj.2017.7.17694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15537%252Fsmj.2017.7.17694%26sid%3Dliteratum%253Aachs%26aulast%3DSaeed%26aufirst%3DM.%26aulast%3DAhmad%26aufirst%3DM.%26aulast%3DIram%26aufirst%3DS.%26aulast%3DRiaz%26aufirst%3DS.%26aulast%3DAkhtar%26aufirst%3DM.%26aulast%3DAslam%26aufirst%3DM.%26atitle%3DGeneXpert%2520technology.%2520A%2520breakthrough%2520for%2520the%2520diagnosis%2520of%2520tuberculous%2520pericarditis%2520and%2520pleuritis%2520in%2520less%2520than%25202%2520h%26jtitle%3DSaudi%2520Medical%2520Journal%26date%3D2017%26volume%3D38%26spage%3D699%26epage%3D705%26doi%3D10.15537%2Fsmj.2017.7.17694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmail, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span> <span> </span><span class="NLM_article-title">Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?</span>. <i>Respirology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1111/resp.13143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1111%2Fresp.13143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28850767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1cbis1WhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=36-45&author=K.+Dhedaauthor=H.+Coxauthor=A.+Esmailauthor=S.+Wassermanauthor=K.+C.+Changauthor=C.+Lange&title=Recent+controversies+about+MDR+and+XDR-TB%3A+Global+implementation+of+the+WHO+shorter+MDR-TB+regimen+and+bedaquiline+for+all+with+MDR-TB%3F&doi=10.1111%2Fresp.13143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?</span></div><div class="casAuthors">Dheda Keertan; Esmail Aliasgar; Cox Helen; Wasserman Sean; Chang Kwok Chiu; Lange Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Respirology (Carlton, Vic.)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis (TB) is now the biggest infectious disease killer worldwide.  Although the estimated incidence of TB has marginally declined over several years, it is out of control in some regions including in Africa.  The advent of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) threatens to further destabilize control in several regions of the world.  Drug-resistant TB constitutes a significant threat because it underpins almost 25% of global TB mortality, is associated with high morbidity, is a threat to healthcare workers and is unsustainably costly to treat.  The advent of highly resistant TB with emerging bacillary resistance to newer drugs has raised further concern.  Encouragingly, in addition to preventative strategies, several interventions have recently been introduced to curb the drug-resistant TB epidemic, including newer molecular diagnostic tools, new (bedaquiline and delamanid) and repurposed (linezolid and clofazimine) drugs and shorter and individualized treatment regimens.  However, there are several controversies that surround the use of new drugs and regimens, including whether, how and to what extent they should be used, and who specifically should be treated so that outcomes are optimally improved without amplifying the burden of drug resistance, and other potential drawbacks, thus sustaining effectiveness of the new drugs.  The equipoise surrounding these controversies is discussed and some recommendations are provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSsDHnyn1vExu_Q9URG6Dx8fW6udTcc2ea6Cc7-XqcUebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbis1WhtA%253D%253D&md5=f6bb79b14b19fcb6e7b09c6c790deba7</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1111%2Fresp.13143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fresp.13143%26sid%3Dliteratum%253Aachs%26aulast%3DDheda%26aufirst%3DK.%26aulast%3DCox%26aufirst%3DH.%26aulast%3DEsmail%26aufirst%3DA.%26aulast%3DWasserman%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DLange%26aufirst%3DC.%26atitle%3DRecent%2520controversies%2520about%2520MDR%2520and%2520XDR-TB%253A%2520Global%2520implementation%2520of%2520the%2520WHO%2520shorter%2520MDR-TB%2520regimen%2520and%2520bedaquiline%2520for%2520all%2520with%2520MDR-TB%253F%26jtitle%3DRespirology%26date%3D2018%26volume%3D23%26spage%3D36%26epage%3D45%26doi%3D10.1111%2Fresp.13143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papaventsis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casali, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontsevaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drobniewski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolayevskyy, V.</span></span> <span> </span><span class="NLM_article-title">Whole genome sequencing of Mycobacterium tuberculosis for detection of drug resistance: a systematic review</span>. <i>Clin. Microbiol. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/j.cmi.2016.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.cmi.2016.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27665704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslCgu73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=61-68&author=D.+Papaventsisauthor=N.+Casaliauthor=I.+Kontsevayaauthor=F.+Drobniewskiauthor=D.+M.+Cirilloauthor=V.+Nikolayevskyy&title=Whole+genome+sequencing+of+Mycobacterium+tuberculosis+for+detection+of+drug+resistance%3A+a+systematic+review&doi=10.1016%2Fj.cmi.2016.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Whole genome sequencing of Mycobacterium tuberculosis for detection of drug resistance: a systematic review</span></div><div class="casAuthors">Papaventsis, D.; Casali, N.; Kontsevaya, I.; Drobniewski, F.; Cirillo, D. M.; Nikolayevskyy, V.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology and Infection</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">61-68</span>CODEN:
                <span class="NLM_cas:coden">CMINFM</span>;
        ISSN:<span class="NLM_cas:issn">1198-743X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We conducted a systematic review to det. the diagnostic accuracy of whole genome sequencing (WGS) of Mycobacterium tuberculosis for the detection of resistance to first- and second-line anti-tuberculosis (TB) drugs.  The study was conducted according to the criteria of the Preferred Reporting Items for Systematic Reviews group.  A total of 20 publications were included.  The sensitivity, specificity, pos.-predictive value and neg.-predictive value of WGS using phenotypic drug susceptibility testing methods as a ref. std. were detd.  Anti-TB agents tested included all first-line drugs, a variety of reserve drugs, as well as new drugs.  Polymorphisms in a total of 53 genes were tested for assocns. with drug resistance.  Pooled sensitivity and specificity values for detection of resistance to selected first-line drugs were 0.98 (95% CI 0.93-0.98) and 0.98 (95% CI 0.98-1.00) for rifampicin and 0.97 (95% CI 0.94-0.99) and 0.93 (95% CI 0.91-0.96) for isoniazid, resp.  Due to high heterogeneity in study designs, lack of data, knowledge of resistance mechanisms and clarity on exclusion of phylogenetic markers, there was a significant variation in anal. performance of WGS for the remaining first-line, reserved drugs and new drugs.  Whole genome sequencing could be considered a promising alternative to existing phenotypic and mol. drug susceptibility testing methods for rifampicin and isoniazid pending standardization of anal. pipelines.  To ensure clin. relevance of WGS for detection of M. tuberculosis complex drug resistance, future studies should include information on clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH5Hg9v0l3R7Vg90H21EOLACvtfcHk0lhbpwtM5tQDIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslCgu73K&md5=ae87ad885a1a547ceb84206b98a5dacb</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.cmi.2016.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmi.2016.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DPapaventsis%26aufirst%3DD.%26aulast%3DCasali%26aufirst%3DN.%26aulast%3DKontsevaya%26aufirst%3DI.%26aulast%3DDrobniewski%26aufirst%3DF.%26aulast%3DCirillo%26aufirst%3DD.%2BM.%26aulast%3DNikolayevskyy%26aufirst%3DV.%26atitle%3DWhole%2520genome%2520sequencing%2520of%2520Mycobacterium%2520tuberculosis%2520for%2520detection%2520of%2520drug%2520resistance%253A%2520a%2520systematic%2520review%26jtitle%3DClin.%2520Microbiol.%2520Infect.%26date%3D2017%26volume%3D23%26spage%3D61%26epage%3D68%26doi%3D10.1016%2Fj.cmi.2016.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phelan, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppong, Y. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Grady, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNerney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibberd, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viveiros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huggett, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T. G.</span></span> <span> </span><span class="NLM_article-title">Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs</span>. <i>Genome Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">41</span>, <span class="refDoi"> DOI: 10.1186/s13073-019-0650-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1186%2Fs13073-019-0650-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31234910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BB3MzgtlWjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=41&author=J.+E.+Phelanauthor=D.+M.+O%E2%80%99Sullivanauthor=D.+Machadoauthor=J.+Ramosauthor=Y.+E.+A.+Oppongauthor=S.+Campinoauthor=J.+O%E2%80%99Gradyauthor=R.+McNerneyauthor=M.+L.+Hibberdauthor=M.+Viveirosauthor=J.+F.+Huggettauthor=T.+G.+Clark&title=Integrating+informatics+tools+and+portable+sequencing+technology+for+rapid+detection+of+resistance+to+anti-tuberculous+drugs&doi=10.1186%2Fs13073-019-0650-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs</span></div><div class="casAuthors">Phelan Jody E; Oppong Yaa E A; Campino Susana; Hibberd Martin L; Clark Taane G; O'Sullivan Denise M; Huggett Jim F; Machado Diana; Ramos Jorge; Viveiros Miguel; Clark Taane G; O'Grady Justin; McNerney Ruth; Huggett Jim F; Clark Taane G</div><div class="citationInfo"><span class="NLM_cas:title">Genome medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Mycobacterium tuberculosis resistance to anti-tuberculosis drugs is a major threat to global public health.  Whole genome sequencing (WGS) is rapidly gaining traction as a diagnostic tool for clinical tuberculosis settings.  To support this informatically, previous work led to the development of the widely used TBProfiler webtool, which predicts resistance to 14 drugs from WGS data.  However, for accurate and rapid high throughput of samples in clinical or epidemiological settings, there is a need for a stand-alone tool and the ability to analyse data across multiple WGS platforms, including Oxford Nanopore MinION.  RESULTS:  We present a new command line version of the TBProfiler webserver, which includes hetero-resistance calling and will facilitate the batch processing of samples.  The TBProfiler database has been expanded to incorporate 178 new markers across 16 anti-tuberculosis drugs.  The predictive performance of the mutation library has been assessed using > 17,000 clinical isolates with WGS and laboratory-based drug susceptibility testing (DST) data.  An integrated MinION analysis pipeline was assessed by performing WGS on 34 replicates across 3 multi-drug resistant isolates with known resistance mutations.  TBProfiler accuracy varied by individual drug.  Assuming DST as the gold standard, sensitivities for detecting multi-drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) were 94% (95%CI 93-95%) and 83% (95%CI 79-87%) with specificities of 98% (95%CI 98-99%) and 96% (95%CI 95-97%) respectively.  Using MinION data, only one resistance mutation was missed by TBProfiler, involving an insertion in the tlyA gene coding for capreomycin resistance.  When compared to alternative platforms (e.g.  Mykrobe predictor TB, the CRyPTIC library), TBProfiler demonstrated superior predictive performance across first- and second-line drugs.  CONCLUSIONS:  The new version of TBProfiler can rapidly and accurately predict anti-TB drug resistance profiles across large numbers of samples with WGS data.  The computing architecture allows for the ability to modify the core bioinformatic pipelines and outputs, including the analysis of WGS data sourced from portable technologies.  TBProfiler has the potential to be integrated into the point of care and WGS diagnostic environments, including in resource-poor settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-KICSfmnhYeb6AVA-44PTfW6udTcc2eY772ccPTLgoLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzgtlWjug%253D%253D&md5=caf70ff8dc919c11d3af9e6649305279</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1186%2Fs13073-019-0650-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13073-019-0650-x%26sid%3Dliteratum%253Aachs%26aulast%3DPhelan%26aufirst%3DJ.%2BE.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DD.%2BM.%26aulast%3DMachado%26aufirst%3DD.%26aulast%3DRamos%26aufirst%3DJ.%26aulast%3DOppong%26aufirst%3DY.%2BE.%2BA.%26aulast%3DCampino%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Grady%26aufirst%3DJ.%26aulast%3DMcNerney%26aufirst%3DR.%26aulast%3DHibberd%26aufirst%3DM.%2BL.%26aulast%3DViveiros%26aufirst%3DM.%26aulast%3DHuggett%26aufirst%3DJ.%2BF.%26aulast%3DClark%26aufirst%3DT.%2BG.%26atitle%3DIntegrating%2520informatics%2520tools%2520and%2520portable%2520sequencing%2520technology%2520for%2520rapid%2520detection%2520of%2520resistance%2520to%2520anti-tuberculous%2520drugs%26jtitle%3DGenome%2520Med.%26date%3D2019%26volume%3D11%26spage%3D41%26doi%3D10.1186%2Fs13073-019-0650-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sada, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, T.</span></span> <span> </span><span class="NLM_article-title">Detection of lipoarabinomannan as a diagnostic test for tuberculosis</span>. <i>J. Clin. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2415</span>– <span class="NLM_lpage">2418</span>, <span class="refDoi"> DOI: 10.1128/JCM.30.9.2415-2418.1992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FJCM.30.9.2415-2418.1992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1401008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaK3s%252Fhs1Oruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1992&pages=2415-2418&author=E.+Sadaauthor=D.+Aguilarauthor=M.+Torresauthor=T.+Herrera&title=Detection+of+lipoarabinomannan+as+a+diagnostic+test+for+tuberculosis&doi=10.1128%2FJCM.30.9.2415-2418.1992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of lipoarabinomannan as a diagnostic test for tuberculosis</span></div><div class="casAuthors">Sada E; Aguilar D; Torres M; Herrera T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical microbiology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2415-8</span>
        ISSN:<span class="NLM_cas:issn">0095-1137</span>.
    </div><div class="casAbstract">A coagglutination technique was established for the detection of lipoarabinomannan of Mycobacterium tuberculosis in human serum samples and evaluated for its utility in the diagnosis of tuberculosis at the Instituto Nacional de Enfermedades Respiratorias in Mexico City.  The test had a sensitivity of 88% in patients with sputum-smear-positive active pulmonary tuberculosis.  The sensitivity in patients with active pulmonary tuberculosis negative for acid-fast bacilli in sputum was 67%.  Less favorable results were obtained for patients with AIDS and tuberculosis, with a sensitivity of 57%.  The specificity in control patients with lung diseases different from tuberculosis and in healthy subjects was 100%.  The positive predictive value was 100%, and the negative predictive value for patients with sputum-positive active pulmonary tuberculosis was 97%.  The results of this study suggest that the detection of lipoarabinomannan is an accurate test for the diagnosis of pulmonary tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgvgIvU2RrCENHe_gFldTbfW6udTcc2eY772ccPTLgoLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s%252Fhs1Oruw%253D%253D&md5=d65eaaa9e2bcf59b5205bd40a6ab6212</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1128%2FJCM.30.9.2415-2418.1992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJCM.30.9.2415-2418.1992%26sid%3Dliteratum%253Aachs%26aulast%3DSada%26aufirst%3DE.%26aulast%3DAguilar%26aufirst%3DD.%26aulast%3DTorres%26aufirst%3DM.%26aulast%3DHerrera%26aufirst%3DT.%26atitle%3DDetection%2520of%2520lipoarabinomannan%2520as%2520a%2520diagnostic%2520test%2520for%2520tuberculosis%26jtitle%3DJ.%2520Clin.%2520Microbiol.%26date%3D1992%26volume%3D30%26spage%3D2415%26epage%3D2418%26doi%3D10.1128%2FJCM.30.9.2415-2418.1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davids, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenders, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meldau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zyl Smit, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sechi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoelscher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitelaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zumla, A.</span></span> <span> </span><span class="NLM_article-title">clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e9848</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0009848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pone.0009848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=20352098" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=e9848&author=K.+Dhedaauthor=V.+Davidsauthor=L.+Lendersauthor=T.+Robertsauthor=R.+Meldauauthor=D.+Lingauthor=L.+Brunetauthor=R.+van+Zyl+Smitauthor=J.+Peterauthor=C.+Greenauthor=M.+Badriauthor=L.+Sechiauthor=S.+Sharmaauthor=M.+Hoelscherauthor=R.+Dawsonauthor=A.+Whitelawauthor=J.+Blackburnauthor=M.+Paiauthor=A.+Zumla&title=clinical+utility+of+a+commercial+LAM-ELISA+assay+for+TB+diagnosis+in+HIV-infected+patients+using+urine+and+sputum+samples&doi=10.1371%2Fjournal.pone.0009848"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0009848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0009848%26sid%3Dliteratum%253Aachs%26aulast%3DDheda%26aufirst%3DK.%26aulast%3DDavids%26aufirst%3DV.%26aulast%3DLenders%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DT.%26aulast%3DMeldau%26aufirst%3DR.%26aulast%3DLing%26aufirst%3DD.%26aulast%3DBrunet%26aufirst%3DL.%26aulast%3Dvan%2BZyl%2BSmit%26aufirst%3DR.%26aulast%3DPeter%26aufirst%3DJ.%26aulast%3DGreen%26aufirst%3DC.%26aulast%3DBadri%26aufirst%3DM.%26aulast%3DSechi%26aufirst%3DL.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DHoelscher%26aufirst%3DM.%26aulast%3DDawson%26aufirst%3DR.%26aulast%3DWhitelaw%26aufirst%3DA.%26aulast%3DBlackburn%26aufirst%3DJ.%26aulast%3DPai%26aufirst%3DM.%26aulast%3DZumla%26aufirst%3DA.%26atitle%3Dclinical%2520utility%2520of%2520a%2520commercial%2520LAM-ELISA%2520assay%2520for%2520TB%2520diagnosis%2520in%2520HIV-infected%2520patients%2520using%2520urine%2520and%2520sputum%2520samples%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26spage%3De9848%26doi%3D10.1371%2Fjournal.pone.0009848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrelles, J. B.</span></span> <span> </span><span class="NLM_article-title">Mannose-capped lipoarabinomannan in Mycobacterium tuberculosis pathogenesis</span>. <i>Pathog. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">fty026</span>, <span class="refDoi"> DOI: 10.1093/femspd/fty026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Ffemspd%2Ffty026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2018&pages=fty026&author=J.+Turnerauthor=J.+B.+Torrelles&title=Mannose-capped+lipoarabinomannan+in+Mycobacterium+tuberculosis+pathogenesis&doi=10.1093%2Ffemspd%2Ffty026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1093%2Ffemspd%2Ffty026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ffemspd%252Ffty026%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DJ.%26aulast%3DTorrelles%26aufirst%3DJ.%2BB.%26atitle%3DMannose-capped%2520lipoarabinomannan%2520in%2520Mycobacterium%2520tuberculosis%2520pathogenesis%26jtitle%3DPathog.%2520Dis.%26date%3D2018%26volume%3D76%26spage%3Dfty026%26doi%3D10.1093%2Ffemspd%2Ffty026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Götze, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seah, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeberger, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tukvadze, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenk, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacAry, P. A.</span></span> <span> </span><span class="NLM_article-title">The diagnostic targeting of a carbohydrate virulence factor from M.Tuberculosis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">10281</span>, <span class="refDoi"> DOI: 10.1038/srep10281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fsrep10281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25975873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFGnsrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=10281&author=C.+E.+Chanauthor=S.+G%C3%B6tzeauthor=G.+T.+Seahauthor=P.+H.+Seebergerauthor=N.+Tukvadzeauthor=M.+R.+Wenkauthor=B.+J.+Hansonauthor=P.+A.+MacAry&title=The+diagnostic+targeting+of+a+carbohydrate+virulence+factor+from+M.Tuberculosis&doi=10.1038%2Fsrep10281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The diagnostic targeting of a carbohydrate virulence factor from M. Tuberculosis</span></div><div class="casAuthors">Chan, Conrad E.; Gotze, Sebastian; Seah, Geok T.; Seeberger, Peter H.; Tukvadze, Nestan; Wenk, Markus R.; Hanson, Brendon J.; MacAry, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10281</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The current clin. management of TB is complicated by the lack of suitable diagnostic tests that can be employed in infrastructure and resource poor regions.  The mannose-capped form of lipoarabinomannan (ManLAM) is unique to the surface envelope of slow-growing, pathogenic mycobacteria such as M. tuberculosis (M.tb) and facilitates passive invasion of mononuclear phagocytes.  The detection of this virulence factor in urine, sputum and serum has engendered interest in its employment as a biomarker for M.tb infection.  The authors use a subtractive screening methodol. to engineer the first high affinity recombinant antibody (My2F12) with exquisite specificity for the α1-2 mannose linkages enriched in ManLAM from M.tb.  My2F12 binds to pathogenic mycobacterial species but not fast growing non-pathogenic species.  Testing on matched urine and serum samples from TB patients indicates that My2F12 works in patient cohorts missed by other diagnostic methodologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqaNfIbUZbd7Vg90H21EOLACvtfcHk0li4TfqbWetCFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFGnsrfM&md5=6d4a2c62bf3f693774cc87cac7df4ddc</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fsrep10281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep10281%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DC.%2BE.%26aulast%3DG%25C3%25B6tze%26aufirst%3DS.%26aulast%3DSeah%26aufirst%3DG.%2BT.%26aulast%3DSeeberger%26aufirst%3DP.%2BH.%26aulast%3DTukvadze%26aufirst%3DN.%26aulast%3DWenk%26aufirst%3DM.%2BR.%26aulast%3DHanson%26aufirst%3DB.%2BJ.%26aulast%3DMacAry%26aufirst%3DP.%2BA.%26atitle%3DThe%2520diagnostic%2520targeting%2520of%2520a%2520carbohydrate%2520virulence%2520factor%2520from%2520M.Tuberculosis%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D10281%26doi%3D10.1038%2Fsrep10281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathiasen, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiset, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wejse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillebaek, T.</span></span> <span> </span><span class="NLM_article-title">Epidemiology of tuberculous lymphadenitis in Denmark: A nationwide register-based study</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">e0221232</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0221232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pone.0221232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31415659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFamtbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=e0221232&author=V.+D.+Mathiasenauthor=A.+H.+Eisetauthor=P.+H.+Andersenauthor=C.+Wejseauthor=T.+Lillebaek&title=Epidemiology+of+tuberculous+lymphadenitis+in+Denmark%3A+A+nationwide+register-based+study&doi=10.1371%2Fjournal.pone.0221232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of tuberculous lymphadenitis in Denmark: A nationwide register-based study</span></div><div class="casAuthors">Mathiasen, Victor Dahl; Eiset, Andreas Halgreen; Andersen, Peter Henrik; Wejse, Christian; Lillebaek, Troels</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e0221232</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Tuberculous lymphadenitis (TBLA) is the most common extrapulmonary manifestation of tuberculosis (TB), often claimed to be reactivation.  We aimed to describe the epidemiol. of TBLA in Denmark, as it has not previously been investigated specifically although extrapulmonary TB has been assocd. with an increased long-term mortality and delays in the diagnosis.  Methods: Register-based study of all patients notified with TBLA in Denmark from 2007 through 2016 utilizing six different nationwide registers.  Patients were identified through the national TB surveillance register, and the diagnosis evaluated based on microbiol., pathol. and/or clin. assessment.  Results: In total, 13.5% (n = 489) of all TB patients in Denmark had TBLA with annual proportions from 9.4 to 15.7%.  Most patients were immigrants between 25-44 years.  Incidence rates ranged from as high as 1,014/100,000 for Nepalese citizens to as a low as 0.06/100,000 for Danes.  Danes had a significant higher median age and significant more risk factors and comorbidities, as well as an increased overall mortality, compared with immigrants (p<0.05).  A significant and much higher proportion of unique MIRU-VNTR genotypes were seen among TBLA patients compared to other TB manifestations.  Conclusion: In Denmark, TBLA is a common manifestation of TB, esp. in young immigrants from high-incidence countries.  In Danes, it is a rare disease manifestation and assocd. with higher morbidity and mortality.  To our knowledge, this is the first study suggesting that TBLA is predominantly assocd. with reactivation of latent TB infection based on genotyping although this remains to be clarified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_JOVDkxmOfLVg90H21EOLACvtfcHk0lhIGaak4igmzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFamtbzM&md5=efecdfe21325dcde2bbe8c518b61c1e6</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0221232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0221232%26sid%3Dliteratum%253Aachs%26aulast%3DMathiasen%26aufirst%3DV.%2BD.%26aulast%3DEiset%26aufirst%3DA.%2BH.%26aulast%3DAndersen%26aufirst%3DP.%2BH.%26aulast%3DWejse%26aufirst%3DC.%26aulast%3DLillebaek%26aufirst%3DT.%26atitle%3DEpidemiology%2520of%2520tuberculous%2520lymphadenitis%2520in%2520Denmark%253A%2520A%2520nationwide%2520register-based%2520study%26jtitle%3DPLoS%2520One%26date%3D2019%26volume%3D14%26spage%3De0221232%26doi%3D10.1371%2Fjournal.pone.0221232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span> <span> </span><span class="NLM_article-title">Diagnosis and treatment of extrapulmonary tuberculosis</span>. <i>Tuberc. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.4046/trd.2015.78.2.47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4046%2Ftrd.2015.78.2.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25861336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2MjjtVOgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2015&pages=47-55&author=J.+Y.+Lee&title=Diagnosis+and+treatment+of+extrapulmonary+tuberculosis&doi=10.4046%2Ftrd.2015.78.2.47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosis and treatment of extrapulmonary tuberculosis</span></div><div class="casAuthors">Lee Ji Yeon</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis and respiratory diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">47-55</span>
        ISSN:<span class="NLM_cas:issn">1738-3536</span>.
    </div><div class="casAbstract">Extrapulmonary tuberculosis (EPTB) constitutes about 20% of all cases of tuberculosis (TB) in Korea.  Diagnosing EPTB remains challenging because clinical samples obtained from relatively inaccessible sites may be paucibacillary, thus decreasing the sensitivity of diagnostic tests.  Whenever practical, every effort should be made to obtain appropriate specimens for both mycobacteriologic and histopathologic examinations.  The measurement of biochemical markers in TB-affected serosal fluids (adenosine deaminase or gamma interferon) and molecular biology techniques such as polymerase chain reaction may be useful adjuncts in the diagnosis of EPTB.  Although the disease usually responds to standard anti-TB drug therapy, the ideal regimen and duration of treatment have not yet been established.  A paradoxical response frequently occurs during anti-TB therapy.  It should be distinguished from other causes of clinical deterioration.  Surgery is required mainly to obtain valid diagnostic specimens and to manage complications.  Because smear microscopy or culture is not available to monitor patients with EPTB, clinical monitoring is the usual way to assess the response to treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJNcIz8EmHw8uCWE5mhx1RfW6udTcc2eZqREeK3IAiB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjjtVOgtw%253D%253D&md5=13a906ea6f703106d8e0891b9ebcdbae</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.4046%2Ftrd.2015.78.2.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4046%252Ftrd.2015.78.2.47%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BY.%26atitle%3DDiagnosis%2520and%2520treatment%2520of%2520extrapulmonary%2520tuberculosis%26jtitle%3DTuberc.%2520Respir.%2520Dis.%26date%3D2015%26volume%3D78%26spage%3D47%26epage%3D55%26doi%3D10.4046%2Ftrd.2015.78.2.47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seong, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yim, J. J.</span></span> <span> </span><span class="NLM_article-title">Accuracy of the Xpert® MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.5588/ijtld.14.0500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.5588%2Fijtld.14.0500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25519795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2MvgvVaqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=81-86&author=Y.+W.+Kimauthor=N.+Kwakauthor=M.+W.+Seongauthor=E.+C.+Kimauthor=C.+G.+Yooauthor=Y.+W.+Kimauthor=S.+K.+Hanauthor=J.+J.+Yim&title=Accuracy+of+the+Xpert%C2%AE+MTB%2FRIF+assay+for+the+diagnosis+of+extra-pulmonary+tuberculosis+in+South+Korea&doi=10.5588%2Fijtld.14.0500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Accuracy of the Xpert® MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea</span></div><div class="casAuthors">Kim Y W; Kwak N; Yoo C-G; Kim Y W; Han S K; Yim J-J; Seong M-W; Kim E-C</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">SETTING:  The Xpert(®) MTB/RIF assay has been endorsed by the World Health Organization for the detection of pulmonary and extra-pulmonary tuberculosis (EPTB).  OBJECTIVE:  To determine the accuracy of the Xpert assay in diagnosing EPTB in South Korea, a country with an intermediate TB burden.  DESIGN:  We retrospectively reviewed the medical records of 1429 patients in whom the Xpert assay using EPTB specimens was requested between 1 January 2011 and 31 October 2013 in a tertiary referral hospital in South Korea.  The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for the diagnosis of EPTB and detection of rifampicin (RMP) resistance were calculated.  RESULTS:  Using culture as gold standard, the sensitivity, specificity, PPV and NPV of the assay were respectively 67.7%, 98.1%, 60% and 98.6%.  Using a composite reference standard, the sensitivity, specificity, PPV and NPV were respectively 49.3%, 100%, 100% and 95.1%.  The sensitivity, specificity, PPV and NPV for the detection of RMP resistance among specimens with positive results for Mycobacterium tuberculosis were respectively 80%, 100%, 100% and 97.7%.  CONCLUSION:  The Xpert assay showed acceptable sensitivity in certain groups and excellent specificity in diagnosing EPTB and detecting RMP resistance in an intermediate TB burden country.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRipRigWBu30IUSrryheKE6fW6udTcc2eZqREeK3IAiB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvgvVaqtg%253D%253D&md5=dcc33c7f0f10541d23bcc85da7cdf8b4</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.5588%2Fijtld.14.0500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5588%252Fijtld.14.0500%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2BW.%26aulast%3DKwak%26aufirst%3DN.%26aulast%3DSeong%26aufirst%3DM.%2BW.%26aulast%3DKim%26aufirst%3DE.%2BC.%26aulast%3DYoo%26aufirst%3DC.%2BG.%26aulast%3DKim%26aufirst%3DY.%2BW.%26aulast%3DHan%26aufirst%3DS.%2BK.%26aulast%3DYim%26aufirst%3DJ.%2BJ.%26atitle%3DAccuracy%2520of%2520the%2520Xpert%25C2%25AE%2520MTB%252FRIF%2520assay%2520for%2520the%2520diagnosis%2520of%2520extra-pulmonary%2520tuberculosis%2520in%2520South%2520Korea%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D2015%26volume%3D19%26spage%3D81%26epage%3D86%26doi%3D10.5588%2Fijtld.14.0500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trunz, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, C.</span></span> <span> </span><span class="NLM_article-title">Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">1173</span>– <span class="NLM_lpage">1180</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(06)68507-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS0140-6736%2806%2968507-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=16616560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD283htVyjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2006&pages=1173-1180&author=B.+B.+Trunzauthor=P.+Fineauthor=C.+Dye&title=Effect+of+BCG+vaccination+on+childhood+tuberculous+meningitis+and+miliary+tuberculosis+worldwide%3A+a+meta-analysis+and+assessment+of+cost-effectiveness&doi=10.1016%2FS0140-6736%2806%2968507-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness</span></div><div class="casAuthors">Trunz B Bourdin; Fine Pem; Dye C</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">9517</span>),
    <span class="NLM_cas:pages">1173-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  BCG vaccine has shown consistently high efficacy against childhood tuberculous meningitis and miliary tuberculosis, but variable efficacy against adult pulmonary tuberculosis and other mycobacterial diseases.  We assess and compare the costs and effects of BCG as an intervention against severe childhood tuberculosis in different regions of the world.  METHODS:  We calculated the number of tuberculous meningitis and miliary tuberculosis cases that have been and will be prevented in all children born in 2002, by combining estimates of the annual risk of tuberculosis infection, the proportion of infections that lead to either of these diseases in unvaccinated children, the number of children vaccinated, and BCG efficacy.  FINDINGS:  We estimated that the 100.5 million BCG vaccinations given to infants in 2002 will have prevented 29,729 cases of tuberculous meningitis (5th-95th centiles, 24,063-36,192) in children during their first 5 years of life, or one case for every 3435 vaccinations (2771-4177), and 11,486 cases of miliary tuberculosis (7304-16,280), or one case for every 9314 vaccinations (6172-13,729).  The numbers of cases prevented would be highest in South East Asia (46%), sub-Saharan Africa (27%), the western Pacific region (15%), and where the risk of tuberculosis infection and vaccine coverage are also highest.  At US2-3 dollars per dose, BCG vaccination costs US206 dollars (150-272) per year of healthy life gained.  INTERPRETATION:  BCG vaccination is a highly cost-effective intervention against severe childhood tuberculosis; it should be retained in high-incidence countries as a strategy to supplement the chemotherapy of active tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtNETSIEn2IMyail4HZd-ifW6udTcc2eaEIPW0w8Ib2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283htVyjsQ%253D%253D&md5=64733a82626cbbb4a1ea0c2a061f4784</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2806%2968507-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252806%252968507-3%26sid%3Dliteratum%253Aachs%26aulast%3DTrunz%26aufirst%3DB.%2BB.%26aulast%3DFine%26aufirst%3DP.%26aulast%3DDye%26aufirst%3DC.%26atitle%3DEffect%2520of%2520BCG%2520vaccination%2520on%2520childhood%2520tuberculous%2520meningitis%2520and%2520miliary%2520tuberculosis%2520worldwide%253A%2520a%2520meta-analysis%2520and%2520assessment%2520of%2520cost-effectiveness%26jtitle%3DLancet%26date%3D2006%26volume%3D367%26spage%3D1173%26epage%3D1180%26doi%3D10.1016%2FS0140-6736%2806%2968507-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dockrell, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. G.</span></span> <span> </span><span class="NLM_article-title">What have we learnt about BCG vaccination in the last 20 Years?</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1134</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2017.01134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3389%2Ffimmu.2017.01134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28955344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFegtLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1134&author=H.+M.+Dockrellauthor=S.+G.+Smith&title=What+have+we+learnt+about+BCG+vaccination+in+the+last+20+Years%3F&doi=10.3389%2Ffimmu.2017.01134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">What have we learnt about BCG vaccination in the last 20 years?</span></div><div class="casAuthors">Dockrell, Hazel M.; Smith, Steven G.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1134/1-1134/10</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A no. of new tuberculosis (TB) vaccines have been or are entering clin. trials, which include genetically modified mycobacteria, mycobacterial antigens delivered by viral vectors, or mycobacterial antigens in adjuvant.  Some of these vaccines aim to replace the existing BCG vaccine but others will be given as a boosting vaccine following BCG vaccination given soon after birth.  It is clear that the existing BCG vaccines provide incomplete and variable protection against pulmonary TB.  This review will discuss what we have learnt over the last 20 years about how the BCG vaccine induces specific and non-specific immunity, what factors influence the immune responses induced by BCG, and progress toward identifying correlates of immunity against TB from BCG vaccination studies.  There is still a lot to learn about the BCG vaccine and the insights gained can help the development of more protective vaccines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojvkmhz2SuirVg90H21EOLACvtfcHk0ljKoSgGqxAapg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFegtLvF&md5=ae5cf1570ffbf63b95ac1c8ff671f6d3</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2017.01134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2017.01134%26sid%3Dliteratum%253Aachs%26aulast%3DDockrell%26aufirst%3DH.%2BM.%26aulast%3DSmith%26aufirst%3DS.%2BG.%26atitle%3DWhat%2520have%2520we%2520learnt%2520about%2520BCG%2520vaccination%2520in%2520the%2520last%252020%2520Years%253F%26jtitle%3DFront.%2520Immunol.%26date%3D2017%26volume%3D8%26spage%3D1134%26doi%3D10.3389%2Ffimmu.2017.01134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, J. L.</span></span> <span> </span><span class="NLM_article-title">Understanding latent tuberculosis: a moving target</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0903856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4049%2Fjimmunol.0903856" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=20562268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3cXns1Crurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2010&pages=15-22&author=P.+L.+Linauthor=J.+L.+Flynn&title=Understanding+latent+tuberculosis%3A+a+moving+target&doi=10.4049%2Fjimmunol.0903856"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding Latent Tuberculosis: A Moving Target</span></div><div class="casAuthors">Lin, Philana Ling; Flynn, JoAnne L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-22</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB) remains a threat to the health of people worldwide.  Infection with Mycobacterium tuberculosis can result in active TB or, more commonly, latent infection.  Latently infected persons, of which there are estd. to be approx. 2 billion in the world, represent an enormous reservoir of potential reactivation TB, which can spread to other people.  The immunol. of TB is complex and multifaceted.  Identifying the immune mechanisms that lead to control of initial infection and prevent reactivation of latent infection is crucial to combating this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb9omQoDRyy7Vg90H21EOLACvtfcHk0ljenHp07bfsdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXns1Crurc%253D&md5=baed5915d0f4433f74956fa5a3db4900</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0903856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0903856%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DP.%2BL.%26aulast%3DFlynn%26aufirst%3DJ.%2BL.%26atitle%3DUnderstanding%2520latent%2520tuberculosis%253A%2520a%2520moving%2520target%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D185%26spage%3D15%26epage%3D22%26doi%3D10.4049%2Fjimmunol.0903856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, D.</span></span> <span> </span><span class="NLM_article-title">How long are TB patients infectious?</span>. <i>CMAJ</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">158</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10934973" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2000&pages=157-158&author=K.+Schwartzmanauthor=D.+Menzies&title=How+long+are+TB+patients+infectious%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartzman%26aufirst%3DK.%26aulast%3DMenzies%26aufirst%3DD.%26atitle%3DHow%2520long%2520are%2520TB%2520patients%2520infectious%253F%26jtitle%3DCMAJ%26date%3D2000%26volume%3D163%26spage%3D157%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, R.</span></span> <span> </span><span class="NLM_article-title">Contact screening in tuberculosis: can we identify those with higher risk?</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">758</span>– <span class="NLM_lpage">760</span>, <span class="refDoi"> DOI: 10.1183/09031936.00164612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1183%2F09031936.00164612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23456937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3svivFyqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=758-760&author=M.+A.+Mendesauthor=R.+Gaioauthor=R.+Reisauthor=R.+Duarte&title=Contact+screening+in+tuberculosis%3A+can+we+identify+those+with+higher+risk%3F&doi=10.1183%2F09031936.00164612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Contact screening in tuberculosis: can we identify those with higher risk?</span></div><div class="casAuthors">Mendes Maria Aurora; Gaio Rita; Reis Ricardo; Duarte Raquel</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">758-60</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrjw-iFBX_0LP3FVUi_gf8fW6udTcc2eZDcCp50WTUQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svivFyqtA%253D%253D&md5=2a769e0604bfc07b064610c01047f5c7</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1183%2F09031936.00164612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00164612%26sid%3Dliteratum%253Aachs%26aulast%3DMendes%26aufirst%3DM.%2BA.%26aulast%3DGaio%26aufirst%3DR.%26aulast%3DReis%26aufirst%3DR.%26aulast%3DDuarte%26aufirst%3DR.%26atitle%3DContact%2520screening%2520in%2520tuberculosis%253A%2520can%2520we%2520identify%2520those%2520with%2520higher%2520risk%253F%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D41%26spage%3D758%26epage%3D760%26doi%3D10.1183%2F09031936.00164612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekaran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saravanan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethunaickan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, S.</span></span> <span> </span><span class="NLM_article-title">Malnutrition: modulator of immune responses in tuberculosis</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1316</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2017.01316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3389%2Ffimmu.2017.01316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29093710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFens7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1316&author=P.+Chandrasekaranauthor=N.+Saravananauthor=R.+Bethunaickanauthor=S.+Tripathy&title=Malnutrition%3A+modulator+of+immune+responses+in+tuberculosis&doi=10.3389%2Ffimmu.2017.01316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Malnutrition: modulator of immune responses in tuberculosis</span></div><div class="casAuthors">Chandrasekaran, Padmapriyadarsini; Saravanan, Natarajan; Bethunaickan, Ramalingam; Tripathy, Srikanth</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1316/1-1316/8</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Nutrition plays a major role in the management of both acute and chronic diseases, in terms of body's response to the pathogenic organism.  An array of nutrients like macroand micro-nutrients, vitamins, etc., are assocd. with boosting the host's immune responses against intracellular pathogens including mycobacterium tuberculosis (M.tb).  These nutrients have an immunomodulatory effects in controlling the infection and inflammation process and nutritional deficiency of any form, i.e., malnutrition may lead to nutritionally acquired immunodeficiency syndrome, which greatly increases an individual's susceptibility to progression of infection to disease.  This narrative review looks at the various mechanisms by which nutrition or its deficiency leads to impaired cell mediated and humoral immune responses, which in turn affects the ability of an individual to fight M.tb infection or disease.  There is very little evidence in the literature that any specific food on its own or a specific quantity can alter the course of TB disease or be effective in the treatment of malnutrition.  Further clin. trials or studies will be needed to recommend and to better understand the link between malnutrition, tuberculosis, and impaired immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFlNM_GZrFErVg90H21EOLACvtfcHk0ljenHp07bfsdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFens7vP&md5=09643fd7d3e40c9c7192d0c6d08e6b5c</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2017.01316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2017.01316%26sid%3Dliteratum%253Aachs%26aulast%3DChandrasekaran%26aufirst%3DP.%26aulast%3DSaravanan%26aufirst%3DN.%26aulast%3DBethunaickan%26aufirst%3DR.%26aulast%3DTripathy%26aufirst%3DS.%26atitle%3DMalnutrition%253A%2520modulator%2520of%2520immune%2520responses%2520in%2520tuberculosis%26jtitle%3DFront.%2520Immunol.%26date%3D2017%26volume%3D8%26spage%3D1316%26doi%3D10.3389%2Ffimmu.2017.01316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span> <i>The End TB Strategy</i>; <span class="NLM_publisher-name">World
Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2015</span>; <a href="https://www.who.int/tb/End_TB_brochure.pdf?ua=1" class="extLink">https://www.who.int/tb/End_TB_brochure.pdf?ua=1</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The+End+TB+Strategy%3B+World%0AHealth+Organization%3A+Geneva%2C+2015%3B+https%3A%2F%2Fwww.who.int%2Ftb%2FEnd_TB_brochure.pdf%3Fua%3D1+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DThe%2520End%2520TB%2520Strategy%26pub%3DWorld%250AHealth%2520Organization%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matteelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Abri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voniatis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, A. C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Ambrosio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spanevello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battista Migliori, G.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis elimination: where are we now?</span>. <i>Eur. Respir. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">180035</span>, <span class="refDoi"> DOI: 10.1183/16000617.0035-2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1183%2F16000617.0035-2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29898905" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=180035&author=A.+Matteelliauthor=A.+Rendonauthor=S.+Tiberiauthor=S.+Al-Abriauthor=C.+Voniatisauthor=A.+C.+C.+Carvalhoauthor=R.+Centisauthor=L.+D%E2%80%99Ambrosioauthor=D.+Viscaauthor=A.+Spanevelloauthor=G.+Battista+Migliori&title=Tuberculosis+elimination%3A+where+are+we+now%3F&doi=10.1183%2F16000617.0035-2018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1183%2F16000617.0035-2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F16000617.0035-2018%26sid%3Dliteratum%253Aachs%26aulast%3DMatteelli%26aufirst%3DA.%26aulast%3DRendon%26aufirst%3DA.%26aulast%3DTiberi%26aufirst%3DS.%26aulast%3DAl-Abri%26aufirst%3DS.%26aulast%3DVoniatis%26aufirst%3DC.%26aulast%3DCarvalho%26aufirst%3DA.%2BC.%2BC.%26aulast%3DCentis%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Ambrosio%26aufirst%3DL.%26aulast%3DVisca%26aufirst%3DD.%26aulast%3DSpanevello%26aufirst%3DA.%26aulast%3DBattista%2BMigliori%26aufirst%3DG.%26atitle%3DTuberculosis%2520elimination%253A%2520where%2520are%2520we%2520now%253F%26jtitle%3DEur.%2520Respir.%2520Rev.%26date%3D2018%26volume%3D27%26spage%3D180035%26doi%3D10.1183%2F16000617.0035-2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lönnroth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliori, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abubakar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Ambrosio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falzon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudreau, M.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goletti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González
Ochoa, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoBue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matteelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Story, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tayeb, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Werf, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zellweger, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel Aziz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Lawati, M. R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliberti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrazola
de Oñate, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreira, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchfeld, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemtob, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colorado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahle, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Paoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattorini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getahun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaziou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goguadze, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Granado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Järvinen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, G.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikiori, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace-Asciak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompa, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popescu, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robalo Cordeiro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rønning, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruhwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sculier, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simunović, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith-Palmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotgiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Duque, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umeki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uplekar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Weezenbeek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasankari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitillo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voniatis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raviglione, M. C.</span></span> <span> </span><span class="NLM_article-title">Towards tuberculosis elimination: an action framework for low-incidence countries</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">928</span>– <span class="NLM_lpage">952</span>, <span class="refDoi"> DOI: 10.1183/09031936.00214014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1183%2F09031936.00214014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25792630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2Mnmt1WjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=928-952&author=K.+L%C3%B6nnrothauthor=G.+B.+Miglioriauthor=I.+Abubakarauthor=L.+D%E2%80%99Ambrosioauthor=G.+de+Vriesauthor=R.+Dielauthor=P.+Douglasauthor=D.+Falzonauthor=M.-A.+Gaudreauauthor=D.+Golettiauthor=E.+R.+Gonz%C3%A1lez%0AOchoaauthor=P.+LoBueauthor=A.+Matteelliauthor=H.+Njooauthor=I.+Solovicauthor=A.+Storyauthor=T.+Tayebauthor=M.+J.+van+der+Werfauthor=D.+Weilauthor=J.-P.+Zellwegerauthor=M.+Abdel+Azizauthor=M.+R.+M.+Al+Lawatiauthor=S.+Alibertiauthor=W.+Arrazola%0Ade+O%C3%B1ateauthor=D.+Barreiraauthor=V.+Bhatiaauthor=F.+Blasiauthor=A.+Bloomauthor=J.+Bruchfeldauthor=F.+Castelliauthor=R.+Centisauthor=D.+Chemtobauthor=D.+M.+Cirilloauthor=A.+Coloradoauthor=A.+Daduauthor=U.+R.+Dahleauthor=L.+De+Paoliauthor=H.+M.+Diasauthor=R.+Duarteauthor=L.+Fattoriniauthor=M.+Gagaauthor=H.+Getahunauthor=P.+Glaziouauthor=L.+Goguadzeauthor=M.+Del+Granadoauthor=W.+Haasauthor=A.+J%C3%A4rvinenauthor=G.-Y.+Kwonauthor=D.+Moscaauthor=P.+Nahidauthor=N.+Nishikioriauthor=I.+Noguerauthor=J.+O%E2%80%99Donnellauthor=A.+Pace-Asciakauthor=M.+G.+Pompaauthor=G.+G.+Popescuauthor=C.+Robalo+Cordeiroauthor=K.+R%C3%B8nningauthor=M.+Ruhwaldauthor=J.-P.+Sculierauthor=A.+Simunovi%C4%87author=A.+Smith-Palmerauthor=G.+Sotgiuauthor=G.+Sulisauthor=C.+A.+Torres-Duqueauthor=K.+Umekiauthor=M.+Uplekarauthor=C.+van+Weezenbeekauthor=T.+Vasankariauthor=R.+J.+Vitilloauthor=C.+Voniatisauthor=M.+Wanlinauthor=M.+C.+Raviglione&title=Towards+tuberculosis+elimination%3A+an+action+framework+for+low-incidence+countries&doi=10.1183%2F09031936.00214014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Towards tuberculosis elimination: an action framework for low-incidence countries</span></div><div class="casAuthors">Lonnroth Knut; Migliori Giovanni Battista; Abubakar Ibrahim; D'Ambrosio Lia; Centis Rosella; de Vries Gerard; van Weezenbeek Catharina; Diel Roland; Douglas Paul; Falzon Dennis; Matteelli Alberto; Weil Diana; Bhatia Vineet; Dias Hannah M; Getahun Haileyesus; Glaziou Philippe; Sulis Giorgia; Uplekar Mukund; Raviglione Mario C; Gaudreau Marc-Andre; Njoo Howard; Goletti Delia; Gonzalez Ochoa Edilberto R; LoBue Philip; Solovic Ivan; Story Alistair; Tayeb Tamara; van der Werf Marieke J; Zellweger Jean-Pierre; Abdel Aziz Mohamed; Al Lawati Mohamed R M; Aliberti Stefano; Arrazola de Onate Wouter; Barreira Draurio; Blasi Francesco; Bloom Amy; Bruchfeld Judith; Castelli Francesco; Chemtob Daniel; Cirillo Daniela M; Colorado Alberto; Dadu Andrei; Dahle Ulf R; Ronning Karin; De Paoli Laura; Duarte Raquel; Fattorini Lanfranco; Gaga Mina; Goguadze Lasha; Del Granado Mirtha; Haas Walter; Jarvinen Asko; Kwon Geun-Yong; Mosca Davide; Nahid Payam; Nishikiori Nobuyuki; Noguer Isabel; O'Donnell Joan; Pace-Asciak Analita; Pompa Maria G; Popescu Gilda G; Robalo Cordeiro Carlos; Ruhwald Morten; Sculier Jean-Paul; Simunovic Aleksandar; Smith-Palmer Alison; Sotgiu Giovanni; Torres-Duque Carlos A; Umeki Kazunori; Vasankari Tuula; Vitillo Robert J; Voniatis Constantia; Wanlin Maryse</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">928-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This paper describes an action framework for countries with low tuberculosis (TB) incidence (<100 TB cases per million population) that are striving for TB elimination.  The framework sets out priority interventions required for these countries to progress first towards "pre-elimination" (<10 cases per million) and eventually the elimination of TB as a public health problem (less than one case per million).  TB epidemiology in most low-incidence countries is characterised by a low rate of transmission in the general population, occasional outbreaks, a majority of TB cases generated from progression of latent TB infection (LTBI) rather than local transmission, concentration to certain vulnerable and hard-to-reach risk groups, and challenges posed by cross-border migration.  Common health system challenges are that political commitment, funding, clinical expertise and general awareness of TB diminishes as TB incidence falls.  The framework presents a tailored response to these challenges, grouped into eight priority action areas: 1) ensure political commitment, funding and stewardship for planning and essential services; 2) address the most vulnerable and hard-to-reach groups; 3) address special needs of migrants and cross-border issues; 4) undertake screening for active TB and LTBI in TB contacts and selected high-risk groups, and provide appropriate treatment; 5) optimise the prevention and care of drug-resistant TB; 6) ensure continued surveillance, programme monitoring and evaluation and case-based data management; 7) invest in research and new tools; and 8) support global TB prevention, care and control.  The overall approach needs to be multisectorial, focusing on equitable access to high-quality diagnosis and care, and on addressing the social determinants of TB.  Because of increasing globalisation and population mobility, the response needs to have both national and global dimensions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT1sTHWz2o7TZPlX7E30qdzfW6udTcc2ebrepv6nTyjQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mnmt1WjsQ%253D%253D&md5=4ca972da5bf04df47c478930ad6776d2</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1183%2F09031936.00214014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00214014%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6nnroth%26aufirst%3DK.%26aulast%3DMigliori%26aufirst%3DG.%2BB.%26aulast%3DAbubakar%26aufirst%3DI.%26aulast%3DD%25E2%2580%2599Ambrosio%26aufirst%3DL.%26aulast%3Dde%2BVries%26aufirst%3DG.%26aulast%3DDiel%26aufirst%3DR.%26aulast%3DDouglas%26aufirst%3DP.%26aulast%3DFalzon%26aufirst%3DD.%26aulast%3DGaudreau%26aufirst%3DM.-A.%26aulast%3DGoletti%26aufirst%3DD.%26aulast%3DGonz%25C3%25A1lez%2BOchoa%26aufirst%3DE.%2BR.%26aulast%3DLoBue%26aufirst%3DP.%26aulast%3DMatteelli%26aufirst%3DA.%26aulast%3DNjoo%26aufirst%3DH.%26aulast%3DSolovic%26aufirst%3DI.%26aulast%3DStory%26aufirst%3DA.%26aulast%3DTayeb%26aufirst%3DT.%26aulast%3Dvan%2Bder%2BWerf%26aufirst%3DM.%2BJ.%26aulast%3DWeil%26aufirst%3DD.%26aulast%3DZellweger%26aufirst%3DJ.-P.%26aulast%3DAbdel%2BAziz%26aufirst%3DM.%26aulast%3DAl%2BLawati%26aufirst%3DM.%2BR.%2BM.%26aulast%3DAliberti%26aufirst%3DS.%26aulast%3DArrazola%2Bde%2BO%25C3%25B1ate%26aufirst%3DW.%26aulast%3DBarreira%26aufirst%3DD.%26aulast%3DBhatia%26aufirst%3DV.%26aulast%3DBlasi%26aufirst%3DF.%26aulast%3DBloom%26aufirst%3DA.%26aulast%3DBruchfeld%26aufirst%3DJ.%26aulast%3DCastelli%26aufirst%3DF.%26aulast%3DCentis%26aufirst%3DR.%26aulast%3DChemtob%26aufirst%3DD.%26aulast%3DCirillo%26aufirst%3DD.%2BM.%26aulast%3DColorado%26aufirst%3DA.%26aulast%3DDadu%26aufirst%3DA.%26aulast%3DDahle%26aufirst%3DU.%2BR.%26aulast%3DDe%2BPaoli%26aufirst%3DL.%26aulast%3DDias%26aufirst%3DH.%2BM.%26aulast%3DDuarte%26aufirst%3DR.%26aulast%3DFattorini%26aufirst%3DL.%26aulast%3DGaga%26aufirst%3DM.%26aulast%3DGetahun%26aufirst%3DH.%26aulast%3DGlaziou%26aufirst%3DP.%26aulast%3DGoguadze%26aufirst%3DL.%26aulast%3DDel%2BGranado%26aufirst%3DM.%26aulast%3DHaas%26aufirst%3DW.%26aulast%3DJ%25C3%25A4rvinen%26aufirst%3DA.%26aulast%3DKwon%26aufirst%3DG.-Y.%26aulast%3DMosca%26aufirst%3DD.%26aulast%3DNahid%26aufirst%3DP.%26aulast%3DNishikiori%26aufirst%3DN.%26aulast%3DNoguer%26aufirst%3DI.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%26aulast%3DPace-Asciak%26aufirst%3DA.%26aulast%3DPompa%26aufirst%3DM.%2BG.%26aulast%3DPopescu%26aufirst%3DG.%2BG.%26aulast%3DRobalo%2BCordeiro%26aufirst%3DC.%26aulast%3DR%25C3%25B8nning%26aufirst%3DK.%26aulast%3DRuhwald%26aufirst%3DM.%26aulast%3DSculier%26aufirst%3DJ.-P.%26aulast%3DSimunovi%25C4%2587%26aufirst%3DA.%26aulast%3DSmith-Palmer%26aufirst%3DA.%26aulast%3DSotgiu%26aufirst%3DG.%26aulast%3DSulis%26aufirst%3DG.%26aulast%3DTorres-Duque%26aufirst%3DC.%2BA.%26aulast%3DUmeki%26aufirst%3DK.%26aulast%3DUplekar%26aufirst%3DM.%26aulast%3Dvan%2BWeezenbeek%26aufirst%3DC.%26aulast%3DVasankari%26aufirst%3DT.%26aulast%3DVitillo%26aufirst%3DR.%2BJ.%26aulast%3DVoniatis%26aufirst%3DC.%26aulast%3DWanlin%26aufirst%3DM.%26aulast%3DRaviglione%26aufirst%3DM.%2BC.%26atitle%3DTowards%2520tuberculosis%2520elimination%253A%2520an%2520action%2520framework%2520for%2520low-incidence%2520countries%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D45%26spage%3D928%26epage%3D952%26doi%3D10.1183%2F09031936.00214014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besozzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barberis, I.</span></span> <span> </span><span class="NLM_article-title">The never-ending story of the fight against tuberculosis: from Koch’s bacillus to global control programs</span>. <i>J. Prev. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">E241</span>– <span class="NLM_lpage">E247</span>, <span class="refDoi"> DOI: 10.15167/2421-4248/jpmh2018.59.3.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.15167%2F2421-4248%2Fjpmh2018.59.3.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30397682" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=E241-E247&author=M.+Martiniauthor=G.+Besozziauthor=I.+Barberis&title=The+never-ending+story+of+the+fight+against+tuberculosis%3A+from+Koch%E2%80%99s+bacillus+to+global+control+programs&doi=10.15167%2F2421-4248%2Fjpmh2018.59.3.105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.15167%2F2421-4248%2Fjpmh2018.59.3.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15167%252F2421-4248%252Fjpmh2018.59.3.105%26sid%3Dliteratum%253Aachs%26aulast%3DMartini%26aufirst%3DM.%26aulast%3DBesozzi%26aufirst%3DG.%26aulast%3DBarberis%26aufirst%3DI.%26atitle%3DThe%2520never-ending%2520story%2520of%2520the%2520fight%2520against%2520tuberculosis%253A%2520from%2520Koch%25E2%2580%2599s%2520bacillus%2520to%2520global%2520control%2520programs%26jtitle%3DJ.%2520Prev.%2520Med.%2520Hyg.%26date%3D2018%26volume%3D59%26spage%3DE241%26epage%3DE247%26doi%3D10.15167%2F2421-4248%2Fjpmh2018.59.3.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waksman, S. A.</span></span> <span> </span><span class="NLM_article-title">Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria</span>. <i>Exp. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">1944</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.3181/00379727-55-14461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3181%2F00379727-55-14461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaH2cXhsVSrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1944&pages=66-69&author=A.+Schatzauthor=E.+Bugleauthor=S.+A.+Waksman&title=Streptomycin%2C+a+substance+exhibiting+antibiotic+activity+against+Gram-positive+and+Gram-negative+bacteria&doi=10.3181%2F00379727-55-14461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria</span></div><div class="casAuthors">Schatz, Albert; Bugie, Elizabeth; Waksman, Selman A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Society for Experimental Biology and Medicine</span>
        (<span class="NLM_cas:date">1944</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">66-9</span>CODEN:
                <span class="NLM_cas:coden">PSEBAA</span>;
        ISSN:<span class="NLM_cas:issn">0037-9727</span>.
    </div><div class="casAbstract">A new antibacterial substance, designated streptomycin, was isolated from 2 strains of an actinomyces related to an organism described as Actinomyces griseus.  This substance resembles streptothricin in its soly. in water, method of isolation and concn., its selective activity against gram-neg. bacteria and its limited toxicity in animals; but the 2 substances differ in the nature of their resp. bacteriostatic spectra and in their quant. action on certain bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomLzs1Xg-0IbVg90H21EOLACvtfcHk0lgifD3ZTLjxnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaH2cXhsVSrug%253D%253D&md5=bdfd9aeddfa1ec7a5b9664ab744b1842</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.3181%2F00379727-55-14461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3181%252F00379727-55-14461%26sid%3Dliteratum%253Aachs%26aulast%3DSchatz%26aufirst%3DA.%26aulast%3DBugle%26aufirst%3DE.%26aulast%3DWaksman%26aufirst%3DS.%2BA.%26atitle%3DStreptomycin%252C%2520a%2520substance%2520exhibiting%2520antibiotic%2520activity%2520against%2520Gram-positive%2520and%2520Gram-negative%2520bacteria%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D1944%26volume%3D55%26spage%3D66%26epage%3D69%26doi%3D10.3181%2F00379727-55-14461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schraufnagel, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopewell, P. C.</span></span> <span> </span><span class="NLM_article-title">Treatment of tuberculosis. A historical perspective</span>. <i>Ann. Am. Thorac. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1749</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1513/AnnalsATS.201509-632PS</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1513%2FAnnalsATS.201509-632PS" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26653188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC28rhsVCnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1749-1759&author=J.+F.+Murrayauthor=D.+E.+Schraufnagelauthor=P.+C.+Hopewell&title=Treatment+of+tuberculosis.+A+historical+perspective&doi=10.1513%2FAnnalsATS.201509-632PS"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Tuberculosis. A Historical Perspective</span></div><div class="casAuthors">Murray John F; Hopewell Philip C; Schraufnagel Dean E</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1749-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Of all achievements in medicine, the successful treatment of tuberculosis has had one of the greatest impacts on society.  Tuberculosis was a leading cause of disease and a mortal enemy of humanity for millennia.  The first step in finding a cure was the discovery of the cause of tuberculosis by Robert Koch in 1882.  The sanatorium movement that began shortly afterward in Europe, and soon spread to the United States, brought attention to the plight of afflicted persons, and catalyzed public health action.  The antituberculosis benefit of streptomycin was announced in 1945, although application was limited by the rapid development of resistance. para-Aminosalicylic acid, also discovered in 1945, when combined with streptomycin was found to greatly reduce the occurrence of drug resistance.  In 1952, isoniazid opened the modern era of treatment; it was inexpensive, well tolerated, and safe.  In the early 1960s, ethambutol was shown to be effective and better tolerated than para-aminosalicylic acid, which it replaced.  In the 1970s, rifampin found its place as a keystone in the therapy of tuberculosis.  The use of rifampin enabled the course of treatment to be reduced to nine months.  Incorporation of pyrazinamide into the first-line regimen led to a further reduction of treatment duration to six months.  Treatment of multiple drug-resistant tuberculosis remains a difficult problem requiring lengthy treatment with toxic drugs.  However, shortened regimens show promise, and two new drugs, bedaquiline and delamanid, have demonstrated effectiveness in preliminary studies and are being used for extensively drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkJKmRJ2pC8wMthz5_Rx5rfW6udTcc2ebBWxfRw76U7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rhsVCnuw%253D%253D&md5=08e20f580f4ac9606ab177f67221c7bf</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1513%2FAnnalsATS.201509-632PS&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252FAnnalsATS.201509-632PS%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DJ.%2BF.%26aulast%3DSchraufnagel%26aufirst%3DD.%2BE.%26aulast%3DHopewell%26aufirst%3DP.%2BC.%26atitle%3DTreatment%2520of%2520tuberculosis.%2520A%2520historical%2520perspective%26jtitle%3DAnn.%2520Am.%2520Thorac.%2520Soc.%26date%3D2015%26volume%3D12%26spage%3D1749%26epage%3D1759%26doi%3D10.1513%2FAnnalsATS.201509-632PS" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siliciano, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Outwitting evolution: fighting drug-resistant TB, malaria, and HIV</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">1271</span>– <span class="NLM_lpage">1283</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2012.02.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.cell.2012.02.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22424234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkt1Ggsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2012&pages=1271-1283&author=D.+E.+Goldbergauthor=R.+F.+Silicianoauthor=W.+R.+Jacobs&title=Outwitting+evolution%3A+fighting+drug-resistant+TB%2C+malaria%2C+and+HIV&doi=10.1016%2Fj.cell.2012.02.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Outwitting Evolution: Fighting Drug-Resistant TB, Malaria, and HIV</span></div><div class="casAuthors">Goldberg, Daniel E.; Siliciano, Robert F.; Jacobs, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1271-1283</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Although caused by vastly different pathogens, the world's three most serious infectious diseases, tuberculosis, malaria, and HIV-1 infection, share the common problem of drug resistance.  The pace of drug development has been very slow for tuberculosis and malaria and rapid for HIV-1.  But for each disease, resistance to most drugs has appeared quickly after the introduction of the drug.  Learning how to manage and prevent resistance is a major medical challenge that requires an understanding of the evolutionary dynamics of each pathogen.  This Review summarizes the similarities and differences in the evolution of drug resistance for these three pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn6p5xi5AClbVg90H21EOLACvtfcHk0ljmCBKUjNDqoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkt1Ggsb0%253D&md5=53f6efa66936569abc9ad91010239569</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DD.%2BE.%26aulast%3DSiliciano%26aufirst%3DR.%2BF.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26atitle%3DOutwitting%2520evolution%253A%2520fighting%2520drug-resistant%2520TB%252C%2520malaria%252C%2520and%2520HIV%26jtitle%3DCell%26date%3D2012%26volume%3D148%26spage%3D1271%26epage%3D1283%26doi%3D10.1016%2Fj.cell.2012.02.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sweany, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entin, S.</span></span> <span> </span><span class="NLM_article-title">A preliminary report on the use of para-amino salicylic acid in the treatment of pulmonary tuberculosis</span>. <i>Dis. Chest</i> <span class="NLM_year" style="font-weight: bold;">1949</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">633</span>– <span class="NLM_lpage">656</span>, <span class="refDoi"> DOI: 10.1378/chest.16.6.633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1378%2Fchest.16.6.633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=15396512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaG3c%252Fgs1Wntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1949&pages=633-656&author=H.+C.+Sweanyauthor=G.+C.+Turnerauthor=M.+Lichtensteinauthor=S.+Entin&title=A+preliminary+report+on+the+use+of+para-amino+salicylic+acid+in+the+treatment+of+pulmonary+tuberculosis&doi=10.1378%2Fchest.16.6.633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">A preliminary report on the use of para-amino salicylic acid in the treatment of pulmonary tuberculosis</span></div><div class="casAuthors">SWEANY H C; TURNER G C</div><div class="citationInfo"><span class="NLM_cas:title">Diseases of the chest</span>
        (<span class="NLM_cas:date">1949</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">633-60, illust</span>
        ISSN:<span class="NLM_cas:issn">0096-0217</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsf1Y54ghI_xpyrDyM_m9cfW6udTcc2ebyTdZEJJUtrrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG3c%252Fgs1Wntg%253D%253D&md5=7986be1efa73a2c88f40c0536f6f315a</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1378%2Fchest.16.6.633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.16.6.633%26sid%3Dliteratum%253Aachs%26aulast%3DSweany%26aufirst%3DH.%2BC.%26aulast%3DTurner%26aufirst%3DG.%2BC.%26aulast%3DLichtenstein%26aufirst%3DM.%26aulast%3DEntin%26aufirst%3DS.%26atitle%3DA%2520preliminary%2520report%2520on%2520the%2520use%2520of%2520para-amino%2520salicylic%2520acid%2520in%2520the%2520treatment%2520of%2520pulmonary%2520tuberculosis%26jtitle%3DDis.%2520Chest%26date%3D1949%26volume%3D16%26spage%3D633%26epage%3D656%26doi%3D10.1378%2Fchest.16.6.633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, J.</span></span> <span> </span><span class="NLM_article-title">Para-aminosalicylic acid in the treatment of tuberculosis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1946</span>,  <span class="NLM_volume"><i>247</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(46)91185-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS0140-6736%2846%2991185-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=1946&pages=15-16&author=J.+Lehmann&title=Para-aminosalicylic+acid+in+the+treatment+of+tuberculosis&doi=10.1016%2FS0140-6736%2846%2991185-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2846%2991185-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252846%252991185-3%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DJ.%26atitle%3DPara-aminosalicylic%2520acid%2520in%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DLancet%26date%3D1946%26volume%3D247%26spage%3D15%26epage%3D16%26doi%3D10.1016%2FS0140-6736%2846%2991185-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, J.</span></span> <span> </span><span class="NLM_article-title">The effect of streptomycin with para-amino salicylic acid on the emergence of resistant strains of tubercle bacilli</span>. <i>Dis. Chest</i> <span class="NLM_year" style="font-weight: bold;">1949</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">666</span>, <span class="refDoi"> DOI: 10.1378/chest.16.6.661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1378%2Fchest.16.6.661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=15396513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaG3c%252Fgs1Wntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1949&pages=661-666&author=E.+Dunnerauthor=W.+B.+Brownauthor=J.+Wallace&title=The+effect+of+streptomycin+with+para-amino+salicylic+acid+on+the+emergence+of+resistant+strains+of+tubercle+bacilli&doi=10.1378%2Fchest.16.6.661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of streptomycin with para-amino salicylic acid on the emergence of resistant strains of tubercle bacilli</span></div><div class="casAuthors">DUNNER E; BROWN W B; WALLACE J</div><div class="citationInfo"><span class="NLM_cas:title">Diseases of the chest</span>
        (<span class="NLM_cas:date">1949</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">661-6</span>
        ISSN:<span class="NLM_cas:issn">0096-0217</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsf1Y54ghI_waK-_ZudimnfW6udTcc2ebyTdZEJJUtrrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG3c%252Fgs1Wntw%253D%253D&md5=e4275eb0fce118824dbabfcaed69c31c</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1378%2Fchest.16.6.661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.16.6.661%26sid%3Dliteratum%253Aachs%26aulast%3DDunner%26aufirst%3DE.%26aulast%3DBrown%26aufirst%3DW.%2BB.%26aulast%3DWallace%26aufirst%3DJ.%26atitle%3DThe%2520effect%2520of%2520streptomycin%2520with%2520para-amino%2520salicylic%2520acid%2520on%2520the%2520emergence%2520of%2520resistant%2520strains%2520of%2520tubercle%2520bacilli%26jtitle%3DDis.%2520Chest%26date%3D1949%26volume%3D16%26spage%3D661%26epage%3D666%26doi%3D10.1378%2Fchest.16.6.661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palomino, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A.</span></span> <span> </span><span class="NLM_article-title">Drug resistance mechanisms in Mycobacterium tuberculosis</span>. <i>Antibiotics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.3390/antibiotics3030317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3390%2Fantibiotics3030317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC28fltFOrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=317-340&author=J.+C.+Palominoauthor=A.+Martin&title=Drug+resistance+mechanisms+in+Mycobacterium+tuberculosis&doi=10.3390%2Fantibiotics3030317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Resistance Mechanisms in Mycobacterium tuberculosis</span></div><div class="casAuthors">Palomino Juan Carlos; Martin Anandi</div><div class="citationInfo"><span class="NLM_cas:title">Antibiotics (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-40</span>
        ISSN:<span class="NLM_cas:issn">2079-6382</span>.
    </div><div class="casAbstract">Tuberculosis (TB) is a serious public health problem worldwide.  Its situation is worsened by the presence of multidrug resistant (MDR) strains of Mycobacterium tuberculosis, the causative agent of the disease.  In recent years, even more serious forms of drug resistance have been reported.  A better knowledge of the mechanisms of drug resistance of M. tuberculosis and the relevant molecular mechanisms involved will improve the available techniques for rapid drug resistance detection and will help to explore new targets for drug activity and development.  This review article discusses the mechanisms of action of anti-tuberculosis drugs and the molecular basis of drug resistance in M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGcT1qwAb8rXwOGIfWJ7-GfW6udTcc2eYJkoAvzEeVGLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fltFOrtQ%253D%253D&md5=d0c81d95447575274fed09d43072d7ce</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.3390%2Fantibiotics3030317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fantibiotics3030317%26sid%3Dliteratum%253Aachs%26aulast%3DPalomino%26aufirst%3DJ.%2BC.%26aulast%3DMartin%26aufirst%3DA.%26atitle%3DDrug%2520resistance%2520mechanisms%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DAntibiotics%26date%3D2014%26volume%3D3%26spage%3D317%26epage%3D340%26doi%3D10.3390%2Fantibiotics3030317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Converse, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peloquin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuermberger, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosset, J. H.</span></span> <span> </span><span class="NLM_article-title">Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">1254</span>– <span class="NLM_lpage">1261</span>, <span class="refDoi"> DOI: 10.1164/rccm.201012-1949OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1164%2Frccm.201012-1949OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21330452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVSntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2011&pages=1254-1261&author=M.+Zhangauthor=S.+Y.+Liauthor=I.+M.+Rosenthalauthor=D.+V.+Almeidaauthor=Z.+Ahmadauthor=P.+J.+Converseauthor=C.+A.+Peloquinauthor=E.+L.+Nuermbergerauthor=J.+H.+Grosset&title=Treatment+of+tuberculosis+with+rifamycin-containing+regimens+in+immune-deficient+mice&doi=10.1164%2Frccm.201012-1949OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice</span></div><div class="casAuthors">Zhang, Ming; Li, Si-Yang; Rosenthal, Ian M.; Almeida, Deepak V.; Ahmad, Zahoor; Converse, Paul J.; Peloquin, Charles A.; Nuermberger, Eric L.; Grosset, Jacques H.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1254-1261</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Daily rifapentine plus isoniazid-pyrazinamide in mice infected with Mycobacterium tuberculosis produces cure in 3 mo.  Whether cure corresponds to latent infection contained by host immunity or true tissue sterilization is unknown.  Objectives: To det. the length of treatment with rifapentine-isoniazid-pyrazinamide or rifampin-isoniazid-pyrazinamide needed to prevent relapse in immune-deficient mice.  Methods: Aerosol-infected BALB/c and nude mice were treated 5 days per wk with either 2 mo of the rifapentine-based regimen followed by rifapentine-isoniazid up to 12 mo or the same regimen with rifampin instead of rifapentine.  Cultures of lung homogenates were performed during the first 3 mo and then every 3 mo.  Relapse rates were assessed after 3, 6, 9, and 12 mo of treatment in BALB/c(± 1 mo of cortisone) and nude mice.  Measurements and Main Results: All rifapentine-treated mice were lung culture-neg. at 3 mo but 13% of BALB/c that received cortisone and 73% of nude mice relapsed.  After 6, 9, and 12 mo of treatment no mouse relapsed.  Rifampin-treated BALB/c mice remained culture pos. at 3 mo.  All were culture neg. at 6, 9, and 12 mo.  None, including those receiving cortisone, relapsed.  Rifampin-treated nude mice harbored more than 4log10 lung cfu at Month 2 and approx. 6 log10 cfu with isoniazid resistance at Month 3.  A supplementary expt. demonstrated that 7 days a week treatment did not prevent isoniazid resistance, whereas addn. of ethambutol did.  Conclusions: In nude mice, sterilization of tuberculosis is obtained with rifapentine-contg. treatment, whereas failure with development of isoniazid resistance is obtained with rifampin-contg. treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptaLdW3FSTF7Vg90H21EOLACvtfcHk0ljvjiIgkJ3rYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVSntrs%253D&md5=f2fd55db1f2b0fe8cc52617babf67488</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1164%2Frccm.201012-1949OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201012-1949OC%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DS.%2BY.%26aulast%3DRosenthal%26aufirst%3DI.%2BM.%26aulast%3DAlmeida%26aufirst%3DD.%2BV.%26aulast%3DAhmad%26aufirst%3DZ.%26aulast%3DConverse%26aufirst%3DP.%2BJ.%26aulast%3DPeloquin%26aufirst%3DC.%2BA.%26aulast%3DNuermberger%26aufirst%3DE.%2BL.%26aulast%3DGrosset%26aufirst%3DJ.%2BH.%26atitle%3DTreatment%2520of%2520tuberculosis%2520with%2520rifamycin-containing%2520regimens%2520in%2520immune-deficient%2520mice%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2011%26volume%3D183%26spage%3D1254%26epage%3D1261%26doi%3D10.1164%2Frccm.201012-1949OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seaworth, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. E.</span></span> <span> </span><span class="NLM_article-title">Therapy of multidrug-resistant and extensively drug-resistant tuberculosis</span>. <i>Microbiol. Spectrum</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">TNMI7-0042-2017</span>, <span class="refDoi"> DOI: 10.1128/microbiolspec.TNMI7-0042-2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2Fmicrobiolspec.TNMI7-0042-2017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=TNMI7-0042-2017&author=B.+J.+Seaworthauthor=D.+E.+Griffith&title=Therapy+of+multidrug-resistant+and+extensively+drug-resistant+tuberculosis&doi=10.1128%2Fmicrobiolspec.TNMI7-0042-2017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1128%2Fmicrobiolspec.TNMI7-0042-2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmicrobiolspec.TNMI7-0042-2017%26sid%3Dliteratum%253Aachs%26aulast%3DSeaworth%26aufirst%3DB.%2BJ.%26aulast%3DGriffith%26aufirst%3DD.%2BE.%26atitle%3DTherapy%2520of%2520multidrug-resistant%2520and%2520extensively%2520drug-resistant%2520tuberculosis%26jtitle%3DMicrobiol.%2520Spectrum%26date%3D2017%26volume%3D5%26spage%3DTNMI7-0042-2017%26doi%3D10.1128%2Fmicrobiolspec.TNMI7-0042-2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaton, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessells, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kon, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supply, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moodley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pym, A. S.</span></span> <span> </span><span class="NLM_article-title">International spread of MDR TB from Tugela Ferry, South Africa</span>. <i>Emerging Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2035</span>– <span class="NLM_lpage">2037</span>, <span class="refDoi"> DOI: 10.3201/eid1711.110291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3201%2Feid1711.110291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22099091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FhtVKgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2035-2037&author=G.+S.+Cookeauthor=R.+K.+Beatonauthor=R.+J.+Lessellsauthor=L.+Johnauthor=S.+Ashworthauthor=O.+M.+Konauthor=O.+M.+Williamsauthor=P.+Supplyauthor=P.+Moodleyauthor=A.+S.+Pym&title=International+spread+of+MDR+TB+from+Tugela+Ferry%2C+South+Africa&doi=10.3201%2Feid1711.110291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">International spread of MDR TB from Tugela Ferry, South Africa</span></div><div class="casAuthors">Cooke Graham S; Beaton R Kate; Lessells Richard J; John Laurence; Ashworth Simon; Kon Onn Min; Williams O Martin; Supply P; Moodley P; Pym Alexander S</div><div class="citationInfo"><span class="NLM_cas:title">Emerging infectious diseases</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2035-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We describe a death associated with multidrug-resistant tuberculosis and HIV infection outside Africa that can be linked to Tugela Ferry (KwaZulu-Natal, South Africa), the town most closely associated with the regional epidemic of drug-resistant tuberculosis.  This case underscores the international relevance of this regional epidemic, particularly among health care workers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQM-P1b8wGFGsrRqEXsZufAfW6udTcc2eZDn3rc8H6x9rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FhtVKgsw%253D%253D&md5=f10bf95f8c979927b6ff3dcd070f6532</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.3201%2Feid1711.110291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3201%252Feid1711.110291%26sid%3Dliteratum%253Aachs%26aulast%3DCooke%26aufirst%3DG.%2BS.%26aulast%3DBeaton%26aufirst%3DR.%2BK.%26aulast%3DLessells%26aufirst%3DR.%2BJ.%26aulast%3DJohn%26aufirst%3DL.%26aulast%3DAshworth%26aufirst%3DS.%26aulast%3DKon%26aufirst%3DO.%2BM.%26aulast%3DWilliams%26aufirst%3DO.%2BM.%26aulast%3DSupply%26aufirst%3DP.%26aulast%3DMoodley%26aufirst%3DP.%26aulast%3DPym%26aufirst%3DA.%2BS.%26atitle%3DInternational%2520spread%2520of%2520MDR%2520TB%2520from%2520Tugela%2520Ferry%252C%2520South%2520Africa%26jtitle%3DEmerging%2520Infect.%2520Dis.%26date%3D2011%26volume%3D17%26spage%3D2035%26epage%3D2037%26doi%3D10.3201%2Feid1711.110291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sotgiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Ambrosio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliori, G. B.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis treatment and drug regimens</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">a017822</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a017822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1101%2Fcshperspect.a017822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25573773" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=a017822&author=G.+Sotgiuauthor=R.+Centisauthor=L.+D%E2%80%99Ambrosioauthor=G.+B.+Migliori&title=Tuberculosis+treatment+and+drug+regimens&doi=10.1101%2Fcshperspect.a017822"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a017822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a017822%26sid%3Dliteratum%253Aachs%26aulast%3DSotgiu%26aufirst%3DG.%26aulast%3DCentis%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Ambrosio%26aufirst%3DL.%26aulast%3DMigliori%26aufirst%3DG.%2BB.%26atitle%3DTuberculosis%2520treatment%2520and%2520drug%2520regimens%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2015%26volume%3D5%26spage%3Da017822%26doi%3D10.1101%2Fcshperspect.a017822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, D.</span></span> <span> </span><span class="NLM_article-title">Directly observed therapy for tuberculosis: history of an idea</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1548</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(95)91090-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS0140-6736%2895%2991090-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=7677849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaK2MzhtFGmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=1995&pages=1545-1548&author=R.+Bayerauthor=D.+Wilkinson&title=Directly+observed+therapy+for+tuberculosis%3A+history+of+an+idea&doi=10.1016%2FS0140-6736%2895%2991090-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Directly observed therapy for tuberculosis: history of an idea</span></div><div class="casAuthors">Bayer R; Wilkinson D</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">8964</span>),
    <span class="NLM_cas:pages">1545-8</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1tXUbrXZOoUloaUqgkFHkfW6udTcc2eZYzkFsP_s1g7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2MzhtFGmsw%253D%253D&md5=69f7b6b4ab1dba3e65d75dbd85ec99d4</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2895%2991090-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252895%252991090-5%26sid%3Dliteratum%253Aachs%26aulast%3DBayer%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DD.%26atitle%3DDirectly%2520observed%2520therapy%2520for%2520tuberculosis%253A%2520history%2520of%2520an%2520idea%26jtitle%3DLancet%26date%3D1995%26volume%3D345%26spage%3D1545%26epage%3D1548%26doi%3D10.1016%2FS0140-6736%2895%2991090-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieden, T. R.</span></span> <span> </span><span class="NLM_article-title">Directly observed therapy in New York City. History, implementation, results, and challenges</span>. <i>Clinics in Chest Medicine</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1016/S0272-5231(05)70363-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS0272-5231%2805%2970363-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=9098618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaK2s3ltlWktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1997&pages=135-148&author=P.+I.+Fujiwaraauthor=C.+Larkinauthor=T.+R.+Frieden&title=Directly+observed+therapy+in+New+York+City.+History%2C+implementation%2C+results%2C+and+challenges&doi=10.1016%2FS0272-5231%2805%2970363-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Directly observed therapy in New York City. History, implementation, results, and challenges</span></div><div class="casAuthors">Fujiwara P I; Larkin C; Frieden T R</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in chest medicine</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">135-48</span>
        ISSN:<span class="NLM_cas:issn">0272-5231</span>.
    </div><div class="casAbstract">The history of the New York City Department of Health Bureau of Tuberculosis Control Program, and the events leading to the adoption of wide-scale directly observed therapy (DOT) in 1992 are described.  The organization and role of Department of Health and non-Department of Health directly observed programs are discussed.  Details are provided regarding the Department of Health's program: the use of standard treatment and program protocols, the use of incentives and enablers, a profile of the successful DOT worker, the detention program, and other issues.  Program data and outcomes from 1992 through 1995 are presented, along with some of the challenges and questions for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZCYSpVMSTqcSzjBFCN0BJfW6udTcc2eZYzkFsP_s1g7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s3ltlWktw%253D%253D&md5=05fb012a12b77e0622588b40373c4c4f</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS0272-5231%2805%2970363-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0272-5231%252805%252970363-4%26sid%3Dliteratum%253Aachs%26aulast%3DFujiwara%26aufirst%3DP.%2BI.%26aulast%3DLarkin%26aufirst%3DC.%26aulast%3DFrieden%26aufirst%3DT.%2BR.%26atitle%3DDirectly%2520observed%2520therapy%2520in%2520New%2520York%2520City.%2520History%252C%2520implementation%252C%2520results%252C%2520and%2520challenges%26jtitle%3DClinics%2520in%2520Chest%2520Medicine%26date%3D1997%26volume%3D18%26spage%3D135%26epage%3D148%26doi%3D10.1016%2FS0272-5231%2805%2970363-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span> <i>Global Tuberculosis Report 2019 Fact Sheet</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2019</span>; <a href="https://www.who.int/publications/m/item/global-tuberculosis-report-2019-fact-sheet" class="extLink">https://www.who.int/publications/m/item/global-tuberculosis-report-2019-fact-sheet</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Tuberculosis+Report+2019+Fact+Sheet%3B+World+Health+Organization%3A+Geneva%2C+2019%3B+https%3A%2F%2Fwww.who.int%2Fpublications%2Fm%2Fitem%2Fglobal-tuberculosis-report-2019-fact-sheet+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlobal%2520Tuberculosis%2520Report%25202019%2520Fact%2520Sheet%26pub%3DWorld%2520Health%2520Organization%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almeida
Da Silva, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomino, J. C.</span></span> <span> </span><span class="NLM_article-title">Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1417</span>– <span class="NLM_lpage">1430</span>, <span class="refDoi"> DOI: 10.1093/jac/dkr173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fjac%2Fdkr173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21558086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFWksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2011&pages=1417-1430&author=P.+E.+Almeida%0ADa+Silvaauthor=J.+C.+Palomino&title=Molecular+basis+and+mechanisms+of+drug+resistance+in+Mycobacterium+tuberculosis%3A+classical+and+new+drugs&doi=10.1093%2Fjac%2Fdkr173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs</span></div><div class="casAuthors">Almeida Da Silva, Pedro Eduardo; Palomino, Juan Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1417-1430</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB) remains one of the leading public health problems worldwide.  Declared as a global emergency in 1993 by the WHO, its control is hampered by the emergence of multidrug resistance (MDR), defined as resistance to at least rifampicin and isoniazid, two key drugs in the treatment of the disease.  More recently, severe forms of drug resistance such as extensively drug-resistant (XDR) TB have been described.  After the discovery of several drugs with anti-TB activity, multidrug therapy became fundamental for control of the disease.  Major advances in mol. biol. and the availability of new information generated after sequencing the genome of Mycobacterium tuberculosis increased our knowledge of the mechanisms of resistance to the main anti-TB drugs.  Better knowledge of the mechanisms of drug resistance in TB and the mol. mechanisms involved will help us to improve current techniques for rapid detection and will also stimulate the exploration of new targets for drug activity and drug development.  This article presents an updated review of the mechanisms and mol. basis of drug resistance in M. tuberculosis.  It also comments on the several gaps in our current knowledge of the mol. mechanisms of drug resistance to the main classical and new anti-TB drugs and briefly discusses some implications of the development of drug resistance and fitness, transmission and pathogenicity of M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnautFX8QYVLVg90H21EOLACvtfcHk0lgUZdapIkMeHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFWksL8%253D&md5=5d2d6af9192d73ecc1621ab94d910cfa</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkr173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkr173%26sid%3Dliteratum%253Aachs%26aulast%3DAlmeida%2BDa%2BSilva%26aufirst%3DP.%2BE.%26aulast%3DPalomino%26aufirst%3DJ.%2BC.%26atitle%3DMolecular%2520basis%2520and%2520mechanisms%2520of%2520drug%2520resistance%2520in%2520Mycobacterium%2520tuberculosis%253A%2520classical%2520and%2520new%2520drugs%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2011%26volume%3D66%26spage%3D1417%26epage%3D1430%26doi%3D10.1093%2Fjac%2Fdkr173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holtz, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sternberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kammerer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laserson, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riekstina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarovska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skripconoka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leimane, V.</span></span> <span> </span><span class="NLM_article-title">Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.7326/0003-4819-144-9-200605020-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.7326%2F0003-4819-144-9-200605020-00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=16670134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD283ks1Sgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2006&pages=650-659&author=T.+H.+Holtzauthor=M.+Sternbergauthor=S.+Kammererauthor=K.+F.+Lasersonauthor=V.+Riekstinaauthor=E.+Zarovskaauthor=V.+Skripconokaauthor=C.+D.+Wellsauthor=V.+Leimane&title=Time+to+sputum+culture+conversion+in+multidrug-resistant+tuberculosis%3A+predictors+and+relationship+to+treatment+outcome&doi=10.7326%2F0003-4819-144-9-200605020-00008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome</span></div><div class="casAuthors">Holtz Timothy H; Sternberg Maya; Kammerer Steve; Laserson Kayla F; Riekstina Vija; Zarovska Evija; Skripconoka Vija; Wells Charles D; Leimane Vaira</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">650-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Conversion of sputum mycobacterial cultures from positive growth to negative growth of Mycobacterium tuberculosis in patients with pulmonary tuberculosis (TB) is considered the most important interim indicator of the efficacy of anti-TB pharmacologic treatment for multidrug-resistant disease.  OBJECTIVE:  To evaluate and compare time to and predictors of initial sputum culture conversion with predictors of treatment outcome for patients with multidrug-resistant TB.  DESIGN:  Retrospective cohort study.  SETTING:  Latvia.  PATIENTS:  All civilian patients with multidrug-resistant TB treated with the DOTS-Plus strategy between 1 January and 31 December 2000.  INTERVENTION:  Individualized treatment for confirmed sputum culture-positive pulmonary multidrug-resistant TB.  MEASUREMENTS:  Time to initial sputum culture conversion and treatment outcome.  RESULTS:  Among 167 patients who were sputum culture-positive at initiation of second-line therapy, 129 (77%) converted in a median time of 60 days (range, 4 to 462 days) and 38 (23%) did not convert.  Independent predictors of a longer sputum culture conversion time, using an accelerated failure time regression model, included previous treatment for multidrug-resistant TB, high initial sputum culture colony count, bilateral cavitations on chest radiography, and the number of drugs the initial isolate was resistant to at treatment initiation.  Treatment outcomes were statistically significantly worse for patients who did not convert their sputum culture within 2 months.  LIMITATIONS:  Twenty-five percent of patients missed 5 or more monthly sputum collections.  CONCLUSIONS:  Under program conditions in Latvia, most patients with multidrug-resistant TB achieved sputum culture conversion within 12 weeks of starting treatment.  Chest radiography and sputum culture drug susceptibility testing can assist physicians in predicting which patients will convert more slowly.  Sputum culture conversion is a useful and appropriate interim indicator of treatment outcome in patients with multidrug-resistant TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWtIP8EY_OHfEeosoOnpOLfW6udTcc2ebLABOlUnF7X7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283ks1Sgsw%253D%253D&md5=584785d11a0cdf1700a1e9fa9d5f0e12</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-144-9-200605020-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-144-9-200605020-00008%26sid%3Dliteratum%253Aachs%26aulast%3DHoltz%26aufirst%3DT.%2BH.%26aulast%3DSternberg%26aufirst%3DM.%26aulast%3DKammerer%26aufirst%3DS.%26aulast%3DLaserson%26aufirst%3DK.%2BF.%26aulast%3DRiekstina%26aufirst%3DV.%26aulast%3DZarovska%26aufirst%3DE.%26aulast%3DSkripconoka%26aufirst%3DV.%26aulast%3DWells%26aufirst%3DC.%2BD.%26aulast%3DLeimane%26aufirst%3DV.%26atitle%3DTime%2520to%2520sputum%2520culture%2520conversion%2520in%2520multidrug-resistant%2520tuberculosis%253A%2520predictors%2520and%2520relationship%2520to%2520treatment%2520outcome%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2006%26volume%3D144%26spage%3D650%26epage%3D659%26doi%3D10.7326%2F0003-4819-144-9-200605020-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroishi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onozaki, K.</span></span> <span> </span><span class="NLM_article-title">Antitubercular activity of disulfiram, an antialcoholism drug, against multidrug- and extensively drug-resistant Mycobacterium tuberculosis isolates</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4140</span>– <span class="NLM_lpage">4145</span>, <span class="refDoi"> DOI: 10.1128/AAC.06445-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.06445-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22615274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFajs7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=4140-4145&author=Y.+Horitaauthor=T.+Takiiauthor=T.+Yagiauthor=K.+Ogawaauthor=N.+Fujiwaraauthor=E.+Inagakiauthor=L.+Kremerauthor=Y.+Satoauthor=R.+Kuroishiauthor=Y.+Leeauthor=T.+Makinoauthor=H.+Mizukamiauthor=T.+Hasegawaauthor=R.+Yamamotoauthor=K.+Onozaki&title=Antitubercular+activity+of+disulfiram%2C+an+antialcoholism+drug%2C+against+multidrug-+and+extensively+drug-resistant+Mycobacterium+tuberculosis+isolates&doi=10.1128%2FAAC.06445-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Antitubercular activity of disulfiram, an antialcoholism drug, against multidrug- and extensively drug-resistant Mycobacterium tuberculosis isolates</span></div><div class="casAuthors">Horita, Yasuhiro; Takii, Takemasa; Yagi, Tetsuya; Ogawa, Kenji; Fujiwara, Nagatoshi; Inagaki, Emi; Kremer, Laurent; Sato, Yasuo; Kuroishi, Ryuji; Lee, YooSa; Makino, Toshiaki; Mizukami, Hajime; Hasegawa, Tomohiro; Yamamoto, Ryuji; Onozaki, Kikuo</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4140-4145</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The antimycobacterial activities of disulfiram (DSF) and diethyldithiocarbamate (DDC) against multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB) clin. isolates were evaluated in vitro.  Both DSF and DDC exhibited potent antitubercular activities against 42 clin. isolates of M. tuberculosis, including MDR/XDR-TB strains.  Moreover, DSF showed remarkable bactericidal activity ex vivo and in vivo.  Therefore, DSF might be a drug re-purposed for the treatment of MDR/XDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5W7IBV2_H-7Vg90H21EOLACvtfcHk0lgjId1J0Vt-bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFajs7zO&md5=d012b8684ba64f73477725a9f2ab7646</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1128%2FAAC.06445-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06445-11%26sid%3Dliteratum%253Aachs%26aulast%3DHorita%26aufirst%3DY.%26aulast%3DTakii%26aufirst%3DT.%26aulast%3DYagi%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DFujiwara%26aufirst%3DN.%26aulast%3DInagaki%26aufirst%3DE.%26aulast%3DKremer%26aufirst%3DL.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DKuroishi%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DMakino%26aufirst%3DT.%26aulast%3DMizukami%26aufirst%3DH.%26aulast%3DHasegawa%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DR.%26aulast%3DOnozaki%26aufirst%3DK.%26atitle%3DAntitubercular%2520activity%2520of%2520disulfiram%252C%2520an%2520antialcoholism%2520drug%252C%2520against%2520multidrug-%2520and%2520extensively%2520drug-resistant%2520Mycobacterium%2520tuberculosis%2520isolates%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D4140%26epage%3D4145%26doi%3D10.1128%2FAAC.06445-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alsaad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilffert, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Altena, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lange, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Werf, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosterink, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alffenaar, J. W.</span></span> <span> </span><span class="NLM_article-title">Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">884</span>– <span class="NLM_lpage">897</span>, <span class="refDoi"> DOI: 10.1183/09031936.00113713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1183%2F09031936.00113713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23988774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslKrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=884-897&author=N.+Alsaadauthor=B.+Wilffertauthor=R.+van+Altenaauthor=W.+C.+de+Langeauthor=T.+S.+van+der%0AWerfauthor=J.+G.+Kosterinkauthor=J.+W.+Alffenaar&title=Potential+antimicrobial+agents+for+the+treatment+of+multidrug-resistant+tuberculosis&doi=10.1183%2F09031936.00113713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis</span></div><div class="casAuthors">Alsaad, Noor; Wilffert, Bob; van Altena, Richard; de Lange, Wiel C. M.; van der Werf, Tjip S.; Kosterink, Jos G. W.; Alffenaar, Jan-Willem C.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">884-897</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">A review.  Treatment of multidrug-resistant (MDR) tuberculosis (TB) is challenging because of the high toxicity of second-line drugs and the longer treatment duration than for drug-susceptible TB patients.  In order to speed up novel treatment for MDR-TB, we suggest considering expanding the indications of already available drugs.  Six drugs with antimicrobial activity (phenothiazine, metronidazole, doxycycline, disulfiram, tigecycline and co-trimoxazole) are not listed in the World Health Organization guidelines on MDR-TB treatment but could be potential candidates for evaluation against Mycobacterium tuberculosis.  A systematic review was conducted to evaluate antituberculous activity of these drugs against M. tuberculosis.  We searched PubMed, Google Scholar and Embase for English articles published up to Dec. 31, 2012.  We reviewed in vitro, in vivo and clin. antituberculous activity of these drugs in addn. to pharmacokinetics and side-effects.  Of the drugs effective against actively replicating M. tuberculosis, co-trimoxazole seems to be the most promising, because of its consistent pharmacokinetic profile, easy penetration into tissue and safety profile.  For the dormant state of TB, thioridazine may play a potential role as an adjuvant for treatment of MDR-TB.  A strategy consisting of pharmacokinetic/pharmacodynamic studies, dose finding and phase III studies is needed to explore the role of these drugs in MDR-TB treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRHqWZp_U1eLVg90H21EOLACvtfcHk0lh_8WHVIiRm-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslKrsrs%253D&md5=c0781099bdd7f87d98aa360c44ea7b00</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1183%2F09031936.00113713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00113713%26sid%3Dliteratum%253Aachs%26aulast%3DAlsaad%26aufirst%3DN.%26aulast%3DWilffert%26aufirst%3DB.%26aulast%3Dvan%2BAltena%26aufirst%3DR.%26aulast%3Dde%2BLange%26aufirst%3DW.%2BC.%26aulast%3Dvan%2Bder%2BWerf%26aufirst%3DT.%2BS.%26aulast%3DKosterink%26aufirst%3DJ.%2BG.%26aulast%3DAlffenaar%26aufirst%3DJ.%2BW.%26atitle%3DPotential%2520antimicrobial%2520agents%2520for%2520the%2520treatment%2520of%2520multidrug-resistant%2520tuberculosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D43%26spage%3D884%26epage%3D897%26doi%3D10.1183%2F09031936.00113713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Soolingen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Pando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orozco, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis-Escurra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Ingen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeree, M. J.</span></span> <span> </span><span class="NLM_article-title">The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e12640</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0012640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pone.0012640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=20844587" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=e12640&author=D.+van%0ASoolingenauthor=R.+Hernandez-Pandoauthor=H.+Orozcoauthor=D.+Aguilarauthor=C.+Magis-Escurraauthor=L.+Amaralauthor=J.+van+Ingenauthor=M.+J.+Boeree&title=The+antipsychotic+thioridazine+shows+promising+therapeutic+activity+in+a+mouse+model+of+multidrug-resistant+tuberculosis&doi=10.1371%2Fjournal.pone.0012640"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0012640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0012640%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BSoolingen%26aufirst%3DD.%26aulast%3DHernandez-Pando%26aufirst%3DR.%26aulast%3DOrozco%26aufirst%3DH.%26aulast%3DAguilar%26aufirst%3DD.%26aulast%3DMagis-Escurra%26aufirst%3DC.%26aulast%3DAmaral%26aufirst%3DL.%26aulast%3Dvan%2BIngen%26aufirst%3DJ.%26aulast%3DBoeree%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520antipsychotic%2520thioridazine%2520shows%2520promising%2520therapeutic%2520activity%2520in%2520a%2520mouse%2520model%2520of%2520multidrug-resistant%2520tuberculosis%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26spage%3De12640%26doi%3D10.1371%2Fjournal.pone.0012640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viveiros, M.</span></span> <span> </span><span class="NLM_article-title">Thioridazine: A non-antibiotic drug highly effective, in combination with first line anti-tuberculosis drugs, against any form of antibiotic resistance of Mycobacterium tuberculosis due to its multi-mechanisms of action</span>. <i>Antibiotics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.3390/antibiotics6010003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3390%2Fantibiotics6010003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=3&author=L.+Amaralauthor=M.+Viveiros&title=Thioridazine%3A+A+non-antibiotic+drug+highly+effective%2C+in+combination+with+first+line+anti-tuberculosis+drugs%2C+against+any+form+of+antibiotic+resistance+of+Mycobacterium+tuberculosis+due+to+its+multi-mechanisms+of+action&doi=10.3390%2Fantibiotics6010003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.3390%2Fantibiotics6010003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fantibiotics6010003%26sid%3Dliteratum%253Aachs%26aulast%3DAmaral%26aufirst%3DL.%26aulast%3DViveiros%26aufirst%3DM.%26atitle%3DThioridazine%253A%2520A%2520non-antibiotic%2520drug%2520highly%2520effective%252C%2520in%2520combination%2520with%2520first%2520line%2520anti-tuberculosis%2520drugs%252C%2520against%2520any%2520form%2520of%2520antibiotic%2520resistance%2520of%2520Mycobacterium%2520tuberculosis%2520due%2520to%2520its%2520multi-mechanisms%2520of%2520action%26jtitle%3DAntibiotics%26date%3D2017%26volume%3D6%26spage%3D3%26doi%3D10.3390%2Fantibiotics6010003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, L. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noursadeghi, M.</span></span> <span> </span><span class="NLM_article-title">Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1038/nrmicro.2017.128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnrmicro.2017.128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29109555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslKlt73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=80-90&author=L.+C.+K.+Bellauthor=M.+Noursadeghi&title=Pathogenesis+of+HIV-1+and+Mycobacterium+tuberculosis+co-infection&doi=10.1038%2Fnrmicro.2017.128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection</span></div><div class="casAuthors">Bell, Lucy C. K.; Noursadeghi, Mahdad</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">80-90</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Co-infection with Mycobacterium tuberculosis is the leading cause of death in individuals infected with HIV-1.  It has long been known that HIV-1 infection alters the course of M. tuberculosis infection and substantially increases the risk of active tuberculosis (TB).  It has also become clear that TB increases levels of HIV-1 replication, propagation and genetic diversity.  Therefore, co-infection provides reciprocal advantages to both pathogens.  In this Review, we describe the epidemiol. assocns. between the two pathogens, selected interactions of each pathogen with the host and our current understanding of how they affect the pathogenesis of TB and HIV-1/AIDS in individuals with co-infections.  We evaluate the mechanisms and consequences of HIV-1 depletion of T cells on immune responses to M. tuberculosis.  We also discuss the effect of HIV-1 infection on the control of M. tuberculosis by macrophages through phagocytosis, autophagy and cell death, and we propose models by which dysregulated inflammatory responses drive the pathogenesis of TB and HIV-1/AIDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLctrehsX_jbVg90H21EOLACvtfcHk0lh_8WHVIiRm-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslKlt73I&md5=4377cf461f74b2efa676dc486cc660c8</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro.2017.128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro.2017.128%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DL.%2BC.%2BK.%26aulast%3DNoursadeghi%26aufirst%3DM.%26atitle%3DPathogenesis%2520of%2520HIV-1%2520and%2520Mycobacterium%2520tuberculosis%2520co-infection%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2018%26volume%3D16%26spage%3D80%26epage%3D90%26doi%3D10.1038%2Fnrmicro.2017.128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tornheim, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooley, K. E.</span></span> <span> </span><span class="NLM_article-title">Challenges of TB and HIV co-treatment: updates and insights</span>. <i>Curr. Opin. HIV AIDS</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1097/COH.0000000000000495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1097%2FCOH.0000000000000495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30080683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVChtrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=486-491&author=J.+A.+Tornheimauthor=K.+E.+Dooley&title=Challenges+of+TB+and+HIV+co-treatment%3A+updates+and+insights&doi=10.1097%2FCOH.0000000000000495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges of TB and HIV co-treatment: updates and insights</span></div><div class="casAuthors">Tornheim, Jeffrey A.; Dooley, Kelly E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in HIV & AIDS</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">486-491</span>CODEN:
                <span class="NLM_cas:coden">COHABM</span>;
        ISSN:<span class="NLM_cas:issn">1746-630X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  In the past few years, tuberculosis (TB) has overtaken HIV as the infectious disease with the highest global mortality.  Successful management of this syndemic will require improved diagnostic tests, shorter preventive therapies, and more effective treatments, particularly in light of drug-resistant TB.  Results from several major studies have been published or presented recently, including the development of a more sensitive rapid, mol. assay for TB; several new symptom-based screening tools; use of a 1-mo regimen for TB prevention; the results of early vs. delayed TB preventive therapy for pregnant women; newer drugs and regimens for multidrug-resistant tuberculosis; and pharmacokinetic, safety, and efficacy studies of new HIV drugs in combination with TB treatment.  We reviewed each of these topic areas and summarize relevant findings for the management of TB and HIV co-infection.  Moving forward, as new treatment regimes for HIV or TB are developed, consideration of the HIV-TB co-infected patient must figure prominently, both when detg. the diagnostic tests employed and to assess properly the drug-drug and drug-disease interactions that influence dosing, safety, and response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5qhlyoAll9LVg90H21EOLACvtfcHk0lhRtpnCVtdvoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVChtrfI&md5=6c9f3dc0d35aefe298f6cb8d0efa0668</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1097%2FCOH.0000000000000495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOH.0000000000000495%26sid%3Dliteratum%253Aachs%26aulast%3DTornheim%26aufirst%3DJ.%2BA.%26aulast%3DDooley%26aufirst%3DK.%2BE.%26atitle%3DChallenges%2520of%2520TB%2520and%2520HIV%2520co-treatment%253A%2520updates%2520and%2520insights%26jtitle%3DCurr.%2520Opin.%2520HIV%2520AIDS%26date%3D2018%26volume%3D13%26spage%3D486%26epage%3D491%26doi%3D10.1097%2FCOH.0000000000000495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J. Q.</span></span> <span> </span><span class="NLM_article-title">Diabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1090</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-01213-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fs41598-017-01213-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28439071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1crgslOnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=1090&author=Q.+Liuauthor=W.+Liauthor=M.+Xueauthor=Y.+Chenauthor=X.+Duauthor=C.+Wangauthor=L.+Hanauthor=Y.+Tangauthor=Y.+Fengauthor=C.+Taoauthor=J.+Q.+He&title=Diabetes+mellitus+and+the+risk+of+multidrug+resistant+tuberculosis%3A+a+meta-analysis&doi=10.1038%2Fs41598-017-01213-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Diabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis</span></div><div class="casAuthors">Liu Qianqian; Chen Yunfeng; Liu Qianqian; Xue Miao; Du Xinmiao; Wang Chengdi; Feng Yulin; He Jian-Qing; Li Wenzhang; Han Lina; Tang Yin; Tao Chuanmin</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1090</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The high prevalence of diabetes mellitus (DM) among multidrug resistant tuberculosis (MDR-TB) patients is a serious cause for concern.  We conducted a meta-analysis to determine whether DM is an independent risk factor for MDR-TB.  Electronic literature searches of the PubMed, Web of Science and EMBASE databases up to July 12, 2016 were conducted.  The pooled adjusted odds ratio (OR) and 95% confidence intervals (CIs) were calculated using the random effects model with STATA 12.0 software.  In total 13 studies, including 9289 individuals with TB, were included in this meta-analysis.  Significant association between DM and MDR-TB (OR = 1.71; 95% CI = 1.32, 2.22) was identified.  Subgroup analyses showed that: 1) Pooled OR was 1.25 (95% CI: 0.82-1.91) for cross-sectional studies, and was 2.14 (95% CI: 1.51-3.02) for longitudinal studies; 2) The pooled OR was 1.69 (95% CI:1.09-2.62) for primary MDR-TB, 1.94 (95% CI:1.42-2.65) for any MDR-TB, and 0.85 for secondary MDR-TB (95% CI: 0.29-2.54); 3) DM was significantly associated with MDR-TB in both Caucasian (OR = 2.26, 95% CI: 1.66-3.07) and Asian (OR = 1.40, 95% CI: 1.01-1.95) subgroups.  No evidence of publication bias was identified.  In conclusion, the pooling analysis indicated that DM was an independent risk factor for MDR-TB, especially for primary MDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTU5VyZSnc3CrGbPKh4T9eAfW6udTcc2eYkN7_1g8-pILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crgslOnug%253D%253D&md5=db60c8400398de1e62b2a211364ec355</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-01213-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-01213-5%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DXue%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DTao%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DJ.%2BQ.%26atitle%3DDiabetes%2520mellitus%2520and%2520the%2520risk%2520of%2520multidrug%2520resistant%2520tuberculosis%253A%2520a%2520meta-analysis%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D1090%26doi%3D10.1038%2Fs41598-017-01213-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huangfu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarte-Gil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchley, J.</span></span> <span> </span><span class="NLM_article-title">The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">796</span>, <span class="refDoi"> DOI: 10.5588/ijtld.18.0433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.5588%2Fijtld.18.0433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31439109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BB3Mrgs1SitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=783-796&author=P.+Huangfuauthor=C.+Ugarte-Gilauthor=J.+Golubauthor=F.+Pearsonauthor=J.+Critchley&title=The+effects+of+diabetes+on+tuberculosis+treatment+outcomes%3A+an+updated+systematic+review+and+meta-analysis&doi=10.5588%2Fijtld.18.0433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis</span></div><div class="casAuthors">Huangfu P; Pearson F; Critchley J; Ugarte-Gil C; Golub J</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">783-796</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND: Previous evidence synthesis has suggested diabetes mellitus (DM) worsens tuberculosis (TB) treatment outcomes.  However, these reviews are limited by the number, robustness and conflicting results among the studies included.  We conducted a systematic review to update earlier analyses and explore heterogeneity among studies.METHODS: MEDLINE, EMBASE, AIM, LILACS, IMEMR, IMSEAR and WPRIM were searched between 1 January 1980 and 23 July 2018 unrestricted by language or region.  All cohort and case-control studies investigating the difference in TB treatment outcomes amongst TB-DM patients compared to those with TB alone were included.  Two reviewers independently assessed titles, abstracts, and extracted data.  Culture conversion at two/three months, all-cause mortality, treatment failure, relapse and multidrug-resistant TB (MDR-TB) were evaluated using random effects meta-analysis with generic inverse variance.  Heterogeneity was explored using subgroup analyses and meta-regression.RESULTS: One hundred and four publications were identified.  Sixty-four studies including 56 122 individuals with TB-DM and 243 035 with TB, reported on death.  Some outcomes showed substantial heterogeneity between studies, which we could not fully explain, though confounding adjustment and country income level accounted for some of the differences.  TB-DM patients had higher odds of death (OR 1.88, 95%CI 1.59-2.21) and relapse (OR 1.64, 95%CI 1.29-2.08) compared to TB patients.  More limited evidence suggested TB-DM patients had double the risk of developing MDR-TB (OR 1.98, 95%CI 1.51-2.60).CONCLUSION: DM is associated with increased risks of poor TB treatment outcomes, particularly mortality, and may increase risk of developing primary MDR-TB.  Cost-effectiveness of interventions to enhance TB-DM treatment should be assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRMtQEKH7hnxYHWj6b1v8uTfW6udTcc2eYkN7_1g8-pILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mrgs1SitA%253D%253D&md5=5f1c64149c97d248c7d4e45e1340edff</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.5588%2Fijtld.18.0433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5588%252Fijtld.18.0433%26sid%3Dliteratum%253Aachs%26aulast%3DHuangfu%26aufirst%3DP.%26aulast%3DUgarte-Gil%26aufirst%3DC.%26aulast%3DGolub%26aufirst%3DJ.%26aulast%3DPearson%26aufirst%3DF.%26aulast%3DCritchley%26aufirst%3DJ.%26atitle%3DThe%2520effects%2520of%2520diabetes%2520on%2520tuberculosis%2520treatment%2520outcomes%253A%2520an%2520updated%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D2019%26volume%3D23%26spage%3D783%26epage%3D796%26doi%3D10.5588%2Fijtld.18.0433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yew, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. C.</span></span> <span> </span><span class="NLM_article-title">Antituberculosis drugs and hepatotoxicity</span>. <i>Respirology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1111/j.1440-1843.2006.00941.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1111%2Fj.1440-1843.2006.00941.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=17052297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD28nitVaiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=699-707&author=W.+W.+Yewauthor=C.+C.+Leung&title=Antituberculosis+drugs+and+hepatotoxicity&doi=10.1111%2Fj.1440-1843.2006.00941.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Antituberculosis drugs and hepatotoxicity</span></div><div class="casAuthors">Yew Wing Wai; Leung Chi Chiu</div><div class="citationInfo"><span class="NLM_cas:title">Respirology (Carlton, Vic.)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">699-707</span>
        ISSN:<span class="NLM_cas:issn">1323-7799</span>.
    </div><div class="casAbstract">Isoniazid, pyrazinamide and rifampicin have hepatotoxic potential, and can lead to such reactions during antituberculosis chemotherapy.  Most of the hepatotoxic reactions are dose-related; some are, however, caused by drug hypersensitivity.  The immunogenetics of antituberculosis drug-induced hepatotoxicity, especially inclusive of acetylaor phenotype polymorphism, have been increasingly unravelled.  Other principal clinical risk factors for hepatotoxicity are old age, malnutrition, alcoholism, HIV infection, as well as chronic hepatitis B and C infections.  Drug-induced hepatic dysfunction usually occurs within the initial few weeks of the intensive phase of antituberculosis chemotherapy.  Vigilant clinical (including patient education on symptoms of hepatitis) and biochemical monitoring are mandatory to improve the outcomes of patients with drug-induced hepatotoxicity during antituberculosis chemotherapy.  Some fluoroquinolones like ofloxacin/levofloxacin may have a role in constituting non-hepatotoxic drug regimens for management of tuberculosis (TB) in the presence of hepatic dysfunction.  Isoniazid administration is currently the standard therapy for latent TB infection.  Rifamycins like rifampicin or rifapentine, alone or in combination with isoniazid, may also be considered as alternatives, pending accumulation of further clinical data.  During treatment of latent TB infection, regular follow up is essential to ensure adherence to therapy and facilitate clinical monitoring for hepatic dysfunction.  Monitoring of liver chemistry is also required for those patients at risk of drug-induced hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUAtmsidhiuZotVjB3IRIyfW6udTcc2eaURidX06zqobntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nitVaiuw%253D%253D&md5=4d6c2d5185364371cc7e5f4dcb46792a</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1111%2Fj.1440-1843.2006.00941.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1440-1843.2006.00941.x%26sid%3Dliteratum%253Aachs%26aulast%3DYew%26aufirst%3DW.%2BW.%26aulast%3DLeung%26aufirst%3DC.%2BC.%26atitle%3DAntituberculosis%2520drugs%2520and%2520hepatotoxicity%26jtitle%3DRespirology%26date%3D2006%26volume%3D11%26spage%3D699%26epage%3D707%26doi%3D10.1111%2Fj.1440-1843.2006.00941.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albanna, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, D.</span></span> <span> </span><span class="NLM_article-title">Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1183/09031936.00180612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1183%2F09031936.00180612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23314904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFCmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2013&pages=721-732&author=A.+S.+Albannaauthor=B.+M.+Smithauthor=D.+Cowanauthor=D.+Menzies&title=Fixed-dose+combination+antituberculosis+therapy%3A+a+systematic+review+and+meta-analysis&doi=10.1183%2F09031936.00180612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis</span></div><div class="casAuthors">Albanna, Amr S.; Smith, Benjamin M.; Cowan, Deanna; Menzies, Dick</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">721-732</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Fixed-dose combination (FDC) formulations are currently recommended for the treatment of active tuberculosis (TB).  We have conducted a systematic review to evaluate the risk of treatment failure or disease relapse, acquired drug resistance, bacterial conversion after 2 mo of treatment, adverse events, adherence and treatment satisfaction assocd. with treatment of active TB using FDC or sep. drug formulations.  We searched four electronic databases for randomized controlled trials and cohort studies.  Results from trials that directly compared FDC to sep. drug formulations were pooled.  Results from other studies were reported sep.  We identified 2450 citations from which 15 controlled trials and four addnl. relevant studies were included.  In the 15 trials there were no differences in acquired drug resistance, bacterial conversion after 2 mo of treatment or adverse drug reactions with FDC or sep. drug formulations.  There was a trend toward higher risk of failure or relapse with FDC (pooled relative risk 1.28 (95% CI 0.99-1.7)).  Based on individual study results, only one of two trials that assessed treatment satisfaction, and none of five that assessed patient adherence, favored FDCs.  Although FDC formulations simplify TB therapy, the current evidence does not indicate that these formulations improve treatment outcomes among patients with active TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhHYCCaUcJyLVg90H21EOLACvtfcHk0lg5e9bQDJ78gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFCmug%253D%253D&md5=aaeedcc2a7ee40f2ce58b3fc97d5b7af</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1183%2F09031936.00180612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00180612%26sid%3Dliteratum%253Aachs%26aulast%3DAlbanna%26aufirst%3DA.%2BS.%26aulast%3DSmith%26aufirst%3DB.%2BM.%26aulast%3DCowan%26aufirst%3DD.%26aulast%3DMenzies%26aufirst%3DD.%26atitle%3DFixed-dose%2520combination%2520antituberculosis%2520therapy%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D42%26spage%3D721%26epage%3D732%26doi%3D10.1183%2F09031936.00180612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span> <i>Global Tuberculosis Report 2017</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2017</span>; <a href="https://www.who.int/news/item/30-10-2017-who-report-signals-urgent-need-for-greater-political-commitment-to-end-tuberculosis" class="extLink">https://www.who.int/news/item/30-10-2017-who-report-signals-urgent-need-for-greater-political-commitment-to-end-tuberculosis</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Tuberculosis+Report+2017%3B+World+Health%0AOrganization%3A+Geneva%2C+2017%3B+https%3A%2F%2Fwww.who.int%2Fnews%2Fitem%2F30-10-2017-who-report-signals-urgent-need-for-greater-political-commitment-to-end-tuberculosis+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlobal%2520Tuberculosis%2520Report%25202017%26pub%3DWorld%2520Health%250AOrganization%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikaido, H.</span></span> <span> </span><span class="NLM_article-title">Efflux-mediated drug resistance in bacteria: an update</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1623</span>, <span class="refDoi"> DOI: 10.2165/11317030-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.2165%2F11317030-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19678712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ehtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1555-1623&author=X.-Z.+Liauthor=H.+Nikaido&title=Efflux-mediated+drug+resistance+in+bacteria%3A+an+update&doi=10.2165%2F11317030-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Efflux-mediated drug resistance in bacteria: an update</span></div><div class="casAuthors">Li, Xian-Zhi; Nikaido, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1555-1623</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Drug efflux pumps play a key role in drug resistance and also serve other functions in bacteria.  There has been a growing list of multidrug and drug-specific efflux pumps characterized from bacteria of human, animal, plant and environmental origins.  These pumps are mostly encoded on the chromosome, although they can also be plasmid-encoded.  A previous article in this journal provided a comprehensive review regarding efflux-mediated drug resistance in bacteria.  In the past 5 years, significant progress has been achieved in further understanding of drug resistance-related efflux transporters and this review focuses on the latest studies in this field since 2003.  This has been demonstrated in multiple aspects that include but are not limited to: further mol. and biochem. characterization of the known drug efflux pumps and identification of novel drug efflux pumps; structural elucidation of the transport mechanisms of drug transporters; regulatory mechanisms of drug efflux pumps; detg. the role of the drug efflux pumps in other functions such as stress responses, virulence and cell communication; and development of efflux pump inhibitors.  Overall, the multifaceted implications of drug efflux transporters warrant novel strategies to combat multidrug resistance in bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaeSr_oxaFNbVg90H21EOLACvtfcHk0ljCjTT1ycmrYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ehtLfI&md5=fd988e21cc23eb9c8347f13a2a431a53</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.2165%2F11317030-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11317030-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.-Z.%26aulast%3DNikaido%26aufirst%3DH.%26atitle%3DEfflux-mediated%2520drug%2520resistance%2520in%2520bacteria%253A%2520an%2520update%26jtitle%3DDrugs%26date%3D2009%26volume%3D69%26spage%3D1555%26epage%3D1623%26doi%3D10.2165%2F11317030-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. J.</span></span> <span> </span><span class="NLM_article-title">Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1016/j.tim.2006.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.tim.2006.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=16759863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsFSlt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=304-312&author=L.+Nguyenauthor=C.+J.+Thompson&title=Foundations+of+antibiotic+resistance+in+bacterial+physiology%3A+the+mycobacterial+paradigm&doi=10.1016%2Fj.tim.2006.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm</span></div><div class="casAuthors">Nguyen, Liem; Thompson, Charles J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">304-312</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The intrinsic resistance of Mycobacterium tuberculosis and related pathogens to most common antibiotics limits chemotherapeutic options to treat tuberculosis and other mycobacterial diseases.  Resistance has traditionally been attributed to the unusual multi-layer cell envelope that functions as an effective barrier to the penetration of antibiotics.  Recent insights into mechanisms that neutralize the toxicity of antibiotics in the cytoplasm have revealed systems that function in synergy with the permeability barrier to provide intrinsic resistance.  Here, the authors highlight the growing pool of information about internal, antibiotic-responsive regulatory proteins and corresponding resistance genes, and present new concepts that rationalize how they might have evolved.  Pharmaceutical inhibition of these intrinsic systems could make many previously available antibiotics active against M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodFnslO_z1UrVg90H21EOLACvtfcHk0ljCjTT1ycmrYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsFSlt7w%253D&md5=6dc68f83a080ee1d52d9ccd0d2923ad2</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2006.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2006.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DThompson%26aufirst%3DC.%2BJ.%26atitle%3DFoundations%2520of%2520antibiotic%2520resistance%2520in%2520bacterial%2520physiology%253A%2520the%2520mycobacterial%2520paradigm%26jtitle%3DTrends%2520Microbiol.%26date%3D2006%26volume%3D14%26spage%3D304%26epage%3D312%26doi%3D10.1016%2Fj.tim.2006.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Rossi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aínsa, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, G.</span></span> <span> </span><span class="NLM_article-title">Role of mycobacterial efflux transporters in drug resistance: an unresolved question</span>. <i>FEMS Microbiology Reviews</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1111/j.1574-6976.2005.00002.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1111%2Fj.1574-6976.2005.00002.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=16438679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFKrsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2006&pages=36-52&author=E.+De+Rossiauthor=J.+A.+A%C3%ADnsaauthor=G.+Riccardi&title=Role+of+mycobacterial+efflux+transporters+in+drug+resistance%3A+an+unresolved+question&doi=10.1111%2Fj.1574-6976.2005.00002.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Role of mycobacterial efflux transporters in drug resistance: an unresolved question</span></div><div class="casAuthors">De Rossi, Edda; Ainsa, Jose A.; Riccardi, Giovanna</div><div class="citationInfo"><span class="NLM_cas:title">FEMS Microbiology Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-52</span>CODEN:
                <span class="NLM_cas:coden">FMREE4</span>;
        ISSN:<span class="NLM_cas:issn">0168-6445</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Two mechanisms are thought to be involved in the natural drug resistance of mycobacteria: the mycobacterial cell wall permeability barrier and active multidrug efflux pumps.  Genes encoding drug efflux transporters have been isolated from several mycobacterial species.  These proteins transport tetracycline, fluoroquinolones, aminoglycosides and other compds.  Recent reports have suggested that efflux pumps may also be involved in transporting isoniazid, one of the main drugs used to treat tuberculosis.  This review highlights recent advances in our understanding of efflux-mediated drug resistance in mycobacteria, including the distribution of efflux systems in these organisms, their substrate profiles and their contribution to drug resistance.  The balance between the drug transport into the cell and drug efflux is not yet clearly understood, and further studies are required in mycobacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpwjdJiKjbO7Vg90H21EOLACvtfcHk0lgKcXgHEVbSxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFKrsbw%253D&md5=41af6cedab317d501c489400a6979920</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1111%2Fj.1574-6976.2005.00002.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1574-6976.2005.00002.x%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BRossi%26aufirst%3DE.%26aulast%3DA%25C3%25ADnsa%26aufirst%3DJ.%2BA.%26aulast%3DRiccardi%26aufirst%3DG.%26atitle%3DRole%2520of%2520mycobacterial%2520efflux%2520transporters%2520in%2520drug%2520resistance%253A%2520an%2520unresolved%2520question%26jtitle%3DFEMS%2520Microbiology%2520Reviews%26date%3D2006%26volume%3D30%26spage%3D36%26epage%3D52%26doi%3D10.1111%2Fj.1574-6976.2005.00002.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yew, W. W.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1276</span>– <span class="NLM_lpage">1289</span>, <span class="refDoi"> DOI: 10.5588/ijtld.15.0389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.5588%2Fijtld.15.0389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26467578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC28zitFWhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=1276-1289&author=Y.+Zhangauthor=W.+W.+Yew&title=Mechanisms+of+drug+resistance+in+Mycobacterium+tuberculosis%3A+update+2015&doi=10.5588%2Fijtld.15.0389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015</span></div><div class="casAuthors">Zhang Y; Yew W-W</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1276-89</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug-resistant tuberculosis (DR-TB), including multi- and extensively drug-resistant TB, is posing a significant challenge to effective treatment and TB control worldwide.  New progress has been made in our understanding of the mechanisms of resistance to anti-tuberculosis drugs.  This review provides an update on the major advances in drug resistance mechanisms since the previous publication in 2009, as well as added information on mechanisms of resistance to new drugs and repurposed agents.  The recent application of whole genome sequencing technologies has provided new insight into the mechanisms and complexity of drug resistance.  However, further research is needed to address the significance of newly discovered gene mutations in causing drug resistance.  Improved knowledge of drug resistance mechanisms will help understand the mechanisms of action of the drugs, devise better molecular diagnostic tests for more effective DR-TB management (and for personalised treatment), and facilitate the development of new drugs to improve the treatment of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSM1i_6Asw352Zyxfu64m4ffW6udTcc2eaUjszkxw81Prntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zitFWhtQ%253D%253D&md5=8373bc72c5223ee9e7753bab3ddfc72e</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.5588%2Fijtld.15.0389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5588%252Fijtld.15.0389%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYew%26aufirst%3DW.%2BW.%26atitle%3DMechanisms%2520of%2520drug%2520resistance%2520in%2520Mycobacterium%2520tuberculosis%253A%2520update%25202015%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D2015%26volume%3D19%26spage%3D1276%26epage%3D1289%26doi%3D10.5588%2Fijtld.15.0389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span> <span> </span><span class="NLM_article-title">Antibiotic resistance mechanisms in M. tuberculosis: an update</span>. <i>Arch. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1585</span>– <span class="NLM_lpage">1604</span>, <span class="refDoi"> DOI: 10.1007/s00204-016-1727-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1007%2Fs00204-016-1727-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27161440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28Xns1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=1585-1604&author=L.+Nguyen&title=Antibiotic+resistance+mechanisms+in+M.+tuberculosis%3A+an+update&doi=10.1007%2Fs00204-016-1727-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Antibiotic resistance mechanisms in M. tuberculosis: an update</span></div><div class="casAuthors">Nguyen, Liem</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1585-1604</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Treatment of tuberculosis (TB) has been a therapeutic challenge because of not only the naturally high resistance level of Mycobacterium tuberculosis to antibiotics but also the newly acquired mutations that confer further resistance.  Currently standardized regimens require patients to daily ingest up to four drugs under direct observation of a healthcare worker for a period of 6-9 mo.  Although they are quite effective in treating drug susceptible TB, these lengthy treatments often lead to patient non-adherence, which catalyzes for the emergence of M. tuberculosis strains that are increasingly resistant to the few available anti-TB drugs.  The rapid evolution of M. tuberculosis, from mono-drug-resistant to multiple drug-resistant, extensively drug-resistant and most recently totally drug-resistant strains, is threatening to make TB once again an untreatable disease if new therapeutic options do not soon become available.  Here, I discuss the mol. mechanisms by which M. tuberculosis confers its profound resistance to antibiotics.  This knowledge may help in developing novel strategies for weakening drug resistance, thus enhancing the potency of available antibiotics against both drug susceptible and resistant M. tuberculosis strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4SQoFNByW5LVg90H21EOLACvtfcHk0lgKcXgHEVbSxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xns1SisLc%253D&md5=06e320bf7fe94fba12a14de2c26e8173</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1007%2Fs00204-016-1727-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-016-1727-6%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DL.%26atitle%3DAntibiotic%2520resistance%2520mechanisms%2520in%2520M.%2520tuberculosis%253A%2520an%2520update%26jtitle%3DArch.%2520Toxicol.%26date%3D2016%26volume%3D90%26spage%3D1585%26epage%3D1604%26doi%3D10.1007%2Fs00204-016-1727-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasipanodya, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumbo, T.</span></span> <span> </span><span class="NLM_article-title">A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">463</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2011.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.coph.2011.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21807559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1eisLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=457-463&author=J.+G.+Pasipanodyaauthor=T.+Gumbo&title=A+new+evolutionary+and+pharmacokinetic-pharmacodynamic+scenario+for+rapid+emergence+of+resistance+to+single+and+multiple+anti-tuberculosis+drugs&doi=10.1016%2Fj.coph.2011.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs</span></div><div class="casAuthors">Pasipanodya, Jotam G.; Gumbo, Tawanda</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">457-463</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The current understanding of the mechanism of anti-tuberculosis drug resistance has been shaped by the history of development of anti-tuberculosis drugs in the past 60 years and was arrived at as part of inductive generalization.  Recently, these std. beliefs have been tested in controlled hollow fiber systems expts.  Drug resistance in Mycobacterium tuberculosis was shown to be related to pharmacokinetic-pharmacodynamic (PK/PD) factors, and factors such as pharmacokinetic variability.  Poor PK/PD exposures owing to our current non-optimized dosing regimens initiate a chain of evolution driven events, starting with induction of multi-drug efflux pumps, followed by the development of chromosomal mutations in time, which together lead to high level resistance multi-drug resistant tuberculosis and extremely drug resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpehp-QwJeOrLVg90H21EOLACvtfcHk0liDGwzPN9fU3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1eisLjP&md5=7b9497f21dfa0a0957eff60d18002cf5</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2011.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2011.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DPasipanodya%26aufirst%3DJ.%2BG.%26aulast%3DGumbo%26aufirst%3DT.%26atitle%3DA%2520new%2520evolutionary%2520and%2520pharmacokinetic-pharmacodynamic%2520scenario%2520for%2520rapid%2520emergence%2520of%2520resistance%2520to%2520single%2520and%2520multiple%2520anti-tuberculosis%2520drugs%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2011%26volume%3D11%26spage%3D457%26epage%3D463%26doi%3D10.1016%2Fj.coph.2011.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchison, D. A.</span></span> <span> </span><span class="NLM_article-title">How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">15</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=9562106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaK1c3itVGktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1998&pages=10-15&author=D.+A.+Mitchison&title=How+drug+resistance+emerges+as+a+result+of+poor+compliance+during+short+course+chemotherapy+for+tuberculosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis</span></div><div class="casAuthors">Mitchison D A</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-5</span>
        ISSN:<span class="NLM_cas:issn">1027-3719</span>.
    </div><div class="casAbstract">OBJECTIVE:  To explore mechanisms by which drug resistance might arise as a result of poor compliance during short course chemotherapy.  DESIGN:  Four theoretical mechanisms are first described.  RESULTS:  Examples of the way the mechanisms probably operate are taken from: 1) a study of once-weekly chemotherapy with streptomycin and isoniazid, and 2) the pattern of drug susceptibility in cultures from patients who relapsed after the end of treatment.  CONCLUSION:  Good compliance is vitally important.  The value of a fourth drug in the initial phase of chemotherapy in preventing resistance is questioned.  An explanation for mono-resistance to rifampicin in patients with the acquired immune deficiency syndrome (AIDS) is suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXWTVX8ij3vVvAgqb2vdc5fW6udTcc2eYOB-vE-HHcwbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3itVGktg%253D%253D&md5=675484192c7ed7e5798c4988f9494e4e</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMitchison%26aufirst%3DD.%2BA.%26atitle%3DHow%2520drug%2520resistance%2520emerges%2520as%2520a%2520result%2520of%2520poor%2520compliance%2520during%2520short%2520course%2520chemotherapy%2520for%2520tuberculosis%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D1998%26volume%3D2%26spage%3D10%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jindani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aber, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchison, D. A.</span></span> <span> </span><span class="NLM_article-title">The early bactericidal activity of drugs in patients with pulmonary tuberculosis</span>. <i>Am. Rev. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">949</span>, <span class="refDoi"> DOI: 10.1164/arrd.1980.121.6.939</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1164%2Farrd.1980.121.6.939" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=6774638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaL3M%252FhvFygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=1980&pages=939-949&author=A.+Jindaniauthor=V.+R.+Aberauthor=E.+A.+Edwardsauthor=D.+A.+Mitchison&title=The+early+bactericidal+activity+of+drugs+in+patients+with+pulmonary+tuberculosis&doi=10.1164%2Farrd.1980.121.6.939"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">The early bactericidal activity of drugs in patients with pulmonary tuberculosis</span></div><div class="casAuthors">Jindani A; Aber V R; Edwards E A; Mitchison D A</div><div class="citationInfo"><span class="NLM_cas:title">The American review of respiratory disease</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">939-49</span>
        ISSN:<span class="NLM_cas:issn">0003-0805</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcStjSO4ST5T0hfKb6ELK8t0fW6udTcc2eYiaXVKjfOaSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3M%252FhvFygtw%253D%253D&md5=78d0d109ec13cbc100ee25ada81ca022</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1164%2Farrd.1980.121.6.939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Farrd.1980.121.6.939%26sid%3Dliteratum%253Aachs%26aulast%3DJindani%26aufirst%3DA.%26aulast%3DAber%26aufirst%3DV.%2BR.%26aulast%3DEdwards%26aufirst%3DE.%2BA.%26aulast%3DMitchison%26aufirst%3DD.%2BA.%26atitle%3DThe%2520early%2520bactericidal%2520activity%2520of%2520drugs%2520in%2520patients%2520with%2520pulmonary%2520tuberculosis%26jtitle%3DAm.%2520Rev.%2520Respir.%2520Dis.%26date%3D1980%26volume%3D121%26spage%3D939%26epage%3D949%26doi%3D10.1164%2Farrd.1980.121.6.939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balganesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinesh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruppath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, U.</span></span> <span> </span><span class="NLM_article-title">Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2643</span>– <span class="NLM_lpage">2651</span>, <span class="refDoi"> DOI: 10.1128/AAC.06003-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.06003-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22314527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=2643-2651&author=M.+Balganeshauthor=N.+Dineshauthor=S.+Sharmaauthor=S.+Kuruppathauthor=A.+V.+Nairauthor=U.+Sharma&title=Efflux+pumps+of+Mycobacterium+tuberculosis+play+a+significant+role+in+antituberculosis+activity+of+potential+drug+candidates&doi=10.1128%2FAAC.06003-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates</span></div><div class="casAuthors">Balganesh, Meenakshi; Dinesh, Neela; Sharma, Sreevalli; Kuruppath, Sanjana; Nair, Anju V.; Sharma, Umender</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2643-2651</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Active efflux of drugs mediated by efflux pumps that confer drug resistance is one of the mechanisms developed by bacteria to counter the adverse effects of antibiotics and chems.  To understand these efflux mechanisms in Mycobacterium tuberculosis, we generated knockout (KO) mutants of four efflux pumps of the pathogen belonging to different classes.  The authors measured the MICs and kill values of two different compd. classes on the wild-type (WT) and the efflux pump (EP) KO mutants in the presence and absence of the efflux inhibitors verapamil and L-phenylalanyl-L-arginyl-β-naphthylamide (PAβN).  Among the pumps studied, the efflux pumps belonging to the ABC (ATP-binding cassette) class, encoded by Rv1218c, and the SMR (small multidrug resistance) class, encoded by Rv3065, appear to play important roles in mediating the efflux of different chem. classes and antibiotics.  Efflux pumps encoded by Rv0849 and Rv1258c also mediate the efflux of these compds., but to a lesser extent.  Increased killing is obsd. in WT M. tuberculosis cells by these compds. in the presence of either verapamil or PAβN.  The efflux pump KO mutants were more susceptible to these compds. in the presence of efflux inhibitors.  We have shown that these four efflux pumps of M. tuberculosis play a vital role in mediating efflux of different chem. scaffolds.  Inhibitors of one or several of these efflux pumps could have a significant impact in the treatment of tuberculosis.  The identification and characterization of Rv0849, a new efflux pump belonging to the MFS (major facilitator superfamily) class, are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZCoB0YRug-7Vg90H21EOLACvtfcHk0lgQiJ72hXAgKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKrsbk%253D&md5=284a84bb5cc3575973cbb3da9cf8a7d6</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1128%2FAAC.06003-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06003-11%26sid%3Dliteratum%253Aachs%26aulast%3DBalganesh%26aufirst%3DM.%26aulast%3DDinesh%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKuruppath%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DA.%2BV.%26aulast%3DSharma%26aufirst%3DU.%26atitle%3DEfflux%2520pumps%2520of%2520Mycobacterium%2520tuberculosis%2520play%2520a%2520significant%2520role%2520in%2520antituberculosis%2520activity%2520of%2520potential%2520drug%2520candidates%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D2643%26epage%3D2651%26doi%3D10.1128%2FAAC.06003-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramón-García, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mick, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dainese, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rossi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manganelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aínsa, J. A.</span></span> <span> </span><span class="NLM_article-title">Functional and genetic characterization of the tap efflux pump in Mycobacterium bovis BCG</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2074</span>– <span class="NLM_lpage">2083</span>, <span class="refDoi"> DOI: 10.1128/AAC.05946-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.05946-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22232275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38XltV2qsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=2074-2083&author=S.+Ram%C3%B3n-Garc%C3%ADaauthor=V.+Mickauthor=E.+Daineseauthor=C.+Mart%C3%ADnauthor=C.+J.+Thompsonauthor=E.+De+Rossiauthor=R.+Manganelliauthor=J.+A.+A%C3%ADnsa&title=Functional+and+genetic+characterization+of+the+tap+efflux+pump+in+Mycobacterium+bovis+BCG&doi=10.1128%2FAAC.05946-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Functional and genetic characterization of the Tap efflux pump in Mycobacterium bovis BCG</span></div><div class="casAuthors">Ramon-Garcia, Santiago; Mick, Virginie; Dainese, Elisa; Martin, Carlos; Thompson, Charles J.; De Rossi, Edda; Manganelli, Riccardo; Ainsa, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2074-2083</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Efflux pumps extrude a wide variety of chem. unrelated compds. conferring multidrug resistance and participating in numerous physiol. processes.  Mycobacterium tuberculosis possesses many efflux pumps, and their roles in drug resistance and physiol. are actively investigated.  The authors found that tap mutant cells showed changes in morphol. and a progressive loss of viability upon subcultivation in liq. medium.  Transcriptome anal. in Mycobacterium bovis BCG revealed that disruption of the Rv1258c gene, encoding the Tap efflux pump, led to an extensive change in gene expression patterns during stationary phase, with no changes during exponential growth.  In stationary phase, Tap inactivation triggered a general stress response and led to a general repression of genes involved in cell wall biosynthesis, in particular the formation of the peptidoglycan; this suggested the accumulation of an unknown Tap substrate that reaches toxic concns. during stationary phase.  The authors also found that both disruption and overexpression of tap altered susceptibility to many clin. approved antibiotics in M. bovis BCG.  Acriflavine and tetracycline accumulation assays and carbonyl cyanide m-chlorophenylhydrazone (CCCP) potentiation expts. demonstrated that this phenotype was due to an active efflux mechanism.  These findings emphasize the important role of the Tap efflux pump in bacterial physiol. and intrinsic drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodh_mhS-rRXrVg90H21EOLACvtfcHk0ljtRBhn_XHfYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltV2qsbw%253D&md5=0eba6afbb2a99674768f66e589e0ed8e</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1128%2FAAC.05946-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.05946-11%26sid%3Dliteratum%253Aachs%26aulast%3DRam%25C3%25B3n-Garc%25C3%25ADa%26aufirst%3DS.%26aulast%3DMick%26aufirst%3DV.%26aulast%3DDainese%26aufirst%3DE.%26aulast%3DMart%25C3%25ADn%26aufirst%3DC.%26aulast%3DThompson%26aufirst%3DC.%2BJ.%26aulast%3DDe%2BRossi%26aufirst%3DE.%26aulast%3DManganelli%26aufirst%3DR.%26aulast%3DA%25C3%25ADnsa%26aufirst%3DJ.%2BA.%26atitle%3DFunctional%2520and%2520genetic%2520characterization%2520of%2520the%2520tap%2520efflux%2520pump%2520in%2520Mycobacterium%2520bovis%2520BCG%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D2074%26epage%3D2083%26doi%3D10.1128%2FAAC.05946-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borovinskaya, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredrick, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cate, J. H. D.</span></span> <span> </span><span class="NLM_article-title">A steric block in translation caused by the antibiotic spectinomycin</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">552</span>, <span class="refDoi"> DOI: 10.1021/cb700100n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb700100n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpvVOhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=545-552&author=M.+A.+Borovinskayaauthor=S.+Shojiauthor=J.+M.+Holtonauthor=K.+Fredrickauthor=J.+H.+D.+Cate&title=A+steric+block+in+translation+caused+by+the+antibiotic+spectinomycin&doi=10.1021%2Fcb700100n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">A steric block in translation caused by the antibiotic spectinomycin</span></div><div class="casAuthors">Borovinskaya, Maria A.; Shoji, Shinichiro; Holton, James M.; Fredrick, Kurt; Cate, Jamie H. D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">545-552</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The widely used antibiotic spectinomycin inhibits bacterial protein synthesis by blocking translocation of mRNA and tRNAs on the ribosome.  Here, we show that in crystals of the Escherichia coli 70S ribosome spectinomycin binding traps a distinct swiveling state of the head domain of the small ribosomal subunit.  Spectinomycin also alters the rate and completeness of reverse translocation in vitro.  These structural and biochem. data indicate that in soln. spectinomycin sterically blocks swiveling of the head domain of the small ribosomal subunit and thereby disrupts the translocation cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHxcqGkUcuJrVg90H21EOLACvtfcHk0ljtRBhn_XHfYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpvVOhtrc%253D&md5=38016b2987936dffc104cf3d46566fb3</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Fcb700100n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb700100n%26sid%3Dliteratum%253Aachs%26aulast%3DBorovinskaya%26aufirst%3DM.%2BA.%26aulast%3DShoji%26aufirst%3DS.%26aulast%3DHolton%26aufirst%3DJ.%2BM.%26aulast%3DFredrick%26aufirst%3DK.%26aulast%3DCate%26aufirst%3DJ.%2BH.%2BD.%26atitle%3DA%2520steric%2520block%2520in%2520translation%2520caused%2520by%2520the%2520antibiotic%2520spectinomycin%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2007%26volume%3D2%26spage%3D545%26epage%3D552%26doi%3D10.1021%2Fcb700100n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Novak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlagel, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeZotte, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeifer, R. T.</span></span> <span> </span><span class="NLM_article-title">The tolerance of high dose intravenous spectinomycin therapy in man</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">442</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1002/j.1552-4604.1974.tb02326.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1002%2Fj.1552-4604.1974.tb02326.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=4277731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaE2cXlsVGqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1974&pages=442-447&author=E.+Novakauthor=C.+A.+Schlagelauthor=L.+A.+LeZotteauthor=R.+T.+Pfeifer&title=The+tolerance+of+high+dose+intravenous+spectinomycin+therapy+in+man&doi=10.1002%2Fj.1552-4604.1974.tb02326.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Tolerance of high dose intravenous spectinomycin therapy in man</span></div><div class="casAuthors">Novak, E.; Schlagel, C. A.; LeZotte, L. A.; Pfeifer, R. T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8-9</span>),
    <span class="NLM_cas:pages">442-7</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    </div><div class="casAbstract">In 25 healthy volunteers given i.v. infusions of spectinomycin-HCl (I) [22193-75-5] (0.5-8 g base equivalence/day for 5 days), no evidence of ototoxicity, hepatotoxicity, nephrotoxicity, or local intolerance developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogpiv1PjVnH7Vg90H21EOLACvtfcHk0lhRYjwkPz_Msg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXlsVGqtrc%253D&md5=3b9612c7ed61e5af0e484c5f53478868</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1002%2Fj.1552-4604.1974.tb02326.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1552-4604.1974.tb02326.x%26sid%3Dliteratum%253Aachs%26aulast%3DNovak%26aufirst%3DE.%26aulast%3DSchlagel%26aufirst%3DC.%2BA.%26aulast%3DLeZotte%26aufirst%3DL.%2BA.%26aulast%3DPfeifer%26aufirst%3DR.%2BT.%26atitle%3DThe%2520tolerance%2520of%2520high%2520dose%2520intravenous%2520spectinomycin%2520therapy%2520in%2520man%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D1974%26volume%3D14%26spage%3D442%26epage%3D447%26doi%3D10.1002%2Fj.1552-4604.1974.tb02326.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurdle, J. G</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruhn, D. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherman, M. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddady, P. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbergenov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhura, D. B</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villellas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. B</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waidyarachchi, S. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, M. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ainsa, J. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Juarrero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibohm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottger, E. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J</span></span> <span> </span><span class="NLM_article-title">Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1038/nm.3458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnm.3458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=24464186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1yru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=152-158&author=R.+E+Leeauthor=J.+G+Hurdleauthor=J.+Liuauthor=D.+F+Bruhnauthor=T.+Mattauthor=M.+S+Schermanauthor=P.+K+Vaddadyauthor=Z.+Zhengauthor=J.+Qiauthor=R.+Akbergenovauthor=S.+Dasauthor=D.+B+Madhuraauthor=C.+Rathiauthor=A.+Trivediauthor=C.+Villellasauthor=R.+B+Leeauthor=+Rakeshauthor=S.+L+Waidyarachchiauthor=D.+Sunauthor=M.+R+McNeilauthor=J.+A+Ainsaauthor=H.+I+Boshoffauthor=M.+Gonzalez-Juarreroauthor=B.+Meibohmauthor=E.+C+Bottgerauthor=A.+J+Lenaerts&title=Spectinamides%3A+a+new+class+of+semisynthetic+antituberculosis+agents+that+overcome+native+drug+efflux&doi=10.1038%2Fnm.3458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux</span></div><div class="casAuthors">Lee, Richard E.; Hurdle, Julian G.; Liu, Jiuyu; Bruhn, David F.; Matt, Tanja; Scherman, Michael S.; Vaddady, Pavan K.; Zheng, Zhong; Qi, Jianjun; Akbergenov, Rashid; Das, Sourav; Madhura, Dora B.; Rathi, Chetan; Trivedi, Ashit; Villellas, Cristina; Lee, Robin B.; Rakesh; Waidyarachchi, Samanthi L.; Sun, Dianqing; McNeil, Michael R.; Ainsa, Jose A.; Boshoff, Helena I.; Gonzalez-Juarrero, Mercedes; Meibohm, Bernd; Boettger, Erik C.; Lenaerts, Anne J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">152-158</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although the classical antibiotic spectinomycin is a potent bacterial protein synthesis inhibitor, poor antimycobacterial activity limits its clin. application for treating tuberculosis.  Using structure-based design, we generated a new semisynthetic series of spectinomycin analogs with selective ribosomal inhibition and excellent narrow-spectrum antitubercular activity.  In multiple murine infection models, these spectinamides were well tolerated, significantly reduced lung mycobacterial burden and increased survival.  In vitro studies demonstrated a lack of cross resistance with existing tuberculosis therapeutics, activity against multidrug-resistant (MDR) and extensively drug-resistant tuberculosis and an excellent pharmacol. profile.  Key to their potent antitubercular properties was their structural modification to evade the Rv1258c efflux pump, which is upregulated in MDR strains and is implicated in macrophage-induced drug tolerance.  The antitubercular efficacy of spectinamides demonstrates that synthetic modifications to classical antibiotics can overcome the challenge of intrinsic efflux pump-mediated resistance and expands opportunities for target-based tuberculosis drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-qFjpPH3d3rVg90H21EOLACvtfcHk0lhRYjwkPz_Msg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1yru7w%253D&md5=7aa68c78473b16a7fd1175b50e9b9bed</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fnm.3458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3458%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DR.%2BE%26aulast%3DHurdle%26aufirst%3DJ.%2BG%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DBruhn%26aufirst%3DD.%2BF%26aulast%3DMatt%26aufirst%3DT.%26aulast%3DScherman%26aufirst%3DM.%2BS%26aulast%3DVaddady%26aufirst%3DP.%2BK%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DAkbergenov%26aufirst%3DR.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DMadhura%26aufirst%3DD.%2BB%26aulast%3DRathi%26aufirst%3DC.%26aulast%3DTrivedi%26aufirst%3DA.%26aulast%3DVillellas%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DR.%2BB%26aulast%3DRakesh%26aulast%3DWaidyarachchi%26aufirst%3DS.%2BL%26aulast%3DSun%26aufirst%3DD.%26aulast%3DMcNeil%26aufirst%3DM.%2BR%26aulast%3DAinsa%26aufirst%3DJ.%2BA%26aulast%3DBoshoff%26aufirst%3DH.%2BI%26aulast%3DGonzalez-Juarrero%26aufirst%3DM.%26aulast%3DMeibohm%26aufirst%3DB.%26aulast%3DBottger%26aufirst%3DE.%2BC%26aulast%3DLenaerts%26aufirst%3DA.%2BJ%26atitle%3DSpectinamides%253A%2520a%2520new%2520class%2520of%2520semisynthetic%2520antituberculosis%2520agents%2520that%2520overcome%2520native%2520drug%2520efflux%26jtitle%3DNat.%2520Med.%26date%3D2014%26volume%3D20%26spage%3D152%26epage%3D158%26doi%3D10.1038%2Fnm.3458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balganesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruppath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, U.</span></span> <span> </span><span class="NLM_article-title">Rv1218c, an ABC transporter of Mycobacterium tuberculosis with implications in drug discovery</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5167</span>– <span class="NLM_lpage">5172</span>, <span class="refDoi"> DOI: 10.1128/AAC.00610-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.00610-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=20921309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2nu7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=5167-5172&author=M.+Balganeshauthor=S.+Kuruppathauthor=N.+Marcelauthor=S.+Sharmaauthor=A.+Nairauthor=U.+Sharma&title=Rv1218c%2C+an+ABC+transporter+of+Mycobacterium+tuberculosis+with+implications+in+drug+discovery&doi=10.1128%2FAAC.00610-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Rv1218c, an ABC transporter of Mycobacterium tuberculosis with implications in drug discovery</span></div><div class="casAuthors">Balganesh, Meenakshi; Kuruppath, Sanjana; Marcel, Nimi; Sharma, Sreevalli; Nair, Anju; Sharma, Umender</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5167-5172</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Efflux systems are important in detg. the efficacy of antibiotics used in the treatment of bacterial infections.  In the last decade much attention has been paid to studying the efflux pumps of mycobacteria.  New classes of compds. are under investigation for development into potential candidate drugs for the treatment of tuberculosis.  Quite often, these have poor bactericidal activities but exhibit excellent target (biochem.) inhibition.  Microarray studies conducted in our labs. for deciphering the mode of action of exptl. drugs revealed the presence of putative ABC transporters.  Among these transporters, Rv1218c was chosen for studying its physiol. relevance in mediating efflux in Mycobacterium tuberculosis.  A ΔRv1218c mutant of M. tuberculosis displayed a 4- to 8-fold increase in the inhibitory and bactericidal potency for different classes of compds.  The MICs and MBCs were reversed to wild-type values when the full-length Rv1218c gene was reintroduced into the ΔRv1218c mutant on a multicopy plasmid.  Most of the compd. classes had significantly better bactericidal activity in the ΔRv1218c mutant than in the wild-type H37Rv, suggesting the involvement of Rv1218c gene product in effluxing these compds. from M. tuberculosis.  The implication of these findings on tuberculosis drug discovery is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp__BkDXaTAAbVg90H21EOLACvtfcHk0ljGJJ_SPgbMRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2nu7fM&md5=3bd448555fc55ba6627e6f1f556c4cba</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1128%2FAAC.00610-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00610-10%26sid%3Dliteratum%253Aachs%26aulast%3DBalganesh%26aufirst%3DM.%26aulast%3DKuruppath%26aufirst%3DS.%26aulast%3DMarcel%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DU.%26atitle%3DRv1218c%252C%2520an%2520ABC%2520transporter%2520of%2520Mycobacterium%2520tuberculosis%2520with%2520implications%2520in%2520drug%2520discovery%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D5167%26epage%3D5172%26doi%3D10.1128%2FAAC.00610-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iseman, M. D.</span></span> <span> </span><span class="NLM_article-title">Treatment of multidrug-resistant tuberculosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>329</i></span>,  <span class="NLM_fpage">784</span>– <span class="NLM_lpage">791</span>, <span class="refDoi"> DOI: 10.1056/NEJM199309093291108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1056%2FNEJM199309093291108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=8350889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaK3szlsVCjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=1993&pages=784-791&author=M.+D.+Iseman&title=Treatment+of+multidrug-resistant+tuberculosis&doi=10.1056%2FNEJM199309093291108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of multidrug-resistant tuberculosis</span></div><div class="casAuthors">Iseman M D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">784-91</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">The frequency of infections with M. tuberculosis resistant to antituberculous drugs is increasing in the United States and globally.  This increase is a major threat to tuberculosis treatment and control programs.  To prevent this situation from worsening, initial treatment programs that entail directly observed therapy supported by effective inducements or enforcements must be used.  Retreatment of patients who have multidrug-resistant tuberculosis should be carried out in programs with comprehensive microbiologic, pharmacokinetic, psychosocial, and nutritional support systems.  Regimens of multiple drugs, which generally are poorly tolerated and more toxic than traditional regimens, must be administered for 18 to 36 months.  Resectional surgery may be required for substantial numbers of patients.  For patients with AIDS who acquire tuberculosis caused by multiply-resistant strains, the disease may prove lethal before effective therapy can be implemented.  Ultraviolet irradiation systems should be used to protect health care personnel and other patients in high-risk environments.  Enhanced federal, state, and local programs for prevention and control are urgently needed, and research to identify new medications and systems for their delivery is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1VHRs8dQZquQ4Pl9hzjQhfW6udTcc2eZ-UpJcL00X5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3szlsVCjtg%253D%253D&md5=494e4c18824f92dac30743ac33cbe9e9</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1056%2FNEJM199309093291108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199309093291108%26sid%3Dliteratum%253Aachs%26aulast%3DIseman%26aufirst%3DM.%2BD.%26atitle%3DTreatment%2520of%2520multidrug-resistant%2520tuberculosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1993%26volume%3D329%26spage%3D784%26epage%3D791%26doi%3D10.1056%2FNEJM199309093291108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span> <i>Companion Handbook to the WHO Guidelines for the Programmatic
Management
of Drug-Resistant Tuberculosis</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2014</span>; <a href="https://www.who.int/tb/publications/pmdt_companionhandbook/en/" class="extLink">https://www.who.int/tb/publications/pmdt_companionhandbook/en/</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Companion+Handbook+to+the+WHO+Guidelines+for+the+Programmatic%0AManagement%0Aof+Drug-Resistant+Tuberculosis%3B+World+Health%0AOrganization%3A+Geneva%2C+2014%3B+https%3A%2F%2Fwww.who.int%2Ftb%2Fpublications%2Fpmdt_companionhandbook%2Fen%2F+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DCompanion%2520Handbook%2520to%2520the%2520WHO%2520Guidelines%2520for%2520the%2520Programmatic%250AManagement%250Aof%2520Drug-Resistant%2520Tuberculosis%26pub%3DWorld%2520Health%250AOrganization%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gey van Pittius, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Helden, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. F.</span></span> <span> </span><span class="NLM_article-title">Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1093/jac/dkt364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fjac%2Fdkt364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=24072169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFOitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=292-302&author=M.+McGrathauthor=N.+C.+Gey+van+Pittiusauthor=P.+D.+van+Heldenauthor=R.+M.+Warrenauthor=D.+F.+Warner&title=Mutation+rate+and+the+emergence+of+drug+resistance+in+Mycobacterium+tuberculosis&doi=10.1093%2Fjac%2Fdkt364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis</span></div><div class="casAuthors">McGrath, M.; Gey van Pittius, N. C.; van Helden, P. D.; Warren, R. M.; Warner, D. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">292-302</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The emergence and spread of multidrug-resistant strains of Mycobacterium tuberculosis remains a major concern of tuberculosis control programs worldwide, as treatment depends on low-efficacy, toxic compds. that often lead to poor outcomes.  M. tuberculosis develops drug resistance exclusively through chromosomal mutations, in particular single-nucleotide polymorphisms.  Moreover, in lab. assays the organism exhibits a spontaneous mutation rate that is at the lower end of the bacterial spectrum.  Despite this, whole-genome sequencing technol. has identified unexpected genetic diversity among clin. M. tuberculosis populations.  This suggests that the mycobacterial mutation rate may be modulated within the host and, in turn, implies a potential role for constitutive and/or transient mutator strains in adaptive evolution.  It also raises the possibility that environmental factors might act as key mutagens during M. tuberculosis infection.  Here we consider the elements that might influence the mycobacterial mutation rate in vivo and evaluate the potential roles of constitutive and transient mutator states in the generation of drug resistance mutations.  In addn., we identify key research questions that will influence future efforts to develop novel therapeutic strategies for a disease that continues to impose a significant global health burden.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV8r6x1IfS9LVg90H21EOLACvtfcHk0ljgKwR0iAYEKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFOitw%253D%253D&md5=bdbbd9257caa6458f919700afb44c111</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkt364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkt364%26sid%3Dliteratum%253Aachs%26aulast%3DMcGrath%26aufirst%3DM.%26aulast%3DGey%2Bvan%2BPittius%26aufirst%3DN.%2BC.%26aulast%3Dvan%2BHelden%26aufirst%3DP.%2BD.%26aulast%3DWarren%26aufirst%3DR.%2BM.%26aulast%3DWarner%26aufirst%3DD.%2BF.%26atitle%3DMutation%2520rate%2520and%2520the%2520emergence%2520of%2520drug%2520resistance%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2014%26volume%3D69%26spage%3D292%26epage%3D302%26doi%3D10.1093%2Fjac%2Fdkt364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burman, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaisson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etkind, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzemska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopewell, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iseman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jasmer, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppaka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reves, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichman, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simone, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernon, A. A.</span></span>; <span class="NLM_contrib-group">American Thoracic Society, C.D.C and Prevention and the Infectious Diseases Society</span> <span> </span><span class="NLM_article-title">American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1164/rccm.167.4.603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1164%2Frccm.167.4.603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=12588714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD3s7gtlyqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2003&pages=603-662&author=H.+M.+Blumbergauthor=W.+J.+Burmanauthor=R.+E.+Chaissonauthor=C.+L.+Daleyauthor=S.+C.+Etkindauthor=L.+N.+Friedmanauthor=P.+Fujiwaraauthor=M.+Grzemskaauthor=P.+C.+Hopewellauthor=M.+D.+Isemanauthor=R.+M.+Jasmerauthor=V.+Koppakaauthor=R.+I.+Menziesauthor=R.+J.+O%E2%80%99Brienauthor=R.+R.+Revesauthor=L.+B.+Reichmanauthor=P.+M.+Simoneauthor=J.+R.+Starkeauthor=A.+A.+Vernonauthor=American+Thoracic+Society%2C+C.D.C+and+Prevention+and+the+Infectious+Diseases+Society&title=American+Thoracic+Society%2FCenters+for+Disease+Control+and+Prevention%2FInfectious+Diseases+Society+of+America%3A+treatment+of+tuberculosis&doi=10.1164%2Frccm.167.4.603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis</span></div><div class="casAuthors">Blumberg Henry M; Burman William J; Chaisson Richard E; Daley Charles L; Etkind Sue C; Friedman Lloyd N; Fujiwara Paula; Grzemska Malgosia; Hopewell Philip C; Iseman Michael D; Jasmer Robert M; Koppaka Venkatarama; Menzies Richard I; O'Brien Richard J; Reves Randall R; Reichman Lee B; Simone Patricia M; Starke Jeffrey R; Vernon Andrew A</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">603-62</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZEQRmpJLo0TMsgLhIoICsfW6udTcc2eYW26gc3-4QKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s7gtlyqtg%253D%253D&md5=f72d60a2f05d5ab216c85c4e466c25b7</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1164%2Frccm.167.4.603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.167.4.603%26sid%3Dliteratum%253Aachs%26aulast%3DBlumberg%26aufirst%3DH.%2BM.%26aulast%3DBurman%26aufirst%3DW.%2BJ.%26aulast%3DChaisson%26aufirst%3DR.%2BE.%26aulast%3DDaley%26aufirst%3DC.%2BL.%26aulast%3DEtkind%26aufirst%3DS.%2BC.%26aulast%3DFriedman%26aufirst%3DL.%2BN.%26aulast%3DFujiwara%26aufirst%3DP.%26aulast%3DGrzemska%26aufirst%3DM.%26aulast%3DHopewell%26aufirst%3DP.%2BC.%26aulast%3DIseman%26aufirst%3DM.%2BD.%26aulast%3DJasmer%26aufirst%3DR.%2BM.%26aulast%3DKoppaka%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DR.%2BI.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DR.%2BJ.%26aulast%3DReves%26aufirst%3DR.%2BR.%26aulast%3DReichman%26aufirst%3DL.%2BB.%26aulast%3DSimone%26aufirst%3DP.%2BM.%26aulast%3DStarke%26aufirst%3DJ.%2BR.%26aulast%3DVernon%26aufirst%3DA.%2BA.%26aulast%3D%26atitle%3DAmerican%2520Thoracic%2520Society%252FCenters%2520for%2520Disease%2520Control%2520and%2520Prevention%252FInfectious%2520Diseases%2520Society%2520of%2520America%253A%2520treatment%2520of%2520tuberculosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2003%26volume%3D167%26spage%3D603%26epage%3D662%26doi%3D10.1164%2Frccm.167.4.603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bark, C. M.</span></span> <span> </span><span class="NLM_article-title">Drug-resistant tuberculosis: challenges and progress</span>. <i>Infect. Dis. Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">522</span>, <span class="refDoi"> DOI: 10.1016/j.idc.2016.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.idc.2016.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27208770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FitFGiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=509-522&author=S.+G.+Kurzauthor=J.+J.+Furinauthor=C.+M.+Bark&title=Drug-resistant+tuberculosis%3A+challenges+and+progress&doi=10.1016%2Fj.idc.2016.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Resistant Tuberculosis: Challenges and Progress</span></div><div class="casAuthors">Kurz Sebastian G; Furin Jennifer J; Bark Charles M</div><div class="citationInfo"><span class="NLM_cas:title">Infectious disease clinics of North America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">509-522</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antimicrobial resistance is a natural evolutionary process, which in the case of Mycobacterium tuberculosis is based on spontaneous chromosomal mutations, meaning that well-designed combination drug regimens provided under supervised therapy will prevent the emergence of drug-resistant strains.  Unfortunately, limited resources, poverty, and neglect have led to the emergence of drug-resistant tuberculosis throughout the world.  The international community has responded with financial and scientific support, leading to new rapid diagnostics, new drugs and regimens in advanced clinical development, and an increasingly sophisticated understanding of resistance mechanisms and their application to all aspects of TB control and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpoedonpWcg8vLc4ARHEmzfW6udTcc2eb5lbdJhxzOA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FitFGiug%253D%253D&md5=7f090ea29415c6bbc45cd9a8e346168a</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.idc.2016.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.idc.2016.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DKurz%26aufirst%3DS.%2BG.%26aulast%3DFurin%26aufirst%3DJ.%2BJ.%26aulast%3DBark%26aufirst%3DC.%2BM.%26atitle%3DDrug-resistant%2520tuberculosis%253A%2520challenges%2520and%2520progress%26jtitle%3DInfect.%2520Dis.%2520Clin.%2520North%2520Am.%26date%3D2016%26volume%3D30%26spage%3D509%26epage%3D522%26doi%3D10.1016%2Fj.idc.2016.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span> <i>Global Tuberculosis
Report 2018</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2018</span>; <a href="https://apps.who.int/iris/handle/10665/274453" class="extLink">https://apps.who.int/iris/handle/10665/274453</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Tuberculosis%0AReport+2018%3B+World+Health%0AOrganization%3A+Geneva%2C+2018%3B+https%3A%2F%2Fapps.who.int%2Firis%2Fhandle%2F10665%2F274453+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlobal%2520Tuberculosis%250AReport%25202018%26pub%3DWorld%2520Health%250AOrganization%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laneelle, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanrelle, G.</span></span> <span> </span><span class="NLM_article-title">Mechanism of isoniazid uptake in Mycobacterium tuberculosis</span>. <i>Microbiology</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">2539</span>– <span class="NLM_lpage">2544</span>, <span class="refDoi"> DOI: 10.1099/00221287-144-9-2539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1099%2F00221287-144-9-2539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=9782502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK1cXmt1yks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=1998&pages=2539-2544&author=F.+Bardouauthor=C.+Raynaudauthor=C.+Ramosauthor=M.+A.+Laneelleauthor=G.+Lanrelle&title=Mechanism+of+isoniazid+uptake+in+Mycobacterium+tuberculosis&doi=10.1099%2F00221287-144-9-2539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of isoniazid uptake in Mycobacterium tuberculosis</span></div><div class="casAuthors">Bardou, Fabienne; Raynaud, Catherine; Ramos, Corinne; Laneelle, Marie Antoinette; Laneelle, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">Microbiology (Reading, United Kingdom)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2539-2544</span>CODEN:
                <span class="NLM_cas:coden">MROBEO</span>;
        ISSN:<span class="NLM_cas:issn">1350-0872</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">Initial transport kinetics of isoniazid (INH) and its uptake at the plateau were studied in Mycobacterium tuberculosis H37Rv under various exptl. conditions.  The initial uptake velocity increased linearly with INH concn. from 2 x 10-6 M to 10-2 M.  It was modified neither by addn. of a protonophore that abolished proline transport, nor following ATP depletion by arsenate, which inhibited glycerol uptake, two transport processes taken as controls for secondary active transport and facilitated diffusion, resp.  Microaerobiosis or low temp. (4°) were without effect on initial uptake.  It is thus likely that INH transport in M. tuberculosis proceeds by a passive diffusion mechanism, and that catalase-peroxidase (KatG) is not involved in the actual transport.  However, conditions inhibiting KatG activity (high INH concn., microaerobiosis, low temp.) decrease cell radioactivity at the uptake plateau.  It is proposed that INH transport occurs by passive diffusion.  KatG is involved only in the intracellular accumulation of oxidized derivs. of INH, esp. of isonicotinic acid, which is trapped inside cells in its ionized form.  This model explains obsd. and previously known characteristics of the accumulation of radioactivity in the presence of [14C]INH for various species and strains of mycobacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJzu8VUyhaq7Vg90H21EOLACvtfcHk0lgZ8C3Vtl8xmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmt1yks7g%253D&md5=ed048b5d4351ce418cb056b11cb88581</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1099%2F00221287-144-9-2539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252F00221287-144-9-2539%26sid%3Dliteratum%253Aachs%26aulast%3DBardou%26aufirst%3DF.%26aulast%3DRaynaud%26aufirst%3DC.%26aulast%3DRamos%26aufirst%3DC.%26aulast%3DLaneelle%26aufirst%3DM.%2BA.%26aulast%3DLanrelle%26aufirst%3DG.%26atitle%3DMechanism%2520of%2520isoniazid%2520uptake%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DMicrobiology%26date%3D1998%26volume%3D144%26spage%3D2539%26epage%3D2544%26doi%3D10.1099%2F00221287-144-9-2539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heym, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span> <span> </span><span class="NLM_article-title">The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">593</span>, <span class="refDoi"> DOI: 10.1038/358591a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2F358591a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1501713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK38Xlt1yjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=1992&pages=591-593&author=Y.+Zhangauthor=B.+Heymauthor=B.+Allenauthor=D.+Youngauthor=S.+Cole&title=The+catalase-peroxidase+gene+and+isoniazid+resistance+of+Mycobacterium+tuberculosis&doi=10.1038%2F358591a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis</span></div><div class="casAuthors">Zhang, Ying; Heym, Beate; Allen, Bryan; Young, Douglas; Cole, Stewart</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">6387</span>),
    <span class="NLM_cas:pages">591-3</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Tuberculosis is responsible for 1 in 4 of all avoidable adult deaths in developing countries.  Increased frequency and accelerated fatality of the disease among individuals infected with human immunodeficiency virus has raised worldwide concern that control programs may be inadequate, and the emergence of multidrug-resistant strains of M. tuberculosis has resulted in several recent fatal outbreaks in the United States.  Isonicotinic acid hydrazid (isoniazid, INH) forms the core of antituberculosis regimens; however, clin. isolates that are resistant to INH show reduced catalase activity and a relative lack of virulence in guinea pigs.  Mycobacterial genetics were used to study the mol. basis of INH resistance.  A single M. tuberculosis gene, katG, encoding both catalase and peroxidase, restored sensitivity to INH in a resistant mutant of Mycobacterium smegmatis, and conferred INH susceptibility in some strains of Escherichia coli.  Deletion of katG from the chromosome was assocd. with INH resistance in 2 patient isolates of M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3JrwTwnhxYLVg90H21EOLACvtfcHk0lgGTMnO2Hu6Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xlt1yjt7s%253D&md5=ba0ceb0723b538e1a10d0aad035c3a24</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1038%2F358591a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F358591a0%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeym%26aufirst%3DB.%26aulast%3DAllen%26aufirst%3DB.%26aulast%3DYoung%26aufirst%3DD.%26aulast%3DCole%26aufirst%3DS.%26atitle%3DThe%2520catalase-peroxidase%2520gene%2520and%2520isoniazid%2520resistance%2520of%2520Mycobacterium%2520tuberculosis%26jtitle%3DNature%26date%3D1992%26volume%3D358%26spage%3D591%26epage%3D593%26doi%3D10.1038%2F358591a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghiladi, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medzihradszky, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz
de Montellano, P. R.</span></span> <span> </span><span class="NLM_article-title">Correlation between isoniazid resistance and superoxide reactivity in mycobacterium tuberculosis KatG</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">13428</span>– <span class="NLM_lpage">13442</span>, <span class="refDoi"> DOI: 10.1021/ja054366t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja054366t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFOrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=13428-13442&author=R.+A.+Ghiladiauthor=K.+F.+Medzihradszkyauthor=F.+M.+Rusnakauthor=P.+R.+Ortiz%0Ade+Montellano&title=Correlation+between+isoniazid+resistance+and+superoxide+reactivity+in+mycobacterium+tuberculosis+KatG&doi=10.1021%2Fja054366t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation between Isoniazid Resistance and Superoxide Reactivity in Mycobacterium tuberculosis KatG</span></div><div class="casAuthors">Ghiladi, Reza A.; Medzihradszky, Katalin F.; Rusnak, Frank M.; Ortiz de Montellano, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">13428-13442</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Isoniazid is an antituberculosis prodrug that requires activation by the catalase-peroxidase (KatG) of Mycobacterium tuberculosis.  The activated species, presumed to be an isonicotinoyl radical, couples to NADH forming an isoniazid-NADH adduct that ultimately confers antitubercular activity.  We have compared the catalytic properties of three KatGs assocd. with isoniazid resistance (resistance mutation KatGs, RMKatGs: R104L, H108Q, S315T) to wild-type enzyme and two addnl. lab mutations (wild-type phenotype KatGs, WTPKatGs: WT KatG, Y229F, R418L).  Neither catalase nor peroxidase activities, nor the presence/absence of the Met-Tyr-Trp cross-link (as probed by LC/MS on tryptic digests of the protein), exhibited any correlation with isoniazid resistance.  The yields of isoniazid-NADH adduct formed were detd. to be 1-5, 4-12, and 20-70-fold greater for the WTPKatGs than the RMKatGs for the compd. I, II, and III pathways, resp., strongly suggesting a role for oxyferrous KatG (supported by superoxide consumption measurements) that correlates with drug resistance.  Stopped-flow UV-visible spectroscopic studies revealed that all KatGs were capable of forming both compd. II and III intermediates.  Rates of compd. II decay were accelerated 4-12-fold in the presence of isoniazid (vs absence) for the WTPKatGs but were unaffected by the drug for the RMKatGs.  A mechanism for isoniazid resistance which accounts for the obsd. reactivity for each of the compd. I, II, and III intermediates is proposed and suggests that the compd. III pathway may be the primary factor in detg. overall isoniazid resistance by specific KatG mutants, with secondary contributions arising from the compd. I and II pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp64U-LLbgb77Vg90H21EOLACvtfcHk0lgGTMnO2Hu6Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFOrtb0%253D&md5=98a8c47d58063c7bd0bd9fd11a3a1229</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Fja054366t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja054366t%26sid%3Dliteratum%253Aachs%26aulast%3DGhiladi%26aufirst%3DR.%2BA.%26aulast%3DMedzihradszky%26aufirst%3DK.%2BF.%26aulast%3DRusnak%26aufirst%3DF.%2BM.%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26atitle%3DCorrelation%2520between%2520isoniazid%2520resistance%2520and%2520superoxide%2520reactivity%2520in%2520mycobacterium%2520tuberculosis%2520KatG%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D13428%26epage%3D13442%26doi%3D10.1021%2Fja054366t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wengenack, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, F.</span></span> <span> </span><span class="NLM_article-title">Evidence for isoniazid-dependent free radical generation catalyzed by Mycobacterium tuberculosis KatG and the isoniazid-resistant mutant KatG(S315T)</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">8990</span>– <span class="NLM_lpage">8996</span>, <span class="refDoi"> DOI: 10.1021/bi002614m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi002614m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3MXksleitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=8990-8996&author=N.+L.+Wengenackauthor=F.+Rusnak&title=Evidence+for+isoniazid-dependent+free+radical+generation+catalyzed+by+Mycobacterium+tuberculosis+KatG+and+the+isoniazid-resistant+mutant+KatG%28S315T%29&doi=10.1021%2Fbi002614m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for Isoniazid-Dependent Free Radical Generation Catalyzed by Mycobacterium tuberculosis KatG and the Isoniazid-Resistant Mutant KatG(S315T)</span></div><div class="casAuthors">Wengenack, Nancy L.; Rusnak, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">8990-8996</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The antitubercular agent isoniazid can be activated by Mycobacterium tuberculosis KatG using either a peroxidase compd. I/II or a superoxide-dependent oxyferrous pathway.  The identity of activated isoniazid is unknown, but it has been suggested that it may be a free radical intermediate.  EPR spin trapping expts. detected isoniazid-derived radicals generated during KatG-mediated oxidn. via the peroxidase compd. I/II pathway.  On the basis of hyperfine splitting patterns and oxygen dependence, these radicals were identified as the acyl, acyl peroxo, and pyridyl radicals of isoniazid.  Isoniazid-resistant KatG(S315T) produced the same radicals found with KatG, while the less potent antitubercular agent nicotinic acid hydrazide produced the corresponding nicotinyl radicals.  The time course of radical prodn. was similar for KatG and KatG(S315T), while a lower steady-state level of radicals was produced from nicotinic acid hydrazide.  These results support an earlier finding that the peroxidase pathway does not correlate with isoniazid resistance conferred by KatG(S315T).  Trace amts. of radicals were detected via the superoxide-dependent pathway.  The low level of isoniazid-derived radicals found in the superoxide-dependent pathway may be due to scavenging by superoxide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCy5-9p6NBH7Vg90H21EOLACvtfcHk0lhmBlxbdHfZyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXksleitrY%253D&md5=cc51e44e36cf21cf8fdfb9640fe3d48c</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fbi002614m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi002614m%26sid%3Dliteratum%253Aachs%26aulast%3DWengenack%26aufirst%3DN.%2BL.%26aulast%3DRusnak%26aufirst%3DF.%26atitle%3DEvidence%2520for%2520isoniazid-dependent%2520free%2520radical%2520generation%2520catalyzed%2520by%2520Mycobacterium%2520tuberculosis%2520KatG%2520and%2520the%2520isoniazid-resistant%2520mutant%2520KatG%2528S315T%2529%26jtitle%3DBiochemistry%26date%3D2001%26volume%3D40%26spage%3D8990%26epage%3D8996%26doi%3D10.1021%2Fbi002614m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Timmins, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Master, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deretic, V.</span></span> <span> </span><span class="NLM_article-title">Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">3006</span>– <span class="NLM_lpage">3009</span>, <span class="refDoi"> DOI: 10.1128/AAC.48.8.3006-3009.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.48.8.3006-3009.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=15273113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlKqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=3006-3009&author=G.+S.+Timminsauthor=S.+Masterauthor=F.+Rusnakauthor=V.+Deretic&title=Nitric+oxide+generated+from+isoniazid+activation+by+KatG%3A+source+of+nitric+oxide+and+activity+against+Mycobacterium+tuberculosis&doi=10.1128%2FAAC.48.8.3006-3009.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide generated from isoniazid activation by KatG: Source of nitric oxide and activity against Mycobacterium tuberculosis</span></div><div class="casAuthors">Timmins, Graham S.; Master, Sharon; Rusnak, Frank; Deretic, Vojo</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3006-3009</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Isonicotinic acid hydrazide (INH) is a frontline antituberculosis agent.  Once taken up by M. tuberculosis, INH requires activation by the catalase-peroxidase KatG, converting INH from its prodrug form into a range of bactericidal reactive species.  Here we used 15N-labeled INH together with ESR spin trapping techniques to demonstrate that NO· is generated from oxidn. at the hydrazide nitrogens during the activation of INH by M. tuberculosis KatG.  We also obsd. that a specific scavenger of NO· provided protection against the antimycobacterial activity of INH in bacterial culture.  No significant increases in mycobacterial protein nitration were detected, suggesting that NO· and not peroxynitrite, a nitrating metabolite of NO·, is involved in antimycobacterial action.  In conclusion, INH-derived NO· has biol. activity, which directly contributes to the antimycobacterial action of INH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmsYpj2VfLW7Vg90H21EOLACvtfcHk0lhmBlxbdHfZyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlKqtrg%253D&md5=332fbcf388c0689487ac2757510d54cd</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1128%2FAAC.48.8.3006-3009.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.48.8.3006-3009.2004%26sid%3Dliteratum%253Aachs%26aulast%3DTimmins%26aufirst%3DG.%2BS.%26aulast%3DMaster%26aufirst%3DS.%26aulast%3DRusnak%26aufirst%3DF.%26aulast%3DDeretic%26aufirst%3DV.%26atitle%3DNitric%2520oxide%2520generated%2520from%2520isoniazid%2520activation%2520by%2520KatG%253A%2520source%2520of%2520nitric%2520oxide%2520and%2520activity%2520against%2520Mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26spage%3D3006%26epage%3D3009%26doi%3D10.1128%2FAAC.48.8.3006-3009.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Timmins, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Master, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deretic, V.</span></span> <span> </span><span class="NLM_article-title">Requirements for nitric oxide generation from isoniazid activation in vitro and inhibition of mycobacterial respiration in vivo</span>. <i>J. Bacteriol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">5427</span>– <span class="NLM_lpage">5431</span>, <span class="refDoi"> DOI: 10.1128/JB.186.16.5427-5431.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FJB.186.16.5427-5431.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=15292144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVKhurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2004&pages=5427-5431&author=G.+S.+Timminsauthor=S.+Masterauthor=F.+Rusnakauthor=V.+Deretic&title=Requirements+for+nitric+oxide+generation+from+isoniazid+activation+in+vitro+and+inhibition+of+mycobacterial+respiration+in+vivo&doi=10.1128%2FJB.186.16.5427-5431.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Requirements for nitric oxide generation from isoniazid activation in vitro and inhibition of mycobacterial respiration in vivo</span></div><div class="casAuthors">Timmins, Graham S.; Master, Sharon; Rusnak, Frank; Deretic, Vojo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bacteriology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5427-5431</span>CODEN:
                <span class="NLM_cas:coden">JOBAAY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9193</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Isoniazid (INH), a front-line antituberculosis agent, is activated by mycobacterial catalase-peroxidase KatG, converting INH into bactericidal reactive species.  Here we investigated the requirements and the pathway of nitric oxide (NO.) generation during oxidative activation of INH by Mycobacterium tuberculosis KatG in vitro.  We also provide in vivo evidence that INH-derived NO. can inhibit key mycobacterial respiratory enzymes, which may contribute to the overall antimycobacterial action of INH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIbpo4JkrED7Vg90H21EOLACvtfcHk0lgQRO4jiNmKAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVKhurc%253D&md5=dec59e2c5d316455e311ac3d05deda2d</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1128%2FJB.186.16.5427-5431.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJB.186.16.5427-5431.2004%26sid%3Dliteratum%253Aachs%26aulast%3DTimmins%26aufirst%3DG.%2BS.%26aulast%3DMaster%26aufirst%3DS.%26aulast%3DRusnak%26aufirst%3DF.%26aulast%3DDeretic%26aufirst%3DV.%26atitle%3DRequirements%2520for%2520nitric%2520oxide%2520generation%2520from%2520isoniazid%2520activation%2520in%2520vitro%2520and%2520inhibition%2520of%2520mycobacterial%2520respiration%2520in%2520vivo%26jtitle%3DJ.%2520Bacteriol.%26date%3D2004%26volume%3D186%26spage%3D5427%26epage%3D5431%26doi%3D10.1128%2FJB.186.16.5427-5431.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchison, D. A.</span></span> <span> </span><span class="NLM_article-title">Basic mechanisms of chemotherapy</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">771</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1378/chest.76.6_Supplement.771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1378%2Fchest.76.6.771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=92392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaL3cXmvFWmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1979&pages=771-781&author=D.+A.+Mitchison&title=Basic+mechanisms+of+chemotherapy&doi=10.1378%2Fchest.76.6_Supplement.771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Basic mechanisms of chemotherapy</span></div><div class="casAuthors">Mitchison, D. A.</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">6, Suppl.</span>),
    <span class="NLM_cas:pages">771-6, 778-81</span>CODEN:
                <span class="NLM_cas:coden">CHETBF</span>;
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    </div><div class="casAbstract">A review with 25 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlpYjWoMW2MrVg90H21EOLACvtfcHk0lgQRO4jiNmKAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXmvFWmsg%253D%253D&md5=96a72c82c5e12e75ecddfc4d428fe784</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1378%2Fchest.76.6.771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.76.6.771%26sid%3Dliteratum%253Aachs%26aulast%3DMitchison%26aufirst%3DD.%2BA.%26atitle%3DBasic%2520mechanisms%2520of%2520chemotherapy%26jtitle%3DChest%26date%3D1979%26volume%3D76%26spage%3D771%26epage%3D781%26doi%3D10.1378%2Fchest.76.6_Supplement.771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, J. S.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of drug resistance in Mycobacterium tuberculosis</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1146/annurev.bi.65.070196.001243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1146%2Fannurev.bi.65.070196.001243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=8811179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK28XktFamtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1996&pages=215-239&author=J.+S.+Blanchard&title=Molecular+mechanisms+of+drug+resistance+in+Mycobacterium+tuberculosis&doi=10.1146%2Fannurev.bi.65.070196.001243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of drug resistance in Mycobacterium tuberculosis</span></div><div class="casAuthors">Blanchard, John S.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">215-239</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review with 127 refs.  In spite of forty years of effective chemotherapy for tuberculosis, the mol. mechanisms of antibacterial compds. in Mycobacterium tuberculosis have only recently been revealed.  Broad spectrum antibacterials, including streptomycin, rifampicin, and fluoroquinolones, have been demonstrated to act on the same targets in M. tuberculosis as they do in Escherichia coli.  Resistance to these agents results from single mutagenic events that lead to amino acid substitutions in their target proteins.  The mechanisms of action of the unique antitubercular drugs, including isoniazid, ethambutol, and pyrazinamide, have also recently been defined.  Resistance to isoniazid can be caused either by mutations in the katG-encoded catalase-peroxidase, the enzyme responsible for drug activation, or by the mol. target, the inhA-encoded long chain enoyl-ACP reductase.  Ethambutol appears to block specifically the biosynthesis of the arabinogalactan component of the mycobacterial cell envelope, and pyrazinamide has no known target.  With the resurgence of tuberculosis and the appearance of strains which are multiply resistant to the above compds., present tuberculosis chemotherapies are threatened.  New approaches to the treatment of multidrug-resistant tuberculosis are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBC4hQKmc42rVg90H21EOLACvtfcHk0lgQRO4jiNmKAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XktFamtLw%253D&md5=8154424e4e4d3c06a4388d561eb9adae</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1146%2Fannurev.bi.65.070196.001243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.bi.65.070196.001243%26sid%3Dliteratum%253Aachs%26aulast%3DBlanchard%26aufirst%3DJ.%2BS.%26atitle%3DMolecular%2520mechanisms%2520of%2520drug%2520resistance%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D1996%26volume%3D65%26spage%3D215%26epage%3D239%26doi%3D10.1146%2Fannurev.bi.65.070196.001243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Telenti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imboden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowrie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colston, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schopfer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodmer, T.</span></span> <span> </span><span class="NLM_article-title">Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1016/0140-6736(93)90417-F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2F0140-6736%2893%2990417-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=8095569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK3sXkvFWjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1993&pages=647-650&author=A.+Telentiauthor=P.+Imbodenauthor=F.+Marchesiauthor=D.+Lowrieauthor=S.+Coleauthor=M.+J.+Colstonauthor=L.+Matterauthor=K.+Schopferauthor=T.+Bodmer&title=Detection+of+rifampicin-resistance+mutations+in+Mycobacterium+tuberculosis&doi=10.1016%2F0140-6736%2893%2990417-F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis</span></div><div class="casAuthors">Telenti, Amalio; Imboden, Paul; Marchesi, Francine; Lowrie, Douglas; Cole, Stewart; Colston, M. Joseph; Matter, Lukas; Schopfer, Kurt; Bodmer, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">8846</span>),
    <span class="NLM_cas:pages">647-50</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">Control of tuberculosis is threatened by widespread emergence of drug resistance in Mycobacterium tuberculosis.  Understanding the mol. basis of resistance might lead to development of novel rapid methods for diagnosing drug resistance.  The authors studied the mol. basis of resistance to rifampicin, a major component of multidrug regimens used for treating tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1fPRoiLSLgrVg90H21EOLACvtfcHk0lhZuTSW1tgR2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXkvFWjsbo%253D&md5=439caf42ddc568b4cba84ded140b9e85</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2F0140-6736%2893%2990417-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0140-6736%252893%252990417-F%26sid%3Dliteratum%253Aachs%26aulast%3DTelenti%26aufirst%3DA.%26aulast%3DImboden%26aufirst%3DP.%26aulast%3DMarchesi%26aufirst%3DF.%26aulast%3DLowrie%26aufirst%3DD.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DColston%26aufirst%3DM.%2BJ.%26aulast%3DMatter%26aufirst%3DL.%26aulast%3DSchopfer%26aufirst%3DK.%26aulast%3DBodmer%26aufirst%3DT.%26atitle%3DDetection%2520of%2520rifampicin-resistance%2520mutations%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DLancet%26date%3D1993%26volume%3D341%26spage%3D647%26epage%3D650%26doi%3D10.1016%2F0140-6736%2893%2990417-F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morlock, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plikaytis, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. T.</span></span> <span> </span><span class="NLM_article-title">Characterization of spontaneous, In vitro-selected, rifampin-resistant mutants of Mycobacterium tuberculosis strain H37Rv</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">3298</span>– <span class="NLM_lpage">3301</span>, <span class="refDoi"> DOI: 10.1128/AAC.44.12.3298-3301.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.44.12.3298-3301.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=11083630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhs1Kitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2000&pages=3298-3301&author=G.+P.+Morlockauthor=B.+B.+Plikaytisauthor=J.+T.+Crawford&title=Characterization+of+spontaneous%2C+In+vitro-selected%2C+rifampin-resistant+mutants+of+Mycobacterium+tuberculosis+strain+H37Rv&doi=10.1128%2FAAC.44.12.3298-3301.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of spontaneous, in vitro-selected, rifampin-resistant mutants of Mycobacterium tuberculosis strain H37Rv</span></div><div class="casAuthors">Morlock, Glenn P.; Plikaytis, Bonnie B.; Crawford, Jack T.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3298-3301</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Resistance to rifampin in Mycobacterium tuberculosis results from mutations in the gene coding for the beta subunit of RNA polymerase (rpoB).  At least 95% of rifampin-resistant isolates have mutations in rpoB, and the mutations are clustered in a small region.  About 40 distinct point mutations and in-frame insertions and deletions in rpoB have been identified, but point mutations in two codons, those coding for Ser531 and His526, are seen in about 70% of rifampin-resistant clin. isolates, with Ser531-to-Leu (TCG-to-TGG) mutations being by far the most common.  To explore this phenomenon, we isolated independent, spontaneous, rifampin-resistant mutant versions of well-characterized M. tuberculosis lab. strain H37Rv by plating 100 sep. cultures, derived from a single low-d. inoculum, onto rifampin-contg. medium.  Rifampin-resistant mutants were obtained from 64 of these cultures.  Although we anticipated that the various point mutations would occur with approx. equal frequencies, sequencing the rpoB gene from one colony per plate revealed that 39 (60.9%) were Ser531 to Leu.  We conclude that, for unknown reasons, the assocd. rpoB mutation occurs at a substantially higher rate than other rpoB mutations.  This higher mutation rate may contribute to the high percentage of this mutation seen in clin. isolates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQltNg8NAsAbVg90H21EOLACvtfcHk0lhZuTSW1tgR2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhs1Kitrg%253D&md5=b94769bfc5e5bdc6c4fc9b281ff331ab</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1128%2FAAC.44.12.3298-3301.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.44.12.3298-3301.2000%26sid%3Dliteratum%253Aachs%26aulast%3DMorlock%26aufirst%3DG.%2BP.%26aulast%3DPlikaytis%26aufirst%3DB.%2BB.%26aulast%3DCrawford%26aufirst%3DJ.%2BT.%26atitle%3DCharacterization%2520of%2520spontaneous%252C%2520In%2520vitro-selected%252C%2520rifampin-resistant%2520mutants%2520of%2520Mycobacterium%2520tuberculosis%2520strain%2520H37Rv%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2000%26volume%3D44%26spage%3D3298%26epage%3D3301%26doi%3D10.1128%2FAAC.44.12.3298-3301.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traore, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fissette, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devleeschouwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portaels, F.</span></span> <span> </span><span class="NLM_article-title">Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">484</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10815743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD3c3ntlWltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2000&pages=481-484&author=H.+Traoreauthor=K.+Fissetteauthor=I.+Bastianauthor=M.+Devleeschouwerauthor=F.+Portaels&title=Detection+of+rifampicin+resistance+in+Mycobacterium+tuberculosis+isolates+from+diverse+countries+by+a+commercial+line+probe+assay+as+an+initial+indicator+of+multidrug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance</span></div><div class="casAuthors">Traore H; Fissette K; Bastian I; Devleeschouwer M; Portaels F</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">481-4</span>
        ISSN:<span class="NLM_cas:issn">1027-3719</span>.
    </div><div class="casAbstract">The line probe assay (LiPA), a rapid molecular method for detecting rifampicin resistance (RMPr) in Mycobacterium tuberculosis, correctly identified all 145 rifampicin-sensitive (RMPs) and 262 (98.5%) of 266 RMPr strains among 411 isolates collected from diverse countries.  If used as a marker of multidrug-resistant tuberculosis (MDR-TB), detection of RMPr by LiPA would have detected 236 of the 240 MDR strains in this study but would have wrongly suggested the presence of MDR in 26 RMP-monoresistant isolates (sensitivity 98.3%, specificity 84.8%).  Hence, the reliability of using LiPA (or any other rapid RMPr-detection method) as a surrogate marker of MDR-TB largely depends on the prevalence of RMP-monoresistance in the study population.  This approach must therefore be validated in each local situation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqwkvb7Zse19LIORRPd5lbfW6udTcc2eayjuR61b7Nnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3ntlWltw%253D%253D&md5=1aa87338f33231f8ff9724571865942c</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTraore%26aufirst%3DH.%26aulast%3DFissette%26aufirst%3DK.%26aulast%3DBastian%26aufirst%3DI.%26aulast%3DDevleeschouwer%26aufirst%3DM.%26aulast%3DPortaels%26aufirst%3DF.%26atitle%3DDetection%2520of%2520rifampicin%2520resistance%2520in%2520Mycobacterium%2520tuberculosis%2520isolates%2520from%2520diverse%2520countries%2520by%2520a%2520commercial%2520line%2520probe%2520assay%2520as%2520an%2520initial%2520indicator%2520of%2520multidrug%2520resistance%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D2000%26volume%3D4%26spage%3D481%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heifets, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindholm-Levy, P.</span></span> <span> </span><span class="NLM_article-title">Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations</span>. <i>Am. Rev. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">1223</span>– <span class="NLM_lpage">1225</span>, <span class="refDoi"> DOI: 10.1164/ajrccm/145.5.1223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1164%2Fajrccm%2F145.5.1223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1586071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK38XksVCnsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=1992&pages=1223-1225&author=L.+Heifetsauthor=P.+Lindholm-Levy&title=Pyrazinamide+sterilizing+activity+in+vitro+against+semidormant+Mycobacterium+tuberculosis+bacterial+populations&doi=10.1164%2Fajrccm%2F145.5.1223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations</span></div><div class="casAuthors">Heifets, Leonid; Lindholm-Levy, Pamela</div><div class="citationInfo"><span class="NLM_cas:title">American Review of Respiratory Disease</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1223-5</span>CODEN:
                <span class="NLM_cas:coden">ARDSBL</span>;
        ISSN:<span class="NLM_cas:issn">0003-0805</span>.
    </div><div class="casAbstract">Previously, it was reported that pyrazinamide has very poor bactericidal activity against M. tuberculosis growing in broth at pH 5.6.  In the present study, cultivation at pH 4.8 to 5.0 in 7H12 broth prevented an increase in the no. of viable bacteria, but the cultures remained metabolically active.  The presence of 50 μg/mL pyrazinamide in semidormant cultures led to a sharp decline in the no. of viable bacteria by more than 1000-fold.  This unfavorable environment probably made the bacilli esp. vulnerable to pyrazinamide, whose mode of action remains unclear.  To distinguish this effect of pyrazinamide on the semidormant bacteria from its mostly bacteriostatic activity against actively multiplying bacteria, the authors suggest interpreting the in vitro effect as "sterilizing.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPYRYLTaxswbVg90H21EOLACvtfcHk0li0o4CSXux8gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XksVCnsr4%253D&md5=6f05dab7f4d6e18eb275f8bc41f9d01a</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1164%2Fajrccm%2F145.5.1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm%252F145.5.1223%26sid%3Dliteratum%253Aachs%26aulast%3DHeifets%26aufirst%3DL.%26aulast%3DLindholm-Levy%26aufirst%3DP.%26atitle%3DPyrazinamide%2520sterilizing%2520activity%2520in%2520vitro%2520against%2520semidormant%2520Mycobacterium%2520tuberculosis%2520bacterial%2520populations%26jtitle%3DAm.%2520Rev.%2520Respir.%2520Dis.%26date%3D1992%26volume%3D145%26spage%3D1223%26epage%3D1225%26doi%3D10.1164%2Fajrccm%2F145.5.1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchison, D. A.</span></span> <span> </span><span class="NLM_article-title">The action of antituberculosis drugs in short-course chemotherapy</span>. <i>Tubercle</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1016/0041-3879(85)90040-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2F0041-3879%2885%2990040-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=3931319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaL28%252FitVajtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1985&pages=219-225&author=D.+A.+Mitchison&title=The+action+of+antituberculosis+drugs+in+short-course+chemotherapy&doi=10.1016%2F0041-3879%2885%2990040-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">The action of antituberculosis drugs in short-course chemotherapy</span></div><div class="casAuthors">Mitchison D A</div><div class="citationInfo"><span class="NLM_cas:title">Tubercle</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-25</span>
        ISSN:<span class="NLM_cas:issn">0041-3879</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ3wobTUofGToqdXsLcGTEUfW6udTcc2eadQ1fDICBgVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL28%252FitVajtA%253D%253D&md5=a89e41a36c2e2051e5c80f5c3e34c220</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2F0041-3879%2885%2990040-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0041-3879%252885%252990040-6%26sid%3Dliteratum%253Aachs%26aulast%3DMitchison%26aufirst%3DD.%2BA.%26atitle%3DThe%2520action%2520of%2520antituberculosis%2520drugs%2520in%2520short-course%2520chemotherapy%26jtitle%3DTubercle%26date%3D1985%26volume%3D66%26spage%3D219%26epage%3D225%26doi%3D10.1016%2F0041-3879%2885%2990040-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franke, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becerra, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tierney, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonilla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayona, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitnick, C. D.</span></span> <span> </span><span class="NLM_article-title">Counting pyrazinamide in regimens for multidrug-resistant tuberculosis</span>. <i>Ann. Am. Thorac. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">674</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1513/AnnalsATS.201411-538OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1513%2FAnnalsATS.201411-538OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25664920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2MrjvFOmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=674-679&author=M.+F.+Frankeauthor=M.+C.+Becerraauthor=D.+B.+Tierneyauthor=M.+L.+Richauthor=C.+Bonillaauthor=J.+Bayonaauthor=M.+M.+McLaughlinauthor=C.+D.+Mitnick&title=Counting+pyrazinamide+in+regimens+for+multidrug-resistant+tuberculosis&doi=10.1513%2FAnnalsATS.201411-538OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Counting pyrazinamide in regimens for multidrug-resistant tuberculosis</span></div><div class="casAuthors">Franke Molly F; Becerra Mercedes C; Tierney Dylan B; Rich Michael L; Bonilla Cesar; Bayona Jaime; McLaughlin Megan M; Mitnick Carole D</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">674-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  For treatment of multidrug-resistant tuberculosis, World Health Organization (WHO) guidelines recommend four likely effective drugs plus pyrazinamide (PZA), irrespective of the likely effectiveness of PZA in an individual patient.  Whether this regimen should be supplemented in the absence of likely PZA effectiveness is an open question.  OBJECTIVES:  The objectives of this study were to examine (1) whether individuals receiving four likely effective drugs (based on documented susceptibility or no prior exposure) experienced higher mortality during the intensive phase of treatment than those receiving five likely effective drugs and (2) whether the WHO-recommended regimen (four likely effective drugs plus PZA) may be compromised in individuals in whom PZA is not likely effective.  METHODS:  Among 668 patients, we compared the hazard of death across regimen groups characterized by the number of likely effective drugs and whether pyrazinamide was one of the likely effective drugs.  MEASUREMENTS AND MAIN RESULTS:  Relative to five likely effective drugs, regimens of four likely effective drugs and the WHO-recommended regimen used in individuals in whom PZA was not likely effective were associated with higher mortality rates (respectively, adjusted hazard ratio [HR], 2.87; 95% confidence interval [CI], 1.35-6.09 and adjusted HR, 2.76; 95% CI, 0.92-8.27).  The mortality rate for a regimen of five likely effective drugs with likely effective PZA was similar to that for the regimen of five likely effective drugs without PZA (HR, 1.00; 95% CI, 0.12-8.00).  CONCLUSIONS:  Mortality may be reduced by the inclusion of five likely effective drugs, including an injectable, during the intensive phase of treatment.  If PZA is unlikely to be effective in an individual patient, these results suggest adding a different, likely effective drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTayfCBOKpiHcuCWE5mhx1RfW6udTcc2eadQ1fDICBgVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrjvFOmuw%253D%253D&md5=0eb2ce28659210a8ce9e5725f6ed5fa0</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1513%2FAnnalsATS.201411-538OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252FAnnalsATS.201411-538OC%26sid%3Dliteratum%253Aachs%26aulast%3DFranke%26aufirst%3DM.%2BF.%26aulast%3DBecerra%26aufirst%3DM.%2BC.%26aulast%3DTierney%26aufirst%3DD.%2BB.%26aulast%3DRich%26aufirst%3DM.%2BL.%26aulast%3DBonilla%26aufirst%3DC.%26aulast%3DBayona%26aufirst%3DJ.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BM.%26aulast%3DMitnick%26aufirst%3DC.%2BD.%26atitle%3DCounting%2520pyrazinamide%2520in%2520regimens%2520for%2520multidrug-resistant%2520tuberculosis%26jtitle%3DAnn.%2520Am.%2520Thorac.%2520Soc.%26date%3D2015%26volume%3D12%26spage%3D674%26epage%3D679%26doi%3D10.1513%2FAnnalsATS.201411-538OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piubello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harouna, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souleymane, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boukary, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daouda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Deun, A.</span></span> <span> </span><span class="NLM_article-title">High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1188</span>– <span class="NLM_lpage">1194</span>, <span class="refDoi"> DOI: 10.5588/ijtld.13.0075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.5588%2Fijtld.13.0075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25216832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2M7gvFyisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=1188-1194&author=A.+Piubelloauthor=S.+H.+Harounaauthor=M.+B.+Souleymaneauthor=I.+Boukaryauthor=S.+Morouauthor=M.+Daoudaauthor=Y.+Hankiauthor=A.+Van+Deun&title=High+cure+rate+with+standardised+short-course+multidrug-resistant+tuberculosis+treatment+in+Niger%3A+no+relapses&doi=10.5588%2Fijtld.13.0075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses</span></div><div class="casAuthors">Piubello A; Harouna S Hassane; Souleymane M B; Boukary I; Morou S; Daouda M; Hanki Y; Van Deun A</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1188-94</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">SETTING:  Niger National Tuberculosis Programme.  Regions supported by the Damien Foundation.  OBJECTIVE:  To evaluate the effectiveness of a short-course standardised treatment regimen for patients with proven multidrug-resistant tuberculosis (MDR-TB) previously untreated with second-line drugs.  METHODS:  Prospective study including all patients enrolled from 2008 to 2010.  The 12-month standardised regimen comprised high doses of gatifloxacin, clofazimine, ethambutol and pyrazinamide throughout, supplemented by kanamycin, prothionamide and medium-high doses of isoniazid during the intensive phase of a minimum of 4 months.  Patients were monitored using sputum smear and culture at start of treatment and every 2 months.  Cured patients were followed up 6-monthly for 24 months.  RESULTS:  Sixty-five patients with MDR-TB were included and analysed.  One of 58 patients tested for human immunodeficiency virus (1.7%) infection was positive.  Twenty-five patients (39.7%) were severely affected (body mass index  16 kg/m(2)).  Cure was achieved in 58 patients (89.2%, 95%CI 81.7-96.7), 6 died and 1 defaulted.  All 49 patients assessed at the 24-month follow-up after cure remained smear- and culture-negative.  The main adverse events were vomiting (26.2%) and hearing impairment (20%), but no treatment had to be stopped.  CONCLUSION:  Standardised 12-month treatment for MDR-TB was highly effective and well tolerated in patients not previously exposed to second-line drugs in Niger.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKjlxBo8hoAsKL0FlyGHDofW6udTcc2eaGeABZIoCk0rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7gvFyisQ%253D%253D&md5=552c1ca5a3f2a724501ed2f0284f818d</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.5588%2Fijtld.13.0075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5588%252Fijtld.13.0075%26sid%3Dliteratum%253Aachs%26aulast%3DPiubello%26aufirst%3DA.%26aulast%3DHarouna%26aufirst%3DS.%2BH.%26aulast%3DSouleymane%26aufirst%3DM.%2BB.%26aulast%3DBoukary%26aufirst%3DI.%26aulast%3DMorou%26aufirst%3DS.%26aulast%3DDaouda%26aufirst%3DM.%26aulast%3DHanki%26aufirst%3DY.%26aulast%3DVan%2BDeun%26aufirst%3DA.%26atitle%3DHigh%2520cure%2520rate%2520with%2520standardised%2520short-course%2520multidrug-resistant%2520tuberculosis%2520treatment%2520in%2520Niger%253A%2520no%2520relapses%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D2014%26volume%3D18%26spage%3D1188%26epage%3D1194%26doi%3D10.5588%2Fijtld.13.0075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tompsett, R.</span></span> <span> </span><span class="NLM_article-title">Activation of pyrazinamide and nicotinamide in acidic environments in vitro</span>. <i>Am. Rev. Tuberc.</i> <span class="NLM_year" style="font-weight: bold;">1954</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1164/art.1954.70.4.748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1164%2Fart.1954.70.4.748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=13197751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaG2MXjs1Cjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1954&pages=748-754&author=D.+McDermottauthor=R.+Tompsett&title=Activation+of+pyrazinamide+and+nicotinamide+in+acidic+environments+in+vitro&doi=10.1164%2Fart.1954.70.4.748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of pyrazinamide and nicotinamide in acidic environments in vitro</span></div><div class="casAuthors">McDermott, Walsh; Tompsett, Ralph</div><div class="citationInfo"><span class="NLM_cas:title">American Review of Tuberculosis</span>
        (<span class="NLM_cas:date">1954</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">748-54</span>CODEN:
                <span class="NLM_cas:coden">ARTUA4</span>;
        ISSN:<span class="NLM_cas:issn">0096-0381</span>.
    </div><div class="casAbstract">Tubercle bacteria (H 37 Rv) are highly susceptible to pyrazinamide in vitro in a standard drug-susceptibility test modified only by reducing the pH to 5.0 or 5.5.  Nicotinamide is likewise active, though to lesser degree, tested in this way.  Tested within physiologic ranges of pH, the H 37 Rv strain is resistant to both pyrazinamide and nicotinamide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoERW1f_rdO0rVg90H21EOLACvtfcHk0ljPFI-PmJ7Jqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG2MXjs1Cjtw%253D%253D&md5=a0e74ae8616e9493b89c2a6dd841d564</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1164%2Fart.1954.70.4.748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fart.1954.70.4.748%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DD.%26aulast%3DTompsett%26aufirst%3DR.%26atitle%3DActivation%2520of%2520pyrazinamide%2520and%2520nicotinamide%2520in%2520acidic%2520environments%2520in%2520vitro%26jtitle%3DAm.%2520Rev.%2520Tuberc.%26date%3D1954%26volume%3D70%26spage%3D748%26epage%3D754%26doi%3D10.1164%2Fart.1954.70.4.748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scorpio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikaido, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span> <span> </span><span class="NLM_article-title">Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide</span>. <i>J. Bacteriol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">2044</span>– <span class="NLM_lpage">2049</span>, <span class="refDoi"> DOI: 10.1128/JB.181.7.2044-2049.1999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FJB.181.7.2044-2049.1999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10094680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK1MXitFKktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=1999&pages=2044-2049&author=Y.+Zhangauthor=A.+Scorpioauthor=H.+Nikaidoauthor=Z.+Sun&title=Role+of+acid+pH+and+deficient+efflux+of+pyrazinoic+acid+in+unique+susceptibility+of+Mycobacterium+tuberculosis+to+pyrazinamide&doi=10.1128%2FJB.181.7.2044-2049.1999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide</span></div><div class="casAuthors">Zhang, Ying; Scorpio, Angelo; Nikaido, Hiroshi; Sun, Zhonghe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bacteriology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2044-2049</span>CODEN:
                <span class="NLM_cas:coden">JOBAAY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9193</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Pyrazinamide (PZA) is an important antituberculosis drug.  Unlike most antibacterial agents, PZA, despite its remarkable in vivo activity, has no activity against Mycobacterium tuberculosis in vitro except at an acidic pH.  M. tuberculosis is uniquely susceptible to PZA, but other mycobacteria as well as nonmycobacteria are intrinsically resistant.  The role of acidic pH in PZA action and the basis for the unique PZA susceptibility of M. tuberculosis are unknown.  We found that in M. tuberculosis, acidic pH enhanced the intracellular accumulation of pyrazinoic acid (POA), the active deriv. of PZA, after conversion of PZA by pyrazinamidase.  In contrast, at neutral or alk. pH, POA was mainly found outside M. tuberculosis cells.  PZA-resistant M. tuberculosis complex organisms did not convert PZA into POA.  Unlike M. tuberculosis, intrinsically PZA-resistant M. smegmatis converted PZA into POA, but it did not accumulate POA even at an acidic pH, due to a very active POA efflux mechanism.  It is proposed that a deficient POA efflux mechanism underlies the unique susceptibility of M. tuberculosis to PZA and that the natural PZA resistance of M. smegmatis is due to a highly active efflux pump.  These findings may have implications with regard to the design of new antimycobacterial drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp16456bDVUKrVg90H21EOLACvtfcHk0ljPFI-PmJ7Jqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitFKktbc%253D&md5=72539d3a60e67f35f91057ff5f0926ab</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1128%2FJB.181.7.2044-2049.1999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJB.181.7.2044-2049.1999%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DScorpio%26aufirst%3DA.%26aulast%3DNikaido%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DZ.%26atitle%3DRole%2520of%2520acid%2520pH%2520and%2520deficient%2520efflux%2520of%2520pyrazinoic%2520acid%2520in%2520unique%2520susceptibility%2520of%2520Mycobacterium%2520tuberculosis%2520to%2520pyrazinamide%26jtitle%3DJ.%2520Bacteriol.%26date%3D1999%26volume%3D181%26spage%3D2044%26epage%3D2049%26doi%3D10.1128%2FJB.181.7.2044-2049.1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, W.</span></span> <span> </span><span class="NLM_article-title">Pyrazinamide susceptibility and amidase activity of tubercle bacilli</span>. <i>Am. Rev. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1164/arrd.1967.95.3.461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1164%2Farrd.1967.95.3.461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=4225184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaF2sXpt1KitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1967&pages=461-469&author=K.+Konnoauthor=F.+M.+Feldmannauthor=W.+McDermott&title=Pyrazinamide+susceptibility+and+amidase+activity+of+tubercle+bacilli&doi=10.1164%2Farrd.1967.95.3.461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazinamide susceptibility and amidase activity of tubercle bacilli</span></div><div class="casAuthors">Konno, Kiyoshi; Feldmann, Floyd M.; McDermott, Walsh</div><div class="citationInfo"><span class="NLM_cas:title">American Review of Respiratory Disease</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">461-9</span>CODEN:
                <span class="NLM_cas:coden">ARDSBL</span>;
        ISSN:<span class="NLM_cas:issn">0003-0805</span>.
    </div><div class="casAbstract">Irrespective of their susceptibility to pyrazinamide (I), tubercle bacilli of human and bovine origin were inhibited in acidic environments in vitro by pyrazinoic acid, which is released from I by bacilli possessing amidase.  A correlation existed between the pyrazinamidase activity of tubercle bacilli and their susceptibility or resistance to I, thus suggesting that I resistance is a function of reduced amidase activity.  Pyrazinoic acid was not effective in vivo in murine tuberculosis, and urine contg. high concns. of an excreted pyrazinoic acid-like material failed to inhibit Mycobacterium tuberculosis when tested in appropriate circumstances in vitro.  Cross-resistance between I and nicotinamide in M. tuberculosis was observed, and resistance to either was accompanied by a decrease in the activity of both pyrazinamidase and nicotinamidase.  Either enzyme could likewise be suppressed by high concns. of the reaction product of the other, i.e., pyrazinoic acid or nicotinic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrZT5hXFB6n7Vg90H21EOLACvtfcHk0lhTM89uGGe_QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXpt1KitA%253D%253D&md5=9d6121a07e2c776350a243282ed8b604</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1164%2Farrd.1967.95.3.461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Farrd.1967.95.3.461%26sid%3Dliteratum%253Aachs%26aulast%3DKonno%26aufirst%3DK.%26aulast%3DFeldmann%26aufirst%3DF.%2BM.%26aulast%3DMcDermott%26aufirst%3DW.%26atitle%3DPyrazinamide%2520susceptibility%2520and%2520amidase%2520activity%2520of%2520tubercle%2520bacilli%26jtitle%3DAm.%2520Rev.%2520Respir.%2520Dis.%26date%3D1967%26volume%3D95%26spage%3D461%26epage%3D469%26doi%3D10.1164%2Farrd.1967.95.3.461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scorpio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">667</span>, <span class="refDoi"> DOI: 10.1038/nm0696-662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnm0696-662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=8640557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK28XjsVSjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=662-667&author=A.+Scorpioauthor=Y.+Zhang&title=Mutations+in+pncA%2C+a+gene+encoding+pyrazinamidase%2Fnicotinamidase%2C+cause+resistance+to+the+antituberculous+drug+pyrazinamide+in+tubercle+bacillus&doi=10.1038%2Fnm0696-662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus</span></div><div class="casAuthors">Scorpio, Angelo; Zhang, Ying</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-667</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Naturally pyrazinamide (PZA)-resistant Mycobacterium bovis and acquired PZA-resistant M. tuberculosis strains lose pyrazinamidase (PZase).  To investigate the mol. mechanism of PZA resistance, we have cloned the gene (pncA) encoding M. tuberculosis PZase.  Mutations in pncA were identified in both types of PZA-resistant strains, and transformation of these strains with a functional pncA gene restored PZase activity and PZA susceptibility.  These findings, besides providing the basis for understanding how PZA works, should have implications for rapid detection of PZA-resistant clin. isolates of M. tuberculosis and also for rapid differentiation of M. bovis from M. tuberculosis strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVdd4sFkh_b7Vg90H21EOLACvtfcHk0lhTM89uGGe_QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjsVSjtbo%253D&md5=8b494b8294bc17e131105a8736fb5a3e</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1038%2Fnm0696-662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0696-662%26sid%3Dliteratum%253Aachs%26aulast%3DScorpio%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DMutations%2520in%2520pncA%252C%2520a%2520gene%2520encoding%2520pyrazinamidase%252Fnicotinamidase%252C%2520cause%2520resistance%2520to%2520the%2520antituberculous%2520drug%2520pyrazinamide%2520in%2520tubercle%2520bacillus%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26spage%3D662%26epage%3D667%26doi%3D10.1038%2Fnm0696-662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Telenti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philipp, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreevatsan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockbauer, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieles, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musser, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1038/nm0597-567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnm0597-567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=9142129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK2sXivFOltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1997&pages=567-570&author=A.+Telentiauthor=W.+J.+Philippauthor=S.+Sreevatsanauthor=C.+Bernasconiauthor=K.+E.+Stockbauerauthor=B.+Wielesauthor=J.+M.+Musserauthor=W.+R.+Jacobs&title=The+emb+operon%2C+a+gene+cluster+of+Mycobacterium+tuberculosis+involved+in+resistance+to+ethambutol&doi=10.1038%2Fnm0597-567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol</span></div><div class="casAuthors">Telenti, Amalio; Philipp, Wolfgang J.; Sreevatasan, Srinand; Bernasconi, Claudia; Stockbauer, Kathryn E.; Wieles, Brigitte; Musser, James M.; Jacobs, William R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">567-570</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Ethambutol (EMB), a frontline antituberculous drug, targets the mycobacterial cell wall, a unique structure among prokaryotes which consists of an outer layer of mycolic acids covalently bound to peptidoglycan via the arabinogalactan.  EMB inhibits the polymn. of cell wall arabinan, and results in the accumulation of the lipid carrier decaprenol phosphoarabinose, which suggests that the drug interferes with the transfer of arabinose to the cell wall acceptor.  Unfortunately, resistance to EMB has been described in up to 4% of clin. isolates of Mycobacterium tuberculosis and is prevalent among isolates from patients with multidrug-resistant tuberculosis.  We used resistance to EMB as a tool to identify genes participating in the biosynthesis of the mycobacterial cell wall.  This approach led to the identification of the embCAB gene cluster, recently proposed to encode for mycobacterial arabinosyl transferases.  Resistance to EMB results from an accumulation of genetic events detg. overexpression of the Emb protein(s), structural mutation to EmbB, or both.  Further characterization of these proteins might provide information on targets for new chemotherapeutic agents and might help development of diagnostic strategies for the detection of resistant M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgWmL8lc0ZDbVg90H21EOLACvtfcHk0lhpi7FNhIRmAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFOltLk%253D&md5=14021c545ec1fcfb6b06c86aedfa049e</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1038%2Fnm0597-567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0597-567%26sid%3Dliteratum%253Aachs%26aulast%3DTelenti%26aufirst%3DA.%26aulast%3DPhilipp%26aufirst%3DW.%2BJ.%26aulast%3DSreevatsan%26aufirst%3DS.%26aulast%3DBernasconi%26aufirst%3DC.%26aulast%3DStockbauer%26aufirst%3DK.%2BE.%26aulast%3DWieles%26aufirst%3DB.%26aulast%3DMusser%26aufirst%3DJ.%2BM.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26atitle%3DThe%2520emb%2520operon%252C%2520a%2520gene%2520cluster%2520of%2520Mycobacterium%2520tuberculosis%2520involved%2520in%2520resistance%2520to%2520ethambutol%26jtitle%3DNat.%2520Med.%26date%3D1997%26volume%3D3%26spage%3D567%26epage%3D570%26doi%3D10.1038%2Fnm0597-567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurcha, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veerapen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. e.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guddat, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span> <span> </span><span class="NLM_article-title">Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1211</span>– <span class="NLM_lpage">1219</span>, <span class="refDoi"> DOI: 10.1126/science.aba9102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1126%2Fscience.aba9102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=32327601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGitLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2020&pages=1211-1219&author=L.+Zhangauthor=Y.+Zhaoauthor=Y.+Gaoauthor=L.+Wuauthor=R.+Gaoauthor=Q.+Zhangauthor=Y.+Wangauthor=C.+Wuauthor=F.+Wuauthor=S.+S.+Gurchaauthor=N.+Veerapenauthor=S.+M.+Battauthor=W.+Zhaoauthor=L.+Qinauthor=X.+Yangauthor=M.+Wangauthor=Y.+Zhuauthor=B.+Zhangauthor=L.+Biauthor=X.+e.+Zhangauthor=H.+Yangauthor=L.+W.+Guddatauthor=W.+Xuauthor=Q.+Wangauthor=J.+Liauthor=G.+S.+Besraauthor=Z.+Rao&title=Structures+of+cell+wall+arabinosyltransferases+with+the+anti-tuberculosis+drug+ethambutol&doi=10.1126%2Fscience.aba9102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol</span></div><div class="casAuthors">Zhang, Lu; Zhao, Yao; Gao, Yan; Wu, Lijie; Gao, Ruogu; Zhang, Qi; Wang, Yinan; Wu, Chengyao; Wu, Fangyu; Gurcha, Sudagar S.; Veerapen, Natacha; Batt, Sarah M.; Zhao, Wei; Qin, Ling; Yang, Xiuna; Wang, Manfu; Zhu, Yan; Zhang, Bing; Bi, Lijun; Zhang, Xian'en; Yang, Haitao; Guddat, Luke W.; Xu, Wenqing; Wang, Quan; Li, Jun; Besra, Gurdyal S.; Rao, Zihe</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">6496</span>),
    <span class="NLM_cas:pages">1211-1219</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The arabinosyltransferases EmbA, EmbB, and EmbC are involved in Mycobacterium tuberculosis cell wall synthesis and are recognized as targets for the anti-tuberculosis drug ethambutol.  In this study, we detd. cryo-electron microscopy and x-ray crystal structures of mycobacterial EmbA-EmbB and EmbC-EmbC complexes in the presence of their glycosyl donor and acceptor substrates and with ethambutol.  These structures show how the donor and acceptor substrates bind in the active site and how ethambutol inhibits arabinosyltransferases by binding to the same site as both substrates in EmbB and EmbC.  Most drug-resistant mutations are located near the ethambutol binding site.  Collectively, our work provides a structural basis for understanding the biochem. function and inhibition of arabinosyltransferases and the development of new anti-tuberculosis agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5khIQiLZo9bVg90H21EOLACvtfcHk0lhpi7FNhIRmAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGitLbP&md5=c88215a3978210ef889d8042f9729f48</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1126%2Fscience.aba9102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aba9102%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DGurcha%26aufirst%3DS.%2BS.%26aulast%3DVeerapen%26aufirst%3DN.%26aulast%3DBatt%26aufirst%3DS.%2BM.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DBi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%2Be.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DGuddat%26aufirst%3DL.%2BW.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DRao%26aufirst%3DZ.%26atitle%3DStructures%2520of%2520cell%2520wall%2520arabinosyltransferases%2520with%2520the%2520anti-tuberculosis%2520drug%2520ethambutol%26jtitle%3DScience%26date%3D2020%26volume%3D368%26spage%3D1211%26epage%3D1219%26doi%3D10.1126%2Fscience.aba9102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, K. L.</span></span> <span> </span><span class="NLM_article-title">Mutations within embCAB Are Associated with variable level of ethambutol resistance in Mycobacterium tuberculosis isolates from China</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">e01279-17</span>, <span class="refDoi"> DOI: 10.1128/AAC.01279-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.01279-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29084750" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&pages=e01279-17&author=Q.+Sunauthor=T.+Y.+Xiaoauthor=H.+C.+Liuauthor=X.+Q.+Zhaoauthor=Z.+G.+Liuauthor=Y.+N.+Liauthor=H.+Zengauthor=L.+L.+Zhaoauthor=K.+L.+Wan&title=Mutations+within+embCAB+Are+Associated+with+variable+level+of+ethambutol+resistance+in+Mycobacterium+tuberculosis+isolates+from+China&doi=10.1128%2FAAC.01279-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1128%2FAAC.01279-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01279-17%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DXiao%26aufirst%3DT.%2BY.%26aulast%3DLiu%26aufirst%3DH.%2BC.%26aulast%3DZhao%26aufirst%3DX.%2BQ.%26aulast%3DLiu%26aufirst%3DZ.%2BG.%26aulast%3DLi%26aufirst%3DY.%2BN.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DL.%2BL.%26aulast%3DWan%26aufirst%3DK.%2BL.%26atitle%3DMutations%2520within%2520embCAB%2520Are%2520Associated%2520with%2520variable%2520level%2520of%2520ethambutol%2520resistance%2520in%2520Mycobacterium%2520tuberculosis%2520isolates%2520from%2520China%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26spage%3De01279-17%26doi%3D10.1128%2FAAC.01279-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winder, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, D.</span></span> <span> </span><span class="NLM_article-title">Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG</span>. <i>J. Gen. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">1971</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1099/00221287-66-3-379</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1099%2F00221287-66-3-379" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=4999216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaE3MXltVKmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1971&pages=379-380&author=F.+G.+Winderauthor=P.+B.+Collinsauthor=D.+Whelan&title=Effects+of+ethionamide+and+isoxyl+on+mycolic+acid+synthesis+in+Mycobacterium+tuberculosis+BCG&doi=10.1099%2F00221287-66-3-379"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG</span></div><div class="casAuthors">Winder, F. G.; Collins, P. B.; Whelan, Dolores</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Microbiology</span>
        (<span class="NLM_cas:date">1971</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">Pt. 3</span>),
    <span class="NLM_cas:pages">379-80</span>CODEN:
                <span class="NLM_cas:coden">JGMIAN</span>;
        ISSN:<span class="NLM_cas:issn">0022-1287</span>.
    </div><div class="casAbstract">The specific antituberculosis agents isoniazid, ethionamide (α-ethylisonicotinoylthioamide), and Isoxyl (4,4'-diisoamyloxythiocarbanilide) (I) have a marked inhibitory effect on mycolic acid synthesis in Mycobacterium tuberculosis BCG, though in the case of I more widespread inhibitory effects were seen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo_4BqOHGBH7Vg90H21EOLACvtfcHk0li36ubJPe2SBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3MXltVKmtbc%253D&md5=f386944ef50034d8623df8ee65029209</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1099%2F00221287-66-3-379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252F00221287-66-3-379%26sid%3Dliteratum%253Aachs%26aulast%3DWinder%26aufirst%3DF.%2BG.%26aulast%3DCollins%26aufirst%3DP.%2BB.%26aulast%3DWhelan%26aufirst%3DD.%26atitle%3DEffects%2520of%2520ethionamide%2520and%2520isoxyl%2520on%2520mycolic%2520acid%2520synthesis%2520in%2520Mycobacterium%2520tuberculosis%2520BCG%26jtitle%3DJ.%2520Gen.%2520Microbiol.%26date%3D1971%26volume%3D66%26spage%3D379%26epage%3D380%26doi%3D10.1099%2F00221287-66-3-379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubnau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quemard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Um, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lisle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1126/science.8284673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1126%2Fscience.8284673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=8284673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK2cXhsFylt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=227-230&author=A.+Banerjeeauthor=E.+Dubnauauthor=A.+Quemardauthor=V.+Balasubramanianauthor=K.+S.+Umauthor=T.+Wilsonauthor=D.+Collinsauthor=G.+de+Lisleauthor=W.+R.+Jacobs&title=inhA%2C+a+gene+encoding+a+target+for+isoniazid+and+ethionamide+in+Mycobacterium+tuberculosis&doi=10.1126%2Fscience.8284673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis</span></div><div class="casAuthors">Banerjee, Asesh; Dubnau, Eugenie; Quemard, Annaik; Balasubramanian, V.; Um, Kyung Sun; Wilson, Theresa; Collins, Des; de Lisle, Geoffrey; Jacobs, William, R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5144</span>),
    <span class="NLM_cas:pages">227-30</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Isoniazid (isonicotinic acid hydrazide, INH) is one of the most widely used antituberculosis drugs, yet its precise target of action on Mycobacterium tuberculosis is unknown.  A missense mutation within the mycobacterial inhA gene was shown to confer resistance to both INH and ethionamide (ETH) in M. smegmatis and in M. bovis.  The wild-type inhA gene also conferred INH and ETH resistance when transferred on a multicopy plasmid vector to M. smegmatis and M. bovis BCG.  The InhA protein shows a significant sequence conservation with the Escherichia coli enzyme EnvM, and cell-free assays indicate that it may be involved in mycolic acid biosynthesis.  These results suggest that InhA is likely a primary target of action for INH and ETH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUYkDS4hfHFrVg90H21EOLACvtfcHk0ljd2z3fJHc5qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhsFylt7c%253D&md5=12f3eabbca02009180332c1e65db8c15</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1126%2Fscience.8284673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8284673%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DA.%26aulast%3DDubnau%26aufirst%3DE.%26aulast%3DQuemard%26aufirst%3DA.%26aulast%3DBalasubramanian%26aufirst%3DV.%26aulast%3DUm%26aufirst%3DK.%2BS.%26aulast%3DWilson%26aufirst%3DT.%26aulast%3DCollins%26aufirst%3DD.%26aulast%3Dde%2BLisle%26aufirst%3DG.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26atitle%3DinhA%252C%2520a%2520gene%2520encoding%2520a%2520target%2520for%2520isoniazid%2520and%2520ethionamide%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D227%26epage%3D230%26doi%3D10.1126%2Fscience.8284673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilchèze, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazbón, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colangeli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisbrod, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1029</span>, <span class="refDoi"> DOI: 10.1038/nm1466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnm1466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=16906155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD28XptFClur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1027-1029&author=C.+Vilch%C3%A8zeauthor=F.+Wangauthor=M.+Araiauthor=M.+H.+Hazb%C3%B3nauthor=R.+Colangeliauthor=L.+Kremerauthor=T.+R.+Weisbrodauthor=D.+Allandauthor=J.+C.+Sacchettiniauthor=W.+R.+Jacobs&title=Transfer+of+a+point+mutation+in+Mycobacterium+tuberculosis+inhA+resolves+the+target+of+isoniazid&doi=10.1038%2Fnm1466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid</span></div><div class="casAuthors">Vilcheze, Catherine; Wang, Feng; Arai, Masayoshi; Hazbon, Manzour Hernando; Colangeli, Roberto; Kremer, Laurent; Weisbrod, Torin R.; Alland, David; Sacchettini, James C.; Jacobs, William R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1027-1029</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Isoniazid is one of the most effective antituberculosis drugs, yet its precise mechanism of action is still controversial.  Using specialized linkage transduction, a single point mutation allele (S94A) within the putative target gene inhA was transferred in Mycobacterium tuberculosis.  The inhA(S94A) allele was sufficient to confer clin. relevant levels of resistance to isoniazid killing and inhibition of mycolic acid biosynthesis.  This resistance correlated with the decreased binding of the INH-NAD inhibitor to InhA, as shown by enzymic and x-ray crystallog. analyses, and establishes InhA as the primary target of isoniazid action in M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUU2WBcC1SIbVg90H21EOLACvtfcHk0ljd2z3fJHc5qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptFClur4%253D&md5=85ae8a98134d187b7c9f96d392589250</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1038%2Fnm1466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1466%26sid%3Dliteratum%253Aachs%26aulast%3DVilch%25C3%25A8ze%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DArai%26aufirst%3DM.%26aulast%3DHazb%25C3%25B3n%26aufirst%3DM.%2BH.%26aulast%3DColangeli%26aufirst%3DR.%26aulast%3DKremer%26aufirst%3DL.%26aulast%3DWeisbrod%26aufirst%3DT.%2BR.%26aulast%3DAlland%26aufirst%3DD.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26atitle%3DTransfer%2520of%2520a%2520point%2520mutation%2520in%2520Mycobacterium%2520tuberculosis%2520inhA%2520resolves%2520the%2520target%2520of%2520isoniazid%26jtitle%3DNat.%2520Med.%26date%3D2006%26volume%3D12%26spage%3D1027%26epage%3D1029%26doi%3D10.1038%2Fnm1466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baulard, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betts, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engohang-Ndong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAdam, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span> <span> </span><span class="NLM_article-title">Activation of the pro-drug ethionamide is regulated in mycobacteria</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">28326</span>– <span class="NLM_lpage">28331</span>, <span class="refDoi"> DOI: 10.1074/jbc.M003744200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1074%2Fjbc.M003744200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10869356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsVKktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=28326-28331&author=A.+R.+Baulardauthor=J.+C.+Bettsauthor=J.+Engohang-Ndongauthor=S.+Quanauthor=R.+A.+McAdamauthor=P.+J.+Brennanauthor=C.+Lochtauthor=G.+S.+Besra&title=Activation+of+the+pro-drug+ethionamide+is+regulated+in+mycobacteria&doi=10.1074%2Fjbc.M003744200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the pro-drug ethionamide is regulated in mycobacteria</span></div><div class="casAuthors">Baulard, Alain R.; Betts, Joanna C.; Engohang-Ndong, Jean; Quan, Selwyn; McAdam, Ruth A.; Brennan, Patrick J.; Locht, Camille; Besra, Gurdyal S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">28326-28331</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The anti-tuberculosis drug ethionamide (ETH), which is a structural analog of isoniazid (INH), is known to strongly inhibit mycolic acid synthesis in Mycobacterium tuberculosis.  Although several targets have been identified for INH, only speculative information is available concerning ETH.  Mutations within the promoter and the coding region of enoyl-acyl carrier protein reductase (InhA) were found to confer resistance to both drugs, thus leading to the impression that INH and ETH may share a common mode of action.  However, a notable distinction between the two drugs lies in the lack of cross-resistance in clin. isolates.  This may be attributed in part to the fact that the pro-drug INH must be activated via KatG, and no activation step for ETH has yet been described.  Here, the authors report the identification of an activator for ETH.  The ETH activator (Rv3854c), which was termed EthA, was found to be homologous to various monooxygenases, and it induced ETH sensitivity when overexpressed in mycobacteria.  The neighboring open reading frame (Rv3855), which was homologous to transcriptional repressors of the tetR family, led to ETH resistance when overexpressed.  In addn., chromosomal inactivation of this gene by transposition led to ETH hypersensitivity.  These data strongly suggest that Rv3855, which was termed EthR, regulates the prodn. of EthA, which subsequently activates the pro-drug ETH.  This study opens up new avenues of research relating to ETH activation in mycobacteria, possibly leading to an improved efficacy of ETH and to the generation of new anti-mycobacterial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0zG8FfdNt87Vg90H21EOLACvtfcHk0lj2_lL0jRKwEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsVKktb4%253D&md5=63e05197e94511fc2d6e3062aa22e555</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M003744200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M003744200%26sid%3Dliteratum%253Aachs%26aulast%3DBaulard%26aufirst%3DA.%2BR.%26aulast%3DBetts%26aufirst%3DJ.%2BC.%26aulast%3DEngohang-Ndong%26aufirst%3DJ.%26aulast%3DQuan%26aufirst%3DS.%26aulast%3DMcAdam%26aufirst%3DR.%2BA.%26aulast%3DBrennan%26aufirst%3DP.%2BJ.%26aulast%3DLocht%26aufirst%3DC.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26atitle%3DActivation%2520of%2520the%2520pro-drug%2520ethionamide%2520is%2520regulated%2520in%2520mycobacteria%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D28326%26epage%3D28331%26doi%3D10.1074%2Fjbc.M003744200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vannelli, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dykman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz de
Montellano, P. R.</span></span> <span> </span><span class="NLM_article-title">The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">12824</span>– <span class="NLM_lpage">12829</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110751200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1074%2Fjbc.M110751200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=11823459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD38XivFSjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=12824-12829&author=T.+A.+Vannelliauthor=A.+Dykmanauthor=P.+R.+Ortiz+de%0AMontellano&title=The+antituberculosis+drug+ethionamide+is+activated+by+a+flavoprotein+monooxygenase&doi=10.1074%2Fjbc.M110751200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase</span></div><div class="casAuthors">Vannelli, Tommaso A.; Dykman, Alina; Ortiz De Montellano, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">12824-12829</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Ethionamide (ETA), a prodrug that must undergo metabolic activation to exert its cytotoxic effects, is a second line drug against tuberculosis, a disease that infects more than a third of the world's population.  It has been proposed, on the basis of genetic expts., that ETA is activated in Mycobacterium tuberculosis by the protein encoded by the gene Rv3854c.  We report here the expression, purifn., and characterization of the protein encoded by this gene.  Our results establish that the enzyme (EtaA) is an FAD-contg. enzyme that oxidizes ETA to the corresponding S-oxide.  The S-oxide, which has a similar biol. activity as ETA, is further oxidized by EtaA to 2-ethyl-4-amidopyridine, presumably via the unstable doubly oxidized sulfinic acid intermediate.  This flavoenzyme also oxidizes thiacetazone, thiobenzamide, and isothionicotinamide and thus is probably responsible, as suggested by the observation of crossover resistance, for the oxidative activation of other thioamide antitubercular drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-O-_9yb5f3bVg90H21EOLACvtfcHk0lj1GLT4FIuWrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivFSjs7s%253D&md5=6e32c0c9ec979adb9a1f488ecb3fbd73</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110751200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110751200%26sid%3Dliteratum%253Aachs%26aulast%3DVannelli%26aufirst%3DT.%2BA.%26aulast%3DDykman%26aufirst%3DA.%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26atitle%3DThe%2520antituberculosis%2520drug%2520ethionamide%2520is%2520activated%2520by%2520a%2520flavoprotein%2520monooxygenase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D12824%26epage%3D12829%26doi%3D10.1074%2Fjbc.M110751200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fraaije, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamerbeek, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidekamp, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, D. B.</span></span> <span> </span><span class="NLM_article-title">The prodrug activator EtaA from Mycobacterium tuberculosis is a Baeyer-Villiger monooxygenase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">3354</span>– <span class="NLM_lpage">3360</span>, <span class="refDoi"> DOI: 10.1074/jbc.M307770200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1074%2Fjbc.M307770200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=14610090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlCgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=3354-3360&author=M.+W.+Fraaijeauthor=N.+M.+Kamerbeekauthor=A.+J.+Heidekampauthor=R.+Fortinauthor=D.+B.+Janssen&title=The+prodrug+activator+EtaA+from+Mycobacterium+tuberculosis+is+a+Baeyer-Villiger+monooxygenase&doi=10.1074%2Fjbc.M307770200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The Prodrug Activator EtaA from Mycobacterium tuberculosis Is a Baeyer-Villiger Monooxygenase</span></div><div class="casAuthors">Fraaije, Marco W.; Kamerbeek, Nanne M.; Heidekamp, Annelies J.; Fortin, Riccardo; Janssen, Dick B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3354-3360</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">EtaA is a newly identified FAD-contg. monooxygenase that is responsible for activation of several thioamide prodrugs in Mycobacterium tuberculosis.  It was found that purified EtaA displays a remarkably low activity with the antitubercular prodrug ethionamide.  As suggested by the presence of a Baeyer-Villiger monooxygenase sequence motif in the EtaA sequence, we have been able to identify a large no. of novel EtaA substrates.  It was discovered that the enzyme converts a wide range of ketones to the corresponding esters or lactones via a Baeyer-Villiger reaction, indicating that EtaA represents a Baeyer-Villiger monooxygenase.  With the exception of arom. ketones (phenylacetone and benzylacetone), long-chain ketones (e.g. 2-hexanone and 2-dodecanone) also are converted.  EtaA is also able to catalyze enantioselective sulfoxidn. of methyl-p-tolylsulfide.  Conversion of all of the identified substrates is relatively slow with typical kcat values of around 0.02 s-1.  The best substrate identified so far is phenylacetone (Km = 61 μM, kcat = 0.017 s-1).  Redox monitoring of the flavin cofactor during turnover of phenylacetone indicates that a step in the reductive half-reaction limits the rate of catalysis.  Intriguingly, EtaA activity could be increased by one order of magnitude by adding bovine serum albumin (BSA).  This reactivity and substrate acceptance-profiling study provides valuable information concerning this newly identified prodrug activator from M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHSYBRoyV0LLVg90H21EOLACvtfcHk0lj1GLT4FIuWrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlCgtA%253D%253D&md5=86a43dff921bc702035ce3e21ef8640b</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M307770200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M307770200%26sid%3Dliteratum%253Aachs%26aulast%3DFraaije%26aufirst%3DM.%2BW.%26aulast%3DKamerbeek%26aufirst%3DN.%2BM.%26aulast%3DHeidekamp%26aufirst%3DA.%2BJ.%26aulast%3DFortin%26aufirst%3DR.%26aulast%3DJanssen%26aufirst%3DD.%2BB.%26atitle%3DThe%2520prodrug%2520activator%2520EtaA%2520from%2520Mycobacterium%2520tuberculosis%2520is%2520a%2520Baeyer-Villiger%2520monooxygenase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D3354%26epage%3D3360%26doi%3D10.1074%2Fjbc.M307770200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulten, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dover, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span> <span> </span><span class="NLM_article-title">Mechanism of thioamide drug action against tuberculosis and leprosy</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>204</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1084/jem.20062100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1084%2Fjem.20062100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=17227913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGjtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2007&pages=73-78&author=F.+Wangauthor=R.+Langleyauthor=G.+Gultenauthor=L.+G.+Doverauthor=G.+S.+Besraauthor=W.+R.+Jacobsauthor=J.+C.+Sacchettini&title=Mechanism+of+thioamide+drug+action+against+tuberculosis+and+leprosy&doi=10.1084%2Fjem.20062100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of thioamide drug action against tuberculosis and leprosy</span></div><div class="casAuthors">Wang, Feng; Langley, Robert; Gulten, Gulcin; Dover, Lynn G.; Besra, Gurdyal S.; Jacobs, William R., Jr.; Sacchettini, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-78</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Thioamide drugs, ethionamide (ETH) and prothionamide (PTH), are clin. effective in the treatment of Mycobacterium tuberculosis, M. leprae, and M. avium complex infections.  Although generally considered second-line drugs for tuberculosis, their use has increased considerably as the no. of multidrug-resistant and extensively drug-resistant tuberculosis cases continues to rise.  Despite the widespread use of thioamide drugs to treat tuberculosis and leprosy, their precise mechanisms of action remain unknown.  Using a cell-based activation method, there is now definitive evidence that both thioamides form covalent adducts with NAD and that these adducts are tight-binding inhibitors of M. tuberculosis and M. leprae InhA.  The crystal structures of the inhibited M. leprae and M. tuberculosis InhA complexes provide the mol. details of target-drug interactions.  The purified ETH-NAD and PTH-NAD adducts both showed nanomolar Kis against M. tuberculosis and M. leprae InhA.  Knowledge of the precise structures and mechanisms of action of these drugs provides insights into designing new drugs that can overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhbBkdGr5bkbVg90H21EOLACvtfcHk0lhZmoRYPJERaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGjtr8%253D&md5=5486bc51cc5c4ea2ebdf6939984d1b70</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1084%2Fjem.20062100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20062100%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLangley%26aufirst%3DR.%26aulast%3DGulten%26aufirst%3DG.%26aulast%3DDover%26aufirst%3DL.%2BG.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26atitle%3DMechanism%2520of%2520thioamide%2520drug%2520action%2520against%2520tuberculosis%2520and%2520leprosy%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2007%26volume%3D204%26spage%3D73%26epage%3D78%26doi%3D10.1084%2Fjem.20062100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frénois, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engohang-Ndong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulard, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeret, V.</span></span> <span> </span><span class="NLM_article-title">Structure of EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">307</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2004.09.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.molcel.2004.09.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=15494316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWit7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2004&pages=301-307&author=F.+Fr%C3%A9noisauthor=J.+Engohang-Ndongauthor=C.+Lochtauthor=A.+R.+Baulardauthor=V.+Villeret&title=Structure+of+EthR+in+a+ligand+bound+conformation+reveals+therapeutic+perspectives+against+tuberculosis&doi=10.1016%2Fj.molcel.2004.09.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis</span></div><div class="casAuthors">Frenois, Frederic; Engohang-Ndong, Jean; Locht, Camille; Baulard, Alain R.; Villeret, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">301-307</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis EthR is a repressor of ethA, a gene encoding a monooxygenase required for the activation of the prodrug ethionamide.  Here the authors describe the x-ray crystal structure of EthR, a homodimer with an entirely helical structure showing similarities to TetR family members.  Each monomer contained a fortuitous ligand identified as hexadecyl octanoate.  The crystal structure of EthR purified in M. smegmatis revealed the presence of a comparable ligand.  The binding of hexadecyl octanoate to EthR induces a conformational state incompatible with repressor function, which should lead to ethA derepression and consequently to an increased sensitivity to ethionamide and other thioamides.  A related, more hydrophilic ketone was found to exhibit synergistic antimycobacterial effects when tested together with ethionamide, indicating that this strategy may help reduce the dosage of potent antibacterial compds. that otherwise are too toxic to be used as first-line drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGEtaas9rcXbVg90H21EOLACvtfcHk0lhZmoRYPJERaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWit7rO&md5=45b96e9298438bf8a7be8d63bd2a943e</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.09.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.09.020%26sid%3Dliteratum%253Aachs%26aulast%3DFr%25C3%25A9nois%26aufirst%3DF.%26aulast%3DEngohang-Ndong%26aufirst%3DJ.%26aulast%3DLocht%26aufirst%3DC.%26aulast%3DBaulard%26aufirst%3DA.%2BR.%26aulast%3DVilleret%26aufirst%3DV.%26atitle%3DStructure%2520of%2520EthR%2520in%2520a%2520ligand%2520bound%2520conformation%2520reveals%2520therapeutic%2520perspectives%2520against%2520tuberculosis%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D16%26spage%3D301%26epage%3D307%26doi%3D10.1016%2Fj.molcel.2004.09.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willand, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirié, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carette, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desroses, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willery, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathys, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Déprez-Poulain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcroix, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frénois, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aumercier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeret, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Déprez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulard, A. R.</span></span> <span> </span><span class="NLM_article-title">Synthetic EthR inhibitors boost antituberculous activity of ethionamide</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1038/nm.1950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnm.1950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19412174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltlSrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=537-544&author=N.+Willandauthor=B.+Diri%C3%A9author=X.+Caretteauthor=P.+Bifaniauthor=A.+Singhalauthor=M.+Desrosesauthor=F.+Lerouxauthor=E.+Willeryauthor=V.+Mathysauthor=R.+D%C3%A9prez-Poulainauthor=G.+Delcroixauthor=F.+Fr%C3%A9noisauthor=M.+Aumercierauthor=C.+Lochtauthor=V.+Villeretauthor=B.+D%C3%A9prezauthor=A.+R.+Baulard&title=Synthetic+EthR+inhibitors+boost+antituberculous+activity+of+ethionamide&doi=10.1038%2Fnm.1950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic EthR inhibitors boost antituberculous activity of ethionamide</span></div><div class="casAuthors">Willand, Nicolas; Dirie, Bertrand; Carette, Xavier; Bifani, Pablo; Singhal, Amit; Desroses, Matthieu; Leroux, Florence; Willery, Eve; Mathys, Vanessa; Deprez-Poulain, Rebecca; Delcroix, Guy; Frenois, Frederic; Aumercier, Marc; Locht, Camille; Villeret, Vincent; Deprez, Benoit; Baulard, Alain R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">537-544</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The side effects assocd. with tuberculosis therapy bring with them the risk of noncompliance and subsequent drug resistance.  Increasing the therapeutic index of antituberculosis drugs should thus improve treatment effectiveness.  Several antituberculosis compds. require in situ metabolic activation to become inhibitory.  Various thiocarbamide-contg. drugs, including ethionamide, are activated by the mycobacterial monooxygenase EthA, the prodn. of which is controlled by the transcriptional repressor EthR.  Here we identify drug-like inhibitors of EthR that boost the bioactivation of ethionamide.  Compds. designed and screened for their capacity to inhibit EthR-DNA interaction were co-crystd. with EthR.  We exploited the three-dimensional structures of the complexes for the synthesis of improved analogs that boosted the ethionamide potency in culture more than tenfold.  In Mycobacterium tuberculosis-infected mice, one of these analogs, BDM31343, enabled a substantially reduced dose of ethionamide to lessen the mycobacterial load as efficiently as the conventional higher-dose treatment.  This provides proof of concept that inhibiting EthR improves the therapeutic index of thiocarbamide derivs., which should prompt reconsideration of their use as first-line drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgknfO8azsTrVg90H21EOLACvtfcHk0lhZmoRYPJERaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltlSrsLk%253D&md5=a119c8e00d9cd41bfa34c2e056e4a1ad</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1038%2Fnm.1950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.1950%26sid%3Dliteratum%253Aachs%26aulast%3DWilland%26aufirst%3DN.%26aulast%3DDiri%25C3%25A9%26aufirst%3DB.%26aulast%3DCarette%26aufirst%3DX.%26aulast%3DBifani%26aufirst%3DP.%26aulast%3DSinghal%26aufirst%3DA.%26aulast%3DDesroses%26aufirst%3DM.%26aulast%3DLeroux%26aufirst%3DF.%26aulast%3DWillery%26aufirst%3DE.%26aulast%3DMathys%26aufirst%3DV.%26aulast%3DD%25C3%25A9prez-Poulain%26aufirst%3DR.%26aulast%3DDelcroix%26aufirst%3DG.%26aulast%3DFr%25C3%25A9nois%26aufirst%3DF.%26aulast%3DAumercier%26aufirst%3DM.%26aulast%3DLocht%26aufirst%3DC.%26aulast%3DVilleret%26aufirst%3DV.%26aulast%3DD%25C3%25A9prez%26aufirst%3DB.%26aulast%3DBaulard%26aufirst%3DA.%2BR.%26atitle%3DSynthetic%2520EthR%2520inhibitors%2520boost%2520antituberculous%2520activity%2520of%2520ethionamide%26jtitle%3DNat.%2520Med.%26date%3D2009%26volume%3D15%26spage%3D537%26epage%3D544%26doi%3D10.1038%2Fnm.1950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blondiaux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moune, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desroses, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frita, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flipo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathys, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soetaert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delorme, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaout, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trebosc, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wintjens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlkönig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coscolla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagneux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitzinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Déprez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willand, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulard, A. R.</span></span> <span> </span><span class="NLM_article-title">Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1206</span>– <span class="NLM_lpage">1211</span>, <span class="refDoi"> DOI: 10.1126/science.aag1006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1126%2Fscience.aag1006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28302858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFOmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2017&pages=1206-1211&author=N.+Blondiauxauthor=M.+Mouneauthor=M.+Desrosesauthor=R.+Fritaauthor=M.+Flipoauthor=V.+Mathysauthor=K.+Soetaertauthor=M.+Kiassauthor=V.+Delormeauthor=K.+Djaoutauthor=V.+Treboscauthor=C.+Kemmerauthor=R.+Wintjensauthor=A.+Wohlk%C3%B6nigauthor=R.+Antoineauthor=L.+Huotauthor=D.+Hotauthor=M.+Coscollaauthor=J.+Feldmannauthor=S.+Gagneuxauthor=C.+Lochtauthor=P.+Brodinauthor=M.+Gitzingerauthor=B.+D%C3%A9prezauthor=N.+Willandauthor=A.+R.+Baulard&title=Reversion+of+antibiotic+resistance+in+Mycobacterium+tuberculosis+by+spiroisoxazoline+SMARt-420&doi=10.1126%2Fscience.aag1006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420</span></div><div class="casAuthors">Blondiaux, Nicolas; Moune, Martin; Desroses, Matthieu; Frita, Rosangela; Flipo, Marion; Mathys, Vanessa; Soetaert, Karine; Kiass, Mehdi; Delorme, Vincent; Djaout, Kamel; Trebosc, Vincent; Kemmer, Christian; Wintjens, Rene; Wohlkoenig, Alexandre; Antoine, Rudy; Huot, Ludovic; Hot, David; Coscolla, Mireia; Feldmann, Julia; Gagneux, Sebastien; Locht, Camille; Brodin, Priscille; Gitzinger, Marc; Deprez, Benoit; Willand, Nicolas; Baulard, Alain R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">6330</span>),
    <span class="NLM_cas:pages">1206-1211</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Antibiotic resistance is one of the biggest threats to human health globally.  Alarmingly, multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis have now spread worldwide.  Some key antituberculosis antibiotics are prodrugs, for which resistance mechanisms are mainly driven by mutations in the bacterial enzymic pathway required for their bioactivation.  We have developed drug-like mols. that activate a cryptic alternative bioactivation pathway of ethionamide in M. tuberculosis, circumventing the classic activation pathway in which resistance mutations have now been obsd.  The first-of-its-kind mol., named SMARt-420 (Small Mol. Aborting Resistance), not only fully reverses ethionamide-acquired resistance and clears ethionamide-resistant infection in mice, it also increases the basal sensitivity of bacteria to ethionamide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKt256e9hpk7Vg90H21EOLACvtfcHk0lgr-pOStR9q4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFOmsb0%253D&md5=7eb7abaead0794592bc48d6e5e25fc3d</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1126%2Fscience.aag1006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aag1006%26sid%3Dliteratum%253Aachs%26aulast%3DBlondiaux%26aufirst%3DN.%26aulast%3DMoune%26aufirst%3DM.%26aulast%3DDesroses%26aufirst%3DM.%26aulast%3DFrita%26aufirst%3DR.%26aulast%3DFlipo%26aufirst%3DM.%26aulast%3DMathys%26aufirst%3DV.%26aulast%3DSoetaert%26aufirst%3DK.%26aulast%3DKiass%26aufirst%3DM.%26aulast%3DDelorme%26aufirst%3DV.%26aulast%3DDjaout%26aufirst%3DK.%26aulast%3DTrebosc%26aufirst%3DV.%26aulast%3DKemmer%26aufirst%3DC.%26aulast%3DWintjens%26aufirst%3DR.%26aulast%3DWohlk%25C3%25B6nig%26aufirst%3DA.%26aulast%3DAntoine%26aufirst%3DR.%26aulast%3DHuot%26aufirst%3DL.%26aulast%3DHot%26aufirst%3DD.%26aulast%3DCoscolla%26aufirst%3DM.%26aulast%3DFeldmann%26aufirst%3DJ.%26aulast%3DGagneux%26aufirst%3DS.%26aulast%3DLocht%26aufirst%3DC.%26aulast%3DBrodin%26aufirst%3DP.%26aulast%3DGitzinger%26aufirst%3DM.%26aulast%3DD%25C3%25A9prez%26aufirst%3DB.%26aulast%3DWilland%26aufirst%3DN.%26aulast%3DBaulard%26aufirst%3DA.%2BR.%26atitle%3DReversion%2520of%2520antibiotic%2520resistance%2520in%2520Mycobacterium%2520tuberculosis%2520by%2520spiroisoxazoline%2520SMARt-420%26jtitle%3DScience%26date%3D2017%26volume%3D355%26spage%3D1206%26epage%3D1211%26doi%3D10.1126%2Fscience.aag1006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frita, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Probst, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sournia-Saquet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Déprez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulard, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willand, N.</span></span> <span> </span><span class="NLM_article-title">Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.09.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.ejmech.2018.09.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30268015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVejsrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2018&pages=35-46&author=M.+Prieriauthor=R.+Fritaauthor=N.+Probstauthor=A.+Sournia-Saquetauthor=M.+Bourotteauthor=B.+D%C3%A9prezauthor=A.+R.+Baulardauthor=N.+Willand&title=Efficient+analoging+around+ethionamide+to+explore+thioamides+bioactivation+pathways+triggered+by+boosters+in+Mycobacterium+tuberculosis&doi=10.1016%2Fj.ejmech.2018.09.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis</span></div><div class="casAuthors">Prieri, Marion; Frita, Rosangela; Probst, Nicolas; Sournia-Saquet, Alix; Bourotte, Marilyne; Deprez, Benoit; Baulard, Alain R.; Willand, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-46</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Ethionamide is a key antibiotic prodrug of the second-line chemotherapy regimen to treat tuberculosis.  It targets the biosynthesis of mycolic acids thanks to a mycobacterial bioactivation carried out by the Baeyer-Villiger monooxygenase EthA, under the control of a transcriptional repressor called EthR.  Recently, the drug-like mol. SMARt-420, which triggers a new transcriptional regulator called EthR2, allowed the derepression a cryptic alternative bioactivation pathway of ethionamide.  In order to study the bioactivation of a collection of thioisonicotinamides through the two bioactivation pathways, we developed a new two-step chem. pathway that led to the efficient synthesis of eighteen ethionamide analogs.  Measurements of the antimycobacterial activity of these derivs., used alone and in combination with boosters BDM41906 or SMARt-420, suggest that the two different bioactivation pathways proceed via the same mechanism, which implies the formation of similar metabolites.  In addn., an electrochem. study of the aliph. thioisonicotinamide analogs was undertaken to see whether their oxidn. potential correlates with their antitubercular activity measured in the presence or in the absence of the two boosters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCNYtCoqieFLVg90H21EOLACvtfcHk0lgr-pOStR9q4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVejsrrF&md5=de4e0bc54021b3221472fc96db8ccc26</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.09.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.09.038%26sid%3Dliteratum%253Aachs%26aulast%3DPrieri%26aufirst%3DM.%26aulast%3DFrita%26aufirst%3DR.%26aulast%3DProbst%26aufirst%3DN.%26aulast%3DSournia-Saquet%26aufirst%3DA.%26aulast%3DBourotte%26aufirst%3DM.%26aulast%3DD%25C3%25A9prez%26aufirst%3DB.%26aulast%3DBaulard%26aufirst%3DA.%2BR.%26aulast%3DWilland%26aufirst%3DN.%26atitle%3DEfficient%2520analoging%2520around%2520ethionamide%2520to%2520explore%2520thioamides%2520bioactivation%2520pathways%2520triggered%2520by%2520boosters%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D159%26spage%3D35%26epage%3D46%26doi%3D10.1016%2Fj.ejmech.2018.09.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowd, C. S.</span></span> <span> </span><span class="NLM_article-title">Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3239</span>– <span class="NLM_lpage">3262</span>, <span class="refDoi"> DOI: 10.2174/1381612043383214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.2174%2F1381612043383214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=15544513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFart7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=3239-3262&author=C.+E.+Barryauthor=H.+I.+Boshoffauthor=C.+S.+Dowd&title=Prospects+for+clinical+introduction+of+nitroimidazole+antibiotics+for+the+treatment+of+tuberculosis&doi=10.2174%2F1381612043383214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis</span></div><div class="casAuthors">Barry, Clifton E., III; Boshoff, Helena I. M.; Dowd, Cynthia S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3239-3262</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Nitroarom. antibiotics have a long and controversial history in human and veterinary medicine.  This controversy lies behind the presumption of many pharmaceutical companies that nitroarom. compds. should be filtered from the list of drug-like compds. but stands at odds with the remarkably safe clin. record of use of such compds.  In this review, the authors will describe the whole-cell structure-activity relationships that have been reported for antimycobacterial nitroimidazoles as well as the available in vivo data supporting efficacy with a particular emphasis on nitroimidazo[2,1-b]oxazines such as PA-824.  The authors will also explore the unique potential of such compds. to shorten the course of tuberculosis therapy by exerting a bactericidal effect on non-replicating bacilli.  The authors will consider the mode of action of such compds. in sensitive organisms and discuss the mechanisms by which resistance may emerge.  Finally, the authors will review the pharmacokinetics, toxicol., and lab. and animal studies linking nitroimidazoles with carcinogenicity and mutagenicity and assess the prospects for the clin. introduction of nitroimidazoles for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH8MsPQNEOOLVg90H21EOLACvtfcHk0ljN2_kLoJmZyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFart7w%253D&md5=38a152ebbd73d1adbd21cadb493393cc</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.2174%2F1381612043383214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612043383214%26sid%3Dliteratum%253Aachs%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DDowd%26aufirst%3DC.%2BS.%26atitle%3DProspects%2520for%2520clinical%2520introduction%2520of%2520nitroimidazole%2520antibiotics%2520for%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2004%26volume%3D10%26spage%3D3239%26epage%3D3262%26doi%3D10.2174%2F1381612043383214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skripconoka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danilovits, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pehme, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skenders, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirule, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leimane, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurve, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiter, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manissero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span> <span> </span><span class="NLM_article-title">Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1183/09031936.00125812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1183%2F09031936.00125812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23018916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252Fgsl2ltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=1393-400&author=V.+Skripconokaauthor=M.+Danilovitsauthor=L.+Pehmeauthor=T.+Tomsonauthor=G.+Skendersauthor=T.+Kummikauthor=A.+Ciruleauthor=V.+Leimaneauthor=A.+Kurveauthor=K.+Levinaauthor=L.+J.+Geiterauthor=D.+Manisseroauthor=C.+D.+Wells&title=Delamanid+improves+outcomes+and+reduces+mortality+in+multidrug-resistant+tuberculosis&doi=10.1183%2F09031936.00125812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis</span></div><div class="casAuthors">Skripconoka Vija; Danilovits Manfred; Pehme Lea; Tomson Tarmo; Skenders Girts; Kummik Tiina; Cirule Andra; Leimane Vaira; Kurve Anu; Levina Klavdia; Geiter Lawrence J; Manissero Davide; Wells Charles D</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1393-400</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are associated with worse treatment outcomes for patients, including higher mortality, than for drug-sensitive tuberculosis.  Delamanid (OPC-67683) is a novel anti-TB medication with demonstrated activity against multidrug-resistant disease.  Patients who participated in the previously reported randomised, placebo-controlled trial of delamanid and the subsequent open-label extension trial were eligible to participate in a 24-month observational study designed to capture treatment outcomes.  Treatment outcomes, as assessed by clinicians and defined by the World Health Organization, were categorised as favourable and unfavourable.  Delamanid treatment groups were combined for analysis, based on their duration of treatment.  In total, for 421 (87.5%) out of 481 patients from the original randomised controlled trial, consent was granted for follow-up assessments.  Favourable outcomes were observed in 143 (74.5%) out of 192 patients who received delamanid for ≥6 months, compared to 126 (55%) out of 229 patients who received delamanid for ≤2 months.  Mortality was reduced to 1.0% among those receiving long-term delamanid versus short-term/no delamanid (8.3%; p<0.001).  Treatment benefit was also seen among patients with extensively drug-resistant TB.  This analysis suggests that treatment with delamanid for 6 months in combination with an optimised background regimen can improve outcomes and reduce mortality among patients with both multidrug-resistant and extensively drug-resistant TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2JcitGJjjkMNIRw0GKUoEfW6udTcc2eZwsPuzjOL_MLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252Fgsl2ltw%253D%253D&md5=63c616aef7dfd5858d274fe1a74ab290</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1183%2F09031936.00125812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00125812%26sid%3Dliteratum%253Aachs%26aulast%3DSkripconoka%26aufirst%3DV.%26aulast%3DDanilovits%26aufirst%3DM.%26aulast%3DPehme%26aufirst%3DL.%26aulast%3DTomson%26aufirst%3DT.%26aulast%3DSkenders%26aufirst%3DG.%26aulast%3DKummik%26aufirst%3DT.%26aulast%3DCirule%26aufirst%3DA.%26aulast%3DLeimane%26aufirst%3DV.%26aulast%3DKurve%26aufirst%3DA.%26aulast%3DLevina%26aufirst%3DK.%26aulast%3DGeiter%26aufirst%3DL.%2BJ.%26aulast%3DManissero%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DC.%2BD.%26atitle%3DDelamanid%2520improves%2520outcomes%2520and%2520reduces%2520mortality%2520in%2520multidrug-resistant%2520tuberculosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D41%26spage%3D1393%26epage%3D400%26doi%3D10.1183%2F09031936.00125812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conradie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngubane, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crook, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendel, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egizi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Treatment of highly drug-resistant pulmonary tuberculosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">893</span>– <span class="NLM_lpage">902</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1901814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1056%2FNEJMoa1901814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=32130813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVKrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=893-902&author=F.+Conradieauthor=A.+H.+Diaconauthor=N.+Ngubaneauthor=P.+Howellauthor=D.+Everittauthor=A.+M.+Crookauthor=C.+M.+Mendelauthor=E.+Egiziauthor=J.+Moreiraauthor=J.+Timm&title=Treatment+of+highly+drug-resistant+pulmonary+tuberculosis&doi=10.1056%2FNEJMoa1901814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of highly drug-resistant pulmonary tuberculosis</span></div><div class="casAuthors">Conradie, Francesca; Diacon, Andreas H.; Ngubane, Nosipho; Howell, Pauline; Everitt, Daniel; Crook, Angela M.; Mendel, Carl M.; Egizi, Erica; Moreira, Joanna; Timm, Juliano; McHugh, Timothy D.; Wills, Genevieve H.; Bateson, Anna; Hunt, Robert; Van Niekerk, Christo; Li, Mengchun; Olugbosi, Morounfolu; Spigelman, Melvin</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">893-902</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes. methods In an open-label, single-group study in which follow-up is ongoing at three South African sites, we investigated treatment with three oral drugs - bedaquiline, pretomanid, and linezolid - that have bactericidal activity against tuberculosis and to which there is little preexisting resistance.  We evaluated the safety and efficacy of the drug combination for 26 wk in patients with extensively drug-resistant tuberculosis and patients with multidrug-resistant tuberculosis that was not responsive to treatment or for which a second-line regimen had been discontinued because of side effects.  The primary end point was the incidence of an unfavorable outcome, defined as treatment failure (bacteriol. or clin.) or relapse during follow-up, which continued until 6 mo after the end of treatment.  Patients were classified as having a favorable outcome at 6 mo if they had resoln. of clin. disease, a neg. culture status, and had not already been classified as having had an unfavorable outcome.  Other efficacy end points and safety were also evaluated. results A total of 109 patients were enrolled in the study and were included in the evaluation of efficacy and safety end points.  At 6 mo after the end of treatment in the intention-to-treat anal., 11 patients (10%) had an unfavorable outcome and 98 patients (90%; 95% confidence interval, 83 to 95) had a favorable outcome.  The 11 unfavorable outcomes were 7 deaths (6 during treatment and 1 from an unknown cause during follow-up), 1 withdrawal of consent during treatment, 2 relapses during follow-up, and 1 loss to follow-up.  The expected linezolid toxic effects of peripheral neuropathy (occurring in 81% of patients) and myelosuppression (48%), although common, were manageable, often leading to dose redns. or interruptions in treatment with linezolid. conclusions The combination of bedaquiline, pretomanid, and linezolid led to a favorable outcome at 6 mo after the end of therapy in a high percentage of patients with highly drug-resistant forms of tuberculosis; some assocd. toxic effects were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoagq93PXO5qrVg90H21EOLACvtfcHk0ljN2_kLoJmZyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVKrsb0%253D&md5=e7210ad01d84d5c99708cdd124a29145</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1901814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1901814%26sid%3Dliteratum%253Aachs%26aulast%3DConradie%26aufirst%3DF.%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DNgubane%26aufirst%3DN.%26aulast%3DHowell%26aufirst%3DP.%26aulast%3DEveritt%26aufirst%3DD.%26aulast%3DCrook%26aufirst%3DA.%2BM.%26aulast%3DMendel%26aufirst%3DC.%2BM.%26aulast%3DEgizi%26aufirst%3DE.%26aulast%3DMoreira%26aufirst%3DJ.%26aulast%3DTimm%26aufirst%3DJ.%26atitle%3DTreatment%2520of%2520highly%2520drug-resistant%2520pulmonary%2520tuberculosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D893%26epage%3D902%26doi%3D10.1056%2FNEJMoa1901814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanDevanter, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arain, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langhorne, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiswirth, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span></span> <span> </span><span class="NLM_article-title">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>405</i></span>,  <span class="NLM_fpage">962</span>– <span class="NLM_lpage">966</span>, <span class="refDoi"> DOI: 10.1038/35016103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2F35016103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10879539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=405&publication_year=2000&pages=962-966&author=C.+K.+Stoverauthor=P.+Warrenerauthor=D.+R.+VanDevanterauthor=D.+R.+Shermanauthor=T.+M.+Arainauthor=M.+H.+Langhorneauthor=S.+W.+Andersonauthor=J.+A.+Towellauthor=Y.+Yuanauthor=D.+N.+McMurrayauthor=B.+N.+Kreiswirthauthor=C.+E.+Barryauthor=W.+R.+Baker&title=A+small-molecule+nitroimidazopyran+drug+candidate+for+the+treatment+of+tuberculosis&doi=10.1038%2F35016103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span></div><div class="casAuthors">Stover, C. Kendall; Warrener, Paul; VanDevanter, Donald R.; Sherman, David R.; Arain, Taraq M.; Langhorne, Michael H.; Anderson, Scott W.; Towell, J. Andrew; Yuan, Ying; McMurray, David N.; Krelswirth, Barry N.; Barry, Clifton E.; Baker, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">405</span>
        (<span class="NLM_cas:issue">6789</span>),
    <span class="NLM_cas:pages">962-966</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis, which causes tuberculosis, is the greatest single infectious cause of mortality worldwide, killing roughly; two million people annually.  Ests. indicate that one-third of the world population is infected with latent M. tuberculosis.  The synergy between tuberculosis and the AIDS epidemic, and the surge of multidrug-resistant clin. isolates of M. tuberculosis have reaffirmed tuberculosis as a primary public health threat.  However, new antitubercular drugs with new mechanisms of action have not been developed in over thirty years.  Here we report a series of compds. contg. a nitroimidazopyran nucleus that possess antitubercular activity.  After activation by a mechanism dependent on M. tuberculosis F420 cofactor, nitroimidazopyrans inhibited the synthesis of protein and cell wall lipid.  In contrast to current antitubercular drugs, nitroimidazopyrans exhibited bactericidal activity against both replicating and static M. tuberculosis.  Lead compd. PA-824 showed potent bactericidal activity against multidrug-resistant M. tuberculosis and promising oral activity in animal infection models.  We conclude that nitroimidazopyrans offer the practical qualities of a small mol. with the potential for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw41eD4TtVwbVg90H21EOLACvtfcHk0lhsePa1HzEYsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D&md5=f5f6e2935928da72e328bddd4995515f</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1038%2F35016103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35016103%26sid%3Dliteratum%253Aachs%26aulast%3DStover%26aufirst%3DC.%2BK.%26aulast%3DWarrener%26aufirst%3DP.%26aulast%3DVanDevanter%26aufirst%3DD.%2BR.%26aulast%3DSherman%26aufirst%3DD.%2BR.%26aulast%3DArain%26aufirst%3DT.%2BM.%26aulast%3DLanghorne%26aufirst%3DM.%2BH.%26aulast%3DAnderson%26aufirst%3DS.%2BW.%26aulast%3DTowell%26aufirst%3DJ.%2BA.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DMcMurray%26aufirst%3DD.%2BN.%26aulast%3DKreiswirth%26aufirst%3DB.%2BN.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBaker%26aufirst%3DW.%2BR.%26atitle%3DA%2520small-molecule%2520nitroimidazopyran%2520drug%2520candidate%2520for%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DNature%26date%3D2000%26volume%3D405%26spage%3D962%26epage%3D966%26doi%3D10.1038%2F35016103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Miranda
Silva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajihosseini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myrick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nole, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drusano, G. L.</span></span> <span> </span><span class="NLM_article-title">Effect of moxifloxacin plus pretomanid against Mycobacterium tuberculosis in log phase, acid phase, and nonreplicating-persister phase in an in vitro assay</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">e01695-18</span>, <span class="refDoi"> DOI: 10.1128/AAC.01695-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.01695-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30397058" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2019&pages=e01695-18&author=C.+de+Miranda%0ASilvaauthor=A.+Hajihosseiniauthor=J.+Myrickauthor=J.+Noleauthor=A.+Louieauthor=S.+Schmidtauthor=G.+L.+Drusano&title=Effect+of+moxifloxacin+plus+pretomanid+against+Mycobacterium+tuberculosis+in+log+phase%2C+acid+phase%2C+and+nonreplicating-persister+phase+in+an+in+vitro+assay&doi=10.1128%2FAAC.01695-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1128%2FAAC.01695-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01695-18%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BMiranda%2BSilva%26aufirst%3DC.%26aulast%3DHajihosseini%26aufirst%3DA.%26aulast%3DMyrick%26aufirst%3DJ.%26aulast%3DNole%26aufirst%3DJ.%26aulast%3DLouie%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DDrusano%26aufirst%3DG.%2BL.%26atitle%3DEffect%2520of%2520moxifloxacin%2520plus%2520pretomanid%2520against%2520Mycobacterium%2520tuberculosis%2520in%2520log%2520phase%252C%2520acid%2520phase%252C%2520and%2520nonreplicating-persister%2520phase%2520in%2520an%2520in%2520vitro%2520assay%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2019%26volume%3D63%26spage%3De01695-18%26doi%3D10.1128%2FAAC.01695-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balganesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinesh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruppath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, U.</span></span> <span> </span><span class="NLM_article-title">Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2643</span>– <span class="NLM_lpage">2651</span>, <span class="refDoi"> DOI: 10.1128/AAC.06003-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.06003-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22314527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=2643-2651&author=M.+Balganeshauthor=N.+Dineshauthor=S.+Sharmaauthor=S.+Kuruppathauthor=A.+V.+Nairauthor=U.+Sharma&title=Efflux+pumps+of+Mycobacterium+tuberculosis+play+a+significant+role+in+antituberculosis+activity+of+potential+drug+candidates&doi=10.1128%2FAAC.06003-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates</span></div><div class="casAuthors">Balganesh, Meenakshi; Dinesh, Neela; Sharma, Sreevalli; Kuruppath, Sanjana; Nair, Anju V.; Sharma, Umender</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2643-2651</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Active efflux of drugs mediated by efflux pumps that confer drug resistance is one of the mechanisms developed by bacteria to counter the adverse effects of antibiotics and chems.  To understand these efflux mechanisms in Mycobacterium tuberculosis, we generated knockout (KO) mutants of four efflux pumps of the pathogen belonging to different classes.  The authors measured the MICs and kill values of two different compd. classes on the wild-type (WT) and the efflux pump (EP) KO mutants in the presence and absence of the efflux inhibitors verapamil and L-phenylalanyl-L-arginyl-β-naphthylamide (PAβN).  Among the pumps studied, the efflux pumps belonging to the ABC (ATP-binding cassette) class, encoded by Rv1218c, and the SMR (small multidrug resistance) class, encoded by Rv3065, appear to play important roles in mediating the efflux of different chem. classes and antibiotics.  Efflux pumps encoded by Rv0849 and Rv1258c also mediate the efflux of these compds., but to a lesser extent.  Increased killing is obsd. in WT M. tuberculosis cells by these compds. in the presence of either verapamil or PAβN.  The efflux pump KO mutants were more susceptible to these compds. in the presence of efflux inhibitors.  We have shown that these four efflux pumps of M. tuberculosis play a vital role in mediating efflux of different chem. scaffolds.  Inhibitors of one or several of these efflux pumps could have a significant impact in the treatment of tuberculosis.  The identification and characterization of Rv0849, a new efflux pump belonging to the MFS (major facilitator superfamily) class, are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZCoB0YRug-7Vg90H21EOLACvtfcHk0lgVsQt6m8eqvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKrsbk%253D&md5=284a84bb5cc3575973cbb3da9cf8a7d6</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1128%2FAAC.06003-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06003-11%26sid%3Dliteratum%253Aachs%26aulast%3DBalganesh%26aufirst%3DM.%26aulast%3DDinesh%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKuruppath%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DA.%2BV.%26aulast%3DSharma%26aufirst%3DU.%26atitle%3DEfflux%2520pumps%2520of%2520Mycobacterium%2520tuberculosis%2520play%2520a%2520significant%2520role%2520in%2520antituberculosis%2520activity%2520of%2520potential%2520drug%2520candidates%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D2643%26epage%3D2651%26doi%3D10.1128%2FAAC.06003-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wayne, L. G.</span></span> <span> </span><span class="NLM_article-title">Synchronized replication of Mycobacterium tuberculosis</span>. <i>Infect. Immun.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1128/IAI.17.3.528-530.1977</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FIAI.17.3.528-530.1977" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=409675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaE2sXlvVSnt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1977&pages=528-530&author=L.+G.+Wayne&title=Synchronized+replication+of+Mycobacterium+tuberculosis&doi=10.1128%2FIAI.17.3.528-530.1977"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Synchronized replication of Mycobacterium tuberculosis</span></div><div class="casAuthors">Wayne, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Infection and Immunity</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">528-30</span>CODEN:
                <span class="NLM_cas:coden">INFIBR</span>;
        ISSN:<span class="NLM_cas:issn">0019-9567</span>.
    </div><div class="casAbstract">When M. tuberculosis was grown in Tween-albumin broth without agitation, the bacilli replicated in the upper, O-rich portion of the medium at a rate that was just balanced by the rate at which the bacilli settled toward the bottom of the tube.  When the organisms that accumulated in the sediment were suspended and dild. into fresh medium, they exhibited synchronous replication.  The bacilli initiated RNA synthesis immediately upon suspension, but marked DNA synthesis was not apparent until after the 1st cellular division was completed, ∼14 h after suspension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDLDsRsccSfrVg90H21EOLACvtfcHk0lgVsQt6m8eqvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXlvVSnt7g%253D&md5=a9baac07fbe58d46d37cb723f6208307</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1128%2FIAI.17.3.528-530.1977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FIAI.17.3.528-530.1977%26sid%3Dliteratum%253Aachs%26aulast%3DWayne%26aufirst%3DL.%2BG.%26atitle%3DSynchronized%2520replication%2520of%2520Mycobacterium%2520tuberculosis%26jtitle%3DInfect.%2520Immun.%26date%3D1977%26volume%3D17%26spage%3D528%26epage%3D530%26doi%3D10.1128%2FIAI.17.3.528-530.1977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. F.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis metabolism</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">a021121</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a021121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1101%2Fcshperspect.a021121" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=a021121&author=D.+F.+Warner&title=Mycobacterium+tuberculosis+metabolism&doi=10.1101%2Fcshperspect.a021121"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a021121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a021121%26sid%3Dliteratum%253Aachs%26aulast%3DWarner%26aufirst%3DD.%2BF.%26atitle%3DMycobacterium%2520tuberculosis%2520metabolism%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2015%26volume%3D5%26spage%3Da021121%26doi%3D10.1101%2Fcshperspect.a021121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vollmer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keep, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, S.</span></span> <span> </span><span class="NLM_article-title">Cell wall peptidoglycan in Mycobacterium tuberculosis: An Achilles’ heel for the TB-causing pathogen</span>. <i>FEMS Microbiology Reviews</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">548</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1093/femsre/fuz016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Ffemsre%2Ffuz016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31183501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosFGkt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2019&pages=548-575&author=A.+Maitraauthor=T.+Munshiauthor=J.+Healyauthor=L.+T.+Martinauthor=W.+Vollmerauthor=N.+H.+Keepauthor=S.+Bhakta&title=Cell+wall+peptidoglycan+in+Mycobacterium+tuberculosis%3A+An+Achilles%E2%80%99+heel+for+the+TB-causing+pathogen&doi=10.1093%2Ffemsre%2Ffuz016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Cell wall peptidoglycan in Mycobacterium tuberculosis: an Achilles' heel for the TB-causing pathogen</span></div><div class="casAuthors">Maitra, Arundhati; Munshi, Tulika; Healy, Jess; Martin, Liam T.; Vollmer, Waldemar; Keep, Nicholas H.; Bhakta, Sanjib</div><div class="citationInfo"><span class="NLM_cas:title">FEMS Microbiology Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">548-575</span>CODEN:
                <span class="NLM_cas:coden">FMREE4</span>;
        ISSN:<span class="NLM_cas:issn">1574-6976</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB), caused by the intracellular pathogen Mycobacterium tuberculosis, remains one of the leading causes of mortality across the world.  There is an urgent requirement to build a robust arsenal of effective antimicrobials, targeting novel mol. mechanisms to overcome the challenges posed by the increase of antibiotic resistance in TB.  Mycobacterium tuberculosis has a unique cell envelope structure and compn., contg. a peptidoglycan layer that is essential for maintaining cellular integrity and for virulence.  The enzymes involved in the biosynthesis, degrdn., remodeling and recycling of peptidoglycan have resurfaced as attractive targets for anti-infective drug discovery.  Here, we review the importance of peptidoglycan, including the structure, function and regulation of key enzymes involved in its metab.  We also discuss known inhibitors of ATP-dependent Mur ligases, and discuss the potential for the development of pan-enzyme inhibitors targeting multiple Mur ligases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6GdlixjHrV7Vg90H21EOLACvtfcHk0li3URtl6AjbyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosFGkt74%253D&md5=8cc7822734ac077b3405a01b8ac48db4</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1093%2Ffemsre%2Ffuz016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ffemsre%252Ffuz016%26sid%3Dliteratum%253Aachs%26aulast%3DMaitra%26aufirst%3DA.%26aulast%3DMunshi%26aufirst%3DT.%26aulast%3DHealy%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DL.%2BT.%26aulast%3DVollmer%26aufirst%3DW.%26aulast%3DKeep%26aufirst%3DN.%2BH.%26aulast%3DBhakta%26aufirst%3DS.%26atitle%3DCell%2520wall%2520peptidoglycan%2520in%2520Mycobacterium%2520tuberculosis%253A%2520An%2520Achilles%25E2%2580%2599%2520heel%2520for%2520the%2520TB-causing%2520pathogen%26jtitle%3DFEMS%2520Microbiology%2520Reviews%26date%3D2019%26volume%3D43%26spage%3D548%26epage%3D575%26doi%3D10.1093%2Ffemsre%2Ffuz016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelopoulos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keep, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, S.</span></span> <span> </span><span class="NLM_article-title">Characterisation of ATP-dependent Mur ligases involved in the biogenesis of cell wall peptidoglycan in Mycobacterium tuberculosis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e60143</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0060143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pone.0060143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23555903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsVSrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e60143&author=T.+Munshiauthor=A.+Guptaauthor=D.+Evangelopoulosauthor=J.+D.+Guzmanauthor=S.+Gibbonsauthor=N.+H.+Keepauthor=S.+Bhakta&title=Characterisation+of+ATP-dependent+Mur+ligases+involved+in+the+biogenesis+of+cell+wall+peptidoglycan+in+Mycobacterium+tuberculosis&doi=10.1371%2Fjournal.pone.0060143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Characterisation of ATP-dependent mur ligases involved in the biogenesis of cell wall peptidoglycan in Mycobacterium tuberculosis</span></div><div class="casAuthors">Munshi, Tulika; Gupta, Antima; Evangelopoulos, Dimitrios; Guzman, Juan David; Gibbons, Simon; Keep, Nicholas H.; Bhakta, Sanjib</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e60143</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">ATP-dependent Mur ligases (Mur synthetases) play essential roles in the biosynthesis of cell wall peptidoglycan (PG) as they catalyze the ligation of key amino acid residues to the stem peptide at the expense of ATP hydrolysis, thus representing potential targets for antibacterial drug discovery.  In this study the authors characterized the division/cell wall (dcw) operon and identified a promoter driving the co-transcription of mur synthetases along with key cell division genes such as ftsQ and ftsW.  Furthermore, the authors have extended their previous investigations of MurE to MurC, MurD and MurF synthetases from Mycobacterium tuberculosis.  Functional analyses of the pure recombinant enzymes revealed that the presence of divalent cations is an abs. requirement for their activities.  The authors also obsd. that higher concns. of ATP and UDP-sugar substrates were inhibitory for the activities of all Mur synthetases suggesting stringent control of the cytoplasmic steps of the peptidoglycan biosynthetic pathway.  In line with the previous findings on the regulation of mycobacterial MurD and corynebacterial MurC synthetases via phosphorylation, the authors found that all of the Mur synthetases interacted with the Ser/Thr protein kinases, PknA and PknB.  In addn., the authors critically analyzed the interaction network of all of the Mur synthetases with proteins involved in cell division and cell wall PG biosynthesis to re-evaluate the importance of these key enzymes as novel therapeutic targets in anti-tubercular drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcMija6vZMjLVg90H21EOLACvtfcHk0li3URtl6AjbyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsVSrtrw%253D&md5=275f3f3194c8bd692a2044ebb9537bfc</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0060143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0060143%26sid%3Dliteratum%253Aachs%26aulast%3DMunshi%26aufirst%3DT.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DEvangelopoulos%26aufirst%3DD.%26aulast%3DGuzman%26aufirst%3DJ.%2BD.%26aulast%3DGibbons%26aufirst%3DS.%26aulast%3DKeep%26aufirst%3DN.%2BH.%26aulast%3DBhakta%26aufirst%3DS.%26atitle%3DCharacterisation%2520of%2520ATP-dependent%2520Mur%2520ligases%2520involved%2520in%2520the%2520biogenesis%2520of%2520cell%2520wall%2520peptidoglycan%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De60143%26doi%3D10.1371%2Fjournal.pone.0060143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">PaweLczyk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span> <span> </span><span class="NLM_article-title">The Molecular Genetics of Mycolic Acid Biosynthesis</span>. <i>Microbiol. Spectrum</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">MGM2-0003-2013</span>, <span class="refDoi"> DOI: 10.1128/microbiolspec.MGM2-0003-2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2Fmicrobiolspec.MGM2-0003-2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26104214" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=MGM2-0003-2013&author=J.+PaweLczykauthor=L.+Kremer&title=The+Molecular+Genetics+of+Mycolic+Acid+Biosynthesis&doi=10.1128%2Fmicrobiolspec.MGM2-0003-2013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1128%2Fmicrobiolspec.MGM2-0003-2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmicrobiolspec.MGM2-0003-2013%26sid%3Dliteratum%253Aachs%26aulast%3DPaweLczyk%26aufirst%3DJ.%26aulast%3DKremer%26aufirst%3DL.%26atitle%3DThe%2520Molecular%2520Genetics%2520of%2520Mycolic%2520Acid%2520Biosynthesis%26jtitle%3DMicrobiol.%2520Spectrum%26date%3D2014%26volume%3D2%26spage%3DMGM2-0003-2013%26doi%3D10.1128%2Fmicrobiolspec.MGM2-0003-2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mashabela, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wet, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. F.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis metabolism</span>. <i>Microbiol. Spectrum</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">GPP3-0067-2019</span>, <span class="refDoi"> DOI: 10.1128/microbiolspec.GPP3-0067-2019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2Fmicrobiolspec.GPP3-0067-2019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=GPP3-0067-2019&author=G.+T.+Mashabelaauthor=T.+J.+de+Wetauthor=D.+F.+Warner&title=Mycobacterium+tuberculosis+metabolism&doi=10.1128%2Fmicrobiolspec.GPP3-0067-2019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1128%2Fmicrobiolspec.GPP3-0067-2019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmicrobiolspec.GPP3-0067-2019%26sid%3Dliteratum%253Aachs%26aulast%3DMashabela%26aufirst%3DG.%2BT.%26aulast%3Dde%2BWet%26aufirst%3DT.%2BJ.%26aulast%3DWarner%26aufirst%3DD.%2BF.%26atitle%3DMycobacterium%2520tuberculosis%2520metabolism%26jtitle%3DMicrobiol.%2520Spectrum%26date%3D2019%26volume%3D7%26spage%3DGPP3-0067-2019%26doi%3D10.1128%2Fmicrobiolspec.GPP3-0067-2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, P. J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1021/ar700156e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar700156e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsl2ksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=11-20&author=H.+Luauthor=P.+J.+Tonge&title=Inhibitors+of+FabI%2C+an+enzyme+drug+target+in+the+bacterial+fatty+acid+biosynthesis+pathway&doi=10.1021%2Far700156e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway</span></div><div class="casAuthors">Lu, Hao; Tonge, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-20</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The modern age of drug discovery, which had been slowly gathering momentum during the early part of the twentieth century, exploded into life in the 1940s with the isolation of penicillin and streptomycin.  The immense success of these early drug discovery efforts prompted the general view that many infectious diseases would now be effectively controlled and even eradicated.  However this initial optimism was misplaced, and pathogens such as multidrug-resistant Mycobacterium tuberculosis and methicillin-resistant Staphylococcus aureus present a major current threat to human health.  Drug resistance arises through the unrelenting pressure of natural selection, and there is thus a continuing need to identify novel drug targets and develop chemotherapeutics that circumvent existing drug resistance mechanisms.  In this Account, we summarize current progress in developing inhibitors of FabI, the NADH-dependent enoyl reductase from the type II bacterial fatty acid biosynthesis pathway (FAS-II), a validated but currently underexploited target for drug discovery.  The FabI inhibitors have been divided into two groups, based on whether they form a covalent adduct with the NAD+ cofactor.  Inhibitors that form a covalent adduct include the diazaborines, as well as the front-line tuberculosis drug isoniazid.  The NAD adducts formed with these compds. are formally bisubstrate enzyme inhibitors, and we summarize progress in developing novel leads based on these pharmacophores.  Inhibitors that do not form covalent adducts form a much larger group, although generally these compds. also require the cofactor to be bound to the enzyme.  Using structure-based approaches, we have developed a series of alkyl di-Ph ethers that are nanomolar inhibitors of InhA, the FabI from M. tuberculosis, and that are active against INH-resistant strains of M. tuberculosis.  This rational approach to inhibitor development is based on the proposal that high-affinity inhibition of the FabI enzymes is coupled to the ordering of a loop of amino acids close to the active site.  Compds. that promote loop ordering are slow onset FabI inhibitors with increased residence time on the enzyme.  The di-Ph ether skeleton has also been used as a framework by us and others to develop potent inhibitors of the FabI enzymes from other pathogens such as Escherichia coli, S. aureus, and Plasmodium falciparum.  Meanwhile chem. optimization of compds. identified in high-throughput screening programs has resulted in the identification of several classes of heteroarom. FabI inhibitors with potent activity both in vitro and in vivo.  Finally, screening of natural product libraries may provide useful chem. entities for the development of novel agents with low toxicity.  While the discovery that not all pathogens contain FabI homologues has led to reduced industrial interest in FabI as a broad spectrum target, there is substantial optimism that FabI inhibitors can be developed for disease-specific applications.  In addn., the availability of genome sequencing data, improved methods for target identification and validation, and the development of novel approaches for detg. the mode of action of current drugs will all play crit. roles in the road ahead and in exploiting other components of the FAS-II pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql1NBfEVjFULVg90H21EOLACvtfcHk0lgO1UujaV_-oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsl2ksA%253D%253D&md5=8d28e2e80a7513c1105265288614a924</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Far700156e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far700156e%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DTonge%26aufirst%3DP.%2BJ.%26atitle%3DInhibitors%2520of%2520FabI%252C%2520an%2520enzyme%2520drug%2520target%2520in%2520the%2520bacterial%2520fatty%2520acid%2520biosynthesis%2520pathway%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D11%26epage%3D20%26doi%3D10.1021%2Far700156e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">AlMatar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makky, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Var, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koksal, F.</span></span> <span> </span><span class="NLM_article-title">Novel compounds targeting InhA for TB therapy</span>. <i>Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">226</span>, <span class="refDoi"> DOI: 10.1016/j.pharep.2017.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.pharep.2017.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29475004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1MrkslKltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2018&pages=217-226&author=M.+AlMatarauthor=E.+A.+Makkyauthor=I.+Varauthor=B.+Kayarauthor=F.+Koksal&title=Novel+compounds+targeting+InhA+for+TB+therapy&doi=10.1016%2Fj.pharep.2017.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Novel compounds targeting InhA for TB therapy</span></div><div class="casAuthors">AlMatar Manaf; Makky Essam A; Var Isil; Kayar Begum; Koksal Fatih</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological reports : PR</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-226</span>
        ISSN:<span class="NLM_cas:issn">1734-1140</span>.
    </div><div class="casAbstract">Tuberculosis (TB) is described as lethal disease in the world.  Resistant to TB drugs is the main reason to have unfavourable outcomes in the treatment of TB.  Therefore, new agents to replace existing drugs are urgently needed.  Previous reports suggested that InhA inhibitors, an enoyl-ACP-reductase, might provide auspicious candidates which can be developed into novel antitubercular agents.  In this review, we explain the role of InhA in the resistance of isoniazid.  Furthermore, five classes of InhA inhibitors, which display novel binding modes and deliver evidence of their prosperous target engagement, have been debated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0iT-MXN5-iwHqQV89nF-2fW6udTcc2eYG9xvCkypc9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrkslKltg%253D%253D&md5=c04c7b5b61a79afd5af78b3718c5aaa4</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.pharep.2017.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharep.2017.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DAlMatar%26aufirst%3DM.%26aulast%3DMakky%26aufirst%3DE.%2BA.%26aulast%3DVar%26aufirst%3DI.%26aulast%3DKayar%26aufirst%3DB.%26aulast%3DKoksal%26aufirst%3DF.%26atitle%3DNovel%2520compounds%2520targeting%2520InhA%2520for%2520TB%2520therapy%26jtitle%3DPharmacol.%2520Rep.%26date%3D2018%26volume%3D70%26spage%3D217%26epage%3D226%26doi%3D10.1016%2Fj.pharep.2017.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parai, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shetty, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolhiser, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hastings, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galaviz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhakal, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakabayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walpole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scullion, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epemolu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snavely, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioerger, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirgel, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Merwe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Helden, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottger, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakousis, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span> <span> </span><span class="NLM_article-title">Development of a novel lead that targets M. tuberculosis polyketide synthase 13</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.06.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.cell.2017.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28669536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSqsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2017&pages=249-259&author=A.+Aggarwalauthor=M.+K.+Paraiauthor=N.+Shettyauthor=D.+Wallisauthor=L.+Woolhiserauthor=C.+Hastingsauthor=N.+K.+Duttaauthor=S.+Galavizauthor=R.+C.+Dhakalauthor=R.+Shresthaauthor=S.+Wakabayashiauthor=C.+Walpoleauthor=D.+Matthewsauthor=D.+Floydauthor=P.+Scullionauthor=J.+Rileyauthor=O.+Epemoluauthor=S.+Norvalauthor=T.+Snavelyauthor=G.+T.+Robertsonauthor=E.+J.+Rubinauthor=T.+R.+Ioergerauthor=F.+A.+Sirgelauthor=R.+van+der+Merweauthor=P.+D.+van+Heldenauthor=P.+Kellerauthor=E.+C.+Bottgerauthor=P.+C.+Karakousisauthor=A.+J.+Lenaertsauthor=J.+C.+Sacchettini&title=Development+of+a+novel+lead+that+targets+M.+tuberculosis+polyketide+synthase+13&doi=10.1016%2Fj.cell.2017.06.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13</span></div><div class="casAuthors">Aggarwal, Anup; Parai, Maloy K.; Shetty, Nishant; Wallis, Deeann; Woolhiser, Lisa; Hastings, Courtney; Dutta, Noton K.; Galaviz, Stacy; Dhakal, Ramesh C.; Shrestha, Rupesh; Wakabayashi, Shoko; Walpole, Chris; Matthews, David; Floyd, David; Scullion, Paul; Riley, Jennifer; Epemolu, Ola; Norval, Suzanne; Snavely, Thomas; Robertson, Gregory T.; Rubin, Eric J.; Ioerger, Thomas R.; Sirgel, Frik A.; van der Merwe, Ruben; van Helden, Paul D.; Keller, Peter; Bottger, Erik C.; Karakousis, Petros C.; Lenaerts, Anne J.; Sacchettini, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">249-259.e25</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Widespread resistance to first-line TB drugs is a major problem that will likely only be resolved through the development of new drugs with novel mechanisms of action.  The authors have used structure-guided methods to develop a lead mol. that targets the thioesterase activity of polyketide synthase Pks13, an essential enzyme that forms mycolic acids, required for the cell wall of Mycobacterium tuberculosis.  The authors' lead, TAM16, is a benzofuran class inhibitor of Pks13 with highly potent in vitro bactericidal activity against drug-susceptible and drug-resistant clin. isolates of M. tuberculosis.  In multiple mouse models of TB infection, TAM16 showed in vivo efficacy equal to the first-line TB drug isoniazid, both as a monotherapy and in combination therapy with rifampicin.  TAM16 has excellent pharmacol. and safety profiles, and the frequency of resistance for TAM16 is ∼100-fold lower than INH, suggesting that it can be developed as a new antitubercular aimed at the acute infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzaTE4I6mQ27Vg90H21EOLACvtfcHk0lgMVhxvThjJ8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSqsL3K&md5=d622d9319d150f6861936ede89467067</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DA.%26aulast%3DParai%26aufirst%3DM.%2BK.%26aulast%3DShetty%26aufirst%3DN.%26aulast%3DWallis%26aufirst%3DD.%26aulast%3DWoolhiser%26aufirst%3DL.%26aulast%3DHastings%26aufirst%3DC.%26aulast%3DDutta%26aufirst%3DN.%2BK.%26aulast%3DGalaviz%26aufirst%3DS.%26aulast%3DDhakal%26aufirst%3DR.%2BC.%26aulast%3DShrestha%26aufirst%3DR.%26aulast%3DWakabayashi%26aufirst%3DS.%26aulast%3DWalpole%26aufirst%3DC.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DFloyd%26aufirst%3DD.%26aulast%3DScullion%26aufirst%3DP.%26aulast%3DRiley%26aufirst%3DJ.%26aulast%3DEpemolu%26aufirst%3DO.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSnavely%26aufirst%3DT.%26aulast%3DRobertson%26aufirst%3DG.%2BT.%26aulast%3DRubin%26aufirst%3DE.%2BJ.%26aulast%3DIoerger%26aufirst%3DT.%2BR.%26aulast%3DSirgel%26aufirst%3DF.%2BA.%26aulast%3Dvan%2Bder%2BMerwe%26aufirst%3DR.%26aulast%3Dvan%2BHelden%26aufirst%3DP.%2BD.%26aulast%3DKeller%26aufirst%3DP.%26aulast%3DBottger%26aufirst%3DE.%2BC.%26aulast%3DKarakousis%26aufirst%3DP.%2BC.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26atitle%3DDevelopment%2520of%2520a%2520novel%2520lead%2520that%2520targets%2520M.%2520tuberculosis%2520polyketide%2520synthase%252013%26jtitle%3DCell%26date%3D2017%26volume%3D170%26spage%3D249%26epage%3D259%26doi%3D10.1016%2Fj.cell.2017.06.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1007/s13238-010-0057-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1007%2Fs13238-010-0057-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21203958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3cXoslelur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=435-442&author=Z.+Louauthor=X.+Zhang&title=Protein+targets+for+structure-based+anti-Mycobacterium+tuberculosis+drug+discovery&doi=10.1007%2Fs13238-010-0057-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery</span></div><div class="casAuthors">Lou, Zhiyong; Zhang, Xiaoxue</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">435-442</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">A review.  Mycobacterium tuberculosis, which belongs to the genus Mycobacterium, is the pathogenic agent for most tuberculosis (TB).  As TB remains one of the most rampant infectious diseases, causing morbidity and death with emergence of multi-drug-resistant and extensively-drug-resistant forms, it is urgent to identify new drugs with novel targets to ensure future therapeutic success.  In this regards, the structural genomics of M. tuberculosis provides important information to identify potential targets, perform biochem. assays, det. crystal structures in complex with potential inhibitor(s), reveal the key sites/residues for biol. activity, and thus validate drug targets and discover novel drugs.  In this review, we will discuss the recent progress on novel targets for structure-based anti-M. tuberculosis drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYIQ6apqOxArVg90H21EOLACvtfcHk0li0NxjIs7NEKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXoslelur4%253D&md5=bbd2583d8094eb7bce9dccf5c41d2a45</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1007%2Fs13238-010-0057-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-010-0057-3%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DProtein%2520targets%2520for%2520structure-based%2520anti-Mycobacterium%2520tuberculosis%2520drug%2520discovery%26jtitle%3DProtein%2520Cell%26date%3D2010%26volume%3D1%26spage%3D435%26epage%3D442%26doi%3D10.1007%2Fs13238-010-0057-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haufroid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wouters, J.</span></span> <span> </span><span class="NLM_article-title">Targeting the Serine Pathway: A promising approach against tuberculosis?</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">66</span>, <span class="refDoi"> DOI: 10.3390/ph12020066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3390%2Fph12020066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslKksLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=66&author=M.+Haufroidauthor=J.+Wouters&title=Targeting+the+Serine+Pathway%3A+A+promising+approach+against+tuberculosis%3F&doi=10.3390%2Fph12020066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the serine pathway: a promising approach against tuberculosis?</span></div><div class="casAuthors">Haufroid, Marie; Wouters, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">66</span>CODEN:
                <span class="NLM_cas:coden">PHARH2</span>;
        ISSN:<span class="NLM_cas:issn">1424-8247</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Tuberculosis is still the leading cause of death by a single infectious agent.  Effective chemotherapy has been used and improved since the 1950s, but strains resistant to this therapy and most antibacterial drugs on the market are emerging.  Only 10 new drugs are in clin. trials, and two of them have already demonstrated resistance.  This paper gives an overview of current treatment options against tuberculosis and points out a promising approach of discovering new effective drugs.  The serine prodn. pathway is composed of three enzymes (SerA1, SerC and SerB2), which are considered essential for bacterial growth, and all of them are considered as a therapeutic drug target.  Their crystal structure are described and essential regulatory domains pointed out.  Sequence alignment with similar enzymes in other host would help to identify key residues to target in order to achieve selective inhibition.  Currently, only inhibitors of SerB2 are described in the literature.  However, inhibitors of human enzymes are discussed, and could be used as a good starting point for a drug discovery program.  The aim of this paper is to give some guidance for the design of new hits for every enzyme in this pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFdU37bL8KyLVg90H21EOLACvtfcHk0li0NxjIs7NEKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslKksLzI&md5=02c4f3dfa6a55af6298e7c23276a0c61</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.3390%2Fph12020066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph12020066%26sid%3Dliteratum%253Aachs%26aulast%3DHaufroid%26aufirst%3DM.%26aulast%3DWouters%26aufirst%3DJ.%26atitle%3DTargeting%2520the%2520Serine%2520Pathway%253A%2520A%2520promising%2520approach%2520against%2520tuberculosis%253F%26jtitle%3DPharmaceuticals%26date%3D2019%26volume%3D12%26spage%3D66%26doi%3D10.3390%2Fph12020066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tantry, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markad, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambady, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raichurkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kedari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudugal, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naveen Kumar, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanduri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panduga, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakar, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saralaya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinesh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guptha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcock, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naylor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteaker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudrapatna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shandil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandamurthy, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mdluli, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavanagh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosagrahara, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solapure, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravishankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hameed P, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of imidazo[1,2-a]pyridine ethers and squaramides as selective and potent inhibitors of Mycobacterial Adenosine Triphosphate (ATP) synthesis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1379</span>– <span class="NLM_lpage">1399</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01358</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01358" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptlajsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1379-1399&author=S.+J.+Tantryauthor=S.+D.+Markadauthor=V.+Shindeauthor=J.+Bhatauthor=G.+Balakrishnanauthor=A.+K.+Guptaauthor=A.+Ambadyauthor=A.+Raichurkarauthor=C.+Kedariauthor=S.+Sharmaauthor=N.+V.+Mudugalauthor=A.+Narayanauthor=C.+N.+Naveen+Kumarauthor=R.+Nanduriauthor=S.+Bharathauthor=J.+Reddyauthor=V.+Pandugaauthor=K.+R.+Prabhakarauthor=K.+Kandaswamyauthor=R.+Saralayaauthor=P.+Kaurauthor=N.+Dineshauthor=S.+Gupthaauthor=K.+Richauthor=D.+Murrayauthor=H.+Plantauthor=M.+Prestonauthor=H.+Ashtonauthor=D.+Plantauthor=J.+Walshauthor=P.+Alcockauthor=K.+Naylorauthor=M.+Collierauthor=J.+Whiteakerauthor=R.+E.+McLaughlinauthor=M.+Mallyaauthor=M.+Pandaauthor=S.+Rudrapatnaauthor=V.+Ramachandranauthor=R.+Shandilauthor=V.+K.+Sambandamurthyauthor=K.+Mdluliauthor=C.+B.+Cooperauthor=H.+Rubinauthor=T.+Yanoauthor=P.+Iyerauthor=S.+Narayananauthor=S.+Kavanaghauthor=K.+Mukherjeeauthor=V.+Balasubramanianauthor=V.+P.+Hosagraharaauthor=S.+Solapureauthor=S.+Ravishankarauthor=S.+Hameed+P&title=Discovery+of+imidazo%5B1%2C2-a%5Dpyridine+ethers+and+squaramides+as+selective+and+potent+inhibitors+of+Mycobacterial+Adenosine+Triphosphate+%28ATP%29+synthesis&doi=10.1021%2Facs.jmedchem.6b01358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis</span></div><div class="casAuthors">Tantry, Subramanyam J.; Markad, Shankar D.; Shinde, Vikas; Bhat, Jyothi; Balakrishnan, Gayathri; Gupta, Amit K.; Ambady, Anisha; Raichurkar, Anandkumar; Kedari, Chaitanyakumar; Sharma, Sreevalli; Mudugal, Naina V.; Narayan, Ashwini; Naveen Kumar, C. N.; Nanduri, Robert; Bharath, Sowmya; Reddy, Jitendar; Panduga, Vijender; Prabhakar, K. R.; Kandaswamy, Karthikeyan; Saralaya, Ramanatha; Kaur, Parvinder; Dinesh, Neela; Guptha, Supreeth; Rich, Kirsty; Murray, David; Plant, Helen; Preston, Marian; Ashton, Helen; Plant, Darren; Walsh, Jarrod; Alcock, Peter; Naylor, Kathryn; Collier, Matthew; Whiteaker, James; McLaughlin, Robert E.; Mallya, Meenakshi; Panda, Manoranjan; Rudrapatna, Suresh; Ramachandran, Vasanthi; Shandil, Radha; Sambandamurthy, Vasan K.; Mdluli, Khisi; Cooper, Christopher B.; Rubin, Harvey; Yano, Takahiro; Iyer, Pravin; Narayanan, Shridhar; Kavanagh, Stefan; Mukherjee, Kakoli; Balasubramanian, V.; Hosagrahara, Vinayak P.; Solapure, Suresh; Ravishankar, Sudha; Hameed P, Shahul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1379-1399</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The approval of bedaquiline to treat tuberculosis has validated ATP synthase as an attractive target to kill Mycobacterium tuberculosis.  Herein, the authors report the discovery of two diverse lead series imidazo[1,2-a]pyridine ethers (IPE) and squaramides (SQA) as inhibitors of mycobacterial ATP-synthesis.  Through medicinal chem. exploration, the authors established a robust structure activity relationship of these two scaffolds resulting in nanomolar potencies in an ATP-synthesis inhibition assay.  A biochem. deconvolution cascade suggested cytochrome c oxidase as the potential target of IPE class of mols., whereas characterization of spontaneous resistant mutants of SQAs unambiguously identified ATP synthase as its mol. target.  Absence of cross resistance against bedaquiline resistant mutants suggested a different binding site for SQAs on ATP synthase.  Furthermore, SQAs were found to be non-cytotoxic and demonstrated efficacy in a mouse model of tuberculosis infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq9ZNK4cN5rbVg90H21EOLACvtfcHk0ljec-ZB56-BuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptlajsw%253D%253D&md5=6b5ae7fe676197f9ffb84f27a79965cd</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01358%26sid%3Dliteratum%253Aachs%26aulast%3DTantry%26aufirst%3DS.%2BJ.%26aulast%3DMarkad%26aufirst%3DS.%2BD.%26aulast%3DShinde%26aufirst%3DV.%26aulast%3DBhat%26aufirst%3DJ.%26aulast%3DBalakrishnan%26aufirst%3DG.%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DAmbady%26aufirst%3DA.%26aulast%3DRaichurkar%26aufirst%3DA.%26aulast%3DKedari%26aufirst%3DC.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DMudugal%26aufirst%3DN.%2BV.%26aulast%3DNarayan%26aufirst%3DA.%26aulast%3DNaveen%2BKumar%26aufirst%3DC.%2BN.%26aulast%3DNanduri%26aufirst%3DR.%26aulast%3DBharath%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DJ.%26aulast%3DPanduga%26aufirst%3DV.%26aulast%3DPrabhakar%26aufirst%3DK.%2BR.%26aulast%3DKandaswamy%26aufirst%3DK.%26aulast%3DSaralaya%26aufirst%3DR.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DDinesh%26aufirst%3DN.%26aulast%3DGuptha%26aufirst%3DS.%26aulast%3DRich%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DD.%26aulast%3DPlant%26aufirst%3DH.%26aulast%3DPreston%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DH.%26aulast%3DPlant%26aufirst%3DD.%26aulast%3DWalsh%26aufirst%3DJ.%26aulast%3DAlcock%26aufirst%3DP.%26aulast%3DNaylor%26aufirst%3DK.%26aulast%3DCollier%26aufirst%3DM.%26aulast%3DWhiteaker%26aufirst%3DJ.%26aulast%3DMcLaughlin%26aufirst%3DR.%2BE.%26aulast%3DMallya%26aufirst%3DM.%26aulast%3DPanda%26aufirst%3DM.%26aulast%3DRudrapatna%26aufirst%3DS.%26aulast%3DRamachandran%26aufirst%3DV.%26aulast%3DShandil%26aufirst%3DR.%26aulast%3DSambandamurthy%26aufirst%3DV.%2BK.%26aulast%3DMdluli%26aufirst%3DK.%26aulast%3DCooper%26aufirst%3DC.%2BB.%26aulast%3DRubin%26aufirst%3DH.%26aulast%3DYano%26aufirst%3DT.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DKavanagh%26aufirst%3DS.%26aulast%3DMukherjee%26aufirst%3DK.%26aulast%3DBalasubramanian%26aufirst%3DV.%26aulast%3DHosagrahara%26aufirst%3DV.%2BP.%26aulast%3DSolapure%26aufirst%3DS.%26aulast%3DRavishankar%26aufirst%3DS.%26aulast%3DHameed%2BP%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520imidazo%255B1%252C2-a%255Dpyridine%2520ethers%2520and%2520squaramides%2520as%2520selective%2520and%2520potent%2520inhibitors%2520of%2520Mycobacterial%2520Adenosine%2520Triphosphate%2520%2528ATP%2529%2520synthesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1379%26epage%3D1399%26doi%3D10.1021%2Facs.jmedchem.6b01358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villellas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span> <span> </span><span class="NLM_article-title">Targeting energy metabolism in Mycobacterium tuberculosis, a new paradigm in antimycobacterial drug discovery</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e00272-17</span>, <span class="refDoi"> DOI: 10.1128/mBio.00272-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FmBio.00272-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28400527" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=e00272-17&author=D.+Baldauthor=C.+Villellasauthor=P.+Luauthor=A.+Koul&title=Targeting+energy+metabolism+in+Mycobacterium+tuberculosis%2C+a+new+paradigm+in+antimycobacterial+drug+discovery&doi=10.1128%2FmBio.00272-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1128%2FmBio.00272-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.00272-17%26sid%3Dliteratum%253Aachs%26aulast%3DBald%26aufirst%3DD.%26aulast%3DVillellas%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DKoul%26aufirst%3DA.%26atitle%3DTargeting%2520energy%2520metabolism%2520in%2520Mycobacterium%2520tuberculosis%252C%2520a%2520new%2520paradigm%2520in%2520antimycobacterial%2520drug%2520discovery%26jtitle%3DmBio%26date%3D2017%26volume%3D8%26spage%3De00272-17%26doi%3D10.1128%2FmBio.00272-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Preiss, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yildiz, Ö.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt-Strelau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J. E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, T.</span></span> <span> </span><span class="NLM_article-title">Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e1500106</span>, <span class="refDoi"> DOI: 10.1126/sciadv.1500106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1126%2Fsciadv.1500106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26601184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslOrs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=e1500106&author=L.+Preissauthor=J.+D.+Langerauthor=%C3%96.+Yildizauthor=L.+Eckhardt-Strelauauthor=J.+E.+G.+Guillemontauthor=A.+Koulauthor=T.+Meier&title=Structure+of+the+mycobacterial+ATP+synthase+Fo+rotor+ring+in+complex+with+the+anti-TB+drug+bedaquiline&doi=10.1126%2Fsciadv.1500106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline</span></div><div class="casAuthors">Preiss, Laura; Langer, Julian D.; Yildiz, Oezkan; Eckhardt-Strelau, Luise; Guillemont, Jerome E. G.; Koul, Anil; Meier, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Science Advances</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e1500106/1-e1500106/8</span>CODEN:
                <span class="NLM_cas:coden">SACDAF</span>;
        ISSN:<span class="NLM_cas:issn">2375-2548</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Multidrug-resistant tuberculosis (MDR-TB) is more prevalent today than at any other time in human history.  Bedaquiline (BDQ), a novel Mycobacterium-specific ATP (ATP) synthase inhibitor, is the first drug in the last 40 years to be approved for the treatment of MDR-TB.  This bactericidal compd. targets the membrane-embedded rotor (c-ring) of the mycobacterial ATP synthase, a key metabolic enzyme required for ATP generation.  We report the x-ray crystal structures of a mycobacterial c9 ring without and with BDQ bound at 1.55- and 1.7- Å resoln., resp.  The structures and supporting functional assays reveal how BDQ specifically interacts with the rotor ring via numerous interactions and thereby completely covers the c-ring's ionbinding sites.  This prevents the rotor ring from acting as an ion shuttle and stalls ATP synthase operation.  The structures explain how diarylquinoline chems. specifically inhibit the mycobacterial ATP synthase and thus enable structure-based drug design of next-generation ATP synthase inhibitors against Mycobacterium tuberculosis and other bacterial pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK91-Dp8_Nh7Vg90H21EOLACvtfcHk0lhj1JwpQLsk2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslOrs78%253D&md5=e15a1dc1a2f30c2d113cf312724975c5</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.1500106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.1500106%26sid%3Dliteratum%253Aachs%26aulast%3DPreiss%26aufirst%3DL.%26aulast%3DLanger%26aufirst%3DJ.%2BD.%26aulast%3DYildiz%26aufirst%3D%25C3%2596.%26aulast%3DEckhardt-Strelau%26aufirst%3DL.%26aulast%3DGuillemont%26aufirst%3DJ.%2BE.%2BG.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DMeier%26aufirst%3DT.%26atitle%3DStructure%2520of%2520the%2520mycobacterial%2520ATP%2520synthase%2520Fo%2520rotor%2520ring%2520in%2520complex%2520with%2520the%2520anti-TB%2520drug%2520bedaquiline%26jtitle%3DSci.%2520Adv.%26date%3D2015%26volume%3D1%26spage%3De1500106%26doi%3D10.1126%2Fsciadv.1500106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, J. L.</span></span> <span> </span><span class="NLM_article-title">Structure of a bacterial ATP synthase</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e43128</span>, <span class="refDoi"> DOI: 10.7554/eLife.43128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.7554%2FeLife.43128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30724163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVegtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=e43128&author=H.+Guoauthor=T.+Suzukiauthor=J.+L.+Rubinstein&title=Structure+of+a+bacterial+ATP+synthase&doi=10.7554%2FeLife.43128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a bacterial ATP synthase</span></div><div class="casAuthors">Guo, Hui; Suzuki, Toshiharu; Rubinstein, John L.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43128</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">ATP synthases produce ATP from ADP and inorg. phosphate with energy from a transmembrane proton motive force.  Bacterial ATP synthases have been studied extensively because they are the simplest form of the enzyme and because of the relative ease of genetic manipulation of these complexes.  We expressed the Bacillus PS3 ATP synthase in Eschericia coli, purified it, and imaged it by cryo-EM, allowing us to build at. models of the complex in three rotational states.  The position of subunit ε shows how it is able to inhibit ATP hydrolysis while allowing ATP synthesis.  The architecture of the membrane region shows how the simple bacterial ATP synthase is able to perform the same core functions as the equiv., but more complicated, mitochondrial complex.  The structures reveal the path of transmembrane proton translocation and provide a model for understanding decades of biochem. anal. interrogating the roles of specific residues in the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo143AXmA-M7rVg90H21EOLACvtfcHk0lhj1JwpQLsk2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVegtrnF&md5=7ef22603f8e8c8c391c7ce61fac7f49a</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.7554%2FeLife.43128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.43128%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DRubinstein%26aufirst%3DJ.%2BL.%26atitle%3DStructure%2520of%2520a%2520bacterial%2520ATP%2520synthase%26jtitle%3DeLife%26date%3D2019%26volume%3D8%26spage%3De43128%26doi%3D10.7554%2FeLife.43128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schep, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bason, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigorieff, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, J. L.</span></span> <span> </span><span class="NLM_article-title">Structure and conformational states of the bovine mitochondrial ATP synthase by cryo-EM</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e10180</span>, <span class="refDoi"> DOI: 10.7554/eLife.10180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.7554%2FeLife.10180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26439008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXls1Sntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=e10180&author=A.+Zhouauthor=A.+Rohouauthor=D.+G.+Schepauthor=J.+V.+Basonauthor=M.+G.+Montgomeryauthor=J.+E.+Walkerauthor=N.+Grigorieffauthor=J.+L.+Rubinstein&title=Structure+and+conformational+states+of+the+bovine+mitochondrial+ATP+synthase+by+cryo-EM&doi=10.7554%2FeLife.10180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and conformational states of the bovine mitochondrial ATP synthase by cryo-EM</span></div><div class="casAuthors">Zhou, Anna; Rohou, Alexis; Schep, Daniel G.; Bason, John V.; Montgomery, Martin G.; Walker, John E.; Grigorieff, Nikolaus; Rubinstein, John L.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e10180/1-e10180/15</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">ATP (ATP), the chem. energy currency of biol., is synthesized in eukaryotic cells primarily by the mitochondrial ATP synthase.  ATP synthases operate by a rotary catalytic mechanism where proton translocation through the membrane-inserted FO region is coupled to ATP synthesis in the catalytic F1 region via rotation of a central rotor subcomplex.  We report here single particle electron cryomicroscopy (cryo-EM) anal. of the bovine mitochondrial ATP synthase.  Combining cryo-EM data with bioinformatic anal. allowed us to det. the fold of the a subunit, suggesting a proton translocation path through the FO region that involves both the a and b subunits. 3D classification of images revealed seven distinct states of the enzyme that show different modes of bending and twisting in the intact ATP synthase.  Rotational fluctuations of the c8-ring within the FO region support a Brownian ratchet mechanism for proton-translocation-driven rotation in ATP synthases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqarqo9J4hYoLVg90H21EOLACvtfcHk0lhj1JwpQLsk2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXls1Sntrg%253D&md5=d5e7fc2c0d177b11c27ec037fb9b30a9</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.7554%2FeLife.10180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.10180%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DRohou%26aufirst%3DA.%26aulast%3DSchep%26aufirst%3DD.%2BG.%26aulast%3DBason%26aufirst%3DJ.%2BV.%26aulast%3DMontgomery%26aufirst%3DM.%2BG.%26aulast%3DWalker%26aufirst%3DJ.%2BE.%26aulast%3DGrigorieff%26aufirst%3DN.%26aulast%3DRubinstein%26aufirst%3DJ.%2BL.%26atitle%3DStructure%2520and%2520conformational%2520states%2520of%2520the%2520bovine%2520mitochondrial%2520ATP%2520synthase%2520by%2520cryo-EM%26jtitle%3DeLife%26date%3D2015%26volume%3D4%26spage%3De10180%26doi%3D10.7554%2FeLife.10180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueler, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, J. L.</span></span> <span> </span><span class="NLM_article-title">Atomic model for the dimeric F(O) region of mitochondrial ATP synthase</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">936</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.1126/science.aao4815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1126%2Fscience.aao4815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29074581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSis77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2017&pages=936-940&author=H.+Guoauthor=S.+A.+Buelerauthor=J.+L.+Rubinstein&title=Atomic+model+for+the+dimeric+F%28O%29+region+of+mitochondrial+ATP+synthase&doi=10.1126%2Fscience.aao4815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic model for the dimeric FO region of mitochondrial ATP synthase</span></div><div class="casAuthors">Guo, Hui; Bueler, Stephanie A.; Rubinstein, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">6365</span>),
    <span class="NLM_cas:pages">936-940</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Mitochondrial ATP synthase produces the majority of ATP in eukaryotic cells, and its dimerization is necessary to create the inner membrane folds, or cristae, characteristic of mitochondria.  Proton translocation through the membrane-embedded FO region turns the rotor that drives ATP synthesis in the sol. F1 region.  Although crystal structures of the F1 region have illustrated how this rotation leads to ATP synthesis, understanding how proton translocation produces the rotation has been impeded by the lack of an exptl. at. model for the FO region.  Using cryo-electron microscopy, we detd. the structure of the dimeric FO complex from Saccharomyces cerevisiae at a resoln. of 3.6 angstroms.  The structure clarifies how the protons travel through the complex, how the complex dimerizes, and how the dimers bend the membrane to produce cristae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpROb-iJVyWh7Vg90H21EOLACvtfcHk0ljENudVVlVs4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSis77I&md5=3a7358d79b31bc4eb8eae8d3b5990478</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1126%2Fscience.aao4815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aao4815%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DBueler%26aufirst%3DS.%2BA.%26aulast%3DRubinstein%26aufirst%3DJ.%2BL.%26atitle%3DAtomic%2520model%2520for%2520the%2520dimeric%2520F%2528O%2529%2520region%2520of%2520mitochondrial%2520ATP%2520synthase%26jtitle%3DScience%26date%3D2017%26volume%3D358%26spage%3D936%26epage%3D940%26doi%3D10.1126%2Fscience.aao4815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courbon, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueler, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, J. L.</span></span> <span> </span><span class="NLM_article-title">Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>589</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1038/s41586-020-3004-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fs41586-020-3004-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=33299175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFCgtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=589&publication_year=2021&pages=143-147&author=H.+Guoauthor=G.+M.+Courbonauthor=S.+A.+Buelerauthor=J.+Maiauthor=J.+Liuauthor=J.+L.+Rubinstein&title=Structure+of+mycobacterial+ATP+synthase+bound+to+the+tuberculosis+drug+bedaquiline&doi=10.1038%2Fs41586-020-3004-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline</span></div><div class="casAuthors">Guo, Hui; Courbon, Gautier M.; Bueler, Stephanie A.; Mai, Juntao; Liu, Jun; Rubinstein, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">589</span>
        (<span class="NLM_cas:issue">7840</span>),
    <span class="NLM_cas:pages">143-147</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Tuberculosis-the world's leading cause of death by infectious disease-is increasingly resistant to current first-line antibiotics1.  The bacterium Mycobacterium tuberculosis (which causes tuberculosis) can survive low-energy conditions, allowing infections to remain dormant and decreasing their susceptibility to many antibiotics2.  Bedaquiline was developed in 2005 from a lead compd. identified in a phenotypic screen against Mycobacterium smegmatis3.  This drug can sterilize even latent M. tuberculosis infections4 and has become a cornerstone of treatment for multidrug-resistant and extensively drug-resistant tuberculosis1,5,6.  Bedaquiline targets the mycobacterial ATP synthase3, which is an essential enzyme in the obligate aerobic Mycobacterium genus3,7, but how it binds the intact enzyme is unknown.  Here we detd. cryo-electron microscopy structures of M. smegmatis ATP synthase alone and in complex with bedaquiline.  The drug-free structure suggests that hook-like extensions from the α-subunits prevent the enzyme from running in reverse, inhibiting ATP hydrolysis and preserving energy in hypoxic conditions.  Bedaquiline binding induces large conformational changes in the ATP synthase, creating tight binding pockets at the interface of subunits a and c that explain the potency of this drug as an antibiotic for tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpPrR1A82-xLVg90H21EOLACvtfcHk0ljENudVVlVs4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFCgtLjI&md5=e5ed1b61faa92bc6c429d36024e5ad0f</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-3004-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-3004-3%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DCourbon%26aufirst%3DG.%2BM.%26aulast%3DBueler%26aufirst%3DS.%2BA.%26aulast%3DMai%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DRubinstein%26aufirst%3DJ.%2BL.%26atitle%3DStructure%2520of%2520mycobacterial%2520ATP%2520synthase%2520bound%2520to%2520the%2520tuberculosis%2520drug%2520bedaquiline%26jtitle%3DNature%26date%3D2021%26volume%3D589%26spage%3D143%26epage%3D147%26doi%3D10.1038%2Fs41586-020-3004-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lutter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrahams, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Raaij, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundqvist, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. E.</span></span> <span> </span><span class="NLM_article-title">Crystallization of F1-ATPase from bovine heart mitochondria</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>229</i></span>,  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1993.1081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1006%2Fjmbi.1993.1081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=8433373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK3sXhs1Ciurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=229&publication_year=1993&pages=787-790&author=R.+Lutterauthor=J.+P.+Abrahamsauthor=M.+J.+van+Raaijauthor=R.+J.+Toddauthor=T.+Lundqvistauthor=S.+K.+Buchananauthor=A.+G.+Leslieauthor=J.+E.+Walker&title=Crystallization+of+F1-ATPase+from+bovine+heart+mitochondria&doi=10.1006%2Fjmbi.1993.1081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Crystallization of F1-ATPase from bovine heart mitochondria</span></div><div class="casAuthors">Lutter, R.; Abrahams, J. P.; Van Raaij, M. J.; Todd, R. J.; Lundqvist, T.; Buchanan, S. K.; Leslie, A. G. W.; Walker, J. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">229</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">787-90</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    </div><div class="casAbstract">Crystals of the F1-ATPase sector of the ATP synthase complex from bovine heart mitochondria have been grown from solns. contg. polyethylene glycol 6000.  The crystals diffract to 2.9-Å resoln. on a lab. x-ray source.  They are orthorhombic and belong to the space group P212121.  The unit cell axes are a = 285 Å, a = 108 Å, c = 140 Å.  There is 1 mol. of F1-ATPase in the asym. unit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3tW1DjcRg_7Vg90H21EOLACvtfcHk0lg7oQgQA2kEug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhs1Ciurc%253D&md5=1ab3c7b07ad35fa0d08234eed7dfd964</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1993.1081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1993.1081%26sid%3Dliteratum%253Aachs%26aulast%3DLutter%26aufirst%3DR.%26aulast%3DAbrahams%26aufirst%3DJ.%2BP.%26aulast%3Dvan%2BRaaij%26aufirst%3DM.%2BJ.%26aulast%3DTodd%26aufirst%3DR.%2BJ.%26aulast%3DLundqvist%26aufirst%3DT.%26aulast%3DBuchanan%26aufirst%3DS.%2BK.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%26aulast%3DWalker%26aufirst%3DJ.%2BE.%26atitle%3DCrystallization%2520of%2520F1-ATPase%2520from%2520bovine%2520heart%2520mitochondria%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1993%26volume%3D229%26spage%3D787%26epage%3D790%26doi%3D10.1006%2Fjmbi.1993.1081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dendouga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergauwen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molenberghs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranckx, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willebrords, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ristic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorange, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span> <span> </span><span class="NLM_article-title">Diarylquinolines target subunit c of mycobacterial ATP synthase</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1038/nchembio884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnchembio884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=17496888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOjurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=323-324&author=A.+Koulauthor=N.+Dendougaauthor=K.+Vergauwenauthor=B.+Molenberghsauthor=L.+Vranckxauthor=R.+Willebrordsauthor=Z.+Risticauthor=H.+Lillauthor=I.+Dorangeauthor=J.+Guillemontauthor=D.+Baldauthor=K.+Andries&title=Diarylquinolines+target+subunit+c+of+mycobacterial+ATP+synthase&doi=10.1038%2Fnchembio884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Diarylquinolines target subunit c of mycobacterial ATP synthase</span></div><div class="casAuthors">Koul, Anil; Dendouga, Najoua; Vergauwen, Karen; Molenberghs, Brenda; Vranckx, Luc; Willebrords, Rudy; Ristic, Zorica; Lill, Holger; Dorange, Ismet; Guillemont, Jerome; Bald, Dirk; Andries, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">323-324</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The diarylquinoline R207910 (TMC207) is a promising candidate in clin. development for the treatment of tuberculosis.  Though R207910-resistant mycobacteria bear mutations in ATP synthase, the compd.'s precise target is not known.  Here we establish by genetic, biochem. and binding assays that the oligomeric subunit c (AtpE) of ATP synthase is the target of R207910.  Thus targeting energy metab. is a new, promising approach for antibacterial drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoo57k1zZdTLVg90H21EOLACvtfcHk0lg7oQgQA2kEug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOjurc%253D&md5=f9ba04042bef448f5910cea0e89715f0</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1038%2Fnchembio884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio884%26sid%3Dliteratum%253Aachs%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DDendouga%26aufirst%3DN.%26aulast%3DVergauwen%26aufirst%3DK.%26aulast%3DMolenberghs%26aufirst%3DB.%26aulast%3DVranckx%26aufirst%3DL.%26aulast%3DWillebrords%26aufirst%3DR.%26aulast%3DRistic%26aufirst%3DZ.%26aulast%3DLill%26aufirst%3DH.%26aulast%3DDorange%26aufirst%3DI.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DBald%26aufirst%3DD.%26aulast%3DAndries%26aufirst%3DK.%26atitle%3DDiarylquinolines%2520target%2520subunit%2520c%2520of%2520mycobacterial%2520ATP%2520synthase%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2007%26volume%3D3%26spage%3D323%26epage%3D324%26doi%3D10.1038%2Fnchembio884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hards, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, G. M.</span></span> <span> </span><span class="NLM_article-title">Bactericidal mode of action of bedaquiline</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">2028</span>– <span class="NLM_lpage">2037</span>, <span class="refDoi"> DOI: 10.1093/jac/dkv054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fjac%2Fdkv054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25754998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFyltr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2015&pages=2028-2037&author=K.+Hardsauthor=J.+R.+Robsonauthor=M.+Berneyauthor=L.+Shawauthor=D.+Baldauthor=A.+Koulauthor=K.+Andriesauthor=G.+M.+Cook&title=Bactericidal+mode+of+action+of+bedaquiline&doi=10.1093%2Fjac%2Fdkv054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Bactericidal mode of action of bedaquiline</span></div><div class="casAuthors">Hards, Kiel; Robson, Jennifer R.; Berney, Michael; Shaw, Lisa; Bald, Dirk; Koul, Anil; Andries, Koen; Cook, Gregory M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2028-2037</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: It is not fully understood why inhibiting ATP synthesis in Mycobacterium species leads to death in non-replicating cells.  We investigated the bactericidal mode of action of the anti-tubercular F1Fo-ATP synthase inhibitor bedaquiline (Sirturo) in order to further understand the lethality of ATP synthase inhibition.  Methods:Mycobacterium smegmatis strains were used for all the expts.  Growth and survival during a bedaquiline challenge were performed in multiple media types.  A time-course microarray was performed during initial bedaquiline challenge in minimal medium.  Oxygen consumption and proton-motive force measurements were performed on whole cells and inverted membrane vesicles, resp.  Results: A killing of 3 log10 cfu/mL was achieved 4-fold more quickly in minimal medium (a glycerol carbon source) vs. rich medium (LB with Tween 80) during bedaquiline challenge.  Assessing the accelerated killing condition, we identified a transcriptional remodelling of metab. that was consistent with respiratory dysfunction but inconsistent with ATP depletion.  In glycerol-energized cell suspensions, bedaquiline caused an immediate 2.3-fold increase in oxygen consumption.  Bedaquiline collapsed the transmembrane pH gradient, but not the membrane potential, in a dose-dependent manner.  Both these effects were dependent on binding to the F1Fo-ATP synthase.  Conclusions: Challenge with bedaquiline results in an electroneutral uncoupling of respiration-driven ATP synthesis.  This may be a determinant of the bactericidal effects of bedaquiline, while ATP depletion may be a determinant of its delayed onset of killing.  We propose that bedaquiline binds to and perturbs the a-c subunit interface of the Fo, leading to futile proton cycling, which is known to be lethal to mycobacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTEo-2TAKMdrVg90H21EOLACvtfcHk0ljAZxRGmPlIbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFyltr7N&md5=22c8df11e6b904ba3645fa7ac74c5074</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkv054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkv054%26sid%3Dliteratum%253Aachs%26aulast%3DHards%26aufirst%3DK.%26aulast%3DRobson%26aufirst%3DJ.%2BR.%26aulast%3DBerney%26aufirst%3DM.%26aulast%3DShaw%26aufirst%3DL.%26aulast%3DBald%26aufirst%3DD.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DCook%26aufirst%3DG.%2BM.%26atitle%3DBactericidal%2520mode%2520of%2520action%2520of%2520bedaquiline%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2015%26volume%3D70%26spage%3D2028%26epage%3D2037%26doi%3D10.1093%2Fjac%2Fdkv054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hards, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillan, D. G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schurig-Briccio, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gennis, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, G. M.</span></span> <span> </span><span class="NLM_article-title">Ionophoric effects of the antitubercular drug bedaquiline</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">7326</span>– <span class="NLM_lpage">7331</span>, <span class="refDoi"> DOI: 10.1073/pnas.1803723115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1073%2Fpnas.1803723115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29941569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCmsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=7326-7331&author=K.+Hardsauthor=D.+G.+G.+McMillanauthor=L.+A.+Schurig-Briccioauthor=R.+B.+Gennisauthor=H.+Lillauthor=D.+Baldauthor=G.+M.+Cook&title=Ionophoric+effects+of+the+antitubercular+drug+bedaquiline&doi=10.1073%2Fpnas.1803723115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Ionophoric effects of the antitubercular drug bedaquiline</span></div><div class="casAuthors">Hards, Kiel; McMillan, Duncan G. G.; Schurig-Briccio, Lici A.; Gennis, Robert B.; Lill, Holger; Bald, Dirk; Cook, Gregory M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">7326-7331</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Bedaquiline (BDQ), an inhibitor of the mycobacterial F1Fo-ATP synthase, has revolutionized the antitubercular drug discovery program by defining energy metab. as a potent new target space.  Several studies have recently suggested that BDQ ultimately causes mycobacterial cell death through a phenomenon known as uncoupling.  The biochem. basis underlying this, in BDQ, is unresolved and may represent a new pathway to the development of effective therapeutics.  In this communication, we demonstrate that BDQ can inhibit ATP synthesis in Escherichia coli by functioning as a H+/K+ ionophore, causing transmembrane pH and potassium gradients to be equilibrated.  Despite the apparent lack of a BDQ-binding site, incorporating the E. coli Fo subunit into liposomes enhanced the ionophoric activity of BDQ.  We discuss the possibility that localization of BDQ at F1Fo-ATP synthases enables BDQ to create an uncoupled microenvironment, by antiporting H+/K+.  Ionophoric properties may be desirable in high-affinity antimicrobials targeting integral membrane proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnzopAp0asdrVg90H21EOLACvtfcHk0ljAZxRGmPlIbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCmsb3L&md5=458eb31c6312ab5573f5d9d3f5bbbf1c</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1803723115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1803723115%26sid%3Dliteratum%253Aachs%26aulast%3DHards%26aufirst%3DK.%26aulast%3DMcMillan%26aufirst%3DD.%2BG.%2BG.%26aulast%3DSchurig-Briccio%26aufirst%3DL.%2BA.%26aulast%3DGennis%26aufirst%3DR.%2BB.%26aulast%3DLill%26aufirst%3DH.%26aulast%3DBald%26aufirst%3DD.%26aulast%3DCook%26aufirst%3DG.%2BM.%26atitle%3DIonophoric%2520effects%2520of%2520the%2520antitubercular%2520drug%2520bedaquiline%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3D7326%26epage%3D7331%26doi%3D10.1073%2Fpnas.1803723115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anurag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, D.</span></span> <span> </span><span class="NLM_article-title">Unraveling the potential of intrinsically disordered proteins as drug targets: application to Mycobacterium tuberculosis</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1752</span>– <span class="NLM_lpage">1757</span>, <span class="refDoi"> DOI: 10.1039/b905518p</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1039%2Fb905518p" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19763328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2ks7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=1752-1757&author=M.+Anuragauthor=D.+Dash&title=Unraveling+the+potential+of+intrinsically+disordered+proteins+as+drug+targets%3A+application+to+Mycobacterium+tuberculosis&doi=10.1039%2Fb905518p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Unraveling the potential of intrinsically disordered proteins as drug targets: application to Mycobacterium tuberculosis</span></div><div class="casAuthors">Anurag, Meenakshi; Dash, Debasis</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1752-1757</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Many eukaryotic and prokaryotic proteins remain disordered under physiol. conditions and often acquire a stable secondary structure on binding to their cellular targets.  Though the process of binding is still under anal., it has been found that the flexibility of proteins can add to their functionality.  This motivated us to explore intrinsically disordered proteins (IDPs) as drug targets.  In silico studies have been carried out on Mycobacterium tuberculosis, which, with emergence of hyper-virulent and drug resistant strains, XDRs and MDRs, is one of the most dreaded pathogens in the modern world.  The authors' study reports 13 IDPs as potential drug targets, and 3 of them - FtsW (Rv2154c), GlmU (Rv1018c) and Obg (Rv2440c) - are chosen as key proteins and are described in detail.  Future applications of this method can provide new insight into understanding the mol. mechanism of IDPs and their potential role as drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVN7gx8lC1arVg90H21EOLACvtfcHk0ljAZxRGmPlIbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2ks7rI&md5=8cc7b07044a7d6223b734b49287f1d17</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1039%2Fb905518p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb905518p%26sid%3Dliteratum%253Aachs%26aulast%3DAnurag%26aufirst%3DM.%26aulast%3DDash%26aufirst%3DD.%26atitle%3DUnraveling%2520the%2520potential%2520of%2520intrinsically%2520disordered%2520proteins%2520as%2520drug%2520targets%253A%2520application%2520to%2520Mycobacterium%2520tuberculosis%26jtitle%3DMol.%2520BioSyst.%26date%3D2009%26volume%3D5%26spage%3D1752%26epage%3D1757%26doi%3D10.1039%2Fb905518p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyson, H. J.</span></span> <span> </span><span class="NLM_article-title">Intrinsically disordered proteins in cellular signalling and regulation</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">18</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1038/nrm3920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnrm3920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25531225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKlt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=18-29&author=P.+E.+Wrightauthor=H.+J.+Dyson&title=Intrinsically+disordered+proteins+in+cellular+signalling+and+regulation&doi=10.1038%2Fnrm3920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Intrinsically disordered proteins in cellular signalling and regulation</span></div><div class="casAuthors">Wright, Peter E.; Dyson, H. Jane</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18-29</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Intrinsically disordered proteins (IDPs) are important components of the cellular signalling machinery, allowing the same polypeptide to undertake different interactions with different consequences.  IDPs are subject to combinatorial post-translational modifications and alternative splicing, adding complexity to regulatory networks and providing a mechanism for tissue-specific signalling.  These proteins participate in the assembly of signalling complexes and in the dynamic self-assembly of membrane-less nuclear and cytoplasmic organelles.  Exptl., computational and bioinformatic analyses combine to identify and characterize disordered regions of proteins, leading to a greater appreciation of their widespread roles in biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw5RO2fjcUD7Vg90H21EOLACvtfcHk0ljrisXvEmIRGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKlt7fK&md5=39845ab9ab74fe94b7f7b810b632503b</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1038%2Fnrm3920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3920%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DP.%2BE.%26aulast%3DDyson%26aufirst%3DH.%2BJ.%26atitle%3DIntrinsically%2520disordered%2520proteins%2520in%2520cellular%2520signalling%2520and%2520regulation%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2015%26volume%3D16%26spage%3D18%26epage%3D29%26doi%3D10.1038%2Fnrm3920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uversky, V. N.</span></span> <span> </span><span class="NLM_article-title">Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators</span>. <i>Front. Mol. Biosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">6</span>, <span class="refDoi"> DOI: 10.3389/fmolb.2014.00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3389%2Ffmolb.2014.00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25988147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsFyrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2014&pages=6&author=V.+N.+Uversky&title=Wrecked+regulation+of+intrinsically+disordered+proteins+in+diseases%3A+pathogenicity+of+deregulated+regulators&doi=10.3389%2Ffmolb.2014.00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators</span></div><div class="casAuthors">Uversky, Vladimir N.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Biosciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6/1-6/24</span>CODEN:
                <span class="NLM_cas:coden">FMBRBS</span>;
        ISSN:<span class="NLM_cas:issn">2296-889X</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Biol. active proteins without stable tertiary structure are common in all known proteomes.  Functions of these intrinsically disordered proteins (IDPs) are typically related to regulation, signaling, and control.  Cellular levels of these important regulators are tightly regulated by a variety mechanisms ranging from firmly controlled expression to precisely targeted degrdn.  Functions of IDPs are controlled by binding to specific partners, alternative splicing, and posttranslational modifications among other means.  In the norm, right amts. of precisely activated IDPs have to be present in right time at right places.  Wrecked regulation brings havoc to the ordered world of disordered proteins, leading to protein misfolding, misidentification, and missignaling that give rise to numerous human diseases, such as cancer, cardiovascular disease, neurodegenerative diseases, and diabetes.  Among factors inducing pathogenic transformations of IDPs are various cellular mechanisms, such as chromosomal translocations, damaged splicing, altered expression, frustrated posttranslational modifications, aberrant proteolytic degrdn., and defective trafficking.  This review presents some of the aspects of deregulated regulation of IDPs leading to human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO-3sQjsU2wbVg90H21EOLACvtfcHk0ljrisXvEmIRGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsFyrtrs%253D&md5=eaa0a8500c57beeade266712316d3e58</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.3389%2Ffmolb.2014.00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmolb.2014.00006%26sid%3Dliteratum%253Aachs%26aulast%3DUversky%26aufirst%3DV.%2BN.%26atitle%3DWrecked%2520regulation%2520of%2520intrinsically%2520disordered%2520proteins%2520in%2520diseases%253A%2520pathogenicity%2520of%2520deregulated%2520regulators%26jtitle%3DFront.%2520Mol.%2520Biosci.%26date%3D2014%26volume%3D1%26spage%3D6%26doi%3D10.3389%2Ffmolb.2014.00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suryawanshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiti, S.</span></span> <span> </span><span class="NLM_article-title">Intrinsically disordered protein from a pathogenic mesophile Mycobacterium tuberculosis adopts structured conformation at high temperature</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1123</span>– <span class="NLM_lpage">1133</span>, <span class="refDoi"> DOI: 10.1002/prot.21798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1002%2Fprot.21798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=18004752" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2008&pages=1123-1133&author=N.+Kumarauthor=S.+Shuklaauthor=S.+Kumarauthor=A.+Suryawanshiauthor=U.+Chaudhryauthor=S.+Ramachandranauthor=S.+Maiti&title=Intrinsically+disordered+protein+from+a+pathogenic+mesophile+Mycobacterium+tuberculosis+adopts+structured+conformation+at+high+temperature&doi=10.1002%2Fprot.21798"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1002%2Fprot.21798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.21798%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DSuryawanshi%26aufirst%3DA.%26aulast%3DChaudhry%26aufirst%3DU.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DMaiti%26aufirst%3DS.%26atitle%3DIntrinsically%2520disordered%2520protein%2520from%2520a%2520pathogenic%2520mesophile%2520Mycobacterium%2520tuberculosis%2520adopts%2520structured%2520conformation%2520at%2520high%2520temperature%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2008%26volume%3D71%26spage%3D1123%26epage%3D1133%26doi%3D10.1002%2Fprot.21798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meszaros, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vertessy, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dosztanyi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, I.</span></span> <span> </span><span class="NLM_article-title">Proteins with complex architecture as potential targets for drug design: a case study of Mycobacterium tuberculosis</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e1002118</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.1002118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pcbi.1002118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21814507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGqs7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=e1002118&author=B.+Meszarosauthor=J.+Tothauthor=B.+G.+Vertessyauthor=Z.+Dosztanyiauthor=I.+Simon&title=Proteins+with+complex+architecture+as+potential+targets+for+drug+design%3A+a+case+study+of+Mycobacterium+tuberculosis&doi=10.1371%2Fjournal.pcbi.1002118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Proteins with complex architecture as potential targets for drug design: a case study of Mycobacterium tuberculosis</span></div><div class="casAuthors">Meszaros, Balint; Toth, Judit; Vertessy, Beata G.; Dosztanyi, Zsuzsanna; Simon, Istvan</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e1002118</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Lengthy co-evolution of Homo sapiens and Mycobacterium tuberculosis, the main causative agent of tuberculosis, resulted in a dramatically successful pathogen species that presents considerable challenge for modern medicine.  The continuous and ever increasing appearance of multi-drug resistant mycobacteria necessitates the identification of novel drug targets and drugs with new mechanisms of action.  However, further insights are needed to establish automated protocols for target selection based on the available complete genome sequences.  In the present study, we perform complete proteome level comparisons between M. tuberculosis, mycobacteria, other prokaryotes and available eukaryotes based on protein domains, local sequence similarities and protein disorder.  We show that the enrichment of certain domains in the genome can indicate an important function specific to M. tuberculosis.  We identified two families, termed pkn and PE/PPE that stand out in this respect.  The common property of these two protein families is a complex domain organization that combines species-specific regions, commonly occurring domains and disordered segments.  Besides highlighting promising novel drug target candidates in M. tuberculosis, the presented anal. can also be viewed as a general protocol to identify proteins involved in species-specific functions in a given organism.  We conclude that target selection protocols should be extended to include proteins with complex domain architectures instead of focusing on sequentially unique and essential proteins only.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpETKVogR9Xs7Vg90H21EOLACvtfcHk0liqgVkXKxQgow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGqs7nI&md5=3a9385712e14ef77aaba9e969d939815</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1002118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1002118%26sid%3Dliteratum%253Aachs%26aulast%3DMeszaros%26aufirst%3DB.%26aulast%3DToth%26aufirst%3DJ.%26aulast%3DVertessy%26aufirst%3DB.%2BG.%26aulast%3DDosztanyi%26aufirst%3DZ.%26aulast%3DSimon%26aufirst%3DI.%26atitle%3DProteins%2520with%2520complex%2520architecture%2520as%2520potential%2520targets%2520for%2520drug%2520design%253A%2520a%2520case%2520study%2520of%2520Mycobacterium%2520tuberculosis%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3De1002118%26doi%3D10.1371%2Fjournal.pcbi.1002118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, S. L.</span></span> <span> </span><span class="NLM_article-title">Mycobacterial PE/PPE proteins at the host-pathogen interface</span>. <i>Clin. Dev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">497203</span>, <span class="refDoi"> DOI: 10.1155/2011/497203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1155%2F2011%2F497203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21318182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3M7ovFKnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=497203&author=S.+L.+Sampson&title=Mycobacterial+PE%2FPPE+proteins+at+the+host-pathogen+interface&doi=10.1155%2F2011%2F497203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Mycobacterial PE/PPE proteins at the host-pathogen interface</span></div><div class="casAuthors">Sampson Samantha L</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & developmental immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">497203</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The mycobacterial PE/PPE proteins have attracted much interest since their formal identification just over a decade ago.  It has been widely speculated that these proteins may play a role in evasion of host immune responses, possibly via antigenic variation.  Although a cohesive understanding of their function(s) has yet to be established, emerging data increasingly supports a role for the PE/PPE proteins at multiple levels of the infectious process.  This paper will delineate salient features of the families revealed by comparative genomics, bioinformatic analyses and genome-wide screening approaches and will summarise existing knowledge of subcellular localization, secretion pathways, and protein structure.  These characteristics will be considered in light of findings on innate and adaptive host responses to PE/PPE proteins, and we will review the increasing body of data on B and T cell recognition of these proteins.  Finally, we will consider how current knowledge and future explorations may contribute to a more comprehensive understanding of these intriguing proteins and their involvement in host pathogen interactions.  Ultimately this information could underpin future intervention strategies, for example, in the area of new and improved diagnostic tools and vaccine candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQa9-ctKunXE7P3FVUi_gf8fW6udTcc2eZvbAKqaVVP6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7ovFKnsg%253D%253D&md5=ee1140a065b79b5276812f6111814268</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1155%2F2011%2F497203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F497203%26sid%3Dliteratum%253Aachs%26aulast%3DSampson%26aufirst%3DS.%2BL.%26atitle%3DMycobacterial%2520PE%252FPPE%2520proteins%2520at%2520the%2520host-pathogen%2520interface%26jtitle%3DClin.%2520Dev.%2520Immunol.%26date%3D2011%26volume%3D2011%26spage%3D497203%26doi%3D10.1155%2F2011%2F497203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blower, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, J. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">1706</span>– <span class="NLM_lpage">1713</span>, <span class="refDoi"> DOI: 10.1073/pnas.1525047113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1073%2Fpnas.1525047113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26792525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=1706-1713&author=T.+R.+Blowerauthor=B.+H.+Williamsonauthor=R.+J.+Kernsauthor=J.+M.+Berger&title=Crystal+structure+and+stability+of+gyrase-fluoroquinolone+cleaved+complexes+from+Mycobacterium+tuberculosis&doi=10.1073%2Fpnas.1525047113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis</span></div><div class="casAuthors">Blower, Tim R.; Williamson, Benjamin H.; Kerns, Robert J.; Berger, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1706-1713</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis (Mtb) infects one-third of the world's population and in 2013 accounted for 1.5 million deaths.  Fluoroquinolone antibacterials, which target DNA gyrase, are crit. agents used to halt the progression from multidrug-resistant tuberculosis to extensively resistant disease; however, fluoroquinolone resistance is emerging and new ways to bypass resistance are required.  To better explain known differences in fluoroquinolone action, the crystal structures of the WT Mtb DNA gyrase cleavage core and a fluoroquinolone-sensitized mutant were detd. in complex with DNA and five fluoroquinolones.  The structures, ranging from 2.4- to 2.6-Å resoln., show that the intrinsically low susceptibility of Mtb to fluoroquinolones correlates with a redn. in contacts to the water shell of an assocd. magnesium ion, which bridges fluoroquinolone-gyrase interactions.  Surprisingly, the structural data revealed few differences in fluoroquinolone-enzyme contacts from drugs that have very different activities against Mtb.  By contrast, a stability assay using purified components showed a clear relationship between ternary complex reversibility and inhibitory activities reported with cultured cells.  Collectively, our data indicate that the stability of fluoroquinolone/DNA interactions is a major determinant of fluoroquinolone activity and that moieties that have been appended to the C7 position of different quinolone scaffolds do not take advantage of specific contacts that might be made with the enzyme.  These concepts point to new approaches for developing quinolone-class compds. that have increased potency against Mtb and the ability to overcome resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotyAfeeRgSebVg90H21EOLACvtfcHk0lg5SA58LRGH0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWjsr8%253D&md5=bde8e79ead3566a890d7e970de8c3292</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1525047113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1525047113%26sid%3Dliteratum%253Aachs%26aulast%3DBlower%26aufirst%3DT.%2BR.%26aulast%3DWilliamson%26aufirst%3DB.%2BH.%26aulast%3DKerns%26aufirst%3DR.%2BJ.%26aulast%3DBerger%26aufirst%3DJ.%2BM.%26atitle%3DCrystal%2520structure%2520and%2520stability%2520of%2520gyrase-fluoroquinolone%2520cleaved%2520complexes%2520from%2520Mycobacterium%2520tuberculosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D1706%26epage%3D1713%26doi%3D10.1073%2Fpnas.1525047113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ditse, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. F.</span></span> <span> </span><span class="NLM_article-title">DNA Replication in Mycobacterium tuberculosis</span>. <i>Microbiol. Spectrum</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">TBTB2-0027-2016</span>, <span class="refDoi"> DOI: 10.1128/microbiolspec.TBTB2-0027-2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2Fmicrobiolspec.TBTB2-0027-2016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=TBTB2-0027-2016&author=Z.+Ditseauthor=M.+H.+Lamersauthor=D.+F.+Warner&title=DNA+Replication+in+Mycobacterium+tuberculosis&doi=10.1128%2Fmicrobiolspec.TBTB2-0027-2016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1128%2Fmicrobiolspec.TBTB2-0027-2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmicrobiolspec.TBTB2-0027-2016%26sid%3Dliteratum%253Aachs%26aulast%3DDitse%26aufirst%3DZ.%26aulast%3DLamers%26aufirst%3DM.%2BH.%26aulast%3DWarner%26aufirst%3DD.%2BF.%26atitle%3DDNA%2520Replication%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DMicrobiol.%2520Spectrum%26date%3D2017%26volume%3D5%26spage%3DTBTB2-0027-2016%26doi%3D10.1128%2Fmicrobiolspec.TBTB2-0027-2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prisic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husson, R. N.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis Serine/Threonine protein kinases</span>. <i>Microbiol. Spectrum</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">MGM2-0006-2013</span>, <span class="refDoi"> DOI: 10.1128/microbiolspec.MGM2-0006-2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2Fmicrobiolspec.MGM2-0006-2013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=MGM2-0006-2013&author=S.+Prisicauthor=R.+N.+Husson&title=Mycobacterium+tuberculosis+Serine%2FThreonine+protein+kinases&doi=10.1128%2Fmicrobiolspec.MGM2-0006-2013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1128%2Fmicrobiolspec.MGM2-0006-2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmicrobiolspec.MGM2-0006-2013%26sid%3Dliteratum%253Aachs%26aulast%3DPrisic%26aufirst%3DS.%26aulast%3DHusson%26aufirst%3DR.%2BN.%26atitle%3DMycobacterium%2520tuberculosis%2520Serine%252FThreonine%2520protein%2520kinases%26jtitle%3DMicrobiol.%2520Spectrum%26date%3D2014%26volume%3D2%26spage%3DMGM2-0006-2013%26doi%3D10.1128%2Fmicrobiolspec.MGM2-0006-2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alber, T.</span></span> <span> </span><span class="NLM_article-title">Signaling mechanisms of the Mycobacterium tuberculosis receptor Ser/Thr protein kinases</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">657</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2009.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.sbi.2009.10.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19914822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsV2gsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=650-657&author=T.+Alber&title=Signaling+mechanisms+of+the+Mycobacterium+tuberculosis+receptor+Ser%2FThr+protein+kinases&doi=10.1016%2Fj.sbi.2009.10.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling mechanisms of the Mycobacterium tuberculosis receptor Ser/Thr protein kinases</span></div><div class="casAuthors">Alber, Tom</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">650-657</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Like eukaryotes, bacteria express receptor Ser/Thr protein kinases (STPKs) that initiate a wide variety of signaling networks.  Recent biochem. and structural studies of the STPKs of M. tuberculosis have revealed that bacterial and eukaryotic STPKs adopt common folds and share mechanisms of substrate recognition and regulation.  Mycobacterial receptor STPKs are activated by dimerization through 2 distinct interfaces that promote activation-loop phosphorylation.  The active STPKs phosphorylate diverse substrates within the bacterial cell, including other kinases as well as proteins involved in many central physiol. processes.  In the case of the FHA-domain protein, GarA, the unphosphorylated protein regulates primary metab., while phosphorylation mediates GarA autoinhibition.  These studies have begun to define the activation mechanisms and the biol. regulatory functions of the mycobacterial STPKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprcpYqq0as2LVg90H21EOLACvtfcHk0lg5SA58LRGH0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsV2gsrfP&md5=d4eb3c345c2ab9d75291c289b113dbc7</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2009.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2009.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DAlber%26aufirst%3DT.%26atitle%3DSignaling%2520mechanisms%2520of%2520the%2520Mycobacterium%2520tuberculosis%2520receptor%2520Ser%252FThr%2520protein%2520kinases%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2009%26volume%3D19%26spage%3D650%26epage%3D657%26doi%3D10.1016%2Fj.sbi.2009.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnappinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrt, S.</span></span> <span> </span><span class="NLM_article-title">Triosephosphate isomerase is dispensable in vitro yet essential for Mycobacterium tuberculosis to establish infection</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e00085</span>, <span class="refDoi"> DOI: 10.1128/mBio.00085-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FmBio.00085-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=24757211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Smsr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=e00085&author=C.+Trujilloauthor=A.+Blumenthalauthor=J.+Marreroauthor=K.+Y.+Rheeauthor=D.+Schnappingerauthor=S.+Ehrt&title=Triosephosphate+isomerase+is+dispensable+in+vitro+yet+essential+for+Mycobacterium+tuberculosis+to+establish+infection&doi=10.1128%2FmBio.00085-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Triosephosphate isomerase is dispensable in vitro yet essential for Mycobacterium tuberculosis to establish infection</span></div><div class="casAuthors">Trujillo, Carolina; Blumenthal, Antje; Marrero, Joeli; Rhee, Kyu Y.; Schnappinger, Dirk; Ehrt, Sabine</div><div class="citationInfo"><span class="NLM_cas:title">mBio</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e00085/1-e00085/12, 12</span>CODEN:
                <span class="NLM_cas:coden">MBIOCL</span>;
        ISSN:<span class="NLM_cas:issn">2150-7511</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Triosephosphate isomerase (TPI) catalyzes the interconversion of dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-phosphate (G3P).  This reaction is required for glycolysis and gluconeogenesis, and tpi has been predicted to be essential for growth of Mycobacterium tuberculosis.  However, when studying a conditionally regulated tpi knockdown mutant, we noticed that depletion of TPI reduced growth of M. tuberculosis in media contg. a single carbon source but not in media that contained both a glycolytic and a gluconeogenic carbon source.  We used such two-carbon-source media to isolate a tpi deletion (Δtpi) mutant.  The Δtpi mutant did not survive with single carbon substrates but grew like wild-type (WT) M. tuberculosis in the presence of both a glycolytic and a gluconeogenic carbon source. 13C metabolite tracing revealed the accumulation of TPI substrates in Δtpi and the absence of alternative triosephosphate isomerases and metabolic bypass reactions, which confirmed the requirement of TPI for glycolysis and gluconeogenesis in M. tuberculosis.  The Δtpi strain was furthermore severely attenuated in the mouse model of tuberculosis, suggesting that M. tuberculosis cannot simultaneously access sufficient quantities of glycolytic and gluconeogenic carbon substrates to establish infection in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiBBsrr76A4LVg90H21EOLACvtfcHk0lhzythsYp8CQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Smsr%252FF&md5=fa624cd5300a2993006d45d6ee309a1e</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1128%2FmBio.00085-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.00085-14%26sid%3Dliteratum%253Aachs%26aulast%3DTrujillo%26aufirst%3DC.%26aulast%3DBlumenthal%26aufirst%3DA.%26aulast%3DMarrero%26aufirst%3DJ.%26aulast%3DRhee%26aufirst%3DK.%2BY.%26aulast%3DSchnappinger%26aufirst%3DD.%26aulast%3DEhrt%26aufirst%3DS.%26atitle%3DTriosephosphate%2520isomerase%2520is%2520dispensable%2520in%2520vitro%2520yet%2520essential%2520for%2520Mycobacterium%2520tuberculosis%2520to%2520establish%2520infection%26jtitle%3DmBio%26date%3D2014%26volume%3D5%26spage%3De00085%26doi%3D10.1128%2FmBio.00085-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torres, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankaran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujol, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliska, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulding, C. W.</span></span> <span> </span><span class="NLM_article-title">Structural insights into RipC, a putative citrate lyase β subunit from a Yersinia pestis virulence operon</span>. <i>Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1107/S1744309111048056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1107%2FS1744309111048056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22232161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkslyiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=2-7&author=R.+Torresauthor=N.+Chimauthor=B.+Sankaranauthor=C.+Pujolauthor=J.+B.+Bliskaauthor=C.+W.+Goulding&title=Structural+insights+into+RipC%2C+a+putative+citrate+lyase+%CE%B2+subunit+from+a+Yersinia+pestis+virulence+operon&doi=10.1107%2FS1744309111048056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into RipC, a putative citrate lyase β subunit from a Yersinia pestis virulence operon</span></div><div class="casAuthors">Torres, Rodrigo; Chim, Nicholas; Sankaran, Banumathi; Pujol, Celine; Bliska, James B.; Goulding, Celia W.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology and Crystallization Communications</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-7</span>CODEN:
                <span class="NLM_cas:coden">ACSFCL</span>;
        ISSN:<span class="NLM_cas:issn">1744-3091</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Comparison of the 2.45 Å resoln. crystal structure of homotrimeric RipC, a putative citrate lyase β subunit from Y. pestis, with structural homologs reveals conserved RipC residues that are implicated in CoA binding.  Yersinia pestis remains a threat, with outbreaks of plague occurring in rural areas and its emergence as a weapon of bioterrorism; thus, an improved understanding of its various pathogenicity pathways is warranted.  The rip (required for intracellular proliferation) virulence operon is required for Y. pestis survival in interferon-γ-treated macrophages and has been implicated in lowering macrophage-produced nitric oxide levels.  RipC, one of three gene products from the rip operon, is annotated as a citrate lyase β subunit.  Furthermore, the Y. pestis genome lacks genes that encode citrate lyase α and γ subunits, suggesting a unique functional role of RipC in the Y. pestis rip-mediated survival pathway.  Here, the 2.45 Å resoln. crystal structure of RipC revealed a homotrimer in which each monomer consists of a (β/α)8 TIM-barrel fold.  Furthermore, the trimeric state was confirmed in soln. by size-exclusion chromatog.  Through sequence and structure comparisons with homologous proteins, it is proposed that RipC is a putative CoA- or CoA-deriv. binding protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreXwfyie5pE7Vg90H21EOLACvtfcHk0lhzythsYp8CQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkslyiuw%253D%253D&md5=65efb3a5c22413763f16573214d02cf3</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1107%2FS1744309111048056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS1744309111048056%26sid%3Dliteratum%253Aachs%26aulast%3DTorres%26aufirst%3DR.%26aulast%3DChim%26aufirst%3DN.%26aulast%3DSankaran%26aufirst%3DB.%26aulast%3DPujol%26aufirst%3DC.%26aulast%3DBliska%26aufirst%3DJ.%2BB.%26aulast%3DGoulding%26aufirst%3DC.%2BW.%26atitle%3DStructural%2520insights%2520into%2520RipC%252C%2520a%2520putative%2520citrate%2520lyase%2520%25CE%25B2%2520subunit%2520from%2520a%2520Yersinia%2520pestis%2520virulence%2520operon%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Cryst.%2520Commun.%26date%3D2012%26volume%3D68%26spage%3D2%26epage%3D7%26doi%3D10.1107%2FS1744309111048056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arora, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidwai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span> <span> </span><span class="NLM_article-title">CitE enzymes are essential for Mycobacterium tuberculosis to establish infection in macrophages and guinea pigs</span>. <i>Front. Cell. Infect. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">385</span>, <span class="refDoi"> DOI: 10.3389/fcimb.2018.00385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3389%2Ffcimb.2018.00385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30460206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWrsrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=385&author=G.+Aroraauthor=D.+Chaudharyauthor=S.+Kidwaiauthor=D.+Sharmaauthor=R.+Singh&title=CitE+enzymes+are+essential+for+Mycobacterium+tuberculosis+to+establish+infection+in+macrophages+and+guinea+pigs&doi=10.3389%2Ffcimb.2018.00385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">CitE enzymes are essential for Mycobacterium tuberculosis to establish infection in macrophages and guinea pigs</span></div><div class="casAuthors">Arora, Garima; Chaudhary, Deepika; Kidwai, Saqib; Sharma, Deepak; Singh, Ramandeep</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular and Infection Microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">385</span>CODEN:
                <span class="NLM_cas:coden">FCIMAB</span>;
        ISSN:<span class="NLM_cas:issn">2235-2988</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Bacterial citrate lyase activity has been demonstrated in various eukaryotes, bacteria and archaea, underscoring their importance in energy metab. of the cell.  While the bacterial citrate lyase comprises of three different subunits, M. tuberculosis genome lacks CitD and CitF subunits of citrate lyase complex but encodes for 2 homologs of CitE subunits, Rv2498c and Rv3075c.  Using temp. sensitive mycobacteriophages, we were able to generate both single and double citE mutant strains of M. tuberculosis.  The survival expts. revealed increased susceptibility of the double mutant strain to oxidative stress in comparison to the parental strain.  Also, simultaneous deletion of both citE1 and citE2 in M. tuberculosis genome resulted in impairment of intracellular replication in macrophages.  The double mutant strain displayed reduced growth in lungs and spleens of guinea pigs.  This is the first study demonstrating that M. tuberculosis critically requires CitE subunits of citrate lyase for pathogenesis.  Taken together, these findings position these enzymes as potential targets for development of anti-tubercular small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfoA3RzRX9kLVg90H21EOLACvtfcHk0liT2z5GRD4qgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWrsrbM&md5=969ddf786680b7b0f15245235d3f4933</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.3389%2Ffcimb.2018.00385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcimb.2018.00385%26sid%3Dliteratum%253Aachs%26aulast%3DArora%26aufirst%3DG.%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DKidwai%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DR.%26atitle%3DCitE%2520enzymes%2520are%2520essential%2520for%2520Mycobacterium%2520tuberculosis%2520to%2520establish%2520infection%2520in%2520macrophages%2520and%2520guinea%2520pigs%26jtitle%3DFront.%2520Cell.%2520Infect.%2520Microbiol.%26date%3D2018%26volume%3D8%26spage%3D385%26doi%3D10.3389%2Ffcimb.2018.00385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruddraraju, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-Y.</span></span> <span> </span><span class="NLM_article-title">Highly potent and selective N-Aryl Oxamic acid-based inhibitors for Mycobacterium tuberculosis protein tyrosine phosphatase B</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9212</span>– <span class="NLM_lpage">9227</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00302</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00302" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFeksLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9212-9227&author=K.+V.+Ruddrarajuauthor=D.+Aggarwalauthor=C.+Niuauthor=E.+A.+Bakerauthor=R.-y.+Zhangauthor=L.+Wuauthor=Z.-Y.+Zhang&title=Highly+potent+and+selective+N-Aryl+Oxamic+acid-based+inhibitors+for+Mycobacterium+tuberculosis+protein+tyrosine+phosphatase+B&doi=10.1021%2Facs.jmedchem.0c00302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium tuberculosis Protein Tyrosine Phosphatase B</span></div><div class="casAuthors">Ruddraraju, Kasi Viswanatharaju; Aggarwal, Devesh; Niu, Congwei; Baker, Erica Anne; Zhang, Ruo-yu; Wu, Li; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9212-9227</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis is an infectious disease caused by the bacterium Mycobacterium tuberculosis (Mtb).  Mtb protein tyrosine phosphatase B (mPTPB) is a virulence factor required for Mtb survival in host macrophages.  Consequently, mPTPB represents an exciting target for tuberculosis treatment.  Here, we identified N-Ph oxamic acid as a highly potent and selective monoacid-based phosphotyrosine mimetic for mPTPB inhibition.  SAR studies on the initial hit, compd. 4 (IC50 = 257 nM), resulted in several highly potent inhibitors with IC50 values lower than 20 nM for mPTPB.  Among them, compd. 4t(I) showed a Ki of 2.7 nM for mPTPB with over 4500-fold preference over 25 mammalian PTPs.  Kinetic, mol. docking, and site-directed mutagenesis analyses confirmed these compds. as active site-directed reversible inhibitors of mPTPB.  These inhibitors can reverse the altered host cell immune responses induced by the bacterial phosphatase.  Furthermore, the inhibitors possess mol. wts. <400 Da, log D7.4 < 2.5, topol. polar surface area < 75, ligand efficiency > 0.43, and good aq. soly. and metabolic stability, thus offering excellent starting points for further therapeutic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTFTilc3_tFbVg90H21EOLACvtfcHk0liT2z5GRD4qgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFeksLvP&md5=62bc5e0ccb29148f023ee1bf3c406faa</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00302%26sid%3Dliteratum%253Aachs%26aulast%3DRuddraraju%26aufirst%3DK.%2BV.%26aulast%3DAggarwal%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DBaker%26aufirst%3DE.%2BA.%26aulast%3DZhang%26aufirst%3DR.-y.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.-Y.%26atitle%3DHighly%2520potent%2520and%2520selective%2520N-Aryl%2520Oxamic%2520acid-based%2520inhibitors%2520for%2520Mycobacterium%2520tuberculosis%2520protein%2520tyrosine%2520phosphatase%2520B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9212%26epage%3D9227%26doi%3D10.1021%2Facs.jmedchem.0c00302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakila, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naseema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paramasivan, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, A. K.</span></span> <span> </span><span class="NLM_article-title">Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs</span>. <i>Mol. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2958.2003.03712.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1046%2Fj.1365-2958.2003.03712.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=14617138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2003&pages=751-762&author=R.+Singhauthor=V.+Raoauthor=H.+Shakilaauthor=R.+Guptaauthor=A.+Kheraauthor=N.+Dharauthor=A.+Singhauthor=A.+Koulauthor=Y.+Singhauthor=M.+Naseemaauthor=P.+R.+Narayananauthor=C.+N.+Paramasivanauthor=V.+D.+Ramanathanauthor=A.+K.+Tyagi&title=Disruption+of+mptpB+impairs+the+ability+of+Mycobacterium+tuberculosis+to+survive+in+guinea+pigs&doi=10.1046%2Fj.1365-2958.2003.03712.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs</span></div><div class="casAuthors">Singh, Ramandeep; Rao, Vivek; Shakila, H.; Gupta, Radhika; Khera, Aparna; Dhar, Neeraj; Singh, Amit; Koul, Anil; Singh, Yogendra; Naseema, M.; Narayanan, P. R.; Paramasivan, C. N.; Ramanathan, V. D.; Tyagi, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Microbiology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">751-762</span>CODEN:
                <span class="NLM_cas:coden">MOMIEE</span>;
        ISSN:<span class="NLM_cas:issn">0950-382X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Protein tyrosine kinases and tyrosine phosphatases from several bacterial pathogens have been shown to act as virulence factors by modulating the phosphorylation and dephosphorylation of host proteins.  The identification and characterization of two tyrosine phosphatases, namely MptpA and MptpB, from M. tuberculosis has been reported earlier.  MptpB is secreted by M. tuberculosis into extracellular milieu and exhibits a pH optimum of 5.6, similar to the pH of the lysosomal compartment of the cell.  To det. the role of MptpB in the pathogenesis of M. tuberculosis, we constructed a mptpB mutant strain by homologous recombination and compared the ability of parent and the mutant strain to survive intracellularly.  We show that disruption of the mptpB gene impairs the ability of the mutant strain to survive in activated macrophages and guinea pigs but not in resting macrophages, suggesting the importance of its role in the host-pathogen interaction.  Infection of guinea pigs with the mutant strain resulted in a 70-fold redn. in the bacillary load of spleens in infected animals as compared with the bacillary load in animals infected with the parental strain.  Upon reintroduction of the mptpB gene into the mutant strain, the complemented strain was able to establish infection and survive in guinea pigs at rates comparable to the parental strain.  These observations demonstrate a role of MptpB in the pathogenesis of M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqna7lf5deGyLVg90H21EOLACvtfcHk0lidHZf__syNSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVyrsbg%253D&md5=88d8f01f758712bb90bf974bf7bf0662</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2958.2003.03712.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2958.2003.03712.x%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DRao%26aufirst%3DV.%26aulast%3DShakila%26aufirst%3DH.%26aulast%3DGupta%26aufirst%3DR.%26aulast%3DKhera%26aufirst%3DA.%26aulast%3DDhar%26aufirst%3DN.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DY.%26aulast%3DNaseema%26aufirst%3DM.%26aulast%3DNarayanan%26aufirst%3DP.%2BR.%26aulast%3DParamasivan%26aufirst%3DC.%2BN.%26aulast%3DRamanathan%26aufirst%3DV.%2BD.%26aulast%3DTyagi%26aufirst%3DA.%2BK.%26atitle%3DDisruption%2520of%2520mptpB%2520impairs%2520the%2520ability%2520of%2520Mycobacterium%2520tuberculosis%2520to%2520survive%2520in%2520guinea%2520pigs%26jtitle%3DMol.%2520Microbiol.%26date%3D2003%26volume%3D50%26spage%3D751%26epage%3D762%26doi%3D10.1046%2Fj.1365-2958.2003.03712.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahairas, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabo, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span> <span> </span><span class="NLM_article-title">Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis</span>. <i>J. Bacteriol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">1274</span>– <span class="NLM_lpage">1282</span>, <span class="refDoi"> DOI: 10.1128/JB.178.5.1274-1282.1996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FJB.178.5.1274-1282.1996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=8631702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK28XhsVSqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=1996&pages=1274-1282&author=G.+G.+Mahairasauthor=P.+J.+Saboauthor=M.+J.+Hickeyauthor=D.+C.+Singhauthor=C.+K.+Stover&title=Molecular+analysis+of+genetic+differences+between+Mycobacterium+bovis+BCG+and+virulent+M.+bovis&doi=10.1128%2FJB.178.5.1274-1282.1996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis</span></div><div class="casAuthors">Mahairas, Gregory G.; Sabo, Peter J.; Hickey, Mark J.; Singh, Devinder C.; Stover, C. Kendall</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bacteriology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1274-82</span>CODEN:
                <span class="NLM_cas:coden">JOBAAY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9193</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The live attenuated bacillus Calmette-Guerin (BCG) vaccine for the prevention of disease assocd. with Mycobacterium tuberculosis was derived from the closely related virulent tubercle bacillus, Mycobacterium bovis.  Although the BCG vaccine has been one of the most widely used vaccines in the world for over 40 yr, the genetic basis of BCG's attenuation has never been elucidated.  We employed subtractive genomic hybridization to identify genetic differences between virulent M. bovis and M. tuberculosis and avirulent BCG.  Three distinct genomic regions of difference (designated RD1 to RD3) were found to be deleted from BCG, and the precise junctions and DNA sequence of each deletion were detd.  RD3, a 9.3-kb genomic segment present in virulent lab. strains of M. bovis and M. tuberculosis, was absent from BCG and 84% of virulent clin. isolates.  RD2, a 10.7-kb DNA segment contg. a novel repetitive element and the previously identified mpt-64 gene, was conserved in all virulent lab. and clin. tubercle bacilli tested and was deleted only from substrains derived from the original BCG Pasteur strain after 1925.  Thus, the RD2 deletion occurred after the original derivation of BCG.  RD1, a 9.5-kb DNA segment found to be deleted from all BCG substrains, was conserved in all virulent lab. and clin. isolates of M. bovis and M. tuberculosis tested.  The reintroduction of RD1 into BCG repressed the expression of at least 10 proteins and resulted in a protein expression profile almost identical to that of virulent M. bovis and M. tuberculosis, as detd. by two-dimensional gel electrophoresis.  These data indicate a role for RD1 in the regulation of multiple genetic loci, suggesting that the loss of virulence by BCG is due to a regulatory mutation.  These findings may be applicable to the rational design of a new attenuated tuberculosis vaccine and the development of new diagnostic tests to distinguish BCG vaccination from tuberculosis infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoYLbk6TnOe7Vg90H21EOLACvtfcHk0lidHZf__syNSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhsVSqur4%253D&md5=9865233434ed40636dcbb6a9eeac9367</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1128%2FJB.178.5.1274-1282.1996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJB.178.5.1274-1282.1996%26sid%3Dliteratum%253Aachs%26aulast%3DMahairas%26aufirst%3DG.%2BG.%26aulast%3DSabo%26aufirst%3DP.%2BJ.%26aulast%3DHickey%26aufirst%3DM.%2BJ.%26aulast%3DSingh%26aufirst%3DD.%2BC.%26aulast%3DStover%26aufirst%3DC.%2BK.%26atitle%3DMolecular%2520analysis%2520of%2520genetic%2520differences%2520between%2520Mycobacterium%2520bovis%2520BCG%2520and%2520virulent%2520M.%2520bovis%26jtitle%3DJ.%2520Bacteriol.%26date%3D1996%26volume%3D178%26spage%3D1274%26epage%3D1282%26doi%3D10.1128%2FJB.178.5.1274-1282.1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behr, M. A.</span></span> <span> </span><span class="NLM_article-title">Region of Difference 2 contributes to virulence of Mycobacterium tuberculosis</span>. <i>Infect. Immun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1128/IAI.00824-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FIAI.00824-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=20974821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVegtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2011&pages=59-66&author=R.+A.+Kozakauthor=D.+C.+Alexanderauthor=R.+Liaoauthor=D.+R.+Shermanauthor=M.+A.+Behr&title=Region+of+Difference+2+contributes+to+virulence+of+Mycobacterium+tuberculosis&doi=10.1128%2FIAI.00824-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Region of difference 2 contributes to virulence of Mycobacterium tuberculosis</span></div><div class="casAuthors">Kozak, Robert A.; Alexander, David C.; Liao, Reiling; Sherman, David R.; Behr, Marcel A.</div><div class="citationInfo"><span class="NLM_cas:title">Infection and Immunity</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-66</span>CODEN:
                <span class="NLM_cas:coden">INFIBR</span>;
        ISSN:<span class="NLM_cas:issn">0019-9567</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Mycobacterium bovis BCG strains are live, attenuated vaccines generated through decades of in vitro passage.  Because in vitro growth does not select for interaction with the host, it has been hypothesized that genetic loci lost from BCG code for virulence determinants that are dispensable for growth in the lab., as exemplified by Region of Difference 1 (RD1), which was lost during the original derivation of BCG between 1908 and 1921.  Region of Difference 2 (RD2) was lost during the ongoing propagation of BCG between 1927 and 1931, a time that coincides with reports of the ongoing attenuation of the vaccine.  In this study, RD2 has been disrupted in M. tuberculosis H37Rv to test whether its loss contributed to the further attenuation of BCG.  The deletion of RD2 did not affect in vitro growth; in contrast, the mutant manifested a decrease in pulmonary and splenic bacterial burdens and reduced pathol. in C57BL/6 mice at early time points.  This attenuated phenotype was complemented by reintroducing the genes Rv1979c to Rv1982 (including mpt64) but not Rv1985c to Rv1986.  In RAW 264.7 macrophages, H37Rv:ΔRD2 showed a decreased proliferation and impaired modulation of the host innate immune response; both observations were complemented with Rv1979c to Rv1982.  To test the effect of RD2 disruption on innate immunity, Rag-/- mice were infected; H37Rv:ΔRD2 had increased survival times compared those of H37Rv.  These findings support the notion that the safety profile of certain BCG vaccines stems from multiple attenuating mutations, with the RD2 deletion resulting in a less-virulent organism through the impaired bacterial manipulation of the host innate immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDMGK4_B1pKrVg90H21EOLACvtfcHk0lidHZf__syNSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVegtrY%253D&md5=29f768465b0dc0718a8a1bcb9a487af0</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1128%2FIAI.00824-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FIAI.00824-10%26sid%3Dliteratum%253Aachs%26aulast%3DKozak%26aufirst%3DR.%2BA.%26aulast%3DAlexander%26aufirst%3DD.%2BC.%26aulast%3DLiao%26aufirst%3DR.%26aulast%3DSherman%26aufirst%3DD.%2BR.%26aulast%3DBehr%26aufirst%3DM.%2BA.%26atitle%3DRegion%2520of%2520Difference%25202%2520contributes%2520to%2520virulence%2520of%2520Mycobacterium%2520tuberculosis%26jtitle%3DInfect.%2520Immun.%26date%3D2011%26volume%3D79%26spage%3D59%26epage%3D66%26doi%3D10.1128%2FIAI.00824-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaaf, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zignol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Soolingen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayona, J.</span></span> <span> </span><span class="NLM_article-title">Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">1830</span>– <span class="NLM_lpage">1843</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(10)60410-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS0140-6736%2810%2960410-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=20488523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3czlvVeitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2010&pages=1830-1843&author=N.+R.+Gandhiauthor=P.+Nunnauthor=K.+Dhedaauthor=H.+S.+Schaafauthor=M.+Zignolauthor=D.+van+Soolingenauthor=P.+Jensenauthor=J.+Bayona&title=Multidrug-resistant+and+extensively+drug-resistant+tuberculosis%3A+a+threat+to+global+control+of+tuberculosis&doi=10.1016%2FS0140-6736%2810%2960410-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis</span></div><div class="casAuthors">Gandhi Neel R; Nunn Paul; Dheda Keertan; Schaaf H Simon; Zignol Matteo; van Soolingen Dick; Jensen Paul; Bayona Jaime</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">9728</span>),
    <span class="NLM_cas:pages">1830-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although progress has been made to reduce global incidence of drug-susceptible tuberculosis, the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis during the past decade threatens to undermine these advances.  However, countries are responding far too slowly.  Of the estimated 440,000 cases of MDR tuberculosis that occurred in 2008, only 7% were identified and reported to WHO.  Of these cases, only a fifth were treated according to WHO standards.  Although treatment of MDR and XDR tuberculosis is possible with currently available diagnostic techniques and drugs, the treatment course is substantially more costly and laborious than for drug-susceptible tuberculosis, with higher rates of treatment failure and mortality.  Nonetheless, a few countries provide examples of how existing technologies can be used to reverse the epidemic of MDR tuberculosis within a decade.  Major improvements in laboratory capacity, infection control, performance of tuberculosis control programmes, and treatment regimens for both drug-susceptible and drug-resistant disease will be needed, together with a massive scale-up in diagnosis and treatment of MDR and XDR tuberculosis to prevent drug-resistant strains from becoming the dominant form of tuberculosis.  New diagnostic tests and drugs are likely to become available during the next few years and should accelerate control of MDR and XDR tuberculosis.  Equally important, especially in the highest-burden countries of India, China, and Russia, will be a commitment to tuberculosis control including improvements in national policies and health systems that remove financial barriers to treatment, encourage rational drug use, and create the infrastructure necessary to manage MDR tuberculosis on a national scale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvkaiZGYx8s5QHPYJuLg8TfW6udTcc2eaNZpb6mmALRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czlvVeitg%253D%253D&md5=189375b5fbd385a829cd0a1699372f5c</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2960410-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252960410-2%26sid%3Dliteratum%253Aachs%26aulast%3DGandhi%26aufirst%3DN.%2BR.%26aulast%3DNunn%26aufirst%3DP.%26aulast%3DDheda%26aufirst%3DK.%26aulast%3DSchaaf%26aufirst%3DH.%2BS.%26aulast%3DZignol%26aufirst%3DM.%26aulast%3Dvan%2BSoolingen%26aufirst%3DD.%26aulast%3DJensen%26aufirst%3DP.%26aulast%3DBayona%26aufirst%3DJ.%26atitle%3DMultidrug-resistant%2520and%2520extensively%2520drug-resistant%2520tuberculosis%253A%2520a%2520threat%2520to%2520global%2520control%2520of%2520tuberculosis%26jtitle%3DLancet%26date%3D2010%26volume%3D375%26spage%3D1830%26epage%3D1843%26doi%3D10.1016%2FS0140-6736%2810%2960410-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumbo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maartens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooley, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNerney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nardell, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessem, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Helden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, G. K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasipanodya, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirgel, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmail, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atre, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaaf, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udwadia, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsburgh, C. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchyard, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesseling, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuermberger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIlleron, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennelly, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goemaere, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jara, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padayatchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, R. M.</span></span> <span> </span><span class="NLM_article-title">The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(17)30079-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS2213-2600%2817%2930079-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=291-360&author=K.+Dhedaauthor=T.+Gumboauthor=G.+Maartensauthor=K.+E.+Dooleyauthor=R.+McNerneyauthor=M.+Murrayauthor=J.+Furinauthor=E.+A.+Nardellauthor=L.+Londonauthor=E.+Lessemauthor=G.+Theronauthor=P.+van+Heldenauthor=S.+Niemannauthor=M.+Merkerauthor=D.+Dowdyauthor=A.+Van+Rieauthor=G.+K.+H.+Siuauthor=J.+G.+Pasipanodyaauthor=C.+Rodriguesauthor=T.+G.+Clarkauthor=F.+A.+Sirgelauthor=A.+Esmailauthor=H.-H.+Linauthor=S.+R.+Atreauthor=H.+S.+Schaafauthor=K.+C.+Changauthor=C.+Langeauthor=P.+Nahidauthor=Z.+F.+Udwadiaauthor=C.+R.+Horsburghauthor=G.+J.+Churchyardauthor=D.+Menziesauthor=A.+C.+Hesselingauthor=E.+Nuermbergerauthor=H.+McIlleronauthor=K.+P.+Fennellyauthor=E.+Goemaereauthor=E.+Jaramilloauthor=M.+Lowauthor=C.+M.+Jaraauthor=N.+Padayatchiauthor=R.+M.+Warren&title=The+epidemiology%2C+pathogenesis%2C+transmission%2C+diagnosis%2C+and+management+of+multidrug-resistant%2C+extensively+drug-resistant%2C+and+incurable+tuberculosis&doi=10.1016%2FS2213-2600%2817%2930079-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2817%2930079-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252817%252930079-6%26sid%3Dliteratum%253Aachs%26aulast%3DDheda%26aufirst%3DK.%26aulast%3DGumbo%26aufirst%3DT.%26aulast%3DMaartens%26aufirst%3DG.%26aulast%3DDooley%26aufirst%3DK.%2BE.%26aulast%3DMcNerney%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DM.%26aulast%3DFurin%26aufirst%3DJ.%26aulast%3DNardell%26aufirst%3DE.%2BA.%26aulast%3DLondon%26aufirst%3DL.%26aulast%3DLessem%26aufirst%3DE.%26aulast%3DTheron%26aufirst%3DG.%26aulast%3Dvan%2BHelden%26aufirst%3DP.%26aulast%3DNiemann%26aufirst%3DS.%26aulast%3DMerker%26aufirst%3DM.%26aulast%3DDowdy%26aufirst%3DD.%26aulast%3DVan%2BRie%26aufirst%3DA.%26aulast%3DSiu%26aufirst%3DG.%2BK.%2BH.%26aulast%3DPasipanodya%26aufirst%3DJ.%2BG.%26aulast%3DRodrigues%26aufirst%3DC.%26aulast%3DClark%26aufirst%3DT.%2BG.%26aulast%3DSirgel%26aufirst%3DF.%2BA.%26aulast%3DEsmail%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DH.-H.%26aulast%3DAtre%26aufirst%3DS.%2BR.%26aulast%3DSchaaf%26aufirst%3DH.%2BS.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DLange%26aufirst%3DC.%26aulast%3DNahid%26aufirst%3DP.%26aulast%3DUdwadia%26aufirst%3DZ.%2BF.%26aulast%3DHorsburgh%26aufirst%3DC.%2BR.%26aulast%3DChurchyard%26aufirst%3DG.%2BJ.%26aulast%3DMenzies%26aufirst%3DD.%26aulast%3DHesseling%26aufirst%3DA.%2BC.%26aulast%3DNuermberger%26aufirst%3DE.%26aulast%3DMcIlleron%26aufirst%3DH.%26aulast%3DFennelly%26aufirst%3DK.%2BP.%26aulast%3DGoemaere%26aufirst%3DE.%26aulast%3DJaramillo%26aufirst%3DE.%26aulast%3DLow%26aufirst%3DM.%26aulast%3DJara%26aufirst%3DC.%2BM.%26aulast%3DPadayatchi%26aufirst%3DN.%26aulast%3DWarren%26aufirst%3DR.%2BM.%26atitle%3DThe%2520epidemiology%252C%2520pathogenesis%252C%2520transmission%252C%2520diagnosis%252C%2520and%2520management%2520of%2520multidrug-resistant%252C%2520extensively%2520drug-resistant%252C%2520and%2520incurable%2520tuberculosis%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2017%26volume%3D5%26spage%3D291%26epage%3D360%26doi%3D10.1016%2FS2213-2600%2817%2930079-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span>New Antibiotic
Approved for Drug-Resistant Tuberculosis.  <i>The Washington Post</i>, <span class="NLM_year">2019</span>; <a href="https://www.washingtonpost.com/health/new-antibiotic-approved-for-drug-resistant-tuberculosis/2019/08/14/559d069a-bde6-11e9-9b73-fd3c65ef8f9c_story.html" class="extLink">https://www.washingtonpost.com/health/new-antibiotic-approved-for-drug-resistant-tuberculosis/2019/08/14/559d069a-bde6-11e9-9b73-fd3c65ef8f9c_story.html</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=New+Antibiotic%0AApproved+for+Drug-Resistant+Tuberculosis.+The+Washington+Post%2C+2019%3B+https%3A%2F%2Fwww.washingtonpost.com%2Fhealth%2Fnew-antibiotic-approved-for-drug-resistant-tuberculosis%2F2019%2F08%2F14%2F559d069a-bde6-11e9-9b73-fd3c65ef8f9c_story.html+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DThe%2520Washington%2520Post%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span>FDA
Approves New Drug for Treatment-Resistant Forms of Tuberculosis That
Affects the Lungs; <span class="NLM_publisher-name">FDA</span>, <span class="NLM_year">2019</span>; <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs#:~:text=The%20U.S.%20Food%20and%20Drug,(TB)%20of%20the%20lungs" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs#:~:text=The%20U.S.%20Food%20and%20Drug,(TB)%20of%20the%20lungs</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA%0AApproves+New+Drug+for+Treatment-Resistant+Forms+of+Tuberculosis+That%0AAffects+the+Lungs%3B+FDA%2C+2019%3B+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs%23%3A%7E%3Atext%3DThe%2520U.S.%2520Food%2520and%2520Drug%2C%28TB%29%2520of%2520the%2520lungs+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26pub%3DFDA%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomishige, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubouchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, M.</span></span> <span> </span><span class="NLM_article-title">OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e466</span>, <span class="refDoi"> DOI: 10.1371/journal.pmed.0030466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pmed.0030466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=17132069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD28npsFKgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=e466&author=M.+Matsumotoauthor=H.+Hashizumeauthor=T.+Tomishigeauthor=M.+Kawasakiauthor=H.+Tsubouchiauthor=H.+Sasakiauthor=Y.+Shimokawaauthor=M.+Komatsu&title=OPC-67683%2C+a+nitro-dihydro-imidazooxazole+derivative+with+promising+action+against+tuberculosis+in+vitro+and+in+mice&doi=10.1371%2Fjournal.pmed.0030466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice</span></div><div class="casAuthors">Matsumoto Makoto; Hashizume Hiroyuki; Tomishige Tatsuo; Kawasaki Masanori; Tsubouchi Hidetsugu; Sasaki Hirofumi; Shimokawa Yoshihiko; Komatsu Makoto</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e466</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Tuberculosis (TB) is still a leading cause of death worldwide.  Almost a third of the world's population is infected with TB bacilli, and each year approximately 8 million people develop active TB and 2 million die as a result.  Today's TB treatment, which dates back to the 1970s, is long and burdensome, requiring at least 6 mo of multidrug chemotherapy.  The situation is further compounded by the emergence of multidrug-resistant TB (MDR-TB) and by the infection's lethal synergy with HIV/AIDS.  Global health and philanthropic organizations are now pleading for new drug interventions that can address these unmet needs in TB treatment.  METHODS AND FINDINGS:  Here we report OPC-67683, a nitro-dihydro-imidazooxazole derivative that was screened to help combat the unmet needs in TB treatment.  The compound is a mycolic acid biosynthesis inhibitor found to be free of mutagenicity and to possess highly potent activity against TB, including MDR-TB, as shown by its exceptionally low minimum inhibitory concentration (MIC) range of 0.006-0.024 microg/ml in vitro and highly effective therapeutic activity at low doses in vivo.  Additionally, the results of the post-antibiotic effect of OPC-67683 on intracellular Mycobacterium tuberculosis showed the agent to be highly and dose-dependently active also against intracellular M. tuberculosis H37Rv after a 4-h pulsed exposure, and this activity at a concentration of 0.1 microg/ml was similar to that of the first-line drug rifampicin (RFP) at a concentration of 3 microg/ml.  The combination of OPC-67683 with RFP and pyrazinamide (PZA) exhibited a remarkably quicker eradication (by at least 2 mo) of viable TB bacilli in the lung in comparison with the standard regimen consisting of RFP, isoniazid (INH), ethambutol (EB), and PZA.  Furthermore, OPC-67683 was not affected by nor did it affect the activity of liver microsome enzymes, suggesting the possibility for OPC-67683 to be used in combination with drugs, including anti-retrovirals, that induce or are metabolized by cytochrome P450 enzymes.  CONCLUSIONS:  We concluded that based on these properties OPC-67683 has the potential to be used as a TB drug to help combat the unmet needs in TB treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSF0z_BNLNYeRS7coPn-RtfW6udTcc2eZCrR8PIhAlIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28npsFKgug%253D%253D&md5=8a80560cc653b1c76ff4d47430317d18</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0030466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0030466%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DTomishige%26aufirst%3DT.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DTsubouchi%26aufirst%3DH.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DShimokawa%26aufirst%3DY.%26aulast%3DKomatsu%26aufirst%3DM.%26atitle%3DOPC-67683%252C%2520a%2520nitro-dihydro-imidazooxazole%2520derivative%2520with%2520promising%2520action%2520against%2520tuberculosis%2520in%2520vitro%2520and%2520in%2520mice%26jtitle%3DPLoS%2520Med.%26date%3D2006%26volume%3D3%26spage%3De466%26doi%3D10.1371%2Fjournal.pmed.0030466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skripconoka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danilovits, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pehme, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skenders, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirule, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leimane, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurve, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiter, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manissero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span> <span> </span><span class="NLM_article-title">Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1400</span>, <span class="refDoi"> DOI: 10.1183/09031936.00125812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1183%2F09031936.00125812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23018916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252Fgsl2ltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=1393-1400&author=V.+Skripconokaauthor=M.+Danilovitsauthor=L.+Pehmeauthor=T.+Tomsonauthor=G.+Skendersauthor=T.+Kummikauthor=A.+Ciruleauthor=V.+Leimaneauthor=A.+Kurveauthor=K.+Levinaauthor=L.+J.+Geiterauthor=D.+Manisseroauthor=C.+D.+Wells&title=Delamanid+improves+outcomes+and+reduces+mortality+in+multidrug-resistant+tuberculosis&doi=10.1183%2F09031936.00125812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis</span></div><div class="casAuthors">Skripconoka Vija; Danilovits Manfred; Pehme Lea; Tomson Tarmo; Skenders Girts; Kummik Tiina; Cirule Andra; Leimane Vaira; Kurve Anu; Levina Klavdia; Geiter Lawrence J; Manissero Davide; Wells Charles D</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1393-400</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are associated with worse treatment outcomes for patients, including higher mortality, than for drug-sensitive tuberculosis.  Delamanid (OPC-67683) is a novel anti-TB medication with demonstrated activity against multidrug-resistant disease.  Patients who participated in the previously reported randomised, placebo-controlled trial of delamanid and the subsequent open-label extension trial were eligible to participate in a 24-month observational study designed to capture treatment outcomes.  Treatment outcomes, as assessed by clinicians and defined by the World Health Organization, were categorised as favourable and unfavourable.  Delamanid treatment groups were combined for analysis, based on their duration of treatment.  In total, for 421 (87.5%) out of 481 patients from the original randomised controlled trial, consent was granted for follow-up assessments.  Favourable outcomes were observed in 143 (74.5%) out of 192 patients who received delamanid for ≥6 months, compared to 126 (55%) out of 229 patients who received delamanid for ≤2 months.  Mortality was reduced to 1.0% among those receiving long-term delamanid versus short-term/no delamanid (8.3%; p<0.001).  Treatment benefit was also seen among patients with extensively drug-resistant TB.  This analysis suggests that treatment with delamanid for 6 months in combination with an optimised background regimen can improve outcomes and reduce mortality among patients with both multidrug-resistant and extensively drug-resistant TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2JcitGJjjkMNIRw0GKUoEfW6udTcc2eZGPUqV2QoBubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252Fgsl2ltw%253D%253D&md5=63c616aef7dfd5858d274fe1a74ab290</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1183%2F09031936.00125812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00125812%26sid%3Dliteratum%253Aachs%26aulast%3DSkripconoka%26aufirst%3DV.%26aulast%3DDanilovits%26aufirst%3DM.%26aulast%3DPehme%26aufirst%3DL.%26aulast%3DTomson%26aufirst%3DT.%26aulast%3DSkenders%26aufirst%3DG.%26aulast%3DKummik%26aufirst%3DT.%26aulast%3DCirule%26aufirst%3DA.%26aulast%3DLeimane%26aufirst%3DV.%26aulast%3DKurve%26aufirst%3DA.%26aulast%3DLevina%26aufirst%3DK.%26aulast%3DGeiter%26aufirst%3DL.%2BJ.%26aulast%3DManissero%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DC.%2BD.%26atitle%3DDelamanid%2520improves%2520outcomes%2520and%2520reduces%2520mortality%2520in%2520multidrug-resistant%2520tuberculosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D41%26spage%3D1393%26epage%3D1400%26doi%3D10.1183%2F09031936.00125812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, R.</span></span> <span> </span><span class="NLM_article-title">Bedaquiline: First FDA-approved tuberculosis drug in 40 years</span>. <i>Int. J. Appl. Basic Med. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">2</span>, <span class="refDoi"> DOI: 10.4103/2229-516X.112228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4103%2F2229-516X.112228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23776831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3sjjsVymsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1-2&author=R.+Mahajan&title=Bedaquiline%3A+First+FDA-approved+tuberculosis+drug+in+40+years&doi=10.4103%2F2229-516X.112228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Bedaquiline: First FDA-approved tuberculosis drug in 40 years</span></div><div class="casAuthors">Mahajan Rajiv</div><div class="citationInfo"><span class="NLM_cas:title">International journal of applied & basic medical research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-2</span>
        ISSN:<span class="NLM_cas:issn">2229-516X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMuPJrm3KbPlw2ofyr07jXfW6udTcc2eZGPUqV2QoBubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjjsVymsQ%253D%253D&md5=b588035f9b17ee7beb4f5c57a58a0eff</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.4103%2F2229-516X.112228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F2229-516X.112228%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan%26aufirst%3DR.%26atitle%3DBedaquiline%253A%2520First%2520FDA-approved%2520tuberculosis%2520drug%2520in%252040%2520years%26jtitle%3DInt.%2520J.%2520Appl.%2520Basic%2520Med.%2520Res.%26date%3D2013%26volume%3D3%26spage%3D1%26epage%3D2%26doi%3D10.4103%2F2229-516X.112228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hittel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiter, L. J.</span></span> <span> </span><span class="NLM_article-title">Delamanid in the treatment of multidrug-resistant tuberculosis</span>. <i>Int. J. Tuberc Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.5588/ijtld.16.0125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.5588%2Fijtld.16.0125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28240570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1czgvFWlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=33-37&author=R.+Guptaauthor=C.+D.+Wellsauthor=N.+Hittelauthor=J.+Hafkinauthor=L.+J.+Geiter&title=Delamanid+in+the+treatment+of+multidrug-resistant+tuberculosis&doi=10.5588%2Fijtld.16.0125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Delamanid in the treatment of multidrug-resistant tuberculosis</span></div><div class="casAuthors">Gupta R; Hafkin J; Geiter L J; Wells C D; Hittel N</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">33-37</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Otsuka has been engaged in anti-tuberculosis drug development efforts for over 30 years, and is the leading private sector funder of tuberculosis (TB) research and development.  Delamanid (DLM), discovered by Otsuka's scientists, has been shown to provide benefit with respect to short-term surrogate markers and long-term treatment outcomes, and it has received regulatory approval for treatment of adult pulmonary multidrug-resistant TB (MDR-TB) as one of only two new anti-tuberculosis drugs in the last 40 years.  Lack of drug-drug interactions with major antiretrovirals and efficacy against MDR-TB allow DLM's applicability in a wide range of MDR-TB patients.  Current and future efforts are focused on replacing less safe and less efficacious second-line drugs with DLM, its contribution to all-oral and/or shortened treatment regimens, and, ultimately, inclusion in a pan-TB regimen.  This manuscript provides a brief review of DLM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeR1dYk1i_c2x8TEN9K18QfW6udTcc2eYesO4y9kdIObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czgvFWlug%253D%253D&md5=f5ca6996b8821bd38bc5ef1fd13f151b</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.5588%2Fijtld.16.0125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5588%252Fijtld.16.0125%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DR.%26aulast%3DWells%26aufirst%3DC.%2BD.%26aulast%3DHittel%26aufirst%3DN.%26aulast%3DHafkin%26aufirst%3DJ.%26aulast%3DGeiter%26aufirst%3DL.%2BJ.%26atitle%3DDelamanid%2520in%2520the%2520treatment%2520of%2520multidrug-resistant%2520tuberculosis%26jtitle%3DInt.%2520J.%2520Tuberc%2520Lung%2520Dis.%26date%3D2016%26volume%3D20%26spage%3D33%26epage%3D37%26doi%3D10.5588%2Fijtld.16.0125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinone structure-activity relationships leading to linezolid</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">2010</span>– <span class="NLM_lpage">2023</span>, <span class="refDoi"> DOI: 10.1002/anie.200200528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1002%2Fanie.200200528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkt1Snu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=2010-2023&issue=18&author=M.+R.+Barbachynauthor=C.+W.+Ford&title=Oxazolidinone+structure-activity+relationships+leading+to+linezolid&doi=10.1002%2Fanie.200200528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinone structure-activity relationships leading to linezolid</span></div><div class="casAuthors">Barbachyn, Michael R.; Ford, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2010-2023</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The development of bacterial resistance to currently available antibacterial agents is a growing global health problem.  Of particular concern are infections caused by multidrug-resistant Gram-pos. pathogens which are responsible for significant morbidity and mortality in both the hospital and community settings.  A no. of solns. to the problem of bacterial resistance are possible.  The most common approach is to continue modifying existing classes of antibacterial agents to provide new analogs with improved attributes.  Other successful strategies are to combine existing antibacterial agents with other drugs as well as the development of improved diagnostic procedures that may lead to rapid identification of the causative pathogen and permit the use of antibacterial agents with a narrow spectrum of activity.  Finally, and most importantly, the discovery of novel classes of antibacterial agents employing new mechanisms of action has considerable promise.  Such agents would exhibit a lack of cross-resistance with existing antimicrobial drugs.  This review describes the work leading to the discovery of linezolid, the first clin. useful oxazolidinone antibacterial agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGritv1CBogyHbVg90H21EOLACvtfcHk0ljoSG3Lfqezsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkt1Snu7k%253D&md5=681744cbb331d9256cc32d8b60987284</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1002%2Fanie.200200528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200200528%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DFord%26aufirst%3DC.%2BW.%26atitle%3DOxazolidinone%2520structure-activity%2520relationships%2520leading%2520to%2520linezolid%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26issue%3D18%26spage%3D2010%26epage%3D2023%26doi%3D10.1002%2Fanie.200200528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sy, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. C.</span></span> <span> </span><span class="NLM_article-title">In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2226</span>– <span class="NLM_lpage">2267</span>, <span class="refDoi"> DOI: 10.1128/AAC.00414-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.00414-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=18391030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvVait7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=2226-2267&author=T.+S.+Huangauthor=Y.+C.+Liuauthor=C.+L.+Syauthor=Y.+S.+Chenauthor=H.+Z.+Tuauthor=B.+C.+Chen&title=In+vitro+activities+of+linezolid+against+clinical+isolates+of+Mycobacterium+tuberculosis+complex+isolated+in+Taiwan+over+10+years&doi=10.1128%2FAAC.00414-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years</span></div><div class="casAuthors">Huang, Tsi-Shu; Liu, Yung-Ching; Sy, Cheng-Len; Chen, Yao-Shen; Tu, Hui-Zin; Chen, Bao-Chen</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2226-2227</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Significant increases in the MIC90s of linezolid in multidrug-resistant Mycobacterium tuberculosis isolates were seen between the baseline period of 2001 to 2003 (0.5 μg/mL) and 2004 (2 μg/mL).  The MICs were 4 μg/mL in three strains.  Both fluoroquinolones (except levofloxacin) and kanamycin were found to have statistically significant degrees of concordance with linezolid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoueJqnCpdKkrVg90H21EOLACvtfcHk0ljoSG3Lfqezsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvVait7g%253D&md5=444b842f9b0931bc13cb0f6d231e3a5e</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1128%2FAAC.00414-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00414-07%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DT.%2BS.%26aulast%3DLiu%26aufirst%3DY.%2BC.%26aulast%3DSy%26aufirst%3DC.%2BL.%26aulast%3DChen%26aufirst%3DY.%2BS.%26aulast%3DTu%26aufirst%3DH.%2BZ.%26aulast%3DChen%26aufirst%3DB.%2BC.%26atitle%3DIn%2520vitro%2520activities%2520of%2520linezolid%2520against%2520clinical%2520isolates%2520of%2520Mycobacterium%2520tuberculosis%2520complex%2520isolated%2520in%2520Taiwan%2520over%252010%2520years%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26spage%3D2226%26epage%3D2267%26doi%3D10.1128%2FAAC.00414-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, Y. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, U. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassall, A.</span></span> <span> </span><span class="NLM_article-title">Costs to health services and the patient of treating tuberculosis: A systematic literature review</span>. <i>PharmacoEconomics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.1007/s40273-015-0279-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1007%2Fs40273-015-0279-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25939501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2MfgsVygsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=939-955&author=Y.+V.+Laurenceauthor=U.+K.+Griffithsauthor=A.+Vassall&title=Costs+to+health+services+and+the+patient+of+treating+tuberculosis%3A+A+systematic+literature+review&doi=10.1007%2Fs40273-015-0279-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review</span></div><div class="casAuthors">Laurence Yoko V; Griffiths Ulla K; Vassall Anna</div><div class="citationInfo"><span class="NLM_cas:title">PharmacoEconomics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">939-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Novel tuberculosis (TB) drugs and the need to treat drug-resistant tuberculosis (DR-TB) are likely to bring about substantial transformations in TB treatment in coming years.  An evidence base for cost and cost-effectiveness analyses of these developments is needed.  OBJECTIVE:  Our objective was to perform a review of papers assessing provider-incurred as well as patient-incurred costs of treating both drug-susceptible (DS) and multidrug-resistant (MDR)-TB.  METHODS:  Five databases (EMBASE, Medline, the National Health Service Economic Evaluation Database, the Cost-Effectiveness Analysis Registry, and Latin American and Caribbean Health Services Literature) were searched for cost and economic evaluation full-text papers containing primary DS-TB and MDR-TB treatment cost data published in peer-reviewed journals between January 1990 and February 2015.  No language restrictions were set.  The search terms were a combination of 'tuberculosis', 'multidrug-resistant tuberculosis', 'cost', and 'treatment'.  In the selected papers, study methods and characteristics, quality indicators and costs were extracted into summary tables according to pre-defined criteria.  Results were analysed according to country income groups and for provider costs, patient costs and productivity losses.  All values were converted to $US, year 2014 values, so that studies could be compared.  RESULTS:  We selected 71 treatment cost papers on DS-TB only, ten papers on MDR-TB only and nine papers that included both DS-TB and MDR-TB.  These papers provided evidence on the costs of treating DS-TB and MDR-TB in 50 and 16 countries, respectively.  In 31 % of the papers, only provider costs were included; 26 % included only patient-incurred costs, and the remaining 43 % estimated costs incurred by both.  From the provider perspective, mean DS-TB treatment costs per patient were US$14,659 in high-income countries (HICs), US$840 in upper middle-income countries (UMICs), US$273 in lower middle-income (LMICs), and US$258 in low-income countries (LICs), showing a strong positive correlation.  The respective costs for treating MDR-TB were US$83,365, US$5284, US$6313 and US$1218.  Costs incurred by patients when seeking treatment for DS-TB accounted for an additional 3 % of the provider costs in HICs.  A greater burden was seen in the other income groups, increasing the costs of DS-TB treatment by 72 % in UMICs, 60 % in LICs and 31 % in LMICs.  When provider costs, patient costs and productivity losses were combined, productivity losses accounted for 16 % in HICs, 29 % in UMICs, 40 % in LMICs and 38 % in LICs.  CONCLUSION:  Cost data for MDR-TB treatment are limited, and the variation in delivery mechanisms, as well as the rapidly evolving diagnosis and treatment regimens, means that it is essential to increase the number of studies assessing the cost from both provider and patient perspectives.  There is substantial evidence available on the costs of DS-TB treatment from all regions of the world.  The patient-incurred costs illustrate that the financial burden of illness is relatively greater for patients in poorer countries without universal healthcare coverage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgJ39ix5e5dWK_SFaaT9INfW6udTcc2eY9rgvL-NR8ebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfgsVygsw%253D%253D&md5=e4709dc54d4b5ab98cad051b14efdbd3</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1007%2Fs40273-015-0279-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40273-015-0279-6%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DY.%2BV.%26aulast%3DGriffiths%26aufirst%3DU.%2BK.%26aulast%3DVassall%26aufirst%3DA.%26atitle%3DCosts%2520to%2520health%2520services%2520and%2520the%2520patient%2520of%2520treating%2520tuberculosis%253A%2520A%2520systematic%2520literature%2520review%26jtitle%3DPharmacoEconomics%26date%3D2015%26volume%3D33%26spage%3D939%26epage%3D955%26doi%3D10.1007%2Fs40273-015-0279-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chellat, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raguž, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, R.</span></span> <span> </span><span class="NLM_article-title">Targeting antibiotic resistance</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6600</span>– <span class="NLM_lpage">6626</span>, <span class="refDoi"> DOI: 10.1002/anie.201506818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1002%2Fanie.201506818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1Cju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=6600-6626&author=M.+F.+Chellatauthor=L.+Ragu%C5%BEauthor=R.+Riedl&title=Targeting+antibiotic+resistance&doi=10.1002%2Fanie.201506818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Antibiotic Resistance</span></div><div class="casAuthors">Chellat, Mathieu F.; Raguz, Luka; Riedl, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6600-6626</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Finding strategies against the development of antibiotic resistance is a major global challenge for the life sciences community and for public health.  The past decades have seen a dramatic worldwide increase in human-pathogenic bacteria that are resistant to one or multiple antibiotics.  More and more infections caused by resistant microorganisms fail to respond to conventional treatment, and in some cases, even last-resort antibiotics have lost their power.  In addn., industry pipelines for the development of novel antibiotics have run dry over the past decades.  A recent world health day by the World Health Organization titled "Combat drug resistance: no action today means no cure tomorrow" triggered an increase in research activity, and several promising strategies have been developed to restore treatment options against infections by resistant bacterial pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRcddMQflU3LVg90H21EOLACvtfcHk0lhSHHmhzuMMSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1Cju7k%253D&md5=b8194ac5902fa3ac4da2e36de71f82b4</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506818%26sid%3Dliteratum%253Aachs%26aulast%3DChellat%26aufirst%3DM.%2BF.%26aulast%3DRagu%25C5%25BE%26aufirst%3DL.%26aulast%3DRiedl%26aufirst%3DR.%26atitle%3DTargeting%2520antibiotic%2520resistance%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D6600%26epage%3D6626%26doi%3D10.1002%2Fanie.201506818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ippolito, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanyo, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steitz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, E. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3353</span>– <span class="NLM_lpage">3356</span>, <span class="refDoi"> DOI: 10.1021/jm800379d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800379d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtF2ku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3353-3356&author=J.+A.+Ippolitoauthor=Z.+F.+Kanyoauthor=D.+Wangauthor=F.+J.+Franceschiauthor=P.+B.+Mooreauthor=T.+A.+Steitzauthor=E.+M.+Duffy&title=Crystal+structure+of+the+oxazolidinone+antibiotic+linezolid+bound+to+the+50S+ribosomal+subunit&doi=10.1021%2Fjm800379d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Oxazolidinone Antibiotic Linezolid Bound to the 50S Ribosomal Subunit</span></div><div class="casAuthors">Ippolito, Joseph A.; Kanyo, Zoltan F.; Wang, Deping; Franceschi, Francois J.; Moore, Peter B.; Steitz, Thomas A.; Duffy, Erin M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3353-3356</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The oxazolidinone antibacterials target the 50S subunit of prokaryotic ribosomes.  To gain insight into their mechanism of action, the crystal structure of the canonical oxazolidinone, linezolid, has been detd. bound to the Haloarcula marismortui 50S subunit.  Linezolid binds the 50S A-site, near the catalytic center, which suggests that inhibition involves competition with incoming A-site substrates.  These results provide a structural basis for the discovery of improved oxazolidinones active against emerging drug-resistant clin. strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2a6yG28gBjbVg90H21EOLACvtfcHk0lgyDbsR9W92vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtF2ku7g%253D&md5=bdf67198829f16561cf447257ac21f8e</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1021%2Fjm800379d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800379d%26sid%3Dliteratum%253Aachs%26aulast%3DIppolito%26aufirst%3DJ.%2BA.%26aulast%3DKanyo%26aufirst%3DZ.%2BF.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DFranceschi%26aufirst%3DF.%2BJ.%26aulast%3DMoore%26aufirst%3DP.%2BB.%26aulast%3DSteitz%26aufirst%3DT.%2BA.%26aulast%3DDuffy%26aufirst%3DE.%2BM.%26atitle%3DCrystal%2520structure%2520of%2520the%2520oxazolidinone%2520antibiotic%2520linezolid%2520bound%2520to%2520the%252050S%2520ribosomal%2520subunit%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3353%26epage%3D3356%26doi%3D10.1021%2Fjm800379d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cynamon, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilburn, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klemens, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grega, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendges, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toops, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">680</span>– <span class="NLM_lpage">685</span>, <span class="refDoi"> DOI: 10.1021/jm950956y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm950956y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK28XlvVCisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=680-685&author=M.+R.+Barbachynauthor=D.+K.+Hutchinsonauthor=S.+J.+Bricknerauthor=M.+H.+Cynamonauthor=J.+O.+Kilburnauthor=S.+P.+Klemensauthor=S.+E.+Glickmanauthor=K.+C.+Gregaauthor=S.+K.+Hendgesauthor=D.+S.+Toopsauthor=C.+W.+Fordauthor=G.+E.+Zurenko&title=Identification+of+a+novel+oxazolidinone+%28U-100480%29+with+potent+antimycobacterial+activity&doi=10.1021%2Fjm950956y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Novel Oxazolidinone (U-100480) with Potent Antimycobacterial Activity</span></div><div class="casAuthors">Barbachyn, Michael R.; Hutchinson, Douglas K.; Brickner, Steven J.; Cynamon, Michael H.; Kilburn, James O.; Klemens, Sally P.; Glickman, Suzanne E.; Grega, Kevin C.; Hendges, Susan K.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">680-5</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A subclass of oxazolidinone antibacterial agents with esp. potent in vitro activity against mycobacteria was discovered.  The salient structural feature of these oxazolidinone analogs, U-100480 [i.e., (S)-N-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide], U-101603, and U-101244 is their appended thiomorpholine moiety.  The rational design, synthesis, and evaluation of the in vitro antimycobacterial activity of these analogs was described.  Potent activity against a screening strain of Mycobacterium tuberculosis was demonstrated by U-100480 and U-101603 (min. inhibitory concns. or MIC's ≤0.125 μg/mL).  Oxazolidinones U-100480 and U-101244 exhibit MIC90 values of 0.50 μg/mL or less against a panel of organisms consisting of five drug-sensitive and five multidrug-resistant strains of M. tuberculosis, with U-100480 being the most active congener.  Potent in vitro activity against other mycobacterial species was also demonstrated by U-100480.  For example, U-100480 exhibited excellent in vitro activity against multiple clin. isolates of Mycobacterium avium complex (MIC's = 0.5-4 μg/mL).  Orally administered U-100480 displays in vivo efficacy against M. tuberculosis and M. avium similar to that of clin. comparators isoniazid and azithromycin, resp.  Consideration of these factors, along with a favorable pharmacokinetic and chronic toxicity profile in rats, suggests that U-100480 is a promising antimycobacterial agent (tuberculostatic).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAvvlFTIROHbVg90H21EOLACvtfcHk0lgyDbsR9W92vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlvVCisQ%253D%253D&md5=8636d20221390257b48f2d3dd6884b78</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1021%2Fjm950956y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950956y%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DHutchinson%26aufirst%3DD.%2BK.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26aulast%3DCynamon%26aufirst%3DM.%2BH.%26aulast%3DKilburn%26aufirst%3DJ.%2BO.%26aulast%3DKlemens%26aufirst%3DS.%2BP.%26aulast%3DGlickman%26aufirst%3DS.%2BE.%26aulast%3DGrega%26aufirst%3DK.%2BC.%26aulast%3DHendges%26aufirst%3DS.%2BK.%26aulast%3DToops%26aufirst%3DD.%2BS.%26aulast%3DFord%26aufirst%3DC.%2BW.%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26atitle%3DIdentification%2520of%2520a%2520novel%2520oxazolidinone%2520%2528U-100480%2529%2520with%2520potent%2520antimycobacterial%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D680%26epage%3D685%26doi%3D10.1021%2Fjm950956y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, S.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, J.-H.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo activities of LCB01–0371, a new oxazolidinone</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5359</span>– <span class="NLM_lpage">5362</span>, <span class="refDoi"> DOI: 10.1128/AAC.00723-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.00723-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=20855730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=5359-5362&author=J.-W.+Jeongauthor=S.-J.+Jungauthor=H.-H.+Leeauthor=Y.-Z.+Kimauthor=T.-K.+Parkauthor=Y.-L.+Choauthor=S.-E.+Chaeauthor=S.-Y.+Baekauthor=S.-H.+Wooauthor=H.-S.+Leeauthor=J.-H.+Kwak&title=In+vitro+and+in+vivo+activities+of+LCB01%E2%80%930371%2C+a+new+oxazolidinone&doi=10.1128%2FAAC.00723-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo activities of LCB01-0371, a new oxazolidinone</span></div><div class="casAuthors">Jeong, Ji-Woong; Jung, Sung-Ji; Lee, Hyun-Hee; Kim, Yong-Zu; Park, Tae-Kyo; Cho, Young-Lag; Chae, Sang-Eun; Baek, Sung-Yoon; Woo, Sung-Ho; Lee, Hyang-Sook; Kwak, Jin-Hwan</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5359-5362</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">LCB01-0371 is a new oxazolidinone with cyclic amidrazone.  In vitro activity of LCB01-0371 against 624 clin. isolates was evaluated and compared with those of linezolid, vancomycin, and other antibiotics.  LCB01-0371 showed good activity against Gram-pos. pathogens.  In vivo activity of LCB01-0371 against systemic infections in mice was also evaluated.  LCB01-0371 was more active than linezolid against these systemic infections.  LCB01-0371 showed bacteriostatic activity against Staphylococcus aureus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobg2lKKc8bzbVg90H21EOLACvtfcHk0lgyDbsR9W92vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FJ&md5=27471d63f1195f29f869689c125f643e</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1128%2FAAC.00723-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00723-10%26sid%3Dliteratum%253Aachs%26aulast%3DJeong%26aufirst%3DJ.-W.%26aulast%3DJung%26aufirst%3DS.-J.%26aulast%3DLee%26aufirst%3DH.-H.%26aulast%3DKim%26aufirst%3DY.-Z.%26aulast%3DPark%26aufirst%3DT.-K.%26aulast%3DCho%26aufirst%3DY.-L.%26aulast%3DChae%26aufirst%3DS.-E.%26aulast%3DBaek%26aufirst%3DS.-Y.%26aulast%3DWoo%26aufirst%3DS.-H.%26aulast%3DLee%26aufirst%3DH.-S.%26aulast%3DKwak%26aufirst%3DJ.-H.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520activities%2520of%2520LCB01%25E2%2580%25930371%252C%2520a%2520new%2520oxazolidinone%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D5359%26epage%3D5362%26doi%3D10.1128%2FAAC.00723-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, Y.</span></span> <span> </span><span class="NLM_article-title">Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in China</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">e00165-18</span>, <span class="refDoi"> DOI: 10.1128/AAC.00165-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.00165-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29844043" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&pages=e00165-18&issue=8&author=Z.+Zongauthor=W.+Jingauthor=J.+Shiauthor=S.+Wenauthor=T.+Zhangauthor=F.+Huoauthor=Y.+Shangauthor=Q.+Liangauthor=H.+Huangauthor=Y.+Pang&title=Comparison+of+in+vitro+activity+and+MIC+distributions+between+the+novel+oxazolidinone+delpazolid+and+linezolid+against+multidrug-resistant+and+extensively+drug-resistant+Mycobacterium+tuberculosis+in+China&doi=10.1128%2FAAC.00165-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1128%2FAAC.00165-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00165-18%26sid%3Dliteratum%253Aachs%26aulast%3DZong%26aufirst%3DZ.%26aulast%3DJing%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DHuo%26aufirst%3DF.%26aulast%3DShang%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DPang%26aufirst%3DY.%26atitle%3DComparison%2520of%2520in%2520vitro%2520activity%2520and%2520MIC%2520distributions%2520between%2520the%2520novel%2520oxazolidinone%2520delpazolid%2520and%2520linezolid%2520against%2520multidrug-resistant%2520and%2520extensively%2520drug-resistant%2520Mycobacterium%2520tuberculosis%2520in%2520China%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26issue%3D8%26spage%3De00165-18%26doi%3D10.1128%2FAAC.00165-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group">ClinicalTrials.gov</span>. <span> </span><span class="NLM_article-title">A Phase 1 Study to Evaluate Safety, Tolerability,
and Pharmacokinetics
of TBI-223 in Healthy Adults</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT03758612" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03758612</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+A+Phase+1+Study+to+Evaluate+Safety%2C+Tolerability%2C%0Aand+Pharmacokinetics%0Aof+TBI-223+in+Healthy+Adults.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03758612+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DA%2520Phase%25201%2520Study%2520to%2520Evaluate%2520Safety%252C%2520Tolerability%252C%250Aand%2520Pharmacokinetics%250Aof%2520TBI-223%2520in%2520Healthy%2520Adults" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubiec, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedarida, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paige, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladutko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. F.</span></span> <span> </span><span class="NLM_article-title">Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1128/AAC.01179-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.01179-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21078950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVyjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=567-574&author=R.+S.+Wallisauthor=W.+Jakubiecauthor=V.+Kumarauthor=G.+Bedaridaauthor=A.+Silviaauthor=D.+Paigeauthor=T.+Zhuauthor=M.+Mitton-Fryauthor=L.+Ladutkoauthor=S.+Campbellauthor=P.+F.+Miller&title=Biomarker-assisted+dose+selection+for+safety+and+efficacy+in+early+development+of+PNU-100480+for+tuberculosis&doi=10.1128%2FAAC.01179-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis</span></div><div class="casAuthors">Wallis, Robert S.; Jakubiec, Wesley; Kumar, Vikas; Bedarida, Gabriella; Silvia, Annette; Paige, Darcy; Zhu, Tong; Mitton-Fry, Mark; Ladutko, Lynn; Campbell, Sheldon; Miller, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">567-574</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tuberculosis is a serious global health threat for which new treatments are urgently needed.  This study examd. the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of the oxazolidinone PNU-100480 in healthy volunteers, using biomarkers for safety and efficacy.  Subjects were randomly assigned to PNU-100480 or placebo (4:1) at schedules of 100, 300, or 600 mg twice daily or 1,200 mg daily for 14 days or a schedule of 600 mg twice daily for 28 days to which pyrazinamide was added on days 27 and 28.  A sixth cohort was given linezolid at 300 mg daily for 4 days.  Signs, symptoms, and routine safety tests were monitored.  Bactericidal activity against Mycobacterium tuberculosis was measured in ex vivo whole-blood culture.  Plasma drug and metabolite concns. were compared to the levels required for inhibition of M. tuberculosis growth and 50% inhibition of mitochondrial protein synthesis.  All doses were safe and well tolerated.  There were no hematol. or other safety signals during 28 days of dosing at 600 mg twice daily.  Plasma concns. of PNU-100480 and metabolites at this dose remained below those required for 50% inhibition of mitochondrial protein synthesis.  Cumulative whole-blood bactericidal activity of PNU-100480 at this dose (-0.316 ± 0.04 log) were superior to the activities of all other doses tested (P < 0.001) and was significantly augmented by pyrazinamide (-0.420 ± 0.06 log) (P = 0.002).  In conclusion, PNU-100480 was safe and well tolerated at all tested doses.  Further studies in patients with tuberculosis are warranted.  Biomarkers can accelerate early development of new tuberculosis treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCYDkvTtgkiLVg90H21EOLACvtfcHk0liu1lxxClwUaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVyjsLs%253D&md5=332e0a4d1903c4f9408b6e5e412eabb0</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1128%2FAAC.01179-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01179-10%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DR.%2BS.%26aulast%3DJakubiec%26aufirst%3DW.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBedarida%26aufirst%3DG.%26aulast%3DSilvia%26aufirst%3DA.%26aulast%3DPaige%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DMitton-Fry%26aufirst%3DM.%26aulast%3DLadutko%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DP.%2BF.%26atitle%3DBiomarker-assisted%2520dose%2520selection%2520for%2520safety%2520and%2520efficacy%2520in%2520early%2520development%2520of%2520PNU-100480%2520for%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D567%26epage%3D574%26doi%3D10.1128%2FAAC.01179-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meintjes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maartens, G.</span></span> <span> </span><span class="NLM_article-title">Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index</span>. <i>Expert Rev. Anti-Infect. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">901</span>– <span class="NLM_lpage">915</span>, <span class="refDoi"> DOI: 10.1080/14787210.2016.1225498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1080%2F14787210.2016.1225498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27532292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVehu7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=901-915&issue=10&author=S.+Wassermanauthor=G.+Meintjesauthor=G.+Maartens&title=Linezolid+in+the+treatment+of+drug-resistant+tuberculosis%3A+the+challenge+of+its+narrow+therapeutic+index&doi=10.1080%2F14787210.2016.1225498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index</span></div><div class="casAuthors">Wasserman, Sean; Meintjes, Graeme; Maartens, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anti-Infective Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">901-915</span>CODEN:
                <span class="NLM_cas:coden">ERATCK</span>;
        ISSN:<span class="NLM_cas:issn">1478-7210</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: Linezolid is an oxazolidinone with potent activity against M tuberculosis, and improves culture conversion and cure rates when added to treatment regimens for drug resistant tuberculosis.  However, linezolid has a narrow therapeutic window, and the optimal dosing strategy that minimizes the substantial toxicity assocd. with linezolid's prolonged use in tuberculosis treatment has not been detd., limiting the potential impact of this anti-mycobacterial agent.  Areas covered: This paper aims to review and summarize the current knowledge on linezolid for the treatment of drug-resistant tuberculosis.  The focus is on the pharmacokinetic-pharmacodynamic determinants of linezolid's efficacy and toxicity in tuberculosis, and how this relates to defining an optimal dose.  Mechanisms of linezolid toxicity and resistance, and the potential role of therapeutic drug monitoring are also covered.  Expert commentary: Prospective pharmacokinetic-pharmacodynamic studies are required to define optimal therapeutic targets and to inform improved linezolid dosing strategies for drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRY5QIBD8h57Vg90H21EOLACvtfcHk0lgPS8kCPjKN4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVehu7vL&md5=4e1bc3ec740ecd73d1e5f70144254214</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1080%2F14787210.2016.1225498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14787210.2016.1225498%26sid%3Dliteratum%253Aachs%26aulast%3DWasserman%26aufirst%3DS.%26aulast%3DMeintjes%26aufirst%3DG.%26aulast%3DMaartens%26aufirst%3DG.%26atitle%3DLinezolid%2520in%2520the%2520treatment%2520of%2520drug-resistant%2520tuberculosis%253A%2520the%2520challenge%2520of%2520its%2520narrow%2520therapeutic%2520index%26jtitle%3DExpert%2520Rev.%2520Anti-Infect.%2520Ther.%26date%3D2016%26volume%3D14%26issue%3D10%26spage%3D901%26epage%3D915%26doi%3D10.1080%2F14787210.2016.1225498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of fluorine-containing benzoxazinyl-oxazolidinones for the treatment of multidrug resistant tuberculosis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00068</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=533-537&author=H.+Zhaoauthor=Y.+Luauthor=L.+Shengauthor=Z.+Yuanauthor=B.+Wangauthor=W.+Wangauthor=Y.+Liauthor=C.+Maauthor=X.+Wangauthor=D.+Zhangauthor=H.+Huang&title=Discovery+of+fluorine-containing+benzoxazinyl-oxazolidinones+for+the+treatment+of+multidrug+resistant+tuberculosis&doi=10.1021%2Facsmedchemlett.7b00068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Fluorine-Containing Benzoxazinyl-oxazolidinones for the Treatment of Multidrug Resistant Tuberculosis</span></div><div class="casAuthors">Zhao, Hongyi; Lu, Yu; Sheng, Li; Yuan, Zishuo; Wang, Bin; Wang, Weiping; Li, Yan; Ma, Chen; Wang, Xiaoliang; Zhang, Dongfeng; Huang, Haihong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">533-537</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of fluorine-contg. benzoxazinyl-oxazolidinones were designed and synthesized as antidrug-resistant tuberculosis agents possessing good activity and improved pharmacokinetic profiles.  Compd. I exhibited not only outstanding in vitro activity with a MIC value of 0.25-0.50 μg/mL against drug-susceptible H37Rv strain and two clin. isolated drug-resistant Mycobacterium tuberculosis strains, but also acceptable in vitro ADME/T properties.  Moreover, this compd. displayed excellent mouse pharmacokinetic profiles with an oral bioavailability of 102% and a longer elimination half-life of 4.22 h, thereby supporting further optimization and development of this promising lead series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogwgObIiYn5rVg90H21EOLACvtfcHk0lgPS8kCPjKN4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVWltL8%253D&md5=288fd039d5f0eb32cd751e6390733dc7</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00068%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520fluorine-containing%2520benzoxazinyl-oxazolidinones%2520for%2520the%2520treatment%2520of%2520multidrug%2520resistant%2520tuberculosis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D533%26epage%3D537%26doi%3D10.1021%2Facsmedchemlett.7b00068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a conformationally constrained oxazolidinone with improved safety and efficacy profiles for the treatment of multidrug-resistant tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9316</span>– <span class="NLM_lpage">9339</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00500</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00500" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9316-9339&author=H.+Zhaoauthor=B.+Wangauthor=L.+Fuauthor=G.+Liauthor=H.+Luauthor=Y.+Liuauthor=L.+Shengauthor=Y.+Liauthor=B.+Zhangauthor=Y.+Luauthor=C.+Maauthor=H.+Huangauthor=D.+Zhangauthor=Y.+Lu&title=Discovery+of+a+conformationally+constrained+oxazolidinone+with+improved+safety+and+efficacy+profiles+for+the+treatment+of+multidrug-resistant+tuberculosis&doi=10.1021%2Facs.jmedchem.0c00500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis</span></div><div class="casAuthors">Zhao, Hongyi; Wang, Bin; Fu, Lei; Li, Gang; Lu, Haijia; Liu, Yuke; Sheng, Li; Li, Yan; Zhang, Baoxi; Lu, Yang; Ma, Chen; Huang, Haihong; Zhang, Dongfeng; Lu, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9316-9339</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis (TB) remains a serious public health challenge, and the research and development of new anti-TB drugs is an essential component of the global strategy to eradicate TB.  In this work, we discovered a conformationally constrained oxazolidinone 19c(I) with improved anti-TB activity and safety profile through a focused lead optimization effort.  Compd. 19c displayed superior in vivo efficacy in a mouse TB infection model compared to linezolid and sutezolid.  The druggability of compd. 19c was demonstrated in a panel of assays including microsomal stability, cytotoxicity, cytochrome P 450 enzyme inhibition, and pharmacokinetics in animals.  Compd. 19c demonstrated an excellent safety profile in a battery of safety assays, including mitochondrial protein synthesis, hERG K+, hCav1.2, and Nav1.5 channels, monoamine oxidase, and genotoxicity.  In a 4 wk repeated dose toxicol. study in rats, 19c appeared to have less bone marrow suppression than linezolid, which has been a major liability of the oxazolidinone class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZxjD-svNTCLVg90H21EOLACvtfcHk0lgPS8kCPjKN4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtbbP&md5=fca65a3a3fb69bc78178ae5b04c6a562</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00500%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520conformationally%2520constrained%2520oxazolidinone%2520with%2520improved%2520safety%2520and%2520efficacy%2520profiles%2520for%2520the%2520treatment%2520of%2520multidrug-resistant%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9316%26epage%3D9339%26doi%3D10.1021%2Facs.jmedchem.0c00500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel 4H-chromen-4-one derivatives as antituberculosis agents against multidrug-resistant tuberculosis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">112075</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.ejmech.2020.112075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31986405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVWju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2020&pages=112075&author=W.+Zhaoauthor=B.+Wangauthor=Y.+Liuauthor=L.+Fuauthor=L.+Shengauthor=H.+Zhaoauthor=Y.+Luauthor=D.+Zhang&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+4H-chromen-4-one+derivatives+as+antituberculosis+agents+against+multidrug-resistant+tuberculosis&doi=10.1016%2Fj.ejmech.2020.112075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of novel 4H-chromen-4-one derivatives as antituberculosis agents against multidrug-resistant tuberculosis</span></div><div class="casAuthors">Zhao, Wenting; Wang, Bin; Liu, Yuke; Fu, Lei; Sheng, Li; Zhao, Hongyi; Lu, Yu; Zhang, Dongfeng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112075pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 4H-chromen-4-one derivs. I (R1 = H, C6H5, 4-FC6H4, etc.; R2 = H, piperidin-1-ylmethyl, pyrrolidin-1-ylmethyl, etc.; R3 = H, 4-HOC6H4, Et formate, etc.) obtained by scaffold morphing of the benzofuran compd., TAM16, were tested for antitubercular activity.  Compd. I (R1 = 4-HOC6H4; R2 = azetidin-1-ylmethyl; R3 = H) was active against drug-sensitive and multidrug-resistant tuberculosis.  A preliminary druggability evaluation showed that the above compd. displayed favorable mouse and human microsomal stability, low cytotoxicity, and acceptable oral bioavailability.  An in vivo study indicated that the above compd. exhibited modest efficacy in an acute mouse model of TB after 3 wk of treatment.  Thus, the above compd. is a promising antituberculosis lead compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqURjJVHJb3UrVg90H21EOLACvtfcHk0lgkvFj3oLzEHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVWju7w%253D&md5=67bdd39407b5ff4ac3d82d21620217cf</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112075%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%25204H-chromen-4-one%2520derivatives%2520as%2520antituberculosis%2520agents%2520against%2520multidrug-resistant%2520tuberculosis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D189%26spage%3D112075%26doi%3D10.1016%2Fj.ejmech.2020.112075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavalda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Léger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Rest, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montrozier, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlet-Schiltz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrakchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daffé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quémard, A.</span></span> <span> </span><span class="NLM_article-title">The Pks13/FadD32 crosstalk for the biosynthesis of mycolic acids in Mycobacterium tuberculosis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">19255</span>– <span class="NLM_lpage">19264</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.006940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1074%2Fjbc.M109.006940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19436070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1MXot12ktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=19255-19264&author=S.+Gavaldaauthor=M.+L%C3%A9gerauthor=B.+van+der+Restauthor=A.+Stellaauthor=F.+Bardouauthor=H.+Montrozierauthor=C.+Chalutauthor=O.+Burlet-Schiltzauthor=H.+Marrakchiauthor=M.+Daff%C3%A9author=A.+Qu%C3%A9mard&title=The+Pks13%2FFadD32+crosstalk+for+the+biosynthesis+of+mycolic+acids+in+Mycobacterium+tuberculosis&doi=10.1074%2Fjbc.M109.006940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">The Pks13/FadD32 Crosstalk for the Biosynthesis of Mycolic Acids in Mycobacterium tuberculosis</span></div><div class="casAuthors">Gavalda, Sabine; Leger, Mathieu; van der Rest, Benoit; Stella, Alexandre; Bardou, Fabienne; Montrozier, Henri; Chalut, Christian; Burlet-Schiltz, Odile; Marrakchi, Hedia; Daffe, Mamadou; Quemard, Annaik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">19255-19264</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The last steps of the biosynthesis of mycolic acids, essential and specific lipids of Mycobacterium tuberculosis and related bacteria, are catalyzed by proteins encoded by the fadD32-pks13-accD4 cluster.  Here, we produced and purified an active form of the Pks13 polyketide synthase, with a phosphopantetheinyl (P-pant) arm at both positions Ser-55 and Ser-1266 of its two acyl carrier protein (ACP) domains.  Combination of liq. chromatog.-tandem mass spectrometry of protein tryptic digests and radiolabeling expts. showed that, in vitro, the enzyme specifically loads long-chain 2-carboxyacyl-CoA substrates onto the P-pant arm of its C-terminal ACP domain via the acyltransferase domain.  The acyl-AMPs produced by the FadD32 enzyme are specifically transferred onto the ketosynthase domain after binding to the P-pant moiety of the N-terminal ACP domain of Pks13 (N-ACPPks13).  Unexpectedly, however, the latter step requires the presence of active FadD32.  Thus, the couple FadD32-(N-ACPPks13) composes the initiation module of the mycolic condensation system.  Pks13 ultimately condenses the two loaded fatty acyl chains to produce α-alkyl β-ketoacids, the precursors of mycolic acids.  The developed in vitro assay will constitute a strategic tool for antimycobacterial drug screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvik29xE2QILVg90H21EOLACvtfcHk0lgkvFj3oLzEHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXot12ktLk%253D&md5=658b560cb616973f8fb44dc5035c5713</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.006940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.006940%26sid%3Dliteratum%253Aachs%26aulast%3DGavalda%26aufirst%3DS.%26aulast%3DL%25C3%25A9ger%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BRest%26aufirst%3DB.%26aulast%3DStella%26aufirst%3DA.%26aulast%3DBardou%26aufirst%3DF.%26aulast%3DMontrozier%26aufirst%3DH.%26aulast%3DChalut%26aufirst%3DC.%26aulast%3DBurlet-Schiltz%26aufirst%3DO.%26aulast%3DMarrakchi%26aufirst%3DH.%26aulast%3DDaff%25C3%25A9%26aufirst%3DM.%26aulast%3DQu%25C3%25A9mard%26aufirst%3DA.%26atitle%3DThe%2520Pks13%252FFadD32%2520crosstalk%2520for%2520the%2520biosynthesis%2520of%2520mycolic%2520acids%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D19255%26epage%3D19264%26doi%3D10.1074%2Fjbc.M109.006940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishai, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.-F.</span></span> <span> </span><span class="NLM_article-title">Identification of novel coumestan derivatives as polyketide synthase 13 inhibitors against Mycobacterium tuberculosis. Part II</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3575</span>– <span class="NLM_lpage">3589</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFeksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3575-3589&author=W.+Zhangauthor=S.+Lunauthor=L.-L.+Liuauthor=S.+Xiaoauthor=G.+Duanauthor=H.+Gunosewoyoauthor=F.+Yangauthor=J.+Tangauthor=W.+R.+Bishaiauthor=L.-F.+Yu&title=Identification+of+novel+coumestan+derivatives+as+polyketide+synthase+13+inhibitors+against+Mycobacterium+tuberculosis.+Part+II&doi=10.1021%2Facs.jmedchem.9b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel coumestan derivatives as polyketide synthase 13 inhibitors against Mycobacterium tuberculosis. part II</span></div><div class="casAuthors">Zhang, Wei; Lun, Shichun; Liu, Ling-Ling; Xiao, Shiqi; Duan, Guanfu; Gunosewoyo, Hendra; Yang, Fan; Tang, Jie; Bishai, William R.; Yu, Li-Fang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3575-3589</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Our group recently reported the identification of novel coumestan derivs. as Mycobacterium tuberculosis (Mtb) Pks13-thioesterase (TE) domain inhibitors, with mutations obsd. (D1644G and N1640K) in the generated coumestan-resistant Mtb colonies.  Herein, we report a further structure-activity relationships exploration exploiting the available Pks13-TE X-ray co-crystal structure that resulted in the discovery of extremely potent coumestan analogs 48(I) and 50(II).  These mols. possess excellent anti-tuberculosis activity against both the drug-susceptible (MIC = 0.0039 μg/mL) and drug-resistant Mtb strains (MIC = 0.0078 μg/mL).  Moreover, the excellent in vitro activity is translated to the in vivo mouse serum inhibitory titrn. assay, with administration of I at 100 mg/kg showing an 8-fold higher activity than that of isoniazid or TAM16 given at 10 or 100 mg/kg, resp.  Preliminary ADME-Tox data for the coumestans were promising and, coupled with the practicality of synthesis, warrant further in vivo efficacy assessments of the coumestan derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolhzlD7NMcz7Vg90H21EOLACvtfcHk0lgkvFj3oLzEHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFeksL0%253D&md5=30c5e50311e413573a0c861fc5c64cb3</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00010%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLun%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DL.-L.%26aulast%3DXiao%26aufirst%3DS.%26aulast%3DDuan%26aufirst%3DG.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DBishai%26aufirst%3DW.%2BR.%26aulast%3DYu%26aufirst%3DL.-F.%26atitle%3DIdentification%2520of%2520novel%2520coumestan%2520derivatives%2520as%2520polyketide%2520synthase%252013%2520inhibitors%2520against%2520Mycobacterium%2520tuberculosis.%2520Part%2520II%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3575%26epage%3D3589%26doi%3D10.1021%2Facs.jmedchem.9b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earl, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishai, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. F.</span></span> <span> </span><span class="NLM_article-title">Identification of novel coumestan derivatives as polyketide synthase 13 inhibitors against Mycobacterium tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01319</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01319" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVyqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=791-803&author=W.+Zhangauthor=S.+Lunauthor=S.+H.+Wangauthor=X.+W.+Jiangauthor=F.+Yangauthor=J.+Tangauthor=A.+L.+Mansonauthor=A.+M.+Earlauthor=H.+Gunosewoyoauthor=W.+R.+Bishaiauthor=L.+F.+Yu&title=Identification+of+novel+coumestan+derivatives+as+polyketide+synthase+13+inhibitors+against+Mycobacterium+tuberculosis&doi=10.1021%2Facs.jmedchem.7b01319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis</span></div><div class="casAuthors">Zhang, Wei; Lun, Shichun; Wang, Shu-Huan; Jiang, Xing-Wu; Yang, Fan; Tang, Jie; Manson, Abigail L.; Earl, Ashlee M.; Gunosewoyo, Hendra; Bishai, William R.; Yu, Li-Fang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">791-803</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the mycolic acid pathway has proven a viable strategy in antitubercular drug discovery.  The AccA3/AccD4/FadD32/Pks13 complex of Mycobacterium tuberculosis constitutes an essential biosynthetic mechanism for mycolic acids.  Small mols. targeting the thioesterase domain of Pks13 have been reported, including a benzofuran-based compd. whose X-ray cocrystal structure has been very recently solved.  Its initial inactivity in a serum inhibition titrn. (SIT) assay led us to further probe other structurally related benzofurans with the aim to improve their potency and bioavailability.  Herein, we report our preliminary structure-activity relationship studies around this scaffold, highlighting a natural product-inspired cyclization strategy to form coumestans that are shown to be active in SIT.  Whole genome deep sequencing of the coumestan-resistant mutants confirmed a single nucleotide polymorphism in the pks13 gene responsible for the resistance phenotype, demonstrating the druggability of this target for the development of new antitubercular agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1LJWIdOrTvLVg90H21EOLACvtfcHk0libHhBE88AOYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVyqtw%253D%253D&md5=053f265d21ca7eff9f396c33907a1d75</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01319%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLun%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%2BH.%26aulast%3DJiang%26aufirst%3DX.%2BW.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DManson%26aufirst%3DA.%2BL.%26aulast%3DEarl%26aufirst%3DA.%2BM.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DBishai%26aufirst%3DW.%2BR.%26aulast%3DYu%26aufirst%3DL.%2BF.%26atitle%3DIdentification%2520of%2520novel%2520coumestan%2520derivatives%2520as%2520polyketide%2520synthase%252013%2520inhibitors%2520against%2520Mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D791%26epage%3D803%26doi%3D10.1021%2Facs.jmedchem.7b01319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campanico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seldon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdigao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portugal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span> <span> </span><span class="NLM_article-title">Azaaurones as potent antimycobacterial agents active against MDR- and XDR-TB</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1537</span>– <span class="NLM_lpage">1546</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201900289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1002%2Fcmdc.201900289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31294529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVaqtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1537-1546&author=A.+Campanicoauthor=M.+P.+Carrascoauthor=M.+Njorogeauthor=R.+Seldonauthor=K.+Chibaleauthor=J.+Perdigaoauthor=I.+Portugalauthor=D.+F.+Warnerauthor=R.+Moreiraauthor=F.+Lopes&title=Azaaurones+as+potent+antimycobacterial+agents+active+against+MDR-+and+XDR-TB&doi=10.1002%2Fcmdc.201900289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Azaaurones as potent antimycobacterial agents active against MDR- and XDR-TB</span></div><div class="casAuthors">Campanico, Andre; Carrasco, Marta P.; Njoroge, Mathew; Seldon, Ronnett; Chibale, Kelly; Perdigao, Joao; Portugal, Isabel; Warner, Digby F.; Moreira, Rui; Lopes, Francisca</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1537-1546</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein we report the screening of a small library of aurones and their isosteric counterparts, azaaurones and N-acetylazaaurones, against Mycobacterium tuberculosis.  Aurones were found to be inactive at 20 μM, whereas azaaurones and N-acetylazaaurones emerged as the most potent compds., with nine derivs. displaying MIC99 values ranging from 0.4 to 2.0 μM.  In addn., several N-acetylazaaurones were found to be active against multidrug-resistant (MDR) and extensively drug-resistant (XDR) clin. M. tuberculosis isolates.  The antimycobacterial mechanism of action of these compds. remains to be detd.; however, a preliminary mechanistic study confirmed that they do not inhibit the mycobacterial cytochrome bc1 complex.  Addnl., microsomal metabolic stability and metabolite identification studies revealed that N-acetylazaaurones are deacetylated to their azaaurone counterparts.  Overall, these results demonstrate that azaaurones and their N-acetyl counterparts represent a new entry in the toolbox of chemotypes capable of inhibiting M. tuberculosis growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPeGhVOhg6wrVg90H21EOLACvtfcHk0libHhBE88AOYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVaqtrnF&md5=3649a282fa61d661da17554f2214b042</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201900289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201900289%26sid%3Dliteratum%253Aachs%26aulast%3DCampanico%26aufirst%3DA.%26aulast%3DCarrasco%26aufirst%3DM.%2BP.%26aulast%3DNjoroge%26aufirst%3DM.%26aulast%3DSeldon%26aufirst%3DR.%26aulast%3DChibale%26aufirst%3DK.%26aulast%3DPerdigao%26aufirst%3DJ.%26aulast%3DPortugal%26aufirst%3DI.%26aulast%3DWarner%26aufirst%3DD.%2BF.%26aulast%3DMoreira%26aufirst%3DR.%26aulast%3DLopes%26aufirst%3DF.%26atitle%3DAzaaurones%2520as%2520potent%2520antimycobacterial%2520agents%2520active%2520against%2520MDR-%2520and%2520XDR-TB%26jtitle%3DChemMedChem%26date%3D2019%26volume%3D14%26spage%3D1537%26epage%3D1546%26doi%3D10.1002%2Fcmdc.201900289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawale, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khedkar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation and molecular docking study of some novel indole and pyridine based 1,3,4-oxadiazole derivatives as potential antitubercular agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1776</span>– <span class="NLM_lpage">1783</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.02.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.bmcl.2016.02.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26920799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1WqsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1776-1783&author=N.+C.+Desaiauthor=H.+Somaniauthor=A.+Trivediauthor=K.+Bhattauthor=L.+Nawaleauthor=V.+M.+Khedkarauthor=P.+C.+Jhaauthor=D.+Sarkar&title=Synthesis%2C+biological+evaluation+and+molecular+docking+study+of+some+novel+indole+and+pyridine+based+1%2C3%2C4-oxadiazole+derivatives+as+potential+antitubercular+agents&doi=10.1016%2Fj.bmcl.2016.02.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluation and molecular docking study of some novel indole and pyridine based 1,3,4-oxadiazole derivatives as potential antitubercular agents</span></div><div class="casAuthors">Desai, N. C.; Somani, Hardik; Trivedi, Amit; Bhatt, Kandarp; Nawale, Laxman; Khedkar, Vijay M.; Jha, Prakash C.; Sarkar, Dhiman</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1776-1783</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">(Indolyl)(pyridinyl)oxadiazolinyl arylpropenones I (R = Ph, 2-HOC6H4, 3-HOC6H4, 4-HOC6H4, 2-O2NC6H4, 3-O2NC6H4, 4-O2NC6H4, 4-MeC6H4, 4-MeOC6H4, 2-FC6H4, 3-FC6H4, 4-FC6H4, 2-ClC6H4, 3-ClC6H4, 4-ClC6H4, 2,3-Cl2C6H3, 2,4-Cl2C6H3, 2,6-Cl2C6H3, 3-BrC6H4, 4-BrC6H4) were prepd. as inhibitors of mycobacterial enoyl-acyl carrier protein (enoyl-ACP) reductase InhA for potential use as antitubercular agents or as potential leads for antitubercular agents; I were tested for their inhibition of Mycobacterium tuberculosis H37Ra and M. bovis BCG and for their antibacterial activities, and the toxicity of the active compds. to human cancer cells was detd.  I (R = 2-HOC6H4, 2-O2NC6H4, 4-O2NC6H4, 2,4-Cl2C6H3) demonstrated safety indexes of ≥10 against all three human cancer cell lines; I (R = 2,4-Cl2C6H3) was highly selective for mycobacteria over cancer cells and bacteria.  Mol. docking calcns. of the binding of I (R = 2-HOC6H4, 2-O2NC6H4, 4-O2NC6H4, 2,4-Cl2C6H3) to mycobacterial enoyl reductase InhA were performed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooPQDArlF-ULVg90H21EOLACvtfcHk0lhrEOEFKvx2Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1WqsLo%253D&md5=b8591802f776a229cf77015a6d87417d</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.02.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.02.043%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DN.%2BC.%26aulast%3DSomani%26aufirst%3DH.%26aulast%3DTrivedi%26aufirst%3DA.%26aulast%3DBhatt%26aufirst%3DK.%26aulast%3DNawale%26aufirst%3DL.%26aulast%3DKhedkar%26aufirst%3DV.%2BM.%26aulast%3DJha%26aufirst%3DP.%2BC.%26aulast%3DSarkar%26aufirst%3DD.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%2520and%2520molecular%2520docking%2520study%2520of%2520some%2520novel%2520indole%2520and%2520pyridine%2520based%25201%252C3%252C4-oxadiazole%2520derivatives%2520as%2520potential%2520antitubercular%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1776%26epage%3D1783%26doi%3D10.1016%2Fj.bmcl.2016.02.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarrete-Vázquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina-Salinas, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte-Fajardo, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas-Villarreal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada-Soto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Salazar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández-Núñez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Said-Fernández, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antimycobacterial activity of 4-(5-substituted-1,3,4-oxadiazol-2-yl)pyridines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5502</span>– <span class="NLM_lpage">5508</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2007.05.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.bmc.2007.05.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=17562368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvV2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=5502-5508&author=G.+Navarrete-V%C3%A1zquezauthor=G.+M.+Molina-Salinasauthor=Z.+V.+Duarte-Fajardoauthor=J.+Vargas-Villarrealauthor=S.+Estrada-Sotoauthor=F.+Gonz%C3%A1lez-Salazarauthor=E.+Hern%C3%A1ndez-N%C3%BA%C3%B1ezauthor=S.+Said-Fern%C3%A1ndez&title=Synthesis+and+antimycobacterial+activity+of+4-%285-substituted-1%2C3%2C4-oxadiazol-2-yl%29pyridines&doi=10.1016%2Fj.bmc.2007.05.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antimycobacterial activity of 4-(5-substituted-1,3,4-oxadiazol-2-yl)pyridines</span></div><div class="casAuthors">Navarrete-Vazquez, Gabriel; Molina-Salinas, Gloria Maria; Duarte-Fajardo, Zetel Vahi; Vargas-Villarreal, Javier; Estrada-Soto, Samuel; Gonzalez-Salazar, Francisco; Hernandez-Nunez, Emanuel; Said-Fernandez, Salvador</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5502-5508</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Twelve 4-(5-Substituted-1,3,4-oxadiazol-2-yl)pyridine derivs. were synthesized and evaluated for their in vitro antimycobacterial activity.  Some compds. showed an interesting activity against Mycobacterium tuberculosis H37Rv and five clin. isolates (drug-sensitive and -resistant strains).  4-(5-Pentadecyl-1,3,4-oxadiazol-2-yl)pyridine was 10 times more active than isoniazid, 20 times more active than streptomycin, and 28 times more potent than ethambutol against drug-resistant strain CIBIN 112.  4-(5-Heptadecyl-1,3,4-oxadiazol-2-yl)pyridine showed the same behavior as 4-(5-pentadecyl-1,3,4-oxadiazol-2-yl)pyridine.  Both of the above structures bear a high lipophilic chain bonded to the 5-position of the oxadiazole moiety.  This fact implies that there exists a contribution of lipophilicity, which could facilitate the entrance of these mols. through lipid-enriched bacterial cell membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0svc0R8Ojz7Vg90H21EOLACvtfcHk0lhrEOEFKvx2Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvV2itrs%253D&md5=df8b1413606bdedd3d91c0898f139344</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.05.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.05.053%26sid%3Dliteratum%253Aachs%26aulast%3DNavarrete-V%25C3%25A1zquez%26aufirst%3DG.%26aulast%3DMolina-Salinas%26aufirst%3DG.%2BM.%26aulast%3DDuarte-Fajardo%26aufirst%3DZ.%2BV.%26aulast%3DVargas-Villarreal%26aufirst%3DJ.%26aulast%3DEstrada-Soto%26aufirst%3DS.%26aulast%3DGonz%25C3%25A1lez-Salazar%26aufirst%3DF.%26aulast%3DHern%25C3%25A1ndez-N%25C3%25BA%25C3%25B1ez%26aufirst%3DE.%26aulast%3DSaid-Fern%25C3%25A1ndez%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520antimycobacterial%2520activity%2520of%25204-%25285-substituted-1%252C3%252C4-oxadiazol-2-yl%2529pyridines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D5502%26epage%3D5508%26doi%3D10.1016%2Fj.bmc.2007.05.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karabanovich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zemanová, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smutný, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Székely, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Šarkan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centárová, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pávková, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Čonka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Němeček, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolaříková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vejsová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vávrová, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimešová, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabálek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pávek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikušová, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roh, J.</span></span> <span> </span><span class="NLM_article-title">Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and thiadiazoles as selective antitubercular agents active against replicating and nonreplicating Mycobacterium tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2362</span>– <span class="NLM_lpage">2380</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00608</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00608" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1yqt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2362-2380&author=G.+Karabanovichauthor=J.+Zemanov%C3%A1author=T.+Smutn%C3%BDauthor=R.+Sz%C3%A9kelyauthor=M.+%C5%A0arkanauthor=I.+Cent%C3%A1rov%C3%A1author=A.+Vocatauthor=I.+P%C3%A1vkov%C3%A1author=P.+%C4%8Conkaauthor=J.+N%C4%9Bme%C4%8Dekauthor=J.+Stola%C5%99%C3%ADkov%C3%A1author=M.+Vejsov%C3%A1author=K.+V%C3%A1vrov%C3%A1author=V.+Klime%C5%A1ov%C3%A1author=A.+Hrab%C3%A1lekauthor=P.+P%C3%A1vekauthor=S.+T.+Coleauthor=K.+Miku%C5%A1ov%C3%A1author=J.+Roh&title=Development+of+3%2C5-Dinitrobenzylsulfanyl-1%2C3%2C4-oxadiazoles+and+thiadiazoles+as+selective+antitubercular+agents+active+against+replicating+and+nonreplicating+Mycobacterium+tuberculosis&doi=10.1021%2Facs.jmedchem.5b00608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis</span></div><div class="casAuthors">Karabanovich, Galina; Zemanova, Julia; Smutny, Tomas; Szekely, Rita; Sarkan, Michal; Centarova, Ivana; Vocat, Anthony; Pavkova, Ivona; Conka, Patrik; Nemecek, Jan; Stolarikova, Jirina; Vejsova, Marcela; Vavrova, Katerina; Klimesova, Vera; Hrabalek, Alexandr; Pavek, Petr; Cole, Stewart T.; Mikusova, Katarina; Roh, Jaroslav</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2362-2380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we report the discovery and structure-activity relationships of 5-substituted-2-[(3,5-dinitrobenzyl)sulfanyl]-1,3,4-oxadiazoles and 1,3,4-thiadiazoles as a new class of antituberculosis agents.  The majority of these compds. exhibited outstanding in vitro activity against Mycobacterium tuberculosis CNCTC My 331/88 and six multidrug-resistant clin. isolated strains of M. tuberculosis, with min. inhibitory concn. values as low as 0.03 μM (0.011-0.026 μg/mL).  The investigated compds. had a highly selective antimycobacterial effect because they showed no activity against the other bacteria or fungi tested in this study.  Furthermore, the investigated compds. exhibited low in vitro toxicities in four proliferating mammalian cell lines and in isolated primary human hepatocytes.  Several in vitro genotoxicity assays indicated that the selected compds. have no mutagenic activity.  The oxadiazole and thiadiazole derivs. with the most favorable activity/toxicity profiles also showed potency comparable to that of rifampicin against the nonreplicating streptomycin-starved M. tuberculosis 18b-Lux strain, and therefore, these derivs., are of particular interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgBb0Hpi3vOrVg90H21EOLACvtfcHk0lhrEOEFKvx2Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1yqt7Y%253D&md5=788b65627cfd13854c699c08ae7aa756</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00608%26sid%3Dliteratum%253Aachs%26aulast%3DKarabanovich%26aufirst%3DG.%26aulast%3DZemanov%25C3%25A1%26aufirst%3DJ.%26aulast%3DSmutn%25C3%25BD%26aufirst%3DT.%26aulast%3DSz%25C3%25A9kely%26aufirst%3DR.%26aulast%3D%25C5%25A0arkan%26aufirst%3DM.%26aulast%3DCent%25C3%25A1rov%25C3%25A1%26aufirst%3DI.%26aulast%3DVocat%26aufirst%3DA.%26aulast%3DP%25C3%25A1vkov%25C3%25A1%26aufirst%3DI.%26aulast%3D%25C4%258Conka%26aufirst%3DP.%26aulast%3DN%25C4%259Bme%25C4%258Dek%26aufirst%3DJ.%26aulast%3DStola%25C5%2599%25C3%25ADkov%25C3%25A1%26aufirst%3DJ.%26aulast%3DVejsov%25C3%25A1%26aufirst%3DM.%26aulast%3DV%25C3%25A1vrov%25C3%25A1%26aufirst%3DK.%26aulast%3DKlime%25C5%25A1ov%25C3%25A1%26aufirst%3DV.%26aulast%3DHrab%25C3%25A1lek%26aufirst%3DA.%26aulast%3DP%25C3%25A1vek%26aufirst%3DP.%26aulast%3DCole%26aufirst%3DS.%2BT.%26aulast%3DMiku%25C5%25A1ov%25C3%25A1%26aufirst%3DK.%26aulast%3DRoh%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%25203%252C5-Dinitrobenzylsulfanyl-1%252C3%252C4-oxadiazoles%2520and%2520thiadiazoles%2520as%2520selective%2520antitubercular%2520agents%2520active%2520against%2520replicating%2520and%2520nonreplicating%2520Mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2362%26epage%3D2380%26doi%3D10.1021%2Facs.jmedchem.5b00608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makane, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishna, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishna, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahizhaveni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azger Dusthackeer, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rode, H. B.</span></span> <span> </span><span class="NLM_article-title">Novel 1,3,4-oxadiazoles as antitubercular agents with limited activity against drug-resistant tuberculosis</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">510</span>, <span class="refDoi"> DOI: 10.4155/fmc-2018-0378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4155%2Ffmc-2018-0378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30892944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmslGntrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=499-510&author=V.+B.+Makaneauthor=V.+S.+Krishnaauthor=E.+V.+Krishnaauthor=M.+Shuklaauthor=B.+Mahizhaveniauthor=S.+Misraauthor=S.+Chopraauthor=D.+Sriramauthor=V.+N.+Azger+Dusthackeerauthor=H.+B.+Rode&title=Novel+1%2C3%2C4-oxadiazoles+as+antitubercular+agents+with+limited+activity+against+drug-resistant+tuberculosis&doi=10.4155%2Ffmc-2018-0378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 1,3,4-oxadiazoles as antitubercular agents with limited activity against drug-resistant tuberculosis</span></div><div class="casAuthors">Makane, Vitthal B.; Krishna, Vagolu Siva; Krishna, Eruva Vamshi; Shukla, Manjulika; Mahizhaveni, Balakrishnan; Misra, Sunil; Chopra, Sidharth; Sriram, Dharmarajan; Azger Dusthackeer, Vijayan N.; Rode, Haridas B.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">499-510</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">In recent times, heterocyclic chemotypes are being explored for the development of new antimycobacterials that target the drug-resistant tuberculosis.  Here, we are disclosing the 5-substitued 2-mercapto-1,3,4-oxadiazoles I (R1 = Ph, 2-BrC6H4, 4-OHC6H4, etc.) as potent antitubercular agents.  A small library of 2-mercapto-1,3,4-oxadiazoles I was synthesized using various acids.  The compds. were evaluated for antituberculosis activity against M. tuberculosis H37Rv.  Compd. I (R1 = 4-OHC6H4) was identified as antitubercular lead with MIC of 0.6μg/mL against M. tuberculosis H37Rv.  This compd. was nontoxic to CHO-K1 cells and showed selectivity index of 39.  Of note, I (R1 = 4-OHC6H4) showed antitubercular activity against pre-extensively drug-resistant clin. isolate of Mycobacterium with MIC of 2μg/mL.  This study provides potent antitubercular agent which can be further optimized to discover novel antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_o0bE374dJrVg90H21EOLACvtfcHk0liZ9e7XX-5S4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmslGntrk%253D&md5=dab28d2697e062de13a388a7e0062e29</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2018-0378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2018-0378%26sid%3Dliteratum%253Aachs%26aulast%3DMakane%26aufirst%3DV.%2BB.%26aulast%3DKrishna%26aufirst%3DV.%2BS.%26aulast%3DKrishna%26aufirst%3DE.%2BV.%26aulast%3DShukla%26aufirst%3DM.%26aulast%3DMahizhaveni%26aufirst%3DB.%26aulast%3DMisra%26aufirst%3DS.%26aulast%3DChopra%26aufirst%3DS.%26aulast%3DSriram%26aufirst%3DD.%26aulast%3DAzger%2BDusthackeer%26aufirst%3DV.%2BN.%26aulast%3DRode%26aufirst%3DH.%2BB.%26atitle%3DNovel%25201%252C3%252C4-oxadiazoles%2520as%2520antitubercular%2520agents%2520with%2520limited%2520activity%2520against%2520drug-resistant%2520tuberculosis%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2019%26volume%3D11%26spage%3D499%26epage%3D510%26doi%3D10.4155%2Ffmc-2018-0378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aidasani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branstetter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everds, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Primack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skiles, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebrec, H.</span></span> <span> </span><span class="NLM_article-title">P450-mediated O-demethylated metabolite is responsible for rat hepatobiliary toxicity of pyridyltriazine-containing PI3K inhibitors</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfu178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Ftoxsci%2Fkfu178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25159132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitl2ntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2014&pages=298-310&author=R.+Subramanianauthor=D.+Aidasaniauthor=K.+Baileyauthor=D.+Branstetterauthor=N.+Everdsauthor=J.+Jiangauthor=M.+H.+Normanauthor=R.+Primackauthor=G.+L.+Skilesauthor=I.+Sotoauthor=M.+M.+Stecauthor=M.+Wagnerauthor=T.+Wuauthor=X.+Zhuauthor=H.+Lebrec&title=P450-mediated+O-demethylated+metabolite+is+responsible+for+rat+hepatobiliary+toxicity+of+pyridyltriazine-containing+PI3K+inhibitors&doi=10.1093%2Ftoxsci%2Fkfu178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">P450-mediated O-demethylated metabolite is responsible for rat hepatobiliary toxicity of pyridyltriazine-containing PI3K inhibitors</span></div><div class="casAuthors">Subramanian, Raju; Aidasani, Divesh; Bailey, Keith; Branstetter, Dan; Everds, Nancy; Jiang, Jian; Norman, Mark H.; Primack, Ronya; Skiles, Gary L.; Soto, Irene; Stec, Markian M.; Wagner, Mylo; Wu, Tian; Zhu, Xiaochun; Lebrec, Herve</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">298-310</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The dysregulation of phosphatidylinositol 3-kinase (PI3K)-dependent pathways is implicated in several human cancers making it an attractive target for small mol. PI3K inhibitors.  A series of potent pyridyltriazine-contg. inhibitors of class Ia PI3Ks were synthesized and a subset of compds. was evaluated in exploratory repeat-dose rat toxicol. studies.  Daily oral dosing of compd. 1 in Sprague Dawley rats for four consecutive days was assocd. with hepatobiliary toxicity that included biliary epithelial hyperplasia and hypertrophy, periductular edema, biliary stasis, and acute peribiliary inflammatory infiltrates.  These histol. changes were assocd. with clin. pathol. changes that included increased serum liver enzymes, total bile acids, and bilirubin.  The predominant clearance pathway of 1 was shown in vitro and in a bile-duct cannulated rat 14C-ADME study to be P 450-mediated oxidative metab.  An O-demethylated pyridine metabolite, M3, was identified as a candidate proximal metabolite that caused the hepatotoxicity.  Co-administration of the pan-P 450 inhibitor 1-aminobenzotriazole with 1 to rats significantly reduced the formation of M3 and prevented liver toxicity, whereas direct administration of M3 reproduced the toxicity.  Structural changes were introduced to 1 to make the methoxypyridine ring less susceptible to P 450 oxidn. (compd. 2), and addn. of a Me group to the benzylic carbon (compd. 3) improved the pharmacokinetic profile.  These changes culminated in the successful design of a clin. candidate 3 (AMG 511) that was devoid of liver toxicity in a 14-day rat toxicity study.  Herein, we describe how a metab.-based structure-activity relationship anal. allowed for the successful identification of a PI3K inhibitor devoid of off-target toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY5I8X5B3sHbVg90H21EOLACvtfcHk0liZ9e7XX-5S4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitl2ntrg%253D&md5=97f39570c10edc65c0768053db628d64</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfu178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfu178%26sid%3Dliteratum%253Aachs%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DAidasani%26aufirst%3DD.%26aulast%3DBailey%26aufirst%3DK.%26aulast%3DBranstetter%26aufirst%3DD.%26aulast%3DEverds%26aufirst%3DN.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DPrimack%26aufirst%3DR.%26aulast%3DSkiles%26aufirst%3DG.%2BL.%26aulast%3DSoto%26aufirst%3DI.%26aulast%3DStec%26aufirst%3DM.%2BM.%26aulast%3DWagner%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLebrec%26aufirst%3DH.%26atitle%3DP450-mediated%2520O-demethylated%2520metabolite%2520is%2520responsible%2520for%2520rat%2520hepatobiliary%2520toxicity%2520of%2520pyridyltriazine-containing%2520PI3K%2520inhibitors%26jtitle%3DToxicol.%2520Sci.%26date%3D2014%26volume%3D142%26spage%3D298%26epage%3D310%26doi%3D10.1093%2Ftoxsci%2Fkfu178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, X.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span> <span> </span><span class="NLM_article-title">Isoniazid metabolism and hepatotoxicity</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">392</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2016.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.apsb.2016.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27709007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2svntVSgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=384-392&author=P.+Wangauthor=K.+Pradhanauthor=X.-B.+Zhongauthor=X.+Ma&title=Isoniazid+metabolism+and+hepatotoxicity&doi=10.1016%2Fj.apsb.2016.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Isoniazid metabolism and hepatotoxicity</span></div><div class="casAuthors">Wang Pengcheng; Pradhan Komal; Ma Xiaochao; Zhong Xiao-Bo</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">384-392</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Isoniazid (INH) is highly effective for the management of tuberculosis.  However, it can cause liver injury and even liver failure.  INH metabolism has been thought to be associated with INH-induced liver injury.  This review summarized the metabolic pathways of INH and discussed their associations with INH-induced liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkZuUUWR4f4-vW160gIxP_fW6udTcc2eaDxnsBmTjIB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svntVSgsQ%253D%253D&md5=8b9e1b64c764bae0be6ab9a97624ebab</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2016.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2016.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DPradhan%26aufirst%3DK.%26aulast%3DZhong%26aufirst%3DX.-B.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DIsoniazid%2520metabolism%2520and%2520hepatotoxicity%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2016%26volume%3D6%26spage%3D384%26epage%3D392%26doi%3D10.1016%2Fj.apsb.2016.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, G. P.</span></span> <span> </span><span class="NLM_article-title">Comparison of the effects of pyridine and its metabolites on rat liver and kidney</span>. <i>Toxicol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1016/0378-4274(96)03660-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2F0378-4274%2896%2903660-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=8644130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK28XjtFentLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1996&pages=173-178&author=G.+P.+Carlson&title=Comparison+of+the+effects+of+pyridine+and+its+metabolites+on+rat+liver+and+kidney&doi=10.1016%2F0378-4274%2896%2903660-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the effects of pyridine and its metabolites on rat liver and kidney</span></div><div class="casAuthors">Carlson, Gary P.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">To evaluate the possibility that the metab. of pyridine may be important for its toxic actions, pyridine was compared with pyridine N-oxide, 2-hydroxypyridine, 3-hydroxypyridine, 4-hydroxypyridine and pyridinium methyliodide in rats given equal molar doses of the chems. i.p.  Hepatotoxicity was assessed by measuring serum sorbitol dehydrogenase, nephrotoxicity by detg. increases in blood urea nitrogen and serum creatinine, and influence on xenobiotic metab. by measuring changes in p-nitrophenol hydroxylase and ethoxyresorufin and benzyloxyresorufin dealkylase activities.  After a single dose of 2.5 mmol/kg, pyridinium methyliodide was the only compd. that was lethal whereas 2-hydroxypyridine was the only one that caused significant hepatotoxicity.  Pyridine, pyridine N-oxide, 3-hydroxypyridine and 4-hydroxypyridine were effective inducers of xenobiotic metab.  Thus the metabolites of pyridine may play a role, either singly or collectively, in the actions of pyridine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq03gJLr7r7mrVg90H21EOLACvtfcHk0lht9TJed1-_-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtFentLk%253D&md5=9ee25734d71ecb8f807f7328f93aa3f1</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1016%2F0378-4274%2896%2903660-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0378-4274%252896%252903660-0%26sid%3Dliteratum%253Aachs%26aulast%3DCarlson%26aufirst%3DG.%2BP.%26atitle%3DComparison%2520of%2520the%2520effects%2520of%2520pyridine%2520and%2520its%2520metabolites%2520on%2520rat%2520liver%2520and%2520kidney%26jtitle%3DToxicol.%2520Lett.%26date%3D1996%26volume%3D85%26spage%3D173%26epage%3D178%26doi%3D10.1016%2F0378-4274%2896%2903660-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, S. C.</span></span> <span> </span><span class="NLM_article-title">Action mechanism of antitubercular isoniazid. Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of inha inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">2520</span>– <span class="NLM_lpage">2526</span>, <span class="refDoi"> DOI: 10.1074/jbc.275.4.2520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1074%2Fjbc.275.4.2520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10644708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3cXpvFChsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=2520-2526&author=B.+Leiauthor=C.+J.+Weiauthor=S.+C.+Tu&title=Action+mechanism+of+antitubercular+isoniazid.+Activation+by+Mycobacterium+tuberculosis+KatG%2C+isolation%2C+and+characterization+of+inha+inhibitor&doi=10.1074%2Fjbc.275.4.2520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Action mechanism of antitubercular isoniazid: Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of InhA inhibitor</span></div><div class="casAuthors">Lei, Benfang; Wei, Chih-Jen; Tu, Shiao-Chun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2520-2526</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Activation of the antitubercular isoniazid (INH) by the Mycobacterium tuberculosis KatG produces an inhibitor for enoyl reductase (InhA).  The mechanism for INH activation remains poorly understood, and the inhibitor has never been isolated.  We have purified the InhA-inhibitor complex generated in the M. tuberculosis KatG-catalyzed INH activation.  The complex exhibited a 278-nm absorption peak and a shoulder around 326 nm with a characteristic A326/A278 ratio of 0.16.  The complex was devoid of enoyl reductase activity.  The inhibitor noncovalently binds to InhA with a Kd < 0.4 nM and can be dissocd. from denatured InhA for chromatog. isolation.  The free inhibitor showed absorption peaks at 326 (ε326 6900 M-1 cm-1) and 260 nm (ε260 27,000 M-1 cm-1).  The inactive complex can be reconstituted from InhA and the isolated inhibitor.  The InhA inhibitor from the KatG-catalyzed INH activation was identical to that from a slow, KatG-independent, Mn2+-mediated reaction based on high pressure liq. chromatog. anal. and absorption and mass spectral characteristics.  By monitoring the formation of the InhA-inhibitor complex, we have found that manganese is not essential to the INH activation by M. tuberculosis KatG.  Furthermore, the formation of the InhA inhibitor in the KatG reaction was independent of InhA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ9v4eqM9M1LVg90H21EOLACvtfcHk0lht9TJed1-_-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXpvFChsA%253D%253D&md5=ed3809e2c3188670d20c5e0bbb2ea564</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1074%2Fjbc.275.4.2520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.275.4.2520%26sid%3Dliteratum%253Aachs%26aulast%3DLei%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DC.%2BJ.%26aulast%3DTu%26aufirst%3DS.%2BC.%26atitle%3DAction%2520mechanism%2520of%2520antitubercular%2520isoniazid.%2520Activation%2520by%2520Mycobacterium%2520tuberculosis%2520KatG%252C%2520isolation%252C%2520and%2520characterization%2520of%2520inha%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D2520%26epage%3D2526%26doi%3D10.1074%2Fjbc.275.4.2520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaiswal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, A.</span></span> <span> </span><span class="NLM_article-title">A study on pre-XDR & XDR tuberculosis and their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India</span>. <i>Indian J. Med. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.4103/0971-5916.182625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4103%2F0971-5916.182625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27241648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFyktb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2016&pages=341-347&author=P.+Singhalauthor=P.+Dixitauthor=P.+Singhauthor=I.+Jaiswalauthor=M.+Singhauthor=A.+Jain&title=A+study+on+pre-XDR+%26+XDR+tuberculosis+and+their+prevalent+genotypes+in+clinical+isolates+of+Mycobacterium+tuberculosis+in+north+India&doi=10.4103%2F0971-5916.182625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">A study on pre-XDR & XDR tuberculosis & their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India</span></div><div class="casAuthors">Singhal, Parul; Dixit, Pratima; Singh, Pooja; Jaiswal, Indu; Singh, Mastan; Jain, Amita</div><div class="citationInfo"><span class="NLM_cas:title">Indian Journal of Medical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-347</span>CODEN:
                <span class="NLM_cas:coden">IMIREV</span>;
        ISSN:<span class="NLM_cas:issn">0971-5916</span>.
    
            (<span class="NLM_cas:orgname">Indian Council of Medical Research</span>)
        </div><div class="casAbstract">Background & objectives: Pre-extensively drug resistant (pre-XDR) and extensively drug resistant tuberculosis (XDR-TB) have been areas of growing concern, and are posing threat to global efforts of TB control.  The present study was planned to study the presence of pre-XDR and XDR Mycobacterium tuberculosis and their genotypes in clin. isolates obtained from previously treated cases of pulmonary TB.  Methods: A total of 219 isolates obtained from previously treated cases of pulmonary TB were subjected to first-line (streptomycin, isoniazid, rifampicin and ethambutol) and second-line (ofloxacin, kanamycin, capreomycin and amikacin) drug susceptibility testing on solid Lowenstein-Jensen medium by proportion method.  Genotyping was done for pre-XDR and XDR-TB isolates using 12 loci Mycobacterial Interspersed Repetitive Units-Variable No. Tandem Repeats (MIRU-VNTR).  Results: Multi-drug resistance was obsd. in 39.7 per cent (87/219) isolates.  Pre-XDR and XDR M. tuberculosis isolates amongst 87 multi-drug resistant (MDR) TB isolates were 43 (49.4%) and 10 (11.4%), resp.  Two most dominant genotypes among pre-XDR and XDR M. tuberculosis isolates were Beijing and Delhi/CAS types.  Interpretation & conclusions: Resistance to second-line anti-tubercular drugs should be routinely assessed in areas endemic for TB.  Similar genotype patterns were seen in pre-XDR and XDR-TB isolates.  Beijing and Delhi/CAS were predominant genotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUm2yb37A4OLVg90H21EOLACvtfcHk0lht9TJed1-_-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFyktb3E&md5=2fb3065993d600a767faf2acaf033654</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.4103%2F0971-5916.182625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0971-5916.182625%26sid%3Dliteratum%253Aachs%26aulast%3DSinghal%26aufirst%3DP.%26aulast%3DDixit%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DJaiswal%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DJain%26aufirst%3DA.%26atitle%3DA%2520study%2520on%2520pre-XDR%2520%2526%2520XDR%2520tuberculosis%2520and%2520their%2520prevalent%2520genotypes%2520in%2520clinical%2520isolates%2520of%2520Mycobacterium%2520tuberculosis%2520in%2520north%2520India%26jtitle%3DIndian%2520J.%2520Med.%2520Res.%26date%3D2016%26volume%3D143%26spage%3D341%26epage%3D347%26doi%3D10.4103%2F0971-5916.182625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Modi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chhabria, M.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis and biological evaluation of a newer series of pyrazolo[1,5-a]pyrimidine analogues as potential anti-tubercular agents</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.02.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.bioorg.2019.02.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30908967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVWmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2019&pages=240-251&author=P.+Modiauthor=S.+Patelauthor=M.+Chhabria&title=Structure-based+design%2C+synthesis+and+biological+evaluation+of+a+newer+series+of+pyrazolo%5B1%2C5-a%5Dpyrimidine+analogues+as+potential+anti-tubercular+agents&doi=10.1016%2Fj.bioorg.2019.02.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design, synthesis and biological evaluation of a newer series of pyrazolo[1,5-a]pyrimidine analogues as potential anti-tubercular agents</span></div><div class="casAuthors">Modi, Palmi; Patel, Shivani; Chhabria, Mahesh</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">240-251</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mnbvcx/jIn this present study, twenty six novel pyrazolo[1,5-a]pyrimidine analogs I [R = H, 3-ClC6H4, 4-MeOC6H4, etc.; R1 = Ph, 4-MeC6H4, 3,4-di-FC6H3, etc.] were designed using mol. docking studies.  Structural elucidation of the synthesized mols. I was carried out using IR, MS, 1H NMR and 13C NMR spectroscopy.  All the synthesized compds. I were evaluated for their in-vitro anti-tubercular activity against H37Rv strain by Alamar Blue assay method.  Amongst all the tested compds. I [R = 4-MeC6H4, R1 = 4-ClC6H4; R = H, R1 = 3,4-di-ClC6H3; R = 2-MeOC6H4, R1 = 3-MeC6H4; R = 4-FC6H4, R1 = 3,4-di-FC6H3] exhibited promising anti-tubercular activity.  Further, these potent compds. I were gauged for MDR-TB, XDR-TB and cytotoxic study.  None of these compds. exhibited potent cytotoxicity.  Stability of protein ligand complex was further evaluated by mol. dynamics simulation for 10 ns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSMtVzF1kfjbVg90H21EOLACvtfcHk0li738ACC4qHKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVWmt7s%253D&md5=9256114240b74f4eca81586941b459c7</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.02.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.02.044%26sid%3Dliteratum%253Aachs%26aulast%3DModi%26aufirst%3DP.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DChhabria%26aufirst%3DM.%26atitle%3DStructure-based%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520newer%2520series%2520of%2520pyrazolo%255B1%252C5-a%255Dpyrimidine%2520analogues%2520as%2520potential%2520anti-tubercular%2520agents%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D87%26spage%3D240%26epage%3D251%26doi%3D10.1016%2Fj.bioorg.2019.02.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblauc, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.09.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.ejmech.2016.09.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27654393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFCmt7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=41-48&author=X.+Luauthor=J.+Tangauthor=S.+Cuiauthor=B.+Wanauthor=S.+G.+Franzblaucauthor=T.+Zhangauthor=X.+Zhangauthor=K.+Ding&title=Pyrazolo%5B1%2C5-a%5Dpyridine-3-carboxamide+hybrids%3A+Design%2C+synthesis+and+evaluation+of+anti-tubercular+activity&doi=10.1016%2Fj.ejmech.2016.09.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity</span></div><div class="casAuthors">Lu, Xiaoyun; Tang, Jian; Cui, Shengyang; Wan, Baojie; Franzblauc, Scott G.; Zhang, Tianyu; Zhang, Xiantao; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41-48</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of pyrazolo[1,5-a]pyridine-3-carboxamide hybrids were designed and evaluated as novel anti-tubercular agents.  The representative hybrid 7 exhibited promising in vitro activity against susceptive strain H37Rv and a panel of drug-resistant Mtb strains with MIC values of 0.006 μg/mL and ranged from 0.003 to 0.014 μg/mL, resp.  More importantly, the hybrid 7 also showed very low cytotoxicity, and could significantly reduce the mycobacterial burden in a mouse model infected with autoluminescent H37Ra strain, which may serve as a lead compd. for further development of new anti-tubercular agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWPYBQv-bpmbVg90H21EOLACvtfcHk0li738ACC4qHKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFCmt7%252FP&md5=4c573c0540b098312d46d426acb4b01e</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.030%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DS.%26aulast%3DWan%26aufirst%3DB.%26aulast%3DFranzblauc%26aufirst%3DS.%2BG.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DPyrazolo%255B1%252C5-a%255Dpyridine-3-carboxamide%2520hybrids%253A%2520Design%252C%2520synthesis%2520and%2520evaluation%2520of%2520anti-tubercular%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D125%26spage%3D41%26epage%3D48%26doi%3D10.1016%2Fj.ejmech.2016.09.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref241"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref241'); return false;" data-citation="" class="refNumLink">241</a></strong><div class="NLM_citation" id="cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A. K.</span></span> <span> </span><span class="NLM_article-title">Structural and functional organization of the animal fatty acid synthase</span>. <i>Prog. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1016/S0163-7827(02)00067-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS0163-7827%2802%2900067-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=12689621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis1yqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=289-317&author=S.+Smithauthor=A.+Witkowskiauthor=A.+K.+Joshi&title=Structural+and+functional+organization+of+the+animal+fatty+acid+synthase&doi=10.1016%2FS0163-7827%2802%2900067-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and functional organization of the animal fatty acid synthase</span></div><div class="casAuthors">Smith, Stuart; Witkowski, Andrzej; Joshi, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Lipid Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">289-317</span>CODEN:
                <span class="NLM_cas:coden">PLIRDW</span>;
        ISSN:<span class="NLM_cas:issn">0163-7827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The entire pathway of palmitate synthesis from malonyl-CoA in mammals is catalyzed by a single, homodimeric, multifunctional enzyme, fatty acid synthase (FAS).  Each subunit contains 3 N-terminal domains, β-ketoacyl synthase, malonyl/acetyltransferase, and dehydrase sepd. by a structural core from 4 C-terminal domains, enoyl reductase, β-ketoacyl reductase, acyl carrier protein (ACP), and thiosterase.  The kinetics and specificities of the substrate loading reaction catalyzed by the malonyl/acetyltransferase, the condensation reaction catalyzed by β-ketoacyl synthase, and the chain-terminating reaction catalyzed by thioesterase ensure that intermediates do not leak off the enzyme, satd. chains exclusively are elongated, and palmitate is released as the major product.  Only in the FAS dimer do the subunits adopt conformations that facilitate productive coupling of the individual reactions for fatty acid synthesis at the 2 ACP centers.  Introduction of a double tagging and dual affinity chromatog. procedure has permitted the engineering and isolation of heterodimeric FAS enzymes carrying different mutations on each subunit.  Characterization of these heterodimers, by activity assays and chem. crosslinking, has been exploited to map the functional topol. of the protein.  The results have revealed that the 2 ACP domains engage in substrate loading and condensation reactions catalyzed by the malonyl/acetyltransferase and β-ketoacyl synthase domains of either subunit.  In contrast, the reactions involved in processing of the β-C atom, following each chain elongation step, together with the release of palmitate, are catalyzed by the cooperation of ACP with catalytic domains of the same subunit.  These findings suggest a revised model for FAS in which the 2 polypeptides are oriented such that head-to-tail contacts are formed both between and within subunits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqurWTMLAX22LVg90H21EOLACvtfcHk0li738ACC4qHKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis1yqtr0%253D&md5=ec5000bee0c38cb05336f637cee922ea</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1016%2FS0163-7827%2802%2900067-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7827%252802%252900067-X%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DWitkowski%26aufirst%3DA.%26aulast%3DJoshi%26aufirst%3DA.%2BK.%26atitle%3DStructural%2520and%2520functional%2520organization%2520of%2520the%2520animal%2520fatty%2520acid%2520synthase%26jtitle%3DProg.%2520Lipid%2520Res.%26date%3D2003%26volume%3D42%26spage%3D289%26epage%3D317%26doi%3D10.1016%2FS0163-7827%2802%2900067-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref242"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref242'); return false;" data-citation="" class="refNumLink">242</a></strong><div class="NLM_citation" id="cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cacciari, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolcato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spalluto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klotz, K.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacilieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deflorian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro, S.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure-activity profile</span>. <i>Purinergic Signalling</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1007/s11302-006-9027-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1007%2Fs11302-006-9027-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=18404432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntlyqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=183-193&author=B.+Cacciariauthor=C.+Bolcatoauthor=G.+Spallutoauthor=K.-N.+Klotzauthor=M.+Bacilieriauthor=F.+Deflorianauthor=S.+Moro&title=Pyrazolo-triazolo-pyrimidines+as+adenosine+receptor+antagonists%3A+A+complete+structure-activity+profile&doi=10.1007%2Fs11302-006-9027-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: a complete structure-activity profile</span></div><div class="casAuthors">Cacciari, Barbara; Bolcato, Chiara; Spalluto, Giampiero; Klotz, Karl-Norbet; Bacilieri, Magdalena; Deflorian, Francesca; Moro, Stefano</div><div class="citationInfo"><span class="NLM_cas:title">Purinergic Signalling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">183-193</span>CODEN:
                <span class="NLM_cas:coden">PSUIA9</span>;
        ISSN:<span class="NLM_cas:issn">1573-9538</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  In the last 5 years, many efforts were conducted searching potent and selective human A3 adenosine antagonists.  In this field several different classes of compds., possessing very good affinity (nM range) and with a broad range of selectivity, were proposed.  Recently, our group synthesized a new series of pyrazolo-triazolo-pyrimidines bearing different substitutions at the N5 and N8 positions, which were described as highly potent and selective human A3 adenosine receptor antagonists.  The present review summarizes available data and provides an overview of the structure-activity relationships found for this class of human A3 adenosine receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovPRM799NFw7Vg90H21EOLACvtfcHk0lhR0Sk_PHETRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntlyqsr8%253D&md5=7a8762e2dd3fa3b4edfc6e3dbf97d85f</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1007%2Fs11302-006-9027-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11302-006-9027-x%26sid%3Dliteratum%253Aachs%26aulast%3DCacciari%26aufirst%3DB.%26aulast%3DBolcato%26aufirst%3DC.%26aulast%3DSpalluto%26aufirst%3DG.%26aulast%3DKlotz%26aufirst%3DK.-N.%26aulast%3DBacilieri%26aufirst%3DM.%26aulast%3DDeflorian%26aufirst%3DF.%26aulast%3DMoro%26aufirst%3DS.%26atitle%3DPyrazolo-triazolo-pyrimidines%2520as%2520adenosine%2520receptor%2520antagonists%253A%2520A%2520complete%2520structure-activity%2520profile%26jtitle%3DPurinergic%2520Signalling%26date%3D2007%26volume%3D3%26spage%3D183%26epage%3D193%26doi%3D10.1007%2Fs11302-006-9027-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref243"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref243'); return false;" data-citation="" class="refNumLink">243</a></strong><div class="NLM_citation" id="cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selleri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costagli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciciani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gratteri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besnard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fohlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Siena, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, P. M.</span></span> <span> </span><span class="NLM_article-title">A novel selective GABA(A) alpha1 receptor agonist displaying sedative and anxiolytic-like properties in rodents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6756</span>– <span class="NLM_lpage">6760</span>, <span class="refDoi"> DOI: 10.1021/jm058002n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058002n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6756-6760&author=S.+Selleriauthor=F.+Bruniauthor=C.+Costagliauthor=A.+Costanzoauthor=G.+Guerriniauthor=G.+Cicianiauthor=P.+Gratteriauthor=F.+Besnardauthor=B.+Costaauthor=M.+Montaliauthor=C.+Martiniauthor=J.+Fohlinauthor=G.+De+Sienaauthor=P.+M.+Aiello&title=A+novel+selective+GABA%28A%29+alpha1+receptor+agonist+displaying+sedative+and+anxiolytic-like+properties+in+rodents&doi=10.1021%2Fjm058002n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Selective GABAA α1 Receptor Agonist Displaying Sedative and Anxiolytic-like Properties in Rodents</span></div><div class="casAuthors">Selleri, Silvia; Bruni, Fabrizio; Costagli, Camilla; Costanzo, Annarella; Guerrini, Gabriella; Ciciani, Giovanna; Gratteri, Paola; Besnard, Francois; Costa, Barbara; Montali, Marina; Martini, Claudia; Fohlin, Jonna; De Siena, Gaetano; Aiello, Petra Malmberg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6756-6760</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective ligands for Bz/GABAA receptor subtypes, a pyrazolo[1,5-a]pyrimidine deriv. I, the azaisostere of zolpidem, was synthesized and evaluated in vitro on bovine brain homogenate and on recombinant benzodiazepine receptors (αxβ2/3γ2, x = 1-3, 5) expressed in HEK293 cells.  I displayed affinity only for α1β2γ2 subtype (Ki = 31 nM), and in an in-depth, in vivo study it revealed sedative and anxiolytic-like properties without any amnesic and myorelaxant effects in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqYlWTHoPb7rVg90H21EOLACvtfcHk0lhR0Sk_PHETRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FK&md5=506a7483989fd3963a7303a5fa1d50fd</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1021%2Fjm058002n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058002n%26sid%3Dliteratum%253Aachs%26aulast%3DSelleri%26aufirst%3DS.%26aulast%3DBruni%26aufirst%3DF.%26aulast%3DCostagli%26aufirst%3DC.%26aulast%3DCostanzo%26aufirst%3DA.%26aulast%3DGuerrini%26aufirst%3DG.%26aulast%3DCiciani%26aufirst%3DG.%26aulast%3DGratteri%26aufirst%3DP.%26aulast%3DBesnard%26aufirst%3DF.%26aulast%3DCosta%26aufirst%3DB.%26aulast%3DMontali%26aufirst%3DM.%26aulast%3DMartini%26aufirst%3DC.%26aulast%3DFohlin%26aufirst%3DJ.%26aulast%3DDe%2BSiena%26aufirst%3DG.%26aulast%3DAiello%26aufirst%3DP.%2BM.%26atitle%3DA%2520novel%2520selective%2520GABA%2528A%2529%2520alpha1%2520receptor%2520agonist%2520displaying%2520sedative%2520and%2520anxiolytic-like%2520properties%2520in%2520rodents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6756%26epage%3D6760%26doi%3D10.1021%2Fjm058002n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref244"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref244'); return false;" data-citation="" class="refNumLink">244</a></strong><div class="NLM_citation" id="cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakashita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitahara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakoda, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluations of condensed pyridine and condensed pyrimidine-based HMG-CoA reductase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1288</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00203-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS0960-894X%2801%2900203-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=11392538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtlSrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1285-1288&author=M.+Suzukiauthor=H.+Iwasakiauthor=Y.+Fujikawaauthor=M.+Sakashitaauthor=M.+Kitaharaauthor=R.+Sakoda&title=Synthesis+and+biological+evaluations+of+condensed+pyridine+and+condensed+pyrimidine-based+HMG-CoA+reductase+inhibitors&doi=10.1016%2FS0960-894X%2801%2900203-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluations of condensed pyridine and condensed pyrimidine-based HMG-CoA reductase inhibitors</span></div><div class="casAuthors">Suzuki, M.; Iwasaki, H.; Fujikawa, Y.; Sakashita, M.; Kitahara, M.; Sakoda, R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1285-1288</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of novel 3,5-dihydroxyheptenoic acid derivs. contg. pyrazolopyridine, e.g. I [R1 = Me2CH, (CH2)2CH; R2 = H, Me, Ph, 4-ClC6H4, (CH2)2CH; R3 = Me, Et, Me3C, Ph, 4-MeOC6H4, 2-pyridyl], isoxazolopyridine, e.g. II (R1 = Me2CH; R2 = Me, Ph), thienopyridine, e.g. III [R1 = Me2CH, (CH2)2CH; R2 = H, Et, Ph; R3 = H, Me, Me2CH, Ph; R2R3 = (CH2)3, (CH2)4, (CH2)5], and pyrazolopyrimidine, e.g. IV [R1 = Me2CH, (CH2)2CH; R2 = Me, Me2CH, Me3C, Ph, 2-furyl; R3 = H, Me, Ph; R2R3 = (CH2)4] as a key scaffold was synthesized from condensed pyridine and condensed pyrimidine carboxylic acid esters by homologation, aldol condensation with Et acetoacetate dianion, and stereoselective redn. of the 5-hydroxyketone.  Most compds. in the series were found to have potent HMG-CoA reductase inhibitory activities in vitro and marked cholesterol biosynthesis inhibitory activities in vivo.  It was demonstrated that these scaffolds can be used as a suitable replacement for the hexahydronaphthalene ring present in naturally occurring HMG-CoA reductase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRZzdSLM8YKLVg90H21EOLACvtfcHk0lhR0Sk_PHETRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtlSrsLg%253D&md5=91247d8f5303eb6671512b41d438d65c</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900203-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900203-7%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DIwasaki%26aufirst%3DH.%26aulast%3DFujikawa%26aufirst%3DY.%26aulast%3DSakashita%26aufirst%3DM.%26aulast%3DKitahara%26aufirst%3DM.%26aulast%3DSakoda%26aufirst%3DR.%26atitle%3DSynthesis%2520and%2520biological%2520evaluations%2520of%2520condensed%2520pyridine%2520and%2520condensed%2520pyrimidine-based%2520HMG-CoA%2520reductase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1285%26epage%3D1288%26doi%3D10.1016%2FS0960-894X%2801%2900203-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref245"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref245'); return false;" data-citation="" class="refNumLink">245</a></strong><div class="NLM_citation" id="cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandrashekharappa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venugopala, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venugopala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmashali, B.</span></span> <span> </span><span class="NLM_article-title">Qualitative anti-tubercular activity of synthetic ethyl 7-acetyl- 2-substituted-3-(4-substituted benzoyl) indolizine-1-carboxylate analogues</span>. <i>J. Appl. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.7324/JAPS.2019.90217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.7324%2FJAPS.2019.90217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVOgtr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=124-128&author=S.+Chandrashekharappaauthor=K.+N.+Venugopalaauthor=R.+Venugopalaauthor=B.+Padmashali&title=Qualitative+anti-tubercular+activity+of+synthetic+ethyl+7-acetyl-+2-substituted-3-%284-substituted+benzoyl%29+indolizine-1-carboxylate+analogues&doi=10.7324%2FJAPS.2019.90217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Qualitative anti-tubercular activity of synthetic ethyl 7-acetyl-2-substituted-3-(4-substituted benzoyl) indolizine-1-carboxylate analogues</span></div><div class="casAuthors">Chandrashekharappa, Sandeep; Venugopala, Katharigatta N.; Venugopala, Rashmi; Padmashali, Basavaraj</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Pharmaceutical Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">124-128</span>CODEN:
                <span class="NLM_cas:coden">JAPSHX</span>;
        ISSN:<span class="NLM_cas:issn">2231-3354</span>.
    
            (<span class="NLM_cas:orgname">Journal of Applied Pharmaceutical Science</span>)
        </div><div class="casAbstract">Both the emergence of multidrug-resistant and extensively drug-resistant tuberculosis (TB) are currently the major challenges in the treatment of TB.  Only delamanid and bedaquiline have been recently approved as anti-TB drugs in the past 40 years.  In an attempt to search for active anti-TB compds. against the sensitive strain of Mycobacterium tuberculosis, H37Rv-a series of synthetic Et 7-acetyl-2-substituted-3-(4-substituted benzoyl)indolizine-1-carboxylates (2a-r)-have been screened for in vitro qual. anti-TB activity using an agar diln. method.  It was found that compds. 2a, 2b, 2c, 2f, 2g, 2i, 2j, 2l, 2o, 2p, and 2r, which have various functional groups on the indolizine nucleus, were active against the H37Rv strain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI7tXr82tYHbVg90H21EOLACvtfcHk0lioPQa-SN159g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVOgtr7J&md5=38d255d0be6cc612f46d8bfeff9ffcbb</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.7324%2FJAPS.2019.90217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7324%252FJAPS.2019.90217%26sid%3Dliteratum%253Aachs%26aulast%3DChandrashekharappa%26aufirst%3DS.%26aulast%3DVenugopala%26aufirst%3DK.%2BN.%26aulast%3DVenugopala%26aufirst%3DR.%26aulast%3DPadmashali%26aufirst%3DB.%26atitle%3DQualitative%2520anti-tubercular%2520activity%2520of%2520synthetic%2520ethyl%25207-acetyl-%25202-substituted-3-%25284-substituted%2520benzoyl%2529%2520indolizine-1-carboxylate%2520analogues%26jtitle%3DJ.%2520Appl.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D9%26spage%3D124%26epage%3D128%26doi%3D10.7324%2FJAPS.2019.90217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref246"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref246'); return false;" data-citation="" class="refNumLink">246</a></strong><div class="NLM_citation" id="cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baravkar, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagh, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawale, L. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhari, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhansali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanjayan, G. J.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of 2-amino-thiophene-proline-conjugates and their anti-tubercular activity against Mycobacterium tuberculosis H37Ra</span>. <i>ChemistrySelect</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2851</span>– <span class="NLM_lpage">2857</span>, <span class="refDoi"> DOI: 10.1002/slct.201803370</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1002%2Fslct.201803370" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktlelu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=2851-2857&author=S.+B.+Baravkarauthor=M.+A.+Waghauthor=L.+U.+Nawaleauthor=A.+S.+Choudhariauthor=S.+Bhansaliauthor=D.+Sarkarauthor=G.+J.+Sanjayan&title=Design+and+synthesis+of+2-amino-thiophene-proline-conjugates+and+their+anti-tubercular+activity+against+Mycobacterium+tuberculosis+H37Ra&doi=10.1002%2Fslct.201803370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of 2-Amino-thiophene-proline-conjugates and Their Anti-tubercular Activity against Mycobacterium Tuberculosis H37Ra</span></div><div class="casAuthors">Baravkar, Sachin B.; Wagh, Mahendra A.; Nawale, Laxman U.; Choudhari, Amit S.; Bhansali, Sujit; Sarkar, Dhiman; Sanjayan, Gangadhar J.</div><div class="citationInfo"><span class="NLM_cas:title">ChemistrySelect</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2851-2857</span>CODEN:
                <span class="NLM_cas:coden">CHEMUD</span>;
        ISSN:<span class="NLM_cas:issn">2365-6549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The emergence of extensively drug resistant tuberculosis (XDR-TB) and multi-drug resistant tuberculosis (MDR-TB) has necessitated the development of new drugs with short chemotherapy treatment regime and cost effectiveness.  To overcome these challenges, we are reporting the synthesis of a series of 2-amino-thiophene-proline-conjugates which show potent in-vitro and ex-vivo anti-tubercular (anti-TB) activity against mycobacterium tuberculosis (mtb) H37Ra.  The synthesis of these 2-amino-thiophene-proline-conjugates was carried out via soln. phase peptide coupling reactions using methyl-2-aminothiophene-3-carboxylate 8 as an intermediate obtained by modified gewald reaction.  Intermediate 8 was coupled with different amino acids to obtain dipeptides 3, 4, 5, 6 a and 7.  Priliminary anti-TB assay data encoureaged us to synthesize modified proline derivs. 6 b-6 k via formation of a benzoxazinone intermediate 16.  Most of these conjugates are active against mtb H37Ra in both active (A) and dormant (D) strains.  They are also active against drug resistant mtb H37Ra strains.  A trifluoroethyl ester analog, 6 i was the most potent among the series [MIC 1 μg/mL] along with 6 f and 6 g [MIC 2-6 μg/mL].  Cytotoxicity studies suggested that, these compds. are less cytotoxic to human cell lines HeLa, MCF-7, HUVEC and hence possess high selectivity index (SI).  Docking studies revealed that the binding mode of most active compds. 6 i, 6 g and 6 f is in accordance with their bioactivity studies having docking score -8.969, -8.446 and -7.865, resp.  Moreover, in silico ADME properties suggest that all the compds. possess drug like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi81D5bBIhoLVg90H21EOLACvtfcHk0lioPQa-SN159g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktlelu78%253D&md5=075b19354cd6037db9f0172ad1cc9f44</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1002%2Fslct.201803370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fslct.201803370%26sid%3Dliteratum%253Aachs%26aulast%3DBaravkar%26aufirst%3DS.%2BB.%26aulast%3DWagh%26aufirst%3DM.%2BA.%26aulast%3DNawale%26aufirst%3DL.%2BU.%26aulast%3DChoudhari%26aufirst%3DA.%2BS.%26aulast%3DBhansali%26aufirst%3DS.%26aulast%3DSarkar%26aufirst%3DD.%26aulast%3DSanjayan%26aufirst%3DG.%2BJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%25202-amino-thiophene-proline-conjugates%2520and%2520their%2520anti-tubercular%2520activity%2520against%2520Mycobacterium%2520tuberculosis%2520H37Ra%26jtitle%3DChemistrySelect%26date%3D2019%26volume%3D4%26spage%3D2851%26epage%3D2857%26doi%3D10.1002%2Fslct.201803370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref247"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref247'); return false;" data-citation="" class="refNumLink">247</a></strong><div class="NLM_citation" id="cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porras de Francisco, E.</span>; <span class="NLM_string-name">Remuinan-Blanco, M. J.</span>; <span class="NLM_string-name">Bourotte, M.</span>; <span class="NLM_string-name">Deprez, B.</span>; <span class="NLM_string-name">Willand, N.</span></span> <span> </span><span class="NLM_article-title">Novel Compounds</span>. <span class="NLM_patent">WO2019/034700Al</span>. February 21, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=E.+Porras+de+Francisco&author=M.+J.+Remuinan-Blanco&author=M.+Bourotte&author=B.+Deprez&author=N.+Willand&title=Novel+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPorras%2Bde%2BFrancisco%26aufirst%3DE.%26atitle%3DNovel%2520Compounds%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref248"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref248'); return false;" data-citation="" class="refNumLink">248</a></strong><div class="NLM_citation" id="cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porras de Francisco, E.</span>; <span class="NLM_string-name">Remuinan-Blanco, M. J.</span>; <span class="NLM_string-name">Bourotte, M.</span>; <span class="NLM_string-name">Deprez, B.</span>; <span class="NLM_string-name">Willand, N.</span></span> <span> </span><span class="NLM_article-title">Novel Compounds</span>. <span class="NLM_patent">WO2019/034701Al</span>. February 21, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=E.+Porras+de+Francisco&author=M.+J.+Remuinan-Blanco&author=M.+Bourotte&author=B.+Deprez&author=N.+Willand&title=Novel+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPorras%2Bde%2BFrancisco%26aufirst%3DE.%26atitle%3DNovel%2520Compounds%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref249"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref249'); return false;" data-citation="" class="refNumLink">249</a></strong><div class="NLM_citation" id="cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porras de Francisco, E. P.</span>; <span class="NLM_string-name">Remuinan-Blanco, M. J.</span>; <span class="NLM_string-name">Bourotte, M.</span>; <span class="NLM_string-name">Deprez, B.</span>; <span class="NLM_string-name">Willand, N.</span></span> <span> </span><span class="NLM_article-title">Novel Compounds</span>. <span class="NLM_patent">WO2019/034702Al</span>. February 21, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=E.+P.+Porras+de+Francisco&author=M.+J.+Remuinan-Blanco&author=M.+Bourotte&author=B.+Deprez&author=N.+Willand&title=Novel+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPorras%2Bde%2BFrancisco%26aufirst%3DE.%2BP.%26atitle%3DNovel%2520Compounds%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref250"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref250'); return false;" data-citation="" class="refNumLink">250</a></strong><div class="NLM_citation" id="cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allemparte-Gallardo, C.</span>; <span class="NLM_string-name">Encinas, L.</span>; <span class="NLM_string-name">Esquivias Provencio, J.</span></span> <span> </span><span class="NLM_article-title">Novel tetrazole compounds and their use in the treatment of tuberculosis</span>. <span class="NLM_patent">WO2019/034729Al</span>. Feb 21, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+Allemparte-Gallardo&author=L.+Encinas&author=J.+Esquivias+Provencio&title=Novel+tetrazole+compounds+and+their+use+in+the+treatment+of+tuberculosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllemparte-Gallardo%26aufirst%3DC.%26atitle%3DNovel%2520tetrazole%2520compounds%2520and%2520their%2520use%2520in%2520the%2520treatment%2520of%2520tuberculosis%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref251"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref251'); return false;" data-citation="" class="refNumLink">251</a></strong><div class="NLM_citation" id="cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dover, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alahari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gratraud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowruth, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span> <span> </span><span class="NLM_article-title">EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1055</span>– <span class="NLM_lpage">1063</span>, <span class="refDoi"> DOI: 10.1128/AAC.01063-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.01063-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=17220416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis12jsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=1055-1063&author=L.+G.+Doverauthor=A.+Alahariauthor=P.+Gratraudauthor=J.+M.+Gomesauthor=V.+Bhowruthauthor=R.+C.+Reynoldsauthor=G.+S.+Besraauthor=L.+Kremer&title=EthA%2C+a+common+activator+of+thiocarbamide-containing+drugs+acting+on+different+mycobacterial+targets&doi=10.1128%2FAAC.01063-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets</span></div><div class="casAuthors">Dover, Lynn G.; Alahari, Anuradha; Gratraud, Paul; Gomes, Jessica M.; Bhowruth, Veemal; Reynolds, Robert C.; Besra, Gurdyal S.; Kremer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1055-1063</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Many of the current antimycobacterial agents require some form of cellular activation unmasking reactive groups, which in turn will bind to their specific targets.  Therefore, understanding the mechanisms of activation of current antimycobacterials not only helps to decipher mechanisms of drug resistance but may also facilitate the development of alternative activation strategies or of analogs that do not require such processes.  Herein, through the use of genetically defined strains of Mycobacterium bovis BCG we provide evidence that EthA, previously shown to activate ethionamide, also converts isoxyl (ISO) and thiacetazone (TAC) into reactive species.  These results were further supported by the development of an in vitro assay using purified recombinant EthA, which allowed direct assessment of the metab. of ISO.  Interestingly, biochem. anal. of [14C]acetate-labeled cultures suggested that all of these EthA-activated drugs inhibit mycolic acid biosynthesis via different mechanisms through binding to specific targets.  This report is also the first description of the mol. mechanism of action of TAC, a thiosemicarbazone antimicrobial agent that is still used in the treatment of tuberculosis as a second-line drug in many developing countries.  Altogether, the results suggest that EthA is a common activator of thiocarbamide-contg. drugs.  The broad specificity of EthA can now be used to improve the activation process of these drugs, which may help overcome the toxicity problems assocd. with clin. thiocarbamide use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN_R6VIHikw7Vg90H21EOLACvtfcHk0liANRRY1wlHJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis12jsLY%253D&md5=e41cb13b90a0031fb69473bd1379c51a</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1128%2FAAC.01063-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01063-06%26sid%3Dliteratum%253Aachs%26aulast%3DDover%26aufirst%3DL.%2BG.%26aulast%3DAlahari%26aufirst%3DA.%26aulast%3DGratraud%26aufirst%3DP.%26aulast%3DGomes%26aufirst%3DJ.%2BM.%26aulast%3DBhowruth%26aufirst%3DV.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DKremer%26aufirst%3DL.%26atitle%3DEthA%252C%2520a%2520common%2520activator%2520of%2520thiocarbamide-containing%2520drugs%2520acting%2520on%2520different%2520mycobacterial%2520targets%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D1055%26epage%3D1063%26doi%3D10.1128%2FAAC.01063-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref252"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref252'); return false;" data-citation="" class="refNumLink">252</a></strong><div class="NLM_citation" id="cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abrahams, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futterer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rullas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega-Muro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moynihan, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Herran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esquivias, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alemparte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span> <span> </span><span class="NLM_article-title">Inhibiting mycobacterial tryptophan synthase by targeting the inter-subunit interface</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">9430</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-09642-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fs41598-017-09642-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28842600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1cbhvVSqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=9430&author=K.+A.+Abrahamsauthor=J.+A.+G.+Coxauthor=K.+Futtererauthor=J.+Rullasauthor=F.+Ortega-Muroauthor=N.+J.+Lomanauthor=P.+J.+Moynihanauthor=E.+Perez-Herranauthor=E.+Jimenezauthor=J.+Esquiviasauthor=D.+Barrosauthor=L.+Ballellauthor=C.+Alemparteauthor=G.+S.+Besra&title=Inhibiting+mycobacterial+tryptophan+synthase+by+targeting+the+inter-subunit+interface&doi=10.1038%2Fs41598-017-09642-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting mycobacterial tryptophan synthase by targeting the inter-subunit interface</span></div><div class="casAuthors">Abrahams Katherine A; Futterer Klaus; Loman Nicholas J; Moynihan Patrick J; Besra Gurdyal S; Cox Jonathan A G; Rullas Joaquin; Ortega-Muro Fatima; Perez-Herran Esther; Jimenez Elena; Esquivias Jorge; Barros David; Ballell Lluis; Alemparte Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9430</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug discovery efforts against the pathogen Mycobacterium tuberculosis (Mtb) have been advanced through phenotypic screens of extensive compound libraries.  Such a screen revealed sulfolane 1 and indoline-5-sulfonamides 2 and 3 as potent inhibitors of mycobacterial growth.  Optimization in the sulfolane series led to compound 4, which has proven activity in an in vivo murine model of Mtb infection.  Here we identify the target and mode of inhibition of these compounds based on whole genome sequencing of spontaneous resistant mutants, which identified mutations locating to the essential α- and β-subunits of tryptophan synthase.  Over-expression studies confirmed tryptophan synthase as the biological target.  Biochemical techniques probed the mechanism of inhibition, revealing the mutant enzyme complex incurs a fitness cost but does not prevent inhibitor binding.  Mapping of the resistance conferring mutations onto a low-resolution crystal structure of Mtb tryptophan synthase showed they locate to the interface between the α- and β-subunits.  The discovery of anti-tubercular agents inhibiting tryptophan synthase highlights the therapeutic potential of this enzyme and draws attention to the prospect of other amino acid biosynthetic pathways as future Mtb drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdKFx3KRVw836oPH0mYWL1fW6udTcc2eaOBOdhPebEfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbhvVSqtw%253D%253D&md5=d5256bcc84a9c06221984116b25aee2e</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-09642-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-09642-y%26sid%3Dliteratum%253Aachs%26aulast%3DAbrahams%26aufirst%3DK.%2BA.%26aulast%3DCox%26aufirst%3DJ.%2BA.%2BG.%26aulast%3DFutterer%26aufirst%3DK.%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DOrtega-Muro%26aufirst%3DF.%26aulast%3DLoman%26aufirst%3DN.%2BJ.%26aulast%3DMoynihan%26aufirst%3DP.%2BJ.%26aulast%3DPerez-Herran%26aufirst%3DE.%26aulast%3DJimenez%26aufirst%3DE.%26aulast%3DEsquivias%26aufirst%3DJ.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DAlemparte%26aufirst%3DC.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26atitle%3DInhibiting%2520mycobacterial%2520tryptophan%2520synthase%2520by%2520targeting%2520the%2520inter-subunit%2520interface%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D9430%26doi%3D10.1038%2Fs41598-017-09642-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref253"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref253'); return false;" data-citation="" class="refNumLink">253</a></strong><div class="NLM_citation" id="cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioerger, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothchild, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trauner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galaviz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttenhower, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behar, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. J.</span></span> <span> </span><span class="NLM_article-title">Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">1296</span>– <span class="NLM_lpage">1308</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2013.10.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.cell.2013.10.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=24315099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFylurzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2013&pages=1296-1308&author=Y.+J.+Zhangauthor=M.+C.+Reddyauthor=T.+R.+Ioergerauthor=A.+C.+Rothchildauthor=V.+Dartoisauthor=B.+M.+Schusterauthor=A.+Traunerauthor=D.+Wallisauthor=S.+Galavizauthor=C.+Huttenhowerauthor=J.+C.+Sacchettiniauthor=S.+M.+Beharauthor=E.+J.+Rubin&title=Tryptophan+biosynthesis+protects+mycobacteria+from+CD4+T-cell-mediated+killing&doi=10.1016%2Fj.cell.2013.10.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing</span></div><div class="casAuthors">Zhang, Yanjia J.; Reddy, Manchi C.; Ioerger, Thomas R.; Rothchild, Alissa C.; Dartois, Veronique; Schuster, Brian M.; Trauner, Andrej; Wallis, Deeann; Galaviz, Stacy; Huttenhower, Curtis; Sacchettini, James C.; Behar, Samuel M.; Rubin, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1296-1308</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Bacteria that cause disease rely on their ability to counteract and overcome host defenses.  Here, we present a genome-scale study of Mycobacterium tuberculosis (Mtb) that uncovers the bacterial determinants of surviving host immunity, sets of genes we term "counteractomes.".  Through this anal., we found that CD4 T cells attempt to contain Mtb growth by starving it of tryptophan - a mechanism that successfully limits infections by Chlamydia and Leishmania, natural tryptophan auxotrophs.  Mtb, however, can synthesize tryptophan under stress conditions, and thus, starvation fails as an Mtb-killing mechanism.  We then identify a small-mol. inhibitor of Mtb tryptophan synthesis, which converts Mtb into a tryptophan auxotroph and restores the efficacy of a failed host defense.  Together, our findings demonstrate that the Mtb immune counteractomes serve as probes of host immunity, uncovering immune-mediated stresses that can be leveraged for therapeutic discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkCUFDhESMVrVg90H21EOLACvtfcHk0lhH1T1Se5lnOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFylurzM&md5=6947753d2524b4f7b352ddc94249317f</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2013.10.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2013.10.045%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BJ.%26aulast%3DReddy%26aufirst%3DM.%2BC.%26aulast%3DIoerger%26aufirst%3DT.%2BR.%26aulast%3DRothchild%26aufirst%3DA.%2BC.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DSchuster%26aufirst%3DB.%2BM.%26aulast%3DTrauner%26aufirst%3DA.%26aulast%3DWallis%26aufirst%3DD.%26aulast%3DGalaviz%26aufirst%3DS.%26aulast%3DHuttenhower%26aufirst%3DC.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DBehar%26aufirst%3DS.%2BM.%26aulast%3DRubin%26aufirst%3DE.%2BJ.%26atitle%3DTryptophan%2520biosynthesis%2520protects%2520mycobacteria%2520from%2520CD4%2520T-cell-mediated%2520killing%26jtitle%3DCell%26date%3D2013%26volume%3D155%26spage%3D1296%26epage%3D1308%26doi%3D10.1016%2Fj.cell.2013.10.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref254"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref254'); return false;" data-citation="" class="refNumLink">254</a></strong><div class="NLM_citation" id="cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Islam, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmud, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, K.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadu, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.-Y.</span></span> <span> </span><span class="NLM_article-title">In vitro activity of DNF-3 against drug-resistant Mycobacterium tuberculosis</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.ijantimicag.2019.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.ijantimicag.2019.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30807817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSqurjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2019&pages=69-74&author=M.+I.+Islamauthor=C.+M.+Hanauthor=H.+Seoauthor=S.+Kimauthor=H.+A.+Mahmudauthor=K.-W.+Namauthor=B.-E.+Leeauthor=V.+S.+Saduauthor=K.-I.+Leeauthor=H.-Y.+Song&title=In+vitro+activity+of+DNF-3+against+drug-resistant+Mycobacterium+tuberculosis&doi=10.1016%2Fj.ijantimicag.2019.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of DNF-3 against drug-resistant Mycobacterium tuberculosis</span></div><div class="casAuthors">Islam, Md Imtiazul; Han, Choi Moon; Seo, Hoonhee; Kim, Sukyung; Mahmud, Hafij Al; Nam, Kung-Woo; Lee, Byung-Eui; Sadu, Venkata S.; Lee, Kee-In; Song, Ho-Yeon</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-74</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Due to the emergence of multidrug-resistant and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, new antituberculosis drugs are urgently required to improve the efficacy of current tuberculosis (TB) treatment.  To achieve this goal, ∼1000 chem. compds. were screened for potential antimycobacterial activity, among which Me 5-(2-diethylaminoethoxy)-7,12-dioxo-7,12 dihydrodinaphtho[1,2-b;2',3'-d]furan-6-carboxylate (DNF-3) showed strong activity against all of the tested drug-susceptible and -resistant M. tuberculosis strains, with 50% min. inhibitory concns. (MIC50 values) of 0.02-0.39 μg/mL both in culture broth and within murine RAW 264.7 macrophage cells.  When DNF-3 was used in combination with rifampicin or streptomycin, it exhibited direct synergy against XDR-TB and an additive effect against M. tuberculosis H37Rv.  DNF-3 displayed a long post-antibiotic effect (PAE) that was comparable with rifampicin but was superior to isoniazid, streptomycin, and ethambutol.  Importantly, DNF-3 showed no cytotoxicity to any cell line tested, with a selectivity index (SI) of >32.  DNF-3 was also active against 27 nontuberculous mycobacteria (NTM) strains, Staphylococcus spp. and Streptococcus spp.  Taken together, these results indicate that DNF-3 is a promising new candidate drug for treating TB.  Further studies are warranted to establish the in vivo effect and therapeutic potential of DNF-3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqml3LoM8XxSrVg90H21EOLACvtfcHk0lhH1T1Se5lnOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSqurjK&md5=6d4ae515b2c81569643e91b4428378c9</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2019.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2019.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DIslam%26aufirst%3DM.%2BI.%26aulast%3DHan%26aufirst%3DC.%2BM.%26aulast%3DSeo%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DMahmud%26aufirst%3DH.%2BA.%26aulast%3DNam%26aufirst%3DK.-W.%26aulast%3DLee%26aufirst%3DB.-E.%26aulast%3DSadu%26aufirst%3DV.%2BS.%26aulast%3DLee%26aufirst%3DK.-I.%26aulast%3DSong%26aufirst%3DH.-Y.%26atitle%3DIn%2520vitro%2520activity%2520of%2520DNF-3%2520against%2520drug-resistant%2520Mycobacterium%2520tuberculosis%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2019%26volume%3D54%26spage%3D69%26epage%3D74%26doi%3D10.1016%2Fj.ijantimicag.2019.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref255"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref255'); return false;" data-citation="" class="refNumLink">255</a></strong><div class="NLM_citation" id="cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craig, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, S. C.</span></span> <span> </span><span class="NLM_article-title">Killing and regrowth of bacteria in vitro: a review</span>. <i>Scand. J. Infect. Dis. Suppl.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">70</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=2097720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaK3M3ntFykuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=1990&pages=63-70&author=W.+A.+Craigauthor=S.+C.+Ebert&title=Killing+and+regrowth+of+bacteria+in+vitro%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Killing and regrowth of bacteria in vitro: a review</span></div><div class="casAuthors">Craig W A; Ebert S C</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian journal of infectious diseases. Supplementum</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-70</span>
        ISSN:<span class="NLM_cas:issn">0300-8878</span>.
    </div><div class="casAbstract">Minimum inhibitory and bactericidal concentrations do not describe the time course of a drug's antimicrobial activity against bacteria.  Some antimicrobials exhibit concentration dependent killing over a wide range of concentrations (e.g. aminoglycosides and quinolones), while others show maximal killing at concentrations near the MIC (e.g. beta-lactams and glycopeptides).  The aminoglycosides and quinolones can require high drug concentrations (about 10-fold higher than the MIC) to prevent the selection of resistant subpopulations of bacteria.  Persistent suppression of bacterial growth after antimicrobial exposure is called the 'postantibiotic effect' (PAE) and varies in duration depending on the drug-organism combination, as well as the concentration and duration of drug exposure.  Antimicrobials which are inhibitors of protein and nucleic acid synthesis exhibit prolonged PAEs with a large variety of bacteria.  While beta-lactam antibiotics demonstrate PAEs with Gram-positive cocci, very short or no PAEs are observed with these drugs with Gram-negative bacilli.  The only exception is that penem antibiotics can induce PAEs with some strains of Gram-negative bacilli, primarily Pseudomonas aeruginosa.  Thus, the pharmacodynamic activity of an antimicrobial can vary markedly depending on the microorganism and the class of drug and its concentration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS61NHJmMpLWqx48Rj5GnGofW6udTcc2ebq-uvpkuOuSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M3ntFykuw%253D%253D&md5=4b1b8bd9de84ad142ceb6e4384acad75</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCraig%26aufirst%3DW.%2BA.%26aulast%3DEbert%26aufirst%3DS.%2BC.%26atitle%3DKilling%2520and%2520regrowth%2520of%2520bacteria%2520in%2520vitro%253A%2520a%2520review%26jtitle%3DScand.%2520J.%2520Infect.%2520Dis.%2520Suppl.%26date%3D1990%26volume%3D74%26spage%3D63%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref256"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref256'); return false;" data-citation="" class="refNumLink">256</a></strong><div class="NLM_citation" id="cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q.</span></span> <span> </span><span class="NLM_article-title">Benzylsulfanyl benzo-heterocycle amides and hydrazones as new agents against drug-susceptible and resistant Mycobacterium tuberculosis</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1303</span>– <span class="NLM_lpage">1306</span>, <span class="refDoi"> DOI: 10.1039/C7MD00146K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1039%2FC7MD00146K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30108841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVCgsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1303-1306&author=X.+Luauthor=X.+Huauthor=Z.+Liuauthor=T.+Zhangauthor=R.+Wangauthor=B.+Wanauthor=S.+G.+Franzblauauthor=Q.+You&title=Benzylsulfanyl+benzo-heterocycle+amides+and+hydrazones+as+new+agents+against+drug-susceptible+and+resistant+Mycobacterium+tuberculosis&doi=10.1039%2FC7MD00146K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Benzylsulfanyl benzo-heterocycle amides and hydrazones as new agents against drug-susceptible and resistant Mycobacterium tuberculosis</span></div><div class="casAuthors">Lu, Xiaoyun; Hu, Xianglong; Liu, Zhiyong; Zhang, Tianyu; Wang, Ruibing; Wan, Baojie; Franzblau, Scott G.; You, Qidong</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1303-1306</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of benzylsulfanyl benzo-heterocycle amides and hydrazones were synthesized and evaluated for anti-tubercular activities.  The isonicotinyl hydrazone derivs. 12d, 12e and 12f exhibited good anti-tubercular activity against Mycobacterium tuberculosis H37Rv (ATCC #27294) with MIC values of 0.23, 0.24 and 0.24 μM, resp., and were also active against SDR-TB, MDR-TB and XDR-TB.  More importantly, compd. 12e also showed low cytotoxicity and good metabolic stability, and could significantly reduce the mycobacterial burden in a mouse model infected with autoluminescent H37Ra strain, which may serve as a lead compd. for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt195vUBgTH7Vg90H21EOLACvtfcHk0lhH1T1Se5lnOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVCgsro%253D&md5=5d4a708f094d8cafe85324deb24393de</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1039%2FC7MD00146K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00146K%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DB.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DYou%26aufirst%3DQ.%26atitle%3DBenzylsulfanyl%2520benzo-heterocycle%2520amides%2520and%2520hydrazones%2520as%2520new%2520agents%2520against%2520drug-susceptible%2520and%2520resistant%2520Mycobacterium%2520tuberculosis%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D1303%26epage%3D1306%26doi%3D10.1039%2FC7MD00146K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref257"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref257'); return false;" data-citation="" class="refNumLink">257</a></strong><div class="NLM_citation" id="cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chhabria, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and anti-tubercular activity of a series of N′-substituted isonicotinohydrazide derivatives</span>. <i>World J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">286</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGmsbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=281-286&author=M.+Chhabriaauthor=S.+Patel&title=Synthesis+and+anti-tubercular+activity+of+a+series+of+N%E2%80%B2-substituted+isonicotinohydrazide+derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and anti-tubercular activity of a series of N'-substituted isonicotinohydrazide derivatives</span></div><div class="casAuthors">Chhabria, Mahesh T.; Patel, Sweta</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">281-286</span>CODEN:
                <span class="NLM_cas:coden">WJPSBT</span>;
        ISSN:<span class="NLM_cas:issn">2321-3086</span>.
    
            (<span class="NLM_cas:orgname">Atom and Cell Publishers</span>)
        </div><div class="casAbstract">Tuberculosis is a leading cause of death worldwide and esp. in developing countries due to the recent emergence and spread of multi-drug resistant tuberculosis (MDR TB), extensive drug resistant tuberculosis (XDR TB), total drug resistant tuberculosis (TDR TB) and HIV/AIDS pandemic.  Discovery of target based newer anti-tubercular agent is area of interest for chemists.  We have designed a series of N'-substituted isonicotinohydrazide derivs. based on pharmacophore modeling.  Designed mols. were synthesized and evaluated for their anti-tubercular activity.  Among synthesized compds., N'-(2-(2-fluorophenyl) acetyl) isonicotinohydrazide (4m) was found to be the most active compd. with MIC value of 6.25 μg/mL against Mycobacterium tuberculosis H37Rv strain using Almar Blue method.  Compd. (4m) was found active against MDR-TB and XDR-TB strain at 62.5 and 250 μg/mL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYQjD6Hawyw7Vg90H21EOLACvtfcHk0lidp98Gb70ocw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGmsbvP&md5=369e0f3d445810e6733dc7f10365aa53</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChhabria%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520anti-tubercular%2520activity%2520of%2520a%2520series%2520of%2520N%25E2%2580%25B2-substituted%2520isonicotinohydrazide%2520derivatives%26jtitle%3DWorld%2520J.%2520Pharm.%2520Sci.%26date%3D2016%26volume%3D4%26spage%3D281%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref258"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref258'); return false;" data-citation="" class="refNumLink">258</a></strong><div class="NLM_citation" id="cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soni, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chhabria, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmkshatriya, P. S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel antitubercular agents by combining pyrazoline and benzoxazole pharmacophores</span>. <i>Int. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.4236/ijoc.2016.63017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4236%2Fijoc.2016.63017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKrsbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=157-176&author=H.+M.+Soniauthor=P.+K.+Patelauthor=M.+T.+Chhabriaauthor=A.+K.+Patelauthor=D.+N.+Ranaauthor=P.+S.+Brahmkshatriya&title=Design%2C+synthesis+and+biological+evaluation+of+novel+antitubercular+agents+by+combining+pyrazoline+and+benzoxazole+pharmacophores&doi=10.4236%2Fijoc.2016.63017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit258R"><div class="casContent"><span class="casTitleNuber">258</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel antitubercular agents by combining pyrazoline and benzoxazole pharmacophores</span></div><div class="casAuthors">Soni, Hemal M.; Patel, Popatbhai K.; Chhabria, Mahesh T.; Patel, Ashish K.; Rana, Dharmraj N.; Brahmkshatriya, Pathik S.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">157-176</span>CODEN:
                <span class="NLM_cas:coden">IJOCCR</span>;
        ISSN:<span class="NLM_cas:issn">2161-4695</span>.
    
            (<span class="NLM_cas:orgname">Scientific Research Publishing, Inc.</span>)
        </div><div class="casAbstract">Various recent reports on Tuberculosis have alarmed an increase in the patient class and subsequent death rates across the globe.  Over and above the spread of more dangerous and fatal forms of tuberculosis like MDR-TB i.e. multiple-drug resistance tuberculosis, XDR-TB i.e. extensively-drug resistance tuberculosis & TDR-TB i.e. total-drug resistance tuberculosis has forwarded an urgent need to discover novel antitubercular agents.  The current work is aimed at combining two previously well-known pharmacophores (pyrazoline and benzoxazole nucleus) in order to design and synthesize a series of novel benzoxazole-based pyrazoline derivs.  The synthesized target compds. were structurally confirmed by LCMS, 1H-NMR and 13C-NMR anal.  The target compds. were In vitro evaluated against M. tuberculosis H37Rv strain, multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains.  The In vitro screening results depicted that majority of the target compds. displayed potent activity with MIC in a range of ∼0.8 to 6.25 μg/mL.  Many compds. were found to be more potent than isoniazid against MDR-TB with MIC value 3.12 μg/mL and XDR-TB with MIC value 12.5 μg/mL.  Cytotoxicity assay of these active compds. on VERO cell lines also displayed good selectivity index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBQQmTMkc7LbVg90H21EOLACvtfcHk0lidp98Gb70ocw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKrsbfI&md5=323108e21fe78106ffc0e5bde1098b1f</span></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.4236%2Fijoc.2016.63017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4236%252Fijoc.2016.63017%26sid%3Dliteratum%253Aachs%26aulast%3DSoni%26aufirst%3DH.%2BM.%26aulast%3DPatel%26aufirst%3DP.%2BK.%26aulast%3DChhabria%26aufirst%3DM.%2BT.%26aulast%3DPatel%26aufirst%3DA.%2BK.%26aulast%3DRana%26aufirst%3DD.%2BN.%26aulast%3DBrahmkshatriya%26aufirst%3DP.%2BS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520antitubercular%2520agents%2520by%2520combining%2520pyrazoline%2520and%2520benzoxazole%2520pharmacophores%26jtitle%3DInt.%2520J.%2520Org.%2520Chem.%26date%3D2016%26volume%3D6%26spage%3D157%26epage%3D176%26doi%3D10.4236%2Fijoc.2016.63017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref259"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref259'); return false;" data-citation="" class="refNumLink">259</a></strong><div class="NLM_citation" id="cit259"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yempalla, K. R.</span>; <span class="NLM_string-name">Munagala, G.</span>; <span class="NLM_string-name">Singh, S.</span>; <span class="NLM_string-name">Sharma, S.</span>; <span class="NLM_string-name">Khan, I. A.</span>; <span class="NLM_string-name">Vishwakarma, R. A.</span>; <span class="NLM_string-name">Singh, P. P.</span></span> <span> </span><span class="NLM_article-title">Substituted l,2,3-triazol-l -yl-methyl-2,3-dihydro-2-methyl-6-nitroimidazo [2,l- bjoxazoles as anti-mycobacterial agents and a process for the preparation thereof</span>. <span class="NLM_patent">WO2016/063298Al</span>. April 28, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=K.+R.+Yempalla&author=G.+Munagala&author=S.+Singh&author=S.+Sharma&author=I.+A.+Khan&author=R.+A.+Vishwakarma&author=P.+P.+Singh&title=Substituted+l%2C2%2C3-triazol-l+-yl-methyl-2%2C3-dihydro-2-methyl-6-nitroimidazo+%5B2%2Cl-+bjoxazoles+as+anti-mycobacterial+agents+and+a+process+for+the+preparation+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYempalla%26aufirst%3DK.%2BR.%26atitle%3DSubstituted%2520l%252C2%252C3-triazol-l%2520-yl-methyl-2%252C3-dihydro-2-methyl-6-nitroimidazo%2520%255B2%252Cl-%2520bjoxazoles%2520as%2520anti-mycobacterial%2520agents%2520and%2520a%2520process%2520for%2520the%2520preparation%2520thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref260"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref260'); return false;" data-citation="" class="refNumLink">260</a></strong><div class="NLM_citation" id="cit260"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, S.</span></span> <span> </span><span class="NLM_article-title">Identification of an anti-TB compound targeting the tyrosyl-tRNA synthetase</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">2287</span>– <span class="NLM_lpage">2294</span>, <span class="refDoi"> DOI: 10.1093/jac/dkv110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fjac%2Fdkv110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25957580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFSrtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2015&pages=2287-2294&author=N.+Zhuauthor=Y.+Linauthor=D.+Liauthor=N.+Gaoauthor=C.+Liuauthor=X.+Youauthor=J.+Jiangauthor=W.+Jiangauthor=S.+Si&title=Identification+of+an+anti-TB+compound+targeting+the+tyrosyl-tRNA+synthetase&doi=10.1093%2Fjac%2Fdkv110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit260R"><div class="casContent"><span class="casTitleNuber">260</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an anti-TB compound targeting the tyrosyl-tRNA synthetase</span></div><div class="casAuthors">Zhu, Ningyu; Lin, Yuan; Li, Dongsheng; Gao, Nana; Liu, Chang; You, Xuefu; Jiang, Jiandong; Jiang, Wei; Si, Shuyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2287-2294</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: Drug-resistant Mycobacterium tuberculosis poses a great threat to human health.  Tyrosyl-tRNA synthetase (TyrRS) is one of the aminoacyl tRNA synthetases that catalyze the attachment of amino acids to their cognate tRNAs and are essential for protein synthesis.  There are several distinctive differences between bacterial and human TyrRS and therefore it could be a potential target for developing antimicrobial agents.  This study aimed to identify a new anti-TB agent targeting M. tuberculosis TyrRS (MtTyrRS).  Methods: We first used Mycobacterium smegmatis for a phenotypic screening of 20000 compds.  The hit compds. were then screened with MtTyrRS.  The interaction between hit compd. IMB-T130 and the target protein was analyzed by surface plasmon resonance (SPR) assay and mol. docking expts.  The target of IMB-T130 was further confirmed by the overexpression of the target protein.  The antibacterial activity of IMB-T130 against various std. and clin. drug-resistant M. tuberculosis strains was evaluated using the microplate Alamar blue assay.  Results: Compd. IMB-T130 was identified as a hit compd. that inhibits the growth of M. smegmatis and the in vitro activity of MtTyrRS.  The interaction between IMB-T130 and MtTyrRS was confirmed by SPR assay and mol. docking anal.  The higher MIC for a strain overexpressing the target protein also suggests that MtTyrRS is likely to be the target of IMB-T130.  IMB-T130 shows excellent anti-TB activity and low cytotoxicity.  Conclusions: IMB-T130 inhibits the growth of MDR-TB and XDR-TB by targeting MtTyrRS.  Because of its low cytotoxicity against mammalian cells, IMB-T130 is a promising new agent against drug-resistant M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4MQPYUu4WMrVg90H21EOLACvtfcHk0liz-FsNcnhK9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFSrtbzN&md5=1db00cb51f4b904f18bd9001a5a7345a</span></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkv110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkv110%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DN.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DYou%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DSi%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520an%2520anti-TB%2520compound%2520targeting%2520the%2520tyrosyl-tRNA%2520synthetase%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2015%26volume%3D70%26spage%3D2287%26epage%3D2294%26doi%3D10.1093%2Fjac%2Fdkv110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref261"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref261'); return false;" data-citation="" class="refNumLink">261</a></strong><div class="NLM_citation" id="cit261"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parashar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilcheze, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veyron-Churlet, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szymonifka, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchiano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colangeli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neiditch, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alland, D.</span></span> <span> </span><span class="NLM_article-title">Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnchembio.1277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23770708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsV2lsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=499-506&author=R.+Wilsonauthor=P.+Kumarauthor=V.+Parasharauthor=C.+Vilchezeauthor=R.+Veyron-Churletauthor=J.+S.+Freundlichauthor=S.+W.+Barnesauthor=J.+R.+Walkerauthor=M.+J.+Szymonifkaauthor=E.+Marchianoauthor=S.+Shenaiauthor=R.+Colangeliauthor=W.+R.+Jacobsauthor=M.+B.+Neiditchauthor=L.+Kremerauthor=D.+Alland&title=Antituberculosis+thiophenes+define+a+requirement+for+Pks13+in+mycolic+acid+biosynthesis&doi=10.1038%2Fnchembio.1277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit261R"><div class="casContent"><span class="casTitleNuber">261</span><div class="casTitle"><span class="NLM_cas:atitle">Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis</span></div><div class="casAuthors">Wilson, Regina; Kumar, Pradeep; Parashar, Vijay; Vilcheze, Catherine; Veyron-Churlet, Romain; Freundlich, Joel S.; Barnes, S. Whitney; Walker, John R.; Szymonifka, Michael J.; Marchiano, Emily; Shenai, Shubhada; Colangeli, Roberto; Jacobs, William R., Jr.; Neiditch, Matthew B.; Kremer, Laurent; Alland, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">499-506</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors report a new class of thiophene (TP) compds. that kill Mycobacterium tuberculosis by a previously uncharacterized mechanism of Pks13 inhibition.  An F79S mutation near the catalytic Ser55 site in Pks13 conferred TP resistance in M. tuberculosis.  Overexpression of wild-type Pks13 resulted in TP resistance, and overexpression of the Pks13F79S mutant conferred high resistance.  In vitro, TP inhibited fatty acyl-AMP loading onto Pks13.  TP inhibited mycolic acid biosynthesis in wild-type M. tuberculosis, but it did so to a much lesser extent in TP-resistant M. tuberculosis.  TP treatment was bactericidal and equiv. to treatment with the first-line drug isoniazid, but it was less likely to permit emergent resistance.  Combined isoniazid and TP treatment resulted in sterilizing activity.  Computational docking identified a possible TP-binding groove within the Pks13 acyl carrier protein domain.  This study confirms that M. tuberculosisPks13 is required for mycolic acid biosynthesis, validates it as a druggable target and demonstrates the therapeutic potential of simultaneously inhibiting multiple targets in the same biosynthetic pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwnc8l43PyebVg90H21EOLACvtfcHk0liz-FsNcnhK9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsV2lsb0%253D&md5=8c6209e87941537c3e2209e8f92579ec</span></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1277%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DParashar%26aufirst%3DV.%26aulast%3DVilcheze%26aufirst%3DC.%26aulast%3DVeyron-Churlet%26aufirst%3DR.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DSzymonifka%26aufirst%3DM.%2BJ.%26aulast%3DMarchiano%26aufirst%3DE.%26aulast%3DShenai%26aufirst%3DS.%26aulast%3DColangeli%26aufirst%3DR.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26aulast%3DNeiditch%26aufirst%3DM.%2BB.%26aulast%3DKremer%26aufirst%3DL.%26aulast%3DAlland%26aufirst%3DD.%26atitle%3DAntituberculosis%2520thiophenes%2520define%2520a%2520requirement%2520for%2520Pks13%2520in%2520mycolic%2520acid%2520biosynthesis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D499%26epage%3D506%26doi%3D10.1038%2Fnchembio.1277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref262"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref262'); return false;" data-citation="" class="refNumLink">262</a></strong><div class="NLM_citation" id="cit262"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisbrod, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition</span>. <i>J. Bacteriol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">1802</span>– <span class="NLM_lpage">1811</span>, <span class="refDoi"> DOI: 10.1128/JB.182.7.1802-1811.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FJB.182.7.1802-1811.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10714983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3cXitFWrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2000&pages=1802-1811&author=D.+Allandauthor=A.+J.+Steynauthor=T.+Weisbrodauthor=K.+Aldrichauthor=W.+R.+Jacobs&title=Characterization+of+the+Mycobacterium+tuberculosis+iniBAC+promoter%2C+a+promoter+that+responds+to+cell+wall+biosynthesis+inhibition&doi=10.1128%2FJB.182.7.1802-1811.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit262R"><div class="casContent"><span class="casTitleNuber">262</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition</span></div><div class="casAuthors">Alland, David; Steyn, Andries J.; Weisbrod, Torin; Aldrich, Kate; Jacobs, William R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bacteriology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1802-1811</span>CODEN:
                <span class="NLM_cas:coden">JOBAAY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9193</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The cell wall provides an attractive target for antibiotics against Mycobacterium tuberculosis.  Agents such as isoniazid and ethambutol that work by inhibiting cell wall biosynthesis are among the most highly effective antibiotics against this pathogen.  Although considerable progress has been made identifying the targets for cell wall active antibiotics, little is known about the intracellular mechanisms that are activated as a consequence of cell wall injury.  These mechanisms are likely to have an important role in growth regulation and in the induction of cell death by antibiotics.  The authors previously discovered three isoniazid-induced genes (iniB, iniA, and iniC) organized in tandem on the M. tuberculosis genome.  Here, the authors investigate the unique features of the putative iniBAC promoter.  This promoter was specifically induced by a broad range of inhibitors of cell wall biosynthesis but was not inducible by other conditions that are toxic to mycobacteria via other mechanisms.  Induction required inhibitory concns. of antibiotics and could be detected only in actively growing cells.  Anal. of the iniBAC promoter sequence revealed both a regulatory element upstream and a potential repressor binding region downstream of the transcriptional start site.  The induction phenotype and structure of the iniBAC promoter suggest that a complex intracellular response occurs when cell wall biosynthesis is inhibited in M. tuberculosis and other mycobacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlrSF2dhk_XrVg90H21EOLACvtfcHk0li68s7s3mDfYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXitFWrsLk%253D&md5=ba637525a688554bbcf204e3dbfb0bfc</span></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=10.1128%2FJB.182.7.1802-1811.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJB.182.7.1802-1811.2000%26sid%3Dliteratum%253Aachs%26aulast%3DAlland%26aufirst%3DD.%26aulast%3DSteyn%26aufirst%3DA.%2BJ.%26aulast%3DWeisbrod%26aufirst%3DT.%26aulast%3DAldrich%26aufirst%3DK.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26atitle%3DCharacterization%2520of%2520the%2520Mycobacterium%2520tuberculosis%2520iniBAC%2520promoter%252C%2520a%2520promoter%2520that%2520responds%2520to%2520cell%2520wall%2520biosynthesis%2520inhibition%26jtitle%3DJ.%2520Bacteriol.%26date%3D2000%26volume%3D182%26spage%3D1802%26epage%3D1811%26doi%3D10.1128%2FJB.182.7.1802-1811.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref263"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref263'); return false;" data-citation="" class="refNumLink">263</a></strong><div class="NLM_citation" id="cit263"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinrick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trefzer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mdluli, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikusova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fütterer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span> <span> </span><span class="NLM_article-title">Identification of a small molecule with activity against drug-resistant and persistent tuberculosis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">e2510</span>– <span class="NLM_lpage">e2517</span>, <span class="refDoi"> DOI: 10.1073/pnas.1309171110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1073%2Fpnas.1309171110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23776209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFejsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=e2510-e2517&author=F.+Wangauthor=D.+Sambandanauthor=R.+Halderauthor=J.+Wangauthor=S.+M.+Battauthor=B.+Weinrickauthor=I.+Ahmadauthor=P.+Yangauthor=Y.+Zhangauthor=J.+Kimauthor=M.+Hassaniauthor=S.+Huszarauthor=C.+Trefzerauthor=Z.+Maauthor=T.+Kanekoauthor=K.+E.+Mdluliauthor=S.+Franzblauauthor=A.+K.+Chatterjeeauthor=K.+Johnssonauthor=K.+Mikusovaauthor=G.+S.+Besraauthor=K.+F%C3%BCttererauthor=S.+H.+Robbinsauthor=S.+W.+Barnesauthor=J.+R.+Walkerauthor=W.+R.+Jacobsauthor=P.+G.+Schultz&title=Identification+of+a+small+molecule+with+activity+against+drug-resistant+and+persistent+tuberculosis&doi=10.1073%2Fpnas.1309171110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit263R"><div class="casContent"><span class="casTitleNuber">263</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a small molecule with activity against drug-resistant and persistent tuberculosis</span></div><div class="casAuthors">Wang, Feng; Sambandan, Dhinakaran; Halder, Rajkumar; Wang, Jianing; Batt, Sarah M.; Weinrick, Brian; Ahmad, Insha; Yang, Pengyu; Zhang, Yong; Kim, John; Hassani, Morad; Huszar, Stanislav; Trefzer, Claudia; Ma, Zhenkun; Kaneko, Takushi; Mdluli, Khisi E.; Franzblau, Scott; Chatterjee, Arnab K.; Johnsson, Kai; Mikusova, Katarina; Besra, Gurdyal S.; Fuetterer, Klaus; Robbins, Scott H.; Barnes, S. Whitney; Walker, John R.; Jacobs, William R., Jr.; Schultz, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">E2510-E2517,SE2510/1-SE2510/6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A cell-based phenotypic screen for inhibitors of biofilm formation in mycobacteria identified the small mol. TCA1, which has bactericidal activity against both drug-susceptible and -resistant Mycobacterium tuberculosis (Mtb) and sterilizes Mtb in vitro combined with rifampicin or isoniazid.  In addn., TCA1 has bactericidal activity against nonreplicating Mtb in vitro and is efficacious in acute and chronic Mtb infection mouse models both alone and combined with rifampicin or isoniazid.  Transcriptional anal. revealed that TCA1 down-regulates genes known to be involved in Mtb persistence.  Genetic and affinity-based methods identified decaprenyl-phosphoryl-β-D-ribofuranose oxidoreductase DprE1 and MoeW, enzymes involved in cell wall and molybdenum cofactor biosynthesis, resp., as targets responsible for the activity of TCA1.  These in vitro and in vivo results indicate that this compd. functions by a unique mechanism and suggest that TCA1 may lead to the development of a class of antituberculosis agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokxlddd-EfbbVg90H21EOLACvtfcHk0li68s7s3mDfYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFejsLnL&md5=caf496e25608bb98e61ab97bd603f2ab</span></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1309171110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1309171110%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DSambandan%26aufirst%3DD.%26aulast%3DHalder%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBatt%26aufirst%3DS.%2BM.%26aulast%3DWeinrick%26aufirst%3DB.%26aulast%3DAhmad%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DHassani%26aufirst%3DM.%26aulast%3DHuszar%26aufirst%3DS.%26aulast%3DTrefzer%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DMdluli%26aufirst%3DK.%2BE.%26aulast%3DFranzblau%26aufirst%3DS.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DJohnsson%26aufirst%3DK.%26aulast%3DMikusova%26aufirst%3DK.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DF%25C3%25BCtterer%26aufirst%3DK.%26aulast%3DRobbins%26aufirst%3DS.%2BH.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26atitle%3DIdentification%2520of%2520a%2520small%2520molecule%2520with%2520activity%2520against%2520drug-resistant%2520and%2520persistent%2520tuberculosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3De2510%26epage%3De2517%26doi%3D10.1073%2Fpnas.1309171110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref264"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref264'); return false;" data-citation="" class="refNumLink">264</a></strong><div class="NLM_citation" id="cit264"><span> <i>Guidelines for Treatment of Tuberculosis</i>, 4th ed.; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2010</span>; <a href="https://www.who.int/tb/publications/2010/9789241547833/en/" class="extLink">https://www.who.int/tb/publications/2010/9789241547833/en/</a> (accessed
December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Guidelines+for+Treatment+of+Tuberculosis%2C+4th+ed.%3B+World+Health+Organization%3A+Geneva%2C+2010%3B+https%3A%2F%2Fwww.who.int%2Ftb%2Fpublications%2F2010%2F9789241547833%2Fen%2F+%28accessed%0ADecember+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGuidelines%2520for%2520Treatment%2520of%2520Tuberculosis%26pub%3DWorld%2520Health%2520Organization%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref265"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref265'); return false;" data-citation="" class="refNumLink">265</a></strong><div class="NLM_citation" id="cit265"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawkey, P. M.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of quinolone action and microbial response</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">Suppl 1</span>),  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1093/jac/dkg207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fjac%2Fdkg207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=12702701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktlOqu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2003&pages=29-35&issue=Suppl+1&author=P.+M.+Hawkey&title=Mechanisms+of+quinolone+action+and+microbial+response&doi=10.1093%2Fjac%2Fdkg207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit265R"><div class="casContent"><span class="casTitleNuber">265</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of quinolone action and microbial response</span></div><div class="casAuthors">Hawkey, Peter M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">Suppl. S1</span>),
    <span class="NLM_cas:pages">29-35</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Over the years, chromosomal mapping of the bacterial genome of Escherichia coli has demonstrated that many loci are assocd. with quinolone resistance, which is mainly a result of chromosomal mutation or alteration of the quantity or type of porins in the outer membrane of Gram-neg. bacteria.  There has been one report of a small and confined episode of plasmid-mediated resistance to fluoroquinolones, which did not appear to persist.  With the increasingly widespread use of an expanding range of fluoroquinolone antibiotics, a range and mix in individual bacterial isolates of the different mechanisms of resistance to fluoroquinolones will undoubtedly be encountered amongst clin. significant bacteria.  Currently, transferable resistance is extremely rare and most resistant bacteria arise from clonal expansion of mutated strains.  However, it is conceivable that in the future, horizontal gene transfer may become a more important means of conferring resistance to fluoroquinolones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpabXEcTKWqObVg90H21EOLACvtfcHk0li68s7s3mDfYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktlOqu7w%253D&md5=696f6b6147a980010442f90550247d46</span></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkg207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkg207%26sid%3Dliteratum%253Aachs%26aulast%3DHawkey%26aufirst%3DP.%2BM.%26atitle%3DMechanisms%2520of%2520quinolone%2520action%2520and%2520microbial%2520response%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2003%26volume%3D51%26issue%3DSuppl%25201%26spage%3D29%26epage%3D35%26doi%3D10.1093%2Fjac%2Fdkg207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref266"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref266'); return false;" data-citation="" class="refNumLink">266</a></strong><div class="NLM_citation" id="cit266"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, D. C.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of fluoroquinolone resistance</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1054/drup.1998.0068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1054%2Fdrup.1998.0068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=11504468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK1MXktVaqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1999&pages=38-55&author=D.+C.+Hooper&title=Mechanisms+of+fluoroquinolone+resistance&doi=10.1054%2Fdrup.1998.0068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit266R"><div class="casContent"><span class="casTitleNuber">266</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of fluoroquinolone resistance</span></div><div class="casAuthors">Hooper, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-55</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Churchill Livingstone</span>)
        </div><div class="casAbstract">A review with 174 refs.  Mechanisms of bacterial resistance to fluoroquinolones fall into two principal categories, alterations in drug target enzymes and alterations that limit permeation of drug to the target, both resulting from chromosomal mutations.  No specific resistance mechanisms of quinolone degrdn. or modification have been found.  The target enzymes, DNA gyrase and topoisomerase IV, are most commonly altered in domains near the enzyme active sites and in some cases reduced drug binding affinity has been demonstrated.  Drug permeation is altered by mutations that increase expression of endogenous multidrug efflux pumps, alter outer membrane diffusion channels, or both.  Recently a new plasmid-mediated resistance of an as yet undefined mechanism was found in clin. isolates of Klebsiella pneumoniae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkXuZhBYHniLVg90H21EOLACvtfcHk0lgC8Au5WvkL0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVaqsb0%253D&md5=885296b07bba88b091e4be26ea425b4a</span></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1054%2Fdrup.1998.0068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fdrup.1998.0068%26sid%3Dliteratum%253Aachs%26aulast%3DHooper%26aufirst%3DD.%2BC.%26atitle%3DMechanisms%2520of%2520fluoroquinolone%2520resistance%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D1999%26volume%3D2%26spage%3D38%26epage%3D55%26doi%3D10.1054%2Fdrup.1998.0068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref267"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref267'); return false;" data-citation="" class="refNumLink">267</a></strong><div class="NLM_citation" id="cit267"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerrini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuppone, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corelli, F.</span></span> <span> </span><span class="NLM_article-title">New fluoroquinolones active against fluoroquinolones-resistant Mycobacterium tuberculosis strains</span>. <i>Tuberculosis</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2013.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.tube.2013.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23523640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFOhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=405-411&author=V.+Guerriniauthor=M.+De+Rosaauthor=S.+Pasquiniauthor=C.+Mugnainiauthor=A.+Brizziauthor=A.+M.+Cupponeauthor=G.+Pozziauthor=F.+Corelli&title=New+fluoroquinolones+active+against+fluoroquinolones-resistant+Mycobacterium+tuberculosis+strains&doi=10.1016%2Fj.tube.2013.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit267R"><div class="casContent"><span class="casTitleNuber">267</span><div class="casTitle"><span class="NLM_cas:atitle">New fluoroquinolones active against fluoroquinolones-resistant Mycobacterium tuberculosis strains</span></div><div class="casAuthors">Guerrini, Valentina; De Rosa, Maria; Pasquini, Serena; Mugnaini, Claudia; Brizzi, Antonella; Cuppone, Anna Maria; Pozzi, Gianni; Corelli, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">405-411</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A set of 21 new fluoroquinolones bearing an arom. or heteroarom. moiety at C-7 and an alkyl group at N-1 were synthesized based on the lead structure of pirfloxacin and tested in vitro against Mycobacterium tuberculosis (M. tuberculosis) H37Rv by MIC detn. in liq. medium.  Among the synthesized compds., 1-(tert-butyl)-6-fluoro-7-(4-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (2o) and 1-(tert-butyl)-6-fluoro-7-(pyridin-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (2n) were found to be the most active ones against M. tuberculosis H37Rv with the same MICs of ref. compds. ciprofloxacin (CFX) and levofloxacin (LFX).  MICs of 2o and 2n were detd. for fluoroquinolone-sensitive and fluoroquinolone-resistant M. tuberculosis clin. isolates and 2o was the most active compd. with up 4-fold difference of MIC with respect to CFX.  The activity of 2o was also tested at the concn. of 16 μg/mL against M. tuberculosis H37Rv in infected murine macrophages.  The results showed a 4-fold decrease in viable count of cell-assocd. mycobacteria with respect to untreated controls after 48 h of drug incubation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXl-ZKXd3HSbVg90H21EOLACvtfcHk0lgC8Au5WvkL0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFOhtLs%253D&md5=fa67450f3905039fcb8f454bf447a6ec</span></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2013.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2013.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DGuerrini%26aufirst%3DV.%26aulast%3DDe%2BRosa%26aufirst%3DM.%26aulast%3DPasquini%26aufirst%3DS.%26aulast%3DMugnaini%26aufirst%3DC.%26aulast%3DBrizzi%26aufirst%3DA.%26aulast%3DCuppone%26aufirst%3DA.%2BM.%26aulast%3DPozzi%26aufirst%3DG.%26aulast%3DCorelli%26aufirst%3DF.%26atitle%3DNew%2520fluoroquinolones%2520active%2520against%2520fluoroquinolones-resistant%2520Mycobacterium%2520tuberculosis%2520strains%26jtitle%3DTuberculosis%26date%3D2013%26volume%3D93%26spage%3D405%26epage%3D411%26doi%3D10.1016%2Fj.tube.2013.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref268"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref268'); return false;" data-citation="" class="refNumLink">268</a></strong><div class="NLM_citation" id="cit268"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stefancich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artico, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panico, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonetti, N.</span></span> <span> </span><span class="NLM_article-title">1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1H-pyrrol-1-yl)-quinoline-3-carb oxylic acid, a new fluorinated compounds of oxacin family with high broad-spectrum antibacterial activities</span>. <i>Farmaco Sci.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">248</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=3926533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaL2MXitFyiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1985&pages=237-248&author=G.+Stefancichauthor=M.+Articoauthor=F.+Corelliauthor=S.+Massaauthor=S.+Panicoauthor=N.+Simonetti&title=1-Ethyl-6-fluoro-1%2C4-dihydro-4-oxo-7-%281H-pyrrol-1-yl%29-quinoline-3-carb+oxylic+acid%2C+a+new+fluorinated+compounds+of+oxacin+family+with+high+broad-spectrum+antibacterial+activities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit268R"><div class="casContent"><span class="casTitleNuber">268</span><div class="casTitle"><span class="NLM_cas:atitle">1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1H-pyrrol-1-yl)quinoline-3-carboxylic acid, a new fluorinated compound of oxacin family with high broad-spectrum antibacterial activities</span></div><div class="casAuthors">Stefancich, G.; Artico, M.; Corelli, F.; Massa, S.; Panico, S.; Simonetti, N.</div><div class="citationInfo"><span class="NLM_cas:title">Farmaco, Edizione Scientifica</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">237-48</span>CODEN:
                <span class="NLM_cas:coden">FRPSAX</span>;
        ISSN:<span class="NLM_cas:issn">0430-0920</span>.
    </div><div class="casAbstract">The title compd. (I) was prepd. by the reaction of 4-fluoro-3-(1H-pyrrol-1-yl)aniline with di-Et ethoxymethylenemalonate, cyclization of the malonate obtained to the quinolinecarboxylate ester, ethylation of the ester, followed by hydrolysis with aq. NaOH.  The new deriv. proved very active against both gram-pos. and gram-neg. bacteria.  Its activities in comparison with those of nalidixic acid, pipemidic acid, piromidic acid, and enoxacin were greatly superior with regard to the unfluorinated compds. and somewhat superior also to enoxacin.  The known 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(pyrrolidin-1-yl)quinoline-3-carboxylic acid, here prepd. by catalytic hydrogenation of the pyrrole moiety of the title compd., was less active as an antibacterial agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrik2m91AXy6rVg90H21EOLACvtfcHk0lgC8Au5WvkL0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXitFyiurc%253D&md5=6ffe48e6897dca4899de32bd3d1b15c4</span></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStefancich%26aufirst%3DG.%26aulast%3DArtico%26aufirst%3DM.%26aulast%3DCorelli%26aufirst%3DF.%26aulast%3DMassa%26aufirst%3DS.%26aulast%3DPanico%26aufirst%3DS.%26aulast%3DSimonetti%26aufirst%3DN.%26atitle%3D1-Ethyl-6-fluoro-1%252C4-dihydro-4-oxo-7-%25281H-pyrrol-1-yl%2529-quinoline-3-carb%2520oxylic%2520acid%252C%2520a%2520new%2520fluorinated%2520compounds%2520of%2520oxacin%2520family%2520with%2520high%2520broad-spectrum%2520antibacterial%2520activities%26jtitle%3DFarmaco%2520Sci.%26date%3D1985%26volume%3D40%26spage%3D237%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref269"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref269'); return false;" data-citation="" class="refNumLink">269</a></strong><div class="NLM_citation" id="cit269"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patra, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraceto, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, E. V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Torres, M. d. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acosta-Torres, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-Torres, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swamy, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habtemariam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H.-S.</span></span> <span> </span><span class="NLM_article-title">Nano based drug delivery systems: recent developments and future prospects</span>. <i>J. Nanobiotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">71</span>, <span class="refDoi"> DOI: 10.1186/s12951-018-0392-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1186%2Fs12951-018-0392-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30231877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjt1OisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=71&author=J.+K.+Patraauthor=G.+Dasauthor=L.+F.+Fracetoauthor=E.+V.+R.+Camposauthor=M.+d.+P.+Rodriguez-Torresauthor=L.+S.+Acosta-Torresauthor=L.+A.+Diaz-Torresauthor=R.+Grilloauthor=M.+K.+Swamyauthor=S.+Sharmaauthor=S.+Habtemariamauthor=H.-S.+Shin&title=Nano+based+drug+delivery+systems%3A+recent+developments+and+future+prospects&doi=10.1186%2Fs12951-018-0392-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">Nano based drug delivery systems: recent developments and future prospects</span></div><div class="casAuthors">Patra, Jayanta Kumar; Das, Gitishree; Fraceto, Leonardo Fernandes; Campos, Estefania Vangelie Ramos; Rodriguez-Torres, Maria Del Pilar; Acosta-Torres, Laura Susana; Diaz-Torres, Luis Armando; Grillo, Renato; Swamy, Mallappa Kumara; Sharma, Shivesh; Habtemariam, Solomon; Shin, Han-Seung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nanobiotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">71/1-71/33</span>CODEN:
                <span class="NLM_cas:coden">JNOAAO</span>;
        ISSN:<span class="NLM_cas:issn">1477-3155</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Nanomedicine and nano delivery systems are a relatively new but rapidly developing science where materials in the nanoscale range are employed to serve as means of diagnostic tools or to deliver therapeutic agents to specific targeted sites in a controlled manner.  Nanotechnol. offers multiple benefits in treating chronic human diseases by site-specific, and target-oriented delivery of precise medicines.  Recently, there are a no. of outstanding applications of the nanomedicine (chemotherapeutic agents, biol. agents, immunotherapeutic agents etc.) in the treatment of various diseases.  The current review, presents an updated summary of recent advances in the field of nanomedicines and nano based drug delivery systems through comprehensive scrutiny of the discovery and application of nanomaterials in improving both the efficacy of novel and old drugs (e.g., natural products) and selective diagnosis through disease marker mols.  The opportunities and challenges of nanomedicines in drug delivery from synthetic/natural sources to their clin. applications are also discussed.  In addn., we have included information regarding the trends and perspectives in nanomedicine area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVgmxuTN7gr7Vg90H21EOLACvtfcHk0lhkO4qlxKL6bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjt1OisL4%253D&md5=a097a21379cd48333d81dffd7c57122f</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1186%2Fs12951-018-0392-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12951-018-0392-8%26sid%3Dliteratum%253Aachs%26aulast%3DPatra%26aufirst%3DJ.%2BK.%26aulast%3DDas%26aufirst%3DG.%26aulast%3DFraceto%26aufirst%3DL.%2BF.%26aulast%3DCampos%26aufirst%3DE.%2BV.%2BR.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%2Bd.%2BP.%26aulast%3DAcosta-Torres%26aufirst%3DL.%2BS.%26aulast%3DDiaz-Torres%26aufirst%3DL.%2BA.%26aulast%3DGrillo%26aufirst%3DR.%26aulast%3DSwamy%26aufirst%3DM.%2BK.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DHabtemariam%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DH.-S.%26atitle%3DNano%2520based%2520drug%2520delivery%2520systems%253A%2520recent%2520developments%2520and%2520future%2520prospects%26jtitle%3DJ.%2520Nanobiotechnol.%26date%3D2018%26volume%3D16%26spage%3D71%26doi%3D10.1186%2Fs12951-018-0392-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref270"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref270'); return false;" data-citation="" class="refNumLink">270</a></strong><div class="NLM_citation" id="cit270"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatfull, G. F.</span>; <span class="NLM_string-name">Vehring, R.</span></span> <span> </span><span class="NLM_article-title">Respirable Bacteriophage Aerosols for the Prevention and Treatment of Tuberculosis</span>. In  <i>Drug Delivery Systems for Tuberculosis Prevention and Treatment</i>, <span class="NLM_edition">1</span>st ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, A. J.</span>, <span class="NLM_string-name">Misra, A.</span>, <span class="NLM_string-name">Fourie, P. B.</span></span>, Eds.; <span class="NLM_publisher-name">John Wiley & Sons, Ltd.</span>, <span class="NLM_year">2016</span>; pp  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">292</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1002%2F9781118943182.ch14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=275-292&author=G.+F.+Hatfull&author=R.+Vehringauthor=A.+J.+Hickey&author=A.+Misra&author=P.+B.+Fourie&title=Drug+Delivery+Systems+for+Tuberculosis+Prevention+and+Treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.1002%2F9781118943182.ch14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118943182.ch14%26sid%3Dliteratum%253Aachs%26aulast%3DHatfull%26aufirst%3DG.%2BF.%26atitle%3DRespirable%2520Bacteriophage%2520Aerosols%2520for%2520the%2520Prevention%2520and%2520Treatment%2520of%2520Tuberculosis%26btitle%3DDrug%2520Delivery%2520Systems%2520for%2520Tuberculosis%2520Prevention%2520and%2520Treatment%26aulast%3DHickey%26aufirst%3DA.%2BJ.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Ltd%26date%3D2016%26spage%3D275%26epage%3D292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref271"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref271'); return false;" data-citation="" class="refNumLink">271</a></strong><div class="NLM_citation" id="cit271"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nasiruddin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyaz, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span> <span> </span><span class="NLM_article-title">Nanotechnology-based approach in tuberculosis treatment</span>. <i>Tuberc. Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2017</i></span>,  <span class="NLM_fpage">4920209</span>, <span class="refDoi"> DOI: 10.1155/2017/4920209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1155%2F2017%2F4920209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28210505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1c3nvFamsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2017&publication_year=2017&pages=4920209&author=M.+Nasiruddinauthor=M.+K.+Neyazauthor=S.+Das&title=Nanotechnology-based+approach+in+tuberculosis+treatment&doi=10.1155%2F2017%2F4920209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit271R"><div class="casContent"><span class="casTitleNuber">271</span><div class="casTitle"><span class="NLM_cas:atitle">Nanotechnology-Based Approach in Tuberculosis Treatment</span></div><div class="casAuthors">Nasiruddin Mohammad; Das Shilpi; Neyaz Md Kausar</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis research and treatment</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2017</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4920209</span>
        ISSN:<span class="NLM_cas:issn">2090-150X</span>.
    </div><div class="casAbstract">Tuberculosis, commonly known as TB, is the second most fatal infectious disease after AIDS, caused by bacterium called Mycobacterium tuberculosis.  Prolonged treatment, high pill burden, low compliance, and stiff administration schedules are factors that are responsible for emergence of MDR and XDR cases of tuberculosis.  Till date, only BCG vaccine is available which is ineffective against adult pulmonary TB, which is the most common form of disease.  Various unique antibodies have been developed to overcome drug resistance, reduce the treatment regimen, and elevate the compliance to treatment.  Therefore, we need an effective and robust system to subdue technological drawbacks and improve the effectiveness of therapeutic drugs which still remains a major challenge for pharmaceutical technology.  Nanoparticle-based ideology has shown convincing treatment and promising outcomes for chronic infectious diseases.  Different types of nanocarriers have been evaluated as promising drug delivery systems for various administration routes.  Controlled and sustained release of drugs is one of the advantages of nanoparticle-based antituberculosis drugs over free drug.  It also reduces the dosage frequency and resolves the difficulty of low poor compliance.  This paper reviews various nanotechnology-based therapies which can be used for the treatment of TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRePK2qLr-wndXdcedVHT5tfW6udTcc2eaZNfzK4pMTErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3nvFamsg%253D%253D&md5=4b60bf666de8e068a32405b57668e950</span></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=10.1155%2F2017%2F4920209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2017%252F4920209%26sid%3Dliteratum%253Aachs%26aulast%3DNasiruddin%26aufirst%3DM.%26aulast%3DNeyaz%26aufirst%3DM.%2BK.%26aulast%3DDas%26aufirst%3DS.%26atitle%3DNanotechnology-based%2520approach%2520in%2520tuberculosis%2520treatment%26jtitle%3DTuberc.%2520Res.%2520Treat.%26date%3D2017%26volume%3D2017%26spage%3D4920209%26doi%3D10.1155%2F2017%2F4920209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref272"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref272'); return false;" data-citation="" class="refNumLink">272</a></strong><div class="NLM_citation" id="cit272"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yetisgin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cetinel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutlu, O.</span></span> <span> </span><span class="NLM_article-title">Therapeutic nanoparticles and their targeted delivery applications</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2193</span>, <span class="refDoi"> DOI: 10.3390/molecules25092193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3390%2Fmolecules25092193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFert7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=2193&author=A.+A.+Yetisginauthor=S.+Cetinelauthor=M.+Zuvinauthor=A.+Kosarauthor=O.+Kutlu&title=Therapeutic+nanoparticles+and+their+targeted+delivery+applications&doi=10.3390%2Fmolecules25092193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit272R"><div class="casContent"><span class="casTitleNuber">272</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic nanoparticles and their targeted delivery applications</span></div><div class="casAuthors">Yetisgin, Abuzer Alp; Cetinel, Sibel; Zuvin, Merve; Kosar, Ali; Kutlu, Ozlem</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2193</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Nanotechnol. offers many advantages in various fields of science.  In this regard, nanoparticles are the essential building blocks of nanotechnol.  Recent advances in nanotechnol. have proven that nanoparticles acquire a great potential in medical applications.  Formation of stable interactions with ligands, variability in size and shape, high carrier capacity, and convenience of binding of both hydrophilic and hydrophobic substances make nanoparticles favorable platforms for the target-specific and controlled delivery of micro- and macromols. in disease therapy.  Nanoparticles combined with the therapeutic agents overcome problems assocd. with conventional therapy; however, some issues like side effects and toxicity are still debated and should be well concerned before their utilization in biol. systems.  It is therefore important to understand the specific properties of therapeutic nanoparticles and their delivery strategies.  Here, we provide an overview on the unique features of nanoparticles in the biol. systems.  We emphasize on the type of clin. used nanoparticles and their specificity for therapeutic applications, as well as on their current delivery strategies for specific diseases such as cancer, infectious, autoimmune, cardiovascular, neurodegenerative, ocular, and pulmonary diseases.  Understanding of the characteristics of nanoparticles and their interactions with the biol. environment will enable us to establish novel strategies for the treatment, prevention, and diagnosis in many diseases, particularly untreatable ones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Gn1H5EngzLVg90H21EOLACvtfcHk0lhkO4qlxKL6bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFert7vM&md5=b344a1b6ddf4cd75b2d479e0f8b976ef</span></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=10.3390%2Fmolecules25092193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules25092193%26sid%3Dliteratum%253Aachs%26aulast%3DYetisgin%26aufirst%3DA.%2BA.%26aulast%3DCetinel%26aufirst%3DS.%26aulast%3DZuvin%26aufirst%3DM.%26aulast%3DKosar%26aufirst%3DA.%26aulast%3DKutlu%26aufirst%3DO.%26atitle%3DTherapeutic%2520nanoparticles%2520and%2520their%2520targeted%2520delivery%2520applications%26jtitle%3DMolecules%26date%3D2020%26volume%3D25%26spage%3D2193%26doi%3D10.3390%2Fmolecules25092193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref273"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref273'); return false;" data-citation="" class="refNumLink">273</a></strong><div class="NLM_citation" id="cit273"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chenthamara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramaniam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essa, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qoronfleh, M. W.</span></span> <span> </span><span class="NLM_article-title">Therapeutic efficacy of nanoparticles and routes of administration</span>. <i>Biomater. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">20</span>, <span class="refDoi"> DOI: 10.1186/s40824-019-0166-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1186%2Fs40824-019-0166-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31832232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSlsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=20&author=D.+Chenthamaraauthor=S.+Subramaniamauthor=S.+G.+Ramakrishnanauthor=S.+Krishnaswamyauthor=M.+M.+Essaauthor=F.-H.+Linauthor=M.+W.+Qoronfleh&title=Therapeutic+efficacy+of+nanoparticles+and+routes+of+administration&doi=10.1186%2Fs40824-019-0166-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit273R"><div class="casContent"><span class="casTitleNuber">273</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic efficacy of nanoparticles and routes of administration</span></div><div class="casAuthors">Chenthamara, Dhrisya; Subramaniam, Sadhasivam; Ramakrishnan, Sankar Ganesh; Krishnaswamy, Swaminathan; Essa, Musthafa Mohamed; Lin, Feng-Huei; Qoronfleh, M. Walid</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20</span>CODEN:
                <span class="NLM_cas:coden">BRIEFJ</span>;
        ISSN:<span class="NLM_cas:issn">2055-7124</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  In modern-day medicine, nanotechnol. and nanoparticles are some of the indispensable tools in disease monitoring and therapy.  However, "engineered" nanomaterials have received significant attention due to their versatility.  Hence, in this review, we have endeavored to briefly explain the most commonly used nanomaterials, their core properties and how surface functionalization would facilitate competent delivery of drugs or therapeutic mols.  Similarly, the suitability of carbon-based nanomaterials like CNT and QD has been discussed for targeted drug delivery and siRNA therapy.  One of the biggest challenges in the formulation of drug delivery systems is fulfilling targeted/specific drug delivery, controlling drug release and preventing opsonization.  Thus, a different mechanism of drug targeting, the role of suitable drug-laden nanocarrier fabrication and methods to augment drug soly. and bioavailability are discussed.  Addnl., different routes of nanocarrier administration are discussed to provide greater understanding of the biol. and other barriers and their impact on drug transport.  The overall aim of this article is to facilitate straightforward perception of nanocarrier design, routes of various nanoparticle administration and the challenges assocd. with each drug delivery method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_nj0618kzoLVg90H21EOLACvtfcHk0ljBoTF8k7AwBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSlsb%252FO&md5=15e5762db8f3889d38b2fef1dbc16200</span></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=10.1186%2Fs40824-019-0166-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40824-019-0166-x%26sid%3Dliteratum%253Aachs%26aulast%3DChenthamara%26aufirst%3DD.%26aulast%3DSubramaniam%26aufirst%3DS.%26aulast%3DRamakrishnan%26aufirst%3DS.%2BG.%26aulast%3DKrishnaswamy%26aufirst%3DS.%26aulast%3DEssa%26aufirst%3DM.%2BM.%26aulast%3DLin%26aufirst%3DF.-H.%26aulast%3DQoronfleh%26aufirst%3DM.%2BW.%26atitle%3DTherapeutic%2520efficacy%2520of%2520nanoparticles%2520and%2520routes%2520of%2520administration%26jtitle%3DBiomater.%2520Res.%26date%3D2019%26volume%3D23%26spage%3D20%26doi%3D10.1186%2Fs40824-019-0166-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref274"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref274'); return false;" data-citation="" class="refNumLink">274</a></strong><div class="NLM_citation" id="cit274"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rath, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, A. K.</span></span> <span> </span><span class="NLM_article-title">Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis- a critical review</span>. <i>Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1676</span>– <span class="NLM_lpage">1698</span>, <span class="refDoi"> DOI: 10.3109/10717544.2015.1074765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3109%2F10717544.2015.1074765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26289212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XotFams78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=1676-1698&author=J.+Singhauthor=T.+Gargauthor=G.+Rathauthor=A.+K.+Goyal&title=Advances+in+nanotechnology-based+carrier+systems+for+targeted+delivery+of+bioactive+drug+molecules+with+special+emphasis+on+immunotherapy+in+drug+resistant+tuberculosis-+a+critical+review&doi=10.3109%2F10717544.2015.1074765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit274R"><div class="casContent"><span class="casTitleNuber">274</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review</span></div><div class="casAuthors">Singh, Jagdeep; Garg, Tarun; Rath, Goutam; Goyal, Amit K.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Delivery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1676-1698</span>CODEN:
                <span class="NLM_cas:coden">DDELEB</span>;
        ISSN:<span class="NLM_cas:issn">1071-7544</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">From the early sixteenth and seventeenth centuries to the present day of life, tuberculosis (TB) still is a global health threat with some new emergence of resistance.  This type of emergence poses a vital challenge to control TB cases across the world.  Mortality and morbidity rates are high due to this new face of TB.  The newer nanotechnol.-based drug-delivery approaches involving micro-metric and nano-metric carriers are much needed at this stage.  These delivery systems would provide more advantages over conventional systems of treatment by producing enhanced therapeutic efficacy, uniform distribution of drug mol. to the target site, sustained and controlled release of drug mols. and lesser side effects.  The main aim to develop these novel drug-delivery systems is to improve the patient compliance and reduce therapy time.  This article reviews and elaborates the new concepts and drug-delivery approaches for the treatment of TB involving solid-lipid particulate drug-delivery systems (solid-lipid micro- and nanoparticles, nanostructured lipid carriers), vesicular drug-delivery systems (liposomes, niosomes and liposphere), emulsion-based drug-delivery systems (micro and nanoemulsion) and some other novel drug-delivery systems for the effective treatment of tuberculosis and role of immunomodulators as an adjuvant therapy for management of MDR-TB and XDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr28PISzG5WB7Vg90H21EOLACvtfcHk0ljBoTF8k7AwBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotFams78%253D&md5=aa543d85d71faf5a41d166acadd1876a</span></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=10.3109%2F10717544.2015.1074765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10717544.2015.1074765%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DGarg%26aufirst%3DT.%26aulast%3DRath%26aufirst%3DG.%26aulast%3DGoyal%26aufirst%3DA.%2BK.%26atitle%3DAdvances%2520in%2520nanotechnology-based%2520carrier%2520systems%2520for%2520targeted%2520delivery%2520of%2520bioactive%2520drug%2520molecules%2520with%2520special%2520emphasis%2520on%2520immunotherapy%2520in%2520drug%2520resistant%2520tuberculosis-%2520a%2520critical%2520review%26jtitle%3DDrug%2520Delivery%26date%3D2016%26volume%3D23%26spage%3D1676%26epage%3D1698%26doi%3D10.3109%2F10717544.2015.1074765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref275"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref275'); return false;" data-citation="" class="refNumLink">275</a></strong><div class="NLM_citation" id="cit275"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gelperina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iseman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heifets, L.</span></span> <span> </span><span class="NLM_article-title">The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">1487</span>– <span class="NLM_lpage">1490</span>, <span class="refDoi"> DOI: 10.1164/rccm.200504-613PP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1164%2Frccm.200504-613PP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=16151040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD2MnlsFeiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2005&pages=1487-1490&author=S.+Gelperinaauthor=K.+Kisichauthor=M.+D.+Isemanauthor=L.+Heifets&title=The+potential+advantages+of+nanoparticle+drug+delivery+systems+in+chemotherapy+of+tuberculosis&doi=10.1164%2Frccm.200504-613PP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis</span></div><div class="casAuthors">Gelperina Svetlana; Kisich Kevin; Iseman Michael D; Heifets Leonid</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1487-90</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Nanoparticle-based drug delivery systems have considerable potential for treatment of tuberculosis (TB).  The important technological advantages of nanoparticles used as drug carriers are high stability, high carrier capacity, feasibility of incorporation of both hydrophilic and hydrophobic substances, and feasibility of variable routes of administration, including oral application and inhalation.  Nanoparticles can also be designed to allow controlled (sustained) drug release from the matrix.  These properties of nanoparticles enable improvement of drug bioavailability and reduction of the dosing frequency, and may resolve the problem of nonadherence to prescribed therapy, which is one of the major obstacles in the control of TB epidemics.  This article highlights some of the issues of nanotechnology relevant to the anti-TB drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ99nfQi50cwJPlX7E30qdzfW6udTcc2eaasxVOglftiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnlsFeiuw%253D%253D&md5=3cd1441a228062dc8c82e3501b068e49</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=10.1164%2Frccm.200504-613PP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200504-613PP%26sid%3Dliteratum%253Aachs%26aulast%3DGelperina%26aufirst%3DS.%26aulast%3DKisich%26aufirst%3DK.%26aulast%3DIseman%26aufirst%3DM.%2BD.%26aulast%3DHeifets%26aufirst%3DL.%26atitle%3DThe%2520potential%2520advantages%2520of%2520nanoparticle%2520drug%2520delivery%2520systems%2520in%2520chemotherapy%2520of%2520tuberculosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2005%26volume%3D172%26spage%3D1487%26epage%3D1490%26doi%3D10.1164%2Frccm.200504-613PP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref276"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref276'); return false;" data-citation="" class="refNumLink">276</a></strong><div class="NLM_citation" id="cit276"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clemens, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nel, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zink, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, M. A.</span></span> <span> </span><span class="NLM_article-title">Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2535</span>– <span class="NLM_lpage">2545</span>, <span class="refDoi"> DOI: 10.1128/AAC.06049-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.06049-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22354311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKrsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=2535-2545&author=D.+L.+Clemensauthor=B.+Y.+Leeauthor=M.+Xueauthor=C.+R.+Thomasauthor=H.+Mengauthor=D.+Ferrisauthor=A.+E.+Nelauthor=J.+I.+Zinkauthor=M.+A.+Horwitz&title=Targeted+intracellular+delivery+of+antituberculosis+drugs+to+Mycobacterium+tuberculosis-infected+macrophages+via+functionalized+mesoporous+silica+nanoparticles&doi=10.1128%2FAAC.06049-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles</span></div><div class="casAuthors">Clemens, Daniel L.; Lee, Bai-Yu; Xue, Min; Thomas, Courtney R.; Meng, Huan; Ferris, Daniel; Nel, Andre E.; Zink, Jeffrey I.; Horwitz, Marcus A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2535-2545</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Delivery of antituberculosis drugs by nanoparticles offers potential advantages over free drug, including the potential to target specifically the tissues and cells that are infected by Mycobacterium tuberculosis, thereby simultaneously increasing therapeutic efficacy and decreasing systemic toxicity, and the capacity for prolonged release of drug, thereby allowing less-frequent dosing.  We have employed mesoporous silica nanoparticle (MSNP) drug delivery systems either equipped with a polyethyleneimine (PEI) coating to release rifampin or equipped with cyclodextrin-based pH-operated valves that open only at acidic pH to release isoniazid (INH) into M. tuberculosis-infected macrophages.  The MSNP are internalized efficiently by human macrophages, traffic to acidified endosomes, and release high concns. of antituberculosis drugs intracellularly.  PEI-coated MSNP show much greater loading of rifampin than uncoated MSNP and much greater efficacy against M. tuberculosis-infected macrophages.  MSNP were devoid of cytotoxicity at the particle doses employed for drug delivery.  Similarly, we have demonstrated that the isoniazid delivered by MSNP equipped with pH-operated nanovalves kill M. tuberculosis within macrophages significantly more effectively than an equiv. amt. of free drug.  These data demonstrate that MSNP provide a versatile platform that can be functionalized to optimize the loading and intracellular release of specific drugs for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkQ_4V2YD_ebVg90H21EOLACvtfcHk0lik17N-iqShiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKrsLw%253D&md5=55323ffebc5d2fd3c27f9ff02ffb574c</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.1128%2FAAC.06049-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06049-11%26sid%3Dliteratum%253Aachs%26aulast%3DClemens%26aufirst%3DD.%2BL.%26aulast%3DLee%26aufirst%3DB.%2BY.%26aulast%3DXue%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DC.%2BR.%26aulast%3DMeng%26aufirst%3DH.%26aulast%3DFerris%26aufirst%3DD.%26aulast%3DNel%26aufirst%3DA.%2BE.%26aulast%3DZink%26aufirst%3DJ.%2BI.%26aulast%3DHorwitz%26aufirst%3DM.%2BA.%26atitle%3DTargeted%2520intracellular%2520delivery%2520of%2520antituberculosis%2520drugs%2520to%2520Mycobacterium%2520tuberculosis-infected%2520macrophages%2520via%2520functionalized%2520mesoporous%2520silica%2520nanoparticles%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D2535%26epage%3D2545%26doi%3D10.1128%2FAAC.06049-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref277"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref277'); return false;" data-citation="" class="refNumLink">277</a></strong><div class="NLM_citation" id="cit277"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghav, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priyanka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rishi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, I.</span></span> <span> </span><span class="NLM_article-title">Exploiting chitosan and gold nanoparticles for antimycobacterial activity of in silico identified antimicrobial motif of human neutrophil peptide-1</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">7866</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-44256-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fs41598-019-44256-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31133658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BB3M3gt1Cisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=7866&author=R.+Sharmaauthor=R.+Raghavauthor=K.+Priyankaauthor=P.+Rishiauthor=S.+Sharmaauthor=S.+Srivastavaauthor=I.+Verma&title=Exploiting+chitosan+and+gold+nanoparticles+for+antimycobacterial+activity+of+in+silico+identified+antimicrobial+motif+of+human+neutrophil+peptide-1&doi=10.1038%2Fs41598-019-44256-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit277R"><div class="casContent"><span class="casTitleNuber">277</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting chitosan and gold nanoparticles for antimycobacterial activity of in silico identified antimicrobial motif of human neutrophil peptide-1</span></div><div class="casAuthors">Sharma Richa; Priyanka Kumari; Sharma Sadhna; Verma Indu; Sharma Richa; Raghav Ragini; Srivastava Sudha; Rishi Praveen</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7866</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The upsurge of drug resistant tuberculosis is major health threat globally.  To counteract, antimicrobial peptides are being explored as possible alternatives.  However, certain limitations of peptide-based drugs such as potential toxicity, high cost and relatively low stability need to be addressed to enhance their clinical applicability.  Use of computer predicted short active motifs of AMPs along with nanotechnology could not only overcome the limitations of AMPs but also potentiate their antimicrobial activity.  Therefore, present study was proposed to in silico identify short antimicrobial motif (Pep-H) of human neutrophil peptide-1 (HNP-1) and explore its antimycobacterial activity in free form and using nanoparticles-based delivery systems.  Based on colony forming unit analysis, motif Pep-H led to killing of more than 90% M. tb in vitro at 10 μg/ml, whereas, similar activity against intracellularly growing M. tb was observed at 5 μg/ml only.  Thereafter, chitosan (244 nm) and gold nanoparticles (20 nm) were prepared for Pep-H with both the formulations showing minimal effects on the viability of human monocyte derived macrophages (MDMs) and RBC integrity.  The antimycobacterial activity of Pep-H against intracellular mycobacteria was enhanced in both the nanoformulations as evident by significant reduction in CFU (>90%) at 5-10 times lower concentrations than that observed for free Pep-H.  Thus, Pep-H is an effective antimycobacterial motif of HNP-1 and its activity is further enhanced by chitosan and gold nanoformulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZNEE2cL_h4nELvajU9pjPfW6udTcc2ebB5QniTMaQQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3gt1Cisg%253D%253D&md5=2b4eadc7b1114e801fd19f2a5af4326d</span></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-44256-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-44256-6%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DRaghav%26aufirst%3DR.%26aulast%3DPriyanka%26aufirst%3DK.%26aulast%3DRishi%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DSrivastava%26aufirst%3DS.%26aulast%3DVerma%26aufirst%3DI.%26atitle%3DExploiting%2520chitosan%2520and%2520gold%2520nanoparticles%2520for%2520antimycobacterial%2520activity%2520of%2520in%2520silico%2520identified%2520antimicrobial%2520motif%2520of%2520human%2520neutrophil%2520peptide-1%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D7866%26doi%3D10.1038%2Fs41598-019-44256-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref278"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref278'); return false;" data-citation="" class="refNumLink">278</a></strong><div class="NLM_citation" id="cit278"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saifullah, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrzastek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naeemullah, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakurazi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussein, M. Z.</span></span> <span> </span><span class="NLM_article-title">Novel anti-tuberculosis nanodelivery formulation of ethambutol with graphene oxide</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1560</span>, <span class="refDoi"> DOI: 10.3390/molecules22101560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3390%2Fmolecules22101560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitl2iurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1560&author=B.+Saifullahauthor=A.+Chrzastekauthor=A.+Maitraauthor=B.+Naeemullahauthor=S.+Fakuraziauthor=S.+Bhaktaauthor=M.+Z.+Hussein&title=Novel+anti-tuberculosis+nanodelivery+formulation+of+ethambutol+with+graphene+oxide&doi=10.3390%2Fmolecules22101560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit278R"><div class="casContent"><span class="casTitleNuber">278</span><div class="casTitle"><span class="NLM_cas:atitle">Novel anti-tuberculosis nanodelivery formulation of ethambutol with graphene oxide</span></div><div class="casAuthors">Saifullah, Bullo; Chrzastek, Alina; Maitra, Arundhati; Naeemullah, Bullo; Fakurazi, Sharida; Bhakta, Sanjib; Hussein, Mohd. Zobir</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1560/1-1560/12</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Tuberculosis (TB) is a bacterial disease responsible for millions of infections and preventable deaths each year.  Its treatment is complicated by patients' noncompliance due to dosing frequency, lengthy treatment, and adverse side effects assocd. with current chemotherapy.  However, no modifications to the half-a-century old std. chemotherapy have been made based on a nanoformulation strategy to improve pharmacokinetic efficacy.  In this study, we have designed a new nanodelivery formulation, using graphene oxide as the nanocarrier, loaded with the anti-TB antibiotic, ethambutol.  The designed formulation was characterized using a no. of mol. anal. techniques.  It was found that sustained release of the drug resulted in better bioavailability.  In addn., the designed formulation demonstrated high biocompatibility with mouse fibroblast cells.  The anti-TB activity of the nanodelivery formulation was detd. using whole-cell resazurin microtiter plate assay, modified-spot culture growth inhibition assay, and biofilm inhibition assay.  The nanodelivery formulation showed good anti-mycobacterial activity.  The anti-mycobacterial activity of Ethambutol was unaffected by the drug loading and release process.  The results of this study demonstrated the potential of this new nanodelivery formulation strategy to be considered for modifying existing chemotherapy to yield more efficacious antibiotic treatment against TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowaawU9u9RFLVg90H21EOLACvtfcHk0lgliGzP86DiUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitl2iurw%253D&md5=b975a2195694885343b04df9e00d63df</span></div><a href="/servlet/linkout?suffix=cit278&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22101560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22101560%26sid%3Dliteratum%253Aachs%26aulast%3DSaifullah%26aufirst%3DB.%26aulast%3DChrzastek%26aufirst%3DA.%26aulast%3DMaitra%26aufirst%3DA.%26aulast%3DNaeemullah%26aufirst%3DB.%26aulast%3DFakurazi%26aufirst%3DS.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DHussein%26aufirst%3DM.%2BZ.%26atitle%3DNovel%2520anti-tuberculosis%2520nanodelivery%2520formulation%2520of%2520ethambutol%2520with%2520graphene%2520oxide%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D1560%26doi%3D10.3390%2Fmolecules22101560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref279"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref279'); return false;" data-citation="" class="refNumLink">279</a></strong><div class="NLM_citation" id="cit279"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gajendiran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balashanmugam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaichelvan, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span> <span> </span><span class="NLM_article-title">Multi-drug delivery of tuberculosis drugs by π-back bonded gold nanoparticles with multiblock copolyesters</span>. <i>Mater. Res. Express</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">065401</span>, <span class="refDoi"> DOI: 10.1088/2053-1591/3/6/065401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1088%2F2053-1591%2F3%2F6%2F065401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Olu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=065401&author=M.+Gajendiranauthor=P.+Balashanmugamauthor=P.+T.+Kalaichelvanauthor=S.+Balasubramanian&title=Multi-drug+delivery+of+tuberculosis+drugs+by+%CF%80-back+bonded+gold+nanoparticles+with+multiblock+copolyesters&doi=10.1088%2F2053-1591%2F3%2F6%2F065401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit279R"><div class="casContent"><span class="casTitleNuber">279</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-drug delivery of tuberculosis drugs by π-back bonded gold nanoparticles with multiblock copolyesters</span></div><div class="casAuthors">Gajendiran, Mani; Balashanmugam, Pannerselvam; Kalaichelvan, P. T.; Balasubramanian, Sengottuvelan</div><div class="citationInfo"><span class="NLM_cas:title">Materials Research Express</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">065401/1-065401/16</span>CODEN:
                <span class="NLM_cas:coden">MREAC3</span>;
        ISSN:<span class="NLM_cas:issn">2053-1591</span>.
    
            (<span class="NLM_cas:orgname">IOP Publishing Ltd.</span>)
        </div><div class="casAbstract">The effect of π-back-bonding between AuNPs and the carbonyl group of multiblock copolyester on tuberculosis multi-drug delivery has been investigated.  The carbonyl group of copolyester has vacant p orbitals and these vacant orbitals accept electron clouds from the filled d orbitals of Au0 to form π-back-bonding, which enhances the electron d. for the carbonyl oxygen.  This high electron d. results in the strong binding of drug mols. with multiblock copolyesters and hence sustained drug release is achieved for a longer duration when compared to polymer systems without AuNPs.  A new series of tartarate-linked poly(lactic-co-glycolic acid) (PLGA)-polyethylene glycol (PEG)-based multiblock copolymers has been synthesized using a solvent-free melt reaction.  The biocompatibility of multiblock copolyesters and AuNP nanoconjugates was investigated with an in vitro cytotoxicity study on the Vero cell line.  Three major tuberculosis drugs, namely, rifampicin-, isoniazid- and pyrazinamide-loaded AuNP multiblock copolymer NPs were prepd. by probe sonication followed by the self-assembly method.  An in vitro drug release expt. was carried out and the amt. of the three drugs released at various time intervals was detd. simultaneously by the HPLC technique.  The nanoconjugates exhibit 33%-40% RIF, 71%-95% INH, 77%-99% PYZ loading efficiencies, while the polymer NPs exhibit relatively lesser values.  The nanoconjugates show sustained drug release for up to 264 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2sZeQJvL4NrVg90H21EOLACvtfcHk0lgliGzP86DiUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Olu7%252FN&md5=bf10f201efc26ec71d6cb0826f3622ad</span></div><a href="/servlet/linkout?suffix=cit279&amp;dbid=16384&amp;doi=10.1088%2F2053-1591%2F3%2F6%2F065401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1088%252F2053-1591%252F3%252F6%252F065401%26sid%3Dliteratum%253Aachs%26aulast%3DGajendiran%26aufirst%3DM.%26aulast%3DBalashanmugam%26aufirst%3DP.%26aulast%3DKalaichelvan%26aufirst%3DP.%2BT.%26aulast%3DBalasubramanian%26aufirst%3DS.%26atitle%3DMulti-drug%2520delivery%2520of%2520tuberculosis%2520drugs%2520by%2520%25CF%2580-back%2520bonded%2520gold%2520nanoparticles%2520with%2520multiblock%2520copolyesters%26jtitle%3DMater.%2520Res.%2520Express%26date%3D2016%26volume%3D3%26spage%3D065401%26doi%3D10.1088%2F2053-1591%2F3%2F6%2F065401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref280"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref280'); return false;" data-citation="" class="refNumLink">280</a></strong><div class="NLM_citation" id="cit280"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshiro Junior, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavan, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorilli, M.</span></span> <span> </span><span class="NLM_article-title">Nanostructured lipid carriers for incorporation of copper(II) complexes to be used against Mycobacterium tuberculosis</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">921</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S127048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.2147%2FDDDT.S127048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28356717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOgs7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=909-921&author=M.+R.+Satoauthor=J.+A.+Oshiro+Juniorauthor=R.+T.+Machadoauthor=P.+C.+de+Souzaauthor=D.+L.+Camposauthor=F.+R.+Pavanauthor=P.+B.+da+Silvaauthor=M.+Chorilli&title=Nanostructured+lipid+carriers+for+incorporation+of+copper%28II%29+complexes+to+be+used+against+Mycobacterium+tuberculosis&doi=10.2147%2FDDDT.S127048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit280R"><div class="casContent"><span class="casTitleNuber">280</span><div class="casTitle"><span class="NLM_cas:atitle">Nanostructured lipid carriers for incorporation of copper(II ) complexes to be used against Mycobacterium tuberculosis</span></div><div class="casAuthors">Sato, Mariana R.; Oshiro, Joao A. Junior; Machado, Rachel T. A.; de Souza, Paula C.; Campos, Debora L.; Pavan, Fernando R.; da Silva, Patricia B.; Chorilli, Marlus</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">909-921</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis.  Cessation of treatment before the recommended conclusion may lead to the emergence of multidrug-resistant strains.  The aim of this study was to develop nanostructured lipid carriers (NLCs) for use in the treatment of M. tuberculosis.  The NLCs comprised the following lipid phase: 2.07% polyoxyethylene 40 stearate, 2.05% caprylic/capric triglyceride, and 0.88% polyoxyl 40 hydrogenated castor oil; the following aq. phase: 3.50% poloxamer 407 (F1-F6), and 0.50% cetyltrimethylammonium bromide (F7-F12); and incorporated the copper(II) complexes [CuCl2(INH)2]·H2O (1), [Cu(NCS)2(INH)2]·5H2O (2), and [Cu(NCO)2(INH)2]·4H2O (3) to form compds. F11.1, F11.2, and F11.3, resp.  The mean diam. of F11, F11.1, F11.2, and F11.3 ranged from 111.27±21.86 to 134.25±22.72 nm, 90.27±12.97 to 116.46±9.17 nm, 112.4±10.22 to 149.3±15.82 nm, and 78.65±6.00 to 122.00±8.70 nm, resp.  The polydispersity index values for the NLCs ranged from 0.13±0.01 to 0.30±0.09.  The NLCs showed significant changes in zeta potential, except for F11.2, with F11, F11.1, F11.2, and F11.3 ranging from 18.87±4.04 to 23.25±1.13 mV, 17.03±1.77 to 21.42±1.87 mV, 20.51±1.88 to 22.60±3.44 mV, and 17.80±1.96 to 25.25±7.78 mV, resp.  Atomic force microscopy confirmed the formation of nanoscale spherical particle dispersions by the NLCs.  Differential scanning calorimetry detd. the m.ps. of the constituents of the NLCs.  The in vitro activity of copper(II) complex-loaded NLCs against M. tuberculosis H37Rv showed an improvement in the anti-TB activity of 55.4, 27.1, and 41.1 times the activity for complexes 1, 2, and 3, resp.  An in vivo acute toxicity study of complex-loaded NLCs demonstrated their reduced toxicity.  The results suggest that NLCs may be a powerful tool to optimize the activity of copper(II) complexes against M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosY_Hf_UEOy7Vg90H21EOLACvtfcHk0lgliGzP86DiUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOgs7nO&md5=bb30c065f3c685e545798b48d4e051fb</span></div><a href="/servlet/linkout?suffix=cit280&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S127048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S127048%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DM.%2BR.%26aulast%3DOshiro%2BJunior%26aufirst%3DJ.%2BA.%26aulast%3DMachado%26aufirst%3DR.%2BT.%26aulast%3Dde%2BSouza%26aufirst%3DP.%2BC.%26aulast%3DCampos%26aufirst%3DD.%2BL.%26aulast%3DPavan%26aufirst%3DF.%2BR.%26aulast%3Dda%2BSilva%26aufirst%3DP.%2BB.%26aulast%3DChorilli%26aufirst%3DM.%26atitle%3DNanostructured%2520lipid%2520carriers%2520for%2520incorporation%2520of%2520copper%2528II%2529%2520complexes%2520to%2520be%2520used%2520against%2520Mycobacterium%2520tuberculosis%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D909%26epage%3D921%26doi%3D10.2147%2FDDDT.S127048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref281"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref281'); return false;" data-citation="" class="refNumLink">281</a></strong><div class="NLM_citation" id="cit281"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidary, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaker Bostanabad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amini, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghalami
Nobar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghodousi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamalzadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darban-Sarokhalil, D.</span></span> <span> </span><span class="NLM_article-title">The anti-mycobacterial activity of Ag, ZnO, And Ag- ZnO nanoparticles against MDR- and XDR-mycobacterium tuberculosis</span>. <i>Infect. Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3425</span>– <span class="NLM_lpage">3435</span>, <span class="refDoi"> DOI: 10.2147/IDR.S221408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.2147%2FIDR.S221408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31807033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXot1yjsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=3425-3435&author=M.+Heidaryauthor=S.+Zaker+Bostanabadauthor=S.+M.+Aminiauthor=A.+Jafariauthor=M.+Ghalami%0ANobarauthor=A.+Ghodousiauthor=M.+Kamalzadehauthor=D.+Darban-Sarokhalil&title=The+anti-mycobacterial+activity+of+Ag%2C+ZnO%2C+And+Ag-+ZnO+nanoparticles+against+MDR-+and+XDR-mycobacterium+tuberculosis&doi=10.2147%2FIDR.S221408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit281R"><div class="casContent"><span class="casTitleNuber">281</span><div class="casTitle"><span class="NLM_cas:atitle">The anti-mycobacterial activity Of Ag, ZnO, and Ag- ZnO nanoparticles against MDR- and XDR-Mycobacterium tuberculosis</span></div><div class="casAuthors">Heidary, Mohsen; Bostanabad, Saeed Zaker; Amini, Seyed Mohammad; Jafari, Alireza; Nobar, Mostafa Ghalami; Ghodousi, Arash; Kamalzadeh, Morteza; Darban-Sarokhalil, Davood</div><div class="citationInfo"><span class="NLM_cas:title">Infection and Drug Resistance</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3425-3435</span>CODEN:
                <span class="NLM_cas:coden">IDRNAV</span>;
        ISSN:<span class="NLM_cas:issn">1178-6973</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Nowadays, tuberculosis (TB) is one of the top ten leading causes of mortality worldwide.  The emergence of multidrug-resistant (MDR) - and extensively drug-resistant (XDR) - Mycobacterium tuberculosis (M. tuberculosis) is identified as one of the most challenging threats to TB control.  Thus, new and safe nano-drugs are urgently required for the elimination of TB.  The aim of this study was to investigate the anti-bacterial effects of Ag, ZnO, and Ag-ZnO nanoparticles (NPs) on MDR- and XDR-M. tuberculosis.  Materials and methods: In this study, Ag, ZnO, and Ag-ZnO NPs were synthesized by the chem. redn. and chem. deposition methods.  NPs were characterized using UV-visible spectroscopy, dynamic light scattering, and transmission electron microscopy.  Then, various dilns. of NPs were prepd. and their min. inhibitory concns. (MICs) and min. bactericidal concns. (MBCs) were detd. against M. tuberculosis strains using the broth microdilution and agar microdilution methods.  Finally, MTT test and cell culture assay were performed.  Results: The effects of concns. of 1-128 μg/mL Ag NPs, ZnO NPs, 2Ag: 8ZnO, 8Ag:2ZnO, 3Ag: 7ZnO, 7Ag:3ZnO, and 5Ag:5ZnO on M. tuberculosis strains were investigated.  MIC results showed the inhibitory effect of 1 μg/mL of all NPs against XDR-M. tuberculosis.  In addn., the concns. of 4 μg/mL Ag, 8 μg/mL 5Ag:5ZnO, 8 μg/mL 7Ag:3ZnO, 32 μg/mL 3Ag:7ZnO, 16 μg/mL 8Ag:2ZnO, and 64 μg/mL 2Ag:8ZnO inhibited MDR-M. tuberculosis growth.  However, MBC results indicated the inability of Ag, ZnO and Ag-ZnO NPs, either in combination or alone, to kill MDR- or XDR-M. tuberculosis.  Conclusion: To the best of our knowledge, this is the first study to evaluate the effects of Ag and ZnO NPs against MDR and XDR strains of M. tuberculosis.  According to the results, Ag and ZnO NPs showed bacteriostatic effects against drug-resistant strains of M. tuberculosis.  Therefore, these NPs may be considered as promising anti-mycobacterial nano-drugs.  However, further studies are required to affirm the bactericidal effects of these NPs against TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlRShshehpXbVg90H21EOLACvtfcHk0ljDVhmRMulkaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXot1yjsro%253D&md5=db456425cf3c228b5a9763532f9cc0a8</span></div><a href="/servlet/linkout?suffix=cit281&amp;dbid=16384&amp;doi=10.2147%2FIDR.S221408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIDR.S221408%26sid%3Dliteratum%253Aachs%26aulast%3DHeidary%26aufirst%3DM.%26aulast%3DZaker%2BBostanabad%26aufirst%3DS.%26aulast%3DAmini%26aufirst%3DS.%2BM.%26aulast%3DJafari%26aufirst%3DA.%26aulast%3DGhalami%2BNobar%26aufirst%3DM.%26aulast%3DGhodousi%26aufirst%3DA.%26aulast%3DKamalzadeh%26aufirst%3DM.%26aulast%3DDarban-Sarokhalil%26aufirst%3DD.%26atitle%3DThe%2520anti-mycobacterial%2520activity%2520of%2520Ag%252C%2520ZnO%252C%2520And%2520Ag-%2520ZnO%2520nanoparticles%2520against%2520MDR-%2520and%2520XDR-mycobacterium%2520tuberculosis%26jtitle%3DInfect.%2520Drug%2520Resist.%26date%3D2019%26volume%3D12%26spage%3D3425%26epage%3D3435%26doi%3D10.2147%2FIDR.S221408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref282"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref282'); return false;" data-citation="" class="refNumLink">282</a></strong><div class="NLM_citation" id="cit282"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khuller, G. K.</span></span> <span> </span><span class="NLM_article-title">Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">766</span>, <span class="refDoi"> DOI: 10.1093/jac/dkh411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fjac%2Fdkh411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=15329364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotVyqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2004&pages=761-766&author=A.+Sharmaauthor=S.+Sharmaauthor=G.+K.+Khuller&title=Lectin-functionalized+poly+%28lactide-co-glycolide%29+nanoparticles+as+oral%2Faerosolized+antitubercular+drug+carriers+for+treatment+of+tuberculosis&doi=10.1093%2Fjac%2Fdkh411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit282R"><div class="casContent"><span class="casTitleNuber">282</span><div class="casTitle"><span class="NLM_cas:atitle">Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis</span></div><div class="casAuthors">Sharma, Anjali; Sharma, Sadhna; Khuller, G. K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">761-766</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">This study was carried out to explore lectin-functionalized poly (lactide-co-glycolide) nanoparticles (PLG-NPs) as bioadhesive drug carriers against tuberculosis (TB), in order to reduce the drug dosage frequency of antitubercular drugs and thus improve patient compliance in TB chemotherapy.  Wheat germ agglutinin (WGA)-coated PLG-NPs were prepd. by a two-step carbodiimide procedure.  This formulation was administered to guinea pigs through the oral/aerosol route for a detailed pharmacokinetic and chemotherapeutic evaluation.  Immunol. or hepatotoxic effects of WGA lectin, if any, were also detd.  WGA-functionalized PLG-NPs were in the size range of 350-400 nm, with binding of 3-3.5 μg of WGA/mg of PLG-NPs and drug encapsulation efficiency of 54%-66%.  Upon administration of lectin-coated PLG-NPs through the oral/aerosol route, the presence of drugs in plasma was obsd. for 6-7 days for rifampicin and 13-14 days for isoniazid and pyrazinamide.  However, upon administration of uncoated PLG-NPs (oral/aerosolized) rifampicin was detectable in plasma for 4-6 days, whereas isoniazid and pyrazinamide were detectable for 8-9 days.  All three drugs were present in lungs, liver and spleen for 15 days.  Administration of WGA-coated PLG-NPs caused a significant (P < 0.001) increase in the relative bioavailability of antitubercular drugs.  Chemotherapeutic studies revealed that three doses of oral/nebulized lectin-coated nanoparticles fortnightly could yield undetectable mycobacterial colony forming units (cfu); this was achievable with 45 doses of oral free drugs.  WGA-functionalized PLG-NPs could be potential drug carriers for antitubercular drugs through the oral as well as aerosol route for effective TB control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK4EYmOtkF9LVg90H21EOLACvtfcHk0ljDVhmRMulkaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotVyqsbo%253D&md5=2269ae52053065827ac149b9082ad642</span></div><a href="/servlet/linkout?suffix=cit282&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkh411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkh411%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKhuller%26aufirst%3DG.%2BK.%26atitle%3DLectin-functionalized%2520poly%2520%2528lactide-co-glycolide%2529%2520nanoparticles%2520as%2520oral%252Faerosolized%2520antitubercular%2520drug%2520carriers%2520for%2520treatment%2520of%2520tuberculosis%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2004%26volume%3D54%26spage%3D761%26epage%3D766%26doi%3D10.1093%2Fjac%2Fdkh411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref283"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref283'); return false;" data-citation="" class="refNumLink">283</a></strong><div class="NLM_citation" id="cit283"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalombo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemmer, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semete-Makokotlela, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalapa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nkuna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booysen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayeshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verschoor, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swai, H. S.</span></span> <span> </span><span class="NLM_article-title">Spray-dried, nanoencapsulated, multi-drug anti-tuberculosis therapy aimed at once weekly administration for the duration of treatment</span>. <i>Nanomaterials</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1167</span>, <span class="refDoi"> DOI: 10.3390/nano9081167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3390%2Fnano9081167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCjs7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1167&author=L.+Kalomboauthor=Y.+Lemmerauthor=B.+Semete-Makokotlelaauthor=B.+Ramalapaauthor=P.+Nkunaauthor=L.+Booysenauthor=S.+Naidooauthor=R.+Hayeshiauthor=J.+A.+Verschoorauthor=H.+S.+Swai&title=Spray-dried%2C+nanoencapsulated%2C+multi-drug+anti-tuberculosis+therapy+aimed+at+once+weekly+administration+for+the+duration+of+treatment&doi=10.3390%2Fnano9081167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit283R"><div class="casContent"><span class="casTitleNuber">283</span><div class="casTitle"><span class="NLM_cas:atitle">Spray-dried, nanoencapsulated, multi-drug anti-tuberculosis therapy aimed at once weekly administration for the duration of treatment</span></div><div class="casAuthors">Kalombo, Lonji; Lemmer, Yolandy; Semete-Makokotlela, Boitumelo; Ramalapa, Bathabile; Nkuna, Patric; Booysen, Laetitia L. L. I. J.; Naidoo, Saloshnee; Hayeshi, Rose; Verschoor, Jan A.; Swai, Hulda S.</div><div class="citationInfo"><span class="NLM_cas:title">Nanomaterials</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1167</span>CODEN:
                <span class="NLM_cas:coden">NANOKO</span>;
        ISSN:<span class="NLM_cas:issn">2079-4991</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Aiming to improve the treatment outcomes of current daily tuberculosis (TB) chemotherapy over several months, we investigated whether nanoencapsulation of existing drugs would allow decreasing the treatment frequency to weekly, thereby ultimately improving patient compliance.  Nanoencapsulation of three first-line anti-TB drugs was achieved by a unique, scalable spray-drying technol. forming free-flowing powders in the nanometer range with encapsulation efficiencies of 82, 75, and 62% resp. for rifampicin, pyrazinamide, and isoniazid.  In a pre-clin. study on TB infected mice, we demonstrate that the encapsulated drugs, administered once weekly for nine weeks, showed comparable efficacy to daily treatment with free drugs over the same exptl. period.  Both treatment approaches had equiv. outcomes for resoln. of inflammation assocd. with the infection of lungs and spleens.  These results demonstrate how scalable technol. could be used to manuf. nanoencapsulated drugs.  The formulations may be used to reduce the oral dose frequency from daily to once weekly in order to treat uncomplicated TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEPt78R3IbnbVg90H21EOLACvtfcHk0ljDVhmRMulkaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCjs7zJ&md5=a2ec906d2106c3548b01b2249d32793f</span></div><a href="/servlet/linkout?suffix=cit283&amp;dbid=16384&amp;doi=10.3390%2Fnano9081167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fnano9081167%26sid%3Dliteratum%253Aachs%26aulast%3DKalombo%26aufirst%3DL.%26aulast%3DLemmer%26aufirst%3DY.%26aulast%3DSemete-Makokotlela%26aufirst%3DB.%26aulast%3DRamalapa%26aufirst%3DB.%26aulast%3DNkuna%26aufirst%3DP.%26aulast%3DBooysen%26aufirst%3DL.%26aulast%3DNaidoo%26aufirst%3DS.%26aulast%3DHayeshi%26aufirst%3DR.%26aulast%3DVerschoor%26aufirst%3DJ.%2BA.%26aulast%3DSwai%26aufirst%3DH.%2BS.%26atitle%3DSpray-dried%252C%2520nanoencapsulated%252C%2520multi-drug%2520anti-tuberculosis%2520therapy%2520aimed%2520at%2520once%2520weekly%2520administration%2520for%2520the%2520duration%2520of%2520treatment%26jtitle%3DNanomaterials%26date%3D2019%26volume%3D9%26spage%3D1167%26doi%3D10.3390%2Fnano9081167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref284"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref284'); return false;" data-citation="" class="refNumLink">284</a></strong><div class="NLM_citation" id="cit284"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaramahalingam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajaram, R.</span></span> <span> </span><span class="NLM_article-title">Size-dependent antimycobacterial activity of titanium oxide nanoparticles against Mycobacterium tuberculosis</span>. <i>J. Mater. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">4338</span>– <span class="NLM_lpage">4346</span>, <span class="refDoi"> DOI: 10.1039/C9TB00784A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref284/cit284&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1039%2FC9TB00784A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref284/cit284&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWks7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=4338-4346&author=V.+Ramalingamauthor=S.+Sundaramahalingamauthor=R.+Rajaram&title=Size-dependent+antimycobacterial+activity+of+titanium+oxide+nanoparticles+against+Mycobacterium+tuberculosis&doi=10.1039%2FC9TB00784A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit284R"><div class="casContent"><span class="casTitleNuber">284</span><div class="casTitle"><span class="NLM_cas:atitle">Size-dependent antimycobacterial activity of titanium oxide nanoparticles against Mycobacterium tuberculosis</span></div><div class="casAuthors">Ramalingam, Vaikundamoorthy; Sundaramahalingam, Subramaniam; Rajaram, Rajendran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Materials Chemistry B: Materials for Biology and Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">4338-4346</span>CODEN:
                <span class="NLM_cas:coden">JMCBDV</span>;
        ISSN:<span class="NLM_cas:issn">2050-7518</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Nanobiotechnol. has offered new approaches for drug delivery and for the development of medicines against microbial infections including the deadly multidrug-resistant tuberculosis (MDR-TB).  The present study deals with the antimycobacterial activity of titanium dioxide (TiO2) nanoparticles against Mycobacterium tuberculosis.  Initially, TiO2 nanoparticles were synthesized from titanium(IV)oxysulfate (TiOSO4) soln. using the sol-gel method.  The shape and size of the TiO2 crystals were analyzed using TEM and SEM and were found to be spherical and 16 nm resp., thereby indicating their morphol.  Moreover, the XRD pattern confirms that the prepd. TiO2 nanoparticles were anatase as well as being tetragonal and FTIR spectra show the stretching vibrations of Ti-O and Ti-O-Ti.  Further, the TiO2 nanoparticles were shown to exhibit excellent size-dependent antimycobacterial activity against Mycobacterium tuberculosis, M. bovis and Mycobacterium sp. in a concn. dependent manner (10-100 μg mL-1).  Confocal laser scanning microscopic anal. also confirmed that the TiO2 nanoparticles inhibit the biofilm formation of all three tested mycobacteria.  The metabolic activity of mycobacteria was decreased up to 3-4 fold with an increase in the concn. of the TiO2 nanoparticles hence affecting the biofilm formation.  Moreover, the TiO2 nanoparticles were less toxic (>25%) against normal lung bronchus cells at 100 μg mL-1 after 24 h treatment revealing that the nanoparticles are less toxic in nature.  Taken together, these results showed that the TiO2 nanoparticles can be a potential biofilm agent against mycobacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE0n_vq5WndLVg90H21EOLACvtfcHk0lgSkAMP-1gdXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWks7nO&md5=74fdb6d7712383d2cd1a28c5a063d034</span></div><a href="/servlet/linkout?suffix=cit284&amp;dbid=16384&amp;doi=10.1039%2FC9TB00784A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9TB00784A%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DV.%26aulast%3DSundaramahalingam%26aufirst%3DS.%26aulast%3DRajaram%26aufirst%3DR.%26atitle%3DSize-dependent%2520antimycobacterial%2520activity%2520of%2520titanium%2520oxide%2520nanoparticles%2520against%2520Mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Mater.%2520Chem.%2520B%26date%3D2019%26volume%3D7%26spage%3D4338%26epage%3D4346%26doi%3D10.1039%2FC9TB00784A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref285"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref285'); return false;" data-citation="" class="refNumLink">285</a></strong><div class="NLM_citation" id="cit285"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidyarthi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadeem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrewala, J. N.</span></span> <span> </span><span class="NLM_article-title">Alteration in the gut microbiota provokes susceptibility to tuberculosis</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">529</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2016.00529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3389%2Ffimmu.2016.00529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27965663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptF2qsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=529-529&author=N.+Khanauthor=A.+Vidyarthiauthor=S.+Nadeemauthor=S.+Negiauthor=G.+Nairauthor=J.+N.+Agrewala&title=Alteration+in+the+gut+microbiota+provokes+susceptibility+to+tuberculosis&doi=10.3389%2Ffimmu.2016.00529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit285R"><div class="casContent"><span class="casTitleNuber">285</span><div class="casTitle"><span class="NLM_cas:atitle">Alteration in the gut microbiota provokes susceptibility to tuberculosis</span></div><div class="casAuthors">Khan, Nargis; Vidyarthi, Aurobind; Nadeem, Sajid; Negi, Shikha; Nair, Girish; Agrewala, Javed N.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">529/1-529/10</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The microbiota that resides in the gastrointestinal tract provides essential health benefits to the host.  In particular, they regulate immune homeostasis.  Recently, several evidences indicate that alteration in the gut microbial community can cause infectious and non-infectious diseases.  Tuberculosis (TB) is the most devastating disease, inflicting mortality and morbidity.  It remains unexplored, whether changes in the gut microbiota can provoke or prevent TB.  In the current study, we have demonstrated the antibiotics driven changes in the gut microbial compn. and their impact on the survival of Mycobacterium tuberculosis (Mtb) in the lungs, liver, and spleen of infected mice, compared to those with intact microbiota.  Interestingly, dysbiosis of microbes showed significant increase in the bacterial burden in lungs and dissemination of Mtb to spleen and liver.  Furthermore, elevation in the no. of Tregs and decline in the pool of IFN-γ- and TNF-α-releasing CD4 T cells was noticed.  Interestingly, fecal transplantation in the gut microbiota disrupted animals exhibited improved Th1 immunity and lesser Tregs population.  Importantly, these animals displayed reduced severity to Mtb infection.  This study for the first time demonstrated the novel role of gut microbes in the susceptibility to TB and its prevention by microbial implants.  In future, microbial therapies may help in treating patients suffering from TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_m_Fy3xWobLVg90H21EOLACvtfcHk0lgSkAMP-1gdXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptF2qsA%253D%253D&md5=8847952d6ef63f27d3553b561bac54e0</span></div><a href="/servlet/linkout?suffix=cit285&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2016.00529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2016.00529%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DVidyarthi%26aufirst%3DA.%26aulast%3DNadeem%26aufirst%3DS.%26aulast%3DNegi%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DG.%26aulast%3DAgrewala%26aufirst%3DJ.%2BN.%26atitle%3DAlteration%2520in%2520the%2520gut%2520microbiota%2520provokes%2520susceptibility%2520to%2520tuberculosis%26jtitle%3DFront.%2520Immunol.%26date%3D2016%26volume%3D7%26spage%3D529%26epage%3D529%26doi%3D10.3389%2Ffimmu.2016.00529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref286"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref286'); return false;" data-citation="" class="refNumLink">286</a></strong><div class="NLM_citation" id="cit286"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pahari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aqdas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrewala, J. N.</span></span> <span> </span><span class="NLM_article-title">Bolstering immunity through pattern recognition receptors: A unique approach to control tuberculosis</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">906</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2017.00906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3389%2Ffimmu.2017.00906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28824632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWntbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=906&author=S.+Pahariauthor=G.+Kaurauthor=M.+Aqdasauthor=S.+Negiauthor=D.+Chatterjeeauthor=H.+Bashirauthor=S.+Singhauthor=J.+N.+Agrewala&title=Bolstering+immunity+through+pattern+recognition+receptors%3A+A+unique+approach+to+control+tuberculosis&doi=10.3389%2Ffimmu.2017.00906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit286R"><div class="casContent"><span class="casTitleNuber">286</span><div class="casTitle"><span class="NLM_cas:atitle">Bolstering immunity through pattern recognition receptors: a unique approach to control tuberculosis</span></div><div class="casAuthors">Pahari, Susanta; Kaur, Gurpreet; Aqdas, Mohammad; Negi, Shikha; Chatterjee, Deepyan; Bashir, Hilal; Singh, Sanpreet; Agrewala, Javed N.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">906/1-906/13</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The global control of tuberculosis (TB) presents a continuous health challenge to mankind.  Despite having effective drugs, TB still has a devastating impact on human health.  Contributing reasons include the emergence of drug-resistant strains of Mycobacterium tuberculosis (Mtb), the AIDS-pandemic, and the absence of effective vaccines against the disease.  Indeed, alternative and effective methods of TB treatment and control are urgently needed.  One such approach may be to more effectively engage the immune system; particularly the frontline pattern recognition receptor (PRR) systems of the host, which sense pathogen-assocd. mol. patterns (PAMPs) of Mtb.  It is well known that 95 % of individuals infected with Mtb in latent form remain healthy throughout their life.  Therefore, we propose that clues can be found to control the remainder by successfully manipulating the innate immune mechanisms, particularly of nasal and mucosal cavities.  This article highlights the importance of signaling through PRRs in restricting Mtb entry and subsequently preventing its infection.  Furthermore, we discuss whether this unique therapy employing PRRs in combination with drugs can help in reducing the dose and duration of current TB regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrabXj90TMiRbVg90H21EOLACvtfcHk0lgSkAMP-1gdXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWntbvL&md5=78fd1998f8376ff632ba991285a7c282</span></div><a href="/servlet/linkout?suffix=cit286&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2017.00906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2017.00906%26sid%3Dliteratum%253Aachs%26aulast%3DPahari%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DAqdas%26aufirst%3DM.%26aulast%3DNegi%26aufirst%3DS.%26aulast%3DChatterjee%26aufirst%3DD.%26aulast%3DBashir%26aufirst%3DH.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DAgrewala%26aufirst%3DJ.%2BN.%26atitle%3DBolstering%2520immunity%2520through%2520pattern%2520recognition%2520receptors%253A%2520A%2520unique%2520approach%2520to%2520control%2520tuberculosis%26jtitle%3DFront.%2520Immunol.%26date%3D2017%26volume%3D8%26spage%3D906%26doi%3D10.3389%2Ffimmu.2017.00906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref287"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref287'); return false;" data-citation="" class="refNumLink">287</a></strong><div class="NLM_citation" id="cit287"><span><span class="NLM_contrib-group"><span class="NLM_string-name">AlMatar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makky, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakıcı, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Var, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köksal, F.</span></span> <span> </span><span class="NLM_article-title">Antimicrobial peptides as an alternative to anti-tuberculosis drugs</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2017.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.phrs.2017.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29079429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1M7lsVaguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=288-305&author=M.+AlMatarauthor=E.+A.+Makkyauthor=G.+Yak%C4%B1c%C4%B1author=I.+Varauthor=B.+Kayarauthor=F.+K%C3%B6ksal&title=Antimicrobial+peptides+as+an+alternative+to+anti-tuberculosis+drugs&doi=10.1016%2Fj.phrs.2017.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit287R"><div class="casContent"><span class="casTitleNuber">287</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobial peptides as an alternative to anti-tuberculosis drugs</span></div><div class="casAuthors">AlMatar Manaf; Makky Essam A; Yakici Gulfer; Kayar Begum; Koksal Fatih; Var Isil</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">288-305</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis (TB) presently accounts for high global mortality and morbidity rates, despite the introduction four decades ago of the affordable and efficient four-drugs (isoniazid, rifampicin, pyrazinamide and ethambutol).  Thus, a strong need exists for new drugs with special structures and uncommon modes of action to effectively overcome M. tuberculosis.  Within this scope, antimicrobial peptides (AMPs), which are small, cationic and amphipathic peptides that comprise a section of the innate immune system, are currently the leading potential agents for the treatment of TB.  Many studies have recently illustrated the capability of anti-mycobacterial peptides to disrupt the normal mycobacterial cell wall function through various modes, thereby interacting with the intracellular targets, as well as encompassing nucleic acids, enzymes and organelles.  This review presents a wide array of antimicrobial activities, alongside the associated properties of the AMPs that could be utilized as potential agents in therapeutic tactics for TB treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWoTa_cySIy3T4ugvCDgnZfW6udTcc2eYLmbbao-7TXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7lsVaguw%253D%253D&md5=a94c7bdb1d892b884f37174a5e8939ec</span></div><a href="/servlet/linkout?suffix=cit287&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2017.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2017.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DAlMatar%26aufirst%3DM.%26aulast%3DMakky%26aufirst%3DE.%2BA.%26aulast%3DYak%25C4%25B1c%25C4%25B1%26aufirst%3DG.%26aulast%3DVar%26aufirst%3DI.%26aulast%3DKayar%26aufirst%3DB.%26aulast%3DK%25C3%25B6ksal%26aufirst%3DF.%26atitle%3DAntimicrobial%2520peptides%2520as%2520an%2520alternative%2520to%2520anti-tuberculosis%2520drugs%26jtitle%3DPharmacol.%2520Res.%26date%3D2018%26volume%3D128%26spage%3D288%26epage%3D305%26doi%3D10.1016%2Fj.phrs.2017.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref288"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref288'); return false;" data-citation="" class="refNumLink">288</a></strong><div class="NLM_citation" id="cit288"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silva, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gama, F. M.</span></span> <span> </span><span class="NLM_article-title">Antimicrobial peptides as novel anti-tuberculosis therapeutics</span>. <i>Biotechnol. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">924</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.1016/j.biotechadv.2016.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.biotechadv.2016.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27235189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVamsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=924-940&author=J.+P.+Silvaauthor=R.+Appelbergauthor=F.+M.+Gama&title=Antimicrobial+peptides+as+novel+anti-tuberculosis+therapeutics&doi=10.1016%2Fj.biotechadv.2016.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit288R"><div class="casContent"><span class="casTitleNuber">288</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobial peptides as novel anti-tuberculosis therapeutics</span></div><div class="casAuthors">Silva, Joao P.; Appelberg, Rui; Gama, Francisco Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology Advances</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">924-940</span>CODEN:
                <span class="NLM_cas:coden">BIADDD</span>;
        ISSN:<span class="NLM_cas:issn">0734-9750</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Tuberculosis (TB), a disease caused by the human pathogen Mycobacterium tuberculosis, has recently joined HIV/AIDS as the world's deadliest infectious disease, affecting around 9.6 million people worldwide in 2014.  Of those, about 1.2 million died from the disease.  Resistance acquisition to existing antibiotics, with the subsequent emergence of Multi-Drug Resistant mycobacteria strains, together with an increasing economic burden, has urged the development of new anti-TB drugs.  In this scope, antimicrobial peptides (AMPs), which are small, cationic and amphipathic peptides that make part of the innate immune system, now arise as promising candidates for TB treatment.  In this review, we analyze the potential of AMPs for this application.  We address the mechanisms of action, advantages and disadvantages over conventional antibiotics and how problems assocd. with its use may be overcome to boost their therapeutic potential.  Addnl., we address the challenges of translational development from bench side to bedside, evaluate the current development pipeline and analyze the expected global impact from a socio-economic standpoint.  The quest for more efficient and more compliant anti-TB drugs, assocd. with the great therapeutic potential of emerging AMPs and the rising peptide market, provide an optimal environment for the emergence of AMPs as promising therapies.  Still, their pharmacol. properties need to be enhanced and manufg.-assocd. issues need to be addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMP2arQ4Jua7Vg90H21EOLACvtfcHk0liv1nEvGp9p2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVamsrg%253D&md5=897105e906ca1c63ac4dbeae9a354b44</span></div><a href="/servlet/linkout?suffix=cit288&amp;dbid=16384&amp;doi=10.1016%2Fj.biotechadv.2016.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biotechadv.2016.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DSilva%26aufirst%3DJ.%2BP.%26aulast%3DAppelberg%26aufirst%3DR.%26aulast%3DGama%26aufirst%3DF.%2BM.%26atitle%3DAntimicrobial%2520peptides%2520as%2520novel%2520anti-tuberculosis%2520therapeutics%26jtitle%3DBiotechnol.%2520Adv.%26date%3D2016%26volume%3D34%26spage%3D924%26epage%3D940%26doi%3D10.1016%2Fj.biotechadv.2016.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref238':['cit238'],'ref239':['cit239'],'ref240':['cit240'],'ref241':['cit241'],'ref242':['cit242'],'ref243':['cit243'],'ref244':['cit244'],'ref245':['cit245'],'ref246':['cit246'],'ref247':['cit247'],'ref248':['cit248'],'ref249':['cit249'],'ref250':['cit250'],'ref251':['cit251'],'ref252':['cit252'],'ref253':['cit253'],'ref254':['cit254'],'ref255':['cit255'],'ref256':['cit256'],'ref257':['cit257'],'ref258':['cit258'],'ref259':['cit259'],'ref260':['cit260'],'ref261':['cit261'],'ref262':['cit262'],'ref263':['cit263'],'ref264':['cit264'],'ref265':['cit265'],'ref266':['cit266'],'ref267':['cit267'],'ref268':['cit268'],'ref269':['cit269'],'ref270':['cit270'],'ref271':['cit271'],'ref272':['cit272'],'ref273':['cit273'],'ref274':['cit274'],'ref275':['cit275'],'ref276':['cit276'],'ref277':['cit277'],'ref278':['cit278'],'ref279':['cit279'],'ref280':['cit280'],'ref281':['cit281'],'ref282':['cit282'],'ref283':['cit283'],'ref284':['cit284'],'ref285':['cit285'],'ref286':['cit286'],'ref287':['cit287'],'ref288':['cit288']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0032.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. World map with incidences of TB in 2019 as provided by the WHO, grouped by region. Each region is represented by a different color, with the areas of highest incident being South East Asian countries and those of lowest incident being American countries. The map was generated using <a href="http://Mapchart.net" class="extLink">Mapchart.net</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Immune system activation in response to <i>Mtb</i> infection. As soon as <i>Mtb</i> infects the lungs, innate and adaptive immune systems are activated. The disease progresses to either latent or active TB. Macrophages, neutrophils, γδ T-cells, and NK cell-mediators of innate immunity along with T-cells of adaptive immunity attempt to kill the pathogen by different mechanisms. CD4<sup>+</sup> T-cells regulate cytokine levels; CD8<sup>+</sup> T-cells, NK cells, and γδ T-cells secrete IFN-γ, a crucial step in activating macrophages to engulf the bacteria and resulting in phagolysosome formation and ultimately in killing the bacteria.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The figure was made using <a href="http://Biorender.com" class="extLink">Biorender.com</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Transmission of tuberculosis from infected to healthy individuals. Coughing, sneezing, and speaking/shouting generate aerosols, which remain suspended in the air and infect healthy individuals. The figure was made using <a href="http://Biorender.com" class="extLink">Biorender.com</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Routes of transmission of zoonotic TB in humans. Zoonotic TB arises from transmission of bovine TB from infected cattle and wildlife to people who come into close contact with such animals. The mode of transmission includes the consumption of unpasteurized dairy products and uncooked meat. It is known to spread via the fecal–oral route, through blood transfusion, and via transmission from mother to child during pregnancy. The figure was made using <a href="http://Biorender.com" class="extLink">Biorender.com</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Extrapulmonary tuberculosis in humans. <i>Mtb</i> affects the central nervous system, causing TB meningitis; infection of lymph nodes leading to lymphadenitis and peritonitis, abdominal TB; urogenital system, causing renal TB; skeletal TB manifests in bone and joint TB and Pott’s disease. The figure was made using <a href="http://Biorender.com" class="extLink">Biorender.com</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) First- and (b) second-line drugs used for TB treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Classifications of drug-resistant TB: Four main types of drug-resistant TB are known so far which occur by mutually exclusive mechanisms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Genes responsible for drug resistance to first and second-line anti-TB regimens<a onclick="showRef(event, 'ref85 ref109'); return false;" href="javascript:void(0);" class="ref ref85 ref109">(85,109)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Molecular interactions between protein–drug seen in the <i>Mtb</i> targets. (A) A complex consisting of <i>Mtb</i> ATP synthase F<sub>0</sub> rotor ring in association with the drug bedaquiline <b>13</b> (shown in yellow); a detailed view of the residues (shown in orange) involved in the interaction between the drug and the enzyme is shown in the box (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4V1F">4V1F</a>). (B) Structure of the <i>Mtb</i> polyketide synthase 13 and its inhibitor TAM 16 (5V8) (<b>14</b>) (shown in red) along with a sulfate molecule (shown in magenta) (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V3Y">5V3Y</a>). (C) Crystal structure of <i>Mtb</i> DNA gyrase and fluoroquinolone <b>9</b>: interaction with magnesium ions, water molecules, and gyrase subunits are shown in the box (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5BS8">5BS8</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structure of antitubercular drugs approved in the last 40 years and currently used for TB treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structure of antitubercular agents based on oxazolidinone pharmacophore under clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. General structure of the rigidified oxazolidinones, SAR exploration, and structure of the optimized lead compound <b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Rational design of new 4<i>H</i>-chromen-4-one derivatives (<b>23a</b>–<b>z</b>, <b>24</b>) and SAR outcomes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structure and substitution pattern of coumestan of new generation <b>25a</b>–<b>s</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structure of <i>N</i>-acetylazaaurone derivatives <b>27a</b>–<b>y</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structure of novel 1,3,4-oxadiazole derivatives <b>30a</b>–<b>x</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures of 7-hydroxy-5-methyl-<i>N</i>-substituted phenyl-pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide <b>31a</b>–<b>z</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Structure of ethyl 7-acetyl-2-substituted-3-(4-substituted benzoyl)indolizine-1-carboxylates (<b>32a</b>–<b>r</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Structures of 2-amino-thiophene-proline conjugates <b>33a</b>–<b>k</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Chemical structures of the scaffolds disclosed by GlaxoSmithKline for the development of novel potential antitubercular compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Chemical structure of dinaphthofuroquinone methyl 5-(2-diethylaminoethoxy)-7,12-dioxo-7,12-dihydrodinaphtho[1,2-<i>b</i>;2,3-<i>d</i>]furan-6-carboxylate (DNF-3, <b>34</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Chemical structure of benzylsulfanyl benzo-heterocycle amide (<b>35a</b>–<b>f</b>) and hydrazone (<b>36a</b>–<b>f</b>) derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Chemical structures of <i>N</i>′-substituted isonicotinohydrazides <b>37a</b>–<b>y</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Chemical structures of novel benzoxazole-based pyrazoline derivatives <b>38a</b>–<b>i</b>, <b>39</b>–<b>40</b>, <b>41a</b>–<b>k</b>, and <b>42</b>–<b>43</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Chemical structures of novel triazoles <b>44a</b>–<b>v</b> as potential antitubercular agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Chemical structure of IMB-T130 (<b>45</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Thiophene-based structure compounds <b>46a</b>–<b>e</b>, <b>47a</b>–<b>f</b>, and <b>48a</b>–<b>b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Chemical structure of <b>49</b>, a potent and selective <i>Mtb</i> inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/medium/jm0c01833_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Structure of clinically used fluoroquinolones [ciprofloxacin (<b>7</b>) and levofloxacin (<b>50</b>)] and ofloxacin (<b>51</b>); structure of lead compound pirfloxacin (<b>52</b>) and novel fluoroquinolone analogues <b>53a</b>–<b>u</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c01833/20210415/images/large/jm0c01833_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01833&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i62">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54516" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54516" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 288 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span> <i>Global
Tuberculosis Report 2020</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2020</span>; <a href="https://www.who.int/publications/i/item/9789240013131" class="extLink">https://www.who.int/publications/i/item/9789240013131</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global%0ATuberculosis+Report+2020%3B+World+Health+Organization%3A+Geneva%2C+2020%3B+https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2F9789240013131+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlobal%250ATuberculosis%2520Report%25202020%26pub%3DWorld%2520Health%2520Organization%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, E. A.</span>; <span class="NLM_string-name">Raffa, B. J.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium Tuberculosis</span>. In  <i>Molecular Medical Microbiology</i>, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.-W.</span>, <span class="NLM_string-name">Sussman, M.</span>, <span class="NLM_string-name">Liu, D.</span>, <span class="NLM_string-name">Poxton, I.</span>, <span class="NLM_string-name">Schwartzman, J.</span></span>, Eds.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Boston</span>, <span class="NLM_year">2015</span>; Vol.  <span class="NLM_volume">3</span>, pp  <span class="NLM_fpage">1637</span>– <span class="NLM_lpage">1653</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=1637-1653&author=E.+A.+Talbot&author=B.+J.+Raffaauthor=Y.-W.+Tang&author=M.+Sussman&author=D.+Liu&author=I.+Poxton&author=J.+Schwartzman&title=Molecular+Medical+Microbiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DTalbot%26aufirst%3DE.%2BA.%26atitle%3DMycobacterium%2520Tuberculosis%26btitle%3DMolecular%2520Medical%2520Microbiology%26aulast%3DTang%26aufirst%3DY.-W.%26pub%3DAcademic%2520Press%26date%3D2015%26volume%3D3%26spage%3D1637%26epage%3D1653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span> <span> </span><span class="NLM_article-title">Miliary tuberculosis: A new look at an old foe</span>. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1016/j.jctube.2016.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.jctube.2016.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31723681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BB3MjovVentw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=13-27&author=S.+K.+Sharmaauthor=A.+Mohanauthor=A.+Sharma&title=Miliary+tuberculosis%3A+A+new+look+at+an+old+foe&doi=10.1016%2Fj.jctube.2016.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Miliary tuberculosis: A new look at an old foe</span></div><div class="casAuthors">Sharma Surendra K; Mohan Alladi; Sharma Animesh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical tuberculosis and other mycobacterial diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Miliary tuberculosis (TB), is a fatal form of disseminated TB characterized by tiny tubercles evident on gross pathology similar to innumerable millet seeds in size and appearance.  Global HIV/AIDS pandemic and increasing use of immunosuppressive drugs have altered the epidemiology of miliary TB.  Keeping in mind its protean manifestations, clinicians should have a low threshold for suspecting miliary TB.  Careful physical examination should focus on identifying organ system involvement early, particularly TB meningitis, as this has therapeutic significance.  Fundus examination for detecting choroid tubercles can help in early diagnosis as their presence is pathognomonic of miliary TB.  Imaging modalities help in recognizing the miliary pattern, define the extent of organ system involvement and facilitate image guided fine-needle aspiration cytology or biopsy from various organ sites.  Sputum or BAL fluid examination, pleural, pericardial, peritoneal fluid and cerebrospinal fluid studies, fine needle aspiration cytology or biopsy of the lymph nodes, needle biopsy of the liver, bone marrow aspiration and biopsy, testing of body fluids must be carried out.  GeneXpert MTB/RIF, line probe assay, mycobacterial culture and drug-susceptibility testing must be carried out as appropriate and feasible.  Treatment of miliary TB should be started at the earliest as this can be life saving.  Response to first-line anti-TB drugs is good.  Screening and monitoring for complications like acute respiratory distress syndrome (ARDS), adverse drug reactions like drug-induced liver injury, drug-drug interactions, especially in patients co-infected with HIV/AIDS, are warranted.  Sparse data are available from randomized controlled trials regarding optimum regimen and duration of anti-TB treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTP1DB8jXwFg4vKgEt20y1XfW6udTcc2eb5ZtN6JGosF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjovVentw%253D%253D&md5=f6394a0cabdd00070d8318a5484b47f0</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.jctube.2016.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jctube.2016.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BK.%26aulast%3DMohan%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DA.%26atitle%3DMiliary%2520tuberculosis%253A%2520A%2520new%2520look%2520at%2520an%2520old%2520foe%26jtitle%3DJournal%2520of%2520Clinical%2520Tuberculosis%2520and%2520Other%2520Mycobacterial%2520Diseases%26date%3D2016%26volume%3D3%26spage%3D13%26epage%3D27%26doi%3D10.1016%2Fj.jctube.2016.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rafiei, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulley, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trauer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkin, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, B. A.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis: Active disease and latent infection in a renal transplant cohort</span>. <i>Nephrology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1111/nep.13386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1111%2Fnep.13386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29660203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1MjjtFymsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=569-574&author=N.+Rafieiauthor=J.+Williamsauthor=W.+R.+Mulleyauthor=J.+M.+Trauerauthor=G.+A.+Jenkinauthor=B.+A.+Rogers&title=Mycobacterium+tuberculosis%3A+Active+disease+and+latent+infection+in+a+renal+transplant+cohort&doi=10.1111%2Fnep.13386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Mycobacterium tuberculosis: Active disease and latent infection in a renal transplant cohort</span></div><div class="casAuthors">Rafiei Nastaran; Williams Jackie; Jenkin Grant A; Rogers Benjamin A; Mulley William R; Mulley William R; Rogers Benjamin A; Trauer James M</div><div class="citationInfo"><span class="NLM_cas:title">Nephrology (Carlton, Vic.)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">569-574</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIM:  Our aim was threefold: first, to determine the incidence of active TB in our cohort, second to investigate the risk factors for active TB and third, to understand current screening practices.  The ultimate goal was to use our findings to inform development of local and national guidelines.  METHODS:  The records of all adult patients who underwent renal transplantation at our centre from 2005 to 2014 were retrospectively reviewed to assess current screening practices, the risks for and burden of active TB.  RESULTS:  A total of 660 individuals underwent renal transplantation during this period, totalling 3647 person years of follow up.  Two patients were diagnosed with active TB after renal transplant, resulting in an incidence of 55 per 100 000 person-years.  Of 656 transplant recipients, 102 (15.5%) were born in high TB incidence countries and 89 (13.5%) had an interferon gamma release assay (IGRA) at any point.  Individuals born in high TB risk countries had a much higher incidence of active TB (353 per 100 000 person-years).  Ten individuals had positive IGRA tests, of whom two were treated for active TB, two received chemoprophylaxis and six were not treated.  CONCLUSIONS:  In the absence of formal guidelines, IGRA-based screening for LTBI was infrequently performed.  Our data suggest that screening and treatment of renal transplant recipients born in high incidence countries is an important preventive measure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQK4RU5kHzSqS-bLEOO4dYpfW6udTcc2eb5ZtN6JGosF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjjtFymsg%253D%253D&md5=e164f9ab1bc3e237cf465e5ca4a7e02b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fnep.13386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnep.13386%26sid%3Dliteratum%253Aachs%26aulast%3DRafiei%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DMulley%26aufirst%3DW.%2BR.%26aulast%3DTrauer%26aufirst%3DJ.%2BM.%26aulast%3DJenkin%26aufirst%3DG.%2BA.%26aulast%3DRogers%26aufirst%3DB.%2BA.%26atitle%3DMycobacterium%2520tuberculosis%253A%2520Active%2520disease%2520and%2520latent%2520infection%2520in%2520a%2520renal%2520transplant%2520cohort%26jtitle%3DNephrology%26date%3D2019%26volume%3D24%26spage%3D569%26epage%3D574%26doi%3D10.1111%2Fnep.13386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torrelles, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlesinger, L. S.</span></span> <span> </span><span class="NLM_article-title">Integrating lung physiology, immunology, and tuberculosis</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">688</span>– <span class="NLM_lpage">697</span>, <span class="refDoi"> DOI: 10.1016/j.tim.2017.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.tim.2017.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28366292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVSqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=688-697&author=J.+B.+Torrellesauthor=L.+S.+Schlesinger&title=Integrating+lung+physiology%2C+immunology%2C+and+tuberculosis&doi=10.1016%2Fj.tim.2017.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Integrating Lung Physiology, Immunology, and Tuberculosis</span></div><div class="casAuthors">Torrelles, Jordi B.; Schlesinger, Larry S.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">688-697</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lungs are directly exposed to the air, have enormous surface area, and enable gas exchange in air-breathing animals.  They are constantly 'attacked' by microbes from both outside and inside and thus possess a unique, highly regulated local immune defense system which efficiently allows for microbial clearance while minimizing damaging inflammatory responses.  As a prototypic host-adapted airborne pathogen, Mycobacterium tuberculosis traverses the lung and has several 'interaction points' (IPs) which it must overcome to cause infection.  These interactions are crit., not only from a pathogenesis perspective but also in considering the effectiveness of therapies and vaccines in the lungs.  Here we discuss emerging views on immunol. interactions occurring in the lungs for M. tuberculosis and their impact on infection and persistence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpluIeURoTrE7Vg90H21EOLACvtfcHk0lh6FRaAlaZwqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVSqtLg%253D&md5=ef5351aa0dffcbad56c8886991b0b1b4</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2017.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2017.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DTorrelles%26aufirst%3DJ.%2BB.%26aulast%3DSchlesinger%26aufirst%3DL.%2BS.%26atitle%3DIntegrating%2520lung%2520physiology%252C%2520immunology%252C%2520and%2520tuberculosis%26jtitle%3DTrends%2520Microbiol.%26date%3D2017%26volume%3D25%26spage%3D688%26epage%3D697%26doi%3D10.1016%2Fj.tim.2017.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raven, M. L.</span></span> <span> </span><span class="NLM_article-title">Ocular tuberculosis</span>. <i>Microbiol. Spectrum</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">TNMI7-0001-2016</span>, <span class="refDoi"> DOI: 10.1128/microbiolspec.TNMI7-0001-2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2Fmicrobiolspec.TNMI7-0001-2016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=TNMI7-0001-2016&author=D.+M.+Albertauthor=M.+L.+Raven&title=Ocular+tuberculosis&doi=10.1128%2Fmicrobiolspec.TNMI7-0001-2016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1128%2Fmicrobiolspec.TNMI7-0001-2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmicrobiolspec.TNMI7-0001-2016%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DD.%2BM.%26aulast%3DRaven%26aufirst%3DM.%2BL.%26atitle%3DOcular%2520tuberculosis%26jtitle%3DMicrobiol.%2520Spectrum%26date%3D2016%26volume%3D4%26spage%3DTNMI7-0001-2016%26doi%3D10.1128%2Fmicrobiolspec.TNMI7-0001-2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharmendra, S.</span></span> <span> </span><span class="NLM_article-title">Female genital tuberculosis: Revisited</span>. <i>Indian J. Med. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">S71</span>– <span class="NLM_lpage">S83</span>, <span class="refDoi"> DOI: 10.4103/ijmr.IJMR_648_18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4103%2Fijmr.IJMR_648_18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30964083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslGms7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=S71-S83&author=J.+B.+Sharmaauthor=E.+Sharmaauthor=S.+Sharmaauthor=S.+Dharmendra&title=Female+genital+tuberculosis%3A+Revisited&doi=10.4103%2Fijmr.IJMR_648_18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Female genital tuberculosis: revisited</span></div><div class="casAuthors">Sharma, Jai Bhagwan; Sharma, Eshani; Sharma, Sangeeta; Dharmendra, Sona</div><div class="citationInfo"><span class="NLM_cas:title">Indian Journal of Medical Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">7Suppl.1</span>),
    <span class="NLM_cas:pages">71-83</span>CODEN:
                <span class="NLM_cas:coden">IMIREV</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications</span>)
        </div><div class="casAbstract">A review.  Female genital tuberculosis (FGTB) is caused by Mycobacterium tuberculosis (rarely Mycobacterium bovis and/or atypical mycobacteria) being usually secondary to TB of the lungs or other organs with infection reaching through haematogenous, lymphatic route or direct spread from abdominal TB.  In FGTB, fallopian tubes are affected in 90 per cent women, whereas uterine endometrium is affected in 70 per cent and ovaries in about 25 per cent women.  It causes menstrual dysfunction and infertility through the damage of genital organs.  Some cases may be asymptomatic.  Diagnosis is often made from proper history taking, meticulous clin. examn. and judicious use of investigations, esp. endometrial aspirate (or biopsy) and endoscopy.  Treatment is through multi-drug antitubercular treatment for adequate time period (rifampicin, isoniazid, pyrazinamide, ethambutol daily for 60 days followed by rifampicin, isoniazid, ethambutol daily for 120 days).  Treatment is given for 18-24 mo using the second-line drugs for drug-resistant (DR) cases.  With the advent of increased access to rapid diagnostics and newer drugs, the management protocol is moving towards achieving universal drug sensitivity testing and treatment with injection-free regimens contg. newer drugs, esp. for new and previously treated DR cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5weO-lT0TmrVg90H21EOLACvtfcHk0ljVVdXz2TFREw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslGms7bK&md5=11e86fdd55640e7f71e85deda1e0225d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.4103%2Fijmr.IJMR_648_18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252Fijmr.IJMR_648_18%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DJ.%2BB.%26aulast%3DSharma%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DDharmendra%26aufirst%3DS.%26atitle%3DFemale%2520genital%2520tuberculosis%253A%2520Revisited%26jtitle%3DIndian%2520J.%2520Med.%2520Res.%26date%3D2018%26volume%3D148%26spage%3DS71%26epage%3DS83%26doi%3D10.4103%2Fijmr.IJMR_648_18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span> <i>Tuberculosis (TB) Disease: Symptoms and Risk Factors</i>; <span class="NLM_publisher-name">CDC</span>: <span class="NLM_publisher-loc">Atlanta, GA</span>;<a href="https://www.cdc.gov/tb/topic/basics/default.htm" class="extLink">https://www.cdc.gov/tb/topic/basics/default.htm</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Tuberculosis+%28TB%29+Disease%3A+Symptoms+and+Risk+Factors%3B+CDC%3A+Atlanta%2C+GA%3Bhttps%3A%2F%2Fwww.cdc.gov%2Ftb%2Ftopic%2Fbasics%2Fdefault.htm+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DTuberculosis%2520%2528TB%2529%2520Disease%253A%2520Symptoms%2520and%2520Risk%2520Factors%26pub%3DCDC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, D.</span></span> <span> </span><span class="NLM_article-title">Treatment of drug-resistant tuberculosis</span>. <i>Infect. Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.2147/IDR.S10332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.2147%2FIDR.S10332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21904458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3MfitlGjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=129-135&author=L.+Pintoauthor=D.+Menzies&title=Treatment+of+drug-resistant+tuberculosis&doi=10.2147%2FIDR.S10332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of drug-resistant tuberculosis</span></div><div class="casAuthors">Pinto Lancelot; Menzies Dick</div><div class="citationInfo"><span class="NLM_cas:title">Infection and drug resistance</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CLINICAL QUESTION:  What is the best approach to the treatment of drug-resistant tuberculosis (TB)?  RESULTS:  Evidence-based treatment of drug-susceptible TB is the best means of preventing the development of drug-resistant disease.  Suspecting the possibility of drug-resistant TB, and prompt detection of all forms of drug-resistant TB, not only multidrug-resistant and extensively drug-resistant TB, should be part of the algorithm for diagnosis and management of all patients with active TB.  IMPLEMENTATION:  Treatment of all forms of drug-resistant TB must be tailored to the specific form of resistance with appropriate and effective drug regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_00VQQycDMA8IxFYvehhofW6udTcc2eYCe_OKU0_A-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfitlGjug%253D%253D&md5=73c50b904da8eff6211a2161eae860a7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2147%2FIDR.S10332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIDR.S10332%26sid%3Dliteratum%253Aachs%26aulast%3DPinto%26aufirst%3DL.%26aulast%3DMenzies%26aufirst%3DD.%26atitle%3DTreatment%2520of%2520drug-resistant%2520tuberculosis%26jtitle%3DInfect.%2520Drug%2520Resist.%26date%3D2011%26volume%3D4%26spage%3D129%26epage%3D135%26doi%3D10.2147%2FIDR.S10332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliori, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotgiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muetterlein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirsten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruesch-Gerdes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group">German TBNET Group</span> <span> </span><span class="NLM_article-title">Multidrug- and extensively drug-resistant tuberculosis, Germany</span>. <i>Emerging Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1700</span>– <span class="NLM_lpage">1706</span>, <span class="refDoi"> DOI: 10.3201/eid1411.080729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3201%2Feid1411.080729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=18976552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD1cjhtlGitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1700-1706&author=B.+Ekerauthor=J.+Ortmannauthor=G.+B.+Miglioriauthor=G.+Sotgiuauthor=R.+Muetterleinauthor=R.+Centisauthor=H.+Hoffmannauthor=D.+Kirstenauthor=T.+Schabergauthor=S.+Ruesch-Gerdesauthor=C.+Langeauthor=German+TBNET+Group&title=Multidrug-+and+extensively+drug-resistant+tuberculosis%2C+Germany&doi=10.3201%2Feid1411.080729"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug- and extensively drug-resistant tuberculosis, Germany</span></div><div class="casAuthors">Eker Barbara; Ortmann Johannes; Migliori Giovanni B; Sotgiu Giovanni; Muetterlein Ralf; Centis Rosella; Hoffmann Harald; Kirsten Detlef; Schaberg Tom; Ruesch-Gerdes Sabine; Lange Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Emerging infectious diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1700-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We evaluated risk factors and treatment outcomes associated with multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) in Germany in 2004-2006.  In 177 (4%) of 4,557 culture-positive TB cases, Mycobacterium tuberculosis isolates were identified as MDR TB; an additional 7 (0.15%) met criteria for XDR TB.  Of these 184 patients, 148 (80%) were born in countries of the former Soviet Union.  In patients with XDR TB, hospitalization was longer (mean +/- SD 202 +/- 130 vs. 123 +/- 81 days; p = 0.015) and resistance to all first-line drugs was more frequent (36% vs. 86%; p = 0.013) than in patients with MDR TB.  Seventy-four (40%) of these 184 patients received treatment with linezolid.  Treatment success rates ranged from 59% for the entire cohort (59% for MDR TB and 57% for XDR TB) to 87% for those with a definitive outcome (n = 125; 89% for MDR TB and 80% for XDR TB).  Extensive drug susceptibility testing and availability of second- and third-line drugs under inpatient management conditions permit relatively high treatment success rates in MDR- and XDR TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLoYYbyenxnWBAiYWy6n3SfW6udTcc2eYs10lhe-Boubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjhtlGitA%253D%253D&md5=4b7a295b71561ea764630adeba04ef0a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3201%2Feid1411.080729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3201%252Feid1411.080729%26sid%3Dliteratum%253Aachs%26aulast%3DEker%26aufirst%3DB.%26aulast%3DOrtmann%26aufirst%3DJ.%26aulast%3DMigliori%26aufirst%3DG.%2BB.%26aulast%3DSotgiu%26aufirst%3DG.%26aulast%3DMuetterlein%26aufirst%3DR.%26aulast%3DCentis%26aufirst%3DR.%26aulast%3DHoffmann%26aufirst%3DH.%26aulast%3DKirsten%26aufirst%3DD.%26aulast%3DSchaberg%26aufirst%3DT.%26aulast%3DRuesch-Gerdes%26aufirst%3DS.%26aulast%3DLange%26aufirst%3DC.%26aulast%3D%26atitle%3DMultidrug-%2520and%2520extensively%2520drug-resistant%2520tuberculosis%252C%2520Germany%26jtitle%3DEmerging%2520Infect.%2520Dis.%26date%3D2008%26volume%3D14%26spage%3D1700%26epage%3D1706%26doi%3D10.3201%2Feid1411.080729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, R.</span></span> <span> </span><span class="NLM_article-title">Pre-XDR & XDR in MDR and ofloxacin and kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates</span>. <i>Tuberculosis (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2012.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.tube.2012.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22789499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GmsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=404-406&author=A.+Jainauthor=P.+Dixitauthor=R.+Prasad&title=Pre-XDR+%26+XDR+in+MDR+and+ofloxacin+and+kanamycin+resistance+in+non-MDR+Mycobacterium+tuberculosis+isolates&doi=10.1016%2Fj.tube.2012.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Pre-XDR & XDR in MDR and Ofloxacin and Kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates</span></div><div class="casAuthors">Jain, Amita; Dixit, Pratima; Prasad, Rajendra</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">404-406</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Resistance to second line anti tubercular drugs is a cause of serious concern.  The present study reports the prevalence of Ofloxacin (OFX) and Kanamycin (KM) resistance in Mycobacterium tuberculosis isolates from cases of pulmonary tuberculosis, who received anti tubercular treatment for >4 wk in past.  Of total 438 enrolled patients, 361 were culture pos. for M. tuberculosis, of which, 95 (26.3%) were OFX resistant & 49 (13.5%) were KM resistant.  Total 130 isolates were Multidrug resistant, of which, 55 (42.3%) were resistant to either OFX or KM (Pre-XDR) & 11 (8.5%) were resistant to both KM & OFX (XDR).  Resistance to quinolones & aminoglycosides should be routinely assessed in areas endemic for tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriluXA41LmmrVg90H21EOLACvtfcHk0lge3m07c75SGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GmsL3I&md5=c4911d6676949c87fe627b078df84bed</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2012.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2012.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DA.%26aulast%3DDixit%26aufirst%3DP.%26aulast%3DPrasad%26aufirst%3DR.%26atitle%3DPre-XDR%2520%2526%2520XDR%2520in%2520MDR%2520and%2520ofloxacin%2520and%2520kanamycin%2520resistance%2520in%2520non-MDR%2520Mycobacterium%2520tuberculosis%2520isolates%26jtitle%3DTuberculosis%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2012%26volume%3D92%26spage%3D404%26epage%3D406%26doi%3D10.1016%2Fj.tube.2012.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velayati, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masjedi, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farnia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabarsi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghanavi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ZiaZarifi, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffner, S. E.</span></span> <span> </span><span class="NLM_article-title">Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1378/chest.08-2427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1378%2Fchest.08-2427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19349380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD1Mrkt1entQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=420-425&author=A.+A.+Velayatiauthor=M.+R.+Masjediauthor=P.+Farniaauthor=P.+Tabarsiauthor=J.+Ghanaviauthor=A.+H.+ZiaZarifiauthor=S.+E.+Hoffner&title=Emergence+of+new+forms+of+totally+drug-resistant+tuberculosis+bacilli%3A+super+extensively+drug-resistant+tuberculosis+or+totally+drug-resistant+strains+in+Iran&doi=10.1378%2Fchest.08-2427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran</span></div><div class="casAuthors">Velayati Ali Akbar; Masjedi Mohammad Reza; Tabarsi Payam; ZiaZarifi Abol Hassan; Farnia Parissa; Ghanavi Jalladein; Hoffner Sven Eric</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-425</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The study documented the emergence of new forms of resistant bacilli (totally drug-resistant [TDR] or super extensively drug-resistant [XDR] tuberculosis [TB] strains) among patients with multidrug-resistant TB (MDR-TB).  METHODS:  Susceptibility testing against first- and second-line drugs was performed on isolated Mycobacterium tuberculosis strains.  Subsequently, the strains identified as XDR or TDR M tuberculosis were subjected to spoligotyping and variable numbers of tandem repeats (VNTR).  RESULTS:  Of 146 MDR-TB strains, 8 XDR isolates (5.4%) and 15 TDR isolates (10.3%) were identified.  The remaining strains were either susceptible (67%) or had other resistant patterns (20%).  Overall, the median of treatments and drugs previously received by MDR-TB patients was two courses of therapy of 15 months' duration with five drugs (isoniazid [INH], rifampicin [RF], streptomycin, ethambutol, and pyrazinamide).  The median of in vitro drug resistance for all studied cases was INH and RF.  The XDR or TDR strains were collected from both immigrants (Afghan, 30.4%; Azerbaijani, 8.6%; Iraqi, 4.3%) and Iranian (56.5%) MDR-TB cases.  In such cases, the smear and cultures remained positive after 18 months of medium treatment with second-line drugs (ethionamide, para-aminosalicylic acid, cycloserine, ofloxacin, amikacin, and ciprofloxacin).  Spoligotyping revealed Haarlem (39.1%), Beijing (21.7%), EAI (21.7%), and CAS (17.3%) superfamilies of M tuberculosis.  These superfamilies had different VNTR profiles, which eliminated the recent transmission among MDR-TB cases.  CONCLUSIONS:  The isolation of TDR strains from MDR-TB patients from different regional countries is alarming and underlines the possible dissemination of such strains in Asian countries.  Now the next question is how one should control and treat such cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTN1nU8IQjBBGLFM_lbR1VmfW6udTcc2eaqvTDXRJcxhbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mrkt1entQ%253D%253D&md5=b7f110877e3a4ffb4a9f5831803ca52c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1378%2Fchest.08-2427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.08-2427%26sid%3Dliteratum%253Aachs%26aulast%3DVelayati%26aufirst%3DA.%2BA.%26aulast%3DMasjedi%26aufirst%3DM.%2BR.%26aulast%3DFarnia%26aufirst%3DP.%26aulast%3DTabarsi%26aufirst%3DP.%26aulast%3DGhanavi%26aufirst%3DJ.%26aulast%3DZiaZarifi%26aufirst%3DA.%2BH.%26aulast%3DHoffner%26aufirst%3DS.%2BE.%26atitle%3DEmergence%2520of%2520new%2520forms%2520of%2520totally%2520drug-resistant%2520tuberculosis%2520bacilli%253A%2520super%2520extensively%2520drug-resistant%2520tuberculosis%2520or%2520totally%2520drug-resistant%2520strains%2520in%2520Iran%26jtitle%3DChest%26date%3D2009%26volume%3D136%26spage%3D420%26epage%3D425%26doi%3D10.1378%2Fchest.08-2427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Udwadia, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amale, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajbani, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, C.</span></span> <span> </span><span class="NLM_article-title">Totally drug-resistant tuberculosis in India</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">579</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1093/cid/cir889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fcid%2Fcir889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22190562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC387ptF2hsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2012&pages=579-581&author=Z.+F.+Udwadiaauthor=R.+A.+Amaleauthor=K.+K.+Ajbaniauthor=C.+Rodrigues&title=Totally+drug-resistant+tuberculosis+in+India&doi=10.1093%2Fcid%2Fcir889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Totally drug-resistant tuberculosis in India</span></div><div class="casAuthors">Udwadia Zarir F; Amale Rohit A; Ajbani Kanchan K; Rodrigues Camilla</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">579-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2_G3WsdaydUbxh97K6Vt6fW6udTcc2eaqvTDXRJcxhbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387ptF2hsQ%253D%253D&md5=237f5c180e0daee51adf5df45a93d428</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcir889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcir889%26sid%3Dliteratum%253Aachs%26aulast%3DUdwadia%26aufirst%3DZ.%2BF.%26aulast%3DAmale%26aufirst%3DR.%2BA.%26aulast%3DAjbani%26aufirst%3DK.%2BK.%26aulast%3DRodrigues%26aufirst%3DC.%26atitle%3DTotally%2520drug-resistant%2520tuberculosis%2520in%2520India%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2012%26volume%3D54%26spage%3D579%26epage%3D581%26doi%3D10.1093%2Fcid%2Fcir889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uplekar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonnroth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falzon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargioni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getahun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilpin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaziou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzemska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzayev, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raviglione, M.</span></span> <span> </span><span class="NLM_article-title">WHO’s new End TB Strategy</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">1799</span>– <span class="NLM_lpage">1801</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)60570-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS0140-6736%2815%2960570-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25814376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2MnosFertw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=1799-1801&author=M.+Uplekarauthor=D.+Weilauthor=K.+Lonnrothauthor=E.+Jaramilloauthor=C.+Lienhardtauthor=H.+M.+Diasauthor=D.+Falzonauthor=K.+Floydauthor=G.+Gargioniauthor=H.+Getahunauthor=C.+Gilpinauthor=P.+Glaziouauthor=M.+Grzemskaauthor=F.+Mirzayevauthor=H.+Nakataniauthor=M.+Raviglione&title=WHO%E2%80%99s+new+End+TB+Strategy&doi=10.1016%2FS0140-6736%2815%2960570-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">WHO's new end TB strategy</span></div><div class="casAuthors">Uplekar Mukund; Weil Diana; Lonnroth Knut; Jaramillo Ernesto; Lienhardt Christian; Dias Hannah Monica; Falzon Dennis; Floyd Katherine; Gargioni Giuliano; Getahun Haileyesus; Gilpin Christopher; Glaziou Philippe; Grzemska Malgorzata; Mirzayev Fuad; Nakatani Hiroki; Raviglione Mario</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">9979</span>),
    <span class="NLM_cas:pages">1799-1801</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTakrzeTv28qPcsfMJQC1ZdfW6udTcc2eaqvTDXRJcxhbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnosFertw%253D%253D&md5=604506d9629c94f0aadebdc380dc10ce</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2960570-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252960570-0%26sid%3Dliteratum%253Aachs%26aulast%3DUplekar%26aufirst%3DM.%26aulast%3DWeil%26aufirst%3DD.%26aulast%3DLonnroth%26aufirst%3DK.%26aulast%3DJaramillo%26aufirst%3DE.%26aulast%3DLienhardt%26aufirst%3DC.%26aulast%3DDias%26aufirst%3DH.%2BM.%26aulast%3DFalzon%26aufirst%3DD.%26aulast%3DFloyd%26aufirst%3DK.%26aulast%3DGargioni%26aufirst%3DG.%26aulast%3DGetahun%26aufirst%3DH.%26aulast%3DGilpin%26aufirst%3DC.%26aulast%3DGlaziou%26aufirst%3DP.%26aulast%3DGrzemska%26aufirst%3DM.%26aulast%3DMirzayev%26aufirst%3DF.%26aulast%3DNakatani%26aufirst%3DH.%26aulast%3DRaviglione%26aufirst%3DM.%26atitle%3DWHO%25E2%2580%2599s%2520new%2520End%2520TB%2520Strategy%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D1799%26epage%3D1801%26doi%3D10.1016%2FS0140-6736%2815%2960570-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span>W <i>HO Consolidated Guidelines on Tuberculosis, Module
4: Treatment-
Drug-Resistant Tuberculosis Treatment</i>; <span class="NLM_publisher-name">World
Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2020</span>; <a href="https://www.who.int/publications/i/item/9789240007048" class="extLink">https://www.who.int/publications/i/item/9789240007048</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=W+HO+Consolidated+Guidelines+on+Tuberculosis%2C+Module%0A4%3A+Treatment-%0ADrug-Resistant+Tuberculosis+Treatment%3B+World%0AHealth+Organization%3A+Geneva%2C+2020%3B+https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2F9789240007048+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DHO%2520Consolidated%2520Guidelines%2520on%2520Tuberculosis%252C%2520Module%250A4%253A%2520Treatment-%250ADrug-Resistant%2520Tuberculosis%2520Treatment%26pub%3DWorld%250AHealth%2520Organization%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gengenbacher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, S. H.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis: success through dormancy</span>. <i>FEMS Microbiology Reviews</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1111/j.1574-6976.2012.00331.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1111%2Fj.1574-6976.2012.00331.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22320122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmtlygs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=514-532&author=M.+Gengenbacherauthor=S.+H.+Kaufmann&title=Mycobacterium+tuberculosis%3A+success+through+dormancy&doi=10.1111%2Fj.1574-6976.2012.00331.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mycobacterium tuberculosis: success through dormancy</span></div><div class="casAuthors">Gengenbacher, Martin; Kaufmann, Stefan H. E.</div><div class="citationInfo"><span class="NLM_cas:title">FEMS Microbiology Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">514-532</span>CODEN:
                <span class="NLM_cas:coden">FMREE4</span>;
        ISSN:<span class="NLM_cas:issn">0168-6445</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB) remains a major health threat, killing nearly 2 million individuals around this globe, annually.  The only vaccine, developed almost a century ago, provides limited protection only during childhood.  After decades without the introduction of new antibiotics, several candidates are currently undergoing clin. investigation.  Curing TB requires prolonged combination of chemotherapy with several drugs.  Moreover, monitoring the success of therapy is questionable owing to the lack of reliable biomarkers.  To substantially improve the situation, a detailed understanding of the cross-talk between human host and the pathogen Mycobacterium tuberculosis (Mtb) is vital.  Principally, the enormous success of Mtb is based on three capacities: first, reprogramming of macrophages after primary infection/phagocytosis to prevent its own destruction; second, initiating the formation of well-organized granulomas, comprising different immune cells to create a confined environment for the host-pathogen standoff; third, the capability to shut down its own central metab., terminate replication, and thereby transit into a stage of dormancy rendering itself extremely resistant to host defense and drug treatment.  Here, we review the mol. mechanisms underlying these processes, draw conclusions in a working model of mycobacterial dormancy, and highlight gaps in our understanding to be addressed in future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2gfZpCQZ6L7Vg90H21EOLACvtfcHk0li5mgug5qDSeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmtlygs7c%253D&md5=b2bd225607ef8873b4120344c90654ff</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1574-6976.2012.00331.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1574-6976.2012.00331.x%26sid%3Dliteratum%253Aachs%26aulast%3DGengenbacher%26aufirst%3DM.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DMycobacterium%2520tuberculosis%253A%2520success%2520through%2520dormancy%26jtitle%3DFEMS%2520Microbiology%2520Reviews%26date%3D2012%26volume%3D36%26spage%3D514%26epage%3D532%26doi%3D10.1111%2Fj.1574-6976.2012.00331.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harisinghani, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLoud, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shroff, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, P. R.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis from head to toe</span>. <i>Radiographics</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1148/radiographics.20.2.g00mc12449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1148%2Fradiographics.20.2.g00mc12449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10715343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD3c7otF2qsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=449-470&author=M.+G.+Harisinghaniauthor=T.+C.+McLoudauthor=J.+A.+Shepardauthor=J.+P.+Koauthor=M.+M.+Shroffauthor=P.+R.+Mueller&title=Tuberculosis+from+head+to+toe&doi=10.1148%2Fradiographics.20.2.g00mc12449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberculosis from head to toe</span></div><div class="casAuthors">Harisinghani M G; McLoud T C; Shepard J A; Ko J P; Shroff M M; Mueller P R</div><div class="citationInfo"><span class="NLM_cas:title">Radiographics : a review publication of the Radiological Society of North America, Inc</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">449-70; quiz 528-9, 532</span>
        ISSN:<span class="NLM_cas:issn">0271-5333</span>.
    </div><div class="casAbstract">Tuberculosis can affect virtually any organ system in the body and can be devastating if left untreated.  The increasing prevalence of tuberculosis in both immunocompetent and immunocompromised individuals in recent years makes this disease a topic of universal concern.  Because tuberculosis demonstrates a variety of clinical and radiologic findings and has a known propensity for dissemination from its primary site, it can mimic numerous other disease entities.  Primary pulmonary tuberculosis typically manifests radiologically as parenchymal disease, lymphadenopathy, pleural effusion, miliary disease, or lobar or segmental atelectasis.  In postprimary tuberculosis, the earliest radiologic finding is the development of patchy, ill-defined segmental consolidation.  Both computed tomography (CT) and magnetic resonance (MR) imaging are helpful in diagnosing tuberculous spondylitis and tuberculous arthritis.  CT is especially useful in depicting gastrointestinal and genitourinary tuberculosis.  In tuberculosis involving the central nervous system, CT and MR imaging findings vary depending on the stage of disease and the character of the lesion.  A high degree of clinical suspicion and familiarity with the various radiologic manifestations of tuberculosis allow early diagnosis and timely initiation of appropriate therapy, thereby reducing patient morbidity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0Enk79OtqnVMGsG_HTXYFfW6udTcc2eZsKSAuUcoWSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7otF2qsg%253D%253D&md5=3cb545c401ba549124fca37ae7461920</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1148%2Fradiographics.20.2.g00mc12449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1148%252Fradiographics.20.2.g00mc12449%26sid%3Dliteratum%253Aachs%26aulast%3DHarisinghani%26aufirst%3DM.%2BG.%26aulast%3DMcLoud%26aufirst%3DT.%2BC.%26aulast%3DShepard%26aufirst%3DJ.%2BA.%26aulast%3DKo%26aufirst%3DJ.%2BP.%26aulast%3DShroff%26aufirst%3DM.%2BM.%26aulast%3DMueller%26aufirst%3DP.%2BR.%26atitle%3DTuberculosis%2520from%2520head%2520to%2520toe%26jtitle%3DRadiographics%26date%3D2000%26volume%3D20%26spage%3D449%26epage%3D470%26doi%3D10.1148%2Fradiographics.20.2.g00mc12449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rathi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambhire, P.</span></span> <span> </span><span class="NLM_article-title">Abdominal tuberculosis</span>. <i>J. Assoc. Physicians India</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">47</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27730779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2svpt12rtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=38-47&author=P.+Rathiauthor=P.+Gambhire&title=Abdominal+tuberculosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Abdominal Tuberculosis</span></div><div class="casAuthors">Rathi Pravin; Gambhire Pravir</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of the Association of Physicians of India</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">38-47</span>
        ISSN:<span class="NLM_cas:issn">0004-5772</span>.
    </div><div class="casAbstract">Abdomen is involved in 11% of patients with extra-pulmonary tuberculosis; The most common site of involvement is the ileocaecal region, other locations of involvement, in order of descending frequency, are the ascending colon, jejunum, appendix, duodenum, stomach, oesophagus, sigmoid colon, and rectum.  Apart from the basic work up, Investigations like CT scan, EUS, Capsule endoscopy, Balloon enteroscopy, Ascitic fluid ADA, TB-PCR, GeneXpert, Laproscopy are being increasingly used to diagnose tuberculosis.Therapy with standard antituberculous drugs is usually highly effective for intestinal TB.  Six-months therapy is as effective as nine-months therapy.  Multi-Drug Resistance (MDR) has been observed in 13% of MTB isolates.  The development of Drug Induced Hepatotoxicity (DIH) during therapy for TB is the most common reason leading to interruption of therapy.  There are various guidelines for the management of TB post DIH.  Surgery is usually reserved for patients who have developed complications or obstruction not responding to medical management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAr-tYS4tz7PSAs_PE1QvifW6udTcc2eZsKSAuUcoWSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svpt12rtQ%253D%253D&md5=8ad4422cafc6ff9ccdd9cbc392a23cd3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRathi%26aufirst%3DP.%26aulast%3DGambhire%26aufirst%3DP.%26atitle%3DAbdominal%2520tuberculosis%26jtitle%3DJ.%2520Assoc.%2520Physicians%2520India%26date%3D2016%26volume%3D64%26spage%3D38%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakroun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharbi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chebil, M.</span></span> <span> </span><span class="NLM_article-title">Renal tuberculosis mimicking renal cell carcinoma: a case report</span>. <i>J. Med. Case Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">139</span>, <span class="refDoi"> DOI: 10.1186/s13256-019-2073-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1186%2Fs13256-019-2073-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31077255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ks1ejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=139&author=K.+Chakerauthor=M.+Chakrounauthor=M.+Gharbiauthor=M.+Chebil&title=Renal+tuberculosis+mimicking+renal+cell+carcinoma%3A+a+case+report&doi=10.1186%2Fs13256-019-2073-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Renal tuberculosis mimicking renal cell carcinoma: a case report</span></div><div class="casAuthors">Chaker Kays; Chakroun Marouene; Gharbi Maroua; Chebil Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medical case reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">139</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Urogenital tuberculosis is still a frequent presentation, and it constitutes a current public health problem in endemic areas.  The clinical presentation of this form of the disease may be misleading.  The pseudotumoral type of renal tuberculosis is extremely uncommon.  CASE PRESENTATION:  We present a case of a 52-year-old African woman who presented with urogenital tuberculosis in its pseudotumoral form.  This case was initially diagnosed and managed as renal cancer.  Histopathology confirmed the diagnosis of pseudotumoral renal tuberculosis.  CONCLUSIONS:  The pseudotumoral form of urinary tuberculosis can be difficult to diagnose.  Only bacteriological or histological confirmation allows diagnosis for adequate treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLLeVlNQNhpBBrI9DTGjC0fW6udTcc2ebd4wGb0CyFObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ks1ejtg%253D%253D&md5=a850291570fc34582ade24df5ac7cdff</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1186%2Fs13256-019-2073-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13256-019-2073-0%26sid%3Dliteratum%253Aachs%26aulast%3DChaker%26aufirst%3DK.%26aulast%3DChakroun%26aufirst%3DM.%26aulast%3DGharbi%26aufirst%3DM.%26aulast%3DChebil%26aufirst%3DM.%26atitle%3DRenal%2520tuberculosis%2520mimicking%2520renal%2520cell%2520carcinoma%253A%2520a%2520case%2520report%26jtitle%3DJ.%2520Med.%2520Case%2520Rep.%26date%3D2019%26volume%3D13%26spage%3D139%26doi%3D10.1186%2Fs13256-019-2073-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeds, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurbatova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Rio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraft, C. S.</span></span> <span> </span><span class="NLM_article-title">Site of extrapulmonary tuberculosis is associated with HIV infection</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1093/cid/cis303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fcid%2Fcis303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22423123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC38vntVKqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=75-81&author=I.+L.+Leedsauthor=M.+J.+Mageeauthor=E.+V.+Kurbatovaauthor=C.+del+Rioauthor=H.+M.+Blumbergauthor=M.+K.+Leonardauthor=C.+S.+Kraft&title=Site+of+extrapulmonary+tuberculosis+is+associated+with+HIV+infection&doi=10.1093%2Fcid%2Fcis303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Site of extrapulmonary tuberculosis is associated with HIV infection</span></div><div class="casAuthors">Leeds Ira L; Magee Matthew J; Kurbatova Ekaterina V; del Rio Carlos; Blumberg Henry M; Leonard Michael K; Kraft Colleen S</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  In the United States, the proportion of patients with extrapulmonary tuberculosis (EPTB) has increased relative to cases of pulmonary tuberculosis.  Patients with central nervous system (CNS)/meningeal and disseminated EPTB and those with human immunodeficiency virus (HIV)/AIDS have increased mortality.  The purpose of our study was to determine risk factors associated with particular types of EPTB.  METHODS:  We retrospectively reviewed 320 cases of EPTB from 1995-2007 at a single urban US public hospital.  Medical records were reviewed to determine site of EPTB and patient demographic and clinical characteristics.  Multivariable logistic regression analyses were performed to determine independent associations between patient characteristics and site of disease.  RESULTS:  Patients were predominantly male (67%), African American (82%), and US-born (76%).  Mean age was 40 years (range 18-89).  The most common sites of EPTB were lymphatic (28%), disseminated (23%), and CNS/meningeal (22%) disease.  One hundred fifty-four (48.1%) were HIV-infected, 40% had concomitant pulmonary tuberculosis, and 14.7% died within 12 months of EPTB diagnosis.  Multivariable analysis demonstrated that HIV-infected patients were less likely to have pleural (adjusted odds ratio [AOR] 0.3; 95% confidence interval [CI] .2, .6) as site of EPTB disease than HIV-uninfected patients.  Among patients with EPTB and HIV-infection, patients with CD4 lymphocyte cell count <100 were more likely to have severe forms of EPTB (CNS/meningeal and/or disseminated) (AOR 1.6; 95% CI, 1.0, 2.4).  CONCLUSIONS:  Among patients hospitalized with EPTB, patients coinfected with HIV and low CD4 counts were more likely to have CNS/meningeal and disseminated disease.  Care for similar patients should include consideration of these forms of EPTB since they carry a high risk of death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYC_8i9nfhJ7qxQ2mb9Pu8fW6udTcc2ebd4wGb0CyFObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vntVKqtw%253D%253D&md5=ffd4b6f5aec3862de0a15cd4b357c699</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcis303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcis303%26sid%3Dliteratum%253Aachs%26aulast%3DLeeds%26aufirst%3DI.%2BL.%26aulast%3DMagee%26aufirst%3DM.%2BJ.%26aulast%3DKurbatova%26aufirst%3DE.%2BV.%26aulast%3Ddel%2BRio%26aufirst%3DC.%26aulast%3DBlumberg%26aufirst%3DH.%2BM.%26aulast%3DLeonard%26aufirst%3DM.%2BK.%26aulast%3DKraft%26aufirst%3DC.%2BS.%26atitle%3DSite%2520of%2520extrapulmonary%2520tuberculosis%2520is%2520associated%2520with%2520HIV%2520infection%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2012%26volume%3D55%26spage%3D75%26epage%3D81%26doi%3D10.1093%2Fcid%2Fcis303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnappinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, D.</span></span> <span> </span><span class="NLM_article-title">The spectrum of latent tuberculosis: rethinking the biology and intervention strategies</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">845</span>– <span class="NLM_lpage">855</span>, <span class="refDoi"> DOI: 10.1038/nrmicro2236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnrmicro2236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19855401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSqsLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=845-855&author=C.+E.+Barryauthor=H.+I.+Boshoffauthor=V.+Dartoisauthor=T.+Dickauthor=S.+Ehrtauthor=J.+Flynnauthor=D.+Schnappingerauthor=R.+J.+Wilkinsonauthor=D.+Young&title=The+spectrum+of+latent+tuberculosis%3A+rethinking+the+biology+and+intervention+strategies&doi=10.1038%2Fnrmicro2236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The spectrum of latent tuberculosis: rethinking the biology and intervention strategies</span></div><div class="casAuthors">Barry, Clifton E., III; Boshoff, Helena I.; Dartois, Veronique; Dick, Thomas; Ehrt, Sabine; Flynn, JoAnne; Schnappinger, Dirk; Wilkinson, Robert J.; Young, Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">845-855</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Immunol. tests provide evidence of latent tuberculosis in one third of the global population, which corresponds to more than two billion individuals.  Latent tuberculosis is defined by the absence of clin. symptoms but carries a risk of subsequent progression to clin. disease, particularly in the context of co-infection with HIV.  In this Review we discuss the biol. of latent tuberculosis as part of a broad range of responses that occur following infection with Mycobacterium tuberculosis, which result in the formation of physiol. distinct granulomatous lesions that provide microenvironments with differential ability to support or suppress the persistence of viable bacteria.  We then show how this model can be used to develop a rational program to discover effective drugs for the eradication of M. tuberculosis infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2NPD_m2QYSLVg90H21EOLACvtfcHk0ljovsCZTgW45Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSqsLbN&md5=df1f98b80f2701c6b3757017420a7755</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro2236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro2236%26sid%3Dliteratum%253Aachs%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DDick%26aufirst%3DT.%26aulast%3DEhrt%26aufirst%3DS.%26aulast%3DFlynn%26aufirst%3DJ.%26aulast%3DSchnappinger%26aufirst%3DD.%26aulast%3DWilkinson%26aufirst%3DR.%2BJ.%26aulast%3DYoung%26aufirst%3DD.%26atitle%3DThe%2520spectrum%2520of%2520latent%2520tuberculosis%253A%2520rethinking%2520the%2520biology%2520and%2520intervention%2520strategies%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2009%26volume%3D7%26spage%3D845%26epage%3D855%26doi%3D10.1038%2Fnrmicro2236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, A. N.</span></span> <span> </span><span class="NLM_article-title">Pulmonary tuberculosis: the essentials</span>. <i>Radiology</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1148/radiology.210.2.r99ja34307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1148%2Fradiology.210.2.r99ja34307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10207408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaK1M3itlyitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=1999&pages=307-322&author=A.+N.+Leung&title=Pulmonary+tuberculosis%3A+the+essentials&doi=10.1148%2Fradiology.210.2.r99ja34307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary tuberculosis: the essentials</span></div><div class="casAuthors">Leung A N</div><div class="citationInfo"><span class="NLM_cas:title">Radiology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">307-22</span>
        ISSN:<span class="NLM_cas:issn">0033-8419</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSx8GQCyEiVP_IW7hznt0zpfW6udTcc2eaScR6Oqg2ON7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3itlyitw%253D%253D&md5=be24063a412cd89cfb86811ba666aad4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1148%2Fradiology.210.2.r99ja34307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1148%252Fradiology.210.2.r99ja34307%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DA.%2BN.%26atitle%3DPulmonary%2520tuberculosis%253A%2520the%2520essentials%26jtitle%3DRadiology%26date%3D1999%26volume%3D210%26spage%3D307%26epage%3D322%26doi%3D10.1148%2Fradiology.210.2.r99ja34307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadkowski, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, J. E.</span></span> <span> </span><span class="NLM_article-title">Cavitary pulmonary disease</span>. <i>Clin. Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1128/CMR.00060-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FCMR.00060-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=18400799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtFKlsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=305-333&author=L.+B.+Gadkowskiauthor=J.+E.+Stout&title=Cavitary+pulmonary+disease&doi=10.1128%2FCMR.00060-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cavitary pulmonary disease</span></div><div class="casAuthors">Gadkowski, L. Beth; Stout, Jason E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">305-333</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">0893-8512</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  A pulmonary cavity is a gas-filled area of the lung in the center of a nodule or area of consolidation and may be clin. obsd. by use of plain chest radiog. or computed tomog.  Cavities are present in a wide variety of infectious and noninfectious processes.  This review discusses the differential diagnosis of pathol. processes assocd. with lung cavities, focusing on infections assocd. with lung cavities.  The goal is to provide the clinician and clin. microbiologist with an overview of the diseases most commonly assocd. with lung cavities, with attention to the epidemiol. and clin. characteristics of the host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAm2coDPVGy7Vg90H21EOLACvtfcHk0ljovsCZTgW45Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtFKlsrg%253D&md5=37803c47a218749586267d649f1a861e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1128%2FCMR.00060-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00060-07%26sid%3Dliteratum%253Aachs%26aulast%3DGadkowski%26aufirst%3DL.%2BB.%26aulast%3DStout%26aufirst%3DJ.%2BE.%26atitle%3DCavitary%2520pulmonary%2520disease%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2008%26volume%3D21%26spage%3D305%26epage%3D333%26doi%3D10.1128%2FCMR.00060-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nachiappan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahbar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortani
Barbosa, E. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shroff, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocazionez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlesinger, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammer, M. M.</span></span> <span> </span><span class="NLM_article-title">Pulmonary tuberculosis: role of radiology in diagnosis and management</span>. <i>Radiographics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1148/rg.2017160032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1148%2Frg.2017160032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28076011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ks1Shsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=52-72&author=A.+C.+Nachiappanauthor=K.+Rahbarauthor=X.+Shiauthor=E.+S.+Guyauthor=E.+J.+Mortani%0ABarbosaauthor=G.+S.+Shroffauthor=D.+Ocazionezauthor=A.+E.+Schlesingerauthor=S.+I.+Katzauthor=M.+M.+Hammer&title=Pulmonary+tuberculosis%3A+role+of+radiology+in+diagnosis+and+management&doi=10.1148%2Frg.2017160032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary Tuberculosis: Role of Radiology in Diagnosis and Management</span></div><div class="casAuthors">Nachiappan Arun C; Rahbar Kasra; Shi Xiao; Guy Elizabeth S; Mortani Barbosa Eduardo J Jr; Shroff Girish S; Ocazionez Daniel; Schlesinger Alan E; Katz Sharyn I; Hammer Mark M</div><div class="citationInfo"><span class="NLM_cas:title">Radiographics : a review publication of the Radiological Society of North America, Inc</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-72</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis is a public health problem worldwide, including in the United States-particularly among immunocompromised patients and other high-risk groups.  Tuberculosis manifests in active and latent forms.  Active disease can occur as primary tuberculosis, developing shortly after infection, or postprimary tuberculosis, developing after a long period of latent infection.  Primary tuberculosis occurs most commonly in children and immunocompromised patients, who present with lymphadenopathy, pulmonary consolidation, and pleural effusion.  Postprimary tuberculosis may manifest with cavities, consolidations, and centrilobular nodules.  Miliary tuberculosis refers to hematogenously disseminated disease that is more commonly seen in immunocompromised patients, who present with miliary lung nodules and multiorgan involvement.  The principal means of testing for active tuberculosis is sputum analysis, including smear, culture, and nucleic acid amplification testing.  Imaging findings, particularly the presence of cavitation, can affect treatment decisions, such as the duration of therapy.  Latent tuberculosis is an asymptomatic infection that can lead to postprimary tuberculosis in the future.  Patients who are suspected of having latent tuberculosis may undergo targeted testing with a tuberculin skin test or interferon-γ release assay.  Chest radiographs are used to stratify for risk and to assess for asymptomatic active disease.  Sequelae of previous tuberculosis that is now inactive manifest characteristically as fibronodular opacities in the apical and upper lung zones.  Stability of radiographic findings for 6 months distinguishes inactive from active disease.  Nontuberculous mycobacterial disease can sometimes mimic the findings of active tuberculosis, and laboratory confirmation is required to make the distinction.  Familiarity with the imaging, clinical, and laboratory features of tuberculosis is important for diagnosis and management. (©)RSNA, 2017.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSt7Z38okWFjLGbPKh4T9eAfW6udTcc2eaScR6Oqg2ON7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ks1Shsg%253D%253D&md5=edfd416f4a9360dc47c80cf73862b5b0</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1148%2Frg.2017160032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1148%252Frg.2017160032%26sid%3Dliteratum%253Aachs%26aulast%3DNachiappan%26aufirst%3DA.%2BC.%26aulast%3DRahbar%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DGuy%26aufirst%3DE.%2BS.%26aulast%3DMortani%2BBarbosa%26aufirst%3DE.%2BJ.%26aulast%3DShroff%26aufirst%3DG.%2BS.%26aulast%3DOcazionez%26aufirst%3DD.%26aulast%3DSchlesinger%26aufirst%3DA.%2BE.%26aulast%3DKatz%26aufirst%3DS.%2BI.%26aulast%3DHammer%26aufirst%3DM.%2BM.%26atitle%3DPulmonary%2520tuberculosis%253A%2520role%2520of%2520radiology%2520in%2520diagnosis%2520and%2520management%26jtitle%3DRadiographics%26date%3D2017%26volume%3D37%26spage%3D52%26epage%3D72%26doi%3D10.1148%2Frg.2017160032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guirado, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlesinger, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, G.</span></span> <span> </span><span class="NLM_article-title">Macrophages in tuberculosis: friend or foe</span>. <i>Semin. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.1007/s00281-013-0388-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1007%2Fs00281-013-0388-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23864058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSit7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2013&pages=563-583&author=E.+Guiradoauthor=L.+S.+Schlesingerauthor=G.+Kaplan&title=Macrophages+in+tuberculosis%3A+friend+or+foe&doi=10.1007%2Fs00281-013-0388-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophages in tuberculosis: friend or foe</span></div><div class="casAuthors">Guirado, Evelyn; Schlesinger, Larry S.; Kaplan, Gilla</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunopathology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">563-583</span>CODEN:
                <span class="NLM_cas:coden">SIEMB7</span>;
        ISSN:<span class="NLM_cas:issn">1863-2297</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB) remains one of the greatest threats to human health.  The causative bacterium, Mycobacterium tuberculosis (Mtb), is acquired by the respiratory route.  It is exquisitely human adapted and a prototypic intracellular pathogen of macrophages, with alveolar macrophages (AMs) being the primary conduit of infection and disease.  The outcome of primary infection is most often a latently infected healthy human host, in whom the bacteria are held in check by the host immune response.  Such individuals can develop active TB later in life with impairment in the immune system.  In contrast, in a minority of infected individuals, the host immune response fails to control the growth of bacilli, and progressive granulomatous disease develops, facilitating spread of the bacilli via infectious aerosols coughed out into the environment and inhaled by new hosts.  The mol. details of the Mtb-macrophage interaction continue to be elucidated.  However, it is clear that a no. of complex processes are involved at the different stages of infection that may benefit either the bacterium or the host.  Macrophages demonstrate tremendous phenotypic heterogeneity and functional plasticity which, depending on the site and stage of infection, facilitate the diverse outcomes.  Moreover, host responses vary depending on the specific characteristics of the infecting Mtb strain.  In this chapter, we describe a contemporary view of the behavior of AMs and their interaction with various Mtb strains in generating unique immunol. lung-specific responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_a9_M6jGdo7Vg90H21EOLACvtfcHk0ljUKQGpv49SeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSit7vJ&md5=937f28d7e8402bc88a6e7ef1187da03a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00281-013-0388-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00281-013-0388-2%26sid%3Dliteratum%253Aachs%26aulast%3DGuirado%26aufirst%3DE.%26aulast%3DSchlesinger%26aufirst%3DL.%2BS.%26aulast%3DKaplan%26aufirst%3DG.%26atitle%3DMacrophages%2520in%2520tuberculosis%253A%2520friend%2520or%2520foe%26jtitle%3DSemin.%2520Immunopathol.%26date%3D2013%26volume%3D35%26spage%3D563%26epage%3D583%26doi%3D10.1007%2Fs00281-013-0388-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demangel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertolino, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britton, W. J.</span></span> <span> </span><span class="NLM_article-title">Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">994</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1002/1521-4141(200204)32:4<994::AID-IMMU994>3.0.CO;2-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1002%2F1521-4141%28200204%2932%3A4%3C994%3A%3AAID-IMMU994%3E3.0.CO%3B2-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=11920565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtFWntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2002&pages=994-1002&author=C.+Demangelauthor=P.+Bertolinoauthor=W.+J.+Britton&title=Autocrine+IL-10+impairs+dendritic+cell+%28DC%29-derived+immune+responses+to+mycobacterial+infection+by+suppressing+DC+trafficking+to+draining+lymph+nodes+and+local+IL-12+production&doi=10.1002%2F1521-4141%28200204%2932%3A4%3C994%3A%3AAID-IMMU994%3E3.0.CO%3B2-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production</span></div><div class="casAuthors">Demangel, Caroline; Bertolino, Patrick; Britton, Warwick J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">994-1002</span>CODEN:
                <span class="NLM_cas:coden">EJIMAF</span>;
        ISSN:<span class="NLM_cas:issn">0014-2980</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">The prodn. of IL-12 by dendritic cells (DC) early in an immune response is considered crit. for the polarization of CD4+ T lymphocyte response towards a Th1 pattern, a key process in the clearance of intracellular pathogens.  Infection of bone marrow-derived DC with Mycobacterium bovis Bacillus Calmette Guerin (BCG) induced a concurrent and dose-dependent release of IL-10 and IL-12.  Here we examd. whether the prodn. of IL-10 by DC affected their IL-12 response to mycobacterial infection and the generation of protective immune responses in vivo.  Compared to wild-type (WT) DC, DC deficient for IL-10 synthesis (IL-10-/-) showed increased IL-12 prodn. in response to BCG infection and CD40 stimuli in vitro.  Moreover, when transferred into mice, infected IL-10-/- DC were more efficient than WT DC at inducing IFN-γ prodn. to mycobacterial antigens in the draining lymph nodes (DLN).  This effect was assocd. with increased trafficking of IL-10-/- DC to the DLN and enhanced IL-12 prodn. by DC within the DLN.  These data show that autocrine IL-10 exerts a dual inhibitory effect on the induction of primary immune responses by DC: first, by down-regulating the migration of infected DC to the DLN and second, by modulating the IL-12 prodn. by DC in the DLN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroiPyZSKrvhrVg90H21EOLACvtfcHk0ljUKQGpv49SeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtFWntb4%253D&md5=15d5be82e17a97d034254f7bbf74d842</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2F1521-4141%28200204%2932%3A4%3C994%3A%3AAID-IMMU994%3E3.0.CO%3B2-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-4141%2528200204%252932%253A4%253C994%253A%253AAID-IMMU994%253E3.0.CO%253B2-6%26sid%3Dliteratum%253Aachs%26aulast%3DDemangel%26aufirst%3DC.%26aulast%3DBertolino%26aufirst%3DP.%26aulast%3DBritton%26aufirst%3DW.%2BJ.%26atitle%3DAutocrine%2520IL-10%2520impairs%2520dendritic%2520cell%2520%2528DC%2529-derived%2520immune%2520responses%2520to%2520mycobacterial%2520infection%2520by%2520suppressing%2520DC%2520trafficking%2520to%2520draining%2520lymph%2520nodes%2520and%2520local%2520IL-12%2520production%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2002%26volume%3D32%26spage%3D994%26epage%3D1002%26doi%3D10.1002%2F1521-4141%28200204%2932%3A4%3C994%3A%3AAID-IMMU994%3E3.0.CO%3B2-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, P. A.</span></span> <span> </span><span class="NLM_article-title">Immunocompetent cells in resistance to bacterial infections</span>. <i>Bacteriol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1128/BR.40.2.284-313.1976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FBR.40.2.284-313.1976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=786253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaE283nslCrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1976&pages=284-313&author=P.+A.+Campbell&title=Immunocompetent+cells+in+resistance+to+bacterial+infections&doi=10.1128%2FBR.40.2.284-313.1976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Immunocompetent cells in resistance to bacterial infections</span></div><div class="casAuthors">Campbell P A</div><div class="citationInfo"><span class="NLM_cas:title">Bacteriological reviews</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">284-313</span>
        ISSN:<span class="NLM_cas:issn">0005-3678</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRaUgmrYG_fa7xanA7vODO6fW6udTcc2ea1l56y00T6D7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE283nslCrug%253D%253D&md5=4f22b5ef1f9d50a65aa795ea7f0e951b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1128%2FBR.40.2.284-313.1976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FBR.40.2.284-313.1976%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DP.%2BA.%26atitle%3DImmunocompetent%2520cells%2520in%2520resistance%2520to%2520bacterial%2520infections%26jtitle%3DBacteriol.%2520Rev.%26date%3D1976%26volume%3D40%26spage%3D284%26epage%3D313%26doi%3D10.1128%2FBR.40.2.284-313.1976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. M.</span></span> <span> </span><span class="NLM_article-title">Cell-mediated immune responses in tuberculosis</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.021908.132703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1146%2Fannurev.immunol.021908.132703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19302046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFSltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=393-422&author=A.+M.+Cooper&title=Cell-mediated+immune+responses+in+tuberculosis&doi=10.1146%2Fannurev.immunol.021908.132703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-mediated immune responses in tuberculosis</span></div><div class="casAuthors">Cooper, Andrea M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">393-422</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Tuberculosis is primarily a disease of the lung, and dissemination of the disease depends on productive infection of this crit. organ.  Upon aerosol infection with Mycobacterium tuberculosis (Mtb), the acquired cellular immune response is slow to be induced and to be expressed within the lung.  This slowness allows infection to become well established; thus, the acquired response is expressed in an inflammatory site that has been initiated and modulated by the bacterium.  Mtb has a variety of surface mols. that interact with the innate response, and this interaction along with the autoregulation of the immune response by several mechanisms results in less-than-optimal control of bacterial growth.  To improve current vaccine strategies, the factors must understand that mediate induction, expression, and regulation of the immune response in the lung.  Also, it has to be detd. how to induce both known and novel immunoprotective responses without inducing immunopathol. consequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw8sN_3Z8az7Vg90H21EOLACvtfcHk0ljUKQGpv49SeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFSltrs%253D&md5=6671250240f7077287d41319359a8664</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.021908.132703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.021908.132703%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DA.%2BM.%26atitle%3DCell-mediated%2520immune%2520responses%2520in%2520tuberculosis%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D27%26spage%3D393%26epage%3D422%26doi%3D10.1146%2Fannurev.immunol.021908.132703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mihret, A.</span></span> <span> </span><span class="NLM_article-title">The role of dendritic cells in Mycobacterium tuberculosis infection</span>. <i>Virulence</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">654</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.4161/viru.22586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4161%2Fviru.22586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23154283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3s7js1aitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=654-659&author=A.+Mihret&title=The+role+of+dendritic+cells+in+Mycobacterium+tuberculosis+infection&doi=10.4161%2Fviru.22586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The role of dendritic cells in Mycobacterium tuberculosis infection</span></div><div class="casAuthors">Mihret Adane</div><div class="citationInfo"><span class="NLM_cas:title">Virulence</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">654-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The immune response against Mycobacterium tuberculosis is multifactorial, involving a network of innate and adaptive immune responses.  Characterization of the immune response, a clear understanding of the dynamics and interplay of different arms of the immune response are critical to allow the development of better tools for combating tuberculosis.  Dendritic cells (DCs) are one of the key cells in bridging innate and adaptive immune response through their significant role in capturing, processing and presenting antigens.  The outcome of interaction of M. tuberculosis with DCs is not fully understood and the available reports are contradictory were some findings reported that DCs strengthen the cellular immune response against mycobacterium infection whereas others reported M. tuberculosis impairs the function of DCs were infected DCs are poor stimulators of M. tuberculosis Ag-specific CD4 T cells.  Other studies showed that the outcome depends on M. tuberculosis strain type and type of receptor on DCs during recognition.  In this review I shall highlight the recent findings in the outcome of interaction of Mycobacterium tuberculosis with DCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0UHQu1DLNKa_dlEzl_fBafW6udTcc2ebQCtB6vJ4Hnbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7js1aitg%253D%253D&md5=4d727a916354c22068f9f351aa20b90a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.4161%2Fviru.22586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fviru.22586%26sid%3Dliteratum%253Aachs%26aulast%3DMihret%26aufirst%3DA.%26atitle%3DThe%2520role%2520of%2520dendritic%2520cells%2520in%2520Mycobacterium%2520tuberculosis%2520infection%26jtitle%3DVirulence%26date%3D2012%26volume%3D3%26spage%3D654%26epage%3D659%26doi%3D10.4161%2Fviru.22586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S.</span></span> <span> </span><span class="NLM_article-title">Alternative activation of macrophages</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1038/nri978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnri978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=12511873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=23-35&author=S.+Gordon&title=Alternative+activation+of+macrophages&doi=10.1038%2Fnri978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Alternative activation of macrophages</span></div><div class="casAuthors">Gordon, Siamon</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-35</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The classical pathway of interferon-γ-dependent activation of macrophages by T helper 1 (TH1)-type responses is a well-established feature of cellular immunity to infection with intracellular pathogens, such as Mycobacterium tuberculosis and HIV.  The concept of an alternative pathway of macrophage activation by the TH2-type cytokines interleukin-4 (IL-4) and IL-13 has gained credence in the past decade, to account for a distinctive macrophage phenotype that is consistent with a different role in humoral immunity and repair.  In this review, I assess the evidence in favor of alternative macrophage activation in the light of macrophage heterogeneity, and define its limits and relevance to a range of immune and inflammatory conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVdXdqFvv23bVg90H21EOLACvtfcHk0lgSaLoHWcDvqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVw%253D&md5=7719c1deabe5175706b9828ec4f0b51f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnri978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri978%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DS.%26atitle%3DAlternative%2520activation%2520of%2520macrophages%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D23%26epage%3D35%26doi%3D10.1038%2Fnri978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qui, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagymasi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Rose, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanarasimhaiah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menoret, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittler, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiner, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vella, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adler, A. J.</span></span> <span> </span><span class="NLM_article-title">CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">3555</span>– <span class="NLM_lpage">3564</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1101244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4049%2Fjimmunol.1101244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21880986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2gsrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2011&pages=3555-3564&author=H.+Z.+Quiauthor=A.+T.+Hagymasiauthor=S.+Bandyopadhyayauthor=M.-C.+St.+Roseauthor=R.+Ramanarasimhaiahauthor=A.+Menoretauthor=R.+S.+Mittlerauthor=S.+M.+Gordonauthor=S.+L.+Reinerauthor=A.+T.+Vellaauthor=A.+J.+Adler&title=CD134+plus+CD137+dual+costimulation+induces+Eomesodermin+in+CD4+T+cells+to+program+cytotoxic+Th1+differentiation&doi=10.4049%2Fjimmunol.1101244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">CD134 Plus CD137 Dual Costimulation Induces Eomesodermin in CD4 T Cells To Program Cytotoxic Th1 Differentiation</span></div><div class="casAuthors">Qui, Harry Z.; Hagymasi, Adam T.; Bandyopadhyay, Suman; St. Rose, Marie-Clare; Ramanarasimhaiah, Raghunath; Menoret, Antoine; Mittler, Robert S.; Gordon, Scott M.; Reiner, Steven L.; Vella, Anthony T.; Adler, Adam J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3555-3564</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Cytotoxic CD4 Th1 cells are emerging as a therapeutically useful T cell lineage that can effectively target tumors, but until now the pathways that govern their differentiation have been poorly understood.  We demonstrate that CD134 (OX40) costimulation programs naive self- and virus-reactive CD4 T cells to undergo in vivo differentiation into cytotoxic Th1 effectors.  CD137 (4-1BB) costimulation maximized clonal expansion, and IL-2 was necessary for cytotoxic Th1 differentiation.  Importantly, the T-box transcription factor Eomesodermin was crit. for inducing the cytotoxic marker granzyme B. CD134 plus CD137 dual costimulation also imprinted a cytotoxic phenotype on bystanding CD4 T cells.  Thus, to our knowledge, the current study identifies for the first time a specific costimulatory pathway and an intracellular mechanism relying on Eomesodermin that induces both Ag-specific and bystander cytotoxic CD4 Th1 cells.  This mechanism might be therapeutically useful because CD134 plus CD137 dual costimulation induced CD4 T cell-dependent tumoricidal function in a mouse melanoma model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqekdAnJgyI8LVg90H21EOLACvtfcHk0lgSaLoHWcDvqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2gsrfM&md5=4b8ee6f56140e844da29ac766a133f8d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1101244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1101244%26sid%3Dliteratum%253Aachs%26aulast%3DQui%26aufirst%3DH.%2BZ.%26aulast%3DHagymasi%26aufirst%3DA.%2BT.%26aulast%3DBandyopadhyay%26aufirst%3DS.%26aulast%3DSt.%2BRose%26aufirst%3DM.-C.%26aulast%3DRamanarasimhaiah%26aufirst%3DR.%26aulast%3DMenoret%26aufirst%3DA.%26aulast%3DMittler%26aufirst%3DR.%2BS.%26aulast%3DGordon%26aufirst%3DS.%2BM.%26aulast%3DReiner%26aufirst%3DS.%2BL.%26aulast%3DVella%26aufirst%3DA.%2BT.%26aulast%3DAdler%26aufirst%3DA.%2BJ.%26atitle%3DCD134%2520plus%2520CD137%2520dual%2520costimulation%2520induces%2520Eomesodermin%2520in%2520CD4%2520T%2520cells%2520to%2520program%2520cytotoxic%2520Th1%2520differentiation%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D187%26spage%3D3555%26epage%3D3564%26doi%3D10.4049%2Fjimmunol.1101244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Valliere, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuertz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoft, D. F.</span></span> <span> </span><span class="NLM_article-title">Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies</span>. <i>Infect. Immun.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">6711</span>– <span class="NLM_lpage">6720</span>, <span class="refDoi"> DOI: 10.1128/IAI.73.10.6711-6720.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FIAI.73.10.6711-6720.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=16177348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVyhurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2005&pages=6711-6720&author=S.+de%0AValliereauthor=G.+Abateauthor=A.+Blazevicauthor=R.+M.+Heuertzauthor=D.+F.+Hoft&title=Enhancement+of+innate+and+cell-mediated+immunity+by+antimycobacterial+antibodies&doi=10.1128%2FIAI.73.10.6711-6720.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies</span></div><div class="casAuthors">de Valliere, S.; Abate, G.; Blazevic, A.; Heuertz, R. M.; Hoft, D. F.</div><div class="citationInfo"><span class="NLM_cas:title">Infection and Immunity</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6711-6720</span>CODEN:
                <span class="NLM_cas:coden">INFIBR</span>;
        ISSN:<span class="NLM_cas:issn">0019-9567</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The authors investigated the ability of human antibodies induced by Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccination to protect against mycobacterial infections.  Serum samples contg. mycobacterium-specific antibodies were obtained from volunteers who had received two intradermal BCG vaccinations 6 mo apart.  Significant increases in lipoarabinomannan (LAM)-specific IgG were detected after both the primary and booster vaccinations.  Effects of mycobacterium-specific antibodies on surface binding and internalization of BCG by neutrophils and monocytes/macrophages were studied, using green fluorescent protein (gfp)-expressing BCG.  Surface-bound gfp-expressing BCG were distinguished from intracellular BCG by surface labeling with LAM-specific monoclonal antibody.  Internalization of BCG by phagocytic cells was shown to be significantly enhanced in postvaccination serum samples.  Furthermore, the inhibitory effects of neutrophils and monocytes/macrophages on mycobacterial growth were significantly enhanced by BCG-induced antibodies.  The growth-inhibiting effects of postvaccination sera were reversed by preabsorption of IgG with Protein G.  Finally, the helper effects of antimycobacterial antibodies for the induction of cell-mediated immune responses were investigated.  BCG-induced antibodies significantly enhanced proliferation and gamma interferon prodn. in mycobacterium-specific CD4+ and CD8+ T cells, as well as the proportion of proliferating and degranulating CD8+ T cells.  The authors conclude that mycobacterium-specific antibodies are capable of enhancing both innate and cell-mediated immune responses to mycobacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofSyEXpFmcmLVg90H21EOLACvtfcHk0licSmccpNOZKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVyhurbL&md5=5e2f2d3c66ea8e31382e30dff24b1704</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1128%2FIAI.73.10.6711-6720.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FIAI.73.10.6711-6720.2005%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BValliere%26aufirst%3DS.%26aulast%3DAbate%26aufirst%3DG.%26aulast%3DBlazevic%26aufirst%3DA.%26aulast%3DHeuertz%26aufirst%3DR.%2BM.%26aulast%3DHoft%26aufirst%3DD.%2BF.%26atitle%3DEnhancement%2520of%2520innate%2520and%2520cell-mediated%2520immunity%2520by%2520antimycobacterial%2520antibodies%26jtitle%3DInfect.%2520Immun.%26date%3D2005%26volume%3D73%26spage%3D6711%26epage%3D6720%26doi%3D10.1128%2FIAI.73.10.6711-6720.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagatay, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagatay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yurt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzergoz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurol, A. O.</span></span> <span> </span><span class="NLM_article-title">Can immune parameters be used as predictors to distinguish between pulmonary multidrug-resistant and drug-sensitive tuberculosis?</span>. <i>Arch. Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.5114/aoms.2010.13511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.5114%2Faoms.2010.13511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22371724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovV2qtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=77-82&author=B.+Kiranauthor=T.+Cagatayauthor=P.+Clarkauthor=F.+Kosarauthor=P.+Cagatayauthor=S.+Yurtauthor=F.+Suzergozauthor=A.+O.+Gurol&title=Can+immune+parameters+be+used+as+predictors+to+distinguish+between+pulmonary+multidrug-resistant+and+drug-sensitive+tuberculosis%3F&doi=10.5114%2Faoms.2010.13511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Can immune parameters be used as predictors to distinguish between pulmonary multidrug-resistant and drug-sensitive tuberculosis?</span></div><div class="casAuthors">Kiran, Bayram; Cagatay, Tulin; Clark, Philip; Kosar, Filiz; Cagatay, Penbe; Yurt, Sibel; Suzergoz, Faruk; Gurol, Ali Osman</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Medical Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-82</span>CODEN:
                <span class="NLM_cas:coden">AMSRDQ</span>;
        ISSN:<span class="NLM_cas:issn">1734-1922</span>.
    
            (<span class="NLM_cas:orgname">Termedia Publishing House</span>)
        </div><div class="casAbstract">Introduction: Despite the development and wide implementation of Directly Obsd. Therapy Strategies (DOTS), multidrug-resistant tuberculosis (MDR-TB) remains a serious global health threat.  In this study, the role of host immune response in patients with MDR-TB is investigated and compared with that of patients with smear-pos. drug-sensitive tuberculosis (SP-TB).  Material and methods: 27 patients with SP-TB, 20 patients with MDR-TB, and 20 healthy controls were included in the study.  Immune parameters were detd. by flow cytometry using monoclonal antibodies in order to compare the percentage values of these markers in the two study groups and the control group.  Results: The levels of lymphocyte subgroups in the gate of CD45(+)/CD14(-) lymphocyte: CD45(+), CD3(+), CD4(+), NK, CD3/HLA-DR, CD 95(+) cells were significantly lower; by contrast CD23(+), CD25(+), CD19(+), CD4(+)/CD8(+), HLA-DR cells were found to be lower, but not significantly so in patients with MDR-TB, compared to levels in patients in the SP-TB and control groups.  Besides these findings, the levels of NKT cells and γδ TCR(+) cells were significantly higher in the MDR-TB than in the healthy control and SP-TB group.  Conclusions: The lower levels of CD3/HLA-DR, CD4 (+), Fas (+), and NK, and the higher level of NKT together with γδ T cells in patients with MDR-TB compared to those in SP-TB may indicate a profound immune suppression in MDR-TB patients and thereby may denote an accumulation in the bacterial load.  Our findings may shed light on the pathogenesis and prognosis of MDR tuberculosis, and may point towards the use of flow cytometry findings as an aid to early diagnosis in MDR-TB patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNW7FhvUZ2iLVg90H21EOLACvtfcHk0licSmccpNOZKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovV2qtL0%253D&md5=e90a3551b950562f6e84aa73d4bc103c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.5114%2Faoms.2010.13511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5114%252Faoms.2010.13511%26sid%3Dliteratum%253Aachs%26aulast%3DKiran%26aufirst%3DB.%26aulast%3DCagatay%26aufirst%3DT.%26aulast%3DClark%26aufirst%3DP.%26aulast%3DKosar%26aufirst%3DF.%26aulast%3DCagatay%26aufirst%3DP.%26aulast%3DYurt%26aufirst%3DS.%26aulast%3DSuzergoz%26aufirst%3DF.%26aulast%3DGurol%26aufirst%3DA.%2BO.%26atitle%3DCan%2520immune%2520parameters%2520be%2520used%2520as%2520predictors%2520to%2520distinguish%2520between%2520pulmonary%2520multidrug-resistant%2520and%2520drug-sensitive%2520tuberculosis%253F%26jtitle%3DArch.%2520Med.%2520Sci.%26date%3D2010%26volume%3D6%26spage%3D77%26epage%3D82%26doi%3D10.5114%2Faoms.2010.13511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkhill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiglmeier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tekaia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badcock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chillingworth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devlin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltwell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamlin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holroyd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornsby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagels, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajandream, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squares, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squares, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulston, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitehead, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrell, B. G.</span></span> <span> </span><span class="NLM_article-title">Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>393</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1038/31159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2F31159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=9634230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK1cXjvV2ksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=393&publication_year=1998&pages=537-544&author=S.+T.+Coleauthor=R.+Broschauthor=J.+Parkhillauthor=T.+Garnierauthor=C.+Churcherauthor=D.+Harrisauthor=S.+V.+Gordonauthor=K.+Eiglmeierauthor=S.+Gasauthor=C.+E.+Barryauthor=F.+Tekaiaauthor=K.+Badcockauthor=D.+Bashamauthor=D.+Brownauthor=T.+Chillingworthauthor=R.+Connorauthor=R.+Daviesauthor=K.+Devlinauthor=T.+Feltwellauthor=S.+Gentlesauthor=N.+Hamlinauthor=S.+Holroydauthor=T.+Hornsbyauthor=K.+Jagelsauthor=A.+Kroghauthor=J.+McLeanauthor=S.+Mouleauthor=L.+Murphyauthor=K.+Oliverauthor=J.+Osborneauthor=M.+A.+Quailauthor=M.+A.+Rajandreamauthor=J.+Rogersauthor=S.+Rutterauthor=K.+Seegerauthor=J.+Skeltonauthor=R.+Squaresauthor=S.+Squaresauthor=J.+E.+Sulstonauthor=K.+Taylorauthor=S.+Whiteheadauthor=B.+G.+Barrell&title=Deciphering+the+biology+of+Mycobacterium+tuberculosis+from+the+complete+genome+sequence&doi=10.1038%2F31159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence</span></div><div class="casAuthors">Cole, S. T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S. V.; Eiglmeier, K.; Gas, S.; Barry, C. E., III; Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.; Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M. A.; Rajandream, M.-A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J. E.; Taylor, K.; Whitehead, S.; Barrell, B. G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">393</span>
        (<span class="NLM_cas:issue">6685</span>),
    <span class="NLM_cas:pages">537-544</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Countless millions of people have died from tuberculosis, a chronic infectious disease caused by the tubercle bacillus.  The complete genome sequence of the best-characterized strain of Mycobacterium tuberculosis, H37Rv, was detd. and analyzed in order to improve our understanding of the biol. of this slow-growing pathogen and to help the conception of new prophylactic and therapeutic interventions.  The genome comprises 4,411,529 base pairs, contains around 4000 genes, and has a very high G+C content that is reflected in the biased amino acid content of the proteins.  M. tuberculosis differs radically from other bacteria in that a very large portion of its coding capacity is devoted to the prodn. of enzymes involved in lipogenesis and lipolysis, and to 2 new families of glycine-rich proteins with a repetitive structure that may represent a source of antigenic variation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9Q-iByIunurVg90H21EOLACvtfcHk0licSmccpNOZKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjvV2ksrY%253D&md5=44d23e7674bfeb1a3e30b55abf5268d2</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2F31159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F31159%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DS.%2BT.%26aulast%3DBrosch%26aufirst%3DR.%26aulast%3DParkhill%26aufirst%3DJ.%26aulast%3DGarnier%26aufirst%3DT.%26aulast%3DChurcher%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DD.%26aulast%3DGordon%26aufirst%3DS.%2BV.%26aulast%3DEiglmeier%26aufirst%3DK.%26aulast%3DGas%26aufirst%3DS.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DTekaia%26aufirst%3DF.%26aulast%3DBadcock%26aufirst%3DK.%26aulast%3DBasham%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DChillingworth%26aufirst%3DT.%26aulast%3DConnor%26aufirst%3DR.%26aulast%3DDavies%26aufirst%3DR.%26aulast%3DDevlin%26aufirst%3DK.%26aulast%3DFeltwell%26aufirst%3DT.%26aulast%3DGentles%26aufirst%3DS.%26aulast%3DHamlin%26aufirst%3DN.%26aulast%3DHolroyd%26aufirst%3DS.%26aulast%3DHornsby%26aufirst%3DT.%26aulast%3DJagels%26aufirst%3DK.%26aulast%3DKrogh%26aufirst%3DA.%26aulast%3DMcLean%26aufirst%3DJ.%26aulast%3DMoule%26aufirst%3DS.%26aulast%3DMurphy%26aufirst%3DL.%26aulast%3DOliver%26aufirst%3DK.%26aulast%3DOsborne%26aufirst%3DJ.%26aulast%3DQuail%26aufirst%3DM.%2BA.%26aulast%3DRajandream%26aufirst%3DM.%2BA.%26aulast%3DRogers%26aufirst%3DJ.%26aulast%3DRutter%26aufirst%3DS.%26aulast%3DSeeger%26aufirst%3DK.%26aulast%3DSkelton%26aufirst%3DJ.%26aulast%3DSquares%26aufirst%3DR.%26aulast%3DSquares%26aufirst%3DS.%26aulast%3DSulston%26aufirst%3DJ.%2BE.%26aulast%3DTaylor%26aufirst%3DK.%26aulast%3DWhitehead%26aufirst%3DS.%26aulast%3DBarrell%26aufirst%3DB.%2BG.%26atitle%3DDeciphering%2520the%2520biology%2520of%2520Mycobacterium%2520tuberculosis%2520from%2520the%2520complete%2520genome%2520sequence%26jtitle%3DNature%26date%3D1998%26volume%3D393%26spage%3D537%26epage%3D544%26doi%3D10.1038%2F31159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span> <span> </span><span class="NLM_article-title">Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">696</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1164/rccm.201006-0963PP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1164%2Frccm.201006-0963PP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21075901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVWnuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2011&pages=696-707&author=S.+Schwanderauthor=K.+Dheda&title=Human+lung+immunity+against+Mycobacterium+tuberculosis%3A+insights+into+pathogenesis+and+protection&doi=10.1164%2Frccm.201006-0963PP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Human lung Immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection</span></div><div class="casAuthors">Schwander, Stephan; Dheda, Keertan</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">696-707</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  The study of human pulmonary immunity against Mycobacterium tuberculosis (M.tb) provides a unique window into the biol. interactions between the human host and M.tb within the bronchoalveolar microenvironment, the site of natural infection.  Studies of bronchoalveolar cells (BACs) and lung tissue evaluate innate, adaptive, and regulatory immune mechanisms that collectively contribute to immunol. protection or its failure.  In aerogenically M.tb-exposed healthy persons lung immune responses reflect early host pathogen interactions that may contribute to sterilization, the development of latent M.tb infection, or progression to active disease.  Studies in these persons may allow the identification of biomarkers of protective immunity before the initiation of inflammatory and disease-assocd. immunopathol. changes.  In healthy close contacts of patients with tuberculosis (TB) and during active pulmonary TB, immune responses are compartmentalized to the lungs and characterized by an exuberant helper T-cell type 1 response, which as suggested by recent evidence is counteracted by local suppressive immune mechanisms.  Here we discuss how exploring human lung immunity may provide insights into disease progression and mechanisms of failure of immunol. protection at the site of the initial host-pathogen interaction.  These findings may also aid in the identification of new biomarkers of protective immunity that are urgently needed for the development of new and the improvement of current TB vaccines, adjuvant immunotherapies, and diagnostic technologies.  To facilitate further work in this area, methodol. and procedural approaches for bronchoalveolar lavage studies and their limitations are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQkEypfHM-_bVg90H21EOLACvtfcHk0lgDfRD1mHKWyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVWnuro%253D&md5=171b0ed617c3a7fb1a62d3d11348dc11</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1164%2Frccm.201006-0963PP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201006-0963PP%26sid%3Dliteratum%253Aachs%26aulast%3DSchwander%26aufirst%3DS.%26aulast%3DDheda%26aufirst%3DK.%26atitle%3DHuman%2520lung%2520immunity%2520against%2520Mycobacterium%2520tuberculosis%253A%2520insights%2520into%2520pathogenesis%2520and%2520protection%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2011%26volume%3D183%26spage%3D696%26epage%3D707%26doi%3D10.1164%2Frccm.201006-0963PP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence</span>. <i>Clin. Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1128/CMR.16.3.463-496.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FCMR.16.3.463-496.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=12857778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsV2qt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2003&pages=463-496&author=I.+Smith&title=Mycobacterium+tuberculosis+pathogenesis+and+molecular+determinants+of+virulence&doi=10.1128%2FCMR.16.3.463-496.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence</span></div><div class="casAuthors">Smith, Issar</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">463-496</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">0893-8512</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB), one of the oldest known human diseases is still is one of the major causes of mortality, since two million people die each year from this malady.  TB has many manifestations, affecting bone, the central nervous system, and many other organ systems, but it is primarily a pulmonary disease that is initiated by the deposition of Mycobacterium tuberculosis, contained in aerosol droplets, onto lung alveolar surfaces.  From this point, the progression of the disease can have several outcomes, detd. largely by the response of the host immune system.  The efficacy of this response is affected by intrinsic factors such as the genetics of the immune system as well as extrinsic factors, e.g., insults to the immune system and the nutritional and physiol. state of the host.  In addn., the pathogen may play a role in disease progression since some M. tuberculosis strains are reportedly more virulent than others, as defined by increased transmissibility as well as being assocd. with higher morbidity and mortality in infected individuals.  Despite the widespread use of an attenuated live vaccine and several antibiotics, there is more TB than ever before, requiring new vaccines and drugs and more specific and rapid diagnostics.  Researchers are utilizing information obtained from the complete sequence of the M. tuberculosis genome and from new genetic and physiol. methods to identify targets in M. tuberculosis that will aid in the development of these sorely needed antitubercular agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-PFlCxatfLLVg90H21EOLACvtfcHk0lgDfRD1mHKWyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsV2qt7c%253D&md5=34257497807bda4aafc60632318486cf</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1128%2FCMR.16.3.463-496.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.16.3.463-496.2003%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DI.%26atitle%3DMycobacterium%2520tuberculosis%2520pathogenesis%2520and%2520molecular%2520determinants%2520of%2520virulence%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2003%26volume%3D16%26spage%3D463%26epage%3D496%26doi%3D10.1128%2FCMR.16.3.463-496.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lonnroth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, C.</span></span> <span> </span><span class="NLM_article-title">Alcohol use as a risk factor for tuberculosis - a systematic review</span>. <i>BMC Public Health</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">289</span>, <span class="refDoi"> DOI: 10.1186/1471-2458-8-289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1186%2F1471-2458-8-289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=18702821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD1crpsFGntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=289&author=K.+Lonnrothauthor=B.+G.+Williamsauthor=S.+Stadlinauthor=E.+Jaramilloauthor=C.+Dye&title=Alcohol+use+as+a+risk+factor+for+tuberculosis+-+a+systematic+review&doi=10.1186%2F1471-2458-8-289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Alcohol use as a risk factor for tuberculosis - a systematic review</span></div><div class="casAuthors">Lonnroth Knut; Williams Brian G; Stadlin Stephanie; Jaramillo Ernesto; Dye Christopher</div><div class="citationInfo"><span class="NLM_cas:title">BMC public health</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">289</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  It has long been evident that there is an association between alcohol use and risk of tuberculosis.  It has not been established to what extent this association is confounded by social and other factors related to alcohol use.  Nor has the strength of the association been established.  The objective of this study was to systematically review the available evidence on the association between alcohol use and the risk of tuberculosis.  METHODS:  Based on a systematic literature review, we identified 3 cohort and 18 case control studies.  These were further categorized according to definition of exposure, type of tuberculosis used as study outcome, and confounders controlled for.  Pooled effect sizes were obtained for each sub-category of studies.  RESULTS:  The pooled relative risk across all studies that used an exposure cut-off level set at 40 g alcohol per day or above, or defined exposure as a clinical diagnosis of an alcohol use disorder, was 3.50 (95% CI: 2.01-5.93).  After exclusion of small studies, because of suspected publication bias, the pooled relative risk was 2.94 (95% CI: 1.89-4.59).  Subgroup analyses of studies that had controlled for various sets of confounders did not give significantly different results and did not explain the significant heterogeneity that was found across the studies.  CONCLUSION:  The risk of active tuberculosis is substantially elevated in people who drink more than 40 g alcohol per day, and/or have an alcohol use disorder.  This may be due to both increased risk of infection related to specific social mixing patterns associated with alcohol use, as well as influence on the immune system of alcohol itself and of alcohol related conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6wjgXo3uPKiSm0e6ZOaemfW6udTcc2eYuiqG4zRrhKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1crpsFGntw%253D%253D&md5=845b5506105d5e79f9b0a4e1dc7765ac</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1186%2F1471-2458-8-289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2458-8-289%26sid%3Dliteratum%253Aachs%26aulast%3DLonnroth%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DB.%2BG.%26aulast%3DStadlin%26aufirst%3DS.%26aulast%3DJaramillo%26aufirst%3DE.%26aulast%3DDye%26aufirst%3DC.%26atitle%3DAlcohol%2520use%2520as%2520a%2520risk%2520factor%2520for%2520tuberculosis%2520-%2520a%2520systematic%2520review%26jtitle%3DBMC%2520Public%2520Health%26date%3D2008%26volume%3D8%26spage%3D289%26doi%3D10.1186%2F1471-2458-8-289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span> <i>Systematic Review
of the Link Between Tobacco and Poverty</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2011</span>; <a href="https://www.who.int/tobacco/publications/economics/syst_rev_tobacco_poverty/en/" class="extLink">https://www.who.int/tobacco/publications/economics/syst_rev_tobacco_poverty/en/</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Systematic+Review%0Aof+the+Link+Between+Tobacco+and+Poverty%3B+World+Health+Organization%3A+Geneva%2C+2011%3B+https%3A%2F%2Fwww.who.int%2Ftobacco%2Fpublications%2Feconomics%2Fsyst_rev_tobacco_poverty%2Fen%2F+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DSystematic%2520Review%250Aof%2520the%2520Link%2520Between%2520Tobacco%2520and%2520Poverty%26pub%3DWorld%2520Health%2520Organization%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezzati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, M.</span></span> <span> </span><span class="NLM_article-title">Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e20</span>, <span class="refDoi"> DOI: 10.1371/journal.pmed.0040020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pmed.0040020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=17227135" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=e20&author=H.+H.+Linauthor=M.+Ezzatiauthor=M.+Murray&title=Tobacco+smoke%2C+indoor+air+pollution+and+tuberculosis%3A+a+systematic+review+and+meta-analysis&doi=10.1371%2Fjournal.pmed.0040020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0040020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0040020%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%2BH.%26aulast%3DEzzati%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DM.%26atitle%3DTobacco%2520smoke%252C%2520indoor%2520air%2520pollution%2520and%2520tuberculosis%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DPLoS%2520Med.%26date%3D2007%26volume%3D4%26spage%3De20%26doi%3D10.1371%2Fjournal.pmed.0040020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LoBue, P.</span></span> <span> </span><span class="NLM_article-title">Extensively drug-resistant tuberculosis</span>. <i>Curr. Opin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1097/QCO.0b013e3283229fab</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1097%2FQCO.0b013e3283229fab" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19283912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD1M3gsFOhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=167-173&author=P.+LoBue&title=Extensively+drug-resistant+tuberculosis&doi=10.1097%2FQCO.0b013e3283229fab"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Extensively drug-resistant tuberculosis</span></div><div class="casAuthors">LoBue Philip</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in infectious diseases</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  To describe the origin, epidemiology, diagnosis, treatment, prevention, and control of extensively drug-resistant tuberculosis (XDR TB).  RECENT FINDINGS:  XDR TB is defined as the occurrence of TB in persons whose Mycobacterium tuberculosis isolates are resistant to isoniazid and rifampin and to any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin).  As of June 2008, XDR TB has been found in 49 countries including the United States.  It generally takes several weeks to detect XDR TB using conventional culture-based methods, although some progress is being made in developing rapid molecular tests.  Treatment for XDR TB is difficult, usually requiring at least 18-24 months of four to six second-line anti-TB drugs.  Treatment success rates are generally 30-50%, with very poor outcomes in HIV-infected patients.  Management of contacts to infectious XDR TB patients is complicated by the lack of a proven effective treatment for XDR latent tuberculosis infection.  SUMMARY:  XDR TB is an emerging global health threat.  The disease is difficult and expensive to diagnose and treat, and outcomes are frequently poor.  New rapid diagnostic tests and new classes of anti-TB drugs are needed to successfully combat this global problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKbrLBFx7v2AWRJ3OJdH_qfW6udTcc2eYXWyZItM_AOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3gsFOhuw%253D%253D&md5=eacd3674848373ef008f3623df463665</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1097%2FQCO.0b013e3283229fab&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQCO.0b013e3283229fab%26sid%3Dliteratum%253Aachs%26aulast%3DLoBue%26aufirst%3DP.%26atitle%3DExtensively%2520drug-resistant%2520tuberculosis%26jtitle%3DCurr.%2520Opin.%2520Infect.%2520Dis.%26date%3D2009%26volume%3D22%26spage%3D167%26epage%3D173%26doi%3D10.1097%2FQCO.0b013e3283229fab" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caminero, J. A.</span></span> <span> </span><span class="NLM_article-title">Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">877</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=18647445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD1cvmvFeqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=869-877&author=J.+A.+Caminero&title=Likelihood+of+generating+MDR-TB+and+XDR-TB+under+adequate+National+Tuberculosis+Control+Programme+implementation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation</span></div><div class="casAuthors">Caminero J A</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">869-77</span>
        ISSN:<span class="NLM_cas:issn">1027-3719</span>.
    </div><div class="casAbstract">The most frequent factors associated with selection of resistance at the community level and the generation of multidrug-resistant tuberculosis (MDR-TB) under epidemic conditions have been described in the last decades.  These factors are multiple, and it is often a combination of these that has been implicated in the origin of MDR-TB epidemics in specific zones or countries.  The analysis of and correct approach to the causes should be the first and most important step in the fight against this critical problem.  However, it has never been investigated whether specific circumstances, even under adequate implementation of a National TB Control Programme (NTP), could lead to selection or amplification of resistance.  The NTP should consider explanations for when there is no decline in MDR-TB rates even after appropriate control measures have been implemented.  Under the special circumstances analysed in this article, the World Health Organization (WHO) Category I regimen can amplify resistance to rifampicin (in initial isoniazid-resistant cases) or ethambutol (EMB) + pyrazinamide (in initial MDR-TB cases).  The WHO Category II regimen can also amplify resistance to EMB or streptomycin.  The subsequent addition of the only second-line drugs available in many countries (fluoroquinolones and/or injectables) can worsen the situation and generate extensively drug-resistant TB.  Strategies for minimising these risks of amplifying resistance are discussed in this article.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSt74dEoWIBbu98rul4nhSdfW6udTcc2ebO3SWojTI-Grntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvmvFeqsg%253D%253D&md5=d256bde49c2f3814fb3cecdf1a9e4292</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaminero%26aufirst%3DJ.%2BA.%26atitle%3DLikelihood%2520of%2520generating%2520MDR-TB%2520and%2520XDR-TB%2520under%2520adequate%2520National%2520Tuberculosis%2520Control%2520Programme%2520implementation%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D2008%26volume%3D12%26spage%3D869%26epage%3D877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azevedo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coetzee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coetzee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Cutsem, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goemaere, E.</span></span> <span> </span><span class="NLM_article-title">Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e13901</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0013901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pone.0013901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21085569" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=e13901&author=H.+S.+Coxauthor=C.+McDermidauthor=V.+Azevedoauthor=O.+Mullerauthor=D.+Coetzeeauthor=J.+Simpsonauthor=M.+Barnardauthor=G.+Coetzeeauthor=G.+van+Cutsemauthor=E.+Goemaere&title=Epidemic+levels+of+drug+resistant+tuberculosis+%28MDR+and+XDR-TB%29+in+a+high+HIV+prevalence+setting+in+Khayelitsha%2C+South+Africa&doi=10.1371%2Fjournal.pone.0013901"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0013901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0013901%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DH.%2BS.%26aulast%3DMcDermid%26aufirst%3DC.%26aulast%3DAzevedo%26aufirst%3DV.%26aulast%3DMuller%26aufirst%3DO.%26aulast%3DCoetzee%26aufirst%3DD.%26aulast%3DSimpson%26aufirst%3DJ.%26aulast%3DBarnard%26aufirst%3DM.%26aulast%3DCoetzee%26aufirst%3DG.%26aulast%3Dvan%2BCutsem%26aufirst%3DG.%26aulast%3DGoemaere%26aufirst%3DE.%26atitle%3DEpidemic%2520levels%2520of%2520drug%2520resistant%2520tuberculosis%2520%2528MDR%2520and%2520XDR-TB%2529%2520in%2520a%2520high%2520HIV%2520prevalence%2520setting%2520in%2520Khayelitsha%252C%2520South%2520Africa%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26spage%3De13901%26doi%3D10.1371%2Fjournal.pone.0013901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benatar, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upshur, R.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis and poverty: what could (and should) be done?</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1215</span>– <span class="NLM_lpage">1221</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=20843410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3cfislCgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=1215-1221&author=S.+R.+Benatarauthor=R.+Upshur&title=Tuberculosis+and+poverty%3A+what+could+%28and+should%29+be+done%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberculosis and poverty: what could (and should) be done?</span></div><div class="casAuthors">Benatar S R; Upshur R</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1215-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJGSKKqrSo6Rcr74wzj5o5fW6udTcc2ebO3SWojTI-Grntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cfislCgtg%253D%253D&md5=1a73de5091c69c726f03b935c4d36999</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBenatar%26aufirst%3DS.%2BR.%26aulast%3DUpshur%26aufirst%3DR.%26atitle%3DTuberculosis%2520and%2520poverty%253A%2520what%2520could%2520%2528and%2520should%2529%2520be%2520done%253F%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D2010%26volume%3D14%26spage%3D1215%26epage%3D1221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lonnroth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raviglione, M.</span></span> <span> </span><span class="NLM_article-title">Drivers of tuberculosis epidemics: the role of risk factors and social determinants</span>. <i>Social Science and Medicine</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2240</span>– <span class="NLM_lpage">2246</span>, <span class="refDoi"> DOI: 10.1016/j.socscimed.2009.03.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.socscimed.2009.03.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19394122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD1Mvhs1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2009&pages=2240-2246&author=K.+Lonnrothauthor=E.+Jaramilloauthor=B.+G.+Williamsauthor=C.+Dyeauthor=M.+Raviglione&title=Drivers+of+tuberculosis+epidemics%3A+the+role+of+risk+factors+and+social+determinants&doi=10.1016%2Fj.socscimed.2009.03.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Drivers of tuberculosis epidemics: the role of risk factors and social determinants</span></div><div class="casAuthors">Lonnroth Knut; Jaramillo Ernesto; Williams Brian G; Dye Christopher; Raviglione Mario</div><div class="citationInfo"><span class="NLM_cas:title">Social science & medicine (1982)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2240-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The main thrust of the World Health Organization's global tuberculosis (TB) control strategy is to ensure effective and equitable delivery of quality assured diagnosis and treatment of TB.  Options for including preventive efforts have not yet been fully considered.  This paper presents a narrative review of the historical and recent progress in TB control and the role of TB risk factors and social determinants.  The review was conducted with a view to assess the prospects of effectively controlling TB under the current strategy, and the potential to increase epidemiological impact through additional preventive interventions.  The review suggests that, while the current strategy is effective in curing patients and saving lives, the epidemiological impact has so far been less than predicted.  In order to reach long-term epidemiological targets for global TB control, additional interventions to reduce peoples' vulnerability for TB may therefore be required.  Risk factors that seem to be of importance at the population level include poor living and working conditions associated with high risk of TB transmission, and factors that impair the host's defence against TB infection and disease, such as HIV infection, malnutrition, smoking, diabetes, alcohol abuse, and indoor air pollution.  Preventive interventions may target these factors directly or via their underlying social determinants.  The identification of risk groups also helps to target strategies for early detection of people in need of TB treatment.  More research is needed on the suitability, feasibility and cost-effectiveness of these intervention options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAX7fiC2q5IsULxIEhxUjPfW6udTcc2eZK0E_S_fpqPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mvhs1CktA%253D%253D&md5=511292622073a7edafb5c4ef15429824</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.socscimed.2009.03.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.socscimed.2009.03.041%26sid%3Dliteratum%253Aachs%26aulast%3DLonnroth%26aufirst%3DK.%26aulast%3DJaramillo%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DB.%2BG.%26aulast%3DDye%26aufirst%3DC.%26aulast%3DRaviglione%26aufirst%3DM.%26atitle%3DDrivers%2520of%2520tuberculosis%2520epidemics%253A%2520the%2520role%2520of%2520risk%2520factors%2520and%2520social%2520determinants%26jtitle%3DSocial%2520Science%2520and%2520Medicine%26date%3D2009%26volume%3D68%26spage%3D2240%26epage%3D2246%26doi%3D10.1016%2Fj.socscimed.2009.03.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crudu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noroc, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romancenco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemann, S.</span></span> <span> </span><span class="NLM_article-title">Nosocomial transmission of multidrug-resistant tuberculosis</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1520</span>– <span class="NLM_lpage">1523</span>, <span class="refDoi"> DOI: 10.5588/ijtld.15.0327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.5588%2Fijtld.15.0327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26614195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC28vlvFOjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=1520-1523&author=V.+Cruduauthor=M.+Merkerauthor=C.+Langeauthor=E.+Norocauthor=E.+Romancencoauthor=D.+Chesovauthor=G.+Guntherauthor=S.+Niemann&title=Nosocomial+transmission+of+multidrug-resistant+tuberculosis&doi=10.5588%2Fijtld.15.0327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Nosocomial transmission of multidrug-resistant tuberculosis</span></div><div class="casAuthors">Crudu V; Noroc E; Romancenco E; Merker M; Niemann S; Lange C; Chesov D; Gunther G</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1520-3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Nosocomial transmission of multidrug-resistant tuberculosis (MDR-TB) was ascertained by 24-locus mycobacterial interspersed repetitive units-variable number of tandem repeats (MIRU-VNTR) and spoligotyping at four hospitals in the Republic of Moldova, a high MDR-TB burden country.  Overall, 5.1% of patients with pan-susceptible TB at baseline were identified with MDR-TB during in-patient treatment.  In 75% of cases, the MDR-TB strain was genetically distinct from the non-MDR-TB strain at baseline, suggesting a high rate of nosocomial transmission of MDR-TB.  The highest proportion (40.3%) of follow-up MDR-TB isolates was associated with the M. tuberculosis URAL 163-15 strain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5nTpLjFNsobBItaL1WaVAfW6udTcc2eZK0E_S_fpqPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vlvFOjug%253D%253D&md5=bae354656c7282547300f23ffefbe708</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.5588%2Fijtld.15.0327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5588%252Fijtld.15.0327%26sid%3Dliteratum%253Aachs%26aulast%3DCrudu%26aufirst%3DV.%26aulast%3DMerker%26aufirst%3DM.%26aulast%3DLange%26aufirst%3DC.%26aulast%3DNoroc%26aufirst%3DE.%26aulast%3DRomancenco%26aufirst%3DE.%26aulast%3DChesov%26aufirst%3DD.%26aulast%3DGunther%26aufirst%3DG.%26aulast%3DNiemann%26aufirst%3DS.%26atitle%3DNosocomial%2520transmission%2520of%2520multidrug-resistant%2520tuberculosis%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D2015%26volume%3D19%26spage%3D1520%26epage%3D1523%26doi%3D10.5588%2Fijtld.15.0327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">von
Delft, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dramowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khosa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotze, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lederer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosidi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Westhuizen, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Delft, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeurer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mwaba, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyirenda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zumla, A.</span></span> <span> </span><span class="NLM_article-title">Why healthcare workers are sick of TB</span>. <i>Int. J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1016/j.ijid.2014.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.ijid.2014.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25809771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2MnotFarsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=147-151&author=A.+von%0ADelftauthor=A.+Dramowskiauthor=C.+Khosaauthor=K.+Kotzeauthor=P.+Ledererauthor=T.+Mosidiauthor=J.+A.+Petersauthor=J.+Smithauthor=H.+M.+van+der+Westhuizenauthor=D.+von+Delftauthor=B.+Willemsauthor=M.+Batesauthor=G.+Craigauthor=M.+Maeurerauthor=B.+J.+Maraisauthor=P.+Mwabaauthor=E.+A.+Nunesauthor=T.+Nyirendaauthor=M.+Oliverauthor=A.+Zumla&title=Why+healthcare+workers+are+sick+of+TB&doi=10.1016%2Fj.ijid.2014.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Why healthcare workers are sick of TB</span></div><div class="casAuthors">von Delft Arne; Dramowski Angela; Khosa Celso; Kotze Koot; van der Westhuizen Helene-Mari; Willems Bart; Lederer Philip; Mosidi Thato; Peters Jurgens A; von Delft Dalene; Smith Jonathan; Bates Matthew; Mwaba Peter; Craig Gill; Maeurer Markus; Marais Ben J; Nunes Elizabete A; Nyirenda Thomas; Oliver Matt; Zumla Alimuddin</div><div class="citationInfo"><span class="NLM_cas:title">International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">147-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dr Thato Mosidi never expected to be diagnosed with tuberculosis (TB), despite widely prevalent exposure and very limited infection control measures.  The life-threatening diagnosis of primary extensively drug-resistant TB (XDR-TB) came as an even greater shock.  The inconvenient truth is that, rather than being protected, Dr Mosidi and thousands of her healthcare colleagues are at an increased risk of TB and especially drug-resistant TB.  In this viewpoint paper we debunk the widely held false belief that healthcare workers are somehow immune to TB disease (TB-proof) and explore some of the key factors contributing to the pervasive stigmatization and subsequent non-disclosure of occupational TB.  Our front-line workers are some of the first to suffer the consequences of a progressively more resistant and fatal TB epidemic, and urgent interventions are needed to ensure the safety and continued availability of these precious healthcare resources.  These include the rapid development and scale-up of improved diagnostic and treatment options, strengthened infection control measures, and focused interventions to tackle stigma and discrimination in all its forms.  We call our colleagues to action to protect themselves and those they care for.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR3ahRjARP6kYIRAdBLKY41fW6udTcc2eYmTXfWN7vRHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnotFarsw%253D%253D&md5=985f2f3878f94f6513879b0c796114b9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ijid.2014.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijid.2014.12.003%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BDelft%26aufirst%3DA.%26aulast%3DDramowski%26aufirst%3DA.%26aulast%3DKhosa%26aufirst%3DC.%26aulast%3DKotze%26aufirst%3DK.%26aulast%3DLederer%26aufirst%3DP.%26aulast%3DMosidi%26aufirst%3DT.%26aulast%3DPeters%26aufirst%3DJ.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BWesthuizen%26aufirst%3DH.%2BM.%26aulast%3Dvon%2BDelft%26aufirst%3DD.%26aulast%3DWillems%26aufirst%3DB.%26aulast%3DBates%26aufirst%3DM.%26aulast%3DCraig%26aufirst%3DG.%26aulast%3DMaeurer%26aufirst%3DM.%26aulast%3DMarais%26aufirst%3DB.%2BJ.%26aulast%3DMwaba%26aufirst%3DP.%26aulast%3DNunes%26aufirst%3DE.%2BA.%26aulast%3DNyirenda%26aufirst%3DT.%26aulast%3DOliver%26aufirst%3DM.%26aulast%3DZumla%26aufirst%3DA.%26atitle%3DWhy%2520healthcare%2520workers%2520are%2520sick%2520of%2520TB%26jtitle%3DInt.%2520J.%2520Infect.%2520Dis.%26date%3D2015%26volume%3D32%26spage%3D147%26epage%3D151%26doi%3D10.1016%2Fj.ijid.2014.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cegielski, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laserson, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtz, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weyer, K.</span></span> <span> </span><span class="NLM_article-title">HIV infection and multidrug-resistant tuberculosis: the perfect storm</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>196</i></span>,  <span class="NLM_fpage">S86</span>– <span class="NLM_lpage">S107</span>, <span class="refDoi"> DOI: 10.1086/518665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1086%2F518665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=17624830" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=196&publication_year=2007&pages=S86-S107&author=C.+D.+Wellsauthor=J.+P.+Cegielskiauthor=L.+J.+Nelsonauthor=K.+F.+Lasersonauthor=T.+H.+Holtzauthor=A.+Finlayauthor=K.+G.+Castroauthor=K.+Weyer&title=HIV+infection+and+multidrug-resistant+tuberculosis%3A+the+perfect+storm&doi=10.1086%2F518665"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1086%2F518665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F518665%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DC.%2BD.%26aulast%3DCegielski%26aufirst%3DJ.%2BP.%26aulast%3DNelson%26aufirst%3DL.%2BJ.%26aulast%3DLaserson%26aufirst%3DK.%2BF.%26aulast%3DHoltz%26aufirst%3DT.%2BH.%26aulast%3DFinlay%26aufirst%3DA.%26aulast%3DCastro%26aufirst%3DK.%2BG.%26aulast%3DWeyer%26aufirst%3DK.%26atitle%3DHIV%2520infection%2520and%2520multidrug-resistant%2520tuberculosis%253A%2520the%2520perfect%2520storm%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2007%26volume%3D196%26spage%3DS86%26epage%3DS107%26doi%3D10.1086%2F518665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Churchyard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustomjee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathema, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasmar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardenas, V.</span></span> <span> </span><span class="NLM_article-title">What We Know About Tuberculosis Transmission: An Overview</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>216</i></span>,  <span class="NLM_fpage">S629</span>– <span class="NLM_lpage">S635</span>, <span class="refDoi"> DOI: 10.1093/infdis/jix362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Finfdis%2Fjix362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29112747" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=2017&pages=S629-S635&author=G.+Churchyardauthor=P.+Kimauthor=N.+S.+Shahauthor=R.+Rustomjeeauthor=N.+Gandhiauthor=B.+Mathemaauthor=D.+Dowdyauthor=A.+Kasmarauthor=V.+Cardenas&title=What+We+Know+About+Tuberculosis+Transmission%3A+An+Overview&doi=10.1093%2Finfdis%2Fjix362"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjix362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjix362%26sid%3Dliteratum%253Aachs%26aulast%3DChurchyard%26aufirst%3DG.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DN.%2BS.%26aulast%3DRustomjee%26aufirst%3DR.%26aulast%3DGandhi%26aufirst%3DN.%26aulast%3DMathema%26aufirst%3DB.%26aulast%3DDowdy%26aufirst%3DD.%26aulast%3DKasmar%26aufirst%3DA.%26aulast%3DCardenas%26aufirst%3DV.%26atitle%3DWhat%2520We%2520Know%2520About%2520Tuberculosis%2520Transmission%253A%2520An%2520Overview%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2017%26volume%3D216%26spage%3DS629%26epage%3DS635%26doi%3D10.1093%2Finfdis%2Fjix362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fox, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britton, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, G. B.</span></span> <span> </span><span class="NLM_article-title">Contact investigation for tuberculosis: a systematic review and meta-analysis</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1183/09031936.00070812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1183%2F09031936.00070812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22936710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC38bivFCrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=140-156&author=G.+J.+Foxauthor=S.+E.+Barryauthor=W.+J.+Brittonauthor=G.+B.+Marks&title=Contact+investigation+for+tuberculosis%3A+a+systematic+review+and+meta-analysis&doi=10.1183%2F09031936.00070812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Contact investigation for tuberculosis: a systematic review and meta-analysis</span></div><div class="casAuthors">Fox Gregory J; Barry Simone E; Britton Warwick J; Marks Guy B</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">140-56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Investigation of contacts of patients with tuberculosis (TB) is a priority for TB control in high-income countries, and is increasingly being considered in resource-limited settings.  This review was commissioned for a World Health Organization Expert Panel to develop global contact investigation guidelines.  We performed a systematic review and meta-analysis of all studies reporting the prevalence of TB and latent TB infection, and the annual incidence of TB among contacts of patients with TB.  After screening 9,555 titles, we included 203 published studies.  In 95 studies from low- and middle-income settings, the prevalence of active TB in all contacts was 3.1% (95% CI 2.2-4.4%, I(2)=99.4%), microbiologically proven TB was 1.2% (95% CI 0.9-1.8%, I(2)=95.9%), and latent TB infection was 51.5% (95% CI 47.1-55.8%, I(2)=98.9%).  The prevalence of TB among household contacts was 3.1% (95% CI 2.1-4.5%, I(2)=98.8%) and among contacts of patients with multidrug-resistant or extensively drug-resistant TB was 3.4% (95% CI 0.8-12.6%, I(2)=95.7%).  Incidence was greatest in the first year after exposure.  In 108 studies from high-income settings, the prevalence of TB among contacts was 1.4% (95% CI 1.1-1.8%, I(2)=98.7%), and the prevalence of latent infection was 28.1% (95% CI 24.2-32.4%, I(2)=99.5%).  There was substantial heterogeneity among published studies.  Contacts of TB patients are a high-risk group for developing TB, particularly within the first year.  Children <5 yrs of age and people living with HIV are particularly at risk.  Policy recommendations must consider evidence of the cost-effectiveness of various contact tracing strategies, and also incorporate complementary strategies to enhance case finding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZeTXPSNnEVn6oPH0mYWL1fW6udTcc2eYmTXfWN7vRHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bivFCrtQ%253D%253D&md5=18f9513f091a72f06f4eaa5fb934181a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1183%2F09031936.00070812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00070812%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DG.%2BJ.%26aulast%3DBarry%26aufirst%3DS.%2BE.%26aulast%3DBritton%26aufirst%3DW.%2BJ.%26aulast%3DMarks%26aufirst%3DG.%2BB.%26atitle%3DContact%2520investigation%2520for%2520tuberculosis%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D41%26spage%3D140%26epage%3D156%26doi%3D10.1183%2F09031936.00070812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathema, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgdorff, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynn, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustomjee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silk, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, R.</span></span> <span> </span><span class="NLM_article-title">Drivers of tuberculosis transmission</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>216</i></span>,  <span class="NLM_fpage">S644</span>– <span class="NLM_lpage">S653</span>, <span class="refDoi"> DOI: 10.1093/infdis/jix354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Finfdis%2Fjix354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29112745" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=2017&pages=S644-S653&author=B.+Mathemaauthor=J.+R.+Andrewsauthor=T.+Cohenauthor=M.+W.+Borgdorffauthor=M.+Behrauthor=J.+R.+Glynnauthor=R.+Rustomjeeauthor=B.+J.+Silkauthor=R.+Wood&title=Drivers+of+tuberculosis+transmission&doi=10.1093%2Finfdis%2Fjix354"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjix354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjix354%26sid%3Dliteratum%253Aachs%26aulast%3DMathema%26aufirst%3DB.%26aulast%3DAndrews%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DT.%26aulast%3DBorgdorff%26aufirst%3DM.%2BW.%26aulast%3DBehr%26aufirst%3DM.%26aulast%3DGlynn%26aufirst%3DJ.%2BR.%26aulast%3DRustomjee%26aufirst%3DR.%26aulast%3DSilk%26aufirst%3DB.%2BJ.%26aulast%3DWood%26aufirst%3DR.%26atitle%3DDrivers%2520of%2520tuberculosis%2520transmission%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2017%26volume%3D216%26spage%3DS644%26epage%3DS653%26doi%3D10.1093%2Finfdis%2Fjix354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Gonzalez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soberanis-Ramos, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Gamboa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez-Mazari, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios-Herrera, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Rojas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz-Hervert, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Garcia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Aguirre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponce de Leon-Garduño, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sifuentes-Osornio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobadilla-Del-Valle, M.</span></span> <span> </span><span class="NLM_article-title">Prevalence of latent and active tuberculosis among dairy farm workers exposed to cattle infected by Mycobacterium bovis</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e2177</span>, <span class="refDoi"> DOI: 10.1371/journal.pntd.0002177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pntd.0002177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23638198" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=e2177&author=P.+Torres-Gonzalezauthor=O.+Soberanis-Ramosauthor=A.+Martinez-Gamboaauthor=B.+Chavez-Mazariauthor=M.+T.+Barrios-Herreraauthor=M.+Torres-Rojasauthor=L.+P.+Cruz-Hervertauthor=L.+Garcia-Garciaauthor=M.+Singhauthor=A.+Gonzalez-Aguirreauthor=A.+Ponce+de+Leon-Gardu%C3%B1oauthor=J.+Sifuentes-Osornioauthor=M.+Bobadilla-Del-Valle&title=Prevalence+of+latent+and+active+tuberculosis+among+dairy+farm+workers+exposed+to+cattle+infected+by+Mycobacterium+bovis&doi=10.1371%2Fjournal.pntd.0002177"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0002177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0002177%26sid%3Dliteratum%253Aachs%26aulast%3DTorres-Gonzalez%26aufirst%3DP.%26aulast%3DSoberanis-Ramos%26aufirst%3DO.%26aulast%3DMartinez-Gamboa%26aufirst%3DA.%26aulast%3DChavez-Mazari%26aufirst%3DB.%26aulast%3DBarrios-Herrera%26aufirst%3DM.%2BT.%26aulast%3DTorres-Rojas%26aufirst%3DM.%26aulast%3DCruz-Hervert%26aufirst%3DL.%2BP.%26aulast%3DGarcia-Garcia%26aufirst%3DL.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DGonzalez-Aguirre%26aufirst%3DA.%26aulast%3DPonce%2Bde%2BLeon-Gardu%25C3%25B1o%26aufirst%3DA.%26aulast%3DSifuentes-Osornio%26aufirst%3DJ.%26aulast%3DBobadilla-Del-Valle%26aufirst%3DM.%26atitle%3DPrevalence%2520of%2520latent%2520and%2520active%2520tuberculosis%2520among%2520dairy%2520farm%2520workers%2520exposed%2520to%2520cattle%2520infected%2520by%2520Mycobacterium%2520bovis%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2013%26volume%3D7%26spage%3De2177%26doi%3D10.1371%2Fjournal.pntd.0002177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simons, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Soolingen, D.</span></span> <span> </span><span class="NLM_article-title">Drug susceptibility testing for optimizing tuberculosis treatment</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2863</span>– <span class="NLM_lpage">2874</span>, <span class="refDoi"> DOI: 10.2174/138161211797470255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.2174%2F138161211797470255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21834762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSis7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2863-2874&author=S.+O.+Simonsauthor=D.+van+Soolingen&title=Drug+susceptibility+testing+for+optimizing+tuberculosis+treatment&doi=10.2174%2F138161211797470255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Drug susceptibility testing for optimizing tuberculosis treatment</span></div><div class="casAuthors">Simons, Sami O.; van Soolingen, Dick</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">2863-2874</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The principles of our current drug susceptibility testing (DST) for tuberculosis (TB) have already been laid out in 1963.  Since then, DST has not gained much popularity owing to the long turn-around time and the introduction of potent antituberculosis drug regimens.  These and other barriers have led to a crit. gap in lab. capacity in DST of Mycobacterium tuberculosis.  However, owing to the emergence of multidrug resistant tuberculosis there is a pressing need for adequate and rapid DST.  In recent years, methods for fastening the diagnosis of drug resistant tuberculosis were developed.  Semi-automated (non)- radiometric liq. culture systems reduced the turn-around-time significantly.  With the introduction of mol. diagnostic methods, such as reverse line probes and the recently introduced semi-automated real-time PCR, the turn-around time of at least an indicative resistance testing has dropped from days to hours.  However, much more can be gained in the development of fast phenotypic and mol. DST methodologies.  Recently also pharmacodynamic studies have also added significantly to our understanding of resistance development in tuberculosis treatment.  This article provides an overview of the most important DST techniques now available, with their characteristics, biosafety aspects, reproducibility, and required quality control.  Also the findings in pharmacodynamic studies and required future research are discussed.  We will argue that drug susceptibility testing in TB treatment is an essential tool for adequate TB control and prevention of resistance and should be applied to all patients to guide TB treatment.  Perhaps in the near future even individualized treatment doses could be an important help to prevent further emergence or further development of resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL_XdGBt8ZBrVg90H21EOLACvtfcHk0liy2pMbN40aSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSis7jE&md5=81546ef81057f80908efd58d294be474</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2174%2F138161211797470255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161211797470255%26sid%3Dliteratum%253Aachs%26aulast%3DSimons%26aufirst%3DS.%2BO.%26aulast%3Dvan%2BSoolingen%26aufirst%3DD.%26atitle%3DDrug%2520susceptibility%2520testing%2520for%2520optimizing%2520tuberculosis%2520treatment%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2011%26volume%3D17%26spage%3D2863%26epage%3D2874%26doi%3D10.2174%2F138161211797470255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Migliori, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Ambrosio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spanevello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borroni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotgiu, G.</span></span> <span> </span><span class="NLM_article-title">Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease?</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1379</span>– <span class="NLM_lpage">1380</span>, <span class="refDoi"> DOI: 10.1093/cid/cis128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fcid%2Fcis128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22492321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC38rjvFOhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2012&pages=1379-1380&author=G.+B.+Miglioriauthor=R.+Centisauthor=L.+D%E2%80%99Ambrosioauthor=A.+Spanevelloauthor=E.+Borroniauthor=D.+M.+Cirilloauthor=G.+Sotgiu&title=Totally+drug-resistant+and+extremely+drug-resistant+tuberculosis%3A+the+same+disease%3F&doi=10.1093%2Fcid%2Fcis128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease?</span></div><div class="casAuthors">Migliori G B; Centis R; D'Ambrosio L; Spanevello A; Borroni E; Cirillo D M; Sotgiu G</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1379-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSoLioDKQt2VkmhnSqMnvzDfW6udTcc2ealfym47iDITLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rjvFOhsA%253D%253D&md5=a8a0866120a71ef761e45c8c17d04583</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcis128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcis128%26sid%3Dliteratum%253Aachs%26aulast%3DMigliori%26aufirst%3DG.%2BB.%26aulast%3DCentis%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Ambrosio%26aufirst%3DL.%26aulast%3DSpanevello%26aufirst%3DA.%26aulast%3DBorroni%26aufirst%3DE.%26aulast%3DCirillo%26aufirst%3DD.%2BM.%26aulast%3DSotgiu%26aufirst%3DG.%26atitle%3DTotally%2520drug-resistant%2520and%2520extremely%2520drug-resistant%2520tuberculosis%253A%2520the%2520same%2520disease%253F%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2012%26volume%3D54%26spage%3D1379%26epage%3D1380%26doi%3D10.1093%2Fcid%2Fcis128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharjya, B.</span></span> <span> </span><span class="NLM_article-title">Mantoux test and its interpretation</span>. <i>Indian Dermatology Online Journal</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.4103/2229-5178.93479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4103%2F2229-5178.93479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23130251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3s7ht1KrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=2-6&author=S.+Nayakauthor=B.+Acharjya&title=Mantoux+test+and+its+interpretation&doi=10.4103%2F2229-5178.93479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Mantoux test and its interpretation</span></div><div class="casAuthors">Nayak Surajit; Acharjya Basanti</div><div class="citationInfo"><span class="NLM_cas:title">Indian dermatology online journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The tuberculin skin test is one of the few investigations dating from the 19(th) century that are still widely used as an important test for diagnosing tuberculosis.  Though very commonly used by physicians worldwide its interpretation always remains difficult and controversial.  Various factors like age, immunological status coexisting illness etc influence its outcome, so also its interpretation.  Utmost care is required while interpreting the result and giving an opinion.  This article has been written with the purpose of elucidating the performance and interpretation of the standard tuberculin test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8kcGdtk6yZlUIs6wFK5xJfW6udTcc2ealfym47iDITLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7ht1KrsA%253D%253D&md5=707982e5e889f6a5cf8345556c20c057</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.4103%2F2229-5178.93479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F2229-5178.93479%26sid%3Dliteratum%253Aachs%26aulast%3DNayak%26aufirst%3DS.%26aulast%3DAcharjya%26aufirst%3DB.%26atitle%3DMantoux%2520test%2520and%2520its%2520interpretation%26jtitle%3DIndian%2520Dermatology%2520Online%2520Journal%26date%3D2012%26volume%3D3%26spage%3D2%26epage%3D6%26doi%3D10.4103%2F2229-5178.93479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idrees, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afzal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, A.</span></span> <span> </span><span class="NLM_article-title">PCR could be a method of choice for identification of both pulmonary and extra-pulmonary tuberculosis</span>. <i>BMC Res. Notes</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">332</span>, <span class="refDoi"> DOI: 10.1186/1756-0500-4-332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1186%2F1756-0500-4-332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21899772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3MfltV2mtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=332&author=I.+Aminauthor=M.+Idreesauthor=Z.+Awanauthor=M.+Shahidauthor=S.+Afzalauthor=A.+Hussain&title=PCR+could+be+a+method+of+choice+for+identification+of+both+pulmonary+and+extra-pulmonary+tuberculosis&doi=10.1186%2F1756-0500-4-332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">PCR could be a method of choice for identification of both pulmonary and extra-pulmonary tuberculosis</span></div><div class="casAuthors">Amin Iram; Idrees Muhammad; Awan Zunaira; Shahid Muhammad; Afzal Samia; Hussain Abrar</div><div class="citationInfo"><span class="NLM_cas:title">BMC research notes</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">332</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Nucleic acid amplification assays including PCR have revolutionized the detection of Mycobacterium tuberculosis (MTB).  Tuberculosis spread to almost every organ of the body and is characterized on the basis of localization of infection.  Therefore, different types of body fluids and tissues can be used for the detection of MTB.From 2004 to 2010 total 766 different types of smear negative samples from patients, clinically suspected for tuberculosis were received and investigated at Division of Molecular Diagnostics, University of the Punjab Lahore for the diagnosis of tuberculosis.  Mycobacterial DNA was extracted followed by PCR amplification.  FINDINGS:  A total of 356 (46.5%) samples were found positive by PCR for MTB.  These included; serum (4.8%), blood (36.3%), urine (46.6%), cerebro spinal fluid (CSF) (42.1%), ascetic fluid (67.6%), pleural fluid (52%), pericardial fluid (30%), pus (38.6%), bone marrow (60%), sputum (38.8%) and bronchoalveolar lavage (BAL) (70%).  Over all there was no significant difference in males and females neither in different age groups for the identification of MTB.  CONCLUSION:  We conclude that PCR is a useful and sensitive tool for the early diagnosis of MTB in variety of clinical samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQH6R-VpJ9QV2LFM_lbR1VmfW6udTcc2ea1EIyG6W3UrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfltV2mtw%253D%253D&md5=63945e244379068bf7af38f73d6761ed</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1186%2F1756-0500-4-332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-0500-4-332%26sid%3Dliteratum%253Aachs%26aulast%3DAmin%26aufirst%3DI.%26aulast%3DIdrees%26aufirst%3DM.%26aulast%3DAwan%26aufirst%3DZ.%26aulast%3DShahid%26aufirst%3DM.%26aulast%3DAfzal%26aufirst%3DS.%26aulast%3DHussain%26aufirst%3DA.%26atitle%3DPCR%2520could%2520be%2520a%2520method%2520of%2520choice%2520for%2520identification%2520of%2520both%2520pulmonary%2520and%2520extra-pulmonary%2520tuberculosis%26jtitle%3DBMC%2520Res.%2520Notes%26date%3D2011%26volume%3D4%26spage%3D332%26doi%3D10.1186%2F1756-0500-4-332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe
Pinhata, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cergole-Novella, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira dos Santos Carmo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruivo Ferro e Silva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrazoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares Sacchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siqueira de Oliveira, R.</span></span> <span> </span><span class="NLM_article-title">Rapid detection of Mycobacterium tuberculosis complex by real-time PCR in sputum samples and its use in the routine diagnosis in a reference laboratory</span>. <i>J. Med. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1040</span>– <span class="NLM_lpage">1045</span>, <span class="refDoi"> DOI: 10.1099/jmm.0.000121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1099%2Fjmm.0.000121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26297002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC287lt1WisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=1040-1045&author=J.+M.+Watanabe%0APinhataauthor=M.+C.+Cergole-Novellaauthor=A.+Moreira+dos+Santos+Carmoauthor=R.+Ruivo+Ferro+e+Silvaauthor=L.+Ferrazoliauthor=C.+Tavares+Sacchiauthor=R.+Siqueira+de+Oliveira&title=Rapid+detection+of+Mycobacterium+tuberculosis+complex+by+real-time+PCR+in+sputum+samples+and+its+use+in+the+routine+diagnosis+in+a+reference+laboratory&doi=10.1099%2Fjmm.0.000121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid detection of Mycobacterium tuberculosis complex by real-time PCR in sputum samples and its use in the routine diagnosis in a reference laboratory</span></div><div class="casAuthors">Watanabe Pinhata Juliana Maira; Ferrazoli Lucilaine; Siqueira de Oliveira Rosangela; Cergole-Novella Maria Cecilia; Moreira Dos Santos Carmo Andreia; Ruivo Ferro E Silva Regina; Tavares Sacchi Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medical microbiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1040-1045</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis (TB) is an infectious disease of global distribution, constituting a serious public health problem in Brazil.  Sao Paulo State, located in the south-east of Brazil, notified 16,580 new TB cases in 2013.  The Instituto Adolfo Lutz is a public health reference laboratory for TB diagnosis for all the State.  Considering that rapid and accurate diagnosis is essential for TB control, the aim of this study was to evaluate the use of an in-house real-time (RT)-PCR assay targeting the mpt64 gene in the routine diagnosis of TB, and to compare this technique with smear microscopy and culture.  From August 2012 to October 2013, 715 sputum samples from 657 patients were included in the study.  Smear microscopy, culture, phenotypic and PRA-hsp65 identification of mycobacteria, and mpt64 RT-PCR were performed.  With respect to confirmed TB cases (n = 62/657; 9.4%), smear microscopy had a sensitivity of 82.3%.  Culture and RT-PCR showed the same sensitivity, i.e. 90.3%.  Specificity was 99.7, 99.4 and 98.6% for smear microscopy, culture and RT-PCR, respectively. mpt64 RT-PCR showed high sensitivity and specificity for the detection of Mycobacterium tuberculosis complex in sputum samples.  This technique can be deployed in laboratories that do not have a rapid test for TB available, enabling the performance of TB diagnosis in up to 5 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdsAqFyKtJQGx8TEN9K18QfW6udTcc2ea1EIyG6W3UrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287lt1WisA%253D%253D&md5=390ada9132debac5ac3d91cb1fdf2bbe</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1099%2Fjmm.0.000121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fjmm.0.000121%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%2BPinhata%26aufirst%3DJ.%2BM.%26aulast%3DCergole-Novella%26aufirst%3DM.%2BC.%26aulast%3DMoreira%2Bdos%2BSantos%2BCarmo%26aufirst%3DA.%26aulast%3DRuivo%2BFerro%2Be%2BSilva%26aufirst%3DR.%26aulast%3DFerrazoli%26aufirst%3DL.%26aulast%3DTavares%2BSacchi%26aufirst%3DC.%26aulast%3DSiqueira%2Bde%2BOliveira%26aufirst%3DR.%26atitle%3DRapid%2520detection%2520of%2520Mycobacterium%2520tuberculosis%2520complex%2520by%2520real-time%2520PCR%2520in%2520sputum%2520samples%2520and%2520its%2520use%2520in%2520the%2520routine%2520diagnosis%2520in%2520a%2520reference%2520laboratory%26jtitle%3DJ.%2520Med.%2520Microbiol.%26date%3D2015%26volume%3D64%26spage%3D1040%26epage%3D1045%26doi%3D10.1099%2Fjmm.0.000121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abeel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desjardins, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, J.</span></span>; <span class="NLM_contrib-group">TBResist Global Genome Consortium</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrielian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jodals, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joloba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jureen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malinga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordenberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noroc, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romancenco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ssengooba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velayati, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winglee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalutskaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Via, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassell, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farnia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galagan, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crudu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homorodean, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pym, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skrahina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Walt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishai, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birren, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earl, A. M.</span></span> <span> </span><span class="NLM_article-title">Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1038/ng.3767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fng.3767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28092681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCls7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=395-402&author=A.+L.+Mansonauthor=K.+A.+Cohenauthor=T.+Abeelauthor=C.+A.+Desjardinsauthor=D.+T.+Armstrongauthor=C.+E.+Barryauthor=J.+Brandauthor=TBResist+Global+Genome+Consortiumauthor=S.+B.+Chapmanauthor=S.+N.+Choauthor=A.+Gabrielianauthor=J.+Gomezauthor=A.+M.+Jodalsauthor=M.+Jolobaauthor=P.+Jureenauthor=J.+S.+Leeauthor=L.+Malingaauthor=M.+Maigaauthor=D.+Nordenbergauthor=E.+Norocauthor=E.+Romancencoauthor=A.+Salazarauthor=W.+Ssengoobaauthor=A.+A.+Velayatiauthor=K.+Wingleeauthor=A.+Zalutskayaauthor=L.+E.+Viaauthor=G.+H.+Cassellauthor=S.+E.+Dormanauthor=J.+Ellnerauthor=P.+Farniaauthor=J.+E.+Galaganauthor=A.+Rosenthalauthor=V.+Cruduauthor=D.+Homorodeanauthor=P.+R.+Hsuehauthor=S.+Narayananauthor=A.+S.+Pymauthor=A.+Skrahinaauthor=S.+Swaminathanauthor=M.+Van+der+Waltauthor=D.+Allandauthor=W.+R.+Bishaiauthor=T.+Cohenauthor=S.+Hoffnerauthor=B.+W.+Birrenauthor=A.+M.+Earl&title=Genomic+analysis+of+globally+diverse+Mycobacterium+tuberculosis+strains+provides+insights+into+the+emergence+and+spread+of+multidrug+resistance&doi=10.1038%2Fng.3767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance</span></div><div class="casAuthors">Manson, Abigail L.; Cohen, Keira A.; Abeel, Thomas; Desjardins, Christopher A.; Armstrong, Derek T.; Barry, Clifton E., III; Brand, Jeannette; Jureen, Pontus; Malinga, Lesibana; Nordenberg, Dale; Velayati, A. A.; Cassell, Gail H.; Farnia, Parissa; Homorodean, Daniela; Van der Walt, Martie; Hoffner, Sven; Chapman, Sinead B.; Cho, Sang-Nae; Gabrielian, Andrei; Gomez, James; Jodals, Andreea M.; Joloba, Moses; Lee, Jong Seok; Maiga, Mamoudou; Noroc, Ecaterina; Romancenco, Elena; Salazar, Alex; Ssengooba, Willy; Winglee, Kathryn; Zalutskaya, Aksana; Via, Laura E.; Dorman, Susan E.; Ellner, Jerrold; Galagan, James E.; Rosenthal, Alex; Crudu, Valeriu; Hsueh, Po-Ren; Narayanan, Sujatha; Pym, Alexander S.; Skrahina, Alena; Swaminathan, Soumya; Alland, David; Bishai, William R.; Cohen, Ted; Birren, Bruce W.; Earl, Ashlee M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">395-402</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Multidrug-resistant tuberculosis (MDR-TB), caused by drug-resistant strains of Mycobacterium tuberculosis, is an increasingly serious problem worldwide.  We examd. a data set of whole-genome sequences from 5310 M. tuberculosis isolates from 5 continents.  Despite the great diversity of these isolates with respect to geog. point of isolation, genetic background, and drug resistance, the patterns for the emergence of drug resistance were conserved globally.  We have identified harbinger mutations that often precede multidrug resistance.  In particular, the katG mutation encoding p.Ser315Thr, which confers resistance to isoniazid, overwhelmingly arose before mutations that conferred rifampicin resistance across all of the lineages, geog. regions, and time periods.  Therefore, mol. diagnostics that include markers for rifampicin resistance alone will be insufficient to identify pre-MDR strains.  Incorporating knowledge of polymorphisms that occur before the emergence of multidrug resistance, particularly katG p.Ser315Thr, into mol. diagnostics should enable targeted treatment of patients with pre-MDR-TB to prevent further development of MDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY1jG-Jbg1MLVg90H21EOLACvtfcHk0lh6_fBarz6Hbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCls7k%253D&md5=9f7153c7db5c35d6a31164f82af54109</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fng.3767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.3767%26sid%3Dliteratum%253Aachs%26aulast%3DManson%26aufirst%3DA.%2BL.%26aulast%3DCohen%26aufirst%3DK.%2BA.%26aulast%3DAbeel%26aufirst%3DT.%26aulast%3DDesjardins%26aufirst%3DC.%2BA.%26aulast%3DArmstrong%26aufirst%3DD.%2BT.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBrand%26aufirst%3DJ.%26aulast%3D%26aulast%3DChapman%26aufirst%3DS.%2BB.%26aulast%3DCho%26aufirst%3DS.%2BN.%26aulast%3DGabrielian%26aufirst%3DA.%26aulast%3DGomez%26aufirst%3DJ.%26aulast%3DJodals%26aufirst%3DA.%2BM.%26aulast%3DJoloba%26aufirst%3DM.%26aulast%3DJureen%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DMalinga%26aufirst%3DL.%26aulast%3DMaiga%26aufirst%3DM.%26aulast%3DNordenberg%26aufirst%3DD.%26aulast%3DNoroc%26aufirst%3DE.%26aulast%3DRomancenco%26aufirst%3DE.%26aulast%3DSalazar%26aufirst%3DA.%26aulast%3DSsengooba%26aufirst%3DW.%26aulast%3DVelayati%26aufirst%3DA.%2BA.%26aulast%3DWinglee%26aufirst%3DK.%26aulast%3DZalutskaya%26aufirst%3DA.%26aulast%3DVia%26aufirst%3DL.%2BE.%26aulast%3DCassell%26aufirst%3DG.%2BH.%26aulast%3DDorman%26aufirst%3DS.%2BE.%26aulast%3DEllner%26aufirst%3DJ.%26aulast%3DFarnia%26aufirst%3DP.%26aulast%3DGalagan%26aufirst%3DJ.%2BE.%26aulast%3DRosenthal%26aufirst%3DA.%26aulast%3DCrudu%26aufirst%3DV.%26aulast%3DHomorodean%26aufirst%3DD.%26aulast%3DHsueh%26aufirst%3DP.%2BR.%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DPym%26aufirst%3DA.%2BS.%26aulast%3DSkrahina%26aufirst%3DA.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DVan%2Bder%2BWalt%26aufirst%3DM.%26aulast%3DAlland%26aufirst%3DD.%26aulast%3DBishai%26aufirst%3DW.%2BR.%26aulast%3DCohen%26aufirst%3DT.%26aulast%3DHoffner%26aufirst%3DS.%26aulast%3DBirren%26aufirst%3DB.%2BW.%26aulast%3DEarl%26aufirst%3DA.%2BM.%26atitle%3DGenomic%2520analysis%2520of%2520globally%2520diverse%2520Mycobacterium%2520tuberculosis%2520strains%2520provides%2520insights%2520into%2520the%2520emergence%2520and%2520spread%2520of%2520multidrug%2520resistance%26jtitle%3DNat.%2520Genet.%26date%3D2017%26volume%3D49%26spage%3D395%26epage%3D402%26doi%3D10.1038%2Fng.3767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riaz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhtar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslam, M.</span></span> <span> </span><span class="NLM_article-title">GeneXpert technology. A breakthrough for the diagnosis of tuberculous pericarditis and pleuritis in less than 2 h</span>. <i>Saudi Medical Journal</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.15537/smj.2017.7.17694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.15537%2Fsmj.2017.7.17694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28674714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1cjkt1OksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=699-705&author=M.+Saeedauthor=M.+Ahmadauthor=S.+Iramauthor=S.+Riazauthor=M.+Akhtarauthor=M.+Aslam&title=GeneXpert+technology.+A+breakthrough+for+the+diagnosis+of+tuberculous+pericarditis+and+pleuritis+in+less+than+2+h&doi=10.15537%2Fsmj.2017.7.17694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">GeneXpert technology. A breakthrough for the diagnosis of tuberculous pericarditis and pleuritis in less than 2 hours</span></div><div class="casAuthors">Saeed Muhammad; Ahmad Mobeen; Iram Shagufta; Riaz Saba; Akhtar Mehwish; Aslam Maleeha</div><div class="citationInfo"><span class="NLM_cas:title">Saudi medical journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">699-705</span>
        ISSN:<span class="NLM_cas:issn">0379-5284</span>.
    </div><div class="casAbstract">OBJECTIVES:  To evaluate the diagnostic validity of GeneXpert for the detection of Mycobacterium tuberculosis (MTB) in pericardial and pleural effusions samples.  METHODS:  A cross sectional study was conducted at the Mycobacteriology Laboratory, Allama Iqbal Medical College, Lahore, Pakistan.  A total of 286 (158 pleural and 128 pericardial fluids) samples were received from tuberculosis (TB) suspects between January 2014 and August 2016.  Every sample was processed for Ziehl-Neelsen (Zn) smear, Lowenstein Jensen (LJ) culture, GeneXpert MTB/RIF assay according to standard protocols.  Validity of GeneXpert assay for the detection of MTB was evaluated using LJ culture as gold standard.  RESULTS:  Out of 286 effusions samples, MTB was isolated by LJ culture in 51 (17.8%) samples followed by GeneXpert in 43 (15%), and acid- fast bacilli (AFB)  was detected by Zn smear microscopy in 11 (3.8%) samples.  GeneXpert showed high sensitivity (84.3%), specificity (100%), with positive predictive value (100%), and  negative predictive value (96.7%), while Zn smear showed sensitivity 18.3%, specificity 99.1%, positive predictive value 81.8%, and negative predictive value  85.4%.  A strikingly high sensitivity of 72.2% was observed for pericardial fluid by GeneXpert.  CONCLUSION:  GeneXpert assay is an innovative tool, for prompt detection of MTB and drug resistance.  It is definitely an attractive point of care test, with high sensitivity and specificity along with turn around time of 2 hours, which facilitates timely diagnosis and appropriate management of TB pleuritis and pericarditis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmFP6kSY9-NB0LsK7uFuY7fW6udTcc2ebOyHJON3yGZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjkt1OksQ%253D%253D&md5=9ab5d770106566578a6e5dcdb0c49f15</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.15537%2Fsmj.2017.7.17694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15537%252Fsmj.2017.7.17694%26sid%3Dliteratum%253Aachs%26aulast%3DSaeed%26aufirst%3DM.%26aulast%3DAhmad%26aufirst%3DM.%26aulast%3DIram%26aufirst%3DS.%26aulast%3DRiaz%26aufirst%3DS.%26aulast%3DAkhtar%26aufirst%3DM.%26aulast%3DAslam%26aufirst%3DM.%26atitle%3DGeneXpert%2520technology.%2520A%2520breakthrough%2520for%2520the%2520diagnosis%2520of%2520tuberculous%2520pericarditis%2520and%2520pleuritis%2520in%2520less%2520than%25202%2520h%26jtitle%3DSaudi%2520Medical%2520Journal%26date%3D2017%26volume%3D38%26spage%3D699%26epage%3D705%26doi%3D10.15537%2Fsmj.2017.7.17694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmail, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span> <span> </span><span class="NLM_article-title">Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?</span>. <i>Respirology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1111/resp.13143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1111%2Fresp.13143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28850767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1cbis1WhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=36-45&author=K.+Dhedaauthor=H.+Coxauthor=A.+Esmailauthor=S.+Wassermanauthor=K.+C.+Changauthor=C.+Lange&title=Recent+controversies+about+MDR+and+XDR-TB%3A+Global+implementation+of+the+WHO+shorter+MDR-TB+regimen+and+bedaquiline+for+all+with+MDR-TB%3F&doi=10.1111%2Fresp.13143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?</span></div><div class="casAuthors">Dheda Keertan; Esmail Aliasgar; Cox Helen; Wasserman Sean; Chang Kwok Chiu; Lange Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Respirology (Carlton, Vic.)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis (TB) is now the biggest infectious disease killer worldwide.  Although the estimated incidence of TB has marginally declined over several years, it is out of control in some regions including in Africa.  The advent of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) threatens to further destabilize control in several regions of the world.  Drug-resistant TB constitutes a significant threat because it underpins almost 25% of global TB mortality, is associated with high morbidity, is a threat to healthcare workers and is unsustainably costly to treat.  The advent of highly resistant TB with emerging bacillary resistance to newer drugs has raised further concern.  Encouragingly, in addition to preventative strategies, several interventions have recently been introduced to curb the drug-resistant TB epidemic, including newer molecular diagnostic tools, new (bedaquiline and delamanid) and repurposed (linezolid and clofazimine) drugs and shorter and individualized treatment regimens.  However, there are several controversies that surround the use of new drugs and regimens, including whether, how and to what extent they should be used, and who specifically should be treated so that outcomes are optimally improved without amplifying the burden of drug resistance, and other potential drawbacks, thus sustaining effectiveness of the new drugs.  The equipoise surrounding these controversies is discussed and some recommendations are provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSsDHnyn1vExu_Q9URG6Dx8fW6udTcc2ebOyHJON3yGZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbis1WhtA%253D%253D&md5=f6bb79b14b19fcb6e7b09c6c790deba7</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1111%2Fresp.13143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fresp.13143%26sid%3Dliteratum%253Aachs%26aulast%3DDheda%26aufirst%3DK.%26aulast%3DCox%26aufirst%3DH.%26aulast%3DEsmail%26aufirst%3DA.%26aulast%3DWasserman%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DLange%26aufirst%3DC.%26atitle%3DRecent%2520controversies%2520about%2520MDR%2520and%2520XDR-TB%253A%2520Global%2520implementation%2520of%2520the%2520WHO%2520shorter%2520MDR-TB%2520regimen%2520and%2520bedaquiline%2520for%2520all%2520with%2520MDR-TB%253F%26jtitle%3DRespirology%26date%3D2018%26volume%3D23%26spage%3D36%26epage%3D45%26doi%3D10.1111%2Fresp.13143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papaventsis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casali, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontsevaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drobniewski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolayevskyy, V.</span></span> <span> </span><span class="NLM_article-title">Whole genome sequencing of Mycobacterium tuberculosis for detection of drug resistance: a systematic review</span>. <i>Clin. Microbiol. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/j.cmi.2016.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.cmi.2016.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27665704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslCgu73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=61-68&author=D.+Papaventsisauthor=N.+Casaliauthor=I.+Kontsevayaauthor=F.+Drobniewskiauthor=D.+M.+Cirilloauthor=V.+Nikolayevskyy&title=Whole+genome+sequencing+of+Mycobacterium+tuberculosis+for+detection+of+drug+resistance%3A+a+systematic+review&doi=10.1016%2Fj.cmi.2016.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Whole genome sequencing of Mycobacterium tuberculosis for detection of drug resistance: a systematic review</span></div><div class="casAuthors">Papaventsis, D.; Casali, N.; Kontsevaya, I.; Drobniewski, F.; Cirillo, D. M.; Nikolayevskyy, V.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology and Infection</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">61-68</span>CODEN:
                <span class="NLM_cas:coden">CMINFM</span>;
        ISSN:<span class="NLM_cas:issn">1198-743X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We conducted a systematic review to det. the diagnostic accuracy of whole genome sequencing (WGS) of Mycobacterium tuberculosis for the detection of resistance to first- and second-line anti-tuberculosis (TB) drugs.  The study was conducted according to the criteria of the Preferred Reporting Items for Systematic Reviews group.  A total of 20 publications were included.  The sensitivity, specificity, pos.-predictive value and neg.-predictive value of WGS using phenotypic drug susceptibility testing methods as a ref. std. were detd.  Anti-TB agents tested included all first-line drugs, a variety of reserve drugs, as well as new drugs.  Polymorphisms in a total of 53 genes were tested for assocns. with drug resistance.  Pooled sensitivity and specificity values for detection of resistance to selected first-line drugs were 0.98 (95% CI 0.93-0.98) and 0.98 (95% CI 0.98-1.00) for rifampicin and 0.97 (95% CI 0.94-0.99) and 0.93 (95% CI 0.91-0.96) for isoniazid, resp.  Due to high heterogeneity in study designs, lack of data, knowledge of resistance mechanisms and clarity on exclusion of phylogenetic markers, there was a significant variation in anal. performance of WGS for the remaining first-line, reserved drugs and new drugs.  Whole genome sequencing could be considered a promising alternative to existing phenotypic and mol. drug susceptibility testing methods for rifampicin and isoniazid pending standardization of anal. pipelines.  To ensure clin. relevance of WGS for detection of M. tuberculosis complex drug resistance, future studies should include information on clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH5Hg9v0l3R7Vg90H21EOLACvtfcHk0ljqU6FZyEw7DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslCgu73K&md5=ae87ad885a1a547ceb84206b98a5dacb</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.cmi.2016.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmi.2016.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DPapaventsis%26aufirst%3DD.%26aulast%3DCasali%26aufirst%3DN.%26aulast%3DKontsevaya%26aufirst%3DI.%26aulast%3DDrobniewski%26aufirst%3DF.%26aulast%3DCirillo%26aufirst%3DD.%2BM.%26aulast%3DNikolayevskyy%26aufirst%3DV.%26atitle%3DWhole%2520genome%2520sequencing%2520of%2520Mycobacterium%2520tuberculosis%2520for%2520detection%2520of%2520drug%2520resistance%253A%2520a%2520systematic%2520review%26jtitle%3DClin.%2520Microbiol.%2520Infect.%26date%3D2017%26volume%3D23%26spage%3D61%26epage%3D68%26doi%3D10.1016%2Fj.cmi.2016.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phelan, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppong, Y. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Grady, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNerney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibberd, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viveiros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huggett, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T. G.</span></span> <span> </span><span class="NLM_article-title">Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs</span>. <i>Genome Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">41</span>, <span class="refDoi"> DOI: 10.1186/s13073-019-0650-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1186%2Fs13073-019-0650-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31234910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BB3MzgtlWjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=41&author=J.+E.+Phelanauthor=D.+M.+O%E2%80%99Sullivanauthor=D.+Machadoauthor=J.+Ramosauthor=Y.+E.+A.+Oppongauthor=S.+Campinoauthor=J.+O%E2%80%99Gradyauthor=R.+McNerneyauthor=M.+L.+Hibberdauthor=M.+Viveirosauthor=J.+F.+Huggettauthor=T.+G.+Clark&title=Integrating+informatics+tools+and+portable+sequencing+technology+for+rapid+detection+of+resistance+to+anti-tuberculous+drugs&doi=10.1186%2Fs13073-019-0650-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs</span></div><div class="casAuthors">Phelan Jody E; Oppong Yaa E A; Campino Susana; Hibberd Martin L; Clark Taane G; O'Sullivan Denise M; Huggett Jim F; Machado Diana; Ramos Jorge; Viveiros Miguel; Clark Taane G; O'Grady Justin; McNerney Ruth; Huggett Jim F; Clark Taane G</div><div class="citationInfo"><span class="NLM_cas:title">Genome medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Mycobacterium tuberculosis resistance to anti-tuberculosis drugs is a major threat to global public health.  Whole genome sequencing (WGS) is rapidly gaining traction as a diagnostic tool for clinical tuberculosis settings.  To support this informatically, previous work led to the development of the widely used TBProfiler webtool, which predicts resistance to 14 drugs from WGS data.  However, for accurate and rapid high throughput of samples in clinical or epidemiological settings, there is a need for a stand-alone tool and the ability to analyse data across multiple WGS platforms, including Oxford Nanopore MinION.  RESULTS:  We present a new command line version of the TBProfiler webserver, which includes hetero-resistance calling and will facilitate the batch processing of samples.  The TBProfiler database has been expanded to incorporate 178 new markers across 16 anti-tuberculosis drugs.  The predictive performance of the mutation library has been assessed using > 17,000 clinical isolates with WGS and laboratory-based drug susceptibility testing (DST) data.  An integrated MinION analysis pipeline was assessed by performing WGS on 34 replicates across 3 multi-drug resistant isolates with known resistance mutations.  TBProfiler accuracy varied by individual drug.  Assuming DST as the gold standard, sensitivities for detecting multi-drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) were 94% (95%CI 93-95%) and 83% (95%CI 79-87%) with specificities of 98% (95%CI 98-99%) and 96% (95%CI 95-97%) respectively.  Using MinION data, only one resistance mutation was missed by TBProfiler, involving an insertion in the tlyA gene coding for capreomycin resistance.  When compared to alternative platforms (e.g.  Mykrobe predictor TB, the CRyPTIC library), TBProfiler demonstrated superior predictive performance across first- and second-line drugs.  CONCLUSIONS:  The new version of TBProfiler can rapidly and accurately predict anti-TB drug resistance profiles across large numbers of samples with WGS data.  The computing architecture allows for the ability to modify the core bioinformatic pipelines and outputs, including the analysis of WGS data sourced from portable technologies.  TBProfiler has the potential to be integrated into the point of care and WGS diagnostic environments, including in resource-poor settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-KICSfmnhYeb6AVA-44PTfW6udTcc2eaPp_EnbqQnFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzgtlWjug%253D%253D&md5=caf70ff8dc919c11d3af9e6649305279</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1186%2Fs13073-019-0650-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13073-019-0650-x%26sid%3Dliteratum%253Aachs%26aulast%3DPhelan%26aufirst%3DJ.%2BE.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DD.%2BM.%26aulast%3DMachado%26aufirst%3DD.%26aulast%3DRamos%26aufirst%3DJ.%26aulast%3DOppong%26aufirst%3DY.%2BE.%2BA.%26aulast%3DCampino%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Grady%26aufirst%3DJ.%26aulast%3DMcNerney%26aufirst%3DR.%26aulast%3DHibberd%26aufirst%3DM.%2BL.%26aulast%3DViveiros%26aufirst%3DM.%26aulast%3DHuggett%26aufirst%3DJ.%2BF.%26aulast%3DClark%26aufirst%3DT.%2BG.%26atitle%3DIntegrating%2520informatics%2520tools%2520and%2520portable%2520sequencing%2520technology%2520for%2520rapid%2520detection%2520of%2520resistance%2520to%2520anti-tuberculous%2520drugs%26jtitle%3DGenome%2520Med.%26date%3D2019%26volume%3D11%26spage%3D41%26doi%3D10.1186%2Fs13073-019-0650-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sada, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, T.</span></span> <span> </span><span class="NLM_article-title">Detection of lipoarabinomannan as a diagnostic test for tuberculosis</span>. <i>J. Clin. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2415</span>– <span class="NLM_lpage">2418</span>, <span class="refDoi"> DOI: 10.1128/JCM.30.9.2415-2418.1992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FJCM.30.9.2415-2418.1992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1401008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaK3s%252Fhs1Oruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1992&pages=2415-2418&author=E.+Sadaauthor=D.+Aguilarauthor=M.+Torresauthor=T.+Herrera&title=Detection+of+lipoarabinomannan+as+a+diagnostic+test+for+tuberculosis&doi=10.1128%2FJCM.30.9.2415-2418.1992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of lipoarabinomannan as a diagnostic test for tuberculosis</span></div><div class="casAuthors">Sada E; Aguilar D; Torres M; Herrera T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical microbiology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2415-8</span>
        ISSN:<span class="NLM_cas:issn">0095-1137</span>.
    </div><div class="casAbstract">A coagglutination technique was established for the detection of lipoarabinomannan of Mycobacterium tuberculosis in human serum samples and evaluated for its utility in the diagnosis of tuberculosis at the Instituto Nacional de Enfermedades Respiratorias in Mexico City.  The test had a sensitivity of 88% in patients with sputum-smear-positive active pulmonary tuberculosis.  The sensitivity in patients with active pulmonary tuberculosis negative for acid-fast bacilli in sputum was 67%.  Less favorable results were obtained for patients with AIDS and tuberculosis, with a sensitivity of 57%.  The specificity in control patients with lung diseases different from tuberculosis and in healthy subjects was 100%.  The positive predictive value was 100%, and the negative predictive value for patients with sputum-positive active pulmonary tuberculosis was 97%.  The results of this study suggest that the detection of lipoarabinomannan is an accurate test for the diagnosis of pulmonary tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgvgIvU2RrCENHe_gFldTbfW6udTcc2eZJkcrY3COb3Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s%252Fhs1Oruw%253D%253D&md5=d65eaaa9e2bcf59b5205bd40a6ab6212</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1128%2FJCM.30.9.2415-2418.1992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJCM.30.9.2415-2418.1992%26sid%3Dliteratum%253Aachs%26aulast%3DSada%26aufirst%3DE.%26aulast%3DAguilar%26aufirst%3DD.%26aulast%3DTorres%26aufirst%3DM.%26aulast%3DHerrera%26aufirst%3DT.%26atitle%3DDetection%2520of%2520lipoarabinomannan%2520as%2520a%2520diagnostic%2520test%2520for%2520tuberculosis%26jtitle%3DJ.%2520Clin.%2520Microbiol.%26date%3D1992%26volume%3D30%26spage%3D2415%26epage%3D2418%26doi%3D10.1128%2FJCM.30.9.2415-2418.1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davids, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenders, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meldau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zyl Smit, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sechi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoelscher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitelaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zumla, A.</span></span> <span> </span><span class="NLM_article-title">clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e9848</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0009848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pone.0009848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=20352098" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=e9848&author=K.+Dhedaauthor=V.+Davidsauthor=L.+Lendersauthor=T.+Robertsauthor=R.+Meldauauthor=D.+Lingauthor=L.+Brunetauthor=R.+van+Zyl+Smitauthor=J.+Peterauthor=C.+Greenauthor=M.+Badriauthor=L.+Sechiauthor=S.+Sharmaauthor=M.+Hoelscherauthor=R.+Dawsonauthor=A.+Whitelawauthor=J.+Blackburnauthor=M.+Paiauthor=A.+Zumla&title=clinical+utility+of+a+commercial+LAM-ELISA+assay+for+TB+diagnosis+in+HIV-infected+patients+using+urine+and+sputum+samples&doi=10.1371%2Fjournal.pone.0009848"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0009848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0009848%26sid%3Dliteratum%253Aachs%26aulast%3DDheda%26aufirst%3DK.%26aulast%3DDavids%26aufirst%3DV.%26aulast%3DLenders%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DT.%26aulast%3DMeldau%26aufirst%3DR.%26aulast%3DLing%26aufirst%3DD.%26aulast%3DBrunet%26aufirst%3DL.%26aulast%3Dvan%2BZyl%2BSmit%26aufirst%3DR.%26aulast%3DPeter%26aufirst%3DJ.%26aulast%3DGreen%26aufirst%3DC.%26aulast%3DBadri%26aufirst%3DM.%26aulast%3DSechi%26aufirst%3DL.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DHoelscher%26aufirst%3DM.%26aulast%3DDawson%26aufirst%3DR.%26aulast%3DWhitelaw%26aufirst%3DA.%26aulast%3DBlackburn%26aufirst%3DJ.%26aulast%3DPai%26aufirst%3DM.%26aulast%3DZumla%26aufirst%3DA.%26atitle%3Dclinical%2520utility%2520of%2520a%2520commercial%2520LAM-ELISA%2520assay%2520for%2520TB%2520diagnosis%2520in%2520HIV-infected%2520patients%2520using%2520urine%2520and%2520sputum%2520samples%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26spage%3De9848%26doi%3D10.1371%2Fjournal.pone.0009848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrelles, J. B.</span></span> <span> </span><span class="NLM_article-title">Mannose-capped lipoarabinomannan in Mycobacterium tuberculosis pathogenesis</span>. <i>Pathog. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">fty026</span>, <span class="refDoi"> DOI: 10.1093/femspd/fty026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Ffemspd%2Ffty026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2018&pages=fty026&author=J.+Turnerauthor=J.+B.+Torrelles&title=Mannose-capped+lipoarabinomannan+in+Mycobacterium+tuberculosis+pathogenesis&doi=10.1093%2Ffemspd%2Ffty026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1093%2Ffemspd%2Ffty026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ffemspd%252Ffty026%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DJ.%26aulast%3DTorrelles%26aufirst%3DJ.%2BB.%26atitle%3DMannose-capped%2520lipoarabinomannan%2520in%2520Mycobacterium%2520tuberculosis%2520pathogenesis%26jtitle%3DPathog.%2520Dis.%26date%3D2018%26volume%3D76%26spage%3Dfty026%26doi%3D10.1093%2Ffemspd%2Ffty026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Götze, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seah, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeberger, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tukvadze, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenk, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacAry, P. A.</span></span> <span> </span><span class="NLM_article-title">The diagnostic targeting of a carbohydrate virulence factor from M.Tuberculosis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">10281</span>, <span class="refDoi"> DOI: 10.1038/srep10281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fsrep10281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25975873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFGnsrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=10281&author=C.+E.+Chanauthor=S.+G%C3%B6tzeauthor=G.+T.+Seahauthor=P.+H.+Seebergerauthor=N.+Tukvadzeauthor=M.+R.+Wenkauthor=B.+J.+Hansonauthor=P.+A.+MacAry&title=The+diagnostic+targeting+of+a+carbohydrate+virulence+factor+from+M.Tuberculosis&doi=10.1038%2Fsrep10281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The diagnostic targeting of a carbohydrate virulence factor from M. Tuberculosis</span></div><div class="casAuthors">Chan, Conrad E.; Gotze, Sebastian; Seah, Geok T.; Seeberger, Peter H.; Tukvadze, Nestan; Wenk, Markus R.; Hanson, Brendon J.; MacAry, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10281</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The current clin. management of TB is complicated by the lack of suitable diagnostic tests that can be employed in infrastructure and resource poor regions.  The mannose-capped form of lipoarabinomannan (ManLAM) is unique to the surface envelope of slow-growing, pathogenic mycobacteria such as M. tuberculosis (M.tb) and facilitates passive invasion of mononuclear phagocytes.  The detection of this virulence factor in urine, sputum and serum has engendered interest in its employment as a biomarker for M.tb infection.  The authors use a subtractive screening methodol. to engineer the first high affinity recombinant antibody (My2F12) with exquisite specificity for the α1-2 mannose linkages enriched in ManLAM from M.tb.  My2F12 binds to pathogenic mycobacterial species but not fast growing non-pathogenic species.  Testing on matched urine and serum samples from TB patients indicates that My2F12 works in patient cohorts missed by other diagnostic methodologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqaNfIbUZbd7Vg90H21EOLACvtfcHk0lg2fCnn82xvyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFGnsrfM&md5=6d4a2c62bf3f693774cc87cac7df4ddc</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fsrep10281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep10281%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DC.%2BE.%26aulast%3DG%25C3%25B6tze%26aufirst%3DS.%26aulast%3DSeah%26aufirst%3DG.%2BT.%26aulast%3DSeeberger%26aufirst%3DP.%2BH.%26aulast%3DTukvadze%26aufirst%3DN.%26aulast%3DWenk%26aufirst%3DM.%2BR.%26aulast%3DHanson%26aufirst%3DB.%2BJ.%26aulast%3DMacAry%26aufirst%3DP.%2BA.%26atitle%3DThe%2520diagnostic%2520targeting%2520of%2520a%2520carbohydrate%2520virulence%2520factor%2520from%2520M.Tuberculosis%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D10281%26doi%3D10.1038%2Fsrep10281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathiasen, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiset, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wejse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillebaek, T.</span></span> <span> </span><span class="NLM_article-title">Epidemiology of tuberculous lymphadenitis in Denmark: A nationwide register-based study</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">e0221232</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0221232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pone.0221232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31415659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFamtbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=e0221232&author=V.+D.+Mathiasenauthor=A.+H.+Eisetauthor=P.+H.+Andersenauthor=C.+Wejseauthor=T.+Lillebaek&title=Epidemiology+of+tuberculous+lymphadenitis+in+Denmark%3A+A+nationwide+register-based+study&doi=10.1371%2Fjournal.pone.0221232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of tuberculous lymphadenitis in Denmark: A nationwide register-based study</span></div><div class="casAuthors">Mathiasen, Victor Dahl; Eiset, Andreas Halgreen; Andersen, Peter Henrik; Wejse, Christian; Lillebaek, Troels</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e0221232</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Tuberculous lymphadenitis (TBLA) is the most common extrapulmonary manifestation of tuberculosis (TB), often claimed to be reactivation.  We aimed to describe the epidemiol. of TBLA in Denmark, as it has not previously been investigated specifically although extrapulmonary TB has been assocd. with an increased long-term mortality and delays in the diagnosis.  Methods: Register-based study of all patients notified with TBLA in Denmark from 2007 through 2016 utilizing six different nationwide registers.  Patients were identified through the national TB surveillance register, and the diagnosis evaluated based on microbiol., pathol. and/or clin. assessment.  Results: In total, 13.5% (n = 489) of all TB patients in Denmark had TBLA with annual proportions from 9.4 to 15.7%.  Most patients were immigrants between 25-44 years.  Incidence rates ranged from as high as 1,014/100,000 for Nepalese citizens to as a low as 0.06/100,000 for Danes.  Danes had a significant higher median age and significant more risk factors and comorbidities, as well as an increased overall mortality, compared with immigrants (p<0.05).  A significant and much higher proportion of unique MIRU-VNTR genotypes were seen among TBLA patients compared to other TB manifestations.  Conclusion: In Denmark, TBLA is a common manifestation of TB, esp. in young immigrants from high-incidence countries.  In Danes, it is a rare disease manifestation and assocd. with higher morbidity and mortality.  To our knowledge, this is the first study suggesting that TBLA is predominantly assocd. with reactivation of latent TB infection based on genotyping although this remains to be clarified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_JOVDkxmOfLVg90H21EOLACvtfcHk0lg2fCnn82xvyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFamtbzM&md5=efecdfe21325dcde2bbe8c518b61c1e6</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0221232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0221232%26sid%3Dliteratum%253Aachs%26aulast%3DMathiasen%26aufirst%3DV.%2BD.%26aulast%3DEiset%26aufirst%3DA.%2BH.%26aulast%3DAndersen%26aufirst%3DP.%2BH.%26aulast%3DWejse%26aufirst%3DC.%26aulast%3DLillebaek%26aufirst%3DT.%26atitle%3DEpidemiology%2520of%2520tuberculous%2520lymphadenitis%2520in%2520Denmark%253A%2520A%2520nationwide%2520register-based%2520study%26jtitle%3DPLoS%2520One%26date%3D2019%26volume%3D14%26spage%3De0221232%26doi%3D10.1371%2Fjournal.pone.0221232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span> <span> </span><span class="NLM_article-title">Diagnosis and treatment of extrapulmonary tuberculosis</span>. <i>Tuberc. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.4046/trd.2015.78.2.47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4046%2Ftrd.2015.78.2.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25861336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2MjjtVOgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2015&pages=47-55&author=J.+Y.+Lee&title=Diagnosis+and+treatment+of+extrapulmonary+tuberculosis&doi=10.4046%2Ftrd.2015.78.2.47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosis and treatment of extrapulmonary tuberculosis</span></div><div class="casAuthors">Lee Ji Yeon</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis and respiratory diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">47-55</span>
        ISSN:<span class="NLM_cas:issn">1738-3536</span>.
    </div><div class="casAbstract">Extrapulmonary tuberculosis (EPTB) constitutes about 20% of all cases of tuberculosis (TB) in Korea.  Diagnosing EPTB remains challenging because clinical samples obtained from relatively inaccessible sites may be paucibacillary, thus decreasing the sensitivity of diagnostic tests.  Whenever practical, every effort should be made to obtain appropriate specimens for both mycobacteriologic and histopathologic examinations.  The measurement of biochemical markers in TB-affected serosal fluids (adenosine deaminase or gamma interferon) and molecular biology techniques such as polymerase chain reaction may be useful adjuncts in the diagnosis of EPTB.  Although the disease usually responds to standard anti-TB drug therapy, the ideal regimen and duration of treatment have not yet been established.  A paradoxical response frequently occurs during anti-TB therapy.  It should be distinguished from other causes of clinical deterioration.  Surgery is required mainly to obtain valid diagnostic specimens and to manage complications.  Because smear microscopy or culture is not available to monitor patients with EPTB, clinical monitoring is the usual way to assess the response to treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJNcIz8EmHw8uCWE5mhx1RfW6udTcc2eYuu9xtxmGX87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjjtVOgtw%253D%253D&md5=13a906ea6f703106d8e0891b9ebcdbae</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.4046%2Ftrd.2015.78.2.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4046%252Ftrd.2015.78.2.47%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BY.%26atitle%3DDiagnosis%2520and%2520treatment%2520of%2520extrapulmonary%2520tuberculosis%26jtitle%3DTuberc.%2520Respir.%2520Dis.%26date%3D2015%26volume%3D78%26spage%3D47%26epage%3D55%26doi%3D10.4046%2Ftrd.2015.78.2.47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seong, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yim, J. J.</span></span> <span> </span><span class="NLM_article-title">Accuracy of the Xpert® MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.5588/ijtld.14.0500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.5588%2Fijtld.14.0500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25519795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2MvgvVaqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=81-86&author=Y.+W.+Kimauthor=N.+Kwakauthor=M.+W.+Seongauthor=E.+C.+Kimauthor=C.+G.+Yooauthor=Y.+W.+Kimauthor=S.+K.+Hanauthor=J.+J.+Yim&title=Accuracy+of+the+Xpert%C2%AE+MTB%2FRIF+assay+for+the+diagnosis+of+extra-pulmonary+tuberculosis+in+South+Korea&doi=10.5588%2Fijtld.14.0500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Accuracy of the Xpert® MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea</span></div><div class="casAuthors">Kim Y W; Kwak N; Yoo C-G; Kim Y W; Han S K; Yim J-J; Seong M-W; Kim E-C</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">SETTING:  The Xpert(®) MTB/RIF assay has been endorsed by the World Health Organization for the detection of pulmonary and extra-pulmonary tuberculosis (EPTB).  OBJECTIVE:  To determine the accuracy of the Xpert assay in diagnosing EPTB in South Korea, a country with an intermediate TB burden.  DESIGN:  We retrospectively reviewed the medical records of 1429 patients in whom the Xpert assay using EPTB specimens was requested between 1 January 2011 and 31 October 2013 in a tertiary referral hospital in South Korea.  The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for the diagnosis of EPTB and detection of rifampicin (RMP) resistance were calculated.  RESULTS:  Using culture as gold standard, the sensitivity, specificity, PPV and NPV of the assay were respectively 67.7%, 98.1%, 60% and 98.6%.  Using a composite reference standard, the sensitivity, specificity, PPV and NPV were respectively 49.3%, 100%, 100% and 95.1%.  The sensitivity, specificity, PPV and NPV for the detection of RMP resistance among specimens with positive results for Mycobacterium tuberculosis were respectively 80%, 100%, 100% and 97.7%.  CONCLUSION:  The Xpert assay showed acceptable sensitivity in certain groups and excellent specificity in diagnosing EPTB and detecting RMP resistance in an intermediate TB burden country.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRipRigWBu30IUSrryheKE6fW6udTcc2eb8hVaCj6FJzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvgvVaqtg%253D%253D&md5=dcc33c7f0f10541d23bcc85da7cdf8b4</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.5588%2Fijtld.14.0500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5588%252Fijtld.14.0500%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2BW.%26aulast%3DKwak%26aufirst%3DN.%26aulast%3DSeong%26aufirst%3DM.%2BW.%26aulast%3DKim%26aufirst%3DE.%2BC.%26aulast%3DYoo%26aufirst%3DC.%2BG.%26aulast%3DKim%26aufirst%3DY.%2BW.%26aulast%3DHan%26aufirst%3DS.%2BK.%26aulast%3DYim%26aufirst%3DJ.%2BJ.%26atitle%3DAccuracy%2520of%2520the%2520Xpert%25C2%25AE%2520MTB%252FRIF%2520assay%2520for%2520the%2520diagnosis%2520of%2520extra-pulmonary%2520tuberculosis%2520in%2520South%2520Korea%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D2015%26volume%3D19%26spage%3D81%26epage%3D86%26doi%3D10.5588%2Fijtld.14.0500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trunz, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, C.</span></span> <span> </span><span class="NLM_article-title">Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">1173</span>– <span class="NLM_lpage">1180</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(06)68507-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS0140-6736%2806%2968507-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=16616560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD283htVyjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2006&pages=1173-1180&author=B.+B.+Trunzauthor=P.+Fineauthor=C.+Dye&title=Effect+of+BCG+vaccination+on+childhood+tuberculous+meningitis+and+miliary+tuberculosis+worldwide%3A+a+meta-analysis+and+assessment+of+cost-effectiveness&doi=10.1016%2FS0140-6736%2806%2968507-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness</span></div><div class="casAuthors">Trunz B Bourdin; Fine Pem; Dye C</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">9517</span>),
    <span class="NLM_cas:pages">1173-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  BCG vaccine has shown consistently high efficacy against childhood tuberculous meningitis and miliary tuberculosis, but variable efficacy against adult pulmonary tuberculosis and other mycobacterial diseases.  We assess and compare the costs and effects of BCG as an intervention against severe childhood tuberculosis in different regions of the world.  METHODS:  We calculated the number of tuberculous meningitis and miliary tuberculosis cases that have been and will be prevented in all children born in 2002, by combining estimates of the annual risk of tuberculosis infection, the proportion of infections that lead to either of these diseases in unvaccinated children, the number of children vaccinated, and BCG efficacy.  FINDINGS:  We estimated that the 100.5 million BCG vaccinations given to infants in 2002 will have prevented 29,729 cases of tuberculous meningitis (5th-95th centiles, 24,063-36,192) in children during their first 5 years of life, or one case for every 3435 vaccinations (2771-4177), and 11,486 cases of miliary tuberculosis (7304-16,280), or one case for every 9314 vaccinations (6172-13,729).  The numbers of cases prevented would be highest in South East Asia (46%), sub-Saharan Africa (27%), the western Pacific region (15%), and where the risk of tuberculosis infection and vaccine coverage are also highest.  At US2-3 dollars per dose, BCG vaccination costs US206 dollars (150-272) per year of healthy life gained.  INTERPRETATION:  BCG vaccination is a highly cost-effective intervention against severe childhood tuberculosis; it should be retained in high-incidence countries as a strategy to supplement the chemotherapy of active tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtNETSIEn2IMyail4HZd-ifW6udTcc2eb8hVaCj6FJzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283htVyjsQ%253D%253D&md5=64733a82626cbbb4a1ea0c2a061f4784</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2806%2968507-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252806%252968507-3%26sid%3Dliteratum%253Aachs%26aulast%3DTrunz%26aufirst%3DB.%2BB.%26aulast%3DFine%26aufirst%3DP.%26aulast%3DDye%26aufirst%3DC.%26atitle%3DEffect%2520of%2520BCG%2520vaccination%2520on%2520childhood%2520tuberculous%2520meningitis%2520and%2520miliary%2520tuberculosis%2520worldwide%253A%2520a%2520meta-analysis%2520and%2520assessment%2520of%2520cost-effectiveness%26jtitle%3DLancet%26date%3D2006%26volume%3D367%26spage%3D1173%26epage%3D1180%26doi%3D10.1016%2FS0140-6736%2806%2968507-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dockrell, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. G.</span></span> <span> </span><span class="NLM_article-title">What have we learnt about BCG vaccination in the last 20 Years?</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1134</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2017.01134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3389%2Ffimmu.2017.01134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28955344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFegtLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1134&author=H.+M.+Dockrellauthor=S.+G.+Smith&title=What+have+we+learnt+about+BCG+vaccination+in+the+last+20+Years%3F&doi=10.3389%2Ffimmu.2017.01134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">What have we learnt about BCG vaccination in the last 20 years?</span></div><div class="casAuthors">Dockrell, Hazel M.; Smith, Steven G.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1134/1-1134/10</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A no. of new tuberculosis (TB) vaccines have been or are entering clin. trials, which include genetically modified mycobacteria, mycobacterial antigens delivered by viral vectors, or mycobacterial antigens in adjuvant.  Some of these vaccines aim to replace the existing BCG vaccine but others will be given as a boosting vaccine following BCG vaccination given soon after birth.  It is clear that the existing BCG vaccines provide incomplete and variable protection against pulmonary TB.  This review will discuss what we have learnt over the last 20 years about how the BCG vaccine induces specific and non-specific immunity, what factors influence the immune responses induced by BCG, and progress toward identifying correlates of immunity against TB from BCG vaccination studies.  There is still a lot to learn about the BCG vaccine and the insights gained can help the development of more protective vaccines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojvkmhz2SuirVg90H21EOLACvtfcHk0ljyj9R87seSww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFegtLvF&md5=ae5cf1570ffbf63b95ac1c8ff671f6d3</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2017.01134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2017.01134%26sid%3Dliteratum%253Aachs%26aulast%3DDockrell%26aufirst%3DH.%2BM.%26aulast%3DSmith%26aufirst%3DS.%2BG.%26atitle%3DWhat%2520have%2520we%2520learnt%2520about%2520BCG%2520vaccination%2520in%2520the%2520last%252020%2520Years%253F%26jtitle%3DFront.%2520Immunol.%26date%3D2017%26volume%3D8%26spage%3D1134%26doi%3D10.3389%2Ffimmu.2017.01134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, J. L.</span></span> <span> </span><span class="NLM_article-title">Understanding latent tuberculosis: a moving target</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0903856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4049%2Fjimmunol.0903856" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=20562268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3cXns1Crurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2010&pages=15-22&author=P.+L.+Linauthor=J.+L.+Flynn&title=Understanding+latent+tuberculosis%3A+a+moving+target&doi=10.4049%2Fjimmunol.0903856"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding Latent Tuberculosis: A Moving Target</span></div><div class="casAuthors">Lin, Philana Ling; Flynn, JoAnne L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-22</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB) remains a threat to the health of people worldwide.  Infection with Mycobacterium tuberculosis can result in active TB or, more commonly, latent infection.  Latently infected persons, of which there are estd. to be approx. 2 billion in the world, represent an enormous reservoir of potential reactivation TB, which can spread to other people.  The immunol. of TB is complex and multifaceted.  Identifying the immune mechanisms that lead to control of initial infection and prevent reactivation of latent infection is crucial to combating this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb9omQoDRyy7Vg90H21EOLACvtfcHk0ljyj9R87seSww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXns1Crurc%253D&md5=baed5915d0f4433f74956fa5a3db4900</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0903856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0903856%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DP.%2BL.%26aulast%3DFlynn%26aufirst%3DJ.%2BL.%26atitle%3DUnderstanding%2520latent%2520tuberculosis%253A%2520a%2520moving%2520target%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D185%26spage%3D15%26epage%3D22%26doi%3D10.4049%2Fjimmunol.0903856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, D.</span></span> <span> </span><span class="NLM_article-title">How long are TB patients infectious?</span>. <i>CMAJ</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">158</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10934973" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2000&pages=157-158&author=K.+Schwartzmanauthor=D.+Menzies&title=How+long+are+TB+patients+infectious%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartzman%26aufirst%3DK.%26aulast%3DMenzies%26aufirst%3DD.%26atitle%3DHow%2520long%2520are%2520TB%2520patients%2520infectious%253F%26jtitle%3DCMAJ%26date%3D2000%26volume%3D163%26spage%3D157%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, R.</span></span> <span> </span><span class="NLM_article-title">Contact screening in tuberculosis: can we identify those with higher risk?</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">758</span>– <span class="NLM_lpage">760</span>, <span class="refDoi"> DOI: 10.1183/09031936.00164612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1183%2F09031936.00164612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23456937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3svivFyqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=758-760&author=M.+A.+Mendesauthor=R.+Gaioauthor=R.+Reisauthor=R.+Duarte&title=Contact+screening+in+tuberculosis%3A+can+we+identify+those+with+higher+risk%3F&doi=10.1183%2F09031936.00164612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Contact screening in tuberculosis: can we identify those with higher risk?</span></div><div class="casAuthors">Mendes Maria Aurora; Gaio Rita; Reis Ricardo; Duarte Raquel</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">758-60</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrjw-iFBX_0LP3FVUi_gf8fW6udTcc2ebzAfEPnDFxLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svivFyqtA%253D%253D&md5=2a769e0604bfc07b064610c01047f5c7</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1183%2F09031936.00164612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00164612%26sid%3Dliteratum%253Aachs%26aulast%3DMendes%26aufirst%3DM.%2BA.%26aulast%3DGaio%26aufirst%3DR.%26aulast%3DReis%26aufirst%3DR.%26aulast%3DDuarte%26aufirst%3DR.%26atitle%3DContact%2520screening%2520in%2520tuberculosis%253A%2520can%2520we%2520identify%2520those%2520with%2520higher%2520risk%253F%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D41%26spage%3D758%26epage%3D760%26doi%3D10.1183%2F09031936.00164612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekaran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saravanan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethunaickan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, S.</span></span> <span> </span><span class="NLM_article-title">Malnutrition: modulator of immune responses in tuberculosis</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1316</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2017.01316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3389%2Ffimmu.2017.01316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29093710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFens7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1316&author=P.+Chandrasekaranauthor=N.+Saravananauthor=R.+Bethunaickanauthor=S.+Tripathy&title=Malnutrition%3A+modulator+of+immune+responses+in+tuberculosis&doi=10.3389%2Ffimmu.2017.01316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Malnutrition: modulator of immune responses in tuberculosis</span></div><div class="casAuthors">Chandrasekaran, Padmapriyadarsini; Saravanan, Natarajan; Bethunaickan, Ramalingam; Tripathy, Srikanth</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1316/1-1316/8</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Nutrition plays a major role in the management of both acute and chronic diseases, in terms of body's response to the pathogenic organism.  An array of nutrients like macroand micro-nutrients, vitamins, etc., are assocd. with boosting the host's immune responses against intracellular pathogens including mycobacterium tuberculosis (M.tb).  These nutrients have an immunomodulatory effects in controlling the infection and inflammation process and nutritional deficiency of any form, i.e., malnutrition may lead to nutritionally acquired immunodeficiency syndrome, which greatly increases an individual's susceptibility to progression of infection to disease.  This narrative review looks at the various mechanisms by which nutrition or its deficiency leads to impaired cell mediated and humoral immune responses, which in turn affects the ability of an individual to fight M.tb infection or disease.  There is very little evidence in the literature that any specific food on its own or a specific quantity can alter the course of TB disease or be effective in the treatment of malnutrition.  Further clin. trials or studies will be needed to recommend and to better understand the link between malnutrition, tuberculosis, and impaired immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFlNM_GZrFErVg90H21EOLACvtfcHk0ljkr1JQOcp66Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFens7vP&md5=09643fd7d3e40c9c7192d0c6d08e6b5c</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2017.01316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2017.01316%26sid%3Dliteratum%253Aachs%26aulast%3DChandrasekaran%26aufirst%3DP.%26aulast%3DSaravanan%26aufirst%3DN.%26aulast%3DBethunaickan%26aufirst%3DR.%26aulast%3DTripathy%26aufirst%3DS.%26atitle%3DMalnutrition%253A%2520modulator%2520of%2520immune%2520responses%2520in%2520tuberculosis%26jtitle%3DFront.%2520Immunol.%26date%3D2017%26volume%3D8%26spage%3D1316%26doi%3D10.3389%2Ffimmu.2017.01316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span> <i>The End TB Strategy</i>; <span class="NLM_publisher-name">World
Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2015</span>; <a href="https://www.who.int/tb/End_TB_brochure.pdf?ua=1" class="extLink">https://www.who.int/tb/End_TB_brochure.pdf?ua=1</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The+End+TB+Strategy%3B+World%0AHealth+Organization%3A+Geneva%2C+2015%3B+https%3A%2F%2Fwww.who.int%2Ftb%2FEnd_TB_brochure.pdf%3Fua%3D1+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DThe%2520End%2520TB%2520Strategy%26pub%3DWorld%250AHealth%2520Organization%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matteelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Abri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voniatis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, A. C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Ambrosio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spanevello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battista Migliori, G.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis elimination: where are we now?</span>. <i>Eur. Respir. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">180035</span>, <span class="refDoi"> DOI: 10.1183/16000617.0035-2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1183%2F16000617.0035-2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29898905" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=180035&author=A.+Matteelliauthor=A.+Rendonauthor=S.+Tiberiauthor=S.+Al-Abriauthor=C.+Voniatisauthor=A.+C.+C.+Carvalhoauthor=R.+Centisauthor=L.+D%E2%80%99Ambrosioauthor=D.+Viscaauthor=A.+Spanevelloauthor=G.+Battista+Migliori&title=Tuberculosis+elimination%3A+where+are+we+now%3F&doi=10.1183%2F16000617.0035-2018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1183%2F16000617.0035-2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F16000617.0035-2018%26sid%3Dliteratum%253Aachs%26aulast%3DMatteelli%26aufirst%3DA.%26aulast%3DRendon%26aufirst%3DA.%26aulast%3DTiberi%26aufirst%3DS.%26aulast%3DAl-Abri%26aufirst%3DS.%26aulast%3DVoniatis%26aufirst%3DC.%26aulast%3DCarvalho%26aufirst%3DA.%2BC.%2BC.%26aulast%3DCentis%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Ambrosio%26aufirst%3DL.%26aulast%3DVisca%26aufirst%3DD.%26aulast%3DSpanevello%26aufirst%3DA.%26aulast%3DBattista%2BMigliori%26aufirst%3DG.%26atitle%3DTuberculosis%2520elimination%253A%2520where%2520are%2520we%2520now%253F%26jtitle%3DEur.%2520Respir.%2520Rev.%26date%3D2018%26volume%3D27%26spage%3D180035%26doi%3D10.1183%2F16000617.0035-2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lönnroth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliori, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abubakar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Ambrosio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falzon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudreau, M.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goletti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González
Ochoa, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoBue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matteelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Story, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tayeb, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Werf, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zellweger, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel Aziz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Lawati, M. R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliberti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrazola
de Oñate, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreira, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchfeld, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemtob, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colorado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahle, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Paoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattorini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getahun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaziou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goguadze, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Granado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Järvinen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, G.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikiori, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace-Asciak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompa, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popescu, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robalo Cordeiro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rønning, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruhwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sculier, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simunović, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith-Palmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotgiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Duque, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umeki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uplekar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Weezenbeek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasankari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitillo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voniatis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raviglione, M. C.</span></span> <span> </span><span class="NLM_article-title">Towards tuberculosis elimination: an action framework for low-incidence countries</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">928</span>– <span class="NLM_lpage">952</span>, <span class="refDoi"> DOI: 10.1183/09031936.00214014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1183%2F09031936.00214014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25792630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2Mnmt1WjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=928-952&author=K.+L%C3%B6nnrothauthor=G.+B.+Miglioriauthor=I.+Abubakarauthor=L.+D%E2%80%99Ambrosioauthor=G.+de+Vriesauthor=R.+Dielauthor=P.+Douglasauthor=D.+Falzonauthor=M.-A.+Gaudreauauthor=D.+Golettiauthor=E.+R.+Gonz%C3%A1lez%0AOchoaauthor=P.+LoBueauthor=A.+Matteelliauthor=H.+Njooauthor=I.+Solovicauthor=A.+Storyauthor=T.+Tayebauthor=M.+J.+van+der+Werfauthor=D.+Weilauthor=J.-P.+Zellwegerauthor=M.+Abdel+Azizauthor=M.+R.+M.+Al+Lawatiauthor=S.+Alibertiauthor=W.+Arrazola%0Ade+O%C3%B1ateauthor=D.+Barreiraauthor=V.+Bhatiaauthor=F.+Blasiauthor=A.+Bloomauthor=J.+Bruchfeldauthor=F.+Castelliauthor=R.+Centisauthor=D.+Chemtobauthor=D.+M.+Cirilloauthor=A.+Coloradoauthor=A.+Daduauthor=U.+R.+Dahleauthor=L.+De+Paoliauthor=H.+M.+Diasauthor=R.+Duarteauthor=L.+Fattoriniauthor=M.+Gagaauthor=H.+Getahunauthor=P.+Glaziouauthor=L.+Goguadzeauthor=M.+Del+Granadoauthor=W.+Haasauthor=A.+J%C3%A4rvinenauthor=G.-Y.+Kwonauthor=D.+Moscaauthor=P.+Nahidauthor=N.+Nishikioriauthor=I.+Noguerauthor=J.+O%E2%80%99Donnellauthor=A.+Pace-Asciakauthor=M.+G.+Pompaauthor=G.+G.+Popescuauthor=C.+Robalo+Cordeiroauthor=K.+R%C3%B8nningauthor=M.+Ruhwaldauthor=J.-P.+Sculierauthor=A.+Simunovi%C4%87author=A.+Smith-Palmerauthor=G.+Sotgiuauthor=G.+Sulisauthor=C.+A.+Torres-Duqueauthor=K.+Umekiauthor=M.+Uplekarauthor=C.+van+Weezenbeekauthor=T.+Vasankariauthor=R.+J.+Vitilloauthor=C.+Voniatisauthor=M.+Wanlinauthor=M.+C.+Raviglione&title=Towards+tuberculosis+elimination%3A+an+action+framework+for+low-incidence+countries&doi=10.1183%2F09031936.00214014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Towards tuberculosis elimination: an action framework for low-incidence countries</span></div><div class="casAuthors">Lonnroth Knut; Migliori Giovanni Battista; Abubakar Ibrahim; D'Ambrosio Lia; Centis Rosella; de Vries Gerard; van Weezenbeek Catharina; Diel Roland; Douglas Paul; Falzon Dennis; Matteelli Alberto; Weil Diana; Bhatia Vineet; Dias Hannah M; Getahun Haileyesus; Glaziou Philippe; Sulis Giorgia; Uplekar Mukund; Raviglione Mario C; Gaudreau Marc-Andre; Njoo Howard; Goletti Delia; Gonzalez Ochoa Edilberto R; LoBue Philip; Solovic Ivan; Story Alistair; Tayeb Tamara; van der Werf Marieke J; Zellweger Jean-Pierre; Abdel Aziz Mohamed; Al Lawati Mohamed R M; Aliberti Stefano; Arrazola de Onate Wouter; Barreira Draurio; Blasi Francesco; Bloom Amy; Bruchfeld Judith; Castelli Francesco; Chemtob Daniel; Cirillo Daniela M; Colorado Alberto; Dadu Andrei; Dahle Ulf R; Ronning Karin; De Paoli Laura; Duarte Raquel; Fattorini Lanfranco; Gaga Mina; Goguadze Lasha; Del Granado Mirtha; Haas Walter; Jarvinen Asko; Kwon Geun-Yong; Mosca Davide; Nahid Payam; Nishikiori Nobuyuki; Noguer Isabel; O'Donnell Joan; Pace-Asciak Analita; Pompa Maria G; Popescu Gilda G; Robalo Cordeiro Carlos; Ruhwald Morten; Sculier Jean-Paul; Simunovic Aleksandar; Smith-Palmer Alison; Sotgiu Giovanni; Torres-Duque Carlos A; Umeki Kazunori; Vasankari Tuula; Vitillo Robert J; Voniatis Constantia; Wanlin Maryse</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">928-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This paper describes an action framework for countries with low tuberculosis (TB) incidence (<100 TB cases per million population) that are striving for TB elimination.  The framework sets out priority interventions required for these countries to progress first towards "pre-elimination" (<10 cases per million) and eventually the elimination of TB as a public health problem (less than one case per million).  TB epidemiology in most low-incidence countries is characterised by a low rate of transmission in the general population, occasional outbreaks, a majority of TB cases generated from progression of latent TB infection (LTBI) rather than local transmission, concentration to certain vulnerable and hard-to-reach risk groups, and challenges posed by cross-border migration.  Common health system challenges are that political commitment, funding, clinical expertise and general awareness of TB diminishes as TB incidence falls.  The framework presents a tailored response to these challenges, grouped into eight priority action areas: 1) ensure political commitment, funding and stewardship for planning and essential services; 2) address the most vulnerable and hard-to-reach groups; 3) address special needs of migrants and cross-border issues; 4) undertake screening for active TB and LTBI in TB contacts and selected high-risk groups, and provide appropriate treatment; 5) optimise the prevention and care of drug-resistant TB; 6) ensure continued surveillance, programme monitoring and evaluation and case-based data management; 7) invest in research and new tools; and 8) support global TB prevention, care and control.  The overall approach needs to be multisectorial, focusing on equitable access to high-quality diagnosis and care, and on addressing the social determinants of TB.  Because of increasing globalisation and population mobility, the response needs to have both national and global dimensions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT1sTHWz2o7TZPlX7E30qdzfW6udTcc2eacM8x57YPp37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mnmt1WjsQ%253D%253D&md5=4ca972da5bf04df47c478930ad6776d2</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1183%2F09031936.00214014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00214014%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6nnroth%26aufirst%3DK.%26aulast%3DMigliori%26aufirst%3DG.%2BB.%26aulast%3DAbubakar%26aufirst%3DI.%26aulast%3DD%25E2%2580%2599Ambrosio%26aufirst%3DL.%26aulast%3Dde%2BVries%26aufirst%3DG.%26aulast%3DDiel%26aufirst%3DR.%26aulast%3DDouglas%26aufirst%3DP.%26aulast%3DFalzon%26aufirst%3DD.%26aulast%3DGaudreau%26aufirst%3DM.-A.%26aulast%3DGoletti%26aufirst%3DD.%26aulast%3DGonz%25C3%25A1lez%2BOchoa%26aufirst%3DE.%2BR.%26aulast%3DLoBue%26aufirst%3DP.%26aulast%3DMatteelli%26aufirst%3DA.%26aulast%3DNjoo%26aufirst%3DH.%26aulast%3DSolovic%26aufirst%3DI.%26aulast%3DStory%26aufirst%3DA.%26aulast%3DTayeb%26aufirst%3DT.%26aulast%3Dvan%2Bder%2BWerf%26aufirst%3DM.%2BJ.%26aulast%3DWeil%26aufirst%3DD.%26aulast%3DZellweger%26aufirst%3DJ.-P.%26aulast%3DAbdel%2BAziz%26aufirst%3DM.%26aulast%3DAl%2BLawati%26aufirst%3DM.%2BR.%2BM.%26aulast%3DAliberti%26aufirst%3DS.%26aulast%3DArrazola%2Bde%2BO%25C3%25B1ate%26aufirst%3DW.%26aulast%3DBarreira%26aufirst%3DD.%26aulast%3DBhatia%26aufirst%3DV.%26aulast%3DBlasi%26aufirst%3DF.%26aulast%3DBloom%26aufirst%3DA.%26aulast%3DBruchfeld%26aufirst%3DJ.%26aulast%3DCastelli%26aufirst%3DF.%26aulast%3DCentis%26aufirst%3DR.%26aulast%3DChemtob%26aufirst%3DD.%26aulast%3DCirillo%26aufirst%3DD.%2BM.%26aulast%3DColorado%26aufirst%3DA.%26aulast%3DDadu%26aufirst%3DA.%26aulast%3DDahle%26aufirst%3DU.%2BR.%26aulast%3DDe%2BPaoli%26aufirst%3DL.%26aulast%3DDias%26aufirst%3DH.%2BM.%26aulast%3DDuarte%26aufirst%3DR.%26aulast%3DFattorini%26aufirst%3DL.%26aulast%3DGaga%26aufirst%3DM.%26aulast%3DGetahun%26aufirst%3DH.%26aulast%3DGlaziou%26aufirst%3DP.%26aulast%3DGoguadze%26aufirst%3DL.%26aulast%3DDel%2BGranado%26aufirst%3DM.%26aulast%3DHaas%26aufirst%3DW.%26aulast%3DJ%25C3%25A4rvinen%26aufirst%3DA.%26aulast%3DKwon%26aufirst%3DG.-Y.%26aulast%3DMosca%26aufirst%3DD.%26aulast%3DNahid%26aufirst%3DP.%26aulast%3DNishikiori%26aufirst%3DN.%26aulast%3DNoguer%26aufirst%3DI.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%26aulast%3DPace-Asciak%26aufirst%3DA.%26aulast%3DPompa%26aufirst%3DM.%2BG.%26aulast%3DPopescu%26aufirst%3DG.%2BG.%26aulast%3DRobalo%2BCordeiro%26aufirst%3DC.%26aulast%3DR%25C3%25B8nning%26aufirst%3DK.%26aulast%3DRuhwald%26aufirst%3DM.%26aulast%3DSculier%26aufirst%3DJ.-P.%26aulast%3DSimunovi%25C4%2587%26aufirst%3DA.%26aulast%3DSmith-Palmer%26aufirst%3DA.%26aulast%3DSotgiu%26aufirst%3DG.%26aulast%3DSulis%26aufirst%3DG.%26aulast%3DTorres-Duque%26aufirst%3DC.%2BA.%26aulast%3DUmeki%26aufirst%3DK.%26aulast%3DUplekar%26aufirst%3DM.%26aulast%3Dvan%2BWeezenbeek%26aufirst%3DC.%26aulast%3DVasankari%26aufirst%3DT.%26aulast%3DVitillo%26aufirst%3DR.%2BJ.%26aulast%3DVoniatis%26aufirst%3DC.%26aulast%3DWanlin%26aufirst%3DM.%26aulast%3DRaviglione%26aufirst%3DM.%2BC.%26atitle%3DTowards%2520tuberculosis%2520elimination%253A%2520an%2520action%2520framework%2520for%2520low-incidence%2520countries%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D45%26spage%3D928%26epage%3D952%26doi%3D10.1183%2F09031936.00214014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besozzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barberis, I.</span></span> <span> </span><span class="NLM_article-title">The never-ending story of the fight against tuberculosis: from Koch’s bacillus to global control programs</span>. <i>J. Prev. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">E241</span>– <span class="NLM_lpage">E247</span>, <span class="refDoi"> DOI: 10.15167/2421-4248/jpmh2018.59.3.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.15167%2F2421-4248%2Fjpmh2018.59.3.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30397682" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=E241-E247&author=M.+Martiniauthor=G.+Besozziauthor=I.+Barberis&title=The+never-ending+story+of+the+fight+against+tuberculosis%3A+from+Koch%E2%80%99s+bacillus+to+global+control+programs&doi=10.15167%2F2421-4248%2Fjpmh2018.59.3.105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.15167%2F2421-4248%2Fjpmh2018.59.3.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15167%252F2421-4248%252Fjpmh2018.59.3.105%26sid%3Dliteratum%253Aachs%26aulast%3DMartini%26aufirst%3DM.%26aulast%3DBesozzi%26aufirst%3DG.%26aulast%3DBarberis%26aufirst%3DI.%26atitle%3DThe%2520never-ending%2520story%2520of%2520the%2520fight%2520against%2520tuberculosis%253A%2520from%2520Koch%25E2%2580%2599s%2520bacillus%2520to%2520global%2520control%2520programs%26jtitle%3DJ.%2520Prev.%2520Med.%2520Hyg.%26date%3D2018%26volume%3D59%26spage%3DE241%26epage%3DE247%26doi%3D10.15167%2F2421-4248%2Fjpmh2018.59.3.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waksman, S. A.</span></span> <span> </span><span class="NLM_article-title">Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria</span>. <i>Exp. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">1944</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.3181/00379727-55-14461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3181%2F00379727-55-14461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaH2cXhsVSrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1944&pages=66-69&author=A.+Schatzauthor=E.+Bugleauthor=S.+A.+Waksman&title=Streptomycin%2C+a+substance+exhibiting+antibiotic+activity+against+Gram-positive+and+Gram-negative+bacteria&doi=10.3181%2F00379727-55-14461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria</span></div><div class="casAuthors">Schatz, Albert; Bugie, Elizabeth; Waksman, Selman A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Society for Experimental Biology and Medicine</span>
        (<span class="NLM_cas:date">1944</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">66-9</span>CODEN:
                <span class="NLM_cas:coden">PSEBAA</span>;
        ISSN:<span class="NLM_cas:issn">0037-9727</span>.
    </div><div class="casAbstract">A new antibacterial substance, designated streptomycin, was isolated from 2 strains of an actinomyces related to an organism described as Actinomyces griseus.  This substance resembles streptothricin in its soly. in water, method of isolation and concn., its selective activity against gram-neg. bacteria and its limited toxicity in animals; but the 2 substances differ in the nature of their resp. bacteriostatic spectra and in their quant. action on certain bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomLzs1Xg-0IbVg90H21EOLACvtfcHk0lhT16Q47wWNvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaH2cXhsVSrug%253D%253D&md5=bdfd9aeddfa1ec7a5b9664ab744b1842</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.3181%2F00379727-55-14461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3181%252F00379727-55-14461%26sid%3Dliteratum%253Aachs%26aulast%3DSchatz%26aufirst%3DA.%26aulast%3DBugle%26aufirst%3DE.%26aulast%3DWaksman%26aufirst%3DS.%2BA.%26atitle%3DStreptomycin%252C%2520a%2520substance%2520exhibiting%2520antibiotic%2520activity%2520against%2520Gram-positive%2520and%2520Gram-negative%2520bacteria%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D1944%26volume%3D55%26spage%3D66%26epage%3D69%26doi%3D10.3181%2F00379727-55-14461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schraufnagel, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopewell, P. C.</span></span> <span> </span><span class="NLM_article-title">Treatment of tuberculosis. A historical perspective</span>. <i>Ann. Am. Thorac. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1749</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1513/AnnalsATS.201509-632PS</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1513%2FAnnalsATS.201509-632PS" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26653188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC28rhsVCnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1749-1759&author=J.+F.+Murrayauthor=D.+E.+Schraufnagelauthor=P.+C.+Hopewell&title=Treatment+of+tuberculosis.+A+historical+perspective&doi=10.1513%2FAnnalsATS.201509-632PS"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Tuberculosis. A Historical Perspective</span></div><div class="casAuthors">Murray John F; Hopewell Philip C; Schraufnagel Dean E</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1749-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Of all achievements in medicine, the successful treatment of tuberculosis has had one of the greatest impacts on society.  Tuberculosis was a leading cause of disease and a mortal enemy of humanity for millennia.  The first step in finding a cure was the discovery of the cause of tuberculosis by Robert Koch in 1882.  The sanatorium movement that began shortly afterward in Europe, and soon spread to the United States, brought attention to the plight of afflicted persons, and catalyzed public health action.  The antituberculosis benefit of streptomycin was announced in 1945, although application was limited by the rapid development of resistance. para-Aminosalicylic acid, also discovered in 1945, when combined with streptomycin was found to greatly reduce the occurrence of drug resistance.  In 1952, isoniazid opened the modern era of treatment; it was inexpensive, well tolerated, and safe.  In the early 1960s, ethambutol was shown to be effective and better tolerated than para-aminosalicylic acid, which it replaced.  In the 1970s, rifampin found its place as a keystone in the therapy of tuberculosis.  The use of rifampin enabled the course of treatment to be reduced to nine months.  Incorporation of pyrazinamide into the first-line regimen led to a further reduction of treatment duration to six months.  Treatment of multiple drug-resistant tuberculosis remains a difficult problem requiring lengthy treatment with toxic drugs.  However, shortened regimens show promise, and two new drugs, bedaquiline and delamanid, have demonstrated effectiveness in preliminary studies and are being used for extensively drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkJKmRJ2pC8wMthz5_Rx5rfW6udTcc2eZuYJxpJIR2bbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rhsVCnuw%253D%253D&md5=08e20f580f4ac9606ab177f67221c7bf</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1513%2FAnnalsATS.201509-632PS&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252FAnnalsATS.201509-632PS%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DJ.%2BF.%26aulast%3DSchraufnagel%26aufirst%3DD.%2BE.%26aulast%3DHopewell%26aufirst%3DP.%2BC.%26atitle%3DTreatment%2520of%2520tuberculosis.%2520A%2520historical%2520perspective%26jtitle%3DAnn.%2520Am.%2520Thorac.%2520Soc.%26date%3D2015%26volume%3D12%26spage%3D1749%26epage%3D1759%26doi%3D10.1513%2FAnnalsATS.201509-632PS" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siliciano, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Outwitting evolution: fighting drug-resistant TB, malaria, and HIV</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">1271</span>– <span class="NLM_lpage">1283</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2012.02.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.cell.2012.02.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22424234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkt1Ggsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2012&pages=1271-1283&author=D.+E.+Goldbergauthor=R.+F.+Silicianoauthor=W.+R.+Jacobs&title=Outwitting+evolution%3A+fighting+drug-resistant+TB%2C+malaria%2C+and+HIV&doi=10.1016%2Fj.cell.2012.02.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Outwitting Evolution: Fighting Drug-Resistant TB, Malaria, and HIV</span></div><div class="casAuthors">Goldberg, Daniel E.; Siliciano, Robert F.; Jacobs, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1271-1283</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Although caused by vastly different pathogens, the world's three most serious infectious diseases, tuberculosis, malaria, and HIV-1 infection, share the common problem of drug resistance.  The pace of drug development has been very slow for tuberculosis and malaria and rapid for HIV-1.  But for each disease, resistance to most drugs has appeared quickly after the introduction of the drug.  Learning how to manage and prevent resistance is a major medical challenge that requires an understanding of the evolutionary dynamics of each pathogen.  This Review summarizes the similarities and differences in the evolution of drug resistance for these three pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn6p5xi5AClbVg90H21EOLACvtfcHk0ljSICcNNbfEwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkt1Ggsb0%253D&md5=53f6efa66936569abc9ad91010239569</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DD.%2BE.%26aulast%3DSiliciano%26aufirst%3DR.%2BF.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26atitle%3DOutwitting%2520evolution%253A%2520fighting%2520drug-resistant%2520TB%252C%2520malaria%252C%2520and%2520HIV%26jtitle%3DCell%26date%3D2012%26volume%3D148%26spage%3D1271%26epage%3D1283%26doi%3D10.1016%2Fj.cell.2012.02.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sweany, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entin, S.</span></span> <span> </span><span class="NLM_article-title">A preliminary report on the use of para-amino salicylic acid in the treatment of pulmonary tuberculosis</span>. <i>Dis. Chest</i> <span class="NLM_year" style="font-weight: bold;">1949</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">633</span>– <span class="NLM_lpage">656</span>, <span class="refDoi"> DOI: 10.1378/chest.16.6.633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1378%2Fchest.16.6.633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=15396512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaG3c%252Fgs1Wntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1949&pages=633-656&author=H.+C.+Sweanyauthor=G.+C.+Turnerauthor=M.+Lichtensteinauthor=S.+Entin&title=A+preliminary+report+on+the+use+of+para-amino+salicylic+acid+in+the+treatment+of+pulmonary+tuberculosis&doi=10.1378%2Fchest.16.6.633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">A preliminary report on the use of para-amino salicylic acid in the treatment of pulmonary tuberculosis</span></div><div class="casAuthors">SWEANY H C; TURNER G C</div><div class="citationInfo"><span class="NLM_cas:title">Diseases of the chest</span>
        (<span class="NLM_cas:date">1949</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">633-60, illust</span>
        ISSN:<span class="NLM_cas:issn">0096-0217</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsf1Y54ghI_xpyrDyM_m9cfW6udTcc2ebZ5emm2rJqG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG3c%252Fgs1Wntg%253D%253D&md5=7986be1efa73a2c88f40c0536f6f315a</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1378%2Fchest.16.6.633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.16.6.633%26sid%3Dliteratum%253Aachs%26aulast%3DSweany%26aufirst%3DH.%2BC.%26aulast%3DTurner%26aufirst%3DG.%2BC.%26aulast%3DLichtenstein%26aufirst%3DM.%26aulast%3DEntin%26aufirst%3DS.%26atitle%3DA%2520preliminary%2520report%2520on%2520the%2520use%2520of%2520para-amino%2520salicylic%2520acid%2520in%2520the%2520treatment%2520of%2520pulmonary%2520tuberculosis%26jtitle%3DDis.%2520Chest%26date%3D1949%26volume%3D16%26spage%3D633%26epage%3D656%26doi%3D10.1378%2Fchest.16.6.633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, J.</span></span> <span> </span><span class="NLM_article-title">Para-aminosalicylic acid in the treatment of tuberculosis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1946</span>,  <span class="NLM_volume"><i>247</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(46)91185-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS0140-6736%2846%2991185-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=1946&pages=15-16&author=J.+Lehmann&title=Para-aminosalicylic+acid+in+the+treatment+of+tuberculosis&doi=10.1016%2FS0140-6736%2846%2991185-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2846%2991185-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252846%252991185-3%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DJ.%26atitle%3DPara-aminosalicylic%2520acid%2520in%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DLancet%26date%3D1946%26volume%3D247%26spage%3D15%26epage%3D16%26doi%3D10.1016%2FS0140-6736%2846%2991185-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, J.</span></span> <span> </span><span class="NLM_article-title">The effect of streptomycin with para-amino salicylic acid on the emergence of resistant strains of tubercle bacilli</span>. <i>Dis. Chest</i> <span class="NLM_year" style="font-weight: bold;">1949</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">666</span>, <span class="refDoi"> DOI: 10.1378/chest.16.6.661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1378%2Fchest.16.6.661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=15396513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaG3c%252Fgs1Wntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1949&pages=661-666&author=E.+Dunnerauthor=W.+B.+Brownauthor=J.+Wallace&title=The+effect+of+streptomycin+with+para-amino+salicylic+acid+on+the+emergence+of+resistant+strains+of+tubercle+bacilli&doi=10.1378%2Fchest.16.6.661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of streptomycin with para-amino salicylic acid on the emergence of resistant strains of tubercle bacilli</span></div><div class="casAuthors">DUNNER E; BROWN W B; WALLACE J</div><div class="citationInfo"><span class="NLM_cas:title">Diseases of the chest</span>
        (<span class="NLM_cas:date">1949</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">661-6</span>
        ISSN:<span class="NLM_cas:issn">0096-0217</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsf1Y54ghI_waK-_ZudimnfW6udTcc2ebZ5emm2rJqG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG3c%252Fgs1Wntw%253D%253D&md5=e4275eb0fce118824dbabfcaed69c31c</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1378%2Fchest.16.6.661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.16.6.661%26sid%3Dliteratum%253Aachs%26aulast%3DDunner%26aufirst%3DE.%26aulast%3DBrown%26aufirst%3DW.%2BB.%26aulast%3DWallace%26aufirst%3DJ.%26atitle%3DThe%2520effect%2520of%2520streptomycin%2520with%2520para-amino%2520salicylic%2520acid%2520on%2520the%2520emergence%2520of%2520resistant%2520strains%2520of%2520tubercle%2520bacilli%26jtitle%3DDis.%2520Chest%26date%3D1949%26volume%3D16%26spage%3D661%26epage%3D666%26doi%3D10.1378%2Fchest.16.6.661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palomino, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A.</span></span> <span> </span><span class="NLM_article-title">Drug resistance mechanisms in Mycobacterium tuberculosis</span>. <i>Antibiotics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.3390/antibiotics3030317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3390%2Fantibiotics3030317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC28fltFOrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=317-340&author=J.+C.+Palominoauthor=A.+Martin&title=Drug+resistance+mechanisms+in+Mycobacterium+tuberculosis&doi=10.3390%2Fantibiotics3030317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Resistance Mechanisms in Mycobacterium tuberculosis</span></div><div class="casAuthors">Palomino Juan Carlos; Martin Anandi</div><div class="citationInfo"><span class="NLM_cas:title">Antibiotics (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-40</span>
        ISSN:<span class="NLM_cas:issn">2079-6382</span>.
    </div><div class="casAbstract">Tuberculosis (TB) is a serious public health problem worldwide.  Its situation is worsened by the presence of multidrug resistant (MDR) strains of Mycobacterium tuberculosis, the causative agent of the disease.  In recent years, even more serious forms of drug resistance have been reported.  A better knowledge of the mechanisms of drug resistance of M. tuberculosis and the relevant molecular mechanisms involved will improve the available techniques for rapid drug resistance detection and will help to explore new targets for drug activity and development.  This review article discusses the mechanisms of action of anti-tuberculosis drugs and the molecular basis of drug resistance in M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGcT1qwAb8rXwOGIfWJ7-GfW6udTcc2eYJMJ-Ba6HepLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fltFOrtQ%253D%253D&md5=d0c81d95447575274fed09d43072d7ce</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.3390%2Fantibiotics3030317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fantibiotics3030317%26sid%3Dliteratum%253Aachs%26aulast%3DPalomino%26aufirst%3DJ.%2BC.%26aulast%3DMartin%26aufirst%3DA.%26atitle%3DDrug%2520resistance%2520mechanisms%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DAntibiotics%26date%3D2014%26volume%3D3%26spage%3D317%26epage%3D340%26doi%3D10.3390%2Fantibiotics3030317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Converse, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peloquin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuermberger, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosset, J. H.</span></span> <span> </span><span class="NLM_article-title">Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">1254</span>– <span class="NLM_lpage">1261</span>, <span class="refDoi"> DOI: 10.1164/rccm.201012-1949OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1164%2Frccm.201012-1949OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21330452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVSntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2011&pages=1254-1261&author=M.+Zhangauthor=S.+Y.+Liauthor=I.+M.+Rosenthalauthor=D.+V.+Almeidaauthor=Z.+Ahmadauthor=P.+J.+Converseauthor=C.+A.+Peloquinauthor=E.+L.+Nuermbergerauthor=J.+H.+Grosset&title=Treatment+of+tuberculosis+with+rifamycin-containing+regimens+in+immune-deficient+mice&doi=10.1164%2Frccm.201012-1949OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice</span></div><div class="casAuthors">Zhang, Ming; Li, Si-Yang; Rosenthal, Ian M.; Almeida, Deepak V.; Ahmad, Zahoor; Converse, Paul J.; Peloquin, Charles A.; Nuermberger, Eric L.; Grosset, Jacques H.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1254-1261</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Daily rifapentine plus isoniazid-pyrazinamide in mice infected with Mycobacterium tuberculosis produces cure in 3 mo.  Whether cure corresponds to latent infection contained by host immunity or true tissue sterilization is unknown.  Objectives: To det. the length of treatment with rifapentine-isoniazid-pyrazinamide or rifampin-isoniazid-pyrazinamide needed to prevent relapse in immune-deficient mice.  Methods: Aerosol-infected BALB/c and nude mice were treated 5 days per wk with either 2 mo of the rifapentine-based regimen followed by rifapentine-isoniazid up to 12 mo or the same regimen with rifampin instead of rifapentine.  Cultures of lung homogenates were performed during the first 3 mo and then every 3 mo.  Relapse rates were assessed after 3, 6, 9, and 12 mo of treatment in BALB/c(± 1 mo of cortisone) and nude mice.  Measurements and Main Results: All rifapentine-treated mice were lung culture-neg. at 3 mo but 13% of BALB/c that received cortisone and 73% of nude mice relapsed.  After 6, 9, and 12 mo of treatment no mouse relapsed.  Rifampin-treated BALB/c mice remained culture pos. at 3 mo.  All were culture neg. at 6, 9, and 12 mo.  None, including those receiving cortisone, relapsed.  Rifampin-treated nude mice harbored more than 4log10 lung cfu at Month 2 and approx. 6 log10 cfu with isoniazid resistance at Month 3.  A supplementary expt. demonstrated that 7 days a week treatment did not prevent isoniazid resistance, whereas addn. of ethambutol did.  Conclusions: In nude mice, sterilization of tuberculosis is obtained with rifapentine-contg. treatment, whereas failure with development of isoniazid resistance is obtained with rifampin-contg. treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptaLdW3FSTF7Vg90H21EOLACvtfcHk0ljhfFdrXsNvww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVSntrs%253D&md5=f2fd55db1f2b0fe8cc52617babf67488</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1164%2Frccm.201012-1949OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201012-1949OC%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DS.%2BY.%26aulast%3DRosenthal%26aufirst%3DI.%2BM.%26aulast%3DAlmeida%26aufirst%3DD.%2BV.%26aulast%3DAhmad%26aufirst%3DZ.%26aulast%3DConverse%26aufirst%3DP.%2BJ.%26aulast%3DPeloquin%26aufirst%3DC.%2BA.%26aulast%3DNuermberger%26aufirst%3DE.%2BL.%26aulast%3DGrosset%26aufirst%3DJ.%2BH.%26atitle%3DTreatment%2520of%2520tuberculosis%2520with%2520rifamycin-containing%2520regimens%2520in%2520immune-deficient%2520mice%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2011%26volume%3D183%26spage%3D1254%26epage%3D1261%26doi%3D10.1164%2Frccm.201012-1949OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seaworth, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. E.</span></span> <span> </span><span class="NLM_article-title">Therapy of multidrug-resistant and extensively drug-resistant tuberculosis</span>. <i>Microbiol. Spectrum</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">TNMI7-0042-2017</span>, <span class="refDoi"> DOI: 10.1128/microbiolspec.TNMI7-0042-2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2Fmicrobiolspec.TNMI7-0042-2017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=TNMI7-0042-2017&author=B.+J.+Seaworthauthor=D.+E.+Griffith&title=Therapy+of+multidrug-resistant+and+extensively+drug-resistant+tuberculosis&doi=10.1128%2Fmicrobiolspec.TNMI7-0042-2017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1128%2Fmicrobiolspec.TNMI7-0042-2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmicrobiolspec.TNMI7-0042-2017%26sid%3Dliteratum%253Aachs%26aulast%3DSeaworth%26aufirst%3DB.%2BJ.%26aulast%3DGriffith%26aufirst%3DD.%2BE.%26atitle%3DTherapy%2520of%2520multidrug-resistant%2520and%2520extensively%2520drug-resistant%2520tuberculosis%26jtitle%3DMicrobiol.%2520Spectrum%26date%3D2017%26volume%3D5%26spage%3DTNMI7-0042-2017%26doi%3D10.1128%2Fmicrobiolspec.TNMI7-0042-2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaton, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessells, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kon, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supply, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moodley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pym, A. S.</span></span> <span> </span><span class="NLM_article-title">International spread of MDR TB from Tugela Ferry, South Africa</span>. <i>Emerging Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2035</span>– <span class="NLM_lpage">2037</span>, <span class="refDoi"> DOI: 10.3201/eid1711.110291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3201%2Feid1711.110291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22099091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FhtVKgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2035-2037&author=G.+S.+Cookeauthor=R.+K.+Beatonauthor=R.+J.+Lessellsauthor=L.+Johnauthor=S.+Ashworthauthor=O.+M.+Konauthor=O.+M.+Williamsauthor=P.+Supplyauthor=P.+Moodleyauthor=A.+S.+Pym&title=International+spread+of+MDR+TB+from+Tugela+Ferry%2C+South+Africa&doi=10.3201%2Feid1711.110291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">International spread of MDR TB from Tugela Ferry, South Africa</span></div><div class="casAuthors">Cooke Graham S; Beaton R Kate; Lessells Richard J; John Laurence; Ashworth Simon; Kon Onn Min; Williams O Martin; Supply P; Moodley P; Pym Alexander S</div><div class="citationInfo"><span class="NLM_cas:title">Emerging infectious diseases</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2035-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We describe a death associated with multidrug-resistant tuberculosis and HIV infection outside Africa that can be linked to Tugela Ferry (KwaZulu-Natal, South Africa), the town most closely associated with the regional epidemic of drug-resistant tuberculosis.  This case underscores the international relevance of this regional epidemic, particularly among health care workers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQM-P1b8wGFGsrRqEXsZufAfW6udTcc2eYyMsO09fd_rbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FhtVKgsw%253D%253D&md5=f10bf95f8c979927b6ff3dcd070f6532</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.3201%2Feid1711.110291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3201%252Feid1711.110291%26sid%3Dliteratum%253Aachs%26aulast%3DCooke%26aufirst%3DG.%2BS.%26aulast%3DBeaton%26aufirst%3DR.%2BK.%26aulast%3DLessells%26aufirst%3DR.%2BJ.%26aulast%3DJohn%26aufirst%3DL.%26aulast%3DAshworth%26aufirst%3DS.%26aulast%3DKon%26aufirst%3DO.%2BM.%26aulast%3DWilliams%26aufirst%3DO.%2BM.%26aulast%3DSupply%26aufirst%3DP.%26aulast%3DMoodley%26aufirst%3DP.%26aulast%3DPym%26aufirst%3DA.%2BS.%26atitle%3DInternational%2520spread%2520of%2520MDR%2520TB%2520from%2520Tugela%2520Ferry%252C%2520South%2520Africa%26jtitle%3DEmerging%2520Infect.%2520Dis.%26date%3D2011%26volume%3D17%26spage%3D2035%26epage%3D2037%26doi%3D10.3201%2Feid1711.110291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sotgiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Ambrosio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliori, G. B.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis treatment and drug regimens</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">a017822</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a017822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1101%2Fcshperspect.a017822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25573773" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=a017822&author=G.+Sotgiuauthor=R.+Centisauthor=L.+D%E2%80%99Ambrosioauthor=G.+B.+Migliori&title=Tuberculosis+treatment+and+drug+regimens&doi=10.1101%2Fcshperspect.a017822"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a017822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a017822%26sid%3Dliteratum%253Aachs%26aulast%3DSotgiu%26aufirst%3DG.%26aulast%3DCentis%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Ambrosio%26aufirst%3DL.%26aulast%3DMigliori%26aufirst%3DG.%2BB.%26atitle%3DTuberculosis%2520treatment%2520and%2520drug%2520regimens%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2015%26volume%3D5%26spage%3Da017822%26doi%3D10.1101%2Fcshperspect.a017822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, D.</span></span> <span> </span><span class="NLM_article-title">Directly observed therapy for tuberculosis: history of an idea</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1548</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(95)91090-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS0140-6736%2895%2991090-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=7677849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaK2MzhtFGmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=1995&pages=1545-1548&author=R.+Bayerauthor=D.+Wilkinson&title=Directly+observed+therapy+for+tuberculosis%3A+history+of+an+idea&doi=10.1016%2FS0140-6736%2895%2991090-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Directly observed therapy for tuberculosis: history of an idea</span></div><div class="casAuthors">Bayer R; Wilkinson D</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">8964</span>),
    <span class="NLM_cas:pages">1545-8</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1tXUbrXZOoUloaUqgkFHkfW6udTcc2eYyMsO09fd_rbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2MzhtFGmsw%253D%253D&md5=69f7b6b4ab1dba3e65d75dbd85ec99d4</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2895%2991090-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252895%252991090-5%26sid%3Dliteratum%253Aachs%26aulast%3DBayer%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DD.%26atitle%3DDirectly%2520observed%2520therapy%2520for%2520tuberculosis%253A%2520history%2520of%2520an%2520idea%26jtitle%3DLancet%26date%3D1995%26volume%3D345%26spage%3D1545%26epage%3D1548%26doi%3D10.1016%2FS0140-6736%2895%2991090-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieden, T. R.</span></span> <span> </span><span class="NLM_article-title">Directly observed therapy in New York City. History, implementation, results, and challenges</span>. <i>Clinics in Chest Medicine</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1016/S0272-5231(05)70363-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS0272-5231%2805%2970363-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=9098618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaK2s3ltlWktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1997&pages=135-148&author=P.+I.+Fujiwaraauthor=C.+Larkinauthor=T.+R.+Frieden&title=Directly+observed+therapy+in+New+York+City.+History%2C+implementation%2C+results%2C+and+challenges&doi=10.1016%2FS0272-5231%2805%2970363-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Directly observed therapy in New York City. History, implementation, results, and challenges</span></div><div class="casAuthors">Fujiwara P I; Larkin C; Frieden T R</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in chest medicine</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">135-48</span>
        ISSN:<span class="NLM_cas:issn">0272-5231</span>.
    </div><div class="casAbstract">The history of the New York City Department of Health Bureau of Tuberculosis Control Program, and the events leading to the adoption of wide-scale directly observed therapy (DOT) in 1992 are described.  The organization and role of Department of Health and non-Department of Health directly observed programs are discussed.  Details are provided regarding the Department of Health's program: the use of standard treatment and program protocols, the use of incentives and enablers, a profile of the successful DOT worker, the detention program, and other issues.  Program data and outcomes from 1992 through 1995 are presented, along with some of the challenges and questions for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZCYSpVMSTqcSzjBFCN0BJfW6udTcc2eY1jXHdSJc_wLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s3ltlWktw%253D%253D&md5=05fb012a12b77e0622588b40373c4c4f</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS0272-5231%2805%2970363-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0272-5231%252805%252970363-4%26sid%3Dliteratum%253Aachs%26aulast%3DFujiwara%26aufirst%3DP.%2BI.%26aulast%3DLarkin%26aufirst%3DC.%26aulast%3DFrieden%26aufirst%3DT.%2BR.%26atitle%3DDirectly%2520observed%2520therapy%2520in%2520New%2520York%2520City.%2520History%252C%2520implementation%252C%2520results%252C%2520and%2520challenges%26jtitle%3DClinics%2520in%2520Chest%2520Medicine%26date%3D1997%26volume%3D18%26spage%3D135%26epage%3D148%26doi%3D10.1016%2FS0272-5231%2805%2970363-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span> <i>Global Tuberculosis Report 2019 Fact Sheet</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2019</span>; <a href="https://www.who.int/publications/m/item/global-tuberculosis-report-2019-fact-sheet" class="extLink">https://www.who.int/publications/m/item/global-tuberculosis-report-2019-fact-sheet</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Tuberculosis+Report+2019+Fact+Sheet%3B+World+Health+Organization%3A+Geneva%2C+2019%3B+https%3A%2F%2Fwww.who.int%2Fpublications%2Fm%2Fitem%2Fglobal-tuberculosis-report-2019-fact-sheet+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlobal%2520Tuberculosis%2520Report%25202019%2520Fact%2520Sheet%26pub%3DWorld%2520Health%2520Organization%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almeida
Da Silva, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomino, J. C.</span></span> <span> </span><span class="NLM_article-title">Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1417</span>– <span class="NLM_lpage">1430</span>, <span class="refDoi"> DOI: 10.1093/jac/dkr173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fjac%2Fdkr173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21558086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFWksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2011&pages=1417-1430&author=P.+E.+Almeida%0ADa+Silvaauthor=J.+C.+Palomino&title=Molecular+basis+and+mechanisms+of+drug+resistance+in+Mycobacterium+tuberculosis%3A+classical+and+new+drugs&doi=10.1093%2Fjac%2Fdkr173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs</span></div><div class="casAuthors">Almeida Da Silva, Pedro Eduardo; Palomino, Juan Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1417-1430</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB) remains one of the leading public health problems worldwide.  Declared as a global emergency in 1993 by the WHO, its control is hampered by the emergence of multidrug resistance (MDR), defined as resistance to at least rifampicin and isoniazid, two key drugs in the treatment of the disease.  More recently, severe forms of drug resistance such as extensively drug-resistant (XDR) TB have been described.  After the discovery of several drugs with anti-TB activity, multidrug therapy became fundamental for control of the disease.  Major advances in mol. biol. and the availability of new information generated after sequencing the genome of Mycobacterium tuberculosis increased our knowledge of the mechanisms of resistance to the main anti-TB drugs.  Better knowledge of the mechanisms of drug resistance in TB and the mol. mechanisms involved will help us to improve current techniques for rapid detection and will also stimulate the exploration of new targets for drug activity and drug development.  This article presents an updated review of the mechanisms and mol. basis of drug resistance in M. tuberculosis.  It also comments on the several gaps in our current knowledge of the mol. mechanisms of drug resistance to the main classical and new anti-TB drugs and briefly discusses some implications of the development of drug resistance and fitness, transmission and pathogenicity of M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnautFX8QYVLVg90H21EOLACvtfcHk0lhULIU4at2a9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFWksL8%253D&md5=5d2d6af9192d73ecc1621ab94d910cfa</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkr173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkr173%26sid%3Dliteratum%253Aachs%26aulast%3DAlmeida%2BDa%2BSilva%26aufirst%3DP.%2BE.%26aulast%3DPalomino%26aufirst%3DJ.%2BC.%26atitle%3DMolecular%2520basis%2520and%2520mechanisms%2520of%2520drug%2520resistance%2520in%2520Mycobacterium%2520tuberculosis%253A%2520classical%2520and%2520new%2520drugs%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2011%26volume%3D66%26spage%3D1417%26epage%3D1430%26doi%3D10.1093%2Fjac%2Fdkr173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holtz, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sternberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kammerer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laserson, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riekstina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarovska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skripconoka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leimane, V.</span></span> <span> </span><span class="NLM_article-title">Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.7326/0003-4819-144-9-200605020-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.7326%2F0003-4819-144-9-200605020-00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=16670134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD283ks1Sgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2006&pages=650-659&author=T.+H.+Holtzauthor=M.+Sternbergauthor=S.+Kammererauthor=K.+F.+Lasersonauthor=V.+Riekstinaauthor=E.+Zarovskaauthor=V.+Skripconokaauthor=C.+D.+Wellsauthor=V.+Leimane&title=Time+to+sputum+culture+conversion+in+multidrug-resistant+tuberculosis%3A+predictors+and+relationship+to+treatment+outcome&doi=10.7326%2F0003-4819-144-9-200605020-00008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome</span></div><div class="casAuthors">Holtz Timothy H; Sternberg Maya; Kammerer Steve; Laserson Kayla F; Riekstina Vija; Zarovska Evija; Skripconoka Vija; Wells Charles D; Leimane Vaira</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">650-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Conversion of sputum mycobacterial cultures from positive growth to negative growth of Mycobacterium tuberculosis in patients with pulmonary tuberculosis (TB) is considered the most important interim indicator of the efficacy of anti-TB pharmacologic treatment for multidrug-resistant disease.  OBJECTIVE:  To evaluate and compare time to and predictors of initial sputum culture conversion with predictors of treatment outcome for patients with multidrug-resistant TB.  DESIGN:  Retrospective cohort study.  SETTING:  Latvia.  PATIENTS:  All civilian patients with multidrug-resistant TB treated with the DOTS-Plus strategy between 1 January and 31 December 2000.  INTERVENTION:  Individualized treatment for confirmed sputum culture-positive pulmonary multidrug-resistant TB.  MEASUREMENTS:  Time to initial sputum culture conversion and treatment outcome.  RESULTS:  Among 167 patients who were sputum culture-positive at initiation of second-line therapy, 129 (77%) converted in a median time of 60 days (range, 4 to 462 days) and 38 (23%) did not convert.  Independent predictors of a longer sputum culture conversion time, using an accelerated failure time regression model, included previous treatment for multidrug-resistant TB, high initial sputum culture colony count, bilateral cavitations on chest radiography, and the number of drugs the initial isolate was resistant to at treatment initiation.  Treatment outcomes were statistically significantly worse for patients who did not convert their sputum culture within 2 months.  LIMITATIONS:  Twenty-five percent of patients missed 5 or more monthly sputum collections.  CONCLUSIONS:  Under program conditions in Latvia, most patients with multidrug-resistant TB achieved sputum culture conversion within 12 weeks of starting treatment.  Chest radiography and sputum culture drug susceptibility testing can assist physicians in predicting which patients will convert more slowly.  Sputum culture conversion is a useful and appropriate interim indicator of treatment outcome in patients with multidrug-resistant TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWtIP8EY_OHfEeosoOnpOLfW6udTcc2eZ_S6R5_rpnGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283ks1Sgsw%253D%253D&md5=584785d11a0cdf1700a1e9fa9d5f0e12</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-144-9-200605020-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-144-9-200605020-00008%26sid%3Dliteratum%253Aachs%26aulast%3DHoltz%26aufirst%3DT.%2BH.%26aulast%3DSternberg%26aufirst%3DM.%26aulast%3DKammerer%26aufirst%3DS.%26aulast%3DLaserson%26aufirst%3DK.%2BF.%26aulast%3DRiekstina%26aufirst%3DV.%26aulast%3DZarovska%26aufirst%3DE.%26aulast%3DSkripconoka%26aufirst%3DV.%26aulast%3DWells%26aufirst%3DC.%2BD.%26aulast%3DLeimane%26aufirst%3DV.%26atitle%3DTime%2520to%2520sputum%2520culture%2520conversion%2520in%2520multidrug-resistant%2520tuberculosis%253A%2520predictors%2520and%2520relationship%2520to%2520treatment%2520outcome%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2006%26volume%3D144%26spage%3D650%26epage%3D659%26doi%3D10.7326%2F0003-4819-144-9-200605020-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroishi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onozaki, K.</span></span> <span> </span><span class="NLM_article-title">Antitubercular activity of disulfiram, an antialcoholism drug, against multidrug- and extensively drug-resistant Mycobacterium tuberculosis isolates</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4140</span>– <span class="NLM_lpage">4145</span>, <span class="refDoi"> DOI: 10.1128/AAC.06445-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.06445-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22615274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFajs7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=4140-4145&author=Y.+Horitaauthor=T.+Takiiauthor=T.+Yagiauthor=K.+Ogawaauthor=N.+Fujiwaraauthor=E.+Inagakiauthor=L.+Kremerauthor=Y.+Satoauthor=R.+Kuroishiauthor=Y.+Leeauthor=T.+Makinoauthor=H.+Mizukamiauthor=T.+Hasegawaauthor=R.+Yamamotoauthor=K.+Onozaki&title=Antitubercular+activity+of+disulfiram%2C+an+antialcoholism+drug%2C+against+multidrug-+and+extensively+drug-resistant+Mycobacterium+tuberculosis+isolates&doi=10.1128%2FAAC.06445-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Antitubercular activity of disulfiram, an antialcoholism drug, against multidrug- and extensively drug-resistant Mycobacterium tuberculosis isolates</span></div><div class="casAuthors">Horita, Yasuhiro; Takii, Takemasa; Yagi, Tetsuya; Ogawa, Kenji; Fujiwara, Nagatoshi; Inagaki, Emi; Kremer, Laurent; Sato, Yasuo; Kuroishi, Ryuji; Lee, YooSa; Makino, Toshiaki; Mizukami, Hajime; Hasegawa, Tomohiro; Yamamoto, Ryuji; Onozaki, Kikuo</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4140-4145</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The antimycobacterial activities of disulfiram (DSF) and diethyldithiocarbamate (DDC) against multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB) clin. isolates were evaluated in vitro.  Both DSF and DDC exhibited potent antitubercular activities against 42 clin. isolates of M. tuberculosis, including MDR/XDR-TB strains.  Moreover, DSF showed remarkable bactericidal activity ex vivo and in vivo.  Therefore, DSF might be a drug re-purposed for the treatment of MDR/XDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5W7IBV2_H-7Vg90H21EOLACvtfcHk0ljXnHLbtbgBYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFajs7zO&md5=d012b8684ba64f73477725a9f2ab7646</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1128%2FAAC.06445-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06445-11%26sid%3Dliteratum%253Aachs%26aulast%3DHorita%26aufirst%3DY.%26aulast%3DTakii%26aufirst%3DT.%26aulast%3DYagi%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DFujiwara%26aufirst%3DN.%26aulast%3DInagaki%26aufirst%3DE.%26aulast%3DKremer%26aufirst%3DL.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DKuroishi%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DMakino%26aufirst%3DT.%26aulast%3DMizukami%26aufirst%3DH.%26aulast%3DHasegawa%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DR.%26aulast%3DOnozaki%26aufirst%3DK.%26atitle%3DAntitubercular%2520activity%2520of%2520disulfiram%252C%2520an%2520antialcoholism%2520drug%252C%2520against%2520multidrug-%2520and%2520extensively%2520drug-resistant%2520Mycobacterium%2520tuberculosis%2520isolates%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D4140%26epage%3D4145%26doi%3D10.1128%2FAAC.06445-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alsaad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilffert, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Altena, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lange, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Werf, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosterink, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alffenaar, J. W.</span></span> <span> </span><span class="NLM_article-title">Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">884</span>– <span class="NLM_lpage">897</span>, <span class="refDoi"> DOI: 10.1183/09031936.00113713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1183%2F09031936.00113713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23988774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslKrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=884-897&author=N.+Alsaadauthor=B.+Wilffertauthor=R.+van+Altenaauthor=W.+C.+de+Langeauthor=T.+S.+van+der%0AWerfauthor=J.+G.+Kosterinkauthor=J.+W.+Alffenaar&title=Potential+antimicrobial+agents+for+the+treatment+of+multidrug-resistant+tuberculosis&doi=10.1183%2F09031936.00113713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis</span></div><div class="casAuthors">Alsaad, Noor; Wilffert, Bob; van Altena, Richard; de Lange, Wiel C. M.; van der Werf, Tjip S.; Kosterink, Jos G. W.; Alffenaar, Jan-Willem C.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">884-897</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">A review.  Treatment of multidrug-resistant (MDR) tuberculosis (TB) is challenging because of the high toxicity of second-line drugs and the longer treatment duration than for drug-susceptible TB patients.  In order to speed up novel treatment for MDR-TB, we suggest considering expanding the indications of already available drugs.  Six drugs with antimicrobial activity (phenothiazine, metronidazole, doxycycline, disulfiram, tigecycline and co-trimoxazole) are not listed in the World Health Organization guidelines on MDR-TB treatment but could be potential candidates for evaluation against Mycobacterium tuberculosis.  A systematic review was conducted to evaluate antituberculous activity of these drugs against M. tuberculosis.  We searched PubMed, Google Scholar and Embase for English articles published up to Dec. 31, 2012.  We reviewed in vitro, in vivo and clin. antituberculous activity of these drugs in addn. to pharmacokinetics and side-effects.  Of the drugs effective against actively replicating M. tuberculosis, co-trimoxazole seems to be the most promising, because of its consistent pharmacokinetic profile, easy penetration into tissue and safety profile.  For the dormant state of TB, thioridazine may play a potential role as an adjuvant for treatment of MDR-TB.  A strategy consisting of pharmacokinetic/pharmacodynamic studies, dose finding and phase III studies is needed to explore the role of these drugs in MDR-TB treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRHqWZp_U1eLVg90H21EOLACvtfcHk0lhNeE6qsGCsoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslKrsrs%253D&md5=c0781099bdd7f87d98aa360c44ea7b00</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1183%2F09031936.00113713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00113713%26sid%3Dliteratum%253Aachs%26aulast%3DAlsaad%26aufirst%3DN.%26aulast%3DWilffert%26aufirst%3DB.%26aulast%3Dvan%2BAltena%26aufirst%3DR.%26aulast%3Dde%2BLange%26aufirst%3DW.%2BC.%26aulast%3Dvan%2Bder%2BWerf%26aufirst%3DT.%2BS.%26aulast%3DKosterink%26aufirst%3DJ.%2BG.%26aulast%3DAlffenaar%26aufirst%3DJ.%2BW.%26atitle%3DPotential%2520antimicrobial%2520agents%2520for%2520the%2520treatment%2520of%2520multidrug-resistant%2520tuberculosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D43%26spage%3D884%26epage%3D897%26doi%3D10.1183%2F09031936.00113713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Soolingen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Pando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orozco, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis-Escurra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Ingen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeree, M. J.</span></span> <span> </span><span class="NLM_article-title">The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e12640</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0012640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pone.0012640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=20844587" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=e12640&author=D.+van%0ASoolingenauthor=R.+Hernandez-Pandoauthor=H.+Orozcoauthor=D.+Aguilarauthor=C.+Magis-Escurraauthor=L.+Amaralauthor=J.+van+Ingenauthor=M.+J.+Boeree&title=The+antipsychotic+thioridazine+shows+promising+therapeutic+activity+in+a+mouse+model+of+multidrug-resistant+tuberculosis&doi=10.1371%2Fjournal.pone.0012640"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0012640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0012640%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BSoolingen%26aufirst%3DD.%26aulast%3DHernandez-Pando%26aufirst%3DR.%26aulast%3DOrozco%26aufirst%3DH.%26aulast%3DAguilar%26aufirst%3DD.%26aulast%3DMagis-Escurra%26aufirst%3DC.%26aulast%3DAmaral%26aufirst%3DL.%26aulast%3Dvan%2BIngen%26aufirst%3DJ.%26aulast%3DBoeree%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520antipsychotic%2520thioridazine%2520shows%2520promising%2520therapeutic%2520activity%2520in%2520a%2520mouse%2520model%2520of%2520multidrug-resistant%2520tuberculosis%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26spage%3De12640%26doi%3D10.1371%2Fjournal.pone.0012640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viveiros, M.</span></span> <span> </span><span class="NLM_article-title">Thioridazine: A non-antibiotic drug highly effective, in combination with first line anti-tuberculosis drugs, against any form of antibiotic resistance of Mycobacterium tuberculosis due to its multi-mechanisms of action</span>. <i>Antibiotics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.3390/antibiotics6010003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3390%2Fantibiotics6010003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=3&author=L.+Amaralauthor=M.+Viveiros&title=Thioridazine%3A+A+non-antibiotic+drug+highly+effective%2C+in+combination+with+first+line+anti-tuberculosis+drugs%2C+against+any+form+of+antibiotic+resistance+of+Mycobacterium+tuberculosis+due+to+its+multi-mechanisms+of+action&doi=10.3390%2Fantibiotics6010003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.3390%2Fantibiotics6010003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fantibiotics6010003%26sid%3Dliteratum%253Aachs%26aulast%3DAmaral%26aufirst%3DL.%26aulast%3DViveiros%26aufirst%3DM.%26atitle%3DThioridazine%253A%2520A%2520non-antibiotic%2520drug%2520highly%2520effective%252C%2520in%2520combination%2520with%2520first%2520line%2520anti-tuberculosis%2520drugs%252C%2520against%2520any%2520form%2520of%2520antibiotic%2520resistance%2520of%2520Mycobacterium%2520tuberculosis%2520due%2520to%2520its%2520multi-mechanisms%2520of%2520action%26jtitle%3DAntibiotics%26date%3D2017%26volume%3D6%26spage%3D3%26doi%3D10.3390%2Fantibiotics6010003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, L. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noursadeghi, M.</span></span> <span> </span><span class="NLM_article-title">Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1038/nrmicro.2017.128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnrmicro.2017.128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29109555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslKlt73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=80-90&author=L.+C.+K.+Bellauthor=M.+Noursadeghi&title=Pathogenesis+of+HIV-1+and+Mycobacterium+tuberculosis+co-infection&doi=10.1038%2Fnrmicro.2017.128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection</span></div><div class="casAuthors">Bell, Lucy C. K.; Noursadeghi, Mahdad</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">80-90</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Co-infection with Mycobacterium tuberculosis is the leading cause of death in individuals infected with HIV-1.  It has long been known that HIV-1 infection alters the course of M. tuberculosis infection and substantially increases the risk of active tuberculosis (TB).  It has also become clear that TB increases levels of HIV-1 replication, propagation and genetic diversity.  Therefore, co-infection provides reciprocal advantages to both pathogens.  In this Review, we describe the epidemiol. assocns. between the two pathogens, selected interactions of each pathogen with the host and our current understanding of how they affect the pathogenesis of TB and HIV-1/AIDS in individuals with co-infections.  We evaluate the mechanisms and consequences of HIV-1 depletion of T cells on immune responses to M. tuberculosis.  We also discuss the effect of HIV-1 infection on the control of M. tuberculosis by macrophages through phagocytosis, autophagy and cell death, and we propose models by which dysregulated inflammatory responses drive the pathogenesis of TB and HIV-1/AIDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLctrehsX_jbVg90H21EOLACvtfcHk0lguA_TR818yBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslKlt73I&md5=4377cf461f74b2efa676dc486cc660c8</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro.2017.128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro.2017.128%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DL.%2BC.%2BK.%26aulast%3DNoursadeghi%26aufirst%3DM.%26atitle%3DPathogenesis%2520of%2520HIV-1%2520and%2520Mycobacterium%2520tuberculosis%2520co-infection%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2018%26volume%3D16%26spage%3D80%26epage%3D90%26doi%3D10.1038%2Fnrmicro.2017.128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tornheim, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooley, K. E.</span></span> <span> </span><span class="NLM_article-title">Challenges of TB and HIV co-treatment: updates and insights</span>. <i>Curr. Opin. HIV AIDS</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1097/COH.0000000000000495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1097%2FCOH.0000000000000495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30080683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVChtrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=486-491&author=J.+A.+Tornheimauthor=K.+E.+Dooley&title=Challenges+of+TB+and+HIV+co-treatment%3A+updates+and+insights&doi=10.1097%2FCOH.0000000000000495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges of TB and HIV co-treatment: updates and insights</span></div><div class="casAuthors">Tornheim, Jeffrey A.; Dooley, Kelly E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in HIV & AIDS</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">486-491</span>CODEN:
                <span class="NLM_cas:coden">COHABM</span>;
        ISSN:<span class="NLM_cas:issn">1746-630X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  In the past few years, tuberculosis (TB) has overtaken HIV as the infectious disease with the highest global mortality.  Successful management of this syndemic will require improved diagnostic tests, shorter preventive therapies, and more effective treatments, particularly in light of drug-resistant TB.  Results from several major studies have been published or presented recently, including the development of a more sensitive rapid, mol. assay for TB; several new symptom-based screening tools; use of a 1-mo regimen for TB prevention; the results of early vs. delayed TB preventive therapy for pregnant women; newer drugs and regimens for multidrug-resistant tuberculosis; and pharmacokinetic, safety, and efficacy studies of new HIV drugs in combination with TB treatment.  We reviewed each of these topic areas and summarize relevant findings for the management of TB and HIV co-infection.  Moving forward, as new treatment regimes for HIV or TB are developed, consideration of the HIV-TB co-infected patient must figure prominently, both when detg. the diagnostic tests employed and to assess properly the drug-drug and drug-disease interactions that influence dosing, safety, and response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5qhlyoAll9LVg90H21EOLACvtfcHk0lguA_TR818yBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVChtrfI&md5=6c9f3dc0d35aefe298f6cb8d0efa0668</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1097%2FCOH.0000000000000495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOH.0000000000000495%26sid%3Dliteratum%253Aachs%26aulast%3DTornheim%26aufirst%3DJ.%2BA.%26aulast%3DDooley%26aufirst%3DK.%2BE.%26atitle%3DChallenges%2520of%2520TB%2520and%2520HIV%2520co-treatment%253A%2520updates%2520and%2520insights%26jtitle%3DCurr.%2520Opin.%2520HIV%2520AIDS%26date%3D2018%26volume%3D13%26spage%3D486%26epage%3D491%26doi%3D10.1097%2FCOH.0000000000000495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J. Q.</span></span> <span> </span><span class="NLM_article-title">Diabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1090</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-01213-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fs41598-017-01213-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28439071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1crgslOnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=1090&author=Q.+Liuauthor=W.+Liauthor=M.+Xueauthor=Y.+Chenauthor=X.+Duauthor=C.+Wangauthor=L.+Hanauthor=Y.+Tangauthor=Y.+Fengauthor=C.+Taoauthor=J.+Q.+He&title=Diabetes+mellitus+and+the+risk+of+multidrug+resistant+tuberculosis%3A+a+meta-analysis&doi=10.1038%2Fs41598-017-01213-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Diabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis</span></div><div class="casAuthors">Liu Qianqian; Chen Yunfeng; Liu Qianqian; Xue Miao; Du Xinmiao; Wang Chengdi; Feng Yulin; He Jian-Qing; Li Wenzhang; Han Lina; Tang Yin; Tao Chuanmin</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1090</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The high prevalence of diabetes mellitus (DM) among multidrug resistant tuberculosis (MDR-TB) patients is a serious cause for concern.  We conducted a meta-analysis to determine whether DM is an independent risk factor for MDR-TB.  Electronic literature searches of the PubMed, Web of Science and EMBASE databases up to July 12, 2016 were conducted.  The pooled adjusted odds ratio (OR) and 95% confidence intervals (CIs) were calculated using the random effects model with STATA 12.0 software.  In total 13 studies, including 9289 individuals with TB, were included in this meta-analysis.  Significant association between DM and MDR-TB (OR = 1.71; 95% CI = 1.32, 2.22) was identified.  Subgroup analyses showed that: 1) Pooled OR was 1.25 (95% CI: 0.82-1.91) for cross-sectional studies, and was 2.14 (95% CI: 1.51-3.02) for longitudinal studies; 2) The pooled OR was 1.69 (95% CI:1.09-2.62) for primary MDR-TB, 1.94 (95% CI:1.42-2.65) for any MDR-TB, and 0.85 for secondary MDR-TB (95% CI: 0.29-2.54); 3) DM was significantly associated with MDR-TB in both Caucasian (OR = 2.26, 95% CI: 1.66-3.07) and Asian (OR = 1.40, 95% CI: 1.01-1.95) subgroups.  No evidence of publication bias was identified.  In conclusion, the pooling analysis indicated that DM was an independent risk factor for MDR-TB, especially for primary MDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTU5VyZSnc3CrGbPKh4T9eAfW6udTcc2eaahWTFCmOfIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crgslOnug%253D%253D&md5=db60c8400398de1e62b2a211364ec355</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-01213-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-01213-5%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DXue%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DTao%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DJ.%2BQ.%26atitle%3DDiabetes%2520mellitus%2520and%2520the%2520risk%2520of%2520multidrug%2520resistant%2520tuberculosis%253A%2520a%2520meta-analysis%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D1090%26doi%3D10.1038%2Fs41598-017-01213-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huangfu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarte-Gil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchley, J.</span></span> <span> </span><span class="NLM_article-title">The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">796</span>, <span class="refDoi"> DOI: 10.5588/ijtld.18.0433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.5588%2Fijtld.18.0433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31439109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BB3Mrgs1SitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=783-796&author=P.+Huangfuauthor=C.+Ugarte-Gilauthor=J.+Golubauthor=F.+Pearsonauthor=J.+Critchley&title=The+effects+of+diabetes+on+tuberculosis+treatment+outcomes%3A+an+updated+systematic+review+and+meta-analysis&doi=10.5588%2Fijtld.18.0433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis</span></div><div class="casAuthors">Huangfu P; Pearson F; Critchley J; Ugarte-Gil C; Golub J</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">783-796</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND: Previous evidence synthesis has suggested diabetes mellitus (DM) worsens tuberculosis (TB) treatment outcomes.  However, these reviews are limited by the number, robustness and conflicting results among the studies included.  We conducted a systematic review to update earlier analyses and explore heterogeneity among studies.METHODS: MEDLINE, EMBASE, AIM, LILACS, IMEMR, IMSEAR and WPRIM were searched between 1 January 1980 and 23 July 2018 unrestricted by language or region.  All cohort and case-control studies investigating the difference in TB treatment outcomes amongst TB-DM patients compared to those with TB alone were included.  Two reviewers independently assessed titles, abstracts, and extracted data.  Culture conversion at two/three months, all-cause mortality, treatment failure, relapse and multidrug-resistant TB (MDR-TB) were evaluated using random effects meta-analysis with generic inverse variance.  Heterogeneity was explored using subgroup analyses and meta-regression.RESULTS: One hundred and four publications were identified.  Sixty-four studies including 56 122 individuals with TB-DM and 243 035 with TB, reported on death.  Some outcomes showed substantial heterogeneity between studies, which we could not fully explain, though confounding adjustment and country income level accounted for some of the differences.  TB-DM patients had higher odds of death (OR 1.88, 95%CI 1.59-2.21) and relapse (OR 1.64, 95%CI 1.29-2.08) compared to TB patients.  More limited evidence suggested TB-DM patients had double the risk of developing MDR-TB (OR 1.98, 95%CI 1.51-2.60).CONCLUSION: DM is associated with increased risks of poor TB treatment outcomes, particularly mortality, and may increase risk of developing primary MDR-TB.  Cost-effectiveness of interventions to enhance TB-DM treatment should be assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRMtQEKH7hnxYHWj6b1v8uTfW6udTcc2eaahWTFCmOfIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mrgs1SitA%253D%253D&md5=5f1c64149c97d248c7d4e45e1340edff</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.5588%2Fijtld.18.0433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5588%252Fijtld.18.0433%26sid%3Dliteratum%253Aachs%26aulast%3DHuangfu%26aufirst%3DP.%26aulast%3DUgarte-Gil%26aufirst%3DC.%26aulast%3DGolub%26aufirst%3DJ.%26aulast%3DPearson%26aufirst%3DF.%26aulast%3DCritchley%26aufirst%3DJ.%26atitle%3DThe%2520effects%2520of%2520diabetes%2520on%2520tuberculosis%2520treatment%2520outcomes%253A%2520an%2520updated%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D2019%26volume%3D23%26spage%3D783%26epage%3D796%26doi%3D10.5588%2Fijtld.18.0433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yew, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. C.</span></span> <span> </span><span class="NLM_article-title">Antituberculosis drugs and hepatotoxicity</span>. <i>Respirology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1111/j.1440-1843.2006.00941.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1111%2Fj.1440-1843.2006.00941.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=17052297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD28nitVaiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=699-707&author=W.+W.+Yewauthor=C.+C.+Leung&title=Antituberculosis+drugs+and+hepatotoxicity&doi=10.1111%2Fj.1440-1843.2006.00941.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Antituberculosis drugs and hepatotoxicity</span></div><div class="casAuthors">Yew Wing Wai; Leung Chi Chiu</div><div class="citationInfo"><span class="NLM_cas:title">Respirology (Carlton, Vic.)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">699-707</span>
        ISSN:<span class="NLM_cas:issn">1323-7799</span>.
    </div><div class="casAbstract">Isoniazid, pyrazinamide and rifampicin have hepatotoxic potential, and can lead to such reactions during antituberculosis chemotherapy.  Most of the hepatotoxic reactions are dose-related; some are, however, caused by drug hypersensitivity.  The immunogenetics of antituberculosis drug-induced hepatotoxicity, especially inclusive of acetylaor phenotype polymorphism, have been increasingly unravelled.  Other principal clinical risk factors for hepatotoxicity are old age, malnutrition, alcoholism, HIV infection, as well as chronic hepatitis B and C infections.  Drug-induced hepatic dysfunction usually occurs within the initial few weeks of the intensive phase of antituberculosis chemotherapy.  Vigilant clinical (including patient education on symptoms of hepatitis) and biochemical monitoring are mandatory to improve the outcomes of patients with drug-induced hepatotoxicity during antituberculosis chemotherapy.  Some fluoroquinolones like ofloxacin/levofloxacin may have a role in constituting non-hepatotoxic drug regimens for management of tuberculosis (TB) in the presence of hepatic dysfunction.  Isoniazid administration is currently the standard therapy for latent TB infection.  Rifamycins like rifampicin or rifapentine, alone or in combination with isoniazid, may also be considered as alternatives, pending accumulation of further clinical data.  During treatment of latent TB infection, regular follow up is essential to ensure adherence to therapy and facilitate clinical monitoring for hepatic dysfunction.  Monitoring of liver chemistry is also required for those patients at risk of drug-induced hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUAtmsidhiuZotVjB3IRIyfW6udTcc2eaahWTFCmOfIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nitVaiuw%253D%253D&md5=4d6c2d5185364371cc7e5f4dcb46792a</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1111%2Fj.1440-1843.2006.00941.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1440-1843.2006.00941.x%26sid%3Dliteratum%253Aachs%26aulast%3DYew%26aufirst%3DW.%2BW.%26aulast%3DLeung%26aufirst%3DC.%2BC.%26atitle%3DAntituberculosis%2520drugs%2520and%2520hepatotoxicity%26jtitle%3DRespirology%26date%3D2006%26volume%3D11%26spage%3D699%26epage%3D707%26doi%3D10.1111%2Fj.1440-1843.2006.00941.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albanna, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, D.</span></span> <span> </span><span class="NLM_article-title">Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1183/09031936.00180612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1183%2F09031936.00180612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23314904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFCmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2013&pages=721-732&author=A.+S.+Albannaauthor=B.+M.+Smithauthor=D.+Cowanauthor=D.+Menzies&title=Fixed-dose+combination+antituberculosis+therapy%3A+a+systematic+review+and+meta-analysis&doi=10.1183%2F09031936.00180612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis</span></div><div class="casAuthors">Albanna, Amr S.; Smith, Benjamin M.; Cowan, Deanna; Menzies, Dick</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">721-732</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Fixed-dose combination (FDC) formulations are currently recommended for the treatment of active tuberculosis (TB).  We have conducted a systematic review to evaluate the risk of treatment failure or disease relapse, acquired drug resistance, bacterial conversion after 2 mo of treatment, adverse events, adherence and treatment satisfaction assocd. with treatment of active TB using FDC or sep. drug formulations.  We searched four electronic databases for randomized controlled trials and cohort studies.  Results from trials that directly compared FDC to sep. drug formulations were pooled.  Results from other studies were reported sep.  We identified 2450 citations from which 15 controlled trials and four addnl. relevant studies were included.  In the 15 trials there were no differences in acquired drug resistance, bacterial conversion after 2 mo of treatment or adverse drug reactions with FDC or sep. drug formulations.  There was a trend toward higher risk of failure or relapse with FDC (pooled relative risk 1.28 (95% CI 0.99-1.7)).  Based on individual study results, only one of two trials that assessed treatment satisfaction, and none of five that assessed patient adherence, favored FDCs.  Although FDC formulations simplify TB therapy, the current evidence does not indicate that these formulations improve treatment outcomes among patients with active TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhHYCCaUcJyLVg90H21EOLACvtfcHk0liPI38suQpnSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFCmug%253D%253D&md5=aaeedcc2a7ee40f2ce58b3fc97d5b7af</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1183%2F09031936.00180612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00180612%26sid%3Dliteratum%253Aachs%26aulast%3DAlbanna%26aufirst%3DA.%2BS.%26aulast%3DSmith%26aufirst%3DB.%2BM.%26aulast%3DCowan%26aufirst%3DD.%26aulast%3DMenzies%26aufirst%3DD.%26atitle%3DFixed-dose%2520combination%2520antituberculosis%2520therapy%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D42%26spage%3D721%26epage%3D732%26doi%3D10.1183%2F09031936.00180612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span> <i>Global Tuberculosis Report 2017</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2017</span>; <a href="https://www.who.int/news/item/30-10-2017-who-report-signals-urgent-need-for-greater-political-commitment-to-end-tuberculosis" class="extLink">https://www.who.int/news/item/30-10-2017-who-report-signals-urgent-need-for-greater-political-commitment-to-end-tuberculosis</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Tuberculosis+Report+2017%3B+World+Health%0AOrganization%3A+Geneva%2C+2017%3B+https%3A%2F%2Fwww.who.int%2Fnews%2Fitem%2F30-10-2017-who-report-signals-urgent-need-for-greater-political-commitment-to-end-tuberculosis+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlobal%2520Tuberculosis%2520Report%25202017%26pub%3DWorld%2520Health%250AOrganization%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikaido, H.</span></span> <span> </span><span class="NLM_article-title">Efflux-mediated drug resistance in bacteria: an update</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1623</span>, <span class="refDoi"> DOI: 10.2165/11317030-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.2165%2F11317030-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19678712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ehtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1555-1623&author=X.-Z.+Liauthor=H.+Nikaido&title=Efflux-mediated+drug+resistance+in+bacteria%3A+an+update&doi=10.2165%2F11317030-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Efflux-mediated drug resistance in bacteria: an update</span></div><div class="casAuthors">Li, Xian-Zhi; Nikaido, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1555-1623</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Drug efflux pumps play a key role in drug resistance and also serve other functions in bacteria.  There has been a growing list of multidrug and drug-specific efflux pumps characterized from bacteria of human, animal, plant and environmental origins.  These pumps are mostly encoded on the chromosome, although they can also be plasmid-encoded.  A previous article in this journal provided a comprehensive review regarding efflux-mediated drug resistance in bacteria.  In the past 5 years, significant progress has been achieved in further understanding of drug resistance-related efflux transporters and this review focuses on the latest studies in this field since 2003.  This has been demonstrated in multiple aspects that include but are not limited to: further mol. and biochem. characterization of the known drug efflux pumps and identification of novel drug efflux pumps; structural elucidation of the transport mechanisms of drug transporters; regulatory mechanisms of drug efflux pumps; detg. the role of the drug efflux pumps in other functions such as stress responses, virulence and cell communication; and development of efflux pump inhibitors.  Overall, the multifaceted implications of drug efflux transporters warrant novel strategies to combat multidrug resistance in bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaeSr_oxaFNbVg90H21EOLACvtfcHk0liPI38suQpnSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ehtLfI&md5=fd988e21cc23eb9c8347f13a2a431a53</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.2165%2F11317030-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11317030-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.-Z.%26aulast%3DNikaido%26aufirst%3DH.%26atitle%3DEfflux-mediated%2520drug%2520resistance%2520in%2520bacteria%253A%2520an%2520update%26jtitle%3DDrugs%26date%3D2009%26volume%3D69%26spage%3D1555%26epage%3D1623%26doi%3D10.2165%2F11317030-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. J.</span></span> <span> </span><span class="NLM_article-title">Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1016/j.tim.2006.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.tim.2006.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=16759863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsFSlt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=304-312&author=L.+Nguyenauthor=C.+J.+Thompson&title=Foundations+of+antibiotic+resistance+in+bacterial+physiology%3A+the+mycobacterial+paradigm&doi=10.1016%2Fj.tim.2006.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm</span></div><div class="casAuthors">Nguyen, Liem; Thompson, Charles J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">304-312</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The intrinsic resistance of Mycobacterium tuberculosis and related pathogens to most common antibiotics limits chemotherapeutic options to treat tuberculosis and other mycobacterial diseases.  Resistance has traditionally been attributed to the unusual multi-layer cell envelope that functions as an effective barrier to the penetration of antibiotics.  Recent insights into mechanisms that neutralize the toxicity of antibiotics in the cytoplasm have revealed systems that function in synergy with the permeability barrier to provide intrinsic resistance.  Here, the authors highlight the growing pool of information about internal, antibiotic-responsive regulatory proteins and corresponding resistance genes, and present new concepts that rationalize how they might have evolved.  Pharmaceutical inhibition of these intrinsic systems could make many previously available antibiotics active against M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodFnslO_z1UrVg90H21EOLACvtfcHk0liPI38suQpnSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsFSlt7w%253D&md5=6dc68f83a080ee1d52d9ccd0d2923ad2</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2006.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2006.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DThompson%26aufirst%3DC.%2BJ.%26atitle%3DFoundations%2520of%2520antibiotic%2520resistance%2520in%2520bacterial%2520physiology%253A%2520the%2520mycobacterial%2520paradigm%26jtitle%3DTrends%2520Microbiol.%26date%3D2006%26volume%3D14%26spage%3D304%26epage%3D312%26doi%3D10.1016%2Fj.tim.2006.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Rossi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aínsa, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, G.</span></span> <span> </span><span class="NLM_article-title">Role of mycobacterial efflux transporters in drug resistance: an unresolved question</span>. <i>FEMS Microbiology Reviews</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1111/j.1574-6976.2005.00002.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1111%2Fj.1574-6976.2005.00002.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=16438679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFKrsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2006&pages=36-52&author=E.+De+Rossiauthor=J.+A.+A%C3%ADnsaauthor=G.+Riccardi&title=Role+of+mycobacterial+efflux+transporters+in+drug+resistance%3A+an+unresolved+question&doi=10.1111%2Fj.1574-6976.2005.00002.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Role of mycobacterial efflux transporters in drug resistance: an unresolved question</span></div><div class="casAuthors">De Rossi, Edda; Ainsa, Jose A.; Riccardi, Giovanna</div><div class="citationInfo"><span class="NLM_cas:title">FEMS Microbiology Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-52</span>CODEN:
                <span class="NLM_cas:coden">FMREE4</span>;
        ISSN:<span class="NLM_cas:issn">0168-6445</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Two mechanisms are thought to be involved in the natural drug resistance of mycobacteria: the mycobacterial cell wall permeability barrier and active multidrug efflux pumps.  Genes encoding drug efflux transporters have been isolated from several mycobacterial species.  These proteins transport tetracycline, fluoroquinolones, aminoglycosides and other compds.  Recent reports have suggested that efflux pumps may also be involved in transporting isoniazid, one of the main drugs used to treat tuberculosis.  This review highlights recent advances in our understanding of efflux-mediated drug resistance in mycobacteria, including the distribution of efflux systems in these organisms, their substrate profiles and their contribution to drug resistance.  The balance between the drug transport into the cell and drug efflux is not yet clearly understood, and further studies are required in mycobacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpwjdJiKjbO7Vg90H21EOLACvtfcHk0lgFazudPgMc0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFKrsbw%253D&md5=41af6cedab317d501c489400a6979920</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1111%2Fj.1574-6976.2005.00002.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1574-6976.2005.00002.x%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BRossi%26aufirst%3DE.%26aulast%3DA%25C3%25ADnsa%26aufirst%3DJ.%2BA.%26aulast%3DRiccardi%26aufirst%3DG.%26atitle%3DRole%2520of%2520mycobacterial%2520efflux%2520transporters%2520in%2520drug%2520resistance%253A%2520an%2520unresolved%2520question%26jtitle%3DFEMS%2520Microbiology%2520Reviews%26date%3D2006%26volume%3D30%26spage%3D36%26epage%3D52%26doi%3D10.1111%2Fj.1574-6976.2005.00002.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yew, W. W.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1276</span>– <span class="NLM_lpage">1289</span>, <span class="refDoi"> DOI: 10.5588/ijtld.15.0389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.5588%2Fijtld.15.0389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26467578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC28zitFWhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=1276-1289&author=Y.+Zhangauthor=W.+W.+Yew&title=Mechanisms+of+drug+resistance+in+Mycobacterium+tuberculosis%3A+update+2015&doi=10.5588%2Fijtld.15.0389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015</span></div><div class="casAuthors">Zhang Y; Yew W-W</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1276-89</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug-resistant tuberculosis (DR-TB), including multi- and extensively drug-resistant TB, is posing a significant challenge to effective treatment and TB control worldwide.  New progress has been made in our understanding of the mechanisms of resistance to anti-tuberculosis drugs.  This review provides an update on the major advances in drug resistance mechanisms since the previous publication in 2009, as well as added information on mechanisms of resistance to new drugs and repurposed agents.  The recent application of whole genome sequencing technologies has provided new insight into the mechanisms and complexity of drug resistance.  However, further research is needed to address the significance of newly discovered gene mutations in causing drug resistance.  Improved knowledge of drug resistance mechanisms will help understand the mechanisms of action of the drugs, devise better molecular diagnostic tests for more effective DR-TB management (and for personalised treatment), and facilitate the development of new drugs to improve the treatment of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSM1i_6Asw352Zyxfu64m4ffW6udTcc2eay0t6EbqEQwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zitFWhtQ%253D%253D&md5=8373bc72c5223ee9e7753bab3ddfc72e</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.5588%2Fijtld.15.0389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5588%252Fijtld.15.0389%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYew%26aufirst%3DW.%2BW.%26atitle%3DMechanisms%2520of%2520drug%2520resistance%2520in%2520Mycobacterium%2520tuberculosis%253A%2520update%25202015%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D2015%26volume%3D19%26spage%3D1276%26epage%3D1289%26doi%3D10.5588%2Fijtld.15.0389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span> <span> </span><span class="NLM_article-title">Antibiotic resistance mechanisms in M. tuberculosis: an update</span>. <i>Arch. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1585</span>– <span class="NLM_lpage">1604</span>, <span class="refDoi"> DOI: 10.1007/s00204-016-1727-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1007%2Fs00204-016-1727-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27161440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28Xns1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=1585-1604&author=L.+Nguyen&title=Antibiotic+resistance+mechanisms+in+M.+tuberculosis%3A+an+update&doi=10.1007%2Fs00204-016-1727-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Antibiotic resistance mechanisms in M. tuberculosis: an update</span></div><div class="casAuthors">Nguyen, Liem</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1585-1604</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Treatment of tuberculosis (TB) has been a therapeutic challenge because of not only the naturally high resistance level of Mycobacterium tuberculosis to antibiotics but also the newly acquired mutations that confer further resistance.  Currently standardized regimens require patients to daily ingest up to four drugs under direct observation of a healthcare worker for a period of 6-9 mo.  Although they are quite effective in treating drug susceptible TB, these lengthy treatments often lead to patient non-adherence, which catalyzes for the emergence of M. tuberculosis strains that are increasingly resistant to the few available anti-TB drugs.  The rapid evolution of M. tuberculosis, from mono-drug-resistant to multiple drug-resistant, extensively drug-resistant and most recently totally drug-resistant strains, is threatening to make TB once again an untreatable disease if new therapeutic options do not soon become available.  Here, I discuss the mol. mechanisms by which M. tuberculosis confers its profound resistance to antibiotics.  This knowledge may help in developing novel strategies for weakening drug resistance, thus enhancing the potency of available antibiotics against both drug susceptible and resistant M. tuberculosis strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4SQoFNByW5LVg90H21EOLACvtfcHk0lgFazudPgMc0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xns1SisLc%253D&md5=06e320bf7fe94fba12a14de2c26e8173</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1007%2Fs00204-016-1727-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-016-1727-6%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DL.%26atitle%3DAntibiotic%2520resistance%2520mechanisms%2520in%2520M.%2520tuberculosis%253A%2520an%2520update%26jtitle%3DArch.%2520Toxicol.%26date%3D2016%26volume%3D90%26spage%3D1585%26epage%3D1604%26doi%3D10.1007%2Fs00204-016-1727-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasipanodya, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumbo, T.</span></span> <span> </span><span class="NLM_article-title">A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">463</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2011.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.coph.2011.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21807559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1eisLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=457-463&author=J.+G.+Pasipanodyaauthor=T.+Gumbo&title=A+new+evolutionary+and+pharmacokinetic-pharmacodynamic+scenario+for+rapid+emergence+of+resistance+to+single+and+multiple+anti-tuberculosis+drugs&doi=10.1016%2Fj.coph.2011.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs</span></div><div class="casAuthors">Pasipanodya, Jotam G.; Gumbo, Tawanda</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">457-463</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The current understanding of the mechanism of anti-tuberculosis drug resistance has been shaped by the history of development of anti-tuberculosis drugs in the past 60 years and was arrived at as part of inductive generalization.  Recently, these std. beliefs have been tested in controlled hollow fiber systems expts.  Drug resistance in Mycobacterium tuberculosis was shown to be related to pharmacokinetic-pharmacodynamic (PK/PD) factors, and factors such as pharmacokinetic variability.  Poor PK/PD exposures owing to our current non-optimized dosing regimens initiate a chain of evolution driven events, starting with induction of multi-drug efflux pumps, followed by the development of chromosomal mutations in time, which together lead to high level resistance multi-drug resistant tuberculosis and extremely drug resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpehp-QwJeOrLVg90H21EOLACvtfcHk0lgOmHgfU5kc0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1eisLjP&md5=7b9497f21dfa0a0957eff60d18002cf5</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2011.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2011.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DPasipanodya%26aufirst%3DJ.%2BG.%26aulast%3DGumbo%26aufirst%3DT.%26atitle%3DA%2520new%2520evolutionary%2520and%2520pharmacokinetic-pharmacodynamic%2520scenario%2520for%2520rapid%2520emergence%2520of%2520resistance%2520to%2520single%2520and%2520multiple%2520anti-tuberculosis%2520drugs%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2011%26volume%3D11%26spage%3D457%26epage%3D463%26doi%3D10.1016%2Fj.coph.2011.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchison, D. A.</span></span> <span> </span><span class="NLM_article-title">How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">15</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=9562106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaK1c3itVGktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1998&pages=10-15&author=D.+A.+Mitchison&title=How+drug+resistance+emerges+as+a+result+of+poor+compliance+during+short+course+chemotherapy+for+tuberculosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis</span></div><div class="casAuthors">Mitchison D A</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-5</span>
        ISSN:<span class="NLM_cas:issn">1027-3719</span>.
    </div><div class="casAbstract">OBJECTIVE:  To explore mechanisms by which drug resistance might arise as a result of poor compliance during short course chemotherapy.  DESIGN:  Four theoretical mechanisms are first described.  RESULTS:  Examples of the way the mechanisms probably operate are taken from: 1) a study of once-weekly chemotherapy with streptomycin and isoniazid, and 2) the pattern of drug susceptibility in cultures from patients who relapsed after the end of treatment.  CONCLUSION:  Good compliance is vitally important.  The value of a fourth drug in the initial phase of chemotherapy in preventing resistance is questioned.  An explanation for mono-resistance to rifampicin in patients with the acquired immune deficiency syndrome (AIDS) is suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXWTVX8ij3vVvAgqb2vdc5fW6udTcc2eYPPDHnbAfMh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3itVGktg%253D%253D&md5=675484192c7ed7e5798c4988f9494e4e</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMitchison%26aufirst%3DD.%2BA.%26atitle%3DHow%2520drug%2520resistance%2520emerges%2520as%2520a%2520result%2520of%2520poor%2520compliance%2520during%2520short%2520course%2520chemotherapy%2520for%2520tuberculosis%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D1998%26volume%3D2%26spage%3D10%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jindani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aber, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchison, D. A.</span></span> <span> </span><span class="NLM_article-title">The early bactericidal activity of drugs in patients with pulmonary tuberculosis</span>. <i>Am. Rev. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">949</span>, <span class="refDoi"> DOI: 10.1164/arrd.1980.121.6.939</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1164%2Farrd.1980.121.6.939" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=6774638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaL3M%252FhvFygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=1980&pages=939-949&author=A.+Jindaniauthor=V.+R.+Aberauthor=E.+A.+Edwardsauthor=D.+A.+Mitchison&title=The+early+bactericidal+activity+of+drugs+in+patients+with+pulmonary+tuberculosis&doi=10.1164%2Farrd.1980.121.6.939"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">The early bactericidal activity of drugs in patients with pulmonary tuberculosis</span></div><div class="casAuthors">Jindani A; Aber V R; Edwards E A; Mitchison D A</div><div class="citationInfo"><span class="NLM_cas:title">The American review of respiratory disease</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">939-49</span>
        ISSN:<span class="NLM_cas:issn">0003-0805</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcStjSO4ST5T0hfKb6ELK8t0fW6udTcc2eYPPDHnbAfMh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3M%252FhvFygtw%253D%253D&md5=78d0d109ec13cbc100ee25ada81ca022</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1164%2Farrd.1980.121.6.939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Farrd.1980.121.6.939%26sid%3Dliteratum%253Aachs%26aulast%3DJindani%26aufirst%3DA.%26aulast%3DAber%26aufirst%3DV.%2BR.%26aulast%3DEdwards%26aufirst%3DE.%2BA.%26aulast%3DMitchison%26aufirst%3DD.%2BA.%26atitle%3DThe%2520early%2520bactericidal%2520activity%2520of%2520drugs%2520in%2520patients%2520with%2520pulmonary%2520tuberculosis%26jtitle%3DAm.%2520Rev.%2520Respir.%2520Dis.%26date%3D1980%26volume%3D121%26spage%3D939%26epage%3D949%26doi%3D10.1164%2Farrd.1980.121.6.939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balganesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinesh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruppath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, U.</span></span> <span> </span><span class="NLM_article-title">Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2643</span>– <span class="NLM_lpage">2651</span>, <span class="refDoi"> DOI: 10.1128/AAC.06003-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.06003-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22314527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=2643-2651&author=M.+Balganeshauthor=N.+Dineshauthor=S.+Sharmaauthor=S.+Kuruppathauthor=A.+V.+Nairauthor=U.+Sharma&title=Efflux+pumps+of+Mycobacterium+tuberculosis+play+a+significant+role+in+antituberculosis+activity+of+potential+drug+candidates&doi=10.1128%2FAAC.06003-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates</span></div><div class="casAuthors">Balganesh, Meenakshi; Dinesh, Neela; Sharma, Sreevalli; Kuruppath, Sanjana; Nair, Anju V.; Sharma, Umender</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2643-2651</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Active efflux of drugs mediated by efflux pumps that confer drug resistance is one of the mechanisms developed by bacteria to counter the adverse effects of antibiotics and chems.  To understand these efflux mechanisms in Mycobacterium tuberculosis, we generated knockout (KO) mutants of four efflux pumps of the pathogen belonging to different classes.  The authors measured the MICs and kill values of two different compd. classes on the wild-type (WT) and the efflux pump (EP) KO mutants in the presence and absence of the efflux inhibitors verapamil and L-phenylalanyl-L-arginyl-β-naphthylamide (PAβN).  Among the pumps studied, the efflux pumps belonging to the ABC (ATP-binding cassette) class, encoded by Rv1218c, and the SMR (small multidrug resistance) class, encoded by Rv3065, appear to play important roles in mediating the efflux of different chem. classes and antibiotics.  Efflux pumps encoded by Rv0849 and Rv1258c also mediate the efflux of these compds., but to a lesser extent.  Increased killing is obsd. in WT M. tuberculosis cells by these compds. in the presence of either verapamil or PAβN.  The efflux pump KO mutants were more susceptible to these compds. in the presence of efflux inhibitors.  We have shown that these four efflux pumps of M. tuberculosis play a vital role in mediating efflux of different chem. scaffolds.  Inhibitors of one or several of these efflux pumps could have a significant impact in the treatment of tuberculosis.  The identification and characterization of Rv0849, a new efflux pump belonging to the MFS (major facilitator superfamily) class, are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZCoB0YRug-7Vg90H21EOLACvtfcHk0lifOfIhebLN4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKrsbk%253D&md5=284a84bb5cc3575973cbb3da9cf8a7d6</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1128%2FAAC.06003-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06003-11%26sid%3Dliteratum%253Aachs%26aulast%3DBalganesh%26aufirst%3DM.%26aulast%3DDinesh%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKuruppath%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DA.%2BV.%26aulast%3DSharma%26aufirst%3DU.%26atitle%3DEfflux%2520pumps%2520of%2520Mycobacterium%2520tuberculosis%2520play%2520a%2520significant%2520role%2520in%2520antituberculosis%2520activity%2520of%2520potential%2520drug%2520candidates%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D2643%26epage%3D2651%26doi%3D10.1128%2FAAC.06003-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramón-García, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mick, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dainese, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rossi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manganelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aínsa, J. A.</span></span> <span> </span><span class="NLM_article-title">Functional and genetic characterization of the tap efflux pump in Mycobacterium bovis BCG</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2074</span>– <span class="NLM_lpage">2083</span>, <span class="refDoi"> DOI: 10.1128/AAC.05946-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.05946-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22232275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38XltV2qsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=2074-2083&author=S.+Ram%C3%B3n-Garc%C3%ADaauthor=V.+Mickauthor=E.+Daineseauthor=C.+Mart%C3%ADnauthor=C.+J.+Thompsonauthor=E.+De+Rossiauthor=R.+Manganelliauthor=J.+A.+A%C3%ADnsa&title=Functional+and+genetic+characterization+of+the+tap+efflux+pump+in+Mycobacterium+bovis+BCG&doi=10.1128%2FAAC.05946-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Functional and genetic characterization of the Tap efflux pump in Mycobacterium bovis BCG</span></div><div class="casAuthors">Ramon-Garcia, Santiago; Mick, Virginie; Dainese, Elisa; Martin, Carlos; Thompson, Charles J.; De Rossi, Edda; Manganelli, Riccardo; Ainsa, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2074-2083</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Efflux pumps extrude a wide variety of chem. unrelated compds. conferring multidrug resistance and participating in numerous physiol. processes.  Mycobacterium tuberculosis possesses many efflux pumps, and their roles in drug resistance and physiol. are actively investigated.  The authors found that tap mutant cells showed changes in morphol. and a progressive loss of viability upon subcultivation in liq. medium.  Transcriptome anal. in Mycobacterium bovis BCG revealed that disruption of the Rv1258c gene, encoding the Tap efflux pump, led to an extensive change in gene expression patterns during stationary phase, with no changes during exponential growth.  In stationary phase, Tap inactivation triggered a general stress response and led to a general repression of genes involved in cell wall biosynthesis, in particular the formation of the peptidoglycan; this suggested the accumulation of an unknown Tap substrate that reaches toxic concns. during stationary phase.  The authors also found that both disruption and overexpression of tap altered susceptibility to many clin. approved antibiotics in M. bovis BCG.  Acriflavine and tetracycline accumulation assays and carbonyl cyanide m-chlorophenylhydrazone (CCCP) potentiation expts. demonstrated that this phenotype was due to an active efflux mechanism.  These findings emphasize the important role of the Tap efflux pump in bacterial physiol. and intrinsic drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodh_mhS-rRXrVg90H21EOLACvtfcHk0lifOfIhebLN4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltV2qsbw%253D&md5=0eba6afbb2a99674768f66e589e0ed8e</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1128%2FAAC.05946-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.05946-11%26sid%3Dliteratum%253Aachs%26aulast%3DRam%25C3%25B3n-Garc%25C3%25ADa%26aufirst%3DS.%26aulast%3DMick%26aufirst%3DV.%26aulast%3DDainese%26aufirst%3DE.%26aulast%3DMart%25C3%25ADn%26aufirst%3DC.%26aulast%3DThompson%26aufirst%3DC.%2BJ.%26aulast%3DDe%2BRossi%26aufirst%3DE.%26aulast%3DManganelli%26aufirst%3DR.%26aulast%3DA%25C3%25ADnsa%26aufirst%3DJ.%2BA.%26atitle%3DFunctional%2520and%2520genetic%2520characterization%2520of%2520the%2520tap%2520efflux%2520pump%2520in%2520Mycobacterium%2520bovis%2520BCG%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D2074%26epage%3D2083%26doi%3D10.1128%2FAAC.05946-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borovinskaya, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredrick, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cate, J. H. D.</span></span> <span> </span><span class="NLM_article-title">A steric block in translation caused by the antibiotic spectinomycin</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">552</span>, <span class="refDoi"> DOI: 10.1021/cb700100n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb700100n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpvVOhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=545-552&author=M.+A.+Borovinskayaauthor=S.+Shojiauthor=J.+M.+Holtonauthor=K.+Fredrickauthor=J.+H.+D.+Cate&title=A+steric+block+in+translation+caused+by+the+antibiotic+spectinomycin&doi=10.1021%2Fcb700100n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">A steric block in translation caused by the antibiotic spectinomycin</span></div><div class="casAuthors">Borovinskaya, Maria A.; Shoji, Shinichiro; Holton, James M.; Fredrick, Kurt; Cate, Jamie H. D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">545-552</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The widely used antibiotic spectinomycin inhibits bacterial protein synthesis by blocking translocation of mRNA and tRNAs on the ribosome.  Here, we show that in crystals of the Escherichia coli 70S ribosome spectinomycin binding traps a distinct swiveling state of the head domain of the small ribosomal subunit.  Spectinomycin also alters the rate and completeness of reverse translocation in vitro.  These structural and biochem. data indicate that in soln. spectinomycin sterically blocks swiveling of the head domain of the small ribosomal subunit and thereby disrupts the translocation cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHxcqGkUcuJrVg90H21EOLACvtfcHk0lifOfIhebLN4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpvVOhtrc%253D&md5=38016b2987936dffc104cf3d46566fb3</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Fcb700100n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb700100n%26sid%3Dliteratum%253Aachs%26aulast%3DBorovinskaya%26aufirst%3DM.%2BA.%26aulast%3DShoji%26aufirst%3DS.%26aulast%3DHolton%26aufirst%3DJ.%2BM.%26aulast%3DFredrick%26aufirst%3DK.%26aulast%3DCate%26aufirst%3DJ.%2BH.%2BD.%26atitle%3DA%2520steric%2520block%2520in%2520translation%2520caused%2520by%2520the%2520antibiotic%2520spectinomycin%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2007%26volume%3D2%26spage%3D545%26epage%3D552%26doi%3D10.1021%2Fcb700100n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Novak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlagel, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeZotte, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeifer, R. T.</span></span> <span> </span><span class="NLM_article-title">The tolerance of high dose intravenous spectinomycin therapy in man</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">442</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1002/j.1552-4604.1974.tb02326.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1002%2Fj.1552-4604.1974.tb02326.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=4277731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaE2cXlsVGqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1974&pages=442-447&author=E.+Novakauthor=C.+A.+Schlagelauthor=L.+A.+LeZotteauthor=R.+T.+Pfeifer&title=The+tolerance+of+high+dose+intravenous+spectinomycin+therapy+in+man&doi=10.1002%2Fj.1552-4604.1974.tb02326.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Tolerance of high dose intravenous spectinomycin therapy in man</span></div><div class="casAuthors">Novak, E.; Schlagel, C. A.; LeZotte, L. A.; Pfeifer, R. T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8-9</span>),
    <span class="NLM_cas:pages">442-7</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    </div><div class="casAbstract">In 25 healthy volunteers given i.v. infusions of spectinomycin-HCl (I) [22193-75-5] (0.5-8 g base equivalence/day for 5 days), no evidence of ototoxicity, hepatotoxicity, nephrotoxicity, or local intolerance developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogpiv1PjVnH7Vg90H21EOLACvtfcHk0lioPz_7hTIH5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXlsVGqtrc%253D&md5=3b9612c7ed61e5af0e484c5f53478868</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1002%2Fj.1552-4604.1974.tb02326.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1552-4604.1974.tb02326.x%26sid%3Dliteratum%253Aachs%26aulast%3DNovak%26aufirst%3DE.%26aulast%3DSchlagel%26aufirst%3DC.%2BA.%26aulast%3DLeZotte%26aufirst%3DL.%2BA.%26aulast%3DPfeifer%26aufirst%3DR.%2BT.%26atitle%3DThe%2520tolerance%2520of%2520high%2520dose%2520intravenous%2520spectinomycin%2520therapy%2520in%2520man%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D1974%26volume%3D14%26spage%3D442%26epage%3D447%26doi%3D10.1002%2Fj.1552-4604.1974.tb02326.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurdle, J. G</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruhn, D. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherman, M. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddady, P. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbergenov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhura, D. B</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villellas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. B</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waidyarachchi, S. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, M. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ainsa, J. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Juarrero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibohm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottger, E. C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J</span></span> <span> </span><span class="NLM_article-title">Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1038/nm.3458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnm.3458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=24464186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1yru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=152-158&author=R.+E+Leeauthor=J.+G+Hurdleauthor=J.+Liuauthor=D.+F+Bruhnauthor=T.+Mattauthor=M.+S+Schermanauthor=P.+K+Vaddadyauthor=Z.+Zhengauthor=J.+Qiauthor=R.+Akbergenovauthor=S.+Dasauthor=D.+B+Madhuraauthor=C.+Rathiauthor=A.+Trivediauthor=C.+Villellasauthor=R.+B+Leeauthor=+Rakeshauthor=S.+L+Waidyarachchiauthor=D.+Sunauthor=M.+R+McNeilauthor=J.+A+Ainsaauthor=H.+I+Boshoffauthor=M.+Gonzalez-Juarreroauthor=B.+Meibohmauthor=E.+C+Bottgerauthor=A.+J+Lenaerts&title=Spectinamides%3A+a+new+class+of+semisynthetic+antituberculosis+agents+that+overcome+native+drug+efflux&doi=10.1038%2Fnm.3458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux</span></div><div class="casAuthors">Lee, Richard E.; Hurdle, Julian G.; Liu, Jiuyu; Bruhn, David F.; Matt, Tanja; Scherman, Michael S.; Vaddady, Pavan K.; Zheng, Zhong; Qi, Jianjun; Akbergenov, Rashid; Das, Sourav; Madhura, Dora B.; Rathi, Chetan; Trivedi, Ashit; Villellas, Cristina; Lee, Robin B.; Rakesh; Waidyarachchi, Samanthi L.; Sun, Dianqing; McNeil, Michael R.; Ainsa, Jose A.; Boshoff, Helena I.; Gonzalez-Juarrero, Mercedes; Meibohm, Bernd; Boettger, Erik C.; Lenaerts, Anne J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">152-158</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although the classical antibiotic spectinomycin is a potent bacterial protein synthesis inhibitor, poor antimycobacterial activity limits its clin. application for treating tuberculosis.  Using structure-based design, we generated a new semisynthetic series of spectinomycin analogs with selective ribosomal inhibition and excellent narrow-spectrum antitubercular activity.  In multiple murine infection models, these spectinamides were well tolerated, significantly reduced lung mycobacterial burden and increased survival.  In vitro studies demonstrated a lack of cross resistance with existing tuberculosis therapeutics, activity against multidrug-resistant (MDR) and extensively drug-resistant tuberculosis and an excellent pharmacol. profile.  Key to their potent antitubercular properties was their structural modification to evade the Rv1258c efflux pump, which is upregulated in MDR strains and is implicated in macrophage-induced drug tolerance.  The antitubercular efficacy of spectinamides demonstrates that synthetic modifications to classical antibiotics can overcome the challenge of intrinsic efflux pump-mediated resistance and expands opportunities for target-based tuberculosis drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-qFjpPH3d3rVg90H21EOLACvtfcHk0lioPz_7hTIH5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1yru7w%253D&md5=7aa68c78473b16a7fd1175b50e9b9bed</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fnm.3458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3458%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DR.%2BE%26aulast%3DHurdle%26aufirst%3DJ.%2BG%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DBruhn%26aufirst%3DD.%2BF%26aulast%3DMatt%26aufirst%3DT.%26aulast%3DScherman%26aufirst%3DM.%2BS%26aulast%3DVaddady%26aufirst%3DP.%2BK%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DAkbergenov%26aufirst%3DR.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DMadhura%26aufirst%3DD.%2BB%26aulast%3DRathi%26aufirst%3DC.%26aulast%3DTrivedi%26aufirst%3DA.%26aulast%3DVillellas%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DR.%2BB%26aulast%3DRakesh%26aulast%3DWaidyarachchi%26aufirst%3DS.%2BL%26aulast%3DSun%26aufirst%3DD.%26aulast%3DMcNeil%26aufirst%3DM.%2BR%26aulast%3DAinsa%26aufirst%3DJ.%2BA%26aulast%3DBoshoff%26aufirst%3DH.%2BI%26aulast%3DGonzalez-Juarrero%26aufirst%3DM.%26aulast%3DMeibohm%26aufirst%3DB.%26aulast%3DBottger%26aufirst%3DE.%2BC%26aulast%3DLenaerts%26aufirst%3DA.%2BJ%26atitle%3DSpectinamides%253A%2520a%2520new%2520class%2520of%2520semisynthetic%2520antituberculosis%2520agents%2520that%2520overcome%2520native%2520drug%2520efflux%26jtitle%3DNat.%2520Med.%26date%3D2014%26volume%3D20%26spage%3D152%26epage%3D158%26doi%3D10.1038%2Fnm.3458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balganesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruppath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, U.</span></span> <span> </span><span class="NLM_article-title">Rv1218c, an ABC transporter of Mycobacterium tuberculosis with implications in drug discovery</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5167</span>– <span class="NLM_lpage">5172</span>, <span class="refDoi"> DOI: 10.1128/AAC.00610-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.00610-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=20921309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2nu7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=5167-5172&author=M.+Balganeshauthor=S.+Kuruppathauthor=N.+Marcelauthor=S.+Sharmaauthor=A.+Nairauthor=U.+Sharma&title=Rv1218c%2C+an+ABC+transporter+of+Mycobacterium+tuberculosis+with+implications+in+drug+discovery&doi=10.1128%2FAAC.00610-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Rv1218c, an ABC transporter of Mycobacterium tuberculosis with implications in drug discovery</span></div><div class="casAuthors">Balganesh, Meenakshi; Kuruppath, Sanjana; Marcel, Nimi; Sharma, Sreevalli; Nair, Anju; Sharma, Umender</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5167-5172</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Efflux systems are important in detg. the efficacy of antibiotics used in the treatment of bacterial infections.  In the last decade much attention has been paid to studying the efflux pumps of mycobacteria.  New classes of compds. are under investigation for development into potential candidate drugs for the treatment of tuberculosis.  Quite often, these have poor bactericidal activities but exhibit excellent target (biochem.) inhibition.  Microarray studies conducted in our labs. for deciphering the mode of action of exptl. drugs revealed the presence of putative ABC transporters.  Among these transporters, Rv1218c was chosen for studying its physiol. relevance in mediating efflux in Mycobacterium tuberculosis.  A ΔRv1218c mutant of M. tuberculosis displayed a 4- to 8-fold increase in the inhibitory and bactericidal potency for different classes of compds.  The MICs and MBCs were reversed to wild-type values when the full-length Rv1218c gene was reintroduced into the ΔRv1218c mutant on a multicopy plasmid.  Most of the compd. classes had significantly better bactericidal activity in the ΔRv1218c mutant than in the wild-type H37Rv, suggesting the involvement of Rv1218c gene product in effluxing these compds. from M. tuberculosis.  The implication of these findings on tuberculosis drug discovery is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp__BkDXaTAAbVg90H21EOLACvtfcHk0ljRsW9W2b3pMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2nu7fM&md5=3bd448555fc55ba6627e6f1f556c4cba</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1128%2FAAC.00610-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00610-10%26sid%3Dliteratum%253Aachs%26aulast%3DBalganesh%26aufirst%3DM.%26aulast%3DKuruppath%26aufirst%3DS.%26aulast%3DMarcel%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DU.%26atitle%3DRv1218c%252C%2520an%2520ABC%2520transporter%2520of%2520Mycobacterium%2520tuberculosis%2520with%2520implications%2520in%2520drug%2520discovery%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D5167%26epage%3D5172%26doi%3D10.1128%2FAAC.00610-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iseman, M. D.</span></span> <span> </span><span class="NLM_article-title">Treatment of multidrug-resistant tuberculosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>329</i></span>,  <span class="NLM_fpage">784</span>– <span class="NLM_lpage">791</span>, <span class="refDoi"> DOI: 10.1056/NEJM199309093291108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1056%2FNEJM199309093291108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=8350889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaK3szlsVCjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=1993&pages=784-791&author=M.+D.+Iseman&title=Treatment+of+multidrug-resistant+tuberculosis&doi=10.1056%2FNEJM199309093291108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of multidrug-resistant tuberculosis</span></div><div class="casAuthors">Iseman M D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">784-91</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">The frequency of infections with M. tuberculosis resistant to antituberculous drugs is increasing in the United States and globally.  This increase is a major threat to tuberculosis treatment and control programs.  To prevent this situation from worsening, initial treatment programs that entail directly observed therapy supported by effective inducements or enforcements must be used.  Retreatment of patients who have multidrug-resistant tuberculosis should be carried out in programs with comprehensive microbiologic, pharmacokinetic, psychosocial, and nutritional support systems.  Regimens of multiple drugs, which generally are poorly tolerated and more toxic than traditional regimens, must be administered for 18 to 36 months.  Resectional surgery may be required for substantial numbers of patients.  For patients with AIDS who acquire tuberculosis caused by multiply-resistant strains, the disease may prove lethal before effective therapy can be implemented.  Ultraviolet irradiation systems should be used to protect health care personnel and other patients in high-risk environments.  Enhanced federal, state, and local programs for prevention and control are urgently needed, and research to identify new medications and systems for their delivery is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1VHRs8dQZquQ4Pl9hzjQhfW6udTcc2eb5dZ0ZorfouLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3szlsVCjtg%253D%253D&md5=494e4c18824f92dac30743ac33cbe9e9</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1056%2FNEJM199309093291108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199309093291108%26sid%3Dliteratum%253Aachs%26aulast%3DIseman%26aufirst%3DM.%2BD.%26atitle%3DTreatment%2520of%2520multidrug-resistant%2520tuberculosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1993%26volume%3D329%26spage%3D784%26epage%3D791%26doi%3D10.1056%2FNEJM199309093291108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span> <i>Companion Handbook to the WHO Guidelines for the Programmatic
Management
of Drug-Resistant Tuberculosis</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2014</span>; <a href="https://www.who.int/tb/publications/pmdt_companionhandbook/en/" class="extLink">https://www.who.int/tb/publications/pmdt_companionhandbook/en/</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Companion+Handbook+to+the+WHO+Guidelines+for+the+Programmatic%0AManagement%0Aof+Drug-Resistant+Tuberculosis%3B+World+Health%0AOrganization%3A+Geneva%2C+2014%3B+https%3A%2F%2Fwww.who.int%2Ftb%2Fpublications%2Fpmdt_companionhandbook%2Fen%2F+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DCompanion%2520Handbook%2520to%2520the%2520WHO%2520Guidelines%2520for%2520the%2520Programmatic%250AManagement%250Aof%2520Drug-Resistant%2520Tuberculosis%26pub%3DWorld%2520Health%250AOrganization%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gey van Pittius, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Helden, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. F.</span></span> <span> </span><span class="NLM_article-title">Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1093/jac/dkt364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fjac%2Fdkt364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=24072169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFOitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=292-302&author=M.+McGrathauthor=N.+C.+Gey+van+Pittiusauthor=P.+D.+van+Heldenauthor=R.+M.+Warrenauthor=D.+F.+Warner&title=Mutation+rate+and+the+emergence+of+drug+resistance+in+Mycobacterium+tuberculosis&doi=10.1093%2Fjac%2Fdkt364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis</span></div><div class="casAuthors">McGrath, M.; Gey van Pittius, N. C.; van Helden, P. D.; Warren, R. M.; Warner, D. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">292-302</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The emergence and spread of multidrug-resistant strains of Mycobacterium tuberculosis remains a major concern of tuberculosis control programs worldwide, as treatment depends on low-efficacy, toxic compds. that often lead to poor outcomes.  M. tuberculosis develops drug resistance exclusively through chromosomal mutations, in particular single-nucleotide polymorphisms.  Moreover, in lab. assays the organism exhibits a spontaneous mutation rate that is at the lower end of the bacterial spectrum.  Despite this, whole-genome sequencing technol. has identified unexpected genetic diversity among clin. M. tuberculosis populations.  This suggests that the mycobacterial mutation rate may be modulated within the host and, in turn, implies a potential role for constitutive and/or transient mutator strains in adaptive evolution.  It also raises the possibility that environmental factors might act as key mutagens during M. tuberculosis infection.  Here we consider the elements that might influence the mycobacterial mutation rate in vivo and evaluate the potential roles of constitutive and transient mutator states in the generation of drug resistance mutations.  In addn., we identify key research questions that will influence future efforts to develop novel therapeutic strategies for a disease that continues to impose a significant global health burden.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV8r6x1IfS9LVg90H21EOLACvtfcHk0ljRsW9W2b3pMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFOitw%253D%253D&md5=bdbbd9257caa6458f919700afb44c111</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkt364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkt364%26sid%3Dliteratum%253Aachs%26aulast%3DMcGrath%26aufirst%3DM.%26aulast%3DGey%2Bvan%2BPittius%26aufirst%3DN.%2BC.%26aulast%3Dvan%2BHelden%26aufirst%3DP.%2BD.%26aulast%3DWarren%26aufirst%3DR.%2BM.%26aulast%3DWarner%26aufirst%3DD.%2BF.%26atitle%3DMutation%2520rate%2520and%2520the%2520emergence%2520of%2520drug%2520resistance%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2014%26volume%3D69%26spage%3D292%26epage%3D302%26doi%3D10.1093%2Fjac%2Fdkt364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burman, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaisson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etkind, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzemska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopewell, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iseman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jasmer, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppaka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reves, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichman, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simone, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernon, A. A.</span></span>; <span class="NLM_contrib-group">American Thoracic Society, C.D.C and Prevention and the Infectious Diseases Society</span> <span> </span><span class="NLM_article-title">American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1164/rccm.167.4.603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1164%2Frccm.167.4.603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=12588714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD3s7gtlyqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2003&pages=603-662&author=H.+M.+Blumbergauthor=W.+J.+Burmanauthor=R.+E.+Chaissonauthor=C.+L.+Daleyauthor=S.+C.+Etkindauthor=L.+N.+Friedmanauthor=P.+Fujiwaraauthor=M.+Grzemskaauthor=P.+C.+Hopewellauthor=M.+D.+Isemanauthor=R.+M.+Jasmerauthor=V.+Koppakaauthor=R.+I.+Menziesauthor=R.+J.+O%E2%80%99Brienauthor=R.+R.+Revesauthor=L.+B.+Reichmanauthor=P.+M.+Simoneauthor=J.+R.+Starkeauthor=A.+A.+Vernonauthor=American+Thoracic+Society%2C+C.D.C+and+Prevention+and+the+Infectious+Diseases+Society&title=American+Thoracic+Society%2FCenters+for+Disease+Control+and+Prevention%2FInfectious+Diseases+Society+of+America%3A+treatment+of+tuberculosis&doi=10.1164%2Frccm.167.4.603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis</span></div><div class="casAuthors">Blumberg Henry M; Burman William J; Chaisson Richard E; Daley Charles L; Etkind Sue C; Friedman Lloyd N; Fujiwara Paula; Grzemska Malgosia; Hopewell Philip C; Iseman Michael D; Jasmer Robert M; Koppaka Venkatarama; Menzies Richard I; O'Brien Richard J; Reves Randall R; Reichman Lee B; Simone Patricia M; Starke Jeffrey R; Vernon Andrew A</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">603-62</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZEQRmpJLo0TMsgLhIoICsfW6udTcc2eZNK-5d8v0eDrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s7gtlyqtg%253D%253D&md5=f72d60a2f05d5ab216c85c4e466c25b7</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1164%2Frccm.167.4.603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.167.4.603%26sid%3Dliteratum%253Aachs%26aulast%3DBlumberg%26aufirst%3DH.%2BM.%26aulast%3DBurman%26aufirst%3DW.%2BJ.%26aulast%3DChaisson%26aufirst%3DR.%2BE.%26aulast%3DDaley%26aufirst%3DC.%2BL.%26aulast%3DEtkind%26aufirst%3DS.%2BC.%26aulast%3DFriedman%26aufirst%3DL.%2BN.%26aulast%3DFujiwara%26aufirst%3DP.%26aulast%3DGrzemska%26aufirst%3DM.%26aulast%3DHopewell%26aufirst%3DP.%2BC.%26aulast%3DIseman%26aufirst%3DM.%2BD.%26aulast%3DJasmer%26aufirst%3DR.%2BM.%26aulast%3DKoppaka%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DR.%2BI.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DR.%2BJ.%26aulast%3DReves%26aufirst%3DR.%2BR.%26aulast%3DReichman%26aufirst%3DL.%2BB.%26aulast%3DSimone%26aufirst%3DP.%2BM.%26aulast%3DStarke%26aufirst%3DJ.%2BR.%26aulast%3DVernon%26aufirst%3DA.%2BA.%26aulast%3D%26atitle%3DAmerican%2520Thoracic%2520Society%252FCenters%2520for%2520Disease%2520Control%2520and%2520Prevention%252FInfectious%2520Diseases%2520Society%2520of%2520America%253A%2520treatment%2520of%2520tuberculosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2003%26volume%3D167%26spage%3D603%26epage%3D662%26doi%3D10.1164%2Frccm.167.4.603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bark, C. M.</span></span> <span> </span><span class="NLM_article-title">Drug-resistant tuberculosis: challenges and progress</span>. <i>Infect. Dis. Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">522</span>, <span class="refDoi"> DOI: 10.1016/j.idc.2016.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.idc.2016.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27208770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FitFGiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=509-522&author=S.+G.+Kurzauthor=J.+J.+Furinauthor=C.+M.+Bark&title=Drug-resistant+tuberculosis%3A+challenges+and+progress&doi=10.1016%2Fj.idc.2016.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Resistant Tuberculosis: Challenges and Progress</span></div><div class="casAuthors">Kurz Sebastian G; Furin Jennifer J; Bark Charles M</div><div class="citationInfo"><span class="NLM_cas:title">Infectious disease clinics of North America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">509-522</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antimicrobial resistance is a natural evolutionary process, which in the case of Mycobacterium tuberculosis is based on spontaneous chromosomal mutations, meaning that well-designed combination drug regimens provided under supervised therapy will prevent the emergence of drug-resistant strains.  Unfortunately, limited resources, poverty, and neglect have led to the emergence of drug-resistant tuberculosis throughout the world.  The international community has responded with financial and scientific support, leading to new rapid diagnostics, new drugs and regimens in advanced clinical development, and an increasingly sophisticated understanding of resistance mechanisms and their application to all aspects of TB control and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpoedonpWcg8vLc4ARHEmzfW6udTcc2eZNK-5d8v0eDrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FitFGiug%253D%253D&md5=7f090ea29415c6bbc45cd9a8e346168a</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.idc.2016.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.idc.2016.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DKurz%26aufirst%3DS.%2BG.%26aulast%3DFurin%26aufirst%3DJ.%2BJ.%26aulast%3DBark%26aufirst%3DC.%2BM.%26atitle%3DDrug-resistant%2520tuberculosis%253A%2520challenges%2520and%2520progress%26jtitle%3DInfect.%2520Dis.%2520Clin.%2520North%2520Am.%26date%3D2016%26volume%3D30%26spage%3D509%26epage%3D522%26doi%3D10.1016%2Fj.idc.2016.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span> <i>Global Tuberculosis
Report 2018</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2018</span>; <a href="https://apps.who.int/iris/handle/10665/274453" class="extLink">https://apps.who.int/iris/handle/10665/274453</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Tuberculosis%0AReport+2018%3B+World+Health%0AOrganization%3A+Geneva%2C+2018%3B+https%3A%2F%2Fapps.who.int%2Firis%2Fhandle%2F10665%2F274453+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlobal%2520Tuberculosis%250AReport%25202018%26pub%3DWorld%2520Health%250AOrganization%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laneelle, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanrelle, G.</span></span> <span> </span><span class="NLM_article-title">Mechanism of isoniazid uptake in Mycobacterium tuberculosis</span>. <i>Microbiology</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">2539</span>– <span class="NLM_lpage">2544</span>, <span class="refDoi"> DOI: 10.1099/00221287-144-9-2539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1099%2F00221287-144-9-2539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=9782502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK1cXmt1yks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=1998&pages=2539-2544&author=F.+Bardouauthor=C.+Raynaudauthor=C.+Ramosauthor=M.+A.+Laneelleauthor=G.+Lanrelle&title=Mechanism+of+isoniazid+uptake+in+Mycobacterium+tuberculosis&doi=10.1099%2F00221287-144-9-2539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of isoniazid uptake in Mycobacterium tuberculosis</span></div><div class="casAuthors">Bardou, Fabienne; Raynaud, Catherine; Ramos, Corinne; Laneelle, Marie Antoinette; Laneelle, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">Microbiology (Reading, United Kingdom)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2539-2544</span>CODEN:
                <span class="NLM_cas:coden">MROBEO</span>;
        ISSN:<span class="NLM_cas:issn">1350-0872</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">Initial transport kinetics of isoniazid (INH) and its uptake at the plateau were studied in Mycobacterium tuberculosis H37Rv under various exptl. conditions.  The initial uptake velocity increased linearly with INH concn. from 2 x 10-6 M to 10-2 M.  It was modified neither by addn. of a protonophore that abolished proline transport, nor following ATP depletion by arsenate, which inhibited glycerol uptake, two transport processes taken as controls for secondary active transport and facilitated diffusion, resp.  Microaerobiosis or low temp. (4°) were without effect on initial uptake.  It is thus likely that INH transport in M. tuberculosis proceeds by a passive diffusion mechanism, and that catalase-peroxidase (KatG) is not involved in the actual transport.  However, conditions inhibiting KatG activity (high INH concn., microaerobiosis, low temp.) decrease cell radioactivity at the uptake plateau.  It is proposed that INH transport occurs by passive diffusion.  KatG is involved only in the intracellular accumulation of oxidized derivs. of INH, esp. of isonicotinic acid, which is trapped inside cells in its ionized form.  This model explains obsd. and previously known characteristics of the accumulation of radioactivity in the presence of [14C]INH for various species and strains of mycobacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJzu8VUyhaq7Vg90H21EOLACvtfcHk0lis70UTCJtsvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmt1yks7g%253D&md5=ed048b5d4351ce418cb056b11cb88581</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1099%2F00221287-144-9-2539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252F00221287-144-9-2539%26sid%3Dliteratum%253Aachs%26aulast%3DBardou%26aufirst%3DF.%26aulast%3DRaynaud%26aufirst%3DC.%26aulast%3DRamos%26aufirst%3DC.%26aulast%3DLaneelle%26aufirst%3DM.%2BA.%26aulast%3DLanrelle%26aufirst%3DG.%26atitle%3DMechanism%2520of%2520isoniazid%2520uptake%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DMicrobiology%26date%3D1998%26volume%3D144%26spage%3D2539%26epage%3D2544%26doi%3D10.1099%2F00221287-144-9-2539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heym, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span> <span> </span><span class="NLM_article-title">The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">593</span>, <span class="refDoi"> DOI: 10.1038/358591a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2F358591a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1501713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK38Xlt1yjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=1992&pages=591-593&author=Y.+Zhangauthor=B.+Heymauthor=B.+Allenauthor=D.+Youngauthor=S.+Cole&title=The+catalase-peroxidase+gene+and+isoniazid+resistance+of+Mycobacterium+tuberculosis&doi=10.1038%2F358591a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis</span></div><div class="casAuthors">Zhang, Ying; Heym, Beate; Allen, Bryan; Young, Douglas; Cole, Stewart</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">6387</span>),
    <span class="NLM_cas:pages">591-3</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Tuberculosis is responsible for 1 in 4 of all avoidable adult deaths in developing countries.  Increased frequency and accelerated fatality of the disease among individuals infected with human immunodeficiency virus has raised worldwide concern that control programs may be inadequate, and the emergence of multidrug-resistant strains of M. tuberculosis has resulted in several recent fatal outbreaks in the United States.  Isonicotinic acid hydrazid (isoniazid, INH) forms the core of antituberculosis regimens; however, clin. isolates that are resistant to INH show reduced catalase activity and a relative lack of virulence in guinea pigs.  Mycobacterial genetics were used to study the mol. basis of INH resistance.  A single M. tuberculosis gene, katG, encoding both catalase and peroxidase, restored sensitivity to INH in a resistant mutant of Mycobacterium smegmatis, and conferred INH susceptibility in some strains of Escherichia coli.  Deletion of katG from the chromosome was assocd. with INH resistance in 2 patient isolates of M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3JrwTwnhxYLVg90H21EOLACvtfcHk0lis70UTCJtsvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xlt1yjt7s%253D&md5=ba0ceb0723b538e1a10d0aad035c3a24</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1038%2F358591a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F358591a0%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeym%26aufirst%3DB.%26aulast%3DAllen%26aufirst%3DB.%26aulast%3DYoung%26aufirst%3DD.%26aulast%3DCole%26aufirst%3DS.%26atitle%3DThe%2520catalase-peroxidase%2520gene%2520and%2520isoniazid%2520resistance%2520of%2520Mycobacterium%2520tuberculosis%26jtitle%3DNature%26date%3D1992%26volume%3D358%26spage%3D591%26epage%3D593%26doi%3D10.1038%2F358591a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghiladi, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medzihradszky, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz
de Montellano, P. R.</span></span> <span> </span><span class="NLM_article-title">Correlation between isoniazid resistance and superoxide reactivity in mycobacterium tuberculosis KatG</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">13428</span>– <span class="NLM_lpage">13442</span>, <span class="refDoi"> DOI: 10.1021/ja054366t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja054366t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFOrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=13428-13442&author=R.+A.+Ghiladiauthor=K.+F.+Medzihradszkyauthor=F.+M.+Rusnakauthor=P.+R.+Ortiz%0Ade+Montellano&title=Correlation+between+isoniazid+resistance+and+superoxide+reactivity+in+mycobacterium+tuberculosis+KatG&doi=10.1021%2Fja054366t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation between Isoniazid Resistance and Superoxide Reactivity in Mycobacterium tuberculosis KatG</span></div><div class="casAuthors">Ghiladi, Reza A.; Medzihradszky, Katalin F.; Rusnak, Frank M.; Ortiz de Montellano, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">13428-13442</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Isoniazid is an antituberculosis prodrug that requires activation by the catalase-peroxidase (KatG) of Mycobacterium tuberculosis.  The activated species, presumed to be an isonicotinoyl radical, couples to NADH forming an isoniazid-NADH adduct that ultimately confers antitubercular activity.  We have compared the catalytic properties of three KatGs assocd. with isoniazid resistance (resistance mutation KatGs, RMKatGs: R104L, H108Q, S315T) to wild-type enzyme and two addnl. lab mutations (wild-type phenotype KatGs, WTPKatGs: WT KatG, Y229F, R418L).  Neither catalase nor peroxidase activities, nor the presence/absence of the Met-Tyr-Trp cross-link (as probed by LC/MS on tryptic digests of the protein), exhibited any correlation with isoniazid resistance.  The yields of isoniazid-NADH adduct formed were detd. to be 1-5, 4-12, and 20-70-fold greater for the WTPKatGs than the RMKatGs for the compd. I, II, and III pathways, resp., strongly suggesting a role for oxyferrous KatG (supported by superoxide consumption measurements) that correlates with drug resistance.  Stopped-flow UV-visible spectroscopic studies revealed that all KatGs were capable of forming both compd. II and III intermediates.  Rates of compd. II decay were accelerated 4-12-fold in the presence of isoniazid (vs absence) for the WTPKatGs but were unaffected by the drug for the RMKatGs.  A mechanism for isoniazid resistance which accounts for the obsd. reactivity for each of the compd. I, II, and III intermediates is proposed and suggests that the compd. III pathway may be the primary factor in detg. overall isoniazid resistance by specific KatG mutants, with secondary contributions arising from the compd. I and II pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp64U-LLbgb77Vg90H21EOLACvtfcHk0lg7TUqZKeUmxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFOrtb0%253D&md5=98a8c47d58063c7bd0bd9fd11a3a1229</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Fja054366t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja054366t%26sid%3Dliteratum%253Aachs%26aulast%3DGhiladi%26aufirst%3DR.%2BA.%26aulast%3DMedzihradszky%26aufirst%3DK.%2BF.%26aulast%3DRusnak%26aufirst%3DF.%2BM.%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26atitle%3DCorrelation%2520between%2520isoniazid%2520resistance%2520and%2520superoxide%2520reactivity%2520in%2520mycobacterium%2520tuberculosis%2520KatG%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D13428%26epage%3D13442%26doi%3D10.1021%2Fja054366t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wengenack, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, F.</span></span> <span> </span><span class="NLM_article-title">Evidence for isoniazid-dependent free radical generation catalyzed by Mycobacterium tuberculosis KatG and the isoniazid-resistant mutant KatG(S315T)</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">8990</span>– <span class="NLM_lpage">8996</span>, <span class="refDoi"> DOI: 10.1021/bi002614m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi002614m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3MXksleitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=8990-8996&author=N.+L.+Wengenackauthor=F.+Rusnak&title=Evidence+for+isoniazid-dependent+free+radical+generation+catalyzed+by+Mycobacterium+tuberculosis+KatG+and+the+isoniazid-resistant+mutant+KatG%28S315T%29&doi=10.1021%2Fbi002614m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for Isoniazid-Dependent Free Radical Generation Catalyzed by Mycobacterium tuberculosis KatG and the Isoniazid-Resistant Mutant KatG(S315T)</span></div><div class="casAuthors">Wengenack, Nancy L.; Rusnak, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">8990-8996</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The antitubercular agent isoniazid can be activated by Mycobacterium tuberculosis KatG using either a peroxidase compd. I/II or a superoxide-dependent oxyferrous pathway.  The identity of activated isoniazid is unknown, but it has been suggested that it may be a free radical intermediate.  EPR spin trapping expts. detected isoniazid-derived radicals generated during KatG-mediated oxidn. via the peroxidase compd. I/II pathway.  On the basis of hyperfine splitting patterns and oxygen dependence, these radicals were identified as the acyl, acyl peroxo, and pyridyl radicals of isoniazid.  Isoniazid-resistant KatG(S315T) produced the same radicals found with KatG, while the less potent antitubercular agent nicotinic acid hydrazide produced the corresponding nicotinyl radicals.  The time course of radical prodn. was similar for KatG and KatG(S315T), while a lower steady-state level of radicals was produced from nicotinic acid hydrazide.  These results support an earlier finding that the peroxidase pathway does not correlate with isoniazid resistance conferred by KatG(S315T).  Trace amts. of radicals were detected via the superoxide-dependent pathway.  The low level of isoniazid-derived radicals found in the superoxide-dependent pathway may be due to scavenging by superoxide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCy5-9p6NBH7Vg90H21EOLACvtfcHk0lg7TUqZKeUmxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXksleitrY%253D&md5=cc51e44e36cf21cf8fdfb9640fe3d48c</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fbi002614m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi002614m%26sid%3Dliteratum%253Aachs%26aulast%3DWengenack%26aufirst%3DN.%2BL.%26aulast%3DRusnak%26aufirst%3DF.%26atitle%3DEvidence%2520for%2520isoniazid-dependent%2520free%2520radical%2520generation%2520catalyzed%2520by%2520Mycobacterium%2520tuberculosis%2520KatG%2520and%2520the%2520isoniazid-resistant%2520mutant%2520KatG%2528S315T%2529%26jtitle%3DBiochemistry%26date%3D2001%26volume%3D40%26spage%3D8990%26epage%3D8996%26doi%3D10.1021%2Fbi002614m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Timmins, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Master, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deretic, V.</span></span> <span> </span><span class="NLM_article-title">Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">3006</span>– <span class="NLM_lpage">3009</span>, <span class="refDoi"> DOI: 10.1128/AAC.48.8.3006-3009.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.48.8.3006-3009.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=15273113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlKqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=3006-3009&author=G.+S.+Timminsauthor=S.+Masterauthor=F.+Rusnakauthor=V.+Deretic&title=Nitric+oxide+generated+from+isoniazid+activation+by+KatG%3A+source+of+nitric+oxide+and+activity+against+Mycobacterium+tuberculosis&doi=10.1128%2FAAC.48.8.3006-3009.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide generated from isoniazid activation by KatG: Source of nitric oxide and activity against Mycobacterium tuberculosis</span></div><div class="casAuthors">Timmins, Graham S.; Master, Sharon; Rusnak, Frank; Deretic, Vojo</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3006-3009</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Isonicotinic acid hydrazide (INH) is a frontline antituberculosis agent.  Once taken up by M. tuberculosis, INH requires activation by the catalase-peroxidase KatG, converting INH from its prodrug form into a range of bactericidal reactive species.  Here we used 15N-labeled INH together with ESR spin trapping techniques to demonstrate that NO· is generated from oxidn. at the hydrazide nitrogens during the activation of INH by M. tuberculosis KatG.  We also obsd. that a specific scavenger of NO· provided protection against the antimycobacterial activity of INH in bacterial culture.  No significant increases in mycobacterial protein nitration were detected, suggesting that NO· and not peroxynitrite, a nitrating metabolite of NO·, is involved in antimycobacterial action.  In conclusion, INH-derived NO· has biol. activity, which directly contributes to the antimycobacterial action of INH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmsYpj2VfLW7Vg90H21EOLACvtfcHk0lgypW1_K7ZB2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlKqtrg%253D&md5=332fbcf388c0689487ac2757510d54cd</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1128%2FAAC.48.8.3006-3009.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.48.8.3006-3009.2004%26sid%3Dliteratum%253Aachs%26aulast%3DTimmins%26aufirst%3DG.%2BS.%26aulast%3DMaster%26aufirst%3DS.%26aulast%3DRusnak%26aufirst%3DF.%26aulast%3DDeretic%26aufirst%3DV.%26atitle%3DNitric%2520oxide%2520generated%2520from%2520isoniazid%2520activation%2520by%2520KatG%253A%2520source%2520of%2520nitric%2520oxide%2520and%2520activity%2520against%2520Mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26spage%3D3006%26epage%3D3009%26doi%3D10.1128%2FAAC.48.8.3006-3009.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Timmins, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Master, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deretic, V.</span></span> <span> </span><span class="NLM_article-title">Requirements for nitric oxide generation from isoniazid activation in vitro and inhibition of mycobacterial respiration in vivo</span>. <i>J. Bacteriol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">5427</span>– <span class="NLM_lpage">5431</span>, <span class="refDoi"> DOI: 10.1128/JB.186.16.5427-5431.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FJB.186.16.5427-5431.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=15292144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVKhurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2004&pages=5427-5431&author=G.+S.+Timminsauthor=S.+Masterauthor=F.+Rusnakauthor=V.+Deretic&title=Requirements+for+nitric+oxide+generation+from+isoniazid+activation+in+vitro+and+inhibition+of+mycobacterial+respiration+in+vivo&doi=10.1128%2FJB.186.16.5427-5431.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Requirements for nitric oxide generation from isoniazid activation in vitro and inhibition of mycobacterial respiration in vivo</span></div><div class="casAuthors">Timmins, Graham S.; Master, Sharon; Rusnak, Frank; Deretic, Vojo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bacteriology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5427-5431</span>CODEN:
                <span class="NLM_cas:coden">JOBAAY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9193</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Isoniazid (INH), a front-line antituberculosis agent, is activated by mycobacterial catalase-peroxidase KatG, converting INH into bactericidal reactive species.  Here we investigated the requirements and the pathway of nitric oxide (NO.) generation during oxidative activation of INH by Mycobacterium tuberculosis KatG in vitro.  We also provide in vivo evidence that INH-derived NO. can inhibit key mycobacterial respiratory enzymes, which may contribute to the overall antimycobacterial action of INH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIbpo4JkrED7Vg90H21EOLACvtfcHk0lgypW1_K7ZB2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVKhurc%253D&md5=dec59e2c5d316455e311ac3d05deda2d</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1128%2FJB.186.16.5427-5431.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJB.186.16.5427-5431.2004%26sid%3Dliteratum%253Aachs%26aulast%3DTimmins%26aufirst%3DG.%2BS.%26aulast%3DMaster%26aufirst%3DS.%26aulast%3DRusnak%26aufirst%3DF.%26aulast%3DDeretic%26aufirst%3DV.%26atitle%3DRequirements%2520for%2520nitric%2520oxide%2520generation%2520from%2520isoniazid%2520activation%2520in%2520vitro%2520and%2520inhibition%2520of%2520mycobacterial%2520respiration%2520in%2520vivo%26jtitle%3DJ.%2520Bacteriol.%26date%3D2004%26volume%3D186%26spage%3D5427%26epage%3D5431%26doi%3D10.1128%2FJB.186.16.5427-5431.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchison, D. A.</span></span> <span> </span><span class="NLM_article-title">Basic mechanisms of chemotherapy</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">771</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1378/chest.76.6_Supplement.771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1378%2Fchest.76.6.771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=92392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaL3cXmvFWmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1979&pages=771-781&author=D.+A.+Mitchison&title=Basic+mechanisms+of+chemotherapy&doi=10.1378%2Fchest.76.6_Supplement.771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Basic mechanisms of chemotherapy</span></div><div class="casAuthors">Mitchison, D. A.</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">6, Suppl.</span>),
    <span class="NLM_cas:pages">771-6, 778-81</span>CODEN:
                <span class="NLM_cas:coden">CHETBF</span>;
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    </div><div class="casAbstract">A review with 25 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlpYjWoMW2MrVg90H21EOLACvtfcHk0lgypW1_K7ZB2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXmvFWmsg%253D%253D&md5=96a72c82c5e12e75ecddfc4d428fe784</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1378%2Fchest.76.6.771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.76.6.771%26sid%3Dliteratum%253Aachs%26aulast%3DMitchison%26aufirst%3DD.%2BA.%26atitle%3DBasic%2520mechanisms%2520of%2520chemotherapy%26jtitle%3DChest%26date%3D1979%26volume%3D76%26spage%3D771%26epage%3D781%26doi%3D10.1378%2Fchest.76.6_Supplement.771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, J. S.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of drug resistance in Mycobacterium tuberculosis</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1146/annurev.bi.65.070196.001243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1146%2Fannurev.bi.65.070196.001243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=8811179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK28XktFamtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1996&pages=215-239&author=J.+S.+Blanchard&title=Molecular+mechanisms+of+drug+resistance+in+Mycobacterium+tuberculosis&doi=10.1146%2Fannurev.bi.65.070196.001243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of drug resistance in Mycobacterium tuberculosis</span></div><div class="casAuthors">Blanchard, John S.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">215-239</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review with 127 refs.  In spite of forty years of effective chemotherapy for tuberculosis, the mol. mechanisms of antibacterial compds. in Mycobacterium tuberculosis have only recently been revealed.  Broad spectrum antibacterials, including streptomycin, rifampicin, and fluoroquinolones, have been demonstrated to act on the same targets in M. tuberculosis as they do in Escherichia coli.  Resistance to these agents results from single mutagenic events that lead to amino acid substitutions in their target proteins.  The mechanisms of action of the unique antitubercular drugs, including isoniazid, ethambutol, and pyrazinamide, have also recently been defined.  Resistance to isoniazid can be caused either by mutations in the katG-encoded catalase-peroxidase, the enzyme responsible for drug activation, or by the mol. target, the inhA-encoded long chain enoyl-ACP reductase.  Ethambutol appears to block specifically the biosynthesis of the arabinogalactan component of the mycobacterial cell envelope, and pyrazinamide has no known target.  With the resurgence of tuberculosis and the appearance of strains which are multiply resistant to the above compds., present tuberculosis chemotherapies are threatened.  New approaches to the treatment of multidrug-resistant tuberculosis are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBC4hQKmc42rVg90H21EOLACvtfcHk0lgVi_JU0bjlKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XktFamtLw%253D&md5=8154424e4e4d3c06a4388d561eb9adae</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1146%2Fannurev.bi.65.070196.001243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.bi.65.070196.001243%26sid%3Dliteratum%253Aachs%26aulast%3DBlanchard%26aufirst%3DJ.%2BS.%26atitle%3DMolecular%2520mechanisms%2520of%2520drug%2520resistance%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D1996%26volume%3D65%26spage%3D215%26epage%3D239%26doi%3D10.1146%2Fannurev.bi.65.070196.001243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Telenti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imboden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowrie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colston, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schopfer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodmer, T.</span></span> <span> </span><span class="NLM_article-title">Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1016/0140-6736(93)90417-F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2F0140-6736%2893%2990417-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=8095569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK3sXkvFWjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1993&pages=647-650&author=A.+Telentiauthor=P.+Imbodenauthor=F.+Marchesiauthor=D.+Lowrieauthor=S.+Coleauthor=M.+J.+Colstonauthor=L.+Matterauthor=K.+Schopferauthor=T.+Bodmer&title=Detection+of+rifampicin-resistance+mutations+in+Mycobacterium+tuberculosis&doi=10.1016%2F0140-6736%2893%2990417-F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis</span></div><div class="casAuthors">Telenti, Amalio; Imboden, Paul; Marchesi, Francine; Lowrie, Douglas; Cole, Stewart; Colston, M. Joseph; Matter, Lukas; Schopfer, Kurt; Bodmer, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">8846</span>),
    <span class="NLM_cas:pages">647-50</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">Control of tuberculosis is threatened by widespread emergence of drug resistance in Mycobacterium tuberculosis.  Understanding the mol. basis of resistance might lead to development of novel rapid methods for diagnosing drug resistance.  The authors studied the mol. basis of resistance to rifampicin, a major component of multidrug regimens used for treating tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1fPRoiLSLgrVg90H21EOLACvtfcHk0lgVi_JU0bjlKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXkvFWjsbo%253D&md5=439caf42ddc568b4cba84ded140b9e85</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2F0140-6736%2893%2990417-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0140-6736%252893%252990417-F%26sid%3Dliteratum%253Aachs%26aulast%3DTelenti%26aufirst%3DA.%26aulast%3DImboden%26aufirst%3DP.%26aulast%3DMarchesi%26aufirst%3DF.%26aulast%3DLowrie%26aufirst%3DD.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DColston%26aufirst%3DM.%2BJ.%26aulast%3DMatter%26aufirst%3DL.%26aulast%3DSchopfer%26aufirst%3DK.%26aulast%3DBodmer%26aufirst%3DT.%26atitle%3DDetection%2520of%2520rifampicin-resistance%2520mutations%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DLancet%26date%3D1993%26volume%3D341%26spage%3D647%26epage%3D650%26doi%3D10.1016%2F0140-6736%2893%2990417-F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morlock, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plikaytis, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. T.</span></span> <span> </span><span class="NLM_article-title">Characterization of spontaneous, In vitro-selected, rifampin-resistant mutants of Mycobacterium tuberculosis strain H37Rv</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">3298</span>– <span class="NLM_lpage">3301</span>, <span class="refDoi"> DOI: 10.1128/AAC.44.12.3298-3301.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.44.12.3298-3301.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=11083630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhs1Kitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2000&pages=3298-3301&author=G.+P.+Morlockauthor=B.+B.+Plikaytisauthor=J.+T.+Crawford&title=Characterization+of+spontaneous%2C+In+vitro-selected%2C+rifampin-resistant+mutants+of+Mycobacterium+tuberculosis+strain+H37Rv&doi=10.1128%2FAAC.44.12.3298-3301.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of spontaneous, in vitro-selected, rifampin-resistant mutants of Mycobacterium tuberculosis strain H37Rv</span></div><div class="casAuthors">Morlock, Glenn P.; Plikaytis, Bonnie B.; Crawford, Jack T.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3298-3301</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Resistance to rifampin in Mycobacterium tuberculosis results from mutations in the gene coding for the beta subunit of RNA polymerase (rpoB).  At least 95% of rifampin-resistant isolates have mutations in rpoB, and the mutations are clustered in a small region.  About 40 distinct point mutations and in-frame insertions and deletions in rpoB have been identified, but point mutations in two codons, those coding for Ser531 and His526, are seen in about 70% of rifampin-resistant clin. isolates, with Ser531-to-Leu (TCG-to-TGG) mutations being by far the most common.  To explore this phenomenon, we isolated independent, spontaneous, rifampin-resistant mutant versions of well-characterized M. tuberculosis lab. strain H37Rv by plating 100 sep. cultures, derived from a single low-d. inoculum, onto rifampin-contg. medium.  Rifampin-resistant mutants were obtained from 64 of these cultures.  Although we anticipated that the various point mutations would occur with approx. equal frequencies, sequencing the rpoB gene from one colony per plate revealed that 39 (60.9%) were Ser531 to Leu.  We conclude that, for unknown reasons, the assocd. rpoB mutation occurs at a substantially higher rate than other rpoB mutations.  This higher mutation rate may contribute to the high percentage of this mutation seen in clin. isolates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQltNg8NAsAbVg90H21EOLACvtfcHk0lhCLYsjDdmSKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhs1Kitrg%253D&md5=b94769bfc5e5bdc6c4fc9b281ff331ab</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1128%2FAAC.44.12.3298-3301.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.44.12.3298-3301.2000%26sid%3Dliteratum%253Aachs%26aulast%3DMorlock%26aufirst%3DG.%2BP.%26aulast%3DPlikaytis%26aufirst%3DB.%2BB.%26aulast%3DCrawford%26aufirst%3DJ.%2BT.%26atitle%3DCharacterization%2520of%2520spontaneous%252C%2520In%2520vitro-selected%252C%2520rifampin-resistant%2520mutants%2520of%2520Mycobacterium%2520tuberculosis%2520strain%2520H37Rv%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2000%26volume%3D44%26spage%3D3298%26epage%3D3301%26doi%3D10.1128%2FAAC.44.12.3298-3301.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traore, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fissette, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devleeschouwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portaels, F.</span></span> <span> </span><span class="NLM_article-title">Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">484</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10815743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD3c3ntlWltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2000&pages=481-484&author=H.+Traoreauthor=K.+Fissetteauthor=I.+Bastianauthor=M.+Devleeschouwerauthor=F.+Portaels&title=Detection+of+rifampicin+resistance+in+Mycobacterium+tuberculosis+isolates+from+diverse+countries+by+a+commercial+line+probe+assay+as+an+initial+indicator+of+multidrug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance</span></div><div class="casAuthors">Traore H; Fissette K; Bastian I; Devleeschouwer M; Portaels F</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">481-4</span>
        ISSN:<span class="NLM_cas:issn">1027-3719</span>.
    </div><div class="casAbstract">The line probe assay (LiPA), a rapid molecular method for detecting rifampicin resistance (RMPr) in Mycobacterium tuberculosis, correctly identified all 145 rifampicin-sensitive (RMPs) and 262 (98.5%) of 266 RMPr strains among 411 isolates collected from diverse countries.  If used as a marker of multidrug-resistant tuberculosis (MDR-TB), detection of RMPr by LiPA would have detected 236 of the 240 MDR strains in this study but would have wrongly suggested the presence of MDR in 26 RMP-monoresistant isolates (sensitivity 98.3%, specificity 84.8%).  Hence, the reliability of using LiPA (or any other rapid RMPr-detection method) as a surrogate marker of MDR-TB largely depends on the prevalence of RMP-monoresistance in the study population.  This approach must therefore be validated in each local situation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqwkvb7Zse19LIORRPd5lbfW6udTcc2ebhNhKaNn1vBrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3ntlWltw%253D%253D&md5=1aa87338f33231f8ff9724571865942c</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTraore%26aufirst%3DH.%26aulast%3DFissette%26aufirst%3DK.%26aulast%3DBastian%26aufirst%3DI.%26aulast%3DDevleeschouwer%26aufirst%3DM.%26aulast%3DPortaels%26aufirst%3DF.%26atitle%3DDetection%2520of%2520rifampicin%2520resistance%2520in%2520Mycobacterium%2520tuberculosis%2520isolates%2520from%2520diverse%2520countries%2520by%2520a%2520commercial%2520line%2520probe%2520assay%2520as%2520an%2520initial%2520indicator%2520of%2520multidrug%2520resistance%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D2000%26volume%3D4%26spage%3D481%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heifets, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindholm-Levy, P.</span></span> <span> </span><span class="NLM_article-title">Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations</span>. <i>Am. Rev. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">1223</span>– <span class="NLM_lpage">1225</span>, <span class="refDoi"> DOI: 10.1164/ajrccm/145.5.1223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1164%2Fajrccm%2F145.5.1223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1586071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK38XksVCnsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=1992&pages=1223-1225&author=L.+Heifetsauthor=P.+Lindholm-Levy&title=Pyrazinamide+sterilizing+activity+in+vitro+against+semidormant+Mycobacterium+tuberculosis+bacterial+populations&doi=10.1164%2Fajrccm%2F145.5.1223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations</span></div><div class="casAuthors">Heifets, Leonid; Lindholm-Levy, Pamela</div><div class="citationInfo"><span class="NLM_cas:title">American Review of Respiratory Disease</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1223-5</span>CODEN:
                <span class="NLM_cas:coden">ARDSBL</span>;
        ISSN:<span class="NLM_cas:issn">0003-0805</span>.
    </div><div class="casAbstract">Previously, it was reported that pyrazinamide has very poor bactericidal activity against M. tuberculosis growing in broth at pH 5.6.  In the present study, cultivation at pH 4.8 to 5.0 in 7H12 broth prevented an increase in the no. of viable bacteria, but the cultures remained metabolically active.  The presence of 50 μg/mL pyrazinamide in semidormant cultures led to a sharp decline in the no. of viable bacteria by more than 1000-fold.  This unfavorable environment probably made the bacilli esp. vulnerable to pyrazinamide, whose mode of action remains unclear.  To distinguish this effect of pyrazinamide on the semidormant bacteria from its mostly bacteriostatic activity against actively multiplying bacteria, the authors suggest interpreting the in vitro effect as "sterilizing.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPYRYLTaxswbVg90H21EOLACvtfcHk0lhCLYsjDdmSKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XksVCnsr4%253D&md5=6f05dab7f4d6e18eb275f8bc41f9d01a</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1164%2Fajrccm%2F145.5.1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm%252F145.5.1223%26sid%3Dliteratum%253Aachs%26aulast%3DHeifets%26aufirst%3DL.%26aulast%3DLindholm-Levy%26aufirst%3DP.%26atitle%3DPyrazinamide%2520sterilizing%2520activity%2520in%2520vitro%2520against%2520semidormant%2520Mycobacterium%2520tuberculosis%2520bacterial%2520populations%26jtitle%3DAm.%2520Rev.%2520Respir.%2520Dis.%26date%3D1992%26volume%3D145%26spage%3D1223%26epage%3D1225%26doi%3D10.1164%2Fajrccm%2F145.5.1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchison, D. A.</span></span> <span> </span><span class="NLM_article-title">The action of antituberculosis drugs in short-course chemotherapy</span>. <i>Tubercle</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1016/0041-3879(85)90040-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2F0041-3879%2885%2990040-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=3931319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaL28%252FitVajtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1985&pages=219-225&author=D.+A.+Mitchison&title=The+action+of+antituberculosis+drugs+in+short-course+chemotherapy&doi=10.1016%2F0041-3879%2885%2990040-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">The action of antituberculosis drugs in short-course chemotherapy</span></div><div class="casAuthors">Mitchison D A</div><div class="citationInfo"><span class="NLM_cas:title">Tubercle</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-25</span>
        ISSN:<span class="NLM_cas:issn">0041-3879</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ3wobTUofGToqdXsLcGTEUfW6udTcc2eYfdrBQDUS9uLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL28%252FitVajtA%253D%253D&md5=a89e41a36c2e2051e5c80f5c3e34c220</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2F0041-3879%2885%2990040-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0041-3879%252885%252990040-6%26sid%3Dliteratum%253Aachs%26aulast%3DMitchison%26aufirst%3DD.%2BA.%26atitle%3DThe%2520action%2520of%2520antituberculosis%2520drugs%2520in%2520short-course%2520chemotherapy%26jtitle%3DTubercle%26date%3D1985%26volume%3D66%26spage%3D219%26epage%3D225%26doi%3D10.1016%2F0041-3879%2885%2990040-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franke, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becerra, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tierney, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonilla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayona, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitnick, C. D.</span></span> <span> </span><span class="NLM_article-title">Counting pyrazinamide in regimens for multidrug-resistant tuberculosis</span>. <i>Ann. Am. Thorac. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">674</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1513/AnnalsATS.201411-538OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1513%2FAnnalsATS.201411-538OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25664920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2MrjvFOmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=674-679&author=M.+F.+Frankeauthor=M.+C.+Becerraauthor=D.+B.+Tierneyauthor=M.+L.+Richauthor=C.+Bonillaauthor=J.+Bayonaauthor=M.+M.+McLaughlinauthor=C.+D.+Mitnick&title=Counting+pyrazinamide+in+regimens+for+multidrug-resistant+tuberculosis&doi=10.1513%2FAnnalsATS.201411-538OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Counting pyrazinamide in regimens for multidrug-resistant tuberculosis</span></div><div class="casAuthors">Franke Molly F; Becerra Mercedes C; Tierney Dylan B; Rich Michael L; Bonilla Cesar; Bayona Jaime; McLaughlin Megan M; Mitnick Carole D</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">674-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  For treatment of multidrug-resistant tuberculosis, World Health Organization (WHO) guidelines recommend four likely effective drugs plus pyrazinamide (PZA), irrespective of the likely effectiveness of PZA in an individual patient.  Whether this regimen should be supplemented in the absence of likely PZA effectiveness is an open question.  OBJECTIVES:  The objectives of this study were to examine (1) whether individuals receiving four likely effective drugs (based on documented susceptibility or no prior exposure) experienced higher mortality during the intensive phase of treatment than those receiving five likely effective drugs and (2) whether the WHO-recommended regimen (four likely effective drugs plus PZA) may be compromised in individuals in whom PZA is not likely effective.  METHODS:  Among 668 patients, we compared the hazard of death across regimen groups characterized by the number of likely effective drugs and whether pyrazinamide was one of the likely effective drugs.  MEASUREMENTS AND MAIN RESULTS:  Relative to five likely effective drugs, regimens of four likely effective drugs and the WHO-recommended regimen used in individuals in whom PZA was not likely effective were associated with higher mortality rates (respectively, adjusted hazard ratio [HR], 2.87; 95% confidence interval [CI], 1.35-6.09 and adjusted HR, 2.76; 95% CI, 0.92-8.27).  The mortality rate for a regimen of five likely effective drugs with likely effective PZA was similar to that for the regimen of five likely effective drugs without PZA (HR, 1.00; 95% CI, 0.12-8.00).  CONCLUSIONS:  Mortality may be reduced by the inclusion of five likely effective drugs, including an injectable, during the intensive phase of treatment.  If PZA is unlikely to be effective in an individual patient, these results suggest adding a different, likely effective drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTayfCBOKpiHcuCWE5mhx1RfW6udTcc2eYfdrBQDUS9uLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrjvFOmuw%253D%253D&md5=0eb2ce28659210a8ce9e5725f6ed5fa0</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1513%2FAnnalsATS.201411-538OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252FAnnalsATS.201411-538OC%26sid%3Dliteratum%253Aachs%26aulast%3DFranke%26aufirst%3DM.%2BF.%26aulast%3DBecerra%26aufirst%3DM.%2BC.%26aulast%3DTierney%26aufirst%3DD.%2BB.%26aulast%3DRich%26aufirst%3DM.%2BL.%26aulast%3DBonilla%26aufirst%3DC.%26aulast%3DBayona%26aufirst%3DJ.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BM.%26aulast%3DMitnick%26aufirst%3DC.%2BD.%26atitle%3DCounting%2520pyrazinamide%2520in%2520regimens%2520for%2520multidrug-resistant%2520tuberculosis%26jtitle%3DAnn.%2520Am.%2520Thorac.%2520Soc.%26date%3D2015%26volume%3D12%26spage%3D674%26epage%3D679%26doi%3D10.1513%2FAnnalsATS.201411-538OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piubello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harouna, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souleymane, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boukary, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daouda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Deun, A.</span></span> <span> </span><span class="NLM_article-title">High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses</span>. <i>Int. J. Tuberc. Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1188</span>– <span class="NLM_lpage">1194</span>, <span class="refDoi"> DOI: 10.5588/ijtld.13.0075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.5588%2Fijtld.13.0075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25216832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2M7gvFyisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=1188-1194&author=A.+Piubelloauthor=S.+H.+Harounaauthor=M.+B.+Souleymaneauthor=I.+Boukaryauthor=S.+Morouauthor=M.+Daoudaauthor=Y.+Hankiauthor=A.+Van+Deun&title=High+cure+rate+with+standardised+short-course+multidrug-resistant+tuberculosis+treatment+in+Niger%3A+no+relapses&doi=10.5588%2Fijtld.13.0075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses</span></div><div class="casAuthors">Piubello A; Harouna S Hassane; Souleymane M B; Boukary I; Morou S; Daouda M; Hanki Y; Van Deun A</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1188-94</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">SETTING:  Niger National Tuberculosis Programme.  Regions supported by the Damien Foundation.  OBJECTIVE:  To evaluate the effectiveness of a short-course standardised treatment regimen for patients with proven multidrug-resistant tuberculosis (MDR-TB) previously untreated with second-line drugs.  METHODS:  Prospective study including all patients enrolled from 2008 to 2010.  The 12-month standardised regimen comprised high doses of gatifloxacin, clofazimine, ethambutol and pyrazinamide throughout, supplemented by kanamycin, prothionamide and medium-high doses of isoniazid during the intensive phase of a minimum of 4 months.  Patients were monitored using sputum smear and culture at start of treatment and every 2 months.  Cured patients were followed up 6-monthly for 24 months.  RESULTS:  Sixty-five patients with MDR-TB were included and analysed.  One of 58 patients tested for human immunodeficiency virus (1.7%) infection was positive.  Twenty-five patients (39.7%) were severely affected (body mass index  16 kg/m(2)).  Cure was achieved in 58 patients (89.2%, 95%CI 81.7-96.7), 6 died and 1 defaulted.  All 49 patients assessed at the 24-month follow-up after cure remained smear- and culture-negative.  The main adverse events were vomiting (26.2%) and hearing impairment (20%), but no treatment had to be stopped.  CONCLUSION:  Standardised 12-month treatment for MDR-TB was highly effective and well tolerated in patients not previously exposed to second-line drugs in Niger.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKjlxBo8hoAsKL0FlyGHDofW6udTcc2eYfdrBQDUS9uLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7gvFyisQ%253D%253D&md5=552c1ca5a3f2a724501ed2f0284f818d</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.5588%2Fijtld.13.0075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5588%252Fijtld.13.0075%26sid%3Dliteratum%253Aachs%26aulast%3DPiubello%26aufirst%3DA.%26aulast%3DHarouna%26aufirst%3DS.%2BH.%26aulast%3DSouleymane%26aufirst%3DM.%2BB.%26aulast%3DBoukary%26aufirst%3DI.%26aulast%3DMorou%26aufirst%3DS.%26aulast%3DDaouda%26aufirst%3DM.%26aulast%3DHanki%26aufirst%3DY.%26aulast%3DVan%2BDeun%26aufirst%3DA.%26atitle%3DHigh%2520cure%2520rate%2520with%2520standardised%2520short-course%2520multidrug-resistant%2520tuberculosis%2520treatment%2520in%2520Niger%253A%2520no%2520relapses%26jtitle%3DInt.%2520J.%2520Tuberc.%2520Lung%2520Dis.%26date%3D2014%26volume%3D18%26spage%3D1188%26epage%3D1194%26doi%3D10.5588%2Fijtld.13.0075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tompsett, R.</span></span> <span> </span><span class="NLM_article-title">Activation of pyrazinamide and nicotinamide in acidic environments in vitro</span>. <i>Am. Rev. Tuberc.</i> <span class="NLM_year" style="font-weight: bold;">1954</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1164/art.1954.70.4.748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1164%2Fart.1954.70.4.748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=13197751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaG2MXjs1Cjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1954&pages=748-754&author=D.+McDermottauthor=R.+Tompsett&title=Activation+of+pyrazinamide+and+nicotinamide+in+acidic+environments+in+vitro&doi=10.1164%2Fart.1954.70.4.748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of pyrazinamide and nicotinamide in acidic environments in vitro</span></div><div class="casAuthors">McDermott, Walsh; Tompsett, Ralph</div><div class="citationInfo"><span class="NLM_cas:title">American Review of Tuberculosis</span>
        (<span class="NLM_cas:date">1954</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">748-54</span>CODEN:
                <span class="NLM_cas:coden">ARTUA4</span>;
        ISSN:<span class="NLM_cas:issn">0096-0381</span>.
    </div><div class="casAbstract">Tubercle bacteria (H 37 Rv) are highly susceptible to pyrazinamide in vitro in a standard drug-susceptibility test modified only by reducing the pH to 5.0 or 5.5.  Nicotinamide is likewise active, though to lesser degree, tested in this way.  Tested within physiologic ranges of pH, the H 37 Rv strain is resistant to both pyrazinamide and nicotinamide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoERW1f_rdO0rVg90H21EOLACvtfcHk0lh0keib_fOHzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG2MXjs1Cjtw%253D%253D&md5=a0e74ae8616e9493b89c2a6dd841d564</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1164%2Fart.1954.70.4.748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fart.1954.70.4.748%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DD.%26aulast%3DTompsett%26aufirst%3DR.%26atitle%3DActivation%2520of%2520pyrazinamide%2520and%2520nicotinamide%2520in%2520acidic%2520environments%2520in%2520vitro%26jtitle%3DAm.%2520Rev.%2520Tuberc.%26date%3D1954%26volume%3D70%26spage%3D748%26epage%3D754%26doi%3D10.1164%2Fart.1954.70.4.748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scorpio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikaido, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span> <span> </span><span class="NLM_article-title">Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide</span>. <i>J. Bacteriol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">2044</span>– <span class="NLM_lpage">2049</span>, <span class="refDoi"> DOI: 10.1128/JB.181.7.2044-2049.1999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FJB.181.7.2044-2049.1999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10094680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK1MXitFKktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=1999&pages=2044-2049&author=Y.+Zhangauthor=A.+Scorpioauthor=H.+Nikaidoauthor=Z.+Sun&title=Role+of+acid+pH+and+deficient+efflux+of+pyrazinoic+acid+in+unique+susceptibility+of+Mycobacterium+tuberculosis+to+pyrazinamide&doi=10.1128%2FJB.181.7.2044-2049.1999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide</span></div><div class="casAuthors">Zhang, Ying; Scorpio, Angelo; Nikaido, Hiroshi; Sun, Zhonghe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bacteriology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2044-2049</span>CODEN:
                <span class="NLM_cas:coden">JOBAAY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9193</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Pyrazinamide (PZA) is an important antituberculosis drug.  Unlike most antibacterial agents, PZA, despite its remarkable in vivo activity, has no activity against Mycobacterium tuberculosis in vitro except at an acidic pH.  M. tuberculosis is uniquely susceptible to PZA, but other mycobacteria as well as nonmycobacteria are intrinsically resistant.  The role of acidic pH in PZA action and the basis for the unique PZA susceptibility of M. tuberculosis are unknown.  We found that in M. tuberculosis, acidic pH enhanced the intracellular accumulation of pyrazinoic acid (POA), the active deriv. of PZA, after conversion of PZA by pyrazinamidase.  In contrast, at neutral or alk. pH, POA was mainly found outside M. tuberculosis cells.  PZA-resistant M. tuberculosis complex organisms did not convert PZA into POA.  Unlike M. tuberculosis, intrinsically PZA-resistant M. smegmatis converted PZA into POA, but it did not accumulate POA even at an acidic pH, due to a very active POA efflux mechanism.  It is proposed that a deficient POA efflux mechanism underlies the unique susceptibility of M. tuberculosis to PZA and that the natural PZA resistance of M. smegmatis is due to a highly active efflux pump.  These findings may have implications with regard to the design of new antimycobacterial drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp16456bDVUKrVg90H21EOLACvtfcHk0lh0keib_fOHzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitFKktbc%253D&md5=72539d3a60e67f35f91057ff5f0926ab</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1128%2FJB.181.7.2044-2049.1999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJB.181.7.2044-2049.1999%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DScorpio%26aufirst%3DA.%26aulast%3DNikaido%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DZ.%26atitle%3DRole%2520of%2520acid%2520pH%2520and%2520deficient%2520efflux%2520of%2520pyrazinoic%2520acid%2520in%2520unique%2520susceptibility%2520of%2520Mycobacterium%2520tuberculosis%2520to%2520pyrazinamide%26jtitle%3DJ.%2520Bacteriol.%26date%3D1999%26volume%3D181%26spage%3D2044%26epage%3D2049%26doi%3D10.1128%2FJB.181.7.2044-2049.1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, W.</span></span> <span> </span><span class="NLM_article-title">Pyrazinamide susceptibility and amidase activity of tubercle bacilli</span>. <i>Am. Rev. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1164/arrd.1967.95.3.461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1164%2Farrd.1967.95.3.461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=4225184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaF2sXpt1KitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1967&pages=461-469&author=K.+Konnoauthor=F.+M.+Feldmannauthor=W.+McDermott&title=Pyrazinamide+susceptibility+and+amidase+activity+of+tubercle+bacilli&doi=10.1164%2Farrd.1967.95.3.461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazinamide susceptibility and amidase activity of tubercle bacilli</span></div><div class="casAuthors">Konno, Kiyoshi; Feldmann, Floyd M.; McDermott, Walsh</div><div class="citationInfo"><span class="NLM_cas:title">American Review of Respiratory Disease</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">461-9</span>CODEN:
                <span class="NLM_cas:coden">ARDSBL</span>;
        ISSN:<span class="NLM_cas:issn">0003-0805</span>.
    </div><div class="casAbstract">Irrespective of their susceptibility to pyrazinamide (I), tubercle bacilli of human and bovine origin were inhibited in acidic environments in vitro by pyrazinoic acid, which is released from I by bacilli possessing amidase.  A correlation existed between the pyrazinamidase activity of tubercle bacilli and their susceptibility or resistance to I, thus suggesting that I resistance is a function of reduced amidase activity.  Pyrazinoic acid was not effective in vivo in murine tuberculosis, and urine contg. high concns. of an excreted pyrazinoic acid-like material failed to inhibit Mycobacterium tuberculosis when tested in appropriate circumstances in vitro.  Cross-resistance between I and nicotinamide in M. tuberculosis was observed, and resistance to either was accompanied by a decrease in the activity of both pyrazinamidase and nicotinamidase.  Either enzyme could likewise be suppressed by high concns. of the reaction product of the other, i.e., pyrazinoic acid or nicotinic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrZT5hXFB6n7Vg90H21EOLACvtfcHk0liynNqhcF5XQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXpt1KitA%253D%253D&md5=9d6121a07e2c776350a243282ed8b604</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1164%2Farrd.1967.95.3.461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Farrd.1967.95.3.461%26sid%3Dliteratum%253Aachs%26aulast%3DKonno%26aufirst%3DK.%26aulast%3DFeldmann%26aufirst%3DF.%2BM.%26aulast%3DMcDermott%26aufirst%3DW.%26atitle%3DPyrazinamide%2520susceptibility%2520and%2520amidase%2520activity%2520of%2520tubercle%2520bacilli%26jtitle%3DAm.%2520Rev.%2520Respir.%2520Dis.%26date%3D1967%26volume%3D95%26spage%3D461%26epage%3D469%26doi%3D10.1164%2Farrd.1967.95.3.461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scorpio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">667</span>, <span class="refDoi"> DOI: 10.1038/nm0696-662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnm0696-662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=8640557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK28XjsVSjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=662-667&author=A.+Scorpioauthor=Y.+Zhang&title=Mutations+in+pncA%2C+a+gene+encoding+pyrazinamidase%2Fnicotinamidase%2C+cause+resistance+to+the+antituberculous+drug+pyrazinamide+in+tubercle+bacillus&doi=10.1038%2Fnm0696-662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus</span></div><div class="casAuthors">Scorpio, Angelo; Zhang, Ying</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-667</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Naturally pyrazinamide (PZA)-resistant Mycobacterium bovis and acquired PZA-resistant M. tuberculosis strains lose pyrazinamidase (PZase).  To investigate the mol. mechanism of PZA resistance, we have cloned the gene (pncA) encoding M. tuberculosis PZase.  Mutations in pncA were identified in both types of PZA-resistant strains, and transformation of these strains with a functional pncA gene restored PZase activity and PZA susceptibility.  These findings, besides providing the basis for understanding how PZA works, should have implications for rapid detection of PZA-resistant clin. isolates of M. tuberculosis and also for rapid differentiation of M. bovis from M. tuberculosis strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVdd4sFkh_b7Vg90H21EOLACvtfcHk0liynNqhcF5XQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjsVSjtbo%253D&md5=8b494b8294bc17e131105a8736fb5a3e</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1038%2Fnm0696-662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0696-662%26sid%3Dliteratum%253Aachs%26aulast%3DScorpio%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DMutations%2520in%2520pncA%252C%2520a%2520gene%2520encoding%2520pyrazinamidase%252Fnicotinamidase%252C%2520cause%2520resistance%2520to%2520the%2520antituberculous%2520drug%2520pyrazinamide%2520in%2520tubercle%2520bacillus%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26spage%3D662%26epage%3D667%26doi%3D10.1038%2Fnm0696-662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Telenti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philipp, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreevatsan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockbauer, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieles, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musser, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1038/nm0597-567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnm0597-567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=9142129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK2sXivFOltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1997&pages=567-570&author=A.+Telentiauthor=W.+J.+Philippauthor=S.+Sreevatsanauthor=C.+Bernasconiauthor=K.+E.+Stockbauerauthor=B.+Wielesauthor=J.+M.+Musserauthor=W.+R.+Jacobs&title=The+emb+operon%2C+a+gene+cluster+of+Mycobacterium+tuberculosis+involved+in+resistance+to+ethambutol&doi=10.1038%2Fnm0597-567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol</span></div><div class="casAuthors">Telenti, Amalio; Philipp, Wolfgang J.; Sreevatasan, Srinand; Bernasconi, Claudia; Stockbauer, Kathryn E.; Wieles, Brigitte; Musser, James M.; Jacobs, William R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">567-570</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Ethambutol (EMB), a frontline antituberculous drug, targets the mycobacterial cell wall, a unique structure among prokaryotes which consists of an outer layer of mycolic acids covalently bound to peptidoglycan via the arabinogalactan.  EMB inhibits the polymn. of cell wall arabinan, and results in the accumulation of the lipid carrier decaprenol phosphoarabinose, which suggests that the drug interferes with the transfer of arabinose to the cell wall acceptor.  Unfortunately, resistance to EMB has been described in up to 4% of clin. isolates of Mycobacterium tuberculosis and is prevalent among isolates from patients with multidrug-resistant tuberculosis.  We used resistance to EMB as a tool to identify genes participating in the biosynthesis of the mycobacterial cell wall.  This approach led to the identification of the embCAB gene cluster, recently proposed to encode for mycobacterial arabinosyl transferases.  Resistance to EMB results from an accumulation of genetic events detg. overexpression of the Emb protein(s), structural mutation to EmbB, or both.  Further characterization of these proteins might provide information on targets for new chemotherapeutic agents and might help development of diagnostic strategies for the detection of resistant M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgWmL8lc0ZDbVg90H21EOLACvtfcHk0liynNqhcF5XQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFOltLk%253D&md5=14021c545ec1fcfb6b06c86aedfa049e</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1038%2Fnm0597-567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0597-567%26sid%3Dliteratum%253Aachs%26aulast%3DTelenti%26aufirst%3DA.%26aulast%3DPhilipp%26aufirst%3DW.%2BJ.%26aulast%3DSreevatsan%26aufirst%3DS.%26aulast%3DBernasconi%26aufirst%3DC.%26aulast%3DStockbauer%26aufirst%3DK.%2BE.%26aulast%3DWieles%26aufirst%3DB.%26aulast%3DMusser%26aufirst%3DJ.%2BM.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26atitle%3DThe%2520emb%2520operon%252C%2520a%2520gene%2520cluster%2520of%2520Mycobacterium%2520tuberculosis%2520involved%2520in%2520resistance%2520to%2520ethambutol%26jtitle%3DNat.%2520Med.%26date%3D1997%26volume%3D3%26spage%3D567%26epage%3D570%26doi%3D10.1038%2Fnm0597-567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurcha, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veerapen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. e.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guddat, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span> <span> </span><span class="NLM_article-title">Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1211</span>– <span class="NLM_lpage">1219</span>, <span class="refDoi"> DOI: 10.1126/science.aba9102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1126%2Fscience.aba9102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=32327601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGitLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2020&pages=1211-1219&author=L.+Zhangauthor=Y.+Zhaoauthor=Y.+Gaoauthor=L.+Wuauthor=R.+Gaoauthor=Q.+Zhangauthor=Y.+Wangauthor=C.+Wuauthor=F.+Wuauthor=S.+S.+Gurchaauthor=N.+Veerapenauthor=S.+M.+Battauthor=W.+Zhaoauthor=L.+Qinauthor=X.+Yangauthor=M.+Wangauthor=Y.+Zhuauthor=B.+Zhangauthor=L.+Biauthor=X.+e.+Zhangauthor=H.+Yangauthor=L.+W.+Guddatauthor=W.+Xuauthor=Q.+Wangauthor=J.+Liauthor=G.+S.+Besraauthor=Z.+Rao&title=Structures+of+cell+wall+arabinosyltransferases+with+the+anti-tuberculosis+drug+ethambutol&doi=10.1126%2Fscience.aba9102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol</span></div><div class="casAuthors">Zhang, Lu; Zhao, Yao; Gao, Yan; Wu, Lijie; Gao, Ruogu; Zhang, Qi; Wang, Yinan; Wu, Chengyao; Wu, Fangyu; Gurcha, Sudagar S.; Veerapen, Natacha; Batt, Sarah M.; Zhao, Wei; Qin, Ling; Yang, Xiuna; Wang, Manfu; Zhu, Yan; Zhang, Bing; Bi, Lijun; Zhang, Xian'en; Yang, Haitao; Guddat, Luke W.; Xu, Wenqing; Wang, Quan; Li, Jun; Besra, Gurdyal S.; Rao, Zihe</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">6496</span>),
    <span class="NLM_cas:pages">1211-1219</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The arabinosyltransferases EmbA, EmbB, and EmbC are involved in Mycobacterium tuberculosis cell wall synthesis and are recognized as targets for the anti-tuberculosis drug ethambutol.  In this study, we detd. cryo-electron microscopy and x-ray crystal structures of mycobacterial EmbA-EmbB and EmbC-EmbC complexes in the presence of their glycosyl donor and acceptor substrates and with ethambutol.  These structures show how the donor and acceptor substrates bind in the active site and how ethambutol inhibits arabinosyltransferases by binding to the same site as both substrates in EmbB and EmbC.  Most drug-resistant mutations are located near the ethambutol binding site.  Collectively, our work provides a structural basis for understanding the biochem. function and inhibition of arabinosyltransferases and the development of new anti-tuberculosis agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5khIQiLZo9bVg90H21EOLACvtfcHk0ljo0-UI-9YgtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGitLbP&md5=c88215a3978210ef889d8042f9729f48</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1126%2Fscience.aba9102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aba9102%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DGurcha%26aufirst%3DS.%2BS.%26aulast%3DVeerapen%26aufirst%3DN.%26aulast%3DBatt%26aufirst%3DS.%2BM.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DBi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%2Be.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DGuddat%26aufirst%3DL.%2BW.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DRao%26aufirst%3DZ.%26atitle%3DStructures%2520of%2520cell%2520wall%2520arabinosyltransferases%2520with%2520the%2520anti-tuberculosis%2520drug%2520ethambutol%26jtitle%3DScience%26date%3D2020%26volume%3D368%26spage%3D1211%26epage%3D1219%26doi%3D10.1126%2Fscience.aba9102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, K. L.</span></span> <span> </span><span class="NLM_article-title">Mutations within embCAB Are Associated with variable level of ethambutol resistance in Mycobacterium tuberculosis isolates from China</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">e01279-17</span>, <span class="refDoi"> DOI: 10.1128/AAC.01279-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.01279-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29084750" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&pages=e01279-17&author=Q.+Sunauthor=T.+Y.+Xiaoauthor=H.+C.+Liuauthor=X.+Q.+Zhaoauthor=Z.+G.+Liuauthor=Y.+N.+Liauthor=H.+Zengauthor=L.+L.+Zhaoauthor=K.+L.+Wan&title=Mutations+within+embCAB+Are+Associated+with+variable+level+of+ethambutol+resistance+in+Mycobacterium+tuberculosis+isolates+from+China&doi=10.1128%2FAAC.01279-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1128%2FAAC.01279-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01279-17%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DXiao%26aufirst%3DT.%2BY.%26aulast%3DLiu%26aufirst%3DH.%2BC.%26aulast%3DZhao%26aufirst%3DX.%2BQ.%26aulast%3DLiu%26aufirst%3DZ.%2BG.%26aulast%3DLi%26aufirst%3DY.%2BN.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DL.%2BL.%26aulast%3DWan%26aufirst%3DK.%2BL.%26atitle%3DMutations%2520within%2520embCAB%2520Are%2520Associated%2520with%2520variable%2520level%2520of%2520ethambutol%2520resistance%2520in%2520Mycobacterium%2520tuberculosis%2520isolates%2520from%2520China%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26spage%3De01279-17%26doi%3D10.1128%2FAAC.01279-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winder, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, D.</span></span> <span> </span><span class="NLM_article-title">Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG</span>. <i>J. Gen. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">1971</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1099/00221287-66-3-379</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1099%2F00221287-66-3-379" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=4999216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaE3MXltVKmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1971&pages=379-380&author=F.+G.+Winderauthor=P.+B.+Collinsauthor=D.+Whelan&title=Effects+of+ethionamide+and+isoxyl+on+mycolic+acid+synthesis+in+Mycobacterium+tuberculosis+BCG&doi=10.1099%2F00221287-66-3-379"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG</span></div><div class="casAuthors">Winder, F. G.; Collins, P. B.; Whelan, Dolores</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Microbiology</span>
        (<span class="NLM_cas:date">1971</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">Pt. 3</span>),
    <span class="NLM_cas:pages">379-80</span>CODEN:
                <span class="NLM_cas:coden">JGMIAN</span>;
        ISSN:<span class="NLM_cas:issn">0022-1287</span>.
    </div><div class="casAbstract">The specific antituberculosis agents isoniazid, ethionamide (α-ethylisonicotinoylthioamide), and Isoxyl (4,4'-diisoamyloxythiocarbanilide) (I) have a marked inhibitory effect on mycolic acid synthesis in Mycobacterium tuberculosis BCG, though in the case of I more widespread inhibitory effects were seen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo_4BqOHGBH7Vg90H21EOLACvtfcHk0lgcfbGqUijeLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3MXltVKmtbc%253D&md5=f386944ef50034d8623df8ee65029209</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1099%2F00221287-66-3-379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252F00221287-66-3-379%26sid%3Dliteratum%253Aachs%26aulast%3DWinder%26aufirst%3DF.%2BG.%26aulast%3DCollins%26aufirst%3DP.%2BB.%26aulast%3DWhelan%26aufirst%3DD.%26atitle%3DEffects%2520of%2520ethionamide%2520and%2520isoxyl%2520on%2520mycolic%2520acid%2520synthesis%2520in%2520Mycobacterium%2520tuberculosis%2520BCG%26jtitle%3DJ.%2520Gen.%2520Microbiol.%26date%3D1971%26volume%3D66%26spage%3D379%26epage%3D380%26doi%3D10.1099%2F00221287-66-3-379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubnau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quemard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Um, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lisle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1126/science.8284673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1126%2Fscience.8284673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=8284673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK2cXhsFylt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=227-230&author=A.+Banerjeeauthor=E.+Dubnauauthor=A.+Quemardauthor=V.+Balasubramanianauthor=K.+S.+Umauthor=T.+Wilsonauthor=D.+Collinsauthor=G.+de+Lisleauthor=W.+R.+Jacobs&title=inhA%2C+a+gene+encoding+a+target+for+isoniazid+and+ethionamide+in+Mycobacterium+tuberculosis&doi=10.1126%2Fscience.8284673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis</span></div><div class="casAuthors">Banerjee, Asesh; Dubnau, Eugenie; Quemard, Annaik; Balasubramanian, V.; Um, Kyung Sun; Wilson, Theresa; Collins, Des; de Lisle, Geoffrey; Jacobs, William, R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5144</span>),
    <span class="NLM_cas:pages">227-30</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Isoniazid (isonicotinic acid hydrazide, INH) is one of the most widely used antituberculosis drugs, yet its precise target of action on Mycobacterium tuberculosis is unknown.  A missense mutation within the mycobacterial inhA gene was shown to confer resistance to both INH and ethionamide (ETH) in M. smegmatis and in M. bovis.  The wild-type inhA gene also conferred INH and ETH resistance when transferred on a multicopy plasmid vector to M. smegmatis and M. bovis BCG.  The InhA protein shows a significant sequence conservation with the Escherichia coli enzyme EnvM, and cell-free assays indicate that it may be involved in mycolic acid biosynthesis.  These results suggest that InhA is likely a primary target of action for INH and ETH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUYkDS4hfHFrVg90H21EOLACvtfcHk0lgcfbGqUijeLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhsFylt7c%253D&md5=12f3eabbca02009180332c1e65db8c15</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1126%2Fscience.8284673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8284673%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DA.%26aulast%3DDubnau%26aufirst%3DE.%26aulast%3DQuemard%26aufirst%3DA.%26aulast%3DBalasubramanian%26aufirst%3DV.%26aulast%3DUm%26aufirst%3DK.%2BS.%26aulast%3DWilson%26aufirst%3DT.%26aulast%3DCollins%26aufirst%3DD.%26aulast%3Dde%2BLisle%26aufirst%3DG.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26atitle%3DinhA%252C%2520a%2520gene%2520encoding%2520a%2520target%2520for%2520isoniazid%2520and%2520ethionamide%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D227%26epage%3D230%26doi%3D10.1126%2Fscience.8284673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilchèze, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazbón, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colangeli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisbrod, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1029</span>, <span class="refDoi"> DOI: 10.1038/nm1466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnm1466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=16906155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD28XptFClur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1027-1029&author=C.+Vilch%C3%A8zeauthor=F.+Wangauthor=M.+Araiauthor=M.+H.+Hazb%C3%B3nauthor=R.+Colangeliauthor=L.+Kremerauthor=T.+R.+Weisbrodauthor=D.+Allandauthor=J.+C.+Sacchettiniauthor=W.+R.+Jacobs&title=Transfer+of+a+point+mutation+in+Mycobacterium+tuberculosis+inhA+resolves+the+target+of+isoniazid&doi=10.1038%2Fnm1466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid</span></div><div class="casAuthors">Vilcheze, Catherine; Wang, Feng; Arai, Masayoshi; Hazbon, Manzour Hernando; Colangeli, Roberto; Kremer, Laurent; Weisbrod, Torin R.; Alland, David; Sacchettini, James C.; Jacobs, William R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1027-1029</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Isoniazid is one of the most effective antituberculosis drugs, yet its precise mechanism of action is still controversial.  Using specialized linkage transduction, a single point mutation allele (S94A) within the putative target gene inhA was transferred in Mycobacterium tuberculosis.  The inhA(S94A) allele was sufficient to confer clin. relevant levels of resistance to isoniazid killing and inhibition of mycolic acid biosynthesis.  This resistance correlated with the decreased binding of the INH-NAD inhibitor to InhA, as shown by enzymic and x-ray crystallog. analyses, and establishes InhA as the primary target of isoniazid action in M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUU2WBcC1SIbVg90H21EOLACvtfcHk0lgcfbGqUijeLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptFClur4%253D&md5=85ae8a98134d187b7c9f96d392589250</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1038%2Fnm1466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1466%26sid%3Dliteratum%253Aachs%26aulast%3DVilch%25C3%25A8ze%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DArai%26aufirst%3DM.%26aulast%3DHazb%25C3%25B3n%26aufirst%3DM.%2BH.%26aulast%3DColangeli%26aufirst%3DR.%26aulast%3DKremer%26aufirst%3DL.%26aulast%3DWeisbrod%26aufirst%3DT.%2BR.%26aulast%3DAlland%26aufirst%3DD.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26atitle%3DTransfer%2520of%2520a%2520point%2520mutation%2520in%2520Mycobacterium%2520tuberculosis%2520inhA%2520resolves%2520the%2520target%2520of%2520isoniazid%26jtitle%3DNat.%2520Med.%26date%3D2006%26volume%3D12%26spage%3D1027%26epage%3D1029%26doi%3D10.1038%2Fnm1466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baulard, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betts, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engohang-Ndong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAdam, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span> <span> </span><span class="NLM_article-title">Activation of the pro-drug ethionamide is regulated in mycobacteria</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">28326</span>– <span class="NLM_lpage">28331</span>, <span class="refDoi"> DOI: 10.1074/jbc.M003744200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1074%2Fjbc.M003744200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10869356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsVKktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=28326-28331&author=A.+R.+Baulardauthor=J.+C.+Bettsauthor=J.+Engohang-Ndongauthor=S.+Quanauthor=R.+A.+McAdamauthor=P.+J.+Brennanauthor=C.+Lochtauthor=G.+S.+Besra&title=Activation+of+the+pro-drug+ethionamide+is+regulated+in+mycobacteria&doi=10.1074%2Fjbc.M003744200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the pro-drug ethionamide is regulated in mycobacteria</span></div><div class="casAuthors">Baulard, Alain R.; Betts, Joanna C.; Engohang-Ndong, Jean; Quan, Selwyn; McAdam, Ruth A.; Brennan, Patrick J.; Locht, Camille; Besra, Gurdyal S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">28326-28331</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The anti-tuberculosis drug ethionamide (ETH), which is a structural analog of isoniazid (INH), is known to strongly inhibit mycolic acid synthesis in Mycobacterium tuberculosis.  Although several targets have been identified for INH, only speculative information is available concerning ETH.  Mutations within the promoter and the coding region of enoyl-acyl carrier protein reductase (InhA) were found to confer resistance to both drugs, thus leading to the impression that INH and ETH may share a common mode of action.  However, a notable distinction between the two drugs lies in the lack of cross-resistance in clin. isolates.  This may be attributed in part to the fact that the pro-drug INH must be activated via KatG, and no activation step for ETH has yet been described.  Here, the authors report the identification of an activator for ETH.  The ETH activator (Rv3854c), which was termed EthA, was found to be homologous to various monooxygenases, and it induced ETH sensitivity when overexpressed in mycobacteria.  The neighboring open reading frame (Rv3855), which was homologous to transcriptional repressors of the tetR family, led to ETH resistance when overexpressed.  In addn., chromosomal inactivation of this gene by transposition led to ETH hypersensitivity.  These data strongly suggest that Rv3855, which was termed EthR, regulates the prodn. of EthA, which subsequently activates the pro-drug ETH.  This study opens up new avenues of research relating to ETH activation in mycobacteria, possibly leading to an improved efficacy of ETH and to the generation of new anti-mycobacterial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0zG8FfdNt87Vg90H21EOLACvtfcHk0liVR9ymW8YW5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsVKktb4%253D&md5=63e05197e94511fc2d6e3062aa22e555</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M003744200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M003744200%26sid%3Dliteratum%253Aachs%26aulast%3DBaulard%26aufirst%3DA.%2BR.%26aulast%3DBetts%26aufirst%3DJ.%2BC.%26aulast%3DEngohang-Ndong%26aufirst%3DJ.%26aulast%3DQuan%26aufirst%3DS.%26aulast%3DMcAdam%26aufirst%3DR.%2BA.%26aulast%3DBrennan%26aufirst%3DP.%2BJ.%26aulast%3DLocht%26aufirst%3DC.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26atitle%3DActivation%2520of%2520the%2520pro-drug%2520ethionamide%2520is%2520regulated%2520in%2520mycobacteria%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D28326%26epage%3D28331%26doi%3D10.1074%2Fjbc.M003744200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vannelli, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dykman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz de
Montellano, P. R.</span></span> <span> </span><span class="NLM_article-title">The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">12824</span>– <span class="NLM_lpage">12829</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110751200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1074%2Fjbc.M110751200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=11823459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD38XivFSjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=12824-12829&author=T.+A.+Vannelliauthor=A.+Dykmanauthor=P.+R.+Ortiz+de%0AMontellano&title=The+antituberculosis+drug+ethionamide+is+activated+by+a+flavoprotein+monooxygenase&doi=10.1074%2Fjbc.M110751200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase</span></div><div class="casAuthors">Vannelli, Tommaso A.; Dykman, Alina; Ortiz De Montellano, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">12824-12829</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Ethionamide (ETA), a prodrug that must undergo metabolic activation to exert its cytotoxic effects, is a second line drug against tuberculosis, a disease that infects more than a third of the world's population.  It has been proposed, on the basis of genetic expts., that ETA is activated in Mycobacterium tuberculosis by the protein encoded by the gene Rv3854c.  We report here the expression, purifn., and characterization of the protein encoded by this gene.  Our results establish that the enzyme (EtaA) is an FAD-contg. enzyme that oxidizes ETA to the corresponding S-oxide.  The S-oxide, which has a similar biol. activity as ETA, is further oxidized by EtaA to 2-ethyl-4-amidopyridine, presumably via the unstable doubly oxidized sulfinic acid intermediate.  This flavoenzyme also oxidizes thiacetazone, thiobenzamide, and isothionicotinamide and thus is probably responsible, as suggested by the observation of crossover resistance, for the oxidative activation of other thioamide antitubercular drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-O-_9yb5f3bVg90H21EOLACvtfcHk0liVR9ymW8YW5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivFSjs7s%253D&md5=6e32c0c9ec979adb9a1f488ecb3fbd73</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110751200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110751200%26sid%3Dliteratum%253Aachs%26aulast%3DVannelli%26aufirst%3DT.%2BA.%26aulast%3DDykman%26aufirst%3DA.%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26atitle%3DThe%2520antituberculosis%2520drug%2520ethionamide%2520is%2520activated%2520by%2520a%2520flavoprotein%2520monooxygenase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D12824%26epage%3D12829%26doi%3D10.1074%2Fjbc.M110751200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fraaije, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamerbeek, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidekamp, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, D. B.</span></span> <span> </span><span class="NLM_article-title">The prodrug activator EtaA from Mycobacterium tuberculosis is a Baeyer-Villiger monooxygenase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">3354</span>– <span class="NLM_lpage">3360</span>, <span class="refDoi"> DOI: 10.1074/jbc.M307770200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1074%2Fjbc.M307770200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=14610090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlCgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=3354-3360&author=M.+W.+Fraaijeauthor=N.+M.+Kamerbeekauthor=A.+J.+Heidekampauthor=R.+Fortinauthor=D.+B.+Janssen&title=The+prodrug+activator+EtaA+from+Mycobacterium+tuberculosis+is+a+Baeyer-Villiger+monooxygenase&doi=10.1074%2Fjbc.M307770200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The Prodrug Activator EtaA from Mycobacterium tuberculosis Is a Baeyer-Villiger Monooxygenase</span></div><div class="casAuthors">Fraaije, Marco W.; Kamerbeek, Nanne M.; Heidekamp, Annelies J.; Fortin, Riccardo; Janssen, Dick B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3354-3360</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">EtaA is a newly identified FAD-contg. monooxygenase that is responsible for activation of several thioamide prodrugs in Mycobacterium tuberculosis.  It was found that purified EtaA displays a remarkably low activity with the antitubercular prodrug ethionamide.  As suggested by the presence of a Baeyer-Villiger monooxygenase sequence motif in the EtaA sequence, we have been able to identify a large no. of novel EtaA substrates.  It was discovered that the enzyme converts a wide range of ketones to the corresponding esters or lactones via a Baeyer-Villiger reaction, indicating that EtaA represents a Baeyer-Villiger monooxygenase.  With the exception of arom. ketones (phenylacetone and benzylacetone), long-chain ketones (e.g. 2-hexanone and 2-dodecanone) also are converted.  EtaA is also able to catalyze enantioselective sulfoxidn. of methyl-p-tolylsulfide.  Conversion of all of the identified substrates is relatively slow with typical kcat values of around 0.02 s-1.  The best substrate identified so far is phenylacetone (Km = 61 μM, kcat = 0.017 s-1).  Redox monitoring of the flavin cofactor during turnover of phenylacetone indicates that a step in the reductive half-reaction limits the rate of catalysis.  Intriguingly, EtaA activity could be increased by one order of magnitude by adding bovine serum albumin (BSA).  This reactivity and substrate acceptance-profiling study provides valuable information concerning this newly identified prodrug activator from M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHSYBRoyV0LLVg90H21EOLACvtfcHk0lhajCTA613vqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlCgtA%253D%253D&md5=86a43dff921bc702035ce3e21ef8640b</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M307770200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M307770200%26sid%3Dliteratum%253Aachs%26aulast%3DFraaije%26aufirst%3DM.%2BW.%26aulast%3DKamerbeek%26aufirst%3DN.%2BM.%26aulast%3DHeidekamp%26aufirst%3DA.%2BJ.%26aulast%3DFortin%26aufirst%3DR.%26aulast%3DJanssen%26aufirst%3DD.%2BB.%26atitle%3DThe%2520prodrug%2520activator%2520EtaA%2520from%2520Mycobacterium%2520tuberculosis%2520is%2520a%2520Baeyer-Villiger%2520monooxygenase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D3354%26epage%3D3360%26doi%3D10.1074%2Fjbc.M307770200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulten, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dover, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span> <span> </span><span class="NLM_article-title">Mechanism of thioamide drug action against tuberculosis and leprosy</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>204</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1084/jem.20062100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1084%2Fjem.20062100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=17227913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGjtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2007&pages=73-78&author=F.+Wangauthor=R.+Langleyauthor=G.+Gultenauthor=L.+G.+Doverauthor=G.+S.+Besraauthor=W.+R.+Jacobsauthor=J.+C.+Sacchettini&title=Mechanism+of+thioamide+drug+action+against+tuberculosis+and+leprosy&doi=10.1084%2Fjem.20062100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of thioamide drug action against tuberculosis and leprosy</span></div><div class="casAuthors">Wang, Feng; Langley, Robert; Gulten, Gulcin; Dover, Lynn G.; Besra, Gurdyal S.; Jacobs, William R., Jr.; Sacchettini, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-78</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Thioamide drugs, ethionamide (ETH) and prothionamide (PTH), are clin. effective in the treatment of Mycobacterium tuberculosis, M. leprae, and M. avium complex infections.  Although generally considered second-line drugs for tuberculosis, their use has increased considerably as the no. of multidrug-resistant and extensively drug-resistant tuberculosis cases continues to rise.  Despite the widespread use of thioamide drugs to treat tuberculosis and leprosy, their precise mechanisms of action remain unknown.  Using a cell-based activation method, there is now definitive evidence that both thioamides form covalent adducts with NAD and that these adducts are tight-binding inhibitors of M. tuberculosis and M. leprae InhA.  The crystal structures of the inhibited M. leprae and M. tuberculosis InhA complexes provide the mol. details of target-drug interactions.  The purified ETH-NAD and PTH-NAD adducts both showed nanomolar Kis against M. tuberculosis and M. leprae InhA.  Knowledge of the precise structures and mechanisms of action of these drugs provides insights into designing new drugs that can overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhbBkdGr5bkbVg90H21EOLACvtfcHk0lhajCTA613vqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGjtr8%253D&md5=5486bc51cc5c4ea2ebdf6939984d1b70</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1084%2Fjem.20062100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20062100%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLangley%26aufirst%3DR.%26aulast%3DGulten%26aufirst%3DG.%26aulast%3DDover%26aufirst%3DL.%2BG.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26atitle%3DMechanism%2520of%2520thioamide%2520drug%2520action%2520against%2520tuberculosis%2520and%2520leprosy%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2007%26volume%3D204%26spage%3D73%26epage%3D78%26doi%3D10.1084%2Fjem.20062100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frénois, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engohang-Ndong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulard, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeret, V.</span></span> <span> </span><span class="NLM_article-title">Structure of EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">307</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2004.09.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.molcel.2004.09.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=15494316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWit7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2004&pages=301-307&author=F.+Fr%C3%A9noisauthor=J.+Engohang-Ndongauthor=C.+Lochtauthor=A.+R.+Baulardauthor=V.+Villeret&title=Structure+of+EthR+in+a+ligand+bound+conformation+reveals+therapeutic+perspectives+against+tuberculosis&doi=10.1016%2Fj.molcel.2004.09.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis</span></div><div class="casAuthors">Frenois, Frederic; Engohang-Ndong, Jean; Locht, Camille; Baulard, Alain R.; Villeret, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">301-307</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis EthR is a repressor of ethA, a gene encoding a monooxygenase required for the activation of the prodrug ethionamide.  Here the authors describe the x-ray crystal structure of EthR, a homodimer with an entirely helical structure showing similarities to TetR family members.  Each monomer contained a fortuitous ligand identified as hexadecyl octanoate.  The crystal structure of EthR purified in M. smegmatis revealed the presence of a comparable ligand.  The binding of hexadecyl octanoate to EthR induces a conformational state incompatible with repressor function, which should lead to ethA derepression and consequently to an increased sensitivity to ethionamide and other thioamides.  A related, more hydrophilic ketone was found to exhibit synergistic antimycobacterial effects when tested together with ethionamide, indicating that this strategy may help reduce the dosage of potent antibacterial compds. that otherwise are too toxic to be used as first-line drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGEtaas9rcXbVg90H21EOLACvtfcHk0ljaMNeIBZ5_4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWit7rO&md5=45b96e9298438bf8a7be8d63bd2a943e</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.09.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.09.020%26sid%3Dliteratum%253Aachs%26aulast%3DFr%25C3%25A9nois%26aufirst%3DF.%26aulast%3DEngohang-Ndong%26aufirst%3DJ.%26aulast%3DLocht%26aufirst%3DC.%26aulast%3DBaulard%26aufirst%3DA.%2BR.%26aulast%3DVilleret%26aufirst%3DV.%26atitle%3DStructure%2520of%2520EthR%2520in%2520a%2520ligand%2520bound%2520conformation%2520reveals%2520therapeutic%2520perspectives%2520against%2520tuberculosis%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D16%26spage%3D301%26epage%3D307%26doi%3D10.1016%2Fj.molcel.2004.09.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willand, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirié, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carette, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desroses, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willery, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathys, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Déprez-Poulain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcroix, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frénois, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aumercier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeret, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Déprez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulard, A. R.</span></span> <span> </span><span class="NLM_article-title">Synthetic EthR inhibitors boost antituberculous activity of ethionamide</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1038/nm.1950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnm.1950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19412174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltlSrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=537-544&author=N.+Willandauthor=B.+Diri%C3%A9author=X.+Caretteauthor=P.+Bifaniauthor=A.+Singhalauthor=M.+Desrosesauthor=F.+Lerouxauthor=E.+Willeryauthor=V.+Mathysauthor=R.+D%C3%A9prez-Poulainauthor=G.+Delcroixauthor=F.+Fr%C3%A9noisauthor=M.+Aumercierauthor=C.+Lochtauthor=V.+Villeretauthor=B.+D%C3%A9prezauthor=A.+R.+Baulard&title=Synthetic+EthR+inhibitors+boost+antituberculous+activity+of+ethionamide&doi=10.1038%2Fnm.1950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic EthR inhibitors boost antituberculous activity of ethionamide</span></div><div class="casAuthors">Willand, Nicolas; Dirie, Bertrand; Carette, Xavier; Bifani, Pablo; Singhal, Amit; Desroses, Matthieu; Leroux, Florence; Willery, Eve; Mathys, Vanessa; Deprez-Poulain, Rebecca; Delcroix, Guy; Frenois, Frederic; Aumercier, Marc; Locht, Camille; Villeret, Vincent; Deprez, Benoit; Baulard, Alain R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">537-544</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The side effects assocd. with tuberculosis therapy bring with them the risk of noncompliance and subsequent drug resistance.  Increasing the therapeutic index of antituberculosis drugs should thus improve treatment effectiveness.  Several antituberculosis compds. require in situ metabolic activation to become inhibitory.  Various thiocarbamide-contg. drugs, including ethionamide, are activated by the mycobacterial monooxygenase EthA, the prodn. of which is controlled by the transcriptional repressor EthR.  Here we identify drug-like inhibitors of EthR that boost the bioactivation of ethionamide.  Compds. designed and screened for their capacity to inhibit EthR-DNA interaction were co-crystd. with EthR.  We exploited the three-dimensional structures of the complexes for the synthesis of improved analogs that boosted the ethionamide potency in culture more than tenfold.  In Mycobacterium tuberculosis-infected mice, one of these analogs, BDM31343, enabled a substantially reduced dose of ethionamide to lessen the mycobacterial load as efficiently as the conventional higher-dose treatment.  This provides proof of concept that inhibiting EthR improves the therapeutic index of thiocarbamide derivs., which should prompt reconsideration of their use as first-line drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgknfO8azsTrVg90H21EOLACvtfcHk0ljaMNeIBZ5_4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltlSrsLk%253D&md5=a119c8e00d9cd41bfa34c2e056e4a1ad</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1038%2Fnm.1950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.1950%26sid%3Dliteratum%253Aachs%26aulast%3DWilland%26aufirst%3DN.%26aulast%3DDiri%25C3%25A9%26aufirst%3DB.%26aulast%3DCarette%26aufirst%3DX.%26aulast%3DBifani%26aufirst%3DP.%26aulast%3DSinghal%26aufirst%3DA.%26aulast%3DDesroses%26aufirst%3DM.%26aulast%3DLeroux%26aufirst%3DF.%26aulast%3DWillery%26aufirst%3DE.%26aulast%3DMathys%26aufirst%3DV.%26aulast%3DD%25C3%25A9prez-Poulain%26aufirst%3DR.%26aulast%3DDelcroix%26aufirst%3DG.%26aulast%3DFr%25C3%25A9nois%26aufirst%3DF.%26aulast%3DAumercier%26aufirst%3DM.%26aulast%3DLocht%26aufirst%3DC.%26aulast%3DVilleret%26aufirst%3DV.%26aulast%3DD%25C3%25A9prez%26aufirst%3DB.%26aulast%3DBaulard%26aufirst%3DA.%2BR.%26atitle%3DSynthetic%2520EthR%2520inhibitors%2520boost%2520antituberculous%2520activity%2520of%2520ethionamide%26jtitle%3DNat.%2520Med.%26date%3D2009%26volume%3D15%26spage%3D537%26epage%3D544%26doi%3D10.1038%2Fnm.1950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blondiaux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moune, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desroses, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frita, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flipo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathys, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soetaert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delorme, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaout, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trebosc, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wintjens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlkönig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coscolla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagneux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitzinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Déprez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willand, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulard, A. R.</span></span> <span> </span><span class="NLM_article-title">Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1206</span>– <span class="NLM_lpage">1211</span>, <span class="refDoi"> DOI: 10.1126/science.aag1006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1126%2Fscience.aag1006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28302858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFOmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2017&pages=1206-1211&author=N.+Blondiauxauthor=M.+Mouneauthor=M.+Desrosesauthor=R.+Fritaauthor=M.+Flipoauthor=V.+Mathysauthor=K.+Soetaertauthor=M.+Kiassauthor=V.+Delormeauthor=K.+Djaoutauthor=V.+Treboscauthor=C.+Kemmerauthor=R.+Wintjensauthor=A.+Wohlk%C3%B6nigauthor=R.+Antoineauthor=L.+Huotauthor=D.+Hotauthor=M.+Coscollaauthor=J.+Feldmannauthor=S.+Gagneuxauthor=C.+Lochtauthor=P.+Brodinauthor=M.+Gitzingerauthor=B.+D%C3%A9prezauthor=N.+Willandauthor=A.+R.+Baulard&title=Reversion+of+antibiotic+resistance+in+Mycobacterium+tuberculosis+by+spiroisoxazoline+SMARt-420&doi=10.1126%2Fscience.aag1006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420</span></div><div class="casAuthors">Blondiaux, Nicolas; Moune, Martin; Desroses, Matthieu; Frita, Rosangela; Flipo, Marion; Mathys, Vanessa; Soetaert, Karine; Kiass, Mehdi; Delorme, Vincent; Djaout, Kamel; Trebosc, Vincent; Kemmer, Christian; Wintjens, Rene; Wohlkoenig, Alexandre; Antoine, Rudy; Huot, Ludovic; Hot, David; Coscolla, Mireia; Feldmann, Julia; Gagneux, Sebastien; Locht, Camille; Brodin, Priscille; Gitzinger, Marc; Deprez, Benoit; Willand, Nicolas; Baulard, Alain R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">6330</span>),
    <span class="NLM_cas:pages">1206-1211</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Antibiotic resistance is one of the biggest threats to human health globally.  Alarmingly, multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis have now spread worldwide.  Some key antituberculosis antibiotics are prodrugs, for which resistance mechanisms are mainly driven by mutations in the bacterial enzymic pathway required for their bioactivation.  We have developed drug-like mols. that activate a cryptic alternative bioactivation pathway of ethionamide in M. tuberculosis, circumventing the classic activation pathway in which resistance mutations have now been obsd.  The first-of-its-kind mol., named SMARt-420 (Small Mol. Aborting Resistance), not only fully reverses ethionamide-acquired resistance and clears ethionamide-resistant infection in mice, it also increases the basal sensitivity of bacteria to ethionamide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKt256e9hpk7Vg90H21EOLACvtfcHk0lja5ulUXy4ORg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFOmsb0%253D&md5=7eb7abaead0794592bc48d6e5e25fc3d</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1126%2Fscience.aag1006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aag1006%26sid%3Dliteratum%253Aachs%26aulast%3DBlondiaux%26aufirst%3DN.%26aulast%3DMoune%26aufirst%3DM.%26aulast%3DDesroses%26aufirst%3DM.%26aulast%3DFrita%26aufirst%3DR.%26aulast%3DFlipo%26aufirst%3DM.%26aulast%3DMathys%26aufirst%3DV.%26aulast%3DSoetaert%26aufirst%3DK.%26aulast%3DKiass%26aufirst%3DM.%26aulast%3DDelorme%26aufirst%3DV.%26aulast%3DDjaout%26aufirst%3DK.%26aulast%3DTrebosc%26aufirst%3DV.%26aulast%3DKemmer%26aufirst%3DC.%26aulast%3DWintjens%26aufirst%3DR.%26aulast%3DWohlk%25C3%25B6nig%26aufirst%3DA.%26aulast%3DAntoine%26aufirst%3DR.%26aulast%3DHuot%26aufirst%3DL.%26aulast%3DHot%26aufirst%3DD.%26aulast%3DCoscolla%26aufirst%3DM.%26aulast%3DFeldmann%26aufirst%3DJ.%26aulast%3DGagneux%26aufirst%3DS.%26aulast%3DLocht%26aufirst%3DC.%26aulast%3DBrodin%26aufirst%3DP.%26aulast%3DGitzinger%26aufirst%3DM.%26aulast%3DD%25C3%25A9prez%26aufirst%3DB.%26aulast%3DWilland%26aufirst%3DN.%26aulast%3DBaulard%26aufirst%3DA.%2BR.%26atitle%3DReversion%2520of%2520antibiotic%2520resistance%2520in%2520Mycobacterium%2520tuberculosis%2520by%2520spiroisoxazoline%2520SMARt-420%26jtitle%3DScience%26date%3D2017%26volume%3D355%26spage%3D1206%26epage%3D1211%26doi%3D10.1126%2Fscience.aag1006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frita, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Probst, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sournia-Saquet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Déprez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulard, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willand, N.</span></span> <span> </span><span class="NLM_article-title">Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.09.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.ejmech.2018.09.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30268015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVejsrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2018&pages=35-46&author=M.+Prieriauthor=R.+Fritaauthor=N.+Probstauthor=A.+Sournia-Saquetauthor=M.+Bourotteauthor=B.+D%C3%A9prezauthor=A.+R.+Baulardauthor=N.+Willand&title=Efficient+analoging+around+ethionamide+to+explore+thioamides+bioactivation+pathways+triggered+by+boosters+in+Mycobacterium+tuberculosis&doi=10.1016%2Fj.ejmech.2018.09.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis</span></div><div class="casAuthors">Prieri, Marion; Frita, Rosangela; Probst, Nicolas; Sournia-Saquet, Alix; Bourotte, Marilyne; Deprez, Benoit; Baulard, Alain R.; Willand, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-46</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Ethionamide is a key antibiotic prodrug of the second-line chemotherapy regimen to treat tuberculosis.  It targets the biosynthesis of mycolic acids thanks to a mycobacterial bioactivation carried out by the Baeyer-Villiger monooxygenase EthA, under the control of a transcriptional repressor called EthR.  Recently, the drug-like mol. SMARt-420, which triggers a new transcriptional regulator called EthR2, allowed the derepression a cryptic alternative bioactivation pathway of ethionamide.  In order to study the bioactivation of a collection of thioisonicotinamides through the two bioactivation pathways, we developed a new two-step chem. pathway that led to the efficient synthesis of eighteen ethionamide analogs.  Measurements of the antimycobacterial activity of these derivs., used alone and in combination with boosters BDM41906 or SMARt-420, suggest that the two different bioactivation pathways proceed via the same mechanism, which implies the formation of similar metabolites.  In addn., an electrochem. study of the aliph. thioisonicotinamide analogs was undertaken to see whether their oxidn. potential correlates with their antitubercular activity measured in the presence or in the absence of the two boosters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCNYtCoqieFLVg90H21EOLACvtfcHk0lja5ulUXy4ORg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVejsrrF&md5=de4e0bc54021b3221472fc96db8ccc26</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.09.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.09.038%26sid%3Dliteratum%253Aachs%26aulast%3DPrieri%26aufirst%3DM.%26aulast%3DFrita%26aufirst%3DR.%26aulast%3DProbst%26aufirst%3DN.%26aulast%3DSournia-Saquet%26aufirst%3DA.%26aulast%3DBourotte%26aufirst%3DM.%26aulast%3DD%25C3%25A9prez%26aufirst%3DB.%26aulast%3DBaulard%26aufirst%3DA.%2BR.%26aulast%3DWilland%26aufirst%3DN.%26atitle%3DEfficient%2520analoging%2520around%2520ethionamide%2520to%2520explore%2520thioamides%2520bioactivation%2520pathways%2520triggered%2520by%2520boosters%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D159%26spage%3D35%26epage%3D46%26doi%3D10.1016%2Fj.ejmech.2018.09.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowd, C. S.</span></span> <span> </span><span class="NLM_article-title">Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3239</span>– <span class="NLM_lpage">3262</span>, <span class="refDoi"> DOI: 10.2174/1381612043383214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.2174%2F1381612043383214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=15544513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFart7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=3239-3262&author=C.+E.+Barryauthor=H.+I.+Boshoffauthor=C.+S.+Dowd&title=Prospects+for+clinical+introduction+of+nitroimidazole+antibiotics+for+the+treatment+of+tuberculosis&doi=10.2174%2F1381612043383214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis</span></div><div class="casAuthors">Barry, Clifton E., III; Boshoff, Helena I. M.; Dowd, Cynthia S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3239-3262</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Nitroarom. antibiotics have a long and controversial history in human and veterinary medicine.  This controversy lies behind the presumption of many pharmaceutical companies that nitroarom. compds. should be filtered from the list of drug-like compds. but stands at odds with the remarkably safe clin. record of use of such compds.  In this review, the authors will describe the whole-cell structure-activity relationships that have been reported for antimycobacterial nitroimidazoles as well as the available in vivo data supporting efficacy with a particular emphasis on nitroimidazo[2,1-b]oxazines such as PA-824.  The authors will also explore the unique potential of such compds. to shorten the course of tuberculosis therapy by exerting a bactericidal effect on non-replicating bacilli.  The authors will consider the mode of action of such compds. in sensitive organisms and discuss the mechanisms by which resistance may emerge.  Finally, the authors will review the pharmacokinetics, toxicol., and lab. and animal studies linking nitroimidazoles with carcinogenicity and mutagenicity and assess the prospects for the clin. introduction of nitroimidazoles for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH8MsPQNEOOLVg90H21EOLACvtfcHk0lja5ulUXy4ORg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFart7w%253D&md5=38a152ebbd73d1adbd21cadb493393cc</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.2174%2F1381612043383214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612043383214%26sid%3Dliteratum%253Aachs%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DDowd%26aufirst%3DC.%2BS.%26atitle%3DProspects%2520for%2520clinical%2520introduction%2520of%2520nitroimidazole%2520antibiotics%2520for%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2004%26volume%3D10%26spage%3D3239%26epage%3D3262%26doi%3D10.2174%2F1381612043383214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skripconoka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danilovits, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pehme, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skenders, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirule, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leimane, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurve, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiter, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manissero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span> <span> </span><span class="NLM_article-title">Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1183/09031936.00125812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1183%2F09031936.00125812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23018916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252Fgsl2ltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=1393-400&author=V.+Skripconokaauthor=M.+Danilovitsauthor=L.+Pehmeauthor=T.+Tomsonauthor=G.+Skendersauthor=T.+Kummikauthor=A.+Ciruleauthor=V.+Leimaneauthor=A.+Kurveauthor=K.+Levinaauthor=L.+J.+Geiterauthor=D.+Manisseroauthor=C.+D.+Wells&title=Delamanid+improves+outcomes+and+reduces+mortality+in+multidrug-resistant+tuberculosis&doi=10.1183%2F09031936.00125812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis</span></div><div class="casAuthors">Skripconoka Vija; Danilovits Manfred; Pehme Lea; Tomson Tarmo; Skenders Girts; Kummik Tiina; Cirule Andra; Leimane Vaira; Kurve Anu; Levina Klavdia; Geiter Lawrence J; Manissero Davide; Wells Charles D</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1393-400</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are associated with worse treatment outcomes for patients, including higher mortality, than for drug-sensitive tuberculosis.  Delamanid (OPC-67683) is a novel anti-TB medication with demonstrated activity against multidrug-resistant disease.  Patients who participated in the previously reported randomised, placebo-controlled trial of delamanid and the subsequent open-label extension trial were eligible to participate in a 24-month observational study designed to capture treatment outcomes.  Treatment outcomes, as assessed by clinicians and defined by the World Health Organization, were categorised as favourable and unfavourable.  Delamanid treatment groups were combined for analysis, based on their duration of treatment.  In total, for 421 (87.5%) out of 481 patients from the original randomised controlled trial, consent was granted for follow-up assessments.  Favourable outcomes were observed in 143 (74.5%) out of 192 patients who received delamanid for ≥6 months, compared to 126 (55%) out of 229 patients who received delamanid for ≤2 months.  Mortality was reduced to 1.0% among those receiving long-term delamanid versus short-term/no delamanid (8.3%; p<0.001).  Treatment benefit was also seen among patients with extensively drug-resistant TB.  This analysis suggests that treatment with delamanid for 6 months in combination with an optimised background regimen can improve outcomes and reduce mortality among patients with both multidrug-resistant and extensively drug-resistant TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2JcitGJjjkMNIRw0GKUoEfW6udTcc2eb13nSoYtrKubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252Fgsl2ltw%253D%253D&md5=63c616aef7dfd5858d274fe1a74ab290</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1183%2F09031936.00125812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00125812%26sid%3Dliteratum%253Aachs%26aulast%3DSkripconoka%26aufirst%3DV.%26aulast%3DDanilovits%26aufirst%3DM.%26aulast%3DPehme%26aufirst%3DL.%26aulast%3DTomson%26aufirst%3DT.%26aulast%3DSkenders%26aufirst%3DG.%26aulast%3DKummik%26aufirst%3DT.%26aulast%3DCirule%26aufirst%3DA.%26aulast%3DLeimane%26aufirst%3DV.%26aulast%3DKurve%26aufirst%3DA.%26aulast%3DLevina%26aufirst%3DK.%26aulast%3DGeiter%26aufirst%3DL.%2BJ.%26aulast%3DManissero%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DC.%2BD.%26atitle%3DDelamanid%2520improves%2520outcomes%2520and%2520reduces%2520mortality%2520in%2520multidrug-resistant%2520tuberculosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D41%26spage%3D1393%26epage%3D400%26doi%3D10.1183%2F09031936.00125812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conradie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngubane, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everitt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crook, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendel, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egizi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Treatment of highly drug-resistant pulmonary tuberculosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">893</span>– <span class="NLM_lpage">902</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1901814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1056%2FNEJMoa1901814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=32130813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVKrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=893-902&author=F.+Conradieauthor=A.+H.+Diaconauthor=N.+Ngubaneauthor=P.+Howellauthor=D.+Everittauthor=A.+M.+Crookauthor=C.+M.+Mendelauthor=E.+Egiziauthor=J.+Moreiraauthor=J.+Timm&title=Treatment+of+highly+drug-resistant+pulmonary+tuberculosis&doi=10.1056%2FNEJMoa1901814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of highly drug-resistant pulmonary tuberculosis</span></div><div class="casAuthors">Conradie, Francesca; Diacon, Andreas H.; Ngubane, Nosipho; Howell, Pauline; Everitt, Daniel; Crook, Angela M.; Mendel, Carl M.; Egizi, Erica; Moreira, Joanna; Timm, Juliano; McHugh, Timothy D.; Wills, Genevieve H.; Bateson, Anna; Hunt, Robert; Van Niekerk, Christo; Li, Mengchun; Olugbosi, Morounfolu; Spigelman, Melvin</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">893-902</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes. methods In an open-label, single-group study in which follow-up is ongoing at three South African sites, we investigated treatment with three oral drugs - bedaquiline, pretomanid, and linezolid - that have bactericidal activity against tuberculosis and to which there is little preexisting resistance.  We evaluated the safety and efficacy of the drug combination for 26 wk in patients with extensively drug-resistant tuberculosis and patients with multidrug-resistant tuberculosis that was not responsive to treatment or for which a second-line regimen had been discontinued because of side effects.  The primary end point was the incidence of an unfavorable outcome, defined as treatment failure (bacteriol. or clin.) or relapse during follow-up, which continued until 6 mo after the end of treatment.  Patients were classified as having a favorable outcome at 6 mo if they had resoln. of clin. disease, a neg. culture status, and had not already been classified as having had an unfavorable outcome.  Other efficacy end points and safety were also evaluated. results A total of 109 patients were enrolled in the study and were included in the evaluation of efficacy and safety end points.  At 6 mo after the end of treatment in the intention-to-treat anal., 11 patients (10%) had an unfavorable outcome and 98 patients (90%; 95% confidence interval, 83 to 95) had a favorable outcome.  The 11 unfavorable outcomes were 7 deaths (6 during treatment and 1 from an unknown cause during follow-up), 1 withdrawal of consent during treatment, 2 relapses during follow-up, and 1 loss to follow-up.  The expected linezolid toxic effects of peripheral neuropathy (occurring in 81% of patients) and myelosuppression (48%), although common, were manageable, often leading to dose redns. or interruptions in treatment with linezolid. conclusions The combination of bedaquiline, pretomanid, and linezolid led to a favorable outcome at 6 mo after the end of therapy in a high percentage of patients with highly drug-resistant forms of tuberculosis; some assocd. toxic effects were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoagq93PXO5qrVg90H21EOLACvtfcHk0lhAQBXna8JWJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVKrsb0%253D&md5=e7210ad01d84d5c99708cdd124a29145</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1901814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1901814%26sid%3Dliteratum%253Aachs%26aulast%3DConradie%26aufirst%3DF.%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DNgubane%26aufirst%3DN.%26aulast%3DHowell%26aufirst%3DP.%26aulast%3DEveritt%26aufirst%3DD.%26aulast%3DCrook%26aufirst%3DA.%2BM.%26aulast%3DMendel%26aufirst%3DC.%2BM.%26aulast%3DEgizi%26aufirst%3DE.%26aulast%3DMoreira%26aufirst%3DJ.%26aulast%3DTimm%26aufirst%3DJ.%26atitle%3DTreatment%2520of%2520highly%2520drug-resistant%2520pulmonary%2520tuberculosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D893%26epage%3D902%26doi%3D10.1056%2FNEJMoa1901814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanDevanter, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arain, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langhorne, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiswirth, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span></span> <span> </span><span class="NLM_article-title">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>405</i></span>,  <span class="NLM_fpage">962</span>– <span class="NLM_lpage">966</span>, <span class="refDoi"> DOI: 10.1038/35016103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2F35016103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10879539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=405&publication_year=2000&pages=962-966&author=C.+K.+Stoverauthor=P.+Warrenerauthor=D.+R.+VanDevanterauthor=D.+R.+Shermanauthor=T.+M.+Arainauthor=M.+H.+Langhorneauthor=S.+W.+Andersonauthor=J.+A.+Towellauthor=Y.+Yuanauthor=D.+N.+McMurrayauthor=B.+N.+Kreiswirthauthor=C.+E.+Barryauthor=W.+R.+Baker&title=A+small-molecule+nitroimidazopyran+drug+candidate+for+the+treatment+of+tuberculosis&doi=10.1038%2F35016103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span></div><div class="casAuthors">Stover, C. Kendall; Warrener, Paul; VanDevanter, Donald R.; Sherman, David R.; Arain, Taraq M.; Langhorne, Michael H.; Anderson, Scott W.; Towell, J. Andrew; Yuan, Ying; McMurray, David N.; Krelswirth, Barry N.; Barry, Clifton E.; Baker, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">405</span>
        (<span class="NLM_cas:issue">6789</span>),
    <span class="NLM_cas:pages">962-966</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis, which causes tuberculosis, is the greatest single infectious cause of mortality worldwide, killing roughly; two million people annually.  Ests. indicate that one-third of the world population is infected with latent M. tuberculosis.  The synergy between tuberculosis and the AIDS epidemic, and the surge of multidrug-resistant clin. isolates of M. tuberculosis have reaffirmed tuberculosis as a primary public health threat.  However, new antitubercular drugs with new mechanisms of action have not been developed in over thirty years.  Here we report a series of compds. contg. a nitroimidazopyran nucleus that possess antitubercular activity.  After activation by a mechanism dependent on M. tuberculosis F420 cofactor, nitroimidazopyrans inhibited the synthesis of protein and cell wall lipid.  In contrast to current antitubercular drugs, nitroimidazopyrans exhibited bactericidal activity against both replicating and static M. tuberculosis.  Lead compd. PA-824 showed potent bactericidal activity against multidrug-resistant M. tuberculosis and promising oral activity in animal infection models.  We conclude that nitroimidazopyrans offer the practical qualities of a small mol. with the potential for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw41eD4TtVwbVg90H21EOLACvtfcHk0lghPnBkEkoilQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D&md5=f5f6e2935928da72e328bddd4995515f</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1038%2F35016103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35016103%26sid%3Dliteratum%253Aachs%26aulast%3DStover%26aufirst%3DC.%2BK.%26aulast%3DWarrener%26aufirst%3DP.%26aulast%3DVanDevanter%26aufirst%3DD.%2BR.%26aulast%3DSherman%26aufirst%3DD.%2BR.%26aulast%3DArain%26aufirst%3DT.%2BM.%26aulast%3DLanghorne%26aufirst%3DM.%2BH.%26aulast%3DAnderson%26aufirst%3DS.%2BW.%26aulast%3DTowell%26aufirst%3DJ.%2BA.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DMcMurray%26aufirst%3DD.%2BN.%26aulast%3DKreiswirth%26aufirst%3DB.%2BN.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBaker%26aufirst%3DW.%2BR.%26atitle%3DA%2520small-molecule%2520nitroimidazopyran%2520drug%2520candidate%2520for%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DNature%26date%3D2000%26volume%3D405%26spage%3D962%26epage%3D966%26doi%3D10.1038%2F35016103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Miranda
Silva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajihosseini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myrick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nole, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drusano, G. L.</span></span> <span> </span><span class="NLM_article-title">Effect of moxifloxacin plus pretomanid against Mycobacterium tuberculosis in log phase, acid phase, and nonreplicating-persister phase in an in vitro assay</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">e01695-18</span>, <span class="refDoi"> DOI: 10.1128/AAC.01695-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.01695-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30397058" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2019&pages=e01695-18&author=C.+de+Miranda%0ASilvaauthor=A.+Hajihosseiniauthor=J.+Myrickauthor=J.+Noleauthor=A.+Louieauthor=S.+Schmidtauthor=G.+L.+Drusano&title=Effect+of+moxifloxacin+plus+pretomanid+against+Mycobacterium+tuberculosis+in+log+phase%2C+acid+phase%2C+and+nonreplicating-persister+phase+in+an+in+vitro+assay&doi=10.1128%2FAAC.01695-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1128%2FAAC.01695-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01695-18%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BMiranda%2BSilva%26aufirst%3DC.%26aulast%3DHajihosseini%26aufirst%3DA.%26aulast%3DMyrick%26aufirst%3DJ.%26aulast%3DNole%26aufirst%3DJ.%26aulast%3DLouie%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DDrusano%26aufirst%3DG.%2BL.%26atitle%3DEffect%2520of%2520moxifloxacin%2520plus%2520pretomanid%2520against%2520Mycobacterium%2520tuberculosis%2520in%2520log%2520phase%252C%2520acid%2520phase%252C%2520and%2520nonreplicating-persister%2520phase%2520in%2520an%2520in%2520vitro%2520assay%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2019%26volume%3D63%26spage%3De01695-18%26doi%3D10.1128%2FAAC.01695-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balganesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinesh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruppath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, U.</span></span> <span> </span><span class="NLM_article-title">Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2643</span>– <span class="NLM_lpage">2651</span>, <span class="refDoi"> DOI: 10.1128/AAC.06003-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.06003-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22314527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=2643-2651&author=M.+Balganeshauthor=N.+Dineshauthor=S.+Sharmaauthor=S.+Kuruppathauthor=A.+V.+Nairauthor=U.+Sharma&title=Efflux+pumps+of+Mycobacterium+tuberculosis+play+a+significant+role+in+antituberculosis+activity+of+potential+drug+candidates&doi=10.1128%2FAAC.06003-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates</span></div><div class="casAuthors">Balganesh, Meenakshi; Dinesh, Neela; Sharma, Sreevalli; Kuruppath, Sanjana; Nair, Anju V.; Sharma, Umender</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2643-2651</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Active efflux of drugs mediated by efflux pumps that confer drug resistance is one of the mechanisms developed by bacteria to counter the adverse effects of antibiotics and chems.  To understand these efflux mechanisms in Mycobacterium tuberculosis, we generated knockout (KO) mutants of four efflux pumps of the pathogen belonging to different classes.  The authors measured the MICs and kill values of two different compd. classes on the wild-type (WT) and the efflux pump (EP) KO mutants in the presence and absence of the efflux inhibitors verapamil and L-phenylalanyl-L-arginyl-β-naphthylamide (PAβN).  Among the pumps studied, the efflux pumps belonging to the ABC (ATP-binding cassette) class, encoded by Rv1218c, and the SMR (small multidrug resistance) class, encoded by Rv3065, appear to play important roles in mediating the efflux of different chem. classes and antibiotics.  Efflux pumps encoded by Rv0849 and Rv1258c also mediate the efflux of these compds., but to a lesser extent.  Increased killing is obsd. in WT M. tuberculosis cells by these compds. in the presence of either verapamil or PAβN.  The efflux pump KO mutants were more susceptible to these compds. in the presence of efflux inhibitors.  We have shown that these four efflux pumps of M. tuberculosis play a vital role in mediating efflux of different chem. scaffolds.  Inhibitors of one or several of these efflux pumps could have a significant impact in the treatment of tuberculosis.  The identification and characterization of Rv0849, a new efflux pump belonging to the MFS (major facilitator superfamily) class, are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZCoB0YRug-7Vg90H21EOLACvtfcHk0ljROJHNYArNVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKrsbk%253D&md5=284a84bb5cc3575973cbb3da9cf8a7d6</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1128%2FAAC.06003-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06003-11%26sid%3Dliteratum%253Aachs%26aulast%3DBalganesh%26aufirst%3DM.%26aulast%3DDinesh%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKuruppath%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DA.%2BV.%26aulast%3DSharma%26aufirst%3DU.%26atitle%3DEfflux%2520pumps%2520of%2520Mycobacterium%2520tuberculosis%2520play%2520a%2520significant%2520role%2520in%2520antituberculosis%2520activity%2520of%2520potential%2520drug%2520candidates%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D2643%26epage%3D2651%26doi%3D10.1128%2FAAC.06003-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wayne, L. G.</span></span> <span> </span><span class="NLM_article-title">Synchronized replication of Mycobacterium tuberculosis</span>. <i>Infect. Immun.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1128/IAI.17.3.528-530.1977</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FIAI.17.3.528-530.1977" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=409675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaE2sXlvVSnt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1977&pages=528-530&author=L.+G.+Wayne&title=Synchronized+replication+of+Mycobacterium+tuberculosis&doi=10.1128%2FIAI.17.3.528-530.1977"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Synchronized replication of Mycobacterium tuberculosis</span></div><div class="casAuthors">Wayne, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Infection and Immunity</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">528-30</span>CODEN:
                <span class="NLM_cas:coden">INFIBR</span>;
        ISSN:<span class="NLM_cas:issn">0019-9567</span>.
    </div><div class="casAbstract">When M. tuberculosis was grown in Tween-albumin broth without agitation, the bacilli replicated in the upper, O-rich portion of the medium at a rate that was just balanced by the rate at which the bacilli settled toward the bottom of the tube.  When the organisms that accumulated in the sediment were suspended and dild. into fresh medium, they exhibited synchronous replication.  The bacilli initiated RNA synthesis immediately upon suspension, but marked DNA synthesis was not apparent until after the 1st cellular division was completed, ∼14 h after suspension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDLDsRsccSfrVg90H21EOLACvtfcHk0ljROJHNYArNVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXlvVSnt7g%253D&md5=a9baac07fbe58d46d37cb723f6208307</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1128%2FIAI.17.3.528-530.1977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FIAI.17.3.528-530.1977%26sid%3Dliteratum%253Aachs%26aulast%3DWayne%26aufirst%3DL.%2BG.%26atitle%3DSynchronized%2520replication%2520of%2520Mycobacterium%2520tuberculosis%26jtitle%3DInfect.%2520Immun.%26date%3D1977%26volume%3D17%26spage%3D528%26epage%3D530%26doi%3D10.1128%2FIAI.17.3.528-530.1977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. F.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis metabolism</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">a021121</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a021121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1101%2Fcshperspect.a021121" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=a021121&author=D.+F.+Warner&title=Mycobacterium+tuberculosis+metabolism&doi=10.1101%2Fcshperspect.a021121"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a021121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a021121%26sid%3Dliteratum%253Aachs%26aulast%3DWarner%26aufirst%3DD.%2BF.%26atitle%3DMycobacterium%2520tuberculosis%2520metabolism%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2015%26volume%3D5%26spage%3Da021121%26doi%3D10.1101%2Fcshperspect.a021121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vollmer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keep, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, S.</span></span> <span> </span><span class="NLM_article-title">Cell wall peptidoglycan in Mycobacterium tuberculosis: An Achilles’ heel for the TB-causing pathogen</span>. <i>FEMS Microbiology Reviews</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">548</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1093/femsre/fuz016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Ffemsre%2Ffuz016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31183501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosFGkt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2019&pages=548-575&author=A.+Maitraauthor=T.+Munshiauthor=J.+Healyauthor=L.+T.+Martinauthor=W.+Vollmerauthor=N.+H.+Keepauthor=S.+Bhakta&title=Cell+wall+peptidoglycan+in+Mycobacterium+tuberculosis%3A+An+Achilles%E2%80%99+heel+for+the+TB-causing+pathogen&doi=10.1093%2Ffemsre%2Ffuz016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Cell wall peptidoglycan in Mycobacterium tuberculosis: an Achilles' heel for the TB-causing pathogen</span></div><div class="casAuthors">Maitra, Arundhati; Munshi, Tulika; Healy, Jess; Martin, Liam T.; Vollmer, Waldemar; Keep, Nicholas H.; Bhakta, Sanjib</div><div class="citationInfo"><span class="NLM_cas:title">FEMS Microbiology Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">548-575</span>CODEN:
                <span class="NLM_cas:coden">FMREE4</span>;
        ISSN:<span class="NLM_cas:issn">1574-6976</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB), caused by the intracellular pathogen Mycobacterium tuberculosis, remains one of the leading causes of mortality across the world.  There is an urgent requirement to build a robust arsenal of effective antimicrobials, targeting novel mol. mechanisms to overcome the challenges posed by the increase of antibiotic resistance in TB.  Mycobacterium tuberculosis has a unique cell envelope structure and compn., contg. a peptidoglycan layer that is essential for maintaining cellular integrity and for virulence.  The enzymes involved in the biosynthesis, degrdn., remodeling and recycling of peptidoglycan have resurfaced as attractive targets for anti-infective drug discovery.  Here, we review the importance of peptidoglycan, including the structure, function and regulation of key enzymes involved in its metab.  We also discuss known inhibitors of ATP-dependent Mur ligases, and discuss the potential for the development of pan-enzyme inhibitors targeting multiple Mur ligases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6GdlixjHrV7Vg90H21EOLACvtfcHk0liqtzjyRJii6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosFGkt74%253D&md5=8cc7822734ac077b3405a01b8ac48db4</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1093%2Ffemsre%2Ffuz016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ffemsre%252Ffuz016%26sid%3Dliteratum%253Aachs%26aulast%3DMaitra%26aufirst%3DA.%26aulast%3DMunshi%26aufirst%3DT.%26aulast%3DHealy%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DL.%2BT.%26aulast%3DVollmer%26aufirst%3DW.%26aulast%3DKeep%26aufirst%3DN.%2BH.%26aulast%3DBhakta%26aufirst%3DS.%26atitle%3DCell%2520wall%2520peptidoglycan%2520in%2520Mycobacterium%2520tuberculosis%253A%2520An%2520Achilles%25E2%2580%2599%2520heel%2520for%2520the%2520TB-causing%2520pathogen%26jtitle%3DFEMS%2520Microbiology%2520Reviews%26date%3D2019%26volume%3D43%26spage%3D548%26epage%3D575%26doi%3D10.1093%2Ffemsre%2Ffuz016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelopoulos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keep, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, S.</span></span> <span> </span><span class="NLM_article-title">Characterisation of ATP-dependent Mur ligases involved in the biogenesis of cell wall peptidoglycan in Mycobacterium tuberculosis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e60143</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0060143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pone.0060143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23555903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsVSrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e60143&author=T.+Munshiauthor=A.+Guptaauthor=D.+Evangelopoulosauthor=J.+D.+Guzmanauthor=S.+Gibbonsauthor=N.+H.+Keepauthor=S.+Bhakta&title=Characterisation+of+ATP-dependent+Mur+ligases+involved+in+the+biogenesis+of+cell+wall+peptidoglycan+in+Mycobacterium+tuberculosis&doi=10.1371%2Fjournal.pone.0060143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Characterisation of ATP-dependent mur ligases involved in the biogenesis of cell wall peptidoglycan in Mycobacterium tuberculosis</span></div><div class="casAuthors">Munshi, Tulika; Gupta, Antima; Evangelopoulos, Dimitrios; Guzman, Juan David; Gibbons, Simon; Keep, Nicholas H.; Bhakta, Sanjib</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e60143</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">ATP-dependent Mur ligases (Mur synthetases) play essential roles in the biosynthesis of cell wall peptidoglycan (PG) as they catalyze the ligation of key amino acid residues to the stem peptide at the expense of ATP hydrolysis, thus representing potential targets for antibacterial drug discovery.  In this study the authors characterized the division/cell wall (dcw) operon and identified a promoter driving the co-transcription of mur synthetases along with key cell division genes such as ftsQ and ftsW.  Furthermore, the authors have extended their previous investigations of MurE to MurC, MurD and MurF synthetases from Mycobacterium tuberculosis.  Functional analyses of the pure recombinant enzymes revealed that the presence of divalent cations is an abs. requirement for their activities.  The authors also obsd. that higher concns. of ATP and UDP-sugar substrates were inhibitory for the activities of all Mur synthetases suggesting stringent control of the cytoplasmic steps of the peptidoglycan biosynthetic pathway.  In line with the previous findings on the regulation of mycobacterial MurD and corynebacterial MurC synthetases via phosphorylation, the authors found that all of the Mur synthetases interacted with the Ser/Thr protein kinases, PknA and PknB.  In addn., the authors critically analyzed the interaction network of all of the Mur synthetases with proteins involved in cell division and cell wall PG biosynthesis to re-evaluate the importance of these key enzymes as novel therapeutic targets in anti-tubercular drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcMija6vZMjLVg90H21EOLACvtfcHk0liqtzjyRJii6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsVSrtrw%253D&md5=275f3f3194c8bd692a2044ebb9537bfc</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0060143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0060143%26sid%3Dliteratum%253Aachs%26aulast%3DMunshi%26aufirst%3DT.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DEvangelopoulos%26aufirst%3DD.%26aulast%3DGuzman%26aufirst%3DJ.%2BD.%26aulast%3DGibbons%26aufirst%3DS.%26aulast%3DKeep%26aufirst%3DN.%2BH.%26aulast%3DBhakta%26aufirst%3DS.%26atitle%3DCharacterisation%2520of%2520ATP-dependent%2520Mur%2520ligases%2520involved%2520in%2520the%2520biogenesis%2520of%2520cell%2520wall%2520peptidoglycan%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De60143%26doi%3D10.1371%2Fjournal.pone.0060143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">PaweLczyk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span> <span> </span><span class="NLM_article-title">The Molecular Genetics of Mycolic Acid Biosynthesis</span>. <i>Microbiol. Spectrum</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">MGM2-0003-2013</span>, <span class="refDoi"> DOI: 10.1128/microbiolspec.MGM2-0003-2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2Fmicrobiolspec.MGM2-0003-2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26104214" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=MGM2-0003-2013&author=J.+PaweLczykauthor=L.+Kremer&title=The+Molecular+Genetics+of+Mycolic+Acid+Biosynthesis&doi=10.1128%2Fmicrobiolspec.MGM2-0003-2013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1128%2Fmicrobiolspec.MGM2-0003-2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmicrobiolspec.MGM2-0003-2013%26sid%3Dliteratum%253Aachs%26aulast%3DPaweLczyk%26aufirst%3DJ.%26aulast%3DKremer%26aufirst%3DL.%26atitle%3DThe%2520Molecular%2520Genetics%2520of%2520Mycolic%2520Acid%2520Biosynthesis%26jtitle%3DMicrobiol.%2520Spectrum%26date%3D2014%26volume%3D2%26spage%3DMGM2-0003-2013%26doi%3D10.1128%2Fmicrobiolspec.MGM2-0003-2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mashabela, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wet, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. F.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis metabolism</span>. <i>Microbiol. Spectrum</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">GPP3-0067-2019</span>, <span class="refDoi"> DOI: 10.1128/microbiolspec.GPP3-0067-2019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2Fmicrobiolspec.GPP3-0067-2019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=GPP3-0067-2019&author=G.+T.+Mashabelaauthor=T.+J.+de+Wetauthor=D.+F.+Warner&title=Mycobacterium+tuberculosis+metabolism&doi=10.1128%2Fmicrobiolspec.GPP3-0067-2019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1128%2Fmicrobiolspec.GPP3-0067-2019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmicrobiolspec.GPP3-0067-2019%26sid%3Dliteratum%253Aachs%26aulast%3DMashabela%26aufirst%3DG.%2BT.%26aulast%3Dde%2BWet%26aufirst%3DT.%2BJ.%26aulast%3DWarner%26aufirst%3DD.%2BF.%26atitle%3DMycobacterium%2520tuberculosis%2520metabolism%26jtitle%3DMicrobiol.%2520Spectrum%26date%3D2019%26volume%3D7%26spage%3DGPP3-0067-2019%26doi%3D10.1128%2Fmicrobiolspec.GPP3-0067-2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, P. J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1021/ar700156e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar700156e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsl2ksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=11-20&author=H.+Luauthor=P.+J.+Tonge&title=Inhibitors+of+FabI%2C+an+enzyme+drug+target+in+the+bacterial+fatty+acid+biosynthesis+pathway&doi=10.1021%2Far700156e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway</span></div><div class="casAuthors">Lu, Hao; Tonge, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-20</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The modern age of drug discovery, which had been slowly gathering momentum during the early part of the twentieth century, exploded into life in the 1940s with the isolation of penicillin and streptomycin.  The immense success of these early drug discovery efforts prompted the general view that many infectious diseases would now be effectively controlled and even eradicated.  However this initial optimism was misplaced, and pathogens such as multidrug-resistant Mycobacterium tuberculosis and methicillin-resistant Staphylococcus aureus present a major current threat to human health.  Drug resistance arises through the unrelenting pressure of natural selection, and there is thus a continuing need to identify novel drug targets and develop chemotherapeutics that circumvent existing drug resistance mechanisms.  In this Account, we summarize current progress in developing inhibitors of FabI, the NADH-dependent enoyl reductase from the type II bacterial fatty acid biosynthesis pathway (FAS-II), a validated but currently underexploited target for drug discovery.  The FabI inhibitors have been divided into two groups, based on whether they form a covalent adduct with the NAD+ cofactor.  Inhibitors that form a covalent adduct include the diazaborines, as well as the front-line tuberculosis drug isoniazid.  The NAD adducts formed with these compds. are formally bisubstrate enzyme inhibitors, and we summarize progress in developing novel leads based on these pharmacophores.  Inhibitors that do not form covalent adducts form a much larger group, although generally these compds. also require the cofactor to be bound to the enzyme.  Using structure-based approaches, we have developed a series of alkyl di-Ph ethers that are nanomolar inhibitors of InhA, the FabI from M. tuberculosis, and that are active against INH-resistant strains of M. tuberculosis.  This rational approach to inhibitor development is based on the proposal that high-affinity inhibition of the FabI enzymes is coupled to the ordering of a loop of amino acids close to the active site.  Compds. that promote loop ordering are slow onset FabI inhibitors with increased residence time on the enzyme.  The di-Ph ether skeleton has also been used as a framework by us and others to develop potent inhibitors of the FabI enzymes from other pathogens such as Escherichia coli, S. aureus, and Plasmodium falciparum.  Meanwhile chem. optimization of compds. identified in high-throughput screening programs has resulted in the identification of several classes of heteroarom. FabI inhibitors with potent activity both in vitro and in vivo.  Finally, screening of natural product libraries may provide useful chem. entities for the development of novel agents with low toxicity.  While the discovery that not all pathogens contain FabI homologues has led to reduced industrial interest in FabI as a broad spectrum target, there is substantial optimism that FabI inhibitors can be developed for disease-specific applications.  In addn., the availability of genome sequencing data, improved methods for target identification and validation, and the development of novel approaches for detg. the mode of action of current drugs will all play crit. roles in the road ahead and in exploiting other components of the FAS-II pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql1NBfEVjFULVg90H21EOLACvtfcHk0lhgeYXKHWIkdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsl2ksA%253D%253D&md5=8d28e2e80a7513c1105265288614a924</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Far700156e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far700156e%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DTonge%26aufirst%3DP.%2BJ.%26atitle%3DInhibitors%2520of%2520FabI%252C%2520an%2520enzyme%2520drug%2520target%2520in%2520the%2520bacterial%2520fatty%2520acid%2520biosynthesis%2520pathway%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D11%26epage%3D20%26doi%3D10.1021%2Far700156e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">AlMatar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makky, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Var, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koksal, F.</span></span> <span> </span><span class="NLM_article-title">Novel compounds targeting InhA for TB therapy</span>. <i>Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">226</span>, <span class="refDoi"> DOI: 10.1016/j.pharep.2017.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.pharep.2017.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29475004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1MrkslKltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2018&pages=217-226&author=M.+AlMatarauthor=E.+A.+Makkyauthor=I.+Varauthor=B.+Kayarauthor=F.+Koksal&title=Novel+compounds+targeting+InhA+for+TB+therapy&doi=10.1016%2Fj.pharep.2017.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Novel compounds targeting InhA for TB therapy</span></div><div class="casAuthors">AlMatar Manaf; Makky Essam A; Var Isil; Kayar Begum; Koksal Fatih</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological reports : PR</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-226</span>
        ISSN:<span class="NLM_cas:issn">1734-1140</span>.
    </div><div class="casAbstract">Tuberculosis (TB) is described as lethal disease in the world.  Resistant to TB drugs is the main reason to have unfavourable outcomes in the treatment of TB.  Therefore, new agents to replace existing drugs are urgently needed.  Previous reports suggested that InhA inhibitors, an enoyl-ACP-reductase, might provide auspicious candidates which can be developed into novel antitubercular agents.  In this review, we explain the role of InhA in the resistance of isoniazid.  Furthermore, five classes of InhA inhibitors, which display novel binding modes and deliver evidence of their prosperous target engagement, have been debated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0iT-MXN5-iwHqQV89nF-2fW6udTcc2earPQ7FEtVlvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrkslKltg%253D%253D&md5=c04c7b5b61a79afd5af78b3718c5aaa4</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.pharep.2017.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharep.2017.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DAlMatar%26aufirst%3DM.%26aulast%3DMakky%26aufirst%3DE.%2BA.%26aulast%3DVar%26aufirst%3DI.%26aulast%3DKayar%26aufirst%3DB.%26aulast%3DKoksal%26aufirst%3DF.%26atitle%3DNovel%2520compounds%2520targeting%2520InhA%2520for%2520TB%2520therapy%26jtitle%3DPharmacol.%2520Rep.%26date%3D2018%26volume%3D70%26spage%3D217%26epage%3D226%26doi%3D10.1016%2Fj.pharep.2017.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parai, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shetty, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolhiser, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hastings, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galaviz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhakal, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakabayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walpole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scullion, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epemolu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snavely, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioerger, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirgel, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Merwe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Helden, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottger, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakousis, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span> <span> </span><span class="NLM_article-title">Development of a novel lead that targets M. tuberculosis polyketide synthase 13</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.06.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.cell.2017.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28669536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSqsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2017&pages=249-259&author=A.+Aggarwalauthor=M.+K.+Paraiauthor=N.+Shettyauthor=D.+Wallisauthor=L.+Woolhiserauthor=C.+Hastingsauthor=N.+K.+Duttaauthor=S.+Galavizauthor=R.+C.+Dhakalauthor=R.+Shresthaauthor=S.+Wakabayashiauthor=C.+Walpoleauthor=D.+Matthewsauthor=D.+Floydauthor=P.+Scullionauthor=J.+Rileyauthor=O.+Epemoluauthor=S.+Norvalauthor=T.+Snavelyauthor=G.+T.+Robertsonauthor=E.+J.+Rubinauthor=T.+R.+Ioergerauthor=F.+A.+Sirgelauthor=R.+van+der+Merweauthor=P.+D.+van+Heldenauthor=P.+Kellerauthor=E.+C.+Bottgerauthor=P.+C.+Karakousisauthor=A.+J.+Lenaertsauthor=J.+C.+Sacchettini&title=Development+of+a+novel+lead+that+targets+M.+tuberculosis+polyketide+synthase+13&doi=10.1016%2Fj.cell.2017.06.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13</span></div><div class="casAuthors">Aggarwal, Anup; Parai, Maloy K.; Shetty, Nishant; Wallis, Deeann; Woolhiser, Lisa; Hastings, Courtney; Dutta, Noton K.; Galaviz, Stacy; Dhakal, Ramesh C.; Shrestha, Rupesh; Wakabayashi, Shoko; Walpole, Chris; Matthews, David; Floyd, David; Scullion, Paul; Riley, Jennifer; Epemolu, Ola; Norval, Suzanne; Snavely, Thomas; Robertson, Gregory T.; Rubin, Eric J.; Ioerger, Thomas R.; Sirgel, Frik A.; van der Merwe, Ruben; van Helden, Paul D.; Keller, Peter; Bottger, Erik C.; Karakousis, Petros C.; Lenaerts, Anne J.; Sacchettini, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">249-259.e25</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Widespread resistance to first-line TB drugs is a major problem that will likely only be resolved through the development of new drugs with novel mechanisms of action.  The authors have used structure-guided methods to develop a lead mol. that targets the thioesterase activity of polyketide synthase Pks13, an essential enzyme that forms mycolic acids, required for the cell wall of Mycobacterium tuberculosis.  The authors' lead, TAM16, is a benzofuran class inhibitor of Pks13 with highly potent in vitro bactericidal activity against drug-susceptible and drug-resistant clin. isolates of M. tuberculosis.  In multiple mouse models of TB infection, TAM16 showed in vivo efficacy equal to the first-line TB drug isoniazid, both as a monotherapy and in combination therapy with rifampicin.  TAM16 has excellent pharmacol. and safety profiles, and the frequency of resistance for TAM16 is ∼100-fold lower than INH, suggesting that it can be developed as a new antitubercular aimed at the acute infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzaTE4I6mQ27Vg90H21EOLACvtfcHk0lgiXFYGyAAalw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSqsL3K&md5=d622d9319d150f6861936ede89467067</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DA.%26aulast%3DParai%26aufirst%3DM.%2BK.%26aulast%3DShetty%26aufirst%3DN.%26aulast%3DWallis%26aufirst%3DD.%26aulast%3DWoolhiser%26aufirst%3DL.%26aulast%3DHastings%26aufirst%3DC.%26aulast%3DDutta%26aufirst%3DN.%2BK.%26aulast%3DGalaviz%26aufirst%3DS.%26aulast%3DDhakal%26aufirst%3DR.%2BC.%26aulast%3DShrestha%26aufirst%3DR.%26aulast%3DWakabayashi%26aufirst%3DS.%26aulast%3DWalpole%26aufirst%3DC.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DFloyd%26aufirst%3DD.%26aulast%3DScullion%26aufirst%3DP.%26aulast%3DRiley%26aufirst%3DJ.%26aulast%3DEpemolu%26aufirst%3DO.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSnavely%26aufirst%3DT.%26aulast%3DRobertson%26aufirst%3DG.%2BT.%26aulast%3DRubin%26aufirst%3DE.%2BJ.%26aulast%3DIoerger%26aufirst%3DT.%2BR.%26aulast%3DSirgel%26aufirst%3DF.%2BA.%26aulast%3Dvan%2Bder%2BMerwe%26aufirst%3DR.%26aulast%3Dvan%2BHelden%26aufirst%3DP.%2BD.%26aulast%3DKeller%26aufirst%3DP.%26aulast%3DBottger%26aufirst%3DE.%2BC.%26aulast%3DKarakousis%26aufirst%3DP.%2BC.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26atitle%3DDevelopment%2520of%2520a%2520novel%2520lead%2520that%2520targets%2520M.%2520tuberculosis%2520polyketide%2520synthase%252013%26jtitle%3DCell%26date%3D2017%26volume%3D170%26spage%3D249%26epage%3D259%26doi%3D10.1016%2Fj.cell.2017.06.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1007/s13238-010-0057-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1007%2Fs13238-010-0057-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21203958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3cXoslelur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=435-442&author=Z.+Louauthor=X.+Zhang&title=Protein+targets+for+structure-based+anti-Mycobacterium+tuberculosis+drug+discovery&doi=10.1007%2Fs13238-010-0057-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery</span></div><div class="casAuthors">Lou, Zhiyong; Zhang, Xiaoxue</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">435-442</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">A review.  Mycobacterium tuberculosis, which belongs to the genus Mycobacterium, is the pathogenic agent for most tuberculosis (TB).  As TB remains one of the most rampant infectious diseases, causing morbidity and death with emergence of multi-drug-resistant and extensively-drug-resistant forms, it is urgent to identify new drugs with novel targets to ensure future therapeutic success.  In this regards, the structural genomics of M. tuberculosis provides important information to identify potential targets, perform biochem. assays, det. crystal structures in complex with potential inhibitor(s), reveal the key sites/residues for biol. activity, and thus validate drug targets and discover novel drugs.  In this review, we will discuss the recent progress on novel targets for structure-based anti-M. tuberculosis drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYIQ6apqOxArVg90H21EOLACvtfcHk0lgiXFYGyAAalw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXoslelur4%253D&md5=bbd2583d8094eb7bce9dccf5c41d2a45</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1007%2Fs13238-010-0057-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-010-0057-3%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DProtein%2520targets%2520for%2520structure-based%2520anti-Mycobacterium%2520tuberculosis%2520drug%2520discovery%26jtitle%3DProtein%2520Cell%26date%3D2010%26volume%3D1%26spage%3D435%26epage%3D442%26doi%3D10.1007%2Fs13238-010-0057-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haufroid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wouters, J.</span></span> <span> </span><span class="NLM_article-title">Targeting the Serine Pathway: A promising approach against tuberculosis?</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">66</span>, <span class="refDoi"> DOI: 10.3390/ph12020066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3390%2Fph12020066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslKksLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=66&author=M.+Haufroidauthor=J.+Wouters&title=Targeting+the+Serine+Pathway%3A+A+promising+approach+against+tuberculosis%3F&doi=10.3390%2Fph12020066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the serine pathway: a promising approach against tuberculosis?</span></div><div class="casAuthors">Haufroid, Marie; Wouters, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">66</span>CODEN:
                <span class="NLM_cas:coden">PHARH2</span>;
        ISSN:<span class="NLM_cas:issn">1424-8247</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Tuberculosis is still the leading cause of death by a single infectious agent.  Effective chemotherapy has been used and improved since the 1950s, but strains resistant to this therapy and most antibacterial drugs on the market are emerging.  Only 10 new drugs are in clin. trials, and two of them have already demonstrated resistance.  This paper gives an overview of current treatment options against tuberculosis and points out a promising approach of discovering new effective drugs.  The serine prodn. pathway is composed of three enzymes (SerA1, SerC and SerB2), which are considered essential for bacterial growth, and all of them are considered as a therapeutic drug target.  Their crystal structure are described and essential regulatory domains pointed out.  Sequence alignment with similar enzymes in other host would help to identify key residues to target in order to achieve selective inhibition.  Currently, only inhibitors of SerB2 are described in the literature.  However, inhibitors of human enzymes are discussed, and could be used as a good starting point for a drug discovery program.  The aim of this paper is to give some guidance for the design of new hits for every enzyme in this pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFdU37bL8KyLVg90H21EOLACvtfcHk0ljdqzz0v7jzuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslKksLzI&md5=02c4f3dfa6a55af6298e7c23276a0c61</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.3390%2Fph12020066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph12020066%26sid%3Dliteratum%253Aachs%26aulast%3DHaufroid%26aufirst%3DM.%26aulast%3DWouters%26aufirst%3DJ.%26atitle%3DTargeting%2520the%2520Serine%2520Pathway%253A%2520A%2520promising%2520approach%2520against%2520tuberculosis%253F%26jtitle%3DPharmaceuticals%26date%3D2019%26volume%3D12%26spage%3D66%26doi%3D10.3390%2Fph12020066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tantry, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markad, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambady, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raichurkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kedari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudugal, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naveen Kumar, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanduri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panduga, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakar, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saralaya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinesh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guptha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcock, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naylor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteaker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudrapatna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shandil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandamurthy, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mdluli, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavanagh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosagrahara, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solapure, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravishankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hameed P, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of imidazo[1,2-a]pyridine ethers and squaramides as selective and potent inhibitors of Mycobacterial Adenosine Triphosphate (ATP) synthesis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1379</span>– <span class="NLM_lpage">1399</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01358</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01358" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptlajsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1379-1399&author=S.+J.+Tantryauthor=S.+D.+Markadauthor=V.+Shindeauthor=J.+Bhatauthor=G.+Balakrishnanauthor=A.+K.+Guptaauthor=A.+Ambadyauthor=A.+Raichurkarauthor=C.+Kedariauthor=S.+Sharmaauthor=N.+V.+Mudugalauthor=A.+Narayanauthor=C.+N.+Naveen+Kumarauthor=R.+Nanduriauthor=S.+Bharathauthor=J.+Reddyauthor=V.+Pandugaauthor=K.+R.+Prabhakarauthor=K.+Kandaswamyauthor=R.+Saralayaauthor=P.+Kaurauthor=N.+Dineshauthor=S.+Gupthaauthor=K.+Richauthor=D.+Murrayauthor=H.+Plantauthor=M.+Prestonauthor=H.+Ashtonauthor=D.+Plantauthor=J.+Walshauthor=P.+Alcockauthor=K.+Naylorauthor=M.+Collierauthor=J.+Whiteakerauthor=R.+E.+McLaughlinauthor=M.+Mallyaauthor=M.+Pandaauthor=S.+Rudrapatnaauthor=V.+Ramachandranauthor=R.+Shandilauthor=V.+K.+Sambandamurthyauthor=K.+Mdluliauthor=C.+B.+Cooperauthor=H.+Rubinauthor=T.+Yanoauthor=P.+Iyerauthor=S.+Narayananauthor=S.+Kavanaghauthor=K.+Mukherjeeauthor=V.+Balasubramanianauthor=V.+P.+Hosagraharaauthor=S.+Solapureauthor=S.+Ravishankarauthor=S.+Hameed+P&title=Discovery+of+imidazo%5B1%2C2-a%5Dpyridine+ethers+and+squaramides+as+selective+and+potent+inhibitors+of+Mycobacterial+Adenosine+Triphosphate+%28ATP%29+synthesis&doi=10.1021%2Facs.jmedchem.6b01358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis</span></div><div class="casAuthors">Tantry, Subramanyam J.; Markad, Shankar D.; Shinde, Vikas; Bhat, Jyothi; Balakrishnan, Gayathri; Gupta, Amit K.; Ambady, Anisha; Raichurkar, Anandkumar; Kedari, Chaitanyakumar; Sharma, Sreevalli; Mudugal, Naina V.; Narayan, Ashwini; Naveen Kumar, C. N.; Nanduri, Robert; Bharath, Sowmya; Reddy, Jitendar; Panduga, Vijender; Prabhakar, K. R.; Kandaswamy, Karthikeyan; Saralaya, Ramanatha; Kaur, Parvinder; Dinesh, Neela; Guptha, Supreeth; Rich, Kirsty; Murray, David; Plant, Helen; Preston, Marian; Ashton, Helen; Plant, Darren; Walsh, Jarrod; Alcock, Peter; Naylor, Kathryn; Collier, Matthew; Whiteaker, James; McLaughlin, Robert E.; Mallya, Meenakshi; Panda, Manoranjan; Rudrapatna, Suresh; Ramachandran, Vasanthi; Shandil, Radha; Sambandamurthy, Vasan K.; Mdluli, Khisi; Cooper, Christopher B.; Rubin, Harvey; Yano, Takahiro; Iyer, Pravin; Narayanan, Shridhar; Kavanagh, Stefan; Mukherjee, Kakoli; Balasubramanian, V.; Hosagrahara, Vinayak P.; Solapure, Suresh; Ravishankar, Sudha; Hameed P, Shahul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1379-1399</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The approval of bedaquiline to treat tuberculosis has validated ATP synthase as an attractive target to kill Mycobacterium tuberculosis.  Herein, the authors report the discovery of two diverse lead series imidazo[1,2-a]pyridine ethers (IPE) and squaramides (SQA) as inhibitors of mycobacterial ATP-synthesis.  Through medicinal chem. exploration, the authors established a robust structure activity relationship of these two scaffolds resulting in nanomolar potencies in an ATP-synthesis inhibition assay.  A biochem. deconvolution cascade suggested cytochrome c oxidase as the potential target of IPE class of mols., whereas characterization of spontaneous resistant mutants of SQAs unambiguously identified ATP synthase as its mol. target.  Absence of cross resistance against bedaquiline resistant mutants suggested a different binding site for SQAs on ATP synthase.  Furthermore, SQAs were found to be non-cytotoxic and demonstrated efficacy in a mouse model of tuberculosis infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq9ZNK4cN5rbVg90H21EOLACvtfcHk0ljdqzz0v7jzuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptlajsw%253D%253D&md5=6b5ae7fe676197f9ffb84f27a79965cd</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01358%26sid%3Dliteratum%253Aachs%26aulast%3DTantry%26aufirst%3DS.%2BJ.%26aulast%3DMarkad%26aufirst%3DS.%2BD.%26aulast%3DShinde%26aufirst%3DV.%26aulast%3DBhat%26aufirst%3DJ.%26aulast%3DBalakrishnan%26aufirst%3DG.%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DAmbady%26aufirst%3DA.%26aulast%3DRaichurkar%26aufirst%3DA.%26aulast%3DKedari%26aufirst%3DC.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DMudugal%26aufirst%3DN.%2BV.%26aulast%3DNarayan%26aufirst%3DA.%26aulast%3DNaveen%2BKumar%26aufirst%3DC.%2BN.%26aulast%3DNanduri%26aufirst%3DR.%26aulast%3DBharath%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DJ.%26aulast%3DPanduga%26aufirst%3DV.%26aulast%3DPrabhakar%26aufirst%3DK.%2BR.%26aulast%3DKandaswamy%26aufirst%3DK.%26aulast%3DSaralaya%26aufirst%3DR.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DDinesh%26aufirst%3DN.%26aulast%3DGuptha%26aufirst%3DS.%26aulast%3DRich%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DD.%26aulast%3DPlant%26aufirst%3DH.%26aulast%3DPreston%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DH.%26aulast%3DPlant%26aufirst%3DD.%26aulast%3DWalsh%26aufirst%3DJ.%26aulast%3DAlcock%26aufirst%3DP.%26aulast%3DNaylor%26aufirst%3DK.%26aulast%3DCollier%26aufirst%3DM.%26aulast%3DWhiteaker%26aufirst%3DJ.%26aulast%3DMcLaughlin%26aufirst%3DR.%2BE.%26aulast%3DMallya%26aufirst%3DM.%26aulast%3DPanda%26aufirst%3DM.%26aulast%3DRudrapatna%26aufirst%3DS.%26aulast%3DRamachandran%26aufirst%3DV.%26aulast%3DShandil%26aufirst%3DR.%26aulast%3DSambandamurthy%26aufirst%3DV.%2BK.%26aulast%3DMdluli%26aufirst%3DK.%26aulast%3DCooper%26aufirst%3DC.%2BB.%26aulast%3DRubin%26aufirst%3DH.%26aulast%3DYano%26aufirst%3DT.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DKavanagh%26aufirst%3DS.%26aulast%3DMukherjee%26aufirst%3DK.%26aulast%3DBalasubramanian%26aufirst%3DV.%26aulast%3DHosagrahara%26aufirst%3DV.%2BP.%26aulast%3DSolapure%26aufirst%3DS.%26aulast%3DRavishankar%26aufirst%3DS.%26aulast%3DHameed%2BP%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520imidazo%255B1%252C2-a%255Dpyridine%2520ethers%2520and%2520squaramides%2520as%2520selective%2520and%2520potent%2520inhibitors%2520of%2520Mycobacterial%2520Adenosine%2520Triphosphate%2520%2528ATP%2529%2520synthesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1379%26epage%3D1399%26doi%3D10.1021%2Facs.jmedchem.6b01358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villellas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span> <span> </span><span class="NLM_article-title">Targeting energy metabolism in Mycobacterium tuberculosis, a new paradigm in antimycobacterial drug discovery</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e00272-17</span>, <span class="refDoi"> DOI: 10.1128/mBio.00272-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FmBio.00272-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28400527" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=e00272-17&author=D.+Baldauthor=C.+Villellasauthor=P.+Luauthor=A.+Koul&title=Targeting+energy+metabolism+in+Mycobacterium+tuberculosis%2C+a+new+paradigm+in+antimycobacterial+drug+discovery&doi=10.1128%2FmBio.00272-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1128%2FmBio.00272-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.00272-17%26sid%3Dliteratum%253Aachs%26aulast%3DBald%26aufirst%3DD.%26aulast%3DVillellas%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DKoul%26aufirst%3DA.%26atitle%3DTargeting%2520energy%2520metabolism%2520in%2520Mycobacterium%2520tuberculosis%252C%2520a%2520new%2520paradigm%2520in%2520antimycobacterial%2520drug%2520discovery%26jtitle%3DmBio%26date%3D2017%26volume%3D8%26spage%3De00272-17%26doi%3D10.1128%2FmBio.00272-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Preiss, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yildiz, Ö.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt-Strelau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J. E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, T.</span></span> <span> </span><span class="NLM_article-title">Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e1500106</span>, <span class="refDoi"> DOI: 10.1126/sciadv.1500106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1126%2Fsciadv.1500106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26601184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslOrs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=e1500106&author=L.+Preissauthor=J.+D.+Langerauthor=%C3%96.+Yildizauthor=L.+Eckhardt-Strelauauthor=J.+E.+G.+Guillemontauthor=A.+Koulauthor=T.+Meier&title=Structure+of+the+mycobacterial+ATP+synthase+Fo+rotor+ring+in+complex+with+the+anti-TB+drug+bedaquiline&doi=10.1126%2Fsciadv.1500106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline</span></div><div class="casAuthors">Preiss, Laura; Langer, Julian D.; Yildiz, Oezkan; Eckhardt-Strelau, Luise; Guillemont, Jerome E. G.; Koul, Anil; Meier, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Science Advances</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e1500106/1-e1500106/8</span>CODEN:
                <span class="NLM_cas:coden">SACDAF</span>;
        ISSN:<span class="NLM_cas:issn">2375-2548</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Multidrug-resistant tuberculosis (MDR-TB) is more prevalent today than at any other time in human history.  Bedaquiline (BDQ), a novel Mycobacterium-specific ATP (ATP) synthase inhibitor, is the first drug in the last 40 years to be approved for the treatment of MDR-TB.  This bactericidal compd. targets the membrane-embedded rotor (c-ring) of the mycobacterial ATP synthase, a key metabolic enzyme required for ATP generation.  We report the x-ray crystal structures of a mycobacterial c9 ring without and with BDQ bound at 1.55- and 1.7- Å resoln., resp.  The structures and supporting functional assays reveal how BDQ specifically interacts with the rotor ring via numerous interactions and thereby completely covers the c-ring's ionbinding sites.  This prevents the rotor ring from acting as an ion shuttle and stalls ATP synthase operation.  The structures explain how diarylquinoline chems. specifically inhibit the mycobacterial ATP synthase and thus enable structure-based drug design of next-generation ATP synthase inhibitors against Mycobacterium tuberculosis and other bacterial pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK91-Dp8_Nh7Vg90H21EOLACvtfcHk0lg3G776o-wxBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslOrs78%253D&md5=e15a1dc1a2f30c2d113cf312724975c5</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.1500106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.1500106%26sid%3Dliteratum%253Aachs%26aulast%3DPreiss%26aufirst%3DL.%26aulast%3DLanger%26aufirst%3DJ.%2BD.%26aulast%3DYildiz%26aufirst%3D%25C3%2596.%26aulast%3DEckhardt-Strelau%26aufirst%3DL.%26aulast%3DGuillemont%26aufirst%3DJ.%2BE.%2BG.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DMeier%26aufirst%3DT.%26atitle%3DStructure%2520of%2520the%2520mycobacterial%2520ATP%2520synthase%2520Fo%2520rotor%2520ring%2520in%2520complex%2520with%2520the%2520anti-TB%2520drug%2520bedaquiline%26jtitle%3DSci.%2520Adv.%26date%3D2015%26volume%3D1%26spage%3De1500106%26doi%3D10.1126%2Fsciadv.1500106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, J. L.</span></span> <span> </span><span class="NLM_article-title">Structure of a bacterial ATP synthase</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e43128</span>, <span class="refDoi"> DOI: 10.7554/eLife.43128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.7554%2FeLife.43128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30724163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVegtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=e43128&author=H.+Guoauthor=T.+Suzukiauthor=J.+L.+Rubinstein&title=Structure+of+a+bacterial+ATP+synthase&doi=10.7554%2FeLife.43128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a bacterial ATP synthase</span></div><div class="casAuthors">Guo, Hui; Suzuki, Toshiharu; Rubinstein, John L.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43128</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">ATP synthases produce ATP from ADP and inorg. phosphate with energy from a transmembrane proton motive force.  Bacterial ATP synthases have been studied extensively because they are the simplest form of the enzyme and because of the relative ease of genetic manipulation of these complexes.  We expressed the Bacillus PS3 ATP synthase in Eschericia coli, purified it, and imaged it by cryo-EM, allowing us to build at. models of the complex in three rotational states.  The position of subunit ε shows how it is able to inhibit ATP hydrolysis while allowing ATP synthesis.  The architecture of the membrane region shows how the simple bacterial ATP synthase is able to perform the same core functions as the equiv., but more complicated, mitochondrial complex.  The structures reveal the path of transmembrane proton translocation and provide a model for understanding decades of biochem. anal. interrogating the roles of specific residues in the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo143AXmA-M7rVg90H21EOLACvtfcHk0ljwJibuJYbZ9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVegtrnF&md5=7ef22603f8e8c8c391c7ce61fac7f49a</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.7554%2FeLife.43128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.43128%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DRubinstein%26aufirst%3DJ.%2BL.%26atitle%3DStructure%2520of%2520a%2520bacterial%2520ATP%2520synthase%26jtitle%3DeLife%26date%3D2019%26volume%3D8%26spage%3De43128%26doi%3D10.7554%2FeLife.43128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schep, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bason, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigorieff, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, J. L.</span></span> <span> </span><span class="NLM_article-title">Structure and conformational states of the bovine mitochondrial ATP synthase by cryo-EM</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e10180</span>, <span class="refDoi"> DOI: 10.7554/eLife.10180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.7554%2FeLife.10180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26439008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXls1Sntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=e10180&author=A.+Zhouauthor=A.+Rohouauthor=D.+G.+Schepauthor=J.+V.+Basonauthor=M.+G.+Montgomeryauthor=J.+E.+Walkerauthor=N.+Grigorieffauthor=J.+L.+Rubinstein&title=Structure+and+conformational+states+of+the+bovine+mitochondrial+ATP+synthase+by+cryo-EM&doi=10.7554%2FeLife.10180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and conformational states of the bovine mitochondrial ATP synthase by cryo-EM</span></div><div class="casAuthors">Zhou, Anna; Rohou, Alexis; Schep, Daniel G.; Bason, John V.; Montgomery, Martin G.; Walker, John E.; Grigorieff, Nikolaus; Rubinstein, John L.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e10180/1-e10180/15</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">ATP (ATP), the chem. energy currency of biol., is synthesized in eukaryotic cells primarily by the mitochondrial ATP synthase.  ATP synthases operate by a rotary catalytic mechanism where proton translocation through the membrane-inserted FO region is coupled to ATP synthesis in the catalytic F1 region via rotation of a central rotor subcomplex.  We report here single particle electron cryomicroscopy (cryo-EM) anal. of the bovine mitochondrial ATP synthase.  Combining cryo-EM data with bioinformatic anal. allowed us to det. the fold of the a subunit, suggesting a proton translocation path through the FO region that involves both the a and b subunits. 3D classification of images revealed seven distinct states of the enzyme that show different modes of bending and twisting in the intact ATP synthase.  Rotational fluctuations of the c8-ring within the FO region support a Brownian ratchet mechanism for proton-translocation-driven rotation in ATP synthases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqarqo9J4hYoLVg90H21EOLACvtfcHk0ljwJibuJYbZ9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXls1Sntrg%253D&md5=d5e7fc2c0d177b11c27ec037fb9b30a9</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.7554%2FeLife.10180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.10180%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DRohou%26aufirst%3DA.%26aulast%3DSchep%26aufirst%3DD.%2BG.%26aulast%3DBason%26aufirst%3DJ.%2BV.%26aulast%3DMontgomery%26aufirst%3DM.%2BG.%26aulast%3DWalker%26aufirst%3DJ.%2BE.%26aulast%3DGrigorieff%26aufirst%3DN.%26aulast%3DRubinstein%26aufirst%3DJ.%2BL.%26atitle%3DStructure%2520and%2520conformational%2520states%2520of%2520the%2520bovine%2520mitochondrial%2520ATP%2520synthase%2520by%2520cryo-EM%26jtitle%3DeLife%26date%3D2015%26volume%3D4%26spage%3De10180%26doi%3D10.7554%2FeLife.10180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueler, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, J. L.</span></span> <span> </span><span class="NLM_article-title">Atomic model for the dimeric F(O) region of mitochondrial ATP synthase</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">936</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.1126/science.aao4815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1126%2Fscience.aao4815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29074581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSis77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2017&pages=936-940&author=H.+Guoauthor=S.+A.+Buelerauthor=J.+L.+Rubinstein&title=Atomic+model+for+the+dimeric+F%28O%29+region+of+mitochondrial+ATP+synthase&doi=10.1126%2Fscience.aao4815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic model for the dimeric FO region of mitochondrial ATP synthase</span></div><div class="casAuthors">Guo, Hui; Bueler, Stephanie A.; Rubinstein, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">6365</span>),
    <span class="NLM_cas:pages">936-940</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Mitochondrial ATP synthase produces the majority of ATP in eukaryotic cells, and its dimerization is necessary to create the inner membrane folds, or cristae, characteristic of mitochondria.  Proton translocation through the membrane-embedded FO region turns the rotor that drives ATP synthesis in the sol. F1 region.  Although crystal structures of the F1 region have illustrated how this rotation leads to ATP synthesis, understanding how proton translocation produces the rotation has been impeded by the lack of an exptl. at. model for the FO region.  Using cryo-electron microscopy, we detd. the structure of the dimeric FO complex from Saccharomyces cerevisiae at a resoln. of 3.6 angstroms.  The structure clarifies how the protons travel through the complex, how the complex dimerizes, and how the dimers bend the membrane to produce cristae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpROb-iJVyWh7Vg90H21EOLACvtfcHk0ljwJibuJYbZ9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSis77I&md5=3a7358d79b31bc4eb8eae8d3b5990478</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1126%2Fscience.aao4815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aao4815%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DBueler%26aufirst%3DS.%2BA.%26aulast%3DRubinstein%26aufirst%3DJ.%2BL.%26atitle%3DAtomic%2520model%2520for%2520the%2520dimeric%2520F%2528O%2529%2520region%2520of%2520mitochondrial%2520ATP%2520synthase%26jtitle%3DScience%26date%3D2017%26volume%3D358%26spage%3D936%26epage%3D940%26doi%3D10.1126%2Fscience.aao4815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courbon, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueler, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, J. L.</span></span> <span> </span><span class="NLM_article-title">Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>589</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1038/s41586-020-3004-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fs41586-020-3004-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=33299175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFCgtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=589&publication_year=2021&pages=143-147&author=H.+Guoauthor=G.+M.+Courbonauthor=S.+A.+Buelerauthor=J.+Maiauthor=J.+Liuauthor=J.+L.+Rubinstein&title=Structure+of+mycobacterial+ATP+synthase+bound+to+the+tuberculosis+drug+bedaquiline&doi=10.1038%2Fs41586-020-3004-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline</span></div><div class="casAuthors">Guo, Hui; Courbon, Gautier M.; Bueler, Stephanie A.; Mai, Juntao; Liu, Jun; Rubinstein, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">589</span>
        (<span class="NLM_cas:issue">7840</span>),
    <span class="NLM_cas:pages">143-147</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Tuberculosis-the world's leading cause of death by infectious disease-is increasingly resistant to current first-line antibiotics1.  The bacterium Mycobacterium tuberculosis (which causes tuberculosis) can survive low-energy conditions, allowing infections to remain dormant and decreasing their susceptibility to many antibiotics2.  Bedaquiline was developed in 2005 from a lead compd. identified in a phenotypic screen against Mycobacterium smegmatis3.  This drug can sterilize even latent M. tuberculosis infections4 and has become a cornerstone of treatment for multidrug-resistant and extensively drug-resistant tuberculosis1,5,6.  Bedaquiline targets the mycobacterial ATP synthase3, which is an essential enzyme in the obligate aerobic Mycobacterium genus3,7, but how it binds the intact enzyme is unknown.  Here we detd. cryo-electron microscopy structures of M. smegmatis ATP synthase alone and in complex with bedaquiline.  The drug-free structure suggests that hook-like extensions from the α-subunits prevent the enzyme from running in reverse, inhibiting ATP hydrolysis and preserving energy in hypoxic conditions.  Bedaquiline binding induces large conformational changes in the ATP synthase, creating tight binding pockets at the interface of subunits a and c that explain the potency of this drug as an antibiotic for tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpPrR1A82-xLVg90H21EOLACvtfcHk0lglOj0QbE_VCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFCgtLjI&md5=e5ed1b61faa92bc6c429d36024e5ad0f</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-3004-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-3004-3%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DCourbon%26aufirst%3DG.%2BM.%26aulast%3DBueler%26aufirst%3DS.%2BA.%26aulast%3DMai%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DRubinstein%26aufirst%3DJ.%2BL.%26atitle%3DStructure%2520of%2520mycobacterial%2520ATP%2520synthase%2520bound%2520to%2520the%2520tuberculosis%2520drug%2520bedaquiline%26jtitle%3DNature%26date%3D2021%26volume%3D589%26spage%3D143%26epage%3D147%26doi%3D10.1038%2Fs41586-020-3004-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lutter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrahams, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Raaij, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundqvist, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. E.</span></span> <span> </span><span class="NLM_article-title">Crystallization of F1-ATPase from bovine heart mitochondria</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>229</i></span>,  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1993.1081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1006%2Fjmbi.1993.1081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=8433373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK3sXhs1Ciurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=229&publication_year=1993&pages=787-790&author=R.+Lutterauthor=J.+P.+Abrahamsauthor=M.+J.+van+Raaijauthor=R.+J.+Toddauthor=T.+Lundqvistauthor=S.+K.+Buchananauthor=A.+G.+Leslieauthor=J.+E.+Walker&title=Crystallization+of+F1-ATPase+from+bovine+heart+mitochondria&doi=10.1006%2Fjmbi.1993.1081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Crystallization of F1-ATPase from bovine heart mitochondria</span></div><div class="casAuthors">Lutter, R.; Abrahams, J. P.; Van Raaij, M. J.; Todd, R. J.; Lundqvist, T.; Buchanan, S. K.; Leslie, A. G. W.; Walker, J. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">229</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">787-90</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    </div><div class="casAbstract">Crystals of the F1-ATPase sector of the ATP synthase complex from bovine heart mitochondria have been grown from solns. contg. polyethylene glycol 6000.  The crystals diffract to 2.9-Å resoln. on a lab. x-ray source.  They are orthorhombic and belong to the space group P212121.  The unit cell axes are a = 285 Å, a = 108 Å, c = 140 Å.  There is 1 mol. of F1-ATPase in the asym. unit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3tW1DjcRg_7Vg90H21EOLACvtfcHk0lglOj0QbE_VCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhs1Ciurc%253D&md5=1ab3c7b07ad35fa0d08234eed7dfd964</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1993.1081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1993.1081%26sid%3Dliteratum%253Aachs%26aulast%3DLutter%26aufirst%3DR.%26aulast%3DAbrahams%26aufirst%3DJ.%2BP.%26aulast%3Dvan%2BRaaij%26aufirst%3DM.%2BJ.%26aulast%3DTodd%26aufirst%3DR.%2BJ.%26aulast%3DLundqvist%26aufirst%3DT.%26aulast%3DBuchanan%26aufirst%3DS.%2BK.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%26aulast%3DWalker%26aufirst%3DJ.%2BE.%26atitle%3DCrystallization%2520of%2520F1-ATPase%2520from%2520bovine%2520heart%2520mitochondria%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1993%26volume%3D229%26spage%3D787%26epage%3D790%26doi%3D10.1006%2Fjmbi.1993.1081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dendouga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergauwen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molenberghs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranckx, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willebrords, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ristic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorange, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span> <span> </span><span class="NLM_article-title">Diarylquinolines target subunit c of mycobacterial ATP synthase</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1038/nchembio884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnchembio884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=17496888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOjurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=323-324&author=A.+Koulauthor=N.+Dendougaauthor=K.+Vergauwenauthor=B.+Molenberghsauthor=L.+Vranckxauthor=R.+Willebrordsauthor=Z.+Risticauthor=H.+Lillauthor=I.+Dorangeauthor=J.+Guillemontauthor=D.+Baldauthor=K.+Andries&title=Diarylquinolines+target+subunit+c+of+mycobacterial+ATP+synthase&doi=10.1038%2Fnchembio884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Diarylquinolines target subunit c of mycobacterial ATP synthase</span></div><div class="casAuthors">Koul, Anil; Dendouga, Najoua; Vergauwen, Karen; Molenberghs, Brenda; Vranckx, Luc; Willebrords, Rudy; Ristic, Zorica; Lill, Holger; Dorange, Ismet; Guillemont, Jerome; Bald, Dirk; Andries, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">323-324</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The diarylquinoline R207910 (TMC207) is a promising candidate in clin. development for the treatment of tuberculosis.  Though R207910-resistant mycobacteria bear mutations in ATP synthase, the compd.'s precise target is not known.  Here we establish by genetic, biochem. and binding assays that the oligomeric subunit c (AtpE) of ATP synthase is the target of R207910.  Thus targeting energy metab. is a new, promising approach for antibacterial drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoo57k1zZdTLVg90H21EOLACvtfcHk0ljfPovGImO3Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOjurc%253D&md5=f9ba04042bef448f5910cea0e89715f0</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1038%2Fnchembio884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio884%26sid%3Dliteratum%253Aachs%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DDendouga%26aufirst%3DN.%26aulast%3DVergauwen%26aufirst%3DK.%26aulast%3DMolenberghs%26aufirst%3DB.%26aulast%3DVranckx%26aufirst%3DL.%26aulast%3DWillebrords%26aufirst%3DR.%26aulast%3DRistic%26aufirst%3DZ.%26aulast%3DLill%26aufirst%3DH.%26aulast%3DDorange%26aufirst%3DI.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DBald%26aufirst%3DD.%26aulast%3DAndries%26aufirst%3DK.%26atitle%3DDiarylquinolines%2520target%2520subunit%2520c%2520of%2520mycobacterial%2520ATP%2520synthase%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2007%26volume%3D3%26spage%3D323%26epage%3D324%26doi%3D10.1038%2Fnchembio884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hards, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, G. M.</span></span> <span> </span><span class="NLM_article-title">Bactericidal mode of action of bedaquiline</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">2028</span>– <span class="NLM_lpage">2037</span>, <span class="refDoi"> DOI: 10.1093/jac/dkv054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fjac%2Fdkv054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25754998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFyltr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2015&pages=2028-2037&author=K.+Hardsauthor=J.+R.+Robsonauthor=M.+Berneyauthor=L.+Shawauthor=D.+Baldauthor=A.+Koulauthor=K.+Andriesauthor=G.+M.+Cook&title=Bactericidal+mode+of+action+of+bedaquiline&doi=10.1093%2Fjac%2Fdkv054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Bactericidal mode of action of bedaquiline</span></div><div class="casAuthors">Hards, Kiel; Robson, Jennifer R.; Berney, Michael; Shaw, Lisa; Bald, Dirk; Koul, Anil; Andries, Koen; Cook, Gregory M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2028-2037</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: It is not fully understood why inhibiting ATP synthesis in Mycobacterium species leads to death in non-replicating cells.  We investigated the bactericidal mode of action of the anti-tubercular F1Fo-ATP synthase inhibitor bedaquiline (Sirturo) in order to further understand the lethality of ATP synthase inhibition.  Methods:Mycobacterium smegmatis strains were used for all the expts.  Growth and survival during a bedaquiline challenge were performed in multiple media types.  A time-course microarray was performed during initial bedaquiline challenge in minimal medium.  Oxygen consumption and proton-motive force measurements were performed on whole cells and inverted membrane vesicles, resp.  Results: A killing of 3 log10 cfu/mL was achieved 4-fold more quickly in minimal medium (a glycerol carbon source) vs. rich medium (LB with Tween 80) during bedaquiline challenge.  Assessing the accelerated killing condition, we identified a transcriptional remodelling of metab. that was consistent with respiratory dysfunction but inconsistent with ATP depletion.  In glycerol-energized cell suspensions, bedaquiline caused an immediate 2.3-fold increase in oxygen consumption.  Bedaquiline collapsed the transmembrane pH gradient, but not the membrane potential, in a dose-dependent manner.  Both these effects were dependent on binding to the F1Fo-ATP synthase.  Conclusions: Challenge with bedaquiline results in an electroneutral uncoupling of respiration-driven ATP synthesis.  This may be a determinant of the bactericidal effects of bedaquiline, while ATP depletion may be a determinant of its delayed onset of killing.  We propose that bedaquiline binds to and perturbs the a-c subunit interface of the Fo, leading to futile proton cycling, which is known to be lethal to mycobacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTEo-2TAKMdrVg90H21EOLACvtfcHk0ljfPovGImO3Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFyltr7N&md5=22c8df11e6b904ba3645fa7ac74c5074</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkv054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkv054%26sid%3Dliteratum%253Aachs%26aulast%3DHards%26aufirst%3DK.%26aulast%3DRobson%26aufirst%3DJ.%2BR.%26aulast%3DBerney%26aufirst%3DM.%26aulast%3DShaw%26aufirst%3DL.%26aulast%3DBald%26aufirst%3DD.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DCook%26aufirst%3DG.%2BM.%26atitle%3DBactericidal%2520mode%2520of%2520action%2520of%2520bedaquiline%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2015%26volume%3D70%26spage%3D2028%26epage%3D2037%26doi%3D10.1093%2Fjac%2Fdkv054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hards, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillan, D. G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schurig-Briccio, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gennis, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, G. M.</span></span> <span> </span><span class="NLM_article-title">Ionophoric effects of the antitubercular drug bedaquiline</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">7326</span>– <span class="NLM_lpage">7331</span>, <span class="refDoi"> DOI: 10.1073/pnas.1803723115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1073%2Fpnas.1803723115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29941569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCmsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=7326-7331&author=K.+Hardsauthor=D.+G.+G.+McMillanauthor=L.+A.+Schurig-Briccioauthor=R.+B.+Gennisauthor=H.+Lillauthor=D.+Baldauthor=G.+M.+Cook&title=Ionophoric+effects+of+the+antitubercular+drug+bedaquiline&doi=10.1073%2Fpnas.1803723115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Ionophoric effects of the antitubercular drug bedaquiline</span></div><div class="casAuthors">Hards, Kiel; McMillan, Duncan G. G.; Schurig-Briccio, Lici A.; Gennis, Robert B.; Lill, Holger; Bald, Dirk; Cook, Gregory M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">7326-7331</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Bedaquiline (BDQ), an inhibitor of the mycobacterial F1Fo-ATP synthase, has revolutionized the antitubercular drug discovery program by defining energy metab. as a potent new target space.  Several studies have recently suggested that BDQ ultimately causes mycobacterial cell death through a phenomenon known as uncoupling.  The biochem. basis underlying this, in BDQ, is unresolved and may represent a new pathway to the development of effective therapeutics.  In this communication, we demonstrate that BDQ can inhibit ATP synthesis in Escherichia coli by functioning as a H+/K+ ionophore, causing transmembrane pH and potassium gradients to be equilibrated.  Despite the apparent lack of a BDQ-binding site, incorporating the E. coli Fo subunit into liposomes enhanced the ionophoric activity of BDQ.  We discuss the possibility that localization of BDQ at F1Fo-ATP synthases enables BDQ to create an uncoupled microenvironment, by antiporting H+/K+.  Ionophoric properties may be desirable in high-affinity antimicrobials targeting integral membrane proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnzopAp0asdrVg90H21EOLACvtfcHk0ljfPovGImO3Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCmsb3L&md5=458eb31c6312ab5573f5d9d3f5bbbf1c</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1803723115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1803723115%26sid%3Dliteratum%253Aachs%26aulast%3DHards%26aufirst%3DK.%26aulast%3DMcMillan%26aufirst%3DD.%2BG.%2BG.%26aulast%3DSchurig-Briccio%26aufirst%3DL.%2BA.%26aulast%3DGennis%26aufirst%3DR.%2BB.%26aulast%3DLill%26aufirst%3DH.%26aulast%3DBald%26aufirst%3DD.%26aulast%3DCook%26aufirst%3DG.%2BM.%26atitle%3DIonophoric%2520effects%2520of%2520the%2520antitubercular%2520drug%2520bedaquiline%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3D7326%26epage%3D7331%26doi%3D10.1073%2Fpnas.1803723115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anurag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, D.</span></span> <span> </span><span class="NLM_article-title">Unraveling the potential of intrinsically disordered proteins as drug targets: application to Mycobacterium tuberculosis</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1752</span>– <span class="NLM_lpage">1757</span>, <span class="refDoi"> DOI: 10.1039/b905518p</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1039%2Fb905518p" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19763328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2ks7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=1752-1757&author=M.+Anuragauthor=D.+Dash&title=Unraveling+the+potential+of+intrinsically+disordered+proteins+as+drug+targets%3A+application+to+Mycobacterium+tuberculosis&doi=10.1039%2Fb905518p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Unraveling the potential of intrinsically disordered proteins as drug targets: application to Mycobacterium tuberculosis</span></div><div class="casAuthors">Anurag, Meenakshi; Dash, Debasis</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1752-1757</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Many eukaryotic and prokaryotic proteins remain disordered under physiol. conditions and often acquire a stable secondary structure on binding to their cellular targets.  Though the process of binding is still under anal., it has been found that the flexibility of proteins can add to their functionality.  This motivated us to explore intrinsically disordered proteins (IDPs) as drug targets.  In silico studies have been carried out on Mycobacterium tuberculosis, which, with emergence of hyper-virulent and drug resistant strains, XDRs and MDRs, is one of the most dreaded pathogens in the modern world.  The authors' study reports 13 IDPs as potential drug targets, and 3 of them - FtsW (Rv2154c), GlmU (Rv1018c) and Obg (Rv2440c) - are chosen as key proteins and are described in detail.  Future applications of this method can provide new insight into understanding the mol. mechanism of IDPs and their potential role as drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVN7gx8lC1arVg90H21EOLACvtfcHk0lhg_eiV5OBqLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2ks7rI&md5=8cc7b07044a7d6223b734b49287f1d17</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1039%2Fb905518p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb905518p%26sid%3Dliteratum%253Aachs%26aulast%3DAnurag%26aufirst%3DM.%26aulast%3DDash%26aufirst%3DD.%26atitle%3DUnraveling%2520the%2520potential%2520of%2520intrinsically%2520disordered%2520proteins%2520as%2520drug%2520targets%253A%2520application%2520to%2520Mycobacterium%2520tuberculosis%26jtitle%3DMol.%2520BioSyst.%26date%3D2009%26volume%3D5%26spage%3D1752%26epage%3D1757%26doi%3D10.1039%2Fb905518p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyson, H. J.</span></span> <span> </span><span class="NLM_article-title">Intrinsically disordered proteins in cellular signalling and regulation</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">18</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1038/nrm3920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnrm3920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25531225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKlt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=18-29&author=P.+E.+Wrightauthor=H.+J.+Dyson&title=Intrinsically+disordered+proteins+in+cellular+signalling+and+regulation&doi=10.1038%2Fnrm3920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Intrinsically disordered proteins in cellular signalling and regulation</span></div><div class="casAuthors">Wright, Peter E.; Dyson, H. Jane</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18-29</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Intrinsically disordered proteins (IDPs) are important components of the cellular signalling machinery, allowing the same polypeptide to undertake different interactions with different consequences.  IDPs are subject to combinatorial post-translational modifications and alternative splicing, adding complexity to regulatory networks and providing a mechanism for tissue-specific signalling.  These proteins participate in the assembly of signalling complexes and in the dynamic self-assembly of membrane-less nuclear and cytoplasmic organelles.  Exptl., computational and bioinformatic analyses combine to identify and characterize disordered regions of proteins, leading to a greater appreciation of their widespread roles in biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw5RO2fjcUD7Vg90H21EOLACvtfcHk0lhg_eiV5OBqLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKlt7fK&md5=39845ab9ab74fe94b7f7b810b632503b</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1038%2Fnrm3920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3920%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DP.%2BE.%26aulast%3DDyson%26aufirst%3DH.%2BJ.%26atitle%3DIntrinsically%2520disordered%2520proteins%2520in%2520cellular%2520signalling%2520and%2520regulation%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2015%26volume%3D16%26spage%3D18%26epage%3D29%26doi%3D10.1038%2Fnrm3920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uversky, V. N.</span></span> <span> </span><span class="NLM_article-title">Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators</span>. <i>Front. Mol. Biosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">6</span>, <span class="refDoi"> DOI: 10.3389/fmolb.2014.00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3389%2Ffmolb.2014.00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25988147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsFyrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2014&pages=6&author=V.+N.+Uversky&title=Wrecked+regulation+of+intrinsically+disordered+proteins+in+diseases%3A+pathogenicity+of+deregulated+regulators&doi=10.3389%2Ffmolb.2014.00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators</span></div><div class="casAuthors">Uversky, Vladimir N.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Biosciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6/1-6/24</span>CODEN:
                <span class="NLM_cas:coden">FMBRBS</span>;
        ISSN:<span class="NLM_cas:issn">2296-889X</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Biol. active proteins without stable tertiary structure are common in all known proteomes.  Functions of these intrinsically disordered proteins (IDPs) are typically related to regulation, signaling, and control.  Cellular levels of these important regulators are tightly regulated by a variety mechanisms ranging from firmly controlled expression to precisely targeted degrdn.  Functions of IDPs are controlled by binding to specific partners, alternative splicing, and posttranslational modifications among other means.  In the norm, right amts. of precisely activated IDPs have to be present in right time at right places.  Wrecked regulation brings havoc to the ordered world of disordered proteins, leading to protein misfolding, misidentification, and missignaling that give rise to numerous human diseases, such as cancer, cardiovascular disease, neurodegenerative diseases, and diabetes.  Among factors inducing pathogenic transformations of IDPs are various cellular mechanisms, such as chromosomal translocations, damaged splicing, altered expression, frustrated posttranslational modifications, aberrant proteolytic degrdn., and defective trafficking.  This review presents some of the aspects of deregulated regulation of IDPs leading to human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO-3sQjsU2wbVg90H21EOLACvtfcHk0ljTh8cq_hzR3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsFyrtrs%253D&md5=eaa0a8500c57beeade266712316d3e58</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.3389%2Ffmolb.2014.00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmolb.2014.00006%26sid%3Dliteratum%253Aachs%26aulast%3DUversky%26aufirst%3DV.%2BN.%26atitle%3DWrecked%2520regulation%2520of%2520intrinsically%2520disordered%2520proteins%2520in%2520diseases%253A%2520pathogenicity%2520of%2520deregulated%2520regulators%26jtitle%3DFront.%2520Mol.%2520Biosci.%26date%3D2014%26volume%3D1%26spage%3D6%26doi%3D10.3389%2Ffmolb.2014.00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suryawanshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiti, S.</span></span> <span> </span><span class="NLM_article-title">Intrinsically disordered protein from a pathogenic mesophile Mycobacterium tuberculosis adopts structured conformation at high temperature</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1123</span>– <span class="NLM_lpage">1133</span>, <span class="refDoi"> DOI: 10.1002/prot.21798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1002%2Fprot.21798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=18004752" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2008&pages=1123-1133&author=N.+Kumarauthor=S.+Shuklaauthor=S.+Kumarauthor=A.+Suryawanshiauthor=U.+Chaudhryauthor=S.+Ramachandranauthor=S.+Maiti&title=Intrinsically+disordered+protein+from+a+pathogenic+mesophile+Mycobacterium+tuberculosis+adopts+structured+conformation+at+high+temperature&doi=10.1002%2Fprot.21798"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1002%2Fprot.21798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.21798%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DSuryawanshi%26aufirst%3DA.%26aulast%3DChaudhry%26aufirst%3DU.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DMaiti%26aufirst%3DS.%26atitle%3DIntrinsically%2520disordered%2520protein%2520from%2520a%2520pathogenic%2520mesophile%2520Mycobacterium%2520tuberculosis%2520adopts%2520structured%2520conformation%2520at%2520high%2520temperature%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2008%26volume%3D71%26spage%3D1123%26epage%3D1133%26doi%3D10.1002%2Fprot.21798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meszaros, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vertessy, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dosztanyi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, I.</span></span> <span> </span><span class="NLM_article-title">Proteins with complex architecture as potential targets for drug design: a case study of Mycobacterium tuberculosis</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e1002118</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.1002118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pcbi.1002118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21814507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGqs7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=e1002118&author=B.+Meszarosauthor=J.+Tothauthor=B.+G.+Vertessyauthor=Z.+Dosztanyiauthor=I.+Simon&title=Proteins+with+complex+architecture+as+potential+targets+for+drug+design%3A+a+case+study+of+Mycobacterium+tuberculosis&doi=10.1371%2Fjournal.pcbi.1002118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Proteins with complex architecture as potential targets for drug design: a case study of Mycobacterium tuberculosis</span></div><div class="casAuthors">Meszaros, Balint; Toth, Judit; Vertessy, Beata G.; Dosztanyi, Zsuzsanna; Simon, Istvan</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e1002118</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Lengthy co-evolution of Homo sapiens and Mycobacterium tuberculosis, the main causative agent of tuberculosis, resulted in a dramatically successful pathogen species that presents considerable challenge for modern medicine.  The continuous and ever increasing appearance of multi-drug resistant mycobacteria necessitates the identification of novel drug targets and drugs with new mechanisms of action.  However, further insights are needed to establish automated protocols for target selection based on the available complete genome sequences.  In the present study, we perform complete proteome level comparisons between M. tuberculosis, mycobacteria, other prokaryotes and available eukaryotes based on protein domains, local sequence similarities and protein disorder.  We show that the enrichment of certain domains in the genome can indicate an important function specific to M. tuberculosis.  We identified two families, termed pkn and PE/PPE that stand out in this respect.  The common property of these two protein families is a complex domain organization that combines species-specific regions, commonly occurring domains and disordered segments.  Besides highlighting promising novel drug target candidates in M. tuberculosis, the presented anal. can also be viewed as a general protocol to identify proteins involved in species-specific functions in a given organism.  We conclude that target selection protocols should be extended to include proteins with complex domain architectures instead of focusing on sequentially unique and essential proteins only.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpETKVogR9Xs7Vg90H21EOLACvtfcHk0ljTh8cq_hzR3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGqs7nI&md5=3a9385712e14ef77aaba9e969d939815</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1002118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1002118%26sid%3Dliteratum%253Aachs%26aulast%3DMeszaros%26aufirst%3DB.%26aulast%3DToth%26aufirst%3DJ.%26aulast%3DVertessy%26aufirst%3DB.%2BG.%26aulast%3DDosztanyi%26aufirst%3DZ.%26aulast%3DSimon%26aufirst%3DI.%26atitle%3DProteins%2520with%2520complex%2520architecture%2520as%2520potential%2520targets%2520for%2520drug%2520design%253A%2520a%2520case%2520study%2520of%2520Mycobacterium%2520tuberculosis%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3De1002118%26doi%3D10.1371%2Fjournal.pcbi.1002118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, S. L.</span></span> <span> </span><span class="NLM_article-title">Mycobacterial PE/PPE proteins at the host-pathogen interface</span>. <i>Clin. Dev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">497203</span>, <span class="refDoi"> DOI: 10.1155/2011/497203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1155%2F2011%2F497203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21318182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3M7ovFKnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=497203&author=S.+L.+Sampson&title=Mycobacterial+PE%2FPPE+proteins+at+the+host-pathogen+interface&doi=10.1155%2F2011%2F497203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Mycobacterial PE/PPE proteins at the host-pathogen interface</span></div><div class="casAuthors">Sampson Samantha L</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & developmental immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">497203</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The mycobacterial PE/PPE proteins have attracted much interest since their formal identification just over a decade ago.  It has been widely speculated that these proteins may play a role in evasion of host immune responses, possibly via antigenic variation.  Although a cohesive understanding of their function(s) has yet to be established, emerging data increasingly supports a role for the PE/PPE proteins at multiple levels of the infectious process.  This paper will delineate salient features of the families revealed by comparative genomics, bioinformatic analyses and genome-wide screening approaches and will summarise existing knowledge of subcellular localization, secretion pathways, and protein structure.  These characteristics will be considered in light of findings on innate and adaptive host responses to PE/PPE proteins, and we will review the increasing body of data on B and T cell recognition of these proteins.  Finally, we will consider how current knowledge and future explorations may contribute to a more comprehensive understanding of these intriguing proteins and their involvement in host pathogen interactions.  Ultimately this information could underpin future intervention strategies, for example, in the area of new and improved diagnostic tools and vaccine candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQa9-ctKunXE7P3FVUi_gf8fW6udTcc2eZU9j_Qc5qVG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7ovFKnsg%253D%253D&md5=ee1140a065b79b5276812f6111814268</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1155%2F2011%2F497203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F497203%26sid%3Dliteratum%253Aachs%26aulast%3DSampson%26aufirst%3DS.%2BL.%26atitle%3DMycobacterial%2520PE%252FPPE%2520proteins%2520at%2520the%2520host-pathogen%2520interface%26jtitle%3DClin.%2520Dev.%2520Immunol.%26date%3D2011%26volume%3D2011%26spage%3D497203%26doi%3D10.1155%2F2011%2F497203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blower, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, J. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">1706</span>– <span class="NLM_lpage">1713</span>, <span class="refDoi"> DOI: 10.1073/pnas.1525047113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1073%2Fpnas.1525047113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26792525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=1706-1713&author=T.+R.+Blowerauthor=B.+H.+Williamsonauthor=R.+J.+Kernsauthor=J.+M.+Berger&title=Crystal+structure+and+stability+of+gyrase-fluoroquinolone+cleaved+complexes+from+Mycobacterium+tuberculosis&doi=10.1073%2Fpnas.1525047113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis</span></div><div class="casAuthors">Blower, Tim R.; Williamson, Benjamin H.; Kerns, Robert J.; Berger, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1706-1713</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis (Mtb) infects one-third of the world's population and in 2013 accounted for 1.5 million deaths.  Fluoroquinolone antibacterials, which target DNA gyrase, are crit. agents used to halt the progression from multidrug-resistant tuberculosis to extensively resistant disease; however, fluoroquinolone resistance is emerging and new ways to bypass resistance are required.  To better explain known differences in fluoroquinolone action, the crystal structures of the WT Mtb DNA gyrase cleavage core and a fluoroquinolone-sensitized mutant were detd. in complex with DNA and five fluoroquinolones.  The structures, ranging from 2.4- to 2.6-Å resoln., show that the intrinsically low susceptibility of Mtb to fluoroquinolones correlates with a redn. in contacts to the water shell of an assocd. magnesium ion, which bridges fluoroquinolone-gyrase interactions.  Surprisingly, the structural data revealed few differences in fluoroquinolone-enzyme contacts from drugs that have very different activities against Mtb.  By contrast, a stability assay using purified components showed a clear relationship between ternary complex reversibility and inhibitory activities reported with cultured cells.  Collectively, our data indicate that the stability of fluoroquinolone/DNA interactions is a major determinant of fluoroquinolone activity and that moieties that have been appended to the C7 position of different quinolone scaffolds do not take advantage of specific contacts that might be made with the enzyme.  These concepts point to new approaches for developing quinolone-class compds. that have increased potency against Mtb and the ability to overcome resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotyAfeeRgSebVg90H21EOLACvtfcHk0lhiIdIrDxNlng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWjsr8%253D&md5=bde8e79ead3566a890d7e970de8c3292</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1525047113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1525047113%26sid%3Dliteratum%253Aachs%26aulast%3DBlower%26aufirst%3DT.%2BR.%26aulast%3DWilliamson%26aufirst%3DB.%2BH.%26aulast%3DKerns%26aufirst%3DR.%2BJ.%26aulast%3DBerger%26aufirst%3DJ.%2BM.%26atitle%3DCrystal%2520structure%2520and%2520stability%2520of%2520gyrase-fluoroquinolone%2520cleaved%2520complexes%2520from%2520Mycobacterium%2520tuberculosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D1706%26epage%3D1713%26doi%3D10.1073%2Fpnas.1525047113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ditse, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. F.</span></span> <span> </span><span class="NLM_article-title">DNA Replication in Mycobacterium tuberculosis</span>. <i>Microbiol. Spectrum</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">TBTB2-0027-2016</span>, <span class="refDoi"> DOI: 10.1128/microbiolspec.TBTB2-0027-2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2Fmicrobiolspec.TBTB2-0027-2016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=TBTB2-0027-2016&author=Z.+Ditseauthor=M.+H.+Lamersauthor=D.+F.+Warner&title=DNA+Replication+in+Mycobacterium+tuberculosis&doi=10.1128%2Fmicrobiolspec.TBTB2-0027-2016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1128%2Fmicrobiolspec.TBTB2-0027-2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmicrobiolspec.TBTB2-0027-2016%26sid%3Dliteratum%253Aachs%26aulast%3DDitse%26aufirst%3DZ.%26aulast%3DLamers%26aufirst%3DM.%2BH.%26aulast%3DWarner%26aufirst%3DD.%2BF.%26atitle%3DDNA%2520Replication%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DMicrobiol.%2520Spectrum%26date%3D2017%26volume%3D5%26spage%3DTBTB2-0027-2016%26doi%3D10.1128%2Fmicrobiolspec.TBTB2-0027-2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prisic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husson, R. N.</span></span> <span> </span><span class="NLM_article-title">Mycobacterium tuberculosis Serine/Threonine protein kinases</span>. <i>Microbiol. Spectrum</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">MGM2-0006-2013</span>, <span class="refDoi"> DOI: 10.1128/microbiolspec.MGM2-0006-2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2Fmicrobiolspec.MGM2-0006-2013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=MGM2-0006-2013&author=S.+Prisicauthor=R.+N.+Husson&title=Mycobacterium+tuberculosis+Serine%2FThreonine+protein+kinases&doi=10.1128%2Fmicrobiolspec.MGM2-0006-2013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1128%2Fmicrobiolspec.MGM2-0006-2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmicrobiolspec.MGM2-0006-2013%26sid%3Dliteratum%253Aachs%26aulast%3DPrisic%26aufirst%3DS.%26aulast%3DHusson%26aufirst%3DR.%2BN.%26atitle%3DMycobacterium%2520tuberculosis%2520Serine%252FThreonine%2520protein%2520kinases%26jtitle%3DMicrobiol.%2520Spectrum%26date%3D2014%26volume%3D2%26spage%3DMGM2-0006-2013%26doi%3D10.1128%2Fmicrobiolspec.MGM2-0006-2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alber, T.</span></span> <span> </span><span class="NLM_article-title">Signaling mechanisms of the Mycobacterium tuberculosis receptor Ser/Thr protein kinases</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">657</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2009.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.sbi.2009.10.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19914822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsV2gsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=650-657&author=T.+Alber&title=Signaling+mechanisms+of+the+Mycobacterium+tuberculosis+receptor+Ser%2FThr+protein+kinases&doi=10.1016%2Fj.sbi.2009.10.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling mechanisms of the Mycobacterium tuberculosis receptor Ser/Thr protein kinases</span></div><div class="casAuthors">Alber, Tom</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">650-657</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Like eukaryotes, bacteria express receptor Ser/Thr protein kinases (STPKs) that initiate a wide variety of signaling networks.  Recent biochem. and structural studies of the STPKs of M. tuberculosis have revealed that bacterial and eukaryotic STPKs adopt common folds and share mechanisms of substrate recognition and regulation.  Mycobacterial receptor STPKs are activated by dimerization through 2 distinct interfaces that promote activation-loop phosphorylation.  The active STPKs phosphorylate diverse substrates within the bacterial cell, including other kinases as well as proteins involved in many central physiol. processes.  In the case of the FHA-domain protein, GarA, the unphosphorylated protein regulates primary metab., while phosphorylation mediates GarA autoinhibition.  These studies have begun to define the activation mechanisms and the biol. regulatory functions of the mycobacterial STPKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprcpYqq0as2LVg90H21EOLACvtfcHk0ljG8RXli6oyNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsV2gsrfP&md5=d4eb3c345c2ab9d75291c289b113dbc7</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2009.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2009.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DAlber%26aufirst%3DT.%26atitle%3DSignaling%2520mechanisms%2520of%2520the%2520Mycobacterium%2520tuberculosis%2520receptor%2520Ser%252FThr%2520protein%2520kinases%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2009%26volume%3D19%26spage%3D650%26epage%3D657%26doi%3D10.1016%2Fj.sbi.2009.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnappinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrt, S.</span></span> <span> </span><span class="NLM_article-title">Triosephosphate isomerase is dispensable in vitro yet essential for Mycobacterium tuberculosis to establish infection</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e00085</span>, <span class="refDoi"> DOI: 10.1128/mBio.00085-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FmBio.00085-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=24757211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Smsr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=e00085&author=C.+Trujilloauthor=A.+Blumenthalauthor=J.+Marreroauthor=K.+Y.+Rheeauthor=D.+Schnappingerauthor=S.+Ehrt&title=Triosephosphate+isomerase+is+dispensable+in+vitro+yet+essential+for+Mycobacterium+tuberculosis+to+establish+infection&doi=10.1128%2FmBio.00085-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Triosephosphate isomerase is dispensable in vitro yet essential for Mycobacterium tuberculosis to establish infection</span></div><div class="casAuthors">Trujillo, Carolina; Blumenthal, Antje; Marrero, Joeli; Rhee, Kyu Y.; Schnappinger, Dirk; Ehrt, Sabine</div><div class="citationInfo"><span class="NLM_cas:title">mBio</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e00085/1-e00085/12, 12</span>CODEN:
                <span class="NLM_cas:coden">MBIOCL</span>;
        ISSN:<span class="NLM_cas:issn">2150-7511</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Triosephosphate isomerase (TPI) catalyzes the interconversion of dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-phosphate (G3P).  This reaction is required for glycolysis and gluconeogenesis, and tpi has been predicted to be essential for growth of Mycobacterium tuberculosis.  However, when studying a conditionally regulated tpi knockdown mutant, we noticed that depletion of TPI reduced growth of M. tuberculosis in media contg. a single carbon source but not in media that contained both a glycolytic and a gluconeogenic carbon source.  We used such two-carbon-source media to isolate a tpi deletion (Δtpi) mutant.  The Δtpi mutant did not survive with single carbon substrates but grew like wild-type (WT) M. tuberculosis in the presence of both a glycolytic and a gluconeogenic carbon source. 13C metabolite tracing revealed the accumulation of TPI substrates in Δtpi and the absence of alternative triosephosphate isomerases and metabolic bypass reactions, which confirmed the requirement of TPI for glycolysis and gluconeogenesis in M. tuberculosis.  The Δtpi strain was furthermore severely attenuated in the mouse model of tuberculosis, suggesting that M. tuberculosis cannot simultaneously access sufficient quantities of glycolytic and gluconeogenic carbon substrates to establish infection in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiBBsrr76A4LVg90H21EOLACvtfcHk0ljG8RXli6oyNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Smsr%252FF&md5=fa624cd5300a2993006d45d6ee309a1e</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1128%2FmBio.00085-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.00085-14%26sid%3Dliteratum%253Aachs%26aulast%3DTrujillo%26aufirst%3DC.%26aulast%3DBlumenthal%26aufirst%3DA.%26aulast%3DMarrero%26aufirst%3DJ.%26aulast%3DRhee%26aufirst%3DK.%2BY.%26aulast%3DSchnappinger%26aufirst%3DD.%26aulast%3DEhrt%26aufirst%3DS.%26atitle%3DTriosephosphate%2520isomerase%2520is%2520dispensable%2520in%2520vitro%2520yet%2520essential%2520for%2520Mycobacterium%2520tuberculosis%2520to%2520establish%2520infection%26jtitle%3DmBio%26date%3D2014%26volume%3D5%26spage%3De00085%26doi%3D10.1128%2FmBio.00085-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torres, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankaran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujol, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliska, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulding, C. W.</span></span> <span> </span><span class="NLM_article-title">Structural insights into RipC, a putative citrate lyase β subunit from a Yersinia pestis virulence operon</span>. <i>Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1107/S1744309111048056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1107%2FS1744309111048056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22232161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkslyiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=2-7&author=R.+Torresauthor=N.+Chimauthor=B.+Sankaranauthor=C.+Pujolauthor=J.+B.+Bliskaauthor=C.+W.+Goulding&title=Structural+insights+into+RipC%2C+a+putative+citrate+lyase+%CE%B2+subunit+from+a+Yersinia+pestis+virulence+operon&doi=10.1107%2FS1744309111048056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into RipC, a putative citrate lyase β subunit from a Yersinia pestis virulence operon</span></div><div class="casAuthors">Torres, Rodrigo; Chim, Nicholas; Sankaran, Banumathi; Pujol, Celine; Bliska, James B.; Goulding, Celia W.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology and Crystallization Communications</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-7</span>CODEN:
                <span class="NLM_cas:coden">ACSFCL</span>;
        ISSN:<span class="NLM_cas:issn">1744-3091</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Comparison of the 2.45 Å resoln. crystal structure of homotrimeric RipC, a putative citrate lyase β subunit from Y. pestis, with structural homologs reveals conserved RipC residues that are implicated in CoA binding.  Yersinia pestis remains a threat, with outbreaks of plague occurring in rural areas and its emergence as a weapon of bioterrorism; thus, an improved understanding of its various pathogenicity pathways is warranted.  The rip (required for intracellular proliferation) virulence operon is required for Y. pestis survival in interferon-γ-treated macrophages and has been implicated in lowering macrophage-produced nitric oxide levels.  RipC, one of three gene products from the rip operon, is annotated as a citrate lyase β subunit.  Furthermore, the Y. pestis genome lacks genes that encode citrate lyase α and γ subunits, suggesting a unique functional role of RipC in the Y. pestis rip-mediated survival pathway.  Here, the 2.45 Å resoln. crystal structure of RipC revealed a homotrimer in which each monomer consists of a (β/α)8 TIM-barrel fold.  Furthermore, the trimeric state was confirmed in soln. by size-exclusion chromatog.  Through sequence and structure comparisons with homologous proteins, it is proposed that RipC is a putative CoA- or CoA-deriv. binding protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreXwfyie5pE7Vg90H21EOLACvtfcHk0ljG8RXli6oyNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkslyiuw%253D%253D&md5=65efb3a5c22413763f16573214d02cf3</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1107%2FS1744309111048056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS1744309111048056%26sid%3Dliteratum%253Aachs%26aulast%3DTorres%26aufirst%3DR.%26aulast%3DChim%26aufirst%3DN.%26aulast%3DSankaran%26aufirst%3DB.%26aulast%3DPujol%26aufirst%3DC.%26aulast%3DBliska%26aufirst%3DJ.%2BB.%26aulast%3DGoulding%26aufirst%3DC.%2BW.%26atitle%3DStructural%2520insights%2520into%2520RipC%252C%2520a%2520putative%2520citrate%2520lyase%2520%25CE%25B2%2520subunit%2520from%2520a%2520Yersinia%2520pestis%2520virulence%2520operon%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Cryst.%2520Commun.%26date%3D2012%26volume%3D68%26spage%3D2%26epage%3D7%26doi%3D10.1107%2FS1744309111048056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arora, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidwai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span> <span> </span><span class="NLM_article-title">CitE enzymes are essential for Mycobacterium tuberculosis to establish infection in macrophages and guinea pigs</span>. <i>Front. Cell. Infect. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">385</span>, <span class="refDoi"> DOI: 10.3389/fcimb.2018.00385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3389%2Ffcimb.2018.00385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30460206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWrsrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=385&author=G.+Aroraauthor=D.+Chaudharyauthor=S.+Kidwaiauthor=D.+Sharmaauthor=R.+Singh&title=CitE+enzymes+are+essential+for+Mycobacterium+tuberculosis+to+establish+infection+in+macrophages+and+guinea+pigs&doi=10.3389%2Ffcimb.2018.00385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">CitE enzymes are essential for Mycobacterium tuberculosis to establish infection in macrophages and guinea pigs</span></div><div class="casAuthors">Arora, Garima; Chaudhary, Deepika; Kidwai, Saqib; Sharma, Deepak; Singh, Ramandeep</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular and Infection Microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">385</span>CODEN:
                <span class="NLM_cas:coden">FCIMAB</span>;
        ISSN:<span class="NLM_cas:issn">2235-2988</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Bacterial citrate lyase activity has been demonstrated in various eukaryotes, bacteria and archaea, underscoring their importance in energy metab. of the cell.  While the bacterial citrate lyase comprises of three different subunits, M. tuberculosis genome lacks CitD and CitF subunits of citrate lyase complex but encodes for 2 homologs of CitE subunits, Rv2498c and Rv3075c.  Using temp. sensitive mycobacteriophages, we were able to generate both single and double citE mutant strains of M. tuberculosis.  The survival expts. revealed increased susceptibility of the double mutant strain to oxidative stress in comparison to the parental strain.  Also, simultaneous deletion of both citE1 and citE2 in M. tuberculosis genome resulted in impairment of intracellular replication in macrophages.  The double mutant strain displayed reduced growth in lungs and spleens of guinea pigs.  This is the first study demonstrating that M. tuberculosis critically requires CitE subunits of citrate lyase for pathogenesis.  Taken together, these findings position these enzymes as potential targets for development of anti-tubercular small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfoA3RzRX9kLVg90H21EOLACvtfcHk0ljXq7nRIe_40w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWrsrbM&md5=969ddf786680b7b0f15245235d3f4933</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.3389%2Ffcimb.2018.00385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcimb.2018.00385%26sid%3Dliteratum%253Aachs%26aulast%3DArora%26aufirst%3DG.%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DKidwai%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DR.%26atitle%3DCitE%2520enzymes%2520are%2520essential%2520for%2520Mycobacterium%2520tuberculosis%2520to%2520establish%2520infection%2520in%2520macrophages%2520and%2520guinea%2520pigs%26jtitle%3DFront.%2520Cell.%2520Infect.%2520Microbiol.%26date%3D2018%26volume%3D8%26spage%3D385%26doi%3D10.3389%2Ffcimb.2018.00385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruddraraju, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-Y.</span></span> <span> </span><span class="NLM_article-title">Highly potent and selective N-Aryl Oxamic acid-based inhibitors for Mycobacterium tuberculosis protein tyrosine phosphatase B</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9212</span>– <span class="NLM_lpage">9227</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00302</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00302" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFeksLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9212-9227&author=K.+V.+Ruddrarajuauthor=D.+Aggarwalauthor=C.+Niuauthor=E.+A.+Bakerauthor=R.-y.+Zhangauthor=L.+Wuauthor=Z.-Y.+Zhang&title=Highly+potent+and+selective+N-Aryl+Oxamic+acid-based+inhibitors+for+Mycobacterium+tuberculosis+protein+tyrosine+phosphatase+B&doi=10.1021%2Facs.jmedchem.0c00302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium tuberculosis Protein Tyrosine Phosphatase B</span></div><div class="casAuthors">Ruddraraju, Kasi Viswanatharaju; Aggarwal, Devesh; Niu, Congwei; Baker, Erica Anne; Zhang, Ruo-yu; Wu, Li; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9212-9227</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis is an infectious disease caused by the bacterium Mycobacterium tuberculosis (Mtb).  Mtb protein tyrosine phosphatase B (mPTPB) is a virulence factor required for Mtb survival in host macrophages.  Consequently, mPTPB represents an exciting target for tuberculosis treatment.  Here, we identified N-Ph oxamic acid as a highly potent and selective monoacid-based phosphotyrosine mimetic for mPTPB inhibition.  SAR studies on the initial hit, compd. 4 (IC50 = 257 nM), resulted in several highly potent inhibitors with IC50 values lower than 20 nM for mPTPB.  Among them, compd. 4t(I) showed a Ki of 2.7 nM for mPTPB with over 4500-fold preference over 25 mammalian PTPs.  Kinetic, mol. docking, and site-directed mutagenesis analyses confirmed these compds. as active site-directed reversible inhibitors of mPTPB.  These inhibitors can reverse the altered host cell immune responses induced by the bacterial phosphatase.  Furthermore, the inhibitors possess mol. wts. <400 Da, log D7.4 < 2.5, topol. polar surface area < 75, ligand efficiency > 0.43, and good aq. soly. and metabolic stability, thus offering excellent starting points for further therapeutic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTFTilc3_tFbVg90H21EOLACvtfcHk0ljXq7nRIe_40w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFeksLvP&md5=62bc5e0ccb29148f023ee1bf3c406faa</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00302%26sid%3Dliteratum%253Aachs%26aulast%3DRuddraraju%26aufirst%3DK.%2BV.%26aulast%3DAggarwal%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DBaker%26aufirst%3DE.%2BA.%26aulast%3DZhang%26aufirst%3DR.-y.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.-Y.%26atitle%3DHighly%2520potent%2520and%2520selective%2520N-Aryl%2520Oxamic%2520acid-based%2520inhibitors%2520for%2520Mycobacterium%2520tuberculosis%2520protein%2520tyrosine%2520phosphatase%2520B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9212%26epage%3D9227%26doi%3D10.1021%2Facs.jmedchem.0c00302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakila, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naseema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paramasivan, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, A. K.</span></span> <span> </span><span class="NLM_article-title">Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs</span>. <i>Mol. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2958.2003.03712.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1046%2Fj.1365-2958.2003.03712.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=14617138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2003&pages=751-762&author=R.+Singhauthor=V.+Raoauthor=H.+Shakilaauthor=R.+Guptaauthor=A.+Kheraauthor=N.+Dharauthor=A.+Singhauthor=A.+Koulauthor=Y.+Singhauthor=M.+Naseemaauthor=P.+R.+Narayananauthor=C.+N.+Paramasivanauthor=V.+D.+Ramanathanauthor=A.+K.+Tyagi&title=Disruption+of+mptpB+impairs+the+ability+of+Mycobacterium+tuberculosis+to+survive+in+guinea+pigs&doi=10.1046%2Fj.1365-2958.2003.03712.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs</span></div><div class="casAuthors">Singh, Ramandeep; Rao, Vivek; Shakila, H.; Gupta, Radhika; Khera, Aparna; Dhar, Neeraj; Singh, Amit; Koul, Anil; Singh, Yogendra; Naseema, M.; Narayanan, P. R.; Paramasivan, C. N.; Ramanathan, V. D.; Tyagi, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Microbiology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">751-762</span>CODEN:
                <span class="NLM_cas:coden">MOMIEE</span>;
        ISSN:<span class="NLM_cas:issn">0950-382X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Protein tyrosine kinases and tyrosine phosphatases from several bacterial pathogens have been shown to act as virulence factors by modulating the phosphorylation and dephosphorylation of host proteins.  The identification and characterization of two tyrosine phosphatases, namely MptpA and MptpB, from M. tuberculosis has been reported earlier.  MptpB is secreted by M. tuberculosis into extracellular milieu and exhibits a pH optimum of 5.6, similar to the pH of the lysosomal compartment of the cell.  To det. the role of MptpB in the pathogenesis of M. tuberculosis, we constructed a mptpB mutant strain by homologous recombination and compared the ability of parent and the mutant strain to survive intracellularly.  We show that disruption of the mptpB gene impairs the ability of the mutant strain to survive in activated macrophages and guinea pigs but not in resting macrophages, suggesting the importance of its role in the host-pathogen interaction.  Infection of guinea pigs with the mutant strain resulted in a 70-fold redn. in the bacillary load of spleens in infected animals as compared with the bacillary load in animals infected with the parental strain.  Upon reintroduction of the mptpB gene into the mutant strain, the complemented strain was able to establish infection and survive in guinea pigs at rates comparable to the parental strain.  These observations demonstrate a role of MptpB in the pathogenesis of M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqna7lf5deGyLVg90H21EOLACvtfcHk0lig_oUTjX3eeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVyrsbg%253D&md5=88d8f01f758712bb90bf974bf7bf0662</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2958.2003.03712.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2958.2003.03712.x%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DRao%26aufirst%3DV.%26aulast%3DShakila%26aufirst%3DH.%26aulast%3DGupta%26aufirst%3DR.%26aulast%3DKhera%26aufirst%3DA.%26aulast%3DDhar%26aufirst%3DN.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DY.%26aulast%3DNaseema%26aufirst%3DM.%26aulast%3DNarayanan%26aufirst%3DP.%2BR.%26aulast%3DParamasivan%26aufirst%3DC.%2BN.%26aulast%3DRamanathan%26aufirst%3DV.%2BD.%26aulast%3DTyagi%26aufirst%3DA.%2BK.%26atitle%3DDisruption%2520of%2520mptpB%2520impairs%2520the%2520ability%2520of%2520Mycobacterium%2520tuberculosis%2520to%2520survive%2520in%2520guinea%2520pigs%26jtitle%3DMol.%2520Microbiol.%26date%3D2003%26volume%3D50%26spage%3D751%26epage%3D762%26doi%3D10.1046%2Fj.1365-2958.2003.03712.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahairas, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabo, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span> <span> </span><span class="NLM_article-title">Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis</span>. <i>J. Bacteriol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">1274</span>– <span class="NLM_lpage">1282</span>, <span class="refDoi"> DOI: 10.1128/JB.178.5.1274-1282.1996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FJB.178.5.1274-1282.1996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=8631702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK28XhsVSqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=1996&pages=1274-1282&author=G.+G.+Mahairasauthor=P.+J.+Saboauthor=M.+J.+Hickeyauthor=D.+C.+Singhauthor=C.+K.+Stover&title=Molecular+analysis+of+genetic+differences+between+Mycobacterium+bovis+BCG+and+virulent+M.+bovis&doi=10.1128%2FJB.178.5.1274-1282.1996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis</span></div><div class="casAuthors">Mahairas, Gregory G.; Sabo, Peter J.; Hickey, Mark J.; Singh, Devinder C.; Stover, C. Kendall</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bacteriology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1274-82</span>CODEN:
                <span class="NLM_cas:coden">JOBAAY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9193</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The live attenuated bacillus Calmette-Guerin (BCG) vaccine for the prevention of disease assocd. with Mycobacterium tuberculosis was derived from the closely related virulent tubercle bacillus, Mycobacterium bovis.  Although the BCG vaccine has been one of the most widely used vaccines in the world for over 40 yr, the genetic basis of BCG's attenuation has never been elucidated.  We employed subtractive genomic hybridization to identify genetic differences between virulent M. bovis and M. tuberculosis and avirulent BCG.  Three distinct genomic regions of difference (designated RD1 to RD3) were found to be deleted from BCG, and the precise junctions and DNA sequence of each deletion were detd.  RD3, a 9.3-kb genomic segment present in virulent lab. strains of M. bovis and M. tuberculosis, was absent from BCG and 84% of virulent clin. isolates.  RD2, a 10.7-kb DNA segment contg. a novel repetitive element and the previously identified mpt-64 gene, was conserved in all virulent lab. and clin. tubercle bacilli tested and was deleted only from substrains derived from the original BCG Pasteur strain after 1925.  Thus, the RD2 deletion occurred after the original derivation of BCG.  RD1, a 9.5-kb DNA segment found to be deleted from all BCG substrains, was conserved in all virulent lab. and clin. isolates of M. bovis and M. tuberculosis tested.  The reintroduction of RD1 into BCG repressed the expression of at least 10 proteins and resulted in a protein expression profile almost identical to that of virulent M. bovis and M. tuberculosis, as detd. by two-dimensional gel electrophoresis.  These data indicate a role for RD1 in the regulation of multiple genetic loci, suggesting that the loss of virulence by BCG is due to a regulatory mutation.  These findings may be applicable to the rational design of a new attenuated tuberculosis vaccine and the development of new diagnostic tests to distinguish BCG vaccination from tuberculosis infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoYLbk6TnOe7Vg90H21EOLACvtfcHk0lig_oUTjX3eeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhsVSqur4%253D&md5=9865233434ed40636dcbb6a9eeac9367</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1128%2FJB.178.5.1274-1282.1996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJB.178.5.1274-1282.1996%26sid%3Dliteratum%253Aachs%26aulast%3DMahairas%26aufirst%3DG.%2BG.%26aulast%3DSabo%26aufirst%3DP.%2BJ.%26aulast%3DHickey%26aufirst%3DM.%2BJ.%26aulast%3DSingh%26aufirst%3DD.%2BC.%26aulast%3DStover%26aufirst%3DC.%2BK.%26atitle%3DMolecular%2520analysis%2520of%2520genetic%2520differences%2520between%2520Mycobacterium%2520bovis%2520BCG%2520and%2520virulent%2520M.%2520bovis%26jtitle%3DJ.%2520Bacteriol.%26date%3D1996%26volume%3D178%26spage%3D1274%26epage%3D1282%26doi%3D10.1128%2FJB.178.5.1274-1282.1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behr, M. A.</span></span> <span> </span><span class="NLM_article-title">Region of Difference 2 contributes to virulence of Mycobacterium tuberculosis</span>. <i>Infect. Immun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1128/IAI.00824-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FIAI.00824-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=20974821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVegtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2011&pages=59-66&author=R.+A.+Kozakauthor=D.+C.+Alexanderauthor=R.+Liaoauthor=D.+R.+Shermanauthor=M.+A.+Behr&title=Region+of+Difference+2+contributes+to+virulence+of+Mycobacterium+tuberculosis&doi=10.1128%2FIAI.00824-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Region of difference 2 contributes to virulence of Mycobacterium tuberculosis</span></div><div class="casAuthors">Kozak, Robert A.; Alexander, David C.; Liao, Reiling; Sherman, David R.; Behr, Marcel A.</div><div class="citationInfo"><span class="NLM_cas:title">Infection and Immunity</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-66</span>CODEN:
                <span class="NLM_cas:coden">INFIBR</span>;
        ISSN:<span class="NLM_cas:issn">0019-9567</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Mycobacterium bovis BCG strains are live, attenuated vaccines generated through decades of in vitro passage.  Because in vitro growth does not select for interaction with the host, it has been hypothesized that genetic loci lost from BCG code for virulence determinants that are dispensable for growth in the lab., as exemplified by Region of Difference 1 (RD1), which was lost during the original derivation of BCG between 1908 and 1921.  Region of Difference 2 (RD2) was lost during the ongoing propagation of BCG between 1927 and 1931, a time that coincides with reports of the ongoing attenuation of the vaccine.  In this study, RD2 has been disrupted in M. tuberculosis H37Rv to test whether its loss contributed to the further attenuation of BCG.  The deletion of RD2 did not affect in vitro growth; in contrast, the mutant manifested a decrease in pulmonary and splenic bacterial burdens and reduced pathol. in C57BL/6 mice at early time points.  This attenuated phenotype was complemented by reintroducing the genes Rv1979c to Rv1982 (including mpt64) but not Rv1985c to Rv1986.  In RAW 264.7 macrophages, H37Rv:ΔRD2 showed a decreased proliferation and impaired modulation of the host innate immune response; both observations were complemented with Rv1979c to Rv1982.  To test the effect of RD2 disruption on innate immunity, Rag-/- mice were infected; H37Rv:ΔRD2 had increased survival times compared those of H37Rv.  These findings support the notion that the safety profile of certain BCG vaccines stems from multiple attenuating mutations, with the RD2 deletion resulting in a less-virulent organism through the impaired bacterial manipulation of the host innate immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDMGK4_B1pKrVg90H21EOLACvtfcHk0liz0fzTbS2kAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVegtrY%253D&md5=29f768465b0dc0718a8a1bcb9a487af0</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1128%2FIAI.00824-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FIAI.00824-10%26sid%3Dliteratum%253Aachs%26aulast%3DKozak%26aufirst%3DR.%2BA.%26aulast%3DAlexander%26aufirst%3DD.%2BC.%26aulast%3DLiao%26aufirst%3DR.%26aulast%3DSherman%26aufirst%3DD.%2BR.%26aulast%3DBehr%26aufirst%3DM.%2BA.%26atitle%3DRegion%2520of%2520Difference%25202%2520contributes%2520to%2520virulence%2520of%2520Mycobacterium%2520tuberculosis%26jtitle%3DInfect.%2520Immun.%26date%3D2011%26volume%3D79%26spage%3D59%26epage%3D66%26doi%3D10.1128%2FIAI.00824-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaaf, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zignol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Soolingen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayona, J.</span></span> <span> </span><span class="NLM_article-title">Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">1830</span>– <span class="NLM_lpage">1843</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(10)60410-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS0140-6736%2810%2960410-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=20488523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3czlvVeitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2010&pages=1830-1843&author=N.+R.+Gandhiauthor=P.+Nunnauthor=K.+Dhedaauthor=H.+S.+Schaafauthor=M.+Zignolauthor=D.+van+Soolingenauthor=P.+Jensenauthor=J.+Bayona&title=Multidrug-resistant+and+extensively+drug-resistant+tuberculosis%3A+a+threat+to+global+control+of+tuberculosis&doi=10.1016%2FS0140-6736%2810%2960410-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis</span></div><div class="casAuthors">Gandhi Neel R; Nunn Paul; Dheda Keertan; Schaaf H Simon; Zignol Matteo; van Soolingen Dick; Jensen Paul; Bayona Jaime</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">9728</span>),
    <span class="NLM_cas:pages">1830-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although progress has been made to reduce global incidence of drug-susceptible tuberculosis, the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis during the past decade threatens to undermine these advances.  However, countries are responding far too slowly.  Of the estimated 440,000 cases of MDR tuberculosis that occurred in 2008, only 7% were identified and reported to WHO.  Of these cases, only a fifth were treated according to WHO standards.  Although treatment of MDR and XDR tuberculosis is possible with currently available diagnostic techniques and drugs, the treatment course is substantially more costly and laborious than for drug-susceptible tuberculosis, with higher rates of treatment failure and mortality.  Nonetheless, a few countries provide examples of how existing technologies can be used to reverse the epidemic of MDR tuberculosis within a decade.  Major improvements in laboratory capacity, infection control, performance of tuberculosis control programmes, and treatment regimens for both drug-susceptible and drug-resistant disease will be needed, together with a massive scale-up in diagnosis and treatment of MDR and XDR tuberculosis to prevent drug-resistant strains from becoming the dominant form of tuberculosis.  New diagnostic tests and drugs are likely to become available during the next few years and should accelerate control of MDR and XDR tuberculosis.  Equally important, especially in the highest-burden countries of India, China, and Russia, will be a commitment to tuberculosis control including improvements in national policies and health systems that remove financial barriers to treatment, encourage rational drug use, and create the infrastructure necessary to manage MDR tuberculosis on a national scale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvkaiZGYx8s5QHPYJuLg8TfW6udTcc2eb6Y8dZtqVhn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czlvVeitg%253D%253D&md5=189375b5fbd385a829cd0a1699372f5c</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2960410-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252960410-2%26sid%3Dliteratum%253Aachs%26aulast%3DGandhi%26aufirst%3DN.%2BR.%26aulast%3DNunn%26aufirst%3DP.%26aulast%3DDheda%26aufirst%3DK.%26aulast%3DSchaaf%26aufirst%3DH.%2BS.%26aulast%3DZignol%26aufirst%3DM.%26aulast%3Dvan%2BSoolingen%26aufirst%3DD.%26aulast%3DJensen%26aufirst%3DP.%26aulast%3DBayona%26aufirst%3DJ.%26atitle%3DMultidrug-resistant%2520and%2520extensively%2520drug-resistant%2520tuberculosis%253A%2520a%2520threat%2520to%2520global%2520control%2520of%2520tuberculosis%26jtitle%3DLancet%26date%3D2010%26volume%3D375%26spage%3D1830%26epage%3D1843%26doi%3D10.1016%2FS0140-6736%2810%2960410-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumbo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maartens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooley, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNerney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nardell, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessem, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Helden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, G. K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasipanodya, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirgel, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmail, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atre, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaaf, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udwadia, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsburgh, C. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchyard, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesseling, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuermberger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIlleron, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennelly, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goemaere, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jara, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padayatchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, R. M.</span></span> <span> </span><span class="NLM_article-title">The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(17)30079-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS2213-2600%2817%2930079-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=291-360&author=K.+Dhedaauthor=T.+Gumboauthor=G.+Maartensauthor=K.+E.+Dooleyauthor=R.+McNerneyauthor=M.+Murrayauthor=J.+Furinauthor=E.+A.+Nardellauthor=L.+Londonauthor=E.+Lessemauthor=G.+Theronauthor=P.+van+Heldenauthor=S.+Niemannauthor=M.+Merkerauthor=D.+Dowdyauthor=A.+Van+Rieauthor=G.+K.+H.+Siuauthor=J.+G.+Pasipanodyaauthor=C.+Rodriguesauthor=T.+G.+Clarkauthor=F.+A.+Sirgelauthor=A.+Esmailauthor=H.-H.+Linauthor=S.+R.+Atreauthor=H.+S.+Schaafauthor=K.+C.+Changauthor=C.+Langeauthor=P.+Nahidauthor=Z.+F.+Udwadiaauthor=C.+R.+Horsburghauthor=G.+J.+Churchyardauthor=D.+Menziesauthor=A.+C.+Hesselingauthor=E.+Nuermbergerauthor=H.+McIlleronauthor=K.+P.+Fennellyauthor=E.+Goemaereauthor=E.+Jaramilloauthor=M.+Lowauthor=C.+M.+Jaraauthor=N.+Padayatchiauthor=R.+M.+Warren&title=The+epidemiology%2C+pathogenesis%2C+transmission%2C+diagnosis%2C+and+management+of+multidrug-resistant%2C+extensively+drug-resistant%2C+and+incurable+tuberculosis&doi=10.1016%2FS2213-2600%2817%2930079-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2817%2930079-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252817%252930079-6%26sid%3Dliteratum%253Aachs%26aulast%3DDheda%26aufirst%3DK.%26aulast%3DGumbo%26aufirst%3DT.%26aulast%3DMaartens%26aufirst%3DG.%26aulast%3DDooley%26aufirst%3DK.%2BE.%26aulast%3DMcNerney%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DM.%26aulast%3DFurin%26aufirst%3DJ.%26aulast%3DNardell%26aufirst%3DE.%2BA.%26aulast%3DLondon%26aufirst%3DL.%26aulast%3DLessem%26aufirst%3DE.%26aulast%3DTheron%26aufirst%3DG.%26aulast%3Dvan%2BHelden%26aufirst%3DP.%26aulast%3DNiemann%26aufirst%3DS.%26aulast%3DMerker%26aufirst%3DM.%26aulast%3DDowdy%26aufirst%3DD.%26aulast%3DVan%2BRie%26aufirst%3DA.%26aulast%3DSiu%26aufirst%3DG.%2BK.%2BH.%26aulast%3DPasipanodya%26aufirst%3DJ.%2BG.%26aulast%3DRodrigues%26aufirst%3DC.%26aulast%3DClark%26aufirst%3DT.%2BG.%26aulast%3DSirgel%26aufirst%3DF.%2BA.%26aulast%3DEsmail%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DH.-H.%26aulast%3DAtre%26aufirst%3DS.%2BR.%26aulast%3DSchaaf%26aufirst%3DH.%2BS.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DLange%26aufirst%3DC.%26aulast%3DNahid%26aufirst%3DP.%26aulast%3DUdwadia%26aufirst%3DZ.%2BF.%26aulast%3DHorsburgh%26aufirst%3DC.%2BR.%26aulast%3DChurchyard%26aufirst%3DG.%2BJ.%26aulast%3DMenzies%26aufirst%3DD.%26aulast%3DHesseling%26aufirst%3DA.%2BC.%26aulast%3DNuermberger%26aufirst%3DE.%26aulast%3DMcIlleron%26aufirst%3DH.%26aulast%3DFennelly%26aufirst%3DK.%2BP.%26aulast%3DGoemaere%26aufirst%3DE.%26aulast%3DJaramillo%26aufirst%3DE.%26aulast%3DLow%26aufirst%3DM.%26aulast%3DJara%26aufirst%3DC.%2BM.%26aulast%3DPadayatchi%26aufirst%3DN.%26aulast%3DWarren%26aufirst%3DR.%2BM.%26atitle%3DThe%2520epidemiology%252C%2520pathogenesis%252C%2520transmission%252C%2520diagnosis%252C%2520and%2520management%2520of%2520multidrug-resistant%252C%2520extensively%2520drug-resistant%252C%2520and%2520incurable%2520tuberculosis%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2017%26volume%3D5%26spage%3D291%26epage%3D360%26doi%3D10.1016%2FS2213-2600%2817%2930079-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span>New Antibiotic
Approved for Drug-Resistant Tuberculosis.  <i>The Washington Post</i>, <span class="NLM_year">2019</span>; <a href="https://www.washingtonpost.com/health/new-antibiotic-approved-for-drug-resistant-tuberculosis/2019/08/14/559d069a-bde6-11e9-9b73-fd3c65ef8f9c_story.html" class="extLink">https://www.washingtonpost.com/health/new-antibiotic-approved-for-drug-resistant-tuberculosis/2019/08/14/559d069a-bde6-11e9-9b73-fd3c65ef8f9c_story.html</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=New+Antibiotic%0AApproved+for+Drug-Resistant+Tuberculosis.+The+Washington+Post%2C+2019%3B+https%3A%2F%2Fwww.washingtonpost.com%2Fhealth%2Fnew-antibiotic-approved-for-drug-resistant-tuberculosis%2F2019%2F08%2F14%2F559d069a-bde6-11e9-9b73-fd3c65ef8f9c_story.html+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DThe%2520Washington%2520Post%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span>FDA
Approves New Drug for Treatment-Resistant Forms of Tuberculosis That
Affects the Lungs; <span class="NLM_publisher-name">FDA</span>, <span class="NLM_year">2019</span>; <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs#:~:text=The%20U.S.%20Food%20and%20Drug,(TB)%20of%20the%20lungs" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs#:~:text=The%20U.S.%20Food%20and%20Drug,(TB)%20of%20the%20lungs</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA%0AApproves+New+Drug+for+Treatment-Resistant+Forms+of+Tuberculosis+That%0AAffects+the+Lungs%3B+FDA%2C+2019%3B+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs%23%3A%7E%3Atext%3DThe%2520U.S.%2520Food%2520and%2520Drug%2C%28TB%29%2520of%2520the%2520lungs+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26pub%3DFDA%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomishige, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubouchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, M.</span></span> <span> </span><span class="NLM_article-title">OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e466</span>, <span class="refDoi"> DOI: 10.1371/journal.pmed.0030466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1371%2Fjournal.pmed.0030466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=17132069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD28npsFKgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=e466&author=M.+Matsumotoauthor=H.+Hashizumeauthor=T.+Tomishigeauthor=M.+Kawasakiauthor=H.+Tsubouchiauthor=H.+Sasakiauthor=Y.+Shimokawaauthor=M.+Komatsu&title=OPC-67683%2C+a+nitro-dihydro-imidazooxazole+derivative+with+promising+action+against+tuberculosis+in+vitro+and+in+mice&doi=10.1371%2Fjournal.pmed.0030466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice</span></div><div class="casAuthors">Matsumoto Makoto; Hashizume Hiroyuki; Tomishige Tatsuo; Kawasaki Masanori; Tsubouchi Hidetsugu; Sasaki Hirofumi; Shimokawa Yoshihiko; Komatsu Makoto</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e466</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Tuberculosis (TB) is still a leading cause of death worldwide.  Almost a third of the world's population is infected with TB bacilli, and each year approximately 8 million people develop active TB and 2 million die as a result.  Today's TB treatment, which dates back to the 1970s, is long and burdensome, requiring at least 6 mo of multidrug chemotherapy.  The situation is further compounded by the emergence of multidrug-resistant TB (MDR-TB) and by the infection's lethal synergy with HIV/AIDS.  Global health and philanthropic organizations are now pleading for new drug interventions that can address these unmet needs in TB treatment.  METHODS AND FINDINGS:  Here we report OPC-67683, a nitro-dihydro-imidazooxazole derivative that was screened to help combat the unmet needs in TB treatment.  The compound is a mycolic acid biosynthesis inhibitor found to be free of mutagenicity and to possess highly potent activity against TB, including MDR-TB, as shown by its exceptionally low minimum inhibitory concentration (MIC) range of 0.006-0.024 microg/ml in vitro and highly effective therapeutic activity at low doses in vivo.  Additionally, the results of the post-antibiotic effect of OPC-67683 on intracellular Mycobacterium tuberculosis showed the agent to be highly and dose-dependently active also against intracellular M. tuberculosis H37Rv after a 4-h pulsed exposure, and this activity at a concentration of 0.1 microg/ml was similar to that of the first-line drug rifampicin (RFP) at a concentration of 3 microg/ml.  The combination of OPC-67683 with RFP and pyrazinamide (PZA) exhibited a remarkably quicker eradication (by at least 2 mo) of viable TB bacilli in the lung in comparison with the standard regimen consisting of RFP, isoniazid (INH), ethambutol (EB), and PZA.  Furthermore, OPC-67683 was not affected by nor did it affect the activity of liver microsome enzymes, suggesting the possibility for OPC-67683 to be used in combination with drugs, including anti-retrovirals, that induce or are metabolized by cytochrome P450 enzymes.  CONCLUSIONS:  We concluded that based on these properties OPC-67683 has the potential to be used as a TB drug to help combat the unmet needs in TB treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSF0z_BNLNYeRS7coPn-RtfW6udTcc2eb9VRJAgyv6mbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28npsFKgug%253D%253D&md5=8a80560cc653b1c76ff4d47430317d18</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0030466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0030466%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DTomishige%26aufirst%3DT.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DTsubouchi%26aufirst%3DH.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DShimokawa%26aufirst%3DY.%26aulast%3DKomatsu%26aufirst%3DM.%26atitle%3DOPC-67683%252C%2520a%2520nitro-dihydro-imidazooxazole%2520derivative%2520with%2520promising%2520action%2520against%2520tuberculosis%2520in%2520vitro%2520and%2520in%2520mice%26jtitle%3DPLoS%2520Med.%26date%3D2006%26volume%3D3%26spage%3De466%26doi%3D10.1371%2Fjournal.pmed.0030466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skripconoka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danilovits, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pehme, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skenders, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirule, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leimane, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurve, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiter, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manissero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span> <span> </span><span class="NLM_article-title">Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1400</span>, <span class="refDoi"> DOI: 10.1183/09031936.00125812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1183%2F09031936.00125812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23018916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252Fgsl2ltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=1393-1400&author=V.+Skripconokaauthor=M.+Danilovitsauthor=L.+Pehmeauthor=T.+Tomsonauthor=G.+Skendersauthor=T.+Kummikauthor=A.+Ciruleauthor=V.+Leimaneauthor=A.+Kurveauthor=K.+Levinaauthor=L.+J.+Geiterauthor=D.+Manisseroauthor=C.+D.+Wells&title=Delamanid+improves+outcomes+and+reduces+mortality+in+multidrug-resistant+tuberculosis&doi=10.1183%2F09031936.00125812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis</span></div><div class="casAuthors">Skripconoka Vija; Danilovits Manfred; Pehme Lea; Tomson Tarmo; Skenders Girts; Kummik Tiina; Cirule Andra; Leimane Vaira; Kurve Anu; Levina Klavdia; Geiter Lawrence J; Manissero Davide; Wells Charles D</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1393-400</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are associated with worse treatment outcomes for patients, including higher mortality, than for drug-sensitive tuberculosis.  Delamanid (OPC-67683) is a novel anti-TB medication with demonstrated activity against multidrug-resistant disease.  Patients who participated in the previously reported randomised, placebo-controlled trial of delamanid and the subsequent open-label extension trial were eligible to participate in a 24-month observational study designed to capture treatment outcomes.  Treatment outcomes, as assessed by clinicians and defined by the World Health Organization, were categorised as favourable and unfavourable.  Delamanid treatment groups were combined for analysis, based on their duration of treatment.  In total, for 421 (87.5%) out of 481 patients from the original randomised controlled trial, consent was granted for follow-up assessments.  Favourable outcomes were observed in 143 (74.5%) out of 192 patients who received delamanid for ≥6 months, compared to 126 (55%) out of 229 patients who received delamanid for ≤2 months.  Mortality was reduced to 1.0% among those receiving long-term delamanid versus short-term/no delamanid (8.3%; p<0.001).  Treatment benefit was also seen among patients with extensively drug-resistant TB.  This analysis suggests that treatment with delamanid for 6 months in combination with an optimised background regimen can improve outcomes and reduce mortality among patients with both multidrug-resistant and extensively drug-resistant TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2JcitGJjjkMNIRw0GKUoEfW6udTcc2eb5Ry548INxCbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252Fgsl2ltw%253D%253D&md5=63c616aef7dfd5858d274fe1a74ab290</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1183%2F09031936.00125812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00125812%26sid%3Dliteratum%253Aachs%26aulast%3DSkripconoka%26aufirst%3DV.%26aulast%3DDanilovits%26aufirst%3DM.%26aulast%3DPehme%26aufirst%3DL.%26aulast%3DTomson%26aufirst%3DT.%26aulast%3DSkenders%26aufirst%3DG.%26aulast%3DKummik%26aufirst%3DT.%26aulast%3DCirule%26aufirst%3DA.%26aulast%3DLeimane%26aufirst%3DV.%26aulast%3DKurve%26aufirst%3DA.%26aulast%3DLevina%26aufirst%3DK.%26aulast%3DGeiter%26aufirst%3DL.%2BJ.%26aulast%3DManissero%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DC.%2BD.%26atitle%3DDelamanid%2520improves%2520outcomes%2520and%2520reduces%2520mortality%2520in%2520multidrug-resistant%2520tuberculosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D41%26spage%3D1393%26epage%3D1400%26doi%3D10.1183%2F09031936.00125812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, R.</span></span> <span> </span><span class="NLM_article-title">Bedaquiline: First FDA-approved tuberculosis drug in 40 years</span>. <i>Int. J. Appl. Basic Med. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">2</span>, <span class="refDoi"> DOI: 10.4103/2229-516X.112228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4103%2F2229-516X.112228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23776831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC3sjjsVymsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1-2&author=R.+Mahajan&title=Bedaquiline%3A+First+FDA-approved+tuberculosis+drug+in+40+years&doi=10.4103%2F2229-516X.112228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Bedaquiline: First FDA-approved tuberculosis drug in 40 years</span></div><div class="casAuthors">Mahajan Rajiv</div><div class="citationInfo"><span class="NLM_cas:title">International journal of applied & basic medical research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-2</span>
        ISSN:<span class="NLM_cas:issn">2229-516X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMuPJrm3KbPlw2ofyr07jXfW6udTcc2eb5Ry548INxCbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjjsVymsQ%253D%253D&md5=b588035f9b17ee7beb4f5c57a58a0eff</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.4103%2F2229-516X.112228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F2229-516X.112228%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan%26aufirst%3DR.%26atitle%3DBedaquiline%253A%2520First%2520FDA-approved%2520tuberculosis%2520drug%2520in%252040%2520years%26jtitle%3DInt.%2520J.%2520Appl.%2520Basic%2520Med.%2520Res.%26date%3D2013%26volume%3D3%26spage%3D1%26epage%3D2%26doi%3D10.4103%2F2229-516X.112228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hittel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiter, L. J.</span></span> <span> </span><span class="NLM_article-title">Delamanid in the treatment of multidrug-resistant tuberculosis</span>. <i>Int. J. Tuberc Lung Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.5588/ijtld.16.0125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.5588%2Fijtld.16.0125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28240570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1czgvFWlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=33-37&author=R.+Guptaauthor=C.+D.+Wellsauthor=N.+Hittelauthor=J.+Hafkinauthor=L.+J.+Geiter&title=Delamanid+in+the+treatment+of+multidrug-resistant+tuberculosis&doi=10.5588%2Fijtld.16.0125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Delamanid in the treatment of multidrug-resistant tuberculosis</span></div><div class="casAuthors">Gupta R; Hafkin J; Geiter L J; Wells C D; Hittel N</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">33-37</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Otsuka has been engaged in anti-tuberculosis drug development efforts for over 30 years, and is the leading private sector funder of tuberculosis (TB) research and development.  Delamanid (DLM), discovered by Otsuka's scientists, has been shown to provide benefit with respect to short-term surrogate markers and long-term treatment outcomes, and it has received regulatory approval for treatment of adult pulmonary multidrug-resistant TB (MDR-TB) as one of only two new anti-tuberculosis drugs in the last 40 years.  Lack of drug-drug interactions with major antiretrovirals and efficacy against MDR-TB allow DLM's applicability in a wide range of MDR-TB patients.  Current and future efforts are focused on replacing less safe and less efficacious second-line drugs with DLM, its contribution to all-oral and/or shortened treatment regimens, and, ultimately, inclusion in a pan-TB regimen.  This manuscript provides a brief review of DLM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeR1dYk1i_c2x8TEN9K18QfW6udTcc2eYlfgb6RUcll7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czgvFWlug%253D%253D&md5=f5ca6996b8821bd38bc5ef1fd13f151b</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.5588%2Fijtld.16.0125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5588%252Fijtld.16.0125%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DR.%26aulast%3DWells%26aufirst%3DC.%2BD.%26aulast%3DHittel%26aufirst%3DN.%26aulast%3DHafkin%26aufirst%3DJ.%26aulast%3DGeiter%26aufirst%3DL.%2BJ.%26atitle%3DDelamanid%2520in%2520the%2520treatment%2520of%2520multidrug-resistant%2520tuberculosis%26jtitle%3DInt.%2520J.%2520Tuberc%2520Lung%2520Dis.%26date%3D2016%26volume%3D20%26spage%3D33%26epage%3D37%26doi%3D10.5588%2Fijtld.16.0125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinone structure-activity relationships leading to linezolid</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">2010</span>– <span class="NLM_lpage">2023</span>, <span class="refDoi"> DOI: 10.1002/anie.200200528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1002%2Fanie.200200528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkt1Snu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=2010-2023&issue=18&author=M.+R.+Barbachynauthor=C.+W.+Ford&title=Oxazolidinone+structure-activity+relationships+leading+to+linezolid&doi=10.1002%2Fanie.200200528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinone structure-activity relationships leading to linezolid</span></div><div class="casAuthors">Barbachyn, Michael R.; Ford, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2010-2023</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The development of bacterial resistance to currently available antibacterial agents is a growing global health problem.  Of particular concern are infections caused by multidrug-resistant Gram-pos. pathogens which are responsible for significant morbidity and mortality in both the hospital and community settings.  A no. of solns. to the problem of bacterial resistance are possible.  The most common approach is to continue modifying existing classes of antibacterial agents to provide new analogs with improved attributes.  Other successful strategies are to combine existing antibacterial agents with other drugs as well as the development of improved diagnostic procedures that may lead to rapid identification of the causative pathogen and permit the use of antibacterial agents with a narrow spectrum of activity.  Finally, and most importantly, the discovery of novel classes of antibacterial agents employing new mechanisms of action has considerable promise.  Such agents would exhibit a lack of cross-resistance with existing antimicrobial drugs.  This review describes the work leading to the discovery of linezolid, the first clin. useful oxazolidinone antibacterial agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGritv1CBogyHbVg90H21EOLACvtfcHk0lhZqFyAsbOzoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkt1Snu7k%253D&md5=681744cbb331d9256cc32d8b60987284</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1002%2Fanie.200200528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200200528%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DFord%26aufirst%3DC.%2BW.%26atitle%3DOxazolidinone%2520structure-activity%2520relationships%2520leading%2520to%2520linezolid%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26issue%3D18%26spage%3D2010%26epage%3D2023%26doi%3D10.1002%2Fanie.200200528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sy, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. C.</span></span> <span> </span><span class="NLM_article-title">In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2226</span>– <span class="NLM_lpage">2267</span>, <span class="refDoi"> DOI: 10.1128/AAC.00414-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.00414-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=18391030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvVait7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=2226-2267&author=T.+S.+Huangauthor=Y.+C.+Liuauthor=C.+L.+Syauthor=Y.+S.+Chenauthor=H.+Z.+Tuauthor=B.+C.+Chen&title=In+vitro+activities+of+linezolid+against+clinical+isolates+of+Mycobacterium+tuberculosis+complex+isolated+in+Taiwan+over+10+years&doi=10.1128%2FAAC.00414-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years</span></div><div class="casAuthors">Huang, Tsi-Shu; Liu, Yung-Ching; Sy, Cheng-Len; Chen, Yao-Shen; Tu, Hui-Zin; Chen, Bao-Chen</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2226-2227</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Significant increases in the MIC90s of linezolid in multidrug-resistant Mycobacterium tuberculosis isolates were seen between the baseline period of 2001 to 2003 (0.5 μg/mL) and 2004 (2 μg/mL).  The MICs were 4 μg/mL in three strains.  Both fluoroquinolones (except levofloxacin) and kanamycin were found to have statistically significant degrees of concordance with linezolid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoueJqnCpdKkrVg90H21EOLACvtfcHk0lhZqFyAsbOzoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvVait7g%253D&md5=444b842f9b0931bc13cb0f6d231e3a5e</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1128%2FAAC.00414-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00414-07%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DT.%2BS.%26aulast%3DLiu%26aufirst%3DY.%2BC.%26aulast%3DSy%26aufirst%3DC.%2BL.%26aulast%3DChen%26aufirst%3DY.%2BS.%26aulast%3DTu%26aufirst%3DH.%2BZ.%26aulast%3DChen%26aufirst%3DB.%2BC.%26atitle%3DIn%2520vitro%2520activities%2520of%2520linezolid%2520against%2520clinical%2520isolates%2520of%2520Mycobacterium%2520tuberculosis%2520complex%2520isolated%2520in%2520Taiwan%2520over%252010%2520years%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26spage%3D2226%26epage%3D2267%26doi%3D10.1128%2FAAC.00414-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, Y. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, U. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassall, A.</span></span> <span> </span><span class="NLM_article-title">Costs to health services and the patient of treating tuberculosis: A systematic literature review</span>. <i>PharmacoEconomics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.1007/s40273-015-0279-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1007%2Fs40273-015-0279-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25939501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2MfgsVygsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=939-955&author=Y.+V.+Laurenceauthor=U.+K.+Griffithsauthor=A.+Vassall&title=Costs+to+health+services+and+the+patient+of+treating+tuberculosis%3A+A+systematic+literature+review&doi=10.1007%2Fs40273-015-0279-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review</span></div><div class="casAuthors">Laurence Yoko V; Griffiths Ulla K; Vassall Anna</div><div class="citationInfo"><span class="NLM_cas:title">PharmacoEconomics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">939-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Novel tuberculosis (TB) drugs and the need to treat drug-resistant tuberculosis (DR-TB) are likely to bring about substantial transformations in TB treatment in coming years.  An evidence base for cost and cost-effectiveness analyses of these developments is needed.  OBJECTIVE:  Our objective was to perform a review of papers assessing provider-incurred as well as patient-incurred costs of treating both drug-susceptible (DS) and multidrug-resistant (MDR)-TB.  METHODS:  Five databases (EMBASE, Medline, the National Health Service Economic Evaluation Database, the Cost-Effectiveness Analysis Registry, and Latin American and Caribbean Health Services Literature) were searched for cost and economic evaluation full-text papers containing primary DS-TB and MDR-TB treatment cost data published in peer-reviewed journals between January 1990 and February 2015.  No language restrictions were set.  The search terms were a combination of 'tuberculosis', 'multidrug-resistant tuberculosis', 'cost', and 'treatment'.  In the selected papers, study methods and characteristics, quality indicators and costs were extracted into summary tables according to pre-defined criteria.  Results were analysed according to country income groups and for provider costs, patient costs and productivity losses.  All values were converted to $US, year 2014 values, so that studies could be compared.  RESULTS:  We selected 71 treatment cost papers on DS-TB only, ten papers on MDR-TB only and nine papers that included both DS-TB and MDR-TB.  These papers provided evidence on the costs of treating DS-TB and MDR-TB in 50 and 16 countries, respectively.  In 31 % of the papers, only provider costs were included; 26 % included only patient-incurred costs, and the remaining 43 % estimated costs incurred by both.  From the provider perspective, mean DS-TB treatment costs per patient were US$14,659 in high-income countries (HICs), US$840 in upper middle-income countries (UMICs), US$273 in lower middle-income (LMICs), and US$258 in low-income countries (LICs), showing a strong positive correlation.  The respective costs for treating MDR-TB were US$83,365, US$5284, US$6313 and US$1218.  Costs incurred by patients when seeking treatment for DS-TB accounted for an additional 3 % of the provider costs in HICs.  A greater burden was seen in the other income groups, increasing the costs of DS-TB treatment by 72 % in UMICs, 60 % in LICs and 31 % in LMICs.  When provider costs, patient costs and productivity losses were combined, productivity losses accounted for 16 % in HICs, 29 % in UMICs, 40 % in LMICs and 38 % in LICs.  CONCLUSION:  Cost data for MDR-TB treatment are limited, and the variation in delivery mechanisms, as well as the rapidly evolving diagnosis and treatment regimens, means that it is essential to increase the number of studies assessing the cost from both provider and patient perspectives.  There is substantial evidence available on the costs of DS-TB treatment from all regions of the world.  The patient-incurred costs illustrate that the financial burden of illness is relatively greater for patients in poorer countries without universal healthcare coverage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgJ39ix5e5dWK_SFaaT9INfW6udTcc2eYQKH7Lea7lJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfgsVygsw%253D%253D&md5=e4709dc54d4b5ab98cad051b14efdbd3</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1007%2Fs40273-015-0279-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40273-015-0279-6%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DY.%2BV.%26aulast%3DGriffiths%26aufirst%3DU.%2BK.%26aulast%3DVassall%26aufirst%3DA.%26atitle%3DCosts%2520to%2520health%2520services%2520and%2520the%2520patient%2520of%2520treating%2520tuberculosis%253A%2520A%2520systematic%2520literature%2520review%26jtitle%3DPharmacoEconomics%26date%3D2015%26volume%3D33%26spage%3D939%26epage%3D955%26doi%3D10.1007%2Fs40273-015-0279-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chellat, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raguž, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, R.</span></span> <span> </span><span class="NLM_article-title">Targeting antibiotic resistance</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6600</span>– <span class="NLM_lpage">6626</span>, <span class="refDoi"> DOI: 10.1002/anie.201506818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1002%2Fanie.201506818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1Cju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=6600-6626&author=M.+F.+Chellatauthor=L.+Ragu%C5%BEauthor=R.+Riedl&title=Targeting+antibiotic+resistance&doi=10.1002%2Fanie.201506818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Antibiotic Resistance</span></div><div class="casAuthors">Chellat, Mathieu F.; Raguz, Luka; Riedl, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6600-6626</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Finding strategies against the development of antibiotic resistance is a major global challenge for the life sciences community and for public health.  The past decades have seen a dramatic worldwide increase in human-pathogenic bacteria that are resistant to one or multiple antibiotics.  More and more infections caused by resistant microorganisms fail to respond to conventional treatment, and in some cases, even last-resort antibiotics have lost their power.  In addn., industry pipelines for the development of novel antibiotics have run dry over the past decades.  A recent world health day by the World Health Organization titled "Combat drug resistance: no action today means no cure tomorrow" triggered an increase in research activity, and several promising strategies have been developed to restore treatment options against infections by resistant bacterial pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRcddMQflU3LVg90H21EOLACvtfcHk0ljxJIW3WW4t_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1Cju7k%253D&md5=b8194ac5902fa3ac4da2e36de71f82b4</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506818%26sid%3Dliteratum%253Aachs%26aulast%3DChellat%26aufirst%3DM.%2BF.%26aulast%3DRagu%25C5%25BE%26aufirst%3DL.%26aulast%3DRiedl%26aufirst%3DR.%26atitle%3DTargeting%2520antibiotic%2520resistance%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D6600%26epage%3D6626%26doi%3D10.1002%2Fanie.201506818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ippolito, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanyo, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steitz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, E. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3353</span>– <span class="NLM_lpage">3356</span>, <span class="refDoi"> DOI: 10.1021/jm800379d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800379d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtF2ku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3353-3356&author=J.+A.+Ippolitoauthor=Z.+F.+Kanyoauthor=D.+Wangauthor=F.+J.+Franceschiauthor=P.+B.+Mooreauthor=T.+A.+Steitzauthor=E.+M.+Duffy&title=Crystal+structure+of+the+oxazolidinone+antibiotic+linezolid+bound+to+the+50S+ribosomal+subunit&doi=10.1021%2Fjm800379d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Oxazolidinone Antibiotic Linezolid Bound to the 50S Ribosomal Subunit</span></div><div class="casAuthors">Ippolito, Joseph A.; Kanyo, Zoltan F.; Wang, Deping; Franceschi, Francois J.; Moore, Peter B.; Steitz, Thomas A.; Duffy, Erin M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3353-3356</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The oxazolidinone antibacterials target the 50S subunit of prokaryotic ribosomes.  To gain insight into their mechanism of action, the crystal structure of the canonical oxazolidinone, linezolid, has been detd. bound to the Haloarcula marismortui 50S subunit.  Linezolid binds the 50S A-site, near the catalytic center, which suggests that inhibition involves competition with incoming A-site substrates.  These results provide a structural basis for the discovery of improved oxazolidinones active against emerging drug-resistant clin. strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2a6yG28gBjbVg90H21EOLACvtfcHk0ljyjNyYbrnzvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtF2ku7g%253D&md5=bdf67198829f16561cf447257ac21f8e</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1021%2Fjm800379d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800379d%26sid%3Dliteratum%253Aachs%26aulast%3DIppolito%26aufirst%3DJ.%2BA.%26aulast%3DKanyo%26aufirst%3DZ.%2BF.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DFranceschi%26aufirst%3DF.%2BJ.%26aulast%3DMoore%26aufirst%3DP.%2BB.%26aulast%3DSteitz%26aufirst%3DT.%2BA.%26aulast%3DDuffy%26aufirst%3DE.%2BM.%26atitle%3DCrystal%2520structure%2520of%2520the%2520oxazolidinone%2520antibiotic%2520linezolid%2520bound%2520to%2520the%252050S%2520ribosomal%2520subunit%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3353%26epage%3D3356%26doi%3D10.1021%2Fjm800379d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cynamon, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilburn, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klemens, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grega, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendges, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toops, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">680</span>– <span class="NLM_lpage">685</span>, <span class="refDoi"> DOI: 10.1021/jm950956y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm950956y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK28XlvVCisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=680-685&author=M.+R.+Barbachynauthor=D.+K.+Hutchinsonauthor=S.+J.+Bricknerauthor=M.+H.+Cynamonauthor=J.+O.+Kilburnauthor=S.+P.+Klemensauthor=S.+E.+Glickmanauthor=K.+C.+Gregaauthor=S.+K.+Hendgesauthor=D.+S.+Toopsauthor=C.+W.+Fordauthor=G.+E.+Zurenko&title=Identification+of+a+novel+oxazolidinone+%28U-100480%29+with+potent+antimycobacterial+activity&doi=10.1021%2Fjm950956y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Novel Oxazolidinone (U-100480) with Potent Antimycobacterial Activity</span></div><div class="casAuthors">Barbachyn, Michael R.; Hutchinson, Douglas K.; Brickner, Steven J.; Cynamon, Michael H.; Kilburn, James O.; Klemens, Sally P.; Glickman, Suzanne E.; Grega, Kevin C.; Hendges, Susan K.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">680-5</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A subclass of oxazolidinone antibacterial agents with esp. potent in vitro activity against mycobacteria was discovered.  The salient structural feature of these oxazolidinone analogs, U-100480 [i.e., (S)-N-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide], U-101603, and U-101244 is their appended thiomorpholine moiety.  The rational design, synthesis, and evaluation of the in vitro antimycobacterial activity of these analogs was described.  Potent activity against a screening strain of Mycobacterium tuberculosis was demonstrated by U-100480 and U-101603 (min. inhibitory concns. or MIC's ≤0.125 μg/mL).  Oxazolidinones U-100480 and U-101244 exhibit MIC90 values of 0.50 μg/mL or less against a panel of organisms consisting of five drug-sensitive and five multidrug-resistant strains of M. tuberculosis, with U-100480 being the most active congener.  Potent in vitro activity against other mycobacterial species was also demonstrated by U-100480.  For example, U-100480 exhibited excellent in vitro activity against multiple clin. isolates of Mycobacterium avium complex (MIC's = 0.5-4 μg/mL).  Orally administered U-100480 displays in vivo efficacy against M. tuberculosis and M. avium similar to that of clin. comparators isoniazid and azithromycin, resp.  Consideration of these factors, along with a favorable pharmacokinetic and chronic toxicity profile in rats, suggests that U-100480 is a promising antimycobacterial agent (tuberculostatic).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAvvlFTIROHbVg90H21EOLACvtfcHk0ljyjNyYbrnzvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlvVCisQ%253D%253D&md5=8636d20221390257b48f2d3dd6884b78</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1021%2Fjm950956y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950956y%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DHutchinson%26aufirst%3DD.%2BK.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26aulast%3DCynamon%26aufirst%3DM.%2BH.%26aulast%3DKilburn%26aufirst%3DJ.%2BO.%26aulast%3DKlemens%26aufirst%3DS.%2BP.%26aulast%3DGlickman%26aufirst%3DS.%2BE.%26aulast%3DGrega%26aufirst%3DK.%2BC.%26aulast%3DHendges%26aufirst%3DS.%2BK.%26aulast%3DToops%26aufirst%3DD.%2BS.%26aulast%3DFord%26aufirst%3DC.%2BW.%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26atitle%3DIdentification%2520of%2520a%2520novel%2520oxazolidinone%2520%2528U-100480%2529%2520with%2520potent%2520antimycobacterial%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D680%26epage%3D685%26doi%3D10.1021%2Fjm950956y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, S.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, J.-H.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo activities of LCB01–0371, a new oxazolidinone</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5359</span>– <span class="NLM_lpage">5362</span>, <span class="refDoi"> DOI: 10.1128/AAC.00723-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.00723-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=20855730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=5359-5362&author=J.-W.+Jeongauthor=S.-J.+Jungauthor=H.-H.+Leeauthor=Y.-Z.+Kimauthor=T.-K.+Parkauthor=Y.-L.+Choauthor=S.-E.+Chaeauthor=S.-Y.+Baekauthor=S.-H.+Wooauthor=H.-S.+Leeauthor=J.-H.+Kwak&title=In+vitro+and+in+vivo+activities+of+LCB01%E2%80%930371%2C+a+new+oxazolidinone&doi=10.1128%2FAAC.00723-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo activities of LCB01-0371, a new oxazolidinone</span></div><div class="casAuthors">Jeong, Ji-Woong; Jung, Sung-Ji; Lee, Hyun-Hee; Kim, Yong-Zu; Park, Tae-Kyo; Cho, Young-Lag; Chae, Sang-Eun; Baek, Sung-Yoon; Woo, Sung-Ho; Lee, Hyang-Sook; Kwak, Jin-Hwan</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5359-5362</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">LCB01-0371 is a new oxazolidinone with cyclic amidrazone.  In vitro activity of LCB01-0371 against 624 clin. isolates was evaluated and compared with those of linezolid, vancomycin, and other antibiotics.  LCB01-0371 showed good activity against Gram-pos. pathogens.  In vivo activity of LCB01-0371 against systemic infections in mice was also evaluated.  LCB01-0371 was more active than linezolid against these systemic infections.  LCB01-0371 showed bacteriostatic activity against Staphylococcus aureus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobg2lKKc8bzbVg90H21EOLACvtfcHk0ljyjNyYbrnzvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FJ&md5=27471d63f1195f29f869689c125f643e</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1128%2FAAC.00723-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00723-10%26sid%3Dliteratum%253Aachs%26aulast%3DJeong%26aufirst%3DJ.-W.%26aulast%3DJung%26aufirst%3DS.-J.%26aulast%3DLee%26aufirst%3DH.-H.%26aulast%3DKim%26aufirst%3DY.-Z.%26aulast%3DPark%26aufirst%3DT.-K.%26aulast%3DCho%26aufirst%3DY.-L.%26aulast%3DChae%26aufirst%3DS.-E.%26aulast%3DBaek%26aufirst%3DS.-Y.%26aulast%3DWoo%26aufirst%3DS.-H.%26aulast%3DLee%26aufirst%3DH.-S.%26aulast%3DKwak%26aufirst%3DJ.-H.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520activities%2520of%2520LCB01%25E2%2580%25930371%252C%2520a%2520new%2520oxazolidinone%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D5359%26epage%3D5362%26doi%3D10.1128%2FAAC.00723-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, Y.</span></span> <span> </span><span class="NLM_article-title">Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in China</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">e00165-18</span>, <span class="refDoi"> DOI: 10.1128/AAC.00165-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.00165-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29844043" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&pages=e00165-18&issue=8&author=Z.+Zongauthor=W.+Jingauthor=J.+Shiauthor=S.+Wenauthor=T.+Zhangauthor=F.+Huoauthor=Y.+Shangauthor=Q.+Liangauthor=H.+Huangauthor=Y.+Pang&title=Comparison+of+in+vitro+activity+and+MIC+distributions+between+the+novel+oxazolidinone+delpazolid+and+linezolid+against+multidrug-resistant+and+extensively+drug-resistant+Mycobacterium+tuberculosis+in+China&doi=10.1128%2FAAC.00165-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1128%2FAAC.00165-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00165-18%26sid%3Dliteratum%253Aachs%26aulast%3DZong%26aufirst%3DZ.%26aulast%3DJing%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DHuo%26aufirst%3DF.%26aulast%3DShang%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DPang%26aufirst%3DY.%26atitle%3DComparison%2520of%2520in%2520vitro%2520activity%2520and%2520MIC%2520distributions%2520between%2520the%2520novel%2520oxazolidinone%2520delpazolid%2520and%2520linezolid%2520against%2520multidrug-resistant%2520and%2520extensively%2520drug-resistant%2520Mycobacterium%2520tuberculosis%2520in%2520China%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26issue%3D8%26spage%3De00165-18%26doi%3D10.1128%2FAAC.00165-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group">ClinicalTrials.gov</span>. <span> </span><span class="NLM_article-title">A Phase 1 Study to Evaluate Safety, Tolerability,
and Pharmacokinetics
of TBI-223 in Healthy Adults</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT03758612" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03758612</a> (accessed December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+A+Phase+1+Study+to+Evaluate+Safety%2C+Tolerability%2C%0Aand+Pharmacokinetics%0Aof+TBI-223+in+Healthy+Adults.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03758612+%28accessed+December+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DA%2520Phase%25201%2520Study%2520to%2520Evaluate%2520Safety%252C%2520Tolerability%252C%250Aand%2520Pharmacokinetics%250Aof%2520TBI-223%2520in%2520Healthy%2520Adults" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubiec, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedarida, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paige, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladutko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. F.</span></span> <span> </span><span class="NLM_article-title">Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1128/AAC.01179-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.01179-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=21078950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVyjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=567-574&author=R.+S.+Wallisauthor=W.+Jakubiecauthor=V.+Kumarauthor=G.+Bedaridaauthor=A.+Silviaauthor=D.+Paigeauthor=T.+Zhuauthor=M.+Mitton-Fryauthor=L.+Ladutkoauthor=S.+Campbellauthor=P.+F.+Miller&title=Biomarker-assisted+dose+selection+for+safety+and+efficacy+in+early+development+of+PNU-100480+for+tuberculosis&doi=10.1128%2FAAC.01179-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis</span></div><div class="casAuthors">Wallis, Robert S.; Jakubiec, Wesley; Kumar, Vikas; Bedarida, Gabriella; Silvia, Annette; Paige, Darcy; Zhu, Tong; Mitton-Fry, Mark; Ladutko, Lynn; Campbell, Sheldon; Miller, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">567-574</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tuberculosis is a serious global health threat for which new treatments are urgently needed.  This study examd. the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of the oxazolidinone PNU-100480 in healthy volunteers, using biomarkers for safety and efficacy.  Subjects were randomly assigned to PNU-100480 or placebo (4:1) at schedules of 100, 300, or 600 mg twice daily or 1,200 mg daily for 14 days or a schedule of 600 mg twice daily for 28 days to which pyrazinamide was added on days 27 and 28.  A sixth cohort was given linezolid at 300 mg daily for 4 days.  Signs, symptoms, and routine safety tests were monitored.  Bactericidal activity against Mycobacterium tuberculosis was measured in ex vivo whole-blood culture.  Plasma drug and metabolite concns. were compared to the levels required for inhibition of M. tuberculosis growth and 50% inhibition of mitochondrial protein synthesis.  All doses were safe and well tolerated.  There were no hematol. or other safety signals during 28 days of dosing at 600 mg twice daily.  Plasma concns. of PNU-100480 and metabolites at this dose remained below those required for 50% inhibition of mitochondrial protein synthesis.  Cumulative whole-blood bactericidal activity of PNU-100480 at this dose (-0.316 ± 0.04 log) were superior to the activities of all other doses tested (P < 0.001) and was significantly augmented by pyrazinamide (-0.420 ± 0.06 log) (P = 0.002).  In conclusion, PNU-100480 was safe and well tolerated at all tested doses.  Further studies in patients with tuberculosis are warranted.  Biomarkers can accelerate early development of new tuberculosis treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCYDkvTtgkiLVg90H21EOLACvtfcHk0liFzqDiywN61g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVyjsLs%253D&md5=332e0a4d1903c4f9408b6e5e412eabb0</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1128%2FAAC.01179-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01179-10%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DR.%2BS.%26aulast%3DJakubiec%26aufirst%3DW.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBedarida%26aufirst%3DG.%26aulast%3DSilvia%26aufirst%3DA.%26aulast%3DPaige%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DMitton-Fry%26aufirst%3DM.%26aulast%3DLadutko%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DP.%2BF.%26atitle%3DBiomarker-assisted%2520dose%2520selection%2520for%2520safety%2520and%2520efficacy%2520in%2520early%2520development%2520of%2520PNU-100480%2520for%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D567%26epage%3D574%26doi%3D10.1128%2FAAC.01179-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meintjes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maartens, G.</span></span> <span> </span><span class="NLM_article-title">Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index</span>. <i>Expert Rev. Anti-Infect. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">901</span>– <span class="NLM_lpage">915</span>, <span class="refDoi"> DOI: 10.1080/14787210.2016.1225498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1080%2F14787210.2016.1225498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27532292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVehu7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=901-915&issue=10&author=S.+Wassermanauthor=G.+Meintjesauthor=G.+Maartens&title=Linezolid+in+the+treatment+of+drug-resistant+tuberculosis%3A+the+challenge+of+its+narrow+therapeutic+index&doi=10.1080%2F14787210.2016.1225498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index</span></div><div class="casAuthors">Wasserman, Sean; Meintjes, Graeme; Maartens, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anti-Infective Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">901-915</span>CODEN:
                <span class="NLM_cas:coden">ERATCK</span>;
        ISSN:<span class="NLM_cas:issn">1478-7210</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: Linezolid is an oxazolidinone with potent activity against M tuberculosis, and improves culture conversion and cure rates when added to treatment regimens for drug resistant tuberculosis.  However, linezolid has a narrow therapeutic window, and the optimal dosing strategy that minimizes the substantial toxicity assocd. with linezolid's prolonged use in tuberculosis treatment has not been detd., limiting the potential impact of this anti-mycobacterial agent.  Areas covered: This paper aims to review and summarize the current knowledge on linezolid for the treatment of drug-resistant tuberculosis.  The focus is on the pharmacokinetic-pharmacodynamic determinants of linezolid's efficacy and toxicity in tuberculosis, and how this relates to defining an optimal dose.  Mechanisms of linezolid toxicity and resistance, and the potential role of therapeutic drug monitoring are also covered.  Expert commentary: Prospective pharmacokinetic-pharmacodynamic studies are required to define optimal therapeutic targets and to inform improved linezolid dosing strategies for drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRY5QIBD8h57Vg90H21EOLACvtfcHk0ljRTM3Tt03WUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVehu7vL&md5=4e1bc3ec740ecd73d1e5f70144254214</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1080%2F14787210.2016.1225498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14787210.2016.1225498%26sid%3Dliteratum%253Aachs%26aulast%3DWasserman%26aufirst%3DS.%26aulast%3DMeintjes%26aufirst%3DG.%26aulast%3DMaartens%26aufirst%3DG.%26atitle%3DLinezolid%2520in%2520the%2520treatment%2520of%2520drug-resistant%2520tuberculosis%253A%2520the%2520challenge%2520of%2520its%2520narrow%2520therapeutic%2520index%26jtitle%3DExpert%2520Rev.%2520Anti-Infect.%2520Ther.%26date%3D2016%26volume%3D14%26issue%3D10%26spage%3D901%26epage%3D915%26doi%3D10.1080%2F14787210.2016.1225498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of fluorine-containing benzoxazinyl-oxazolidinones for the treatment of multidrug resistant tuberculosis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00068</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=533-537&author=H.+Zhaoauthor=Y.+Luauthor=L.+Shengauthor=Z.+Yuanauthor=B.+Wangauthor=W.+Wangauthor=Y.+Liauthor=C.+Maauthor=X.+Wangauthor=D.+Zhangauthor=H.+Huang&title=Discovery+of+fluorine-containing+benzoxazinyl-oxazolidinones+for+the+treatment+of+multidrug+resistant+tuberculosis&doi=10.1021%2Facsmedchemlett.7b00068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Fluorine-Containing Benzoxazinyl-oxazolidinones for the Treatment of Multidrug Resistant Tuberculosis</span></div><div class="casAuthors">Zhao, Hongyi; Lu, Yu; Sheng, Li; Yuan, Zishuo; Wang, Bin; Wang, Weiping; Li, Yan; Ma, Chen; Wang, Xiaoliang; Zhang, Dongfeng; Huang, Haihong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">533-537</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of fluorine-contg. benzoxazinyl-oxazolidinones were designed and synthesized as antidrug-resistant tuberculosis agents possessing good activity and improved pharmacokinetic profiles.  Compd. I exhibited not only outstanding in vitro activity with a MIC value of 0.25-0.50 μg/mL against drug-susceptible H37Rv strain and two clin. isolated drug-resistant Mycobacterium tuberculosis strains, but also acceptable in vitro ADME/T properties.  Moreover, this compd. displayed excellent mouse pharmacokinetic profiles with an oral bioavailability of 102% and a longer elimination half-life of 4.22 h, thereby supporting further optimization and development of this promising lead series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogwgObIiYn5rVg90H21EOLACvtfcHk0ljRTM3Tt03WUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVWltL8%253D&md5=288fd039d5f0eb32cd751e6390733dc7</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00068%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520fluorine-containing%2520benzoxazinyl-oxazolidinones%2520for%2520the%2520treatment%2520of%2520multidrug%2520resistant%2520tuberculosis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D533%26epage%3D537%26doi%3D10.1021%2Facsmedchemlett.7b00068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a conformationally constrained oxazolidinone with improved safety and efficacy profiles for the treatment of multidrug-resistant tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9316</span>– <span class="NLM_lpage">9339</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00500</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00500" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9316-9339&author=H.+Zhaoauthor=B.+Wangauthor=L.+Fuauthor=G.+Liauthor=H.+Luauthor=Y.+Liuauthor=L.+Shengauthor=Y.+Liauthor=B.+Zhangauthor=Y.+Luauthor=C.+Maauthor=H.+Huangauthor=D.+Zhangauthor=Y.+Lu&title=Discovery+of+a+conformationally+constrained+oxazolidinone+with+improved+safety+and+efficacy+profiles+for+the+treatment+of+multidrug-resistant+tuberculosis&doi=10.1021%2Facs.jmedchem.0c00500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis</span></div><div class="casAuthors">Zhao, Hongyi; Wang, Bin; Fu, Lei; Li, Gang; Lu, Haijia; Liu, Yuke; Sheng, Li; Li, Yan; Zhang, Baoxi; Lu, Yang; Ma, Chen; Huang, Haihong; Zhang, Dongfeng; Lu, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9316-9339</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tuberculosis (TB) remains a serious public health challenge, and the research and development of new anti-TB drugs is an essential component of the global strategy to eradicate TB.  In this work, we discovered a conformationally constrained oxazolidinone 19c(I) with improved anti-TB activity and safety profile through a focused lead optimization effort.  Compd. 19c displayed superior in vivo efficacy in a mouse TB infection model compared to linezolid and sutezolid.  The druggability of compd. 19c was demonstrated in a panel of assays including microsomal stability, cytotoxicity, cytochrome P 450 enzyme inhibition, and pharmacokinetics in animals.  Compd. 19c demonstrated an excellent safety profile in a battery of safety assays, including mitochondrial protein synthesis, hERG K+, hCav1.2, and Nav1.5 channels, monoamine oxidase, and genotoxicity.  In a 4 wk repeated dose toxicol. study in rats, 19c appeared to have less bone marrow suppression than linezolid, which has been a major liability of the oxazolidinone class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZxjD-svNTCLVg90H21EOLACvtfcHk0lgUYnk_Mac8TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtbbP&md5=fca65a3a3fb69bc78178ae5b04c6a562</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00500%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520conformationally%2520constrained%2520oxazolidinone%2520with%2520improved%2520safety%2520and%2520efficacy%2520profiles%2520for%2520the%2520treatment%2520of%2520multidrug-resistant%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9316%26epage%3D9339%26doi%3D10.1021%2Facs.jmedchem.0c00500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel 4H-chromen-4-one derivatives as antituberculosis agents against multidrug-resistant tuberculosis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">112075</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.ejmech.2020.112075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31986405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVWju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2020&pages=112075&author=W.+Zhaoauthor=B.+Wangauthor=Y.+Liuauthor=L.+Fuauthor=L.+Shengauthor=H.+Zhaoauthor=Y.+Luauthor=D.+Zhang&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+4H-chromen-4-one+derivatives+as+antituberculosis+agents+against+multidrug-resistant+tuberculosis&doi=10.1016%2Fj.ejmech.2020.112075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of novel 4H-chromen-4-one derivatives as antituberculosis agents against multidrug-resistant tuberculosis</span></div><div class="casAuthors">Zhao, Wenting; Wang, Bin; Liu, Yuke; Fu, Lei; Sheng, Li; Zhao, Hongyi; Lu, Yu; Zhang, Dongfeng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112075pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 4H-chromen-4-one derivs. I (R1 = H, C6H5, 4-FC6H4, etc.; R2 = H, piperidin-1-ylmethyl, pyrrolidin-1-ylmethyl, etc.; R3 = H, 4-HOC6H4, Et formate, etc.) obtained by scaffold morphing of the benzofuran compd., TAM16, were tested for antitubercular activity.  Compd. I (R1 = 4-HOC6H4; R2 = azetidin-1-ylmethyl; R3 = H) was active against drug-sensitive and multidrug-resistant tuberculosis.  A preliminary druggability evaluation showed that the above compd. displayed favorable mouse and human microsomal stability, low cytotoxicity, and acceptable oral bioavailability.  An in vivo study indicated that the above compd. exhibited modest efficacy in an acute mouse model of TB after 3 wk of treatment.  Thus, the above compd. is a promising antituberculosis lead compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqURjJVHJb3UrVg90H21EOLACvtfcHk0lgUYnk_Mac8TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVWju7w%253D&md5=67bdd39407b5ff4ac3d82d21620217cf</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112075%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%25204H-chromen-4-one%2520derivatives%2520as%2520antituberculosis%2520agents%2520against%2520multidrug-resistant%2520tuberculosis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D189%26spage%3D112075%26doi%3D10.1016%2Fj.ejmech.2020.112075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavalda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Léger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Rest, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montrozier, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlet-Schiltz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrakchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daffé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quémard, A.</span></span> <span> </span><span class="NLM_article-title">The Pks13/FadD32 crosstalk for the biosynthesis of mycolic acids in Mycobacterium tuberculosis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">19255</span>– <span class="NLM_lpage">19264</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.006940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1074%2Fjbc.M109.006940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=19436070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD1MXot12ktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=19255-19264&author=S.+Gavaldaauthor=M.+L%C3%A9gerauthor=B.+van+der+Restauthor=A.+Stellaauthor=F.+Bardouauthor=H.+Montrozierauthor=C.+Chalutauthor=O.+Burlet-Schiltzauthor=H.+Marrakchiauthor=M.+Daff%C3%A9author=A.+Qu%C3%A9mard&title=The+Pks13%2FFadD32+crosstalk+for+the+biosynthesis+of+mycolic+acids+in+Mycobacterium+tuberculosis&doi=10.1074%2Fjbc.M109.006940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">The Pks13/FadD32 Crosstalk for the Biosynthesis of Mycolic Acids in Mycobacterium tuberculosis</span></div><div class="casAuthors">Gavalda, Sabine; Leger, Mathieu; van der Rest, Benoit; Stella, Alexandre; Bardou, Fabienne; Montrozier, Henri; Chalut, Christian; Burlet-Schiltz, Odile; Marrakchi, Hedia; Daffe, Mamadou; Quemard, Annaik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">19255-19264</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The last steps of the biosynthesis of mycolic acids, essential and specific lipids of Mycobacterium tuberculosis and related bacteria, are catalyzed by proteins encoded by the fadD32-pks13-accD4 cluster.  Here, we produced and purified an active form of the Pks13 polyketide synthase, with a phosphopantetheinyl (P-pant) arm at both positions Ser-55 and Ser-1266 of its two acyl carrier protein (ACP) domains.  Combination of liq. chromatog.-tandem mass spectrometry of protein tryptic digests and radiolabeling expts. showed that, in vitro, the enzyme specifically loads long-chain 2-carboxyacyl-CoA substrates onto the P-pant arm of its C-terminal ACP domain via the acyltransferase domain.  The acyl-AMPs produced by the FadD32 enzyme are specifically transferred onto the ketosynthase domain after binding to the P-pant moiety of the N-terminal ACP domain of Pks13 (N-ACPPks13).  Unexpectedly, however, the latter step requires the presence of active FadD32.  Thus, the couple FadD32-(N-ACPPks13) composes the initiation module of the mycolic condensation system.  Pks13 ultimately condenses the two loaded fatty acyl chains to produce α-alkyl β-ketoacids, the precursors of mycolic acids.  The developed in vitro assay will constitute a strategic tool for antimycobacterial drug screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvik29xE2QILVg90H21EOLACvtfcHk0lgUYnk_Mac8TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXot12ktLk%253D&md5=658b560cb616973f8fb44dc5035c5713</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.006940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.006940%26sid%3Dliteratum%253Aachs%26aulast%3DGavalda%26aufirst%3DS.%26aulast%3DL%25C3%25A9ger%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BRest%26aufirst%3DB.%26aulast%3DStella%26aufirst%3DA.%26aulast%3DBardou%26aufirst%3DF.%26aulast%3DMontrozier%26aufirst%3DH.%26aulast%3DChalut%26aufirst%3DC.%26aulast%3DBurlet-Schiltz%26aufirst%3DO.%26aulast%3DMarrakchi%26aufirst%3DH.%26aulast%3DDaff%25C3%25A9%26aufirst%3DM.%26aulast%3DQu%25C3%25A9mard%26aufirst%3DA.%26atitle%3DThe%2520Pks13%252FFadD32%2520crosstalk%2520for%2520the%2520biosynthesis%2520of%2520mycolic%2520acids%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D19255%26epage%3D19264%26doi%3D10.1074%2Fjbc.M109.006940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishai, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.-F.</span></span> <span> </span><span class="NLM_article-title">Identification of novel coumestan derivatives as polyketide synthase 13 inhibitors against Mycobacterium tuberculosis. Part II</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3575</span>– <span class="NLM_lpage">3589</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFeksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3575-3589&author=W.+Zhangauthor=S.+Lunauthor=L.-L.+Liuauthor=S.+Xiaoauthor=G.+Duanauthor=H.+Gunosewoyoauthor=F.+Yangauthor=J.+Tangauthor=W.+R.+Bishaiauthor=L.-F.+Yu&title=Identification+of+novel+coumestan+derivatives+as+polyketide+synthase+13+inhibitors+against+Mycobacterium+tuberculosis.+Part+II&doi=10.1021%2Facs.jmedchem.9b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel coumestan derivatives as polyketide synthase 13 inhibitors against Mycobacterium tuberculosis. part II</span></div><div class="casAuthors">Zhang, Wei; Lun, Shichun; Liu, Ling-Ling; Xiao, Shiqi; Duan, Guanfu; Gunosewoyo, Hendra; Yang, Fan; Tang, Jie; Bishai, William R.; Yu, Li-Fang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3575-3589</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Our group recently reported the identification of novel coumestan derivs. as Mycobacterium tuberculosis (Mtb) Pks13-thioesterase (TE) domain inhibitors, with mutations obsd. (D1644G and N1640K) in the generated coumestan-resistant Mtb colonies.  Herein, we report a further structure-activity relationships exploration exploiting the available Pks13-TE X-ray co-crystal structure that resulted in the discovery of extremely potent coumestan analogs 48(I) and 50(II).  These mols. possess excellent anti-tuberculosis activity against both the drug-susceptible (MIC = 0.0039 μg/mL) and drug-resistant Mtb strains (MIC = 0.0078 μg/mL).  Moreover, the excellent in vitro activity is translated to the in vivo mouse serum inhibitory titrn. assay, with administration of I at 100 mg/kg showing an 8-fold higher activity than that of isoniazid or TAM16 given at 10 or 100 mg/kg, resp.  Preliminary ADME-Tox data for the coumestans were promising and, coupled with the practicality of synthesis, warrant further in vivo efficacy assessments of the coumestan derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolhzlD7NMcz7Vg90H21EOLACvtfcHk0lhk9iAD6vBFsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFeksL0%253D&md5=30c5e50311e413573a0c861fc5c64cb3</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00010%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLun%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DL.-L.%26aulast%3DXiao%26aufirst%3DS.%26aulast%3DDuan%26aufirst%3DG.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DBishai%26aufirst%3DW.%2BR.%26aulast%3DYu%26aufirst%3DL.-F.%26atitle%3DIdentification%2520of%2520novel%2520coumestan%2520derivatives%2520as%2520polyketide%2520synthase%252013%2520inhibitors%2520against%2520Mycobacterium%2520tuberculosis.%2520Part%2520II%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3575%26epage%3D3589%26doi%3D10.1021%2Facs.jmedchem.9b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earl, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishai, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. F.</span></span> <span> </span><span class="NLM_article-title">Identification of novel coumestan derivatives as polyketide synthase 13 inhibitors against Mycobacterium tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01319</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01319" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVyqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=791-803&author=W.+Zhangauthor=S.+Lunauthor=S.+H.+Wangauthor=X.+W.+Jiangauthor=F.+Yangauthor=J.+Tangauthor=A.+L.+Mansonauthor=A.+M.+Earlauthor=H.+Gunosewoyoauthor=W.+R.+Bishaiauthor=L.+F.+Yu&title=Identification+of+novel+coumestan+derivatives+as+polyketide+synthase+13+inhibitors+against+Mycobacterium+tuberculosis&doi=10.1021%2Facs.jmedchem.7b01319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis</span></div><div class="casAuthors">Zhang, Wei; Lun, Shichun; Wang, Shu-Huan; Jiang, Xing-Wu; Yang, Fan; Tang, Jie; Manson, Abigail L.; Earl, Ashlee M.; Gunosewoyo, Hendra; Bishai, William R.; Yu, Li-Fang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">791-803</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the mycolic acid pathway has proven a viable strategy in antitubercular drug discovery.  The AccA3/AccD4/FadD32/Pks13 complex of Mycobacterium tuberculosis constitutes an essential biosynthetic mechanism for mycolic acids.  Small mols. targeting the thioesterase domain of Pks13 have been reported, including a benzofuran-based compd. whose X-ray cocrystal structure has been very recently solved.  Its initial inactivity in a serum inhibition titrn. (SIT) assay led us to further probe other structurally related benzofurans with the aim to improve their potency and bioavailability.  Herein, we report our preliminary structure-activity relationship studies around this scaffold, highlighting a natural product-inspired cyclization strategy to form coumestans that are shown to be active in SIT.  Whole genome deep sequencing of the coumestan-resistant mutants confirmed a single nucleotide polymorphism in the pks13 gene responsible for the resistance phenotype, demonstrating the druggability of this target for the development of new antitubercular agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1LJWIdOrTvLVg90H21EOLACvtfcHk0lhk9iAD6vBFsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVyqtw%253D%253D&md5=053f265d21ca7eff9f396c33907a1d75</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01319%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLun%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%2BH.%26aulast%3DJiang%26aufirst%3DX.%2BW.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DManson%26aufirst%3DA.%2BL.%26aulast%3DEarl%26aufirst%3DA.%2BM.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DBishai%26aufirst%3DW.%2BR.%26aulast%3DYu%26aufirst%3DL.%2BF.%26atitle%3DIdentification%2520of%2520novel%2520coumestan%2520derivatives%2520as%2520polyketide%2520synthase%252013%2520inhibitors%2520against%2520Mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D791%26epage%3D803%26doi%3D10.1021%2Facs.jmedchem.7b01319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campanico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seldon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdigao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portugal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span> <span> </span><span class="NLM_article-title">Azaaurones as potent antimycobacterial agents active against MDR- and XDR-TB</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1537</span>– <span class="NLM_lpage">1546</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201900289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1002%2Fcmdc.201900289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31294529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVaqtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1537-1546&author=A.+Campanicoauthor=M.+P.+Carrascoauthor=M.+Njorogeauthor=R.+Seldonauthor=K.+Chibaleauthor=J.+Perdigaoauthor=I.+Portugalauthor=D.+F.+Warnerauthor=R.+Moreiraauthor=F.+Lopes&title=Azaaurones+as+potent+antimycobacterial+agents+active+against+MDR-+and+XDR-TB&doi=10.1002%2Fcmdc.201900289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Azaaurones as potent antimycobacterial agents active against MDR- and XDR-TB</span></div><div class="casAuthors">Campanico, Andre; Carrasco, Marta P.; Njoroge, Mathew; Seldon, Ronnett; Chibale, Kelly; Perdigao, Joao; Portugal, Isabel; Warner, Digby F.; Moreira, Rui; Lopes, Francisca</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1537-1546</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein we report the screening of a small library of aurones and their isosteric counterparts, azaaurones and N-acetylazaaurones, against Mycobacterium tuberculosis.  Aurones were found to be inactive at 20 μM, whereas azaaurones and N-acetylazaaurones emerged as the most potent compds., with nine derivs. displaying MIC99 values ranging from 0.4 to 2.0 μM.  In addn., several N-acetylazaaurones were found to be active against multidrug-resistant (MDR) and extensively drug-resistant (XDR) clin. M. tuberculosis isolates.  The antimycobacterial mechanism of action of these compds. remains to be detd.; however, a preliminary mechanistic study confirmed that they do not inhibit the mycobacterial cytochrome bc1 complex.  Addnl., microsomal metabolic stability and metabolite identification studies revealed that N-acetylazaaurones are deacetylated to their azaaurone counterparts.  Overall, these results demonstrate that azaaurones and their N-acetyl counterparts represent a new entry in the toolbox of chemotypes capable of inhibiting M. tuberculosis growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPeGhVOhg6wrVg90H21EOLACvtfcHk0lgRJlznLLxBDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVaqtrnF&md5=3649a282fa61d661da17554f2214b042</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201900289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201900289%26sid%3Dliteratum%253Aachs%26aulast%3DCampanico%26aufirst%3DA.%26aulast%3DCarrasco%26aufirst%3DM.%2BP.%26aulast%3DNjoroge%26aufirst%3DM.%26aulast%3DSeldon%26aufirst%3DR.%26aulast%3DChibale%26aufirst%3DK.%26aulast%3DPerdigao%26aufirst%3DJ.%26aulast%3DPortugal%26aufirst%3DI.%26aulast%3DWarner%26aufirst%3DD.%2BF.%26aulast%3DMoreira%26aufirst%3DR.%26aulast%3DLopes%26aufirst%3DF.%26atitle%3DAzaaurones%2520as%2520potent%2520antimycobacterial%2520agents%2520active%2520against%2520MDR-%2520and%2520XDR-TB%26jtitle%3DChemMedChem%26date%3D2019%26volume%3D14%26spage%3D1537%26epage%3D1546%26doi%3D10.1002%2Fcmdc.201900289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawale, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khedkar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation and molecular docking study of some novel indole and pyridine based 1,3,4-oxadiazole derivatives as potential antitubercular agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1776</span>– <span class="NLM_lpage">1783</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.02.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.bmcl.2016.02.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26920799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1WqsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1776-1783&author=N.+C.+Desaiauthor=H.+Somaniauthor=A.+Trivediauthor=K.+Bhattauthor=L.+Nawaleauthor=V.+M.+Khedkarauthor=P.+C.+Jhaauthor=D.+Sarkar&title=Synthesis%2C+biological+evaluation+and+molecular+docking+study+of+some+novel+indole+and+pyridine+based+1%2C3%2C4-oxadiazole+derivatives+as+potential+antitubercular+agents&doi=10.1016%2Fj.bmcl.2016.02.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluation and molecular docking study of some novel indole and pyridine based 1,3,4-oxadiazole derivatives as potential antitubercular agents</span></div><div class="casAuthors">Desai, N. C.; Somani, Hardik; Trivedi, Amit; Bhatt, Kandarp; Nawale, Laxman; Khedkar, Vijay M.; Jha, Prakash C.; Sarkar, Dhiman</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1776-1783</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">(Indolyl)(pyridinyl)oxadiazolinyl arylpropenones I (R = Ph, 2-HOC6H4, 3-HOC6H4, 4-HOC6H4, 2-O2NC6H4, 3-O2NC6H4, 4-O2NC6H4, 4-MeC6H4, 4-MeOC6H4, 2-FC6H4, 3-FC6H4, 4-FC6H4, 2-ClC6H4, 3-ClC6H4, 4-ClC6H4, 2,3-Cl2C6H3, 2,4-Cl2C6H3, 2,6-Cl2C6H3, 3-BrC6H4, 4-BrC6H4) were prepd. as inhibitors of mycobacterial enoyl-acyl carrier protein (enoyl-ACP) reductase InhA for potential use as antitubercular agents or as potential leads for antitubercular agents; I were tested for their inhibition of Mycobacterium tuberculosis H37Ra and M. bovis BCG and for their antibacterial activities, and the toxicity of the active compds. to human cancer cells was detd.  I (R = 2-HOC6H4, 2-O2NC6H4, 4-O2NC6H4, 2,4-Cl2C6H3) demonstrated safety indexes of ≥10 against all three human cancer cell lines; I (R = 2,4-Cl2C6H3) was highly selective for mycobacteria over cancer cells and bacteria.  Mol. docking calcns. of the binding of I (R = 2-HOC6H4, 2-O2NC6H4, 4-O2NC6H4, 2,4-Cl2C6H3) to mycobacterial enoyl reductase InhA were performed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooPQDArlF-ULVg90H21EOLACvtfcHk0lgRJlznLLxBDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1WqsLo%253D&md5=b8591802f776a229cf77015a6d87417d</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.02.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.02.043%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DN.%2BC.%26aulast%3DSomani%26aufirst%3DH.%26aulast%3DTrivedi%26aufirst%3DA.%26aulast%3DBhatt%26aufirst%3DK.%26aulast%3DNawale%26aufirst%3DL.%26aulast%3DKhedkar%26aufirst%3DV.%2BM.%26aulast%3DJha%26aufirst%3DP.%2BC.%26aulast%3DSarkar%26aufirst%3DD.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%2520and%2520molecular%2520docking%2520study%2520of%2520some%2520novel%2520indole%2520and%2520pyridine%2520based%25201%252C3%252C4-oxadiazole%2520derivatives%2520as%2520potential%2520antitubercular%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1776%26epage%3D1783%26doi%3D10.1016%2Fj.bmcl.2016.02.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarrete-Vázquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina-Salinas, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte-Fajardo, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas-Villarreal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada-Soto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Salazar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández-Núñez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Said-Fernández, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antimycobacterial activity of 4-(5-substituted-1,3,4-oxadiazol-2-yl)pyridines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5502</span>– <span class="NLM_lpage">5508</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2007.05.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.bmc.2007.05.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=17562368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvV2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=5502-5508&author=G.+Navarrete-V%C3%A1zquezauthor=G.+M.+Molina-Salinasauthor=Z.+V.+Duarte-Fajardoauthor=J.+Vargas-Villarrealauthor=S.+Estrada-Sotoauthor=F.+Gonz%C3%A1lez-Salazarauthor=E.+Hern%C3%A1ndez-N%C3%BA%C3%B1ezauthor=S.+Said-Fern%C3%A1ndez&title=Synthesis+and+antimycobacterial+activity+of+4-%285-substituted-1%2C3%2C4-oxadiazol-2-yl%29pyridines&doi=10.1016%2Fj.bmc.2007.05.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antimycobacterial activity of 4-(5-substituted-1,3,4-oxadiazol-2-yl)pyridines</span></div><div class="casAuthors">Navarrete-Vazquez, Gabriel; Molina-Salinas, Gloria Maria; Duarte-Fajardo, Zetel Vahi; Vargas-Villarreal, Javier; Estrada-Soto, Samuel; Gonzalez-Salazar, Francisco; Hernandez-Nunez, Emanuel; Said-Fernandez, Salvador</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5502-5508</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Twelve 4-(5-Substituted-1,3,4-oxadiazol-2-yl)pyridine derivs. were synthesized and evaluated for their in vitro antimycobacterial activity.  Some compds. showed an interesting activity against Mycobacterium tuberculosis H37Rv and five clin. isolates (drug-sensitive and -resistant strains).  4-(5-Pentadecyl-1,3,4-oxadiazol-2-yl)pyridine was 10 times more active than isoniazid, 20 times more active than streptomycin, and 28 times more potent than ethambutol against drug-resistant strain CIBIN 112.  4-(5-Heptadecyl-1,3,4-oxadiazol-2-yl)pyridine showed the same behavior as 4-(5-pentadecyl-1,3,4-oxadiazol-2-yl)pyridine.  Both of the above structures bear a high lipophilic chain bonded to the 5-position of the oxadiazole moiety.  This fact implies that there exists a contribution of lipophilicity, which could facilitate the entrance of these mols. through lipid-enriched bacterial cell membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0svc0R8Ojz7Vg90H21EOLACvtfcHk0liN85GXbr8Lqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvV2itrs%253D&md5=df8b1413606bdedd3d91c0898f139344</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.05.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.05.053%26sid%3Dliteratum%253Aachs%26aulast%3DNavarrete-V%25C3%25A1zquez%26aufirst%3DG.%26aulast%3DMolina-Salinas%26aufirst%3DG.%2BM.%26aulast%3DDuarte-Fajardo%26aufirst%3DZ.%2BV.%26aulast%3DVargas-Villarreal%26aufirst%3DJ.%26aulast%3DEstrada-Soto%26aufirst%3DS.%26aulast%3DGonz%25C3%25A1lez-Salazar%26aufirst%3DF.%26aulast%3DHern%25C3%25A1ndez-N%25C3%25BA%25C3%25B1ez%26aufirst%3DE.%26aulast%3DSaid-Fern%25C3%25A1ndez%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520antimycobacterial%2520activity%2520of%25204-%25285-substituted-1%252C3%252C4-oxadiazol-2-yl%2529pyridines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D5502%26epage%3D5508%26doi%3D10.1016%2Fj.bmc.2007.05.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karabanovich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zemanová, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smutný, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Székely, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Šarkan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centárová, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pávková, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Čonka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Němeček, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolaříková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vejsová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vávrová, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimešová, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabálek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pávek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikušová, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roh, J.</span></span> <span> </span><span class="NLM_article-title">Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and thiadiazoles as selective antitubercular agents active against replicating and nonreplicating Mycobacterium tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2362</span>– <span class="NLM_lpage">2380</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00608</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00608" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1yqt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2362-2380&author=G.+Karabanovichauthor=J.+Zemanov%C3%A1author=T.+Smutn%C3%BDauthor=R.+Sz%C3%A9kelyauthor=M.+%C5%A0arkanauthor=I.+Cent%C3%A1rov%C3%A1author=A.+Vocatauthor=I.+P%C3%A1vkov%C3%A1author=P.+%C4%8Conkaauthor=J.+N%C4%9Bme%C4%8Dekauthor=J.+Stola%C5%99%C3%ADkov%C3%A1author=M.+Vejsov%C3%A1author=K.+V%C3%A1vrov%C3%A1author=V.+Klime%C5%A1ov%C3%A1author=A.+Hrab%C3%A1lekauthor=P.+P%C3%A1vekauthor=S.+T.+Coleauthor=K.+Miku%C5%A1ov%C3%A1author=J.+Roh&title=Development+of+3%2C5-Dinitrobenzylsulfanyl-1%2C3%2C4-oxadiazoles+and+thiadiazoles+as+selective+antitubercular+agents+active+against+replicating+and+nonreplicating+Mycobacterium+tuberculosis&doi=10.1021%2Facs.jmedchem.5b00608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis</span></div><div class="casAuthors">Karabanovich, Galina; Zemanova, Julia; Smutny, Tomas; Szekely, Rita; Sarkan, Michal; Centarova, Ivana; Vocat, Anthony; Pavkova, Ivona; Conka, Patrik; Nemecek, Jan; Stolarikova, Jirina; Vejsova, Marcela; Vavrova, Katerina; Klimesova, Vera; Hrabalek, Alexandr; Pavek, Petr; Cole, Stewart T.; Mikusova, Katarina; Roh, Jaroslav</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2362-2380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we report the discovery and structure-activity relationships of 5-substituted-2-[(3,5-dinitrobenzyl)sulfanyl]-1,3,4-oxadiazoles and 1,3,4-thiadiazoles as a new class of antituberculosis agents.  The majority of these compds. exhibited outstanding in vitro activity against Mycobacterium tuberculosis CNCTC My 331/88 and six multidrug-resistant clin. isolated strains of M. tuberculosis, with min. inhibitory concn. values as low as 0.03 μM (0.011-0.026 μg/mL).  The investigated compds. had a highly selective antimycobacterial effect because they showed no activity against the other bacteria or fungi tested in this study.  Furthermore, the investigated compds. exhibited low in vitro toxicities in four proliferating mammalian cell lines and in isolated primary human hepatocytes.  Several in vitro genotoxicity assays indicated that the selected compds. have no mutagenic activity.  The oxadiazole and thiadiazole derivs. with the most favorable activity/toxicity profiles also showed potency comparable to that of rifampicin against the nonreplicating streptomycin-starved M. tuberculosis 18b-Lux strain, and therefore, these derivs., are of particular interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgBb0Hpi3vOrVg90H21EOLACvtfcHk0liN85GXbr8Lqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1yqt7Y%253D&md5=788b65627cfd13854c699c08ae7aa756</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00608%26sid%3Dliteratum%253Aachs%26aulast%3DKarabanovich%26aufirst%3DG.%26aulast%3DZemanov%25C3%25A1%26aufirst%3DJ.%26aulast%3DSmutn%25C3%25BD%26aufirst%3DT.%26aulast%3DSz%25C3%25A9kely%26aufirst%3DR.%26aulast%3D%25C5%25A0arkan%26aufirst%3DM.%26aulast%3DCent%25C3%25A1rov%25C3%25A1%26aufirst%3DI.%26aulast%3DVocat%26aufirst%3DA.%26aulast%3DP%25C3%25A1vkov%25C3%25A1%26aufirst%3DI.%26aulast%3D%25C4%258Conka%26aufirst%3DP.%26aulast%3DN%25C4%259Bme%25C4%258Dek%26aufirst%3DJ.%26aulast%3DStola%25C5%2599%25C3%25ADkov%25C3%25A1%26aufirst%3DJ.%26aulast%3DVejsov%25C3%25A1%26aufirst%3DM.%26aulast%3DV%25C3%25A1vrov%25C3%25A1%26aufirst%3DK.%26aulast%3DKlime%25C5%25A1ov%25C3%25A1%26aufirst%3DV.%26aulast%3DHrab%25C3%25A1lek%26aufirst%3DA.%26aulast%3DP%25C3%25A1vek%26aufirst%3DP.%26aulast%3DCole%26aufirst%3DS.%2BT.%26aulast%3DMiku%25C5%25A1ov%25C3%25A1%26aufirst%3DK.%26aulast%3DRoh%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%25203%252C5-Dinitrobenzylsulfanyl-1%252C3%252C4-oxadiazoles%2520and%2520thiadiazoles%2520as%2520selective%2520antitubercular%2520agents%2520active%2520against%2520replicating%2520and%2520nonreplicating%2520Mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2362%26epage%3D2380%26doi%3D10.1021%2Facs.jmedchem.5b00608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makane, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishna, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishna, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahizhaveni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azger Dusthackeer, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rode, H. B.</span></span> <span> </span><span class="NLM_article-title">Novel 1,3,4-oxadiazoles as antitubercular agents with limited activity against drug-resistant tuberculosis</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">510</span>, <span class="refDoi"> DOI: 10.4155/fmc-2018-0378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4155%2Ffmc-2018-0378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30892944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmslGntrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=499-510&author=V.+B.+Makaneauthor=V.+S.+Krishnaauthor=E.+V.+Krishnaauthor=M.+Shuklaauthor=B.+Mahizhaveniauthor=S.+Misraauthor=S.+Chopraauthor=D.+Sriramauthor=V.+N.+Azger+Dusthackeerauthor=H.+B.+Rode&title=Novel+1%2C3%2C4-oxadiazoles+as+antitubercular+agents+with+limited+activity+against+drug-resistant+tuberculosis&doi=10.4155%2Ffmc-2018-0378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 1,3,4-oxadiazoles as antitubercular agents with limited activity against drug-resistant tuberculosis</span></div><div class="casAuthors">Makane, Vitthal B.; Krishna, Vagolu Siva; Krishna, Eruva Vamshi; Shukla, Manjulika; Mahizhaveni, Balakrishnan; Misra, Sunil; Chopra, Sidharth; Sriram, Dharmarajan; Azger Dusthackeer, Vijayan N.; Rode, Haridas B.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">499-510</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">In recent times, heterocyclic chemotypes are being explored for the development of new antimycobacterials that target the drug-resistant tuberculosis.  Here, we are disclosing the 5-substitued 2-mercapto-1,3,4-oxadiazoles I (R1 = Ph, 2-BrC6H4, 4-OHC6H4, etc.) as potent antitubercular agents.  A small library of 2-mercapto-1,3,4-oxadiazoles I was synthesized using various acids.  The compds. were evaluated for antituberculosis activity against M. tuberculosis H37Rv.  Compd. I (R1 = 4-OHC6H4) was identified as antitubercular lead with MIC of 0.6μg/mL against M. tuberculosis H37Rv.  This compd. was nontoxic to CHO-K1 cells and showed selectivity index of 39.  Of note, I (R1 = 4-OHC6H4) showed antitubercular activity against pre-extensively drug-resistant clin. isolate of Mycobacterium with MIC of 2μg/mL.  This study provides potent antitubercular agent which can be further optimized to discover novel antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_o0bE374dJrVg90H21EOLACvtfcHk0lgKEaLkw3swKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmslGntrk%253D&md5=dab28d2697e062de13a388a7e0062e29</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2018-0378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2018-0378%26sid%3Dliteratum%253Aachs%26aulast%3DMakane%26aufirst%3DV.%2BB.%26aulast%3DKrishna%26aufirst%3DV.%2BS.%26aulast%3DKrishna%26aufirst%3DE.%2BV.%26aulast%3DShukla%26aufirst%3DM.%26aulast%3DMahizhaveni%26aufirst%3DB.%26aulast%3DMisra%26aufirst%3DS.%26aulast%3DChopra%26aufirst%3DS.%26aulast%3DSriram%26aufirst%3DD.%26aulast%3DAzger%2BDusthackeer%26aufirst%3DV.%2BN.%26aulast%3DRode%26aufirst%3DH.%2BB.%26atitle%3DNovel%25201%252C3%252C4-oxadiazoles%2520as%2520antitubercular%2520agents%2520with%2520limited%2520activity%2520against%2520drug-resistant%2520tuberculosis%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2019%26volume%3D11%26spage%3D499%26epage%3D510%26doi%3D10.4155%2Ffmc-2018-0378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aidasani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branstetter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everds, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Primack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skiles, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebrec, H.</span></span> <span> </span><span class="NLM_article-title">P450-mediated O-demethylated metabolite is responsible for rat hepatobiliary toxicity of pyridyltriazine-containing PI3K inhibitors</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfu178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Ftoxsci%2Fkfu178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25159132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitl2ntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2014&pages=298-310&author=R.+Subramanianauthor=D.+Aidasaniauthor=K.+Baileyauthor=D.+Branstetterauthor=N.+Everdsauthor=J.+Jiangauthor=M.+H.+Normanauthor=R.+Primackauthor=G.+L.+Skilesauthor=I.+Sotoauthor=M.+M.+Stecauthor=M.+Wagnerauthor=T.+Wuauthor=X.+Zhuauthor=H.+Lebrec&title=P450-mediated+O-demethylated+metabolite+is+responsible+for+rat+hepatobiliary+toxicity+of+pyridyltriazine-containing+PI3K+inhibitors&doi=10.1093%2Ftoxsci%2Fkfu178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">P450-mediated O-demethylated metabolite is responsible for rat hepatobiliary toxicity of pyridyltriazine-containing PI3K inhibitors</span></div><div class="casAuthors">Subramanian, Raju; Aidasani, Divesh; Bailey, Keith; Branstetter, Dan; Everds, Nancy; Jiang, Jian; Norman, Mark H.; Primack, Ronya; Skiles, Gary L.; Soto, Irene; Stec, Markian M.; Wagner, Mylo; Wu, Tian; Zhu, Xiaochun; Lebrec, Herve</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">298-310</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The dysregulation of phosphatidylinositol 3-kinase (PI3K)-dependent pathways is implicated in several human cancers making it an attractive target for small mol. PI3K inhibitors.  A series of potent pyridyltriazine-contg. inhibitors of class Ia PI3Ks were synthesized and a subset of compds. was evaluated in exploratory repeat-dose rat toxicol. studies.  Daily oral dosing of compd. 1 in Sprague Dawley rats for four consecutive days was assocd. with hepatobiliary toxicity that included biliary epithelial hyperplasia and hypertrophy, periductular edema, biliary stasis, and acute peribiliary inflammatory infiltrates.  These histol. changes were assocd. with clin. pathol. changes that included increased serum liver enzymes, total bile acids, and bilirubin.  The predominant clearance pathway of 1 was shown in vitro and in a bile-duct cannulated rat 14C-ADME study to be P 450-mediated oxidative metab.  An O-demethylated pyridine metabolite, M3, was identified as a candidate proximal metabolite that caused the hepatotoxicity.  Co-administration of the pan-P 450 inhibitor 1-aminobenzotriazole with 1 to rats significantly reduced the formation of M3 and prevented liver toxicity, whereas direct administration of M3 reproduced the toxicity.  Structural changes were introduced to 1 to make the methoxypyridine ring less susceptible to P 450 oxidn. (compd. 2), and addn. of a Me group to the benzylic carbon (compd. 3) improved the pharmacokinetic profile.  These changes culminated in the successful design of a clin. candidate 3 (AMG 511) that was devoid of liver toxicity in a 14-day rat toxicity study.  Herein, we describe how a metab.-based structure-activity relationship anal. allowed for the successful identification of a PI3K inhibitor devoid of off-target toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY5I8X5B3sHbVg90H21EOLACvtfcHk0lgKEaLkw3swKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitl2ntrg%253D&md5=97f39570c10edc65c0768053db628d64</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfu178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfu178%26sid%3Dliteratum%253Aachs%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DAidasani%26aufirst%3DD.%26aulast%3DBailey%26aufirst%3DK.%26aulast%3DBranstetter%26aufirst%3DD.%26aulast%3DEverds%26aufirst%3DN.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DPrimack%26aufirst%3DR.%26aulast%3DSkiles%26aufirst%3DG.%2BL.%26aulast%3DSoto%26aufirst%3DI.%26aulast%3DStec%26aufirst%3DM.%2BM.%26aulast%3DWagner%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLebrec%26aufirst%3DH.%26atitle%3DP450-mediated%2520O-demethylated%2520metabolite%2520is%2520responsible%2520for%2520rat%2520hepatobiliary%2520toxicity%2520of%2520pyridyltriazine-containing%2520PI3K%2520inhibitors%26jtitle%3DToxicol.%2520Sci.%26date%3D2014%26volume%3D142%26spage%3D298%26epage%3D310%26doi%3D10.1093%2Ftoxsci%2Fkfu178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, X.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span> <span> </span><span class="NLM_article-title">Isoniazid metabolism and hepatotoxicity</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">392</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2016.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.apsb.2016.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27709007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC2svntVSgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=384-392&author=P.+Wangauthor=K.+Pradhanauthor=X.-B.+Zhongauthor=X.+Ma&title=Isoniazid+metabolism+and+hepatotoxicity&doi=10.1016%2Fj.apsb.2016.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Isoniazid metabolism and hepatotoxicity</span></div><div class="casAuthors">Wang Pengcheng; Pradhan Komal; Ma Xiaochao; Zhong Xiao-Bo</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">384-392</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Isoniazid (INH) is highly effective for the management of tuberculosis.  However, it can cause liver injury and even liver failure.  INH metabolism has been thought to be associated with INH-induced liver injury.  This review summarized the metabolic pathways of INH and discussed their associations with INH-induced liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkZuUUWR4f4-vW160gIxP_fW6udTcc2ebxwAPU8zUlpbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svntVSgsQ%253D%253D&md5=8b9e1b64c764bae0be6ab9a97624ebab</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2016.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2016.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DPradhan%26aufirst%3DK.%26aulast%3DZhong%26aufirst%3DX.-B.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DIsoniazid%2520metabolism%2520and%2520hepatotoxicity%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2016%26volume%3D6%26spage%3D384%26epage%3D392%26doi%3D10.1016%2Fj.apsb.2016.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, G. P.</span></span> <span> </span><span class="NLM_article-title">Comparison of the effects of pyridine and its metabolites on rat liver and kidney</span>. <i>Toxicol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1016/0378-4274(96)03660-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2F0378-4274%2896%2903660-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=8644130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK28XjtFentLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1996&pages=173-178&author=G.+P.+Carlson&title=Comparison+of+the+effects+of+pyridine+and+its+metabolites+on+rat+liver+and+kidney&doi=10.1016%2F0378-4274%2896%2903660-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the effects of pyridine and its metabolites on rat liver and kidney</span></div><div class="casAuthors">Carlson, Gary P.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">To evaluate the possibility that the metab. of pyridine may be important for its toxic actions, pyridine was compared with pyridine N-oxide, 2-hydroxypyridine, 3-hydroxypyridine, 4-hydroxypyridine and pyridinium methyliodide in rats given equal molar doses of the chems. i.p.  Hepatotoxicity was assessed by measuring serum sorbitol dehydrogenase, nephrotoxicity by detg. increases in blood urea nitrogen and serum creatinine, and influence on xenobiotic metab. by measuring changes in p-nitrophenol hydroxylase and ethoxyresorufin and benzyloxyresorufin dealkylase activities.  After a single dose of 2.5 mmol/kg, pyridinium methyliodide was the only compd. that was lethal whereas 2-hydroxypyridine was the only one that caused significant hepatotoxicity.  Pyridine, pyridine N-oxide, 3-hydroxypyridine and 4-hydroxypyridine were effective inducers of xenobiotic metab.  Thus the metabolites of pyridine may play a role, either singly or collectively, in the actions of pyridine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq03gJLr7r7mrVg90H21EOLACvtfcHk0litp3IQlHgMog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtFentLk%253D&md5=9ee25734d71ecb8f807f7328f93aa3f1</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1016%2F0378-4274%2896%2903660-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0378-4274%252896%252903660-0%26sid%3Dliteratum%253Aachs%26aulast%3DCarlson%26aufirst%3DG.%2BP.%26atitle%3DComparison%2520of%2520the%2520effects%2520of%2520pyridine%2520and%2520its%2520metabolites%2520on%2520rat%2520liver%2520and%2520kidney%26jtitle%3DToxicol.%2520Lett.%26date%3D1996%26volume%3D85%26spage%3D173%26epage%3D178%26doi%3D10.1016%2F0378-4274%2896%2903660-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, S. C.</span></span> <span> </span><span class="NLM_article-title">Action mechanism of antitubercular isoniazid. Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of inha inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">2520</span>– <span class="NLM_lpage">2526</span>, <span class="refDoi"> DOI: 10.1074/jbc.275.4.2520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1074%2Fjbc.275.4.2520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10644708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3cXpvFChsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=2520-2526&author=B.+Leiauthor=C.+J.+Weiauthor=S.+C.+Tu&title=Action+mechanism+of+antitubercular+isoniazid.+Activation+by+Mycobacterium+tuberculosis+KatG%2C+isolation%2C+and+characterization+of+inha+inhibitor&doi=10.1074%2Fjbc.275.4.2520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Action mechanism of antitubercular isoniazid: Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of InhA inhibitor</span></div><div class="casAuthors">Lei, Benfang; Wei, Chih-Jen; Tu, Shiao-Chun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2520-2526</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Activation of the antitubercular isoniazid (INH) by the Mycobacterium tuberculosis KatG produces an inhibitor for enoyl reductase (InhA).  The mechanism for INH activation remains poorly understood, and the inhibitor has never been isolated.  We have purified the InhA-inhibitor complex generated in the M. tuberculosis KatG-catalyzed INH activation.  The complex exhibited a 278-nm absorption peak and a shoulder around 326 nm with a characteristic A326/A278 ratio of 0.16.  The complex was devoid of enoyl reductase activity.  The inhibitor noncovalently binds to InhA with a Kd < 0.4 nM and can be dissocd. from denatured InhA for chromatog. isolation.  The free inhibitor showed absorption peaks at 326 (ε326 6900 M-1 cm-1) and 260 nm (ε260 27,000 M-1 cm-1).  The inactive complex can be reconstituted from InhA and the isolated inhibitor.  The InhA inhibitor from the KatG-catalyzed INH activation was identical to that from a slow, KatG-independent, Mn2+-mediated reaction based on high pressure liq. chromatog. anal. and absorption and mass spectral characteristics.  By monitoring the formation of the InhA-inhibitor complex, we have found that manganese is not essential to the INH activation by M. tuberculosis KatG.  Furthermore, the formation of the InhA inhibitor in the KatG reaction was independent of InhA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ9v4eqM9M1LVg90H21EOLACvtfcHk0lj0D2TzIdCelA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXpvFChsA%253D%253D&md5=ed3809e2c3188670d20c5e0bbb2ea564</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1074%2Fjbc.275.4.2520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.275.4.2520%26sid%3Dliteratum%253Aachs%26aulast%3DLei%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DC.%2BJ.%26aulast%3DTu%26aufirst%3DS.%2BC.%26atitle%3DAction%2520mechanism%2520of%2520antitubercular%2520isoniazid.%2520Activation%2520by%2520Mycobacterium%2520tuberculosis%2520KatG%252C%2520isolation%252C%2520and%2520characterization%2520of%2520inha%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D2520%26epage%3D2526%26doi%3D10.1074%2Fjbc.275.4.2520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaiswal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, A.</span></span> <span> </span><span class="NLM_article-title">A study on pre-XDR & XDR tuberculosis and their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India</span>. <i>Indian J. Med. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.4103/0971-5916.182625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4103%2F0971-5916.182625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27241648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFyktb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2016&pages=341-347&author=P.+Singhalauthor=P.+Dixitauthor=P.+Singhauthor=I.+Jaiswalauthor=M.+Singhauthor=A.+Jain&title=A+study+on+pre-XDR+%26+XDR+tuberculosis+and+their+prevalent+genotypes+in+clinical+isolates+of+Mycobacterium+tuberculosis+in+north+India&doi=10.4103%2F0971-5916.182625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">A study on pre-XDR & XDR tuberculosis & their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India</span></div><div class="casAuthors">Singhal, Parul; Dixit, Pratima; Singh, Pooja; Jaiswal, Indu; Singh, Mastan; Jain, Amita</div><div class="citationInfo"><span class="NLM_cas:title">Indian Journal of Medical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-347</span>CODEN:
                <span class="NLM_cas:coden">IMIREV</span>;
        ISSN:<span class="NLM_cas:issn">0971-5916</span>.
    
            (<span class="NLM_cas:orgname">Indian Council of Medical Research</span>)
        </div><div class="casAbstract">Background & objectives: Pre-extensively drug resistant (pre-XDR) and extensively drug resistant tuberculosis (XDR-TB) have been areas of growing concern, and are posing threat to global efforts of TB control.  The present study was planned to study the presence of pre-XDR and XDR Mycobacterium tuberculosis and their genotypes in clin. isolates obtained from previously treated cases of pulmonary TB.  Methods: A total of 219 isolates obtained from previously treated cases of pulmonary TB were subjected to first-line (streptomycin, isoniazid, rifampicin and ethambutol) and second-line (ofloxacin, kanamycin, capreomycin and amikacin) drug susceptibility testing on solid Lowenstein-Jensen medium by proportion method.  Genotyping was done for pre-XDR and XDR-TB isolates using 12 loci Mycobacterial Interspersed Repetitive Units-Variable No. Tandem Repeats (MIRU-VNTR).  Results: Multi-drug resistance was obsd. in 39.7 per cent (87/219) isolates.  Pre-XDR and XDR M. tuberculosis isolates amongst 87 multi-drug resistant (MDR) TB isolates were 43 (49.4%) and 10 (11.4%), resp.  Two most dominant genotypes among pre-XDR and XDR M. tuberculosis isolates were Beijing and Delhi/CAS types.  Interpretation & conclusions: Resistance to second-line anti-tubercular drugs should be routinely assessed in areas endemic for TB.  Similar genotype patterns were seen in pre-XDR and XDR-TB isolates.  Beijing and Delhi/CAS were predominant genotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUm2yb37A4OLVg90H21EOLACvtfcHk0lj0D2TzIdCelA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFyktb3E&md5=2fb3065993d600a767faf2acaf033654</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.4103%2F0971-5916.182625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0971-5916.182625%26sid%3Dliteratum%253Aachs%26aulast%3DSinghal%26aufirst%3DP.%26aulast%3DDixit%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DJaiswal%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DJain%26aufirst%3DA.%26atitle%3DA%2520study%2520on%2520pre-XDR%2520%2526%2520XDR%2520tuberculosis%2520and%2520their%2520prevalent%2520genotypes%2520in%2520clinical%2520isolates%2520of%2520Mycobacterium%2520tuberculosis%2520in%2520north%2520India%26jtitle%3DIndian%2520J.%2520Med.%2520Res.%26date%3D2016%26volume%3D143%26spage%3D341%26epage%3D347%26doi%3D10.4103%2F0971-5916.182625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Modi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chhabria, M.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis and biological evaluation of a newer series of pyrazolo[1,5-a]pyrimidine analogues as potential anti-tubercular agents</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.02.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.bioorg.2019.02.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30908967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVWmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2019&pages=240-251&author=P.+Modiauthor=S.+Patelauthor=M.+Chhabria&title=Structure-based+design%2C+synthesis+and+biological+evaluation+of+a+newer+series+of+pyrazolo%5B1%2C5-a%5Dpyrimidine+analogues+as+potential+anti-tubercular+agents&doi=10.1016%2Fj.bioorg.2019.02.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design, synthesis and biological evaluation of a newer series of pyrazolo[1,5-a]pyrimidine analogues as potential anti-tubercular agents</span></div><div class="casAuthors">Modi, Palmi; Patel, Shivani; Chhabria, Mahesh</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">240-251</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mnbvcx/jIn this present study, twenty six novel pyrazolo[1,5-a]pyrimidine analogs I [R = H, 3-ClC6H4, 4-MeOC6H4, etc.; R1 = Ph, 4-MeC6H4, 3,4-di-FC6H3, etc.] were designed using mol. docking studies.  Structural elucidation of the synthesized mols. I was carried out using IR, MS, 1H NMR and 13C NMR spectroscopy.  All the synthesized compds. I were evaluated for their in-vitro anti-tubercular activity against H37Rv strain by Alamar Blue assay method.  Amongst all the tested compds. I [R = 4-MeC6H4, R1 = 4-ClC6H4; R = H, R1 = 3,4-di-ClC6H3; R = 2-MeOC6H4, R1 = 3-MeC6H4; R = 4-FC6H4, R1 = 3,4-di-FC6H3] exhibited promising anti-tubercular activity.  Further, these potent compds. I were gauged for MDR-TB, XDR-TB and cytotoxic study.  None of these compds. exhibited potent cytotoxicity.  Stability of protein ligand complex was further evaluated by mol. dynamics simulation for 10 ns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSMtVzF1kfjbVg90H21EOLACvtfcHk0lj0D2TzIdCelA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVWmt7s%253D&md5=9256114240b74f4eca81586941b459c7</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.02.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.02.044%26sid%3Dliteratum%253Aachs%26aulast%3DModi%26aufirst%3DP.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DChhabria%26aufirst%3DM.%26atitle%3DStructure-based%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520newer%2520series%2520of%2520pyrazolo%255B1%252C5-a%255Dpyrimidine%2520analogues%2520as%2520potential%2520anti-tubercular%2520agents%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D87%26spage%3D240%26epage%3D251%26doi%3D10.1016%2Fj.bioorg.2019.02.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblauc, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.09.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.ejmech.2016.09.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27654393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFCmt7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=41-48&author=X.+Luauthor=J.+Tangauthor=S.+Cuiauthor=B.+Wanauthor=S.+G.+Franzblaucauthor=T.+Zhangauthor=X.+Zhangauthor=K.+Ding&title=Pyrazolo%5B1%2C5-a%5Dpyridine-3-carboxamide+hybrids%3A+Design%2C+synthesis+and+evaluation+of+anti-tubercular+activity&doi=10.1016%2Fj.ejmech.2016.09.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity</span></div><div class="casAuthors">Lu, Xiaoyun; Tang, Jian; Cui, Shengyang; Wan, Baojie; Franzblauc, Scott G.; Zhang, Tianyu; Zhang, Xiantao; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41-48</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of pyrazolo[1,5-a]pyridine-3-carboxamide hybrids were designed and evaluated as novel anti-tubercular agents.  The representative hybrid 7 exhibited promising in vitro activity against susceptive strain H37Rv and a panel of drug-resistant Mtb strains with MIC values of 0.006 μg/mL and ranged from 0.003 to 0.014 μg/mL, resp.  More importantly, the hybrid 7 also showed very low cytotoxicity, and could significantly reduce the mycobacterial burden in a mouse model infected with autoluminescent H37Ra strain, which may serve as a lead compd. for further development of new anti-tubercular agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWPYBQv-bpmbVg90H21EOLACvtfcHk0lhdt_VDw33uHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFCmt7%252FP&md5=4c573c0540b098312d46d426acb4b01e</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.030%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DS.%26aulast%3DWan%26aufirst%3DB.%26aulast%3DFranzblauc%26aufirst%3DS.%2BG.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DPyrazolo%255B1%252C5-a%255Dpyridine-3-carboxamide%2520hybrids%253A%2520Design%252C%2520synthesis%2520and%2520evaluation%2520of%2520anti-tubercular%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D125%26spage%3D41%26epage%3D48%26doi%3D10.1016%2Fj.ejmech.2016.09.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref241"><div class="reference"><strong class="refLabel"><a href="#ref241" class="rightTabRefNumLink">241</a></strong><div class="NLM_citation" id="rightTab-cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A. K.</span></span> <span> </span><span class="NLM_article-title">Structural and functional organization of the animal fatty acid synthase</span>. <i>Prog. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1016/S0163-7827(02)00067-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS0163-7827%2802%2900067-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=12689621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis1yqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=289-317&author=S.+Smithauthor=A.+Witkowskiauthor=A.+K.+Joshi&title=Structural+and+functional+organization+of+the+animal+fatty+acid+synthase&doi=10.1016%2FS0163-7827%2802%2900067-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and functional organization of the animal fatty acid synthase</span></div><div class="casAuthors">Smith, Stuart; Witkowski, Andrzej; Joshi, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Lipid Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">289-317</span>CODEN:
                <span class="NLM_cas:coden">PLIRDW</span>;
        ISSN:<span class="NLM_cas:issn">0163-7827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The entire pathway of palmitate synthesis from malonyl-CoA in mammals is catalyzed by a single, homodimeric, multifunctional enzyme, fatty acid synthase (FAS).  Each subunit contains 3 N-terminal domains, β-ketoacyl synthase, malonyl/acetyltransferase, and dehydrase sepd. by a structural core from 4 C-terminal domains, enoyl reductase, β-ketoacyl reductase, acyl carrier protein (ACP), and thiosterase.  The kinetics and specificities of the substrate loading reaction catalyzed by the malonyl/acetyltransferase, the condensation reaction catalyzed by β-ketoacyl synthase, and the chain-terminating reaction catalyzed by thioesterase ensure that intermediates do not leak off the enzyme, satd. chains exclusively are elongated, and palmitate is released as the major product.  Only in the FAS dimer do the subunits adopt conformations that facilitate productive coupling of the individual reactions for fatty acid synthesis at the 2 ACP centers.  Introduction of a double tagging and dual affinity chromatog. procedure has permitted the engineering and isolation of heterodimeric FAS enzymes carrying different mutations on each subunit.  Characterization of these heterodimers, by activity assays and chem. crosslinking, has been exploited to map the functional topol. of the protein.  The results have revealed that the 2 ACP domains engage in substrate loading and condensation reactions catalyzed by the malonyl/acetyltransferase and β-ketoacyl synthase domains of either subunit.  In contrast, the reactions involved in processing of the β-C atom, following each chain elongation step, together with the release of palmitate, are catalyzed by the cooperation of ACP with catalytic domains of the same subunit.  These findings suggest a revised model for FAS in which the 2 polypeptides are oriented such that head-to-tail contacts are formed both between and within subunits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqurWTMLAX22LVg90H21EOLACvtfcHk0lhdt_VDw33uHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis1yqtr0%253D&md5=ec5000bee0c38cb05336f637cee922ea</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1016%2FS0163-7827%2802%2900067-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7827%252802%252900067-X%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DWitkowski%26aufirst%3DA.%26aulast%3DJoshi%26aufirst%3DA.%2BK.%26atitle%3DStructural%2520and%2520functional%2520organization%2520of%2520the%2520animal%2520fatty%2520acid%2520synthase%26jtitle%3DProg.%2520Lipid%2520Res.%26date%3D2003%26volume%3D42%26spage%3D289%26epage%3D317%26doi%3D10.1016%2FS0163-7827%2802%2900067-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref242"><div class="reference"><strong class="refLabel"><a href="#ref242" class="rightTabRefNumLink">242</a></strong><div class="NLM_citation" id="rightTab-cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cacciari, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolcato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spalluto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klotz, K.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacilieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deflorian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro, S.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure-activity profile</span>. <i>Purinergic Signalling</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1007/s11302-006-9027-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1007%2Fs11302-006-9027-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=18404432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntlyqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=183-193&author=B.+Cacciariauthor=C.+Bolcatoauthor=G.+Spallutoauthor=K.-N.+Klotzauthor=M.+Bacilieriauthor=F.+Deflorianauthor=S.+Moro&title=Pyrazolo-triazolo-pyrimidines+as+adenosine+receptor+antagonists%3A+A+complete+structure-activity+profile&doi=10.1007%2Fs11302-006-9027-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: a complete structure-activity profile</span></div><div class="casAuthors">Cacciari, Barbara; Bolcato, Chiara; Spalluto, Giampiero; Klotz, Karl-Norbet; Bacilieri, Magdalena; Deflorian, Francesca; Moro, Stefano</div><div class="citationInfo"><span class="NLM_cas:title">Purinergic Signalling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">183-193</span>CODEN:
                <span class="NLM_cas:coden">PSUIA9</span>;
        ISSN:<span class="NLM_cas:issn">1573-9538</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  In the last 5 years, many efforts were conducted searching potent and selective human A3 adenosine antagonists.  In this field several different classes of compds., possessing very good affinity (nM range) and with a broad range of selectivity, were proposed.  Recently, our group synthesized a new series of pyrazolo-triazolo-pyrimidines bearing different substitutions at the N5 and N8 positions, which were described as highly potent and selective human A3 adenosine receptor antagonists.  The present review summarizes available data and provides an overview of the structure-activity relationships found for this class of human A3 adenosine receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovPRM799NFw7Vg90H21EOLACvtfcHk0lh2ZvqtnuN5Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntlyqsr8%253D&md5=7a8762e2dd3fa3b4edfc6e3dbf97d85f</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1007%2Fs11302-006-9027-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11302-006-9027-x%26sid%3Dliteratum%253Aachs%26aulast%3DCacciari%26aufirst%3DB.%26aulast%3DBolcato%26aufirst%3DC.%26aulast%3DSpalluto%26aufirst%3DG.%26aulast%3DKlotz%26aufirst%3DK.-N.%26aulast%3DBacilieri%26aufirst%3DM.%26aulast%3DDeflorian%26aufirst%3DF.%26aulast%3DMoro%26aufirst%3DS.%26atitle%3DPyrazolo-triazolo-pyrimidines%2520as%2520adenosine%2520receptor%2520antagonists%253A%2520A%2520complete%2520structure-activity%2520profile%26jtitle%3DPurinergic%2520Signalling%26date%3D2007%26volume%3D3%26spage%3D183%26epage%3D193%26doi%3D10.1007%2Fs11302-006-9027-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref243"><div class="reference"><strong class="refLabel"><a href="#ref243" class="rightTabRefNumLink">243</a></strong><div class="NLM_citation" id="rightTab-cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selleri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costagli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciciani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gratteri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besnard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fohlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Siena, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, P. M.</span></span> <span> </span><span class="NLM_article-title">A novel selective GABA(A) alpha1 receptor agonist displaying sedative and anxiolytic-like properties in rodents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6756</span>– <span class="NLM_lpage">6760</span>, <span class="refDoi"> DOI: 10.1021/jm058002n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058002n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6756-6760&author=S.+Selleriauthor=F.+Bruniauthor=C.+Costagliauthor=A.+Costanzoauthor=G.+Guerriniauthor=G.+Cicianiauthor=P.+Gratteriauthor=F.+Besnardauthor=B.+Costaauthor=M.+Montaliauthor=C.+Martiniauthor=J.+Fohlinauthor=G.+De+Sienaauthor=P.+M.+Aiello&title=A+novel+selective+GABA%28A%29+alpha1+receptor+agonist+displaying+sedative+and+anxiolytic-like+properties+in+rodents&doi=10.1021%2Fjm058002n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Selective GABAA α1 Receptor Agonist Displaying Sedative and Anxiolytic-like Properties in Rodents</span></div><div class="casAuthors">Selleri, Silvia; Bruni, Fabrizio; Costagli, Camilla; Costanzo, Annarella; Guerrini, Gabriella; Ciciani, Giovanna; Gratteri, Paola; Besnard, Francois; Costa, Barbara; Montali, Marina; Martini, Claudia; Fohlin, Jonna; De Siena, Gaetano; Aiello, Petra Malmberg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6756-6760</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective ligands for Bz/GABAA receptor subtypes, a pyrazolo[1,5-a]pyrimidine deriv. I, the azaisostere of zolpidem, was synthesized and evaluated in vitro on bovine brain homogenate and on recombinant benzodiazepine receptors (αxβ2/3γ2, x = 1-3, 5) expressed in HEK293 cells.  I displayed affinity only for α1β2γ2 subtype (Ki = 31 nM), and in an in-depth, in vivo study it revealed sedative and anxiolytic-like properties without any amnesic and myorelaxant effects in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqYlWTHoPb7rVg90H21EOLACvtfcHk0lh2ZvqtnuN5Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FK&md5=506a7483989fd3963a7303a5fa1d50fd</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1021%2Fjm058002n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058002n%26sid%3Dliteratum%253Aachs%26aulast%3DSelleri%26aufirst%3DS.%26aulast%3DBruni%26aufirst%3DF.%26aulast%3DCostagli%26aufirst%3DC.%26aulast%3DCostanzo%26aufirst%3DA.%26aulast%3DGuerrini%26aufirst%3DG.%26aulast%3DCiciani%26aufirst%3DG.%26aulast%3DGratteri%26aufirst%3DP.%26aulast%3DBesnard%26aufirst%3DF.%26aulast%3DCosta%26aufirst%3DB.%26aulast%3DMontali%26aufirst%3DM.%26aulast%3DMartini%26aufirst%3DC.%26aulast%3DFohlin%26aufirst%3DJ.%26aulast%3DDe%2BSiena%26aufirst%3DG.%26aulast%3DAiello%26aufirst%3DP.%2BM.%26atitle%3DA%2520novel%2520selective%2520GABA%2528A%2529%2520alpha1%2520receptor%2520agonist%2520displaying%2520sedative%2520and%2520anxiolytic-like%2520properties%2520in%2520rodents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6756%26epage%3D6760%26doi%3D10.1021%2Fjm058002n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref244"><div class="reference"><strong class="refLabel"><a href="#ref244" class="rightTabRefNumLink">244</a></strong><div class="NLM_citation" id="rightTab-cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakashita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitahara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakoda, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluations of condensed pyridine and condensed pyrimidine-based HMG-CoA reductase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1288</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00203-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2FS0960-894X%2801%2900203-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=11392538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtlSrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1285-1288&author=M.+Suzukiauthor=H.+Iwasakiauthor=Y.+Fujikawaauthor=M.+Sakashitaauthor=M.+Kitaharaauthor=R.+Sakoda&title=Synthesis+and+biological+evaluations+of+condensed+pyridine+and+condensed+pyrimidine-based+HMG-CoA+reductase+inhibitors&doi=10.1016%2FS0960-894X%2801%2900203-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluations of condensed pyridine and condensed pyrimidine-based HMG-CoA reductase inhibitors</span></div><div class="casAuthors">Suzuki, M.; Iwasaki, H.; Fujikawa, Y.; Sakashita, M.; Kitahara, M.; Sakoda, R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1285-1288</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of novel 3,5-dihydroxyheptenoic acid derivs. contg. pyrazolopyridine, e.g. I [R1 = Me2CH, (CH2)2CH; R2 = H, Me, Ph, 4-ClC6H4, (CH2)2CH; R3 = Me, Et, Me3C, Ph, 4-MeOC6H4, 2-pyridyl], isoxazolopyridine, e.g. II (R1 = Me2CH; R2 = Me, Ph), thienopyridine, e.g. III [R1 = Me2CH, (CH2)2CH; R2 = H, Et, Ph; R3 = H, Me, Me2CH, Ph; R2R3 = (CH2)3, (CH2)4, (CH2)5], and pyrazolopyrimidine, e.g. IV [R1 = Me2CH, (CH2)2CH; R2 = Me, Me2CH, Me3C, Ph, 2-furyl; R3 = H, Me, Ph; R2R3 = (CH2)4] as a key scaffold was synthesized from condensed pyridine and condensed pyrimidine carboxylic acid esters by homologation, aldol condensation with Et acetoacetate dianion, and stereoselective redn. of the 5-hydroxyketone.  Most compds. in the series were found to have potent HMG-CoA reductase inhibitory activities in vitro and marked cholesterol biosynthesis inhibitory activities in vivo.  It was demonstrated that these scaffolds can be used as a suitable replacement for the hexahydronaphthalene ring present in naturally occurring HMG-CoA reductase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRZzdSLM8YKLVg90H21EOLACvtfcHk0lgN0H5FrcoLUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtlSrsLg%253D&md5=91247d8f5303eb6671512b41d438d65c</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900203-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900203-7%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DIwasaki%26aufirst%3DH.%26aulast%3DFujikawa%26aufirst%3DY.%26aulast%3DSakashita%26aufirst%3DM.%26aulast%3DKitahara%26aufirst%3DM.%26aulast%3DSakoda%26aufirst%3DR.%26atitle%3DSynthesis%2520and%2520biological%2520evaluations%2520of%2520condensed%2520pyridine%2520and%2520condensed%2520pyrimidine-based%2520HMG-CoA%2520reductase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1285%26epage%3D1288%26doi%3D10.1016%2FS0960-894X%2801%2900203-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref245"><div class="reference"><strong class="refLabel"><a href="#ref245" class="rightTabRefNumLink">245</a></strong><div class="NLM_citation" id="rightTab-cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandrashekharappa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venugopala, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venugopala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmashali, B.</span></span> <span> </span><span class="NLM_article-title">Qualitative anti-tubercular activity of synthetic ethyl 7-acetyl- 2-substituted-3-(4-substituted benzoyl) indolizine-1-carboxylate analogues</span>. <i>J. Appl. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.7324/JAPS.2019.90217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.7324%2FJAPS.2019.90217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVOgtr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=124-128&author=S.+Chandrashekharappaauthor=K.+N.+Venugopalaauthor=R.+Venugopalaauthor=B.+Padmashali&title=Qualitative+anti-tubercular+activity+of+synthetic+ethyl+7-acetyl-+2-substituted-3-%284-substituted+benzoyl%29+indolizine-1-carboxylate+analogues&doi=10.7324%2FJAPS.2019.90217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Qualitative anti-tubercular activity of synthetic ethyl 7-acetyl-2-substituted-3-(4-substituted benzoyl) indolizine-1-carboxylate analogues</span></div><div class="casAuthors">Chandrashekharappa, Sandeep; Venugopala, Katharigatta N.; Venugopala, Rashmi; Padmashali, Basavaraj</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Pharmaceutical Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">124-128</span>CODEN:
                <span class="NLM_cas:coden">JAPSHX</span>;
        ISSN:<span class="NLM_cas:issn">2231-3354</span>.
    
            (<span class="NLM_cas:orgname">Journal of Applied Pharmaceutical Science</span>)
        </div><div class="casAbstract">Both the emergence of multidrug-resistant and extensively drug-resistant tuberculosis (TB) are currently the major challenges in the treatment of TB.  Only delamanid and bedaquiline have been recently approved as anti-TB drugs in the past 40 years.  In an attempt to search for active anti-TB compds. against the sensitive strain of Mycobacterium tuberculosis, H37Rv-a series of synthetic Et 7-acetyl-2-substituted-3-(4-substituted benzoyl)indolizine-1-carboxylates (2a-r)-have been screened for in vitro qual. anti-TB activity using an agar diln. method.  It was found that compds. 2a, 2b, 2c, 2f, 2g, 2i, 2j, 2l, 2o, 2p, and 2r, which have various functional groups on the indolizine nucleus, were active against the H37Rv strain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI7tXr82tYHbVg90H21EOLACvtfcHk0lgN0H5FrcoLUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVOgtr7J&md5=38d255d0be6cc612f46d8bfeff9ffcbb</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.7324%2FJAPS.2019.90217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7324%252FJAPS.2019.90217%26sid%3Dliteratum%253Aachs%26aulast%3DChandrashekharappa%26aufirst%3DS.%26aulast%3DVenugopala%26aufirst%3DK.%2BN.%26aulast%3DVenugopala%26aufirst%3DR.%26aulast%3DPadmashali%26aufirst%3DB.%26atitle%3DQualitative%2520anti-tubercular%2520activity%2520of%2520synthetic%2520ethyl%25207-acetyl-%25202-substituted-3-%25284-substituted%2520benzoyl%2529%2520indolizine-1-carboxylate%2520analogues%26jtitle%3DJ.%2520Appl.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D9%26spage%3D124%26epage%3D128%26doi%3D10.7324%2FJAPS.2019.90217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref246"><div class="reference"><strong class="refLabel"><a href="#ref246" class="rightTabRefNumLink">246</a></strong><div class="NLM_citation" id="rightTab-cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baravkar, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagh, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawale, L. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhari, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhansali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanjayan, G. J.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of 2-amino-thiophene-proline-conjugates and their anti-tubercular activity against Mycobacterium tuberculosis H37Ra</span>. <i>ChemistrySelect</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2851</span>– <span class="NLM_lpage">2857</span>, <span class="refDoi"> DOI: 10.1002/slct.201803370</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1002%2Fslct.201803370" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktlelu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=2851-2857&author=S.+B.+Baravkarauthor=M.+A.+Waghauthor=L.+U.+Nawaleauthor=A.+S.+Choudhariauthor=S.+Bhansaliauthor=D.+Sarkarauthor=G.+J.+Sanjayan&title=Design+and+synthesis+of+2-amino-thiophene-proline-conjugates+and+their+anti-tubercular+activity+against+Mycobacterium+tuberculosis+H37Ra&doi=10.1002%2Fslct.201803370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of 2-Amino-thiophene-proline-conjugates and Their Anti-tubercular Activity against Mycobacterium Tuberculosis H37Ra</span></div><div class="casAuthors">Baravkar, Sachin B.; Wagh, Mahendra A.; Nawale, Laxman U.; Choudhari, Amit S.; Bhansali, Sujit; Sarkar, Dhiman; Sanjayan, Gangadhar J.</div><div class="citationInfo"><span class="NLM_cas:title">ChemistrySelect</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2851-2857</span>CODEN:
                <span class="NLM_cas:coden">CHEMUD</span>;
        ISSN:<span class="NLM_cas:issn">2365-6549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The emergence of extensively drug resistant tuberculosis (XDR-TB) and multi-drug resistant tuberculosis (MDR-TB) has necessitated the development of new drugs with short chemotherapy treatment regime and cost effectiveness.  To overcome these challenges, we are reporting the synthesis of a series of 2-amino-thiophene-proline-conjugates which show potent in-vitro and ex-vivo anti-tubercular (anti-TB) activity against mycobacterium tuberculosis (mtb) H37Ra.  The synthesis of these 2-amino-thiophene-proline-conjugates was carried out via soln. phase peptide coupling reactions using methyl-2-aminothiophene-3-carboxylate 8 as an intermediate obtained by modified gewald reaction.  Intermediate 8 was coupled with different amino acids to obtain dipeptides 3, 4, 5, 6 a and 7.  Priliminary anti-TB assay data encoureaged us to synthesize modified proline derivs. 6 b-6 k via formation of a benzoxazinone intermediate 16.  Most of these conjugates are active against mtb H37Ra in both active (A) and dormant (D) strains.  They are also active against drug resistant mtb H37Ra strains.  A trifluoroethyl ester analog, 6 i was the most potent among the series [MIC 1 μg/mL] along with 6 f and 6 g [MIC 2-6 μg/mL].  Cytotoxicity studies suggested that, these compds. are less cytotoxic to human cell lines HeLa, MCF-7, HUVEC and hence possess high selectivity index (SI).  Docking studies revealed that the binding mode of most active compds. 6 i, 6 g and 6 f is in accordance with their bioactivity studies having docking score -8.969, -8.446 and -7.865, resp.  Moreover, in silico ADME properties suggest that all the compds. possess drug like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi81D5bBIhoLVg90H21EOLACvtfcHk0lii-H1NyhbDLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktlelu78%253D&md5=075b19354cd6037db9f0172ad1cc9f44</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1002%2Fslct.201803370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fslct.201803370%26sid%3Dliteratum%253Aachs%26aulast%3DBaravkar%26aufirst%3DS.%2BB.%26aulast%3DWagh%26aufirst%3DM.%2BA.%26aulast%3DNawale%26aufirst%3DL.%2BU.%26aulast%3DChoudhari%26aufirst%3DA.%2BS.%26aulast%3DBhansali%26aufirst%3DS.%26aulast%3DSarkar%26aufirst%3DD.%26aulast%3DSanjayan%26aufirst%3DG.%2BJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%25202-amino-thiophene-proline-conjugates%2520and%2520their%2520anti-tubercular%2520activity%2520against%2520Mycobacterium%2520tuberculosis%2520H37Ra%26jtitle%3DChemistrySelect%26date%3D2019%26volume%3D4%26spage%3D2851%26epage%3D2857%26doi%3D10.1002%2Fslct.201803370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref247"><div class="reference"><strong class="refLabel"><a href="#ref247" class="rightTabRefNumLink">247</a></strong><div class="NLM_citation" id="rightTab-cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porras de Francisco, E.</span>; <span class="NLM_string-name">Remuinan-Blanco, M. J.</span>; <span class="NLM_string-name">Bourotte, M.</span>; <span class="NLM_string-name">Deprez, B.</span>; <span class="NLM_string-name">Willand, N.</span></span> <span> </span><span class="NLM_article-title">Novel Compounds</span>. <span class="NLM_patent">WO2019/034700Al</span>. February 21, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=E.+Porras+de+Francisco&author=M.+J.+Remuinan-Blanco&author=M.+Bourotte&author=B.+Deprez&author=N.+Willand&title=Novel+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPorras%2Bde%2BFrancisco%26aufirst%3DE.%26atitle%3DNovel%2520Compounds%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref248"><div class="reference"><strong class="refLabel"><a href="#ref248" class="rightTabRefNumLink">248</a></strong><div class="NLM_citation" id="rightTab-cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porras de Francisco, E.</span>; <span class="NLM_string-name">Remuinan-Blanco, M. J.</span>; <span class="NLM_string-name">Bourotte, M.</span>; <span class="NLM_string-name">Deprez, B.</span>; <span class="NLM_string-name">Willand, N.</span></span> <span> </span><span class="NLM_article-title">Novel Compounds</span>. <span class="NLM_patent">WO2019/034701Al</span>. February 21, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=E.+Porras+de+Francisco&author=M.+J.+Remuinan-Blanco&author=M.+Bourotte&author=B.+Deprez&author=N.+Willand&title=Novel+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPorras%2Bde%2BFrancisco%26aufirst%3DE.%26atitle%3DNovel%2520Compounds%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref249"><div class="reference"><strong class="refLabel"><a href="#ref249" class="rightTabRefNumLink">249</a></strong><div class="NLM_citation" id="rightTab-cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porras de Francisco, E. P.</span>; <span class="NLM_string-name">Remuinan-Blanco, M. J.</span>; <span class="NLM_string-name">Bourotte, M.</span>; <span class="NLM_string-name">Deprez, B.</span>; <span class="NLM_string-name">Willand, N.</span></span> <span> </span><span class="NLM_article-title">Novel Compounds</span>. <span class="NLM_patent">WO2019/034702Al</span>. February 21, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=E.+P.+Porras+de+Francisco&author=M.+J.+Remuinan-Blanco&author=M.+Bourotte&author=B.+Deprez&author=N.+Willand&title=Novel+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPorras%2Bde%2BFrancisco%26aufirst%3DE.%2BP.%26atitle%3DNovel%2520Compounds%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref250"><div class="reference"><strong class="refLabel"><a href="#ref250" class="rightTabRefNumLink">250</a></strong><div class="NLM_citation" id="rightTab-cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allemparte-Gallardo, C.</span>; <span class="NLM_string-name">Encinas, L.</span>; <span class="NLM_string-name">Esquivias Provencio, J.</span></span> <span> </span><span class="NLM_article-title">Novel tetrazole compounds and their use in the treatment of tuberculosis</span>. <span class="NLM_patent">WO2019/034729Al</span>. Feb 21, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+Allemparte-Gallardo&author=L.+Encinas&author=J.+Esquivias+Provencio&title=Novel+tetrazole+compounds+and+their+use+in+the+treatment+of+tuberculosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllemparte-Gallardo%26aufirst%3DC.%26atitle%3DNovel%2520tetrazole%2520compounds%2520and%2520their%2520use%2520in%2520the%2520treatment%2520of%2520tuberculosis%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref251"><div class="reference"><strong class="refLabel"><a href="#ref251" class="rightTabRefNumLink">251</a></strong><div class="NLM_citation" id="rightTab-cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dover, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alahari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gratraud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowruth, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span> <span> </span><span class="NLM_article-title">EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1055</span>– <span class="NLM_lpage">1063</span>, <span class="refDoi"> DOI: 10.1128/AAC.01063-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.01063-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=17220416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis12jsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=1055-1063&author=L.+G.+Doverauthor=A.+Alahariauthor=P.+Gratraudauthor=J.+M.+Gomesauthor=V.+Bhowruthauthor=R.+C.+Reynoldsauthor=G.+S.+Besraauthor=L.+Kremer&title=EthA%2C+a+common+activator+of+thiocarbamide-containing+drugs+acting+on+different+mycobacterial+targets&doi=10.1128%2FAAC.01063-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets</span></div><div class="casAuthors">Dover, Lynn G.; Alahari, Anuradha; Gratraud, Paul; Gomes, Jessica M.; Bhowruth, Veemal; Reynolds, Robert C.; Besra, Gurdyal S.; Kremer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1055-1063</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Many of the current antimycobacterial agents require some form of cellular activation unmasking reactive groups, which in turn will bind to their specific targets.  Therefore, understanding the mechanisms of activation of current antimycobacterials not only helps to decipher mechanisms of drug resistance but may also facilitate the development of alternative activation strategies or of analogs that do not require such processes.  Herein, through the use of genetically defined strains of Mycobacterium bovis BCG we provide evidence that EthA, previously shown to activate ethionamide, also converts isoxyl (ISO) and thiacetazone (TAC) into reactive species.  These results were further supported by the development of an in vitro assay using purified recombinant EthA, which allowed direct assessment of the metab. of ISO.  Interestingly, biochem. anal. of [14C]acetate-labeled cultures suggested that all of these EthA-activated drugs inhibit mycolic acid biosynthesis via different mechanisms through binding to specific targets.  This report is also the first description of the mol. mechanism of action of TAC, a thiosemicarbazone antimicrobial agent that is still used in the treatment of tuberculosis as a second-line drug in many developing countries.  Altogether, the results suggest that EthA is a common activator of thiocarbamide-contg. drugs.  The broad specificity of EthA can now be used to improve the activation process of these drugs, which may help overcome the toxicity problems assocd. with clin. thiocarbamide use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN_R6VIHikw7Vg90H21EOLACvtfcHk0lii-H1NyhbDLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis12jsLY%253D&md5=e41cb13b90a0031fb69473bd1379c51a</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1128%2FAAC.01063-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01063-06%26sid%3Dliteratum%253Aachs%26aulast%3DDover%26aufirst%3DL.%2BG.%26aulast%3DAlahari%26aufirst%3DA.%26aulast%3DGratraud%26aufirst%3DP.%26aulast%3DGomes%26aufirst%3DJ.%2BM.%26aulast%3DBhowruth%26aufirst%3DV.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DKremer%26aufirst%3DL.%26atitle%3DEthA%252C%2520a%2520common%2520activator%2520of%2520thiocarbamide-containing%2520drugs%2520acting%2520on%2520different%2520mycobacterial%2520targets%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D1055%26epage%3D1063%26doi%3D10.1128%2FAAC.01063-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref252"><div class="reference"><strong class="refLabel"><a href="#ref252" class="rightTabRefNumLink">252</a></strong><div class="NLM_citation" id="rightTab-cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abrahams, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futterer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rullas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega-Muro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moynihan, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Herran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esquivias, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alemparte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span> <span> </span><span class="NLM_article-title">Inhibiting mycobacterial tryptophan synthase by targeting the inter-subunit interface</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">9430</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-09642-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fs41598-017-09642-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28842600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1cbhvVSqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=9430&author=K.+A.+Abrahamsauthor=J.+A.+G.+Coxauthor=K.+Futtererauthor=J.+Rullasauthor=F.+Ortega-Muroauthor=N.+J.+Lomanauthor=P.+J.+Moynihanauthor=E.+Perez-Herranauthor=E.+Jimenezauthor=J.+Esquiviasauthor=D.+Barrosauthor=L.+Ballellauthor=C.+Alemparteauthor=G.+S.+Besra&title=Inhibiting+mycobacterial+tryptophan+synthase+by+targeting+the+inter-subunit+interface&doi=10.1038%2Fs41598-017-09642-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting mycobacterial tryptophan synthase by targeting the inter-subunit interface</span></div><div class="casAuthors">Abrahams Katherine A; Futterer Klaus; Loman Nicholas J; Moynihan Patrick J; Besra Gurdyal S; Cox Jonathan A G; Rullas Joaquin; Ortega-Muro Fatima; Perez-Herran Esther; Jimenez Elena; Esquivias Jorge; Barros David; Ballell Lluis; Alemparte Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9430</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug discovery efforts against the pathogen Mycobacterium tuberculosis (Mtb) have been advanced through phenotypic screens of extensive compound libraries.  Such a screen revealed sulfolane 1 and indoline-5-sulfonamides 2 and 3 as potent inhibitors of mycobacterial growth.  Optimization in the sulfolane series led to compound 4, which has proven activity in an in vivo murine model of Mtb infection.  Here we identify the target and mode of inhibition of these compounds based on whole genome sequencing of spontaneous resistant mutants, which identified mutations locating to the essential α- and β-subunits of tryptophan synthase.  Over-expression studies confirmed tryptophan synthase as the biological target.  Biochemical techniques probed the mechanism of inhibition, revealing the mutant enzyme complex incurs a fitness cost but does not prevent inhibitor binding.  Mapping of the resistance conferring mutations onto a low-resolution crystal structure of Mtb tryptophan synthase showed they locate to the interface between the α- and β-subunits.  The discovery of anti-tubercular agents inhibiting tryptophan synthase highlights the therapeutic potential of this enzyme and draws attention to the prospect of other amino acid biosynthetic pathways as future Mtb drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdKFx3KRVw836oPH0mYWL1fW6udTcc2ea-QtrMRjVykrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbhvVSqtw%253D%253D&md5=d5256bcc84a9c06221984116b25aee2e</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-09642-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-09642-y%26sid%3Dliteratum%253Aachs%26aulast%3DAbrahams%26aufirst%3DK.%2BA.%26aulast%3DCox%26aufirst%3DJ.%2BA.%2BG.%26aulast%3DFutterer%26aufirst%3DK.%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DOrtega-Muro%26aufirst%3DF.%26aulast%3DLoman%26aufirst%3DN.%2BJ.%26aulast%3DMoynihan%26aufirst%3DP.%2BJ.%26aulast%3DPerez-Herran%26aufirst%3DE.%26aulast%3DJimenez%26aufirst%3DE.%26aulast%3DEsquivias%26aufirst%3DJ.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DAlemparte%26aufirst%3DC.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26atitle%3DInhibiting%2520mycobacterial%2520tryptophan%2520synthase%2520by%2520targeting%2520the%2520inter-subunit%2520interface%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D9430%26doi%3D10.1038%2Fs41598-017-09642-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref253"><div class="reference"><strong class="refLabel"><a href="#ref253" class="rightTabRefNumLink">253</a></strong><div class="NLM_citation" id="rightTab-cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioerger, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothchild, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trauner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galaviz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttenhower, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behar, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. J.</span></span> <span> </span><span class="NLM_article-title">Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">1296</span>– <span class="NLM_lpage">1308</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2013.10.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.cell.2013.10.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=24315099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFylurzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2013&pages=1296-1308&author=Y.+J.+Zhangauthor=M.+C.+Reddyauthor=T.+R.+Ioergerauthor=A.+C.+Rothchildauthor=V.+Dartoisauthor=B.+M.+Schusterauthor=A.+Traunerauthor=D.+Wallisauthor=S.+Galavizauthor=C.+Huttenhowerauthor=J.+C.+Sacchettiniauthor=S.+M.+Beharauthor=E.+J.+Rubin&title=Tryptophan+biosynthesis+protects+mycobacteria+from+CD4+T-cell-mediated+killing&doi=10.1016%2Fj.cell.2013.10.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing</span></div><div class="casAuthors">Zhang, Yanjia J.; Reddy, Manchi C.; Ioerger, Thomas R.; Rothchild, Alissa C.; Dartois, Veronique; Schuster, Brian M.; Trauner, Andrej; Wallis, Deeann; Galaviz, Stacy; Huttenhower, Curtis; Sacchettini, James C.; Behar, Samuel M.; Rubin, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1296-1308</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Bacteria that cause disease rely on their ability to counteract and overcome host defenses.  Here, we present a genome-scale study of Mycobacterium tuberculosis (Mtb) that uncovers the bacterial determinants of surviving host immunity, sets of genes we term "counteractomes.".  Through this anal., we found that CD4 T cells attempt to contain Mtb growth by starving it of tryptophan - a mechanism that successfully limits infections by Chlamydia and Leishmania, natural tryptophan auxotrophs.  Mtb, however, can synthesize tryptophan under stress conditions, and thus, starvation fails as an Mtb-killing mechanism.  We then identify a small-mol. inhibitor of Mtb tryptophan synthesis, which converts Mtb into a tryptophan auxotroph and restores the efficacy of a failed host defense.  Together, our findings demonstrate that the Mtb immune counteractomes serve as probes of host immunity, uncovering immune-mediated stresses that can be leveraged for therapeutic discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkCUFDhESMVrVg90H21EOLACvtfcHk0lgnovnKTI5PfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFylurzM&md5=6947753d2524b4f7b352ddc94249317f</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2013.10.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2013.10.045%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BJ.%26aulast%3DReddy%26aufirst%3DM.%2BC.%26aulast%3DIoerger%26aufirst%3DT.%2BR.%26aulast%3DRothchild%26aufirst%3DA.%2BC.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DSchuster%26aufirst%3DB.%2BM.%26aulast%3DTrauner%26aufirst%3DA.%26aulast%3DWallis%26aufirst%3DD.%26aulast%3DGalaviz%26aufirst%3DS.%26aulast%3DHuttenhower%26aufirst%3DC.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DBehar%26aufirst%3DS.%2BM.%26aulast%3DRubin%26aufirst%3DE.%2BJ.%26atitle%3DTryptophan%2520biosynthesis%2520protects%2520mycobacteria%2520from%2520CD4%2520T-cell-mediated%2520killing%26jtitle%3DCell%26date%3D2013%26volume%3D155%26spage%3D1296%26epage%3D1308%26doi%3D10.1016%2Fj.cell.2013.10.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref254"><div class="reference"><strong class="refLabel"><a href="#ref254" class="rightTabRefNumLink">254</a></strong><div class="NLM_citation" id="rightTab-cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Islam, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmud, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, K.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadu, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.-Y.</span></span> <span> </span><span class="NLM_article-title">In vitro activity of DNF-3 against drug-resistant Mycobacterium tuberculosis</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.ijantimicag.2019.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.ijantimicag.2019.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30807817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSqurjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2019&pages=69-74&author=M.+I.+Islamauthor=C.+M.+Hanauthor=H.+Seoauthor=S.+Kimauthor=H.+A.+Mahmudauthor=K.-W.+Namauthor=B.-E.+Leeauthor=V.+S.+Saduauthor=K.-I.+Leeauthor=H.-Y.+Song&title=In+vitro+activity+of+DNF-3+against+drug-resistant+Mycobacterium+tuberculosis&doi=10.1016%2Fj.ijantimicag.2019.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of DNF-3 against drug-resistant Mycobacterium tuberculosis</span></div><div class="casAuthors">Islam, Md Imtiazul; Han, Choi Moon; Seo, Hoonhee; Kim, Sukyung; Mahmud, Hafij Al; Nam, Kung-Woo; Lee, Byung-Eui; Sadu, Venkata S.; Lee, Kee-In; Song, Ho-Yeon</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-74</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Due to the emergence of multidrug-resistant and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, new antituberculosis drugs are urgently required to improve the efficacy of current tuberculosis (TB) treatment.  To achieve this goal, ∼1000 chem. compds. were screened for potential antimycobacterial activity, among which Me 5-(2-diethylaminoethoxy)-7,12-dioxo-7,12 dihydrodinaphtho[1,2-b;2',3'-d]furan-6-carboxylate (DNF-3) showed strong activity against all of the tested drug-susceptible and -resistant M. tuberculosis strains, with 50% min. inhibitory concns. (MIC50 values) of 0.02-0.39 μg/mL both in culture broth and within murine RAW 264.7 macrophage cells.  When DNF-3 was used in combination with rifampicin or streptomycin, it exhibited direct synergy against XDR-TB and an additive effect against M. tuberculosis H37Rv.  DNF-3 displayed a long post-antibiotic effect (PAE) that was comparable with rifampicin but was superior to isoniazid, streptomycin, and ethambutol.  Importantly, DNF-3 showed no cytotoxicity to any cell line tested, with a selectivity index (SI) of >32.  DNF-3 was also active against 27 nontuberculous mycobacteria (NTM) strains, Staphylococcus spp. and Streptococcus spp.  Taken together, these results indicate that DNF-3 is a promising new candidate drug for treating TB.  Further studies are warranted to establish the in vivo effect and therapeutic potential of DNF-3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqml3LoM8XxSrVg90H21EOLACvtfcHk0lhOMMMRcO6y-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSqurjK&md5=6d4ae515b2c81569643e91b4428378c9</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2019.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2019.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DIslam%26aufirst%3DM.%2BI.%26aulast%3DHan%26aufirst%3DC.%2BM.%26aulast%3DSeo%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DMahmud%26aufirst%3DH.%2BA.%26aulast%3DNam%26aufirst%3DK.-W.%26aulast%3DLee%26aufirst%3DB.-E.%26aulast%3DSadu%26aufirst%3DV.%2BS.%26aulast%3DLee%26aufirst%3DK.-I.%26aulast%3DSong%26aufirst%3DH.-Y.%26atitle%3DIn%2520vitro%2520activity%2520of%2520DNF-3%2520against%2520drug-resistant%2520Mycobacterium%2520tuberculosis%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2019%26volume%3D54%26spage%3D69%26epage%3D74%26doi%3D10.1016%2Fj.ijantimicag.2019.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref255"><div class="reference"><strong class="refLabel"><a href="#ref255" class="rightTabRefNumLink">255</a></strong><div class="NLM_citation" id="rightTab-cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craig, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, S. C.</span></span> <span> </span><span class="NLM_article-title">Killing and regrowth of bacteria in vitro: a review</span>. <i>Scand. J. Infect. Dis. Suppl.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">70</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=2097720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADyaK3M3ntFykuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=1990&pages=63-70&author=W.+A.+Craigauthor=S.+C.+Ebert&title=Killing+and+regrowth+of+bacteria+in+vitro%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Killing and regrowth of bacteria in vitro: a review</span></div><div class="casAuthors">Craig W A; Ebert S C</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian journal of infectious diseases. Supplementum</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-70</span>
        ISSN:<span class="NLM_cas:issn">0300-8878</span>.
    </div><div class="casAbstract">Minimum inhibitory and bactericidal concentrations do not describe the time course of a drug's antimicrobial activity against bacteria.  Some antimicrobials exhibit concentration dependent killing over a wide range of concentrations (e.g. aminoglycosides and quinolones), while others show maximal killing at concentrations near the MIC (e.g. beta-lactams and glycopeptides).  The aminoglycosides and quinolones can require high drug concentrations (about 10-fold higher than the MIC) to prevent the selection of resistant subpopulations of bacteria.  Persistent suppression of bacterial growth after antimicrobial exposure is called the 'postantibiotic effect' (PAE) and varies in duration depending on the drug-organism combination, as well as the concentration and duration of drug exposure.  Antimicrobials which are inhibitors of protein and nucleic acid synthesis exhibit prolonged PAEs with a large variety of bacteria.  While beta-lactam antibiotics demonstrate PAEs with Gram-positive cocci, very short or no PAEs are observed with these drugs with Gram-negative bacilli.  The only exception is that penem antibiotics can induce PAEs with some strains of Gram-negative bacilli, primarily Pseudomonas aeruginosa.  Thus, the pharmacodynamic activity of an antimicrobial can vary markedly depending on the microorganism and the class of drug and its concentration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS61NHJmMpLWqx48Rj5GnGofW6udTcc2eZE3i_TiSlEvLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M3ntFykuw%253D%253D&md5=4b1b8bd9de84ad142ceb6e4384acad75</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCraig%26aufirst%3DW.%2BA.%26aulast%3DEbert%26aufirst%3DS.%2BC.%26atitle%3DKilling%2520and%2520regrowth%2520of%2520bacteria%2520in%2520vitro%253A%2520a%2520review%26jtitle%3DScand.%2520J.%2520Infect.%2520Dis.%2520Suppl.%26date%3D1990%26volume%3D74%26spage%3D63%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref256"><div class="reference"><strong class="refLabel"><a href="#ref256" class="rightTabRefNumLink">256</a></strong><div class="NLM_citation" id="rightTab-cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q.</span></span> <span> </span><span class="NLM_article-title">Benzylsulfanyl benzo-heterocycle amides and hydrazones as new agents against drug-susceptible and resistant Mycobacterium tuberculosis</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1303</span>– <span class="NLM_lpage">1306</span>, <span class="refDoi"> DOI: 10.1039/C7MD00146K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1039%2FC7MD00146K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30108841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVCgsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1303-1306&author=X.+Luauthor=X.+Huauthor=Z.+Liuauthor=T.+Zhangauthor=R.+Wangauthor=B.+Wanauthor=S.+G.+Franzblauauthor=Q.+You&title=Benzylsulfanyl+benzo-heterocycle+amides+and+hydrazones+as+new+agents+against+drug-susceptible+and+resistant+Mycobacterium+tuberculosis&doi=10.1039%2FC7MD00146K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Benzylsulfanyl benzo-heterocycle amides and hydrazones as new agents against drug-susceptible and resistant Mycobacterium tuberculosis</span></div><div class="casAuthors">Lu, Xiaoyun; Hu, Xianglong; Liu, Zhiyong; Zhang, Tianyu; Wang, Ruibing; Wan, Baojie; Franzblau, Scott G.; You, Qidong</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1303-1306</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of benzylsulfanyl benzo-heterocycle amides and hydrazones were synthesized and evaluated for anti-tubercular activities.  The isonicotinyl hydrazone derivs. 12d, 12e and 12f exhibited good anti-tubercular activity against Mycobacterium tuberculosis H37Rv (ATCC #27294) with MIC values of 0.23, 0.24 and 0.24 μM, resp., and were also active against SDR-TB, MDR-TB and XDR-TB.  More importantly, compd. 12e also showed low cytotoxicity and good metabolic stability, and could significantly reduce the mycobacterial burden in a mouse model infected with autoluminescent H37Ra strain, which may serve as a lead compd. for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt195vUBgTH7Vg90H21EOLACvtfcHk0lipRNxSTPQWNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVCgsro%253D&md5=5d4a708f094d8cafe85324deb24393de</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1039%2FC7MD00146K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00146K%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DB.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DYou%26aufirst%3DQ.%26atitle%3DBenzylsulfanyl%2520benzo-heterocycle%2520amides%2520and%2520hydrazones%2520as%2520new%2520agents%2520against%2520drug-susceptible%2520and%2520resistant%2520Mycobacterium%2520tuberculosis%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D1303%26epage%3D1306%26doi%3D10.1039%2FC7MD00146K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref257"><div class="reference"><strong class="refLabel"><a href="#ref257" class="rightTabRefNumLink">257</a></strong><div class="NLM_citation" id="rightTab-cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chhabria, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and anti-tubercular activity of a series of N′-substituted isonicotinohydrazide derivatives</span>. <i>World J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">286</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGmsbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=281-286&author=M.+Chhabriaauthor=S.+Patel&title=Synthesis+and+anti-tubercular+activity+of+a+series+of+N%E2%80%B2-substituted+isonicotinohydrazide+derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and anti-tubercular activity of a series of N'-substituted isonicotinohydrazide derivatives</span></div><div class="casAuthors">Chhabria, Mahesh T.; Patel, Sweta</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">281-286</span>CODEN:
                <span class="NLM_cas:coden">WJPSBT</span>;
        ISSN:<span class="NLM_cas:issn">2321-3086</span>.
    
            (<span class="NLM_cas:orgname">Atom and Cell Publishers</span>)
        </div><div class="casAbstract">Tuberculosis is a leading cause of death worldwide and esp. in developing countries due to the recent emergence and spread of multi-drug resistant tuberculosis (MDR TB), extensive drug resistant tuberculosis (XDR TB), total drug resistant tuberculosis (TDR TB) and HIV/AIDS pandemic.  Discovery of target based newer anti-tubercular agent is area of interest for chemists.  We have designed a series of N'-substituted isonicotinohydrazide derivs. based on pharmacophore modeling.  Designed mols. were synthesized and evaluated for their anti-tubercular activity.  Among synthesized compds., N'-(2-(2-fluorophenyl) acetyl) isonicotinohydrazide (4m) was found to be the most active compd. with MIC value of 6.25 μg/mL against Mycobacterium tuberculosis H37Rv strain using Almar Blue method.  Compd. (4m) was found active against MDR-TB and XDR-TB strain at 62.5 and 250 μg/mL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYQjD6Hawyw7Vg90H21EOLACvtfcHk0lipRNxSTPQWNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGmsbvP&md5=369e0f3d445810e6733dc7f10365aa53</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChhabria%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520anti-tubercular%2520activity%2520of%2520a%2520series%2520of%2520N%25E2%2580%25B2-substituted%2520isonicotinohydrazide%2520derivatives%26jtitle%3DWorld%2520J.%2520Pharm.%2520Sci.%26date%3D2016%26volume%3D4%26spage%3D281%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref258"><div class="reference"><strong class="refLabel"><a href="#ref258" class="rightTabRefNumLink">258</a></strong><div class="NLM_citation" id="rightTab-cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soni, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chhabria, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmkshatriya, P. S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel antitubercular agents by combining pyrazoline and benzoxazole pharmacophores</span>. <i>Int. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.4236/ijoc.2016.63017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.4236%2Fijoc.2016.63017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKrsbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=157-176&author=H.+M.+Soniauthor=P.+K.+Patelauthor=M.+T.+Chhabriaauthor=A.+K.+Patelauthor=D.+N.+Ranaauthor=P.+S.+Brahmkshatriya&title=Design%2C+synthesis+and+biological+evaluation+of+novel+antitubercular+agents+by+combining+pyrazoline+and+benzoxazole+pharmacophores&doi=10.4236%2Fijoc.2016.63017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit258R"><div class="casContent"><span class="casTitleNuber">258</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel antitubercular agents by combining pyrazoline and benzoxazole pharmacophores</span></div><div class="casAuthors">Soni, Hemal M.; Patel, Popatbhai K.; Chhabria, Mahesh T.; Patel, Ashish K.; Rana, Dharmraj N.; Brahmkshatriya, Pathik S.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">157-176</span>CODEN:
                <span class="NLM_cas:coden">IJOCCR</span>;
        ISSN:<span class="NLM_cas:issn">2161-4695</span>.
    
            (<span class="NLM_cas:orgname">Scientific Research Publishing, Inc.</span>)
        </div><div class="casAbstract">Various recent reports on Tuberculosis have alarmed an increase in the patient class and subsequent death rates across the globe.  Over and above the spread of more dangerous and fatal forms of tuberculosis like MDR-TB i.e. multiple-drug resistance tuberculosis, XDR-TB i.e. extensively-drug resistance tuberculosis & TDR-TB i.e. total-drug resistance tuberculosis has forwarded an urgent need to discover novel antitubercular agents.  The current work is aimed at combining two previously well-known pharmacophores (pyrazoline and benzoxazole nucleus) in order to design and synthesize a series of novel benzoxazole-based pyrazoline derivs.  The synthesized target compds. were structurally confirmed by LCMS, 1H-NMR and 13C-NMR anal.  The target compds. were In vitro evaluated against M. tuberculosis H37Rv strain, multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains.  The In vitro screening results depicted that majority of the target compds. displayed potent activity with MIC in a range of ∼0.8 to 6.25 μg/mL.  Many compds. were found to be more potent than isoniazid against MDR-TB with MIC value 3.12 μg/mL and XDR-TB with MIC value 12.5 μg/mL.  Cytotoxicity assay of these active compds. on VERO cell lines also displayed good selectivity index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBQQmTMkc7LbVg90H21EOLACvtfcHk0lhrFNu7JERxvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKrsbfI&md5=323108e21fe78106ffc0e5bde1098b1f</span></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.4236%2Fijoc.2016.63017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4236%252Fijoc.2016.63017%26sid%3Dliteratum%253Aachs%26aulast%3DSoni%26aufirst%3DH.%2BM.%26aulast%3DPatel%26aufirst%3DP.%2BK.%26aulast%3DChhabria%26aufirst%3DM.%2BT.%26aulast%3DPatel%26aufirst%3DA.%2BK.%26aulast%3DRana%26aufirst%3DD.%2BN.%26aulast%3DBrahmkshatriya%26aufirst%3DP.%2BS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520antitubercular%2520agents%2520by%2520combining%2520pyrazoline%2520and%2520benzoxazole%2520pharmacophores%26jtitle%3DInt.%2520J.%2520Org.%2520Chem.%26date%3D2016%26volume%3D6%26spage%3D157%26epage%3D176%26doi%3D10.4236%2Fijoc.2016.63017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref259"><div class="reference"><strong class="refLabel"><a href="#ref259" class="rightTabRefNumLink">259</a></strong><div class="NLM_citation" id="rightTab-cit259"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yempalla, K. R.</span>; <span class="NLM_string-name">Munagala, G.</span>; <span class="NLM_string-name">Singh, S.</span>; <span class="NLM_string-name">Sharma, S.</span>; <span class="NLM_string-name">Khan, I. A.</span>; <span class="NLM_string-name">Vishwakarma, R. A.</span>; <span class="NLM_string-name">Singh, P. P.</span></span> <span> </span><span class="NLM_article-title">Substituted l,2,3-triazol-l -yl-methyl-2,3-dihydro-2-methyl-6-nitroimidazo [2,l- bjoxazoles as anti-mycobacterial agents and a process for the preparation thereof</span>. <span class="NLM_patent">WO2016/063298Al</span>. April 28, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=K.+R.+Yempalla&author=G.+Munagala&author=S.+Singh&author=S.+Sharma&author=I.+A.+Khan&author=R.+A.+Vishwakarma&author=P.+P.+Singh&title=Substituted+l%2C2%2C3-triazol-l+-yl-methyl-2%2C3-dihydro-2-methyl-6-nitroimidazo+%5B2%2Cl-+bjoxazoles+as+anti-mycobacterial+agents+and+a+process+for+the+preparation+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYempalla%26aufirst%3DK.%2BR.%26atitle%3DSubstituted%2520l%252C2%252C3-triazol-l%2520-yl-methyl-2%252C3-dihydro-2-methyl-6-nitroimidazo%2520%255B2%252Cl-%2520bjoxazoles%2520as%2520anti-mycobacterial%2520agents%2520and%2520a%2520process%2520for%2520the%2520preparation%2520thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref260"><div class="reference"><strong class="refLabel"><a href="#ref260" class="rightTabRefNumLink">260</a></strong><div class="NLM_citation" id="rightTab-cit260"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, S.</span></span> <span> </span><span class="NLM_article-title">Identification of an anti-TB compound targeting the tyrosyl-tRNA synthetase</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">2287</span>– <span class="NLM_lpage">2294</span>, <span class="refDoi"> DOI: 10.1093/jac/dkv110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fjac%2Fdkv110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=25957580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFSrtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2015&pages=2287-2294&author=N.+Zhuauthor=Y.+Linauthor=D.+Liauthor=N.+Gaoauthor=C.+Liuauthor=X.+Youauthor=J.+Jiangauthor=W.+Jiangauthor=S.+Si&title=Identification+of+an+anti-TB+compound+targeting+the+tyrosyl-tRNA+synthetase&doi=10.1093%2Fjac%2Fdkv110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit260R"><div class="casContent"><span class="casTitleNuber">260</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an anti-TB compound targeting the tyrosyl-tRNA synthetase</span></div><div class="casAuthors">Zhu, Ningyu; Lin, Yuan; Li, Dongsheng; Gao, Nana; Liu, Chang; You, Xuefu; Jiang, Jiandong; Jiang, Wei; Si, Shuyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2287-2294</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: Drug-resistant Mycobacterium tuberculosis poses a great threat to human health.  Tyrosyl-tRNA synthetase (TyrRS) is one of the aminoacyl tRNA synthetases that catalyze the attachment of amino acids to their cognate tRNAs and are essential for protein synthesis.  There are several distinctive differences between bacterial and human TyrRS and therefore it could be a potential target for developing antimicrobial agents.  This study aimed to identify a new anti-TB agent targeting M. tuberculosis TyrRS (MtTyrRS).  Methods: We first used Mycobacterium smegmatis for a phenotypic screening of 20000 compds.  The hit compds. were then screened with MtTyrRS.  The interaction between hit compd. IMB-T130 and the target protein was analyzed by surface plasmon resonance (SPR) assay and mol. docking expts.  The target of IMB-T130 was further confirmed by the overexpression of the target protein.  The antibacterial activity of IMB-T130 against various std. and clin. drug-resistant M. tuberculosis strains was evaluated using the microplate Alamar blue assay.  Results: Compd. IMB-T130 was identified as a hit compd. that inhibits the growth of M. smegmatis and the in vitro activity of MtTyrRS.  The interaction between IMB-T130 and MtTyrRS was confirmed by SPR assay and mol. docking anal.  The higher MIC for a strain overexpressing the target protein also suggests that MtTyrRS is likely to be the target of IMB-T130.  IMB-T130 shows excellent anti-TB activity and low cytotoxicity.  Conclusions: IMB-T130 inhibits the growth of MDR-TB and XDR-TB by targeting MtTyrRS.  Because of its low cytotoxicity against mammalian cells, IMB-T130 is a promising new agent against drug-resistant M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4MQPYUu4WMrVg90H21EOLACvtfcHk0lhrFNu7JERxvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFSrtbzN&md5=1db00cb51f4b904f18bd9001a5a7345a</span></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkv110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkv110%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DN.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DYou%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DSi%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520an%2520anti-TB%2520compound%2520targeting%2520the%2520tyrosyl-tRNA%2520synthetase%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2015%26volume%3D70%26spage%3D2287%26epage%3D2294%26doi%3D10.1093%2Fjac%2Fdkv110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref261"><div class="reference"><strong class="refLabel"><a href="#ref261" class="rightTabRefNumLink">261</a></strong><div class="NLM_citation" id="rightTab-cit261"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parashar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilcheze, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veyron-Churlet, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlich, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szymonifka, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchiano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colangeli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neiditch, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alland, D.</span></span> <span> </span><span class="NLM_article-title">Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fnchembio.1277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23770708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsV2lsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=499-506&author=R.+Wilsonauthor=P.+Kumarauthor=V.+Parasharauthor=C.+Vilchezeauthor=R.+Veyron-Churletauthor=J.+S.+Freundlichauthor=S.+W.+Barnesauthor=J.+R.+Walkerauthor=M.+J.+Szymonifkaauthor=E.+Marchianoauthor=S.+Shenaiauthor=R.+Colangeliauthor=W.+R.+Jacobsauthor=M.+B.+Neiditchauthor=L.+Kremerauthor=D.+Alland&title=Antituberculosis+thiophenes+define+a+requirement+for+Pks13+in+mycolic+acid+biosynthesis&doi=10.1038%2Fnchembio.1277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit261R"><div class="casContent"><span class="casTitleNuber">261</span><div class="casTitle"><span class="NLM_cas:atitle">Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis</span></div><div class="casAuthors">Wilson, Regina; Kumar, Pradeep; Parashar, Vijay; Vilcheze, Catherine; Veyron-Churlet, Romain; Freundlich, Joel S.; Barnes, S. Whitney; Walker, John R.; Szymonifka, Michael J.; Marchiano, Emily; Shenai, Shubhada; Colangeli, Roberto; Jacobs, William R., Jr.; Neiditch, Matthew B.; Kremer, Laurent; Alland, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">499-506</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors report a new class of thiophene (TP) compds. that kill Mycobacterium tuberculosis by a previously uncharacterized mechanism of Pks13 inhibition.  An F79S mutation near the catalytic Ser55 site in Pks13 conferred TP resistance in M. tuberculosis.  Overexpression of wild-type Pks13 resulted in TP resistance, and overexpression of the Pks13F79S mutant conferred high resistance.  In vitro, TP inhibited fatty acyl-AMP loading onto Pks13.  TP inhibited mycolic acid biosynthesis in wild-type M. tuberculosis, but it did so to a much lesser extent in TP-resistant M. tuberculosis.  TP treatment was bactericidal and equiv. to treatment with the first-line drug isoniazid, but it was less likely to permit emergent resistance.  Combined isoniazid and TP treatment resulted in sterilizing activity.  Computational docking identified a possible TP-binding groove within the Pks13 acyl carrier protein domain.  This study confirms that M. tuberculosisPks13 is required for mycolic acid biosynthesis, validates it as a druggable target and demonstrates the therapeutic potential of simultaneously inhibiting multiple targets in the same biosynthetic pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwnc8l43PyebVg90H21EOLACvtfcHk0lhORFH8FUZlUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsV2lsb0%253D&md5=8c6209e87941537c3e2209e8f92579ec</span></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1277%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DParashar%26aufirst%3DV.%26aulast%3DVilcheze%26aufirst%3DC.%26aulast%3DVeyron-Churlet%26aufirst%3DR.%26aulast%3DFreundlich%26aufirst%3DJ.%2BS.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DSzymonifka%26aufirst%3DM.%2BJ.%26aulast%3DMarchiano%26aufirst%3DE.%26aulast%3DShenai%26aufirst%3DS.%26aulast%3DColangeli%26aufirst%3DR.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26aulast%3DNeiditch%26aufirst%3DM.%2BB.%26aulast%3DKremer%26aufirst%3DL.%26aulast%3DAlland%26aufirst%3DD.%26atitle%3DAntituberculosis%2520thiophenes%2520define%2520a%2520requirement%2520for%2520Pks13%2520in%2520mycolic%2520acid%2520biosynthesis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D499%26epage%3D506%26doi%3D10.1038%2Fnchembio.1277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref262"><div class="reference"><strong class="refLabel"><a href="#ref262" class="rightTabRefNumLink">262</a></strong><div class="NLM_citation" id="rightTab-cit262"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisbrod, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition</span>. <i>J. Bacteriol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">1802</span>– <span class="NLM_lpage">1811</span>, <span class="refDoi"> DOI: 10.1128/JB.182.7.1802-1811.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FJB.182.7.1802-1811.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10714983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3cXitFWrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2000&pages=1802-1811&author=D.+Allandauthor=A.+J.+Steynauthor=T.+Weisbrodauthor=K.+Aldrichauthor=W.+R.+Jacobs&title=Characterization+of+the+Mycobacterium+tuberculosis+iniBAC+promoter%2C+a+promoter+that+responds+to+cell+wall+biosynthesis+inhibition&doi=10.1128%2FJB.182.7.1802-1811.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit262R"><div class="casContent"><span class="casTitleNuber">262</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition</span></div><div class="casAuthors">Alland, David; Steyn, Andries J.; Weisbrod, Torin; Aldrich, Kate; Jacobs, William R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bacteriology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1802-1811</span>CODEN:
                <span class="NLM_cas:coden">JOBAAY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9193</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The cell wall provides an attractive target for antibiotics against Mycobacterium tuberculosis.  Agents such as isoniazid and ethambutol that work by inhibiting cell wall biosynthesis are among the most highly effective antibiotics against this pathogen.  Although considerable progress has been made identifying the targets for cell wall active antibiotics, little is known about the intracellular mechanisms that are activated as a consequence of cell wall injury.  These mechanisms are likely to have an important role in growth regulation and in the induction of cell death by antibiotics.  The authors previously discovered three isoniazid-induced genes (iniB, iniA, and iniC) organized in tandem on the M. tuberculosis genome.  Here, the authors investigate the unique features of the putative iniBAC promoter.  This promoter was specifically induced by a broad range of inhibitors of cell wall biosynthesis but was not inducible by other conditions that are toxic to mycobacteria via other mechanisms.  Induction required inhibitory concns. of antibiotics and could be detected only in actively growing cells.  Anal. of the iniBAC promoter sequence revealed both a regulatory element upstream and a potential repressor binding region downstream of the transcriptional start site.  The induction phenotype and structure of the iniBAC promoter suggest that a complex intracellular response occurs when cell wall biosynthesis is inhibited in M. tuberculosis and other mycobacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlrSF2dhk_XrVg90H21EOLACvtfcHk0lhORFH8FUZlUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXitFWrsLk%253D&md5=ba637525a688554bbcf204e3dbfb0bfc</span></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=10.1128%2FJB.182.7.1802-1811.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJB.182.7.1802-1811.2000%26sid%3Dliteratum%253Aachs%26aulast%3DAlland%26aufirst%3DD.%26aulast%3DSteyn%26aufirst%3DA.%2BJ.%26aulast%3DWeisbrod%26aufirst%3DT.%26aulast%3DAldrich%26aufirst%3DK.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26atitle%3DCharacterization%2520of%2520the%2520Mycobacterium%2520tuberculosis%2520iniBAC%2520promoter%252C%2520a%2520promoter%2520that%2520responds%2520to%2520cell%2520wall%2520biosynthesis%2520inhibition%26jtitle%3DJ.%2520Bacteriol.%26date%3D2000%26volume%3D182%26spage%3D1802%26epage%3D1811%26doi%3D10.1128%2FJB.182.7.1802-1811.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref263"><div class="reference"><strong class="refLabel"><a href="#ref263" class="rightTabRefNumLink">263</a></strong><div class="NLM_citation" id="rightTab-cit263"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinrick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trefzer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mdluli, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikusova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fütterer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, W. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span> <span> </span><span class="NLM_article-title">Identification of a small molecule with activity against drug-resistant and persistent tuberculosis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">e2510</span>– <span class="NLM_lpage">e2517</span>, <span class="refDoi"> DOI: 10.1073/pnas.1309171110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1073%2Fpnas.1309171110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23776209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFejsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=e2510-e2517&author=F.+Wangauthor=D.+Sambandanauthor=R.+Halderauthor=J.+Wangauthor=S.+M.+Battauthor=B.+Weinrickauthor=I.+Ahmadauthor=P.+Yangauthor=Y.+Zhangauthor=J.+Kimauthor=M.+Hassaniauthor=S.+Huszarauthor=C.+Trefzerauthor=Z.+Maauthor=T.+Kanekoauthor=K.+E.+Mdluliauthor=S.+Franzblauauthor=A.+K.+Chatterjeeauthor=K.+Johnssonauthor=K.+Mikusovaauthor=G.+S.+Besraauthor=K.+F%C3%BCttererauthor=S.+H.+Robbinsauthor=S.+W.+Barnesauthor=J.+R.+Walkerauthor=W.+R.+Jacobsauthor=P.+G.+Schultz&title=Identification+of+a+small+molecule+with+activity+against+drug-resistant+and+persistent+tuberculosis&doi=10.1073%2Fpnas.1309171110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit263R"><div class="casContent"><span class="casTitleNuber">263</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a small molecule with activity against drug-resistant and persistent tuberculosis</span></div><div class="casAuthors">Wang, Feng; Sambandan, Dhinakaran; Halder, Rajkumar; Wang, Jianing; Batt, Sarah M.; Weinrick, Brian; Ahmad, Insha; Yang, Pengyu; Zhang, Yong; Kim, John; Hassani, Morad; Huszar, Stanislav; Trefzer, Claudia; Ma, Zhenkun; Kaneko, Takushi; Mdluli, Khisi E.; Franzblau, Scott; Chatterjee, Arnab K.; Johnsson, Kai; Mikusova, Katarina; Besra, Gurdyal S.; Fuetterer, Klaus; Robbins, Scott H.; Barnes, S. Whitney; Walker, John R.; Jacobs, William R., Jr.; Schultz, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">E2510-E2517,SE2510/1-SE2510/6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A cell-based phenotypic screen for inhibitors of biofilm formation in mycobacteria identified the small mol. TCA1, which has bactericidal activity against both drug-susceptible and -resistant Mycobacterium tuberculosis (Mtb) and sterilizes Mtb in vitro combined with rifampicin or isoniazid.  In addn., TCA1 has bactericidal activity against nonreplicating Mtb in vitro and is efficacious in acute and chronic Mtb infection mouse models both alone and combined with rifampicin or isoniazid.  Transcriptional anal. revealed that TCA1 down-regulates genes known to be involved in Mtb persistence.  Genetic and affinity-based methods identified decaprenyl-phosphoryl-β-D-ribofuranose oxidoreductase DprE1 and MoeW, enzymes involved in cell wall and molybdenum cofactor biosynthesis, resp., as targets responsible for the activity of TCA1.  These in vitro and in vivo results indicate that this compd. functions by a unique mechanism and suggest that TCA1 may lead to the development of a class of antituberculosis agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokxlddd-EfbbVg90H21EOLACvtfcHk0lhORFH8FUZlUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFejsLnL&md5=caf496e25608bb98e61ab97bd603f2ab</span></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1309171110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1309171110%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DSambandan%26aufirst%3DD.%26aulast%3DHalder%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBatt%26aufirst%3DS.%2BM.%26aulast%3DWeinrick%26aufirst%3DB.%26aulast%3DAhmad%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DHassani%26aufirst%3DM.%26aulast%3DHuszar%26aufirst%3DS.%26aulast%3DTrefzer%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DMdluli%26aufirst%3DK.%2BE.%26aulast%3DFranzblau%26aufirst%3DS.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DJohnsson%26aufirst%3DK.%26aulast%3DMikusova%26aufirst%3DK.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DF%25C3%25BCtterer%26aufirst%3DK.%26aulast%3DRobbins%26aufirst%3DS.%2BH.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DJacobs%26aufirst%3DW.%2BR.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26atitle%3DIdentification%2520of%2520a%2520small%2520molecule%2520with%2520activity%2520against%2520drug-resistant%2520and%2520persistent%2520tuberculosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3De2510%26epage%3De2517%26doi%3D10.1073%2Fpnas.1309171110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref264"><div class="reference"><strong class="refLabel"><a href="#ref264" class="rightTabRefNumLink">264</a></strong><div class="NLM_citation" id="rightTab-cit264"><span> <i>Guidelines for Treatment of Tuberculosis</i>, 4th ed.; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2010</span>; <a href="https://www.who.int/tb/publications/2010/9789241547833/en/" class="extLink">https://www.who.int/tb/publications/2010/9789241547833/en/</a> (accessed
December 29, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Guidelines+for+Treatment+of+Tuberculosis%2C+4th+ed.%3B+World+Health+Organization%3A+Geneva%2C+2010%3B+https%3A%2F%2Fwww.who.int%2Ftb%2Fpublications%2F2010%2F9789241547833%2Fen%2F+%28accessed%0ADecember+29%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGuidelines%2520for%2520Treatment%2520of%2520Tuberculosis%26pub%3DWorld%2520Health%2520Organization%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref265"><div class="reference"><strong class="refLabel"><a href="#ref265" class="rightTabRefNumLink">265</a></strong><div class="NLM_citation" id="rightTab-cit265"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawkey, P. M.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of quinolone action and microbial response</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">Suppl 1</span>),  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1093/jac/dkg207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fjac%2Fdkg207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=12702701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktlOqu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2003&pages=29-35&issue=Suppl+1&author=P.+M.+Hawkey&title=Mechanisms+of+quinolone+action+and+microbial+response&doi=10.1093%2Fjac%2Fdkg207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit265R"><div class="casContent"><span class="casTitleNuber">265</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of quinolone action and microbial response</span></div><div class="casAuthors">Hawkey, Peter M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">Suppl. S1</span>),
    <span class="NLM_cas:pages">29-35</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Over the years, chromosomal mapping of the bacterial genome of Escherichia coli has demonstrated that many loci are assocd. with quinolone resistance, which is mainly a result of chromosomal mutation or alteration of the quantity or type of porins in the outer membrane of Gram-neg. bacteria.  There has been one report of a small and confined episode of plasmid-mediated resistance to fluoroquinolones, which did not appear to persist.  With the increasingly widespread use of an expanding range of fluoroquinolone antibiotics, a range and mix in individual bacterial isolates of the different mechanisms of resistance to fluoroquinolones will undoubtedly be encountered amongst clin. significant bacteria.  Currently, transferable resistance is extremely rare and most resistant bacteria arise from clonal expansion of mutated strains.  However, it is conceivable that in the future, horizontal gene transfer may become a more important means of conferring resistance to fluoroquinolones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpabXEcTKWqObVg90H21EOLACvtfcHk0lgI163dtpDx6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktlOqu7w%253D&md5=696f6b6147a980010442f90550247d46</span></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkg207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkg207%26sid%3Dliteratum%253Aachs%26aulast%3DHawkey%26aufirst%3DP.%2BM.%26atitle%3DMechanisms%2520of%2520quinolone%2520action%2520and%2520microbial%2520response%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2003%26volume%3D51%26issue%3DSuppl%25201%26spage%3D29%26epage%3D35%26doi%3D10.1093%2Fjac%2Fdkg207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref266"><div class="reference"><strong class="refLabel"><a href="#ref266" class="rightTabRefNumLink">266</a></strong><div class="NLM_citation" id="rightTab-cit266"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, D. C.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of fluoroquinolone resistance</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1054/drup.1998.0068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1054%2Fdrup.1998.0068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=11504468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaK1MXktVaqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1999&pages=38-55&author=D.+C.+Hooper&title=Mechanisms+of+fluoroquinolone+resistance&doi=10.1054%2Fdrup.1998.0068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit266R"><div class="casContent"><span class="casTitleNuber">266</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of fluoroquinolone resistance</span></div><div class="casAuthors">Hooper, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-55</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Churchill Livingstone</span>)
        </div><div class="casAbstract">A review with 174 refs.  Mechanisms of bacterial resistance to fluoroquinolones fall into two principal categories, alterations in drug target enzymes and alterations that limit permeation of drug to the target, both resulting from chromosomal mutations.  No specific resistance mechanisms of quinolone degrdn. or modification have been found.  The target enzymes, DNA gyrase and topoisomerase IV, are most commonly altered in domains near the enzyme active sites and in some cases reduced drug binding affinity has been demonstrated.  Drug permeation is altered by mutations that increase expression of endogenous multidrug efflux pumps, alter outer membrane diffusion channels, or both.  Recently a new plasmid-mediated resistance of an as yet undefined mechanism was found in clin. isolates of Klebsiella pneumoniae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkXuZhBYHniLVg90H21EOLACvtfcHk0lgI163dtpDx6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVaqsb0%253D&md5=885296b07bba88b091e4be26ea425b4a</span></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1054%2Fdrup.1998.0068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fdrup.1998.0068%26sid%3Dliteratum%253Aachs%26aulast%3DHooper%26aufirst%3DD.%2BC.%26atitle%3DMechanisms%2520of%2520fluoroquinolone%2520resistance%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D1999%26volume%3D2%26spage%3D38%26epage%3D55%26doi%3D10.1054%2Fdrup.1998.0068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref267"><div class="reference"><strong class="refLabel"><a href="#ref267" class="rightTabRefNumLink">267</a></strong><div class="NLM_citation" id="rightTab-cit267"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerrini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuppone, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corelli, F.</span></span> <span> </span><span class="NLM_article-title">New fluoroquinolones active against fluoroquinolones-resistant Mycobacterium tuberculosis strains</span>. <i>Tuberculosis</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1016/j.tube.2013.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.tube.2013.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=23523640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFOhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=405-411&author=V.+Guerriniauthor=M.+De+Rosaauthor=S.+Pasquiniauthor=C.+Mugnainiauthor=A.+Brizziauthor=A.+M.+Cupponeauthor=G.+Pozziauthor=F.+Corelli&title=New+fluoroquinolones+active+against+fluoroquinolones-resistant+Mycobacterium+tuberculosis+strains&doi=10.1016%2Fj.tube.2013.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit267R"><div class="casContent"><span class="casTitleNuber">267</span><div class="casTitle"><span class="NLM_cas:atitle">New fluoroquinolones active against fluoroquinolones-resistant Mycobacterium tuberculosis strains</span></div><div class="casAuthors">Guerrini, Valentina; De Rosa, Maria; Pasquini, Serena; Mugnaini, Claudia; Brizzi, Antonella; Cuppone, Anna Maria; Pozzi, Gianni; Corelli, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">405-411</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A set of 21 new fluoroquinolones bearing an arom. or heteroarom. moiety at C-7 and an alkyl group at N-1 were synthesized based on the lead structure of pirfloxacin and tested in vitro against Mycobacterium tuberculosis (M. tuberculosis) H37Rv by MIC detn. in liq. medium.  Among the synthesized compds., 1-(tert-butyl)-6-fluoro-7-(4-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (2o) and 1-(tert-butyl)-6-fluoro-7-(pyridin-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (2n) were found to be the most active ones against M. tuberculosis H37Rv with the same MICs of ref. compds. ciprofloxacin (CFX) and levofloxacin (LFX).  MICs of 2o and 2n were detd. for fluoroquinolone-sensitive and fluoroquinolone-resistant M. tuberculosis clin. isolates and 2o was the most active compd. with up 4-fold difference of MIC with respect to CFX.  The activity of 2o was also tested at the concn. of 16 μg/mL against M. tuberculosis H37Rv in infected murine macrophages.  The results showed a 4-fold decrease in viable count of cell-assocd. mycobacteria with respect to untreated controls after 48 h of drug incubation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXl-ZKXd3HSbVg90H21EOLACvtfcHk0lhteci16w3VfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFOhtLs%253D&md5=fa67450f3905039fcb8f454bf447a6ec</span></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2013.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2013.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DGuerrini%26aufirst%3DV.%26aulast%3DDe%2BRosa%26aufirst%3DM.%26aulast%3DPasquini%26aufirst%3DS.%26aulast%3DMugnaini%26aufirst%3DC.%26aulast%3DBrizzi%26aufirst%3DA.%26aulast%3DCuppone%26aufirst%3DA.%2BM.%26aulast%3DPozzi%26aufirst%3DG.%26aulast%3DCorelli%26aufirst%3DF.%26atitle%3DNew%2520fluoroquinolones%2520active%2520against%2520fluoroquinolones-resistant%2520Mycobacterium%2520tuberculosis%2520strains%26jtitle%3DTuberculosis%26date%3D2013%26volume%3D93%26spage%3D405%26epage%3D411%26doi%3D10.1016%2Fj.tube.2013.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref268"><div class="reference"><strong class="refLabel"><a href="#ref268" class="rightTabRefNumLink">268</a></strong><div class="NLM_citation" id="rightTab-cit268"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stefancich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artico, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panico, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonetti, N.</span></span> <span> </span><span class="NLM_article-title">1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1H-pyrrol-1-yl)-quinoline-3-carb oxylic acid, a new fluorinated compounds of oxacin family with high broad-spectrum antibacterial activities</span>. <i>Farmaco Sci.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">248</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=3926533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADyaL2MXitFyiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1985&pages=237-248&author=G.+Stefancichauthor=M.+Articoauthor=F.+Corelliauthor=S.+Massaauthor=S.+Panicoauthor=N.+Simonetti&title=1-Ethyl-6-fluoro-1%2C4-dihydro-4-oxo-7-%281H-pyrrol-1-yl%29-quinoline-3-carb+oxylic+acid%2C+a+new+fluorinated+compounds+of+oxacin+family+with+high+broad-spectrum+antibacterial+activities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit268R"><div class="casContent"><span class="casTitleNuber">268</span><div class="casTitle"><span class="NLM_cas:atitle">1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1H-pyrrol-1-yl)quinoline-3-carboxylic acid, a new fluorinated compound of oxacin family with high broad-spectrum antibacterial activities</span></div><div class="casAuthors">Stefancich, G.; Artico, M.; Corelli, F.; Massa, S.; Panico, S.; Simonetti, N.</div><div class="citationInfo"><span class="NLM_cas:title">Farmaco, Edizione Scientifica</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">237-48</span>CODEN:
                <span class="NLM_cas:coden">FRPSAX</span>;
        ISSN:<span class="NLM_cas:issn">0430-0920</span>.
    </div><div class="casAbstract">The title compd. (I) was prepd. by the reaction of 4-fluoro-3-(1H-pyrrol-1-yl)aniline with di-Et ethoxymethylenemalonate, cyclization of the malonate obtained to the quinolinecarboxylate ester, ethylation of the ester, followed by hydrolysis with aq. NaOH.  The new deriv. proved very active against both gram-pos. and gram-neg. bacteria.  Its activities in comparison with those of nalidixic acid, pipemidic acid, piromidic acid, and enoxacin were greatly superior with regard to the unfluorinated compds. and somewhat superior also to enoxacin.  The known 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(pyrrolidin-1-yl)quinoline-3-carboxylic acid, here prepd. by catalytic hydrogenation of the pyrrole moiety of the title compd., was less active as an antibacterial agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrik2m91AXy6rVg90H21EOLACvtfcHk0lhteci16w3VfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXitFyiurc%253D&md5=6ffe48e6897dca4899de32bd3d1b15c4</span></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStefancich%26aufirst%3DG.%26aulast%3DArtico%26aufirst%3DM.%26aulast%3DCorelli%26aufirst%3DF.%26aulast%3DMassa%26aufirst%3DS.%26aulast%3DPanico%26aufirst%3DS.%26aulast%3DSimonetti%26aufirst%3DN.%26atitle%3D1-Ethyl-6-fluoro-1%252C4-dihydro-4-oxo-7-%25281H-pyrrol-1-yl%2529-quinoline-3-carb%2520oxylic%2520acid%252C%2520a%2520new%2520fluorinated%2520compounds%2520of%2520oxacin%2520family%2520with%2520high%2520broad-spectrum%2520antibacterial%2520activities%26jtitle%3DFarmaco%2520Sci.%26date%3D1985%26volume%3D40%26spage%3D237%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref269"><div class="reference"><strong class="refLabel"><a href="#ref269" class="rightTabRefNumLink">269</a></strong><div class="NLM_citation" id="rightTab-cit269"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patra, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraceto, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, E. V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Torres, M. d. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acosta-Torres, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-Torres, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swamy, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habtemariam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H.-S.</span></span> <span> </span><span class="NLM_article-title">Nano based drug delivery systems: recent developments and future prospects</span>. <i>J. Nanobiotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">71</span>, <span class="refDoi"> DOI: 10.1186/s12951-018-0392-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1186%2Fs12951-018-0392-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=30231877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjt1OisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=71&author=J.+K.+Patraauthor=G.+Dasauthor=L.+F.+Fracetoauthor=E.+V.+R.+Camposauthor=M.+d.+P.+Rodriguez-Torresauthor=L.+S.+Acosta-Torresauthor=L.+A.+Diaz-Torresauthor=R.+Grilloauthor=M.+K.+Swamyauthor=S.+Sharmaauthor=S.+Habtemariamauthor=H.-S.+Shin&title=Nano+based+drug+delivery+systems%3A+recent+developments+and+future+prospects&doi=10.1186%2Fs12951-018-0392-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">Nano based drug delivery systems: recent developments and future prospects</span></div><div class="casAuthors">Patra, Jayanta Kumar; Das, Gitishree; Fraceto, Leonardo Fernandes; Campos, Estefania Vangelie Ramos; Rodriguez-Torres, Maria Del Pilar; Acosta-Torres, Laura Susana; Diaz-Torres, Luis Armando; Grillo, Renato; Swamy, Mallappa Kumara; Sharma, Shivesh; Habtemariam, Solomon; Shin, Han-Seung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nanobiotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">71/1-71/33</span>CODEN:
                <span class="NLM_cas:coden">JNOAAO</span>;
        ISSN:<span class="NLM_cas:issn">1477-3155</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Nanomedicine and nano delivery systems are a relatively new but rapidly developing science where materials in the nanoscale range are employed to serve as means of diagnostic tools or to deliver therapeutic agents to specific targeted sites in a controlled manner.  Nanotechnol. offers multiple benefits in treating chronic human diseases by site-specific, and target-oriented delivery of precise medicines.  Recently, there are a no. of outstanding applications of the nanomedicine (chemotherapeutic agents, biol. agents, immunotherapeutic agents etc.) in the treatment of various diseases.  The current review, presents an updated summary of recent advances in the field of nanomedicines and nano based drug delivery systems through comprehensive scrutiny of the discovery and application of nanomaterials in improving both the efficacy of novel and old drugs (e.g., natural products) and selective diagnosis through disease marker mols.  The opportunities and challenges of nanomedicines in drug delivery from synthetic/natural sources to their clin. applications are also discussed.  In addn., we have included information regarding the trends and perspectives in nanomedicine area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVgmxuTN7gr7Vg90H21EOLACvtfcHk0lhTEvlQiAOXpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjt1OisL4%253D&md5=a097a21379cd48333d81dffd7c57122f</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1186%2Fs12951-018-0392-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12951-018-0392-8%26sid%3Dliteratum%253Aachs%26aulast%3DPatra%26aufirst%3DJ.%2BK.%26aulast%3DDas%26aufirst%3DG.%26aulast%3DFraceto%26aufirst%3DL.%2BF.%26aulast%3DCampos%26aufirst%3DE.%2BV.%2BR.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%2Bd.%2BP.%26aulast%3DAcosta-Torres%26aufirst%3DL.%2BS.%26aulast%3DDiaz-Torres%26aufirst%3DL.%2BA.%26aulast%3DGrillo%26aufirst%3DR.%26aulast%3DSwamy%26aufirst%3DM.%2BK.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DHabtemariam%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DH.-S.%26atitle%3DNano%2520based%2520drug%2520delivery%2520systems%253A%2520recent%2520developments%2520and%2520future%2520prospects%26jtitle%3DJ.%2520Nanobiotechnol.%26date%3D2018%26volume%3D16%26spage%3D71%26doi%3D10.1186%2Fs12951-018-0392-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref270"><div class="reference"><strong class="refLabel"><a href="#ref270" class="rightTabRefNumLink">270</a></strong><div class="NLM_citation" id="rightTab-cit270"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatfull, G. F.</span>; <span class="NLM_string-name">Vehring, R.</span></span> <span> </span><span class="NLM_article-title">Respirable Bacteriophage Aerosols for the Prevention and Treatment of Tuberculosis</span>. In  <i>Drug Delivery Systems for Tuberculosis Prevention and Treatment</i>, <span class="NLM_edition">1</span>st ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, A. J.</span>, <span class="NLM_string-name">Misra, A.</span>, <span class="NLM_string-name">Fourie, P. B.</span></span>, Eds.; <span class="NLM_publisher-name">John Wiley & Sons, Ltd.</span>, <span class="NLM_year">2016</span>; pp  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">292</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1002%2F9781118943182.ch14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=275-292&author=G.+F.+Hatfull&author=R.+Vehringauthor=A.+J.+Hickey&author=A.+Misra&author=P.+B.+Fourie&title=Drug+Delivery+Systems+for+Tuberculosis+Prevention+and+Treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.1002%2F9781118943182.ch14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118943182.ch14%26sid%3Dliteratum%253Aachs%26aulast%3DHatfull%26aufirst%3DG.%2BF.%26atitle%3DRespirable%2520Bacteriophage%2520Aerosols%2520for%2520the%2520Prevention%2520and%2520Treatment%2520of%2520Tuberculosis%26btitle%3DDrug%2520Delivery%2520Systems%2520for%2520Tuberculosis%2520Prevention%2520and%2520Treatment%26aulast%3DHickey%26aufirst%3DA.%2BJ.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Ltd%26date%3D2016%26spage%3D275%26epage%3D292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref271"><div class="reference"><strong class="refLabel"><a href="#ref271" class="rightTabRefNumLink">271</a></strong><div class="NLM_citation" id="rightTab-cit271"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nasiruddin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyaz, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span> <span> </span><span class="NLM_article-title">Nanotechnology-based approach in tuberculosis treatment</span>. <i>Tuberc. Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2017</i></span>,  <span class="NLM_fpage">4920209</span>, <span class="refDoi"> DOI: 10.1155/2017/4920209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1155%2F2017%2F4920209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28210505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1c3nvFamsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2017&publication_year=2017&pages=4920209&author=M.+Nasiruddinauthor=M.+K.+Neyazauthor=S.+Das&title=Nanotechnology-based+approach+in+tuberculosis+treatment&doi=10.1155%2F2017%2F4920209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit271R"><div class="casContent"><span class="casTitleNuber">271</span><div class="casTitle"><span class="NLM_cas:atitle">Nanotechnology-Based Approach in Tuberculosis Treatment</span></div><div class="casAuthors">Nasiruddin Mohammad; Das Shilpi; Neyaz Md Kausar</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis research and treatment</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2017</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4920209</span>
        ISSN:<span class="NLM_cas:issn">2090-150X</span>.
    </div><div class="casAbstract">Tuberculosis, commonly known as TB, is the second most fatal infectious disease after AIDS, caused by bacterium called Mycobacterium tuberculosis.  Prolonged treatment, high pill burden, low compliance, and stiff administration schedules are factors that are responsible for emergence of MDR and XDR cases of tuberculosis.  Till date, only BCG vaccine is available which is ineffective against adult pulmonary TB, which is the most common form of disease.  Various unique antibodies have been developed to overcome drug resistance, reduce the treatment regimen, and elevate the compliance to treatment.  Therefore, we need an effective and robust system to subdue technological drawbacks and improve the effectiveness of therapeutic drugs which still remains a major challenge for pharmaceutical technology.  Nanoparticle-based ideology has shown convincing treatment and promising outcomes for chronic infectious diseases.  Different types of nanocarriers have been evaluated as promising drug delivery systems for various administration routes.  Controlled and sustained release of drugs is one of the advantages of nanoparticle-based antituberculosis drugs over free drug.  It also reduces the dosage frequency and resolves the difficulty of low poor compliance.  This paper reviews various nanotechnology-based therapies which can be used for the treatment of TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRePK2qLr-wndXdcedVHT5tfW6udTcc2eZhSWJ2OEwvcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3nvFamsg%253D%253D&md5=4b60bf666de8e068a32405b57668e950</span></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=10.1155%2F2017%2F4920209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2017%252F4920209%26sid%3Dliteratum%253Aachs%26aulast%3DNasiruddin%26aufirst%3DM.%26aulast%3DNeyaz%26aufirst%3DM.%2BK.%26aulast%3DDas%26aufirst%3DS.%26atitle%3DNanotechnology-based%2520approach%2520in%2520tuberculosis%2520treatment%26jtitle%3DTuberc.%2520Res.%2520Treat.%26date%3D2017%26volume%3D2017%26spage%3D4920209%26doi%3D10.1155%2F2017%2F4920209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref272"><div class="reference"><strong class="refLabel"><a href="#ref272" class="rightTabRefNumLink">272</a></strong><div class="NLM_citation" id="rightTab-cit272"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yetisgin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cetinel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutlu, O.</span></span> <span> </span><span class="NLM_article-title">Therapeutic nanoparticles and their targeted delivery applications</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2193</span>, <span class="refDoi"> DOI: 10.3390/molecules25092193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3390%2Fmolecules25092193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFert7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=2193&author=A.+A.+Yetisginauthor=S.+Cetinelauthor=M.+Zuvinauthor=A.+Kosarauthor=O.+Kutlu&title=Therapeutic+nanoparticles+and+their+targeted+delivery+applications&doi=10.3390%2Fmolecules25092193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit272R"><div class="casContent"><span class="casTitleNuber">272</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic nanoparticles and their targeted delivery applications</span></div><div class="casAuthors">Yetisgin, Abuzer Alp; Cetinel, Sibel; Zuvin, Merve; Kosar, Ali; Kutlu, Ozlem</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2193</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Nanotechnol. offers many advantages in various fields of science.  In this regard, nanoparticles are the essential building blocks of nanotechnol.  Recent advances in nanotechnol. have proven that nanoparticles acquire a great potential in medical applications.  Formation of stable interactions with ligands, variability in size and shape, high carrier capacity, and convenience of binding of both hydrophilic and hydrophobic substances make nanoparticles favorable platforms for the target-specific and controlled delivery of micro- and macromols. in disease therapy.  Nanoparticles combined with the therapeutic agents overcome problems assocd. with conventional therapy; however, some issues like side effects and toxicity are still debated and should be well concerned before their utilization in biol. systems.  It is therefore important to understand the specific properties of therapeutic nanoparticles and their delivery strategies.  Here, we provide an overview on the unique features of nanoparticles in the biol. systems.  We emphasize on the type of clin. used nanoparticles and their specificity for therapeutic applications, as well as on their current delivery strategies for specific diseases such as cancer, infectious, autoimmune, cardiovascular, neurodegenerative, ocular, and pulmonary diseases.  Understanding of the characteristics of nanoparticles and their interactions with the biol. environment will enable us to establish novel strategies for the treatment, prevention, and diagnosis in many diseases, particularly untreatable ones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Gn1H5EngzLVg90H21EOLACvtfcHk0lgGbmPrkXF5nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFert7vM&md5=b344a1b6ddf4cd75b2d479e0f8b976ef</span></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=10.3390%2Fmolecules25092193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules25092193%26sid%3Dliteratum%253Aachs%26aulast%3DYetisgin%26aufirst%3DA.%2BA.%26aulast%3DCetinel%26aufirst%3DS.%26aulast%3DZuvin%26aufirst%3DM.%26aulast%3DKosar%26aufirst%3DA.%26aulast%3DKutlu%26aufirst%3DO.%26atitle%3DTherapeutic%2520nanoparticles%2520and%2520their%2520targeted%2520delivery%2520applications%26jtitle%3DMolecules%26date%3D2020%26volume%3D25%26spage%3D2193%26doi%3D10.3390%2Fmolecules25092193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref273"><div class="reference"><strong class="refLabel"><a href="#ref273" class="rightTabRefNumLink">273</a></strong><div class="NLM_citation" id="rightTab-cit273"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chenthamara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramaniam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essa, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qoronfleh, M. W.</span></span> <span> </span><span class="NLM_article-title">Therapeutic efficacy of nanoparticles and routes of administration</span>. <i>Biomater. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">20</span>, <span class="refDoi"> DOI: 10.1186/s40824-019-0166-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1186%2Fs40824-019-0166-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31832232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSlsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=20&author=D.+Chenthamaraauthor=S.+Subramaniamauthor=S.+G.+Ramakrishnanauthor=S.+Krishnaswamyauthor=M.+M.+Essaauthor=F.-H.+Linauthor=M.+W.+Qoronfleh&title=Therapeutic+efficacy+of+nanoparticles+and+routes+of+administration&doi=10.1186%2Fs40824-019-0166-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit273R"><div class="casContent"><span class="casTitleNuber">273</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic efficacy of nanoparticles and routes of administration</span></div><div class="casAuthors">Chenthamara, Dhrisya; Subramaniam, Sadhasivam; Ramakrishnan, Sankar Ganesh; Krishnaswamy, Swaminathan; Essa, Musthafa Mohamed; Lin, Feng-Huei; Qoronfleh, M. Walid</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20</span>CODEN:
                <span class="NLM_cas:coden">BRIEFJ</span>;
        ISSN:<span class="NLM_cas:issn">2055-7124</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  In modern-day medicine, nanotechnol. and nanoparticles are some of the indispensable tools in disease monitoring and therapy.  However, "engineered" nanomaterials have received significant attention due to their versatility.  Hence, in this review, we have endeavored to briefly explain the most commonly used nanomaterials, their core properties and how surface functionalization would facilitate competent delivery of drugs or therapeutic mols.  Similarly, the suitability of carbon-based nanomaterials like CNT and QD has been discussed for targeted drug delivery and siRNA therapy.  One of the biggest challenges in the formulation of drug delivery systems is fulfilling targeted/specific drug delivery, controlling drug release and preventing opsonization.  Thus, a different mechanism of drug targeting, the role of suitable drug-laden nanocarrier fabrication and methods to augment drug soly. and bioavailability are discussed.  Addnl., different routes of nanocarrier administration are discussed to provide greater understanding of the biol. and other barriers and their impact on drug transport.  The overall aim of this article is to facilitate straightforward perception of nanocarrier design, routes of various nanoparticle administration and the challenges assocd. with each drug delivery method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_nj0618kzoLVg90H21EOLACvtfcHk0lgGbmPrkXF5nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSlsb%252FO&md5=15e5762db8f3889d38b2fef1dbc16200</span></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=10.1186%2Fs40824-019-0166-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40824-019-0166-x%26sid%3Dliteratum%253Aachs%26aulast%3DChenthamara%26aufirst%3DD.%26aulast%3DSubramaniam%26aufirst%3DS.%26aulast%3DRamakrishnan%26aufirst%3DS.%2BG.%26aulast%3DKrishnaswamy%26aufirst%3DS.%26aulast%3DEssa%26aufirst%3DM.%2BM.%26aulast%3DLin%26aufirst%3DF.-H.%26aulast%3DQoronfleh%26aufirst%3DM.%2BW.%26atitle%3DTherapeutic%2520efficacy%2520of%2520nanoparticles%2520and%2520routes%2520of%2520administration%26jtitle%3DBiomater.%2520Res.%26date%3D2019%26volume%3D23%26spage%3D20%26doi%3D10.1186%2Fs40824-019-0166-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref274"><div class="reference"><strong class="refLabel"><a href="#ref274" class="rightTabRefNumLink">274</a></strong><div class="NLM_citation" id="rightTab-cit274"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rath, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, A. K.</span></span> <span> </span><span class="NLM_article-title">Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis- a critical review</span>. <i>Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1676</span>– <span class="NLM_lpage">1698</span>, <span class="refDoi"> DOI: 10.3109/10717544.2015.1074765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3109%2F10717544.2015.1074765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=26289212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XotFams78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=1676-1698&author=J.+Singhauthor=T.+Gargauthor=G.+Rathauthor=A.+K.+Goyal&title=Advances+in+nanotechnology-based+carrier+systems+for+targeted+delivery+of+bioactive+drug+molecules+with+special+emphasis+on+immunotherapy+in+drug+resistant+tuberculosis-+a+critical+review&doi=10.3109%2F10717544.2015.1074765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit274R"><div class="casContent"><span class="casTitleNuber">274</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review</span></div><div class="casAuthors">Singh, Jagdeep; Garg, Tarun; Rath, Goutam; Goyal, Amit K.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Delivery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1676-1698</span>CODEN:
                <span class="NLM_cas:coden">DDELEB</span>;
        ISSN:<span class="NLM_cas:issn">1071-7544</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">From the early sixteenth and seventeenth centuries to the present day of life, tuberculosis (TB) still is a global health threat with some new emergence of resistance.  This type of emergence poses a vital challenge to control TB cases across the world.  Mortality and morbidity rates are high due to this new face of TB.  The newer nanotechnol.-based drug-delivery approaches involving micro-metric and nano-metric carriers are much needed at this stage.  These delivery systems would provide more advantages over conventional systems of treatment by producing enhanced therapeutic efficacy, uniform distribution of drug mol. to the target site, sustained and controlled release of drug mols. and lesser side effects.  The main aim to develop these novel drug-delivery systems is to improve the patient compliance and reduce therapy time.  This article reviews and elaborates the new concepts and drug-delivery approaches for the treatment of TB involving solid-lipid particulate drug-delivery systems (solid-lipid micro- and nanoparticles, nanostructured lipid carriers), vesicular drug-delivery systems (liposomes, niosomes and liposphere), emulsion-based drug-delivery systems (micro and nanoemulsion) and some other novel drug-delivery systems for the effective treatment of tuberculosis and role of immunomodulators as an adjuvant therapy for management of MDR-TB and XDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr28PISzG5WB7Vg90H21EOLACvtfcHk0lgGbmPrkXF5nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotFams78%253D&md5=aa543d85d71faf5a41d166acadd1876a</span></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=10.3109%2F10717544.2015.1074765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10717544.2015.1074765%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DGarg%26aufirst%3DT.%26aulast%3DRath%26aufirst%3DG.%26aulast%3DGoyal%26aufirst%3DA.%2BK.%26atitle%3DAdvances%2520in%2520nanotechnology-based%2520carrier%2520systems%2520for%2520targeted%2520delivery%2520of%2520bioactive%2520drug%2520molecules%2520with%2520special%2520emphasis%2520on%2520immunotherapy%2520in%2520drug%2520resistant%2520tuberculosis-%2520a%2520critical%2520review%26jtitle%3DDrug%2520Delivery%26date%3D2016%26volume%3D23%26spage%3D1676%26epage%3D1698%26doi%3D10.3109%2F10717544.2015.1074765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref275"><div class="reference"><strong class="refLabel"><a href="#ref275" class="rightTabRefNumLink">275</a></strong><div class="NLM_citation" id="rightTab-cit275"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gelperina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iseman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heifets, L.</span></span> <span> </span><span class="NLM_article-title">The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">1487</span>– <span class="NLM_lpage">1490</span>, <span class="refDoi"> DOI: 10.1164/rccm.200504-613PP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1164%2Frccm.200504-613PP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=16151040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BD2MnlsFeiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2005&pages=1487-1490&author=S.+Gelperinaauthor=K.+Kisichauthor=M.+D.+Isemanauthor=L.+Heifets&title=The+potential+advantages+of+nanoparticle+drug+delivery+systems+in+chemotherapy+of+tuberculosis&doi=10.1164%2Frccm.200504-613PP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis</span></div><div class="casAuthors">Gelperina Svetlana; Kisich Kevin; Iseman Michael D; Heifets Leonid</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1487-90</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Nanoparticle-based drug delivery systems have considerable potential for treatment of tuberculosis (TB).  The important technological advantages of nanoparticles used as drug carriers are high stability, high carrier capacity, feasibility of incorporation of both hydrophilic and hydrophobic substances, and feasibility of variable routes of administration, including oral application and inhalation.  Nanoparticles can also be designed to allow controlled (sustained) drug release from the matrix.  These properties of nanoparticles enable improvement of drug bioavailability and reduction of the dosing frequency, and may resolve the problem of nonadherence to prescribed therapy, which is one of the major obstacles in the control of TB epidemics.  This article highlights some of the issues of nanotechnology relevant to the anti-TB drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ99nfQi50cwJPlX7E30qdzfW6udTcc2eYkyaJ7u3GeqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnlsFeiuw%253D%253D&md5=3cd1441a228062dc8c82e3501b068e49</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=10.1164%2Frccm.200504-613PP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200504-613PP%26sid%3Dliteratum%253Aachs%26aulast%3DGelperina%26aufirst%3DS.%26aulast%3DKisich%26aufirst%3DK.%26aulast%3DIseman%26aufirst%3DM.%2BD.%26aulast%3DHeifets%26aufirst%3DL.%26atitle%3DThe%2520potential%2520advantages%2520of%2520nanoparticle%2520drug%2520delivery%2520systems%2520in%2520chemotherapy%2520of%2520tuberculosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2005%26volume%3D172%26spage%3D1487%26epage%3D1490%26doi%3D10.1164%2Frccm.200504-613PP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref276"><div class="reference"><strong class="refLabel"><a href="#ref276" class="rightTabRefNumLink">276</a></strong><div class="NLM_citation" id="rightTab-cit276"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clemens, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nel, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zink, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, M. A.</span></span> <span> </span><span class="NLM_article-title">Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2535</span>– <span class="NLM_lpage">2545</span>, <span class="refDoi"> DOI: 10.1128/AAC.06049-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1128%2FAAC.06049-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=22354311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKrsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=2535-2545&author=D.+L.+Clemensauthor=B.+Y.+Leeauthor=M.+Xueauthor=C.+R.+Thomasauthor=H.+Mengauthor=D.+Ferrisauthor=A.+E.+Nelauthor=J.+I.+Zinkauthor=M.+A.+Horwitz&title=Targeted+intracellular+delivery+of+antituberculosis+drugs+to+Mycobacterium+tuberculosis-infected+macrophages+via+functionalized+mesoporous+silica+nanoparticles&doi=10.1128%2FAAC.06049-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles</span></div><div class="casAuthors">Clemens, Daniel L.; Lee, Bai-Yu; Xue, Min; Thomas, Courtney R.; Meng, Huan; Ferris, Daniel; Nel, Andre E.; Zink, Jeffrey I.; Horwitz, Marcus A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2535-2545</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Delivery of antituberculosis drugs by nanoparticles offers potential advantages over free drug, including the potential to target specifically the tissues and cells that are infected by Mycobacterium tuberculosis, thereby simultaneously increasing therapeutic efficacy and decreasing systemic toxicity, and the capacity for prolonged release of drug, thereby allowing less-frequent dosing.  We have employed mesoporous silica nanoparticle (MSNP) drug delivery systems either equipped with a polyethyleneimine (PEI) coating to release rifampin or equipped with cyclodextrin-based pH-operated valves that open only at acidic pH to release isoniazid (INH) into M. tuberculosis-infected macrophages.  The MSNP are internalized efficiently by human macrophages, traffic to acidified endosomes, and release high concns. of antituberculosis drugs intracellularly.  PEI-coated MSNP show much greater loading of rifampin than uncoated MSNP and much greater efficacy against M. tuberculosis-infected macrophages.  MSNP were devoid of cytotoxicity at the particle doses employed for drug delivery.  Similarly, we have demonstrated that the isoniazid delivered by MSNP equipped with pH-operated nanovalves kill M. tuberculosis within macrophages significantly more effectively than an equiv. amt. of free drug.  These data demonstrate that MSNP provide a versatile platform that can be functionalized to optimize the loading and intracellular release of specific drugs for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkQ_4V2YD_ebVg90H21EOLACvtfcHk0lhi79pr92bddA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKrsLw%253D&md5=55323ffebc5d2fd3c27f9ff02ffb574c</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.1128%2FAAC.06049-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06049-11%26sid%3Dliteratum%253Aachs%26aulast%3DClemens%26aufirst%3DD.%2BL.%26aulast%3DLee%26aufirst%3DB.%2BY.%26aulast%3DXue%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DC.%2BR.%26aulast%3DMeng%26aufirst%3DH.%26aulast%3DFerris%26aufirst%3DD.%26aulast%3DNel%26aufirst%3DA.%2BE.%26aulast%3DZink%26aufirst%3DJ.%2BI.%26aulast%3DHorwitz%26aufirst%3DM.%2BA.%26atitle%3DTargeted%2520intracellular%2520delivery%2520of%2520antituberculosis%2520drugs%2520to%2520Mycobacterium%2520tuberculosis-infected%2520macrophages%2520via%2520functionalized%2520mesoporous%2520silica%2520nanoparticles%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D2535%26epage%3D2545%26doi%3D10.1128%2FAAC.06049-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref277"><div class="reference"><strong class="refLabel"><a href="#ref277" class="rightTabRefNumLink">277</a></strong><div class="NLM_citation" id="rightTab-cit277"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghav, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priyanka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rishi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, I.</span></span> <span> </span><span class="NLM_article-title">Exploiting chitosan and gold nanoparticles for antimycobacterial activity of in silico identified antimicrobial motif of human neutrophil peptide-1</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">7866</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-44256-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1038%2Fs41598-019-44256-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31133658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BB3M3gt1Cisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=7866&author=R.+Sharmaauthor=R.+Raghavauthor=K.+Priyankaauthor=P.+Rishiauthor=S.+Sharmaauthor=S.+Srivastavaauthor=I.+Verma&title=Exploiting+chitosan+and+gold+nanoparticles+for+antimycobacterial+activity+of+in+silico+identified+antimicrobial+motif+of+human+neutrophil+peptide-1&doi=10.1038%2Fs41598-019-44256-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit277R"><div class="casContent"><span class="casTitleNuber">277</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting chitosan and gold nanoparticles for antimycobacterial activity of in silico identified antimicrobial motif of human neutrophil peptide-1</span></div><div class="casAuthors">Sharma Richa; Priyanka Kumari; Sharma Sadhna; Verma Indu; Sharma Richa; Raghav Ragini; Srivastava Sudha; Rishi Praveen</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7866</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The upsurge of drug resistant tuberculosis is major health threat globally.  To counteract, antimicrobial peptides are being explored as possible alternatives.  However, certain limitations of peptide-based drugs such as potential toxicity, high cost and relatively low stability need to be addressed to enhance their clinical applicability.  Use of computer predicted short active motifs of AMPs along with nanotechnology could not only overcome the limitations of AMPs but also potentiate their antimicrobial activity.  Therefore, present study was proposed to in silico identify short antimicrobial motif (Pep-H) of human neutrophil peptide-1 (HNP-1) and explore its antimycobacterial activity in free form and using nanoparticles-based delivery systems.  Based on colony forming unit analysis, motif Pep-H led to killing of more than 90% M. tb in vitro at 10 μg/ml, whereas, similar activity against intracellularly growing M. tb was observed at 5 μg/ml only.  Thereafter, chitosan (244 nm) and gold nanoparticles (20 nm) were prepared for Pep-H with both the formulations showing minimal effects on the viability of human monocyte derived macrophages (MDMs) and RBC integrity.  The antimycobacterial activity of Pep-H against intracellular mycobacteria was enhanced in both the nanoformulations as evident by significant reduction in CFU (>90%) at 5-10 times lower concentrations than that observed for free Pep-H.  Thus, Pep-H is an effective antimycobacterial motif of HNP-1 and its activity is further enhanced by chitosan and gold nanoformulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZNEE2cL_h4nELvajU9pjPfW6udTcc2eYkyaJ7u3GeqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3gt1Cisg%253D%253D&md5=2b4eadc7b1114e801fd19f2a5af4326d</span></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-44256-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-44256-6%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DRaghav%26aufirst%3DR.%26aulast%3DPriyanka%26aufirst%3DK.%26aulast%3DRishi%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DSrivastava%26aufirst%3DS.%26aulast%3DVerma%26aufirst%3DI.%26atitle%3DExploiting%2520chitosan%2520and%2520gold%2520nanoparticles%2520for%2520antimycobacterial%2520activity%2520of%2520in%2520silico%2520identified%2520antimicrobial%2520motif%2520of%2520human%2520neutrophil%2520peptide-1%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D7866%26doi%3D10.1038%2Fs41598-019-44256-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref278"><div class="reference"><strong class="refLabel"><a href="#ref278" class="rightTabRefNumLink">278</a></strong><div class="NLM_citation" id="rightTab-cit278"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saifullah, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrzastek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naeemullah, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakurazi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussein, M. Z.</span></span> <span> </span><span class="NLM_article-title">Novel anti-tuberculosis nanodelivery formulation of ethambutol with graphene oxide</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1560</span>, <span class="refDoi"> DOI: 10.3390/molecules22101560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3390%2Fmolecules22101560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitl2iurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1560&author=B.+Saifullahauthor=A.+Chrzastekauthor=A.+Maitraauthor=B.+Naeemullahauthor=S.+Fakuraziauthor=S.+Bhaktaauthor=M.+Z.+Hussein&title=Novel+anti-tuberculosis+nanodelivery+formulation+of+ethambutol+with+graphene+oxide&doi=10.3390%2Fmolecules22101560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit278R"><div class="casContent"><span class="casTitleNuber">278</span><div class="casTitle"><span class="NLM_cas:atitle">Novel anti-tuberculosis nanodelivery formulation of ethambutol with graphene oxide</span></div><div class="casAuthors">Saifullah, Bullo; Chrzastek, Alina; Maitra, Arundhati; Naeemullah, Bullo; Fakurazi, Sharida; Bhakta, Sanjib; Hussein, Mohd. Zobir</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1560/1-1560/12</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Tuberculosis (TB) is a bacterial disease responsible for millions of infections and preventable deaths each year.  Its treatment is complicated by patients' noncompliance due to dosing frequency, lengthy treatment, and adverse side effects assocd. with current chemotherapy.  However, no modifications to the half-a-century old std. chemotherapy have been made based on a nanoformulation strategy to improve pharmacokinetic efficacy.  In this study, we have designed a new nanodelivery formulation, using graphene oxide as the nanocarrier, loaded with the anti-TB antibiotic, ethambutol.  The designed formulation was characterized using a no. of mol. anal. techniques.  It was found that sustained release of the drug resulted in better bioavailability.  In addn., the designed formulation demonstrated high biocompatibility with mouse fibroblast cells.  The anti-TB activity of the nanodelivery formulation was detd. using whole-cell resazurin microtiter plate assay, modified-spot culture growth inhibition assay, and biofilm inhibition assay.  The nanodelivery formulation showed good anti-mycobacterial activity.  The anti-mycobacterial activity of Ethambutol was unaffected by the drug loading and release process.  The results of this study demonstrated the potential of this new nanodelivery formulation strategy to be considered for modifying existing chemotherapy to yield more efficacious antibiotic treatment against TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowaawU9u9RFLVg90H21EOLACvtfcHk0ljeNutZsOcdhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitl2iurw%253D&md5=b975a2195694885343b04df9e00d63df</span></div><a href="/servlet/linkout?suffix=cit278&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22101560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22101560%26sid%3Dliteratum%253Aachs%26aulast%3DSaifullah%26aufirst%3DB.%26aulast%3DChrzastek%26aufirst%3DA.%26aulast%3DMaitra%26aufirst%3DA.%26aulast%3DNaeemullah%26aufirst%3DB.%26aulast%3DFakurazi%26aufirst%3DS.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DHussein%26aufirst%3DM.%2BZ.%26atitle%3DNovel%2520anti-tuberculosis%2520nanodelivery%2520formulation%2520of%2520ethambutol%2520with%2520graphene%2520oxide%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D1560%26doi%3D10.3390%2Fmolecules22101560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref279"><div class="reference"><strong class="refLabel"><a href="#ref279" class="rightTabRefNumLink">279</a></strong><div class="NLM_citation" id="rightTab-cit279"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gajendiran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balashanmugam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaichelvan, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span> <span> </span><span class="NLM_article-title">Multi-drug delivery of tuberculosis drugs by π-back bonded gold nanoparticles with multiblock copolyesters</span>. <i>Mater. Res. Express</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">065401</span>, <span class="refDoi"> DOI: 10.1088/2053-1591/3/6/065401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1088%2F2053-1591%2F3%2F6%2F065401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Olu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=065401&author=M.+Gajendiranauthor=P.+Balashanmugamauthor=P.+T.+Kalaichelvanauthor=S.+Balasubramanian&title=Multi-drug+delivery+of+tuberculosis+drugs+by+%CF%80-back+bonded+gold+nanoparticles+with+multiblock+copolyesters&doi=10.1088%2F2053-1591%2F3%2F6%2F065401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit279R"><div class="casContent"><span class="casTitleNuber">279</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-drug delivery of tuberculosis drugs by π-back bonded gold nanoparticles with multiblock copolyesters</span></div><div class="casAuthors">Gajendiran, Mani; Balashanmugam, Pannerselvam; Kalaichelvan, P. T.; Balasubramanian, Sengottuvelan</div><div class="citationInfo"><span class="NLM_cas:title">Materials Research Express</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">065401/1-065401/16</span>CODEN:
                <span class="NLM_cas:coden">MREAC3</span>;
        ISSN:<span class="NLM_cas:issn">2053-1591</span>.
    
            (<span class="NLM_cas:orgname">IOP Publishing Ltd.</span>)
        </div><div class="casAbstract">The effect of π-back-bonding between AuNPs and the carbonyl group of multiblock copolyester on tuberculosis multi-drug delivery has been investigated.  The carbonyl group of copolyester has vacant p orbitals and these vacant orbitals accept electron clouds from the filled d orbitals of Au0 to form π-back-bonding, which enhances the electron d. for the carbonyl oxygen.  This high electron d. results in the strong binding of drug mols. with multiblock copolyesters and hence sustained drug release is achieved for a longer duration when compared to polymer systems without AuNPs.  A new series of tartarate-linked poly(lactic-co-glycolic acid) (PLGA)-polyethylene glycol (PEG)-based multiblock copolymers has been synthesized using a solvent-free melt reaction.  The biocompatibility of multiblock copolyesters and AuNP nanoconjugates was investigated with an in vitro cytotoxicity study on the Vero cell line.  Three major tuberculosis drugs, namely, rifampicin-, isoniazid- and pyrazinamide-loaded AuNP multiblock copolymer NPs were prepd. by probe sonication followed by the self-assembly method.  An in vitro drug release expt. was carried out and the amt. of the three drugs released at various time intervals was detd. simultaneously by the HPLC technique.  The nanoconjugates exhibit 33%-40% RIF, 71%-95% INH, 77%-99% PYZ loading efficiencies, while the polymer NPs exhibit relatively lesser values.  The nanoconjugates show sustained drug release for up to 264 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2sZeQJvL4NrVg90H21EOLACvtfcHk0ljeNutZsOcdhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Olu7%252FN&md5=bf10f201efc26ec71d6cb0826f3622ad</span></div><a href="/servlet/linkout?suffix=cit279&amp;dbid=16384&amp;doi=10.1088%2F2053-1591%2F3%2F6%2F065401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1088%252F2053-1591%252F3%252F6%252F065401%26sid%3Dliteratum%253Aachs%26aulast%3DGajendiran%26aufirst%3DM.%26aulast%3DBalashanmugam%26aufirst%3DP.%26aulast%3DKalaichelvan%26aufirst%3DP.%2BT.%26aulast%3DBalasubramanian%26aufirst%3DS.%26atitle%3DMulti-drug%2520delivery%2520of%2520tuberculosis%2520drugs%2520by%2520%25CF%2580-back%2520bonded%2520gold%2520nanoparticles%2520with%2520multiblock%2520copolyesters%26jtitle%3DMater.%2520Res.%2520Express%26date%3D2016%26volume%3D3%26spage%3D065401%26doi%3D10.1088%2F2053-1591%2F3%2F6%2F065401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref280"><div class="reference"><strong class="refLabel"><a href="#ref280" class="rightTabRefNumLink">280</a></strong><div class="NLM_citation" id="rightTab-cit280"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshiro Junior, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavan, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorilli, M.</span></span> <span> </span><span class="NLM_article-title">Nanostructured lipid carriers for incorporation of copper(II) complexes to be used against Mycobacterium tuberculosis</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">921</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S127048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.2147%2FDDDT.S127048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28356717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOgs7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=909-921&author=M.+R.+Satoauthor=J.+A.+Oshiro+Juniorauthor=R.+T.+Machadoauthor=P.+C.+de+Souzaauthor=D.+L.+Camposauthor=F.+R.+Pavanauthor=P.+B.+da+Silvaauthor=M.+Chorilli&title=Nanostructured+lipid+carriers+for+incorporation+of+copper%28II%29+complexes+to+be+used+against+Mycobacterium+tuberculosis&doi=10.2147%2FDDDT.S127048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit280R"><div class="casContent"><span class="casTitleNuber">280</span><div class="casTitle"><span class="NLM_cas:atitle">Nanostructured lipid carriers for incorporation of copper(II ) complexes to be used against Mycobacterium tuberculosis</span></div><div class="casAuthors">Sato, Mariana R.; Oshiro, Joao A. Junior; Machado, Rachel T. A.; de Souza, Paula C.; Campos, Debora L.; Pavan, Fernando R.; da Silva, Patricia B.; Chorilli, Marlus</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">909-921</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis.  Cessation of treatment before the recommended conclusion may lead to the emergence of multidrug-resistant strains.  The aim of this study was to develop nanostructured lipid carriers (NLCs) for use in the treatment of M. tuberculosis.  The NLCs comprised the following lipid phase: 2.07% polyoxyethylene 40 stearate, 2.05% caprylic/capric triglyceride, and 0.88% polyoxyl 40 hydrogenated castor oil; the following aq. phase: 3.50% poloxamer 407 (F1-F6), and 0.50% cetyltrimethylammonium bromide (F7-F12); and incorporated the copper(II) complexes [CuCl2(INH)2]·H2O (1), [Cu(NCS)2(INH)2]·5H2O (2), and [Cu(NCO)2(INH)2]·4H2O (3) to form compds. F11.1, F11.2, and F11.3, resp.  The mean diam. of F11, F11.1, F11.2, and F11.3 ranged from 111.27±21.86 to 134.25±22.72 nm, 90.27±12.97 to 116.46±9.17 nm, 112.4±10.22 to 149.3±15.82 nm, and 78.65±6.00 to 122.00±8.70 nm, resp.  The polydispersity index values for the NLCs ranged from 0.13±0.01 to 0.30±0.09.  The NLCs showed significant changes in zeta potential, except for F11.2, with F11, F11.1, F11.2, and F11.3 ranging from 18.87±4.04 to 23.25±1.13 mV, 17.03±1.77 to 21.42±1.87 mV, 20.51±1.88 to 22.60±3.44 mV, and 17.80±1.96 to 25.25±7.78 mV, resp.  Atomic force microscopy confirmed the formation of nanoscale spherical particle dispersions by the NLCs.  Differential scanning calorimetry detd. the m.ps. of the constituents of the NLCs.  The in vitro activity of copper(II) complex-loaded NLCs against M. tuberculosis H37Rv showed an improvement in the anti-TB activity of 55.4, 27.1, and 41.1 times the activity for complexes 1, 2, and 3, resp.  An in vivo acute toxicity study of complex-loaded NLCs demonstrated their reduced toxicity.  The results suggest that NLCs may be a powerful tool to optimize the activity of copper(II) complexes against M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosY_Hf_UEOy7Vg90H21EOLACvtfcHk0lgGBjAeXBNSCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOgs7nO&md5=bb30c065f3c685e545798b48d4e051fb</span></div><a href="/servlet/linkout?suffix=cit280&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S127048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S127048%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DM.%2BR.%26aulast%3DOshiro%2BJunior%26aufirst%3DJ.%2BA.%26aulast%3DMachado%26aufirst%3DR.%2BT.%26aulast%3Dde%2BSouza%26aufirst%3DP.%2BC.%26aulast%3DCampos%26aufirst%3DD.%2BL.%26aulast%3DPavan%26aufirst%3DF.%2BR.%26aulast%3Dda%2BSilva%26aufirst%3DP.%2BB.%26aulast%3DChorilli%26aufirst%3DM.%26atitle%3DNanostructured%2520lipid%2520carriers%2520for%2520incorporation%2520of%2520copper%2528II%2529%2520complexes%2520to%2520be%2520used%2520against%2520Mycobacterium%2520tuberculosis%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D909%26epage%3D921%26doi%3D10.2147%2FDDDT.S127048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref281"><div class="reference"><strong class="refLabel"><a href="#ref281" class="rightTabRefNumLink">281</a></strong><div class="NLM_citation" id="rightTab-cit281"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidary, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaker Bostanabad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amini, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghalami
Nobar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghodousi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamalzadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darban-Sarokhalil, D.</span></span> <span> </span><span class="NLM_article-title">The anti-mycobacterial activity of Ag, ZnO, And Ag- ZnO nanoparticles against MDR- and XDR-mycobacterium tuberculosis</span>. <i>Infect. Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3425</span>– <span class="NLM_lpage">3435</span>, <span class="refDoi"> DOI: 10.2147/IDR.S221408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.2147%2FIDR.S221408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=31807033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BB3cXot1yjsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=3425-3435&author=M.+Heidaryauthor=S.+Zaker+Bostanabadauthor=S.+M.+Aminiauthor=A.+Jafariauthor=M.+Ghalami%0ANobarauthor=A.+Ghodousiauthor=M.+Kamalzadehauthor=D.+Darban-Sarokhalil&title=The+anti-mycobacterial+activity+of+Ag%2C+ZnO%2C+And+Ag-+ZnO+nanoparticles+against+MDR-+and+XDR-mycobacterium+tuberculosis&doi=10.2147%2FIDR.S221408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit281R"><div class="casContent"><span class="casTitleNuber">281</span><div class="casTitle"><span class="NLM_cas:atitle">The anti-mycobacterial activity Of Ag, ZnO, and Ag- ZnO nanoparticles against MDR- and XDR-Mycobacterium tuberculosis</span></div><div class="casAuthors">Heidary, Mohsen; Bostanabad, Saeed Zaker; Amini, Seyed Mohammad; Jafari, Alireza; Nobar, Mostafa Ghalami; Ghodousi, Arash; Kamalzadeh, Morteza; Darban-Sarokhalil, Davood</div><div class="citationInfo"><span class="NLM_cas:title">Infection and Drug Resistance</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3425-3435</span>CODEN:
                <span class="NLM_cas:coden">IDRNAV</span>;
        ISSN:<span class="NLM_cas:issn">1178-6973</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Nowadays, tuberculosis (TB) is one of the top ten leading causes of mortality worldwide.  The emergence of multidrug-resistant (MDR) - and extensively drug-resistant (XDR) - Mycobacterium tuberculosis (M. tuberculosis) is identified as one of the most challenging threats to TB control.  Thus, new and safe nano-drugs are urgently required for the elimination of TB.  The aim of this study was to investigate the anti-bacterial effects of Ag, ZnO, and Ag-ZnO nanoparticles (NPs) on MDR- and XDR-M. tuberculosis.  Materials and methods: In this study, Ag, ZnO, and Ag-ZnO NPs were synthesized by the chem. redn. and chem. deposition methods.  NPs were characterized using UV-visible spectroscopy, dynamic light scattering, and transmission electron microscopy.  Then, various dilns. of NPs were prepd. and their min. inhibitory concns. (MICs) and min. bactericidal concns. (MBCs) were detd. against M. tuberculosis strains using the broth microdilution and agar microdilution methods.  Finally, MTT test and cell culture assay were performed.  Results: The effects of concns. of 1-128 μg/mL Ag NPs, ZnO NPs, 2Ag: 8ZnO, 8Ag:2ZnO, 3Ag: 7ZnO, 7Ag:3ZnO, and 5Ag:5ZnO on M. tuberculosis strains were investigated.  MIC results showed the inhibitory effect of 1 μg/mL of all NPs against XDR-M. tuberculosis.  In addn., the concns. of 4 μg/mL Ag, 8 μg/mL 5Ag:5ZnO, 8 μg/mL 7Ag:3ZnO, 32 μg/mL 3Ag:7ZnO, 16 μg/mL 8Ag:2ZnO, and 64 μg/mL 2Ag:8ZnO inhibited MDR-M. tuberculosis growth.  However, MBC results indicated the inability of Ag, ZnO and Ag-ZnO NPs, either in combination or alone, to kill MDR- or XDR-M. tuberculosis.  Conclusion: To the best of our knowledge, this is the first study to evaluate the effects of Ag and ZnO NPs against MDR and XDR strains of M. tuberculosis.  According to the results, Ag and ZnO NPs showed bacteriostatic effects against drug-resistant strains of M. tuberculosis.  Therefore, these NPs may be considered as promising anti-mycobacterial nano-drugs.  However, further studies are required to affirm the bactericidal effects of these NPs against TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlRShshehpXbVg90H21EOLACvtfcHk0lgGBjAeXBNSCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXot1yjsro%253D&md5=db456425cf3c228b5a9763532f9cc0a8</span></div><a href="/servlet/linkout?suffix=cit281&amp;dbid=16384&amp;doi=10.2147%2FIDR.S221408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIDR.S221408%26sid%3Dliteratum%253Aachs%26aulast%3DHeidary%26aufirst%3DM.%26aulast%3DZaker%2BBostanabad%26aufirst%3DS.%26aulast%3DAmini%26aufirst%3DS.%2BM.%26aulast%3DJafari%26aufirst%3DA.%26aulast%3DGhalami%2BNobar%26aufirst%3DM.%26aulast%3DGhodousi%26aufirst%3DA.%26aulast%3DKamalzadeh%26aufirst%3DM.%26aulast%3DDarban-Sarokhalil%26aufirst%3DD.%26atitle%3DThe%2520anti-mycobacterial%2520activity%2520of%2520Ag%252C%2520ZnO%252C%2520And%2520Ag-%2520ZnO%2520nanoparticles%2520against%2520MDR-%2520and%2520XDR-mycobacterium%2520tuberculosis%26jtitle%3DInfect.%2520Drug%2520Resist.%26date%3D2019%26volume%3D12%26spage%3D3425%26epage%3D3435%26doi%3D10.2147%2FIDR.S221408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref282"><div class="reference"><strong class="refLabel"><a href="#ref282" class="rightTabRefNumLink">282</a></strong><div class="NLM_citation" id="rightTab-cit282"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khuller, G. K.</span></span> <span> </span><span class="NLM_article-title">Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">766</span>, <span class="refDoi"> DOI: 10.1093/jac/dkh411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1093%2Fjac%2Fdkh411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=15329364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotVyqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2004&pages=761-766&author=A.+Sharmaauthor=S.+Sharmaauthor=G.+K.+Khuller&title=Lectin-functionalized+poly+%28lactide-co-glycolide%29+nanoparticles+as+oral%2Faerosolized+antitubercular+drug+carriers+for+treatment+of+tuberculosis&doi=10.1093%2Fjac%2Fdkh411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit282R"><div class="casContent"><span class="casTitleNuber">282</span><div class="casTitle"><span class="NLM_cas:atitle">Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis</span></div><div class="casAuthors">Sharma, Anjali; Sharma, Sadhna; Khuller, G. K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">761-766</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">This study was carried out to explore lectin-functionalized poly (lactide-co-glycolide) nanoparticles (PLG-NPs) as bioadhesive drug carriers against tuberculosis (TB), in order to reduce the drug dosage frequency of antitubercular drugs and thus improve patient compliance in TB chemotherapy.  Wheat germ agglutinin (WGA)-coated PLG-NPs were prepd. by a two-step carbodiimide procedure.  This formulation was administered to guinea pigs through the oral/aerosol route for a detailed pharmacokinetic and chemotherapeutic evaluation.  Immunol. or hepatotoxic effects of WGA lectin, if any, were also detd.  WGA-functionalized PLG-NPs were in the size range of 350-400 nm, with binding of 3-3.5 μg of WGA/mg of PLG-NPs and drug encapsulation efficiency of 54%-66%.  Upon administration of lectin-coated PLG-NPs through the oral/aerosol route, the presence of drugs in plasma was obsd. for 6-7 days for rifampicin and 13-14 days for isoniazid and pyrazinamide.  However, upon administration of uncoated PLG-NPs (oral/aerosolized) rifampicin was detectable in plasma for 4-6 days, whereas isoniazid and pyrazinamide were detectable for 8-9 days.  All three drugs were present in lungs, liver and spleen for 15 days.  Administration of WGA-coated PLG-NPs caused a significant (P < 0.001) increase in the relative bioavailability of antitubercular drugs.  Chemotherapeutic studies revealed that three doses of oral/nebulized lectin-coated nanoparticles fortnightly could yield undetectable mycobacterial colony forming units (cfu); this was achievable with 45 doses of oral free drugs.  WGA-functionalized PLG-NPs could be potential drug carriers for antitubercular drugs through the oral as well as aerosol route for effective TB control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK4EYmOtkF9LVg90H21EOLACvtfcHk0lhRNfQ8mEEmDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotVyqsbo%253D&md5=2269ae52053065827ac149b9082ad642</span></div><a href="/servlet/linkout?suffix=cit282&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkh411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkh411%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKhuller%26aufirst%3DG.%2BK.%26atitle%3DLectin-functionalized%2520poly%2520%2528lactide-co-glycolide%2529%2520nanoparticles%2520as%2520oral%252Faerosolized%2520antitubercular%2520drug%2520carriers%2520for%2520treatment%2520of%2520tuberculosis%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2004%26volume%3D54%26spage%3D761%26epage%3D766%26doi%3D10.1093%2Fjac%2Fdkh411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref283"><div class="reference"><strong class="refLabel"><a href="#ref283" class="rightTabRefNumLink">283</a></strong><div class="NLM_citation" id="rightTab-cit283"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalombo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemmer, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semete-Makokotlela, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalapa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nkuna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booysen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayeshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verschoor, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swai, H. S.</span></span> <span> </span><span class="NLM_article-title">Spray-dried, nanoencapsulated, multi-drug anti-tuberculosis therapy aimed at once weekly administration for the duration of treatment</span>. <i>Nanomaterials</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1167</span>, <span class="refDoi"> DOI: 10.3390/nano9081167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3390%2Fnano9081167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCjs7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1167&author=L.+Kalomboauthor=Y.+Lemmerauthor=B.+Semete-Makokotlelaauthor=B.+Ramalapaauthor=P.+Nkunaauthor=L.+Booysenauthor=S.+Naidooauthor=R.+Hayeshiauthor=J.+A.+Verschoorauthor=H.+S.+Swai&title=Spray-dried%2C+nanoencapsulated%2C+multi-drug+anti-tuberculosis+therapy+aimed+at+once+weekly+administration+for+the+duration+of+treatment&doi=10.3390%2Fnano9081167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit283R"><div class="casContent"><span class="casTitleNuber">283</span><div class="casTitle"><span class="NLM_cas:atitle">Spray-dried, nanoencapsulated, multi-drug anti-tuberculosis therapy aimed at once weekly administration for the duration of treatment</span></div><div class="casAuthors">Kalombo, Lonji; Lemmer, Yolandy; Semete-Makokotlela, Boitumelo; Ramalapa, Bathabile; Nkuna, Patric; Booysen, Laetitia L. L. I. J.; Naidoo, Saloshnee; Hayeshi, Rose; Verschoor, Jan A.; Swai, Hulda S.</div><div class="citationInfo"><span class="NLM_cas:title">Nanomaterials</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1167</span>CODEN:
                <span class="NLM_cas:coden">NANOKO</span>;
        ISSN:<span class="NLM_cas:issn">2079-4991</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Aiming to improve the treatment outcomes of current daily tuberculosis (TB) chemotherapy over several months, we investigated whether nanoencapsulation of existing drugs would allow decreasing the treatment frequency to weekly, thereby ultimately improving patient compliance.  Nanoencapsulation of three first-line anti-TB drugs was achieved by a unique, scalable spray-drying technol. forming free-flowing powders in the nanometer range with encapsulation efficiencies of 82, 75, and 62% resp. for rifampicin, pyrazinamide, and isoniazid.  In a pre-clin. study on TB infected mice, we demonstrate that the encapsulated drugs, administered once weekly for nine weeks, showed comparable efficacy to daily treatment with free drugs over the same exptl. period.  Both treatment approaches had equiv. outcomes for resoln. of inflammation assocd. with the infection of lungs and spleens.  These results demonstrate how scalable technol. could be used to manuf. nanoencapsulated drugs.  The formulations may be used to reduce the oral dose frequency from daily to once weekly in order to treat uncomplicated TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEPt78R3IbnbVg90H21EOLACvtfcHk0lhRNfQ8mEEmDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCjs7zJ&md5=a2ec906d2106c3548b01b2249d32793f</span></div><a href="/servlet/linkout?suffix=cit283&amp;dbid=16384&amp;doi=10.3390%2Fnano9081167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fnano9081167%26sid%3Dliteratum%253Aachs%26aulast%3DKalombo%26aufirst%3DL.%26aulast%3DLemmer%26aufirst%3DY.%26aulast%3DSemete-Makokotlela%26aufirst%3DB.%26aulast%3DRamalapa%26aufirst%3DB.%26aulast%3DNkuna%26aufirst%3DP.%26aulast%3DBooysen%26aufirst%3DL.%26aulast%3DNaidoo%26aufirst%3DS.%26aulast%3DHayeshi%26aufirst%3DR.%26aulast%3DVerschoor%26aufirst%3DJ.%2BA.%26aulast%3DSwai%26aufirst%3DH.%2BS.%26atitle%3DSpray-dried%252C%2520nanoencapsulated%252C%2520multi-drug%2520anti-tuberculosis%2520therapy%2520aimed%2520at%2520once%2520weekly%2520administration%2520for%2520the%2520duration%2520of%2520treatment%26jtitle%3DNanomaterials%26date%3D2019%26volume%3D9%26spage%3D1167%26doi%3D10.3390%2Fnano9081167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref284"><div class="reference"><strong class="refLabel"><a href="#ref284" class="rightTabRefNumLink">284</a></strong><div class="NLM_citation" id="rightTab-cit284"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaramahalingam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajaram, R.</span></span> <span> </span><span class="NLM_article-title">Size-dependent antimycobacterial activity of titanium oxide nanoparticles against Mycobacterium tuberculosis</span>. <i>J. Mater. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">4338</span>– <span class="NLM_lpage">4346</span>, <span class="refDoi"> DOI: 10.1039/C9TB00784A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref284/cit284&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1039%2FC9TB00784A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref284/cit284&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWks7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=4338-4346&author=V.+Ramalingamauthor=S.+Sundaramahalingamauthor=R.+Rajaram&title=Size-dependent+antimycobacterial+activity+of+titanium+oxide+nanoparticles+against+Mycobacterium+tuberculosis&doi=10.1039%2FC9TB00784A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit284R"><div class="casContent"><span class="casTitleNuber">284</span><div class="casTitle"><span class="NLM_cas:atitle">Size-dependent antimycobacterial activity of titanium oxide nanoparticles against Mycobacterium tuberculosis</span></div><div class="casAuthors">Ramalingam, Vaikundamoorthy; Sundaramahalingam, Subramaniam; Rajaram, Rajendran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Materials Chemistry B: Materials for Biology and Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">4338-4346</span>CODEN:
                <span class="NLM_cas:coden">JMCBDV</span>;
        ISSN:<span class="NLM_cas:issn">2050-7518</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Nanobiotechnol. has offered new approaches for drug delivery and for the development of medicines against microbial infections including the deadly multidrug-resistant tuberculosis (MDR-TB).  The present study deals with the antimycobacterial activity of titanium dioxide (TiO2) nanoparticles against Mycobacterium tuberculosis.  Initially, TiO2 nanoparticles were synthesized from titanium(IV)oxysulfate (TiOSO4) soln. using the sol-gel method.  The shape and size of the TiO2 crystals were analyzed using TEM and SEM and were found to be spherical and 16 nm resp., thereby indicating their morphol.  Moreover, the XRD pattern confirms that the prepd. TiO2 nanoparticles were anatase as well as being tetragonal and FTIR spectra show the stretching vibrations of Ti-O and Ti-O-Ti.  Further, the TiO2 nanoparticles were shown to exhibit excellent size-dependent antimycobacterial activity against Mycobacterium tuberculosis, M. bovis and Mycobacterium sp. in a concn. dependent manner (10-100 μg mL-1).  Confocal laser scanning microscopic anal. also confirmed that the TiO2 nanoparticles inhibit the biofilm formation of all three tested mycobacteria.  The metabolic activity of mycobacteria was decreased up to 3-4 fold with an increase in the concn. of the TiO2 nanoparticles hence affecting the biofilm formation.  Moreover, the TiO2 nanoparticles were less toxic (>25%) against normal lung bronchus cells at 100 μg mL-1 after 24 h treatment revealing that the nanoparticles are less toxic in nature.  Taken together, these results showed that the TiO2 nanoparticles can be a potential biofilm agent against mycobacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE0n_vq5WndLVg90H21EOLACvtfcHk0lhRNfQ8mEEmDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWks7nO&md5=74fdb6d7712383d2cd1a28c5a063d034</span></div><a href="/servlet/linkout?suffix=cit284&amp;dbid=16384&amp;doi=10.1039%2FC9TB00784A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9TB00784A%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DV.%26aulast%3DSundaramahalingam%26aufirst%3DS.%26aulast%3DRajaram%26aufirst%3DR.%26atitle%3DSize-dependent%2520antimycobacterial%2520activity%2520of%2520titanium%2520oxide%2520nanoparticles%2520against%2520Mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Mater.%2520Chem.%2520B%26date%3D2019%26volume%3D7%26spage%3D4338%26epage%3D4346%26doi%3D10.1039%2FC9TB00784A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref285"><div class="reference"><strong class="refLabel"><a href="#ref285" class="rightTabRefNumLink">285</a></strong><div class="NLM_citation" id="rightTab-cit285"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidyarthi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadeem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrewala, J. N.</span></span> <span> </span><span class="NLM_article-title">Alteration in the gut microbiota provokes susceptibility to tuberculosis</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">529</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2016.00529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3389%2Ffimmu.2016.00529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27965663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptF2qsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=529-529&author=N.+Khanauthor=A.+Vidyarthiauthor=S.+Nadeemauthor=S.+Negiauthor=G.+Nairauthor=J.+N.+Agrewala&title=Alteration+in+the+gut+microbiota+provokes+susceptibility+to+tuberculosis&doi=10.3389%2Ffimmu.2016.00529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit285R"><div class="casContent"><span class="casTitleNuber">285</span><div class="casTitle"><span class="NLM_cas:atitle">Alteration in the gut microbiota provokes susceptibility to tuberculosis</span></div><div class="casAuthors">Khan, Nargis; Vidyarthi, Aurobind; Nadeem, Sajid; Negi, Shikha; Nair, Girish; Agrewala, Javed N.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">529/1-529/10</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The microbiota that resides in the gastrointestinal tract provides essential health benefits to the host.  In particular, they regulate immune homeostasis.  Recently, several evidences indicate that alteration in the gut microbial community can cause infectious and non-infectious diseases.  Tuberculosis (TB) is the most devastating disease, inflicting mortality and morbidity.  It remains unexplored, whether changes in the gut microbiota can provoke or prevent TB.  In the current study, we have demonstrated the antibiotics driven changes in the gut microbial compn. and their impact on the survival of Mycobacterium tuberculosis (Mtb) in the lungs, liver, and spleen of infected mice, compared to those with intact microbiota.  Interestingly, dysbiosis of microbes showed significant increase in the bacterial burden in lungs and dissemination of Mtb to spleen and liver.  Furthermore, elevation in the no. of Tregs and decline in the pool of IFN-γ- and TNF-α-releasing CD4 T cells was noticed.  Interestingly, fecal transplantation in the gut microbiota disrupted animals exhibited improved Th1 immunity and lesser Tregs population.  Importantly, these animals displayed reduced severity to Mtb infection.  This study for the first time demonstrated the novel role of gut microbes in the susceptibility to TB and its prevention by microbial implants.  In future, microbial therapies may help in treating patients suffering from TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_m_Fy3xWobLVg90H21EOLACvtfcHk0ljwZPPzHST3AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptF2qsA%253D%253D&md5=8847952d6ef63f27d3553b561bac54e0</span></div><a href="/servlet/linkout?suffix=cit285&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2016.00529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2016.00529%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DVidyarthi%26aufirst%3DA.%26aulast%3DNadeem%26aufirst%3DS.%26aulast%3DNegi%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DG.%26aulast%3DAgrewala%26aufirst%3DJ.%2BN.%26atitle%3DAlteration%2520in%2520the%2520gut%2520microbiota%2520provokes%2520susceptibility%2520to%2520tuberculosis%26jtitle%3DFront.%2520Immunol.%26date%3D2016%26volume%3D7%26spage%3D529%26epage%3D529%26doi%3D10.3389%2Ffimmu.2016.00529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref286"><div class="reference"><strong class="refLabel"><a href="#ref286" class="rightTabRefNumLink">286</a></strong><div class="NLM_citation" id="rightTab-cit286"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pahari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aqdas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrewala, J. N.</span></span> <span> </span><span class="NLM_article-title">Bolstering immunity through pattern recognition receptors: A unique approach to control tuberculosis</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">906</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2017.00906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.3389%2Ffimmu.2017.00906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=28824632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWntbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=906&author=S.+Pahariauthor=G.+Kaurauthor=M.+Aqdasauthor=S.+Negiauthor=D.+Chatterjeeauthor=H.+Bashirauthor=S.+Singhauthor=J.+N.+Agrewala&title=Bolstering+immunity+through+pattern+recognition+receptors%3A+A+unique+approach+to+control+tuberculosis&doi=10.3389%2Ffimmu.2017.00906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit286R"><div class="casContent"><span class="casTitleNuber">286</span><div class="casTitle"><span class="NLM_cas:atitle">Bolstering immunity through pattern recognition receptors: a unique approach to control tuberculosis</span></div><div class="casAuthors">Pahari, Susanta; Kaur, Gurpreet; Aqdas, Mohammad; Negi, Shikha; Chatterjee, Deepyan; Bashir, Hilal; Singh, Sanpreet; Agrewala, Javed N.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">906/1-906/13</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The global control of tuberculosis (TB) presents a continuous health challenge to mankind.  Despite having effective drugs, TB still has a devastating impact on human health.  Contributing reasons include the emergence of drug-resistant strains of Mycobacterium tuberculosis (Mtb), the AIDS-pandemic, and the absence of effective vaccines against the disease.  Indeed, alternative and effective methods of TB treatment and control are urgently needed.  One such approach may be to more effectively engage the immune system; particularly the frontline pattern recognition receptor (PRR) systems of the host, which sense pathogen-assocd. mol. patterns (PAMPs) of Mtb.  It is well known that 95 % of individuals infected with Mtb in latent form remain healthy throughout their life.  Therefore, we propose that clues can be found to control the remainder by successfully manipulating the innate immune mechanisms, particularly of nasal and mucosal cavities.  This article highlights the importance of signaling through PRRs in restricting Mtb entry and subsequently preventing its infection.  Furthermore, we discuss whether this unique therapy employing PRRs in combination with drugs can help in reducing the dose and duration of current TB regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrabXj90TMiRbVg90H21EOLACvtfcHk0ljwZPPzHST3AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWntbvL&md5=78fd1998f8376ff632ba991285a7c282</span></div><a href="/servlet/linkout?suffix=cit286&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2017.00906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2017.00906%26sid%3Dliteratum%253Aachs%26aulast%3DPahari%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DAqdas%26aufirst%3DM.%26aulast%3DNegi%26aufirst%3DS.%26aulast%3DChatterjee%26aufirst%3DD.%26aulast%3DBashir%26aufirst%3DH.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DAgrewala%26aufirst%3DJ.%2BN.%26atitle%3DBolstering%2520immunity%2520through%2520pattern%2520recognition%2520receptors%253A%2520A%2520unique%2520approach%2520to%2520control%2520tuberculosis%26jtitle%3DFront.%2520Immunol.%26date%3D2017%26volume%3D8%26spage%3D906%26doi%3D10.3389%2Ffimmu.2017.00906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref287"><div class="reference"><strong class="refLabel"><a href="#ref287" class="rightTabRefNumLink">287</a></strong><div class="NLM_citation" id="rightTab-cit287"><span><span class="NLM_contrib-group"><span class="NLM_string-name">AlMatar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makky, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakıcı, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Var, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köksal, F.</span></span> <span> </span><span class="NLM_article-title">Antimicrobial peptides as an alternative to anti-tuberculosis drugs</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2017.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.phrs.2017.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=29079429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A280%3ADC%252BC1M7lsVaguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=288-305&author=M.+AlMatarauthor=E.+A.+Makkyauthor=G.+Yak%C4%B1c%C4%B1author=I.+Varauthor=B.+Kayarauthor=F.+K%C3%B6ksal&title=Antimicrobial+peptides+as+an+alternative+to+anti-tuberculosis+drugs&doi=10.1016%2Fj.phrs.2017.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit287R"><div class="casContent"><span class="casTitleNuber">287</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobial peptides as an alternative to anti-tuberculosis drugs</span></div><div class="casAuthors">AlMatar Manaf; Makky Essam A; Yakici Gulfer; Kayar Begum; Koksal Fatih; Var Isil</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">288-305</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis (TB) presently accounts for high global mortality and morbidity rates, despite the introduction four decades ago of the affordable and efficient four-drugs (isoniazid, rifampicin, pyrazinamide and ethambutol).  Thus, a strong need exists for new drugs with special structures and uncommon modes of action to effectively overcome M. tuberculosis.  Within this scope, antimicrobial peptides (AMPs), which are small, cationic and amphipathic peptides that comprise a section of the innate immune system, are currently the leading potential agents for the treatment of TB.  Many studies have recently illustrated the capability of anti-mycobacterial peptides to disrupt the normal mycobacterial cell wall function through various modes, thereby interacting with the intracellular targets, as well as encompassing nucleic acids, enzymes and organelles.  This review presents a wide array of antimicrobial activities, alongside the associated properties of the AMPs that could be utilized as potential agents in therapeutic tactics for TB treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWoTa_cySIy3T4ugvCDgnZfW6udTcc2ebfEpUjoehCurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7lsVaguw%253D%253D&md5=a94c7bdb1d892b884f37174a5e8939ec</span></div><a href="/servlet/linkout?suffix=cit287&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2017.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2017.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DAlMatar%26aufirst%3DM.%26aulast%3DMakky%26aufirst%3DE.%2BA.%26aulast%3DYak%25C4%25B1c%25C4%25B1%26aufirst%3DG.%26aulast%3DVar%26aufirst%3DI.%26aulast%3DKayar%26aufirst%3DB.%26aulast%3DK%25C3%25B6ksal%26aufirst%3DF.%26atitle%3DAntimicrobial%2520peptides%2520as%2520an%2520alternative%2520to%2520anti-tuberculosis%2520drugs%26jtitle%3DPharmacol.%2520Res.%26date%3D2018%26volume%3D128%26spage%3D288%26epage%3D305%26doi%3D10.1016%2Fj.phrs.2017.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref288"><div class="reference"><strong class="refLabel"><a href="#ref288" class="rightTabRefNumLink">288</a></strong><div class="NLM_citation" id="rightTab-cit288"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silva, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gama, F. M.</span></span> <span> </span><span class="NLM_article-title">Antimicrobial peptides as novel anti-tuberculosis therapeutics</span>. <i>Biotechnol. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">924</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.1016/j.biotechadv.2016.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=10.1016%2Fj.biotechadv.2016.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=27235189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVamsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=924-940&author=J.+P.+Silvaauthor=R.+Appelbergauthor=F.+M.+Gama&title=Antimicrobial+peptides+as+novel+anti-tuberculosis+therapeutics&doi=10.1016%2Fj.biotechadv.2016.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit288R"><div class="casContent"><span class="casTitleNuber">288</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobial peptides as novel anti-tuberculosis therapeutics</span></div><div class="casAuthors">Silva, Joao P.; Appelberg, Rui; Gama, Francisco Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology Advances</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">924-940</span>CODEN:
                <span class="NLM_cas:coden">BIADDD</span>;
        ISSN:<span class="NLM_cas:issn">0734-9750</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Tuberculosis (TB), a disease caused by the human pathogen Mycobacterium tuberculosis, has recently joined HIV/AIDS as the world's deadliest infectious disease, affecting around 9.6 million people worldwide in 2014.  Of those, about 1.2 million died from the disease.  Resistance acquisition to existing antibiotics, with the subsequent emergence of Multi-Drug Resistant mycobacteria strains, together with an increasing economic burden, has urged the development of new anti-TB drugs.  In this scope, antimicrobial peptides (AMPs), which are small, cationic and amphipathic peptides that make part of the innate immune system, now arise as promising candidates for TB treatment.  In this review, we analyze the potential of AMPs for this application.  We address the mechanisms of action, advantages and disadvantages over conventional antibiotics and how problems assocd. with its use may be overcome to boost their therapeutic potential.  Addnl., we address the challenges of translational development from bench side to bedside, evaluate the current development pipeline and analyze the expected global impact from a socio-economic standpoint.  The quest for more efficient and more compliant anti-TB drugs, assocd. with the great therapeutic potential of emerging AMPs and the rising peptide market, provide an optimal environment for the emergence of AMPs as promising therapies.  Still, their pharmacol. properties need to be enhanced and manufg.-assocd. issues need to be addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMP2arQ4Jua7Vg90H21EOLACvtfcHk0lhjdyHSMHcsRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVamsrg%253D&md5=897105e906ca1c63ac4dbeae9a354b44</span></div><a href="/servlet/linkout?suffix=cit288&amp;dbid=16384&amp;doi=10.1016%2Fj.biotechadv.2016.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biotechadv.2016.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DSilva%26aufirst%3DJ.%2BP.%26aulast%3DAppelberg%26aufirst%3DR.%26aulast%3DGama%26aufirst%3DF.%2BM.%26atitle%3DAntimicrobial%2520peptides%2520as%2520novel%2520anti-tuberculosis%2520therapeutics%26jtitle%3DBiotechnol.%2520Adv.%26date%3D2016%26volume%3D34%26spage%3D924%26epage%3D940%26doi%3D10.1016%2Fj.biotechadv.2016.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4V1F" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4V1F','PDB','4V1F'); return false;">PDB: 4V1F</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V3Y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5V3Y','PDB','5V3Y'); return false;">PDB: 5V3Y</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5BS8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5BS8','PDB','5BS8'); return false;">PDB: 5BS8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JGC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JGC','PDB','7JGC'); return false;">PDB: 7JGC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JG5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JG5','PDB','7JG5'); return false;">PDB: 7JG5</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01833&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-8%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01833%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01833" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799bf68bf03d18f","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
